These	O
data	O
indicate	O
that	O
CD4	B-PRGE
(+)	O
T	O
cells	O
have	O
a	O
pivotal	O
role	O
in	O
accelerating	O
CNS	O
inflammation	O
and	O
demyelination	O
within	O
infected	O
mice	O
,	O
possibly	O
by	O
regulating	O
RANTES	B-PRGE
expression	O
,	O
which	O
in	O
turn	O
coordinates	O
the	O
trafficking	O
of	O
macrophages	O
into	O
the	O
CNS	O
,	O
leading	O
to	O
myelin	O
destruction	O
.	O

The	O
parental	O
virus	O
was	O
found	O
to	O
have	O
an	O
increased	O
resistance	O
to	O
the	O
detergent	O
octylglucoside	O
compared	O
to	O
the	O
HAD	B-PRGE
mutants	I-PRGE
.	O

If	O
the	O
binding	O
of	O
sialylated	O
macromolecules	O
was	O
prevented	O
by	O
neuraminidase	B-PRGE
treatment	O
,	O
the	O
parental	O
virus	O
was	O
as	O
sensitive	O
to	O
octylglucoside	O
as	O
were	O
the	O
HAD	B-PRGE
mutants	I-PRGE
.	O

This	O
anti	O
-	O
body	O
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
FIPV	O
infection	O
is	O
dependent	O
on	O
mouse	O
MAb	O
subclass	O
,	O
and	O
MAb	O
of	O
IgG2a	B-PRGE
subclass	O
has	O
a	O
strong	O
ADE	O
activity	O
.	O

As	O
judged	O
by	O
their	O
colabeling	O
with	O
antibodies	O
to	O
E	O
and	O
to	O
Rab	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
marker	O
for	O
the	O
intermediate	O
compartment	O
and	O
endoplasmic	O
reticulum	O
,	O
the	O
E	B-PRGE
protein	I-PRGE
accumulates	O
in	O
and	O
induces	O
curvature	O
into	O
these	O
pre	O
-	O
Golgi	O
membranes	O
where	O
coronaviruses	O
have	O
been	O
shown	O
earlier	O
to	O
assemble	O
by	O
budding	O
.	O

ABSTRACT	O
:	O
The	O
pathogenesis	O
of	O
the	O
neurotropic	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
in	O
Fas	B-PRGE
-	O
deficient	O
mice	O
suggested	O
that	O
Fas	B-PRGE
-	O
mediated	O
cytotoxicity	O
may	O
be	O
required	O
during	O
viral	O
clearance	O
after	O
the	O
loss	O
of	O
perforin	B-PRGE
-	O
mediated	O
cytotoxicity	O
.	O

In	O
all	O
groups	O
of	O
patients	O
,	O
the	O
changes	O
in	O
the	O
lavage	O
enzymatic	O
activities	O
were	O
paralleled	O
by	O
manifold	O
increased	O
BALF	O
concentrations	O
of	O
fibrinopeptide	B-PRGE
A	I-PRGE
and	O
D	O
-	O
dimer	O
,	O
reflecting	O
in	O
vivo	O
coagulation	O
processes	O
.	O

ABSTRACT	O
:	O
Procalcitonin	O
(	O
PCT	B-PRGE
),	O
the	O
precursor	O
protein	O
of	O
the	O
hormone	O
calcitonin	B-PRGE
,	O
appears	O
to	O
be	O
an	O
early	O
marker	O
of	O
the	O
presence	O
of	O
severe	O
systemic	O
infection	O
.	O

The	O
third	O
construct	O
contained	O
the	O
D	O
epitope	O
-	O
coding	O
region	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
,	O
from	O
nucleotide	O
1201	O
to	O
1591	O
,	O
which	O
was	O
fused	O
to	O
the	O
alfalfa	B-PRGE
beta	I-PRGE
-	I-PRGE
amylase	I-PRGE
gene	I-PRGE
.	O

Variations	O
in	O
the	O
Pao2	B-PRGE
/	O
Fio2	O
ratio	O
were	O
lower	O
at	O
start	O
of	O
NO	O
therapy	O
(	O
11	O
+/-	O
4	O
ppm	O
)	O
than	O
that	O
observed	O
at	O
prone	O
positioning	O
initiation	O
(	O
23	O
+/-	O
31	O
vs	O
.	O
62	O
+/-	O
78	O
torr	O
,	O
p	O
<.	O
05	O
).	O

The	O
majority	O
of	O
complexes	O
containing	O
the	O
gene	O
1	O
proteins	O
were	O
distinct	O
from	O
sites	O
of	O
accumulation	O
of	O
the	O
M	B-PRGE
assembly	I-PRGE
protein	I-PRGE
.	O

Treatment	O
with	O
the	O
anti	B-PRGE
-	I-PRGE
CD18	I-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
reduced	O
mortality	O
by	O
approximately	O
40	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Assays	O
have	O
been	O
developed	O
to	O
identify	O
Gray	O
strain	O
IBV	O
-	O
specific	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
responses	O
using	O
viral	O
infected	O
antigen	O
presenting	O
cells	O
(	O
APC	O
)	O
and	O
using	O
the	O
Semliki	O
Forest	O
virus	O
vector	O
infected	O
APC	B-PRGE
expressing	O
individual	O
viral	O
polypeptides	O
.	O

Elevated	O
numbers	O
of	O
splenic	O
CD4	B-PRGE
(+)	O
cells	O
during	O
the	O
acute	O
phase	O
of	O
infection	O
may	O
be	O
associated	O
with	O
viral	O
clearance	O
.	O

Treatment	O
with	O
thalidomide	O
,	O
which	O
is	O
a	O
potent	O
TNF	B-PRGE
down	O
-	O
regulatory	O
drug	O
,	O
prevented	O
HEV	O
-	O
induced	O
intestinal	O
haemorrhage	O
and	O
treatment	O
with	O
an	O
IFN	B-PRGE
-	O
inducing	O
chemical	O
prevented	O
HEV	O
-	O
replication	O
and	O
inhibited	O
HEV	O
-	O
induced	O
pathological	O
and	O
histopathological	O
lesions	O
.	O

ORF	B-PRGE
3b	I-PRGE
begins	O
at	O
base	O
432	O
on	O
mRNA	O
3	O
in	O
Purdue	O
strain	O
.	O

With	O
mRNA	B-PRGE
3	I-PRGE
-	I-PRGE
like	I-PRGE
transcripts	I-PRGE
modified	O
to	O
carry	O
large	O
ORFs	O
upstream	O
of	O
ORF	B-PRGE
3a	I-PRGE
,	O
it	O
was	O
demonstrated	O
that	O
ribosomes	O
can	O
reach	O
ORF	B-PRGE
3b	I-PRGE
by	O
entering	O
at	O
a	O
distant	O
downstream	O
site	O
in	O
a	O
manner	O
resembling	O
ribosomal	O
shunting	O
.	O

Deletion	O
analysis	O
failed	O
to	O
identify	O
a	O
postulated	O
internal	O
ribosomal	O
entry	O
structure	O
(	O
IRES	O
)	O
within	O
ORF	B-PRGE
3a	I-PRGE
.	O

TITLE	O
:	O
Adoptive	O
transfer	O
of	O
infectious	O
bronchitis	O
virus	O
primed	O
alphabeta	O
T	O
cells	O
bearing	O
CD8	B-PRGE
antigen	I-PRGE
protects	O
chicks	O
from	O
acute	O
infection	O
.	O

As	O
determined	O
by	O
respiratory	O
illness	O
and	O
viral	O
load	O
,	O
transfer	O
of	O
syngeneic	O
immune	O
T	O
lymphocytes	O
protected	O
chicks	O
from	O
challenge	O
infection	O
,	O
whereas	O
no	O
protection	O
was	O
observed	O
in	O
the	O
chicks	O
receiving	O
the	O
MHC	B-PRGE
compatible	O
lymphocytes	O
from	O
uninfected	O
chicks	O
.	O

We	O
also	O
demonstrated	O
that	O
this	O
substitution	O
added	O
N	O
-	O
linked	O
glycans	O
to	O
MHV	B-PRGE
-	I-PRGE
2	I-PRGE
M	I-PRGE
protein	I-PRGE
resulting	O
in	O
increment	O
of	O
molecular	O
mass	O
of	O
MHV	B-PRGE
-	I-PRGE
2	I-PRGE
M	I-PRGE
protein	I-PRGE
compared	O
with	O
JHM	O
strain	O
having	O
only	O
O	O
-	O
linked	O
glycans	O
.	O

TITLE	O
:	O
Capture	O
ELISA	O
systems	O
for	O
the	O
detection	O
of	O
bovine	B-PRGE
coronavirus	I-PRGE
-	I-PRGE
specific	I-PRGE
IgA	I-PRGE
and	I-PRGE
IgM	I-PRGE
antibodies	I-PRGE
in	O
milk	O
and	O
serum	O
.	O

The	O
homologous	O
(	O
anti	B-PRGE
-	I-PRGE
SSA	I-PRGE
)	O
antiserum	O
was	O
positive	O
by	O
ELISA	O
.	O

ABSTRACT	O
:	O
To	O
group	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
isolates	O
,	O
a	O
genetic	O
grouping	O
method	O
based	O
on	O
hypervariable	O
region	O
1	O
(	O
HVR	O
1	O
,	O
nucleotides	O
168	O
to	O
197	O
)	O
was	O
compared	O
with	O
that	O
based	O
on	O
the	O
whole	O
S1	B-PRGE
gene	I-PRGE
.	O

TITLE	O
:	O
Contributions	O
of	O
CD8	B-PRGE
+	I-PRGE
T	I-PRGE
cells	O
and	O
viral	O
spread	O
to	O
demyelinating	O
disease	O
.	O

When	O
expressed	O
using	O
recombinant	O
vaccinia	O
virus	O
,	O
the	O
IBV	B-PRGE
E	I-PRGE
protein	I-PRGE
is	O
released	O
from	O
cells	O
at	O
low	O
levels	O
in	O
sedimentable	O
particles	O
that	O
have	O
a	O
density	O
similar	O
to	O
that	O
of	O
coronavirus	O
virions	O
.	O

In	O
order	O
to	O
identify	O
domains	O
in	O
the	O
N	B-PRGE
protein	I-PRGE
that	O
bind	O
to	O
RNA	O
,	O
the	O
whole	O
protein	O
(	O
409	O
amino	O
acids	O
)	O
and	O
six	O
overlapping	O
fragments	O
were	O
expressed	O
as	O
fusion	O
polypeptides	O
with	O
six	O
histidine	O
-	O
tags	O
.	O

These	O
results	O
hold	O
promise	O
for	O
the	O
development	O
of	O
a	O
gene	O
therapy	O
treatment	O
for	O
chronic	O
viral	O
hepatitis	O
based	O
on	O
liver	O
-	O
restricted	O
expression	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha2	I-PRGE
.	O

The	O
proinflammatory	O
cytokines	O
interferon	B-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
),	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
have	O
been	O
shown	O
to	O
play	O
key	O
roles	O
in	O
several	O
respiratory	O
disease	O
conditions	O
.	O

CNI	O
-	O
1493	O
,	O
which	O
attenuates	O
mediator	O
production	O
through	O
p38	B-PRGE
MAP	I-PRGE
kinase	I-PRGE
inhibition	O
,	O
was	O
administered	O
intraperitoneally	O
to	O
mice	O
while	O
control	O
animals	O
received	O
saline	O
.	O

Activation	O
of	O
nuclear	B-PRGE
factor	I-PRGE
kappa	I-PRGE
B	I-PRGE
occurred	O
30	O
min	O
after	O
elastase	O
administration	O
.	O

TITLE	O
:	O
Host	O
protein	O
interactions	O
with	O
the	O
3	O
'	O
end	O
of	O
bovine	B-PRGE
coronavirus	I-PRGE
RNA	I-PRGE
and	O
the	O
requirement	O
of	O
the	O
poly	O
(	O
A	O
)	O
tail	O
for	O
coronavirus	O
defective	O
genome	O
replication	O
.	O

A	O
clinicopathologic	O
study	O
using	O
immunohistochemical	O
staining	O
and	O
viral	O
genome	O
detection	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
performed	O
with	O
this	O
autopsied	O
case	O
.	O

In	O
the	O
groups	O
immunized	O
with	O
CL	B-PRGE
antigen	I-PRGE
at	O
an	O
HA	O
titer	O
of	O
1000	O
or	O
250	O
,	O
HI	O
antibody	O
titers	O
were	O
40	O
to	O
160	O
and	O
SN	O
titers	O
were	O
80	O
to	O
640	O
.	O

ABSTRACT	O
:	O
The	O
kinetics	O
of	O
T	O
-	O
cells	O
(	O
CD3	B-PRGE
positive	O
(+),	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
cells	O
)	O
and	O
B	O
-	O
cells	O
(	O
IgG	B-PRGE
+,	I-PRGE
IgM	B-PRGE
+	I-PRGE
and	O
IgA	B-PRGE
+	I-PRGE
cells	O
)	O
in	O
chicken	O
trachea	O
were	O
studied	O
immunohistochemically	O
and	O
histopathologically	O
following	O
an	O
intratracheal	O
inoculation	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

In	O
this	O
study	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)-	O
infected	O
cells	O
were	O
fractionated	O
and	O
analyzed	O
to	O
determine	O
if	O
gene	B-PRGE
1	I-PRGE
proteins	I-PRGE
segregated	O
to	O
more	O
than	O
one	O
membrane	O
population	O
.	O

ABSTRACT	O
:	O
The	O
defective	O
RNA	O
(	O
D	O
-	O
RNA	O
)	O
CD	O
-	O
61	O
,	O
derived	O
from	O
the	O
Beaudette	O
strain	O
of	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
was	O
used	O
as	O
an	O
RNA	O
vector	O
for	O
the	O
expression	O
of	O
two	O
reporter	O
genes	O
,	O
luciferase	O
and	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
).	O

TITLE	O
:	O
Further	O
characterization	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	B-PRGE
virus	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
and	O
determination	O
of	O
a	O
new	O
cleavage	O
site	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
encodes	O
a	O
trypsin	O
-	O
like	O
proteinase	O
(	O
3C	O
-	O
like	O
proteinase	O
)	O
by	O
ORF	B-PRGE
1a	I-PRGE
,	O
which	O
has	O
been	O
demonstrated	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
proteolytic	O
processing	O
of	O
gene	B-PRGE
1	I-PRGE
-	I-PRGE
encoded	I-PRGE
polyproteins	I-PRGE
.	O

Intestines	O
,	O
thymus	O
,	O
bursa	O
,	O
and	O
spleens	O
were	O
examined	O
for	O
SRV	B-PRGE
antigen	I-PRGE
at	O
various	O
days	O
postinoculation	O
(	O
DPI	O
).	O

Flow	O
cytometry	O
analysis	O
revealed	O
a	O
sudden	O
decline	O
at	O
2	O
DPI	O
in	O
the	O
numbers	O
of	O
CD4	B-PRGE
-	O
CD8	B-PRGE
+	I-PRGE
lymphocyte	O
subset	O
in	O
PBLs	O
of	O
SRV	O
-	O
infected	O
poults	O
.	O

On	O
the	O
contrary	O
,	O
thymocytes	O
had	O
higher	O
percentages	O
of	O
CD4	B-PRGE
-	O
CD8	B-PRGE
+	I-PRGE
lymphocytes	O
at	O
2	O
and	O
4	O
DPI	O
and	O
reached	O
comparable	O
levels	O
at	O
8	O
DPI	O
in	O
controls	O
and	O
SRV	O
-	O
infected	O
poults	O
.	O

IL	B-PRGE
-	I-PRGE
1	I-PRGE
levels	O
(	O
106	O
-	O
1631	O
U	O
/	O
ml	O
versus	O
28	O
-	O
654	O
U	O
/	O
ml	O
after	O
LPS	O
only	O
)	O
were	O
also	O
increased	O
,	O
but	O
persisted	O
for	O
longer	O
after	O
clinical	O
recovery	O
than	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

The	O
putative	O
functional	O
site	O
for	O
acetylesterase	O
activity	O
was	O
present	O
in	O
the	O
HE	B-PRGE
protein	I-PRGE
as	O
Phe	O
-	O
Gly	O
-	O
Asp	O
-	O
Ser	O
(	O
FGDS	O
),	O
suggesting	O
that	O
the	O
SDAV	B-PRGE
HE	I-PRGE
protein	I-PRGE
might	O
have	O
retained	O
the	O
esterase	B-PRGE
activity	O
.	O

These	O
observations	O
suggest	O
that	O
inefficient	O
infections	O
in	O
BHK	O
-	O
R2	O
cells	O
by	O
srr	B-PRGE
mutants	I-PRGE
occur	O
in	O
the	O
absence	O
of	O
a	O
functional	O
receptor	O
MHVR1	B-PRGE
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
srr	B-PRGE
entry	O
into	O
cells	O
.	O

The	O
methods	O
used	O
were	O
(	O
1	O
)	O
DNA	O
electrophoresis	O
for	O
detection	O
of	O
DNA	O
fragmentation	O
,	O
and	O
(	O
2	O
)	O
terminal	O
deoxynucleotidyl	O
transferase	B-PRGE
-	O
mediated	O
deoxyuridine	O
triphosphate	O
-	O
fluorescein	O
nick	O
and	O
labelling	O
(	O
TUNEL	O
).	O

In	O
the	O
host	O
infected	O
by	O
endotoxin	O
(	O
lipopolysaccharide	O
,	O
LPS	O
),	O
the	O
expression	O
and	O
release	O
of	O
proinflammatory	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNFalpha	B-PRGE
)	O
rapidly	O
increases	O
,	O
and	O
this	O
cytokine	O
production	O
is	O
regulated	O
by	O
agents	O
elevating	O
cyclic	O
AMP	O
.	O

Pathogen	O
-	O
free	O
Sprague	O
-	O
Dawley	O
rats	O
weighing	O
225	O
-	O
250	O
g	O
.	O
Sterile	O
,	O
endotoxin	O
-	O
and	O
cytokine	O
-	O
free	O
pancreatic	O
ascites	O
tested	O
for	O
interleukin	B-PRGE
(	O
IL	O
)-	O
1beta	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
was	O
obtained	O
from	O
rats	O
18	O
hrs	O
after	O
the	O
induction	O
of	O
severe	O
,	O
acute	O
pancreatitis	O
.	O

Pulmonary	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
protein	I-PRGE
was	O
detected	O
by	O
immunohistochemistry	O
.	O

Mice	O
received	O
pancreatic	O
elastase	B-PRGE
,	O
amylase	B-PRGE
,	O
lipase	B-PRGE
,	O
or	O
trypsin	B-PRGE
intraperitoneally	O
.	O

Pulmonary	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
activation	O
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	B-PRGE
)	O
gene	O
expression	O
,	O
and	O
neutrophil	O
infiltration	O
(	O
myeloperoxidase	B-PRGE
)	O
were	O
determined	O
and	O
myeloperoxidase	B-PRGE
experiments	O
repeated	O
in	O
p55	B-PRGE
TNF	B-PRGE
receptor	I-PRGE
-	O
deficient	O
(	O
TNF	B-PRGE
KO	I-PRGE
)	O
animals	O
.	O

TITLE	O
:	O
CD4	B-PRGE
and	O
CD8	B-PRGE
T	I-PRGE
cells	O
have	O
redundant	O
but	O
not	O
identical	O
roles	O
in	O
virus	O
-	O
induced	O
demyelination	O
.	O

In	O
this	O
study	O
,	O
the	O
individual	O
roles	O
of	O
CD4	B-PRGE
and	O
CD8	B-PRGE
T	I-PRGE
cells	O
in	O
MHV	O
-	O
induced	O
demyelination	O
were	O
investigated	O
using	O
recombination	O
-	O
activating	O
gene	O
1	O
-/-	O
(	O
RAG1	B-PRGE
-/-)	O
mice	O
infected	O
with	O
an	O
attenuated	O
strain	O
of	O
MHV	O
-	O
JHM	O
.	O

Adoptive	O
transfer	O
of	O
CD4	B-PRGE
T	I-PRGE
cell	O
-	O
enriched	O
donors	O
resulted	O
in	O
more	O
severe	O
clinical	O
disease	O
accompanied	O
by	O
less	O
demyelination	O
than	O
was	O
detected	O
in	O
the	O
recipients	O
of	O
undepleted	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
continued	O
presence	O
of	O
virus	O
-	O
specific	O
CD8	B-PRGE
(+)	O
T	O
cells	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
following	O
resolution	O
of	O
acute	O
viral	O
encephalomyelitis	O
implicates	O
organ	O
-	O
specific	O
retention	O
.	O

Class	O
I	O
tetramer	O
technology	O
revealed	O
more	O
infiltrating	O
virus	O
-	O
specific	O
CD8	B-PRGE
(+)	O
T	O
cells	O
during	O
acute	O
V	O
-	O
1	O
compared	O
to	O
V	O
-	O
2	O
infection	O
.	O

Decreasing	O
viral	O
RNA	O
levels	O
in	O
both	O
brains	O
and	O
spinal	O
cords	O
following	O
initial	O
virus	O
clearance	O
coincided	O
with	O
an	O
overall	O
progressive	O
loss	O
of	O
both	O
total	O
and	O
virus	O
-	O
specific	O
CD8	B-PRGE
(+)	O
T	O
cells	O
.	O

To	O
date	O
,	O
two	O
of	O
the	O
MHV	B-PRGE
replicase	I-PRGE
-	I-PRGE
encoded	I-PRGE
proteinases	I-PRGE
,	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
1	I-PRGE
(	O
PLP1	B-PRGE
)	O
and	O
the	O
poliovirus	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
(	O
3CLpro	O
),	O
have	O
been	O
shown	O
to	O
process	O
the	O
replicase	B-PRGE
polyprotein	O
.	O

Comparisons	O
of	O
TGEV	O
and	O
PRCV	O
strains	O
suggest	O
that	O
tropism	O
and	O
pathogenicity	O
are	O
influenced	O
by	O
the	O
S	B-PRGE
gene	I-PRGE
and	O
ORF3	O
,	O
respectively	O
.	O

Sequence	O
analysis	O
of	O
the	O
TGEV	O
isolate	O
in	O
the	O
partial	O
S	B-PRGE
gene	I-PRGE
and	O
ORF3	B-PRGE
/	O
3a	O
and	O
ORF3	B-PRGE
-	I-PRGE
1	I-PRGE
/	I-PRGE
3b	I-PRGE
revealed	O
high	O
homology	O
with	O
enteropathogenic	O
TGEV	O
strains	O
.	O

Immunohistochemical	O
staining	O
for	O
coronavirus	O
antigen	O
was	O
performed	O
on	O
paraffin	O
-	O
embedded	O
tissues	O
from	O
approximately	O
10	O
%	O
of	O
affected	O
ferrets	O
to	O
identify	O
viral	B-PRGE
antigen	I-PRGE
and	O
determine	O
its	O
distribution	O
.	O

The	O
expression	O
of	O
interferon	B-PRGE
response	I-PRGE
gene	I-PRGE
47	I-PRGE
and	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
1	I-PRGE
genes	I-PRGE
takes	O
place	O
after	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
activation	O
in	O
both	O
macrophages	O
,	O
indicating	O
their	O
activation	O
.	O

Apoptotic	O
events	O
within	O
the	O
retina	O
were	O
associated	O
with	O
the	O
presence	O
of	O
viral	O
antigen	O
,	O
infiltration	O
of	O
CD8	B-PRGE
(+)	O
T	O
cells	O
,	O
and	O
clearance	O
of	O
infectious	O
virus	O
.	O

In	O
contrast	O
,	O
no	O
specific	O
18S	B-PRGE
rRNA	I-PRGE
cleavage	O
was	O
detected	O
in	O
infected	O
cells	O
.	O

The	O
helicase	B-PRGE
mutants	I-PRGE
showed	O
no	O
function	O
in	O
any	O
assays	O
used	O
:	O
they	O
were	O
strongly	O
defective	O
in	O
template	O
recruitment	O
for	O
RNA	O
replication	O
,	O
as	O
measured	O
by	O
1a	O
-	O
induced	O
stabilization	O
of	O
RNA3	B-PRGE
,	O
and	O
they	O
synthesized	O
no	O
detectable	O
negative	O
-	O
strand	O
or	O
subgenomic	O
RNA	O
.	O

XRN1	B-PRGE
deletion	O
suppressed	O
the	O
second	O
but	O
not	O
the	O
first	O
group	O
of	O
capping	O
mutants	O
,	O
allowing	O
synthesis	O
and	O
accumulation	O
of	O
large	O
amounts	O
of	O
uncapped	O
subgenomic	O
mRNAs	O
,	O
thus	O
providing	O
direct	O
evidence	O
for	O
the	O
importance	O
of	O
the	O
viral	O
RNA	O
capping	O
function	O
.	O

RNase	B-PRGE
protection	O
assays	O
using	O
the	O
purified	O
genome	O
-	O
length	O
RI	O
and	O
two	O
probes	O
,	O
which	O
corresponded	O
to	O
the	O
5	O
'	O
300	O
-	O
nt	O
region	O
of	O
mRNA	O
6	O
and	O
to	O
the	O
same	O
region	O
of	O
mRNA	O
7	O
,	O
showed	O
the	O
presence	O
of	O
nascent	O
leader	O
sequence	O
-	O
containing	O
subgenomic	O
mRNAs	O
in	O
the	O
genome	O
-	O
length	O
RI	O
.	O

TITLE	O
:	O
Biochemical	O
characterization	O
of	O
the	O
equine	O
arteritis	O
virus	O
helicase	B-PRGE
suggests	O
a	O
close	O
functional	O
relationship	O
between	O
arterivirus	O
and	O
coronavirus	O
helicases	O
.	O

ABSTRACT	O
:	O
The	O
arterivirus	O
equine	O
arteritis	O
virus	O
nonstructural	O
protein	O
10	O
(	O
nsp10	O
)	O
has	O
previously	O
been	O
predicted	O
to	O
contain	O
a	O
Zn	O
finger	O
structure	O
linked	O
to	O
a	O
superfamily	O
1	O
(	O
SF1	B-PRGE
)	O
helicase	B-PRGE
domain	O
.	O

Results	O
of	O
this	O
study	O
suggest	O
a	O
close	O
functional	O
relationship	O
between	O
the	O
arterivirus	O
nsp10	O
and	O
the	O
coronavirus	O
helicase	O
,	O
for	O
which	O
NTPase	B-PRGE
and	O
duplex	O
-	O
unwinding	O
activities	O
were	O
recently	O
demonstrated	O
.	O

Factors	O
possibly	O
influencing	O
the	O
emergence	O
of	O
the	O
Ark	B-PRGE
subtype	O
in	O
commercial	O
broilers	O
are	O
discussed	O
.	O

The	O
3	O
'	O
end	O
of	O
the	O
polymerase	O
gene	O
and	O
the	O
5	O
'	O
end	O
of	O
the	O
S2	B-PRGE
gene	I-PRGE
of	O
the	O
DE072	O
strain	O
were	O
sequenced	O
and	O
compared	O
with	O
the	O
forward	O
and	O
reverse	O
RT	O
-	O
PCR	O
primers	O
,	O
respectively	O
.	O

Because	O
of	O
the	O
inhaled	O
NO	O
uptake	O
by	O
the	O
lung	O
,	O
the	O
extra	O
vascular	O
lung	O
effects	O
might	O
be	O
in	O
the	O
future	O
the	O
most	O
important	O
development	O
in	O
relation	O
with	O
platelet	B-PRGE
anti	I-PRGE
-	I-PRGE
agregant	I-PRGE
and	O
anti	O
-	O
inflammatory	O
properties	O
.	O

In	O
normal	O
and	O
lesioned	O
white	O
matter	O
,	O
oligodendrocyte	O
lineage	O
cells	O
,	O
including	O
progenitors	O
and	O
mature	O
cells	O
,	O
were	O
found	O
to	O
express	O
multiple	O
FGFR	O
types	O
(	O
FGFR1	B-PRGE
,	O
FGFR2	B-PRGE
,	O
and	O
/	O
or	O
FGFR3	B-PRGE
).	O

On	O
Day	O
7	O
,	O
sTNF	O
-	O
R55	O
was	O
,	O
independently	O
of	O
%	O
FM	O
,	O
correlated	O
with	O
the	O
natural	O
logarithm	O
(	O
LN	O
)	O
of	O
leptin	B-PRGE
(	O
r	O
=	O
0	O
.	O
65	O
,	O
p	O
=	O
0	O
.	O
041	O
)	O
and	O
with	O
plasma	O
glucose	O
(	O
r	O
=	O
0	O
.	O
81	O
,	O
p	O
=	O
0	O
.	O
015	O
).	O

This	O
deletion	O
effectively	O
eliminated	O
the	O
replication	O
of	O
the	O
DI	B-PRGE
-	I-PRGE
chloramphenicol	I-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)-	O
reporter	O
,	O
as	O
demonstrated	O
by	O
the	O
sensitive	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	O
.	O

These	O
studies	O
should	O
prove	O
useful	O
in	O
expression	O
of	O
other	O
RNA	B-PRGE
viral	I-PRGE
genes	I-PRGE
in	O
the	O
E3	O
region	O
of	O
BAV	O
-	O
3	O
expression	O
system	O
.	O

N	O
-	O
viral	O
RNA	O
complexes	O
were	O
detected	O
in	O
bovine	O
coronavirus	O
(	O
BCV	O
)-	O
infected	O
cells	O
and	O
in	O
cells	O
transiently	O
expressing	O
the	O
N	B-PRGE
protein	I-PRGE
.	O

Presumably	O
this	O
occurs	O
because	O
the	O
consensus	O
IG	O
sequence	O
serves	O
as	O
the	O
template	O
switching	O
site	O
for	O
the	O
viral	B-PRGE
encoded	I-PRGE
polymerase	I-PRGE
.	O

ABSTRACT	O
:	O
To	O
report	O
a	O
case	O
of	O
fatal	O
systemic	O
reaction	O
after	O
intravesical	O
administrations	O
of	O
bacillus	O
Calmette	O
-	O
GuÃ©rin	O
(	O
BCG	B-PRGE
)	O
for	O
polyposis	O
.	O

BCG	B-PRGE
instillation	O
is	O
a	O
valuable	O
tool	O
in	O
the	O
therapy	O
of	O
bladder	O
carcinoma	O
,	O
but	O
increasing	O
reports	O
of	O
severe	O
adverse	O
reactions	O
should	O
continue	O
to	O
remind	O
practicing	O
urologists	O
to	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
common	O
and	O
uncommon	O
reactions	O
after	O
its	O
use	O
.	O

To	O
determine	O
whether	O
this	O
sequence	O
functions	O
independently	O
as	O
a	O
promoter	O
,	O
we	O
cloned	O
a	O
140	O
-	O
nt	O
sequence	O
(	O
from	O
approximately	O
70	O
nt	O
upstream	O
to	O
approximately	O
70	O
nt	O
downstream	O
of	O
the	O
fusion	O
site	O
)	O
from	O
viral	O
genomic	O
RNA	O
and	O
placed	O
it	O
in	O
front	O
of	O
a	O
reporter	O
gene	O
in	O
the	O
defective	O
-	O
interfering	O
(	O
DI	O
)	O
RNA	O
-	O
chloramphenicol	B-PRGE
acetyltransferase	I-PRGE
(	O
CAT	B-PRGE
)	O
reporter	O
vector	O
.	O

Serum	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
macrophage	B-PRGE
inflammatory	I-PRGE
protein	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
MIP	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
levels	O
are	O
markedly	O
increased	O
1	O
h	O
and	O
beyond	O
after	O
cryo	O
compared	O
with	O
partial	O
hepatectomy	O
where	O
no	O
elevation	O
occurs	O
.	O

It	O
is	O
proposed	O
that	O
the	O
M	B-PRGE
protein	I-PRGE
is	O
embedded	O
within	O
the	O
virus	O
membrane	O
and	O
that	O
the	O
C	O
region	O
,	O
exposed	O
to	O
the	O
interior	O
face	O
of	O
the	O
virion	O
in	O
a	O
population	O
of	O
these	O
molecules	O
,	O
interacts	O
with	O
the	O
nucleocapsid	O
to	O
which	O
it	O
is	O
anchored	O
,	O
forming	O
the	O
core	O
.	O

Penn98	O
-	O
1	O
,	O
expressing	O
the	O
MHV	B-PRGE
-	I-PRGE
2	I-PRGE
spike	I-PRGE
gene	I-PRGE
,	O
replicated	O
to	O
high	O
titer	O
in	O
the	O
liver	O
,	O
similar	O
to	O
MHV	O
-	O
2	O
,	O
and	O
induced	O
severe	O
hepatitis	O
with	O
extensive	O
hepatocellular	O
necrosis	O
.	O

Digestion	O
with	O
RNase	B-PRGE
T1	I-PRGE
at	O
1	O
-	O
10	O
units	O
/	O
microgram	O
RNA	O
resolved	O
RI	O
/	O
TIs	B-PRGE
into	O
RF	O
/	O
TF	O
cores	O
and	O
left	O
native	O
RF	O
/	O
TFs	O
intact	O
,	O
whereas	O
RNase	B-PRGE
A	I-PRGE
at	O
concentrations	O
of	O
0	O
.	O
02	O
microgram	O
/	O
microgram	O
RNA	O
or	O
higher	O
degraded	O
both	O
native	O
RF	O
/	O
TFs	O
and	O
RI	O
/	O
TIs	B-PRGE
.	O

This	O
patient	O
was	O
treated	O
with	O
high	O
doses	O
of	O
methylprednisolone	O
,	O
antibiotics	O
,	O
globulins	O
,	O
urinastatin	O
,	O
neutrophilic	B-PRGE
elastase	I-PRGE
inhibitor	O
,	O
nitric	O
oxide	O
inhalation	O
,	O
and	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
but	O
died	O
on	O
the	O
thirteenth	O
hospital	O
day	O
.	O

SPF	B-PRGE
chickens	I-PRGE
were	O
bled	O
several	O
times	O
after	O
their	O
introduction	O
and	O
examined	O
for	O
their	O
sero	O
-	O
conversion	O
to	O
avian	O
pathogens	O
.	O

Viral	O
inactivation	O
is	O
all	O
the	O
more	O
easy	O
when	O
there	O
is	O
an	O
envelope	B-PRGE
.	O

The	O
HE	B-PRGE
and	I-PRGE
S	I-PRGE
glycoproteins	I-PRGE
were	O
recognized	O
earliest	O
by	O
the	O
bovine	O
immune	O
system	O
while	O
the	O
N	O
protein	O
induced	O
antibody	O
responses	O
during	O
the	O
later	O
stage	O
of	O
initial	O
infection	O
and	O
the	O
early	O
stage	O
of	O
reinfection	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
hepatitis	B-PRGE
C	I-PRGE
virus	I-PRGE
NS3	I-PRGE
protease	I-PRGE
activity	O
by	O
product	O
-	O
based	O
peptides	O
is	O
dependent	O
on	O
helicase	B-PRGE
domain	I-PRGE
.	O

This	O
virus	O
encodes	O
spike	O
(	O
S	O
)	O
glycoproteins	O
that	O
are	O
extraordinarily	O
effective	O
mediators	O
of	O
intercellular	O
membrane	O
fusion	O
,	O
unique	O
in	O
their	O
ability	O
to	O
initiate	O
fusion	O
even	O
without	O
prior	O
interaction	O
with	O
the	O
primary	O
MHV	B-PRGE
receptor	I-PRGE
,	O
a	O
murine	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecule	O
(	O
CEACAM	O
).	O

In	O
mice	O
with	O
chronic	O
demyelination	O
,	O
10	O
to	O
15	O
%	O
of	O
the	O
CD4	B-PRGE
T	I-PRGE
cells	O
secreted	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
response	O
to	O
MHV	O
-	O
specific	O
peptides	O
.	O

Thus	O
,	O
these	O
results	O
show	O
that	O
infection	O
of	O
the	O
CNS	O
is	O
characterized	O
by	O
a	O
large	O
influx	O
of	O
CD4	B-PRGE
T	I-PRGE
cells	O
specific	O
for	O
MHV	O
and	O
that	O
these	O
cells	O
remain	O
functional	O
,	O
as	O
measured	O
by	O
cytokine	O
secretion	O
,	O
in	O
mice	O
with	O
chronic	O
demyelination	O
.	O

The	O
following	O
laboratory	O
parameters	O
were	O
abnormal	O
:	O
sedimentation	O
rate	O
64	O
/	O
70	O
mmHg	O
,	O
CD4	B-PRGE
+	I-PRGE
cells	O
462	O
/	O
ml	O
,	O
CD4	B-PRGE
/	O
CD8	B-PRGE
ratio	O
0	O
.	O
3	O
,	O
serum	O
CRP	B-PRGE
16	I-PRGE
mg	I-PRGE
/	I-PRGE
l	I-PRGE
,	O
antistreptolysin	O
titre	O
542	O
kU	O
/	O
l	O
,	O
complement	B-PRGE
C3	I-PRGE
<	O
0	O
.	O
1	O
g	O
/	O
l	O
,	O
GPT	O
37	O
U	O
/	O
l	O
,	O
albumin	B-PRGE
49	I-PRGE
.	I-PRGE
5	I-PRGE
%	I-PRGE
and	I-PRGE
gamma	I-PRGE
-	I-PRGE
globulin	I-PRGE
28	O
.	O
5	O
%,	O
in	O
urine	O
,	O
leukocytes	O
25	O
/	O
microliter	O
and	O
protein	O
0	O
.	O
25	O
g	O
/	O
l	O
.	O

TITLE	O
:	O
Mitochondrial	B-PRGE
aconitase	I-PRGE
binds	O
to	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
mouse	O
hepatitis	O
virus	O
genome	O
.	O

Antibody	O
raised	O
against	O
purified	O
mitochondrial	O
aconitase	O
recognizes	O
the	O
RNA	B-PRGE
-	I-PRGE
protein	I-PRGE
complex	I-PRGE
and	O
the	O
90	O
-	O
kDa	O
protein	O
,	O
which	O
can	O
be	O
released	O
from	O
the	O
complex	O
by	O
RNase	B-PRGE
digestion	O
.	O

Serum	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
were	O
assayed	O
at	O
1	O
and	O
4	O
hours	O
after	O
the	O
injury	O
stimuli	O
.	O

TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
did	O
not	O
change	O
after	O
any	O
injury	O
at	O
any	O
time	O
.	O

TITLE	O
:	O
Interferon	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
producing	O
cells	O
are	O
localized	O
in	O
gut	O
-	O
associated	O
lymphoid	O
tissues	O
in	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
infected	O
piglets	O
.	O

In	O
addition	O
,	O
double	O
staining	O
with	O
anti	O
-	O
TGEV	O
and	O
anti	B-PRGE
-	I-PRGE
IFN	I-PRGE
-	I-PRGE
alpha	I-PRGE
MAbs	I-PRGE
showed	O
that	O
viral	O
antigens	O
were	O
present	O
in	O
MLN	B-PRGE
,	O
close	O
to	O
IPC	O
.	O

Moreover	O
,	O
this	O
work	O
shows	O
that	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
released	O
in	O
serum	O
is	O
likely	O
to	O
originate	O
almost	O
exclusively	O
from	O
gut	O
IPC	O
triggered	O
locally	O
by	O
viral	O
antigens	O
to	O
produce	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
since	O
there	O
were	O
very	O
few	O
IPC	O
in	O
spleen	O
or	O
peripheral	O
lymph	O
nodes	O
.	O

The	O
high	O
prevalence	O
of	O
virus	O
specific	O
T	O
cells	O
correlates	O
with	O
ex	O
vivo	O
cytolytic	O
activity	O
,	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
secretion	O
and	O
efficient	O
reduction	O
in	O
virus	O
.	O

However	O
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
is	O
essential	O
for	O
controlling	O
virus	O
replication	O
in	O
oligodendrocytes	O
.	O

The	O
N	O
-	O
terminal	O
two	O
-	O
thirds	O
of	O
the	O
E	B-PRGE
protein	I-PRGE
is	O
hydrophobic	O
and	O
lies	O
buried	O
within	O
the	O
membrane	O
,	O
but	O
its	O
orientation	O
in	O
the	O
lipid	O
membrane	O
is	O
not	O
known	O
.	O

Mice	O
immunized	O
orally	O
with	O
a	O
Salmonella	O
vaccine	O
strain	O
which	O
expressed	O
chimeric	O
fimbriae	O
from	O
the	O
pagC	O
promoter	O
elicited	O
significantly	O
higher	O
mucosal	O
and	O
systemic	O
immune	O
responses	O
to	O
both	O
the	O
987P	O
fimbriae	O
and	O
the	O
TGEV	O
epitopes	O
than	O
mice	O
immunized	O
with	O
the	O
same	O
strain	O
hosting	O
a	O
tetA	B-PRGE
or	O
nirB	O
promoter	O
-	O
driven	O
expression	O
plasmid	O
.	O

However	O
,	O
successful	O
discontinuation	O
of	O
iNO	B-PRGE
therapy	O
was	O
achieved	O
by	O
combination	O
of	O
L	O
-	O
Arginine	O
and	O
dipyridamole	O
.	O

We	O
conclude	O
that	O
ARDS	O
can	O
be	O
safely	O
treated	O
with	O
plasminogen	B-PRGE
activator	I-PRGE
.	O

These	O
studies	O
suggest	O
that	O
hnRNP	O
A1	O
-	O
PTB	B-PRGE
interactions	O
provide	O
a	O
molecular	O
mechanism	O
for	O
potential	O
5	O
'-	O
3	O
'	O
cross	O
talks	O
in	O
MHV	O
RNA	O
,	O
which	O
may	O
be	O
important	O
for	O
RNA	O
replication	O
and	O
transcription	O
.	O

The	O
differences	O
in	O
the	O
decrease	O
in	O
the	O
feeding	O
pattern	O
between	O
the	O
SDA	O
viral	O
and	O
a	O
bacterial	O
infection	O
suggest	O
that	O
factors	O
other	O
than	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
alone	O
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
anorexia	O
during	O
a	O
viral	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
effects	O
of	O
infusion	O
of	O
atrial	B-PRGE
natriuretic	I-PRGE
peptide	I-PRGE
(	O
ANP	B-PRGE
)	O
versus	O
the	O
inhalation	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
in	O
patients	O
with	O
an	O
early	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

This	O
study	O
shows	O
that	O
,	O
in	O
contrast	O
to	O
NO	O
inhalation	O
,	O
infusion	O
of	O
ANP	B-PRGE
neither	O
improves	O
oxygenation	O
nor	O
attenuates	O
pulmonary	O
hypertension	O
or	O
pulmonary	O
edema	O
in	O
patients	O
with	O
severe	O
ARDS	O
.	O

Four	O
factors	O
independently	O
predicted	O
mortality	O
:	O
a	O
time	O
from	O
symptom	O
onset	O
to	O
treatment	O
of	O
more	O
than	O
1	O
month	O
(	O
OR	O
,	O
3	O
.	O
49	O
;	O
CI	O
,	O
1	O
.	O
20	O
-	O
10	O
.	O
20	O
),	O
the	O
number	O
of	O
organ	O
failures	O
(	O
OR	O
,	O
3	O
.	O
15	O
;	O
CI	O
,	O
1	O
.	O
76	O
-	O
5	O
.	O
76	O
),	O
a	O
serum	O
albumin	B-PRGE
level	O
above	O
20	O
g	O
/	O
l	O
(	O
OR	O
,	O
3	O
.	O
96	O
;	O
CI	O
,	O
1	O
.	O
04	O
-	O
15	O
.	O
10	O
),	O
and	O
a	O
larger	O
number	O
of	O
lobes	O
involved	O
on	O
chest	O
radiograph	O
(	O
OR	O
,	O
1	O
.	O
83	O
;	O
CI	O
,	O
1	O
.	O
12	O
-	O
2	O
.	O
98	O
).	O

Analysis	O
of	O
the	O
S1	O
portion	O
of	O
the	O
S	B-PRGE
glycoprotein	I-PRGE
revealed	O
a	O
total	O
of	O
eight	O
aa	O
changes	O
specific	O
to	O
enteropathogenic	O
(	O
EBCoV	O
)	O
strains	O
and	O
eight	O
aa	O
changes	O
specific	O
to	O
RBCoV	O
strains	O
.	O

The	O
IgA	B-PRGE
antibody	I-PRGE
response	O
in	O
serum	O
was	O
detected	O
up	O
to	O
17	O
months	O
post	O
-	O
infection	O
and	O
the	O
duration	O
showed	O
an	O
age	O
-	O
related	O
variation	O
indicating	O
a	O
more	O
prominent	O
IgA	B-PRGE
memory	O
in	O
the	O
adult	O
cattle	O
and	O
in	O
the	O
older	O
calves	O
than	O
in	O
the	O
younger	O
ones	O
.	O

To	O
this	O
end	O
,	O
an	O
expression	O
cassette	O
consisting	O
of	O
the	O
gene	O
for	O
a	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
GFP	O
)	O
flanked	O
at	O
its	O
3	O
'	O
end	O
by	O
EAV	O
-	O
specific	O
transcription	O
-	O
regulating	O
sequences	O
was	O
constructed	O
.	O

Mapping	O
of	O
the	O
leader	O
-	O
to	O
-	O
body	O
junctions	O
of	O
the	O
ninth	O
mRNA	O
indicated	O
that	O
the	O
3	O
'	O
part	O
of	O
the	O
GFP	B-PRGE
gene	I-PRGE
contains	O
cryptic	O
transcription	O
signals	O
which	O
gave	O
rise	O
to	O
at	O
least	O
five	O
different	O
RNA	O
species	O
ranging	O
in	O
size	O
from	O
1277	O
to	O
1439	O
nt	O
[	O
without	O
oligo	O
(	O
A	O
)	O
tract	O
].	O

Caspase	B-PRGE
-	O
dependent	O
apoptosis	O
,	O
as	O
characterized	O
by	O
chromosomal	O
condensation	O
,	O
DNA	O
fragmentation	O
,	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
activation	O
,	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
degradation	O
,	O
was	O
detected	O
in	O
IBV	O
-	O
infected	O
Vero	O
cells	O
.	O

TITLE	O
:	O
Study	O
of	O
protection	O
by	O
recombinant	B-PRGE
fowl	I-PRGE
poxvirus	I-PRGE
expressing	I-PRGE
C	I-PRGE
-	I-PRGE
terminal	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
of	O
infectious	O
bronchitis	O
virus	O
against	O
challenge	O
.	O

The	O
N	B-PRGE
protein	I-PRGE
was	O
expressed	O
under	O
control	O
of	O
the	O
vaccinia	B-PRGE
virus	I-PRGE
promoter	I-PRGE
P7	I-PRGE
.	I-PRGE
5	I-PRGE
in	I-PRGE
chicken	I-PRGE
embryo	O
fibroblast	O
cell	O
cultures	O
as	O
seen	O
in	O
immunofluorescence	O
assay	O
and	O
in	O
rFPV	O
-	O
inoculated	O
specific	O
-	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
by	O
detecting	O
antibodies	O
with	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

An	O
IBV	O
monoclonal	O
antibody	O
neutralization	O
-	O
resistant	O
mutant	O
(	O
NR	O
18	O
)	O
had	O
an	O
unusual	O
substitution	O
of	O
Ile	O
for	O
Arg	O
at	O
the	O
fourth	O
position	O
,	O
giving	O
the	O
sequence	O
Arg	O
-	O
Arg	O
-	O
Ser	O
-	O
Ile	O
-	O
Arg	O
,	O
which	O
likely	O
prevents	O
cleavage	O
and	O
,	O
thus	O
,	O
destroys	O
the	O
conformationally	O
dependent	O
monoclonal	B-PRGE
antibody	I-PRGE
binding	I-PRGE
epitope	I-PRGE
.	O

4	O
.	O
06	O
In	O
NICU	O
-	O
patients	O
,	O
on	O
the	O
other	O
hand	O
,	O
CPK	B-PRGE
was	O
14273	O
+/-	O

Second	O
,	O
in	O
vitro	O
synthesized	O
proteins	O
representing	O
different	O
parts	O
of	O
pp1a	B-PRGE
were	O
autocatalytically	O
processed	O
at	O
the	O
predicted	O
site	O
.	O

Surprisingly	O
,	O
both	O
PL1pro	O
and	O
PL2pro	O
cleaved	O
between	O
p87	B-PRGE
and	O
p195	B-PRGE
/	O
p210	B-PRGE
.	O

Collectively	O
,	O
our	O
results	O
imply	O
that	O
the	O
p195	B-PRGE
/	O
p210	B-PRGE
autoprocessing	O
mechanisms	O
may	O
be	O
conserved	O
among	O
coronaviruses	O
to	O
an	O
extent	O
not	O
appreciated	O
previously	O
,	O
with	O
PL2pro	O
playing	O
a	O
major	O
role	O
.	O

Each	O
virus	O
vigorously	O
induced	O
an	O
NK	O
cell	O
infiltrate	O
into	O
the	O
peritoneal	O
cavity	O
and	O
liver	O
,	O
causing	O
some	O
redistributions	O
of	O
NK	O
cell	O
subsets	O
defined	O
by	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
directed	O
against	O
Ly49A	B-PRGE
,	O
C	O
/	O
I	O
,	O
D	O
,	O
and	O
G2	O
.	O

One	O
specific	O
site	O
on	O
the	O
S	B-PRGE
glycoprotein	I-PRGE
of	O
bovine	O
coronavirus	O
must	O
be	O
cleaved	O
by	O
an	O
intracellular	O
protease	O
or	O
trypsin	B-PRGE
to	O
activate	O
viral	O
infectivity	O
and	O
cell	O
fusion	O
.	O

Reactive	O
immunoglobulins	O
pertained	O
to	O
the	O
IgG1	B-PRGE
,	O
IgG2a	B-PRGE
and	O
IgG2b	B-PRGE
subclasses	O
,	O
recognized	O
cryptic	O
epitopes	O
and	O
were	O
detected	O
from	O
10	O
days	O
up	O
to	O
8	O
weeks	O
after	O
MHV	O
-	O
infection	O
.	O

Impaired	O
ex	O
vivo	O
cytolytic	O
activity	O
of	O
muMT	O
CNS	O
mononuclear	O
cells	O
,	O
concomitant	O
with	O
reduced	O
frequencies	O
,	O
implicated	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
as	O
the	O
primary	O
anti	O
viral	O
factor	O
early	O
in	O
infection	O
.	O

To	O
design	O
type	O
-	O
specific	O
primers	O
for	O
our	O
assay	O
,	O
we	O
sequenced	O
the	O
Ad21	B-PRGE
hexon	I-PRGE
gene	I-PRGE
and	O
compared	O
this	O
sequence	O
with	O
previously	O
published	O
sequences	O
of	O
Ad3	O
,	O
Ad7	O
,	O
and	O
Ad16	O
.	O

Antibodies	O
to	O
CCV	O
and	O
,	O
at	O
high	O
levels	O
,	O
to	O
CAV	B-PRGE
-	I-PRGE
1	I-PRGE
also	O
were	O
detected	O
in	O
several	O
puppies	O
.	O

ACE	B-PRGE
inhibitors	O
certainly	O
do	O
not	O
mediate	O
angioedema	O
through	O
an	O
allergic	O
or	O
idiosyncratic	O
reaction	O
.	O

Estrogen	O
and	O
ACE	B-PRGE
inhibitors	O
should	O
be	O
avoided	O
in	O
a	O
patient	O
with	O
congenital	O
or	O
acquired	O
C1	O
-	O
INH	O
deficiency	O
.	O

The	O
analytic	O
sensitivity	O
of	O
these	O
original	O
primers	O
were	O
compared	O
with	O
primers	O
defined	O
in	O
the	O
N	B-PRGE
gene	I-PRGE
and	O
described	O
previously	O
.	O

Recent	O
work	O
has	O
shown	O
that	O
either	O
virus	O
-	O
specific	O
CD4	B-PRGE
(+)	O
or	O
CD8	B-PRGE
(+)	O
T	O
cells	O
are	O
able	O
to	O
mediate	O
demyelination	O
and	O
also	O
that	O
the	O
antibody	O
response	O
is	O
crucial	O
for	O
clearing	O
infectious	O
virus	O
.	O

TITLE	O
:	O
Fas	B-PRGE
/	O
Fas	B-PRGE
ligand	O
system	O
mediates	O
epithelial	O
injury	O
,	O
but	O
not	O
pulmonary	O
host	O
defenses	O
,	O
in	O
response	O
to	O
inhaled	O
bacteria	O
.	O

TITLE	O
:	O
Genomic	O
and	O
antigenic	O
variations	O
of	O
the	O
HE	B-PRGE
glycoprotein	I-PRGE
of	O
bovine	O
coronaviruses	O
associated	O
with	O
neonatal	O
calf	O
diarrhea	O
and	O
winter	O
dysentery	O
.	O

Attempts	O
to	O
define	O
sequence	O
differences	O
in	O
the	O
HE	O
genes	O
of	O
the	O
WD	O
and	O
NCD	O
strains	O
revealed	O
high	O
nucleotide	O
(	O
NT	O
)	O
identities	O
with	O
only	O
scattered	O
amino	O
acid	O
differences	O
,	O
seemingly	O
unrelated	O
to	O
the	O
clinical	O
origin	O
of	O
the	O
isolates	O
or	O
HAI	B-PRGE
MAb	I-PRGE
reactivities	O
.	O

A	O
multivariate	O
analysis	O
individualized	O
Paco2	O
level	O
as	O
the	O
sole	O
factor	O
independently	O
associated	O
with	O
ACP	B-PRGE
,	O
suggesting	O
that	O
ACP	B-PRGE
development	O
in	O
ARDS	O
is	O
influenced	O
by	O
the	O
severity	O
of	O
lung	O
damage	O
and	O
/	O
or	O
the	O
respiratory	O
strategy	O
.	O

Concomitantly	O
,	O
pulmonary	O
shunt	O
fraction	O
,	O
alveolar	O
-	O
arterial	O
oxygen	O
tension	O
difference	O
[	O
P	O
(	O
a	O
-	O
a	O
)	O
o2	O
]/	O
Pao2	B-PRGE
,	O
and	O
cardiac	O
index	O
increased	O
as	O
well	O
,	O
whereas	O
pulmonary	O
vascular	O
resistance	O
and	O
Pao2	B-PRGE
/	O
Fio2	O
declined	O
.	O

ABSTRACT	O
:	O
Organophosphate	O
(	O
OP	O
)	O
insecticides	O
inhibit	O
both	O
cholinesterase	B-PRGE
and	O
pseudo	B-PRGE
-	I-PRGE
cholinesterase	I-PRGE
activities	O
.	O

Four	O
PCR	O
assays	O
with	O
primers	O
specific	O
for	O
N	B-PRGE
-	I-PRGE
protein	I-PRGE
of	O
human	O
coronavirus	O
strain	O
229E	O
and	O
three	O
PCR	O
assays	O
with	O
primers	O
specific	O
for	O
the	O
nucleocapsid	O
protein	O
of	O
human	O
coronavirus	O
strain	O
OC43	O
were	O
performed	O
.	O

Furthermore	O
,	O
our	O
data	O
suggested	O
that	O
this	O
leader	O
switching	O
,	O
a	O
type	O
of	O
homologous	O
RNA	B-PRGE
-	I-PRGE
RNA	I-PRGE
recombination	O
,	O
occurred	O
during	O
positive	O
-	O
strand	O
DI	O
RNA	O
synthesis	O
and	O
that	O
MHV	O
positive	O
-	O
strand	O
RNA	O
synthesis	O
mechanism	O
may	O
have	O
a	O
preference	O
toward	O
recognizing	O
double	O
-	O
stranded	O
RNA	O
structures	O
over	O
single	O
-	O
stranded	O
negative	O
-	O
strand	O
RNA	O
to	O
produce	O
positive	O
-	O
strand	O
DI	O
RNAs	O
.	O

Regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
the	O
packaging	O
signal	O
,	O
N	B-PRGE
protein	I-PRGE
bound	O
to	O
MHV	O
defective	O
interfering	O
RNAs	O
and	O
intracellularly	O
expressed	O
non	O
-	O
MHV	O
RNA	O
transcripts	O
to	O
form	O
ribonucleoprotein	O
complexes	O
;	O
M	B-PRGE
protein	I-PRGE
,	O
however	O
,	O
interacted	O
selectively	O
with	O
RNAs	O
containing	O
the	O
packaging	O
signal	O
.	O

In	O
addition	O
,	O
infected	O
CCR5	O
(-/-)	O
mice	O
exhibited	O
reduced	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
02	O
)	O
macrophage	O
(	O
CD45	B-PRGE
(	O
high	O
)	O
F4	O
/	O
80	O
(+))	O
infiltration	O
,	O
which	O
correlated	O
with	O
a	O
significant	O
reduction	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
in	O
the	O
severity	O
of	O
demyelination	O
compared	O
to	O
CCR5	B-PRGE
(+/+)	I-PRGE
mice	O
.	O

A	O
therapeutic	O
approach	O
with	O
intravenous	O
immunoglobulins	O
(	O
IVIG	O
)	O
associated	O
with	O
pulse	O
methylprednisolone	O
,	O
based	O
on	O
the	O
inhibition	O
of	O
Fas	B-PRGE
-	O
mediated	O
keratinocyte	O
death	O
by	O
naturally	O
occurring	O
Fas	B-PRGE
-	I-PRGE
blocking	I-PRGE
antibodies	I-PRGE
included	O
in	O
human	B-PRGE
immunoglobulin	I-PRGE
preparations	O
,	O
has	O
produced	O
good	O
preliminary	O
results	O
.	O

CONCLUSIONS	O
:	O
IVIG	O
therapy	O
represents	O
a	O
safe	O
and	O
valid	O
approach	O
for	O
TEN	B-PRGE
.	O

Previous	O
studies	O
have	O
shown	O
that	O
during	O
the	O
acute	O
phase	O
of	O
infection	O
,	O
T	O
lymphocytes	O
are	O
recruited	O
into	O
the	O
CNS	O
by	O
the	O
chemokines	O
CXCL10	B-PRGE
and	O
CXCL9	B-PRGE
.	O

To	O
further	O
investigate	O
the	O
site	O
of	O
demyelination	O
and	O
hepatitis	O
determinants	O
within	O
the	O
S	B-PRGE
gene	I-PRGE
,	O
we	O
sequenced	O
the	O
S	B-PRGE
gene	I-PRGE
of	O
several	O
nondemyelinating	O
recombinant	O
viruses	O
.	O

ARF	B-PRGE
necessitating	O
dialysis	O
was	O
seen	O
in	O
92	O
%	O
of	O
patients	O
with	O
ARF	O
in	O
malaria	O
.	O

A	O
complementary	O
DNA	O
of	O
the	O
entire	O
N	B-PRGE
gene	I-PRGE
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
,	O
and	O
inserted	O
into	O
a	O
mammalian	O
expression	O
vector	O
(	O
pcDNA3	O
.	O
1	O
)	O
to	O
construct	O
a	O
recombinant	O
plasmid	O
(	O
pcDNA	O
/	O
N	O
).	O

To	O
further	O
study	O
the	O
mechanism	O
of	O
neutralisation	O
,	O
Fab	B-PRGE
fragments	I-PRGE
as	O
well	O
as	O
a	O
series	O
of	O
recombinant	O
bacterial	O
single	O
chain	O
antibody	O
(	O
scAb	B-PRGE
)	O
fragments	O
were	O
generated	O
from	O
the	O
three	O
anti	O
-	O
VHSV	O
Mabs	O
and	O
their	O
variable	O
domain	O
genes	O
,	O
respectively	O
.	O

Using	O
this	O
approach	O
,	O
a	O
recombinant	O
MHV	O
-	O
JHM	O
was	O
constructed	O
in	O
which	O
gene	B-PRGE
4	I-PRGE
was	O
genetically	O
inactivated	O
.	O

Cores	O
purified	O
from	O
glycosidase	O
-	O
treated	O
virions	O
included	O
M	O
protein	O
molecules	O
that	O
completely	O
or	O
partially	O
lost	O
the	O
carbohydrate	O
moiety	O
,	O
which	O
strongly	O
suggests	O
that	O
the	O
M	B-PRGE
protein	I-PRGE
found	O
in	O
the	O
cores	O
was	O
also	O
exposed	O
in	O
the	O
virus	O
envelope	O
and	O
was	O
not	O
present	O
exclusively	O
in	O
the	O
virus	O
interior	O
.	O

It	O
reduced	O
pulmonary	B-PRGE
myeloperoxidase	I-PRGE
activity	O
and	O
peripheral	O
neutropenia	O
and	O
increased	O
neutrophil	O
respiratory	O
burst	O
activity	O
.	O

The	O
ORF1a	B-PRGE
and	I-PRGE
ORF1b	I-PRGE
sequences	I-PRGE
overlapped	O
at	O
a	O
potential	O
ribosomal	O
frame	O
shift	O
site	O
.	O

TITLE	O
:	O
Recovery	O
from	O
mouse	O
hepatitis	O
virus	O
infection	O
depends	O
on	O
recruitment	O
of	O
CD8	B-PRGE
(+)	O
cells	O
rather	O
than	O
activation	O
of	O
intrahepatic	O
CD4	B-PRGE
(+)	I-PRGE
alphabeta	I-PRGE
(-)	I-PRGE
TCR	B-PRGE
(	O
inter	O
)	O
or	O
NK	O
-	O
T	O
cells	O
.	O

Antibody	O
levels	O
to	O
SRBC	B-PRGE
were	O
higher	O
in	O
birds	O
supplemented	O
with	O
50	O
IU	O
of	O
VE	O
/	O
kg	O
compared	O
to	O
those	O
supplemented	O
with	O
0	O
or	O
200	O
IU	O
/	O
kg	O
of	O
VE	O
.	O

Immunohistochemistry	O
for	O
VEGFA	O
(	O
165	O
),	O
an	O
endothelial	O
cell	O
mitogen	O
,	O
and	O
its	O
receptor	O
Flt	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
was	O
performed	O
on	O
lung	O
tissues	O
from	O
autopsies	O
from	O
four	O
fetuses	O
,	O
three	O
preterm	O
infants	O
,	O
four	O
term	O
infants	O
without	O
primary	O
lung	O
disease	O
,	O
four	O
infants	O
with	O
BPD	O
,	O
and	O
four	O
infants	O
with	O
PPHN	O
.	O

Immunohistochemistry	O
for	O
VEGF	B-PRGE
and	O
Flt	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
similar	O
in	O
fetuses	O
,	O
preterm	O
infants	O
,	O
and	O
term	O
infants	O
:	O
for	O
VEGF	B-PRGE
mostly	O
in	O
bronchial	O
epithelium	O
and	O
alveolar	O
macrophages	O
,	O
and	O
for	O
Flt	B-PRGE
-	I-PRGE
1	I-PRGE
mostly	O
in	O
vascular	O
endothelial	O
cells	O
and	O
bronchial	O
epithelial	O
cells	O
.	O

In	O
patients	O
with	O
BPD	O
,	O
and	O
PPHN	O
,	O
staining	O
for	O
VEGF	B-PRGE
and	O
Flt	B-PRGE
-	I-PRGE
1	I-PRGE
appeared	O
also	O
in	O
Type	O
II	O
pneumocytes	O
.	O

Concomitantly	O
,	O
surfactant	O
proteins	O
and	O
Clara	B-PRGE
cell	I-PRGE
secretory	I-PRGE
protein	I-PRGE
mRNA	I-PRGE
expression	O
decreased	O
.	O

Stool	O
and	O
serum	O
samples	O
were	O
analysed	O
for	O
RV	O
and	O
bovine	B-PRGE
CV	I-PRGE
antigen	I-PRGE
and	O
antibody	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

We	O
conclude	O
that	O
the	O
binding	O
of	O
soMHVR	O
to	O
the	O
S	B-PRGE
protein	I-PRGE
converts	O
the	O
S	B-PRGE
protein	I-PRGE
to	O
a	O
fusion	O
-	O
active	O
form	O
competent	O
to	O
mediate	O
cell	O
-	O
cell	O
fusion	O
,	O
in	O
a	O
fashion	O
similar	O
to	O
the	O
fusion	O
of	O
virus	O
and	O
cell	O
membranes	O
.	O

BHK	O
cells	O
were	O
either	O
cotransfected	O
with	O
TGEV	B-PRGE
-	I-PRGE
Rep	I-PRGE
(	O
AvrII	O
)	O
(	O
E	O
gene	O
deletion	O
)	O
and	O
VEE	B-PRGE
-	I-PRGE
TGEV	I-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
RNA	I-PRGE
transcripts	I-PRGE
or	O
transfected	O
with	O
TGEV	B-PRGE
-	I-PRGE
Rep	I-PRGE
(	O
AvrII	O
)	O
RNA	O
transcripts	O
and	O
subsequently	O
infected	O
with	O
VEE	O
VRPs	O
carrying	O
the	O
TGEV	B-PRGE
E	I-PRGE
gene	I-PRGE
.	O

Special	O
questionnaires	O
were	O
sent	O
out	O
to	O
all	O
hospitals	O
with	O
dialysis	O
units	O
known	O
to	O
have	O
admitted	O
earthquake	O
victims	O
with	O
ARF	B-PRGE
and	O
related	O
crush	O
injuries	O
.	O

The	O
TOCVs	O
also	O
cross	O
-	O
reacted	O
in	O
an	O
AC	O
-	O
ELISA	O
with	O
MAbs	O
against	O
the	O
M	B-PRGE
and	I-PRGE
subunit	I-PRGE
2	I-PRGE
of	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
of	O
IBV	O
.	O

TITLE	O
:	O
Chicken	O
interferon	B-PRGE
type	I-PRGE
I	I-PRGE
inhibits	O
infectious	O
bronchitis	O
virus	O
replication	O
and	O
associated	O
respiratory	O
illness	O
.	O

This	O
case	O
is	O
characteristic	O
for	O
acute	O
intoxications	O
with	O
irreversible	O
acetylcholinesterase	B-PRGE
inhibitors	O
,	O
such	O
as	O
organophosphate	O
compounds	O
.	O

However	O
,	O
all	O
calves	O
challenged	O
with	O
heterologous	O
BCV	O
strains	O
showed	O
subclinical	O
BCV	O
infection	O
evident	O
by	O
detection	O
of	O
nasal	O
and	O
fecal	O
shedding	O
of	O
BCV	B-PRGE
RNA	I-PRGE
detected	O
only	O
by	O
nested	O
PCR	O
.	O

TITLE	O
:	O
Regulated	O
and	O
prolonged	O
expression	O
of	O
mIFN	B-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
in	O
immunocompetent	O
mice	O
mediated	O
by	O
a	O
helper	O
-	O
dependent	O
adenovirus	O
vector	O
.	O

Transcriptional	O
activation	O
of	O
mIFN	B-PRGE
(	I-PRGE
alpha	I-PRGE
)	I-PRGE
induced	O
by	O
doxycycline	O
resulted	O
in	O
prolonged	O
survival	O
and	O
reduced	O
liver	O
damage	O
in	O
HD	O
-	O
TET	B-PRGE
-	O
IFN	B-PRGE
-	O
injected	O
mice	O
challenged	O
with	O
a	O
lethal	O
dose	O
of	O
coronavirus	O
.	O

Similar	O
numbers	O
of	O
lymphocytes	O
were	O
present	O
in	O
the	O
CNS	O
of	O
recipients	O
of	O
either	O
C57BL	O
/	O
6	O
or	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
(-/-)	O
CD8	B-PRGE
T	O
cells	O
,	O
suggesting	O
that	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
was	O
not	O
crucial	O
for	O
lymphocyte	O
entry	O
into	O
the	O
CNS	O
.	O

GUS	B-PRGE
expression	O
levels	O
increased	O
about	O
eightfold	O
with	O
the	O
m	O
.	O
o	O
.	O
i	O
.	O
and	O
were	O
maintained	O
for	O
more	O
than	O
eight	O
passages	O
in	O
cell	O
culture	O
.	O

Comparative	O
sequence	O
analyses	O
revealed	O
that	O
FIPV	O
3CL	O
(	O
pro	B-PRGE
)	O
and	O
other	O
coronavirus	O
main	O
proteases	O
are	O
related	O
most	O
closely	O
to	O
the	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
proteases	I-PRGE
of	O
potyviruses	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
human	B-PRGE
coronavirus	I-PRGE
(	O
HCoV	O
)	O
3CL	O
(	O
pro	O
)	O
mutants	O
in	O
which	O
the	O
equivalent	O
Asn	O
residue	O
(	O
HCoV	O
3CL	O
(	O
pro	O
)	O
Asn	O
(	O
64	O
))	O
was	O
substituted	O
.	O

High	O
serum	O
levels	O
of	O
soluble	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
human	B-PRGE
interleukin	I-PRGE
-	I-PRGE
10	I-PRGE
and	O
macrophage	B-PRGE
-	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
were	O
observed	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
nitric	B-PRGE
oxide	I-PRGE
synthase	I-PRGE
type	O
-	O
2	O
(	O
NOS2	B-PRGE
)-	O
derived	O
nitric	O
oxide	O
(	O
NO	O
)	O
in	O
the	O
pathogenesis	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)-	O
induced	O
central	O
nervous	O
system	O
disease	O
was	O
examined	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
adenovectors	O
could	O
efficiently	O
transduce	O
injured	O
alveoli	O
by	O
exposing	O
adult	O
,	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
to	O
100	O
%	O
oxygen	O
for	O
48	O
or	O
60	O
h	O
before	O
endotracheal	O
instillation	O
of	O
either	O
1	O
x	O
10	O
(	O
9	O
)	O
or	O
4	O
x	O
10	O
(	O
9	O
)	O
plaque	O
-	O
forming	O
units	O
of	O
an	O
adenovirus	O
that	O
expresses	O
an	O
Escherichia	O
coli	O
lac	O
Z	B-PRGE
gene	I-PRGE
(	O
adbeta	B-PRGE
-	I-PRGE
gal	I-PRGE
)	O
in	O
a	O
surfactant	O
-	O
based	O
vehicle	O
(	O
Survanta	O
).	O

TITLE	O
:	O
The	O
spike	O
but	O
not	O
the	O
hemagglutinin	O
/	O
esterase	B-PRGE
protein	O
of	O
bovine	O
coronavirus	O
is	O
necessary	O
and	O
sufficient	O
for	O
viral	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
and	O
hemagglutinin	O
/	O
esterase	B-PRGE
(	O
HE	O
)	O
of	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
are	O
the	O
two	O
envelope	O
proteins	O
that	O
recognize	O
the	O
same	O
receptor	O
-	O
determinant	O
of	O
9	O
-	O
O	O
-	O
acetylneuraminic	O
acid	O
on	O
host	O
cells	O
.	O

To	O
unequivocally	O
determine	O
their	O
roles	O
in	O
viral	O
cytopathogenicity	O
,	O
we	O
developed	O
a	O
system	O
in	O
which	O
phenotypically	O
chimeric	O
viruses	O
were	O
generated	O
by	O
infecting	O
a	O
closely	O
related	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
in	O
cells	O
that	O
stably	O
express	O
an	O
individual	O
BCV	B-PRGE
protein	I-PRGE
(	O
S	O
or	O
HE	O
).	O

Vascular	O
immunotargeting	O
of	O
the	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)-	O
generating	O
enzyme	O
glucose	B-PRGE
oxidase	I-PRGE
(	O
GOX	B-PRGE
)	O
to	O
the	O
pulmonary	O
endothelium	O
causes	O
an	O
acute	O
oxidative	O
lung	O
injury	O
in	O
mice	O
.(	O
1	O
)	O
In	O
the	O
present	O
study	O
we	O
compared	O
the	O
pulmonary	O
thrombosis	O
and	O
leukocyte	O
transmigration	O
caused	O
by	O
GOX	O
targeting	O
to	O
the	O
endothelial	B-PRGE
antigens	I-PRGE
platelet	I-PRGE
-	I-PRGE
endothelial	I-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
(	O
PECAM	B-PRGE
)	O
and	O
thrombomodulin	B-PRGE
(	O
TM	O
).	O

Both	O
anti	B-PRGE
-	I-PRGE
PECAM	I-PRGE
and	O
anti	O
-	O
TM	O
delivered	O
similar	O
amounts	O
of	O
(	O
125	O
)	O
I	O
-	O
GOX	O
to	O
the	O
lungs	O
and	O
caused	O
a	O
dose	O
-	O
dependent	O
,	O
tissue	O
-	O
selective	O
lung	O
injury	O
manifested	O
within	O
2	O
to	O
4	O
hours	O
by	O
high	O
lethality	O
,	O
vascular	O
congestion	O
,	O
polymorphonuclear	O
neutrophil	O
(	O
PMN	O
)	O
sequestration	O
in	O
the	O
pulmonary	O
vasculature	O
,	O
severe	O
pulmonary	O
edema	O
,	O
and	O
tissue	O
oxidation	O
,	O
yet	O
at	O
an	O
equal	O
dose	O
,	O
anti	O
-	O
TM	O
/	O
GOX	O
inflicted	O
more	O
severe	O
lung	O
injury	O
than	O
anti	O
-	O
PECAM	O
/	O
GOX	O
.	O

Anti	B-PRGE
-	I-PRGE
TM	I-PRGE
/	I-PRGE
GOX	I-PRGE
caused	O
markedly	O
more	O
severe	O
pulmonary	O
thrombosis	O
than	O
anti	B-PRGE
-	I-PRGE
PECAM	I-PRGE
/	I-PRGE
GOX	I-PRGE
,	O
likely	O
because	O
of	O
TM	O
inhibition	O
.	O

We	O
conclude	O
from	O
these	O
data	O
that	O
the	O
DMVs	O
carry	O
the	O
MHV	B-PRGE
RNA	I-PRGE
replication	I-PRGE
complex	I-PRGE
and	O
are	O
the	O
site	O
of	O
MHV	B-PRGE
RNA	I-PRGE
synthesis	O
.	O

iNO	O
had	O
no	O
adverse	O
effects	O
on	O
surfactant	O
phospholipids	O
and	O
lung	O
fluid	O
balance	O
,	O
but	O
attenuated	O
expression	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
,	O
beta2	B-PRGE
integrin	I-PRGE
CD11b	I-PRGE
,	O
and	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
mRNA	I-PRGE
in	O
the	O
lungs	O
by	O
22	O
%,	O
44	O
%,	O
and	O
25	O
%,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Sorbent	O
columns	O
of	O
charcoal	O
and	O
an	O
anion	O
exchanger	O
remove	O
hepatic	O
toxins	O
from	O
the	O
albumin	B-PRGE
dialysate	O
,	O
and	O
a	O
second	O
dialyzer	O
removes	O
water	O
-	O
soluble	O
toxins	O
,	O
such	O
as	O
ammonium	O
.	O

2	O
.	O
ExPLIs	O
markedly	O
inhibited	O
LPS	O
and	O
LTA	O
induced	O
production	O
and	O
mRNA	O
expression	O
of	O
the	O
neutrophile	O
attracting	O
chemokines	O
IL	O
-	O
8	O
,	O
Gro	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
ENA	B-PRGE
-	I-PRGE
78	I-PRGE
,	O
as	O
well	O
as	O
of	O
the	O
adhesion	O
molecules	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
.	O

Results	O
of	O
mutagenesis	O
and	O
in	O
vitro	O
cleavage	O
assays	O
show	O
that	O
PLP	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
able	O
to	O
cleave	O
in	O
trans	O
when	O
the	O
proposed	O
p50	O
cleavage	O
sequence	O
replaced	O
the	O
p28	B-PRGE
cleavage	O
sequence	O
.	O

Analysis	O
of	O
multiple	O
second	O
-	O
site	O
revertants	O
of	O
the	O
M	B-PRGE
(	I-PRGE
Delta	I-PRGE
)	I-PRGE
2	I-PRGE
mutant	I-PRGE
has	O
revealed	O
changes	O
in	O
regions	O
of	O
both	O
the	O
M	B-PRGE
protein	I-PRGE
and	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
that	O
can	O
compensate	O
for	O
the	O
loss	O
of	O
the	O
last	O
two	O
residues	O
of	O
the	O
M	B-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
murine	O
sCEACAM1a	O
[	O
1	O
,	O
4	O
]:	O
a	O
coronavirus	O
receptor	O
in	O
the	O
CEA	B-PRGE
family	I-PRGE
.	O

ABSTRACT	O
:	O
CEACAM1	B-PRGE
is	O
a	O
member	O
of	O
the	O
carcinoembryonic	B-PRGE
antigen	I-PRGE
(	O
CEA	B-PRGE
)	O
family	O
.	O

Furthermore	O
,	O
the	O
upstream	O
kinase	O
responsible	O
for	O
eIF4E	B-PRGE
phosphorylation	O
,	O
MAPK	B-PRGE
-	I-PRGE
interacting	I-PRGE
kinase	I-PRGE
1	I-PRGE
,	O
was	O
also	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
MHV	O
infection	O
.	O

MHV	O
utilized	O
this	O
p38	B-PRGE
MAPK	O
-	O
dependent	O
increase	O
in	O
eIF4E	B-PRGE
phosphorylation	O
to	O
promote	O
virus	O
-	O
specific	O
protein	O
synthesis	O
and	O
subsequent	O
progeny	O
virus	O
production	O
.	O

(	O
i	O
)	O
Binding	O
to	O
porcine	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
(	O
pAPN	O
)	O
is	O
essential	O
for	O
the	O
initiation	O
of	O
infection	O
.	O

Srr7A	O
and	O
srr7B	O
S	O
proteins	O
showed	O
high	O
fusogenicity	O
in	O
both	O
BHK	O
-	O
R1	O
and	O
BHK	O
-	O
R2	O
cells	O
,	O
like	O
the	O
wt	O
virus	O
,	O
while	O
srr7Aa	O
and	O
srr7Ba	O
S	O
proteins	O
,	O
which	O
had	O
mutations	O
in	O
S1N330	B-PRGE
-	I-PRGE
III	I-PRGE
but	O
not	O
at	O
amino	O
acid	O
1114	O
,	O
exhibited	O
profoundly	O
reduced	O
fusion	O
activity	O
in	O
these	O
cell	O
lines	O
.	O

A	O
breed	O
x	O
time	O
interaction	O
existed	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
for	O
plasma	B-PRGE
prolactin	I-PRGE
,	O
LH	O
,	O
insulin	B-PRGE
,	O
glucagon	B-PRGE
,	O
cortisol	O
,	O
triiodothyronine	O
and	O
glucose	O
concentrations	O
.	O

Both	O
breeds	O
responded	O
to	O
ergotamine	O
with	O
increased	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
plasma	O
cortisol	O
,	O
glucagon	B-PRGE
,	O
and	O
glucose	O
and	O
reduced	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
insulin	B-PRGE
concentrations	O
.	O

The	O
individual	O
SNAP	O
items	O
that	O
contributed	O
most	O
to	O
SNAP	B-PRGE
moderate	O
and	O
severe	O
categories	O
were	O
blood	O
gas	O
items	O
,	O
creatinine	O
,	O
urine	O
output	O
,	O
blood	O
glucose	O
,	O
and	O
seizures	O
.	O

The	O
best	O
predictors	O
were	O
LOV	O
for	O
LOS	O
,	O
and	O
a	O
combination	O
of	O
SNAP	B-PRGE
and	O
the	O
reason	O
for	O
ventilation	O
for	O
LOV	O
.	O

ABSTRACT	O
:	O
The	O
early	O
cytokines	B-PRGE
interferon	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
),	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
),	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
,	I-PRGE
-	I-PRGE
6	I-PRGE
and	I-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
-	O
6	O
,	O
-	O
8	O
)	O
are	O
produced	O
during	O
the	O
most	O
early	O
stage	O
of	O
an	O
infection	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
,	O
in	O
contrast	O
,	O
that	O
demyelination	O
and	O
lymphocyte	O
infiltration	O
were	O
increased	O
in	O
recipients	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
(-/-)	I-PRGE
CD4	I-PRGE
T	I-PRGE
cells	O
when	O
compared	O
to	O
levels	O
in	O
mice	O
receiving	O
C57BL	B-PRGE
/	I-PRGE
6	I-PRGE
CD4	I-PRGE
T	I-PRGE
cells	O
.	O

The	O
kinetics	O
of	O
virus	O
-	O
specific	O
IgA	B-PRGE
antibody	I-PRGE
responses	O
in	O
duodenum	O
,	O
jejunum	O
,	O
and	O
ileum	O
were	O
similar	O
:	O
gradually	O
increased	O
from	O
1	O
week	O
PI	O
,	O
reached	O
the	O
peak	O
at	O
3	O
or	O
4	O
weeks	O
PI	O
,	O
and	O
declined	O
afterward	O
.	O

ABSTRACT	O
:	O
The	O
key	O
enzyme	O
in	O
coronavirus	O
polyprotein	O
processing	O
is	O
the	O
viral	B-PRGE
main	I-PRGE
proteinase	I-PRGE
,	I-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
),	I-PRGE
a	O
protein	O
with	O
extremely	O
low	O
sequence	O
similarity	O
to	O
other	O
viral	O
and	O
cellular	O
proteinases	O
.	O

GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
-	O
treated	O
patients	O
showed	O
improvement	O
in	O
Pa	O
(	O
O	O
(	O
2	O
))/	O
FI	O
(	O
O	O
(	O
2	O
))	O
over	O
5	O
days	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
and	O
increased	O
peripheral	O
blood	O
neutrophils	O
(	O
p	O
=	O
0	O
.	O
08	O
),	O
whereas	O
alveolar	O
neutrophils	O
decreased	O
(	O
p	O
=	O
0	O
.	O
02	O
).	O

The	O
expression	O
of	O
MIF	B-PRGE
mRNA	I-PRGE
and	O
protein	O
in	O
the	O
lung	O
tissues	O
were	O
detected	O
by	O
using	O
double	O
immuno	O
histochemistry	O
labeling	O
and	O
in	O
situ	O
hybridization	O
.	O

In	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
showed	O
undetectable	O
or	O
weak	O
MIF	B-PRGE
mRNA	I-PRGE
and	O
protein	O
expression	O
in	O
normal	O
lungs	O
.	O

CONCLUSIONS	O
The	O
serum	O
level	O
of	O
MIF	B-PRGE
and	O
PBMC	B-PRGE
MIF	I-PRGE
expression	O
increased	O
in	O
ARDS	O
patients	O
with	O
enhanced	O
pulmonary	O
MIF	O
expression	O
and	O
macrophage	O
infiltration	O
,	O
which	O
suggests	O
that	O
MIF	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	O
of	O
ARDS	O
.	O

All	O
samples	O
ELISA	O
positive	O
for	O
BCV	O
were	O
matched	O
with	O
an	O
equal	O
number	O
of	O
BCV	O
ELISA	O
-	O
negative	O
samples	O
and	O
analyzed	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
of	O
the	O
N	B-PRGE
gene	I-PRGE
.	O

Lung	O
injury	O
,	O
quantitated	O
by	O
measuring	O
lung	B-PRGE
myeloperoxidase	I-PRGE
activity	O
(	O
an	O
indicator	O
of	O
neutrophil	O
sequestration	O
),	O
alveolar	O
-	O
capillary	O
permeability	O
,	O
and	O
alveolar	O
membrane	O
thickness	O
was	O
less	O
severe	O
in	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
-/-	O
than	O
in	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
+/+	O
mice	O
.	O

Lung	O
levels	O
of	O
macrophage	B-PRGE
inflammatory	I-PRGE
protein	I-PRGE
(	O
MIP	O
)-	O
2	O
are	O
also	O
increased	O
during	O
pancreatitis	O
,	O
but	O
,	O
in	O
this	O
case	O
,	O
the	O
rise	O
is	O
less	O
profound	O
in	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
-/-	O
mice	O
than	O
in	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
+/+	O
controls	O
.	O

The	O
patient	O
had	O
a	O
markedly	O
elevated	O
serum	B-PRGE
ferritin	I-PRGE
concentration	O
of	O
7880	O
micrograms	O
/	O
L	O
,	O
a	O
specific	O
finding	O
for	O
the	O
adult	O
onset	O
Still	O
'	O
s	O
disease	O
(	O
AOSD	O
).	O

These	O
isolates	O
were	O
identified	O
by	O
immunofluorescence	O
using	O
monoclonal	O
antibodies	O
produced	O
against	O
reference	O
serotypes	O
:	O
Mass	O
,	O
Conn	O
,	O
and	O
Ark	B-PRGE
.	O
RT	O
-	O
PCRs	O
were	O
performed	O
on	O
viral	O
RNAs	O
to	O
amplify	O
S1	B-PRGE
gene	I-PRGE
using	O
a	O
specific	O
set	O
of	O
primers	O
S1OLIGO3	O
'	O
and	O
S1OLIGO5	O
'.	O

Major	O
amino	O
acid	O
changes	O
involved	O
insertion	O
of	O
two	O
stretches	O
(	O
aa118	O
-	O
119	O
:	O
Arg	O
-	O
Ser	O
and	O
aa141	B-PRGE
-	I-PRGE
145	I-PRGE
:	O
Sys	B-PRGE
-	I-PRGE
Ser	I-PRGE
-	I-PRGE
Asn	I-PRGE
-	I-PRGE
Ala	I-PRGE
-	I-PRGE
Ser	I-PRGE
-	I-PRGE
Cys	I-PRGE
)	O
located	O
at	O
N	O
-	O
terrminal	O
and	O
C	O
-	O
terminal	O
regions	O
of	O
HVR	O
-	O
2	O
.	O

Activation	O
of	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
increased	O
in	O
lungs	O
from	O
the	O
hemorrhage	O
and	O
CLP	O
group	O
compared	O
with	O
shams	O
.	O

These	O
studies	O
demonstrate	O
that	O
the	O
FGF2	B-PRGE
genotype	O
regulates	O
oligodendrocyte	O
regeneration	O
and	O
that	O
FGF2	B-PRGE
appears	O
to	O
inhibit	O
oligodendrocyte	O
lineage	O
differentiation	O
during	O
remyelination	O
.	O

TITLE	O
:	O
Superimposition	O
of	O
post	O
-	O
streptococcal	O
acute	O
glomerulonephritis	O
on	O
the	O
course	O
of	O
IgA	B-PRGE
nephropathy	O
:	O
predominance	O
of	O
Th1	O
type	O
immune	O
response	O
.	O

On	O
admission	O
,	O
hypertension	O
,	O
nephrotic	O
syndrome	O
and	O
hypocomplementemia	O
were	O
evident	O
together	O
with	O
a	O
high	O
titer	O
of	O
anti	O
-	O
streptokinase	O
(	O
ASK	B-PRGE
).	O

Many	O
interstitial	O
infiltrating	O
cells	O
were	O
positive	O
for	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
but	O
their	O
number	O
diminished	O
after	O
treatment	O
.	O

ABSTRACT	O
:	O
Replication	O
-	O
competent	O
propagation	O
-	O
deficient	O
virus	O
vectors	O
based	O
on	O
the	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
genome	O
that	O
are	O
deficient	O
in	O
the	O
essential	O
E	B-PRGE
gene	I-PRGE
have	O
been	O
developed	O
by	O
complementation	O
within	O
E	O
(+)	O
packaging	O
cell	O
lines	O
.	O

Cell	O
lines	O
expressing	O
the	O
TGEV	B-PRGE
E	I-PRGE
protein	I-PRGE
were	O
established	O
using	O
the	O
noncytopathic	O
Sindbis	O
virus	O
replicon	O
pSINrep21	O
.	O

ABSTRACT	O
:	O
The	O
observation	O
that	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
develop	O
autoantibodies	O
directed	O
mainly	O
to	O
liver	O
fumarylacetoacetate	B-PRGE
hydrolase	I-PRGE
(	O
FAH	B-PRGE
)	O
enabled	O
the	O
development	O
of	O
an	O
ELISA	O
applicable	O
to	O
the	O
detection	O
of	O
MHV	O
-	O
infection	O
.	O

As	O
'	O
phylogeny	O
'	O
PCR	O
,	O
a	O
fragment	O
of	O
the	O
spike	B-PRGE
protein	I-PRGE
gene	I-PRGE
(	O
S1	O
)	O
was	O
amplified	O
and	O
the	O
PCR	O
products	O
were	O
directly	O
sequenced	O
.	O

ABSTRACT	O
:	O
Targeted	O
recombination	O
was	O
used	O
to	O
select	O
mouse	O
hepatitis	O
virus	O
isolates	O
with	O
stable	O
and	O
efficient	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
enhanced	B-PRGE
green	I-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
EGFP	O
).	O

The	O
EGFP	B-PRGE
gene	I-PRGE
was	O
inserted	O
into	O
the	O
murine	O
coronavirus	O
genome	O
in	O
place	O
of	O
the	O
nonessential	O
gene	O
4	O
.	O

After	O
30	O
minutes	O
of	O
iNO	B-PRGE
therapy	O
,	O
there	O
was	O
a	O
50	O
per	O
cent	O
increase	O
in	O
partial	O
pressure	O
of	O
oxygen	O
tension	O
(	O
PaO2	O
)	O
and	O
15	O
per	O
cent	O
reduction	O
in	O
OI	O
,	O
(	O
p	O
=	O
0	O
.	O
02	O
and	O
p	O
=	O
0	O
.	O
04	O
vs	O
baseline	O
,	O
respectively	O
).	O

TITLE	O
:	O
Use	O
of	O
TaqMan	B-PRGE
reverse	I-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
analysis	O
and	O
serologic	O
testing	O
to	O
eliminate	O
an	O
enzootic	O
infection	O
of	O
mouse	O
hepatitis	O
virus	O
.	O

The	O
surfactant	O
preparation	O
used	O
reduced	O
baseline	O
TNF	O
production	O
by	O
murine	O
alveolar	O
macrophages	O
,	O
indicating	O
that	O
the	O
exaggeration	O
of	O
ventilation	O
-	O
induced	O
TNF	B-PRGE
release	O
cannot	O
be	O
explained	O
by	O
a	O
direct	O
effect	O
of	O
surfactant	O
on	O
these	O
cells	O
.	O

ABSTRACT	O
:	O
Although	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
enters	O
cells	O
by	O
virus	O
-	O
cell	O
membrane	O
fusion	O
triggered	O
by	O
its	O
spike	O
(	O
S	O
)	O
protein	O
,	O
it	O
is	O
not	O
well	O
known	O
how	O
the	O
S	B-PRGE
protein	I-PRGE
participates	O
in	O
fusion	O
events	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
receptor	O
-	O
induced	O
conformational	O
changes	O
of	O
the	O
membrane	O
-	O
anchored	O
fragment	O
of	O
the	O
coronavirus	B-PRGE
S	I-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
The	O
role	O
of	O
feline	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
as	O
a	O
receptor	O
for	O
infectious	O
bronchitis	O
virus	O
.	O

TITLE	O
:	O
Severe	O
acute	O
pancreatitis	O
is	O
related	O
to	O
increased	O
early	O
urinary	O
levels	O
of	O
the	O
activation	O
Peptide	O
of	O
pancreatic	O
phospholipase	B-PRGE
A	I-PRGE
(	O
2	O
).	O

Under	O
physiological	O
circumstances	O
,	O
secretory	O
phospholipase	O
A	O
(	O
2	O
)	O
type	O
I	O
(	O
sPLA	O
(	O
2	O
)-	O
I	O
)	O
is	O
activated	O
by	O
trypsinogen	B-PRGE
,	O
but	O
the	O
extent	O
of	O
this	O
activation	O
in	O
acute	O
pancreatitis	O
is	O
unclear	O
.	O

In	O
conclusion	O
,	O
the	O
study	O
shows	O
that	O
activatable	O
scu	B-PRGE
-	I-PRGE
PA	I-PRGE
can	O
be	O
nebulized	O
to	O
the	O
lower	O
respiratory	O
tract	O
and	O
can	O
increase	O
the	O
alveolar	O
fibrinolysis	O
without	O
any	O
significant	O
systemic	O
effects	O
.	O

TITLE	O
:	O
Functional	O
expression	O
of	O
chemokine	B-PRGE
receptor	I-PRGE
CCR5	I-PRGE
on	O
CD4	B-PRGE
(+)	O
T	O
cells	O
during	O
virus	O
-	O
induced	O
central	O
nervous	O
system	O
disease	O
.	O

Adoptive	O
transfer	O
of	O
CCR5	B-PRGE
(+/+)-	I-PRGE
derived	I-PRGE
CD4	I-PRGE
(+)	O
T	O
cells	O
to	O
MHV	O
-	O
infected	O
RAG1	O
(-/-)	O
mice	O
resulted	O
in	O
CD4	B-PRGE
(+)-	O
T	O
-	O
cell	O
entry	O
into	O
the	O
CNS	O
and	O
clearance	O
of	O
virus	O
from	O
the	O
brain	O
.	O

Given	O
that	O
PTB	B-PRGE
interacts	O
with	O
the	O
viral	B-PRGE
N	I-PRGE
protein	I-PRGE
,	O
which	O
is	O
one	O
of	O
the	O
components	O
of	O
the	O
MHV	B-PRGE
replication	I-PRGE
complex	I-PRGE
,	O
PTB	B-PRGE
may	O
exert	O
its	O
function	O
on	O
viral	O
replication	O
/	O
transcription	O
by	O
association	O
with	O
viral	O
RNA	O
as	O
well	O
as	O
other	O
viral	O
and	O
cellular	O
factors	O
in	O
the	O
replication	O
complex	O
.	O

TITLE	O
:	O
Construction	O
and	O
immunogenicity	O
studies	O
of	O
recombinant	O
fowl	O
poxvirus	O
containing	O
the	O
S1	B-PRGE
gene	I-PRGE
of	O
Massachusetts	O
41	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

On	O
the	O
basis	O
of	O
these	O
observations	O
,	O
recombinant	O
fowl	O
poxvirus	O
(	O
rFPV	O
)	O
containing	O
a	O
cDNA	O
copy	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
of	O
IBV	O
Mass	O
41	O
(	O
rFPV	O
-	O
S1	O
)	O
was	O
constructed	O
and	O
its	O
immunogenicity	O
and	O
vaccine	O
potential	O
were	O
evaluated	O
.	O

Later	O
,	O
in	O
vivo	O
expression	O
was	O
demonstrated	O
by	O
the	O
detection	O
of	O
IBV	O
-	O
specific	O
serum	O
immunoglobulin	B-PRGE
G	I-PRGE
and	O
neutralization	O
antibodies	O
in	O
the	O
sera	O
of	O
chickens	O
immunized	O
with	O
rFPV	O
-	O
S1	O
.	O

Oral	O
administration	O
of	O
IgY	O
has	O
proved	O
successful	O
for	O
treatment	O
of	O
a	O
variety	O
of	O
GI	O
infections	O
,	O
such	O
as	O
bovine	O
and	O
human	O
rotaviruses	O
,	O
bovine	B-PRGE
coronavirus	I-PRGE
,	I-PRGE
Yersinia	I-PRGE
ruckeri	I-PRGE
,	I-PRGE
enterotoxigenic	I-PRGE
Escherichia	I-PRGE
coli	I-PRGE
,	I-PRGE
Salmonella	I-PRGE
spp	I-PRGE
.,	O
Edwardsiella	O
tarda	O
,	O
Staphylococcus	O
,	O
and	O
Pseudomonas	O
.	O

Mice	O
deficient	O
in	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	O
-	O
2Ralpha	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
2Rbeta	I-PRGE
are	O
each	O
characterized	O
by	O
a	O
rapid	O
lethal	O
autoimmune	O
lymphoproliferative	O
disorder	O
that	O
complicates	O
their	O
use	O
in	O
studies	O
aimed	O
at	O
investigating	O
the	O
role	O
of	O
these	O
cytokines	O
and	O
receptors	O
for	O
immune	O
responses	O
in	O
vivo	O
.	O

Receptor	O
binding	O
induced	O
a	O
profound	O
,	O
apparently	O
irreversible	O
conformational	O
change	O
in	O
S	O
on	O
the	O
viral	O
envelope	O
that	O
allowed	O
S2	O
,	O
but	O
not	O
S1	O
,	O
to	O
be	O
degraded	O
by	O
trypsin	B-PRGE
at	O
4	O
degrees	O
C	O
.	O
Various	O
murine	O
CEACAM	O
proteins	O
triggered	O
conformational	O
changes	O
in	O
S	O
on	O
recombinant	O
MHV	O
strains	O
expressing	O
S	O
glycoproteins	O
of	O
MHV	O
-	O
A59	O
or	O
MHV	O
-	O
4	O
(	O
MHV	O
-	O
JHM	O
)	O
with	O
the	O
same	O
specificities	O
as	O
seen	O
for	O
virus	O
neutralization	O
and	O
virus	O
-	O
receptor	O
activities	O
.	O

Subcutaneous	O
insulin	B-PRGE
and	O
diet	O
are	O
continued	O
but	O
from	O
the	O
first	O
dexamethasone	O
dose	O
until	O
12	O
h	O
after	O
the	O
second	O
,	O
supplementary	O
intravenous	O
insulin	B-PRGE
is	O
infused	O
according	O
to	O
hourly	O
blood	O
glucose	O
measurements	O
.	O

Activated	O
STAT1	B-PRGE
alpha	I-PRGE
/	I-PRGE
beta	I-PRGE
and	O
STAT3	B-PRGE
alpha	I-PRGE
/	I-PRGE
beta	I-PRGE
ratio	O
in	O
liver	O
were	O
similar	O
in	O
resistant	O
and	O
sensitive	O
mouse	O
strains	O
.	O

Neutrophil	B-PRGE
elastase	I-PRGE
and	O
sThrombomodulin	O
levels	O
in	O
the	O
DIC	O
patients	O
persistently	O
increased	O
during	O
the	O
study	O
period	O
compared	O
to	O
those	O
in	O
the	O
non	O
-	O
DIC	O
patients	O
.	O

Blood	O
gas	O
measurements	O
were	O
obtained	O
10	O
-	O
15	O
mins	O
after	O
initiation	O
or	O
any	O
increase	O
in	O
INO	O
dosage	O
to	O
assess	O
the	O
effect	O
on	O
Pao2	B-PRGE
/	O
Fio2	O
.	O

In	O
contrast	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
antagonist	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
1ra	I-PRGE
)	O
were	O
the	O
most	O
abundant	O
cytokines	O
in	O
the	O
PF	O
and	O
plasma	O
,	O
and	O
the	O
concentrations	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
were	O
also	O
elevated	O
in	O
both	O
compartments	O
.	O

ABSTRACT	O
:	O
Mannan	B-PRGE
-	I-PRGE
binding	I-PRGE
lectin	I-PRGE
(	O
MBL	B-PRGE
)	O
is	O
a	O
glycoprotein	O
and	O
a	O
member	O
of	O
the	O
C	B-PRGE
-	I-PRGE
type	I-PRGE
lectin	I-PRGE
super	I-PRGE
family	I-PRGE
,	O
the	O
collectin	B-PRGE
family	I-PRGE
,	O
and	O
the	O
acute	O
phase	O
protein	O
family	O
.	O

Differential	O
susceptibility	O
of	O
infected	O
cell	O
types	O
to	O
clearance	O
by	O
perforin	B-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
uncovered	O
distinct	O
,	O
nonredundant	O
roles	O
for	O
these	O
antiviral	O
mechanisms	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
showed	O
that	O
an	O
intraperitoneal	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
resulted	O
in	O
acute	O
hepatic	O
failure	O
accompanying	O
extremely	O
elevated	O
viral	O
growth	O
in	O
the	O
liver	O
in	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
deficient	O
BALB	O
/	O
c	O
(	O
BALB	O
-	O
GKO	O
),	O
but	O
not	O
C57BL	O
/	O
6	O
(	O
B6	O
-	O
GKO	O
)	O
mice	O
.	O

Since	O
a	O
significant	O
difference	O
in	O
MHV	O
replication	O
in	O
hepatocytes	O
was	O
not	O
observed	O
between	O
wild	O
type	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
deficient	O
mice	O
of	O
the	O
same	O
genetic	O
background	O
,	O
the	O
phenomenon	O
is	O
thought	O
to	O
be	O
independent	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

Previous	O
studies	O
demonstrated	O
that	O
primary	O
CD8	B-PRGE
(+)	O
T	O
lymphocytes	O
collected	O
at	O
10	O
days	O
post	O
-	O
infection	O
(	O
p	O
.	O
i	O
.)	O
are	O
important	O
in	O
controlling	O
acute	O
infection	O
.	O

These	O
results	O
demonstrated	O
that	O
IBV	O
specific	O
CD8	B-PRGE
(+)	O
memory	O
T	O
cells	O
generated	O
at	O
3	O
to	O
6	O
weeks	O
p	O
.	O
i	O
.	O

It	O
is	O
characterized	O
by	O
increased	O
expression	O
of	O
TGF	B-PRGE
beta	I-PRGE
and	O
other	O
cytokines	O
on	O
airway	O
epithelial	O
cells	O
,	O
increased	O
expression	O
of	O
class	O
II	O
antigens	O
in	O
the	O
airways	O
,	O
lymphocytic	O
bronchiolitis	O
,	O
and	O
bronchial	O
epithelial	O
cell	O
proliferation	O
mediated	O
by	O
numerous	O
cytokines	O
.	O

ABSTRACT	O
:	O
Vascular	B-PRGE
endothelial	I-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
VEGF	B-PRGE
),	O
an	O
angiogenic	O
and	O
chemotactic	O
peptide	O
,	O
is	O
abundantly	O
expressed	O
in	O
normal	O
lung	O
tissue	O
,	O
especially	O
in	O
alveolar	O
and	O
bronchial	O
epithelium	O
,	O
glandular	O
cells	O
of	O
the	O
bronchi	O
,	O
and	O
activated	O
alveolar	O
macrophages	O
.	O

We	O
evaluated	O
pulmonary	O
VEGF	B-PRGE
expression	O
in	O
lung	O
autopsy	O
material	O
from	O
septic	O
patients	O
who	O
had	O
been	O
cared	O
for	O
by	O
intensive	O
care	O
medicine	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
immunohistochemical	O
methods	O
.	O

As	O
monitored	O
by	O
RT	O
-	O
PCR	O
,	O
mRNA	O
for	O
the	O
2	O
splice	O
variants	O
,	O
VEGF	B-PRGE
(	I-PRGE
121	I-PRGE
)	I-PRGE
and	O
VEGF	B-PRGE
(	O
165	O
),	O
and	O
for	O
VEGFR	B-PRGE
-	I-PRGE
2	I-PRGE
/	O
KDR	B-PRGE
were	O
expressed	O
in	O
both	O
groups	O
,	O
the	O
yields	O
being	O
lower	O
in	O
the	O
sepsis	O
group	O
.	O

Bronchial	O
microscope	O
in	O
group	O
D	O
presented	O
the	O
bronchus	O
filled	O
with	O
bronchoalveolar	O
fluid	O
,	O
and	O
blood	B-PRGE
LDH	I-PRGE
-	I-PRGE
L	I-PRGE
and	O
ALP	B-PRGE
levels	O
kept	O
rising	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Neutralizing	O
immunoglobulin	B-PRGE
G	I-PRGE
(	O
IgG	B-PRGE
)	O
but	O
not	O
IgA	B-PRGE
anti	O
-	O
spike	O
Ab	O
suppressed	O
virus	O
recrudescence	O
,	O
reduced	B-PRGE
viral	I-PRGE
antigen	I-PRGE
in	O
most	O
cell	O
types	O
except	O
oligodendroglia	O
,	O
and	O
was	O
associated	O
with	O
reduced	O
demyelination	O
.	O

Interestingly	O
,	O
expression	O
of	O
the	O
A59	B-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
within	O
the	O
background	O
of	O
the	O
neurotropic	O
JHM	O
strain	O
does	O
not	O
reproduce	O
the	O
A59	O
hepatotropic	O
phenotype	O
.	O

TITLE	O
:	O
Bystander	O
CD4	B-PRGE
T	I-PRGE
cells	O
do	O
not	O
mediate	O
demyelination	O
in	O
mice	O
infected	O
with	O
a	O
neurotropic	O
coronavirus	O
.	O

Sequence	O
analysis	O
of	O
the	O
hypervariable	O
region	O
(	O
HVR	O
)	O
of	O
S1	B-PRGE
gene	I-PRGE
exhibited	O
high	O
variations	O
among	O
Taiwanese	O
IBV	O
isolates	O
.	O

Other	O
common	O
findings	O
were	O
lymphopenia	O
(	O
in	O
69	O
.	O
6	O
percent	O
),	O
thrombocytopenia	O
(	O
44	O
.	O
8	O
percent	O
),	O
and	O
elevated	O
lactate	B-PRGE
dehydrogenase	I-PRGE
and	O
creatine	B-PRGE
kinase	I-PRGE
levels	O
(	O
71	O
.	O
0	O
percent	O
and	O
32	O
.	O
1	O
percent	O
,	O
respectively	O
).	O

In	O
a	O
multivariate	O
analysis	O
,	O
the	O
independent	O
predictors	O
of	O
an	O
adverse	O
outcome	O
were	O
advanced	O
age	O
(	O
odds	O
ratio	O
per	O
decade	O
of	O
life	O
,	O
1	O
.	O
80	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
16	O
to	O
2	O
.	O
81	O
;	O
P	O
=	O
0	O
.	O
009	O
),	O
a	O
high	O
peak	O
lactate	B-PRGE
dehydrogenase	I-PRGE
level	O
(	O
odds	O
ratio	O
per	O
100	O
U	O
per	O
liter	O
,	O
2	O
.	O
09	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
28	O
to	O
3	O
.	O
42	O
;	O
P	O
=	O
0	O
.	O
003	O
),	O
and	O
an	O
absolute	O
neutrophil	O
count	O
that	O
exceeded	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
on	O
presentation	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
60	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
03	O
to	O
2	O
.	O
50	O
;	O
P	O
=	O
0	O
.	O
04	O
).	O

This	O
article	O
reviews	O
some	O
of	O
the	O
physiologic	O
actions	O
of	O
proteases	B-PRGE
,	I-PRGE
specifically	I-PRGE
elastase	I-PRGE
,	O
the	O
evidence	O
for	O
neutrophil	B-PRGE
elastase	I-PRGE
involvement	O
in	O
ARDS	O
,	O
and	O
the	O
potential	O
therapeutic	O
use	O
of	O
neutrophil	B-PRGE
elastase	I-PRGE
inhibitors	O
in	O
lung	O
injury	O
.	O

Although	O
the	O
data	O
support	O
a	O
key	O
role	O
for	O
neutrophil	B-PRGE
elastase	I-PRGE
in	O
the	O
pathogenesis	O
of	O
ARDS	O
,	O
further	O
study	O
is	O
needed	O
to	O
fully	O
define	O
the	O
actions	O
of	O
neutrophil	B-PRGE
elastase	I-PRGE
,	O
and	O
how	O
these	O
actions	O
affect	O
host	O
functions	O
,	O
before	O
we	O
can	O
exploit	O
this	O
knowledge	O
for	O
therapeutic	O
benefit	O
.	O

CONCLUSIONS	O
:	O
Although	O
the	O
data	O
support	O
a	O
key	O
role	O
for	O
neutrophil	B-PRGE
elastase	I-PRGE
in	O
the	O
pathogenesis	O
of	O
ARDS	O
,	O
further	O
study	O
is	O
needed	O
to	O
fully	O
define	O
the	O
actions	O
of	O
neutrophil	B-PRGE
elastase	I-PRGE
,	O
and	O
how	O
these	O
actions	O
affect	O
host	O
functions	O
,	O
before	O
we	O
can	O
exploit	O
this	O
knowledge	O
for	O
therapeutic	O
benefit	O
.	O

This	O
is	O
consistent	O
with	O
the	O
lower	O
levels	O
of	O
hepatocellular	B-PRGE
necrosis	I-PRGE
and	I-PRGE
serum	I-PRGE
ALT	I-PRGE
and	O
the	O
decreased	O
titers	O
of	O
MHV	O
-	O
2	O
virus	O
in	O
the	O
liver	O
tissues	O
(	O
48	O
hr	O
,	O
P	O
<	O
0	O
.	O
001	O
;	O
72	O
hr	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

We	O
identified	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
binding	I-PRGE
HPV16	I-PRGE
E7	I-PRGE
variant	I-PRGE
peptides	I-PRGE
from	O
human	O
,	O
bacterial	O
,	O
or	O
viral	O
origin	O
which	O
are	O
able	O
to	O
drive	O
CD8	B-PRGE
(+)-	O
T	O
-	O
cell	O
responses	O
directed	O
against	O
wild	B-PRGE
-	I-PRGE
type	I-PRGE
HPV16	I-PRGE
E7	I-PRGE
amino	O
acid	O
11	O
to	O
19	O
/	O
20	O
(	O
E7	O
(	O
11	O
-	O
19	O
/	O
20	O
))	O
epitope	O
YMLDLQPET	O
(	O
T	O
)	O
in	O
vitro	O
.	O

These	O
data	O
provide	O
evidence	O
that	O
BoTV	B-PRGE
is	O
an	O
important	O
pathogen	O
of	O
neonatal	O
veal	O
calves	O
.	O

In	O
DS	O
patients	O
,	O
superfluous	O
toxicities	O
due	O
to	O
MTX	B-PRGE
and	O
AraC	O
treatment	O
have	O
been	O
reported	O
,	O
and	O
these	O
toxicities	O
have	O
been	O
considered	O
due	O
to	O
altered	O
pharmacokinetics	O
in	O
patients	O
with	O
DS	O
.	O

From	O
November	O
1999	O
to	O
May	O
2001	O
,	O
259	O
specimens	O
from	O
53	O
calves	O
(<	O
or	O
=	O
6	O
months	O
old	O
),	O
27	O
young	O
adults	O
(	O
52	O
years	O
),	O
125	O
adults	O
(>	O
or	O
=	O
2	O
years	O
),	O
and	O
54	O
animals	O
of	O
unknown	O
age	O
were	O
examined	O
by	O
an	O
antigen	O
-	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
developed	O
to	O
detect	O
BoTV	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
heterogeneity	O
of	O
polymerase	B-PRGE
gene	I-PRGE
fragment	I-PRGE
of	O
SARS	O
-	O
associated	O
coronavirus	O
from	O
SARS	O
patients	O
,	O
and	O
establish	O
a	O
RT	O
-	O
PCR	O
method	O
for	O
detecting	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

Lung	O
static	O
compliance	O
on	O
day	O
15	O
was	O
severely	O
decreased	O
with	O
bleomycin	O
alone	O
and	O
showed	O
a	O
further	O
significant	O
decrease	O
when	O
granulocyte	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
was	O
added	O
(	O
controls	O
,	O
3	O
.	O
85	O
+/-	O

Lung	O
morphology	O
with	O
bleomycin	O
+	O
granulocyte	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
showed	O
,	O
in	O
addition	O
to	O
the	O
changes	O
observed	O
with	O
bleomycin	O
alone	O
,	O
four	O
patterns	O
indicating	O
more	O
severe	O
disease	O
:	O
honeycomb	O
foci	O
,	O
pleural	O
thickening	O
with	O
hyaline	O
fibrosis	O
,	O
interstitial	O
granuloma	O
with	O
increased	O
number	O
of	O
macrophages	O
but	O
not	O
neutrophils	O
,	O
and	O
established	O
interstitial	O
fibrosis	O
.	O

In	O
the	O
hemorrhagic	O
shock	O
model	O
,	O
plasma	O
concentrations	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
were	O
significantly	O
lower	O
and	O
interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
was	O
significantly	O
higher	O
in	O
the	O
albumin	B-PRGE
-	O
treated	O
groups	O
compared	O
with	O
the	O
Ringer	O
'	O
s	O
lactate	O
-	O
treated	O
group	O
.	O

TITLE	O
:	O
Possible	O
mechanisms	O
underlying	O
development	O
of	O
transfusion	O
-	O
related	O
acute	O
lung	O
injury	O
:	O
roles	O
of	O
anti	B-PRGE
-	I-PRGE
major	I-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
class	I-PRGE
II	I-PRGE
DR	I-PRGE
antibody	I-PRGE
.	O

Furthermore	O
,	O
FcepsilonRI	B-PRGE
expression	O
,	O
in	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
-	O
treated	O
PMNs	O
,	O
suggests	O
the	O
involvement	O
of	O
PMNs	O
in	O
IgE	B-PRGE
-	O
mediated	O
immune	O
reactions	O
.	O

On	O
the	O
basis	O
of	O
comparative	O
genomics	O
,	O
the	O
homology	O
search	O
,	O
phylogenetic	O
analyses	O
,	O
and	O
multi	O
-	O
sequence	O
alignment	O
were	O
used	O
to	O
predict	O
CD13	B-PRGE
related	O
interacting	O
domains	O
and	O
binding	O
sites	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Molecular	O
modeling	O
and	O
docking	O
simulation	O
methods	O
were	O
employed	O
to	O
address	O
the	O
interaction	O
feature	O
between	O
CD13	B-PRGE
and	O
S	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
validating	O
the	O
bioinformatics	O
predictions	O
.	O

Based	O
on	O
the	O
studies	O
about	O
the	O
genomic	O
packaging	O
signals	O
of	O
MHV	O
and	O
BCoV	O
,	O
especially	O
the	O
information	O
about	O
primary	O
and	O
secondary	O
structures	O
,	O
the	O
putative	O
genomic	O
packaging	O
signal	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
were	O
analyzed	O
by	O
using	O
bioinformatic	O
tools	O
.	O

The	O
probable	O
genomic	O
packaging	O
signal	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
analogous	O
to	O
that	O
of	O
MHV	O
and	O
BCoV	O
,	O
with	O
the	O
corresponding	O
secondary	O
RNA	O
structure	O
locating	O
at	O
the	O
similar	O
region	O
of	O
ORF1b	O
.	O

The	O
transmembrane	O
(	O
TM	O
)	O
segment	O
of	O
the	O
SARS	B-PRGE
E	I-PRGE
protein	I-PRGE
is	O
relatively	O
more	O
conserved	O
in	O
the	O
whole	O
protein	O
than	O
other	O
regions	O
.	O

The	O
results	O
show	O
that	O
the	O
diameter	O
of	O
newly	O
isolated	O
virus	O
is	O
about	O
50	O
nm	O
without	O
envelope	O
or	O
100	O
nm	O
with	O
envelope	B-PRGE
.	O

FAV	O
antibody	O
ELISA	O
confirmed	O
that	O
maternal	O
antibody	O
directed	O
against	O
inclusion	O
body	O
hepatitis	O
(	O
serotype	O
8	O
)	O
had	O
decayed	O
in	O
control	O
birds	O
and	O
that	O
FAV	B-PRGE
specific	I-PRGE
serum	I-PRGE
IgG	I-PRGE
responses	O
were	O
produced	O
in	O
vaccinated	O
birds	O
at	O
the	O
time	O
of	O
challenge	O
.	O

To	O
determine	O
the	O
approximate	O
position	O
of	O
the	O
cleavage	O
site	O
,	O
we	O
expressed	O
constructs	O
that	O
extended	O
various	O
distances	O
upstream	O
from	O
the	O
previously	O
defined	O
C	O
-	O
terminal	O
end	O
of	O
MP1	B-PRGE
.	O

Finally	O
,	O
to	O
unequivocally	O
identify	O
this	O
cleavage	O
site	O
,	O
we	O
isolated	O
radiolabeled	O
MP1	B-PRGE
protein	I-PRGE
and	O
determined	O
the	O
position	O
of	O
[(	O
35	O
)	O
S	O
]	O
methionine	O
residues	O
released	O
by	O
Edman	O
degradation	O
reaction	O
.	O

Patient	O
demographics	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
rate	O
of	O
intensive	O
care	O
unit	O
admission	O
,	O
peak	O
lactate	B-PRGE
dehydrogenase	I-PRGE
level	O
,	O
pulsed	O
intravenous	O
methylprednisolone	O
therapy	O
,	O
and	O
peak	O
opacification	O
on	O
chest	O
radiographs	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

The	O
amino	O
terminal	O
half	O
of	O
the	O
S	B-PRGE
glycoprotein	I-PRGE
gene	O
including	O
antigenic	O
sites	O
A	O
,	O
B	O
,	O
C	O
and	O
D	O
,	O
were	O
amplified	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Insertion	O
of	O
the	O
first	O
649	O
nucleotides	O
(	O
nt	O
)	O
of	O
the	O
TGEV	O
genome	O
led	O
to	O
the	O
specific	O
encapsidation	O
of	O
the	O
mRNA	O
,	O
indicating	O
that	O
a	O
Psi	B-PRGE
was	O
located	O
within	O
this	O
region	O
which	O
was	O
absent	O
from	O
all	O
of	O
the	O
other	O
virus	O
mRNAs	O
.	O

In	O
contrast	O
,	O
viral	O
mRNAs	O
presented	O
significantly	O
lower	O
encapsidation	O
efficiencies	O
(	O
about	O
100	O
-	O
fold	O
)	O
than	O
those	O
of	O
the	O
virus	O
genome	O
,	O
strongly	O
suggesting	O
that	O
TGEV	O
mRNAs	O
in	O
fact	O
lacked	O
an	O
alternative	O
TGEV	B-PRGE
Psi	I-PRGE
.	O

Common	O
laboratory	O
findings	O
included	O
lymphopenia	O
,	O
thrombocytopenia	O
,	O
and	O
mild	O
elevations	O
of	O
activated	O
partial	O
thromboplastin	B-PRGE
time	O
,	O
alanine	B-PRGE
transaminase	I-PRGE
,	O
lactic	B-PRGE
dehydrogenase	I-PRGE
,	O
and	O
creatine	O
phosphokinase	O
.	O

To	O
explore	O
if	O
the	O
least	O
expressed	O
ORF	B-PRGE
,	O
ORF	B-PRGE
3b	I-PRGE
,	O
which	O
encodes	O
a	O
nonstructural	O
protein	O
,	O
is	O
evolutionarily	O
conserved	O
and	O
functionally	O
indispensable	O
for	O
viral	O
propagation	O
in	O
cultured	O
cells	O
,	O
the	O
Beaudette	O
strain	O
of	O
IBV	O
was	O
propagated	O
in	O
chicken	O
embryonated	O
eggs	O
for	O
three	O
passages	O
and	O
then	O
adapted	O
to	O
a	O
monkey	O
kidney	O
cell	O
line	O
,	O
Vero	O
.	O

(	O
3	O
)	O
Timely	O
administration	O
of	O
Ribavirin	O
,	O
Methylprednisolone	O
,	O
immunoenhancer	O
(	O
such	O
as	O
interferon	B-PRGE
alpha	I-PRGE
-	I-PRGE
2b	I-PRGE
,	O
thymosin	B-PRGE
-	I-PRGE
alpha1	I-PRGE
)	O
to	O
SARS	O
patients	O
was	O
efficacious	O
to	O
certain	O
extent	O
in	O
controlling	O
the	O
development	O
of	O
the	O
disease	O
.	O

The	O
possible	O
mechanisms	O
of	O
this	O
coronavirus	O
on	O
blood	O
system	O
may	O
include	O
(	O
1	O
)	O
directly	O
infect	O
blood	O
cells	O
and	O
bone	O
marrow	O
stromal	O
cells	O
via	O
CD13	B-PRGE
or	O
CD66a	B-PRGE
;	O
and	O
/	O
or	O
(	O
2	O
)	O
induce	O
auto	O
-	O
antibodies	O
and	O
immune	O
complexes	O
to	O
damage	O
these	O
cells	O
.	O

SARS	B-PRGE
is	O
a	O
systemic	O
disease	O
that	O
injures	O
many	O
organs	O
.	O

The	O
positive	O
rates	O
of	O
specific	O
IgG	B-PRGE
and	O
IgM	B-PRGE
against	O
SARS	O
virus	O
within	O
10	O
days	O
after	O
onset	O
of	O
the	O
disease	O
were	O
55	O
.	O
1	O
%	O
and	O
16	O
.	O
3	O
%	O
respectively	O

and	O
then	O
increased	O
up	O
to	O
89	O
.	O
8	O
%	O
for	O
IgG	B-PRGE
and	O
65	O
.	O
3	O
%	O
for	O
IgM	B-PRGE
.	O
After	O
25	O
days	O
of	O
the	O
onset	O
of	O
the	O
disease	O
,	O
90	O
.	O
9	O
%	O
patients	O
became	O
positive	O
for	O
both	O
IgG	B-PRGE
and	O
IgM	B-PRGE
.	O
Results	O
from	O
chi	O
-	O
square	O
for	O
trend	O
test	O
revealed	O
that	O
the	O
positive	O
rates	O
of	O
both	O
IgG	B-PRGE
and	O
IgM	B-PRGE
increased	O
with	O
time	O
(	O
chi	O
(	O
2	O
)	O
for	O
trend	O
=	O
16	O
.	O
376	O
,	O
P	O
=	O
0	O
.	O
00005	O
for	O
IgG	B-PRGE
;	O
chi	O
(	O
2	O
)	O
for	O
trend	O
=	O
28	O
.	O
736	O
,	O
P	O
=	O
0	O
.	O
00000	O
for	O
IgM	B-PRGE
).	O

The	O
further	O
experiments	O
demonstrated	O
that	O
N1	O
peptide	O
-	O
induced	O
polyclonal	O
antibodies	O
had	O
a	O
high	O
affinity	O
to	O
bind	O
to	O
E	O
.	O
coli	O
expressed	O
N	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Furthermore	O
,	O
it	O
was	O
confirmed	O
that	O
N1	B-PRGE
peptide	I-PRGE
-	I-PRGE
specific	I-PRGE
IgG	I-PRGE
antibodies	I-PRGE
were	O
detectable	O
in	O
the	O
sera	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
.	O

The	O
results	O
indicated	O
that	O
an	O
epitope	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
has	O
been	O
identified	O
and	O
N	O
protein	O
specific	O
Abs	O
were	O
produced	O
by	O
peptide	O
immunization	O
,	O
which	O
will	O
be	O
usefull	O
for	O
the	O
study	O
of	O
SARS	O
-	O
CoV	O
.	O

IgM	B-PRGE
seroprotection	O
rates	O
was	O
61	O
.	O
5	O
%	O
in	O
the	O
second	O
month	O
,	O
and	O
38	O
.	O
5	O
%	O
at	O
third	O
month	O
.	O

The	O
IgG	B-PRGE
peaked	O
one	O
month	O
after	O
the	O
onset	O
and	O
remained	O
at	O
high	O
levels	O
in	O
the	O
following	O
2	O
months	O
.	O

This	O
ELISA	O
-	O
based	O
test	O
for	O
detecting	O
anti	B-PRGE
-	I-PRGE
N	I-PRGE
antigen	I-PRGE
may	O
be	O
of	O
significant	O
value	O
for	O
SARS	O
diagnosis	O
.	O

RESULTS	O
:	O
The	O
IgM	B-PRGE
positive	O
critical	O
value	O
of	O
0	O
.	O
233	O
and	O
IgG	B-PRGE
of	O
0	O
.	O
239	O
were	O
selected	O
as	O
the	O
threshold	O
value	O
for	O
positive	O
results	O
that	O
equals	O
the	O
product	O
of	O
2	O
.	O
1	O
and	O
the	O
mean	O
IgM	B-PRGE
and	O
IgG	B-PRGE
levels	O
of	O
200	O
healthy	O
blood	O
donors	O
.	O

However	O
,	O
one	O
out	O
of	O
27	O
patients	O
investigated	O
had	O
high	O
levels	O
of	O
aPL	B-PRGE
antibodies	I-PRGE
in	O
both	O
BALF	O
and	O
serum	O
.	O

The	O
high	O
aPL	B-PRGE
antibody	I-PRGE
levels	O
in	O
serum	O
possibly	O
triggered	O
by	O
sepsis	O
were	O
associated	O
with	O
high	O
aPL	B-PRGE
antibody	I-PRGE
levels	O
in	O
BALF	O
,	O
which	O
can	O
be	O
explained	O
by	O
high	O
capillary	O
-	O
alveolar	O
permeability	O
.	O

Antibiotics	B-PRGE
,	I-PRGE
human	I-PRGE
gamma	I-PRGE
-	I-PRGE
globulin	I-PRGE
,	O
interferon	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
and	O
antiviral	O
drugs	O
,	O
although	O
empirically	O
,	O
might	O
be	O
useful	O
to	O
shorten	O
the	O
clinical	O
course	O
.	O

During	O
follow	O
up	O
(	O
14	O
-	O
32	O
months	O
),	O
none	O
of	O
the	O
6	O
patients	O
developed	O
viral	O
complications	O
related	O
to	O
transfusion	O
therapy	O
,	O
alloimmunization	O
or	O
recurrence	O
of	O
ACS	B-PRGE
.	O

SARS	B-PRGE
is	O
a	O
recently	O
recognized	O
infectious	O
disease	O
that	O
may	O
lead	O
to	O
death	O
and	O
severe	O
pulmonary	O
sequelae	O
.	O

Gefitinib	O
acts	O
by	O
inhibition	O
of	O
the	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
receptor	I-PRGE
tyrosine	I-PRGE
kinase	I-PRGE
.	O

Under	O
the	O
electronic	O
microscopy	O
observation	O
,	O
virus	O
-	O
like	O
particles	O
with	O
80	O
-	O
160	O
nm	O
diameter	O
and	O
halo	O
or	O
garland	O
envelope	B-PRGE
were	O
found	O
in	O
mononuclear	O
macrophage	O
and	O
cytoplasm	O
of	O
alveolar	O
epithelium	O
.	O

TITLE	O
:	O
The	O
critical	O
role	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
experimental	O
coronavirus	O
retinopathy	O
.	O

In	O
the	O
present	O
study	O
,	O
interferon	B-PRGE
(	O
IFN	O
)-	O
gamma	O
production	O
during	O
ECOR	O
was	O
studied	O
and	O
its	O
role	O
evaluated	O
in	O
the	O
clearance	O
of	O
infectious	O
virus	O
from	O
the	O
retina	O
.	O

Mouse	O
eyes	O
were	O
evaluated	O
for	O
infiltrating	O
cells	O
and	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
(	O
MHC	B-PRGE
)	O
expression	O
by	O
immunocytochemical	O
staining	O
.	O

These	O
studies	O
indicate	O
that	O
generation	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
by	O
cells	O
infiltrating	O
the	O
retina	O
is	O
an	O
essential	O
part	O
of	O
an	O
immune	O
mechanism	O
responsible	O
for	O
noncytolytic	O
clearance	O
of	O
infectious	O
virus	O
from	O
the	O
retina	O
.	O

TITLE	O
:	O
Expression	O
of	O
immunogenic	B-PRGE
S1	I-PRGE
glycoprotein	I-PRGE
of	O
infectious	O
bronchitis	O
virus	O
in	O
transgenic	O
potatoes	O
.	O

Common	O
laboratory	O
findings	O
were	O
lymphopenia	O
,	O
and	O
elevated	O
serum	O
levels	O
of	O
lactate	B-PRGE
dehydrogenase	I-PRGE
and	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
.	O

The	O
level	O
of	O
serum	B-PRGE
IL	I-PRGE
is	O
closely	O
related	O
to	O
cell	O
immunity	O
in	O
SARS	O
patients	O
.	O

The	O
level	O
of	O
serum	B-PRGE
IL	I-PRGE
is	O
increased	O
evidently	O
while	O
CD	O
(	O
3	O
)(+),	O
CD	O
(	O
4	O
)(+)	O
and	O
CD	O
(	O
8	O
)(+)	O
counts	O
decrease	O
.	O

Replication	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
macaques	O
of	O
pneumonia	O
similar	O
to	O
that	O
in	O
human	O
beings	O
with	O
SARS	O
,	O
combined	O
with	O
the	O
high	O
prevalence	O
of	O
SARS	O
-	O
CoV	O
infection	O
in	O
SARS	O
patients	O
,	O
fulfill	O
the	O
criteria	O
required	O
to	O
prove	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
the	O
primary	O
cause	O
of	O
SARS	O
.	O

In	O
a	O
multivariate	O
analysis	O
(	O
Stata	B-PRGE
7	I-PRGE
.	I-PRGE
0	I-PRGE
),	O
the	O
independent	O
predictor	O
of	O
an	O
adverse	O
outcome	O
was	O
advanced	O
age	O
(	O
odds	O
ratio	O
per	O
decade	O
of	O
life	O
,	O
1	O
.	O
6	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
08	O
to	O
2	O
.	O
63	O
;	O
P	O
=	O
0	O
.	O
007	O
).	O

ABSTRACT	O
:	O
A	O
novel	O
coronavirus	O
(	O
SARS	O
-	O
coronavirus	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
was	O
discovered	O
in	O
association	O
with	O
cases	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
recently	O
.	O

Specific	O
antibodies	O
of	O
IgM	B-PRGE
and	O
IgG	B-PRGE
against	O
SARS	O
virus	O
in	O
267	O
serum	O
specimens	O
from	O
patients	O
with	O
SARS	O
and	O
132	O
from	O
non	O
-	O
SARS	O
patients	O
or	O
healthy	O
persons	O
were	O
assayed	O
with	O
IFA	O
or	O
ELISA	O
.	O

The	O
positive	O
rate	O
of	O
specific	O
IgM	B-PRGE
and	O
IgG	B-PRGE
detected	O
by	O
IFA	O
increased	O
sharply	O
on	O
the	O
eleventh	O
day	O
of	O
the	O
disease	O
.	O

RESULTS	O
:	O
The	O
positive	O
rate	O
of	O
specific	O
IgM	B-PRGE
and	O
IgG	B-PRGE
detected	O
by	O
IFA	O
increased	O
sharply	O
on	O
the	O
eleventh	O
day	O
of	O
the	O
disease	O
.	O

The	O
Kappa	O
of	O
IFA	O
and	O
ELISA	O
for	O
IgM	B-PRGE
and	O
IgG	B-PRGE
were	O
0	O
.	O
640	O
and	O
0	O
.	O
779	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
levels	O
of	O
CD3	B-PRGE
(+),	I-PRGE
CD4	B-PRGE
(+)	O
and	O
CD8	B-PRGE
(+)	O
T	O
-	O
lymphocyte	O
subsets	O
in	O
peripheral	O
blood	O
of	O
SARS	O
patients	O
decrease	O
significantly	O
and	O
go	O
down	O
to	O
the	O
lowest	O
point	O
at	O
days	O
10	O
approximately	O
12	O
after	O
onset	O
of	O
the	O
disease	O
.	O

At	O
the	O
early	O
stage	O
,	O
white	O
blood	O
cell	O
count	O
,	O
lymphocyte	O
count	O
and	O
ratio	O
of	O
lymphocyte	O
,	O
proalbumin	O
,	O
transferring	O
,	O
CD	O
(	O
3	O
)(+),	O
CD	O
(	O
4	O
)(+),	O
CD	O
(	O
8	O
)(+)	O
cell	O
count	O
were	O
remarkably	O
decreased	O
,	O
and	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
,	O
alpha	B-PRGE
-	I-PRGE
acid	I-PRGE
glycoprotein	I-PRGE
,	I-PRGE
and	I-PRGE
alpha	I-PRGE
(	I-PRGE
2	I-PRGE
)-	I-PRGE
globulin	I-PRGE
were	O
remarkably	O
increased	O
.	O

To	O
resolve	O
this	O
apparent	O
contradiction	O
,	O
we	O
engineered	O
a	O
recombinant	O
variant	O
of	O
JHM	O
that	O
expressed	O
the	O
well	O
-	O
characterized	O
gp33	B-PRGE
epitope	I-PRGE
of	O
lymphocytic	O
choriomeningitis	O
virus	O
,	O
an	O
epitope	O
with	O
high	O
functional	O
avidity	O
.	O

We	O
obtained	O
20	O
SARS	O
-	O
CoV	O
virus	O
genome	O
sequences	O
from	O
NCBI	O
database	O
,	O
and	O
calculated	O
the	O
ratio	O
of	O
non	O
-	O
synonymous	O
nucleotide	O
substitution	O
per	O
non	O
-	O
synonymous	O
site	O
(	O
Ka	O
)	O
and	O
synonymous	O
nucleotide	O
substitution	O
per	O
synonymous	O
site	O
(	O
Ks	O
)	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
virus	I-PRGE
genes	I-PRGE
.	O

The	O
Ka	O
/	O
Ks	O
ratios	O
for	O
replicase	B-PRGE
polyprotein	I-PRGE
ORF1a	I-PRGE
,	O
ORF1b	O
,	O
and	O
spike	O
protein	O
gene	O
are	O
1	O
.	O
09	O
(	O
P	O
=	O
0	O
.	O
6501	O
),	O
0	O
.	O
38	O
(	O
P	O
=	O
0	O
.	O
0074	O
),	O
0	O
.	O
65	O
(	O
P	O
=	O
0	O
.	O
0685	O
)	O
respectively	O
.	O

The	O
surviving	O
patients	O
required	O
less	O
insulin	B-PRGE
when	O
compared	O
to	O
those	O
who	O
died	O
.	O

The	O
amount	O
of	O
insulin	B-PRGE
used	O
in	O
the	O
surviving	O
group	O
was	O
significant	O
lower	O
than	O
that	O
in	O
the	O
group	O
who	O
died	O
[(	O
24	O
+/-	O
2	O
)	O
IU	O
/	O
d	O
vs	O
(	O
72	O
+/-	O
9	O
)	O
IU	O
/	O
d	O
]	O
(	O
P	O
=	O
0	O
.	O
01	O
).	O

The	O
IgG	B-PRGE
antibody	I-PRGE
was	O
detected	O
in	O
22	O
out	O
of	O
34	O
(	O
64	O
.	O
7	O
%)	O
patients	O
and	O
the	O
average	O
time	O
for	O
the	O
occurrence	O
of	O
antibody	O
was	O
(	O
18	O
.	O
2	O
+/-	O

Plasma	B-PRGE
anti	I-PRGE
-	I-PRGE
SARS	I-PRGE
coronavirus	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
was	O
not	O
detected	O
in	O
normal	O
subjects	O
and	O
the	O
clinical	O
personnel	O
.	O

Analysis	O
of	O
the	O
dimeric	O
interface	O
suggests	O
the	O
3CL	B-PRGE
proteinase	I-PRGE
may	O
have	O
dimer	O
form	O
in	O
solution	O
.	O

The	O
antiviral	O
activity	O
may	O
be	O
mediated	O
in	O
part	O
by	O
2	O
',	O
5	B-PRGE
'-	I-PRGE
oligoadenylate	I-PRGE
synthetase	I-PRGE
,	I-PRGE
RNA	I-PRGE
-	I-PRGE
dependent	I-PRGE
protein	I-PRGE
kinase	I-PRGE
,	O
and	O
Mx	B-PRGE
protein	I-PRGE
,	O
which	O
inhibit	O
viral	O
replication	O
or	O
degrade	O
viral	O
components	O
,	O
because	O
limitin	B-PRGE
induced	O
their	O
mRNA	O
expression	O
and	O
enzyme	O
activity	O
.	O

TITLE	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
NTPase	B-PRGE
/	O
helicase	B-PRGE
belongs	O
to	O
a	O
distinct	O
class	O
of	O
5	O
'	O
to	O
3	O
'	O
viral	O
helicases	O
.	O

The	O
enzyme	O
exhibited	O
a	O
preference	O
for	O
ATP	O
,	O
dATP	O
,	O
and	O
dCTP	O
over	O
the	O
other	O
NTP	B-PRGE
/	I-PRGE
dNTP	I-PRGE
substrates	O
.	O

Activities	O
of	O
three	O
SARS	O
coronavirus	O
enzymes	O
,	O
the	O
helicase	B-PRGE
and	O
two	O
cysteine	B-PRGE
proteinases	I-PRGE
,	O
which	O
are	O
known	O
to	O
be	O
critically	O
involved	O
in	O
replication	O
,	O
transcription	O
and	O
/	O
or	O
post	O
-	O
translational	O
polyprotein	O
processing	O
,	O
were	O
characterized	O
.	O

TITLE	O
:	O
Typing	O
of	O
field	O
isolates	O
of	O
infectious	O
bronchitis	O
virus	O
based	O
on	O
the	O
sequence	O
of	O
the	O
hypervariable	O
region	O
in	O
the	O
S1	B-PRGE
gene	I-PRGE
.	O

These	O
data	O
indicate	O
that	O
CCR5	B-PRGE
signaling	O
on	O
CD8	B-PRGE
(+)	O
T	O
cells	O
modulates	O
antiviral	O
activities	O
but	O
is	O
not	O
essential	O
for	O
entry	O
into	O
the	O
CNS	O
.	O

ABSTRACT	O
:	O
Inducible	B-PRGE
nitric	I-PRGE
oxide	I-PRGE
synthase	I-PRGE
(	O
iNOS	B-PRGE
)	O
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Corticosteroids	O
,	O
antibiotics	O
,	O
human	B-PRGE
gamma	I-PRGE
-	I-PRGE
globulin	I-PRGE
,	O
interferon	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
and	O
antiviral	O
drugs	O
,	O
although	O
used	O
empirically	O
,	O
might	O
be	O
of	O
some	O
benefits	O
in	O
shortening	O
the	O
clinical	O
course	O
.	O

The	O
positive	O
rates	O
of	O
TnI	B-PRGE
,	O
CK	O
-	O
MB	O
and	O
MYO	O
in	O
patients	O
were	O
higher	O
than	O
those	O
in	O
controls	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Here	O
,	O
the	O
cloning	O
,	O
Escherichia	O
coli	O
expression	O
,	O
purification	O
and	O
crystallization	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
Nsp9	I-PRGE
protein	I-PRGE
,	O
the	O
first	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
protein	I-PRGE
to	O
be	O
crystallized	O
,	O
are	O
reported	O
.	O

The	O
4382	O
-	O
and	O
7073	O
amino	O
acid	O
residue	O
SARS	O
-	O
CoV	O
replicase	B-PRGE
polyproteins	O
are	O
predicted	O
to	O
be	O
cleaved	O
into	O
16	O
subunits	O
by	O
two	O
viral	O
proteinases	O
(	O
bringing	O
the	O
total	O
number	O
of	O
SARS	O
-	O
CoV	O
proteins	O
to	O
28	O
).	O

These	O
findings	O
provide	O
morphological	O
evidence	O
of	O
the	O
increase	O
of	O
SP	B-PRGE
-	I-PRGE
A	I-PRGE
during	O
the	O
early	O
phase	O
of	O
ARDS	O
,	O
including	O
some	O
molecular	O
alteration	O
and	O
its	O
decrease	O
during	O
the	O
late	O
phase	O
.	O

The	O
serum	O
samples	O
were	O
taken	O
from	O
46	O
patients	O
to	O
detect	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
endotoxin	O
and	O
hepatitis	O
related	O
viral	O
inclusions	O
.	O

Abnormal	O
liver	O
function	O
mainly	O
resulted	O
from	O
ALT	B-PRGE
elevation	O
(	O
70	O
.	O
7	O
%),	O
then	O
both	O
ALT	B-PRGE
and	O
AST	B-PRGE
elevation	O
(	O
22	O
.	O
4	O
%).	O

Serum	B-PRGE
albumin	I-PRGE
and	O
prealbumin	B-PRGE
levels	O
decreased	O
in	O
24	O
.	O
0	O
%	O
and	O
28	O
.	O
6	O
%	O
patients	O
,	O
respectively	O
.	O

Infiltration	O
of	O
pancreatic	O
and	O
lung	O
tissue	O
with	O
neutrophils	O
(	O
measured	O
as	O
increase	O
in	O
myeloperoxidase	B-PRGE
activity	O
)	O
was	O
associated	O
with	O
enhanced	O
lipid	O
peroxidation	O
(	O
increased	O
tissue	O
levels	O
of	O
malondialdehyde	O
).	O

In	O
an	O
effort	O
to	O
establish	O
a	O
screening	O
program	O
for	O
high	O
risk	O
personal	O
,	O
the	O
distribution	O
of	O
HLA	B-PRGE
class	I-PRGE
I	I-PRGE
and	I-PRGE
II	I-PRGE
alleles	I-PRGE
in	O
case	O
and	O
control	O
groups	O
was	O
examined	O
for	O
the	O
presence	O
of	O
an	O
association	O
to	O
a	O
genetic	O
susceptibly	O
or	O
resistance	O
to	O
SARS	O
coronavirus	O
infection	O
.	O

After	O
selecting	O
only	O
a	O
""""	O
severe	O
cases	O
""""	O
patient	O
group	O
from	O
the	O
infected	O
""""	O
probable	O
SARS	O
""""	O
patient	O
group	O
and	O
comparing	O
them	O
with	O
the	O
high	O
risk	O
health	O
care	O
workers	O
group	O
,	O
the	O
severity	O
of	O
SARS	B-PRGE
was	O
shown	O
to	O
be	O
significantly	O
associated	O
with	O
HLA	B-PRGE
-	O
B	O
*	O
4601	O
(	O
P	O
=	O
0	O
.	O
0008	O
or	O
Pc	O
=	O
0	O
.	O
0279	O
).	O

These	O
results	O
appeared	O
to	O
indicate	O
association	O
of	O
HLA	B-PRGE
-	I-PRGE
B	I-PRGE
*	I-PRGE
4601	O
with	O
the	O
severity	O
of	O
SARS	O
infection	O
in	O
Asian	O
populations	O
.	O

The	O
following	O
interventions	O
were	O
systematically	O
reviewed	O
for	O
inclusion	O
in	O
the	O
guidelines	O
:	O
enteral	O
nutrition	O
(	O
EN	O
)	O
versus	O
parenteral	O
nutrition	O
(	O
PN	O
),	O
early	O
versus	O
late	O
EN	O
,	O
dose	O
of	O
EN	O
,	O
composition	O
of	O
EN	O
(	O
protein	O
,	O
carbohydrates	O
,	O
lipids	O
,	O
immune	O
-	O
enhancing	O
additives	O
),	O
strategies	O
to	O
optimize	O
delivery	O
of	O
EN	O
and	O
minimize	O
risks	O
(	O
ie	O
,	O
rate	O
of	O
advancement	O
,	O
checking	O
residuals	O
,	O
use	O
of	O
bedside	O
algorithms	O
,	O
motility	O
agents	O
,	O
small	O
bowel	O
versus	O
gastric	O
feedings	O
,	O
elevation	O
of	O
the	O
head	O
of	O
the	O
bed	O
,	O
closed	O
delivery	O
systems	O
,	O
probiotics	O
,	O
bolus	O
administration	O
),	O
enteral	O
nutrition	O
in	O
combination	O
with	O
supplemental	O
PN	O
,	O
use	O
of	O
PN	O
versus	O
standard	O
care	O
in	O
patients	O
with	O
an	O
intact	O
gastrointestinal	O
tract	O
,	O
dose	O
of	O
PN	O
and	O
composition	O
of	O
PN	O
(	O
protein	O
,	O
carbohydrates	O
,	O
IV	O
lipids	O
,	O
additives	O
,	O
vitamins	O
,	O
trace	O
elements	O
,	O
immune	O
enhancing	O
substances	O
),	O
and	O
the	O
use	O
of	O
intensive	O
insulin	B-PRGE
therapy	O
.	O

A	O
decrease	O
in	O
LVEF	O
correlated	O
moderately	O
with	O
an	O
elevated	O
lactate	B-PRGE
dehydrogenase	I-PRGE
level	O
(	O
r	O
=-	O
0	O
.	O
605	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
whereas	O
a	O
higher	O
IMP	O
correlated	O
weakly	O
with	O
an	O
increase	O
in	O
creatine	B-PRGE
kinase	I-PRGE
level	O
(	O
r	O
=	O
0	O
.	O
38	O
,	O
P	O
=	O
0	O
.	O
016	O
).	O

ABSTRACT	O
:	O
Fas	B-PRGE
ligand	I-PRGE
(	O
FasL	B-PRGE
)-	O
induced	O
lung	O
inflammation	O
has	O
recently	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
acute	O
respiratory	O
disease	O
syndrome	O
(	O
ARDS	O
).	O

The	O
intestinal	O
tropism	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
has	O
major	O
implications	O
on	O
clinical	O
presentation	O
and	O
viral	O
transmission	O
.	O

Nasopharyngeal	O
swab	O
specimens	O
were	O
negative	O
for	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
by	O
an	O
in	O
-	O
house	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
in	O
all	O
25	O
children	O
.	O

Serum	O
levels	O
of	O
ILs	B-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
1	I-PRGE
were	O
measured	O
in	O
all	O
subjects	O
.	O

SARS	O
patients	O
experienced	O
higher	O
concentration	O
of	O
serum	B-PRGE
IL	I-PRGE
-	I-PRGE
13	I-PRGE
compared	O
with	O
the	O
controls	O
in	O
initial	O
stage	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
but	O
returned	O
to	O
normal	O
levels	O
in	O
peak	O
stage	O
and	O
in	O
remission	O
and	O
recovery	O
stage	O
.	O

Concurrently	O
,	O
the	O
mean	O
concentration	O
of	O
serum	B-PRGE
IL	I-PRGE
-	I-PRGE
13	I-PRGE
decreased	O
gradually	O
,	O
and	O
the	O
mean	O
concentration	O
of	O
serum	B-PRGE
IL	I-PRGE
-	I-PRGE
18	I-PRGE
level	O
in	O
SARS	O
patients	O
was	O
lower	O
than	O
that	O
of	O
the	O
control	O
group	O
during	O
all	O
the	O
courses	O
of	O
SARS	O
,	O
suggesting	O
that	O
the	O
immune	O
state	O
of	O
the	O
patients	O
with	O
SARS	O
was	O
obviously	O
abnormal	O
.	O

Human	O
immunodeficiency	O
Retroviridae	O
(	O
HIVs	O
)	O
could	O
possibly	O
be	O
influenced	O
by	O
B6RA	O
and	O
BNP	B-PRGE
.	O

Finally	O
,	O
SARS	B-PRGE
also	O
emphasized	O
the	O
importance	O
of	O
the	O
duty	O
of	O
health	O
care	O
administrators	O
and	O
senior	O
physicians	O
to	O
rapidly	O
institute	O
procedures	O
to	O
maximize	O
the	O
safety	O
of	O
frontline	O
physicians	O
and	O
nurses	O
.	O

The	O
deduced	O
protein	O
was	O
a	O
polypeptide	O
of	O
218	O
amino	O
acids	O
,	O
which	O
was	O
almost	O
identical	O
to	O
human	B-PRGE
19	I-PRGE
-	I-PRGE
kD	I-PRGE
interacting	I-PRGE
protein	I-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
like	I-PRGE
(	I-PRGE
NIP3L	I-PRGE
)	I-PRGE
protein	I-PRGE
.	O

NIP3L	B-PRGE
may	O
be	O
involved	O
in	O
lung	O
injury	O
,	O
which	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
death	O
in	O
cases	O
of	O
severe	O
acute	O
pancreatitis	O
.	O

RESULTS	O
:	O
Thirty	O
six	O
caveolin	B-PRGE
-	I-PRGE
binding	I-PRGE
motifs	I-PRGE
in	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
proteins	I-PRGE
have	O
been	O
mapped	O
out	O
using	O
bioinformatics	O
analysis	O
tools	O
.	O

CONCLUSIONS	O
:	O
Caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
may	O
serve	O
as	O
a	O
possible	O
receptor	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
proteins	I-PRGE
,	O
which	O
may	O
be	O
associated	O
with	O
the	O
SARS	O
-	O
CoV	O
infection	O
,	O
replication	O
,	O
assembly	O
,	O
and	O
budding	O
.	O

RESULTS	O
:	O
The	O
positive	O
ratio	O
of	O
IgG	B-PRGE
was	O
higher	O
than	O
that	O
of	O
IgM	B-PRGE
in	O
SARS	O
patients	O
during	O
the	O
first	O
stage	O
.	O

All	O
the	O
serum	O
samples	O
from	O
the	O
1	O
,	O
060	O
non	O
-	O
SARS	O
children	O
were	O
negative	O
for	O
both	O
IgG	B-PRGE
and	O
IgM	B-PRGE
antibodies	O
against	O
SARS	O
coronavirus	O
as	O
determined	O
by	O
indirect	O
immunofluorescent	O
assay	O
,	O
with	O
only	O
two	O
serum	O
samples	O
showing	O
weak	O
positivity	O
for	O
SARS	B-PRGE
coronavirus	I-PRGE
-	I-PRGE
specific	I-PRGE
antibodies	I-PRGE
identified	O
by	O
double	O
-	O
antigen	O
sandwich	O
ELISA	O
.	O

The	O
cleavage	O
sites	O
of	O
the	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
and	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
are	O
highly	O
conserved	O
.	O

The	O
ELISA	O
kit	O
coated	O
by	O
non	O
-	O
purification	O
antigen	O
may	O
induce	O
the	O
false	O
-	O
positive	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antibody	I-PRGE
in	O
patients	O
with	O
SLE	O
.	O

TITLE	O
:	O
[	O
Detection	O
of	O
the	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
coronavirus	I-PRGE
specific	I-PRGE
antibody	I-PRGE
levels	O
in	O
156	O
SARS	O
patients	O
].	O

TITLE	O
:	O
[	O
Genomic	O
variations	O
in	O
the	O
locus	O
for	O
aminopeptidase	B-PRGE
N	I-PRGE
:	O
a	O
putative	O
cellular	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
].	O

PCP	B-PRGE
is	O
a	O
weak	O
mutagen	O
but	O
the	O
available	O
data	O
for	O
humans	O
are	O
insufficient	O
to	O
classify	O
it	O
more	O
strongly	O
than	O
as	O
a	O
probable	O
carcinogen	O
.	O

We	O
showed	O
previously	O
that	O
these	O
persistently	O
infected	O
mice	O
did	O
not	O
mount	O
a	O
measurable	O
serum	B-PRGE
anti	I-PRGE
-	I-PRGE
MHV	I-PRGE
neutralizing	I-PRGE
antibody	I-PRGE
response	O
.	O

Other	O
common	O
findings	O
were	O
lymphopenia	O
(	O
57	O
%,	O
26	O
/	O
46	O
),	O
thrombocytopenia	O
(	O
39	O
%,	O
18	O
/	O
46	O
),	O
elevated	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
63	O
%,	O
29	O
/	O
46	O
),	O
and	O
elevated	O
creatine	B-PRGE
kinase	I-PRGE
(	O
24	O
%,	O
11	O
/	O
46	O
).	O

In	O
this	O
study	O
,	O
we	O
use	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
and	O
docking	O
techniques	O
to	O
screen	O
29	O
approved	O
and	O
experimental	O
drugs	O
against	O
the	O
theoretical	O
model	O
of	O
the	O
SARS	B-PRGE
CoV	I-PRGE
proteinase	I-PRGE
as	O
well	O
as	O
the	O
experimental	O
structure	O
of	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
proteinase	O
.	O

ABSTRACT	O
:	O
5	O
'	O
and	O
3	O
'	O
UTR	O
sequences	O
on	O
the	O
coronavirus	O
genome	O
are	O
known	O
to	O
carry	O
cis	O
-	O
acting	O
elements	O
for	O
DI	B-PRGE
RNA	I-PRGE
replication	O
and	O
presumably	O
also	O
virus	O
genome	O
replication	O
.	O

The	O
clinical	O
features	O
included	O
recurrent	O
fever	O
,	O
worsened	O
breathlessness	O
,	O
exacerbation	O
in	O
radiological	O
lesions	O
and	O
elevated	O
LDH	B-PRGE
,	O
etc	O
..	O

Three	O
of	O
the	O
patients	O
were	O
homozygous	O
for	O
the	O
'	O
common	O
'	O
1528G	O
>	O
C	O
mutation	O
in	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
MTP	O
,	O
giving	O
rise	O
to	O
long	B-PRGE
-	I-PRGE
chain	I-PRGE
3	I-PRGE
-	I-PRGE
hydroxyacyl	I-PRGE
-	I-PRGE
CoA	I-PRGE
dehydrogenase	I-PRGE
deficiency	O
.	O

SARS	B-PRGE
is	O
a	O
highly	O
contagious	O
,	O
infectious	O
process	O
that	O
can	O
advance	O
to	O
significant	O
hypoxemic	O
respiratory	O
failure	O
requiring	O
ICU	O
monitoring	O
and	O
support	O
.	O

PCR	O
and	O
Southern	O
blot	O
analyses	O
showed	O
that	O
IBV	B-PRGE
S1	I-PRGE
gene	I-PRGE
was	O
integrated	O
into	O
genomic	O
DNA	O
of	O
the	O
potato	O
plant	O
and	O
most	O
transgenic	O
plants	O
had	O
two	O
copies	O
of	O
S1	B-PRGE
gene	I-PRGE
of	O
IBV	O
.	O

TITLE	O
:	O
Changes	O
in	O
some	O
acute	O
phase	O
protein	O
and	O
immunoglobulin	B-PRGE
concentrations	O
in	O
cats	O
affected	O
by	O
feline	O
infectious	O
peritonitis	O
or	O
exposed	O
to	O
feline	O
coronavirus	O
infection	O
.	O

In	O
addition	O
,	O
bioinformatic	O
analysis	O
has	O
predicted	O
a	O
number	O
of	O
enzymatic	O
activities	O
associated	O
with	O
proteins	O
of	O
the	O
viral	B-PRGE
replicase	I-PRGE
-	I-PRGE
transcriptase	I-PRGE
complex	O
.	O

The	O
serum	B-PRGE
anti	I-PRGE
-	I-PRGE
coronavirus	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
titer	O
in	O
medical	O
personnel	O
who	O
had	O
closely	O
contacted	O
with	O
SARS	O
patients	O
,	O
healthy	O
individuals	O
,	O
patients	O
with	O
community	O
acquired	O
pneumonia	O
and	O
patients	O
recovered	O
from	O
SARS	O
was	O
detected	O
by	O
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
method	O
.	O

Although	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
in	O
sera	O
decreased	O
in	O
over	O
14	O
day	O
group	O
,	O
the	O
average	O
was	O
still	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

This	O
case	O
had	O
the	O
following	O
features	O
:	O
(	O
1	O
)	O
a	O
history	O
of	O
contact	O
with	O
mild	O
cats	O
and	O
eating	O
the	O
animal	O
'	O
s	O
meat	O
;	O
(	O
2	O
)	O
high	O
fever	O
(	O
temperature	O
,	O
>	O
38	O
degrees	O
C	O
),	O
followed	O
by	O
dry	O
cough	O
,	O
rapid	O
progression	O
to	O
respiratory	O
failure	O
,	O
followed	O
by	O
radiographic	O
evidence	O
of	O
bilateral	O
air	O
-	O
space	O
lesions	O
;	O
(	O
3	O
)	O
no	O
leukocytosis	O
;	O
(	O
4	O
)	O
spread	O
to	O
4	O
family	O
members	O
who	O
had	O
had	O
direct	O
contact	O
with	O
this	O
patient	O
;	O
(	O
5	O
)	O
the	O
patient	O
'	O
s	O
serum	O
SARS	O
virus	O
IgG	B-PRGE
was	O
confirmed	O
to	O
be	O
positive	O
;	O
(	O
6	O
)	O
the	O
patient	O
was	O
treated	O
with	O
anti	O
-	O
viral	O
agents	O
,	O
antibiotics	O
and	O
mechanical	O
ventilation	O
and	O
molecular	O
adsorbent	O
re	O
-	O
circulating	O
system	O
(	O
MARS	O
).	O

Generally	O
,	O
affected	O
tissues	O
had	O
lower	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
12	I-PRGE
-	I-PRGE
p40	I-PRGE
mRNA	I-PRGE
and	O
higher	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
mRNA	I-PRGE
.	O

Although	O
no	O
differences	O
in	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
or	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	I-PRGE
were	O
measured	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
protein	I-PRGE
expression	O
was	O
greater	O
in	O
affected	O
tissues	O
and	O
demonstrated	O
a	O
shift	O
in	O
the	O
source	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
from	O
macrophages	O
to	O
lymphocytes	O
.	O

Together	O
our	O
data	O
indicate	O
that	O
ACE2	B-PRGE
is	O
a	O
functional	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O

The	O
cDNA	O
clones	O
which	O
cover	O
the	O
whole	O
genome	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PUMC2	I-PRGE
strain	O
were	O
obtained	O
.	O

RESULTS	O
:	O
Prokaryoticly	O
expressed	O
and	O
purified	O
N	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
coronavirus	I-PRGE
PUMC2	I-PRGE
strain	O
was	O
obtained	O
.	O

During	O
the	O
8th	O
-	O
12th	O
week	O
,	O
the	O
cell	O
counts	O
of	O
CD4	B-PRGE
+	I-PRGE
cell	O
[(	O
578	O
+/-	O

Using	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
ELISA	O
kit	O
to	O
detect	O
relevant	O
antibody	O
in	O
fresh	O
serum	O
of	O
healthy	O
,	O
fever	O
,	O
probable	O
,	O
and	O
suspect	O
cases	O
.	O

RESULTS	O
:	O
Statistical	O
analysis	O
by	O
means	O
of	O
SAS	O
software	O
showed	O
that	O
there	O
was	O
significant	O
decrease	O
in	O
absolute	O
counts	O
(	O
AC	O
)	O
of	O
T	O
lymphocyte	O
and	O
its	O
subsets	O
in	O
SARS	O
patients	O
when	O
compared	O
with	O
normal	O
people	O
,	O
while	O
percentages	O
(	O
PC	O
)	O
of	O
CD3	B-PRGE
+	I-PRGE
CD25	I-PRGE
+	I-PRGE
and	O
CD3	B-PRGE
+	I-PRGE
HLA	I-PRGE
-	I-PRGE
DR	I-PRGE
+	I-PRGE
subsets	I-PRGE
were	O
increased	O
markedly	O
.	O

In	O
addition	O
,	O
the	O
AC	O
and	O
PC	O
of	O
CD95	B-PRGE
+	I-PRGE
CD4	I-PRGE
+/	I-PRGE
CD4	B-PRGE
and	O
CD95	B-PRGE
+	I-PRGE
CD8	I-PRGE
/	O
CD8	B-PRGE
subset	O
in	O
group	O
III	O
were	O
highest	O
while	O
group	O
I	O
was	O
lowest	O
.	O

Because	O
the	O
RNP	B-PRGE
complexes	I-PRGE
that	O
specifically	O
interact	O
with	O
the	O
M	B-PRGE
protein	I-PRGE
are	O
selectively	O
packaged	O
into	O
MHV	O
particles	O
,	O
the	O
present	O
data	O
suggested	O
that	O
there	O
was	O
a	O
distinct	O
difference	O
between	O
N	O
protein	O
association	O
in	O
viral	O
genomic	O
RNP	O
complexes	O
that	O
undergo	O
packaging	O
into	O
virus	O
particles	O
and	O
the	O
subgenomic	O
RNP	O
complexes	O
that	O
are	O
not	O
packaged	O
into	O
MHV	O
particles	O
.	O

Tissue	O
sections	O
were	O
stained	O
with	O
haematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
),	O
and	O
in	O
situ	O
reverse	O
transcriptase	B-PRGE
polymerase	I-PRGE
chain	I-PRGE
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
on	O
lung	O
sections	O
was	O
performed	O
using	O
SARS	O
coronavirus	O
-	O
specific	O
primers	O
.	O

Matching	O
was	O
done	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
the	O
presence	O
of	O
co	O
-	O
morbidities	O
,	O
lactate	B-PRGE
dehydrogenase	I-PRGE
level	O
and	O
the	O
use	O
of	O
pulse	O
steroid	O
therapy	O
.	O

Common	O
laboratory	O
features	O
included	O
lymphopenia	O
(	O
72	O
.	O
4	O
%),	O
thrombocytopenia	O
(	O
34	O
.	O
5	O
%)	O
and	O
elevated	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
),	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
LDH	B-PRGE
),	O
and	O
aspartate	B-PRGE
aminotransferase	I-PRGE
(	O
AST	B-PRGE
)	O
(	O
93	O
.	O
1	O
,	O
62	O
.	O
1	O
,	O
44	O
.	O
8	O
%,	O
respectively	O
).	O

Smaller	B-PRGE
S	I-PRGE
protein	I-PRGE
fragments	I-PRGE
,	O
expressing	O
residues	O
327	O
-	O
510	O
or	O
318	O
-	O
490	O
,	O
did	O
not	O
detectably	O
bind	O
ACE2	B-PRGE
.	O

The	O
analyses	O
support	O
a	O
mammalian	O
-	O
like	O
origin	O
for	O
the	O
replicase	B-PRGE
protein	I-PRGE
,	O
an	O
avian	O
-	O
like	O
origin	O
for	O
the	O
matrix	B-PRGE
and	I-PRGE
nucleocapsid	I-PRGE
proteins	I-PRGE
,	O
and	O
a	O
mammalian	O
-	O
avian	O
mosaic	O
origin	O
for	O
the	O
host	O
-	O
determining	O
spike	O
protein	O
.	O

We	O
assessed	O
the	O
abilities	O
of	O
these	O
three	O
types	O
of	O
soMHVR	O
to	O
bind	O
to	O
MHV	O
,	O
activate	O
fusogenicity	O
,	O
and	O
induce	O
conformational	O
changes	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
membrane	O
-	O
associated	O
carboxypeptidase	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
is	O
an	O
essential	O
regulator	O
of	O
heart	O
function	O
.	O

This	O
increases	O
protection	O
of	O
the	O
laying	O
birds	O
against	O
egg	O
production	O
losses	O
and	O
induces	O
a	O
sustained	O
level	O
of	O
serum	B-PRGE
antibody	I-PRGE
,	O
which	O
is	O
passed	O
to	O
progeny	O
.	O

The	O
neuraminidase	B-PRGE
inhibitors	I-PRGE
(	O
NAIs	O
)	O
are	O
a	O
new	O
class	O
of	O
antiviral	O
drug	O
targeting	O
a	O
viral	O
influenza	O
enzyme	O
,	O
the	O
neuraminidase	B-PRGE
,	O
which	O
acts	O
both	O
to	O
facilitate	O
virus	O
infection	O
of	O
cells	O
by	O
clearing	O
a	O
passage	O
through	O
otherwise	O
protective	O
respiratory	O
fluids	O
and	O
also	O
by	O
helping	O
release	O
of	O
the	O
virus	O
by	O
cutting	O
the	O
chemical	O
umbilical	O
cord	O
which	O
links	O
up	O
the	O
virus	O
to	O
the	O
infected	O
cell	O
.	O

A	O
series	O
of	O
co	O
-	O
immunoprecipitation	O
assays	O
have	O
established	O
that	O
these	O
four	O
MHV	B-PRGE
RNA	I-PRGE
binding	I-PRGE
proteins	I-PRGE
are	O
associated	O
,	O
even	O
in	O
the	O
absence	O
of	O
MHV	O
RNA	O
.	O

Salmonella	B-PRGE
spp	I-PRGE
were	O
not	O
isolated	O
.	O

The	O
interferon	B-PRGE
alfacon	I-PRGE
-	I-PRGE
1	I-PRGE
treatment	O
group	O
had	O
a	O
shorter	O
time	O
to	O
50	O
%	O
resolution	O
of	O
lung	O
radiographic	O
abnormalities	O
(	O
median	O
time	O
,	O
4	O
days	O
vs	O
9	O
days	O
;	O
P	O
=.	O
001	O
),	O
had	O
better	O
oxygen	O
saturation	O
(	O
P	O
=.	O
02	O
),	O
resolved	O
their	O
need	O
for	O
supplemental	O
oxygen	O
more	O
rapidly	O
(	O
median	O
,	O
10	O
days	O
vs	O
16	O
days	O
;	O
P	O
=.	O
02	O
),	O
had	O
less	O
of	O
an	O
increase	O
in	O
creatine	B-PRGE
kinase	I-PRGE
levels	O
(	O
P	O
=.	O
03	O
),	O
and	O
showed	O
a	O
trend	O
toward	O
more	O
rapid	O
resolution	O
of	O
lactate	B-PRGE
dehydrogenase	I-PRGE
levels	O
compared	O
with	O
the	O
group	O
receiving	O
corticosteroids	O
alone	O
.	O

These	O
results	O
indicate	O
that	O
CXCL10	B-PRGE
expression	O
plays	O
a	O
pivotal	O
role	O
in	O
defense	O
following	O
coronavirus	O
infection	O
of	O
the	O
CNS	O
by	O
enhancing	O
innate	O
immune	O
responses	O
.	O

This	O
element	O
,	O
beginning	O
immediately	O
downstream	O
of	O
the	O
nucleocapsid	B-PRGE
gene	I-PRGE
stop	O
codon	O
,	O
was	O
shown	O
to	O
be	O
essential	O
for	O
virus	O
replication	O
.	O

Plasma	O
inflammatory	O
cytokine	O
concentrations	O
(	O
interleukin	B-PRGE
[	I-PRGE
IL	I-PRGE
]-	I-PRGE
1beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
IL	O
-	O
12p70	O
,	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
were	O
monitored	O
longitudinally	O
on	O
admission	O
,	O
immediately	O
before	O
corticosteroids	O
,	O
and	O
1	O
to	O
2	O
days	O
and	O
7	O
to	O
10	O
days	O
after	O
the	O
drug	O
treatment	O
in	O
a	O
cohort	O
of	O
pediatric	O
patients	O
(	O
n	O
=	O
8	O
)	O
with	O
virologic	O
confirmed	O
SARS	O
-	O
associated	O
coronavirus	O
infection	O
.	O

Pediatric	O
SARS	O
patients	O
have	O
markedly	O
elevated	O
circulating	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
levels	O
,	O
which	O
suggests	O
selective	O
activation	O
of	O
the	O
caspase	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
dependent	O
pathway	O
.	O

Serum	O
ALT	B-PRGE
,	O
AST	B-PRGE
,	O
LDH	B-PRGE
and	O
CK	O
were	O
elevated	O
in	O
45	O
.	O
2	O
%,	O
29	O
.	O
4	O
%,	O
42	O
.	O
1	O
%,	O
and	O
18	O
.	O
3	O
%	O
of	O
the	O
patients	O
respectively	O
.	O

TITLE	O
:	O
Antigenicity	O
and	O
receptor	O
-	O
binding	O
ability	O
of	O
recombinant	B-PRGE
SARS	I-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

RESULTS	O
:	O
Diagnostic	O
test	O
results	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
were	O
available	O
for	O
110	O
of	O
the	O
117	O
patients	O
.	O

Infliximab	O
treatment	O
significantly	O
decreased	O
serum	O
amylase	B-PRGE
activity	O
(	O
11939	O
+/-	O

The	O
ACE2	B-PRGE
sequence	I-PRGE
is	O
similar	O
(	O
sequence	O
identities	O
43	O
%	O
and	B-PRGE
35	O
%,	O
and	O
similarities	O
61	O
%	O
and	O
55	O
%,	O
respectively	O
)	O
to	O
those	O
of	O
the	O
testis	O
-	O
specific	O
form	O
of	O
ACE	B-PRGE
(	O
tACE	B-PRGE
)	O
and	O
the	O
Drosophila	B-PRGE
homolog	I-PRGE
of	I-PRGE
ACE	I-PRGE
(	O
AnCE	B-PRGE
).	O

The	O
complex	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
pathway	O
offers	O
a	O
variety	O
of	O
potential	O
molecular	O
targets	O
for	O
chemotherapeutic	O
intervention	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
an	O
epitope	O
-	O
specific	O
CD8	B-PRGE
(+)	O
T	O
-	O
cell	O
response	O
on	O
acute	O
infection	O
of	O
MHV	O
,	O
strain	O
A59	O
,	O
in	O
the	O
murine	O
CNS	O
.	O

Virus	O
recovered	O
from	O
perforin	B-PRGE
-	O
deficient	O
mice	O
did	O
not	O
exhibit	O
loss	O
of	O
EGFP	O
expression	O
and	O
the	O
gp33	B-PRGE
-	I-PRGE
41	I-PRGE
epitope	I-PRGE
.	O

ABSTRACT	O
:	O
To	O
prepare	O
and	O
characterize	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
against	O
S1	B-PRGE
protein	I-PRGE
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

6	O
-	O
His	O
-	O
tagged	O
recombinant	O
fragment	O
at	O
N	O
-	O
terminal	O
residues	O
249	O
to	O
667	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S1	I-PRGE
protein	I-PRGE
including	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
was	O
expressed	O
in	O
E	O
.	O
coli	O
.	O

RESULTS	O
:	O
Three	O
hybridomas	O
producing	O
mAbs	O
specific	O
to	O
the	O
S1	B-PRGE
domain	I-PRGE
was	O
obtained	O
,	O
with	O
a	O
relative	O
molecular	O
mass	O
of	O
48	O
,	O
500	O
.	O

TITLE	O
:	O
[	O
Amplification	O
and	O
cloning	O
of	O
the	O
N	B-PRGE
gene	I-PRGE
of	O
SARS	O
-	O
associated	O
coronavirus	O
].	O

Furthermore	O
,	O
the	O
result	O
of	O
recombinant	B-PRGE
-	I-PRGE
protein	I-PRGE
-	O
based	O
WB	O
showed	O
a	O
90	O
%	O
agreement	O
with	O
that	O
of	O
the	O
whole	O
-	O
virus	O
-	O
based	O
immunofluorescence	O
assay	O
.	O

Cdyn	O
and	O
Raw	B-PRGE
were	O
only	O
improved	O
for	O
short	O
time	O
in	O
the	O
Surf	O
,	O
NO	O
and	O
SNO	O
groups	O
.	O

iNO	B-PRGE
had	O
a	O
mild	O
response	O
at	O
1	O
x	O
10	O
(-	O
6	O
)	O
to	O
good	O
response	O
at	O
10	O
and	O
20	O
x	O
10	O
(-	O
6	O
),	O
but	O
no	O
further	O
improvement	O
occurred	O
at	O
40	O
x	O
10	O
(-	O
6	O
).	O

The	O
mouse	B-PRGE
serum	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
was	O
measured	O
by	O
ELISA	O
with	O
E	O
.	O
coli	O
expressed	O
truncated	B-PRGE
S	I-PRGE
protein	I-PRGE
or	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
lysate	O
as	O
diagnostic	O
antigen	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
mentioned	O
above	O
suggest	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
responding	O
to	O
host	O
immunological	O
pressures	O
and	O
experiencing	O
variation	O
which	O
provide	O
clues	O
,	O
information	O
and	O
evidence	O
of	O
molecular	O
biology	O
for	O
the	O
clinical	O
pathology	O
,	O
vaccine	O
developing	O
and	O
epidemic	O
investigation	O
.	O

Nested	O
RT	O
-	O
PCR	O
was	O
also	O
developed	O
to	O
detect	O
SARS	B-PRGE
coronavirus	I-PRGE
gene	I-PRGE
fragment	I-PRGE
from	O
the	O
specimens	O
.	O

The	O
serum	O
collected	O
before	O
her	O
discharge	O
from	O
the	O
hospital	O
(	O
19	O
days	O
after	O
the	O
onset	O
of	O
the	O
disease	O
)	O
showed	O
SARS	B-PRGE
specific	O
IgM	B-PRGE
and	O
IgG	B-PRGE
antibodies	I-PRGE
.	O

IgG	B-PRGE
and	O
IgM	B-PRGE
antibodies	O
to	O
Mycoplasma	O
pneumoniae	O
and	O
Chlamydia	O
pneumoniae	O
as	O
well	O
as	O
blood	O
culture	O
for	O
bacteria	O
were	O
all	O
negative	O
.	O

These	O
results	O
indicated	O
that	O
the	O
expressed	O
N	B-PRGE
protein	I-PRGE
is	O
a	O
superior	O
source	O
of	O
TCoV	B-PRGE
antigen	I-PRGE
for	O
development	O
of	O
antibody	O
-	O
capture	O
ELISA	O
for	O
detection	O
of	O
antibodies	O
to	O
TCoV	O
.	O

Herein	O
we	O
show	O
that	O
this	O
process	O
of	O
bystander	O
T	O
-	O
cell	O
-	O
mediated	O
demyelination	O
is	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)-	O
dependent	O
.	O

TITLE	O
:	O
Perforin	B-PRGE
and	O
gamma	B-PRGE
interferon	I-PRGE
-	O
mediated	O
control	O
of	O
coronavirus	O
central	O
nervous	O
system	O
infection	O
by	O
CD8	B-PRGE
T	I-PRGE
cells	O
in	O
the	O
absence	O
of	O
CD4	B-PRGE
T	I-PRGE
cells	O
.	O

In	O
contrast	O
,	O
cells	O
that	O
secreted	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
but	O
lacked	O
cytolytic	O
activity	O
inhibited	O
replication	O
in	O
oligodendroglia	O
,	O
but	O
not	O
astrocytes	O
.	O

These	O
data	O
demonstrate	O
the	O
effective	O
control	O
of	O
virus	O
replication	O
by	O
CD8	B-PRGE
(+)	O
T	O
cells	O
in	O
the	O
absence	O
of	O
CD4	B-PRGE
(+)	O
T	O
cells	O
and	O
support	O
the	O
necessity	O
for	O
the	O
expression	O
of	O
distinct	O
effector	O
mechanisms	O
in	O
the	O
control	O
of	O
viral	O
replication	O
in	O
distinct	O
CNS	O
glial	O
cell	O
types	O
.	O

ACE2	B-PRGE
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
heart	O
function	O
and	O
also	O
as	O
a	O
functional	O
receptor	O
for	O
the	O
coronavirus	O
that	O
causes	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Further	O
studies	O
showed	O
the	O
susceptibility	O
of	O
this	O
cell	O
was	O
due	O
to	O
the	O
expression	O
of	O
endogenous	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
which	O
was	O
activated	O
by	O
inserted	O
LTR	O
from	O
retroviral	O
vector	O
used	O
for	O
expression	O
cloning	O
.	O

TITLE	O
:	O
Association	O
of	O
endogenous	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
with	O
anti	O
-	O
inflammatory	O
mediators	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Results	O
in	O
patients	O
with	O
ARDS	O
and	O
ALI	O
exhibited	O
significant	O
positive	O
correlations	O
in	O
BALF	O
of	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
levels	O
with	O
that	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
sTNFRII	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
1RA	I-PRGE
and	O
of	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
levels	O
in	O
serum	O
with	O
that	O
of	O
serum	B-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1RA	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
.	O

Given	O
the	O
potential	O
of	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
to	O
directly	O
induce	O
anti	O
-	O
inflammatory	O
cytokines	O
in	O
vitro	O
,	O
significant	O
associations	O
of	O
endogenous	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
levels	O
with	O
these	O
mediators	O
early	O
in	O
the	O
development	O
of	O
severe	O
lung	O
injury	O
suggest	O
an	O
endogenous	O
anti	O
-	O
inflammatory	O
role	O
of	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
in	O
vivo	O
.	O

The	O
molecular	O
weight	O
of	O
recombinant	B-PRGE
fusion	I-PRGE
protein	I-PRGE
is	O
about	O
64	O
000	O
.	O

The	O
recombinant	B-PRGE
S1	I-PRGE
protein	I-PRGE
could	O
react	O
with	O
three	O
antibody	O
positive	O
samples	O
from	O
recovered	O
SARS	O
patients	O
,	O
which	O
showed	O
specific	O
bands	O
at	O
64	O
000	O
,	O
but	O
not	O
with	O
the	O
control	O
samples	O
according	O
to	O
results	O
of	O
western	O
blot	O
.	O

Instead	O
,	O
similar	O
to	O
the	O
MHV	O
-	O
JHM	O
infection	O
,	O
reduced	O
survival	O
following	O
S4R22	O
infection	O
was	O
observed	O
in	O
the	O
presence	O
of	O
elevated	O
MIP	B-PRGE
-	I-PRGE
1alpha	I-PRGE
and	O
MIP	B-PRGE
-	I-PRGE
1beta	I-PRGE
mRNA	I-PRGE
accumulation	O
and	O
enhanced	O
macrophage	O
numbers	O
within	O
infected	O
brains	O
.	O

Furthermore	O
,	O
high	O
levels	O
of	O
macrophage	B-PRGE
-	I-PRGE
inflammatory	I-PRGE
protein	I-PRGE
(	I-PRGE
MIP	I-PRGE
)-	I-PRGE
1alpha	I-PRGE
,	O
MIP	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
and	O
MIP	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	I-PRGE
were	O
observed	O
at	O
the	O
onset	O
of	O
MHV	O
-	O
JHM	O
infection	O
and	O
correlated	O
with	O
a	O
marked	O
elevation	O
in	O
the	O
number	O
of	O
macrophages	O
in	O
the	O
brain	O
on	O
day	O
7	O
compared	O
to	O
MHV	O
-	O
A59	O
infection	O
.	O

Currently	O
,	O
an	O
antisense	O
drug	O
targeting	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
G3139	O
/	O
Genasense	O
(	O
TM	O
),	O
Genta	O
,	O
Inc	O
.)	O
is	O
in	O
late	O
-	O
stage	O
cancer	O
trials	O
and	O
may	O
be	O
on	O
the	O
market	O
for	O
those	O
indications	O
in	O
months	O
.	O

ABSTRACT	O
:	O
We	O
measured	O
CD8	B-PRGE
T	I-PRGE
cell	O
clonotypic	O
diversity	O
to	O
three	O
epitopes	O
recognized	O
in	O
C57BL	O
/	O
6	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
,	O
strain	O
JHM	O
,	O
or	O
lymphocytic	O
choriomeningitis	O
virus	O
.	O

They	O
identified	O
a	O
combination	O
of	O
mutations	O
in	O
the	O
S1	B-PRGE
gene	I-PRGE
(	O
I375M	O
and	O
L652I	O
)	O
that	O
abolishes	O
demyelination	O
.	O

The	O
antiviral	O
mechanism	O
of	O
GA	O
appears	O
to	O
be	O
associated	O
with	O
Hsp90	B-PRGE
inactivation	O
and	O
cell	O
cycle	O
restoration	O
,	O
which	O
indicates	O
that	O
GA	O
exhibits	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
.	O

80R	O
scFv	O
competed	O
with	O
soluble	O
ACE2	B-PRGE
for	O
association	O
with	O
the	O
S1	B-PRGE
domain	I-PRGE
and	O
bound	O
S1	O
with	O
high	O
affinity	O
(	O
equilibrium	O
dissociation	O
constant	O
,	O
Kd	O
=	O
32	O
.	O
3	O
nM	O
).	O

Lopinavir	O
/	O
ritonavir	O
treatment	O
was	O
associated	O
with	O
a	O
better	O
outcome	O
even	O
when	O
adjusted	O
for	O
baseline	O
lactate	B-PRGE
dehydrogenase	I-PRGE
level	O
.	O

ABSTRACT	O
:	O
The	O
spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
of	O
coronaviruses	O
mediates	O
viral	O
entry	O
into	O
host	O
cells	O
.	O

Here	O
,	O
we	O
report	O
the	O
crystal	O
structure	O
at	O
2	O
.	O
7	O
-	O
A	O
resolution	O
of	O
nsp9	O
,	O
a	O
hitherto	O
uncharacterized	O
subunit	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
replicative	I-PRGE
polyproteins	I-PRGE
.	O

Staphylococcus	O
aureus	O
Cowan	O
1	O
(	O
SAC	O
)-	O
stimulated	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
secreting	O
cells	O
were	O
increased	O
in	O
early	O
SARS	O
but	O
fell	O
during	O
treatment	O
.	O

A	O
panel	O
of	O
S	O
protein	O
-	O
derived	O
peptides	O
was	O
tested	O
for	O
their	O
binding	O
affinity	O
to	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
0201	I-PRGE
molecules	O
.	O

We	O
propose	O
that	O
the	O
newly	O
identified	O
epitope	B-PRGE
SSp	I-PRGE
-	I-PRGE
1	I-PRGE
will	O
help	O
in	O
the	O
characterization	O
of	O
virus	O
control	O
mechanisms	O
and	O
immunopathology	O
in	O
SARS	O
-	O
CoV	O
infection	O
,	O
and	O
may	O
be	O
relevant	O
to	O
the	O
development	O
of	O
immunotherapeutic	O
approaches	O
for	O
SARS	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
has	O
probably	O
jumped	O
from	O
an	O
animal	O
host	O
to	O
humans	O
.	O

Common	O
laboratory	O
features	O
include	O
lymphopenia	O
with	O
depletion	O
of	O
CD4	B-PRGE
and	O
CD8	B-PRGE
lymphocytes	O
,	O
thrombocytopenia	O
,	O
prolonged	O
activated	O
partial	O
thromboplastin	B-PRGE
time	O
,	O
elevated	O
D	O
-	O
Dimer	O
,	O
elevated	O
alanine	O
transminases	O
,	O
lactate	B-PRGE
dehydrogenase	I-PRGE
and	O
creatinine	B-PRGE
kinase	I-PRGE
.	O

Furthermore	O
,	O
mutational	O
analyses	O
characterized	O
that	O
a	O
serine	O
/	O
arginine	O
-	O
rich	O
motif	O
(	O
SSRSSSRSRGNSR	O
)	O
between	O
amino	O
acids	O
184	O
and	O
196	O
is	O
crucial	O
for	O
N	B-PRGE
protein	I-PRGE
oligomerization	O
,	O
since	O
deletion	O
of	O
this	O
region	O
completely	O
abolished	O
the	O
N	B-PRGE
protein	I-PRGE
self	O
-	O
multimerization	O
.	O

Bilateral	O
femur	O
fracture	O
produced	O
a	O
significant	O
lung	O
injury	O
,	O
measured	O
by	O
increases	O
in	O
MPO	O
(	O
25	O
-	O
43	O
microg	O
/	O
g	O
tissue	O
)	O
and	O
BAL	B-PRGE
protein	I-PRGE
(	O
460	O
-	O
605	O
microg	O
/	O
mL	O
).	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
four	O
serologic	O
tests	O
(	O
neutralization	O
test	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
[	O
ELISA	O
],	O
immunofluorescent	O
assay	O
[	O
IFA	O
],	O
and	O
immunochromatographic	O
test	O
[	O
ICT	O
])	O
for	O
detecting	O
antibodies	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
sera	O
of	O
537	O
probable	O
SARS	O
case	O
-	O
patients	O
with	O
correlation	O
to	O
the	O
RT	O
-	O
PCR	O
.	O

Here	O
,	O
we	O
report	O
that	O
recombinant	B-PRGE
human	I-PRGE
interferon	I-PRGE
-	I-PRGE
beta	I-PRGE
1a	I-PRGE
potently	O
inhibits	O
SARS	O
coronavirus	O
replication	O
in	O
vitro	O
.	O

Western	O
-	O
blot	O
analysis	O
showed	O
that	O
the	O
nucleocapsid	O
protein	O
and	O
spike	O
polypeptide	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
are	O
highly	O
immunogenic	O
.	O

Many	O
biological	O
functions	O
involve	O
formation	O
of	O
protein	B-PRGE
-	I-PRGE
protein	I-PRGE
complexes	I-PRGE
;	O
in	O
which	O
the	O
protein	O
molecules	O
behave	O
dynamically	O
in	O
the	O
course	O
of	O
binding	O
.	O

Anti	B-PRGE
-	I-PRGE
CCL5	I-PRGE
treatment	O
decreased	O
T	O
cell	O
accumulation	O
within	O
the	O
CNS	O
based	O
,	O
in	O
part	O
,	O
on	O
viral	O
Ag	O
specificity	O
,	O
indicating	O
the	O
ability	O
to	O
differentially	O
target	O
select	O
populations	O
of	O
T	O
cells	O
.	O

The	O
tissue	O
concentrations	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
-	O
1	O
(	O
CINC	O
-	O
1	O
)	O
were	O
also	O
measured	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-PRGE
acute	I-PRGE
respiratory	I-PRGE
syndrome	I-PRGE
(	O
SARS	B-PRGE
)	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
consists	O
of	O
two	O
distinct	O
folds	O
,	O
namely	O
the	O
N	O
-	O
terminal	O
chymotrypsin	B-PRGE
fold	O
containing	O
the	O
domains	O
I	O
and	O
II	O
hosting	O
the	O
complete	O
catalytic	O
machinery	O
and	O
the	O
C	O
-	O
terminal	O
extra	O
helical	O
domain	O
III	O
unique	O
for	O
the	O
coronavirus	O
3CL	O
proteases	O
.	O

To	O
understand	O
the	O
functional	O
role	O
of	O
the	O
extra	O
domain	O
and	O
to	O
characterize	O
the	O
enzyme	O
-	O
substrate	O
interactions	O
by	O
use	O
of	O
the	O
dynamic	O
light	O
scattering	O
,	O
circular	O
dichroism	O
,	O
and	O
NMR	O
spectroscopy	O
,	O
we	O
1	O
)	O
dissected	O
the	O
full	O
-	O
length	O
SARS	B-PRGE
3CL	I-PRGE
protease	I-PRGE
into	O
two	O
distinct	O
folds	O
and	O
subsequently	O
investigated	O
their	O
structural	O
and	O
dimerization	O
properties	O
and	O
2	O
)	O
studied	O
the	O
structural	O
and	O
binding	O
interactions	O
of	O
three	O
substrate	O
peptides	O
with	O
the	O
entire	O
enzyme	O
and	O
its	O
two	O
dissected	O
folds	O
.	O

The	O
data	O
indicate	O
that	O
measurement	O
of	O
sPLA2	B-PRGE
can	O
be	O
useful	O
in	O
alerting	O
the	O
clinician	O
to	O
patients	O
with	O
impending	O
ACS	O
,	O
and	O
suggest	O
that	O
instituting	O
early	O
therapies	O
based	O
on	O
sPLA2	B-PRGE
levels	O
,	O
including	O
inhibition	O
of	O
sPLA2	B-PRGE
activity	O
,	O
may	O
be	O
useful	O
to	O
prevent	O
or	O
reduce	O
the	O
clinical	O
morbidity	O
of	O
ACS	O
in	O
sickle	O
cell	O
disease	O
.	O

Antisera	O
collected	O
1	O
week	O
after	O
the	O
second	O
immunization	O
were	O
analyzed	O
by	O
ELISA	O
and	O
tested	O
for	O
antibody	O
specificity	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
by	O
immunofluorescent	O
confocal	O
microscopy	O
.	O

This	O
suggested	O
that	O
our	O
S5	O
and	O
S6	O
peptides	O
may	O
represent	O
two	O
minimum	O
biologically	O
active	O
sequences	O
of	O
the	O
immunogenic	O
regions	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
.	O

Serum	O
total	O
LD	O
and	O
LD	O
isoenzyme	O
activities	O
,	O
complete	O
blood	O
picture	O
with	O
total	O
leucocyte	O
count	O
and	O
differential	O
counts	O
,	O
absolute	O
counts	O
of	O
CD3	B-PRGE
+,	I-PRGE
CD4	B-PRGE
+,	I-PRGE
CD8	B-PRGE
+,	I-PRGE
natural	O
killer	O
cells	O
and	O
B	O
lymphocytes	O
were	O
measured	O
daily	O
upon	O
admission	O
.	O

Age	B-PRGE
was	O
found	O
to	O
be	O
an	O
independent	O
prognostic	O
indicator	O
for	O
death	O
with	O
an	O
area	O
under	O
curve	O
(	O
AUC	O
)	O
of	O
0	O
.	O
96	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
0	O
.	O
90	O
-	O
0	O
.	O
99	O
]	O
but	O
not	O
for	O
admission	O
to	O
ICU	O
[	O
AUC	O
=	O
0	O
.	O
61	O
(	O
CI	O
=	O
0	O
.	O
51	O
-	O
0	O
.	O
70	O
)].	O

Blood	O
CD3	B-PRGE
+,	I-PRGE
CD4	B-PRGE
+,	I-PRGE
CD8	B-PRGE
+	I-PRGE
and	O
natural	O
killer	O
cell	O
counts	O
were	O
found	O
to	O
be	O
good	O
prognostic	O
indicators	O
for	O
predicting	O
admission	O
to	O
ICU	O
in	O
patients	O
with	O
SARS	O
compared	O
with	O
age	O
,	O
leucocyte	O
count	O
and	O
LD	O
isoenzymes	O
.	O

The	O
suppressed	O
CD3	B-PRGE
+,	I-PRGE
CD4	B-PRGE
+,	I-PRGE
CD8	B-PRGE
+,	I-PRGE
and	O
natural	O
killer	O
cell	O
counts	O
were	O
also	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
SARS	O
.	O

Acute	O
lung	O
injury	O
was	O
associated	O
with	O
higher	O
PRL	B-PRGE
serum	O
level	O
and	O
was	O
independent	O
from	O
the	O
LH	O
and	O
T	O
serum	O
level	O
.	O

Several	O
investigations	O
showed	O
a	O
close	O
association	O
of	O
single	O
or	O
multiple	O
parameters	O
,	O
such	O
as	O
total	O
antioxidative	O
capacity	O
,	O
lipid	O
peroxidation	O
,	O
vitamins	O
C	O
and	O
E	O
,	O
the	O
activation	O
of	O
nuclear	B-PRGE
factor	I-PRGE
kappa	I-PRGE
B	I-PRGE
,	O
and	O
respiratory	O
burst	O
,	O
with	O
the	O
patient	O
'	O
s	O
outcome	O
.	O

Since	O
SARS	B-PRGE
3CL	I-PRGE
proteinase	I-PRGE
belongs	O
to	O
the	O
cysteine	O
protease	O
family	O
(	O
family	O
C3	O
in	O
clan	O
CB	O
)	O
with	O
a	O
chymotrypsin	B-PRGE
fold	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
catalytic	O
mechanism	O
of	O
SARS	B-PRGE
3CL	I-PRGE
proteinase	I-PRGE
to	O
determine	O
whether	O
the	O
proteolysis	O
proceeds	O
through	O
a	O
general	O
base	O
catalysis	O
mechanism	O
like	O
chymotrypsin	B-PRGE
or	O
an	O
ion	O
pair	O
mechanism	O
like	O
papain	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
possible	O
noncanonical	O
interactions	O
,	O
potential	O
inhibitors	O
,	O
and	O
binding	O
pockets	O
in	O
the	O
main	O
proteinase	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
based	O
on	O
its	O
recently	O
determined	O
crystal	O
structure	O
.	O

A	O
significant	O
association	O
between	O
the	O
history	O
of	O
positive	O
exposure	O
to	O
pesticides	O
(	O
i	O
.	O
e	O
.	O
the	O
women	O
themselves	O
or	O
their	O
newborns	O
who	O
showed	O
acetylcholinesterase	B-PRGE
activity	O
levels	O
lower	O
than	O
20	O
%)	O
and	O
the	O
presence	O
of	O
IUGR	O
was	O
found	O
.	O

ABSTRACT	O
:	O
Chronic	O
Immune	O
Dysschwannian	O
/	O
Dysneuronal	O
Polyneuropathy	O
is	O
an	O
autoimmune	O
peripheral	O
-	O
nerve	O
and	O
/	O
or	O
nerve	O
-	O
root	O
disorder	O
known	O
to	O
usually	O
respond	O
to	O
intravenous	O
immunoglobulin	B-PRGE
-	I-PRGE
G	I-PRGE
treatment	O
.	O

Intravenous	O
immunoglobulin	B-PRGE
-	I-PRGE
G	I-PRGE
is	O
herein	O
suggested	O
as	O
a	O
treatment	O
for	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
,	O
a	O
recent	O
,	O
and	O
feared	O
-	O
repetitive	O
,	O
pandemic	O
with	O
many	O
fatalities	O
caused	O
by	O
a	O
highly	O
-	O
contagious	O
mutant	O
coronavirus	O
,	O
for	O
which	O
there	O
is	O
no	O
definitive	O
treatment	O
.	O

Intravenous	O
immunoglobulin	B-PRGE
-	I-PRGE
G	I-PRGE
might	O
:	O
a	O
)	O
combat	O
a	O
dysimmune	O
component	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
,	O
including	O
the	O
reactive	O
cytokine	O
-	O
chemokine	O
storm	O
against	O
respiratory	O
tissues	O
;	O
b	O
)	O
contain	O
some	O
antibodies	O
effective	O
against	O
the	O
coronavirus	O
non	O
-	O
specific	O
components	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
;	O
c	O
)	O
block	O
host	O
-	O
cell	O
receptors	O
for	O
the	O
virus	O
;	O
and	O
d	O
)	O
counteract	O
secondary	O
infections	O
.	O

TITLE	O
:	O
Respiratory	O
and	O
fecal	O
shedding	O
of	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
in	O
sentinel	O
weaned	O
pigs	O
and	O
sequence	O
of	O
the	O
partial	B-PRGE
S	I-PRGE
-	I-PRGE
gene	I-PRGE
of	O
the	O
PRCV	O
isolates	O
.	O

The	O
recommendation	O
to	O
use	O
Biosafety	O
Level	O
(	O
BSL	O
)	O
3	O
practices	O
within	O
a	O
BSL2	B-PRGE
environment	O
appears	O
to	O
have	O
been	O
a	O
practical	O
decision	O
based	O
on	O
available	O
resources	O
;	O
most	O
diagnostic	O
laboratories	O
operate	O
at	O
BSL2	B-PRGE
.	O

Furthermore	O
,	O
pediatric	O
PMs	O
had	O
an	O
11	O
-	O
fold	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
-	O
induced	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
production	O
,	O
while	O
adult	O
PMs	O
did	O
not	O
produce	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
.	O

Therefore	O
,	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
induces	O
both	O
a	O
pro	O
-	O
and	O
an	O
anti	O
-	O
inflammatory	O
response	O
in	O
pediatric	O
PMs	O
,	O
whereas	O
adult	O
PMs	O
produce	O
only	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
response	O
to	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
.	O

The	O
exaggerated	O
anti	B-PRGE
-	I-PRGE
inflammatory	I-PRGE
IL	I-PRGE
-	I-PRGE
10	I-PRGE
response	O
in	O
children	O
may	O
be	O
an	O
important	O
factor	O
in	O
the	O
observed	O
differences	O
in	O
ALI	O
between	O
children	O
and	O
adults	O
.	O

Exact	O
knowledge	O
of	O
how	O
the	O
immune	O
system	O
handles	O
protein	O
antigens	O
would	O
allow	O
for	O
the	O
identification	O
of	O
such	O
linear	O
sequences	O
directly	O
from	O
genomic	O
/	O
proteomic	O
sequence	O
information	O
(	O
Lauemoller	O
et	O
al	O
.,	O
Rev	B-PRGE
Immunogenet	I-PRGE
2001	O
:	O
2	O
:	O
477	O
-	O
91	O
).	O

We	O
have	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
)	O
as	O
well	O
as	O
a	O
truncated	O
form	O
containing	O
only	O
the	O
catalytic	O
domains	O
.	O

TITLE	O
:	O
Tissue	O
distribution	O
of	O
a	O
feline	O
AGP	O
related	O
protein	O
(	O
fAGPrP	O
)	O
in	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	B-PRGE
).	O

The	O
overall	O
positive	O
rate	O
of	O
specific	O
IgG	B-PRGE
and	O
IgM	B-PRGE
was	O
2	O
.	O
57	O
%	O
(	O
29	O
/	O
1	O
127	O
);	O
the	O
positive	O
rates	O
in	O
nurses	O
,	O
doctors	O
and	O
laboratory	O
workers	O
,	O
and	O
supervisors	O
were	O
3	O
.	O
46	O
%,	O
1	O
.	O
41	O
%,	O
2	O
.	O
86	O
%,	O
respectively	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
two	O
second	O
-	O
generation	O
,	O
replicase	B-PRGE
(	O
R	O
)	O
gene	O
-	O
based	O
,	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
test	O
kits	O
--	O
the	O
RealArt	O
HPA	O
coronavirus	O
LC	O
kit	O
(	O
Artus	O
,	O
Hamburg	O
,	O
Germany	O
)	O
and	O
the	O
LightCycler	O
SARS	O
-	O
CoV	O
quantification	O
kit	O
(	O
Roche	O
,	O
Penzberg	O
,	O
Germany	O
)--	O
and	O
a	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
for	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
.	O

Alanine	B-PRGE
aminotransferase	I-PRGE
(	O
ALT	B-PRGE
),	O
aspartate	B-PRGE
aminotransferase	I-PRGE
(	O
AST	B-PRGE
),	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
LDH	B-PRGE
),	O
total	O
bilirubin	O
(	O
TBil	O
)	O
of	O
patients	O
with	O
SARS	O
were	O
higher	O
than	O
those	O
of	O
controls	O
,	O
they	O
were	O
(	O
91	O
.	O
61	O
+/-	O
50	O
.	O
53	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
32	O
.	O
91	O
+/-	O
10	O
.	O
56	O
)	O
U	O
/	O
L	O
,	O
(	O
78	O
.	O
68	O
+/-	O
33	O
.	O
32	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
29	O
.	O
43	O
+/-	O
8	O
.	O
89	O
)	O
U	O
/	O
L	O
,	O
(	O
429	O
.	O
95	O
+/-	O
188	O
.	O
94	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
200	O
.	O
83	O
+/-	O
44	O
.	O
86	O
)	O
U	O
/	O
L	O
,	O
(	O
11	O
.	O
67	O
+/-	O
4	O
.	O
26	O
)	O
micromol	O
/	O
L	O
vs	O
.	O
(	O
8	O
.	O
44	O
+/-	O
3	O
.	O
86	O
)	O
micromol	O
/	O
L	O
,	O
all	O
P	O
<	O
0	O
.	O
001	O
.	O

RESULTS	O
:	O
Alanine	B-PRGE
aminotransferase	I-PRGE
(	O
ALT	B-PRGE
),	O
aspartate	B-PRGE
aminotransferase	I-PRGE
(	O
AST	B-PRGE
),	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
LDH	B-PRGE
),	O
total	O
bilirubin	O
(	O
TBil	O
)	O
of	O
patients	O
with	O
SARS	O
were	O
higher	O
than	O
those	O
of	O
controls	O
,	O
they	O
were	O
(	O
91	O
.	O
61	O
+/-	O
50	O
.	O
53	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
32	O
.	O
91	O
+/-	O
10	O
.	O
56	O
)	O
U	O
/	O
L	O
,	O
(	O
78	O
.	O
68	O
+/-	O
33	O
.	O
32	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
29	O
.	O
43	O
+/-	O
8	O
.	O
89	O
)	O
U	O
/	O
L	O
,	O
(	O
429	O
.	O
95	O
+/-	O
188	O
.	O
94	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
200	O
.	O
83	O
+/-	O
44	O
.	O
86	O
)	O
U	O
/	O
L	O
,	O
(	O
11	O
.	O
67	O
+/-	O
4	O
.	O
26	O
)	O
micromol	O
/	O
L	O
vs	O
.	O
(	O
8	O
.	O
44	O
+/-	O
3	O
.	O
86	O
)	O
micromol	O
/	O
L	O
,	O
all	O
P	O
<	O
0	O
.	O
001	O
.	O

The	O
lymphocytes	O
and	O
their	O
subpopulations	O
(	O
CD45	B-PRGE
,	O
CD3	B-PRGE
,	O
CD4	B-PRGE
,	O
CD8	B-PRGE
)	O
declined	O
in	O
the	O
1st	O
week	O
and	O
to	O
the	O
lowest	O
level	O
(	O
977	O
+/-	O
579	O
,	O
641	O
+/-	O

The	O
PCR	O
designated	O
primer	O
sets	O
of	O
spike	O
protein	O
detected	O
only	O
HEV	B-PRGE
viral	I-PRGE
RNA	I-PRGE
among	O
other	O
related	O
nidoviruses	O
.	O

Anti	O
-	O
P2	O
antibodies	O
and	O
the	O
sera	O
from	O
SARS	O
patients	O
could	O
specifically	O
detect	O
the	O
recombinant	B-PRGE
SARS	I-PRGE
protein	I-PRGE
3a	I-PRGE
expressed	O
in	O
Escherichia	O
coli	O
and	O
in	O
Vero	O
E6	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
multiplication	O
of	O
SARS	O
-	O
CoV	O
in	O
cell	O
culture	O
can	O
be	O
strongly	O
inhibited	O
by	O
pretreatment	O
with	O
interferon	B-PRGE
-	I-PRGE
beta	I-PRGE
.	O

To	O
detect	O
false	O
negative	O
results	O
due	O
to	O
PCR	O
inhibitors	O
or	O
faulty	O
RNA	O
extraction	O
,	O
we	O
have	O
further	O
modified	O
this	O
one	O
step	O
RT	O
-	O
PCR	O
assay	O
for	O
simultaneous	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
and	O
18S	O
ribosomal	B-PRGE
RNA	I-PRGE
(	O
rRNA	B-PRGE
)	O
as	O
an	O
internal	O
positive	O
control	O
.	O

ABSTRACT	O
:	O
The	O
immunogenicity	O
of	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
-	O
restricted	O
T	O
-	O
cell	O
epitopes	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
the	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
of	O
human	O
coronavirus	O
strain	O
229e	O
(	O
HCoV	O
-	O
229e	O
)	O
was	O
analyzed	O
for	O
the	O
elicitation	O
of	O
a	O
T	O
-	O
cell	O
immune	O
response	O
in	O
donors	O
who	O
had	O
fully	O
recovered	O
from	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
gamma	B-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
release	O
Elispot	O
assay	O
revealed	O
that	O
only	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
specific	I-PRGE
peptides	I-PRGE
S1203	I-PRGE
and	O
S978	O
induced	O
a	O
high	O
frequency	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
secreting	O
T	O
-	O
cell	O
response	O
in	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
(+)	O
donors	O
who	O
had	O
fully	O
recovered	O
from	O
SARS	O
-	O
CoV	O
infection	O
;	O
such	O
a	O
T	O
-	O
cell	O
epitope	O
-	O
specific	O
response	O
was	O
not	O
observed	O
in	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
(+)	O
healthy	O
donors	O
or	O
in	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
(-)	O
donors	O
who	O
had	O
been	O
infected	O
with	O
SARS	O
-	O
CoV	O
after	O
full	O
recovery	O
.	O

Coronavirus	O
replication	O
and	O
transcription	O
are	O
highly	O
specialized	O
processes	O
of	O
cytoplasmic	O
RNA	O
synthesis	O
that	O
localize	O
to	O
virus	O
-	O
induced	O
membrane	O
structures	O
and	O
were	O
recently	O
proposed	O
to	O
involve	O
a	O
complex	O
enzymatic	O
machinery	O
that	O
,	O
besides	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
,	O
helicase	B-PRGE
,	O
and	O
protease	O
activities	O
,	O
also	O
involves	O
a	O
series	O
of	O
RNA	O
-	O
processing	O
enzymes	O
that	O
are	O
not	O
found	O
in	O
most	O
other	O
RNA	O
virus	O
families	O
.	O

MHV	O
replication	O
inhibited	O
hyperphosphorylation	O
of	O
the	O
retinoblastoma	B-PRGE
protein	I-PRGE
(	O
pRb	B-PRGE
),	O
the	O
event	O
that	O
is	O
necessary	O
for	O
cell	O
cycle	O
progression	O
through	O
late	O
G	O
(	O
1	O
)	O
and	O
into	O
the	O
S	O
phase	O
.	O

MHV	O
infection	O
in	O
quiescent	O
17Cl	O
-	O
1	O
cells	O
prevented	O
normal	O
increases	O
in	O
Cdk4	B-PRGE
,	O
Cdk6	B-PRGE
,	O
cyclin	B-PRGE
D1	I-PRGE
,	O
and	O
cyclin	B-PRGE
D3	I-PRGE
levels	O
after	O
serum	O
stimulation	O
.	O

Although	O
critical	O
residues	O
for	O
CS1	B-PRGE
cleavage	O
have	O
been	O
mapped	O
in	O
vitro	O
,	O
the	O
requirements	O
for	O
cleavage	O
have	O
not	O
been	O
studied	O
in	O
infected	O
cells	O
.	O

No	O
p28	B-PRGE
or	O
p65	B-PRGE
was	O
detected	O
in	O
cells	O
infected	O
with	O
predicted	O
noncleaving	O
CS1	O
mutants	O
or	O
the	O
CS1	B-PRGE
deletion	O
mutant	O
;	O
however	O
,	O
a	O
new	O
protein	O
of	O
93	O
kDa	O
was	O
detected	O
.	O

However	O
,	O
proteolytic	O
separation	O
of	O
p28	B-PRGE
from	O
p65	B-PRGE
is	O
necessary	O
for	O
optimal	O
RNA	O
synthesis	O
and	O
virus	O
growth	O
,	O
suggesting	O
important	O
roles	O
for	O
these	O
proteins	O
in	O
the	O
formation	O
or	O
function	O
of	O
viral	O
replication	O
complexes	O
.	O

TITLE	O
:	O
Cleavage	O
inhibition	O
of	O
the	O
murine	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
by	O
a	O
furin	B-PRGE
-	I-PRGE
like	I-PRGE
enzyme	I-PRGE
affects	O
cell	O
-	O
cell	O
but	O
not	O
virus	O
-	O
cell	O
fusion	O
.	O

Recently	O
,	O
a	O
metallopeptidase	B-PRGE
named	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
has	O
been	O
identified	O
as	O
the	O
functional	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Although	O
ACE2	B-PRGE
mRNA	I-PRGE
is	O
known	O
to	O
be	O
present	O
in	O
virtually	O
all	O
organs	O
,	O
its	O
protein	O
expression	O
is	O
largely	O
unknown	O
.	O

Here	O
we	O
report	O
that	O
the	O
HIV	B-PRGE
-	I-PRGE
1	I-PRGE
protease	I-PRGE
inhibitor	O
,	O
nelfinavir	O
,	O
strongly	O
inhibited	O
replication	O
of	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

We	O
found	O
that	O
the	O
membrane	O
and	O
envelope	B-PRGE
proteins	O
are	O
sufficient	O
for	O
the	O
efficient	O
formation	O
of	O
virus	O
-	O
like	O
particles	O
and	O
could	O
be	O
visualized	O
by	O
electron	O
microscopy	O
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
a	O
peptide	O
with	O
fluorescence	O
quenching	O
pair	O
(	O
Dabcyl	O
and	O
Edans	O
)	O
at	O
both	O
ends	O
of	O
a	O
peptide	O
substrate	O
and	O
used	O
this	O
fluorogenic	O
peptide	O
substrate	O
to	O
characterize	O
SARS	B-PRGE
main	I-PRGE
protease	I-PRGE
and	O
screen	O
inhibitors	O
.	O

This	O
enzyme	O
in	O
conjunction	O
with	O
fluorogenic	O
peptide	O
substrate	O
provides	O
us	O
a	O
suitable	O
tool	O
for	O
identifying	O
potent	O
inhibitors	O
of	O
SARS	B-PRGE
protease	I-PRGE
.	O

hCMV	B-PRGE
/	I-PRGE
beta	I-PRGE
-	O
actin	B-PRGE
-	O
eGFP	O
-	O
3	B-PRGE
'	I-PRGE
UTR	I-PRGE
t	I-PRGE
-	I-PRGE
PA	I-PRGE
transgenic	O
mice	O
express	O
eGFP	B-PRGE
mRNA	I-PRGE
in	O
all	O
brain	O
structures	O
analyzed	O
but	O
lack	O
eGFP	O
fluorescence	O
,	O
with	O
the	O
exception	O
of	O
blood	O
vessels	O
,	O
choroid	O
plexus	O
,	O
and	O
Purkinje	O
cells	O
.	O

TITLE	O
:	O
Cloning	O
,	O
sequencing	O
,	O
expression	O
,	O
and	O
purification	O
of	O
SARS	B-PRGE
-	I-PRGE
associated	I-PRGE
coronavirus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
for	O
serodiagnosis	O
of	O
SARS	O
.	O

Infection	O
of	O
the	O
hepatoma	O
cell	O
line	O
Huh	O
-	O
7	O
was	O
also	O
observed	O
with	O
replication	O
-	O
competent	O
SARS	O
-	O
CoV	O
,	O
indicating	O
that	O
hepatocytes	O
might	O
be	O
targeted	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
vivo	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
make	O
differential	O
diagnosis	O
between	O
Pneumoniae	O
associated	O
with	O
SIRS	O
and	O
Coagulopathy	O
(	O
PASC	O
)	O
and	O
Simple	O
Pneumoniae	O
(	O
SP	O
)	O
by	O
using	O
a	O
newly	O
developed	O
SF	O
test	O
utilizing	O
an	O
SF	B-PRGE
specific	I-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
(	O
IF	O
-	O
43	O
).	O

Unexpectedly	O
,	O
ACE2	B-PRGE
also	O
serves	O
as	O
the	O
cellular	O
entry	O
point	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
virus	O
and	O
the	O
enzyme	O
is	O
therefore	O
a	O
prime	O
target	O
for	O
pharmacological	O
intervention	O
on	O
several	O
disease	O
fronts	O
.	O

ABSTRACT	O
:	O
Nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
kappaB	I-PRGE
(	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
)	O
is	O
a	O
transcription	O
factor	O
which	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
induction	O
of	O
genes	O
involved	O
in	O
the	O
response	O
to	O
injury	O
and	O
inflammation	O
.	O

Type	O
I	O
interferons	O
(	O
IFNs	B-PRGE
-	I-PRGE
alpha	I-PRGE
/	I-PRGE
beta	I-PRGE
)	O
were	O
suggested	O
as	O
potential	O
candidates	O
to	O
treat	O
SARS	O
.	O

Cleavage	O
sites	O
were	O
predicted	O
in	O
proteins	O
such	O
as	O
the	O
cystic	B-PRGE
fibrosis	I-PRGE
transmembrane	I-PRGE
conductance	I-PRGE
regulator	I-PRGE
(	O
CFTR	B-PRGE
),	O
transcription	O
factors	O
CREB	B-PRGE
-	I-PRGE
RP	I-PRGE
and	O
OCT	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
components	O
of	O
the	O
ubiquitin	B-PRGE
pathway	O
.	O

Recombinant	B-PRGE
N	I-PRGE
protein	I-PRGE
was	O
used	O
as	O
a	O
standard	O
to	O
establish	O
a	O
detection	O
sensitivity	O
of	O
approximated	O
50	O
pg	O
/	O
ml	O
.	O

Using	O
a	O
panel	O
of	O
sera	O
collected	O
at	O
different	O
points	O
in	O
time	O
,	O
the	O
amount	O
of	O
circulating	O
N	B-PRGE
antigen	I-PRGE
was	O
found	O
to	O
peak	O
6	O
to	O
10	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

ABSTRACT	O
:	O
A	O
Taqman	O
amplicon	O
targeting	O
the	O
nucleocapsid	O
gene	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
5	O
log	O
(	O
10	O
)	O
times	O
more	O
sensitive	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
target	O
RNA	O
extracted	O
from	O
infected	O
cells	O
and	O
2	O
.	O
79	O
log	O
(	O
10	O
)	O
times	O
more	O
sensitive	O
for	O
RNA	O
extracted	O
from	O
patient	O
material	O
of	O
the	O
index	O
case	O
in	O
Frankfurt	O
than	O
an	O
amplicon	O
targeting	O
the	O
polymerase	B-PRGE
gene	I-PRGE
.	O

Blood	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
and	O
nitrite	O
/	O
nitrate	O
levels	O
were	O
not	O
significantly	O
elevated	O
.	O

The	O
Trx	B-PRGE
-	O
S2	O
fusion	O
protein	O
provides	O
a	O
basis	O
for	O
the	O
research	O
on	O
its	O
role	O
in	O
the	O
course	O
of	O
SARS	O
virus	O
infection	O
of	O
host	O
cells	O
and	O
preparation	O
of	O
recombinant	O
vaccine	O
against	O
SARS	O
virus	O
.	O

In	O
two	O
follow	O
-	O
up	O
surveys	O
of	O
the	O
SARS	O
patients	O
discharged	O
from	O
our	O
hospital	O
,	O
the	O
changes	O
of	O
CD3	B-PRGE
(+),	I-PRGE
CD4	B-PRGE
(+),	O
CD8	B-PRGE
(+),	O
CD8	B-PRGE
(+)	I-PRGE
CD28	I-PRGE
(+),	I-PRGE
CD8	B-PRGE
(+)	I-PRGE
CD28	I-PRGE
(-),	I-PRGE
CD3	B-PRGE
(+)	I-PRGE
CD25	I-PRGE
(+),	I-PRGE
CD3	B-PRGE
(+)	I-PRGE
CD69	I-PRGE
(+),	I-PRGE
CD3	B-PRGE
(+)	I-PRGE
HLA	I-PRGE
-	I-PRGE
DR	I-PRGE
(+)	O
T	O
cells	O
and	O
the	O
ratio	O
of	O
CD4	B-PRGE
(+)/	O
CD8	B-PRGE
(+)	O
T	O
cells	O
in	O
peripheral	O
blood	O
of	O
SARS	O
patients	O
treated	O
unitedly	O
with	O
Chinese	O
and	O
Western	O
medicines	O
were	O
detected	O
by	O
flow	O
cytometry	O
.	O

To	O
analyze	O
the	O
antigenic	O
structure	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S2	I-PRGE
domain	I-PRGE
,	O
the	O
carboxyl	O
-	O
terminal	O
half	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
,	O
we	O
first	O
used	O
sera	O
from	O
convalescent	O
SARS	O
patients	O
to	O
test	O
the	O
antigenicity	O
of	O
12	O
overlapping	O
fragments	O
spanning	O
the	O
entire	O
S2	O
and	O
identified	O
two	O
antigenic	O
determinants	O
(	O
Leu	O
803	O
to	O
Ala	O
828	O
and	O
Pro	O
1061	O
to	O
Ser	O
1093	O
).	O

In	O
some	O
animals	O
,	O
however	O
,	O
only	O
one	O
determinant	O
(	O
Leu	O
803	O
to	O
Ala	O
828	O
)	O
was	O
able	O
to	O
induce	O
the	O
antisera	O
with	O
the	O
binding	O
ability	O
to	O
the	O
native	B-PRGE
S	I-PRGE
protein	I-PRGE
and	O
the	O
neutralizing	O
activity	O
to	O
the	O
SARS	O
-	O
CoV	O
pseudovirus	O
.	O

Gas	B-PRGE
insufflation	O
through	O
the	O
trachea	O
is	O
a	O
promising	O
therapeutic	O
option	O
for	O
correcting	O
hypercapnia	O
secondary	O
to	O
ventilation	O
for	O
lung	O
protection	O
in	O
such	O
patients	O
.	O

This	O
study	O
demonstrates	O
that	O
expression	O
of	O
NOS2	B-PRGE
in	O
lung	O
epithelial	O
cells	O
is	O
critical	O
for	O
the	O
development	O
of	O
lung	O
injury	O
and	O
mediates	O
surfactant	O
dysfunction	O
independent	O
of	O
NOS2	B-PRGE
inflammatory	O
cell	O
expression	O
and	O
cytokine	O
production	O
.	O

We	O
expressed	O
the	O
complete	O
SARS	B-PRGE
coronavirus	I-PRGE
envelope	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
from	O
a	O
recombinant	O
attenuated	O
parainfluenza	O
virus	O
(	O
BHPIV3	O
)	O
that	O
is	O
being	O
developed	O
as	O
a	O
live	O
attenuated	O
,	O
intranasal	O
paediatric	O
vaccine	O
against	O
human	O
parainfluenza	O
virus	O
type	O
3	O
(	O
HPIV3	O
).	O

Receptor	O
down	O
regulation	O
was	O
independent	O
of	O
neutrophils	O
,	O
NK	O
cells	O
,	O
gamma	B-PRGE
interferon	I-PRGE
,	O
or	O
perforin	O
.	O

Angiotensin	B-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
has	O
recently	O
been	O
identified	O
as	O
the	O
functional	O
cellular	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Studies	O
of	O
the	O
tissue	O
and	O
cellular	O
distribution	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
and	O
ACE2	B-PRGE
protein	I-PRGE
expression	O
,	O
reveal	O
new	O
insights	O
into	O
the	O
pathogenesis	O
of	O
this	O
deadly	O
disease	O
.	O

After	O
conducting	O
extensive	O
literature	O
searches	O
and	O
evaluations	O
,	O
pharmacists	O
prepared	O
administration	O
and	O
dosing	O
guidelines	O
for	O
the	O
two	O
investigational	O
drugs	O
,	O
ribavirin	O
and	O
interferon	B-PRGE
alfacon	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
that	O
were	O
being	O
used	O
to	O
treat	O
the	O
syndrome	O
.	O

The	O
nucleotide	O
and	O
amino	O
acid	O
identity	O
of	O
the	O
S1	B-PRGE
protein	I-PRGE
gene	I-PRGE
between	O
the	O
five	O
Chinese	O
IBV	O
isolates	O
and	O
16	O
strains	O
of	O
other	O
IBVs	O
varied	O
from	O
60	O
to	O
81	O
%.	O

One	O
week	O
after	O
the	O
second	O
immunization	O
,	O
mice	O
sera	O
were	O
collected	O
to	O
detect	O
serum	B-PRGE
neutralizing	I-PRGE
antibodies	I-PRGE
.	O

ABSTRACT	O
:	O
To	O
compare	O
the	O
sensitivity	O
and	O
specificity	O
of	O
four	O
kits	O
for	O
detection	O
of	O
anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
IgG	B-PRGE
in	O
sera	O
of	O
SARS	O
patients	O
.	O

Anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
was	O
detected	O
in	O
99	O
serial	O
sera	O
from	O
18	O
SARS	O
patients	O
and	O
in	O
123	O
negative	O
reference	O
sera	O
,	O
using	O
two	O
enzyme	O
linked	O
immunosorbent	O
assays	O
(	O
EIA	O
No	O
.	O
A	O
and	O
No	O
.	O
B	O
)	O
and	O
two	O
indirect	O
immunofluorescence	O
assays	O
(	O
Australian	O
IFA	O
and	O
Euroimmun	O
IFA	O
).	O

The	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
was	O
first	O
determined	O
in	O
sera	O
on	O
the	O
9th	O
day	O
by	O
Euroimmun	O
IFA	O
,	O
12th	O
day	O
by	O
EIA	O
No	O
.	O
B	O
,	O
13th	O
day	O
by	O
Australian	O
IFA	O
,	O
and	O
16th	O
day	O
by	O
EIA	B-PRGE
No	I-PRGE
.	I-PRGE
A	I-PRGE
.	O
The	O
positive	O
rates	O
of	O
antibody	O
on	O
the	O
3rd	O
week	O
after	O
onset	O
were	O
84	O
.	O
2	O
%	O
(	O
16	O
/	O
19	O
),	O
94	O
.	O
7	O
%	O
(	O
18	O
/	O
19	O
),	O
78	O
.	O
9	O
%	O
(	O
15	O
/	O
19	O
)	O
and	O
52	O
.	O
6	O
%	O
(	O
10	O
/	O
19	O
)	O
respectively	O
.	O

ABSTRACT	O
:	O
By	O
using	O
a	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
serum	O
specimens	O
serially	O
collected	O
(	O
from	O
day	O
0	O
to	O
day	O
240	O
after	O
symptom	O
onset	O
)	O
from	O
patients	O
with	O
pneumonia	O
due	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
we	O
analyzed	O
the	O
longitudinal	O
profiles	O
of	O
immunoglobulin	B-PRGE
G	I-PRGE
(	O
IgG	B-PRGE
),	O
IgM	B-PRGE
,	O
and	O
IgA	B-PRGE
antibodies	I-PRGE
against	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
in	O
patients	O
with	O
pneumonia	O
due	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
For	O
IgG	B-PRGE
,	O
the	O
median	O
optical	O
density	O
at	O
450	O
nm	O
(	O
OD450	O
)	O
turned	O
positive	O
at	O
day	O
17	O
and	O
a	O
biphasic	O
response	O
was	O
observed	O
.	O

At	O
day	O
240	O
,	O
all	O
patients	O
were	O
still	O
positive	O
for	O
anti	B-PRGE
-	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
.	O

For	O
IgA	B-PRGE
,	O
the	O
median	O
OD450	O
turned	O
positive	O
at	O
day	O
17	O
,	O
peaked	O
at	O
about	O
day	O
50	O
,	O
and	O
fell	O
to	O
below	O
the	O
baseline	O
level	O
at	O
about	O
day	O
180	O
.	O

By	O
use	O
of	O
an	O
immunofluorescent	O
(	O
IF	O
)	O
test	O
as	O
the	O
""""	O
gold	O
standard	O
""","	O
both	O
the	O
ELISA	O
and	O
the	O
immunochromatographic	O
test	O
were	O
able	O
to	O
detect	O
immunoglobulin	B-PRGE
G	I-PRGE
antibodies	I-PRGE
to	O
SARS	O
not	O
only	O
from	O
late	O
-	O
convalescent	O
-	O
stage	O
samples	O
(>	O
21	O
days	O
from	O
the	O
onset	O
of	O
clinical	O
symptoms	O
),	O
as	O
previously	O
established	O
,	O
but	O
also	O
from	O
early	O
-	O
acute	O
-	O
phase	O
samples	O
(	O
1	O
to	O
10	O
days	O
from	O
onset	O
).	O

The	O
assay	O
was	O
carried	O
out	O
with	O
hyperimmune	O
polyclonal	O
nucleocapsid	O
-	O
specific	O
antibodies	O
from	O
guinea	O
pigs	O
and	O
rabbits	O
immunized	O
with	O
recombinant	O
His	O
(	O
6	O
)-	O
tagged	O
SARS	B-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
.	O

Mink	B-PRGE
lung	O
epithelial	O
cells	O
(	O
Mv1Lu	O
)	O
and	O
R	B-PRGE
-	I-PRGE
Mix	I-PRGE
,	O
a	O
mixed	O
monolayer	O
of	O
human	O
lung	O
-	O
derived	O
cells	O
(	O
A549	O
)	O
and	O
mink	O
lung	O
-	O
derived	O
cells	O
(	O
Mv1Lu	O
),	O
are	O
used	O
by	O
diagnostic	O
laboratories	O
to	O
detect	O
respiratory	O
viruses	O
(	O
e	O
.	O
g	O
.,	O
influenza	O
virus	O
);	O
they	O
were	O
also	O
infected	O
with	O
SARS	O
-	O
CoV	O
,	O
indicating	O
that	O
the	O
practices	O
of	O
diagnostic	O
laboratories	O
should	O
be	O
examined	O
to	O
ensure	O
appropriate	O
biosafety	O
precautions	O
.	O

CD13	B-PRGE
has	O
been	O
identified	O
in	O
human	B-PRGE
bone	I-PRGE
marrow	I-PRGE
CD34	I-PRGE
+	I-PRGE
cells	O
,	O
platelets	O
,	O
megakaryocytes	O
,	O
myeloid	O
cells	O
,	O
and	O
erythroid	O
cells	O
,	O
but	O
not	O
in	O
lymphocytes	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
safe	O
neutralization	O
assay	O
for	O
SARS	O
-	O
CoV	O
and	O
characterization	O
of	O
S	B-PRGE
-	I-PRGE
glycoprotein	I-PRGE
.	O

The	O
detection	O
of	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
by	O
immunoassays	O
was	O
difficult	O
using	O
human	O
convalescent	O
sera	O
,	O
suggesting	O
that	O
the	O
protein	O
may	O
not	O
elicit	O
strong	O
humoral	O
immune	O
response	O
in	O
virus	O
-	O
infected	O
patients	O
.	O

MULTIPRED	O
predicted	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
and	O
HLA	B-PRGE
-	O
A3	O
hot	O
spots	O
in	O
each	O
of	O
these	O
proteins	O
.	O

TITLE	O
:	O
[	O
Quantitative	O
detection	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
in	O
excreta	O
and	O
oropharyngeal	O
washing	O
fluid	O
from	O
convalescence	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

The	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
levels	O
were	O
decreased	O
,	O
while	O
the	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
were	O
increased	O
,	O
and	O
the	O
differences	O
between	O
convalescent	O
SARS	O
patients	O
and	O
other	O
patient	O
groups	O
were	O
statistically	O
significant	O
.	O

ABSTRACT	O
:	O
This	O
study	O
established	O
a	O
modified	O
alkaline	B-PRGE
phosphatase	I-PRGE
-	O
labelled	O
avidin	B-PRGE
-	I-PRGE
biotin	I-PRGE
-	I-PRGE
complex	I-PRGE
(	O
ABC	B-PRGE
-	I-PRGE
AP	I-PRGE
)	O
method	O
for	O
diagnosis	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
Mycoplasma	O
pulmonis	O
infection	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
wax	O
-	O
embedded	O
sections	O
,	O
murine	O
antibody	O
-	O
positive	O
serum	O
being	O
used	O
as	O
the	O
primary	O
reagent	O
.	O

TITLE	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
229E	I-PRGE
binds	O
to	O
CD13	B-PRGE
in	O
rafts	O
and	O
enters	O
the	O
cell	O
through	O
caveolae	O
.	O

ABSTRACT	O
:	O
The	O
complete	O
genome	O
sequences	O
of	O
the	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
(	O
HCoV	O
-	O
OC43	O
)	O
laboratory	O
strain	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
),	O
and	O
a	O
HCoV	O
-	O
OC43	O
clinical	O
isolate	O
,	O
designated	O
Paris	O
,	O
were	O
obtained	O
.	O

RESULTS	O
:	O
Anti	O
-	O
viral	O
(	O
IgG	B-PRGE
)	O
and	O
anti	O
-	O
nucleocaspid	O
antibodies	O
were	O
observed	O
in	O
13	O
of	O
14	O
patients	O
at	O
14	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
,	O
and	O
in	O
all	O
14	O
patients	O
at	O
30	O
-	O
210	O
days	O
thereafter	O
.	O

So	O
far	O
,	O
five	O
specific	O
therapies	O
have	O
proven	O
their	O
efficacy	O
to	O
achieve	O
such	O
goal	O
in	O
large	O
randomised	O
controlled	O
trials	O
:	O
early	O
goal	O
-	O
directed	O
therapy	O
,	O
recombinant	B-PRGE
activated	I-PRGE
protein	I-PRGE
C	I-PRGE
,	O
moderate	O
doses	O
of	O
steroids	O
,	O
low	O
tidal	O
volume	O
ventilation	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
intensive	O
insulin	B-PRGE
therapy	O
to	O
control	O
hyperglycemia	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
show	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
is	O
capable	O
of	O
inducing	O
apoptosis	O
of	O
COS	O
-	O
1	O
monkey	O
kidney	O
cells	O
in	O
the	O
absence	O
of	O
growth	O
factors	O
by	O
down	O
-	O
regulating	O
ERK	B-PRGE
(	O
extracellular	B-PRGE
-	I-PRGE
signal	I-PRGE
-	I-PRGE
regulated	I-PRGE
kinase	I-PRGE
),	O
up	O
-	O
regulating	O
JNK	B-PRGE
(	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
kinase	I-PRGE
)	O
and	O
p38	B-PRGE
MAPK	I-PRGE
(	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
)	O
pathways	O
,	O
and	O
affecting	O
their	O
downstream	O
effectors	O
.	O

SARS	O
-	O
CoV	O
N	O
expression	O
also	O
down	O
-	O
regulated	O
phospho	O
-	O
Akt	B-PRGE
and	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
levels	O
,	O
and	O
activated	O
caspases	B-PRGE
3	I-PRGE
and	I-PRGE
7	I-PRGE
.	O

Furthermore	O
,	O
activation	O
of	O
the	O
p38	B-PRGE
MAPK	O
pathway	O
was	O
found	O
to	O
induce	O
actin	B-PRGE
reorganization	O
in	O
cells	O
devoid	O
of	O
growth	O
factors	O
.	O

At	O
the	O
cytoskeletal	O
level	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
down	O
-	O
regulated	O
FAK	B-PRGE
(	O
focal	B-PRGE
adhesion	I-PRGE
kinase	I-PRGE
)	O
activity	O
and	O
also	O
down	O
-	O
regulated	O
fibronectin	B-PRGE
expression	O
.	O

The	O
affinity	O
(	O
equilibrium	O
dissociation	O
constant	O
,	O
K	O
(	O
d	O
))	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
was	O
5	O
.	O
7	O
x	O
10	O
(-	O
8	O
)	O
M	O
for	O
B10	O
and	O
8	O
.	O
9	O
x	O
10	O
(-	O
8	O
)	O
M	O
for	O
C20	O
.	O

Viral	O
genetic	O
factors	O
have	O
also	O
been	O
implicated	O
in	O
the	O
emergence	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
with	O
the	O
suggestion	O
that	O
this	O
virus	O
is	O
a	O
recombinant	O
between	O
mammalian	O
and	O
avian	O
coronaviruses	O
.	O

The	O
first	O
of	O
these	O
studies	O
has	O
shown	O
that	O
pegylated	O
interferon	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
a	O
drug	O
approved	O
for	O
human	O
use	O
,	O
limits	O
SARS	O
-	O
CoV	O
replication	O
and	O
lung	O
damage	O
in	O
experimentally	O
infected	O
macaques	O
.	O

TITLE	O
:	O
The	O
N	O
-	O
terminal	O
region	O
of	O
the	O
murine	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
is	O
associated	O
with	O
the	O
extended	O
host	O
range	O
of	O
viruses	O
from	O
persistently	O
infected	O
murine	O
cells	O
.	O

Nearly	O
18	O
.	O
2	O
%	O
stated	O
that	O
they	O
would	O
not	O
wear	O
a	O
mask	O
in	O
public	O
places	O
at	O
the	O
destination	O
if	O
they	O
had	O
flu	B-PRGE
-	I-PRGE
like	I-PRGE
symptoms	I-PRGE
.	O

Eye	B-PRGE
shield	O
was	O
worn	O
in	O
22	O
.	O
8	O
%	O
(	O
18	O
/	O
79	O
)	O
of	O
the	O
dialysis	O
units	O
centers	O
.	O

ABSTRACT	O
:	O
Proteomics	O
was	O
used	O
to	O
identify	O
a	O
protein	O
encoded	O
by	O
ORF	B-PRGE
3a	I-PRGE
in	O
a	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Furthermore	O
,	O
the	O
UV	O
-	O
inactivated	O
virion	O
induced	O
regional	O
lymph	O
node	O
T	O
-	O
cell	O
proliferation	O
and	O
significant	O
levels	O
of	O
cytokine	O
production	O
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
upon	O
restimulation	O
with	O
inactivated	O
SARS	B-PRGE
-	O
CoV	O
virion	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Activated	B-PRGE
protein	I-PRGE
C	I-PRGE
(	O
APC	B-PRGE
),	O
a	O
natural	O
anticoagulant	O
,	O
is	O
formed	O
from	O
protein	O
C	O
by	O
the	O
action	O
of	O
thrombin	B-PRGE
bound	O
to	O
thrombomodulin	B-PRGE
on	O
the	O
endothelial	O
cell	O
surface	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	B-PRGE
protein	I-PRGE
(	O
N	B-PRGE
protein	I-PRGE
)	O
is	O
one	O
of	O
the	O
major	O
virion	O
structural	O
proteins	O
of	O
a	O
newly	O
identified	O
coronavirus	O
,	O
which	O
has	O
been	O
confirmed	O
as	O
the	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

We	O
examined	O
oral	O
specimens	O
,	O
including	O
throat	O
wash	O
and	O
saliva	O
,	O
and	O
found	O
large	O
amounts	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
in	O
both	O
throat	O
wash	O
(	O
9	O
.	O
58	O
x	O
10	O
(	O
2	O
)	O
to	O
5	O
.	O
93	O
x	O
10	O
(	O
6	O
)	O
copies	O
/	O
mL	O
)	O
and	O
saliva	O
(	O
7	O
.	O
08	O
x	O
10	O
(	O
3	O
)	O
to	O
6	O
.	O
38	O
x	O
10	O
(	O
8	O
)	O
copies	O
/	O
mL	O
)	O
from	O
all	O
specimens	O
of	O
17	O
consecutive	O
probable	O
SARS	O
case	O
-	O
patients	O
,	O
supporting	O
the	O
possibility	O
of	O
transmission	O
through	O
oral	O
droplets	O
.	O

ABSTRACT	O
:	O
Murine	O
models	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
will	O
greatly	O
advance	O
research	O
on	O
this	O
emerging	O
virus	O
.	O

TITLE	O
:	O
The	O
CC	B-PRGE
chemokine	I-PRGE
ligand	I-PRGE
3	I-PRGE
regulates	O
CD11c	B-PRGE
+	I-PRGE
CD11b	I-PRGE
+	I-PRGE
CD8alpha	I-PRGE
-	O
dendritic	O
cell	O
maturation	O
and	O
activation	O
following	O
viral	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
:	O
implications	O
for	O
a	O
role	O
in	O
T	O
cell	O
activation	O
.	O

His	O
symptoms	O
improved	O
substantially	O
,	O
and	O
serum	O
methemoglobin	B-PRGE
levels	O
decreased	O
to	O
0	O
.	O
7	O
%	O
after	O
the	O
initiation	O
of	O
methylene	O
blue	O
therapy	O
.	O

Celecoxib	O
is	O
a	O
nonsteroidal	O
antiinflammatory	O
drug	O
that	O
selectively	O
inhibits	O
cyclooxygenase	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

The	O
S	B-PRGE
protein	I-PRGE
is	O
a	O
type	B-PRGE
I	I-PRGE
transmembrane	I-PRGE
protein	I-PRGE
that	O
is	O
very	O
large	O
compared	O
to	O
other	O
viral	O
fusion	O
proteins	O
,	O
and	O
all	O
except	O
a	O
short	O
carboxy	O
-	O
terminal	O
segment	O
of	O
the	O
S	O
molecule	O
constitutes	O
the	O
ectodomain	O
.	O

For	O
the	O
prototype	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
it	O
has	O
previously	O
been	O
established	O
that	O
S	B-PRGE
protein	I-PRGE
assembly	O
into	O
virions	O
is	O
specified	O
by	O
the	O
carboxy	O
-	O
terminal	O
segment	O
,	O
which	O
comprises	O
the	O
transmembrane	O
domain	O
and	O
the	O
endodomain	O
.	O

Additionally	O
,	O
we	O
found	O
that	O
the	O
adjacent	O
cysteine	O
-	O
rich	O
region	O
of	O
the	O
endodomain	O
is	O
critical	O
for	O
fusion	O
of	O
infected	O
cells	O
,	O
confirming	O
results	O
previously	O
obtained	O
with	O
S	B-PRGE
protein	I-PRGE
expression	O
systems	O
.	O

TITLE	O
:	O
Identification	O
and	O
characterization	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replicase	B-PRGE
proteins	O
.	O

There	O
was	O
no	O
significant	O
difference	O
among	O
positive	O
rates	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
for	O
generations	O
,	O
Chi	O
square	O
=	O
5	O
.	O
11	O
,	O
P	O
greater	O
than	O
0	O
.	O
05	O
.	O

The	O
counts	O
of	O
CD3	B-PRGE
+,	I-PRGE
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
T	O
-	O
lymphocyte	O
of	O
two	O
groups	O
were	O
systematically	O
recorded	O
and	O
analyzed	O
.	O

After	O
15th	O
day	O
of	O
disease	O
course	O
,	O
the	O
counts	O
gradually	O
returned	O
to	O
normal	O
CD3	B-PRGE
+,	I-PRGE
CD4	B-PRGE
+,	I-PRGE
CD8	B-PRGE
+	I-PRGE
T	O
-	O
lymphocyte	O
counts	O
of	O
non	O
-	O
SARS	O
patients	O
were	O
normal	O
.	O

TITLE	O
:	O
[	O
Studies	O
on	O
IgG	B-PRGE
antibodies	I-PRGE
of	O
SARS	O
patients	O
].	O

RESULTS	O
:	O
Out	O
of	O
121	O
patients	O
studied	O
,	O
71	O
.	O
1	O
%	O
were	O
SARS	B-PRGE
specific	O
IgG	B-PRGE
positive	O
.	O

TITLE	O
:	O
[	O
Anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
virus	O
activities	O
of	O
different	O
recombinant	O
human	O
interferons	O
in	O
cell	O
culture	O
system	O
].	O

Anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
virus	O
activities	O
of	O
interferons	O
were	O
determined	O
by	O
using	O
CPE	O
inhibition	O
test	O
in	O
human	O
skeletal	O
muscle	O
sarcoma	O
(	O
Rda	O
)	O
cell	O
culture	O
.	O

The	O
recent	O
emergence	O
of	O
this	O
new	O
pathogen	O
,	O
the	O
careful	O
tracing	O
of	O
its	O
transmission	O
patterns	O
,	O
and	O
the	O
ability	O
to	O
propagate	O
in	O
culture	O
allows	O
the	O
exploration	O
of	O
the	O
mutational	O
dynamics	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
human	O
populations	O
.	O

Our	O
recent	O
study	O
indicated	O
that	O
SARS	O
-	O
CoV	O
infection	O
induces	O
activation	O
of	O
the	O
p38	B-PRGE
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
MAPK	B-PRGE
)	O
signaling	O
pathway	O
and	O
the	O
p38	B-PRGE
MAPK	I-PRGE
inhibitor	O
partially	O
inhibited	O
its	O
cytopathic	O
effect	O
in	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
aquaporin	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
AQP1	B-PRGE
)	O
expression	O
in	O
a	O
murine	O
model	O
of	O
lipopolysaccharide	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

Most	O
impressively	O
,	O
mRNA	O
for	O
CXCR3	B-PRGE
,	O
the	O
receptor	O
for	O
CXCL9	B-PRGE
and	O
CXCL10	B-PRGE
,	O
was	O
massively	O
up	O
-	O
regulated	O
in	O
the	O
lungs	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
mice	O
.	O

Moreover	O
,	O
beige	O
,	O
CD1	B-PRGE
-/-,	O
and	O
RAG1	B-PRGE
-/-	O
mice	O
cleared	O
the	O
virus	O
normally	O
.	O

In	O
this	O
study	O
,	O
we	O
therefore	O
examine	O
the	O
immune	O
response	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
over	O
the	O
first	O
24	O
hours	O
.	O

We	O
observed	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
was	O
capable	O
of	O
infecting	O
and	O
replicating	O
in	O
PBMCs	O
and	O
the	O
kinetics	O
of	O
viral	O
replication	O
was	O
variable	O
among	O
the	O
donors	O
.	O

SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antibody	I-PRGE
binding	O
assays	O
indicated	O
that	O
SARS	O
specific	O
antibodies	O
inhibited	O
SARS	O
-	O
CoV	O
viral	O
replication	O
.	O

Array	O
data	O
showed	O
monocyte	O
-	O
macrophage	O
cell	O
activation	O
,	O
coagulation	O
pathway	O
upregulation	O
and	O
cytokine	O
production	O
together	O
with	O
lung	O
trafficking	O
chemokines	O
such	O
as	O
IL8	B-PRGE
and	O
IL17	B-PRGE
,	O
possibly	O
activated	O
through	O
the	O
TLR9	B-PRGE
signaling	O
pathway	O
;	O
that	O
mimicked	O
clinical	O
features	O
of	O
the	O
disease	O
.	O

In	O
addition	O
,	O
we	O
also	O
demonstrated	O
angiotensin	O
1	O
converting	O
enzyme	O
(	O
ACE	B-PRGE
)-	O
the	O
homologue	O
of	O
ACE2	B-PRGE
could	O
not	O
function	O
as	O
a	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O

These	O
changes	O
included	O
peribronchial	O
leukocyte	O
infiltration	O
,	O
epithelial	O
shedding	O
,	O
collagen	B-PRGE
deposition	O
,	O
proliferation	O
of	O
bronchial	O
smooth	O
muscle	O
cells	O
and	O
fibrosis	O
of	O
the	O
lung	O
.	O

Phage	O
antibody	O
library	O
for	O
human	O
Fab	B-PRGE
fragment	I-PRGE
has	O
been	O
constructed	O
successfully	O
,	O
which	O
lays	O
the	O
foundation	O
for	O
further	O
study	O
.	O

Our	O
present	O
data	O
suggest	O
the	O
following	O
model	O
of	O
p28	B-PRGE
-	O
induced	O
G	O
(	O
0	O
)/	O
G	O
(	O
1	O
)	O
cell	O
cycle	O
arrest	O
.	O

There	O
is	O
discordant	O
phylogenetic	O
clustering	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
coronaviruses	O
sequences	O
,	O
throughout	O
the	O
genome	O
,	O
compatible	O
with	O
either	O
ancient	O
recombination	O
events	O
or	O
altered	O
evolutionary	O
rates	O
in	O
different	O
lineages	O
,	O
or	O
a	O
combination	O
of	O
both	O
.	O

By	O
using	O
proteomic	O
technology	O
,	O
truncated	O
forms	O
of	O
alpha	B-PRGE
(	I-PRGE
1	I-PRGE
)-	I-PRGE
antitrypsin	I-PRGE
(	O
TF	B-PRGE
-	I-PRGE
alpha	I-PRGE
(	I-PRGE
1	I-PRGE
)-	I-PRGE
AT	I-PRGE
)	O
were	O
found	O
to	O
increase	O
significantly	O
and	O
consistently	O
in	O
sera	O
of	O
SARS	O
patients	O
compared	O
to	O
control	O
subjects	O
.	O

The	O
ancestral	O
,	O
unduplicated	O
form	O
of	O
ACE	B-PRGE
is	O
still	O
expressed	O
during	O
the	O
terminal	O
differentiation	O
of	O
human	O
spermatocytes	O
,	O
suggesting	O
a	O
critical	O
role	O
in	O
reproduction	O
.	O

TITLE	O
:	O
ACE1	B-PRGE
polymorphism	O
and	O
progression	O
of	O
SARS	O
.	O

The	O
neutralizing	O
ability	O
of	O
antisera	O
directed	O
against	O
the	O
expressed	O
structural	O
proteins	O
was	O
greater	O
than	O
that	O
of	O
convalescent	O
patient	O
antisera	O
,	O
confirming	O
that	O
,	O
as	O
immunogens	O
,	O
the	O
former	O
induce	O
strong	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
specific	I-PRGE
neutralizing	I-PRGE
antibody	I-PRGE
responses	O
.	O

TITLE	O
:	O
Detecting	O
specific	O
cytotoxic	O
T	O
lymphocytes	O
against	O
SARS	O
-	O
coronavirus	O
with	O
DimerX	B-PRGE
HLA	I-PRGE
-	I-PRGE
A2	I-PRGE
:	O
Ig	B-PRGE
fusion	I-PRGE
protein	I-PRGE
.	O

The	O
two	O
-	O
step	O
screening	O
method	O
described	O
here	O
yielded	O
several	O
small	O
molecules	O
that	O
can	O
be	O
used	O
for	O
developing	O
new	O
classes	O
of	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
drugs	O
and	O
is	O
potentially	O
useful	O
for	O
the	O
high	O
-	O
throughput	O
screening	O
of	O
drugs	O
inhibiting	O
the	O
entry	O
of	O
HIV	O
,	O
hepatitis	O
C	O
virus	O
,	O
and	O
other	O
insidious	O
viruses	O
into	O
their	O
host	O
cells	O
.	O

Some	O
samples	O
were	O
examined	O
for	O
anti	B-PRGE
-	I-PRGE
herpes	I-PRGE
simplex	I-PRGE
virus	I-PRGE
type	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
HSV	O
-	O
1	O
)	O
activity	O
.	O

Despite	O
regular	O
vaccination	O
of	O
incoming	O
dogs	O
against	O
distemper	O
,	O
canine	O
adenovirus	B-PRGE
type	I-PRGE
2	I-PRGE
(	O
CAV	B-PRGE
-	I-PRGE
2	I-PRGE
),	O
and	O
canine	O
parainfluenza	O
virus	O
(	O
CPIV	O
),	O
respiratory	O
disease	O
was	O
endemic	O
.	O

The	O
expression	O
level	O
,	O
size	O
and	O
authenticity	O
of	O
each	O
recombinant	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
protein	I-PRGE
were	O
determined	O
.	O

In	O
addition	O
,	O
immunofluorescence	O
and	O
FACS	O
analysis	O
confirmed	O
the	O
cell	O
surface	O
expression	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CLpro	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
has	O
been	O
proposed	O
as	O
an	O
attractive	O
target	O
for	O
drug	O
design	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
,	O
a	O
glycoprotein	O
essential	O
for	O
viral	O
entry	O
,	O
is	O
a	O
primary	O
target	O
for	O
vaccine	O
and	O
drug	O
development	O
.	O

Two	O
peptides	O
denoted	O
HR	O
-	O
N	O
(	O
SN50	O
)	O
and	O
HR	O
-	O
C	O
(	O
SC40	O
),	O
corresponding	O
to	O
the	O
Leu	O
/	O
Ile	O
/	O
Val	O
-	O
rich	O
heptad	O
-	O
repeat	O
regions	O
from	O
the	O
N	O
-	O
terminal	O
and	O
C	O
-	O
terminal	O
segments	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
S2	I-PRGE
sequence	I-PRGE
,	O
respectively	O
,	O
were	O
synthesized	O
and	O
predicted	O
to	O
form	O
trimeric	O
assembly	O
of	O
hairpin	O
-	O
like	O
structures	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
),	O
a	O
type	B-PRGE
I	I-PRGE
transmembrane	I-PRGE
envelope	I-PRGE
glycoprotein	I-PRGE
,	O
consists	O
of	O
S1	O
and	O
S2	O
domains	O
responsible	O
for	O
virus	O
binding	O
and	O
fusion	O
,	O
respectively	O
.	O

Here	O
we	O
show	O
that	O
a	O
recombinant	B-PRGE
fusion	I-PRGE
protein	I-PRGE
(	O
designated	O
RBD	O
-	O
Fc	O
)	O
containing	O
193	O
-	O
amino	O
acid	O
RBD	O
(	O
residues	O
318	O
-	O
510	O
)	O
and	O
a	O
human	B-PRGE
IgG1	I-PRGE
Fc	I-PRGE
fragment	I-PRGE
can	O
induce	O
highly	O
potent	O
antibody	O
responses	O
in	O
the	O
immunized	O
rabbits	O
.	O

TITLE	O
:	O
DC	O
-	O
SIGN	O
and	O
DC	O
-	O
SIGNR	O
interact	O
with	O
the	O
glycoprotein	O
of	O
Marburg	O
virus	O
and	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Like	O
the	O
other	O
coronaviruses	O
used	O
in	O
the	O
analysis	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
also	O
a	O
mosaic	O
structure	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
peptide	O
-	O
based	O
enzyme	O
immunoassay	O
for	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
coronavirus	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
.	O

The	O
performance	O
of	O
a	O
microplate	O
enzyme	O
immunoassay	O
,	O
DETECT	O
-	O
SARS	O
was	O
evaluated	O
for	O
the	O
detection	O
of	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
.	O

When	O
the	O
host	O
produces	O
antibodies	O
against	O
these	O
viral	O
antigens	O
,	O
the	O
antibodies	O
also	O
bind	O
to	O
the	O
host	O
'	O
s	O
own	O
ACTH	B-PRGE
,	O
which	O
limits	O
the	O
host	O
'	O
s	O
stress	O
response	O
by	O
interfering	O
with	O
ACTH	B-PRGE
'	O
s	O
ability	O
to	O
stimulate	O
the	O
secretion	O
of	O
corticosteroids	O
.	O

She	O
developed	O
fever	O
on	O
April	O
21	O
and	O
respiratory	O
distress	O
on	O
April	O
25	O
,	O
and	O
received	O
ribavirin	O
,	O
intravenous	O
immunoglobulin	B-PRGE
,	O
and	O
steroid	O
.	O

It	O
suggests	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
of	O
similar	O
mutation	O
frequency	O
and	O
dynamic	O
mutant	O
distributions	O
like	O
other	O
RNA	O
viruses	O
,	O
though	O
relatively	O
less	O
identified	O
variation	O
number	O
than	O
those	O
causing	O
chronic	O
infections	O
.	O

Serum	B-PRGE
anti	I-PRGE
-	I-PRGE
SARS	I-PRGE
IgG	I-PRGE
was	O
checked	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
at	O
the	O
convalescent	O
phase	O
.	O

We	O
have	O
identified	O
a	O
different	O
human	O
cellular	O
glycoprotein	O
that	O
can	O
serve	O
as	O
an	O
alternative	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
A	O
human	O
lung	O
cDNA	O
library	O
in	O
vesicular	O
stomatitis	O
virus	O
G	O
pseudotyped	O
retrovirus	O
was	O
transduced	O
into	O
Chinese	O
hamster	O
ovary	O
cells	O
,	O
and	O
the	O
cells	O
were	O
sorted	O
for	O
binding	O
of	O
soluble	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoproteins	I-PRGE
,	O
S	O
(	O
590	O
)	O
and	O
S	O
(	O
1180	O
).	O

Clones	O
of	O
transduced	O
cells	O
that	O
bound	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
glycoprotein	I-PRGE
were	O
inoculated	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
and	O
increases	O
in	O
subgenomic	O
viral	O
RNA	O
from	O
1	O
-	O
16	O
h	O
or	O
more	O
were	O
detected	O
by	O
multiplex	O
RT	O
-	O
PCR	O
in	O
four	O
cloned	O
cell	O
lines	O
.	O

ABSTRACT	O
:	O
The	O
cleavage	O
mechanism	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
main	O
proteinase	O
(	O
M	B-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
or	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
))	O
for	O
the	O
octapeptide	O
AVLQSGFR	O
is	O
studied	O
using	O
molecular	O
mechanics	O
(	O
MM	O
)	O
and	O
quantum	O
mechanics	O
(	O
QM	O
).	O

TITLE	O
:	O
Silencing	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
gene	I-PRGE
by	O
small	O
interfering	O
RNA	O
in	O
HEK	O
293T	O
cells	O
.	O

The	O
results	O
showed	O
that	O
the	O
cells	O
transfected	O
with	O
pEGFP	O
-	O
optS	O
expressed	O
S	B-PRGE
-	I-PRGE
EGFP	I-PRGE
fusion	I-PRGE
protein	I-PRGE
at	O
a	O
higher	O
level	O
compared	O
with	O
those	O
transfected	O
with	O
pEGFP	O
-	O
S	O
,	O
which	O
contains	O
wildtype	O
SARS	O
-	O
CoV	O
spike	O
gene	O
sequence	O
.	O

TITLE	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
Nsp15	B-PRGE
protein	I-PRGE
is	O
an	O
endoribonuclease	O
that	O
prefers	O
manganese	O
as	O
a	O
cofactor	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
previously	O
unidentified	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
a	O
major	O
viral	O
protein	O
recognized	O
by	O
acute	O
and	O
early	O
convalescent	O
sera	O
from	O
SARS	O
patients	O
.	O

Recombinant	B-PRGE
hexa	I-PRGE
-	I-PRGE
histidine	I-PRGE
-	I-PRGE
tagged	I-PRGE
N	I-PRGE
protein	I-PRGE
with	O
a	O
molecular	O
mass	O
of	O
47	O
kD	O
was	O
produced	O
in	O
insect	O
cells	O
.	O

The	O
N	B-PRGE
protein	I-PRGE
was	O
found	O
localized	O
in	O
the	O
cytoplasm	O
as	O
well	O
as	O
in	O
the	O
nucleolus	O
.	O

In	O
contrast	O
,	O
CCR2	B-PRGE
(-/-)	O
mice	O
displayed	O
an	O
impaired	O
ability	O
to	O
clear	O
virus	O
from	O
the	O
brain	O
that	O
was	O
accompanied	O
by	O
a	O
reduction	O
in	O
the	O
numbers	O
of	O
antigen	O
-	O
specific	O
T	O
cells	O
as	O
compared	O
to	O
both	O
CCL2	B-PRGE
(-/-)	O
and	O
wild	O
-	O
type	O
mice	O
.	O

ABSTRACT	O
:	O
Overlapping	O
fragments	O
of	O
genomic	O
RNA	O
spanning	O
6963	O
nucleotides	O
from	O
5	O
'	O
end	O
of	O
spike	O
(	O
S	O
)	O
protein	O
gene	O
to	O
3	O
'	O
end	O
of	O
nucleocapsid	B-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
protein	I-PRGE
gene	I-PRGE
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
were	O
amplified	O
by	O
reverse	O
-	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Phylogenetic	O
analysis	O
based	O
on	O
the	O
deduced	O
amino	O
acid	O
sequences	O
of	O
S	O
,	O
M	O
,	O
or	O
N	B-PRGE
protein	I-PRGE
demonstrated	O
that	O
TCoV	O
was	O
clustered	O
within	O
the	O
same	O
genomic	O
lineage	O
as	O
the	O
IBV	O
strains	O
while	O
all	O
the	O
other	O
mammalian	O
coronaviruses	O
were	O
grouped	O
into	O
separate	O
clusters	O
corresponding	O
to	O
antigenic	O
groups	O
I	O
or	O
II	O
.	O

p38	B-PRGE
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
MAPK	B-PRGE
)	O
and	O
its	O
downstream	O
targets	O
are	O
activated	O
in	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
infected	O
Vero	O
E6	O
cells	O
and	O
activation	O
of	O
p38	B-PRGE
MAPK	O
enhances	O
the	O
cytopathic	O
effects	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
addition	O
to	O
phosphorylation	O
of	O
p38	B-PRGE
MAPK	I-PRGE
in	O
virus	O
-	O
infected	O
cells	O
,	O
other	O
MAPKs	O
,	O
i	O
.	O
e	O
.,	O
extracellular	B-PRGE
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
1	O
/	O
2	O
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
kinase	I-PRGE
(	O
JNK	B-PRGE
),	O
were	O
phosphorylated	O
.	O

Affinity	O
-	O
purified	O
polyclonal	O
antibodies	O
recognizing	O
the	O
N	O
-	O
terminal	O
19	O
residues	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
were	O
used	O
to	O
establish	O
the	O
specificity	O
of	O
channel	O
formation	O
by	O
inhibiting	O
the	O
ion	O
currents	O
generated	O
in	O
the	O
presence	O
of	O
the	O
E	O
protein	O
peptides	O
.	O

These	O
data	O
suggest	O
that	O
an	O
instructional	O
program	O
intrinsic	O
to	O
T	O
cell	O
differentiation	O
,	O
rather	O
than	O
Ag	O
load	O
or	O
factors	O
in	O
the	O
inflamed	O
CNS	O
,	O
prominently	O
regulate	O
CD8	B-PRGE
+	I-PRGE
T	O
cell	O
function	O
.	O

TITLE	O
:	O
S1	O
and	O
N	B-PRGE
gene	I-PRGE
analysis	O
of	O
avian	O
infectious	O
bronchitis	O
viruses	O
in	O
Taiwan	O
.	O

No	O
recombination	O
was	O
found	O
between	O
H120	O
and	O
the	O
Taiwanese	O
strains	O
in	O
the	O
S1	B-PRGE
gene	I-PRGE
.	O

However	O
,	O
caution	O
should	O
be	O
taken	O
in	O
using	O
the	O
inactivated	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
as	O
a	O
vaccine	O
since	O
it	O
may	O
also	O
cause	O
harmful	O
immune	O
and	O
/	O
or	O
inflammatory	O
responses	O
.	O

Both	O
patients	O
with	O
myopathy	O
had	O
elevated	O
serum	B-PRGE
creatine	I-PRGE
kinase	I-PRGE
levels	O
.	O

The	O
final	O
optimal	O
concentration	O
of	O
methanol	O
was	O
20	O
mL	O
/	O
L	O
,	O
the	O
DO	O
had	O
a	O
significant	O
effect	O
on	O
rSCoVN	B-PRGE
protein	I-PRGE
expression	O
and	O
growth	O
of	O
recombinant	O
strains	O
.	O

The	O
rSCoVN	B-PRGE
protein	I-PRGE
has	O
a	O
high	O
specificity	O
against	O
SARS	B-PRGE
-	I-PRGE
CoVN	I-PRGE
-	I-PRGE
mAb	I-PRGE
and	O
SARS	O
positive	O
sera	O
,	O
but	O
has	O
no	O
cross	O
-	O
reaction	O
with	O
normal	O
human	O
serum	O
.	O

CONCLUSIONS	O
:	O
SARS	O
cases	O
may	O
develop	O
leucocytosis	O
,	O
low	O
lymphocyte	O
count	O
,	O
low	O
platelet	O
count	O
,	O
low	O
hemoglobin	B-PRGE
level	O
and	O
abnormal	O
liver	O
function	O
.	O

In	O
convalescent	O
stage	O
,	O
all	O
the	O
tests	O
were	O
returned	O
to	O
normal	O
ranges	O
except	O
ALT	B-PRGE
,	O
AST	B-PRGE
were	O
still	O
elevated	O
in	O
SARS	O
patients	O
.	O

TITLE	O
:	O
Specific	O
immunoglobulin	B-PRGE
g	I-PRGE
antibody	I-PRGE
detected	O
in	O
umbilical	O
blood	O
and	O
amniotic	O
fluid	O
from	O
a	O
pregnant	O
woman	O
infected	O
by	O
the	O
coronavirus	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

The	O
need	O
for	O
mechanical	O
ventilation	O
was	O
associated	O
with	O
bilateral	O
lung	O
involvement	O
on	O
the	O
initial	O
chest	O
radiograph	O
and	O
higher	O
peak	O
levels	O
of	O
LDH	B-PRGE
and	O
CRP	B-PRGE
.	O

CONCLUSIONS	O
:	O
The	O
clinical	O
picture	O
of	O
our	O
patients	O
presenting	O
with	O
hospital	O
-	O
acquired	O
SARS	O
revealed	O
atypical	O
pneumonia	O
associated	O
with	O
lymphopenia	O
,	O
elevated	O
serum	O
levels	O
of	O
LDH	B-PRGE
,	O
rapid	O
clinical	O
deterioration	O
,	O
and	O
lack	O
of	O
response	O
to	O
empirical	O
antibiotic	O
therapy	O
.	O

ACE2	B-PRGE
efficiently	O
hydrolyses	O
the	O
potent	O
vasoconstrictor	O
angiotensin	B-PRGE
II	I-PRGE
to	O
angiotensin	O
(	O
1	O
-	O
7	O
).	O

We	O
found	O
that	O
nsp1	B-PRGE
(	O
p20	B-PRGE
)	O
is	O
rapidly	O
processed	O
from	O
the	O
replicase	B-PRGE
polyprotein	O
.	O

ABSTRACT	O
:	O
We	O
have	O
replaced	O
the	O
ectodomain	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
Beaudette	O
strain	O
(	O
Beau	O
-	O
R	O
;	O
apathogenic	O
for	O
Gallus	O
domesticus	O
chickens	O
)	O
of	O
avian	O
infectious	O
bronchitis	O
coronavirus	O
(	O
IBV	O
)	O
with	O
that	O
from	O
the	O
pathogenic	O
M41	O
strain	O
to	O
produce	O
recombinant	B-PRGE
IBV	I-PRGE
BeauR	I-PRGE
-	I-PRGE
M41	I-PRGE
(	O
S	O
).	O

7a	O
induces	O
apoptosis	O
via	O
a	O
caspase	B-PRGE
-	O
dependent	O
pathway	O
and	O
in	O
cell	O
lines	O
derived	O
from	O
different	O
organs	O
,	O
including	O
lung	O
,	O
kidney	O
,	O
and	O
liver	O
.	O

The	O
target	O
specificity	O
of	O
the	O
SCoV	B-PRGE
P1	I-PRGE
/	I-PRGE
P2	I-PRGE
repressor	I-PRGE
was	O
evaluated	O
by	O
coexpression	O
of	O
this	O
repressor	O
with	O
a	O
chemically	O
synthesized	O
SCoV	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
gene	B-PRGE
construct	I-PRGE
.	O

BALF	O
from	O
ARDS	O
patients	O
induced	O
41	O
%	O
greater	O
procollagen	B-PRGE
I	I-PRGE
promoter	I-PRGE
activation	O
than	O
that	O
from	O
negative	O
controls	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
a	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
blocking	O
antibody	O
significantly	O
reduced	O
this	O
activation	O
in	O
ARDS	O
patients	O
.	O

Procollagen	B-PRGE
I	I-PRGE
promoter	I-PRGE
activation	O
was	O
not	O
associated	O
with	O
mortality	O
;	O
however	O
,	O
lower	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
levels	O
were	O
associated	O
with	O
more	O
ventilator	O
-	O
free	O
and	O
ICU	O
-	O
free	O
days	O
.	O

Procollagen	B-PRGE
I	I-PRGE
promoter	I-PRGE
activation	O
was	O
not	O
associated	O
with	O
mortality	O
;	O
however	O
,	O
lower	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
levels	O
were	O
associated	O
with	O
more	O
ventilator	O
-	O
free	O
and	O
ICU	O
-	O
free	O
days	O
.	O

IgG	B-PRGE
was	O
detected	O
in	O
each	O
sample	O
with	O
the	O
mean	O
of	O
A	O
value	O
of	O
0	O
.	O
97	O
+/-	O

Manuscripts	O
address	O
the	O
use	O
of	O
molecular	O
techniques	O
in	O
the	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
bacterial	B-PRGE
ribosome	I-PRGE
mutations	I-PRGE
,	O
which	O
may	O
lead	O
to	O
ribosome	O
-	O
targeted	O
drug	O
resistance	O
;	O
pharmacogenomics	O
as	O
a	O
clinical	O
laboratory	O
service	O
and	O
example	O
of	O
warfarin	O
dosing	O
using	O
CYP2C9	B-PRGE
mutation	I-PRGE
analysis	O
;	O
definition	O
of	O
the	O
potential	O
of	O
cytosine	O
arabinoside	O
incorporation	O
into	O
DNA	O
to	O
disrupt	O
transcription	O
using	O
an	O
in	O
vitro	O
model	O
of	O
oligonucleotides	O
;	O
use	O
of	O
laser	O
capture	O
microdissection	O
to	O
isolate	O
solid	O
tumor	O
cells	O
free	O
of	O
nontumor	O
cells	O
;	O
and	O
molecular	O
methods	O
used	O
to	O
classify	O
lymphomas	O
.	O

This	O
study	O
investigated	O
the	O
capability	O
of	O
an	O
exogenous	O
nitric	O
oxide	O
(	O
NO	O
)	O
donor	O
,	O
sodium	O
nitroprusside	O
(	O
NP	O
);	O
a	O
NO	O
substrate	O
,	O
L	O
-	O
arginine	O
;	O
and	O
an	O
inducible	O
NO	B-PRGE
synthase	I-PRGE
inhibitor	O
,	O
L	O
-	O
N6	O
-(	O
1	O
-	O
iminoethyl	O
)	O
lysine	O
(	O
L	O
-	O
NIL	O
)	O
to	O
reduce	O
lung	O
injury	O
in	O
an	O
animal	O
model	O
of	O
mixed	O
controlled	O
and	O
uncontrolled	O
hemorrhagic	O
shock	O
.	O

These	O
data	O
suggest	O
that	O
limiting	O
inducible	O
NO	B-PRGE
synthase	I-PRGE
-	O
generated	O
NO	O
availability	O
with	O
the	O
exogenous	O
NO	O
donor	O
,	O
sodium	O
nitroprusside	O
,	O
may	O
reduce	O
lung	O
injury	O
after	O
severe	O
hemorrhage	O
,	O
possibly	O
,	O
among	O
other	O
effects	O
,	O
by	O
downregulating	O
the	O
expression	O
of	O
inflammatory	O
cytokines	O
.	O

L	B-PRGE
-	I-PRGE
arginine	I-PRGE
and	I-PRGE
L	I-PRGE
-	I-PRGE
NIL	I-PRGE
also	O
had	O
a	O
beneficial	O
effect	O
on	O
lung	O
function	O
and	O
structure	O
.	O

Expression	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
was	O
observed	O
in	O
COS1	O
cells	O
following	O
transfection	O
with	O
pCI	O
-	O
N	O
.	O
The	O
immune	O
responses	O
induced	O
by	O
intramuscular	O
immunization	O
with	O
pCI	O
-	O
N	O
were	O
evaluated	O
in	O
a	O
murine	O
model	O
.	O

This	O
interaction	O
could	O
be	O
blocked	O
by	O
either	O
the	O
serum	O
from	O
a	O
SARS	O
convalescent	O
patient	O
or	O
a	O
goat	O
anti	B-PRGE
-	I-PRGE
ACE2	I-PRGE
antibody	I-PRGE
,	O
indicating	O
that	O
the	O
interaction	O
is	O
specific	O
.	O

However	O
,	O
the	O
different	O
composition	O
of	O
the	O
tested	O
samples	O
affected	O
the	O
heat	O
sensitivity	O
of	O
the	O
virus	O
strain	O
:	O
the	O
infectivity	O
of	O
the	O
virus	O
in	O
Antithrombin	B-PRGE
III	I-PRGE
preparation	O
still	O
remained	O
after	O
heating	O
for	O
30	O
min	O
at	O
60	O
degrees	O
C	O
.	O
CONCLUSIONS	O
:	O
If	O
by	O
rare	O
chance	O
SARS	O
-	O
CoV	O
contaminates	O
source	O
plasma	O
,	O
there	O
should	O
be	O
no	O
or	O
only	O
minor	O
risk	O
of	O
this	O
virus	O
infection	O
,	O
due	O
to	O
sufficient	O
inactivation	O
by	O
the	O
60	O
degrees	O
C	O
10	O
h	O
liquid	O
heating	O
step	O
,	O
although	O
we	O
must	O
pay	O
attention	O
to	O
the	O
composition	O
used	O
for	O
blood	O
product	O
preparation	O
.	O

Cholinesterase	B-PRGE
(	O
ChE	B-PRGE
)	O
activity	O
was	O
dynamically	O
monitored	O
.	O

IL	O
-	O
8	O
release	O
was	O
effectively	O
induced	O
by	O
vAtEpGS688	O
,	O
a	O
baculovirus	O
exhibiting	O
the	O
aa	O
17	O
-	O
688	O
fragment	O
of	O
S	B-PRGE
protein	I-PRGE
,	O
and	O
this	O
induction	O
was	O
attenuated	O
by	O
the	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	O
Ab	O
.	O

Activations	O
of	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
DNA	I-PRGE
-	I-PRGE
protein	I-PRGE
binding	O
and	O
MAPKs	O
after	O
vAtEpGS688	O
transduction	O
were	O
demonstrated	O
,	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
-	O
induced	O
IL	O
-	O
8	O
promoter	O
activity	O
was	O
inhibited	O
by	O
the	O
specific	O
inhibitors	O
of	O
MAPK	B-PRGE
cascades	O
.	O

These	O
results	O
suggested	O
that	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
could	O
induce	O
release	O
of	O
IL	O
-	O
8	O
in	O
the	O
lung	O
cells	O
via	O
activations	O
of	O
MAPKs	O
and	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Analysis	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
(	O
S	O
)	O
using	O
recombinant	O
plasmid	O
and	O
virus	O
infections	O
demonstrated	O
that	O
the	O
S	B-PRGE
-	I-PRGE
precursor	I-PRGE
(	O
proS	B-PRGE
)	O
exists	O
as	O
a	O
approximately	O
190	O
kDa	O
endoplasmic	O
reticulum	O
form	O
and	O
a	O
approximately	O
210	O
kDa	O
Golgi	O
-	O
modified	O
form	O
.	O

The	O
membrane	O
-	O
bound	O
proprotein	O
convertases	O
(	O
PCs	B-PRGE
)	O
furin	B-PRGE
,	O
PC7	B-PRGE
or	O
PC5B	O
enhanced	O
the	O
production	O
of	O
the	O
approximately	O
80	O
kDa	O
protein	O
.	O

IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
,	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
MIG	O
,	O
and	O
IL	O
-	O
8	O
,	O
but	O
not	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
,	O
or	O
TNFRI	B-PRGE
,	O
were	O
highly	O
elevated	O
in	O
the	O
acute	O
phase	O
sera	O
of	O
Taiwan	O
SARS	O
patients	O
.	O

IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
,	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
MIG	O
,	O
and	O
IP	O
-	O
10	O
were	O
already	O
elevated	O
at	O
early	O
days	O
post	O
fever	O
onset	O
.	O

For	O
the	O
survival	O
group	O
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
were	O
inversely	O
associated	O
with	O
circulating	O
lymphocytes	O
count	O
and	O
monocytes	O
count	O
,	O
but	O
positively	O
associated	O
with	O
circulating	O
neutrophils	O
count	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
recombinant	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
-	O
based	O
assay	O
for	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
detection	O
.	O

TITLE	O
:	O
Intranasal	O
immunization	O
with	O
inactivated	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
SARS	B-PRGE
-	O
associated	O
coronavirus	O
)	O
induced	O
local	O
and	O
serum	O
antibodies	O
in	O
mice	O
.	O

In	O
the	O
present	O
study	O
,	O
an	O
E1	O
/	O
partially	O
E3	O
-	O
deleted	O
,	O
replication	O
-	O
defective	O
human	O
adenovirus	O
5	O
(	O
Ad5	O
)	O
vector	O
(	O
Ad5	O
-	O
N	O
-	O
V	O
)	O
expressing	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
was	O
constructed	O
.	O

The	O
results	O
showed	O
that	O
the	O
expression	O
level	O
of	O
E	B-PRGE
-	I-PRGE
CR1	I-PRGE
(	O
referred	O
to	O
as	O
net	O
fluorescence	O
intensity	O
values	O
,	O
NFI	O
)	O
was	O
statistically	O
correlated	O
with	O
the	O
relevant	O
genetic	O
genotypes	O
among	O
the	O
Chinese	O
population	O
including	O
the	O
healthy	O
individuals	O
(	O
NFI	O
:	O
5	O
.	O
14	O
+/-	O
0	O
.	O
82	O
,	O
3	O
.	O
57	O
+/-	O
0	O
.	O
66	O
and	O
2	O
.	O
67	O
+/-	O

TITLE	O
:	O
Ribavirin	O
and	O
interferon	B-PRGE
-	I-PRGE
beta	I-PRGE
synergistically	O
inhibit	O
SARS	O
-	O
associated	O
coronavirus	O
replication	O
in	O
animal	O
and	O
human	O
cell	O
lines	O
.	O

The	O
replicase	B-PRGE
complex	I-PRGE
is	O
believed	O
to	O
be	O
comprised	O
of	O
up	O
to	O
16	O
viral	O
subunits	O
and	O
a	O
number	O
of	O
cellular	O
proteins	O
.	O

In	O
addition	O
to	O
viral	O
proteins	O
,	O
several	O
cellular	O
proteins	O
,	O
such	O
as	O
heterogeneous	B-PRGE
nuclear	B-PRGE
ribonucleoprotein	I-PRGE
(	I-PRGE
hnRNP	I-PRGE
)	I-PRGE
A1	I-PRGE
,	O
polypyrimidine	B-PRGE
-	I-PRGE
tract	I-PRGE
-	I-PRGE
binding	I-PRGE
(	I-PRGE
PTB	I-PRGE
)	I-PRGE
protein	I-PRGE
,	O
poly	B-PRGE
(	I-PRGE
A	I-PRGE
)-	I-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
PABP	B-PRGE
),	O
and	O
mitochondrial	O
aconitase	O
(	O
m	O
-	O
aconitase	O
),	O
have	O
been	O
identified	O
to	O
interact	O
with	O
the	O
critical	O
cis	O
-	O
acting	O
elements	O
of	O
coronavirus	O
replication	O
.	O

Quantitative	O
reverse	O
transcription	O
-	O
PCR	O
showed	O
that	O
the	O
amount	O
of	O
CoV	B-PRGE
-	I-PRGE
HKU1	I-PRGE
RNA	I-PRGE
was	O
8	O
.	O
5	O
to	O
9	O
.	O
6	O
x	O
10	O
(	O
6	O
)	O
copies	O
per	O
ml	O
in	O
his	O
nasopharyngeal	O
aspirates	O
(	O
NPAs	O
)	O
during	O
the	O
first	O
week	O
of	O
the	O
illness	O
and	O
dropped	O
progressively	O
to	O
undetectable	O
levels	O
in	O
subsequent	O
weeks	O
.	O

A	O
severe	O
recurrent	O
infection	O
developed	O
,	O
typified	O
by	O
viral	O
persistence	O
and	O
acute	O
lymphopenia	O
,	O
with	O
waves	O
of	O
enhanced	O
viral	O
replication	O
coinciding	O
with	O
fever	O
,	O
weight	O
loss	O
,	O
and	O
depletion	O
of	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
39	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
with	O
post	O
-	O
streptococcal	O
acute	O
glomerulonephritis	O
(	O
PSAGN	O
)	O
super	O
-	O
imposed	O
on	O
long	O
-	O
term	O
immunoglobulin	B-PRGE
A	O
nephropathy	O
(	O
IgA	B-PRGE
-	I-PRGE
N	I-PRGE
).	O

The	O
possible	O
antigenic	O
determinants	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
are	O
predicted	O
,	O
and	O
the	O
result	O
is	O
confirmed	O
by	O
ELISA	O
(	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
)	O
with	O
synthesized	O
peptides	O
.	O

Another	O
profound	O
finding	O
is	O
that	O
three	O
disulfide	O
bonds	O
are	O
defined	O
at	O
the	O
C	O
-	O
terminus	O
with	O
the	O
N	O
-	O
terminus	O
of	O
the	O
E	B-PRGE
(	I-PRGE
envelope	I-PRGE
)	I-PRGE
protein	I-PRGE
,	O
based	O
on	O
the	O
typical	O
sequence	O
and	O
positions	O
,	O
thus	O
establishing	O
the	O
structural	O
connection	O
with	O
these	O
two	O
important	O
structural	O
proteins	O
,	O
if	O
confirmed	O
.	O

TITLE	O
:	O
The	O
M	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
:	O
basic	O
structural	O
and	O
immunological	O
properties	O
.	O

The	O
abundant	O
antigenic	O
sites	O
predicted	O
in	O
the	O
N	B-PRGE
protein	I-PRGE
,	O
as	O
well	O
as	O
experimental	O
evidence	O
with	O
synthesized	O
polypeptides	O
,	O
indicate	O
that	O
the	O
N	B-PRGE
protein	I-PRGE
is	O
one	O
of	O
the	O
major	O
antigens	O
of	O
the	O
SARS	O
-	O
CoV	O
.	O
Compared	O
with	O
other	O
viral	O
structural	O
proteins	O
,	O
the	O
low	O
variation	O
rate	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
with	O
regards	O
to	O
its	O
size	O
suggests	O
its	O
importance	O
to	O
the	O
survival	O
of	O
the	O
virus	O
.	O

The	O
functional	O
domains	O
in	O
all	O
NSPs	O
of	O
the	O
R	B-PRGE
protein	I-PRGE
give	O
different	O
phylogenetic	O
results	O
that	O
suggest	O
their	O
different	O
mutation	O
rate	O
under	O
selective	O
pressure	O
.	O

Eleven	O
highly	O
conserved	O
regions	O
in	O
RdRp	O
and	O
twelve	O
cleavage	O
sites	O
by	O
3CLP	O
(	O
chymotrypsin	B-PRGE
-	I-PRGE
like	I-PRGE
protein	I-PRGE
)	O
have	O
been	O
identified	O
as	O
potential	O
drug	O
targets	O
.	O

TITLE	O
:	O
The	O
epitope	O
study	O
on	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
.	O

Whether	O
the	O
N	B-PRGE
protein	I-PRGE
in	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
antigenic	O
remains	O
to	O
be	O
elucidated	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
potential	O
epitope	O
regions	O
were	O
located	O
at	O
Codons	O
469	O
-	O
882	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
,	O
and	O
one	O
epitope	O
site	O
was	O
located	O
at	O
Codons	O
599	O
-	O
620	O
.	O

Our	O
manual	O
analysis	O
of	O
the	O
BLASTN	O
results	O
demonstrates	O
that	O
the	O
HE	O
(	O
hemagglutinin	O
-	O
esterase	B-PRGE
)	O
gene	O
exists	O
in	O
the	O
SARS	O
-	O
CoV	O
,	O
and	O
many	O
mutations	O
made	O
it	O
unfamiliar	O
to	O
us	O
.	O

Detailed	O
biological	O
knowledge	O
is	O
crucial	O
for	O
the	O
development	O
of	O
effective	O
countermeasures	O
,	O
diagnostic	O
tests	O
,	O
vaccines	O
and	O
antiviral	O
drugs	O
against	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
This	O
article	O
reviews	O
the	O
present	O
state	O
of	O
molecular	O
knowledge	O
about	O
SARS	O
-	O
CoV	O
,	O
from	O
the	O
aspects	O
of	O
comparative	O
genomics	O
,	O
molecular	O
biology	O
of	O
viral	O
genes	O
,	O
evolution	O
,	O
and	O
epidemiology	O
,	O
and	O
describes	O
the	O
diagnostic	O
tests	O
and	O
the	O
anti	O
-	O
viral	O
drugs	O
derived	O
so	O
far	O
based	O
on	O
the	O
available	O
molecular	O
information	O
.	O

Human	O
phage	O
antibody	O
library	O
against	O
SARS	O
virus	O
has	O
been	O
constructed	O
successfully	O
,	O
from	O
which	O
10	B-PRGE
anti	I-PRGE
-	I-PRGE
SARS	I-PRGE
virus	I-PRGE
antibodies	I-PRGE
were	O
obtained	O
.	O

N	B-PRGE
protein	I-PRGE
expressed	O
in	O
E	O
.	O
coli	O
was	O
recovered	O
from	O
SDS	O
-	O
PAGE	O
gel	O
and	O
served	O
as	O
immunogen	O
in	O
the	O
preparation	O
of	O
the	O
mAb	O
.	O

And	O
the	O
expressions	O
of	O
TCR	B-PRGE
Vbeta4	I-PRGE
,	O
Vbeta22	O
and	O
Vbeta23	O
in	O
SARS	O
patients	O
treated	O
with	O
glucocorticoid	O
(>	O
1	O
000	O
U	O
)	O
were	O
higher	O
than	O
those	O
in	O
SARS	O
patients	O
without	O
treatment	O
.	O

(	O
3	O
)	O
The	O
IgG	B-PRGE
antibody	I-PRGE
emerged	O
in	O
one	O
of	O
24	O
children	O
,	O
whose	O
mother	O
,	O
a	O
nurse	O
,	O
had	O
suffered	O
from	O
SARS	O
(	O
4	O
%).	O

(	O
4	O
)	O
Among	O
23	O
parents	O
of	O
children	O
with	O
SARS	O
,	O
one	O
was	O
positive	O
for	O
IgG	B-PRGE
and	O
the	O
mixed	O
antibodies	O
,	O
whose	O
grandson	O
and	O
husband	O
suffered	O
from	O
SARS	O
;	O
The	O
IgG	B-PRGE
antibody	I-PRGE
and	O
the	O
mixed	O
antibodies	O
were	O
also	O
positive	O
in	O
another	O
adult	O
who	O
had	O
close	O
contact	O
with	O
adult	O
SARS	O
cases	O
(	O
3	O
%).	O

The	O
specific	O
IgM	B-PRGE
disappeared	O
as	O
early	O
as	O
42	O
days	O
after	O
the	O
onset	O
of	O
SARS	O
.	O

Specific	O
IgG	B-PRGE
antibody	I-PRGE
against	O
SARS	O
-	O
CoV	O
in	O
serum	O
samples	O
from	O
contacts	O
to	O
patients	O
,	O
five	O
months	O
before	O
an	O
SARS	O
outbreak	O
in	O
Beijing	O
.	O

CONCLUSIONS	O
:	O
Monoclonal	O
antibodies	O
we	O
made	O
were	O
specific	O
to	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
and	O
they	O
had	O
been	O
used	O
to	O
detect	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
autopsy	O
lung	O
tissues	O
specimens	O
with	O
positive	O
results	O
.	O

ABSTRACT	O
:	O
In	O
contrast	O
to	O
BALB	O
/	O
c	O
mouse	O
macrophages	O
(	O
Mphi	O
),	O
Mphi	O
from	O
the	O
A	O
/	O
J	O
mouse	O
strain	O
,	O
upon	O
activation	O
by	O
exogenous	O
interferon	B-PRGE
gamma	I-PRGE
(	O
IFNgamma	O
),	O
develop	O
an	O
anti	O
-	O
mouse	O
hepatitis	O
virus	O
3	O
(	O
MHV3	O
)	O
state	O
which	O
correlates	O
with	O
resistance	O
to	O
virus	O
infection	O
.	O

For	O
pneumonia	O
,	O
NAATs	O
offer	O
advantages	O
over	O
conventional	O
tests	O
for	O
the	O
detection	O
of	O
Mycoplasma	B-PRGE
pneumoniae	I-PRGE
,	I-PRGE
Legionella	I-PRGE
spp	I-PRGE
.	O

In	O
this	O
study	O
,	O
HMGB1	B-PRGE
was	O
detected	O
in	O
pulmonary	O
endothelial	O
cells	O
and	O
macrophages	O
under	O
baseline	O
conditions	O
.	O

All	O
patients	O
had	O
at	O
least	O
one	O
site	O
that	O
was	O
positive	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
on	O
presentation	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
the	O
monoclonal	O
antibody	O
against	O
N	B-PRGE
protein	I-PRGE
of	O
SARS	O
virus	O
and	O
study	O
its	O
applicability	O
.	O

The	O
ELISA	O
for	O
detection	O
of	O
SARS	B-PRGE
virus	I-PRGE
antigen	I-PRGE
was	O
developed	O
with	O
McAb	O
7	O
.	O

CONCLUSIONS	O
:	O
The	O
monoclonal	O
antibody	O
has	O
good	O
specificity	O
and	O
may	O
be	O
used	O
to	O
detect	O
SARS	B-PRGE
virus	I-PRGE
antigen	I-PRGE
.	O

S1	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
,	O
which	O
has	O
been	O
demonstrated	O
harboring	O
the	O
receptor	O
binding	O
domain	O
,	O
successfully	O
elicited	O
SARS	B-PRGE
-	O
CoV	O
specific	O
IgG	B-PRGE
antibody	I-PRGE
in	O
mouse	O
after	O
combined	O
immunization	O
with	O
DNA	O
and	O
purified	O
S1	B-PRGE
protein	I-PRGE
;	O
the	O
antibody	O
elicited	O
solely	O
by	O
S1	O
could	O
potently	O
neutralize	O
SARS	B-PRGE
-	O
CoV	O
(	O
HKU	O
-	O
39849	O
)	O
in	O
vitro	O
,	O
50	O
%	O
of	O
1	O
000	O
TCID50	O
SARS	O
-	O
CoV	O
challenged	O
cells	O
were	O
protected	O
from	O
viral	O
infection	O
by	O
a	O
1	O
:	O
1499	O
.	O
68	O
dilution	O
of	O
mice	O
sera	O
immunized	O
with	O
S1	B-PRGE
protein	I-PRGE
,	O
but	O
negative	O
control	O
sera	O
showed	O
no	O
protection	O
.	O

TITLE	O
:	O
Expression	O
and	O
purification	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
membrane	I-PRGE
protein	I-PRGE
.	O

Taken	O
together	O
,	O
our	O
findings	O
provide	O
a	O
structural	O
and	O
cellular	O
framework	O
in	O
which	O
to	O
explore	O
the	O
role	O
of	O
orf7a	O
in	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
pathogenesis	O
.	O

This	O
means	O
that	O
our	O
pharmacophore	O
model	O
can	O
lead	O
to	O
the	O
discovery	O
of	O
potent	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
inhibitors	O
or	O
promising	O
lead	O
compounds	O
for	O
further	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
main	I-PRGE
proteinase	I-PRGE
inhibitor	O
development	O
.	O

Unexpectedly	O
,	O
Abs	O
that	O
neutralized	O
most	O
human	B-PRGE
S	I-PRGE
glycoproteins	I-PRGE
enhanced	O
entry	O
mediated	O
by	O
the	O
civet	O
virus	O
S	O
glycoproteins	O
.	O

High	O
hydrocortisone	O
concentrations	O
(>	O
or	O
=	O
50	O
microg	O
/	O
ml	O
)	O
completely	O
prevented	O
increased	O
DNA	O
binding	O
activity	O
of	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
and	O
inhibited	O
up	O
-	O
regulation	O
of	O
CXCL8	B-PRGE
and	O
CXCL10	B-PRGE
,	O
but	O
did	O
not	O
reduce	O
chemokine	O
expression	O
to	O
basal	O
levels	O
.	O

TITLE	O
:	O
Complete	O
genomic	O
sequence	O
of	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
:	O
molecular	O
clock	O
analysis	O
suggests	O
a	O
relatively	O
recent	O
zoonotic	O
coronavirus	O
transmission	O
event	O
.	O

By	O
monitoring	O
the	O
effect	O
of	O
this	O
peptide	O
library	O
on	O
membrane	O
leakage	O
in	O
model	O
membranes	O
,	O
we	O
have	O
identified	O
three	O
regions	O
on	O
the	O
SARS	B-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
with	O
membrane	O
-	O
interacting	O
capabilities	O
:	O
region	O
1	O
,	O
located	O
immediately	O
upstream	O
of	O
heptad	O
repeat	O
1	O
(	O
HR1	O
)	O
and	O
suggested	O
to	O
be	O
the	O
fusion	O
peptide	O
;	O
region	O
2	O
,	O
located	O
between	O
HR1	O
and	O
HR2	O
,	O
which	O
would	O
be	O
analogous	O
to	O
the	O
loop	O
domain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
;	O
and	O
region	O
3	O
,	O
which	O
would	O
correspond	O
to	O
the	O
pretransmembrane	O
region	O
.	O

Western	O
blot	O
and	O
indirect	O
fluorescence	O
assay	O
showed	O
that	O
the	O
McAbs	O
reacted	O
specifically	O
with	O
nucleocapsid	B-PRGE
protein	I-PRGE
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Among	O
the	O
six	O
McAbs	O
,	O
three	O
recognize	O
the	O
epitopes	O
located	O
in	O
the	O
N	O
-	O
terminus	O
of	O
the	O
protein	O
,	O
whereas	O
the	O
others	O
reacted	O
with	O
those	O
located	O
in	O
the	O
C	O
-	O
terminus	O
.	O

CONCLUSIONS	O
:	O
The	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
McAbs	I-PRGE
were	O
developed	O
and	O
these	O
McAbs	O
may	O
be	O
useful	O
in	O
the	O
development	O
of	O
diagnosis	O
assays	O
and	O
basic	O
research	O
of	O
SARS	O
.	O

SARS	B-PRGE
coronavirus	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
was	O
detected	O
positive	O
in	O
6	O
of	O
the	O
9	O
patients	O
,	O
it	O
was	O
still	O
positive	O
in	O
the	O
sera	O
twelve	O
months	O
after	O
recovery	O
;	O
1	O
of	O
the	O
closely	O
contacted	O
persons	O
and	O
3	O
normal	O
subjects	O
were	O
found	O
positive	O
.	O

Transgenic	O
mice	O
with	O
human	B-PRGE
immunoglobulin	I-PRGE
genes	I-PRGE
were	O
immunized	O
with	O
the	O
recombinant	O
major	O
surface	O
(	O
S	O
)	O
glycoprotein	O
ectodomain	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Epitopes	O
of	O
2	O
neutralizing	O
MAbs	O
derived	O
from	O
these	O
mice	O
were	O
mapped	O
and	O
evaluated	O
in	O
a	O
murine	O
model	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Two	O
neutralizing	O
epitopes	O
were	O
defined	O
for	O
MAbs	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
glycoprotein	I-PRGE
.	O

ABSTRACT	O
:	O
To	O
characterize	O
enzymatic	O
activity	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CL	O
(	O
pro	O
))	O
and	O
its	O
four	O
site	O
-	O
directed	O
mutants	O
.	O

The	O
N	O
-	O
producing	O
strain	O
MG1363	O
/	O
pSECN	O
and	O
the	O
purified	O
hGST	B-PRGE
-	I-PRGE
N	I-PRGE
protein	I-PRGE
were	O
respectively	O
administered	O
to	O
mice	O
,	O
either	O
orally	O
or	O
intranasally	O
.	O

Maximum	O
titers	O
of	O
IgG	B-PRGE
(	O
8	O
.	O
38	O
+/-	O
0	O
.	O
19	O
ng	O
/	O
ml	O
of	O
serum	O
)	O
and	O
IgA	B-PRGE
(	O
64	O
.	O
82	O
+/-	O
2	O
.	O
9	O
ng	O
/	O
ml	O
of	O
intestinal	O
water	O
)	O
were	O
attained	O
32	O
days	O
post	O
oral	O
inturbation	O
.	O

Serum	O
samples	O
were	O
tested	O
for	O
antibodies	O
to	O
bovine	O
parainfluenza	O
virus	O
-	O
3	O
(	O
PIV	O
-	O
3	O
),	O
bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
),	O
bovine	O
coronavirus	O
(	O
BCV	O
),	O
bovine	O
adenovirus	O
-	O
3	O
(	O
BAV	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
and	O
bovine	O
adenovirus	O
-	O
7	O
(	O
BAV	O
-	O
7	O
).	O

ABSTRACT	O
:	O
A	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
the	O
detection	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
messenger	O
RNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
is	O
described	O
.	O

The	O
test	O
was	O
applied	O
to	O
1075	O
feline	O
blood	O
samples	O
(	O
424	O
from	O
healthy	O
,	O
651	O
from	O
sick	O
cats	O
suspected	O
of	O
FIP	O
)	O
and	O
returned	O
46	O
%	O
of	O
the	O
diseased	O
cats	O
as	O
positive	O
for	O
feline	B-PRGE
coronavirus	I-PRGE
mRNA	I-PRGE
in	O
their	O
peripheral	O
blood	O
cells	O
;	O
of	O
the	O
healthy	O
cats	O
,	O
5	O
%	O
tested	O
positive	O
.	O

Forty	O
-	O
five	O
motifs	O
relating	O
to	O
superantigens	O
,	O
toxins	O
and	O
other	O
bioactive	O
molecules	O
were	O
detected	O
in	O
the	O
proteins	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
results	O
showed	O
that	O
the	O
distribution	O
of	O
the	O
motifs	O
varied	O
in	O
different	O
proteins	O
.	O

The	O
immunological	O
fragment	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
(	O
Ala251	O
-	O
His641	O
,	O
SARS_S1b	O
)	O
is	O
believed	O
to	O
be	O
essential	O
for	O
SARS_CoV	O
entering	O
the	O
host	O
cell	O
through	O
S	B-PRGE
protein	I-PRGE
-	O
ACE	B-PRGE
-	O
2	O
interaction	O
.	O

RESULTS	O
:	O
Both	O
the	O
truncated	B-PRGE
recombinant	I-PRGE
proteins	I-PRGE
were	O
expressed	O
in	O
soluble	O
forms	O
and	O
reacted	O
specifically	O
with	O
the	O
sera	O
from	O
immunized	O
pSecS	O
mice	O
and	O
clinically	O
diagnosed	O
SARS	O
patients	O
.	O

TITLE	O
:	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
protease	O
inhibitors	O
design	O
using	O
virtual	O
screening	O
method	O
from	O
natural	O
products	O
libraries	O
.	O

ABSTRACT	O
:	O
Two	O
natural	O
products	O
databases	O
,	O
the	O
marine	O
natural	O
products	O
database	O
(	O
MNPD	O
)	O
and	O
the	O
traditional	O
Chinese	O
medicines	O
database	O
(	O
TCMD	O
),	O
were	O
used	O
to	O
find	O
novel	O
structures	O
of	O
potent	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
protease	I-PRGE
inhibitors	O
through	O
virtual	O
screening	O
.	O

Our	O
data	O
showed	O
that	O
the	O
newly	O
developed	O
IFA	O
could	O
detect	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
22	O
of	O
the	O
23	O
SARS	O
-	O
CoV	O
-	O
positive	O
serum	O
samples	O
and	O
gave	O
no	O
false	O
-	O
positive	O
results	O
when	O
the	O
sera	O
from	O
patients	O
with	O
autoimmune	O
diseases	O
and	O
healthy	O
individuals	O
were	O
tested	O
.	O

After	O
the	O
intramuscular	O
introduction	O
into	O
animals	O
,	O
we	O
observed	O
that	O
the	O
constructs	O
of	O
the	O
E	O
,	O
M	O
,	O
and	O
N	O
genes	O
could	O
induce	O
high	O
levels	O
of	O
specific	O
antibodies	O
,	O
T	O
cell	O
proliferations	O
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
DTH	B-PRGE
responses	O
,	O
and	O
in	O
vivo	O
cytotoxic	O
T	O
cells	O
activities	O
specifically	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antigens	I-PRGE
.	O

TITLE	O
:	O
Recombinant	O
modified	O
vaccinia	O
virus	O
Ankara	O
expressing	O
the	O
spike	O
glycoprotein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
induces	O
protective	O
neutralizing	O
antibodies	O
primarily	O
targeting	O
the	O
receptor	B-PRGE
binding	I-PRGE
region	I-PRGE
.	O

Moreover	O
,	O
using	O
a	O
recombinant	O
soluble	O
RBR	B-PRGE
-	I-PRGE
Fc	I-PRGE
protein	I-PRGE
,	O
we	O
were	O
able	O
to	O
absorb	O
and	O
remove	O
the	O
majority	O
of	O
the	O
neutralizing	O
antibodies	O
despite	O
observing	O
that	O
the	O
full	B-PRGE
S	I-PRGE
protein	I-PRGE
tends	O
to	O
induce	O
a	O
broader	O
spectrum	O
of	O
neutralizing	O
activities	O
in	O
comparison	O
with	O
fragmented	O
S	O
proteins	O
.	O

Our	O
data	O
suggest	O
that	O
a	O
major	O
mechanism	O
for	O
neutralizing	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
likely	O
occurs	O
through	O
blocking	O
the	O
interaction	O
between	O
virus	O
and	O
the	O
cellular	O
receptor	O
ACE2	B-PRGE
.	O

3a	O
protein	O
appeared	O
to	O
undergo	O
posttranslational	O
modifications	O
in	O
infected	O
cells	O
and	O
was	O
incorporated	O
into	O
SCoV	O
particles	O
,	O
establishing	O
that	O
3a	B-PRGE
protein	I-PRGE
was	O
a	O
SCoV	B-PRGE
structural	I-PRGE
protein	I-PRGE
.	O

Partial	O
genomic	O
sequence	O
analysis	O
showed	O
that	O
these	O
isolates	O
had	O
the	O
S	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
M	I-PRGE
-	I-PRGE
5	I-PRGE
-	I-PRGE
N	I-PRGE
gene	I-PRGE
order	O
that	O
is	O
typical	O
of	O
avian	O
coronaviruses	O
.	O

The	O
changes	O
of	O
the	O
PaO	O
(	O
2	O
)	O
were	O
similar	O
to	O
the	O
PaO	B-PRGE
(	I-PRGE
2	I-PRGE
)/	I-PRGE
FiO	I-PRGE
(	I-PRGE
2	I-PRGE
).	I-PRGE

The	O
abnormalities	O
of	O
serum	O
alanine	B-PRGE
aminotransferase	I-PRGE
(	O
ALT	B-PRGE
)	O
were	O
52	O
.	O
5	O
%,	O
71	O
.	O
8	O
%,	O
85	O
.	O
7	O
%	O
and	O
85	O
.	O
2	O
%.	O

Our	O
results	O
show	O
that	O
CD14	B-PRGE
and	O
TLR4	B-PRGE
are	O
necessary	O
for	O
low	O
-	O
dose	O
(	O
300	O
-	O
microg	O
/	O
ml	O
)	O
LPS	O
-	O
induced	O
microvascular	O
leakage	O
,	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
activation	O
,	O
neutrophil	O
influx	O
,	O
cytokine	O
and	O
chemokine	O
(	O
KC	O
,	O
macrophage	B-PRGE
inflammatory	I-PRGE
protein	I-PRGE
2	I-PRGE
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
expression	O
,	O
and	O
subsequent	O
lung	O
damage	O
.	O

Sequencing	O
of	O
the	O
cloned	O
genome	O
cDNA	O
fragments	O
identified	O
two	O
single	O
-	O
nucleotide	O
mutations	O
in	O
cloned	O
genome	O
fragment	O
F	O
,	O
encoding	O
a	O
Tyr6398His	O
substitution	O
in	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1b	O
p59	B-PRGE
-	O
nsp14	O
and	O
a	O
Leu94Pro	O
substitution	O
in	O
the	O
ORF	O
2a	O
30	O
-	O
kDa	O
protein	O
.	O

The	O
Leu94Pro	O
mutant	O
virus	O
had	O
reduced	O
but	O
measurable	O
log10	B-PRGE
LD5	I-PRGE
),	O
and	O
the	O
""""	O
corrected	O
""""	O
Tyr6398	O
/	O
Leu94	O
virus	O
had	O
a	O
log10	O
LD50	O
identical	O
to	O
wild	O
-	O
type	O
MHV	O
-	O
A59	O
.	O

Immunoassays	O
found	O
that	O
most	O
of	O
the	O
patients	O
who	O
had	O
recovered	O
from	O
SARS	O
developed	O
complementary	O
antibodies	O
to	O
the	O
epitope	O
-	O
rich	O
region	O
on	O
the	O
spike	O
S2	O
protein	O
,	O
indicating	O
that	O
this	O
is	O
an	O
immunodominant	O
site	O
on	O
the	O
viral	O
envelope	O
comprising	O
the	O
spike	O
,	O
matrix	O
,	O
and	O
small	B-PRGE
envelope	I-PRGE
glycoproteins	I-PRGE
.	O

TITLE	O
:	O
Development	O
of	O
a	O
quantitative	O
assay	O
for	O
SARS	O
coronavirus	O
and	O
correlation	O
of	O
GAPDH	B-PRGE
mRNA	I-PRGE
with	O
SARS	O
coronavirus	O
in	O
clinical	O
specimens	O
.	O

The	O
relation	O
between	O
SARS	O
positivity	O
and	O
GAPDH	B-PRGE
mRNA	I-PRGE
concentration	O
was	O
investigated	O
using	O
the	O
chi2	O
test	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
early	O
diagnostic	O
reagents	O
,	O
effective	O
vaccines	O
,	O
and	O
even	O
drugs	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
the	O
human	O
single	O
fold	O
single	O
-	O
chain	O
antibody	O
fragments	O
,	O
(	O
scFv	O
)	O
libraries	O
I	O
+	O
J	O
(	O
Tomlinson	O
I	O
+	O
J	O
)	O
were	O
used	O
to	O
identify	O
novel	O
scFvs	O
,	O
which	O
can	O
specifically	O
bind	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Interestingly	O
,	O
two	O
scFvs	O
(	O
B5	O
and	O
B9	O
)	O
exhibited	O
higher	O
binding	O
specificity	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
with	O
the	O
OD	O
(	O
450	O
)	O
value	O
0	O
.	O
608	O
and	O
0	O
.	O
545	O
,	O
respectively	O
,	O
and	O
their	O
coding	O
sequences	O
shared	O
the	O
identical	O
sequence	O
composed	O
of	O
V	O
(	O
H	O
)	O
gene	O
(	O
351bp	O
)	O
and	O
V	O
(	O
L	O
)	O
gene	O
(	O
327bp	O
),	O
so	O
the	O
two	O
scFvs	O
were	O
uniformly	O
named	O
as	O
SA59B	O
and	O
chosen	O
for	O
further	O
analysis	O
.	O

The	O
soluble	O
30kDa	B-PRGE
SA59B	I-PRGE
scFv	I-PRGE
-	I-PRGE
antibody	I-PRGE
was	O
verified	O
in	O
SDS	O
-	O
PAGE	O
and	O
Western	O
-	O
blot	O
.	O

Depletion	O
of	O
RBD	O
-	O
specific	O
antibodies	O
from	O
patient	O
or	O
rabbit	O
immune	O
sera	O
by	O
immunoadsorption	O
significantly	O
reduced	O
serum	O
-	O
mediated	O
neutralizing	O
activity	O
,	O
while	O
affinity	O
-	O
purified	O
anti	O
-	O
RBD	O
antibodies	O
had	O
relatively	O
higher	O
potency	O
neutralizing	O
infectivity	O
of	O
SARS	O
pseudovirus	O
,	O
indicating	O
that	O
the	O
RBD	O
of	O
S	B-PRGE
protein	I-PRGE
is	O
a	O
critical	O
neutralization	O
determinant	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
during	O
viral	O
infection	O
and	O
immunization	O
.	O

We	O
further	O
demonstrated	O
that	O
2C5	O
,	O
but	O
not	O
1A5	O
,	O
was	O
able	O
to	O
block	O
binding	O
of	O
the	O
RBD	O
to	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
the	O
functional	O
receptor	O
on	O
targeted	O
cells	O
.	O

It	O
is	O
somewhat	O
unexpected	O
that	O
no	O
N	O
-	O
specific	O
mAbs	O
were	O
identified	O
albeit	O
anti	B-PRGE
-	I-PRGE
N	I-PRGE
IgG	I-PRGE
was	O
easily	O
identified	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
.	O

TITLE	O
:	O
Late	O
recognition	O
of	O
SARS	B-PRGE
in	O
nosocomial	O
outbreak	O
,	O
Toronto	O
.	O

Granulocyte	B-PRGE
-	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
is	O
commonly	O
administered	O
to	O
healthy	O
donors	O
to	O
mobilize	O
peripheral	O
blood	O
stem	O
cells	O
(	O
PBSC	O
)	O
for	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
allo	O
-	O
HSCT	O
).	O

The	O
cytokine	O
-	O
related	O
mechanisms	O
of	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
administration	O
that	O
contribute	O
to	O
ALI	O
are	O
discussed	O
.	O

TITLE	O
:	O
Use	O
of	O
the	O
COOH	O
portion	O
of	O
the	O
nucleocapsid	B-PRGE
protein	I-PRGE
in	O
an	O
antigen	O
-	O
capturing	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
specific	O
and	O
sensitive	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Retroviral	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
pseudotypes	I-PRGE
have	O
been	O
constructed	O
and	O
used	O
to	O
develop	O
an	O
in	O
vitro	O
microneutralization	O
assay	O
that	O
is	O
both	O
sensitive	O
and	O
specific	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
neutralizing	I-PRGE
antibodies	I-PRGE
.	O

Antibodies	O
against	O
the	O
NP	O
peptides	O
could	O
detect	O
the	O
cognate	O
N	B-PRGE
protein	I-PRGE
clearly	O
.	O

Recent	O
studies	O
revealed	O
that	O
3a	O
could	O
interact	O
specifically	O
with	O
many	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
structural	I-PRGE
proteins	I-PRGE
,	O
such	O
as	O
M	O
,	O
E	O
and	O
S	O
protein	O
.	O

TITLE	O
:	O
Retrospective	O
evidence	O
that	O
the	O
MHC	B-PRGE
(	I-PRGE
B	I-PRGE
haplotype	I-PRGE
)	I-PRGE
of	I-PRGE
chickens	I-PRGE
influences	O
genetic	O
resistance	O
to	O
attenuated	O
infectious	O
bronchitis	O
vaccine	O
strains	O
in	O
chickens	O
.	O

The	O
data	O
indicates	O
that	O
strains	O
within	O
the	O
793	O
/	O
B	O
serotype	O
have	O
>	O
or	O
=	O
96	O
%	O
nucleotide	O
identity	O
within	O
the	O
whole	O
S1	B-PRGE
gene	I-PRGE
and	O
>	O
or	O
=	O
93	O
%	O
nucleotide	O
identity	O
within	O
the	O
first	O
560	O
nucleotides	O
,	O
and	O
>	O
or	O
=	O
92	O
%	O
and	O
>	O
or	O
=	O
86	O
%	O
amino	O
acid	O
identities	O
in	O
the	O
corresponding	O
protein	O
regions	O
.	O

IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
was	O
found	O
to	O
be	O
the	O
most	O
highly	O
active	O
antiviral	O
agent	O
,	O
followed	O
by	O
natural	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
whereas	O
the	O
2	O
recombinant	B-PRGE
IFN	I-PRGE
-	I-PRGE
alpha2	I-PRGE
species	O
were	O
poorly	O
active	O
in	O
the	O
system	O
used	O
.	O

ABSTRACT	O
:	O
To	O
probe	O
blood	O
serum	B-PRGE
Ab	I-PRGE
-	I-PRGE
IgG	I-PRGE
characteristics	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
in	O
Guangzhou	O
and	O
investigate	O
the	O
related	O
factors	O
.	O

As	O
a	O
whole	O
SARS	O
-	O
CoV	O
Ab	O
-	O
IgG	B-PRGE
detective	O
rate	O
for	O
the	O
clinic	O
diagnosed	O
SARS	O
patients	O
was	O
53	O
.	O
7	O
%	O
only	O
.	O

Also	O
expressed	O
in	O
infected	O
cells	O
was	O
the	O
C	O
-	O
terminal	O
alternative	O
splice	O
variant	O
of	O
the	O
p53	B-PRGE
tumor	I-PRGE
suppressor	I-PRGE
gene	I-PRGE
encoding	O
a	O
modified	O
truncated	O
protein	O
that	O
can	O
influence	O
the	O
activity	O
of	O
wild	B-PRGE
-	I-PRGE
type	I-PRGE
p53	I-PRGE
.	O

TITLE	O
:	O
Spike	B-PRGE
protein	I-PRGE
assembly	O
into	O
the	O
coronavirion	O
:	O
exploring	O
the	O
limits	O
of	O
its	O
sequence	O
requirements	O
.	O

All	O
had	O
raised	O
plasma	B-PRGE
interferon	I-PRGE
gamma	I-PRGE
inducible	I-PRGE
protein	I-PRGE
(	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
concentrations	O
,	O
which	O
suggested	O
an	O
active	O
type	O
1	O
T	O
-	O
helper	O
lymphocyte	O
mediated	O
immune	O
response	O
.	O

Results	O
showed	O
that	O
interleukin	B-PRGE
(	O
IL	O
)-	O
10	O
and	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
beta	I-PRGE
(	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
)	O
were	O
continuously	O
up	O
-	O
regulated	O
during	O
the	O
entirety	O
of	O
SARS	O
.	O

CD3	B-PRGE
+	I-PRGE
CD8	I-PRGE
+	I-PRGE
CD45RO	I-PRGE
+	I-PRGE
T	O
lymphocytes	O
were	O
decreased	O
by	O
36	O
.	O
78	O
%	O
in	O
the	O
convalescent	O
patients	O
.	O

Prolonged	O
overproduction	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
may	O
play	O
an	O
important	O
role	O
in	O
the	O
disease	O
.	O

To	O
study	O
the	O
humoral	O
immune	O
responses	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
the	O
authors	O
evaluated	O
IgG	B-PRGE
and	O
IgM	B-PRGE
specific	O
antibodies	O
in	O
patients	O
'	O
sera	O
.	O

Nucleocapsid	B-PRGE
antigen	I-PRGE
was	O
detected	O
in	O
the	O
majority	O
of	O
cells	O
after	O
initial	O
inoculation	O
but	O
in	O
only	O
10	O
%-	O
40	O
%	O
of	O
cells	O
at	O
passages	O
2	O
-	O
11	O
.	O

Following	O
establishment	O
of	O
an	O
endogenous	O
p18	B-PRGE
-	O
specific	O
memory	O
CD8	B-PRGE
+	I-PRGE
T	O
-	O
cell	O
population	O
,	O
mice	O
were	O
challenged	O
with	O
coronavirus	O
to	O
directly	O
compare	O
recruitment	O
,	O
longevity	O
,	O
and	O
activation	O
characteristics	O
of	O
both	O
primary	O
coronavirus	O
-	O
specific	O
and	O
bystander	O
memory	O
populations	O
trafficking	O
into	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
).	O

Furthermore	O
,	O
in	O
contrast	O
to	O
highly	O
activated	O
pN	O
-	O
specific	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
,	O
bystander	O
p18	B-PRGE
-	I-PRGE
specific	I-PRGE
CD8	I-PRGE
+	I-PRGE
T	I-PRGE
cells	O
recruited	O
to	O
the	O
site	O
of	O
inflammation	O
maintained	O
a	O
nonactivated	O
memory	O
phenotype	O
and	O
did	O
not	O
express	O
ex	O
vivo	O
cytolytic	O
activity	O
.	O

Whereas	O
virus	O
-	O
induced	O
MMP	O
-	O
3	O
expression	O
was	O
restricted	O
to	O
CNS	O
resident	O
astrocytes	O
,	O
MMP	B-PRGE
-	I-PRGE
12	I-PRGE
mRNA	I-PRGE
was	O
expressed	O
by	O
both	O
inflammatory	O
cells	O
and	O
CNS	O
resident	O
cells	O
.	O

By	O
contrast	O
,	O
in	O
the	O
immunosuppressed	O
host	B-PRGE
TIMP	I-PRGE
-	I-PRGE
1	I-PRGE
mRNA	I-PRGE
was	O
expressed	O
by	O
CNS	O
resident	O
cells	O
.	O

Analysis	O
of	O
cytokine	O
and	O
chemokine	O
mRNA	O
induction	O
within	O
the	O
infected	O
CNS	O
of	O
healthy	O
and	O
immunocompromised	O
mice	O
suggested	O
a	O
possible	O
correlation	O
between	O
increased	O
viral	O
replication	O
and	O
increased	O
levels	O
of	O
beta	B-PRGE
interferon	I-PRGE
,	O
MMP	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
MMP	B-PRGE
-	I-PRGE
12	I-PRGE
,	O
and	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
mRNA	I-PRGE
.	O

CONCLUSIONS	O
:	O
The	O
S450	O
-	O
650	O
-	O
based	O
ELISA	O
can	O
detect	O
anti	B-PRGE
-	I-PRGE
S	I-PRGE
IgG	I-PRGE
Abs	I-PRGE
with	O
high	O
sensitivity	O
and	O
specificity	O
.	O

Eighteen	O
sequences	O
of	O
coronavirus	O
polyprotein	O
were	O
downloaded	O
from	O
NCBI	O
(	O
http	O
://	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	B-PRGE
.	I-PRGE
gov	I-PRGE
).	O

ABSTRACT	O
:	O
On	O
22	O
March	O
2003	O
,	O
the	O
Ministry	O
of	O
Health	O
,	O
Singapore	O
,	O
designated	O
Tan	B-PRGE
Tock	O
Seng	O
Hospital	O
as	O
the	O
nationwide	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
hospital	O
and	O
its	O
Emergency	O
Department	O
(	O
ED	O
)	O
took	O
over	O
the	O
role	O
as	O
the	O
screening	O
center	O
for	O
SARS	O
on	O
26	O
March	O
2003	O
.	O

In	O
the	O
absence	O
of	O
CD4	B-PRGE
(+)	O
T	O
cells	O
,	O
fewer	O
CD8	B-PRGE
(+)	O
T	O
cells	O
are	O
found	O
within	O
the	O
CNS	O
in	O
association	O
with	O
a	O
coordinate	O
increase	O
in	O
apoptotic	O
lymphocytes	O
.	O

Twenty	O
-	O
two	O
patients	O
received	O
immunoglobulin	B-PRGE
therapy	O
,	O
and	O
32	O
were	O
given	O
corticosteroids	O
.	O

A	O
higher	O
body	O
temperature	O
at	O
presentation	O
(	O
median	O
39	O
.	O
5	O
vs	O
38	O
.	O
6	O
degrees	O
C	O
),	O
and	O
higher	O
peak	O
values	O
of	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
410	O
vs	O
282	O
U	O
/	O
L	O
)	O
and	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
10	O
.	O
2	O
vs	O
2	O
.	O
5	O
mg	O
/	O
dL	O
),	O
were	O
associated	O
with	O
subsequent	O
respiratory	O
failure	O
.	O

In	O
one	O
child	O
synthetic	O
ACTH	B-PRGE
was	O
stopped	O
because	O
of	O
arterial	O
hypertension	O
.	O

Vigabatrin	O
can	O
be	O
suggested	O
as	O
the	O
first	O
drug	O
for	O
WS	O
;	O
if	O
spasms	O
persist	O
after	O
15	O
days	O
with	O
a	O
dose	O
of	O
150	O
mg	O
/	O
kg	O
,	O
synthetic	O
ACTH	B-PRGE
should	O
be	O
considered	O
.	O

Hereditary	O
hemochromatosis	O
is	O
now	O
a	O
complex	O
entity	O
with	O
various	O
clinicopathological	O
forms	O
based	O
on	O
mutations	O
in	O
the	O
HFE	B-PRGE
gene	I-PRGE
and	O
other	O
iron	O
-	O
homeostatic	O
genes	O
such	O
as	O
transferrin	B-PRGE
receptor	I-PRGE
2	I-PRGE
and	O
ferroportin	B-PRGE
1	I-PRGE
.	O

The	O
skeletal	O
muscle	O
specimens	O
of	O
2	O
patients	O
who	O
had	O
rhabdomyolysis	O
were	O
also	O
negative	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
SARS	O
-	O
CoV	O
is	O
mainly	O
present	O
in	O
the	O
cytoplasm	O
of	O
type	O
II	O
pneumocytes	O
and	O
can	O
only	O
be	O
detected	O
in	O
the	O
lung	O
tissue	O
during	O
the	O
early	O
stage	O
of	O
the	O
disease	O
.	O

Moreover	O
,	O
the	O
ACE	B-PRGE
D	I-PRGE
allele	I-PRGE
has	O
been	O
shown	O
to	O
be	O
more	O
prevalent	O
in	O
patients	O
suffering	O
from	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
a	O
previous	O
study	O
.	O

Thus	O
,	O
we	O
have	O
investigated	O
the	O
association	O
between	O
ACE	B-PRGE
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
polymorphism	O
and	O
the	O
progression	O
to	O
ARDS	O
or	O
requirement	O
of	O
intensive	O
care	O
in	O
SARS	O
patients	O
.	O

Moreover	O
,	O
there	O
is	O
also	O
no	O
evidence	O
that	O
ACE	B-PRGE
I	I-PRGE
/	I-PRGE
D	I-PRGE
polymorphism	O
is	O
associated	O
with	O
the	O
progression	O
to	O
ARDS	O
or	O
the	O
requirement	O
of	O
intensive	O
care	O
in	O
the	O
SARS	O
patients	O
.	O

The	O
ACE	B-PRGE
I	I-PRGE
/	I-PRGE
D	I-PRGE
genotypes	I-PRGE
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
and	O
agarose	O
gel	O
electrophoresis	O
.	O

RESULTS	O
:	O
There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
genotypic	O
distributions	O
and	O
the	O
allelic	O
frequencies	O
of	O
the	O
ACE	B-PRGE
I	I-PRGE
/	I-PRGE
D	I-PRGE
polymorphism	O
between	O
the	O
SARS	O
patients	O
and	O
the	O
healthy	O
control	O
subjects	O
.	O

TITLE	O
:	O
Identification	O
of	O
murine	O
CD8	B-PRGE
T	I-PRGE
cell	I-PRGE
epitopes	I-PRGE
in	O
codon	O
-	O
optimized	O
SARS	O
-	O
associated	O
coronavirus	O
spike	O
protein	O
.	O

The	O
ORF7	B-PRGE
gene	I-PRGE
named	O
hp	O
gene	O
(	O
Genbank	O
accession	O
number	O
:	O
AY337931	O
)	O
consists	O
of	O
237	O
bp	O
in	O
length	O
encoding	O
a	O
hydrophobic	O
protein	O
(	O
HP	O
)	O
of	O
78	O
aa	O
with	O
a	O
molecular	O
weight	O
of	O
9	O
.	O
1	O
kDa	O
.	O

The	O
E	B-PRGE
protein	I-PRGE
is	O
not	O
glycosylated	O
.	O

ABSTRACT	O
:	O
The	O
immunogenicity	O
of	O
a	O
candidate	O
-	O
inactivated	O
vaccine	O
prepared	O
from	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
F69	I-PRGE
strain	O
was	O
evaluated	O
in	O
Balb	O
/	O
c	O
mice	O
.	O

Unusually	O
for	O
a	O
helminth	O
product	O
,	O
the	O
rOv	B-PRGE
-	I-PRGE
ASP	I-PRGE
-	I-PRGE
1	I-PRGE
adjuvant	O
augmented	O
not	O
only	O
Th2	B-PRGE
but	O
also	O
Th1	O
responses	O
,	O
the	O
latter	O
property	O
being	O
of	O
potential	O
utility	O
in	O
stimulating	O
anti	O
-	O
viral	O
immune	O
responses	O
.	O

CONCLUSIONS	O
:	O
TRFIA	O
is	O
a	O
new	O
,	O
sensitive	O
and	O
specific	O
immunoassay	O
for	O
detecting	O
SARS	B-PRGE
N	I-PRGE
protein	I-PRGE
with	O
potential	O
value	O
in	O
clinical	O
applications	O
.	O

MBL	B-PRGE
could	O
bind	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
a	O
dose	O
-	O
and	O
calcium	O
-	O
dependent	O
and	O
mannan	O
-	O
inhibitable	O
fashion	O
in	O
vitro	O
,	O
suggesting	O
that	O
binding	O
is	O
through	O
the	O
carbohydrate	O
recognition	O
domains	O
of	O
MBL	O
.	O

hAPN	B-PRGE
protein	I-PRGE
was	O
specifically	O
expressed	O
on	O
epithelial	O
cells	O
of	O
the	O
proximal	O
convoluted	O
renal	O
tubules	O
,	O
bronchi	O
,	O
alveolar	O
sacs	O
,	O
and	O
intestinal	O
villi	O
.	O

Here	O
,	O
we	O
report	O
the	O
X	O
-	O
ray	O
structure	O
of	O
a	O
previously	O
characterized	O
HR1	O
/	O
HR2	B-PRGE
complex	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	O
.	O

TITLE	O
:	O
Human	O
monoclonal	O
antibodies	O
to	O
the	O
S	B-PRGE
glycoprotein	I-PRGE
and	O
related	O
proteins	O
as	O
potential	O
therapeutics	O
for	O
SARS	O
.	O

Similar	O
to	O
other	O
coronavirus	O
N	O
proteins	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
is	O
predicted	O
to	O
be	O
phosphorylated	O
and	O
may	O
contain	O
nuclear	O
localization	O
signals	O
,	O
serine	O
/	O
arginine	O
-	O
rich	O
motif	O
,	O
RNA	O
binding	O
domain	O
and	O
regions	O
responsible	O
for	O
self	O
-	O
association	O
and	O
homo	O
-	O
oligomerization	O
.	O

The	O
major	O
sumoylation	O
site	O
was	O
mapped	O
to	O
the	O
(	O
62	O
)	O
lysine	O
residue	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
viral	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
plays	O
an	O
essential	O
role	O
in	O
viral	O
RNA	O
packaging	O
.	O

In	O
this	O
study	O
,	O
recombinant	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
was	O
shown	O
to	O
be	O
dimeric	O
by	O
analytical	O
ultracentrifugation	O
,	O
size	O
exclusion	O
chromatography	O
coupled	O
with	O
light	O
scattering	O
,	O
and	O
chemical	O
cross	O
-	O
linking	O
.	O

When	O
in	O
excess	O
,	O
the	O
truncated	O
construct	O
285	O
-	O
422	O
inhibits	O
the	O
homodimerization	O
of	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
N	I-PRGE
protein	I-PRGE
by	O
forming	O
a	O
heterodimer	O
with	O
the	O
full	O
-	O
length	O
N	O
protein	O
.	O

Treatment	O
with	O
steroids	O
,	O
chemotherapy	O
,	O
interferon	B-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
),	O
or	O
imatinib	O
-	O
mesylate	O
may	O
improve	O
the	O
prognosis	O
.	O

In	O
present	O
work	O
,	O
we	O
sought	O
to	O
characterize	O
the	O
replication	O
of	O
SARS	O
-	O
CoV	O
at	O
the	O
presence	O
of	O
RANTES	B-PRGE
in	O
THP	B-PRGE
-	I-PRGE
1	I-PRGE
cells	O
.	O

Inactive	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
could	O
induce	O
THP	O
-	O
1	O
cells	O
secret	O
RANTES	O
and	O
this	O
increase	O
effect	O
could	O
not	O
be	O
suppressed	O
by	O
DXM	O
.	O

B	O
cell	O
hybridomas	O
were	O
generated	O
from	O
mice	O
that	O
were	O
hyper	O
-	O
immunized	O
with	O
inactivated	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
virion	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	O
of	O
SARS	O
coronavirus	O
has	O
a	O
high	O
binding	O
affinity	O
to	O
the	O
human	O
cellular	O
heterogeneous	O
nuclear	B-PRGE
ribonucleoprotein	I-PRGE
A1	I-PRGE
.	O

Heterogeneous	B-PRGE
nuclear	I-PRGE
ribonucleoprotein	I-PRGE
A1	I-PRGE
(	O
hnRNP	B-PRGE
A1	I-PRGE
)	O
is	O
related	O
to	O
the	O
pre	O
-	O
mRNA	O
splicing	O
in	O
the	O
nucleus	O
and	O
translation	O
regulation	O
in	O
the	O
cytoplasm	O
.	O

In	O
addition	O
,	O
the	O
determined	O
results	O
showed	O
that	O
SARS_N	O
protein	O
has	O
only	O
one	O
binding	O
domain	O
for	O
interacting	O
with	O
human	B-PRGE
hnRNP	I-PRGE
A1	I-PRGE
,	O
which	O
is	O
different	O
from	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
binding	O
case	O
where	O
the	O
nucleocapsid	O
protein	O
of	O
MHV	O
(	O
MHV_N	O
)	O
was	O
found	O
to	O
have	O
two	O
binding	O
domains	O
involved	O
in	O
the	O
MHV_N	O
/	O
hnRNP	B-PRGE
A1	O
interaction	O
,	O
thereby	O
suggesting	O
that	O
SARS_N	B-PRGE
protein	I-PRGE
might	O
carry	O
out	O
a	O
different	O
binding	O
mode	O
to	O
bind	O
to	O
human	B-PRGE
hnRNP	I-PRGE
A1	I-PRGE
for	O
its	O
further	O
function	O
performance	O
in	O
comparison	O
with	O
MHV_N	O
.	O

No	O
single	O
cytokine	O
profile	O
was	O
observed	O
in	O
all	O
patients	O
,	O
yet	O
serum	O
concentrations	O
of	O
interferon	B-PRGE
(	O
IFN	O
)-	O
gamma	O
,	O
interleukin	B-PRGE
(	O
IL	O
)-	O
10	O
,	O
CXCL10	B-PRGE
,	O
CCL5	B-PRGE
and	O
CXCL8	B-PRGE
were	O
found	O
to	O
be	O
elevated	O
above	O
normal	O
levels	O
during	O
the	O
course	O
of	O
the	O
disease	O
in	O
all	O
patients	O
.	O

A	O
large	O
quantity	O
of	O
the	O
nsp13	B-PRGE
protein	I-PRGE
obtained	O
with	O
this	O
method	O
may	O
be	O
useful	O
for	O
further	O
study	O
of	O
its	O
structure	O
and	O
function	O
.	O

Using	O
rolling	O
circle	O
amplification	O
(	O
RCA	O
),	O
we	O
were	O
able	O
to	O
achieve	O
sensitive	O
detection	O
levels	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
in	O
both	O
solid	O
and	O
liquid	O
phases	O
.	O

Therefore	O
,	O
the	O
availability	O
of	O
effective	O
antiviral	O
drugs	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
may	O
be	O
crucial	O
for	O
the	O
control	O
of	O
future	O
SARS	O
outbreaks	O
.	O

TITLE	O
:	O
Mutational	O
and	O
inhibitive	O
analysis	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
by	O
fluorescence	O
resonance	O
energy	O
transfer	O
-	O
based	O
assays	O
.	O

ABSTRACT	O
:	O
The	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CL	O
(	O
pro	O
))	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
plays	O
key	O
roles	O
in	O
viral	O
replication	O
and	O
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
SARS	O
drug	O
discovery	O
.	O

Mutational	O
analysis	O
demonstrated	O
that	O
the	O
His41	O
residue	O
,	O
the	O
N	O
-	O
terminal	O
7	O
amino	O
acids	O
,	O
and	O
the	O
domain	O
III	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
)	O
were	O
important	O
for	O
the	O
enzymatic	O
activity	O
.	O

Antibodies	O
recognizing	O
domain	O
III	O
could	O
significantly	O
inhibit	O
the	O
enzymatic	O
activity	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
).	O

ABSTRACT	O
:	O
Monoclonal	O
antibodies	O
(	O
Mabs	O
)	O
against	O
the	O
Urbani	O
strain	O
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
developed	O
and	O
characterized	O
for	O
reactivity	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
SARS	O
-	O
CoV	O
S	O
,	O
N	O
,	O
M	O
,	O
and	O
E	O
proteins	O
using	O
enzyme	O
-	O
linked	O
immunoabsorbent	O
(	O
ELISA	O
),	O
radioimmunoprecipitation	O
,	O
immunofluorescence	O
,	O
Western	O
Blot	O
and	O
microneutralization	O
assays	O
.	O

Firstly	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
specific	I-PRGE
IgGs	I-PRGE
were	O
detected	O
in	O
the	O
sera	O
of	O
macaques	O
from	O
11	O
to	O
60	O
days	O
after	O
inoculation	O
.	O

Specific	O
binding	O
of	O
the	O
MAb	O
S	O
-	O
A5D5	O
to	O
both	O
purified	O
N195	O
and	O
SARS	B-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
antigen	I-PRGE
was	O
effectively	O
inhibited	O
by	O
human	O
SARS	O
positive	O
serum	O
and	O
guinea	O
pig	O
anti	O
-	O
N195	O
serum	O
.	O

Specific	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
against	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
are	O
vital	O
for	O
early	O
diagnosis	O
and	O
pathological	O
studies	O
of	O
SARS	O
.	O

Single	O
intrasplenic	O
immunization	O
of	O
plasmid	O
DNA	O
encoding	O
S1	O
-(	O
3	O
)	O
induced	O
anti	B-PRGE
-	I-PRGE
spike	I-PRGE
protein	I-PRGE
antibodies	I-PRGE
.	O

Baseline	B-PRGE
total	I-PRGE
protein	I-PRGE
C	I-PRGE
,	O
IL	O
-	O
8	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
and	O
procalcitonin	O
concentrations	O
,	O
and	O
the	O
change	O
in	O
plasma	O
cytokine	O
concentrations	O
from	O
baseline	O
over	O
the	O
initial	O
4	O
days	O
were	O
not	O
useful	O
in	O
predicting	O
outcome	O
.	O

IL	B-PRGE
-	I-PRGE
6	I-PRGE
concentration	O
is	O
a	O
strong	O
candidate	O
for	O
predicting	O
clinical	O
outcome	O
in	O
patients	O
with	O
severe	O
sepsis	O
alone	O
,	O
or	O
when	O
combined	O
with	O
the	O
APACHE	O
II	O
or	O
MOD	O
scores	O
.	O

Antigens	O
of	O
SARS	O
-	O
CoV	O
and	O
HCoV	O
-	O
OC43	O
were	O
more	O
cross	O
-	O
reactive	O
than	O
were	O
those	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
HCoV	O
-	O
229E	O
.	O

Without	O
sufficient	O
knowledge	O
about	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
it	O
is	O
impossible	O
to	O
define	O
the	O
candidate	O
for	O
the	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
targets	I-PRGE
.	O

The	O
expressive	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp2	I-PRGE
was	O
analyzed	O
by	O
7	O
%	O
sodium	O
dodecylsulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
).	O

RESULTS	O
:	O
The	O
putative	O
polymerase	B-PRGE
nsp2	I-PRGE
gene	I-PRGE
of	O
GD	O
strain	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
eukaryotic	O
expression	O
plasmid	O
pEGFP	O
-	O
C1	O
-	O
N	O
,	O
containing	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
gene	I-PRGE
,	O
was	O
co	O
-	O
transfected	O
into	O
293	O
cells	O
with	O
either	O
the	O
RNAi	O
plasmid	O
pshRNA	O
-	O
N	O
or	O
unrelated	O
control	O
plasmid	O
pshRNA	O
-	O
HBV	O
-	O
C4	O
.	O

Our	O
results	O
demonstrate	O
that	O
RNAi	O
mediated	O
silencing	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
gene	I-PRGE
could	O
effectively	O
inhibit	O
expression	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antigen	I-PRGE
,	O
hence	O
RNAi	O
based	O
strategy	O
should	O
be	O
further	O
explored	O
as	O
a	O
more	O
efficacious	O
antiviral	O
therapy	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

RESULTS	O
:	O
In	O
n	O
=	O
6	O
non	O
-	O
responders	O
to	O
iNO	B-PRGE
(	O
DeltaPaO2	O
<	O
10	O
%),	O
we	O
determined	O
a	O
short	O
relative	O
borderline	O
between	O
normal	O
and	O
consolidated	O
lung	O
tissue	O
due	O
to	O
the	O
presence	O
of	O
large	O
and	O
coherently	O
consolidated	O
lung	O
regions	O
.	O

ABSTRACT	O
:	O
Preliminary	O
data	O
examining	O
interferon	B-PRGE
alfacon1	I-PRGE
treatment	O
of	O
SARS	O
-	O
CoV	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
corona	O
virus	O
)-	O
infected	O
patients	O
suggests	O
this	O
therapy	O
is	O
well	O
tolerated	O
and	O
of	O
therapeutic	O
benefit	O
.	O

We	O
report	O
herein	O
that	O
interferon	B-PRGE
alfacon1	I-PRGE
,	O
has	O
potent	O
in	O
vitro	O
antiviral	O
activity	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
In	O
a	O
cytopathic	O
effect	O
protection	O
(	O
CPE	O
)	O
assay	O
,	O
interferon	B-PRGE
alfacon1	I-PRGE
inhibited	O
the	O
generation	O
of	O
CPE	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
an	O
IC50	O
of	O
0	O
.	O
001	O
microg	O
/	O
ml	O
,	O
a	O
clinically	O
achievable	O
level	O
.	O

The	O
in	O
vitro	O
antiviral	O
activity	O
of	O
interferon	B-PRGE
alfacon1	I-PRGE
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
suggests	O
continued	O
evaluation	O
of	O
interferon	B-PRGE
alfacon1	I-PRGE
as	O
a	O
therapeutic	O
treatment	O
for	O
patients	O
infected	O
with	O
SARS	O
-	O
CoV	O
.	O

TITLE	O
:	O
The	O
design	O
and	O
application	O
of	O
DNA	O
chips	O
for	O
early	O
detection	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
from	O
clinical	O
samples	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
furosemide	O
infusion	O
on	O
serum	B-PRGE
epidermal	I-PRGE
growth	I-PRGE
factor	I-PRGE
concentration	O
after	O
acute	O
lung	O
injury	O
.	O

Our	O
previous	O
studies	O
demonstrated	O
that	O
signaling	O
pathways	O
of	O
extracellular	B-PRGE
signal	I-PRGE
-	I-PRGE
related	I-PRGE
kinase	I-PRGE
(	O
ERK1	B-PRGE
/	I-PRGE
2	I-PRGE
),	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
JNK	B-PRGE
),	O
p38	B-PRGE
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
MAPK	B-PRGE
),	O
and	O
phosphatidylinositol	O
3	O
'-	O
kinase	O
(	O
PI3K	B-PRGE
)/	O
Akt	B-PRGE
were	O
activated	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

Previous	O
studies	O
also	O
showed	O
that	O
the	O
activation	O
of	O
p38	B-PRGE
MAPK	I-PRGE
by	O
viral	O
infection	O
-	O
induced	O
apoptosis	O
,	O
and	O
a	O
weak	O
activation	O
of	O
Akt	B-PRGE
was	O
not	O
sufficient	O
to	O
protect	O
from	O
apoptosis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
the	O
inhibitors	O
of	O
JNK	B-PRGE
and	O
PI3K	B-PRGE
/	O
Akt	B-PRGE
inhibited	O
the	O
establishment	O
of	O
persistence	O
,	O
but	O
those	O
of	O
MAPK	B-PRGE
/	O
ERK	B-PRGE
kinase	I-PRGE
(	O
MEK	B-PRGE
;	O
as	O
an	O
inhibitor	O
for	O
ERK1	B-PRGE
/	I-PRGE
2	I-PRGE
)	O
and	O
p38	B-PRGE
MAPK	I-PRGE
did	O
not	O
.	O

Serum	O
levels	O
of	O
Hsp60	B-PRGE
detected	O
within	O
30	O
min	O
after	O
trauma	O
correlate	O
with	O
the	O
development	O
of	O
ALI	O
.	O

We	O
show	O
here	O
that	O
the	O
expression	O
of	O
aminopeptidase	B-PRGE
N	I-PRGE
(	O
APN	B-PRGE
,	O
also	O
termed	O
CD13	B-PRGE
),	O
the	O
receptor	O
for	O
HCoV	O
-	O
229E	O
,	O
is	O
required	O
but	O
not	O
sufficient	O
to	O
confer	O
susceptibility	O
in	O
vivo	O
.	O

HCoV	O
-	O
229E	O
infection	O
was	O
facilitated	O
by	O
crossing	O
APN	O
transgenic	O
mice	O
into	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
Stat	O
)	O
1	O
null	O
mice	O
and	O
by	O
adaptation	O
of	O
HCoV	O
-	O
229E	O
to	O
grow	O
in	O
primary	O
APN	O
transgenic	O
,	O
Stat1	B-PRGE
null	O
fibroblasts	O
.	O

Furthermore	O
,	O
SARS	O
-	O
CoV	O
induced	O
the	O
expression	O
of	O
chemokines	O
such	O
as	O
CXCL10	B-PRGE
/	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	I-PRGE
inducible	I-PRGE
protein	I-PRGE
10	I-PRGE
and	O
CCL2	B-PRGE
/	I-PRGE
monocyte	I-PRGE
chemotactic	I-PRGE
protein	I-PRGE
1	I-PRGE
.	O

In	O
162	O
serum	O
samples	O
,	O
90	O
.	O
2	O
%	O
(	O
55	O
/	O
61	O
)	O
became	O
N	B-PRGE
protein	I-PRGE
positive	O
in	O
1	O
-	O
5	O
days	O
and	O
92	O
.	O
8	O
%	O
(	O
13	O
/	O
14	O
)	O
became	O
positive	O
IgM	B-PRGE
and	O
IgG	B-PRGE
in	O
15	O
-	O
18	O
days	O
after	O
the	O
onset	O
of	O
disease	O
,	O
respectively	O
.	O

Evolution	O
of	O
new	O
viral	O
pathogens	O
,	O
such	O
as	O
avian	O
influenza	O
virus	O
and	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
are	O
discussed	O
.	O

ABSTRACT	O
:	O
Neopterin	O
and	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
)	O
concentrations	O
were	O
determined	O
in	O
serum	O
samples	O
from	O
129	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
and	O
156	O
healthy	O
blood	O
donors	O
.	O

In	O
contrast	O
,	O
the	O
mean	O
CRP	B-PRGE
concentrations	O
in	O
both	O
acute	O
and	O
convalescent	O
sera	O
of	O
SARS	O
patients	O
were	O
in	O
the	O
normal	O
range	O
(<	O
10	O
mg	O
/	O
L	O
).	O

Immunohistochemistry	O
was	O
used	O
,	O
with	O
monoclonal	O
antibodies	O
,	O
to	O
detect	O
the	O
thyroglobulin	B-PRGE
(	O
TG	O
),	O
calcitonin	B-PRGE
and	O
parathyroid	B-PRGE
hormone	I-PRGE
(	O
PTH	B-PRGE
)	O
in	O
the	O
thyroid	O
glands	O
.	O

PTH	B-PRGE
positive	O
cells	O
were	O
seen	O
in	O
the	O
normal	O
thyroid	O
glands	O
and	O
those	O
of	O
the	O
SARS	O
patients	O
with	O
a	O
slightly	O
weaker	O
intensity	O
of	O
reaction	O
,	O
however	O
,	O
with	O
significant	O
difference	O
in	O
IOD	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
without	O
significant	O
difference	O
in	O
mean	O
slight	O
absorption	O
MOD	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Inhibition	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
Protease	I-PRGE
Activity	O
by	O
Theaflavin	O
-	O
3	O
,	O
3	O
'-	O
digallate	O
(	O
TF3	O
).	O

Two	O
compounds	O
in	O
the	O
library	O
were	O
found	O
to	O
be	O
inhibitive	O
:	O
tannic	O
acid	O
(	O
IC	O
(	O
50	O
)	O
=	O
3	O
microM	O
)	O
and	O
3	O
-	O
isotheaflavin	O
-	O
3	O
-	O
gallate	O
(	O
TF2B	B-PRGE
)	O
(	O
IC	O
(	O
50	O
)	O
=	O
7	O
microM	O
).	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
significance	O
of	O
serum	B-PRGE
C	I-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
)	O
elevation	O
in	O
the	O
development	O
of	O
oxygenation	O
impairment	O
and	O
clinical	O
outcome	O
with	O
distal	O
type	O
AAD	O
.	O

TITLE	O
:	O
[	O
Study	O
on	O
the	O
dynamics	O
of	O
IgG	B-PRGE
antibody	I-PRGE
in	O
311	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

Data	O
showed	O
that	O
all	O
the	O
SARS	O
convalescent	O
patients	O
had	O
generated	O
high	O
level	O
of	O
specific	O
IgG	B-PRGE
antibody	I-PRGE
against	O
coronavirus	O
in	O
the	O
early	O
stage	O
of	O
recovery	O
,	O
but	O
the	O
antibody	O
level	O
declined	O
along	O
with	O
the	O
progress	O
of	O
convalescence	O
,	O
suggesting	O
that	O
the	O
detection	O
of	O
the	O
IgG	B-PRGE
antibody	I-PRGE
should	O
go	O
on	O
until	O
it	O
disappeared	O
.	O

IgG	B-PRGE
antibody	O
level	O
showed	O
a	O
35	O
.	O
8	O
%	O
decrease	O
within	O
one	O
year	O
.	O

The	O
existence	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
in	O
the	O
excretion	O
of	O
some	O
convalescent	O
patients	O
with	O
SARS	O
showed	O
that	O
the	O
excretion	O
from	O
these	O
patients	O
should	O
be	O
carefully	O
treated	O
whilthe	O
re	O
-	O
transmission	O
of	O
SARS	O
by	O
which	O
,	O
should	O
be	O
further	O
studied	O
.	O

All	O
of	O
the	O
FeIFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
subtypes	O
showed	O
high	O
activity	O
to	O
vesicular	O
stomatitis	O
virus	O
,	O
and	O
the	O
three	O
species	O
of	O
feline	O
viruses	O
belonging	O
to	O
different	O
families	O
.	O

Also	O
,	O
exposure	O
to	O
infectious	O
SARS	O
-	O
CoV	O
led	O
to	O
the	O
phenotypic	O
and	O
functional	O
maturation	O
of	O
DC	O
,	O
with	O
regard	O
to	O
MHC	B-PRGE
class	I-PRGE
II	I-PRGE
and	I-PRGE
costimulatory	I-PRGE
molecule	I-PRGE
expression	O
,	O
T	O
cell	O
-	O
stimulatory	O
capacity	O
,	O
and	O
cytokine	O
production	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
laws	O
of	O
the	O
appearance	O
of	O
the	O
specific	O
serum	O
antibodies	O
against	O
the	O
nucleocapsid	B-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
protein	I-PRGE
and	O
the	O
S1	B-PRGE
domain	I-PRGE
of	O
spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
to	O
evaluate	O
the	O
value	O
of	O
these	O
two	O
proteins	O
to	O
be	O
used	O
as	O
diagnostic	O
makers	O
for	O
SARS	O
.	O

RESULTS	O
:	O
The	O
positive	O
rates	O
of	O
anti	B-PRGE
-	I-PRGE
N	I-PRGE
-	I-PRGE
IgG	I-PRGE
,	O
anti	B-PRGE
S1	I-PRGE
-	I-PRGE
IgG	I-PRGE
,	O
and	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
were	O
14	O
%	O
(	O
6	O
/	O
44	O
),	O
5	O
%	O
(	O
2	O
/	O
44	O
),	O
and	O
14	O
%	O
(	O
6	O
/	O
44	O
)	O
respectively	O
in	O
the	O
first	O
week	O
of	O
the	O
course	O
of	O
disease	O
,	O
56	O
%	O
(	O
10	O
/	O
18	O
),	O
39	O
%	O
(	O
7	O
/	O
18	O
),	O
and	O
56	O
%	O
(	O
10	O
/	O
18	O
)	O
respectively	O
in	O
the	O
second	O
week	O
,	O
and	O
100	O
%	O
(	O
24	O
/	O
24	O
),	O
S1	O
-	O
IgG	B-PRGE
83	O
%	O
(	O
20	O
/	O
24	O
),	O
and	O
100	O
%	O
(	O
24	O
/	O
24	O
)	O
respectively	O
in	O
the	O
third	O
week	O
.	O

CONCLUSIONS	O
:	O
The	O
N	B-PRGE
protein	I-PRGE
and	O
S1	B-PRGE
protein	I-PRGE
may	O
be	O
used	O
as	O
antigens	O
in	O
the	O
development	O
of	O
serological	O
assay	O
for	O
detection	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Nucleocapsid	B-PRGE
gene	I-PRGE
was	O
obtained	O
by	O
reverse	O
transcription	O
and	O
polymerase	O
chain	O
reaction	O
from	O
a	O
SARS	O
patient	O
and	O
inserted	O
into	O
the	O
vector	O
pFastBacHTa	O
expressing	O
baculovirus	O
.	O

The	O
tissue	O
tropism	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
includes	O
not	O
only	O
the	O
lung	O
,	O
but	O
also	O
the	O
gastrointestinal	O
tract	O
,	O
kidney	O
and	O
liver	O
.	O

Moreover	O
,	O
lymphopenia	O
with	O
decreased	O
numbers	O
of	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
is	O
common	O
during	O
the	O
acute	O
phase	O
.	O

Convalescent	O
patients	O
have	O
IgG	B-PRGE
-	O
class	O
neutralizing	O
antibodies	O
that	O
recognize	O
amino	O
acids	O
441	O
-	O
700	O
of	O
the	O
spike	B-PRGE
protein	I-PRGE
(	O
S	B-PRGE
protein	I-PRGE
)	O
as	O
the	O
major	O
epitope	O
.	O

Toward	O
the	O
development	O
of	O
a	O
safe	O
,	O
effective	O
,	O
and	O
inexpensive	O
vaccine	O
candidate	O
,	O
we	O
have	O
expressed	O
the	O
N	O
-	O
terminal	O
fragment	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
(	I-PRGE
S1	I-PRGE
)	I-PRGE
in	I-PRGE
tomato	I-PRGE
and	O
low	B-PRGE
-	I-PRGE
nicotine	I-PRGE
tobacco	I-PRGE
plants	I-PRGE
.	O

TITLE	O
:	O
Genetic	O
lesions	O
within	O
the	O
3a	O
gene	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
ABSTRACT	O
:	O
A	O
series	O
of	O
frameshift	O
mutations	O
within	O
the	O
3a	O
gene	O
has	O
been	O
observed	O
in	O
culture	O
-	O
derived	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Finally	O
,	O
brefeldin	O
A	O
powerfully	O
blocks	O
the	O
viroporin	O
activity	O
of	O
the	O
E	B-PRGE
protein	I-PRGE
in	O
BHK	O
cells	O
,	O
suggesting	O
that	O
an	O
intact	O
vesicular	O
system	O
is	O
necessary	O
for	O
this	O
coronavirus	O
to	O
permeabilize	O
mammalian	O
cells	O
.	O

TITLE	O
:	O
Using	O
DNA	O
shuffling	O
to	O
create	O
novel	O
infectious	O
bronchitis	O
virus	O
S1	O
genes	O
:	O
implications	O
for	O
S1	B-PRGE
gene	I-PRGE
recombination	O
.	O

Firefly	O
luciferase	O
expression	O
of	O
pGL	B-PRGE
-	I-PRGE
R	I-PRGE
was	O
reduced	O
to	O
13	O
%	O
by	O
esiRNA	O
-	O
R	O
.	O
Expression	O
of	O
pGLS	O
was	O
reduced	O
to	O
11	O
%	O
by	O
esiRNA	O
-	O
S	O
.	O
Expression	O
of	O
pGL	O
-	O
N	O
was	O
reduced	O
to	O
40	O
%	O
by	O
esiRNA	O
-	O
N	O
.	O
Control	O
esiRNAs	O
didn	O
'	O
t	O
affect	O
luciferase	O
expression	O
;	O
Hybrid	O
mRNAs	O
'	O
abundance	O
was	O
dramatically	O
reduced	O
by	O
corresponding	O
esiRNAs	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
eliminated	O
rapidly	O
.	O

TITLE	O
:	O
[	O
Prospective	O
clinical	O
study	O
on	O
serum	O
immunity	O
in	O
IgG	B-PRGE
-	I-PRGE
antibodies	I-PRGE
positive	O
patients	O
convalescent	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

Intriguingly	O
,	O
heat	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
elicited	O
recall	O
-	O
like	O
CTL	O
responses	O
to	O
SSp	B-PRGE
-	I-PRGE
1	I-PRGE
but	O
not	O
to	O
S978	O
,	O
S1202	O
,	O
or	O
dominant	O
epitopes	O
from	O
several	O
other	O
human	O
viruses	O
in	O
5	O
of	O
36	O
(	O
13	O
.	O
8	O
%)	O
HLA	O
-	O
A	O
*	O
0201	O
(+)	O
healthy	O
donors	O
without	O
any	O
contact	O
history	O
with	O
SARS	O
-	O
CoV	O
.	O
SSp	B-PRGE
-	I-PRGE
1	I-PRGE
-	I-PRGE
specific	I-PRGE
CTLs	I-PRGE
expanded	O
from	O
memory	O
T	O
cells	O
of	O
both	O
recovered	O
SARS	O
patients	O
,	O
and	O
the	O
five	O
exceptional	O
healthy	O
donors	O
shared	O
a	O
differentiated	O
effector	O
CTL	O
phenotype	O
,	O
CD45RA	B-PRGE
(+)	I-PRGE
CCR7	I-PRGE
(-)	I-PRGE
CD62L	I-PRGE
(-),	O
and	O
expressed	O
CCR5	B-PRGE
and	O
CD44	B-PRGE
.	O

The	O
antibody	O
responses	O
to	O
the	O
N	B-PRGE
protein	I-PRGE
fragments	I-PRGE
in	O
mammalian	O
sera	O
revealed	O
that	O
3	O
regions	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
are	O
strong	O
antigenic	O
domains	O
.	O

Here	O
,	O
to	O
extend	O
our	O
experimental	O
observation	O
,	O
we	O
have	O
incorporated	O
protein	B-PRGE
structural	O
studies	O
(	O
with	O
positive	O
/	O
negative	O
controls	O
)	O
to	O
investigate	O
the	O
potential	O
binding	O
modes	O
/	O
sites	O
of	O
ATA	B-PRGE
onto	I-PRGE
RNA	I-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
from	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
other	O
pathogenic	O
positive	O
-	O
strand	O
RNA	O
-	O
viruses	O
,	O
as	O
well	O
as	O
other	O
proteins	O
in	O
SARS	O
-	O
CoV	O
based	O
on	O
the	O
fact	O
that	O
ATA	B-PRGE
binds	O
to	O
Ca2	O
+-	O
activated	O
neutral	O
protease	O
(	O
m	O
-	O
calpain	O
),	O
the	O
protein	B-PRGE
tyrosine	I-PRGE
phosphatase	I-PRGE
(	O
PTP	B-PRGE
)	O
and	O
HIV	B-PRGE
integrase	I-PRGE
which	O
have	O
existing	O
crystal	O
structures	O
.	O

Furthermore	O
,	O
ablation	O
of	O
ADAM17	B-PRGE
expression	O
using	O
specific	O
small	O
interfering	O
RNA	O
duplexes	O
reduced	O
regulated	O
ACE2	O
shedding	O
,	O
whereas	O
overexpression	O
of	O
ADAM17	B-PRGE
significantly	O
increased	O
shedding	O
.	O

Taken	O
together	O
,	O
these	O
data	O
provided	O
direct	O
evidence	O
for	O
the	O
involvement	O
of	O
ADAM17	B-PRGE
in	O
the	O
regulated	O
ectodomain	O
shedding	O
of	O
ACE2	B-PRGE
.	O

The	O
identification	O
of	O
ADAM17	B-PRGE
as	O
the	O
protease	O
responsible	O
for	O
ACE2	O
shedding	O
may	O
provide	O
new	O
insight	O
into	O
the	O
physiological	O
roles	O
of	O
ACE2	B-PRGE
.	O

In	O
addition	O
,	O
a	O
discussion	O
of	O
the	O
zoonotic	O
implications	O
of	O
torovirus	O
-	O
like	O
particles	O
detected	O
in	O
patients	O
with	O
gastroenteritis	O
that	O
resemble	O
and	O
cross	O
-	O
react	O
with	O
BoTV	B-PRGE
is	O
presented	O
.	O

Expression	O
of	O
SP	O
-	O
B	O
,	O
-	O
C	O
,	O
and	O
ABCA3	B-PRGE
are	O
coregulated	O
during	O
late	O
gestation	O
by	O
transcriptional	O
programs	O
influenced	O
by	O
thyroid	B-PRGE
transcription	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
forkhead	B-PRGE
box	I-PRGE
a2	I-PRGE
,	O
transcription	O
factors	O
that	O
regulate	O
both	O
differentiation	O
of	O
the	O
respiratory	O
epithelium	O
and	O
transcription	O
of	O
genes	O
required	O
for	O
perinatal	O
adaptation	O
to	O
air	O
breathing	O
.	O

Tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
),	O
interleukin	B-PRGE
(	O
IL	O
)-	O
1beta	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
concentrations	O
were	O
measured	O
in	O
portal	O
and	O
systemic	O
serum	O
,	O
and	O
in	O
the	O
perfusate	O
30	O
and	O
90	O
min	O
after	O
the	O
'	O
second	O
hit	O
'.	O

RESULTS	O
:	O
We	O
observed	O
a	O
six	O
-	O
fold	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
concentration	O
across	O
the	O
liver	O
during	O
AP	O
.	O

High	O
IgG	B-PRGE
levels	O
were	O
detected	O
in	O
mice	O
immunized	O
with	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.)	O
recombinant	O
spike	O
polypeptide	O
generated	O
by	O
Escherichia	O
coli	O
(	O
S	O
-	O
peptide	O
),	O
mice	O
primed	O
with	O
intramuscular	O
(	O
i	O
.	O
m	O
.)	O
tPA	O
-	O
optimize800	O
DNA	O
vaccine	O
(	O
tPA	O
-	O
S	O
-	O
DNA	O
)	O
and	O
boosted	O
with	O
i	O
.	O
p	O
.	O

No	O
statistical	O
significant	O
difference	O
was	O
observed	O
among	O
the	O
Th1	O
/	O
Th2	O
index	O
among	O
these	O
six	O
groups	O
of	O
mice	O
with	O
high	O
IgG	B-PRGE
levels	O
.	O

CTLA4	B-PRGE
-	I-PRGE
S	I-PRGE
-	I-PRGE
DNA	I-PRGE
,	O
oral	O
Salmonella	O
-	O
S	O
-	O
DNA	O
-	O
control	O
boosted	O
with	O
i	O
.	O
p	O
.	O

VEGF	B-PRGE
levels	O
are	O
reported	O
to	O
be	O
lower	O
in	O
bronchoalveolar	O
lavage	O
from	O
ALI	O
patients	O
compared	O
with	O
normals	O
,	O
but	O
these	O
studies	O
did	O
not	O
include	O
a	O
comparably	O
ill	O
control	O
group	O
with	O
noninflammatory	O
pulmonary	O
oedema	O
.	O

The	O
decrease	O
in	O
air	O
space	O
concentrations	O
of	O
vascular	B-PRGE
endothelial	I-PRGE
growth	I-PRGE
factor	I-PRGE
in	O
acute	O
lung	O
injury	O
may	O
not	O
be	O
a	O
function	O
of	O
the	O
degree	O
of	O
lung	O
injury	O
,	O
but	O
rather	O
may	O
result	O
from	O
alveolar	O
flooding	O
.	O

Whereas	O
recombinants	O
expressing	O
the	O
wild	B-PRGE
-	I-PRGE
type	I-PRGE
JHM	I-PRGE
spike	I-PRGE
(	O
SJHM	O
/	O
RA59	O
)	O
were	O
highly	O
neurovirulent	O
,	O
A59	O
recombinants	O
containing	O
the	O
N514S	O
mutation	O
(	O
SJHM	O
(	O
N514S	O
)/	O
RA59	O
)	O
were	O
attenuated	O
,	O
replicated	O
less	O
efficiently	O
,	O
and	O
exhibited	O
reduced	O
virus	O
spread	O
in	O
the	O
brain	O
at	O
5	O
days	O
postinfection	O
(	O
peak	O
of	O
infectious	O
virus	O
titers	O
in	O
the	O
central	O
nervous	O
system	O
)	O
compared	O
to	O
parental	O
virus	O
encoding	O
wild	O
-	O
type	O
spike	O
.	O

In	O
this	O
study	O
,	O
bioinformatics	O
methods	O
were	O
employed	O
to	O
predict	O
the	O
secondary	O
structure	O
and	O
construct	O
3	O
-	O
D	O
models	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
GD	I-PRGE
strain	I-PRGE
nsp5	I-PRGE
.	O

Blood	O
gases	O
were	O
measured	O
in	O
the	O
PP	O
and	O
supine	O
(	O
SP	O
)	O
positions	O
3	O
h	O
after	O
each	O
turn	O
,	O
for	O
36	O
h	O
,	O
yielding	O
six	O
measurement	O
sets	O
(	O
SP1	B-PRGE
,	O
PP1	B-PRGE
,	O
SP2	B-PRGE
,	O
PP2	B-PRGE
,	O
SP3	B-PRGE
,	O
and	O
PP3	B-PRGE
).	O

The	O
tracheal	O
aspirate	O
volume	O
improved	O
significantly	O
from	O
SP1	B-PRGE
to	O
PP1	B-PRGE
.	O

ABSTRACT	O
:	O
The	O
prevalence	O
of	O
cryptosporidia	O
,	O
rotavirus	O
,	O
bovine	B-PRGE
coronavirus	I-PRGE
and	I-PRGE
Escherichia	I-PRGE
coli	I-PRGE
F5	I-PRGE
(	O
K99	O
)	O
in	O
dairy	O
calves	O
with	O
diarrhea	O
and	O
in	O
healthy	O
calves	O
was	O
established	O
in	O
a	O
limited	O
area	O
served	O
by	O
a	O
veterinary	O
practice	O
.	O

The	O
simpler	O
operation	O
of	O
LAMP	B-PRGE
might	O
be	O
a	O
possible	O
solution	O
for	O
on	O
-	O
site	O
diagnosis	O
.	O

ACE	B-PRGE
cleaves	O
angiotensin	B-PRGE
I	I-PRGE
to	O
generate	O
angiotensin	B-PRGE
II	I-PRGE
,	O
whereas	O
ACE2	B-PRGE
inactivates	O
angiotensin	B-PRGE
II	I-PRGE
and	O
is	O
a	O
negative	O
regulator	O
of	O
the	O
system	O
.	O

The	O
mean	O
peak	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
and	O
lactate	B-PRGE
dehydrogenase	I-PRGE
levels	O
were	O
higher	O
in	O
SARS	O
patients	O
who	O
were	O
receiving	O
ribavirin	O
therapy	O
than	O
in	O
SARS	O
patients	O
who	O
were	O
not	O
receiving	O
ribavirin	O
therapy	O
.	O

The	O
hemoglobin	B-PRGE
began	O
decreasing	O
in	O
two	O
thirds	O
of	O
SARS	O
patients	O
(	O
32	O
of	O
44	O
patients	O
;	O
73	O
%)	O
who	O
were	O
receiving	O
ribavirin	O
3	O
days	O
after	O
therapy	O
with	O
the	O
antiviral	O
drug	O
was	O
started	O
.	O

When	O
both	O
the	O
liver	O
and	O
lung	O
were	O
perfused	O
,	O
endotoxin	O
caused	O
marked	O
hypoxemia	O
,	O
large	O
increases	O
in	O
perfusate	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
8	O
-	O
isoprostane	O
concentrations	O
,	O
and	O
severe	O
lung	O
edema	O
.	O

In	O
cell	O
lines	O
,	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
has	O
been	O
identified	O
as	O
a	O
potential	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
.	O

SARS	O
-	O
CoV	O
infections	O
and	O
the	O
Spike	O
protein	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
reduce	O
ACE2	B-PRGE
expression	O
.	O

TITLE	O
:	O
Identification	O
of	O
critical	O
active	O
-	O
site	O
residues	O
in	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

The	O
unusual	O
property	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
membrane	I-PRGE
protein	I-PRGE
aggregation	O
induced	O
by	O
heat	O
also	O
provides	O
a	O
model	O
for	O
the	O
study	O
of	O
protein	O
aggregation	O
.	O

Of	O
174	O
samples	O
collected	O
from	O
naturally	O
infected	O
dogs	O
,	O
77	O
were	O
positive	O
for	O
CCoV	B-PRGE
type	I-PRGE
I	I-PRGE
and	I-PRGE
46	I-PRGE
for	O
CCoV	B-PRGE
type	I-PRGE
II	I-PRGE
.	O

TITLE	O
:	O
Variations	O
in	O
the	O
nucleocapsid	B-PRGE
protein	I-PRGE
gene	I-PRGE
of	O
infectious	O
bronchitis	O
viruses	O
isolated	O
in	O
Korea	O
.	O

SDS	O
-	O
PAGE	O
and	O
Western	O
blot	O
showed	O
that	O
the	O
N	B-PRGE
protein	I-PRGE
was	O
expressed	O
at	O
a	O
level	O
of	O
3mg	O
/	O
ml	O
of	O
culture	O
medium	O
.	O

The	O
P	O
.	O
pastoris	O
-	O
expressed	O
N	B-PRGE
protein	I-PRGE
is	O
believed	O
to	O
more	O
closely	O
resemble	O
native	O
SARS	O
N	O
protein	O
than	O
the	O
bacterially	O
expressed	O
N	B-PRGE
protein	I-PRGE
.	O

The	O
toxicity	O
of	O
beta	B-PRGE
-	I-PRGE
propiolactone	I-PRGE
was	O
hydrolyzed	O
completely	O
when	O
the	O
inactivated	O
virus	O
was	O
cultured	O
for	O
16	O
hours	O
at	O
2	O
degrees	O
C	O
,	O
8	O
degrees	O
C	O
and	O
in	O
water	O
bath	O
for	O
2	O
hours	O
at	O
37	O
degrees	O
C	O
.	O
CONCLUSIONS	O
:	O
The	O
titer	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
was	O
the	O
highest	O
when	O
it	O
was	O
cultured	O
in	O
Vero	O
or	O
Vero	O
-	O
E6	O
cells	O
for	O
72	O
hours	O
at	O
37	O
degrees	O
C	O
in	O
5	O
percent	O
CO2	O
incubator	O
.	O

The	O
results	O
revealed	O
that	O
serum	O
levels	O
of	O
IgG	B-PRGE
anti	O
-	O
A549	O
cells	O
antibodies	O
,	O
IgG	B-PRGE
anti	I-PRGE
-	I-PRGE
HUVEC	I-PRGE
antibodies	I-PRGE
,	O
and	O
IgM	B-PRGE
anti	I-PRGE
-	I-PRGE
HPEC	I-PRGE
antibodies	I-PRGE
were	O
significantly	O
higher	O
in	O
SARS	O
patients	O
at	O
phase	O
II	O
/	O
phase	O
III	O
than	O
those	O
in	O
healthy	O
controls	O
.	O

Confocal	O
microscopy	O
showed	O
that	O
the	O
N	B-PRGE
protein	I-PRGE
found	O
in	O
mitochondria	O
-	O
Golgi	O
-	O
ERGIC	O
fractions	O
localized	O
within	O
the	O
Golgi	O
-	O
ERGIC	O
compartments	O
and	O
not	O
with	O
mitochondria	O
.	O

Recent	O
studies	O
suggest	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
zoonotic	O
and	O
may	O
have	O
a	O
broad	O
host	O
range	O
besides	O
humans	O
.	O

The	O
expression	O
of	O
the	O
Spike	O
and	O
Nucleoprotein	O
genes	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
at	O
mRNA	O
and	O
protein	O
levels	O
in	O
small	O
interfering	O
(	O
si	O
)	O
RNA	O
-	O
expressing	O
cells	O
was	O
significantly	O
less	O
than	O
that	O
in	O
controls	O
when	O
analysed	O
with	O
PCR	O
and	O
Western	O
-	O
blot	O
assays	O
,	O
3	O
days	O
post	O
SARS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Retinal	O
degeneration	O
in	O
experimental	O
coronavirus	O
retinopathy	O
(	O
ECOR	O
)	O
is	O
associated	O
with	O
increased	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
soluble	O
TNFR2	B-PRGE
and	O
altered	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
signaling	O
.	O

TITLE	O
:	O
High	O
-	O
resolution	O
structure	O
of	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
1101	I-PRGE
in	O
complex	O
with	O
SARS	B-PRGE
nucleocapsid	I-PRGE
peptide	I-PRGE
.	O

All	O
residues	O
except	O
Thr2p	O
and	O
Lys9p	B-PRGE
are	O
accessible	O
for	O
T	O
-	O
cell	O
recognition	O
.	O

In	O
cells	O
infected	O
with	O
this	O
recombinant	O
,	O
S	B-PRGE
protein	I-PRGE
was	O
synthesized	O
,	O
glycosylated	O
at	O
approximately	O
17	O
Asn	O
residues	O
,	O
and	O
transported	O
via	O
the	O
Golgi	O
to	O
the	O
cell	O
surface	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
in	O
SARS	O
patient	O
sera	O
there	O
were	O
autoantibodies	O
(	O
autoAbs	O
)	O
that	O
reacted	O
with	O
A549	O
cells	O
,	O
the	O
type	O
-	O
2	O
pneumocytes	O
,	O
and	O
that	O
these	O
autoAbs	O
were	O
mainly	O
IgG	B-PRGE
.	O
The	O
autoAbs	O
were	O
detectable	O
20	O
days	O
after	O
fever	O
onset	O
.	O

During	O
experimentation	O
to	O
characterize	O
immune	O
components	O
of	O
the	O
gland	O
,	O
proteomics	O
analysis	O
revealed	O
the	O
presence	O
of	O
hematopoietic	B-PRGE
prostaglandin	I-PRGE
D	I-PRGE
synthase	I-PRGE
(	O
H	B-PRGE
-	I-PRGE
PGDS	I-PRGE
).	O

Our	O
results	O
showed	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
induced	O
apoptosis	O
in	O
the	O
transfected	O
Jurkat	O
T	O
-	O
cells	O
,	O
which	O
was	O
amplified	O
to	O
higher	O
apoptosis	O
rates	O
in	O
the	O
absence	O
of	O
growth	O
factors	O
.	O

TITLE	O
:	O
LSECtin	B-PRGE
interacts	O
with	O
filovirus	O
glycoproteins	O
and	O
the	O
spike	O
protein	O
of	O
SARS	O
coronavirus	O
.	O

It	O
is	O
necessary	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
replication	O
and	O
rationalize	O
the	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
therapeutic	O
intervention	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
an	O
in	O
vitro	O
GST	B-PRGE
pull	O
-	O
down	O
assay	O
to	O
investigate	O
the	O
interaction	O
between	O
the	O
membrane	O
(	O
M	O
)	O
and	O
the	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
.	O

CONCLUSIONS	O
:	O
Rapid	O
infusion	O
of	O
albumin	B-PRGE
might	O
be	O
a	O
rescue	O
option	O
in	O
cases	O
of	O
severe	O
TRALI	O
with	O
extensive	O
pulmonary	O
capillary	O
leak	O
during	O
the	O
acute	O
phase	O
.	O

ACE2	B-PRGE
is	O
a	O
type	B-PRGE
I	I-PRGE
integral	I-PRGE
membrane	I-PRGE
protein	I-PRGE
with	O
its	O
active	O
site	O
domain	O
exposed	O
to	O
the	O
extracellular	O
surface	O
of	O
endothelial	O
cells	O
and	O
the	O
renal	O
tubular	O
epithelium	O
.	O

Here	O
ACE2	O
is	O
poised	O
to	O
metabolise	O
circulating	O
peptides	O
which	O
may	O
include	O
angiotensin	B-PRGE
II	I-PRGE
,	O
a	O
potent	O
vasoconstrictor	O
and	O
the	O
product	O
of	O
angiotensin	B-PRGE
I	I-PRGE
cleavage	O
by	O
ACE	B-PRGE
.	O

As	O
the	O
complexity	O
of	O
this	O
crucial	O
pathway	O
is	O
unravelled	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
therapeutic	O
potential	O
of	O
agents	O
that	O
modulate	O
the	O
activity	O
of	O
ACE2	B-PRGE
.	O

At	O
the	O
second	O
examination	O
,	O
scores	O
for	O
ground	O
-	O
glass	O
opacity	O
and	O
interstitial	O
opacity	O
correlated	O
with	O
peak	O
lactate	B-PRGE
dehydrogenase	I-PRGE
level	O
;	O
that	O
for	O
air	O
trapping	O
,	O
with	O
age	O
and	O
peak	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
level	O
.	O

The	O
overall	O
results	O
clearly	O
demonstrate	O
that	O
serological	O
diagnosis	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
remains	O
at	O
an	O
early	O
stage	O
of	O
development	O
,	O
with	O
further	O
technical	O
improvements	O
required	O
,	O
particularly	O
with	O
respect	O
to	O
the	O
use	O
of	O
SARS	O
specific	O
EIAs	O
.	O

Such	O
a	O
relationship	O
was	O
not	O
found	O
with	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
).	O

Such	O
a	O
relationship	O
was	O
not	O
found	O
with	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
).	O

This	O
study	O
is	O
aimed	O
at	O
investigating	O
the	O
capability	O
of	O
SARS	B-PRGE
-	O
CoV	O
to	O
activate	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	I-PRGE
-	I-PRGE
gamma	I-PRGE
expression	O
in	O
lymphomonocytes	O
(	O
PBMC	O
)	O
from	O
healthy	O
donors	O
,	O
evaluating	O
whether	O
viral	O
replication	O
is	O
necessary	O
for	O
this	O
activation	O
.	O

SARS	O
-	O
CoV	O
virus	O
is	O
able	O
to	O
induce	O
both	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	I-PRGE
-	I-PRGE
gamma	I-PRGE
mRNA	I-PRGE
accumulation	O
and	O
protein	O
release	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
MOI	O
10	O
being	O
the	O
most	O
effective	O
.	O

This	O
study	O
provides	O
evidence	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
able	O
to	O
induce	O
in	O
normal	O
PBMC	O
a	O
coordinate	O
induction	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	I-PRGE
-	I-PRGE
gamma	I-PRGE
gene	I-PRGE
expression	O
.	O

Concomitant	O
activation	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	I-PRGE
-	I-PRGE
gamma	I-PRGE
gene	I-PRGE
expression	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
vivo	O
may	O
be	O
relevant	O
for	O
the	O
pathogenesis	O
of	O
the	O
disease	O
,	O
both	O
for	O
the	O
possible	O
involvement	O
in	O
immunomediated	O
damage	O
of	O
the	O
tissues	O
and	O
for	O
the	O
strong	O
inhibition	O
of	O
SARS	O
-	O
CoV	O
replication	O
as	O
a	O
result	O
of	O
combined	O
cytokine	O
action	O
.	O

A	O
combination	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	I-PRGE
-	I-PRGE
gamma	I-PRGE
strongly	O
inhibited	O
SARS	B-PRGE
-	O
CoV	O
replication	O
in	O
Vero	O
cells	O
,	O
while	O
the	O
single	O
cytokines	O
were	O
much	O
less	O
effective	O
.	O

TITLE	O
:	O
Protective	O
effects	O
of	O
a	O
selective	B-PRGE
neutrophil	I-PRGE
elastase	I-PRGE
inhibitor	I-PRGE
(	O
sivelestat	O
)	O
on	O
lipopolysaccharide	O
-	O
induced	O
acute	O
dysfunction	O
of	O
the	O
pulmonary	O
microcirculation	O
.	O

In	O
the	O
lipopolysaccharide	O
group	O
,	O
DSMSS	O
measurements	O
of	O
erythrocyte	O
velocity	O
and	O
hemoglobin	B-PRGE
oxygenation	O
in	O
single	O
capillaries	O
were	O
decreased	O
significantly	O
(	O
vs	O
.	O
control	O
p	O
<	O
.	O
05	O
,	O
vs	O
.	O
sivelestat	O
p	O
<	O
.	O
01	O
),	O
whereas	O
tissue	O
blood	O
flow	O
and	O
erythrocyte	O
velocity	O
measurements	O
from	O
laser	O
-	O
Doppler	O
flowmeter	O
were	O
increased	O
significantly	O
(	O
vs	O
.	O
control	O
p	O
<	O
.	O
05	O
,	O
vs	O
.	O
sivelestat	O
p	O
<	O
.	O
01	O
).	O

Lipopolysaccharide	O
induces	O
leukocyte	O
adhesion	O
in	O
the	O
pulmonary	O
microcirculation	O
,	O
resulting	O
in	O
decreased	O
tissue	B-PRGE
hemoglobin	I-PRGE
oxygen	I-PRGE
and	O
alveolar	O
and	O
interstitial	O
edema	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
mediates	O
membrane	O
fusion	O
events	O
during	O
virus	O
entry	O
and	O
virus	O
-	O
induced	O
cell	O
-	O
to	O
-	O
cell	O
fusion	O
.	O

TITLE	O
:	O
Apoptosis	O
induced	O
by	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
in	O
Vero	O
cells	O
is	O
replication	O
-	O
dependent	O
and	O
involves	O
caspase	B-PRGE
.	O

Although	O
there	O
is	O
a	O
positive	O
correlation	O
between	O
apoptosis	O
and	O
virus	O
replication	O
,	O
the	O
latter	O
is	O
not	O
significantly	O
blocked	O
by	O
treatment	O
with	O
the	O
caspase	B-PRGE
inhibitor	O
z	O
-	O
DEVD	O
-	O
FMK	O
.	O

Identification	O
of	O
antigenic	O
epitopes	O
of	O
the	O
spike	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
may	O
provide	O
the	O
basis	O
for	O
the	O
development	O
of	O
immunity	O
-	O
based	O
prophylactic	O
,	O
therapeutic	O
,	O
and	O
diagnostic	O
clinical	O
techniques	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
humoral	O
immunity	O
against	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
we	O
studied	O
the	O
profiles	O
of	O
IgG	B-PRGE
antibodies	I-PRGE
to	O
the	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Serum	O
specimens	O
from	O
10	O
SARS	O
patients	O
were	O
analyzed	O
by	O
Western	O
blotting	O
and	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
purified	O
recombinant	B-PRGE
N	I-PRGE
and	I-PRGE
truncated	I-PRGE
S	I-PRGE
(	I-PRGE
S1	I-PRGE
,	I-PRGE
S2	I-PRGE
,	I-PRGE
and	I-PRGE
S3	I-PRGE
)	I-PRGE
proteins	I-PRGE
as	O
antigens	O
.	O

The	O
average	O
titers	O
of	O
IgG	B-PRGE
against	O
recombinant	O
proteins	O
N	O
,	O
S1	O
,	O
S2	O
,	O
and	O
S3	O
were	O
,	O
respectively	O
,	O
691	O
,	O
56	O
,	O
38	O
,	O
and	O
84	O
after	O
3	O
weeks	O
.	O

Four	O
of	O
the	O
eleven	O
bananins	O
(	O
BN	O
,	O
IBNCA	O
,	O
VANBA	O
,	O
euBN	O
)	O
were	O
already	O
demonstrated	O
to	O
constitute	O
effective	O
inhibitors	O
of	O
SARS	O
-	O
CoV	O
NSP10	O
/	O
nsp13	B-PRGE
RNA	I-PRGE
/	I-PRGE
DNA	I-PRGE
helicase	I-PRGE
/	O
NTPase	B-PRGE
protein	O
ATPase	B-PRGE
enzymatic	O
function	O
.	O

IA	O
did	O
not	O
increase	O
KC	O
or	O
MIP	B-PRGE
-	I-PRGE
2	I-PRGE
mRNA	I-PRGE
or	O
protein	O
levels	O
.	O

Furthermore	O
,	O
these	O
results	O
suggest	O
that	O
the	O
attenuated	O
murine	O
coronavirus	O
lacks	O
a	O
virulence	O
gene	O
residing	O
in	O
SARS	O
-	O
CoV	O
.	O
Recombinant	O
murine	O
coronaviruses	O
cause	O
a	O
reproducible	O
and	O
well	O
-	O
characterized	O
clinical	O
disease	O
,	O
offer	O
virtually	O
no	O
risk	O
to	O
laboratory	O
personnel	O
,	O
and	O
should	O
be	O
useful	O
for	O
elucidating	O
the	O
role	O
of	O
SARS	B-PRGE
-	O
CoV	O
nonstructural	O
proteins	O
in	O
viral	O
replication	O
and	O
pathogenesis	O
.	O

14	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
3	I-PRGE
proteins	I-PRGE
are	O
a	O
family	O
of	O
highly	O
conserved	O
,	O
ubiquitously	O
expressed	O
eukaryotic	O
proteins	O
that	O
function	O
primarily	O
as	O
adapters	O
that	O
modulate	O
interactions	O
between	O
components	O
of	O
various	O
cellular	O
signaling	O
and	O
cell	O
cycle	O
regulatory	O
pathways	O
through	O
phosphorylation	O
-	O
dependent	O
protein	O
-	O
protein	O
interactions	O
.	O

Using	O
short	O
interfering	O
RNA	O
specific	O
to	O
14	O
-	O
3	O
-	O
3theta	O
we	O
have	O
inhibited	O
its	O
expression	O
to	O
show	O
accumulation	O
of	O
phosphorylated	O
N	B-PRGE
protein	I-PRGE
in	O
the	O
nucleus	O
.	O

ABSTRACT	O
:	O
The	O
clinical	O
relevance	O
of	O
infections	O
with	O
the	O
novel	O
human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
(	O
HCoV	O
-	O
NL63	O
)	O
has	O
not	O
been	O
investigated	O
systematically	O
.	O

Forty	O
-	O
nine	O
samples	O
(	O
5	O
.	O
2	O
%),	O
mainly	O
derived	O
from	O
the	O
winter	O
season	O
,	O
were	O
positive	O
for	O
HCoV	B-PRGE
-	I-PRGE
NL63	I-PRGE
RNA	I-PRGE
.	O

Till	O
now	O
,	O
there	O
is	O
no	O
report	O
about	O
the	O
function	O
of	O
3b	B-PRGE
protein	I-PRGE
.	O

After	O
inoculated	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
all	O
inoculated	O
cynomolgus	O
and	O
rhesus	O
macaques	O
had	O
developed	O
interstitial	O
pneumonia	O
of	O
differing	O
severity	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
325	O
laboratory	O
-	O
confirmed	O
SARS	O
cases	O
were	O
analyzed	O
;	O
of	O
which	O
301	O
(	O
92	O
.	O
6	O
%)	O
had	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
detected	O
in	O
their	O
sera	O
at	O
the	O
time	O
of	O
sampling	O
.	O

The	O
kit	O
was	O
able	O
to	O
specifically	O
detect	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
proteins	I-PRGE
in	O
serum	O
samples	O
.	O

In	O
addition	O
to	O
the	O
well	O
-	O
known	O
functions	O
of	O
chloroquine	O
such	O
as	O
elevations	O
of	O
endosomal	O
pH	O
,	O
the	O
drug	O
appears	O
to	O
interfere	O
with	O
terminal	O
glycosylation	O
of	O
the	O
cellular	O
receptor	O
,	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
.	O

We	O
found	O
that	O
proteases	O
such	O
as	O
trypsin	B-PRGE
and	O
thermolysin	O
enabled	O
SARS	B-PRGE
-	O
CoV	O
adsorbed	O
onto	O
the	O
cell	O
surface	O
to	O
enter	O
cells	O
directly	O
from	O
that	O
site	O
.	O

Likewise	O
,	O
elastase	B-PRGE
,	O
a	O
major	O
protease	O
produced	O
in	O
the	O
lungs	O
during	O
inflammation	O
,	O
also	O
enhanced	O
SARS	O
-	O
CoV	O
infection	O
in	O
cultured	O
cells	O
.	O

Eighty	O
-	O
seven	O
serum	O
samples	O
were	O
confirmed	O
to	O
be	O
positive	O
for	O
SARS	B-PRGE
antibodies	I-PRGE
.	O

To	O
detect	O
early	O
SARS	O
-	O
CoV	O
infection	O
,	O
a	O
one	O
-	O
step	O
,	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
was	O
developed	O
that	O
could	O
simultaneously	O
detect	O
nucleocapsid	O
(	O
N	O
),	O
membrane	O
(	O
M	O
),	O
and	O
spike	O
(	O
S	O
)	O
genes	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
with	O
the	O
same	O
PCR	O
condition	O
using	O
either	O
Applied	O
Biosystems	O
(	O
ABI	O
)	O
Prism	O
7700	O
Sequence	O
Detection	O
System	O
or	O
Roche	O
LightCycler	O
.	O

TITLE	O
:	O
The	O
SARS	B-PRGE
coronavirus	I-PRGE
S	I-PRGE
glycoprotein	I-PRGE
receptor	I-PRGE
binding	I-PRGE
domain	I-PRGE
:	O
fine	O
mapping	O
and	O
functional	O
characterization	O
.	O

To	O
further	O
characterize	O
the	O
role	O
of	O
glycosylation	O
and	O
identify	O
residues	O
important	O
for	O
its	O
function	O
as	O
an	O
interacting	O
partner	O
of	O
ACE2	B-PRGE
,	O
we	O
have	O
cloned	O
,	O
expressed	O
and	O
characterized	O
various	O
soluble	O
fragments	O
of	O
S	O
containing	O
RBD	O
,	O
and	O
mutated	O
all	O
potential	O
glycosylation	O
sites	O
and	O
32	O
other	O
residues	O
.	O

On	O
the	O
contrary	O
,	O
a	O
lot	O
of	O
IFN	B-PRGE
-	O
stimulated	O
genes	O
like	O
PKR	B-PRGE
,	O
GBP	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
2	O
,	O
CXCL	O
-	O
10	O
and	O
11	O
,	O
and	O
JAK	B-PRGE
/	O
STAT	B-PRGE
signal	O
pathway	O
were	O
downregulated	O
in	O
the	O
acute	O
severe	O
case	O
compared	O
to	O
the	O
convalescent	O
case	O
.	O

The	O
expression	O
of	O
haPrP	B-PRGE
protein	I-PRGE
reduced	O
to	O
21	O
.	O
8	O
%	O
in	O
the	O
preparation	O
of	O
Sf9	O
cells	O
infected	O
with	O
recombinant	O
baculovirus	O
exposed	O
for	O
5	O
min	O
and	O
was	O
undetectable	O
exposed	O
for	O
20	O
min	O
.	O

After	O
immunization	O
with	O
rS268	O
,	O
S	B-PRGE
protein	I-PRGE
-	O
specific	O
BALB	O
/	O
c	O
antisera	O
and	O
mAbs	O
were	O
induced	O
and	O
confirmed	O
using	O
ELISA	O
,	O
Western	O
blot	O
and	O
IFA	O
.	O

A	O
total	O
of	O
295	O
patients	O
with	O
unexplained	O
respiratory	O
illnesses	O
,	O
admitted	O
to	O
Queen	O
Mary	O
Hospital	O
,	O
Hong	O
Kong	O
SAR	O
,	O
China	O
,	O
in	O
March	O
to	O
July	O
2003	O
,	O
were	O
evaluated	O
for	O
clinical	O
,	O
radiological	O
,	O
haematological	O
and	O
alanine	B-PRGE
transaminase	I-PRGE
(	O
ALT	B-PRGE
)	O
data	O
daily	O
for	O
3	O
days	O
after	O
hospitalisation	O
.	O

Among	O
them	O
,	O
26	O
(	O
53	O
.	O
06	O
%)	O
substitutions	O
were	O
located	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

The	O
genome	O
has	O
a	O
length	O
of	O
28	O
.	O
475	O
kb	O
and	O
consisted	O
mainly	O
of	O
the	O
replicase	B-PRGE
gene	I-PRGE
(	O
approximately	O
20	O
.	O
2	O
kb	O
)	O
which	O
contains	O
two	O
large	O
overlapping	O
ORFs	B-PRGE
,	I-PRGE
ORF1a	I-PRGE
and	I-PRGE
ORF1b	I-PRGE
,	O
encoding	O
polyproteins	O
pp1a	B-PRGE
and	O
pp1b	O
,	O
respectively	O
.	O

Sequence	O
analysis	O
identified	O
conserved	O
domains	O
within	O
the	O
predicted	O
sequences	O
of	O
pp1a	B-PRGE
and	O
pp1b	O
.	O

TITLE	O
:	O
Activation	O
of	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
by	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
of	O
the	O
SARS	O
coronavirus	O
.	O

Our	O
data	O
indicated	O
the	O
possible	O
role	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
in	O
the	O
pathogenesis	O
of	O
SARS	O
.	O

ABSTRACT	O
:	O
A	O
10	O
-	O
mer	O
overlapping	O
peptide	O
library	O
has	O
been	O
synthesized	O
for	O
screening	O
and	O
identification	O
of	O
linear	O
B	O
-	O
cell	O
epitopes	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
which	O
spanned	O
the	O
major	O
structural	O
proteins	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
One	O
hundred	O
and	O
eleven	O
candidate	O
peptides	O
were	O
positive	O
according	O
to	O
the	O
result	O
of	O
PEPscan	O
,	O
which	O
were	O
assembled	O
into	O
22	O
longer	O
peptides	O
.	O

Apoptosis	O
appeared	O
after	O
the	O
onset	O
of	O
CPE	O
and	O
completion	O
of	O
virus	O
replication	O
,	O
and	O
could	O
be	O
prevented	O
by	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

RESULTS	O
:	O
Both	O
hospital	O
groups	O
had	O
comparable	O
demographics	O
and	O
clinical	O
profiles	O
,	O
but	O
NIV	O
Hospital	O
(	O
42	O
patients	O
)	O
had	O
higher	O
lactate	B-PRGE
dehydrogenase	I-PRGE
ratio	O
and	O
worse	O
radiographic	O
score	O
on	O
admission	O
and	O
ribavirin	O
-	O
corticosteroid	O
commencement	O
.	O

Here	O
,	O
we	O
describe	O
evidence	O
that	O
stem	O
-	O
loop	O
IV	O
,	O
a	O
bulged	O
stem	O
-	O
loop	O
mapping	O
at	O
nt	O
186	O
through	O
215	O
,	O
(	O
i	O
)	O
is	O
phylogenetically	O
conserved	O
among	O
group	O
2	O
coronaviruses	O
and	O
may	O
have	O
a	O
homolog	O
in	O
groups	O
1	O
and	O
3	O
,	O
(	O
ii	O
)	O
exists	O
as	O
a	O
higher	O
-	O
order	O
structure	O
on	O
the	O
basis	O
of	O
enzyme	O
probing	O
,	O
(	O
iii	O
)	O
is	O
required	O
as	O
a	O
higher	O
-	O
order	O
element	O
for	O
replication	O
of	O
a	O
BCoV	O
defective	O
interfering	B-PRGE
(	I-PRGE
DI	I-PRGE
)	I-PRGE
RNA	I-PRGE
in	O
the	O
positive	O
but	O
not	O
the	O
negative	O
strand	O
,	O
and	O
(	O
iv	O
)	O
as	O
a	O
higher	O
-	O
order	O
structure	O
in	O
wild	O
-	O
type	O
(	O
wt	O
)	O
and	O
mutant	O
molecules	O
that	O
replicate	O
,	O
specifically	O
binds	O
six	O
cellular	O
proteins	O
in	O
the	O
molecular	O
mass	O
range	O
of	O
25	O
to	O
58	O
kDa	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
and	O
UV	O
cross	O
-	O
linking	O
assays	O
;	O
binding	O
to	O
viral	O
proteins	O
was	O
not	O
detected	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
a	O
29	O
-	O
bp	O
insertion	O
in	O
ORF	O
8	O
of	O
bat	O
-	O
SARS	O
-	O
CoV	O
genome	O
,	O
not	O
in	O
most	O
human	O
SARS	O
-	O
CoV	O
genomes	O
,	O
suggests	O
that	O
it	O
has	O
a	O
common	O
ancestor	O
with	O
civet	O
SARS	O
-	O
CoV	O
.	O
Antibody	O
against	O
recombinant	B-PRGE
bat	I-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
was	O
detected	O
in	O
84	O
%	O
of	O
Chinese	O
horseshoe	O
bats	O
by	O
using	O
an	O
enzyme	O
immunoassay	O
.	O

We	O
assessed	O
whether	O
mannose	B-PRGE
-	I-PRGE
binding	I-PRGE
lectin	I-PRGE
(	O
MBL	B-PRGE
)	O
gene	O
polymorphisms	O
were	O
associated	O
with	O
susceptibility	O
to	O
SARS	O
-	O
CoV	O
infection	O
or	O
disease	O
severity	O
in	O
an	O
ethnically	O
homogeneous	O
population	O
born	O
in	O
northern	O
China	O
.	O

The	O
frequencies	O
of	O
1	O
mutation	O
in	O
codon	B-PRGE
54	I-PRGE
and	I-PRGE
3	I-PRGE
promoter	I-PRGE
polymorphisms	O
at	O
nt	O
-	O
550	O
,	O
-	O
221	O
,	O
and	O
4	O
were	O
ascertained	O
in	O
352	O
patients	O
with	O
SARS	O
and	O
392	O
control	O
subjects	O
,	O
by	O
means	O
of	O
polymerase	O
chain	O
reaction	O
direct	O
sequencing	O
.	O

When	O
patients	O
deteriorate	O
clinically	O
despite	O
treatment	O
with	O
ribavirin	O
and	O
corticosteroids	O
,	O
rescue	O
treatment	O
with	O
convalescent	O
plasma	O
and	O
immunoglobulin	B-PRGE
may	O
be	O
beneficial	O
.	O

The	O
DNA	O
/	O
RNA	O
hybrid	O
formed	O
by	O
a	O
modified	O
oligodeoxynucleotide	O
and	O
its	O
target	O
RNA	O
could	O
activate	O
RNase	B-PRGE
H	I-PRGE
.	O
The	O
3	O
'-	O
end	O
-	O
modified	O
antisense	O
oligodeoxynucelotides	O
inhibited	O
S	B-PRGE
-	I-PRGE
glycoprotein	I-PRGE
expression	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
at	O
the	O
mRNA	O
levels	O
in	O
insect	O
Sf9	O
cells	O
.	O

The	O
use	O
of	O
the	O
GAP	B-PRGE
approach	O
has	O
proved	O
useful	O
in	O
analyzing	O
the	O
complexity	O
and	O
continuity	O
of	O
biological	O
systems	O
.	O

SARS	B-PRGE
is	O
a	O
serious	O
respiratory	O
illness	O
,	O
and	O
its	O
aetiology	O
is	O
a	O
novel	O
coronavirus	O
.	O

sVCAM	O
-	O
1	O
levels	O
correlated	O
negatively	O
with	O
total	O
leukocytes	O
and	O
platelet	O
counts	O
,	O
but	O
positively	O
with	O
plasma	B-PRGE
sFasL	I-PRGE
levels	O
.	O

As	O
part	O
of	O
the	O
routine	O
check	O
with	O
donated	O
plasma	O
,	O
the	O
convalescent	O
plasma	O
was	O
confirmed	O
free	O
of	O
residual	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
by	O
RT	O
-	O
PCR	O
.	O

ABSTRACT	O
:	O
Replication	O
of	O
the	O
approximately	O
30	O
-	O
kb	O
plus	O
-	O
strand	O
RNA	O
genome	O
of	O
coronaviruses	O
and	O
synthesis	O
of	O
an	O
extensive	O
set	O
of	O
subgenome	O
-	O
length	O
RNAs	O
are	O
mediated	O
by	O
the	O
replicase	B-PRGE
-	I-PRGE
transcriptase	I-PRGE
,	O
a	O
membrane	O
-	O
bound	O
protein	O
complex	O
containing	O
several	O
cellular	O
proteins	O
and	O
up	O
to	O
16	O
viral	O
nonstructural	O
proteins	O
(	O
nsps	O
)	O
with	O
multiple	O
enzymatic	O
activities	O
,	O
including	O
protease	O
,	O
polymerase	B-PRGE
,	I-PRGE
helicase	I-PRGE
,	I-PRGE
methyltransferase	I-PRGE
,	O
and	O
RNase	B-PRGE
activities	O
.	O

A	O
truncated	O
S	O
protein	O
of	O
the	O
TW1	O
strain	O
,	O
STR2	O
(	O
88	O
kDa	O
),	O
carrying	O
three	O
S	O
fragments	O
(	O
S74	O
-	O
253	O
,	O
S294	O
-	O
739	O
,	O
and	O
S1129	O
-	O
1255	O
)	O
was	O
investigated	O
to	O
study	O
the	O
influences	O
of	O
intron	O
and	O
exon	O
splicing	O
enhancers	O
to	O
improve	O
STR2	B-PRGE
protein	I-PRGE
expression	O
in	O
mammalian	O
cells	O
.	O

TITLE	O
:	O
Early	O
enhanced	O
expression	O
of	O
interferon	B-PRGE
-	O
inducible	O
protein	O
-	O
10	O
(	O
CXCL	O
-	O
10	O
)	O
and	O
other	O
chemokines	O
predicts	O
adverse	O
outcome	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
prevalence	O
of	O
antibodies	O
to	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
serotypes	O
1	O
and	O
2	O
in	O
Switzerland	O
and	O
their	O
association	O
with	O
different	O
disease	O
manifestations	O
,	O
a	O
serological	O
study	O
based	O
on	O
immunofluorescence	O
tests	O
was	O
conducted	O
with	O
Swiss	O
field	O
cats	O
using	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
FCoV	B-PRGE
type	I-PRGE
1	I-PRGE
and	O
FCoV	B-PRGE
type	I-PRGE
2	I-PRGE
as	O
antigens	O
.	O

Herein	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
FLAP	B-PRGE
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
membrane	I-PRGE
proteins	I-PRGE
are	O
greatly	O
enhanced	O
by	O
SUMO	B-PRGE
fusions	I-PRGE
in	O
E	O
.	O
coli	O
.	O

Support	O
vector	O
machines	O
(	O
SVM	O
),	O
useful	O
for	O
predicting	O
the	O
functional	O
class	O
of	O
distantly	O
related	O
proteins	O
,	O
is	O
employed	O
to	O
ascribe	O
a	O
possible	O
functional	O
class	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
proteins	I-PRGE
.	O

CD4	B-PRGE
+	I-PRGE
T	O
cell	O
responses	O
against	O
the	O
N	B-PRGE
protein	I-PRGE
have	O
been	O
observed	O
in	O
SARS	O
patients	O
and	O
an	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
-	O
restricted	O
cytotoxic	O
T	O
lymphocyte	O
epitope	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
has	O
been	O
identified	O
.	O

We	O
further	O
found	O
that	O
3a	O
misexpression	O
induces	O
apoptosis	O
,	O
which	O
could	O
be	O
modulated	O
by	O
cellular	O
cytochrome	O
c	O
levels	O
and	O
caspase	B-PRGE
activity	O
.	O

ABSTRACT	O
:	O
We	O
have	O
employed	O
NMR	O
to	O
investigate	O
the	O
structure	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
dimer	O
.	O

In	O
addition	O
,	O
cell	O
mediated	O
immunity	O
as	O
measured	O
by	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
stimulation	O
,	O
was	O
elicited	O
by	O
vaccination	O
.	O

Overexpression	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
did	O
not	O
change	O
proliferation	O
despite	O
decreasing	O
gut	O
apoptosis	O
.	O

Neucleocapsid	B-PRGE
protein	I-PRGE
induces	O
protective	O
specific	O
CTL	O
to	O
SARS	O
-	O
Cov	O
.	O

The	O
aza	O
-	O
peptide	O
component	O
of	O
APE	B-PRGE
binds	O
in	O
the	O
substrate	O
-	O
binding	O
regions	O
of	O
M	O
(	O
pro	O
)	O
in	O
a	O
substrate	O
-	O
like	O
manner	O
,	O
with	O
excellent	O
structural	O
and	O
chemical	O
complementarity	O
.	O

The	O
positive	O
results	O
of	O
in	O
-	O
situ	O
hybridization	O
showed	O
that	O
the	O
lung	O
tissues	O
of	O
all	O
cases	O
expressed	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
,	O
and	O
positive	O
signals	O
displayed	O
in	O
cytoplasms	O
(	O
purple	O
-	O
blue	O
,	O
NBP	O
-	O
BCIP	O
.	O

All	O
of	O
them	O
belonged	O
to	O
the	O
IgG2a	B-PRGE
isotype	I-PRGE
proved	O
by	O
antigen	O
mediated	O
ELISA	O
.	O

Recently	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
protease	I-PRGE
has	O
been	O
implied	O
to	O
be	O
possible	O
relevance	O
to	O
SARS	O
-	O
CoV	O
pathogenesis	O
.	O

Our	O
data	O
strongly	O
suggest	O
that	O
SCV	O
fails	O
to	O
activate	O
host	B-PRGE
cell	I-PRGE
cytokine	I-PRGE
gene	I-PRGE
expression	O
in	O
human	O
macrophages	O
and	O
DCs	O
.	O

Although	O
it	O
has	O
been	O
known	O
that	O
TGEV	B-PRGE
spiker	I-PRGE
protein	I-PRGE
is	O
essential	O
for	O
the	O
viral	O
entry	O
for	O
many	O
years	O
,	O
the	O
detail	O
knowledge	O
of	O
the	O
TGEV	O
fusion	O
protein	O
core	O
is	O
still	O
very	O
limited	O
.	O

Experiments	O
,	O
including	O
purification	O
and	O
C	O
-	O
terminal	O
amino	O
acid	O
sequencing	O
of	O
the	O
CoV	B-PRGE
-	I-PRGE
HKU1	I-PRGE
helicase	I-PRGE
and	O
trans	O
-	O
cleavage	O
assays	O
of	O
the	O
CoV	B-PRGE
-	I-PRGE
HKU1	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
will	O
confirm	O
the	O
presence	O
of	O
this	O
novel	O
cleavage	O
site	O
.	O

Increased	O
activation	O
of	O
the	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
protein	I-PRGE
38	I-PRGE
,	O
Akt	B-PRGE
,	O
and	O
nuclear	B-PRGE
factor	I-PRGE
(	O
NF	O
)-	O
kappa	O
B	O
in	O
neutrophils	O
and	O
other	O
cell	O
populations	O
obtained	O
at	O
early	O
time	O
points	O
in	O
the	O
clinical	O
course	O
of	O
sepsis	O
-	O
induced	O
acute	O
lung	O
injury	O
or	O
after	O
accidental	O
trauma	O
is	O
associated	O
with	O
a	O
more	O
-	O
severe	O
clinical	O
course	O
,	O
suggesting	O
that	O
a	O
proinflammatory	O
cellular	O
phenotype	O
contributes	O
to	O
organ	O
system	O
dysfunction	O
in	O
such	O
settings	O
.	O

A	O
Taiwan	O
Group	O
I	O
(	O
TW	O
I	O
)	O
strain	O
was	O
passaged	O
74	O
times	O
through	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chicken	O
embryonated	O
eggs	O
,	O
and	O
then	O
tested	O
in	O
SPF	B-PRGE
chickens	I-PRGE
.	O

Furthermore	O
,	O
these	O
studies	O
revealed	O
etacrynic	O
acid	O
amide	O
(	O
6b	O
)	O
as	O
a	O
promising	O
lead	O
for	O
nonpeptidic	O
active	O
-	O
site	O
-	O
directed	O
M	B-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibitors	O
.	O

In	O
a	O
fluorimetric	O
enzyme	O
assay	O
using	O
a	O
novel	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
pair	O
labeled	O
substrate	O
,	O
compound	O
6b	O
showed	O
a	O
K	B-PRGE
(	I-PRGE
i	I-PRGE
)	I-PRGE
value	I-PRGE
of	I-PRGE
35	I-PRGE
.	I-PRGE
3	I-PRGE
muM	I-PRGE
.	O
Since	O
the	O
novel	O
lead	O
compound	O
does	O
not	O
target	O
the	O
S1	O
',	O
S1	O
,	O
and	O
S2	O
subsites	O
of	O
the	O
enzyme	O
'	O
s	O
substrate	O
-	O
binding	O
pockets	O
,	O
there	O
is	O
room	O
for	O
improvement	O
that	O
underlines	O
the	O
lead	O
character	O
of	O
compound	O
6b	O
.	O

Recognition	O
of	O
a	O
specific	O
sequence	O
,	O
termed	O
the	O
packaging	O
signal	O
(	O
PS	O
),	O
by	O
a	O
virus	O
N	O
protein	O
is	O
often	O
the	O
first	O
step	O
in	O
the	O
assembly	O
of	O
viral	O
RNA	O
,	O
but	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
assembly	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
are	O
not	O
clear	O
.	O

In	O
this	O
study	O
,	O
Vero	O
E6	O
cells	O
were	O
cotransfected	O
with	O
plasmids	O
encoding	O
the	O
four	O
structural	O
proteins	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
This	O
generated	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
of	O
SARS	O
-	O
CoV	O
that	O
can	O
be	O
partially	O
purified	O
on	O
a	O
discontinuous	O
sucrose	O
gradient	O
from	O
the	O
culture	O
medium	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
VLPs	I-PRGE
thus	O
produced	O
were	O
designated	O
VLP	B-PRGE
(	O
GFP	O
-	O
PS580	O
).	O

The	O
use	O
of	O
inactivated	O
SARS	O
virus	O
with	O
MF59	O
enhanced	O
the	O
CD4	B-PRGE
and	O
antibody	O
response	O
even	O
after	O
gene	O
-	O
based	O
vaccination	O
.	O

TITLE	O
:	O
[	O
Expression	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
and	O
construction	O
of	O
its	O
DNA	O
vaccine	O
].	O

In	O
addition	O
,	O
the	O
N	B-PRGE
gene	I-PRGE
was	O
cloned	O
into	O
the	O
eukaryotic	O
expression	O
plasmid	O
pSecTagB	O
and	O
the	O
eukaryotic	O
recombinant	O
expression	O
vector	O
pSecN	O
was	O
obtained	O
.	O

RESULTS	O
:	O
Recombinant	B-PRGE
N	I-PRGE
protein	I-PRGE
reacted	O
strongly	O
and	O
specifically	O
with	O
the	O
sera	O
from	O
immunized	O
mice	O
and	O
SARS	O
patients	O
.	O

Since	O
studies	O
applying	O
molecular	O
diagnostic	O
assays	O
usually	O
report	O
reductions	O
in	O
the	O
number	O
of	O
undiagnosed	O
cases	O
of	O
infectious	O
disease	O
compared	O
to	O
traditional	O
techniques	O
,	O
we	O
applied	O
PCR	O
assays	O
to	O
investigate	O
the	O
role	O
of	O
two	O
recently	O
described	O
viruses	O
,	O
namely	O
human	B-PRGE
coronavirus	I-PRGE
(	O
HCoV	O
)	O
HKU1	O
and	O
human	B-PRGE
bocavirus	I-PRGE
(	I-PRGE
HBoV	I-PRGE
),	I-PRGE
in	O
a	O
hospital	O
-	O
based	O
paediatric	O
population	O
.	O

RESULTS	O
:	O
After	O
virus	O
attack	O
,	O
the	O
level	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
specific	I-PRGE
IgG	I-PRGE
and	I-PRGE
neutralizing	I-PRGE
antibody	I-PRGE
were	O
induced	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
the	O
interferon	B-PRGE
group	I-PRGE
was	O
weaker	O
than	O
in	O
control	O
group	O
.	O

TITLE	O
:	O
[	O
A	O
field	O
trial	O
of	O
recombinant	B-PRGE
human	I-PRGE
interferon	I-PRGE
alpha	I-PRGE
-	I-PRGE
2b	I-PRGE
for	O
nasal	O
spray	O
to	O
prevent	O
SARS	O
and	O
other	O
respiratory	O
viral	O
infections	O
].	O

Interferon	B-PRGE
alpha	I-PRGE
-	I-PRGE
2b	I-PRGE
was	O
given	O
twice	O
per	O
day	O
,	O
once	O
9	O
x	O
10	O
(	O
5	O
)	O
IU	O
by	O
nasal	O
spray	O
for	O
5	O
days	O
.	O

Serological	O
tests	O
included	O
SARS	O
IgG	B-PRGE
antibody	I-PRGE
and	O
IgM	B-PRGE
antibodies	O
against	O
influenza	O
B	O
,	O
parainfluenza	O
virus	O
types	O
1	O
-	O
3	O
,	O
adenovirus	O
type	O
3	O
,	O
7	O
and	O
respiratory	O
syncytial	O
virus	O
by	O
using	O
commercial	O
ELISA	O
kits	O
.	O

The	O
recombinant	B-PRGE
human	I-PRGE
interferon	I-PRGE
alpha	I-PRGE
-	I-PRGE
2b	I-PRGE
for	O
nasal	O
spray	O
could	O
decrease	O
the	O
rates	O
of	O
common	O
respiratory	O
viruses	O
infection	O
in	O
the	O
selected	O
population	O
.	O

The	O
ACE	B-PRGE
-	I-PRGE
2	I-PRGE
encoding	I-PRGE
gene	I-PRGE
was	O
then	O
cloned	O
into	O
pcDNA4	O
/	O
HisMax	O
-	O
TOPO	O
eukaryotic	O
expression	O
vector	O
to	O
construct	O
the	O
recombinant	B-PRGE
plasmid	I-PRGE
pcDNA4	I-PRGE
/	I-PRGE
ACE	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
which	O
was	O
then	O
transfected	O
into	O
293	O
T	O
cell	O
and	O
ACE	B-PRGE
-	I-PRGE
2	I-PRGE
eukaryotic	O
transient	O
expression	O
was	O
detected	O
by	O
Western	O
Blot	O
.	O

CONCLUSIONS	O
:	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
ACE	I-PRGE
-	I-PRGE
2	I-PRGE
gene	I-PRGE
was	O
successfully	O
cloned	O
and	O
eukaryotic	O
expressed	O
,	O
and	O
used	O
to	O
establish	O
syncytia	O
inhibition	O
assay	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
neutralizing	I-PRGE
antibody	I-PRGE
assay	O
.	O

Three	O
recombinant	O
plasmids	O
(	O
pQE	O
-	O
30	O
/	O
S1a	B-PRGE
,	O
pQE	O
-	O
30	O
/	O
S1b	B-PRGE
,	O
pQE	O
-	O
30	O
/	O
S1c	O
)	O
were	O
constructed	O
.	O

We	O
measured	O
systemic	O
and	O
mesenteric	O
(	O
portal	O
venous	O
blood	O
flow	O
,	O
jejunal	O
mucosal	O
perfusion	O
)	O
haemodynamic	O
parameters	O
,	O
mesenteric	O
oxygenation	O
(	O
jejunal	O
tissue	O
oxygen	O
tension	O
)	O
and	O
systemic	O
cytokines	O
(	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
).	O

Acute	O
infection	O
of	O
Vero	O
E6	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
produced	O
a	O
lytic	O
infection	O
with	O
characteristic	O
rounding	O
cytopathic	O
effects	O
(	O
CPE	O
)	O
and	O
the	O
production	O
of	O
a	O
large	O
number	O
of	O
infectious	O
particles	O
in	O
the	O
culture	O
fluid	O
within	O
3	O
days	O
post	O
-	O
infection	O
.	O

Anti	B-PRGE
-	I-PRGE
AGP	I-PRGE
antiserum	I-PRGE
,	O
as	O
confirmed	O
by	O
ELISA	O
and	O
Western	O
blot	O
techniques	O
,	O
and	O
a	O
pool	O
of	O
peritoneal	O
fluid	O
from	O
cats	O
with	O
FIP	O
were	O
used	O
to	O
prepare	O
standards	O
.	O

ABSTRACT	O
:	O
The	O
detection	O
of	O
typical	O
lesions	O
and	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antigen	O
in	O
tissues	O
is	O
the	O
only	O
conclusive	O
method	O
for	O
making	O
a	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	B-PRGE
).	O

TITLE	O
:	O
Structural	O
basis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
ADP	O
-	O
ribose	O
-	O
1	O
''-	O
phosphate	O
dephosphorylation	O
by	O
a	O
conserved	O
domain	O
of	O
nsP3	B-PRGE
.	O

SCT	B-PRGE
recipients	O
comprise	O
a	O
heterogeneous	O
group	O
;	O
to	O
further	O
advance	O
this	O
field	O
,	O
prospective	O
multicenter	O
trials	O
involving	O
larger	O
populations	O
from	O
many	O
centers	O
are	O
needed	O
to	O
reduce	O
the	O
biases	O
of	O
retrospective	O
and	O
single	O
-	O
center	O
reports	O
.	O

Three	O
fusion	O
tags	O
(	O
glutathione	B-PRGE
S	I-PRGE
-	I-PRGE
transferase	I-PRGE
,	O
GST	B-PRGE
;	O
thioredoxin	B-PRGE
,	O
Trx	B-PRGE
;	O
maltose	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
,	O
MBP	B-PRGE
),	O
which	O
preferably	O
contributes	O
to	O
increasing	O
solubility	O
and	O
to	O
facilitating	O
the	O
proper	O
folding	O
of	O
heteroprotein	O
,	O
were	O
used	O
to	O
acquire	O
the	O
soluble	O
and	O
functional	O
expression	O
of	O
RBD	B-PRGE
protein	I-PRGE
in	O
Escherichia	O
coli	O
(	O
BL21	O
(	O
DE3	O
)	O
and	O
Rosetta	O
-	O
gamiB	O
(	O
DE3	O
)	O
strains	O
).	O

Further	O
flow	O
cytometry	O
assay	O
demonstrated	O
the	O
high	O
efficiency	O
of	O
RBD	O
'	O
s	O
binding	O
ability	O
to	O
ACE2	B-PRGE
(	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
)	O
positive	O
Vero	O
E6	O
cell	O
.	O

The	O
geometrical	O
mean	O
of	O
GST	B-PRGE
and	O
GST	B-PRGE
/	O
RBD	O
binding	O
to	O
Vero	O
E6	O
cells	O
were	O
77	O
.	O
08	O
and	O
352	O
.	O
73	O
respectively	O
.	O

The	O
geometrical	O
mean	O
of	O
GST	B-PRGE
and	O
GST	B-PRGE
/	O
RBD	O
binding	O
to	O
Vero	O
E6	O
cells	O
were	O
77	O
.	O
08	O
and	O
352	O
.	O
73	O
respectively	O
.	O

ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
genetic	O
expression	O
moved	O
up	O
after	O
1	O
h	O
and	O
reached	O
its	O
peak	O
value	O
after	O
9	O
h	O
.	O
MD	O
plays	O
an	O
important	O
role	O
in	O
ASP	O
following	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

ABSTRACT	O
:	O
To	O
detect	O
the	O
presence	O
of	O
endothelial	O
injury	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
via	O
enhanced	O
levels	O
of	O
tissue	B-PRGE
-	I-PRGE
type	I-PRGE
plasminogen	I-PRGE
activator	I-PRGE
(	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
)	O
and	O
soluble	B-PRGE
thrombomodulin	I-PRGE
(	O
sTM	B-PRGE
).	O

Endothelial	O
injury	O
bio	O
-	O
markers	O
tPA	B-PRGE
and	O
sTM	B-PRGE
were	O
detected	O
by	O
commercial	O
ELISA	O
-	O
methods	O
.	O

Blood	O
samples	O
of	O
patients	O
and	O
household	O
contacts	O
were	O
collected	O
at	O
least	O
28	O
days	O
after	O
symptom	O
onset	O
in	O
the	O
index	O
patients	O
or	O
household	O
exposure	O
in	O
the	O
contacts	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
IgG	B-PRGE
testing	O
.	O

Although	O
SARS	B-PRGE
CoV	I-PRGE
IgM	I-PRGE
was	O
still	O
detectable	O
by	O
IF	O
tests	O
with	O
8	O
of	O
11	O
patients	O
at	O
7	O
months	O
postinfection	O
,	O
the	O
geometric	O
mean	O
titers	O
dropped	O
from	O
282	O
at	O
1	O
month	O
postinfection	O
to	O
19	O
at	O
7	O
months	O
(	O
P	O
=	O
0	O
.	O
001	O
).	O

MULTIPRED	O
is	O
useful	O
for	O
the	O
identification	O
of	O
peptides	O
that	O
bind	O
multiple	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
variants	I-PRGE
as	O
a	O
group	O
.	O

As	O
assessed	O
by	O
immunofluorescence	O
staining	O
and	O
membrane	O
biotinylation	O
,	O
ACE2	B-PRGE
protein	I-PRGE
was	O
more	O
abundantly	O
expressed	O
on	O
the	O
apical	O
than	O
the	O
basolateral	O
surface	O
of	O
polarized	O
airway	O
epithelia	O
.	O

Furthermore	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
replicated	O
in	O
polarized	O
epithelia	O
and	O
preferentially	O
exited	O
via	O
the	O
apical	O
surface	O
.	O

In	O
addition	O
,	O
the	O
multimeric	O
ability	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
could	O
be	O
weakened	O
by	O
the	O
SR	O
-	O
rich	O
motif	O
interaction	O
with	O
the	O
central	O
region	O
(	O
amino	O
acids	O
211	O
-	O
290	O
).	O

TITLE	O
:	O
A	O
novel	O
fingerprint	O
map	O
for	O
detecting	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
ABSTRACT	O
:	O
Spike	O
(	O
S	O
)	O
protein	O
is	O
the	O
most	O
important	O
membrane	O
protein	O
on	O
the	O
surface	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

As	O
an	O
outcome	O
,	O
a	O
novel	O
method	O
for	O
visualizing	O
the	O
characteristic	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
suggested	O
.	O

RESULTS	O
:	O
The	O
specific	O
IgG	B-PRGE
and	O
neutralizing	O
antibody	O
titers	O
peaked	O
at	O
approximately	O
week	O
7	O
after	O
the	O
first	O
immunization	O
,	O
with	O
a	O
maximum	O
value	O
of	O
1	O
:	O
14210	O
.	O

PEDV	O
shedding	O
was	O
monitored	O
every	O
day	O
and	O
virus	O
levels	O
were	O
measured	O
using	O
a	O
quantitative	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
method	O
.	O

ACE2	B-PRGE
expression	O
is	O
dramatically	O
reduced	O
with	O
aging	O
in	O
both	O
genders	O
:	O
young	O
-	O
adult	O
vs	O
.	O
old	O
P	O
<	O
0	O
.	O
001	O
(	O
by	O
78	O
%	O
in	O
male	O
and	O
67	O
%	O
in	O
female	O
,	O
respectively	O
)	O
and	O
middle	O
-	O
aged	O
vs	O
.	O
old	O
P	O
<	O
0	O
.	O
001	O
(	O
by	O
71	O
%	O
in	O
male	O
rats	O
and	O
59	O
%	O
in	O
female	O
rats	O
,	O
respectively	O
).	O

Here	O
,	O
we	O
observed	O
that	O
transient	O
expression	O
of	O
ORF7a	B-PRGE
protein	I-PRGE
fused	O
with	O
myc	B-PRGE
or	O
GFP	O
tags	O
at	O
its	O
N	O
or	O
C	O
terminus	O
inhibited	O
cell	O
growth	O
and	O
prevented	O
BrdU	O
incorporation	O
in	O
different	O
cultural	O
cells	O
,	O
suggesting	O
that	O
ORF7a	O
expression	O
may	O
regulate	O
cell	O
cycle	O
progression	O
.	O

This	O
position	O
is	O
predicted	O
to	O
map	O
in	O
the	O
N	O
-	O
terminal	O
polyprotein	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
(	O
PLP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
cleavage	O
site	O
at	O
the	O
p9	O
/	O
p87	B-PRGE
junction	O
.	O

By	O
using	O
targeted	O
RNA	O
recombination	O
,	O
we	O
generated	O
isogenic	O
recombinant	O
MHVs	O
which	O
differ	O
exclusively	O
in	O
their	O
expression	O
of	O
HE	O
and	O
produce	O
either	O
the	O
wild	B-PRGE
-	I-PRGE
type	I-PRGE
protein	I-PRGE
(	O
HE	O
+),	O
an	O
enzymatically	O
inactive	O
HE	B-PRGE
protein	I-PRGE
(	O
HE0	O
),	O
or	O
no	O
HE	O
at	O
all	O
.	O

The	O
JHM	O
strain	O
of	O
MHV	O
is	O
highly	O
neurovirulent	O
and	O
expresses	O
a	O
second	O
spike	O
glycoprotein	O
,	O
the	O
hemagglutinin	B-PRGE
esterase	I-PRGE
(	O
HE	O
),	O
which	O
is	O
not	O
produced	O
by	O
MHV	O
-	O
A59	O
,	O
a	O
hepatotropic	O
but	O
only	O
mildly	O
neurovirulent	O
strain	O
.	O

To	O
investigate	O
a	O
possible	O
role	O
for	O
HE	O
in	O
MHV	O
-	O
induced	O
neurovirulence	O
,	O
isogenic	O
recombinant	O
MHV	O
-	O
A59	O
viruses	O
were	O
generated	O
that	O
produced	O
either	O
(	O
i	O
)	O
the	O
wild	O
-	O
type	O
protein	O
,	O
(	O
ii	O
)	O
an	O
enzymatically	O
inactive	O
HE	B-PRGE
protein	I-PRGE
,	O
or	O
(	O
iii	O
)	O
no	O
HE	O
at	O
all	O
(	O
A	O
.	O
Lissenberg	O
,	O
M	O
.	O
M	O
.	O
Vrolijk	O
,	O
A	O
.	O
L	O
.	O
W	O
.	O
van	O
Vliet	O
,	O
M	O
.	O
A	O
.	O
Langereis	O
,	O
J	O
.	O
D	O
.	O
F	O
.	O
de	O
Groot	O
-	O
Mijnes	O
,	O
P	O
.	O
J	O
.	O
M	O
.	O
Rottier	O
,	O
and	O
R	O
.	O
J	O
.	O
de	O
Groot	O
,	O
J	O
.	O
Virol	O
.	O

A	O
second	O
,	O
mirror	O
set	O
of	O
recombinant	O
viruses	O
was	O
constructed	O
in	O
which	O
,	O
in	O
addition	O
,	O
the	O
MHV	B-PRGE
-	I-PRGE
A59	I-PRGE
S	I-PRGE
gene	I-PRGE
had	O
been	O
replaced	O
with	O
that	O
from	O
MHV	O
-	O
JHM	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
properties	O
of	O
S	B-PRGE
receptor	I-PRGE
utilization	O
and	O
/	O
or	O
fusogenicity	O
mainly	O
determine	O
organ	O
and	O
host	O
cell	O
tropism	O
but	O
that	O
HE	O
enhances	O
the	O
efficiency	O
of	O
infection	O
and	O
promotes	O
viral	O
dissemination	O
,	O
at	O
least	O
in	O
some	O
tissues	O
,	O
presumably	O
by	O
serving	O
as	O
a	O
second	O
receptor	O
-	O
binding	O
protein	O
.	O

TITLE	O
:	O
The	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
has	O
deubiquitinating	O
activity	O
.	O

Mutagenesis	O
studies	O
revealed	O
that	O
Asp1826	O
and	O
the	O
four	O
cysteine	O
residues	O
involved	O
in	O
zinc	O
binding	O
are	O
essential	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
activity	O
.	O

In	O
order	O
to	O
confirm	O
this	O
prediction	O
,	O
we	O
overexpressed	O
and	O
purified	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
(	O
amino	O
acids	O
[	O
aa	O
]	O
1507	O
to	O
1858	O
)	O
from	O
Escherichia	O
coli	O
.	O

In	O
addition	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
was	O
inhibited	O
by	O
the	O
specific	O
deubiquitinating	O
enzyme	O
inhibitor	B-PRGE
ubiquitin	I-PRGE
aldehyde	I-PRGE
,	O
with	O
an	O
inhibition	O
constant	O
of	O
210	O
nM	O
.	O
The	O
purified	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
disassembles	O
branched	B-PRGE
polyubiquitin	I-PRGE
chains	I-PRGE
with	O
lengths	O
of	O
two	O
to	O
seven	O
(	O
Ub2	O
-	O
7	O
)	O
or	O
four	O
(	O
Ub4	O
)	O
units	O
,	O
which	O
involves	O
isopeptide	O
bond	O
cleavage	O
.	O

In	O
fingerpad	O
tests	O
,	O
the	O
formulation	O
produced	O
a	O
log10	O
reduction	O
factor	O
of	O
the	O
titre	O
of	O
poliovirus	B-PRGE
type	I-PRGE
1	I-PRGE
(	O
Sabin	O
)	O
of	O
3	O
.	O
04	O
in	O
30s	O
compared	O
with	O
1	O
.	O
32	O
by	O
60	O
%	O
propan	O
-	O
2	O
-	O
ol	O
.	O

TITLE	O
:	O
Surface	O
ultrastructure	O
of	O
SARS	B-PRGE
coronavirus	O
revealed	O
by	O
atomic	O
force	O
microscopy	O
.	O

TITLE	O
:	O
Absence	O
of	O
heme	B-PRGE
oxygenase	I-PRGE
-	I-PRGE
1	I-PRGE
expression	O
in	O
the	O
lung	O
parenchyma	O
exacerbates	O
endotoxin	O
-	O
induced	O
acute	O
lung	O
injury	O
and	O
decreases	O
surfactant	O
protein	O
-	O
B	O
levels	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
-	O
CoV	O
open	O
reading	O
frame	O
6	O
(	O
ORF6	B-PRGE
)	O
is	O
transcribed	O
into	O
mRNA6	O
and	O
encodes	O
a	O
putative	O
7	O
.	O
5	O
kDa	O
accessory	O
protein	O
,	O
SARS	O
6	O
,	O
with	O
unknown	O
function	O
.	O

An	O
animal	O
model	O
of	O
human	O
coronavirus	O
infectious	O
disease	O
has	O
been	O
generated	O
by	O
gene	O
transfer	O
of	O
the	O
human	O
receptor	O
for	O
virus	O
-	O
cell	O
interaction	O
(	O
aminopeptidase	B-PRGE
N	I-PRGE
,	O
APN	B-PRGE
,	O
CD13	B-PRGE
)	O
into	O
mice	O
.	O

TITLE	O
:	O
Preparation	O
and	O
evaluation	O
of	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
coronavirus	I-PRGE
IgY	I-PRGE
from	I-PRGE
yolks	I-PRGE
of	I-PRGE
immunized	I-PRGE
SPF	I-PRGE
chickens	I-PRGE
.	O

Yolk	B-PRGE
immunoglobulin	I-PRGE
(	O
IgY	O
)	O
was	O
extracted	O
using	O
the	O
water	O
dilution	O
method	O
,	O
followed	O
by	O
further	O
purification	O
on	O
a	O
Sephadex	O
G	O
-	O
75	O
column	O
.	O

Antifungal	O
therapy	O
may	O
also	O
be	O
indicated	O
with	O
prolonged	O
treatment	O
and	O
the	O
use	O
of	O
the	O
monoclonal	B-PRGE
anti	I-PRGE
-	I-PRGE
CD20	I-PRGE
molecule	I-PRGE
,	O
Rituximab	O
,	O
has	O
proven	O
useful	O
in	O
those	O
patients	O
where	O
thrombocytopenia	O
poses	O
a	O
major	O
risk	O
of	O
hemorrhage	O
.	O

The	O
fold	O
of	O
the	O
protein	O
is	O
the	O
first	O
member	O
of	O
a	O
further	O
variation	O
of	O
the	O
immunoglobulin	B-PRGE
like	I-PRGE
beta	I-PRGE
-	O
sandwich	O
fold	O
.	O

SP	B-PRGE
-	I-PRGE
10	I-PRGE
blocked	O
both	O
binding	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
and	O
infectivity	O
of	O
S	O
protein	O
-	O
pseudotyped	O
retrovirus	O
to	O
Vero	O
E6	O
cells	O
.	O

Our	O
findings	O
suggest	O
that	O
SP	B-PRGE
-	I-PRGE
10	I-PRGE
may	O
be	O
developed	O
as	O
an	O
anti	O
-	O
SARS	O
-	O
CoV	O
agent	O
for	O
the	O
treatment	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Crosslinking	O
studies	O
demonstrate	O
the	O
formation	O
of	O
dimers	O
,	O
tetramers	O
,	O
and	O
higher	O
multimers	O
of	O
IBV	O
-	O
N	O
.	O
A	O
model	O
for	O
coronavirus	O
shell	O
formation	O
is	O
proposed	O
in	O
which	O
dimerization	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
IBV	O
-	O
N	O
leads	O
to	O
oligomerization	O
of	O
the	O
IBV	B-PRGE
-	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
and	O
viral	O
RNA	O
condensation	O
.	O

Here	O
we	O
show	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
but	O
not	O
HCoV	O
-	O
NL63	O
,	O
utilizes	O
the	O
enzymatic	O
activity	O
of	O
the	O
cysteine	B-PRGE
protease	I-PRGE
cathepsin	B-PRGE
L	I-PRGE
to	O
infect	O
ACE2	B-PRGE
-	O
expressing	O
cells	O
.	O

Geldanamycin	O
,	O
an	O
hsp90	B-PRGE
inhibitor	O
,	O
attenuated	O
chronic	O
EtOH	O
-	O
mediated	O
increases	O
in	O
NO	O
production	O
.	O

Geldanamycin	O
,	O
an	O
hsp90	B-PRGE
inhibitor	O
,	O
attenuated	O
chronic	O
EtOH	O
-	O
mediated	O
increases	O
in	O
NO	O
production	O
.	O

Both	O
classical	O
and	O
biochemical	O
complementation	O
analysis	O
leads	O
us	O
to	O
predict	O
that	O
the	O
majority	O
of	O
MHV	B-PRGE
-	I-PRGE
A59	I-PRGE
ORF1a	I-PRGE
replicase	I-PRGE
gene	I-PRGE
products	I-PRGE
(	O
non	O
-	O
structural	O
proteins	O
nsp1	B-PRGE
-	I-PRGE
nsp11	I-PRGE
)	O
form	O
a	O
single	O
complementation	O
group	O
(	O
cistron1	O
)	O
while	O
the	O
replicase	B-PRGE
gene	I-PRGE
products	I-PRGE
encoded	I-PRGE
in	I-PRGE
ORF1b	I-PRGE
(	O
non	O
-	O
structural	O
proteins	O
nsp12	O
-	O
nsp16	O
)	O
are	O
able	O
to	O
function	O
in	O
trans	O
and	O
comprise	O
at	O
least	O
three	O
,	O
and	O
possibly	O
five	O
,	O
further	O
complementation	O
groups	O
(	O
cistrons	O
II	O
-	O
VI	O
).	O

Also	O
,	O
we	O
have	O
identified	O
mutations	O
in	O
the	O
non	O
-	O
structural	O
proteins	O
nsp	B-PRGE
4	I-PRGE
,	O
nsp5	B-PRGE
,	O
nsp10	O
,	O
nsp12	O
,	O
nsp14	O
,	O
and	O
nsp16	O
that	O
are	O
responsible	O
for	O
the	O
ts	O
phenotype	O
of	O
eight	O
MHV	O
-	O
A59	O
mutants	O
,	O
which	O
allows	O
us	O
to	O
conclude	O
that	O
these	O
proteins	O
are	O
essential	O
for	O
the	O
assembly	O
of	O
a	O
functional	O
replicase	B-PRGE
-	I-PRGE
transcriptase	I-PRGE
complex	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
the	O
recombinant	O
IBV	O
produced	O
fivefold	O
less	O
E	B-PRGE
protein	I-PRGE
.	O

Thus	O
,	O
neither	O
the	O
tricistronic	O
arrangement	O
of	O
gene	B-PRGE
3	I-PRGE
,	O
the	O
internal	O
initiation	O
of	O
translation	O
of	O
E	B-PRGE
protein	I-PRGE
,	O
nor	O
the	O
3a	O
and	O
3b	O
proteins	O
are	O
essential	O
for	O
replication	O
per	O
se	O
,	O
suggesting	O
that	O
these	O
proteins	O
are	O
accessory	O
proteins	O
that	O
may	O
have	O
roles	O
in	O
vivo	O
.	O

We	O
found	O
a	O
drastic	O
increase	O
in	O
caspase	B-PRGE
-	I-PRGE
8	I-PRGE
activity	O
and	O
cleavage	O
of	O
Bid	O
at	O
24	O
h	O
p	O
.	O
i	O
.	O

There	O
was	O
no	O
effect	O
of	O
milk	O
replacer	O
feeding	O
on	O
concentrations	O
of	O
nonesterified	O
fatty	O
acids	O
,	O
total	O
protein	O
,	O
or	O
growth	B-PRGE
hormone	I-PRGE
concentrations	O
.	O

Following	O
a	O
review	O
of	O
the	O
function	O
of	O
immunoglobulin	B-PRGE
A	I-PRGE
in	O
defence	O
against	O
infection	O
,	O
a	O
group	O
of	O
articles	O
considers	O
vaccination	O
and	O
gene	O
therapy	O
approaches	O
,	O
the	O
latter	O
involving	O
consideration	O
of	O
both	O
viral	O
and	O
bacterial	O
strategies	O
.	O

Western	O
blot	O
analysis	O
using	O
phosphospecific	O
antibodies	O
indicated	O
that	O
7a	B-PRGE
protein	I-PRGE
activated	O
p38	B-PRGE
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
MAPK	B-PRGE
),	O
but	O
not	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
protein	I-PRGE
kinase	I-PRGE
/	O
stress	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
.	O

Two	O
of	O
them	O
were	O
located	O
within	O
the	O
HR2	B-PRGE
region	I-PRGE
and	O
two	O
immediately	O
upstream	O
of	O
the	O
HR2	O
domain	O
.	O

The	O
median	O
duration	O
from	O
onset	O
of	O
fever	O
to	O
the	O
nadir	O
level	O
or	O
most	O
severe	O
condition	O
was	O
9	O
days	O
for	O
hypoxia	O
,	O
7	O
days	O
for	O
lymphocytopenia	O
,	O
6	O
.	O
5	O
days	O
for	O
thrombocytopenia	O
,	O
9	O
.	O
5	O
days	O
for	O
maximal	O
pulmonary	O
infiltrates	O
;	O
to	O
peak	O
serum	O
levels	O
was	O
9	O
days	O
for	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
),	O
10	O
.	O
5	O
days	O
for	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
13	O
.	O
5	O
days	O
for	O
IL	O
-	O
8	O
and	O
12	O
days	O
for	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
;	O
to	O
defervescence	O
was	O
13	O
days	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
peak	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
between	O
patients	O
with	O
and	O
without	O
ARDS	O
.	O

CONCLUSIONS	O
:	O
Rapid	O
elevation	O
of	O
inflammatory	O
cytokines	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
might	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
SARS	O
-	O
related	O
ARDS	O
.	O

CONCLUSIONS	O
:	O
The	O
level	O
of	O
SARS	B-PRGE
-	O
IgG	B-PRGE
descends	O
slowly	O
,	O
and	O
it	O
may	O
last	O
for	O
a	O
long	O
time	O
.	O

TITLE	O
:	O
Anti	O
-	O
HIV	O
,	O
anti	O
-	O
poxvirus	O
,	O
and	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
activity	O
of	O
a	O
nontoxic	O
,	O
acidic	O
plant	O
extract	O
from	O
the	O
Trifollium	O
species	O
Secomet	O
-	O
V	O
/	O
anti	O
-	O
vac	O
suggests	O
that	O
it	O
contains	O
a	O
novel	O
broad	O
-	O
spectrum	O
antiviral	O
.	O

An	O
unusually	O
high	O
number	O
of	O
isolations	O
occurred	O
in	O
1997	O
(	O
318	O
isolations	O
)	O
and	O
1999	O
(	O
246	O
isolations	O
),	O
which	O
coincided	O
with	O
the	O
GAV	B-PRGE
variant	I-PRGE
virus	I-PRGE
and	I-PRGE
GA98	I-PRGE
variant	I-PRGE
virus	I-PRGE
outbreaks	O
respectively	O
.	O

By	O
far	O
,	O
the	O
Ark	B-PRGE
-	I-PRGE
DPI	I-PRGE
strain	O
was	O
the	O
most	O
frequently	O
identified	O
type	O
of	O
IBV	O
and	O
ranged	O
from	O
23	O
%	O
to	O
65	O
%	O
of	O
total	O
isolations	O
per	O
year	O
.	O

In	O
addition	O
,	O
new	O
Ark	B-PRGE
-	O
like	O
isolates	O
continued	O
to	O
emerge	O
each	O
year	O
(	O
except	O
in	O
the	O
year	O
2000	O
)	O
beginning	O
in	O
1997	O
,	O
reflecting	O
the	O
ability	O
of	O
that	O
IBV	O
type	O
to	O
undergo	O
genetic	O
drift	O
.	O

(	O
4	O
)	O
Compared	O
with	O
Nc	O
group	O
,	O
the	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
in	O
both	O
serum	O
and	O
BALF	O
of	O
P1	O
group	O
were	O
significantly	O
increased	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
the	O
levels	O
of	O
these	O
cytokines	O
in	O
P2	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
P1	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
but	O
significantly	O
lower	O
in	O
P	O
+	O
D	O
group	O
compared	O
with	O
P2	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

We	O
identified	O
three	O
changes	O
in	O
the	O
HCoV	B-PRGE
-	I-PRGE
OC43	I-PRGE
surface	I-PRGE
glycoprotein	I-PRGE
that	O
correlated	O
with	O
enhanced	O
neurovirulence	O
in	O
mice	O
;	O
these	O
were	O
located	O
in	O
the	O
domain	O
of	O
the	O
protein	O
responsible	O
for	O
binding	O
to	O
host	O
cells	O
.	O

Here	O
,	O
the	O
roles	O
of	O
the	O
transmembrane	O
and	O
cytoplasmic	O
domains	O
of	O
S	O
in	O
the	O
infectivity	O
and	O
membrane	O
fusion	O
activity	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
have	O
been	O
studied	O
.	O

Two	O
different	O
fragments	O
S260	O
-	O
600	O
and	O
S397	O
-	O
796	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
were	O
expressed	O
in	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
)	O
using	O
a	O
pET	B-PRGE
expression	O
vector	O
,	O
respectively	O
.	O

TITLE	O
:	O
Significant	O
redox	O
insensitivity	O
of	O
the	O
functions	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
:	O
comparison	O
with	O
HIV	B-PRGE
envelope	I-PRGE
.	O

Antibodies	O
were	O
not	O
detected	O
within	O
the	O
first	O
7	O
days	O
of	O
illness	O
,	O
but	O
IgG	B-PRGE
titre	O
increased	O
dramatically	O
on	O
day	O
15	O
,	O
reaching	O
a	O
peak	O
on	O
day	O
60	O
,	O
and	O
remained	O
high	O
until	O
day	O
180	O
from	O
when	O
it	O
declined	O
gradually	O
until	O
day	O
720	O
.	O

After	O
lymphocytes	O
were	O
stimulated	O
with	O
10mug	O
/	O
ml	O
purified	O
N	B-PRGE
antigen	I-PRGE
,	O
The	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
of	O
N	O
and	O
M	O
plus	O
N	O
group	O
were	O
increased	O
compared	O
with	O
those	O
of	O
control	O
groups	O
,	O
and	O
the	O
M	B-PRGE
protein	I-PRGE
could	O
augment	O
the	O
activation	O
of	O
lymphocytes	O
induced	O
by	O
N	O
DNA	O
vaccine	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
inhibits	O
the	O
activity	O
of	O
cyclin	B-PRGE
-	I-PRGE
cyclin	I-PRGE
-	I-PRGE
dependent	I-PRGE
kinase	I-PRGE
complex	I-PRGE
and	O
blocks	O
S	O
phase	O
progression	O
in	O
mammalian	O
cells	O
.	O

Whereas	O
N	B-PRGE
protein	I-PRGE
could	O
directly	O
bind	O
to	O
cyclin	B-PRGE
D	I-PRGE
and	O
inhibit	O
the	O
activity	O
of	O
CDK4	B-PRGE
-	O
cyclin	B-PRGE
D	I-PRGE
complex	I-PRGE
;	O
inhibition	O
of	O
CDK2	B-PRGE
activity	O
appeared	O
to	O
be	O
achieved	O
in	O
two	O
different	O
ways	O
:	O
indirectly	O
by	O
down	O
-	O
regulation	O
of	O
protein	O
levels	O
of	O
CDK2	B-PRGE
,	O
cyclin	B-PRGE
E	I-PRGE
,	O
and	O
cyclin	B-PRGE
A	I-PRGE
and	O
by	O
direct	O
binding	O
of	O
N	B-PRGE
protein	I-PRGE
to	O
CDK2	B-PRGE
-	O
cyclin	B-PRGE
complex	O
.	O

These	O
data	O
suggest	O
that	O
the	O
S	O
phase	O
inhibitory	O
activity	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
may	O
have	O
major	O
significance	O
during	O
viral	O
pathogenesis	O
.	O

TITLE	O
:	O
Amino	O
terminus	O
of	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
protein	I-PRGE
3a	I-PRGE
elicits	O
strong	O
,	O
potentially	O
protective	O
humoral	O
responses	O
in	O
infected	O
patients	O
.	O

The	O
transient	O
increase	O
in	O
CD4	B-PRGE
/	O
CD8	B-PRGE
ratio	O
was	O
likely	O
due	O
to	O
the	O
TCM	O
intake	O
.	O

The	O
count	O
of	O
CD4	B-PRGE
+,	I-PRGE
CD8	B-PRGE
+	I-PRGE
T	I-PRGE
lymphocytes	O
of	O
peripheral	O
blood	O
is	O
useful	O
in	O
the	O
adjustment	O
of	O
immunosuppressants	O
and	O
the	O
prediction	O
of	O
patient	O
outcome	O
.	O

Using	O
a	O
newly	O
established	O
human	B-PRGE
monoclonal	I-PRGE
anti	I-PRGE
-	I-PRGE
M	I-PRGE
antibody	I-PRGE
we	O
detected	O
glycosylated	O
and	O
nonglycosylated	O
membrane	O
-	O
associated	O
M	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infected	O
cells	O
and	O
in	O
purified	O
virions	O
.	O

Our	O
work	O
includes	O
a	O
total	O
of	O
54	O
peptides	O
derived	O
from	O
immunodominant	O
linear	O
epitopes	O
of	O
the	O
T7	B-PRGE
phage	I-PRGE
capsid	I-PRGE
protein	I-PRGE
,	O
Herpes	B-PRGE
simplex	I-PRGE
virus	I-PRGE
glycoprotein	I-PRGE
D	I-PRGE
,	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
protein	I-PRGE
,	O
and	O
three	O
domains	O
of	O
the	O
Human	B-PRGE
coronavirus	I-PRGE
polymerase	I-PRGE
polyprotein	I-PRGE
and	O
their	O
cognate	O
mAbs	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
phosphorylation	O
status	O
of	O
p90RSK	B-PRGE
,	O
which	O
is	O
a	O
well	O
-	O
known	O
substrate	O
of	O
these	O
signaling	O
pathways	O
,	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

A	O
set	O
of	O
deletion	O
mutant	O
plasmids	O
,	O
of	O
which	O
pGL3	B-PRGE
-	I-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
pGL3	B-PRGE
-	I-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
pGL3	B-PRGE
-	I-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
-	I-PRGE
3	I-PRGE
and	O
pGL3	B-PRGE
-	I-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
-	I-PRGE
4	I-PRGE
are	O
with	O
3	O
,	O
2	O
,	O
1	O
,	O
and	O
0	O
residual	O
stem	O
-	O
loops	O
of	O
3	O
'	O
termini	O
respectively	O
,	O
were	O
constructed	O
from	O
pGL3	B-PRGE
-	I-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
and	O
were	O
transfected	O
into	O
HepG2	O
cells	O
to	O
express	B-PRGE
reporter	I-PRGE
gene	I-PRGE
luc	I-PRGE
+,	I-PRGE
with	O
pGL3	B-PRGE
-	I-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
containing	O
full	O
sequence	O
as	O
control	O
.	O

Thus	O
,	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3a	I-PRGE
protein	I-PRGE
is	O
an	O
O	O
-	O
glycosylated	O
glycoprotein	O
,	O
like	O
the	O
group	O
2	O
coronavirus	O
M	O
proteins	O
but	O
unlike	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
,	O
which	O
is	O
N	O
glycosylated	O
.	O

ABSTRACT	O
:	O
Interferon	B-PRGE
(	O
IFN	B-PRGE
)-	O
alphas	O
bind	O
to	O
and	O
activate	O
their	O
cognate	O
cell	O
surface	O
receptor	O
to	O
invoke	O
an	O
antiviral	O
response	O
in	O
target	O
cells	O
.	O

TITLE	O
:	O
The	O
catalysis	O
of	O
the	O
SARS	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
is	O
under	O
extensive	O
regulation	O
by	O
its	O
extra	O
domain	O
.	O

The	O
compliance	O
of	O
the	O
respiratory	O
system	O
obtained	O
from	O
the	O
pressure	O
-	O
volume	O
curves	O
was	O
significantly	O
correlated	O
with	O
markers	O
for	O
collagen	O
turn	O
-	O
over	O
(	O
type	O
III	O
procollagen	O
peptide	O
and	O
matrix	B-PRGE
metalloproteinase	I-PRGE
2	I-PRGE
)	O
and	O
with	O
markers	O
of	O
surfactant	O
degradation	O
(	O
type	B-PRGE
-	I-PRGE
IIA	I-PRGE
secretory	I-PRGE
phospholipase	I-PRGE
A2	I-PRGE
).	O

The	O
marker	O
for	O
surfactant	O
degradation	O
was	O
associated	O
with	O
ongoing	O
alveolar	O
inflammation	O
(	O
cellularity	O
of	O
bronchoalveolar	O
lavage	O
fluid	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
concentration	O
).	O

ABSTRACT	O
:	O
In	O
a	O
cohort	O
study	O
of	O
56	O
convalescent	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
titers	O
of	O
immunoglobulin	B-PRGE
G	I-PRGE
(	O
IgG	B-PRGE
)	O
antibodies	O
and	O
neutralizing	O
antibodies	O
(	O
NAbs	O
)	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
were	O
assessed	O
at	O
regular	O
intervals	O
(	O
at	O
1	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
16	O
,	O
and	O
24	O
months	O
after	O
the	O
onset	O
of	O
disease	O
)	O
by	O
use	O
of	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
neutralization	O
assay	O
.	O

TITLE	O
:	O
Differential	O
roles	O
for	O
CXCR3	B-PRGE
in	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
T	O
cell	O
trafficking	O
following	O
viral	O
infection	O
of	O
the	O
CNS	O
.	O

Administration	O
of	O
anti	B-PRGE
-	I-PRGE
CXCR3	I-PRGE
antibody	I-PRGE
reduced	O
CD4	B-PRGE
+	I-PRGE
T	O
cell	O
infiltration	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
05	O
),	O
while	O
CD8	B-PRGE
+	I-PRGE
T	O
cell	O
trafficking	O
was	O
not	O
affected	O
.	O

Therefore	O
,	O
CXCR3	B-PRGE
signaling	O
has	O
a	O
non	O
-	O
redundant	O
role	O
in	O
T	O
cell	O
subset	O
trafficking	O
in	O
response	O
to	O
viral	O
infection	O
.	O

Therefore	O
,	O
SARS	O
-	O
CoV	O
replication	O
was	O
suppressed	O
by	O
pretreatment	O
with	O
IFN	B-PRGE
.	O

However	O
,	O
treatment	O
with	O
glycogen	B-PRGE
synthase	I-PRGE
kinase	I-PRGE
-	I-PRGE
3beta	I-PRGE
small	I-PRGE
interfering	I-PRGE
RNA	I-PRGE
indicated	O
that	O
the	O
glycogen	B-PRGE
synthase	I-PRGE
kinase	I-PRGE
-	I-PRGE
3beta	I-PRGE
signaling	O
pathway	O
was	O
not	O
related	O
to	O
inhibition	O
of	O
cell	O
proliferation	O
.	O

Cellular	B-PRGE
mRNA	I-PRGE
transcription	O
,	O
which	O
was	O
reported	O
to	O
be	O
up	O
-	O
regulated	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Caco	O
-	O
2	O
cells	O
,	O
was	O
not	O
up	O
-	O
regulated	O
in	O
virus	O
-	O
infected	O
Vero	O
E6	O
cells	O
,	O
partially	O
as	O
a	O
result	O
of	O
apoptosis	O
.	O

Potential	O
epidemiological	O
and	O
laboratory	O
pitfalls	O
are	O
also	O
discussed	O
as	O
they	O
may	O
give	O
rise	O
to	O
false	O
or	O
inconsistent	O
results	O
in	O
measuring	O
the	O
seroprevalence	O
of	O
IgG	B-PRGE
antibodies	I-PRGE
to	O
SARS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
Side	O
effects	O
of	O
interferon	B-PRGE
-	I-PRGE
ribavirin	I-PRGE
combination	O
therapy	O
limit	O
the	O
sustained	O
viral	O
response	O
achievable	O
in	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
patients	O
.	O

HRC	O
203	O
had	O
greater	O
anti	O
-	O
viral	O
activity	O
on	O
both	O
isolated	O
hepatocytes	O
and	O
macrophages	O
,	O
whereas	O
both	O
ribavirin	O
and	O
HRC	O
203	O
inhibited	O
production	O
of	O
the	O
pro	O
-	O
inflammatory	O
cytokines	B-PRGE
interferon	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
by	O
macrophages	O
.	O

A	O
truncated	O
version	O
of	O
S	B-PRGE
glycoprotein	I-PRGE
,	O
containing	O
only	O
the	O
ecto	O
-	O
domain	O
,	O
as	O
well	O
as	O
a	O
His	O
-	O
tagged	O
full	O
-	O
length	O
version	O
were	O
cloned	O
and	O
expressed	O
in	O
a	O
serum	O
-	O
free	O
insect	O
cell	O
line	O
,	O
ExpresSF	O
+.	O

Neutralizing	O
antibody	O
titers	O
correlated	O
closely	O
with	O
standard	O
ELISA	O
reactivity	O
against	O
the	O
S	B-PRGE
glycoprotein	I-PRGE
.	O

TITLE	O
:	O
Identification	O
of	O
Hepta	O
-	O
and	O
Octo	O
-	O
Uridine	O
stretches	O
as	O
sole	O
signals	O
for	O
programmed	O
+	O
1	O
and	O
-	O
1	O
ribosomal	O
frameshifting	O
during	O
translation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
ORF	I-PRGE
3a	I-PRGE
variants	O
.	O

SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
ORF	I-PRGE
3a	I-PRGE
encodes	O
a	O
minor	O
structural	O
protein	O
of	O
274	O
amino	O
acids	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
expression	O
of	O
clones	O
with	O
six	O
,	O
seven	O
and	O
eight	O
Ts	O
,	O
respectively	O
,	O
showed	O
the	O
detection	O
of	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
3a	I-PRGE
protein	I-PRGE
.	O

However	O
,	O
the	O
N	B-PRGE
protein	I-PRGE
and	O
the	O
3	O
'	O
untranslated	O
region	O
were	O
similar	O
to	O
subgroup	O
1	O
:	O
90	O
to	O
97	O
%	O
identical	O
with	O
the	O
N	O
protein	O
of	O
subgroup	O
1	O
strains	O
.	O

Serum	O
IgG	B-PRGE
antibody	I-PRGE
against	O
SARS	O
coronavirus	O
was	O
detected	O
in	O
all	O
the	O
19	O
SARS	O
patients	O
,	O
and	O
among	O
the	O
200	O
staff	O
members	O
,	O
20	O
(	O
10	O
%)	O
were	O
found	O
positive	O
for	O
the	O
antibody	O
but	O
with	O
no	O
obvious	O
or	O
only	O
mild	O
symptoms	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
insulin	B-PRGE
on	O
the	O
acute	O
lung	O
injury	O
induced	O
by	O
lipopolysaccharide	O
using	O
a	O
conscious	O
rat	O
model	O
.	O

Insulin	B-PRGE
infusion	O
at	O
doses	O
of	O
0	O
.	O
5	O
,	O
1	O
,	O
and	O
5	O
microU	O
/	O
kg	O
/	O
min	O
was	O
given	O
5	O
mins	O
before	O
lipopolysaccharide	O
administration	O
.	O

In	O
this	O
work	O
we	O
present	O
the	O
NMR	O
structure	O
of	O
the	O
HR2	O
domain	O
(	O
residues	O
1141	O
-	O
1193	O
)	O
from	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
termed	O
S2	O
-	O
HR2	O
)	O
in	O
the	O
presence	O
of	O
the	O
co	O
-	O
solvent	O
trifluoroethanol	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
signaling	O
in	O
oligodendroglia	O
delays	O
coronavirus	O
clearance	O
without	O
altering	O
demyelination	O
.	O

To	O
examine	O
the	O
anti	O
-	O
viral	O
and	O
/	O
or	O
regulatory	O
role	O
of	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
signaling	O
in	O
the	O
cell	O
that	O
synthesizes	O
and	O
maintains	O
the	O
myelin	O
sheath	O
,	O
we	O
analyzed	O
JHMV	O
pathogenesis	O
in	O
transgenic	O
mice	O
expressing	O
a	O
dominant	O
-	O
negative	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
receptor	I-PRGE
on	O
oligodendroglia	O
.	O

However	O
,	O
the	O
CNS	O
inflammatory	O
cell	O
composition	O
and	O
CD8	B-PRGE
(+)	O
T	O
-	O
cell	O
effector	O
functions	O
were	O
similar	O
between	O
transgenic	O
and	O
wild	O
-	O
type	O
mice	O
,	O
supporting	O
unimpaired	O
peripheral	O
and	O
CNS	O
immune	O
responses	O
in	O
transgenic	O
mice	O
.	O

None	O
of	O
these	O
mutations	O
affected	O
cell	O
surface	O
expression	O
or	O
binding	O
to	O
its	O
cognate	O
ACE2	B-PRGE
receptor	I-PRGE
.	O

Among	O
the	O
HIV	B-PRGE
-	I-PRGE
1	I-PRGE
integrase	I-PRGE
inhibitors	O
,	O
the	O
beta	O
-	O
diketo	O
acids	O
(	O
DKAs	O
)	O
represent	O
a	O
major	O
lead	O
for	O
anti	O
-	O
HIV	O
-	O
1	O
drug	O
development	O
.	O

The	O
selected	O
Fab	B-PRGE
antibodies	I-PRGE
expressed	O
in	O
the	O
periplasma	O
of	O
E	O
.	O
coli	O
were	O
soluble	O
and	O
further	O
purified	O
and	O
tested	O
for	O
their	O
binding	O
properties	O
and	O
antiviral	O
function	O
to	O
SARS	O
virus	O
.	O

A	O
sequence	O
of	O
68	O
residuals	O
was	O
identified	O
as	O
a	O
potential	O
DNA	O
-	O
binding	O
domain	O
essential	O
for	O
activating	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

APTT	O
,	O
PC	O
,	O
AT	B-PRGE
-	I-PRGE
III	I-PRGE
,	O
PAI	B-PRGE
,	O
APC	B-PRGE
-	I-PRGE
R	I-PRGE
,	O
and	O
PLG	O
were	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

The	O
expressed	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
with	O
Myc	B-PRGE
/	I-PRGE
His	I-PRGE
tag	I-PRGE
was	O
purified	O
from	O
culture	O
medium	O
with	O
Ni	O
-	O
NTA	O
agarose	O
beads	O
followed	O
by	O
dialysis	O
.	O

The	O
possible	O
role	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CLpro	O
)	O
in	O
virus	O
-	O
induced	O
apoptosis	O
is	O
characterized	O
in	O
this	O
study	O
.	O

The	O
relationship	O
existing	O
between	O
SARS	O
-	O
CoV	O
and	O
other	O
groups	O
of	O
coronaviruses	O
was	O
determined	O
via	O
analyses	O
of	O
phylogenetic	O
trees	O
and	O
comparative	O
genomic	O
analyses	O
of	O
the	O
coronavirus	O
genes	O
:	O
polymerase	O
(	O
Orf1ab	O
),	O
spike	O
(	O
S	O
),	O
envelope	B-PRGE
(	O
E	O
),	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
).	O

Overall	O
results	O
were	O
very	O
similar	O
for	O
both	O
testing	O
devices	O
with	O
the	O
advantage	O
of	O
ImmunoCard	O
STAT	B-PRGE
!	O

TITLE	O
:	O
Only	O
one	O
protomer	O
is	O
active	O
in	O
the	O
dimer	O
of	O
SARS	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
.	O

LXA	O
(	O
4	O
)	O
is	O
generated	O
in	O
vivo	O
during	O
acute	O
lung	O
injury	O
,	O
and	O
we	O
observed	O
that	O
nanomolar	O
quantities	O
increased	O
basal	O
epithelial	O
cell	O
proliferation	O
and	O
potently	O
blocked	O
acid	O
-	O
triggered	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
release	O
and	O
neutrophil	O
transmigration	O
across	O
well	O
-	O
differentiated	O
normal	O
human	O
bronchial	O
epithelial	O
cells	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
cytokine	O
response	O
of	O
two	O
human	O
non	O
-	O
lymphatic	O
cell	O
lines	O
,	O
Caco	O
-	O
2	O
and	O
HEK	B-PRGE
293	I-PRGE
,	O
which	O
are	O
fully	O
permissive	O
for	O
SARS	O
-	O
CoV	O
.	O
A	O
comparison	O
with	O
established	O
cytokine	O
-	O
inducing	O
viruses	O
revealed	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
only	O
weakly	O
triggered	O
a	O
cytokine	O
response	O
.	O

Interestingly	O
,	O
however	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
strongly	O
induced	O
the	O
chemokines	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IL	O
-	O
8	O
in	O
the	O
colon	O
carcinoma	O
cell	O
line	O
Caco	O
-	O
2	O
,	O
but	O
not	O
in	O
the	O
embryonic	O
kidney	O
cell	O
line	O
293	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
indicate	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
suppresses	O
the	O
antiviral	O
cytokine	O
system	O
of	O
non	O
-	O
immune	O
cells	O
to	O
a	O
large	O
extent	O
,	O
thus	O
buying	O
time	O
for	O
dissemination	O
in	O
the	O
host	O
.	O

Neu5	B-PRGE
,	O
9Ac	O
(	O
2	O
)	O
was	O
also	O
found	O
in	O
these	O
tissues	O
,	O
except	O
in	O
the	O
liver	O
.	O

TITLE	O
:	O
Tertiary	O
structure	O
prediction	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
helicase	I-PRGE
.	O

Coronavirus	O
helicases	O
are	O
very	O
conserved	O
and	O
peculiar	O
proteins	O
which	O
have	O
been	O
proposed	O
as	O
suitable	O
targets	O
for	O
antiviral	O
drugs	O
,	O
such	O
as	O
bananins	O
,	O
which	O
have	O
been	O
recently	O
shown	O
to	O
inhibit	O
the	O
SCV	B-PRGE
helicase	I-PRGE
in	O
vitro	O
.	O

ACE2	B-PRGE
,	O
a	O
close	O
homologue	O
of	O
ACE	B-PRGE
,	O
functions	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
angiotensin	O
system	O
and	O
was	O
identified	O
as	O
a	O
key	O
receptor	O
for	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)	O
coronavirus	O
infections	O
.	O

Indeed	O
,	O
increasing	O
ACE2	B-PRGE
activity	O
might	O
be	O
a	O
novel	O
approach	O
for	O
the	O
treatment	O
of	O
acute	O
lung	O
failure	O
in	O
several	O
diseases	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp3	I-PRGE
gene	I-PRGE
region	O
corresponding	O
to	O
amino	O
acids	O
182	O
-	O
355	O
has	O
been	O
cloned	O
,	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
purified	O
and	O
crystallized	O
.	O

TITLE	O
:	O
Anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
immune	O
responses	O
:	O
the	O
role	O
played	O
by	O
V	B-PRGE
gamma	I-PRGE
9V	I-PRGE
delta	I-PRGE
2	I-PRGE
T	I-PRGE
cells	O
.	O

The	O
expansion	O
of	O
the	O
V	B-PRGE
gamma	I-PRGE
9V	I-PRGE
delta	I-PRGE
2	I-PRGE
T	O
cell	O
population	O
was	O
associated	O
with	O
higher	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
immunoglobulin	I-PRGE
G	O
titers	O
.	O

These	O
findings	O
are	O
compatible	O
with	O
the	O
possibility	O
that	O
V	B-PRGE
gamma	I-PRGE
9V	I-PRGE
delta	I-PRGE
2	I-PRGE
T	I-PRGE
cells	O
play	O
a	O
protective	O
role	O
during	O
SARS	O
.	O

Human	O
interferons	O
,	O
in	O
particular	O
alpha	O
-	O
and	O
beta	B-PRGE
-	I-PRGE
interferon	I-PRGE
,	O
as	O
well	O
as	O
short	O
interfering	O
RNAs	O
could	O
further	O
be	O
pursued	O
for	O
the	O
control	O
of	O
SARS	O
.	O

The	O
antibody	O
epitope	O
is	O
dominated	O
by	O
a	O
10	B-PRGE
-	I-PRGE
residue	I-PRGE
-	I-PRGE
long	I-PRGE
protruding	I-PRGE
beta6	I-PRGE
-	I-PRGE
beta7	I-PRGE
loop	O
with	O
two	O
putative	O
ACE2	B-PRGE
-	I-PRGE
binding	I-PRGE
hotspot	I-PRGE
residues	O
(	O
Ile	O
-	O
489	O
and	O
Tyr	O
-	O
491	O
).	O

The	O
binding	O
interface	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
)	O
that	O
is	O
facing	O
the	O
P1	O
'	O
position	O
is	O
suggested	O
to	O
be	O
occupied	O
by	O
acidic	O
amino	O
acids	O
,	O
thus	O
the	O
P1	O
'	O
position	O
is	O
intolerant	O
to	O
acidic	O
residue	O
substitution	O
,	O
owing	O
to	O
electrostatic	O
repulsion	O
.	O

In	O
the	O
present	O
study	O
,	O
therefore	O
,	O
we	O
analyzed	O
the	O
other	O
structure	O
genes	O
,	O
the	O
hemagglutinin	O
/	O
esterase	B-PRGE
(	O
HE	O
)	O
protein	O
,	O
the	O
transmembrane	O
(	O
M	O
)	O
protein	O
and	O
the	O
small	O
membrane	O
(	O
E	O
)	O
protein	O
to	O
characterize	O
10	O
WD	O
BCoV	O
circulated	O
in	O
Korea	O
during	O
2002	O
-	O
2003	O
and	O
compared	O
the	O
nucleotide	O
and	O
deduced	O
amino	O
acid	O
sequences	O
with	O
the	O
other	O
known	O
BCoV	O
.	O
Phylogenetic	O
analysis	O
indicated	O
that	O
the	O
HE	O
gene	O
among	O
BCoV	O
could	O
be	O
divided	O
into	O
three	O
groups	O
.	O

However	O
,	O
the	O
M	O
gene	O
sequence	O
of	O
both	O
BCoV	O
and	O
HCV	O
-	O
OC43	O
might	O
not	O
contain	O
a	O
signal	O
peptide	O
,	O
suggesting	O
the	O
M	B-PRGE
protein	I-PRGE
might	O
be	O
unlikely	O
to	O
be	O
exposed	O
to	O
the	O
O	O
-	O
glycosylation	O
machinery	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
Volume	O
replacement	O
was	O
studied	O
prospectively	O
in	O
208	O
infants	O
with	O
dengue	O
hemorrhagic	O
fever	O
/	O
dengue	O
shock	O
syndrome	O
(	O
DHF	O
/	O
DSS	B-PRGE
).	O

Multiple	O
organ	O
system	O
failure	O
usually	O
accompanied	O
ARF	B-PRGE
.	O

Hypotension	O
(	O
77	O
%)	O
caused	O
by	O
nosocomial	O
infections	O
,	O
gastrointestinal	O
bleeding	O
,	O
or	O
SARS	O
per	O
se	O
,	O
and	O
rhabdomyolysis	O
(	O
43	O
%)	O
was	O
associated	O
with	O
ARF	B-PRGE
in	O
addition	O
to	O
pre	O
-	O
renal	O
factors	O
.	O

ABSTRACT	O
:	O
Helicases	B-PRGE
are	O
promising	O
antiviral	O
drug	O
targets	O
because	O
their	O
enzymatic	O
activities	O
are	O
essential	O
for	O
viral	O
genome	O
replication	O
,	O
transcription	O
,	O
and	O
translation	O
.	O

The	O
obvious	O
functional	O
differences	O
of	O
lymphatic	O
tissues	O
in	O
FCoV	O
-	O
infected	O
cats	O
with	O
and	O
without	O
FIP	B-PRGE
suggest	O
that	O
they	O
contribute	O
to	O
the	O
outcome	O
of	O
FCoV	O
infection	O
.	O

Compared	O
to	O
cats	O
with	O
FIP	O
,	O
FCoV	O
-	O
infected	O
cats	O
without	O
FIP	O
exhibited	O
significantly	O
higher	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
levels	O
in	O
the	O
spleen	O
and	O
significantly	O
lower	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
G	O
-	O
and	O
M	B-PRGE
-	I-PRGE
CSF	I-PRGE
in	O
mesenteric	O
lymph	O
nodes	O
.	O

TITLE	O
:	O
Enhancement	O
of	O
the	O
infectivity	O
of	O
SARS	O
-	O
CoV	O
in	O
BALB	O
/	O
c	O
mice	O
by	O
IMP	B-PRGE
dehydrogenase	I-PRGE
inhibitors	O
,	O
including	O
ribavirin	O
.	O

Our	O
data	O
do	O
not	O
support	O
the	O
use	O
of	O
ribavirin	O
or	O
other	O
IMP	B-PRGE
dehydrogenase	I-PRGE
inhibitors	O
for	O
treating	O
SARS	O
infections	O
in	O
humans	O
.	O

Boosting	O
with	O
the	O
same	O
vaccine	O
enhances	O
CD4	B-PRGE
(+)	O
and	O
CD8	B-PRGE
(+)	O
T	O
cell	O
responses	O
in	O
both	O
lymphoid	O
and	O
nonlymphoid	O
organs	O
and	O
were	O
persistent	O
over	O
two	O
months	O
.	O

CONCLUSIONS	O
:	O
S2	O
gene	O
of	O
GD322	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
relatively	O
stable	O
during	O
the	O
epidemic	O
spread	O
of	O
the	O
virus	O
,	O
and	O
mutation	O
at	O
the	O
57th	O
amino	O
acids	O
of	O
S2	B-PRGE
protein	I-PRGE
may	O
affect	O
the	O
T	B-PRGE
cell	I-PRGE
antigen	I-PRGE
epitope	I-PRGE
.	O

We	O
have	O
previously	O
shown	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
forms	O
a	O
dimer	O
in	O
solution	O
through	O
its	O
C	O
-	O
terminal	O
domain	O
.	O

The	O
structure	O
shows	O
a	O
dimer	O
with	O
extensive	O
interactions	O
between	O
the	O
two	O
subunits	O
,	O
suggesting	O
that	O
the	O
dimeric	O
form	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
is	O
the	O
functional	O
unit	O
in	O
vivo	O
.	O

TITLE	O
:	O
Role	O
of	O
natural	O
interferon	B-PRGE
-	O
producing	O
cells	O
and	O
T	O
lymphocytes	O
in	O
porcine	O
monocyte	O
-	O
derived	O
dendritic	O
cell	O
maturation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
defined	O
the	O
role	O
of	O
particular	O
cytokines	O
,	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
(	O
TLR	O
)	O
ligands	O
and	O
T	O
lymphocytes	O
in	O
the	O
porcine	O
monocyte	O
-	O
derived	O
DC	O
(	O
MoDC	O
).	O

Indeed	O
,	O
MoDC	O
did	O
not	O
respond	O
to	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
whereas	O
NIPC	O
produced	O
high	O
levels	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
after	O
TGEV	O
stimulation	O
.	O

TITLE	O
:	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
0201	I-PRGE
T	O
-	O
cell	O
epitopes	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	O
and	O
spike	O
proteins	O
.	O

TITLE	O
:	O
Kinetics	O
and	O
synergistic	O
effects	O
of	O
siRNAs	O
targeting	O
structural	O
and	O
replicase	B-PRGE
genes	I-PRGE
of	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

Because	O
all	O
infected	O
individuals	O
were	O
devoid	O
of	O
preeexisting	O
protective	O
immunity	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
the	O
biological	O
basis	O
for	O
the	O
variable	O
virus	O
burdens	O
in	O
different	O
patients	O
remains	O
elusive	O
.	O

TITLE	O
:	O
Cross	O
-	O
neutralization	O
of	O
human	O
and	O
palm	O
civet	O
severe	O
acute	O
respiratory	O
syndrome	O
coronaviruses	O
by	O
antibodies	O
targeting	O
the	O
receptor	B-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
of	I-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

Timely	O
recognition	O
of	O
SARS	B-PRGE
is	O
extremely	O
important	O
.	O

TITLE	O
:	O
The	O
interferon	B-PRGE
gamma	I-PRGE
gene	I-PRGE
polymorphism	I-PRGE
+	I-PRGE
874	I-PRGE
A	I-PRGE
/	I-PRGE
T	I-PRGE
is	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

The	O
polymorphisms	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
were	O
not	O
associated	O
with	O
SARS	B-PRGE
susceptibility	I-PRGE
.	O

We	O
recruited	O
353	O
and	O
361	O
children	O
,	O
respectively	O
,	O
from	O
the	O
high	O
-	O
risk	O
and	O
low	O
-	O
risk	O
areas	O
and	O
collected	O
3	O
to	O
5	O
mL	O
of	O
blood	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
IgG	B-PRGE
antibody	I-PRGE
testing	O
by	O
immunofluorescence	O
antibody	O
assay	O
and	O
confirmation	O
by	O
neutralization	O
test	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3b	I-PRGE
fused	O
with	O
EGFP	O
at	O
its	O
N	O
-	O
or	O
C	O
-	O
terminus	O
co	O
-	O
localized	O
with	O
a	O
mitochondria	O
-	O
specific	O
marker	O
in	O
some	O
transfected	O
cells	O
.	O

The	O
N	O
-	O
specific	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
(+)	I-PRGE
CD4	I-PRGE
(+)	O
T	O
cells	O
were	O
mainly	O
composed	O
of	O
CD45RA	B-PRGE
(-)	I-PRGE
CCR7	I-PRGE
(+)	I-PRGE
CD62L	I-PRGE
(-)	O
cells	O
,	O
whereas	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
(+)	I-PRGE
CD8	I-PRGE
(+)	O
memory	O
T	O
cells	O
were	O
mostly	O
contained	O
within	O
CD45RA	B-PRGE
(+)	I-PRGE
CCR7	I-PRGE
(-)	I-PRGE
CD62L	I-PRGE
(-)	O
cell	O
population	O
.	O

Epitope	O
mapping	O
study	O
indicated	O
that	O
a	O
cluster	O
of	O
overlapping	O
peptides	O
located	O
in	O
the	O
C	O
-	O
terminal	O
region	O
(	O
amino	O
acids	O
[	O
aa	O
]	O
331	O
to	O
362	O
)	O
of	O
N	B-PRGE
protein	I-PRGE
contained	O
at	O
least	O
two	O
different	O
T	O
-	O
cell	O
epitopes	O
.	O

TITLE	O
:	O
Analysis	O
of	O
ACE2	B-PRGE
in	O
polarized	O
epithelial	O
cells	O
:	O
surface	O
expression	O
and	O
function	O
as	O
receptor	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
.	O

A	O
similarity	O
search	O
using	O
SARS	B-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
protease	I-PRGE
subpockets	I-PRGE
as	O
queries	O
retrieved	O
ligands	O
and	O
ligand	O
fragments	O
accommodated	O
in	O
a	O
physicochemical	O
environment	O
similar	O
to	O
that	O
of	O
the	O
query	O
.	O

Our	O
results	O
show	O
that	O
all	O
of	O
the	O
elicited	O
anti	O
-	O
sera	O
can	O
specifically	O
recognize	O
HRN	O
or	O
HRC	B-PRGE
peptides	I-PRGE
and	O
the	O
native	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
in	O
an	O
ELISA	O
format	O
.	O

Cell	O
-	O
associated	O
CD14	B-PRGE
in	O
lung	O
tissue	O
increased	O
up	O
to	O
15	O
times	O
throughout	O
the	O
infection	O
,	O
due	O
to	O
an	O
increase	O
in	O
highly	O
CD14	B-PRGE
+	I-PRGE
monocyte	O
-	O
macrophages	O
from	O
1	O
to	O
12DPI	O
and	O
CD14	O
+	O
type	O
2	O
pneumocytes	O
from	O
7	O
to	O
9DPI	O
.	O

TITLE	O
:	O
Model	O
of	O
a	O
putative	O
pore	O
:	O
the	O
pentameric	O
alpha	O
-	O
helical	O
bundle	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
E	I-PRGE
protein	I-PRGE
in	O
lipid	O
bilayers	O
.	O

ABSTRACT	O
:	O
In	O
the	O
winter	O
-	O
spring	O
seasons	O
2003	O
-	O
2004	O
and	O
2004	O
-	O
2005	O
,	O
47	O
(	O
5	O
.	O
7	O
%)	O
patients	O
with	O
acute	O
respiratory	O
infection	O
associated	O
with	O
human	O
coronavirus	O
(	O
hCoV	O
)	O
229E	O
-,	O
NL63	O
-,	O
and	O
OC43	B-PRGE
-	I-PRGE
like	I-PRGE
strains	O
were	O
identified	O
among	O
823	O
(	O
597	O
immunocompetent	O
and	O
226	O
immunocompromised	O
)	O
patients	O
admitted	O
to	O
hospital	O
with	O
acute	O
respiratory	O
syndromes	O
.	O

NL63	B-PRGE
-	I-PRGE
like	I-PRGE
strains	O
were	O
not	O
found	O
to	O
circulate	O
in	O
2003	O
-	O
2004	O
,	O
and	O
229E	O
-	O
like	O
strains	O
did	O
not	O
circulate	O
in	O
2004	O
-	O
2005	O
,	O
while	O
OC43	B-PRGE
-	I-PRGE
like	I-PRGE
strains	O
were	O
detected	O
in	O
both	O
seasons	O
.	O

Group	O
A	O
,	O
B	O
,	O
C	O
mAbs	O
target	O
the	O
epitopes	O
that	O
may	O
overlap	O
with	O
the	O
previously	O
characterized	O
Conf	B-PRGE
I	I-PRGE
,	I-PRGE
III	I-PRGE
,	O
and	O
VI	O
respectively	O
,	O
but	O
they	O
display	O
different	O
capacity	O
to	O
block	O
the	O
receptor	O
binding	O
.	O

In	O
parallel	O
,	O
another	O
recombinant	O
pHS	O
was	O
generated	O
by	O
introducing	O
a	O
fragment	O
designated	O
S1	O
encoding	O
the	O
major	O
antigen	O
sites	O
of	O
S	B-PRGE
gene	I-PRGE
from	O
TGEV	O
strain	O
TH	O
-	O
98	O
into	O
a	O
prokaryotic	O
expression	O
vector	O
pP	O
(	O
RO	O
)	O
EX	O
HTc	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
mediates	O
the	O
receptor	O
interaction	O
and	O
immune	O
recognition	O
and	O
is	O
considered	O
a	O
major	O
target	O
for	O
vaccine	O
design	O
.	O

Opposite	O
to	O
what	O
was	O
described	O
for	O
mouse	O
hepatitis	O
virus	O
,	O
we	O
did	O
not	O
observe	O
the	O
late	O
relocalization	O
of	O
specific	O
replicase	B-PRGE
subunits	O
to	O
the	O
presumed	O
site	O
of	O
virus	O
assembly	O
,	O
which	O
was	O
labeled	O
using	O
an	O
antiserum	O
against	O
the	O
viral	O
membrane	O
protein	O
.	O

Total	O
lymphocytes	O
,	O
T	B-PRGE
lymphocyte	I-PRGE
,	I-PRGE
CD4	I-PRGE
+	I-PRGE
T	I-PRGE
and	O
naive	O
CD4	B-PRGE
+	O
T	O
cell	O
were	O
still	O
significantly	O
lower	O
than	O
the	O
normal	O
levels	O
even	O
one	O
year	O
after	O
disease	O
onset	O
.	O

Total	O
lymphocytes	O
,	O
T	B-PRGE
lymphocyte	I-PRGE
,	I-PRGE
CD4	I-PRGE
+	I-PRGE
T	I-PRGE
and	O
naive	O
CD4	B-PRGE
+	O
T	O
cell	O
were	O
still	O
significantly	O
lower	O
than	O
the	O
normal	O
levels	O
even	O
one	O
year	O
after	O
disease	O
onset	O
.	O

Confocal	O
microscopy	O
results	O
indicated	O
that	O
SARS	B-PRGE
8b	I-PRGE
is	O
localized	O
in	O
both	O
nucleus	O
and	O
cytoplasm	O
of	O
mammalian	O
cells	O
.	O

ABSTRACT	O
:	O
Serum	O
antibody	O
responses	O
and	O
haemolytic	O
complement	O
activity	O
were	O
evaluated	O
in	O
White	O
Leghorn	O
(	O
WLH	O
)	O
and	O
Rhode	B-PRGE
Island	I-PRGE
Red	I-PRGE
(	O
RIR	O
)	O
chickens	O
that	O
were	O
vaccinated	O
with	O
live	O
-	O
attenuated	O
vaccines	O
of	O
Newcastle	O
disease	O
virus	O
,	O
or	O
infectious	O
bronchitis	O
virus	O
,	O
or	O
infectious	O
bursal	O
disease	O
virus	O
by	O
means	O
of	O
ocular	O
challenge	O
at	O
10	O
times	O
the	O
normal	O
vaccination	O
dose	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
)	O
or	O
M	O
(	O
pro	B-PRGE
))	O
is	O
an	O
attractive	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
drugs	O
because	O
of	O
its	O
crucial	O
role	O
in	O
the	O
viral	O
life	O
cycle	O
.	O

Monocyte	O
-	O
derived	O
DCs	O
were	O
infected	O
with	O
SARS	O
-	O
CoV	O
and	O
analysed	O
for	O
viability	O
,	O
surface	O
-	O
marker	O
expression	O
and	O
alpha	B-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
induction	O
.	O

Immature	O
DCs	O
were	O
activated	O
by	O
SARS	O
-	O
CoV	O
infection	O
and	O
by	O
UV	O
-	O
inactivated	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Infected	O
DCs	O
were	O
still	O
viable	O
on	O
day	O
6	O
post	O
-	O
infection	O
,	O
but	O
major	O
histocompatibility	O
complex	O
class	O
I	O
upregulation	O
was	O
missing	O
,	O
indicating	O
that	O
DC	O
function	O
was	O
impaired	O
.	O

Additionally	O
,	O
SARS	O
-	O
CoV	O
infection	O
induced	O
a	O
delayed	O
activation	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
expression	O
.	O

Lastly	O
,	O
these	O
Oct	B-PRGE
-	I-PRGE
4	I-PRGE
+	I-PRGE
epithelial	O
colony	O
cells	O
,	O
which	O
also	O
express	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
,	O
are	O
the	O
target	O
cells	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
in	O
primary	O
cultures	O
and	O
support	O
active	O
virus	O
replication	O
leading	O
to	O
their	O
own	O
destruction	O
.	O

ABSTRACT	O
:	O
Our	O
previous	O
reports	O
,	O
both	O
experimental	O
and	O
human	O
studies	O
,	O
have	O
shown	O
the	O
importance	O
of	O
fibrinogen	B-PRGE
-	I-PRGE
like	I-PRGE
protein	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
fgl2	B-PRGE
)	O
prothrombinase	B-PRGE
in	O
the	O
development	O
of	O
fulminant	O
viral	O
hepatitis	O
,	O
a	O
disease	O
with	O
a	O
mortality	O
of	O
more	O
than	O
80	O
%	O
in	O
cases	O
lacking	O
immediate	O
organ	O
transplantation	O
.	O

All	O
the	O
409	O
serum	O
specimens	O
were	O
tested	O
for	O
specific	O
antibodies	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
by	O
different	O
methods	O
including	O
ELISA	O
for	O
specific	O
IgM	B-PRGE
and	O
IgG	B-PRGE
,	O
whole	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
,	O
IFA	O
for	O
specific	O
IgM	B-PRGE
and	O
IgG	B-PRGE
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
and	O
Western	O
-	O
blot	O
for	O
IgG	B-PRGE
to	O
expressed	O
N	B-PRGE
protein	I-PRGE
from	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
positive	O
rates	O
of	O
specific	O
IgG	B-PRGE
and	O
whole	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
ranged	O
from	O
39	O
.	O
1	O
%	O
to	O
43	O
.	O
5	O
%	O
in	O
the	O
children	O
who	O
had	O
been	O
clinically	O
diagnosed	O
as	O
SARS	O
,	O
zero	O
in	O
children	O
and	O
6	O
.	O
0	O
%	O
to	O
9	O
.	O
0	O
%	O
in	O
adults	O
who	O
had	O
closely	O
contacted	O
with	O
the	O
clinically	O
diagnosed	O
SARS	O
children	O
.	O

Flow	O
cytometric	O
analysis	O
showed	O
that	O
both	O
CD4	B-PRGE
(+)	O
and	O
CD8	B-PRGE
(+)	O
T	O
cells	O
were	O
involved	O
in	O
cellular	O
responses	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

These	O
cytokines	O
,	O
especially	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
IL	O
-	O
8	O
,	O
have	O
important	O
roles	O
in	O
the	O
lung	O
dysfunction	O
.	O

In	O
view	O
of	O
this	O
,	O
the	O
softwares	O
,	O
ZCURVE_CoV	O
1	O
.	O
0	O
and	O
ZCURVE_CoV	O
2	O
.	O
0	O
(	O
http	O
://	O
tubic	O
.	O
tju	O
.	O
edu	O
.	O
cn	O
/	O
sars	O
/),	O
developed	O
recently	O
for	O
SARS	O
-	O
Coronavirus	O
are	O
used	O
to	O
analyze	O
the	O
36	O
complete	O
SARS	O
-	O
Coronavirus	O
RNA	O
sequences	O
in	O
the	O
gene	O
bank	O
NCBI	O
(	O
http	O
://	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/)	O
from	O
different	O
sources	O
for	O
protein	O
coding	O
genes	O
,	O
and	O
to	O
search	O
for	O
the	O
cleavage	O
sites	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
in	O
polyproteins	O
pp1a	B-PRGE
and	O
pp1ab	O
.	O

Upon	O
expression	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
using	O
the	O
baculovirus	O
/	O
insect	O
cell	O
expression	O
system	O
,	O
however	O
,	O
we	O
found	O
that	O
the	O
expressed	O
M	B-PRGE
protein	I-PRGE
triggered	O
accelerated	O
apoptosis	O
in	O
insect	O
cells	O
,	O
as	O
characterized	O
by	O
rapid	O
cell	O
death	O
,	O
elevated	O
cytotoxicity	O
,	O
cell	O
shrinkage	O
,	O
nuclear	O
condensation	O
and	O
DNA	O
fragmentation	O
.	O

This	O
is	O
the	O
first	O
report	O
describing	O
the	O
induction	O
of	O
apoptosis	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
in	O
animal	O
cells	O
and	O
possible	O
implications	O
are	O
discussed	O
.	O

Factors	O
significantly	O
associated	O
with	O
initial	O
CRP	B-PRGE
concentration	O
>	O
47	O
.	O
5	O
mg	O
/	O
L	O
included	O
dyspnea	O
(	O
OR	O
=	O
4	O
.	O
3	O
),	O
red	O
blood	O
cell	O
count	O
<	O
4	O
.	O
1	O
x	O
106	O
/	O
microL	O
(	O
OR	O
=	O
4	O
.	O
3	O
)	O
and	O
serum	B-PRGE
aspartate	I-PRGE
aminotransferase	I-PRGE
>	O
57	O
IU	O
/	O
L	O
(	O
OR	O
=	O
3	O
.	O
1	O
).	O

In	O
this	O
brief	O
review	O
,	O
we	O
describe	O
the	O
current	O
understanding	O
of	O
how	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
able	O
to	O
use	O
the	O
cellular	O
machinery	O
for	O
its	O
replication	O
.	O

As	O
part	O
of	O
the	O
Sino	O
-	O
European	O
Project	O
on	O
SARS	O
Diagnostics	O
and	O
Antivirals	O
(	O
SEPSDA	O
),	O
an	O
immune	O
phage	O
-	O
display	O
library	O
is	O
being	O
created	O
from	O
convalescent	O
patients	O
in	O
a	O
phagemid	O
system	O
for	O
the	O
selection	O
of	O
single	O
-	O
chain	O
fragment	O
variables	O
(	O
scFv	O
)	O
antibodies	O
recognizing	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
reported	O
the	O
establishment	O
of	O
cells	O
with	O
persistent	O
SARS	O
-	O
CoV	O
infection	O
after	O
apoptotic	O
events	O
and	O
showed	O
that	O
both	O
JNK	B-PRGE
and	O
PI3K	B-PRGE
/	O
Akt	B-PRGE
signaling	O
pathways	O
are	O
important	O
for	O
persistence	O
by	O
treatment	O
with	O
inhibitors	O
at	O
the	O
early	O
stages	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

From	O
nsp4	B-PRGE
to	O
nsp6	O
,	O
the	O
genotype	O
A	O
strains	O
were	O
clustered	O
with	O
the	O
genotype	O
B	O
strains	O
.	O

ABSTRACT	O
:	O
All	O
coronaviruses	O
encode	O
a	O
small	B-PRGE
hydrophobic	I-PRGE
envelope	I-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
,	O
which	O
mediates	O
viral	O
assembly	O
and	O
morphogenesis	O
by	O
an	O
unknown	O
mechanism	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
E	B-PRGE
protein	I-PRGE
from	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
forms	O
cation	O
-	O
selective	O
ion	O
channels	O
in	O
planar	O
lipid	O
bilayers	O
(	O
Wilson	O
,	O
L	O
.,	O
McKinlay	O
,	O
C	O
.,	O
Gage	O
,	O
P	O
.,	O
Ewart	O
,	O
G	O
.,	O
2004	O
.	O

Hexamethylene	O
amiloride	O
(	O
HMA	O
)--	O
an	O
inhibitor	O
of	O
the	O
HIV	O
-	O
1	O
Vpu	O
virus	O
ion	O
channel	O
--	O
inhibited	O
the	O
HCoV	O
-	O
229E	O
and	O
MHV	B-PRGE
E	I-PRGE
protein	I-PRGE
ion	O
channel	O
conductance	O
in	O
bilayers	O
and	O
also	O
inhibited	O
replication	O
of	O
the	O
parent	O
coronaviruses	O
in	O
cultured	O
cells	O
,	O
as	O
determined	O
by	O
plaque	O
assay	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
host	O
response	O
to	O
a	O
single	O
JHMV	B-PRGE
-	I-PRGE
specific	I-PRGE
immunodominant	I-PRGE
CD4	I-PRGE
T	I-PRGE
-	I-PRGE
cell	I-PRGE
epitope	I-PRGE
is	O
critical	O
for	O
severe	O
disease	O
.	O

The	O
decrease	O
in	O
disease	O
severity	O
was	O
not	O
due	O
to	O
a	O
switch	O
from	O
Th1	O
to	O
Th2	O
predominance	O
in	O
rJ	O
.	O
M	O
(	O
Y135Q	O
)-	O
infected	O
mice	O
,	O
an	O
effect	O
on	O
CD8	B-PRGE
T	O
-	O
cell	O
function	O
,	O
or	O
differential	O
expression	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
by	O
JHMV	B-PRGE
-	I-PRGE
specific	I-PRGE
CD4	I-PRGE
T	I-PRGE
cells	O
.	O

SARS	O
-	O
CoV	O
,	O
reovirus	O
and	O
poliovirus	O
RNA	O
was	O
detected	O
by	O
using	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	B-PRGE
;	O
IgG	B-PRGE
antibody	I-PRGE
to	O
the	O
poliovirus	O
type	O
1	O
and	O
3	O
and	O
the	O
antibody	O
to	O
SARS	O
-	O
CoV	O
were	O
determined	O
using	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

No	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
reovirus	O
,	O
and	O
poliovirus	O
were	O
found	O
in	O
the	O
normal	O
controls	O
.	O

However	O
,	O
research	O
on	O
different	O
aspects	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
not	O
waning	O
,	O
as	O
it	O
is	O
not	O
known	O
if	O
this	O
virus	O
will	O
re	O
-	O
emerge	O
,	O
especially	O
since	O
its	O
origins	O
and	O
potential	O
reservoir	O
(	O
s	O
)	O
are	O
unresolved	O
.	O

These	O
in	O
-	O
depth	O
molecular	O
and	O
biochemical	O
characterizations	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
accessory	I-PRGE
proteins	I-PRGE
,	O
which	O
have	O
no	O
homologues	O
in	O
other	O
coronaviruses	O
,	O
may	O
offer	O
clues	O
as	O
to	O
why	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
causes	O
such	O
a	O
severe	O
and	O
rapid	O
attack	O
in	O
humans	O
,	O
while	O
other	O
coronaviruses	O
that	O
infect	O
humans	O
seem	O
to	O
be	O
more	O
forgiving	O
.	O

End	O
point	O
real	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
PCR	O
-	O
based	O
Restriction	O
Fragment	O
Length	O
Polymorphism	O
(	O
RFLP	O
)	O
analysis	O
were	O
used	O
to	O
detect	O
the	O
single	O
nucleic	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
OAS1	B-PRGE
and	O
MxA	B-PRGE
genes	I-PRGE
.	O

The	O
associations	O
of	O
AG	O
genotype	O
in	O
OAS1	B-PRGE
and	O
GT	O
genotype	O
in	O
MxA	O
remained	O
significant	O
in	O
multivariate	O
analyses	O
after	O
adjusting	O
for	O
SARS	O
protective	O
measures	O
(	O
OR	O
=	O
0	O
.	O
38	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
14	O
-	O
0	O
.	O
98	O
and	O
OR	O
=	O
3	O
.	O
22	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
13	O
-	O
9	O
.	O
18	O
,	O
respectively	O
).	O

The	O
associations	O
of	O
AG	O
genotype	O
in	O
OAS1	B-PRGE
and	O
GT	O
genotype	O
in	O
MxA	O
remained	O
significant	O
in	O
multivariate	O
analyses	O
after	O
adjusting	O
for	O
SARS	O
protective	O
measures	O
(	O
OR	O
=	O
0	O
.	O
38	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
14	O
-	O
0	O
.	O
98	O
and	O
OR	O
=	O
3	O
.	O
22	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
13	O
-	O
9	O
.	O
18	O
,	O
respectively	O
).	O

TITLE	O
:	O
Identification	O
and	O
structure	O
-	O
based	O
optimization	O
of	O
novel	O
dihydropyrones	O
as	O
potent	O
HCV	B-PRGE
RNA	I-PRGE
polymerase	I-PRGE
inhibitors	O
.	O

Analysis	O
of	O
the	O
immune	O
responses	O
by	O
flow	O
cytometry	O
showed	O
that	O
both	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
T	I-PRGE
cells	O
were	O
involved	O
in	O
the	O
SARS	O
-	O
CoV	O
E	O
-	O
specific	O
immune	O
responses	O
after	O
stimulation	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
peptides	I-PRGE
.	O

Moreover	O
,	O
the	O
majority	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
+	I-PRGE
CD4	I-PRGE
+	I-PRGE
T	I-PRGE
cells	O
were	O
central	O
memory	O
cells	O
expressing	O
CD45RO	B-PRGE
+	I-PRGE
CCR7	I-PRGE
+	I-PRGE
CD62L	I-PRGE
-;	O
whereas	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
+	I-PRGE
CD8	I-PRGE
+	I-PRGE
memory	O
T	O
cells	O
were	O
mostly	O
effector	O
memory	O
cells	O
expressing	O
CD45RO	O
-	O
CCR7	B-PRGE
-	O
CD62L	B-PRGE
-.	O

Reductions	O
in	O
phosphatidylglycerol	O
strongly	O
correlated	O
with	O
decreased	O
Pao2	B-PRGE
/	O
Fio2	O
values	O
(	O
r	O
=	O
.	O
72	O
).	O

Gamma	B-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
is	O
an	O
important	O
cytokine	O
produced	O
during	O
the	O
early	O
stages	O
of	O
an	O
infection	O
by	O
macrophages	O
,	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
,	O
and	O
other	O
cell	O
types	O
,	O
and	O
it	O
is	O
also	O
a	O
central	O
cytokine	O
mediator	O
for	O
the	O
induction	O
of	O
cellular	O
or	O
Th1	O
immunity	O
.	O

Two	O
other	O
respiratory	O
viruses	O
of	O
pigs	O
,	O
Porcine	O
respiratory	O
coronavirus	O
and	O
Swine	O
influenza	O
virus	O
,	O
do	O
not	O
appear	O
to	O
induce	O
serum	B-PRGE
IFN	I-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

In	O
contrast	O
to	O
IFNs	O
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
did	O
not	O
show	O
antiviral	O
activity	O
when	O
administered	O
immediately	O
after	O
SARS	O
-	O
CoV	O
infection	O
,	O
suggesting	O
that	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
acts	O
early	O
during	O
the	O
SARS	O
-	O
CoV	O
replication	O
cycle	O
.	O

By	O
in	O
situ	O
hybridization	O
,	O
the	O
IBV	B-PRGE
Nc	I-PRGE
gene	I-PRGE
was	O
more	O
consistently	O
detected	O
in	O
the	O
trachea	O
at	O
early	O
stages	O
of	O
infection	O
(	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
)	O
and	O
in	O
the	O
cecal	O
tonsils	O
at	O
late	O
stages	O
of	O
infection	O
(	O
21	O
,	O
28	O
,	O
and	O
35	O
days	O
).	O

Plasma	O
BNP	B-PRGE
and	O
ANP	B-PRGE
levels	O
were	O
measured	O
by	O
radioimmunoassay	O
.	O

Plasma	O
levels	O
of	O
BNP	B-PRGE
and	O
ANP	B-PRGE
were	O
markedly	O
elevated	O
in	O
patients	O
with	O
septic	O
shock	O
/	O
severe	O
sepsis	O
compared	O
with	O
controls	O
(	O
BNP	O
,	O
7	O
+/-	O
0	O
.	O
3	O
pg	O
mL	O
;	O
ANP	O
,	O
13	O
+/-	O

Bovine	B-PRGE
coronavirus	I-PRGE
antigen	I-PRGE
and	I-PRGE
antibodies	I-PRGE
were	O
detected	O
by	O
use	O
of	O
an	O
ELISA	O
.	O

This	O
information	O
may	O
be	O
applied	O
toward	O
the	O
design	O
of	O
other	O
3CL	B-PRGE
protease	I-PRGE
inhibitors	O
.	O

Bronchiolitis	O
was	O
frequently	O
diagnosed	O
in	O
patients	O
who	O
tested	O
positive	O
for	O
RSV	B-PRGE
,	O
PIV	O
-	O
3	O
,	O
or	O
rhinovirus	O
,	O
whereas	O
influenza	O
A	O
,	O
PIV	O
-	O
1	O
,	O
and	O
HCoV	O
-	O
NL63	O
were	O
commonly	O
found	O
in	O
patients	O
with	O
croup	O
.	O

Thus	O
,	O
P15	B-PRGE
may	O
be	O
a	O
novel	O
SARS	O
-	O
associated	O
coronavirus	O
-	O
specific	O
CTL	O
epitope	O
and	O
a	O
potential	O
target	O
for	O
characterization	O
of	O
virus	O
control	O
mechanisms	O
and	O
evaluation	O
of	O
candidate	O
SARS	O
vaccines	O
.	O

TITLE	O
:	O
Human	O
neutralizing	O
Fab	B-PRGE
molecules	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
generated	O
by	O
phage	O
display	O
.	O

In	O
this	O
study	O
we	O
confirmed	O
the	O
3a	B-PRGE
protein	I-PRGE
expression	O
and	O
investigated	O
its	O
localization	O
at	O
the	O
surface	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
or	O
3a	O
-	O
cDNA	O
-	O
transfected	O
cells	O
.	O

Here	O
we	O
characterized	O
the	O
activation	O
of	O
an	O
immediate	B-PRGE
-	I-PRGE
early	I-PRGE
transcription	I-PRGE
factor	I-PRGE
Egr	I-PRGE
-	I-PRGE
1	I-PRGE
by	O
MHV	O
infection	O
in	O
an	O
astrocytoma	O
cell	O
line	O
.	O

These	O
results	O
indicate	O
a	O
correlation	O
between	O
the	O
ability	O
of	O
MHVs	O
to	O
induce	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
and	O
their	O
ability	O
to	O
cause	O
demyelination	O
in	O
the	O
CNS	O
,	O
which	O
may	O
suggest	O
a	O
potential	O
role	O
for	O
the	O
induction	O
of	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
viral	O
pathogenesis	O
.	O

TITLE	O
:	O
Cytokine	O
storm	O
in	O
a	O
phase	O
1	O
trial	O
of	O
the	O
anti	B-PRGE
-	I-PRGE
CD28	I-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
TGN1412	I-PRGE
.	O

SCoV	O
replication	O
also	O
promoted	O
degradation	O
of	O
expressed	O
RNA	O
transcripts	O
and	O
host	O
mRNAs	O
,	O
suggesting	O
that	O
nsp1	B-PRGE
exerted	O
its	O
mRNA	O
destabilization	O
function	O
in	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
-	O
mediated	O
cell	O
fusion	O
is	O
important	O
for	O
the	O
viral	O
entry	O
mechanism	O
and	O
identification	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
entry	O
inhibitors	O
.	O

Our	O
data	O
showed	O
that	O
H5N1	O
viral	O
infection	O
in	O
mice	O
resulted	O
in	O
typical	O
ARDS	O
,	O
which	O
was	O
characterized	O
by	O
the	O
following	O
features	O
:	O
(	O
1	O
)	O
about	O
80	O
%	O
of	O
mice	O
(	O
13	O
of	O
16	O
)	O
dead	O
on	O
Days	O
6	O
to	O
8	O
postinoculation	O
;	O
(	O
2	O
)	O
highly	O
edematous	O
lungs	O
and	O
dramatically	O
increased	O
lung	O
wet	O
:	O
dry	O
weight	O
ratios	O
and	O
lung	O
wet	O
weight	O
:	O
body	O
weight	O
ratios	O
;	O
(	O
3	O
)	O
inflammatory	O
cellular	O
infiltration	O
,	O
alveolar	O
and	O
interstitial	O
edema	O
,	O
and	O
hemorrhage	O
in	O
lungs	O
;	O
(	O
4	O
)	O
progressive	O
and	O
severe	O
hypoxemia	O
;	O
and	O
(	O
5	O
)	O
significant	O
increase	O
in	O
neutrophils	O
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
and	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
BALF	O
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
a	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
in	O
mice	O
:	O
implications	O
for	O
a	O
subunit	O
vaccine	O
.	O

ABSTRACT	O
:	O
Consensus	O
covariation	O
-	O
based	O
secondary	O
structural	O
models	O
for	O
the	O
5	O
'	O
140	O
nucleotides	O
of	O
the	O
5	O
'	O
untranslated	O
regions	O
(	O
5	O
'	O
UTRs	O
)	O
from	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SCoV	O
)	O
were	O
developed	O
and	O
predicted	O
three	O
major	O
helical	O
stem	O
-	O
loop	O
structures	O
,	O
designated	O
stem	O
-	O
loop	O
1	O
(	O
SL1	B-PRGE
),	O
SL2	B-PRGE
,	O
and	O
SL4	O
.	O

cDNAs	O
corresponding	O
to	O
MHV	O
/	O
SCoV	O
chimeric	O
genomes	O
were	O
constructed	O
by	O
replacing	O
the	O
complete	O
MHV	B-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
with	O
the	O
corresponding	O
SCoV	O
sequence	O
and	O
by	O
separately	O
replacing	O
MHV	B-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
putative	O
SL1	B-PRGE
,	O
putative	O
SL2	B-PRGE
,	O
TRS	O
,	O
and	O
putative	O
SL4	O
with	O
the	O
corresponding	O
SCoV	O
sequences	O
.	O

Chimeras	O
containing	O
the	O
complete	O
SCoV	B-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
or	O
the	O
predicted	O
SCoV	O
SL3	O
were	O
not	O
viable	O
.	O

The	O
polyuria	O
might	O
also	O
be	O
attributed	O
to	O
reduced	O
aquaporin	B-PRGE
2	I-PRGE
expression	O
and	O
the	O
attendant	O
urinary	O
concentrating	O
defect	O
.	O

The	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
detected	O
down	O
to	O
10	O
cRNA	O
copies	O
from	O
TGEV	O
,	O
BCoV	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
IBV	O
.	O

Alternatively	O
,	O
APN	B-PRGE
should	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
systemic	O
diseases	O
that	O
cause	O
gallbladder	O
wall	O
thickening	O
to	O
avoid	O
misdiagnosing	O
it	O
as	O
acute	O
cholecystitis	O
.	O

TITLE	O
:	O
Accumulation	O
of	O
recombinant	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
in	O
plant	O
cytosol	O
and	O
chloroplasts	O
indicate	O
potential	O
for	O
development	O
of	O
plant	O
-	O
derived	O
oral	O
vaccines	O
.	O

Recombinant	O
M13	O
phages	O
displaying	O
the	O
peptides	O
SHRLP	O
(	O
Y	O
/	O
Q	O
)(	O
P	O
/	O
V	O
)	O
or	O
GPRPVTH	O
on	O
the	O
g3p	B-PRGE
minor	I-PRGE
coat	I-PRGE
protein	I-PRGE
showed	O
strong	O
binding	O
affinity	O
with	O
2C10	O
(	O
70	O
%	O
and	O
30	O
%	O
of	O
recovered	O
phages	O
,	O
respectively	O
)	O
after	O
multiple	O
panning	O
.	O

The	O
observations	O
suggest	O
that	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
,	O
including	O
the	O
receptor	O
-	O
binding	O
domain	O
,	O
and	O
a	O
region	O
in	O
the	O
central	O
part	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
containing	O
HR1	O
and	O
FP	O
,	O
i	O
.	O
e	O
.,	O
regions	O
far	O
apart	O
in	O
the	O
linear	O
sequence	O
,	O
communicate	O
and	O
may	O
even	O
interact	O
physically	O
in	O
the	O
higher	O
-	O
order	O
structure	O
of	O
the	O
spike	O
.	O

Both	O
ARDS	O
and	O
death	O
were	O
prevented	O
by	O
administration	O
of	O
a	O
plasminogen	B-PRGE
activator	I-PRGE
,	O
and	O
ARDS	O
in	O
human	O
septic	O
or	O
traumatic	O
shock	O
were	O
safely	O
and	O
effectively	O
treated	O
by	O
administration	O
of	O
a	O
plasminogen	B-PRGE
activator	I-PRGE
.	O

The	O
3bDelta124	O
-	O
154	O
mutant	O
behaves	O
in	O
a	O
similar	O
manner	O
indicating	O
that	O
the	O
localization	O
of	O
the	O
3b	B-PRGE
protein	I-PRGE
does	O
not	O
seems	O
to	O
be	O
important	O
for	O
the	O
cell	O
-	O
death	O
pathways	O
since	O
full	O
-	O
length	O
3b	O
is	O
localized	O
predominantly	O
to	O
the	O
nucleolus	O
,	O
while	O
the	O
mutant	O
is	O
found	O
to	O
be	O
concentrated	O
in	O
the	O
peri	O
-	O
nuclear	O
regions	O
.	O

In	O
response	O
to	O
the	O
WHO	O
request	O
we	O
conducted	O
a	O
systematic	O
review	O
of	O
the	O
published	O
literature	O
on	O
ribavirin	O
,	O
corticosteroids	O
,	O
lopinavir	O
and	O
ritonavir	O
(	O
LPV	O
/	O
r	O
),	O
type	O
I	O
interferon	B-PRGE
(	O
IFN	B-PRGE
),	O
intravenous	B-PRGE
immunoglobulin	I-PRGE
(	O
IVIG	O
),	O
and	O
SARS	O
convalescent	O
plasma	O
from	O
both	O
in	O
vitro	O
studies	O
and	O
in	O
SARS	O
patients	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
positive	O
-	O
strand	O
RNA	O
viruses	O
that	O
translate	O
their	O
genome	O
RNA	O
into	O
polyproteins	O
that	O
are	O
co	O
-	O
and	O
posttranslationally	O
processed	O
into	O
intermediate	O
and	O
mature	O
replicase	B-PRGE
nonstructural	O
proteins	O
(	O
nsps	O
).	O

In	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
nsps	O
1	O
,	O
2	O
,	O
and	O
3	O
are	O
processed	O
by	O
two	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
activities	O
within	O
nsp3	B-PRGE
(	O
PLP1	B-PRGE
and	O
PLP2	B-PRGE
)	O
to	O
yield	O
nsp1	B-PRGE
,	O
an	O
nsp2	B-PRGE
-	I-PRGE
3	I-PRGE
intermediate	O
,	O
and	O
mature	O
nsp2	B-PRGE
and	O
nsp3	B-PRGE
.	O

To	O
determine	O
the	O
role	O
in	O
replication	O
of	O
processing	O
between	O
nsp2	B-PRGE
and	O
nsp3	B-PRGE
at	O
cleavage	O
site	O
2	O
(	O
CS2	O
)	O
and	O
PLP1	B-PRGE
proteinase	I-PRGE
activity	O
,	O
mutations	O
were	O
engineered	O
into	O
the	O
MHV	O
genome	O
at	O
CS2	O
,	O
at	O
CS1	B-PRGE
and	O
CS2	B-PRGE
,	O
and	O
at	O
the	O
PLP1	B-PRGE
catalytic	I-PRGE
site	I-PRGE
,	O
alone	O
and	O
in	O
combination	O
.	O

These	O
results	O
demonstrate	O
that	O
interactions	O
of	O
PLP1	B-PRGE
with	O
CS1	B-PRGE
and	O
CS2	B-PRGE
are	O
critical	O
for	O
protein	O
processing	O
and	O
suggest	O
that	O
the	O
interactions	O
play	O
specific	O
roles	O
in	O
regulation	O
of	O
the	O
functions	O
of	O
nsp1	B-PRGE
,	O
2	O
,	O
and	O
3	O
in	O
viral	O
RNA	O
synthesis	O
.	O

They	O
confirm	O
its	O
infectivity	O
for	O
calves	O
and	O
complete	O
cross	O
-	O
protection	O
against	O
a	O
bovine	O
coronavirus	O
(	O
DB2	O
strain	O
)	O
showing	O
98	O
.	O
2	O
%	O
amino	O
acid	O
identity	O
to	O
HECV	O
-	O
4408	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
adopts	O
a	O
fold	O
resembling	O
a	O
right	O
hand	O
with	O
a	O
flexible	O
,	O
positively	O
charged	O
beta	B-PRGE
-	I-PRGE
hairpin	I-PRGE
and	O
a	O
hydrophobic	O
palm	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
B	O
-	O
cell	O
antigenic	O
epitope	O
at	O
the	O
N	O
-	O
terminus	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
and	O
characterization	O
of	O
monoclonal	O
antibody	O
against	O
the	O
protein	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
potential	O
B	O
-	O
cell	O
antigenic	O
epitopes	O
within	O
the	O
N	O
-	O
terminus	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
SARS	B-PRGE
-	O
associated	O
coronavirus	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
M	B-PRGE
protein	I-PRGE
and	O
characterize	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
against	O
the	O
protein	O
as	O
well	O
as	O
its	O
recognizing	O
region	O
,	O
we	O
expressed	O
and	O
purified	O
a	O
portion	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
(	O
amino	B-PRGE
acid	I-PRGE
1	I-PRGE
-	I-PRGE
43	I-PRGE
)	O
in	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
).	O

In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
purified	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	B-PRGE
N	I-PRGE
protein	I-PRGE
also	O
has	O
RNA	O
chaperone	O
activity	O
.	O

During	O
construction	O
of	O
an	O
infectious	O
clone	O
from	O
a	O
Vero	O
cell	O
-	O
adapted	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
we	O
found	O
that	O
a	O
G	O
-	O
C	O
point	O
mutation	O
at	O
nucleotide	O
position	O
15526	O
,	O
causing	O
Arg	O
-	O
to	O
-	O
Pro	O
mutation	O
at	O
amino	O
acid	O
position	O
132	O
of	O
the	O
helicase	B-PRGE
protein	I-PRGE
,	O
is	O
lethal	O
to	O
the	O
infectivity	O
of	O
IBV	O
on	O
Vero	O
cells	O
.	O

This	O
is	O
true	O
not	O
only	O
for	O
SARS	B-PRGE
but	O
also	O
during	O
other	O
public	O
health	O
crises	O
where	O
widespread	O
transmission	O
of	O
infection	O
such	O
as	O
the	O
danger	O
of	O
avian	O
flu	O
pandemic	O
is	O
a	O
concern	O
,	O
in	O
particular	O
at	O
places	O
like	O
hospitals	O
and	O
cross	O
-	O
border	O
checkpoints	O
.	O

We	O
also	O
found	O
that	O
the	O
GxxxG	O
motif	O
contributes	O
toward	O
the	O
trimerization	O
of	O
the	O
entire	O
spike	O
protein	O
;	O
in	O
that	O
,	O
mutations	O
in	O
the	O
GxxxG	O
motif	O
decrease	O
trimerization	O
of	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
protein	I-PRGE
expressed	O
in	O
mammalian	O
cells	O
.	O

In	O
our	O
study	O
,	O
genetically	O
determined	O
low	O
production	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
was	O
associated	O
with	O
some	O
parameters	O
indicating	O
a	O
more	O
severe	O
clinical	O
course	O
of	O
Puumala	O
Hantavirus	O
infection	O
in	O
humans	O
,	O
possibly	O
by	O
impaired	O
activation	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
dependent	O
antiviral	O
mechanisms	O
,	O
which	O
could	O
in	O
turn	O
result	O
in	O
decreased	O
clearance	O
of	O
Hantavirus	O
.	O

TITLE	O
:	O
Hyper	O
-	O
activated	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
STAT1	B-PRGE
contribute	O
to	O
enhanced	O
interferon	B-PRGE
stimulated	I-PRGE
gene	I-PRGE
(	O
ISG	O
)	O
expression	O
by	O
interferon	B-PRGE
alpha	I-PRGE
and	O
gamma	O
co	O
-	O
treatment	O
in	O
human	O
hepatoma	O
cells	O
.	O

Furthermore	O
,	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
activation	O
was	O
found	O
to	O
be	O
generally	O
required	O
in	O
this	O
cluster	O
of	O
ISGs	O
.	O

STAT1	B-PRGE
tyrosine	O
phosphorylation	O
was	O
elevated	O
by	O
IFN	B-PRGE
combination	O
treatment	O
,	O
however	O
,	O
only	O
the	O
hyper	O
-	O
transactivation	O
of	O
GAS	B-PRGE
but	O
not	O
ISRE	O
was	O
observed	O
.	O

In	O
conclusion	O
,	O
hyper	O
-	O
activation	O
of	O
IRF	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
elevated	O
STAT1	B-PRGE
dimer	O
formation	O
may	O
be	O
two	O
general	O
switches	O
which	O
contribute	O
to	O
a	O
much	O
more	O
robust	O
antiviral	O
symphony	O
against	O
virus	O
replication	O
when	O
type	O
I	O
and	O
type	O
II	O
IFNs	O
are	O
co	O
-	O
administered	O
.	O

Accumulating	O
evidence	O
in	O
recent	O
years	O
has	O
demonstrated	O
a	O
physiological	O
and	O
pathological	O
role	O
of	O
ACE2	B-PRGE
in	O
the	O
cardiovascular	O
systems	O
.	O

TITLE	O
:	O
Quantitative	O
comparison	O
of	O
the	O
efficiency	O
of	O
antibodies	O
against	O
S1	O
and	O
S2	O
subunit	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
in	O
virus	O
neutralization	O
and	O
blocking	O
of	O
receptor	O
binding	O
:	O
implications	O
for	O
the	O
functional	O
roles	O
of	O
S2	B-PRGE
subunit	I-PRGE
.	O

More	O
than	O
250	O
field	O
samples	O
were	O
tested	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
using	O
two	O
sets	O
of	O
primers	O
corresponding	O
to	O
the	O
most	O
conserved	O
3	O
'-	O
untranslated	O
region	O
and	O
the	O
most	O
variable	O
S1	B-PRGE
gene	I-PRGE
region	O
of	O
the	O
viral	O
genome	O
.	O

ABSTRACT	O
:	O
The	O
entire	O
S1	B-PRGE
protein	I-PRGE
genes	O
of	O
eight	O
infectious	O
bronchitis	O
(	O
IB	O
)	O
vaccine	O
strains	O
used	O
in	O
China	O
were	O
compared	O
with	O
those	O
of	O
the	O
IB	O
virus	O
isolates	O
present	O
in	O
the	O
field	O
in	O
China	O
.	O

Our	O
results	O
showed	O
that	O
S	O
(	O
d	O
)	O
that	O
encoded	O
a	O
truncated	B-PRGE
S	I-PRGE
protein	I-PRGE
with	O
422	O
amino	O
acid	O
residues	O
(	O
from	O
1	O
to	O
422	O
aa	O
),	O
a	O
part	O
of	O
672	O
amino	O
-	O
acid	O
S1	O
subunit	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

We	O
also	O
compared	O
S	O
protein	O
sequences	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
isolated	O
during	O
the	O
SARS	O
break	O
with	O
that	O
from	O
palm	O
civets	O
,	O
a	O
possible	O
source	O
of	O
SARS	O
-	O
CoV	O
found	O
in	O
humans	O
.	O

The	O
terminal	B-PRGE
deoxynucleotidyl	I-PRGE
transferase	I-PRGE
-	O
mediated	O
dUPT	O
nick	O
end	O
-	O
labeling	O
assay	O
demonstrated	O
many	O
cells	O
undergoing	O
apoptosis	O
.	O

This	O
is	O
the	O
first	O
report	O
demonstrating	O
the	O
interaction	O
of	O
hUbc9	B-PRGE
with	O
a	O
structural	O
protein	O
of	O
plus	O
-	O
strand	O
RNA	O
viruses	O
,	O
indicating	O
a	O
new	O
drug	O
target	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O

Heat	O
,	O
ultraviolet	O
(	O
UV	O
)	O
irradiation	O
,	O
octanoic	O
acid	O
,	O
and	O
solvent	O
/	O
detergent	O
(	O
S	O
/	O
D	O
)	O
methods	O
were	O
tested	O
individually	O
for	O
their	O
ability	O
to	O
inactivate	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
protein	O
solutions	O
appropriately	O
mimicking	O
blood	O
-	O
derived	O
products	O
.	O

The	O
variation	O
of	O
positive	O
selective	O
pressures	O
and	O
positively	O
selected	O
sites	O
are	O
likely	O
to	O
contribute	O
to	O
the	O
adaptive	O
evolution	O
of	O
S	B-PRGE
protein	I-PRGE
from	O
animals	O
to	O
humans	O
.	O

RESULTS	O
:	O
By	O
investigating	O
the	O
adaptive	O
evolution	O
of	O
S	B-PRGE
protein	I-PRGE
,	O
we	O
identified	O
twelve	O
amino	O
acid	O
sites	O
(	O
75	O
,	O
239	O
,	O
244	O
,	O
311	O
,	O
479	O
,	O
609	O
,	O
613	O
,	O
743	O
,	O
765	O
,	O
778	O
,	O
1148	O
,	O
and	O
1163	O
)	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
under	O
positive	O
selective	O
pressure	O
.	O

The	O
use	O
of	O
PPE	B-PRGE
is	O
associated	O
with	O
high	O
rates	O
of	O
adverse	O
skin	O
reactions	O
.	O

In	O
this	O
study	O
,	O
complete	O
genome	O
sequences	O
of	O
two	O
additional	O
group	O
2b	O
coronaviruses	O
(	O
G2b	O
-	O
CoVs	O
)	O
were	O
determined	O
from	O
horseshoe	B-PRGE
bat	I-PRGE
Rhinolophus	I-PRGE
ferrumequinum	I-PRGE
(	O
G2b	B-PRGE
-	I-PRGE
CoV	I-PRGE
Rf1	I-PRGE
)	O
and	O
Rhinolophus	O
macrotis	O
(	O
G2b	B-PRGE
-	I-PRGE
CoV	I-PRGE
Rm1	I-PRGE
).	O

Sequence	O
analysis	O
of	O
the	O
60	B-PRGE
-	I-PRGE
kDa	I-PRGE
glycoprotein	I-PRGE
gene	I-PRGE
identified	O
16	O
IIa	O
subtypes	O
and	O
a	O
new	O
subtype	O
family	O
,	O
with	O
120	O
of	O
the	O
216	O
(	O
55	O
.	O
6	O
%)	O
positive	O
specimens	O
having	O
the	O
subtype	O
IIaA18G3R1	O
.	O

In	O
the	O
present	O
study	O
,	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
in	O
situ	O
hybridization	O
(	O
ISH	O
)	O
assays	O
were	O
used	O
to	O
analyse	O
the	O
expression	O
of	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
,	O
and	O
some	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
PICs	O
)	O
including	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
autopsy	O
tissues	O
from	O
four	O
patients	O
who	O
died	O
of	O
SARS	O
.	O

TITLE	O
:	O
Effects	O
of	O
mutagenesis	O
of	O
murine	B-PRGE
hepatitis	I-PRGE
virus	I-PRGE
nsp1	I-PRGE
and	O
nsp14	O
on	O
replication	O
in	O
culture	O
.	O

The	O
nsp2	B-PRGE
protein	I-PRGE
domain	I-PRGE
resides	O
in	O
a	O
region	O
of	O
the	O
coronavirus	O
replicase	B-PRGE
that	O
is	O
relatively	O
nonconserved	O
across	O
coronaviruses	O
.	O

While	O
this	O
may	O
be	O
the	O
case	O
,	O
it	O
should	O
be	O
noted	O
that	O
nsp2	B-PRGE
,	O
in	O
some	O
form	O
,	O
exists	O
in	O
all	O
coronaviruses	O
studied	O
to	O
date	O
and	O
likely	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
viral	O
life	O
cycle	O
.	O

A	O
previous	O
study	O
from	O
our	O
laboratory	O
identified	O
a	O
coronavirus	O
replicase	B-PRGE
protein	O
that	O
plays	O
an	O
important	O
role	O
in	O
viral	O
pathogenesis	O
.	O

Alternatively	O
,	O
beacuse	O
nsp2	B-PRGE
exists	O
as	O
a	O
detectable	O
precursor	O
protein	O
nsp2	B-PRGE
-	I-PRGE
3	I-PRGE
prior	O
to	O
processing	O
of	O
nsp2	B-PRGE
and	O
nsp3	B-PRGE
into	O
mature	O
proteins	O
,	O
nsp2	B-PRGE
may	O
play	O
a	O
critical	O
adaptor	O
/	O
regulatory	O
role	O
for	O
nsp3	B-PRGE
function	O
.	O

As	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
thought	O
to	O
infect	O
the	O
alveolar	O
epithelial	O
cell	O
of	O
the	O
lung	O
,	O
in	O
the	O
present	O
study	O
,	O
a	O
type	O
II	O
alveolar	O
epithelial	O
cell	O
clone	O
,	O
T7	O
,	O
was	O
used	O
to	O
analyze	O
the	O
mechanism	O
of	O
CTL	O
against	O
SARS	B-PRGE
CoV	I-PRGE
membrane	I-PRGE
antigens	I-PRGE
.	O

Scientists	O
examining	O
coronavirus	O
isolates	O
from	O
a	O
variety	O
of	O
animals	O
in	O
and	O
around	O
Guangdong	O
Province	O
reported	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
has	O
similarities	O
with	O
many	O
different	O
coronaviruses	O
including	O
avian	O
coronaviruses	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
like	I-PRGE
viruses	I-PRGE
from	O
a	O
variety	O
of	O
mammals	O
found	O
in	O
live	O
-	O
animal	O
markets	O
.	O

Based	O
on	O
phylogenetic	O
analysis	O
designed	O
to	O
elucidate	O
evolutionary	O
links	O
among	O
viruses	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
believed	O
to	O
have	O
branched	O
from	O
the	O
modern	O
Group	O
2	O
coronaviruses	O
,	O
suggesting	O
that	O
it	O
evolved	O
relatively	O
rapidly	O
.	O

We	O
then	O
generated	O
nine	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
against	O
the	O
S	B-PRGE
protein	I-PRGE
to	O
map	O
the	O
DC	O
-	O
SIGN	O
-	O
binding	O
domain	O
using	O
capture	O
assays	O
with	O
pseudotyped	O
viruses	O
and	O
observed	O
that	O
MAb	O
SIa5	O
significantly	O
blocked	O
S	B-PRGE
protein	I-PRGE
-	O
DC	O
-	O
SIGN	O
interaction	O
.	O

Furthermore	O
,	O
FGL2	B-PRGE
/	O
fibroleukin	B-PRGE
mRNA	O
transcripts	O
and	O
protein	O
and	O
fibrin	O
deposits	O
were	O
markedly	O
increased	O
in	O
the	O
lungs	O
of	O
infected	O
A	O
/	O
J	O
mice	O
.	O

ABSTRACT	O
:	O
Feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
cats	O
show	O
a	O
decrease	O
in	O
peripheral	O
blood	O
lymphocyte	O
counts	O
,	O
and	O
a	O
particularly	O
marked	O
decrease	O
in	O
T	O
cells	O
including	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
lymphopenia	O
observed	O
in	O
FIP	O
cats	O
was	O
due	O
to	O
apoptosis	O
,	O
and	O
that	O
the	O
ascitic	O
fluid	O
,	O
plasma	O
,	O
and	O
culture	O
supernatant	O
of	O
peritoneal	O
exudate	O
cells	O
(	O
adherent	O
cells	O
with	O
macrophage	O
morphology	O
,	O
or	O
PEC	O
)	O
from	O
FIP	O
cats	O
readily	O
induced	O
apoptosis	O
in	O
specific	O
pathogen	O
-	O
free	O
cat	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
particularly	O
CD8	B-PRGE
+	I-PRGE
cells	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
produced	O
by	O
virus	O
-	O
infected	O
macrophages	O
,	O
is	O
responsible	O
for	O
induction	O
of	O
apoptosis	O
in	O
uninfected	O
T	O
cells	O
,	O
primarily	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CL	O
(	O
pro	O
))	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
one	O
of	O
the	O
most	O
promising	O
targets	O
for	O
discovery	O
of	O
drugs	O
against	O
SARS	O
,	O
because	O
of	O
its	O
critical	O
role	O
in	O
the	O
viral	O
life	O
cycle	O
.	O

In	O
this	O
study	O
,	O
a	O
natural	O
compound	O
called	O
quercetin	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
beta	I-PRGE
-	I-PRGE
galactoside	I-PRGE
was	O
identified	O
as	O
an	O
inhibitor	O
of	O
the	O
protease	O
by	O
molecular	O
docking	O
,	O
SPR	B-PRGE
/	O
FRET	O
-	O
based	O
bioassays	O
,	O
and	O
mutagenesis	O
studies	O
.	O

In	O
the	O
multivariate	O
analysis	O
,	O
only	O
three	O
factors	O
were	O
significant	O
:	O
delay	O
to	O
isolation	O
,	O
admission	O
to	O
a	O
non	O
-	O
isolation	O
facility	O
and	O
higher	O
lactate	B-PRGE
dehydrogenase	I-PRGE
levels	O
of	O
>	O
650	O
IU	O
/	O
L	O
(	O
OR	O
6	O
.	O
4	O
,	O
23	O
.	O
8	O
and	O
4	O
.	O
7	O
respectively	O
).	O

TITLE	O
:	O
Studies	O
on	O
the	O
interactions	O
of	O
Ti	O
-	O
containing	O
polyoxometalates	O
(	O
POMs	O
)	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
by	O
molecular	O
modeling	O
.	O

Among	O
the	O
chemokines	O
/	O
cytokines	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
levels	O
correlated	O
most	O
strongly	O
with	O
radiographic	O
scores	O
(	O
r	O
=	O
0	O
.	O
62	O
).	O

The	O
interaction	O
of	O
N	B-PRGE
protein	I-PRGE
with	O
viral	O
RNA	O
was	O
investigated	O
using	O
circular	O
dichroism	O
and	O
surface	O
plasmon	O
resonance	O
.	O

The	O
emergence	O
of	O
SARS	B-PRGE
is	O
a	O
timely	O
reminder	O
of	O
the	O
need	O
to	O
expect	O
the	O
unexpected	O
and	O
to	O
ensure	O
strong	O
national	O
and	O
global	O
public	O
health	O
partnerships	O
when	O
preparing	O
for	O
and	O
responding	O
to	O
infectious	O
diseases	O
.	O

A	O
total	O
of	O
56	O
serum	O
samples	O
collected	O
from	O
22	O
healthcare	O
workers	O
in	O
the	O
Hanoi	O
French	O
Hospital	O
during	O
the	O
SARS	O
epidemic	O
in	O
2003	O
were	O
evaluated	O
and	O
compared	O
to	O
the	O
conventional	O
neutralizing	O
assay	O
using	O
infectious	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
results	O
of	O
the	O
neutralization	O
assay	O
using	O
VSV	O
-	O
SARS	O
-	O
St19	O
pseudotype	O
showed	O
good	O
correlations	O
with	O
those	O
using	O
infectious	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
newly	O
developed	O
neutralization	O
assay	O
was	O
more	O
sensitive	O
to	O
low	O
antibody	O
titers	O
in	O
serum	O
samples	O
.	O

Analysis	O
of	O
the	O
innate	O
immune	O
response	O
in	O
the	O
DNA	O
-	O
PKcs	O
-	O
deficient	O
mice	O
with	O
short	O
dysfunctional	O
telomeres	O
revealed	O
high	O
basal	O
serum	O
levels	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNFalpha	B-PRGE
)	O
and	O
hyper	O
-	O
active	O
cytokine	O
responses	O
upon	O
challenge	O
with	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
(	O
poly	O
-	O
IC	O
).	O

Immunocytes	O
in	O
the	O
red	O
pulp	O
were	O
decreased	O
by	O
68	O
.	O
0	O
-	O
90	O
.	O
7	O
%	O
except	O
for	O
CD68	B-PRGE
+	I-PRGE
macrophages	O
and	O
human	B-PRGE
leukocyte	I-PRGE
antigen	I-PRGE
(	O
HLA	B-PRGE
)-	O
DR	O
positive	O
antigen	O
-	O
presenting	O
cells	O
(	O
APC	O
),	O
which	O
were	O
decreased	O
to	O
a	O
lesser	O
degree	O
.	O

On	O
average	O
,	O
CD68	B-PRGE
+	I-PRGE
macrophages	O
were	O
increased	O
in	O
size	O
by	O
2	O
.	O
21	O
-	O
fold	O
.	O

We	O
assessed	O
the	O
influence	O
of	O
the	O
replicase	B-PRGE
genes	I-PRGE
of	O
the	O
highly	O
neurovirulent	O
MHV	O
-	O
JHM	O
strain	O
and	O
the	O
hepatotropic	O
and	O
mildly	O
neurovirulent	O
A59	O
strain	O
in	O
acute	O
infection	O
of	O
the	O
mouse	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
does	O
not	O
induce	O
Beta	B-PRGE
interferon	I-PRGE
synthesis	O
and	O
does	O
not	O
inhibit	O
its	O
induction	O
by	O
double	O
-	O
stranded	O
RNA	O
.	O

The	O
ORF7b	B-PRGE
protein	I-PRGE
is	O
a	O
putative	O
viral	O
accessory	O
protein	O
encoded	O
on	O
subgenomic	O
(	O
sg	O
)	O
RNA	O
7	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
demonstrated	O
that	O
infection	O
of	O
cultured	O
cells	O
with	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
resulted	O
in	O
activation	O
of	O
the	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
Raf	B-PRGE
/	O
MEK	B-PRGE
/	O
ERK	B-PRGE
)	O
signal	O
transduction	O
pathway	O
(	O
Y	O
.	O
Cai	O
et	O
al	O
.,	O
Virology	O
355	O
:	O
152	O
-	O
163	O
,	O
2006	O
).	O

Patients	O
were	O
then	O
separated	O
into	O
AKI	B-PRGE
and	O
non	O
-	O
AKI	O
patients	O
(	O
control	O
group	O
).	O

ABSTRACT	O
:	O
Synthetic	O
decapeptides	O
(	O
N	O
=	O
206	O
)	O
covering	O
the	O
entire	O
sequence	O
of	O
mouse	O
liver	O
fumarylacetoacetate	B-PRGE
hydrolase	I-PRGE
(	O
FAH	B-PRGE
)	O
were	O
used	O
to	O
analyze	O
the	O
specificities	O
of	O
the	O
autoantibodies	O
(	O
autoAb	O
)	O
elicited	O
towards	O
this	O
enzyme	O
in	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

Therefore	O
,	O
even	O
in	O
CD8	B-PRGE
T	I-PRGE
cell	O
responses	O
that	O
appear	O
to	O
be	O
oligoclonotypic	O
,	O
the	O
total	O
response	O
is	O
highly	O
diverse	O
.	O

Sodium	O
taurocholate	O
was	O
infused	O
through	O
the	O
pancreatic	O
membrane	O
to	O
induce	O
ANP	B-PRGE
.	O

The	O
effects	O
of	O
ligustrazine	O
on	O
the	O
severity	O
of	O
lung	O
injury	O
were	O
assessed	O
by	O
lung	O
wet	O
/	O
dry	O
weight	O
ratio	O
,	O
myeloperoxidase	B-PRGE
(	O
MPO	B-PRGE
)	O
activity	O
and	O
histopathological	O
changes	O
.	O

In	O
the	O
T	O
group	O
,	O
although	O
the	O
MPO	B-PRGE
activity	O
was	O
also	O
higher	O
than	O
in	O
the	O
C	O
group	O
,	O
it	O
much	O
less	O
increased	O
than	O
in	O
the	O
P	O
group	O
.	O

After	O
induction	O
of	O
the	O
ANP	B-PRGE
model	O
,	O
the	O
pancreas	O
showed	O
mild	O
edema	O
and	O
congestion	O
;	O
the	O
longer	O
the	O
time	O
,	O
the	O
more	O
severe	O
this	O
became	O
.	O

The	O
preadministration	O
of	O
TJ	O
-	O
41	O
significantly	O
inhibited	O
increases	O
in	O
the	O
serum	O
level	O
of	O
keratinocyte	O
chemoattractant	O
(	O
KC	O
),	O
which	O
is	O
a	O
murine	O
chemotaxin	O
for	O
neutrophils	O
that	O
corresponds	O
to	O
human	B-PRGE
interleukin	I-PRGE
-	I-PRGE
8	I-PRGE
,	O
with	O
respect	O
to	O
its	O
concentration	O
at	O
24	O
h	O
after	O
LPS	O
challenge	O
.	O

CRCoV	O
-	O
4182	O
showed	O
a	O
mutation	O
within	O
the	O
non	O
-	O
structural	O
protein	O
region	O
downstream	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
leading	O
to	O
the	O
translation	O
of	O
an	O
8	O
.	O
8	O
kDa	O
putative	O
protein	O
comprising	O
a	O
fusion	O
of	O
the	O
equivalent	O
of	O
the	O
BCoV	O
4	O
.	O
9	O
kDa	O
protein	O
to	O
a	O
truncated	O
version	O
of	O
the	O
BCoV	B-PRGE
4	I-PRGE
.	I-PRGE
8	I-PRGE
kDa	I-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
An	O
integrated	O
system	O
has	O
been	O
developed	O
for	O
discovering	O
potent	O
inhibitors	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
))	O
by	O
virtual	O
screening	O
correlating	O
with	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
and	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
technologies	O
-	O
based	O
assays	O
.	O

Pulsed	O
methylprednisolone	O
,	O
gamma	B-PRGE
-	I-PRGE
globulin	I-PRGE
,	O
granulocyte	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
and	O
sivelestat	O
sodium	O
hydrate	O
were	O
administrated	O
,	O
and	O
thereafter	O
the	O
patient	O
recovered	O
from	O
cytopenia	O
and	O
organ	O
failure	O
.	O

All	O
three	O
proteins	O
were	O
able	O
to	O
inhibit	O
expression	O
from	O
an	O
interferon	B-PRGE
-	I-PRGE
stimulated	I-PRGE
response	I-PRGE
element	I-PRGE
(	O
ISRE	O
)	O
promoter	O
after	O
infection	O
with	O
Sendai	O
virus	O
,	O
while	O
only	O
ORF	B-PRGE
3b	I-PRGE
and	I-PRGE
ORF	I-PRGE
6	I-PRGE
proteins	I-PRGE
were	O
able	O
to	O
inhibit	O
expression	O
from	O
the	O
ISRE	O
promoter	O
after	O
treatment	O
with	O
interferon	B-PRGE
.	O

This	O
indicates	O
that	O
N	B-PRGE
protein	I-PRGE
inhibits	O
only	O
the	O
synthesis	O
of	O
interferon	B-PRGE
,	O
while	O
ORF	B-PRGE
3b	I-PRGE
and	I-PRGE
ORF	I-PRGE
6	I-PRGE
proteins	I-PRGE
inhibit	O
both	O
interferon	B-PRGE
synthesis	O
and	O
signaling	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
these	O
three	O
interferon	B-PRGE
antagonists	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
inhibit	O
the	O
interferon	B-PRGE
response	O
by	O
different	O
mechanisms	O
.	O

The	O
recovered	O
deletion	O
mutant	O
grew	O
in	O
Vero	O
E6	O
,	O
Huh	O
-	O
7	O
,	O
and	O
CaCo	O
-	O
2	O
cells	O
to	O
titers	O
20	O
-,	O
200	O
-,	O
and	O
200	O
-	O
fold	O
lower	O
than	O
the	O
recombinant	O
wild	O
-	O
type	O
virus	O
,	O
respectively	O
,	O
indicating	O
that	O
although	O
the	O
E	B-PRGE
protein	I-PRGE
has	O
an	O
effect	O
on	O
growth	O
,	O
it	O
is	O
not	O
essential	O
for	O
virus	O
replication	O
.	O

The	O
rJ	O
.	O
6	O
infections	O
were	O
also	O
set	O
apart	O
by	O
early	B-PRGE
viral	I-PRGE
protein	I-PRGE
accumulation	O
and	O
by	O
robust	O
expansion	O
via	O
syncytia	O
,	O
a	O
characteristic	O
feature	O
of	O
JHM	O
virus	O
dissemination	O
.	O

TITLE	O
:	O
The	O
STAT4	B-PRGE
and	O
STAT6	B-PRGE
pathways	O
in	O
pancreatitis	O
-	O
associated	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
The	O
STAT	B-PRGE
pathways	O
are	O
integral	O
to	O
the	O
inflammatory	O
response	O
and	O
these	O
proteins	O
provide	O
a	O
direct	O
link	O
between	O
the	O
cytokine	O
receptors	O
and	O
cytokine	O
-	O
induced	O
gene	O
transcription	O
.	O

Local	O
specific	O
IgA	B-PRGE
production	O
was	O
delayed	O
and	O
lower	O
levels	O
were	O
achieved	O
in	O
immunodeficient	O
chickens	O
.	O

RESULTS	O
:	O
Interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
inducible	O
protein	O
10	O
(	O
IP	O
-	O
10	O
)	O
was	O
markedly	O
elevated	O
in	O
the	O
blood	O
during	O
the	O
early	O
stage	O
of	O
SARS	O
[(	O
7	O
,	O
600	O
+/-	O
2	O
,	O
400	O
)	O
ng	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
01	O
],	O
and	O
remained	O
at	O
a	O
high	O
level	O
in	O
the	O
progressive	O
stage	O
[(	O
8	O
,	O
100	O
+/-	O

These	O
results	O
show	O
that	O
the	O
S	B-PRGE
cytoplasmic	I-PRGE
domain	I-PRGE
is	O
palmitoylated	O
and	O
that	O
palmitoylation	O
of	O
the	O
membrane	O
proximal	O
cysteine	O
clusters	O
I	O
and	O
II	O
may	O
be	O
important	O
for	O
S	O
-	O
mediated	O
cell	O
fusion	O
.	O

The	O
effects	O
of	O
adenovirus	O
-	O
delivered	O
small	O
hairpin	O
RNA	O
on	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
gene	I-PRGE
expression	O
were	O
determined	O
by	O
RT	O
-	O
PCR	O
,	O
Western	O
blot	O
,	O
and	O
luciferase	O
activity	O
assays	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
performed	O
to	O
further	O
identify	O
the	O
previously	O
uncharacterized	O
human	B-PRGE
coronavirus	I-PRGE
229E	I-PRGE
(	O
hCoV	O
-	O
229E	O
)	O
and	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
(	O
hCoV	O
-	O
OC43	O
)	O
in	O
Thailand	O
by	O
using	O
the	O
RT	O
-	O
PCR	O
technique	O
.	O

ABSTRACT	O
:	O
The	O
chemokine	O
CXCL10	B-PRGE
is	O
expressed	O
within	O
the	O
CNS	O
in	O
response	O
to	O
intracerebral	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

During	O
in	O
vivo	O
passage	O
of	O
SARS	O
-	O
CoV	O
,	O
a	O
single	O
amino	O
acid	O
substitution	O
was	O
introduced	O
within	O
the	O
binding	O
domain	O
of	O
the	O
viral	O
spike	O
protein	O
recognizing	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
which	O
is	O
known	O
as	O
a	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
-	O
induced	O
oligodendrocyte	O
apoptosis	O
is	O
mediated	O
through	O
the	O
activation	O
of	O
the	O
Fas	B-PRGE
signaling	O
pathway	O
.	O

TITLE	O
:	O
Generation	O
and	O
characterization	O
of	O
human	B-PRGE
monoclonal	I-PRGE
neutralizing	I-PRGE
antibodies	I-PRGE
with	O
distinct	O
binding	O
and	O
sequence	O
features	O
against	O
SARS	O
coronavirus	O
using	O
XenoMouse	O
.	O

TITLE	O
:	O
Essential	O
role	O
for	O
collectrin	B-PRGE
in	O
renal	O
amino	O
acid	O
transport	O
.	O

A	O
gene	O
encoding	O
a	O
homologue	O
to	O
ACE2	B-PRGE
,	O
termed	O
collectrin	B-PRGE
(	O
Tmem27	O
),	O
has	O
been	O
identified	O
in	O
immediate	O
proximity	O
to	O
the	O
ace2	B-PRGE
locus	I-PRGE
.	O

Though	O
the	O
enzyme	O
is	O
a	O
cysteine	B-PRGE
protease	I-PRGE
with	O
a	O
chymotrypsin	B-PRGE
fold	O
,	O
SARS	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
follows	O
the	O
general	O
base	O
catalytic	O
mechanism	O
similar	O
to	O
chymotrypsin	B-PRGE
.	O

It	O
is	O
expected	O
that	O
inhibitors	O
targeting	O
CoV	B-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
s	I-PRGE
could	O
be	O
developed	O
into	O
wide	O
-	O
spectrum	O
antiviral	O
drugs	O
against	O
existing	O
and	O
possible	O
future	O
emerging	O
CoV	O
-	O
associated	O
diseases	O
.	O

The	O
TGEV	O
C	O
and	O
A	O
epitopes	O
were	O
fused	O
to	O
the	O
passenger	O
domain	O
of	O
the	O
MisL	B-PRGE
autotransporter	I-PRGE
of	O
Salmonella	O
.	O

HCoV	O
-	O
NL63	O
S	O
is	O
expressed	O
as	O
a	O
single	O
-	O
chain	O
glycoprotein	O
and	O
consists	O
of	O
an	O
N	B-PRGE
-	I-PRGE
terminal	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
S1	O
)	O
and	O
a	O
C	O
-	O
terminal	O
transmembrane	O
fusion	O
domain	O
(	O
S2	O
).	O

When	O
mice	O
were	O
dosed	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.)	O
with	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
B	I-PRGE
/	O
D	O
once	O
daily	O
for	O
3	O
days	O
beginning	O
4	O
h	O
after	O
virus	O
exposure	O
,	O
SARS	O
-	O
CoV	O
replication	O
in	O
the	O
lungs	O
of	O
infected	O
mice	O
was	O
reduced	O
by	O
1	O
log10	O
at	O
10	O
,	O
000	O
and	O
32	O
,	O
000	O
IU	O
;	O
at	O
the	O
highest	O
dose	O
of	O
100	O
,	O
000	O
IU	O
,	O
virus	O
lung	O
titres	O
were	O
below	O
detectable	O
limits	O
.	O

In	O
summary	O
,	O
the	O
data	O
suggest	O
that	O
induction	O
of	O
IFN	B-PRGE
by	O
mismatched	O
dsRNA	O
or	O
actual	O
treatment	O
with	O
exogenous	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
can	O
inhibit	O
SARS	O
-	O
CoV	O
replication	O
in	O
the	O
lungs	O
of	O
mice	O
.	O

The	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
rescued	O
VVDeltaE3L	O
from	O
IFN	B-PRGE
sensitivity	O
.	O

Surprisingly	O
,	O
however	O
,	O
we	O
were	O
also	O
able	O
to	O
isolate	O
a	O
viable	O
MHV	O
mutant	O
(	O
DeltaE	O
)	O
in	O
which	O
the	O
entire	O
E	B-PRGE
gene	I-PRGE
,	O
as	O
well	O
as	O
the	O
nonessential	O
upstream	O
genes	O
4	O
and	O
5a	O
,	O
were	O
deleted	O
.	O

However	O
,	O
the	O
E	B-PRGE
protein	I-PRGE
of	O
a	O
group	O
1	O
coronavirus	O
,	O
transmissible	O
gastroenteritis	O
virus	O
,	O
became	O
functional	O
in	O
MHV	O
only	O
after	O
acquisition	O
of	O
particular	O
mutations	O
.	O

The	O
coronavirus	O
(	O
CoV	O
)	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
which	O
plays	O
a	O
pivotal	O
role	O
in	O
viral	O
gene	O
expression	O
and	O
replication	O
through	O
a	O
highly	O
complex	O
cascade	O
involving	O
the	O
proteolytic	O
processing	O
of	O
replicase	B-PRGE
polyproteins	I-PRGE
,	O
is	O
an	O
attractive	O
target	O
for	O
antiviral	O
drug	O
design	O
.	O

Subcutaneous	O
injection	O
with	O
purified	O
S	O
-	O
displayed	O
baculoviruses	O
without	O
adjuvant	O
elicited	O
highly	O
effective	O
production	O
of	O
specific	O
and	O
neutralizing	O
antibodies	O
against	O
S	B-PRGE
protein	I-PRGE
in	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
(	O
CoV	O
)	O
responsible	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
encodes	O
two	O
large	O
polyproteins	O
(	O
pp1a	B-PRGE
and	O
pp1ab	O
)	O
that	O
are	O
processed	O
by	O
two	O
viral	O
proteases	O
to	O
yield	O
mature	O
non	O
-	O
structural	O
proteins	O
(	O
nsps	O
).	O

The	O
mature	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
protein	I-PRGE
is	O
present	O
in	O
cells	O
several	O
hours	O
post	O
-	O
infection	O
and	O
co	O
-	O
localizes	O
to	O
the	O
viral	O
replication	O
complex	O
,	O
but	O
its	O
function	O
in	O
the	O
viral	O
life	O
cycle	O
remains	O
unknown	O
.	O

In	O
order	O
to	O
initiate	O
structural	O
and	O
biophysical	O
studies	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp1	I-PRGE
,	O
a	O
recombinant	O
expression	O
system	O
and	O
a	O
purification	O
protocol	O
have	O
been	O
developed	O
,	O
yielding	O
milligram	O
quantities	O
of	O
highly	O
purified	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp1	I-PRGE
.	O

In	O
this	O
study	O
,	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
)	O
was	O
used	O
to	O
specifically	O
remove	O
the	O
GST	B-PRGE
tag	I-PRGE
in	O
a	O
new	O
fusion	O
protein	O
expression	O
system	O
.	O

We	O
report	O
a	O
new	O
method	O
to	O
produce	O
wild	O
-	O
type	O
(	O
WT	O
)	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
)	O
with	O
authentic	O
N	O
and	O
C	O
termini	O
,	O
and	O
compare	O
the	O
activity	O
of	O
WT	B-PRGE
protease	I-PRGE
with	O
those	O
of	O
three	O
different	O
types	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
with	O
additional	O
residues	O
at	O
the	O
N	O
or	O
C	O
terminus	O
.	O

ABSTRACT	O
:	O
Interferon	B-PRGE
(	O
IFN	O
)-	O
alpha	O
,	O
-	O
beta	O
and	O
-	O
gamma	O
have	O
been	O
shown	O
to	O
be	O
only	O
marginally	O
effective	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
replication	O
in	O
Vero	O
cell	O
lines	O
.	O

The	O
highly	O
synergistic	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
action	O
of	O
type	B-PRGE
I	I-PRGE
IFNs	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
parallels	O
the	O
marked	O
increase	O
in	O
2	O
'-	O
5	O
'-	O
oligoadenylate	B-PRGE
synthetase	I-PRGE
and	O
p56	B-PRGE
mRNAs	I-PRGE
following	O
exposure	O
in	O
Vero	O
cells	O
to	O
either	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
or	I-PRGE
-	I-PRGE
beta	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
compared	O
with	O
the	O
transcriptional	O
levels	O
obtained	O
after	O
stimulation	O
with	O
either	O
IFN	B-PRGE
alone	O
.	O

These	O
results	O
demonstrate	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
although	O
only	O
moderately	O
sensitive	O
to	O
the	O
antiviral	O
action	O
of	O
the	O
individual	O
types	O
of	O
IFN	B-PRGE
,	O
is	O
highly	O
sensitive	O
to	O
a	O
combination	O
of	O
type	O
I	O
and	O
II	O
IFNs	O
,	O
which	O
suggests	O
that	O
such	O
combinations	O
may	O
have	O
potential	O
in	O
the	O
treatment	O
of	O
SARS	O
-	O
CoV	O
infections	O
.	O

First	O
,	O
ATA	O
blocks	O
the	O
phosphorylation	O
of	O
extracellular	B-PRGE
signal	I-PRGE
-	I-PRGE
regulated	I-PRGE
kinase	I-PRGE
1	I-PRGE
/	I-PRGE
2	I-PRGE
,	O
an	O
event	O
shown	O
to	O
be	O
essential	O
for	O
vaccinia	O
virus	O
replication	O
.	O

The	O
prototype	O
virus	O
has	O
a	O
split	O
gene	O
,	O
encoding	O
the	O
putative	O
ORF4a	B-PRGE
and	I-PRGE
ORF4b	I-PRGE
proteins	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
SARS	B-PRGE
coronavirus	I-PRGE
main	I-PRGE
peptidase	I-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
(	O
pro	B-PRGE
))	O
plays	O
an	O
essential	O
role	O
in	O
the	O
life	O
-	O
cycle	O
of	O
the	O
virus	O
and	O
is	O
a	O
primary	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
agents	O
.	O

Using	O
serial	O
serum	O
samples	O
collected	O
from	O
SARS	O
patients	O
,	O
the	O
times	O
to	O
seroconversion	O
were	O
determined	O
by	O
IgM	B-PRGE
antibody	O
detection	O
after	O
SARS	O
-	O
CoV	O
infection	O
.	O

We	O
detected	O
cytoplasmic	O
accumulations	O
containing	O
the	O
viral	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
,	O
viral	O
RNA	O
and	O
the	O
non	O
-	O
structural	O
protein	O
nsp3	B-PRGE
.	O

MHV	O
nsp3	B-PRGE
contains	O
multiple	O
domains	O
including	O
two	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
domains	I-PRGE
,	O
PLP1	B-PRGE
and	O
PLP2	B-PRGE
,	O
and	O
a	O
predicted	O
transmembrane	O
(	O
TM	O
)	O
domain	O
.	O

Anti	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
IgG	I-PRGE
was	O
measured	O
in	O
CSF	O
and	O
serum	O
by	O
indirect	O
immunofluorescence	O
assay	O
.	O

Except	O
for	O
diffusion	B-PRGE
capacity	I-PRGE
adjusted	I-PRGE
for	I-PRGE
haemoglobin	I-PRGE
concentration	I-PRGE
(	O
DLCO	O
)	O
measured	O
at	O
12	O
months	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
pulmonary	O
function	O
measurement	O
between	O
those	O
who	O
had	O
mechanical	O
ventilation	O
and	O
those	O
who	O
did	O
not	O
.	O

ABSTRACT	O
:	O
Conserved	O
among	O
all	O
coronaviruses	O
are	O
four	O
structural	O
proteins	O
:	O
the	O
matrix	O
(	O
M	O
),	O
small	B-PRGE
envelope	I-PRGE
(	I-PRGE
E	I-PRGE
),	I-PRGE
and	O
spike	O
(	O
S	O
)	O
proteins	O
that	O
are	O
embedded	O
in	O
the	O
viral	O
membrane	O
and	O
the	O
nucleocapsid	O
phosphoprotein	O
(	O
N	O
),	O
which	O
exists	O
in	O
a	O
ribonucleoprotein	O
complex	O
in	O
the	O
lumen	O
.	O

Comparison	O
of	O
crystal	O
packing	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
IBV	O
N	O
-	O
NTDs	O
suggests	O
a	O
common	O
mode	O
of	O
RNA	O
recognition	O
,	O
but	O
they	O
probably	O
associate	O
differently	O
in	O
vivo	O
during	O
the	O
formation	O
of	O
the	O
ribonucleoprotein	O
complex	O
.	O

Pro	O
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
particularly	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
IL	O
-	O
8	O
,	O
and	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
are	O
elevated	O
in	O
the	O
lungs	O
and	O
peripheral	O
blood	O
,	O
but	O
there	O
is	O
an	O
unusual	O
lack	O
of	O
an	O
antiviral	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
response	O
.	O

Here	O
,	O
we	O
characterized	O
the	O
proteolytic	O
processing	O
of	O
the	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
amino	O
-	O
proximal	O
pp1a	B-PRGE
/	O
pp1ab	O
region	O
by	O
two	O
paralogous	O
PLpro	O
activities	O
.	O

In	O
the	O
induction	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
production	O
,	O
the	O
homologous	O
combination	O
of	O
rAd	O
-	O
N	O
/	O
rAd	O
-	O
N	O
/	O
rAd	O
-	O
N	O
/	O
rAd	O
-	O
N	O
was	O
significantly	O
stronger	O
than	O
that	O
of	O
pcDNA3	O
.	O
1	O
-	O
N	O
/	O
pcDNA3	O
.	O
1	O
-	O
N	O
/	O
pcDNA3	O
.	O
1	O
-	O
N	O
/	O
pcDNA3	O
.	O
1	O
-	O
N	O
,	O
but	O
was	O
relatively	O
weaker	O
than	O
the	O
heterogeneous	O
combination	O
of	O
pcDAN3	O
.	O
1	O
-	O
N	O
/	O
pcDAN3	O
.	O
1	O
-	O
N	O
/	O
pcDAN3	O
.	O
1	O
-	O
N	O
/	O
rAd	O
-	O
N	O
.	O
This	O
combination	O
was	O
a	O
most	O
efficient	O
immunization	O
regimen	O
in	O
induction	O
of	O
SARS	O
-	O
CoV	O
-	O
N	O
-	O
specific	O
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
secretion	O
just	O
as	O
the	O
antibody	O
response	O
.	O

TITLE	O
:	O
Establishment	O
of	O
a	O
reference	O
panel	O
for	O
the	O
detection	O
of	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
antibodies	I-PRGE
.	O

For	O
experimentally	O
infected	O
samples	O
,	O
the	O
results	O
of	O
PCR	O
/	O
electrophoresis	O
were	O
in	O
complete	O
accord	O
with	O
those	O
of	O
this	O
system	O
when	O
anodic	O
currents	O
of	O
6	B-PRGE
.	I-PRGE
1	I-PRGE
(	I-PRGE
Cp	I-PRGE
),	I-PRGE
8	I-PRGE
.	I-PRGE
5	I-PRGE
(	I-PRGE
Hb	I-PRGE
),	I-PRGE
2	I-PRGE
.	I-PRGE
4	I-PRGE
(	O
Hh	O
),	O
and	O
3	O
.	O
1	O
nA	O
(	O
MHV	O
)	O
were	O
taken	O
as	O
the	O
cut	O
-	O
off	O
value	O
.	O

We	O
also	O
demonstrated	O
that	O
another	O
unusual	O
pathway	O
,	O
the	O
calcium	O
-	O
independent	O
PI3K	B-PRGE
/	I-PRGE
PKC	I-PRGE
epsilon	I-PRGE
/	O
JNK	B-PRGE
/	O
CREB	B-PRGE
pathway	O
,	O
functioned	O
in	O
cooperation	O
with	O
the	O
calcium	O
-	O
dependent	O
pathway	O
to	O
induce	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
upon	O
stimulation	O
by	O
spike	O
protein	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
helps	O
us	O
understand	O
the	O
function	O
of	O
SRAS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
in	O
SARS	O
pathogenesis	O
.	O

We	O
conclude	O
that	O
TTM	B-PRGE
is	O
able	O
to	O
depict	O
the	O
position	O
,	O
morphology	O
,	O
and	O
progress	O
of	O
lesions	O
with	O
the	O
same	O
degree	O
of	O
success	O
as	O
CT	O
.	O

Using	O
the	O
N	B-PRGE
protein	I-PRGE
gene	I-PRGE
as	O
target	O
,	O
IBVs	O
were	O
analyzed	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
/	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RT	O
-	O
PCR	O
/	O
RFLP	O
)	O
with	O
the	O
restriction	O
enzymes	O
AvaII	O
,	O
HphI	O
,	O
Sau96I	O
,	O
and	O
Tsp509I	O
and	O
cDNA	O
sequencing	O
.	O

TITLE	O
:	O
Therapeutic	O
effects	O
of	O
caspase	B-PRGE
-	I-PRGE
1	I-PRGE
inhibitors	O
on	O
acute	O
lung	O
injury	O
in	O
experimental	O
severe	O
acute	O
pancreatitis	O
.	O

Serum	B-PRGE
IL	I-PRGE
-	I-PRGE
1beta	I-PRGE
levels	O
in	O
SAP	B-PRGE
-	I-PRGE
S	I-PRGE
group	I-PRGE
were	O
276	O
.	O
77	O
+/-	O

Caspase	B-PRGE
-	I-PRGE
1	I-PRGE
inhibitors	O
ameliorated	O
the	O
severity	O
of	O
ALI	O
in	O
SAP	B-PRGE
.	O

RESULTS	O
:	O
Serum	B-PRGE
IL	I-PRGE
-	I-PRGE
1beta	I-PRGE
levels	O
in	O
SAP	B-PRGE
-	I-PRGE
S	I-PRGE
group	I-PRGE
were	O
276	O
.	O
77	O
+/-	O

TITLE	O
:	O
Pathogenesis	O
of	O
avian	B-PRGE
flu	I-PRGE
H5N1	I-PRGE
and	O
SARS	O
.	O

Three	O
methods	O
were	O
used	O
:	O
C4	O
.	O
5	O
,	O
neural	O
network	O
(	O
NN	O
)	O
and	O
CART	B-PRGE
.	O

Final	O
result	O
shows	O
that	O
70	O
.	O
94	O
%	O
SARS	O
cases	O
can	O
be	O
detected	O
by	O
CART	B-PRGE
.	O

The	O
rabbit	O
was	O
immunized	O
by	O
purified	O
Chap10	O
-	O
S2epi	O
for	O
the	O
preparation	O
of	O
antiserum	O
,	O
which	O
was	O
used	O
to	O
identify	O
the	O
mimic	O
antigenicity	O
of	O
Chap10	O
-	O
S2epi	O
to	O
S2	B-PRGE
protein	I-PRGE
by	O
ELISA	O
.	O

Alternatively	O
,	O
SARS	O
M	O
DNA	O
vaccines	O
inducing	O
human	O
neutralizing	O
antibodies	O
and	O
human	O
monoclonal	O
antibodies	O
against	O
SARS	B-PRGE
CoV	I-PRGE
are	O
now	O
being	O
developed	O
.	O

The	O
identity	O
of	O
the	O
S1	B-PRGE
protein	I-PRGE
gene	O
between	O
the	O
four	O
Chinese	O
IBV	O
isolates	O
and	O
14	O
strains	O
of	O
other	O
IBVs	O
varied	O
from	O
70	O
.	O
06	O
to	O
81	O
.	O
59	O
%.	O

Levels	O
of	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
,	O
sICAM	O
-	O
1	O
,	O
L	B-PRGE
-	I-PRGE
and	I-PRGE
sE	I-PRGE
-	I-PRGE
Selectins	I-PRGE
were	O
determined	O
using	O
solid	O
-	O
phase	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
in	O
plasma	O
of	O
10	O
patients	O
with	O
sepsis	O
,	O
10	O
patients	O
with	O
TBI	O
,	O
10	O
patients	O
with	O
ARDS	O
,	O
compared	O
to	O
10	O
ventilated	O
controls	O
with	O
chronic	O
illness	O
but	O
not	O
in	O
acute	O
stress	O
,	O
on	O
days	O
1	O
,	O
3	O
,	O
5	O
,	O
7	O
and	O
10	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
viral	O
gene	O
products	O
are	O
capable	O
of	O
triggering	O
apoptotic	O
cell	O
death	O
through	O
interfering	O
with	O
cellular	O
signaling	O
cascades	O
,	O
including	O
the	O
Akt	B-PRGE
kinase	I-PRGE
pathway	O
.	O

Total	O
IgM	B-PRGE
and	O
IgG	B-PRGE
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
were	O
tested	O
with	O
commercial	O
ELISA	O
kits	O
.	O

Moreover	O
,	O
pseudoviruses	O
generated	O
in	O
our	O
laboratory	O
with	O
four	O
civet	O
S	O
genes	O
,	O
each	O
with	O
a	O
distinct	O
RBD	O
,	O
infected	O
cells	O
expressing	O
human	B-PRGE
receptor	I-PRGE
angiotensin	I-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
,	O
but	O
with	O
90	O
to	O
95	O
%	O
less	O
efficiency	O
compared	O
to	O
that	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
These	O
four	O
civet	O
S	O
genes	O
were	O
also	O
constructed	O
as	O
DNA	O
vaccines	O
to	O
immunize	O
mice	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
design	O
of	O
SARS	O
vaccine	O
should	O
consider	O
not	O
only	O
preventing	O
the	O
reemergence	O
of	O
SARS	B-PRGE
-	O
CoV	O
but	O
also	O
providing	O
cross	O
-	O
protection	O
,	O
thus	O
interrupting	O
zoonotic	O
transmission	O
of	O
a	O
group	O
of	O
genetically	O
divergent	O
civet	O
CoVs	O
of	O
broad	O
geographic	O
origin	O
.	O

Our	O
data	O
indicate	O
that	O
shielding	O
of	O
viral	O
RNA	O
to	O
host	O
cell	O
sensors	O
might	O
be	O
the	O
main	O
general	O
mechanism	O
for	O
coronaviruses	O
to	O
prevent	O
IFN	B-PRGE
induction	O
.	O

TITLE	O
:	O
A	O
human	O
anti	O
-	O
neuronal	O
autoantibody	O
against	O
GABA	B-PRGE
B	I-PRGE
receptor	I-PRGE
induces	O
experimental	O
autoimmune	O
agrypnia	O
.	O

In	O
order	O
to	O
verify	O
the	O
pathogenic	O
role	O
of	O
these	O
purified	O
antibodies	O
,	O
we	O
injected	O
patient	O
IgG	B-PRGE
intrathecally	O
into	O
cisterna	O
magna	O
of	O
C57BL	O
/	O
6	O
mice	O
pre	O
-	O
implanted	O
with	O
EEG	O
electrodes	O
and	O
we	O
observed	O
severe	O
ataxia	O
followed	O
by	O
breathing	O
depression	O
and	O
total	O
suppression	O
of	O
slow	O
wave	O
sleep	O
,	O
as	O
evidenced	O
by	O
EEG	O
recording	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
order	O
to	O
establish	O
whether	O
these	O
fluctuations	O
depend	O
on	O
the	O
FCoV	O
status	O
,	O
the	O
serum	O
concentration	O
of	O
AGP	B-PRGE
and	O
anti	O
-	O
FCoV	O
antibody	O
titres	O
and	O
/	O
or	O
faecal	O
shedding	O
of	O
FCoVs	O
in	O
clinically	O
healthy	O
cats	O
from	O
catteries	O
with	O
different	O
levels	O
of	O
prevalence	O
of	O
FCoV	O
infection	O
were	O
monitored	O
over	O
time	O
.	O

Detailed	O
sequence	O
analysis	O
of	O
the	O
GiCoV	B-PRGE
-	I-PRGE
OH3	I-PRGE
spike	I-PRGE
gene	I-PRGE
demonstrated	O
the	O
presence	O
of	O
a	O
deletion	O
in	O
the	O
variable	O
region	O
of	O
the	O
S1	O
subunit	O
(	O
from	O
amino	O
acid	O
543	O
to	O
amino	O
acid	O
547	O
),	O
which	O
is	O
a	O
region	O
associated	O
with	O
pathogenicity	O
and	O
tissue	O
tropism	O
for	O
other	O
CoVs	O
.	O

Cells	O
transfected	O
with	O
plasmid	O
expressing	O
the	O
6	O
protein	O
released	O
SCoV	O
6	O
protein	O
;	O
however	O
,	O
infected	O
cells	O
released	O
SCoV	B-PRGE
6	I-PRGE
protein	I-PRGE
only	O
in	O
association	O
with	O
SCoV	O
particles	O
.	O

The	O
imino	O
protons	O
of	O
U48	O
in	O
the	O
wild	O
-	O
type	O
RNA	O
,	O
and	O
G48	O
in	O
the	O
U48G	B-PRGE
SL2	I-PRGE
mutant	I-PRGE
RNA	I-PRGE
,	O
are	O
significantly	O
protected	O
from	O
exchange	O
with	O
solvent	O
,	O
consistent	O
with	O
a	O
hydrogen	O
bonding	O
interaction	O
critical	O
to	O
the	O
hairpin	O
loop	O
architecture	O
.	O

Thus	O
,	O
the	O
anti	O
-	O
cancer	O
utility	O
of	O
suppressing	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
cancer	O
cells	O
is	O
limited	O
.	O

Moreover	O
,	O
Drak2	B-PRGE
-	O
deficient	O
T	O
cell	O
activation	O
,	O
expansion	O
and	O
cytokine	O
production	O
were	O
unimpaired	O
in	O
response	O
to	O
acute	O
MHV	O
infection	O
.	O

These	O
results	O
demonstrate	O
that	O
DRAK2	B-PRGE
signaling	O
is	O
dispensable	O
for	O
T	O
cell	O
recruitment	O
into	O
the	O
CNS	O
following	O
viral	O
infection	O
,	O
suggesting	O
that	O
the	O
resistance	O
of	O
Drak2	B-PRGE
-	O
/	O
-	O
mice	O
to	O
EAE	O
is	O
not	O
due	O
to	O
overt	O
T	O
cell	O
trafficking	O
defects	O
.	O

Rutamarin	O
(	O
4	O
)	O
showed	O
significant	O
inhibitory	O
activities	O
against	O
A	O
-	O
549	O
,	O
Bel	B-PRGE
-	I-PRGE
7402	I-PRGE
,	O
HepG	O
-	O
2	O
and	O
HCT	O
-	O
8	O
tumour	O
cell	O
lines	O
with	O
IC50s	O
of	O
1	O
.	O
318	O
,	O
2	O
.	O
082	O
,	O
2	O
.	O
306	O
and	O
2	O
.	O
497	O
microg	O
/	O
ml	O
.	O

TITLE	O
:	O
Positive	O
rate	O
of	O
serum	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
immunoglobulin	I-PRGE
G	I-PRGE
antibody	I-PRGE
among	O
healthcare	O
workers	O
.	O

High	O
performance	O
liquid	O
chromatography	O
coupled	O
with	O
electrospray	O
ionization	O
tandem	O
mass	O
spectrometry	O
(	O
HPLC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
)	O
was	O
used	O
to	O
identify	O
phosphorylated	O
sites	O
on	O
the	O
N	B-PRGE
protein	I-PRGE
from	O
both	O
infected	O
cells	O
and	O
purified	O
extracellular	O
virions	O
.	O

ABSTRACT	O
:	O
An	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISA	O
)	O
based	O
on	O
recombinant	B-PRGE
nucleocapsid	I-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
protein	I-PRGE
generated	O
in	O
Escherichia	O
coli	O
was	O
evaluated	O
for	O
its	O
sensitivity	O
and	O
specificity	O
for	O
diagnosis	O
of	O
porcine	O
epidemic	O
diarrhea	O
(	O
PEDV	O
)	O
infection	O
.	O

Therefore	O
,	O
the	O
systematic	O
analysis	O
of	O
innate	O
and	O
adaptive	O
immune	O
responses	O
to	O
SARS	B-PRGE
CoV	I-PRGE
is	O
imperative	O
in	O
building	O
as	O
complete	O
an	O
immunological	O
model	O
as	O
possible	O
of	O
host	O
immunity	O
and	O
inflammatory	O
responses	O
during	O
illness	O
.	O

We	O
contend	O
that	O
dysregulated	O
type	O
I	O
and	O
II	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
responses	O
during	O
SARS	O
may	O
culminate	O
in	O
a	O
failure	O
of	O
the	O
switch	O
from	O
hyper	O
-	O
innate	O
immunity	O
to	O
protective	O
adaptive	O
immune	O
responses	O
in	O
the	O
human	O
host	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
polymorphic	O
region	O
of	O
the	O
S	B-PRGE
glycoprotein	I-PRGE
gene	O
of	O
these	O
isolates	O
,	O
together	O
with	O
those	O
of	O
other	O
known	O
strains	O
,	O
classified	O
the	O
BCoV	O
strains	O
and	O
isolates	O
into	O
four	O
clusters	O
.	O

To	O
determine	O
outcome	O
of	O
administration	O
of	O
iNO	B-PRGE
in	O
severe	O
hypoxic	O
respiratory	O
failure	O
.	O

The	O
nucleocapsid	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
highly	O
antigenic	O
and	O
associated	O
with	O
several	O
host	O
-	O
cell	O
interactions	O
.	O

TITLE	O
:	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
produced	O
by	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)-	O
infected	O
macrophages	O
,	O
upregulates	O
expression	O
of	O
type	B-PRGE
II	I-PRGE
FIPV	I-PRGE
receptor	I-PRGE
feline	I-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
in	O
feline	O
macrophages	O
.	O

These	O
findings	O
suggested	O
that	O
FIPV	O
replication	O
in	O
macrophages	O
increases	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
in	O
macrophages	O
,	O
and	O
the	O
produced	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
acts	O
and	O
upregulates	O
fAPN	O
expression	O
,	O
increasing	O
FIPV	O
sensitivity	O
.	O

Reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
used	O
to	O
detect	O
and	O
quantify	O
SARS	O
-	O
CoV	O
in	O
934	O
sera	O
and	O
self	O
-	O
collected	O
throat	O
washes	O
and	O
fecal	O
samples	O
from	O
271	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
SARS	O
managed	O
at	O
a	O
single	O
institution	O
.	O

ABSTRACT	O
:	O
New	O
emerging	O
infectious	O
diseases	O
include	O
""""	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
""""	O
(	O
SARS	O
)	O
and	O
avian	B-PRGE
influenza	I-PRGE
A	I-PRGE
H5N1	I-PRGE
.	O

These	O
data	O
provide	O
useful	O
insights	O
regarding	O
immunity	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
have	O
the	O
potential	O
to	O
help	O
guide	O
the	O
design	O
of	O
peptide	O
-	O
based	O
vaccines	O
.	O

Finally	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
common	O
assay	O
components	O
including	O
DTT	O
,	O
NaCl	O
,	O
EDTA	O
and	O
DMSO	O
on	O
enzymatic	O
activity	O
,	O
and	O
we	O
recommend	O
standardized	O
assay	O
conditions	O
and	O
constructs	O
for	O
routine	O
SARS	O
-	O
CoV	O
3CLpro	O
assays	O
to	O
facilitate	O
direct	O
comparisons	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
inhibitors	O
under	O
development	O
worldwide	O
.	O

The	O
SARS	O
epidemic	O
also	O
brought	O
new	O
attention	O
to	O
the	O
proteins	O
translated	O
from	O
ORF1a	B-PRGE
and	I-PRGE
ORF1b	I-PRGE
of	O
the	O
input	O
genome	O
RNA	O
,	O
also	O
known	O
as	O
the	O
replicase	B-PRGE
/	I-PRGE
transcriptase	I-PRGE
gene	I-PRGE
.	O

In	O
addition	O
,	O
confocal	O
image	O
analysis	O
has	O
shown	O
release	O
of	O
mitochondrial	O
apoptogenic	O
apoptosis	O
-	O
inducing	O
factor	O
and	O
cytochrome	B-PRGE
c	I-PRGE
into	O
the	O
cytosol	O
.	O

Our	O
results	O
revealed	O
that	O
SARS	B-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
could	O
be	O
considered	O
to	O
induce	O
mitochondrial	O
-	O
mediated	O
apoptosis	O
.	O

The	O
study	O
provides	O
system	O
-	O
level	O
insights	O
into	O
the	O
interaction	O
of	O
SARS	B-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
with	O
host	O
cells	O
,	O
which	O
will	O
be	O
helpful	O
in	O
elucidating	O
the	O
molecular	O
basis	O
of	O
SARS	O
CoV	O
pathogenesis	O
.	O

TITLE	O
:	O
The	O
SARS	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
is	O
selectively	O
recognized	O
by	O
lung	O
surfactant	O
protein	O
D	O
and	O
activates	O
macrophages	O
.	O

In	O
healthy	O
volunteers	O
,	O
S100A12	B-PRGE
was	O
elevated	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
after	O
lipopolysaccharide	O
inhalation	O
.	O

In	O
vitro	O
experiments	O
confirmed	O
strong	O
proinflammatory	O
effects	O
of	O
human	B-PRGE
S100A12	I-PRGE
.	O

S100A12	B-PRGE
and	O
its	O
receptor	O
RAGE	O
are	O
found	O
at	O
high	O
concentrations	O
in	O
pulmonary	O
tissue	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
in	O
acute	O
lung	O
injury	O
.	O

Furthermore	O
,	O
the	O
mature	O
forms	O
of	O
nsp4	B-PRGE
to	O
nsp10	O
are	O
thought	O
to	O
serve	O
as	O
cofactors	O
with	O
other	O
replicase	B-PRGE
proteins	I-PRGE
to	O
assemble	O
a	O
larger	O
replication	O
complex	O
specifically	O
formed	O
to	O
transcribe	O
positive	O
-	O
strand	O
RNAs	O
.	O

Genetically	O
,	O
point	O
mutations	O
,	O
insertions	O
,	O
and	O
deletions	O
in	O
the	O
S1	B-PRGE
protein	I-PRGE
can	O
be	O
observed	O
at	O
many	O
positions	O
,	O
especially	O
at	O
the	O
first	O
150	O
amino	O
acids	O
in	O
the	O
N	O
-	O
terminal	O
of	O
the	O
S1	B-PRGE
protein	I-PRGE
.	O

Spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
has	O
been	O
suggested	O
as	O
an	O
important	O
determinant	O
for	O
PEDV	O
biological	O
properties	O
.	O

Endothelial	O
cells	O
are	O
capable	O
of	O
inhibiting	O
TNF	B-PRGE
production	O
by	O
producing	O
prostaglandins	O
that	O
inhibit	O
TNF	B-PRGE
production	O
.	O

Interestingly	O
,	O
twelve	O
human	O
milk	O
samples	O
were	O
positive	O
for	O
IgA	B-PRGE
against	O
porcine	O
transmissible	O
gastroenteritis	O
coronavirus	O
,	O
and	O
this	O
represented	O
5	O
%.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
,	O
human	B-PRGE
angiotensin	I-PRGE
1	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
hACE2	O
),	O
was	O
detected	O
exclusively	O
on	O
the	O
apical	O
surface	O
of	O
cells	O
in	O
polarized	O
Calu	O
-	O
3	O
cells	O
and	O
human	O
airway	O
epithelial	O
cultures	O
(	O
HAE	B-PRGE
),	O
indicating	O
that	O
hACE2	O
was	O
accessible	O
by	O
SARS	O
-	O
CoV	O
after	O
lumenal	O
airway	O
delivery	O
.	O

In	O
2005	O
,	O
horseshoe	O
bats	O
were	O
identified	O
as	O
the	O
natural	O
reservoir	O
of	O
a	O
group	O
of	O
coronaviruses	O
that	O
are	O
distantly	O
related	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
genome	O
sequences	O
of	O
bat	O
SARS	O
-	O
like	O
coronavirus	O
had	O
about	O
88	O
-	O
92	O
%	O
nt	O
identity	O
with	O
that	O
of	O
the	O
SARS	O
-	O
CoV	O
.	O
The	O
prevalence	O
of	O
antibodies	O
and	O
viral	O
RNA	O
in	O
different	O
bat	O
species	O
and	O
the	O
characteristics	O
of	O
the	O
bat	O
SARS	O
-	O
like	O
coronavirus	O
were	O
elucidated	O
.	O

After	O
removal	O
of	O
serum	O
in	O
COS	O
-	O
1	O
cells	O
,	O
we	O
observed	O
the	O
loss	O
of	O
DeltaPsim	O
,	O
the	O
increase	O
of	O
ROS	B-PRGE
and	O
cytochrome	B-PRGE
C	I-PRGE
release	O
into	O
cytosol	O
and	O
subsequent	O
activation	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
PARP	B-PRGE
cleavage	O
.	O

SARS	B-PRGE
coronavirus	I-PRGE
M	I-PRGE
,	O
S	B-PRGE
protein	I-PRGE
can	O
not	O
induce	O
apoptosis	O
in	O
COS	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
HepG2	O
and	O
Huh	O
-	O
7	O
and	O
SARS	B-PRGE
coronavirus	I-PRGE
N	I-PRGE
protein	I-PRGE
can	O
not	O
induce	O
apoptosis	O
in	O
HepG2	O
and	O
Huh	O
-	O
7	O
by	O
methods	O
used	O
in	O
this	O
study	O
.	O

Newer	O
diagnostic	O
tests	O
such	O
as	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
have	O
greatly	O
expanded	O
our	O
understanding	O
of	O
the	O
importance	O
of	O
these	O
respiratory	O
viruses	O
.	O

Phylogenetic	O
analysis	O
suggests	O
that	O
ACoV	O
shares	O
the	O
same	O
ancestor	O
as	O
BCoV	B-PRGE
ENT	I-PRGE
and	O
LUN	O
.	O

The	O
comparison	O
of	O
serum	B-PRGE
AGP	I-PRGE
levels	O
in	O
the	O
different	O
groups	O
and	O
the	O
analysis	O
of	O
the	O
ROC	O
curve	O
confirmed	O
that	O
serum	B-PRGE
AGP	I-PRGE
is	O
a	O
powerful	O
discriminating	O
marker	O
for	O
FIP	O
.	O

In	O
addition	O
,	O
MHV	O
was	O
able	O
to	O
significantly	O
decrease	O
the	O
level	O
of	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
protein	I-PRGE
induced	O
by	O
both	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
)	O
and	O
Sendai	O
virus	O
infections	O
,	O
without	O
targeting	O
it	O
for	O
proteasomal	O
degradation	O
and	O
without	O
altering	O
the	O
nuclear	O
translocation	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
mRNA	I-PRGE
production	O
or	O
stability	O
.	O

Thus	O
,	O
rather	O
than	O
disarming	O
the	O
antiviral	O
activity	O
induced	O
by	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
pretreatment	O
completely	O
,	O
MHV	O
may	O
be	O
inherently	O
resistant	O
to	O
some	O
aspects	O
of	O
the	O
antiviral	O
state	O
induced	O
by	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
.	O

Phylogenetic	O
analyses	O
revealed	O
that	O
the	O
envelope	B-PRGE
,	O
membrane	O
,	O
and	O
nucleoprotein	O
structural	O
proteins	O
and	O
the	O
two	O
conserved	O
replicase	B-PRGE
domains	O
,	O
putative	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
and	O
RNA	B-PRGE
helicase	I-PRGE
,	O
of	O
these	O
novel	O
coronaviruses	O
were	O
most	O
closely	O
related	O
to	O
those	O
of	O
group	O
3	O
coronaviruses	O
identified	O
from	O
birds	O
,	O
while	O
the	O
spike	O
protein	O
gene	O
was	O
most	O
closely	O
related	O
to	O
that	O
of	O
group	O
1	O
coronaviruses	O
from	O
mammals	O
.	O

ABSTRACT	O
:	O
The	O
renin	B-PRGE
-	O
angiotensin	O
-	O
aldosterone	O
system	O
(	O
RAAS	O
)	O
is	O
a	O
key	O
regulator	O
of	O
systemic	O
blood	O
pressure	O
and	O
renal	O
function	O
and	O
a	O
key	O
player	O
in	O
renal	O
and	O
cardiovascular	O
disease	O
.	O

In	O
particular	O
,	O
the	O
human	B-PRGE
homologue	I-PRGE
of	I-PRGE
ACE	I-PRGE
(	O
ACE2	B-PRGE
)	O
has	O
added	O
a	O
higher	O
level	O
of	O
complexity	O
to	O
the	O
RAAS	O
.	O

TITLE	O
:	O
Insertion	O
/	O
deletion	O
polymorphism	O
in	O
the	O
promoter	O
of	O
NFKB1	B-PRGE
influences	O
severity	O
but	O
not	O
mortality	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Anti	B-PRGE
-	I-PRGE
GBM	I-PRGE
antibodies	I-PRGE
were	O
negative	O
.	O

The	O
preliminary	O
purified	O
recombinant	O
protein	O
was	O
evaluated	O
for	O
its	O
antigenicity	O
and	O
reactivity	O
through	O
Western	O
blotting	O
and	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
monoclonal	O
antibody	O
against	O
M	B-PRGE
protein	I-PRGE
of	O
PEDV	O
and	O
porcine	O
polyclonal	O
anti	O
-	O
PEDV	O
antiserum	O
as	O
the	O
primary	O
antibody	O
.	O

TITLE	O
:	O
Comparison	O
of	O
immunoglobulin	B-PRGE
G	I-PRGE
responses	O
to	O
the	O
spike	O
and	O
nucleocapsid	O
proteins	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
in	O
patients	O
with	O
SARS	O
.	O

The	O
use	O
of	O
colloids	O
and	O
steroids	O
may	O
be	O
beneficial	O
,	O
but	O
other	O
new	O
therapies	O
such	O
as	O
insulin	B-PRGE
and	O
activated	O
protein	O
C	O
still	O
need	O
further	O
assessment	O
.	O

This	O
conclusion	O
was	O
drawn	O
based	O
on	O
the	O
observations	O
that	O
apoptosis	O
occurred	O
in	O
both	O
IBV	O
-	O
infected	O
H1299	O
and	O
Vero	O
cells	O
,	O
and	O
that	O
IBV	O
infection	O
did	O
not	O
affect	O
the	O
expression	O
of	O
p53	B-PRGE
in	O
host	O
cells	O
.	O

Index	O
patients	O
who	O
were	O
aged	O
60	O
years	O
or	O
older	O
or	O
whose	O
lactate	B-PRGE
dehydrogenase	I-PRGE
level	O
was	O
elevated	O
upon	O
admission	O
to	O
the	O
hospital	O
(	O
indicating	O
higher	O
viral	O
loads	O
)	O
were	O
more	O
likely	O
to	O
transmit	O
SARS	O
to	O
their	O
contacts	O
.	O

A	O
coronavirus	O
was	O
detected	O
by	O
electron	O
microscopy	O
and	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
in	O
the	O
faeces	O
and	O
in	O
the	O
intestinal	O
content	O
of	O
the	O
dead	O
quails	O
.	O

In	O
further	O
analysis	O
to	O
determine	O
the	O
correlation	O
between	O
the	O
phosphorylation	O
and	O
the	O
antigenicity	O
of	O
SARS	O
-	O
N	O
protein	O
,	O
dephosphorylated	O
SARS	B-PRGE
-	I-PRGE
N	I-PRGE
protein	I-PRGE
treated	O
with	O
protein	O
phosphatase	B-PRGE
1	I-PRGE
(	O
PP1	B-PRGE
)	O
remarkably	O
enhanced	O
the	O
cross	O
-	O
reactivity	O
against	O
SARS	O
negative	O
serum	O
and	O
considerably	O
reduced	O
immunoreactivity	O
with	O
SARS	B-PRGE
-	I-PRGE
N	I-PRGE
mAb	I-PRGE
.	O

Using	O
the	O
same	O
expression	O
system	O
,	O
two	O
structural	O
proteins	O
,	O
membrane	O
(	O
M	O
)	O
and	O
envelope	B-PRGE
(	O
E	O
),	O
were	O
co	O
-	O
expressed	O
to	O
form	O
SARS	O
-	O
CoV	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
within	O
an	O
insect	O
cell	O
.	O

ABSTRACT	O
:	O
The	O
implication	O
of	O
the	O
renin	B-PRGE
-	O
angiotensin	O
system	O
(	O
RAS	B-PRGE
)	O
in	O
the	O
regulation	O
of	O
the	O
cardiovascular	O
system	O
has	O
been	O
well	O
known	O
for	O
many	O
years	O
.	O

NGEN	O
and	O
ResPlex	O
II	O
gave	O
comparable	O
sensitivities	O
for	O
Flu	B-PRGE
-	I-PRGE
A	I-PRGE
(	O
82	O
.	O
8	O
to	O
86	O
.	O
2	O
%),	O
Flu	B-PRGE
-	I-PRGE
B	I-PRGE
(	O
90	O
.	O
0	O
to	O
100	O
.	O
0	O
%),	O
PIV	O
-	O
1	O
(	O
87	O
.	O
5	O
to	O
93	O
.	O
8	O
%),	O
PIV	O
-	O
3	O
(	O
66	O
.	O
7	O
to	O
72	O
.	O
2	O
%),	O
and	O
RSV	O
(	O
63	O
.	O
3	O
to	O
73	O
.	O
3	O
%);	O
both	O
assays	O
achieved	O
excellent	O
specificities	O
(	O
99	O
.	O
1	O
to	O
100	O
.	O
0	O
%)	O
for	O
these	O
five	O
common	O
viruses	O
.	O

Moreover	O
,	O
both	O
vaccines	O
induced	O
similar	O
frequencies	O
of	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
-	O
producing	O
cells	O
in	O
bone	O
marrow	O
.	O

Interestingly	O
,	O
the	O
UV	O
-	O
F	O
-	O
V	O
vaccine	O
induced	O
fewer	O
IgG	B-PRGE
(	I-PRGE
2a	I-PRGE
)	I-PRGE
subtype	I-PRGE
antibodies	I-PRGE
and	O
higher	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
production	O
in	O
vaccinated	O
mice	O
than	O
did	O
UV	O
-	O
V	O
.	O
Thus	O
,	O
UV	O
-	O
F	O
-	O
V	O
imposes	O
a	O
Th2	O
-	O
type	O
bias	O
on	O
the	O
immune	O
response	O
,	O
unlike	O
UV	O
-	O
V	O
.	O
We	O
propose	O
here	O
that	O
doubly	O
-	O
inactivated	O
SARS	O
-	O
CoV	O
virions	O
by	O
UV	O
and	O
formalin	O
constitute	O
a	O
safe	O
vaccine	O
that	O
may	O
effectively	O
induce	O
neutralizing	O
antibodies	O
in	O
humans	O
.	O

The	O
spike	B-PRGE
envelope	I-PRGE
glycoprotein	I-PRGE
of	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
the	O
main	O
determinant	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
tropism	I-PRGE
,	O
was	O
isolated	O
and	O
used	O
to	O
pseudotype	O
a	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)-	O
based	O
vector	O
.	O

Nsp2	B-PRGE
,	O
nsp8	O
and	O
ORF9b	O
showed	O
a	O
wide	O
range	O
of	O
interactions	O
with	O
other	O
viral	O
proteins	O
.	O

We	O
show	O
that	O
also	O
accessory	B-PRGE
protein	I-PRGE
ORF9b	I-PRGE
does	O
not	O
play	O
a	O
pivotal	O
role	O
for	O
viral	O
replication	O
,	O
as	O
it	O
can	O
be	O
deleted	O
from	O
the	O
virus	O
displaying	O
normal	O
plaque	O
sizes	O
and	O
growth	O
characteristics	O
in	O
Vero	O
cells	O
.	O

Shortly	O
after	O
the	O
rabbits	O
were	O
killed	O
at	O
3	O
hour	O
after	O
iv	O
OA	O
injection	O
,	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
was	O
colleted	O
,	O
and	O
the	O
concentrations	O
of	O
protein	O
,	O
platelet	B-PRGE
-	I-PRGE
activating	I-PRGE
factor	I-PRGE
(	O
PAF	B-PRGE
),	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
),	O
interleukin	B-PRGE
8	I-PRGE
(	O
IL	O
-	O
8	O
)	O
in	O
BALF	O
were	O
then	O
measured	O
by	O
ELISA	O
.	O

The	O
OA	O
-	O
induced	O
elevation	O
of	O
arterial	O
blood	O
oxygen	O
pressure	O
was	O
inhibited	O
,	O
as	O
well	O
as	O
PAF	B-PRGE
,	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
IL	O
-	O
8	O
in	O
BALF	O
in	O
rupatadine	O
group	O
.	O

Both	O
features	O
can	O
be	O
evoked	O
by	O
pneumolysin	O
(	O
PLY	B-PRGE
),	O
an	O
important	O
virulence	O
factor	O
of	O
Streptococcus	O
pneumoniae	O
.	O

The	O
antibody	O
titer	O
in	O
BALB	O
/	O
c	O
mice	O
following	O
immunization	O
with	O
recombinant	B-PRGE
S	I-PRGE
protein	I-PRGE
was	O
detectable	O
after	O
the	O
first	O
immunization	O
.	O

TITLE	O
:	O
Cleavage	O
of	O
spike	O
protein	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
by	I-PRGE
protease	I-PRGE
factor	I-PRGE
Xa	I-PRGE
is	O
associated	O
with	O
viral	O
infectivity	O
.	O

Taken	O
together	O
,	O
our	O
study	O
suggests	O
a	O
plausible	O
mechanism	O
by	O
which	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
cleaves	O
its	O
S	B-PRGE
protein	I-PRGE
to	O
facilitate	O
viral	O
infection	O
.	O

ABSTRACT	O
:	O
All	O
plus	O
-	O
strand	O
RNA	O
viruses	O
encode	O
an	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
that	O
functions	O
as	O
the	O
catalytic	O
subunit	O
of	O
the	O
viral	O
replication	O
/	O
transcription	O
complex	O
,	O
directing	O
viral	O
RNA	O
synthesis	O
in	O
concert	O
with	O
other	O
viral	O
proteins	O
and	O
,	O
sometimes	O
,	O
host	O
proteins	O
.	O

We	O
tested	O
the	O
polymorphisms	O
of	O
RANTES	B-PRGE
,	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
Mig	B-PRGE
for	O
their	O
associations	O
with	O
SARS	O
in	O
495	O
Hong	O
Kong	O
Chinese	O
SARS	O
patients	O
and	O
578	O
controls	O
.	O

This	O
study	O
showed	O
that	O
BoTV	B-PRGE
is	O
a	O
common	O
virus	O
in	O
fecal	O
specimens	O
of	O
calves	O
with	O
diarrhea	O
in	O
Japan	O
and	O
may	O
be	O
an	O
important	O
pathogen	O
of	O
cattle	O
,	O
principally	O
in	O
young	O
calves	O
less	O
than	O
2	O
weeks	O
of	O
age	O
.	O

TITLE	O
:	O
[	O
Construction	O
of	O
recombinant	O
Lactococcus	O
lactis	O
expressing	O
porcine	B-PRGE
transmissible	I-PRGE
gastroenteritis	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
and	O
analysis	O
of	O
immunogenicity	O
].	O

ABSTRACT	O
:	O
A	O
multicentre	O
retrospective	O
study	O
was	O
undertaken	O
to	O
examine	O
patients	O
with	O
interstitial	O
lung	O
disease	O
(	O
ILD	O
)	O
with	O
the	O
initial	O
clinical	O
manifestation	O
of	O
an	O
anti	B-PRGE
-	I-PRGE
synthetase	I-PRGE
syndrome	I-PRGE
(	O
anti	O
-	O
Jo	O
-	O
1	O
antibodies	O
),	O
and	O
to	O
analyse	O
the	O
characteristics	O
and	O
long	O
-	O
term	O
outcome	O
of	O
these	O
patients	O
according	O
to	O
their	O
clinical	O
presentation	O
(	O
acute	O
or	O
gradual	O
onset	O
),	O
treatment	O
and	O
adverse	O
events	O
related	O
to	O
treatment	O
.	O

Intriguingly	O
,	O
the	O
SARS	O
coronavirus	O
,	O
the	O
cause	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
utilizes	O
ACE2	B-PRGE
as	O
an	O
essential	O
receptor	O
for	O
cell	O
fusion	O
and	O
in	O
vivo	O
infections	O
.	O

In	O
addition	O
,	O
we	O
identified	O
the	O
expression	O
of	O
inducible	B-PRGE
nitric	I-PRGE
oxide	I-PRGE
synthase	I-PRGE
(	O
iNOS	B-PRGE
)	O
using	O
immunohistochemical	O
stain	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
important	O
human	O
and	O
animal	O
pathogens	O
,	O
the	O
relevance	O
of	O
which	O
increased	O
due	O
to	O
the	O
emergence	O
of	O
new	O
human	O
coronaviruses	O
like	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
HKU1	O
and	O
NL63	O
.	O

In	O
this	O
study	O
,	O
colostrum	O
-	O
deprived	O
calves	O
were	O
experimentally	O
infected	O
with	O
a	O
Korean	O
WD	O
-	O
BCoV	O
strain	O
and	O
examined	O
for	O
viremia	O
,	O
enteric	O
and	O
nasal	O
virus	O
shedding	O
as	O
well	O
as	O
for	O
viral	B-PRGE
antigen	I-PRGE
expression	O
and	O
virus	O
-	O
associated	O
lesions	O
in	O
the	O
small	O
and	O
large	O
intestines	O
and	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
from	O
1	O
to	O
8	O
days	O
after	O
an	O
oral	O
infection	O
.	O

Both	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptors	I-PRGE
of	O
ACE2	B-PRGE
and	O
CD209L	O
were	O
expressed	O
in	O
the	O
8	O
organ	O
/	O
tissue	O
-	O
derived	O
endothelial	O
cells	O
.	O

Virus	O
-	O
cell	O
membrane	O
fusion	O
is	O
mediated	O
by	O
the	O
virus	B-PRGE
envelope	I-PRGE
complex	I-PRGE
,	O
and	O
its	O
fusogenicity	O
is	O
the	O
result	O
of	O
an	O
active	O
virus	O
-	O
cell	O
interaction	O
process	O
that	O
induces	O
conformation	O
changes	O
within	O
the	O
envelope	O
.	O

However	O
,	O
patients	O
with	O
SARS	O
homozygous	O
for	O
ICAM3	B-PRGE
Gly143	O
showed	O
significant	O
association	O
with	O
higher	O
lactate	B-PRGE
dehydrogenase	I-PRGE
levels	O
(	O
P	O
=.	O
0067	O
;	O
odds	O
ratio	O
[	O
OR	O
],	O
4	O
.	O
31	O
[	O
95	O
%	O
confidence	O
interval	O
{	O
CI	O
},	O
1	O
.	O
37	O
-	O
13	O
.	O
56	O
])	O
and	O
lower	O
total	O
white	O
blood	O
cell	O
counts	O
(	O
P	O
=.	O
022	O
;	O
OR	O
,	O
0	O
.	O
30	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
10	O
-	O
0	O
.	O
89	O
])	O
on	O
admission	O
.	O

The	O
M	B-PRGE
-	I-PRGE
41	I-PRGE
antigen	I-PRGE
was	O
also	O
detected	O
in	O
lungs	O
and	O
tracheal	O
tissues	O
of	O
the	O
clinically	O
positive	O
infectious	O
bronchitis	O
cases	O
.	O

Although	O
neuraminidase	B-PRGE
inhibitors	O
are	O
effective	O
in	O
treating	O
avian	O
influenza	O
,	O
especially	O
if	O
given	O
within	O
48	O
h	O
of	O
infection	O
,	O
it	O
is	O
harder	O
to	O
prevent	O
the	O
resultant	O
hypercytokinaemia	O
from	O
developing	O
if	O
the	O
patient	O
does	O
not	O
seek	O
timely	O
medical	O
assistance	O
.	O

Furthermore	O
,	O
the	O
new	O
method	O
has	O
been	O
successfully	O
applied	O
to	O
the	O
screening	O
of	O
inhibitors	O
for	O
influenza	O
A	O
virus	O
and	O
SARS	O
coronavirus	O
,	O
as	O
well	O
as	O
the	O
construction	O
of	O
quartz	O
crystal	O
microbalance	O
(	O
QCM	O
)	O
biosensor	O
for	O
human	B-PRGE
interferon	I-PRGE
-	I-PRGE
beta	I-PRGE
.	O

Histologically	O
,	O
pancreatic	O
and	O
lung	O
damage	O
was	O
less	O
severe	O
following	O
leptin	B-PRGE
administration	O
.	O

Recent	O
studies	O
revealed	O
that	O
M	B-PRGE
protein	I-PRGE
could	O
interact	O
with	O
N	B-PRGE
protein	I-PRGE
in	O
the	O
Golgi	O
complex	O
.	O

Using	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
as	O
a	O
model	O
,	O
we	O
demonstrate	O
that	O
SARS	B-PRGE
-	I-PRGE
COV	I-PRGE
ORF6	I-PRGE
protein	I-PRGE
is	O
localized	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)/	O
Golgi	O
membrane	O
in	O
infected	O
cells	O
,	O
where	O
it	O
binds	O
to	O
and	O
disrupts	O
nuclear	O
import	O
complex	O
formation	O
by	O
tethering	O
karyopherin	B-PRGE
alpha	I-PRGE
2	I-PRGE
and	O
karyopherin	B-PRGE
beta	I-PRGE
1	I-PRGE
to	O
the	O
membrane	O
.	O

siRNA	O
against	O
orf8a	O
significantly	O
reduced	O
VLs	B-PRGE
and	O
interrupted	O
the	O
CPE	O
.	O

PCR	O
assays	O
for	O
hBoV	O
DNA	O
were	O
performed	O
using	O
the	O
primer	O
sets	O
for	O
noncapsid	B-PRGE
protein	I-PRGE
(	O
NP1	B-PRGE
)	O
and	O
nonstructural	O
protein	O
(	O
NS1	B-PRGE
)	O
genes	O
.	O

TITLE	O
:	O
A	O
mechanistic	O
view	O
of	O
enzyme	O
inhibition	O
and	O
peptide	O
hydrolysis	O
in	O
the	O
active	O
site	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
peptidase	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
main	I-PRGE
peptidase	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
)	O
is	O
a	O
viral	O
polyprotein	O
processing	O
enzyme	O
essential	O
for	O
the	O
viability	O
of	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

TITLE	O
:	O
Distinct	O
regulation	O
of	O
MHC	B-PRGE
molecule	I-PRGE
expression	O
on	O
astrocytes	O
and	O
microglia	O
during	O
viral	O
encephalomyelitis	O
.	O

Transgenic	O
mice	O
expressing	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
under	O
control	O
of	O
the	O
astrocyte	O
-	O
specific	O
glial	B-PRGE
fibrillary	I-PRGE
acidic	I-PRGE
protein	I-PRGE
promoter	I-PRGE
were	O
infected	O
with	O
a	O
neurotropic	O
coronavirus	O
to	O
facilitate	O
phenotypic	O
characterization	O
of	O
astrocytes	O
and	O
microglia	O
using	O
flow	O
cytometry	O
.	O

Despite	O
a	O
decline	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
concomitant	O
to	O
virus	O
clearance	O
,	O
MHC	B-PRGE
molecule	I-PRGE
expression	O
on	O
glia	O
was	O
sustained	O
.	O

SARS	O
-	O
CoV	O
viral	O
load	O
and	O
SARS	B-PRGE
-	O
CoV	O
/	O
GAPDH	B-PRGE
RNA	O
ratio	O
for	O
each	O
organ	O
type	O
were	O
related	O
to	O
four	O
time	O
durations	O
:	O
onset	O
of	O
illness	O
to	O
death	O
,	O
death	O
to	O
post	O
-	O
mortem	O
tissue	O
sampling	O
,	O
and	O
total	O
durations	O
of	O
treatment	O
with	O
ribavirin	O
and	O
hydrocortisone	O
.	O

TITLE	O
:	O
Antibodies	O
to	O
AChR	B-PRGE
,	O
MuSK	B-PRGE
and	O
VGKC	O
in	O
a	O
patient	O
with	O
myasthenia	O
gravis	O
and	O
Morvan	O
'	O
s	O
syndrome	O
.	O

Combined	O
treatment	O
with	O
prednisone	O
,	O
intravenous	O
immunoglobulin	B-PRGE
,	O
ciclosporin	O
,	O
and	O
rituximab	O
.	O

Pathological	O
findings	O
and	O
immunohistochemical	O
identification	O
using	O
a	O
monoclonal	B-PRGE
anti	I-PRGE
-	I-PRGE
canine	I-PRGE
Coronavirus	I-PRGE
antibody	I-PRGE
are	O
included	O
.	O

Trypsin	B-PRGE
was	O
not	O
the	O
determinant	O
for	O
the	O
viral	O
replication	O
,	O
suggesting	O
that	O
the	O
restriction	O
of	O
IBV	O
replication	O
in	O
HeLa	O
cells	O
is	O
the	O
result	O
of	O
intracellular	O
events	O
rather	O
than	O
the	O
binding	O
to	O
or	O
fusion	O
with	O
host	O
cells	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
C5a	B-PRGE
in	O
the	O
innate	O
immune	O
response	O
after	O
experimental	O
blunt	O
chest	O
trauma	O
.	O

The	O
following	O
time	O
-	O
points	O
were	O
investigated	O
posttrauma	O
:	O
sham	O
,	O
1	O
,	O
6	O
,	O
12	O
,	O
and	O
24	O
h	O
.	O
There	O
was	O
a	O
time	O
-	O
dependent	O
systemic	O
activation	O
of	O
complement	O
as	O
determined	O
by	O
CH	O
-	O
50	O
and	O
presence	O
of	O
C5a	B-PRGE
-	O
dependent	O
chemotactic	O
plasma	O
activity	O
.	O

Anti	B-PRGE
-	I-PRGE
C5a	I-PRGE
treatment	O
immediately	O
after	O
trauma	O
ameliorated	O
these	O
peaks	O
.	O

The	O
latter	O
was	O
normalized	O
by	O
C5a	B-PRGE
blockade	O
.	O

Fusion	O
is	O
mediated	O
by	O
the	O
viral	B-PRGE
S	I-PRGE
protein	I-PRGE
.	O

Cross	O
virus	O
-	O
neutralization	O
testing	O
showed	O
that	O
none	O
of	O
the	O
2003	O
-	O
04	O
California	O
IBV	O
variant	O
viruses	O
were	O
serologically	O
related	O
to	O
each	O
other	O
or	O
to	O
Ark	B-PRGE
,	O
Conn	O
,	O
or	O
Mass	O
vaccine	O
strains	O
.	O

Intratracheally	O
administered	O
LTA	O
and	O
,	O
to	O
a	O
minor	O
extent	O
,	O
lipopolysaccharide	O
significantly	O
enhanced	O
secondary	O
total	O
and	O
IgG	B-PRGE
Ab	I-PRGE
responses	O
to	O
HuSA	O
.	O

The	O
application	O
of	O
using	O
the	O
N220	O
peptide	O
sequence	O
with	O
a	O
single	O
-	O
chain	O
-	O
trimer	O
(	O
SCT	O
)	O
approach	O
to	O
produce	O
a	O
potential	O
DNA	O
vaccine	O
candidate	O
was	O
investigated	O
in	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
.	I-PRGE
1K	I-PRGE
(	I-PRGE
b	I-PRGE
)	I-PRGE
transgenic	O
mice	O
.	O

ACE2	B-PRGE
is	O
also	O
the	O
receptor	O
for	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
a	O
group	O
II	O
coronavirus	O
.	O

In	O
addition	O
,	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
-	I-PRGE
protein	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
inhibited	O
entry	O
mediated	O
by	O
the	O
HCoV	B-PRGE
-	I-PRGE
NL63	I-PRGE
S	I-PRGE
protein	I-PRGE
.	O

Serum	O
IFN	B-PRGE
-	O
concentration	O
was	O
increased	O
significantly	O
but	O
the	O
concentrations	O
of	O
Il	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
had	O
no	O
significant	O
change	O
.	O

The	O
results	O
showed	O
that	O
recombinant	O
proteins	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
induced	O
hormonal	O
and	O
cellular	O
immune	O
response	O
in	O
Balb	O
/	O
c	O
mice	O
.	O

Using	O
a	O
phage	O
display	O
technology	O
in	O
a	O
chicken	O
system	O
,	O
high	O
-	O
affinity	O
monoclonal	O
antibody	O
fragments	O
against	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
were	O
characterized	O
.	O

A	O
highly	O
significant	O
correlation	O
was	O
observed	O
between	O
PaO2	O
/	O
FiO2	O
and	O
minimum	O
surface	O
tension	O
(	O
r	O
=	O
-	O
0	O
.	O
83	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
SP	B-PRGE
-	I-PRGE
C	I-PRGE
(	O
r	O
=	O
0	O
.	O
64	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
DPPC	O
(	O
r	O
=	O
0	O
.	O
59	O
;	O
p	O
=	O
0	O
.	O
003	O
).	O

RESULTS	O
:	O
At	O
T0	O
,	O
a	O
severe	O
and	O
highly	O
significant	O
reduction	O
in	O
SP	B-PRGE
-	I-PRGE
A	I-PRGE
,	O
SP	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
SP	B-PRGE
-	I-PRGE
C	I-PRGE
,	O
the	O
LA	O
fraction	O
,	O
PC	O
and	O
phosphatidylglycerol	O
(	O
PG	O
)	O
percentages	O
,	O
and	O
dipalmitoylation	O
of	O
PC	O
(	O
DPPC	O
)	O
was	O
encountered	O
.	O

By	O
virus	O
isolation	O
and	O
RT	O
-	O
PCR	O
targeting	O
the	O
S	B-PRGE
gene	I-PRGE
,	O
BCoV	O
was	O
identified	O
as	O
the	O
etiological	O
agent	O
of	O
the	O
outbreak	O
,	O
whereas	O
bacteriological	O
,	O
parasitological	O
and	O
toxicological	O
investigations	O
failed	O
to	O
detect	O
other	O
causes	O
of	O
disease	O
.	O

Human	O
interleukin	B-PRGE
8	I-PRGE
and	O
its	O
mouse	O
functional	O
counterpart	O
,	O
CXCL2	B-PRGE
,	O
are	O
early	O
-	O
expressed	O
chemokines	O
.	O

ABSTRACT	O
:	O
Apelin	B-PRGE
constitutes	O
a	O
novel	O
endogenous	O
peptide	O
system	O
suggested	O
to	O
be	O
involved	O
in	O
a	O
broad	O
range	O
of	O
physiological	O
functions	O
,	O
including	O
cardiovascular	O
function	O
,	O
heart	O
development	O
,	O
control	O
of	O
fluid	O
homeostasis	O
,	O
and	O
obesity	O
.	O

TITLE	O
:	O
Selectivity	O
in	O
ISG15	B-PRGE
and	O
ubiquitin	B-PRGE
recognition	O
by	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
.	O

With	O
k	O
(	O
cat	O
)/	O
K	O
(	O
M	O
)	O
of	O
602	O
,	O
000	O
M	O
(-	O
1	O
)	O
s	O
(-	O
1	O
),	O
PLpro	O
hydrolyzes	O
ISG15	O
-	O
AMC	O
30	O
-	O
and	O
60	O
-	O
fold	O
more	O
efficiently	O
than	O
Ub	O
-	O
AMC	O
and	O
Nedd8	B-PRGE
-	I-PRGE
AMC	I-PRGE
,	O
respectively	O
.	O

ABSTRACT	O
:	O
A	O
recombinant	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
rTGEV	O
)	O
in	O
which	O
E	B-PRGE
gene	I-PRGE
was	O
deleted	O
(	O
rTGEV	O
-	O
DeltaE	O
)	O
has	O
been	O
engineered	O
.	O

Analysis	O
of	O
gene	O
signatures	O
revealed	O
induction	O
of	O
a	O
strong	O
innate	O
immune	O
response	O
characterized	O
by	O
the	O
stimulation	O
of	O
various	O
cytokine	O
and	O
chemokine	O
genes	O
,	O
including	O
interleukin	B-PRGE
(	O
IL	O
)-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
IP	O
-	O
10	O
,	O
which	O
corresponds	O
to	O
the	O
host	O
response	O
seen	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
To	O
examine	O
recent	O
literature	O
regarding	O
corticotherapy	O
in	O
critically	O
ill	O
patients	O
suffering	O
from	O
sepsis	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
severe	O
community	O
-	O
acquired	O
pneumonia	O
(	O
SCAP	B-PRGE
).	O

These	O
results	O
indicate	O
that	O
a	O
profound	O
depletion	O
of	O
mucosal	O
CD4	B-PRGE
+	I-PRGE
T	I-PRGE
cells	O
is	O
not	O
sufficient	O
per	O
se	O
to	O
induce	O
loss	O
of	O
mucosal	O
immunity	O
and	O
disease	O
progression	O
during	O
a	O
primate	O
lentiviral	O
infection	O
.	O

The	O
inhibition	O
of	O
the	O
IFN	B-PRGE
response	O
does	O
not	O
require	O
the	O
protease	O
activity	O
of	O
PLpro	O
.	O

TITLE	O
:	O
Conductance	O
and	O
amantadine	O
binding	O
of	O
a	O
pore	O
formed	O
by	O
a	O
lysine	O
-	O
flanked	O
transmembrane	O
domain	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
envelope	I-PRGE
protein	I-PRGE
.	O

Syngeneic	O
MSCs	O
with	O
or	O
without	O
transfection	O
with	O
plasmid	B-PRGE
containing	I-PRGE
the	I-PRGE
human	I-PRGE
ANGPT1	I-PRGE
gene	I-PRGE
(	O
pANGPT1	O
)	O
were	O
delivered	O
through	O
the	O
right	O
jugular	O
vein	O
of	O
mice	O
30	O
min	O
after	O
intratracheal	O
instillation	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
to	O
induce	O
lung	O
injury	O
.	O

Furthermore	O
,	O
administration	O
of	O
MSCs	O
transfected	O
with	O
pANGPT1	O
resulted	O
in	O
nearly	O
complete	O
reversal	O
of	O
LPS	O
-	O
induced	O
increases	O
in	O
lung	O
permeability	O
as	O
assessed	O
by	O
reductions	O
in	O
IgM	B-PRGE
and	O
albumin	B-PRGE
levels	O
in	O
BAL	O
(	O
96	O
%,	O
CI	O
6	O
%-	O
185	O
%;	O
and	O
74	O
%,	O
CI	O
23	O
%-	O
126	O
%,	O
respectively	O
).	O

Virus	O
-	O
induced	O
chemokine	O
expression	O
was	O
reduced	O
by	O
the	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
antagonist	O
,	O
suggesting	O
that	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
produced	O
by	O
infected	O
cells	O
induces	O
uninfected	O
cells	O
to	O
express	O
chemokines	O
.	O

Its	O
inclusion	O
as	O
a	O
clinical	O
sign	O
associated	O
with	O
FIP	B-PRGE
may	O
facilitate	O
a	O
diagnosis	O
.	O

In	O
four	O
(	O
36	O
.	O
4	O
%)	O
patients	O
at	O
least	O
one	O
other	O
viral	O
pathogen	O
was	O
found	O
(	O
plus	O
RSV	B-PRGE
n	I-PRGE
=	I-PRGE
3	I-PRGE
;	O
27	O
.	O
3	O
%;	O
Norovirus	O
n	O
=	O
1	O
;	O
9	O
.	O
1	O
%).	O

TITLE	O
:	O
Structure	O
-	O
based	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
peptidomimetic	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
inhibitors	O
.	O

The	O
amino	O
terminus	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp4	I-PRGE
,	O
but	O
not	O
that	O
of	O
MHV	B-PRGE
nsp4	I-PRGE
,	O
was	O
shown	O
to	O
be	O
(	O
partially	O
)	O
processed	O
by	O
signal	O
peptidase	O
.	O

TITLE	O
:	O
Genetic	O
analysis	O
of	O
Murine	O
hepatitis	B-PRGE
virus	I-PRGE
nsp4	I-PRGE
in	O
virus	O
replication	O
.	O

ABSTRACT	O
:	O
Coronavirus	B-PRGE
replicase	I-PRGE
polyproteins	I-PRGE
are	O
translated	O
from	O
the	O
genomic	O
positive	O
-	O
strand	O
RNA	O
and	O
are	O
proteolytically	O
processed	O
by	O
three	O
viral	O
proteases	O
to	O
yield	O
16	O
mature	O
nonstructural	O
proteins	O
(	O
nsp1	B-PRGE
to	O
nsp16	O
).	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
memory	O
T	O
cells	O
against	O
M	B-PRGE
protein	I-PRGE
were	O
persistent	O
in	O
recovered	O
SARS	O
patients	O
by	O
detecting	O
gamma	B-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
production	O
using	O
ELISA	O
and	O
ELISpot	O
assays	O
.	O

Flow	O
cytometric	O
analysis	O
showed	O
that	O
both	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
were	O
involved	O
in	O
cellular	O
responses	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
antigen	I-PRGE
.	O

The	O
epitope	O
screening	O
from	O
30	O
synthetic	O
overlapping	O
peptides	O
that	O
cover	O
the	O
entire	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
identified	O
four	O
human	O
T	O
-	O
cell	O
immunodominant	O
peptides	O
,	O
p21	B-PRGE
-	I-PRGE
44	I-PRGE
,	O
p65	B-PRGE
-	I-PRGE
91	I-PRGE
,	O
p117	B-PRGE
-	I-PRGE
140	I-PRGE
and	O
p200	B-PRGE
-	O
220	O
.	O

All	O
four	O
immunodominant	O
peptides	O
could	O
elicit	O
cellular	O
immunity	O
with	O
a	O
predominance	O
of	O
CD8	B-PRGE
+	I-PRGE
T	O
-	O
cell	O
response	O
.	O

RNAi	O
uses	O
short	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
to	O
trigger	O
degradation	O
or	O
translation	O
repression	O
of	O
homologous	B-PRGE
RNA	I-PRGE
targets	I-PRGE
in	O
a	O
sequence	O
-	O
specific	O
manner	O
.	O

In	O
the	O
first	O
part	O
of	O
this	O
review	O
,	O
we	O
will	O
discuss	O
these	O
different	O
properties	O
of	O
the	O
N	B-PRGE
-	I-PRGE
protein	I-PRGE
in	O
a	O
consolidated	O
manner	O
.	O

In	O
two	O
of	O
these	O
patients	O
,	O
sequential	O
serum	O
samples	O
were	O
also	O
tested	O
for	O
IgG	B-PRGE
avidity	O
against	O
human	O
CoV	O
strains	O
OC43	O
and	O
229E	O
in	O
parallel	O
.	O

TITLE	O
:	O
[	O
Sequence	O
analysis	O
for	O
genes	O
encoding	O
nucleoprotein	O
and	O
envelope	B-PRGE
protein	O
of	O
a	O
new	O
human	O
coronavirus	O
NL63	O
identified	O
from	O
a	O
pediatric	O
patient	O
in	O
Beijing	O
by	O
bioinformatics	O
].	O

Variations	O
of	O
the	O
deduced	O
amino	O
acids	O
of	O
M	B-PRGE
gene	I-PRGE
mainly	O
occurred	O
at	O
positions	O
2	O
to	O
17	O
and	O
221	O
to	O
233	O
,	O
comparing	O
with	O
that	O
of	O
the	O
IBV	O
strain	O
LX4	O
.	O

In	O
this	O
study	O
,	O
two	O
recombinant	O
baculoviruses	O
,	O
vAc	O
-	O
N	O
and	O
vAc	O
-	O
S	O
,	O
were	O
constructed	O
,	O
which	O
contained	O
the	O
mammalian	B-PRGE
-	I-PRGE
cell	I-PRGE
activate	I-PRGE
promoter	I-PRGE
element	I-PRGE
,	O
human	B-PRGE
elongation	I-PRGE
factor	I-PRGE
1alpha	I-PRGE
-	I-PRGE
subunit	I-PRGE
(	O
EF	B-PRGE
-	I-PRGE
1alpha	I-PRGE
),	O
the	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
immediate	O
-	O
early	O
promoter	O
,	O
and	O
the	O
nucleocapsid	O
(	O
N	O
)	O
or	O
spike	O
(	O
S	O
)	O
gene	O
of	O
bat	B-PRGE
SARS	I-PRGE
-	I-PRGE
like	I-PRGE
CoV	I-PRGE
(	O
SL	O
-	O
CoV	O
)	O
under	O
the	O
control	O
of	O
the	O
CMV	O
promoter	O
.	O

The	O
secretion	O
level	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
was	O
much	O
higher	O
than	O
that	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
in	O
vAc	O
-	O
N	O
or	O
vAc	O
-	O
S	O
immunized	O
groups	O
,	O
suggesting	O
a	O
strong	O
Th1	O
bias	O
towards	O
cellular	O
immune	O
responses	O
.	O

Using	O
Escherichia	O
coli	O
-	O
expressed	O
recombinant	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
and	O
fragments	O
,	O
the	O
cross	O
-	O
reactive	O
region	O
was	O
localized	O
between	O
amino	O
acids	O
(	O
aa	O
)	O
120	O
to	O
208	O
.	O

The	O
prevalence	O
of	O
the	O
CD14	B-PRGE
-	I-PRGE
159CC	I-PRGE
polymorphism	O
was	O
significantly	O
higher	O
in	O
the	O
patients	O
with	O
severe	O
SARS	O
than	O
in	O
the	O
those	O
with	O
mild	O
SARS	O
or	O
controls	O
(	O
31	O
%	O
versus	O
15	O
%	O
[	O
mild	O
SARS	O
]	O
or	O
20	O
%	O
[	O
controls	O
];	O
mild	O
SARS	O
:	O
P	O
=	O
0	O
.	O
029	O
;	O
odds	O
ratio	O
,	O
2	O
.	O
74	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
15	O
to	O
6	O
.	O
57	O
;	O
controls	O
,	O
P	O
=	O
0	O
.	O
04	O
;	O
odds	O
ratio	O
,	O
2	O
.	O
41	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
05	O
to	O
5	O
.	O
54	O
),	O
and	O
both	O
CD14	B-PRGE
-	I-PRGE
159CC	I-PRGE
and	O
FcgammaRIIA	O
-	O
RR131	O
are	O
risk	O
genotypes	O
for	O
severe	O
SARS	O
-	O
CoV	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
nsp14	B-PRGE
protein	I-PRGE
is	O
an	O
exoribonuclease	O
that	O
is	O
encoded	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

In	O
both	O
lines	O
of	O
birds	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
mRNA	I-PRGE
levels	O
were	O
elevated	O
in	O
the	O
kidneys	O
at	O
4	O
d	O
postinfection	O
.	O

In	O
addition	O
,	O
S	O
-	O
line	O
birds	O
also	O
showed	O
three	O
times	O
higher	O
serum	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
levels	O
than	O
HWL	O
birds	O
after	O
IBV	O
infection	O
.	O

The	O
IBV	B-PRGE
N	I-PRGE
protein	I-PRGE
has	O
been	O
found	O
to	O
be	O
essential	O
for	O
the	O
successful	O
recovery	O
of	O
IBV	O
using	O
reverse	O
genetics	O
systems	O
.	O

Based	O
on	O
the	O
chemical	O
structure	O
of	O
a	O
lead	O
compound	O
from	O
a	O
previous	O
screening	O
,	O
we	O
have	O
designed	O
and	O
synthesized	O
a	O
number	O
of	O
non	O
-	O
peptidyl	O
inhibitors	O
,	O
some	O
of	O
which	O
have	O
shown	O
significantly	O
improved	O
inhibitory	O
activity	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
with	O
IC	O
(	O
50	O
)	O
values	O
of	O
approximately	O
60	O
nM	O
.	O
In	O
the	O
absence	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
crystal	O
structures	O
in	O
complex	O
with	O
these	O
synthetic	O
inhibitors	O
,	O
molecular	O
docking	O
tools	O
have	O
been	O
employed	O
to	O
study	O
possible	O
interactions	O
between	O
these	O
inhibitors	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
).	I-PRGE

TITLE	O
:	O
A	O
CXCL2	B-PRGE
polymorphism	O
is	O
associated	O
with	O
better	O
outcomes	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

By	O
using	O
various	O
biochemical	O
,	O
biophysical	O
and	O
genetic	O
techniques	O
,	O
interaction	O
of	O
the	O
3a	O
protein	O
with	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
demonstrated	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
bismuth	O
complexes	O
were	O
synthesized	O
and	O
characterized	O
,	O
and	O
most	O
of	O
them	O
exhibited	O
inhibition	O
against	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
helicase	I-PRGE
ATPase	I-PRGE
and	O
duplex	O
-	O
unwinding	O
activities	O
at	O
micromolar	O
concentrations	O
.	O

Cells	O
exposed	O
to	O
hypoxia	O
generate	O
reactive	O
oxygen	O
species	O
which	O
activate	O
PKC	B-PRGE
zeta	I-PRGE
which	O
in	O
turn	O
phosphorylates	O
the	O
Na	B-PRGE
,	I-PRGE
K	I-PRGE
-	I-PRGE
ATPase	I-PRGE
at	O
the	O
Ser18	O
residue	O
in	O
the	O
N	O
-	O
terminus	O
of	O
the	O
alpha1	O
-	O
subunit	O
leading	O
the	O
ubiquitination	O
of	O
any	O
of	O
the	O
four	O
lysines	O
(	O
K16	O
,	O
K17	O
,	O
K19	O
,	O
K20	O
)	O
adjacent	O
to	O
the	O
Ser18	O
residue	O
.	O

This	O
process	O
promotes	O
the	O
alpha1	B-PRGE
-	I-PRGE
subunit	I-PRGE
recognition	O
by	O
the	O
mu2	O
subunit	O
of	O
the	O
adaptor	O
protein	O
-	O
2	O
and	O
its	O
endocytosis	O
trough	O
a	O
clathrin	B-PRGE
dependent	O
mechanism	O
.	O

TITLE	O
:	O
Mutation	O
of	O
Gly	O
-	O
11	O
on	O
the	O
dimer	O
interface	O
results	O
in	O
the	O
complete	O
crystallographic	O
dimer	O
dissociation	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
:	O
crystal	O
structure	O
with	O
molecular	O
dynamics	O
simulations	O
.	O

TITLE	O
:	O
Structural	O
basis	O
of	O
mercury	O
-	O
and	O
zinc	O
-	O
conjugated	O
complexes	O
as	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
inhibitors	O
.	O

The	O
samples	O
were	O
screened	O
for	O
astrovirus	O
,	O
rotavirus	O
,	O
reovirus	O
,	O
and	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
by	O
a	O
reverse	B-PRGE
transcriptase	I-PRGE
and	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
for	O
groups	O
1	O
and	O
2	O
adenovirus	O
by	O
PCR	O
.	O

The	O
levels	O
of	O
IBV	O
-	O
specific	O
IgA	B-PRGE
in	O
tears	O
of	O
vaccinated	O
and	O
challenged	O
chickens	O
did	O
not	O
differ	O
significantly	O
between	O
MHC	B-PRGE
genotypes	I-PRGE
.	O

The	O
general	O
physiological	O
indexes	O
did	O
not	O
differ	O
between	O
animals	O
injected	O
with	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
F	I-PRGE
(	O
ab	O
')(	O
2	O
)	O
or	O
saline	O
.	O

As	O
it	O
has	O
been	O
already	O
suggested	O
for	O
other	O
viral	O
fusion	O
proteins	O
such	O
as	O
HIV	O
gp41	O
,	O
the	O
region	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
protein	I-PRGE
where	O
the	O
PTM	O
peptide	O
resides	O
could	O
be	O
involved	O
in	O
the	O
merging	O
of	O
the	O
viral	O
and	O
target	O
cell	O
membranes	O
working	O
synergistically	O
with	O
other	O
membrane	O
-	O
active	O
regions	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
glycoprotein	I-PRGE
to	O
heighten	O
the	O
fusion	O
process	O
and	O
therefore	O
might	O
be	O
essential	O
for	O
the	O
assistance	O
and	O
enhancement	O
of	O
the	O
viral	O
and	O
cell	O
fusion	O
process	O
.	O

These	O
observations	O
are	O
confirmed	O
by	O
direct	O
in	O
vitro	O
binding	O
of	O
recombinant	B-PRGE
protein	I-PRGE
7a	I-PRGE
to	O
the	O
wild	O
type	O
and	O
mutant	O
K287C	O
/	O
K294C	O
I	O
domain	O
showing	O
that	O
the	O
I	B-PRGE
domain	I-PRGE
is	O
the	O
7a	O
binding	O
site	O
in	O
the	O
alpha	B-PRGE
(	I-PRGE
L	I-PRGE
)	I-PRGE
chain	I-PRGE
of	O
LFA	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

In	O
this	O
report	O
,	O
recombinant	O
PPV	O
(	O
plum	B-PRGE
pox	I-PRGE
virus	I-PRGE
)	O
NIa	O
protease	O
was	O
employed	O
to	O
process	O
fusion	O
proteins	O
with	O
artificial	O
cleavage	O
site	O
in	O
vitro	O
.	O

Recombinant	B-PRGE
PPV	I-PRGE
NIa	I-PRGE
protease	I-PRGE
was	O
resistant	O
to	O
self	O
-	O
lysis	O
for	O
at	O
least	O
five	O
days	O
.	O

Sequencing	O
of	O
the	O
V51	B-PRGE
spike	I-PRGE
gene	I-PRGE
,	O
the	O
mediator	O
of	O
virus	O
entry	O
,	O
revealed	O
13	O
amino	O
acid	O
substitutions	O
relative	O
to	O
the	O
originating	O
MHV	O
A59	O
strain	O
.	O

The	O
CLEIA	O
was	O
established	O
with	O
an	O
optical	O
combination	O
of	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
against	O
SARS	B-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
prepared	O
from	O
mice	O
immunized	O
with	O
recombinant	O
N	O
protein	O
without	O
cultivating	O
the	O
virus	O
.	O

The	O
CLEIA	O
was	O
capable	O
of	O
detecting	O
recombinant	B-PRGE
N	I-PRGE
protein	I-PRGE
at	O
1	O
.	O
56	O
pg	O
/	O
ml	O
and	O
viral	O
N	O
protein	O
in	O
SARS	O
CoV	O
cell	O
culture	O
lysates	O
at	O
0	O
.	O
087	O
of	O
50	O
%	O
tissue	O
culture	O
infective	O
doses	O
/	O
ml	O
.	O

Herein	O
,	O
we	O
show	O
that	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
act	O
in	O
concert	O
as	O
part	O
of	O
the	O
innate	O
immune	O
response	O
to	O
the	O
retinal	O
infection	O
.	O

In	O
this	O
review	O
,	O
we	O
have	O
compiled	O
the	O
current	O
knowledge	O
about	O
SARS	O
-	O
CoV	O
accessory	O
proteins	O
,	O
obtained	O
from	O
studies	O
in	O
cell	O
culture	O
systems	O
,	O
reverse	O
genetics	O
and	O
animal	O
models	O
,	O
to	O
shed	O
some	O
light	O
into	O
the	O
possible	O
role	O
of	O
these	O
proteins	O
in	O
the	O
propagation	O
and	O
virulence	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
its	O
natural	O
host	O
.	O

Absorbance	O
of	O
IgG	B-PRGE
in	O
pregnant	O
sow	O
sera	O
highly	O
increased	O
duration	O
of	O
the	O
experiment	O
.	O

Our	O
results	O
reveal	O
a	O
novel	O
mode	O
of	O
Smad3	B-PRGE
action	O
in	O
a	O
Smad4	B-PRGE
-	O
independent	O
manner	O
and	O
may	O
lead	O
to	O
successful	O
strategies	O
for	O
SARS	O
treatment	O
by	O
targeting	O
the	O
TGF	B-PRGE
-	I-PRGE
beta	I-PRGE
signaling	O
molecules	O
.	O

Recommendations	O
specific	O
to	O
pediatric	O
severe	O
sepsis	O
include	O
:	O
greater	O
use	O
of	O
physical	O
examination	O
therapeutic	O
end	O
points	O
(	O
2C	O
);	O
dopamine	O
as	O
the	O
first	O
drug	O
of	O
choice	O
for	O
hypotension	O
(	O
2C	O
);	O
steroids	O
only	O
in	O
children	O
with	O
suspected	O
or	O
proven	O
adrenal	O
insufficiency	O
(	O
2C	O
);	O
a	O
recommendation	O
against	O
the	O
use	O
of	O
recombinant	B-PRGE
activated	I-PRGE
protein	I-PRGE
C	I-PRGE
in	O
children	O
(	O
1B	O
).	O

ABSTRACT	O
:	O
The	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
of	O
a	O
289	O
base	O
pair	O
Alu	O
repeat	O
sequence	O
polymorphism	O
in	O
the	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
gene	I-PRGE
(	O
ACE	B-PRGE
)	O
has	O
been	O
shown	O
to	O
predict	O
susceptibility	O
and	O
outcome	O
in	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ACE	B-PRGE
I	I-PRGE
/	I-PRGE
D	I-PRGE
polymorphism	O
was	O
not	O
associated	O
with	O
severe	O
sepsis	O
susceptibility	O
or	O
mortality	O
.	O

Benefits	O
in	O
recognizing	O
mild	O
cases	O
of	O
TRALI	O
include	O
quantifying	O
the	O
true	O
incidence	O
of	O
TRALI	O
,	O
understanding	O
the	O
physiology	O
of	O
mild	O
versus	O
severe	O
TRALI	O
,	O
and	O
preventing	O
subsequent	O
cases	O
of	O
TRALI	O
due	O
to	O
donors	O
found	O
to	O
have	O
HLA	B-PRGE
antibodies	I-PRGE
.	O

TITLE	O
:	O
Heterologous	O
expression	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
ORF10	I-PRGE
and	O
X5	O
genes	O
in	O
E	O
.	O
coli	O
and	O
Streptomyces	O
lividans	O
TK24	O
.	O

SDS	O
-	O
PAGE	O
and	O
Western	O
blot	O
revealed	O
that	O
the	O
ORF10	B-PRGE
and	O
X5	O
genes	O
have	O
been	O
expressed	O
in	O
the	O
two	O
hosts	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
inhibitors	O
of	O
calmodulin	B-PRGE
also	O
stimulate	O
shedding	O
of	O
the	O
ACE2	B-PRGE
ectodomain	I-PRGE
,	O
a	O
process	O
at	O
least	O
partially	O
mediated	O
by	O
a	O
metalloproteinase	B-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
receptor	O
usage	O
of	O
the	O
SL	O
-	O
CoV	O
S	O
by	O
combining	O
a	O
human	O
immunodeficiency	O
virus	O
-	O
based	O
pseudovirus	O
system	O
with	O
cell	O
lines	O
expressing	O
the	O
ACE2	B-PRGE
molecules	I-PRGE
of	O
human	O
,	O
civet	O
,	O
or	O
horseshoe	O
bat	O
.	O

ABSTRACT	O
:	O
Immunocompetent	O
,	O
but	O
not	O
RAG1	B-PRGE
(-/-)	O
mice	O
infected	O
with	O
MHV	O
-	O
JHM	O
develop	O
demyelination	O
.	O

IFN	B-PRGE
-	I-PRGE
gammaR1	I-PRGE
(-/-)	O
CD8	B-PRGE
T	I-PRGE
cells	O
retain	O
virus	O
-	O
specific	O
effector	O
function	O
regardless	O
of	O
IFN	B-PRGE
-	I-PRGE
gammaR1	I-PRGE
expression	O
.	O

Organophosphate	O
compounds	O
inhibit	O
acetylcholinesterase	B-PRGE
resulting	O
in	O
acute	O
toxicity	O
.	O

A	O
monomeric	O
form	O
of	O
IBV	O
M	O
(	O
pro	O
)	O
was	O
identified	O
for	O
the	O
first	O
time	O
in	O
CoV	B-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
structures	O
.	O

The	O
in	O
vitro	O
evolution	O
of	O
icSZ16	O
-	O
S	O
K479N	O
on	O
human	B-PRGE
airway	O
epithelial	O
(	O
HAE	O
)	O
cells	O
produced	O
two	O
viruses	O
(	O
icSZ16	O
-	O
S	O
K479N	O
D8	O
and	O
D22	O
)	O
with	O
enhanced	O
growth	O
on	O
HAE	O
cells	O
and	O
on	O
delayed	O
brain	O
tumor	O
cells	O
expressing	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
,	O
human	B-PRGE
angiotensin	I-PRGE
I	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
hACE2	O
).	O

We	O
have	O
reported	O
that	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
is	O
elevated	O
in	O
pulmonary	O
edema	O
fluid	O
in	O
those	O
with	O
ALI	O
and	O
mediates	O
an	O
autocrine	O
-	O
acting	O
,	O
fibroblast	O
mitogenic	O
pathway	O
.	O

The	O
suppressive	O
effects	O
of	O
PGE2	O
were	O
mimicked	O
by	O
the	O
EP2	B-PRGE
-	I-PRGE
selective	I-PRGE
receptor	I-PRGE
agonist	O
,	O
butaprost	O
,	O
by	O
cAMP	O
activation	O
,	O
and	O
were	O
lost	O
in	O
murine	O
lung	O
fibroblasts	O
that	O
lack	O
EP2	B-PRGE
.	O

In	O
an	O
inhibition	O
assay	O
of	O
EA	O
-	O
rosette	O
formation	O
as	O
a	O
representation	O
of	O
immune	O
phagocytosis	O
,	O
FcgammaRIII	B-PRGE
-	I-PRGE
specific	I-PRGE
MoAbs	I-PRGE
,	O
TAG1	B-PRGE
,	O
TAG2	O
and	O
TAG3	O
inhibited	O
EA	O
-	O
rosette	O
formation	O
,	O
but	O
HNA	O
-	O
2a	O
-	O
specific	O
MoAb	O
,	O
TAG4	O
,	O
did	O
not	O
markedly	O
inhibit	O
EA	O
-	O
rosette	O
formation	O
.	O

In	O
addition	O
,	O
our	O
studies	O
indicate	O
that	O
the	O
nuclear	O
localization	O
of	O
N	O
is	O
essential	O
for	O
its	O
caspase	B-PRGE
-	I-PRGE
6	I-PRGE
-	O
mediated	O
cleavage	O
.	O

To	O
date	O
,	O
12	O
structures	O
have	O
been	O
determined	O
by	O
X	O
-	O
ray	O
crystallography	O
or	O
NMR	O
from	O
the	O
28	O
proteins	O
encoded	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
One	O
key	O
protein	O
,	O
the	O
SARS	O
-	O
CoV	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
has	O
been	O
the	O
focus	O
of	O
considerable	O
structure	O
-	O
based	O
drug	O
discovery	O
efforts	O
.	O

Recommendations	O
specific	O
to	O
pediatric	O
severe	O
sepsis	O
include	O
greater	O
use	O
of	O
physical	O
examination	O
therapeutic	O
end	O
points	O
(	O
2C	O
);	O
dopamine	O
as	O
the	O
first	O
drug	O
of	O
choice	O
for	O
hypotension	O
(	O
2C	O
);	O
steroids	O
only	O
in	O
children	O
with	O
suspected	O
or	O
proven	O
adrenal	O
insufficiency	O
(	O
2C	O
);	O
and	O
a	O
recommendation	O
against	O
the	O
use	O
of	O
recombinant	B-PRGE
activated	I-PRGE
protein	I-PRGE
C	I-PRGE
in	O
children	O
(	O
1B	O
).	O

Differences	O
in	O
growth	O
rate	O
and	O
CPE	O
between	O
the	O
KT2	B-PRGE
-	I-PRGE
L	I-PRGE
and	O
KT2	B-PRGE
-	I-PRGE
H	I-PRGE
strains	O
were	O
discovered	O
in	O
swine	O
testicular	O
cells	O
(	O
STCs	O
).	O

Considering	O
the	O
cross	O
-	O
reactivity	O
of	O
FCoV	B-PRGE
type	I-PRGE
I	I-PRGE
and	I-PRGE
type	I-PRGE
II	I-PRGE
,	O
ELISA	O
was	O
able	O
to	O
detect	O
antibodies	O
against	O
both	O
serotypes	O
,	O
allowing	O
the	O
use	O
of	O
the	O
assay	O
as	O
a	O
reference	O
test	O
for	O
sera	O
screening	O
.	O

In	O
this	O
study	O
,	O
we	O
confirmed	O
that	O
mouse	B-PRGE
hepatitis	I-PRGE
coronavirus	I-PRGE
A59	I-PRGE
E	I-PRGE
protein	I-PRGE
is	O
palmitoylated	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
define	O
the	O
genotypic	O
patterns	O
of	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
,	O
-	O
B	O
and	O
-	O
DRB1	B-PRGE
loci	O
in	O
SARS	O
patients	O
and	O
a	O
co	O
-	O
resident	O
population	O
of	O
Guangdong	O
province	O
,	O
southern	O
China	O
,	O
where	O
the	O
first	O
SARS	O
case	O
was	O
reported	O
.	O

Our	O
results	O
show	O
that	O
chimeric	O
VLP	B-PRGE
can	O
be	O
an	O
effective	O
vaccine	O
strategy	O
against	O
SCoV	O
infection	O
.	O

Although	O
there	O
have	O
been	O
many	O
reports	O
of	O
such	O
work	O
done	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
these	O
were	O
mainly	O
focused	O
on	O
the	O
immune	O
responses	O
of	O
humans	O
and	O
mice	O
.	O

Analysis	O
of	O
the	O
apo	B-PRGE
and	O
complexed	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
INF	B-PRGE
-	I-PRGE
C	I-PRGE
esterase	I-PRGE
revealed	O
that	O
binding	O
of	O
9	O
-	O
O	O
-	O
acetylated	O
N	O
-	O
acetylneuraminic	O
acids	O
is	O
a	O
dynamic	O
process	O
that	O
involves	O
conformational	O
rearrangement	O
of	O
serine	B-PRGE
-	I-PRGE
57	I-PRGE
in	O
the	O
esterase	B-PRGE
active	O
site	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
survival	O
time	O
of	O
cats	O
treated	O
with	O
FeIFN	B-PRGE
-	I-PRGE
omega	I-PRGE
versus	O
placebo	O
or	O
in	O
any	O
other	O
variable	O
evaluated	O
(	O
with	O
the	O
exception	O
of	O
the	O
lymphocyte	O
count	O
).	O

A	O
reporter	O
gene	O
encoding	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
GFP	O
)	O
was	O
inserted	O
into	O
one	O
segment	O
,	O
and	O
a	O
red	O
fluorescent	O
protein	O
dsRed	O
gene	O
was	O
inserted	O
into	O
the	O
other	O
segment	O
in	O
order	O
to	O
easily	O
detect	O
the	O
replication	O
and	O
transcription	O
of	O
segments	O
in	O
infected	O
cells	O
.	O

Rapid	O
hACE2	O
-	O
dependent	O
S	O
-	O
mediated	O
cell	O
-	O
cell	O
fusion	O
was	O
reduced	O
to	O
60	O
to	O
70	O
%	O
of	O
the	O
wild	O
-	O
type	O
level	O
for	O
all	O
single	O
alanine	O
substitutions	O
and	O
the	O
Y1188A	B-PRGE
/	I-PRGE
Y1191A	I-PRGE
protein	I-PRGE
.	O

The	O
M	B-PRGE
protein	I-PRGE
genes	O
of	O
six	O
Chinese	O
PEDV	O
isolates	O
consisted	O
of	O
692	O
nucleotides	O
containing	O
a	O
single	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
681	O
nucleotides	O
,	O
which	O
encoded	O
a	O
226aa	O
-	O
long	O
peptide	O
.	O

The	O
M	B-PRGE
protein	I-PRGE
of	O
six	O
isolates	O
had	O
three	O
main	O
transmembrane	O
domains	O
(	O
aa20	O
-	O
38	O
,	O
aa43	O
-	O
65	O
,	O
aa75	O
-	O
97	O
).	O

More	O
than	O
twelve	O
peaks	O
were	O
differentially	O
expressed	O
in	O
SARS	O
patients	O
with	O
one	O
at	O
m	O
/	O
z	O
of	O
11	O
,	O
695	O
(	O
later	O
identified	O
to	O
be	O
serum	B-PRGE
amyloid	I-PRGE
A	I-PRGE
protein	I-PRGE
),	O
which	O
had	O
increase	O
in	O
peak	O
intensity	O
correlating	O
with	O
the	O
extent	O
of	O
SARS	O
-	O
coronavirus	O
induced	O
pneumonia	O
as	O
defined	O
by	O
a	O
serial	O
chest	O
X	O
-	O
ray	O
opacity	O
score	O
.	O

In	O
addition	O
,	O
the	O
spike	O
-	O
bearing	O
pseudoviruses	O
and	O
early	B-PRGE
endosome	I-PRGE
antigen	I-PRGE
1	I-PRGE
were	O
found	O
to	O
colocalize	O
in	O
endosomes	O
.	O

To	O
investigate	O
the	O
underlying	O
mechanisms	O
,	O
yeast	O
two	O
-	O
hybrid	O
screen	O
was	O
carried	O
out	O
using	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
proteins	I-PRGE
as	O
baits	O
,	O
revealing	O
that	O
a	O
subunit	O
of	O
the	O
eukaryotic	B-PRGE
initiation	I-PRGE
factor	I-PRGE
3	I-PRGE
(	O
eIF3	B-PRGE
),	O
eIF3f	B-PRGE
,	O
may	O
interact	O
with	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
.	O

Meanwhile	O
,	O
parallel	O
experiments	O
confirmed	O
that	O
eIF3f	B-PRGE
could	O
also	O
interact	O
with	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
another	O
coronavirus	O
,	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

Interestingly	O
,	O
IBV	O
-	O
infected	O
cells	O
stably	O
expressing	O
a	O
Flag	O
-	O
tagged	O
eIF3f	B-PRGE
showed	O
much	O
higher	O
translation	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	O
-	O
8	O
,	O
suggesting	O
that	O
the	O
interaction	O
between	O
coronavirus	B-PRGE
S	I-PRGE
protein	I-PRGE
and	O
eIF3f	B-PRGE
plays	O
a	O
functional	O
role	O
in	O
controlling	O
the	O
expression	O
of	O
host	O
genes	O
,	O
especially	O
genes	O
that	O
are	O
induced	O
during	O
coronavirus	O
infection	O
cycles	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
was	O
a	O
worldwide	O
epidemic	O
caused	O
by	O
a	O
coronavirus	O
that	O
has	O
a	O
cysteine	B-PRGE
protease	I-PRGE
(	O
3CLpro	O
)	O
essential	O
to	O
its	O
life	O
cycle	O
.	O

Acute	O
respiratory	O
failure	O
frequency	O
differed	O
significantly	O
with	O
the	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	I-PRGE
1082	I-PRGE
genotype	I-PRGE
(	O
P	O
=	O
.	O
007	O
;	O
P	O
corrected	O
,	O
.	O
03	O
),	O
whereas	O
there	O
was	O
no	O
significant	O
relation	O
to	O
any	O
other	O
cytokine	O
genotype	O
after	O
Bonferroni	O
correction	O
for	O
multiple	O
testing	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
the	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	I-PRGE
1082	I-PRGE
genotype	I-PRGE
may	O
be	O
a	O
risk	O
marker	O
for	O
development	O
of	O
acute	O
respiratory	O
failure	O
after	O
trauma	O
.	O

In	O
this	O
study	O
,	O
the	O
N	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
was	O
found	O
to	O
associate	O
with	O
B23	O
,	O
a	O
phosphoprotein	O
in	O
nucleolus	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
examined	O
the	O
evolutionary	O
relationships	O
between	O
bat	O
CoVs	O
and	O
their	O
hosts	O
by	O
using	O
sequence	O
data	O
of	O
the	O
virus	O
RNA	O
-	O
dependent	O
RNA	B-PRGE
polymerase	I-PRGE
gene	I-PRGE
and	O
the	O
bat	B-PRGE
cytochrome	I-PRGE
b	I-PRGE
gene	I-PRGE
.	O

TITLE	O
:	O
Modulation	O
of	O
signaling	O
pathways	O
by	O
RNA	B-PRGE
virus	I-PRGE
capsid	I-PRGE
proteins	I-PRGE
.	O

We	O
describe	O
a	O
hypophosphatemia	O
-	O
related	O
ARDS	O
case	O
report	O
of	O
a	O
50	O
-	O
year	O
-	O
old	O
woman	O
with	O
ACTH	B-PRGE
dependent	O
Cushing	O
'	O
s	O
syndrome	O
secondary	O
to	O
ectopic	O
CRH	B-PRGE
production	O
.	O

TITLE	O
:	O
[	O
Potent	O
immune	O
responses	O
elicited	O
by	O
a	O
bicistronic	O
IBV	O
DNA	O
vaccine	O
expressing	O
S1	O
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
gene	I-PRGE
].	O

Base	B-PRGE
pairing	O
between	O
the	O
leader	O
TRS	O
(	O
TRS	O
-	O
L	O
)	O
and	O
the	O
complement	O
of	O
the	O
body	O
TRS	O
(	O
cTRS	O
-	O
B	O
)	O
in	O
the	O
nascent	O
RNA	O
is	O
a	O
determinant	O
factor	O
during	O
CoV	O
transcription	O
.	O

Young	O
age	O
was	O
the	O
most	O
important	O
predictor	O
of	O
AOM	O
that	O
complicated	O
URI	B-PRGE
.	O

Recently	O
,	O
the	O
Acute	O
Dialysis	O
Quality	O
Initiative	O
proposed	O
the	O
RIFLE	O
consensus	O
classification	O
for	O
AKI	B-PRGE
.	O

This	O
classification	O
defines	O
3	O
stages	O
of	O
severity	O
of	O
AKI	B-PRGE
,	O
including	O
less	O
severe	O
AKI	O
.	O

Feline	O
leukemia	B-PRGE
virus	I-PRGE
antigen	I-PRGE
,	O
feline	O
immunodeficiency	O
virus	O
antibody	O
,	O
or	O
coronavirus	O
antibodies	O
were	O
not	O
detected	O
.	O

Herein	O
,	O
we	O
show	O
that	O
SL1	B-PRGE
is	O
functionally	O
and	O
structurally	O
bipartite	O
.	O

Although	O
not	O
conserved	O
at	O
the	O
nucleotide	O
sequence	O
level	O
,	O
these	O
general	O
structural	O
characteristics	O
of	O
SL1	B-PRGE
appear	O
to	O
be	O
conserved	O
in	O
other	O
coronaviral	O
genomes	O
.	O

The	O
replicase	B-PRGE
complex	I-PRGE
assembles	O
on	O
double	O
membrane	O
vesicles	O
(	O
DMVs	O
).	O

Here	O
,	O
we	O
studied	O
the	O
role	O
of	O
a	O
putative	O
replicase	O
anchor	O
,	O
nonstructural	B-PRGE
protein	I-PRGE
4	I-PRGE
(	O
nsp4	B-PRGE
),	O
in	O
the	O
assembly	O
of	O
murine	O
coronavirus	O
DMVs	O
.	O

A	O
series	O
of	O
ketones	O
and	O
corresponding	O
mono	O
-	O
and	O
di	O
-	O
fluoro	O
ketones	O
having	O
two	O
or	O
three	O
aromatic	O
rings	O
were	O
synthesized	O
as	O
possible	O
reversible	O
inhibitors	O
of	O
SARS	B-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
).	I-PRGE

Accordingly	O
,	O
SJHM	O
/	O
RA59	O
induced	O
higher	O
levels	O
of	O
CXCL9	B-PRGE
,	O
CXCL10	B-PRGE
,	O
and	O
CCL2	B-PRGE
protein	I-PRGE
compared	O
to	O
SA59	O
/	O
RJHM	O
.	O

ABSTRACT	O
:	O
The	O
main	O
protease	O
(	O
M	O
(	O
pro	O
))	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
plays	O
an	O
essential	O
role	O
in	O
the	O
extensive	O
proteolytic	O
processing	O
of	O
the	O
viral	O
polyproteins	O
(	O
pp1a	B-PRGE
and	O
pp1ab	O
),	O
and	O
it	O
is	O
an	O
important	O
target	O
for	O
anti	O
-	O
SARS	O
drug	O
development	O
.	O

Meanwhile	O
,	O
the	O
N	B-PRGE
-	I-PRGE
finger	I-PRGE
deletion	I-PRGE
mutant	I-PRGE
of	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
also	O
exists	O
as	O
both	O
a	O
stable	O
monomer	O
and	O
a	O
stable	O
dimer	O
,	O
and	O
the	O
dimer	O
is	O
formed	O
through	O
the	O
same	O
C	O
-	O
terminal	O
-	O
domain	O
interaction	O
as	O
that	O
in	O
the	O
M	O
(	O
pro	O
)-	O
C	O
dimer	O
.	O

Apparently	O
,	O
without	O
the	O
N	B-PRGE
-	I-PRGE
finger	I-PRGE
,	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
can	O
no	O
longer	O
retain	O
the	O
active	O
dimer	O
structure	O
;	O
instead	O
,	O
it	O
can	O
form	O
a	O
new	O
type	O
of	O
dimer	O
which	O
is	O
inactive	O
.	O

Both	O
a	O
SARS	O
-	O
CoV	O
mutant	O
virus	O
,	O
encoding	O
the	O
nsp1	B-PRGE
-	I-PRGE
mt	I-PRGE
protein	I-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
mt	I-PRGE
),	O
and	O
a	O
wild	O
-	O
type	O
virus	O
(	O
SARS	O
-	O
CoV	O
-	O
WT	O
)	O
replicated	O
efficiently	O
and	O
exhibited	O
similar	O
one	O
-	O
step	O
growth	O
kinetics	O
in	O
susceptible	O
cells	O
.	O

Six	O
days	O
before	O
the	O
operation	O
,	O
he	O
had	O
a	O
high	O
-	O
grade	O
fever	O
,	O
and	O
elevated	O
leukocyte	O
count	O
and	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
concentration	O
,	O
but	O
this	O
was	O
resolved	O
by	O
an	O
intravenous	O
antibiotic	O
.	O

TITLE	O
:	O
Roles	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	I-PRGE
polymorphisms	O
in	O
the	O
occurrence	O
and	O
progress	O
of	O
SARS	O
-	O
Cov	O
infection	O
:	O
a	O
case	O
-	O
control	O
study	O
.	O

Using	O
a	O
ELISA	O
method	O
,	O
we	O
found	O
an	O
increase	O
in	O
thrombopoietin	B-PRGE
(	O
TPO	B-PRGE
)	O
levels	O
in	O
the	O
plasma	O
of	O
convalesced	O
SARS	O
patients	O
(	O
290	O
+/-	O
53	O
pg	O
/	O
ml	O
)	O
and	O
active	O
SARS	O
patients	O
(	O
251	O
+/-	O
23	O
pg	O
/	O
ml	O
)	O
comparing	O
to	O
that	O
from	O
normal	O
control	O
patients	O
(	O
228	O
+/-	O
17	O
pg	O
/	O
ml	O
).	O

Our	O
objective	O
was	O
to	O
study	O
amiodarone	O
uptake	O
,	O
clarify	O
the	O
origin	O
of	O
vacuoles	O
,	O
and	O
investigate	O
the	O
effect	O
of	O
amiodarone	O
on	O
the	O
life	O
cycle	O
of	O
the	O
coronavirus	O
responsible	O
for	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
),	O
which	O
,	O
to	O
enter	O
cells	O
,	O
relies	O
on	O
the	O
proteolytic	O
cleavage	O
of	O
a	O
viral	O
spike	O
protein	O
by	O
the	O
endosomal	B-PRGE
proteinase	I-PRGE
cathepsin	I-PRGE
L	I-PRGE
.	O
Using	O
alveolar	O
macrophages	O
,	O
we	O
studied	O
uptake	O
of	O
(	O
125	O
)	O
I	O
-	O
amiodarone	O
and	O
(	O
125	O
)	O
I	O
-	O
B2	O
,	O
an	O
analog	O
lacking	O
the	O
lateral	O
group	O
diethylamino	O
-	O
beta	O
-	O
ethoxy	O
,	O
and	O
analyzed	O
the	O
effects	O
of	O
amiodarone	O
on	O
the	O
distribution	O
of	O
endosomal	O
markers	O
and	O
on	O
the	O
uptake	O
of	O
an	O
acidotropic	O
dye	O
.	O

To	O
investigate	O
endotoxemia	O
,	O
plasma	O
TNFalpha	B-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
the	O
liberation	O
capacity	O
of	O
those	O
cytokines	O
from	O
mononuclear	O
cells	O
after	O
LPS	O
challenge	O
(	O
Delta	O
values	O
),	O
and	O
plasma	O
antibodies	O
to	O
endotoxins	O
and	O
alpha	B-PRGE
-	I-PRGE
hemolysin	I-PRGE
of	O
Staphylococcus	O
aureus	O
in	O
ALI	O
/	O
ARDS	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
and	O
evaluation	O
of	O
trifluoromethyl	O
ketones	O
as	O
inhibitors	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
protease	I-PRGE
.	O

Three	O
different	O
amino	O
acids	O
were	O
explored	O
in	O
the	O
P1	O
-	O
position	O
and	O
in	O
the	O
P2	O
-	O
P4	O
positions	O
varying	O
amino	B-PRGE
acids	I-PRGE
and	I-PRGE
long	I-PRGE
alkyl	I-PRGE
chain	I-PRGE
were	O
incorporated	O
.	O

ABSTRACT	O
:	O
During	O
acute	O
viral	O
hepatitis	O
,	O
the	O
intrahepatic	O
tolerance	O
sustained	O
by	O
immunosuppressive	O
cytokines	O
such	O
as	O
interleukin	B-PRGE
(	O
IL	O
)-	O
4	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
TGF	O
)-	O
beta	O
and	O
prostaglandin	O
E2	O
(	O
PGE2	O
),	O
produced	O
by	O
Kupffer	O
cells	O
(	O
KC	O
),	O
liver	O
sinusoidal	O
endothelial	O
cells	O
(	O
LSEC	O
),	O
natural	O
killer	O
(	O
NK	O
)	O
T	O
cells	O
and	O
natural	O
regulatory	O
T	O
cells	O
may	O
be	O
disturbed	O
.	O

NK	O
cells	O
are	O
recruited	O
normally	O
in	O
the	O
liver	O
and	O
produce	O
interferon	B-PRGE
(	O
IFN	O
)-	O
gamma	O
to	O
control	O
viral	O
replication	O
.	O

The	O
use	O
of	O
mouse	B-PRGE
hepatitis	I-PRGE
virus	I-PRGE
type	I-PRGE
3	I-PRGE
(	O
MHV3	O
)	O
attenuated	O
variants	O
showing	O
selected	O
tropisms	O
for	O
KC	O
or	O
LSEC	O
have	O
allowed	O
determining	O
their	O
roles	O
in	O
the	O
disturbances	O
of	O
immune	O
tolerance	O
during	O
viral	O
hepatitis	O
.	O

These	O
results	O
indicate	O
that	O
viral	O
permissivity	O
of	O
KC	O
and	O
LSEC	O
is	O
involved	O
in	O
the	O
decrease	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
PGE2	B-PRGE
,	O
while	O
KC	O
may	O
play	O
an	O
additional	O
role	O
in	O
the	O
apoptosis	O
of	O
NK	O
and	O
NK	O
T	O
cells	O
during	O
acute	O
viral	O
hepatitis	O
.	O

Mimicyp	O
adopts	O
a	O
typical	O
cyclophilin	B-PRGE
-	O
fold	O
,	O
yet	O
it	O
also	O
forms	O
trimers	O
unlike	O
any	O
previously	O
characterized	O
homologue	O
.	O

TITLE	O
:	O
Structure	O
-	O
based	O
virtual	O
screening	O
against	O
SARS	B-PRGE
-	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
)	O
to	O
identify	O
novel	O
non	O
-	O
peptidic	O
hits	O
.	O

To	O
identify	O
residues	O
in	O
the	O
spike	O
protein	O
of	O
NL63	O
that	O
are	O
important	O
for	O
hACE2	O
binding	O
,	O
this	O
study	O
first	O
generated	O
a	O
series	O
of	O
S1	O
-	O
truncated	O
variants	O
,	O
examined	O
their	O
associations	O
with	O
the	O
hACE2	B-PRGE
receptor	I-PRGE
and	O
subsequently	O
mapped	O
a	O
minimal	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
that	O
consisted	O
of	O
141	O
residues	O
(	O
aa	O
476	O
-	O
616	O
)	O
towards	O
the	O
C	O
terminus	O
of	O
the	O
S1	B-PRGE
domain	I-PRGE
.	O

L	O
.	O
nobilis	O
oil	O
exerted	O
an	O
interesting	O
activity	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
120	O
microg	O
/	O
ml	O
and	O
a	O
selectivity	O
index	O
(	O
SI	O
)	O
of	O
4	O
.	O
16	O
.	O

Plasma	O
biomarkers	O
of	O
inflammation	O
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
,	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
1	I-PRGE
),	O
of	O
coagulation	O
(	O
thrombomodulin	B-PRGE
,	O
protein	B-PRGE
C	I-PRGE
)	O
and	O
of	O
fibrinolysis	O
(	O
plasminogen	B-PRGE
activator	I-PRGE
inhibitor	I-PRGE
1	I-PRGE
)	O
were	O
measured	O
by	O
ELISA	O
.	O

Three	O
biomarkers	O
-	O
IL	O
-	O
8	O
,	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
1	I-PRGE
and	I-PRGE
protein	I-PRGE
C	I-PRGE
-	O
remained	O
significantly	O
different	O
by	O
multivariate	O
analysis	O
that	O
included	O
age	O
,	O
gender	O
,	O
Simplified	O
Acute	O
Physiology	O
Score	O
II	O
and	O
all	O
biomarkers	O
that	O
were	O
significant	O
on	O
bivariate	O
analysis	O
.	O

RESULTS	O
:	O
The	O
mRNA	O
of	O
human	B-PRGE
beta	I-PRGE
actin	I-PRGE
gene	I-PRGE
could	O
be	O
amplified	O
efficiently	O
in	O
all	O
the	O
tissue	O
samples	O
.	O

Further	O
mutational	O
experiments	O
identified	O
two	O
substitutions	O
,	O
Y442C	O
and	O
L472F	O
,	O
within	O
the	O
receptor	O
binding	O
domain	O
that	O
could	O
be	O
critical	O
for	O
the	O
reduced	O
S	O
incorporation	O
,	O
as	O
well	O
as	O
reduced	O
binding	O
affinity	O
between	O
the	O
S	B-PRGE
protein	I-PRGE
and	O
ACE2	B-PRGE
receptor	I-PRGE
.	O

ABSTRACT	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
PBL	B-PRGE
is	O
an	O
effective	O
method	O
for	O
preparing	O
multidisciplinary	O
learner	O
groups	O
at	O
community	O
health	O
centers	O
(	O
CHCs	O
)	O
for	O
pandemics	O
,	O
quantitative	O
and	O
qualitative	O
methods	O
were	O
utilized	O
to	O
evaluate	O
the	O
conduct	O
of	O
a	O
PBL	O
case	O
of	O
a	O
hypothetical	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
at	O
two	O
CHCs	O
in	O
Hawaii	O
,	O
with	O
multidisciplinary	O
health	O
professional	O
and	O
student	O
participants	O
.	O

Using	O
recombinant	B-PRGE
protein	I-PRGE
domains	I-PRGE
expressed	O
in	O
Escherichia	O
coli	O
,	O
we	O
identified	O
two	O
additional	O
RNA	O
-	O
binding	O
domains	O
of	O
nsp3	B-PRGE
.	O

ABSTRACT	O
:	O
Apple	O
latent	O
spherical	O
virus	O
(	O
ALSV	O
)	O
expressing	O
green	O
,	O
cyan	O
,	O
and	O
yellow	O
fluorescent	O
proteins	O
(	O
GFP	O
,	O
CFP	B-PRGE
,	O
and	O
YFP	O
)	O
was	O
constructed	O
and	O
used	O
to	O
analyze	O
the	O
local	O
and	O
systemic	O
movement	O
of	O
the	O
virus	O
in	O
infected	O
plants	O
.	O

The	O
inducible	O
nitric	B-PRGE
oxide	I-PRGE
synthase	I-PRGE
was	O
up	O
-	O
regulated	O
.	O

Notably	O
,	O
sera	O
demonstrated	O
cross	O
-	O
reactivity	O
against	O
nucleocapsid	O
peptide	O
sequences	O
common	O
to	O
HCoV	O
-	O
OC43	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
These	O
findings	O
underscore	O
the	O
virulence	O
of	O
human	B-PRGE
CoV	I-PRGE
-	I-PRGE
OC43	I-PRGE
in	O
elderly	O
populations	O
and	O
confirm	O
that	O
cross	O
-	O
reactivity	O
to	O
antibody	O
against	O
nucleocapsid	O
proteins	O
from	O
these	O
viruses	O
must	O
be	O
considered	O
when	O
interpreting	O
serological	O
tests	O
for	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
Ninety	O
-	O
five	O
of	O
142	O
residents	O
(	O
67	O
%)	O
and	O
53	O
of	O
160	O
staff	O
members	O
(	O
33	O
%)	O
experienced	O
symptoms	O
of	O
respiratory	O
infection	O
.	O

Sequence	O
analysis	O
of	O
40	O
degrees	O
C	O
revertants	O
of	O
Alb	B-PRGE
/	O
ts	O
/	O
nsp5	B-PRGE
/	O
V148A	O
identified	O
primary	O
reversion	O
to	O
Ala148Val	O
in	O
nsp5	B-PRGE
,	O
as	O
well	O
as	O
two	O
independent	O
second	O
-	O
site	O
mutations	O
resulting	O
in	O
Ser133Asn	O
and	O
His134Tyr	O
substitutions	O
in	O
nsp5	B-PRGE
.	O

A	O
consensus	O
sequence	O
of	O
2681	O
nucleotides	O
was	O
obtained	O
through	O
direct	O
sequencing	O
of	O
seven	O
overlapping	O
PCR	O
fragments	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
.	O

Translation	O
initiated	O
in	O
-	O
frame	O
from	O
the	O
third	O
Met	O
is	O
unusual	O
since	O
the	O
sequence	O
around	O
the	O
first	O
Met	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
contains	O
the	O
optimal	O
consensus	O
Kozak	O
sequence	O
.	O

The	O
antisera	O
of	O
the	O
epitopes	O
S1D5	O
and	O
S1D6	O
could	O
react	O
with	O
the	O
native	B-PRGE
S	I-PRGE
protein	I-PRGE
of	O
PEDV	O
.	O

TITLE	O
:	O
Cleavage	O
of	O
group	O
1	O
coronavirus	O
spike	O
proteins	O
:	O
how	O
furin	B-PRGE
cleavage	O
is	O
traded	O
off	O
against	O
heparan	O
sulfate	O
binding	O
upon	O
cell	O
culture	O
adaptation	O
.	O

The	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
has	O
been	O
identified	O
as	O
a	O
functional	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
ACE	B-PRGE
-	I-PRGE
2	I-PRGE
has	O
been	O
shown	O
to	O
be	O
expressed	O
at	O
the	O
apical	O
domain	O
of	O
polarized	O
Calu	O
-	O
3	O
cells	O
.	O

Interferon	B-PRGE
alfacon	I-PRGE
1	I-PRGE
demonstrated	O
significant	O
antiviral	O
activity	O
in	O
neutral	O
red	O
uptake	O
assay	O
and	O
virus	O
yield	O
reduction	O
assay	O
.	O

The	O
serum	O
concentration	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
was	O
not	O
significantly	O
different	O
in	O
cats	O
with	O
FIP	O
compared	O
with	O
clinically	O
normal	O
FCoV	O
-	O
infected	O
animals	O
living	O
in	O
catteries	O
with	O
a	O
low	O
prevalence	O
of	O
the	O
disease	O
.	O

TITLE	O
:	O
Heteroaromatic	O
ester	O
inhibitors	O
of	O
hepatitis	B-PRGE
A	I-PRGE
virus	I-PRGE
3C	I-PRGE
proteinase	I-PRGE
:	O
Evaluation	O
of	O
mode	O
of	O
action	O
.	O

Three	O
of	O
the	O
compounds	O
,	O
which	O
also	O
had	O
furan	O
rings	O
,	O
inhibited	O
the	O
cleavage	O
activity	O
of	O
HAV	O
3C	O
(	O
pro	O
)	O
with	O
K	O
(	O
ic	O
)	O
s	O
of	O
120	O
-	O
240nM	O
.	O
HPLC	O
-	O
based	O
assays	O
revealed	O
that	O
the	O
inhibitors	O
were	O
slowly	O
hydrolyzed	O
by	O
both	O
HAV	B-PRGE
3C	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
and	I-PRGE
SARS	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
),	I-PRGE
confirming	O
the	O
identity	O
of	O
the	O
expected	O
products	O
.	O

ABSTRACT	O
:	O
Virus	O
-	O
specific	O
CD8	B-PRGE
(+)	O
T	O
cells	O
are	O
critical	O
for	O
protection	O
against	O
neurotropic	O
coronaviruses	O
;	O
however	O
,	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
infection	O
with	O
the	O
recombinant	O
JHM	O
(	O
RJHM	O
)	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
elicits	O
a	O
weak	O
CD8	B-PRGE
(+)	O
T	O
-	O
cell	O
response	O
in	O
the	O
brain	O
and	O
causes	O
lethal	O
encephalomyelitis	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
failure	O
of	O
RJHM	O
to	O
prime	O
a	O
robust	O
CD8	B-PRGE
(+)	O
T	O
-	O
cell	O
response	O
during	O
CNS	O
infection	O
is	O
likely	O
due	O
to	O
its	O
failure	O
to	O
replicate	O
in	O
the	O
CLN	O
.	O

Here	O
,	O
we	O
report	O
the	O
full	O
genomic	O
sequences	O
of	O
bat	B-PRGE
CoVs	I-PRGE
1A	I-PRGE
,	O
1B	O
and	O
HKU8	O
.	O

Procalcitonin	O
(	O
PCT	B-PRGE
)	O
has	O
been	O
evaluated	O
for	O
its	O
utility	O
in	O
determining	O
the	O
aetiology	O
of	O
community	O
-	O
acquired	O
pneumonia	O
(	O
CAP	O
),	O
choice	O
of	O
antibiotics	O
and	O
prediction	O
of	O
outcome	O
.	O

Here	O
we	O
report	O
that	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
4	I-PRGE
(	O
TLR4	B-PRGE
)	O
mutant	O
mice	O
display	O
natural	O
resistance	O
to	O
acid	O
-	O
induced	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

This	O
reveals	O
the	O
coexistence	O
of	O
2	O
cohorts	O
of	O
phagocytes	O
whose	O
FIP	B-PRGE
viral	O
contents	O
differed	O
by	O
the	O
presence	O
or	O
absence	O
of	O
the	O
FIPV3	O
-	O
70	O
-	O
recognized	O
epitope	O
.	O

The	O
most	O
promising	O
compounds	O
include	O
carbohydrate	O
-	O
binding	O
agents	O
,	O
neutralizing	O
antibodies	O
and	O
drugs	O
targeting	O
a	O
coronaviral	B-PRGE
envelope	I-PRGE
protein	I-PRGE
.	O

Furthermore	O
,	O
we	O
co	O
-	O
immunoprecipitated	O
HEPIS	B-PRGE
with	O
BTF3	B-PRGE
,	O
a	O
component	O
of	O
the	O
RNA	B-PRGE
pol	I-PRGE
II	I-PRGE
initiation	I-PRGE
complex	I-PRGE
,	O
and	O
observed	O
reduced	O
proliferation	O
of	O
HeLa	O
cells	O
transfected	O
with	O
the	O
HEPIS	B-PRGE
gene	I-PRGE
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
HEPIS	B-PRGE
may	O
function	O
as	O
a	O
potential	O
transcriptional	O
repressor	O
.	O

In	O
this	O
study	O
,	O
three	O
fragments	O
[	O
N1	O
(	O
residues	O
:	O
1	O
-	O
422	O
);	O
N2	O
(	O
residues	O
:	O
1	O
-	O
109	O
);	O
N3	O
(	O
residues	O
:	O
110	O
-	O
422	O
)]	O
of	O
N	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
were	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
analyzed	O
by	O
pooled	O
sera	O
of	O
convalescence	O
phase	O
of	O
SARS	O
patients	O
.	O

ADS	B-PRGE
-	I-PRGE
J1	I-PRGE
,	O
which	O
has	O
been	O
used	O
to	O
interfere	O
with	O
the	O
fusogenesis	O
of	O
HIV	O
-	O
1	O
onto	O
CD4	B-PRGE
+	I-PRGE
cells	O
,	O
demonstrated	O
the	O
highest	O
HIV	O
-	O
luc	O
/	O
SARS	O
pseudotyped	O
virus	O
-	O
entry	O
inhibition	O
activity	O
among	O
the	O
other	O
small	O
-	O
molecule	O
drugs	O
.	O

By	O
expressing	O
a	O
U6	O
promoter	O
-	O
driven	O
small	O
interfering	O
RNA	O
containing	O
sequences	O
homologous	O
to	O
part	O
of	O
ACE2	B-PRGE
mRNA	I-PRGE
,	O
we	O
successfully	O
silenced	O
ACE2	B-PRGE
expression	O
in	O
Vero	O
E6	O
cells	O
.	O

ABSTRACT	O
:	O
Recombinant	O
severe	O
acute	O
respiratory	O
virus	O
(	O
SARS	O
-	O
CoV	O
)	O
variants	O
lacking	O
the	O
group	O
specific	O
genes	O
6	O
,	O
7a	O
,	O
7b	O
,	O
8a	O
,	O
8b	O
and	O
9b	O
(	O
rSARS	O
-	O
CoV	O
-	O
Delta	O
[	O
6	O
-	O
9b	O
]),	O
the	O
structural	O
gene	B-PRGE
E	I-PRGE
(	O
rSARS	O
-	O
CoV	O
-	O
DeltaE	O
),	O
and	O
a	O
combination	O
of	O
both	O
sets	O
of	O
genes	O
(	O
rSARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
Delta	I-PRGE
[	O
E	O
,	O
6	O
-	O
9b	O
])	O
have	O
been	O
generated	O
.	O

Fifteen	O
potential	O
factors	O
influencing	O
the	O
prognosis	O
of	O
SAP	B-PRGE
were	O
analyzed	O
with	O
Logistic	O
regression	O
analysis	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
a	O
multiplex	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
PCR	O
method	O
using	O
Seeplex	O
RV	O
Detection	O
kit	O
(	O
Seegene	O
,	O
Korea	O
)	O
for	O
the	O
detection	O
of	O
rhinovirus	O
,	O
coronavirus	O
,	O
and	O
human	O
metapneumovirus	O
(	O
hMPV	O
).	O

Plasma	O
cytokine	O
and	O
chemokine	O
profiles	O
showed	O
markedly	O
elevated	O
Th1	O
cytokine	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)-	O
gamma	O
,	O
inflammatory	O
cytokines	O
interleukin	B-PRGE
(	O
IL	O
)-	O
1beta	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
12	I-PRGE
,	I-PRGE
neutrophil	I-PRGE
chemokine	I-PRGE
IL	I-PRGE
-	I-PRGE
8	I-PRGE
,	I-PRGE
monocyte	I-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
),	O
and	O
Th1	B-PRGE
chemokine	I-PRGE
IFN	I-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
)	O
for	O
at	O
least	O
two	O
weeks	O
after	O
disease	O
onset	O
,	O
but	O
there	O
was	O
no	O
significant	O
elevation	O
of	O
inflammatory	O
cytokine	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	O
)-	O
alpha	O
and	O
anti	B-PRGE
-	I-PRGE
inflammatory	I-PRGE
cytokine	I-PRGE
IL	I-PRGE
-	I-PRGE
10	I-PRGE
.	O

We	O
examined	O
the	O
immune	O
responses	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
both	O
young	O
and	O
adult	O
mice	O
.	O

These	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
antibodies	I-PRGE
were	O
discovered	O
using	O
a	O
novel	O
DNA	O
display	O
method	O
,	O
which	O
can	O
identify	O
new	O
antibodies	O
within	O
days	O
.	O

In	O
this	O
paper	O
,	O
a	O
novel	O
phylogenomic	O
method	O
,	O
named	O
as	O
Base	B-PRGE
-	O
Base	B-PRGE
Correlation	O
(	O
BBC	O
),	O
has	O
been	O
proposed	O
to	O
infer	O
phylogenetic	O
relationships	O
from	O
complete	O
genomes	O
,	O
with	O
particular	O
emphasis	O
on	O
coronavirus	O
phylogeny	O
.	O

TITLE	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
and	O
229E	O
seroconversion	O
in	O
children	O
.	O

A	O
programmed	O
-	O
1	O
ribosomal	O
frameshift	O
is	O
required	O
by	O
coronaviruses	O
for	O
the	O
production	O
of	O
the	O
RNA	B-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
which	O
in	O
turn	O
is	O
essential	O
for	O
viral	O
replication	O
.	O

Nonsurvivors	O
had	O
higher	O
IAP	B-PRGE
(	O
max	B-PRGE
),	O
IAP	O
(	O
mean	O
),	O
and	O
fluid	O
balances	O
and	O
lower	O
abdominal	O
perfusion	O
pressure	O
.	O

Logistic	O
regression	O
identified	O
IAP	B-PRGE
(	O
max	B-PRGE
)	O
as	O
an	O
independent	O
predictor	O
of	O
mortality	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
17	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
05	O
-	O
1	O
.	O
30	O
;	O
p	O
=	O
.	O
003	O
)	O
after	O
adjusting	O
with	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
and	O
comorbidities	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
15	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
06	O
-	O
1	O
.	O
25	O
;	O
p	O
=	O
.	O
001	O
;	O
and	O
odds	O
ratio	O
,	O
2	O
.	O
68	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
27	O
-	O
5	O
.	O
67	O
;	O
p	O
=	O
.	O
013	O
,	O
respectively	O
).	O

TITLE	O
:	O
A	O
chimeric	O
multi	O
-	O
epitope	O
DNA	O
vaccine	O
elicited	O
specific	O
antibody	O
response	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
which	O
attenuated	O
the	O
virulence	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
vitro	O
.	O

Compared	O
with	O
control	O
cats	O
,	O
pleocytosis	O
was	O
evident	O
in	O
8	O
of	O
12	O
(	O
67	O
%)	O
cats	O
and	O
CSF	B-PRGE
-	I-PRGE
TP	I-PRGE
was	O
increased	O
in	O
3	O
of	O
12	O
(	O
25	O
%)	O
cats	O
with	O
CNS	O
-	O
FIP	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
the	O
S1	B-PRGE
gene	I-PRGE
showed	O
that	O
the	O
vaccine	O
strains	O
and	O
the	O
field	O
strain	O
belonged	O
to	O
different	O
clusters	O
and	O
had	O
larger	O
evolutionary	O
distances	O
,	O
indicating	O
that	O
they	O
were	O
of	O
different	O
genotypes	O
.	O

ABSTRACT	O
:	O
The	O
envelope	B-PRGE
glycoproteins	I-PRGE
of	O
the	O
class	B-PRGE
I	I-PRGE
family	I-PRGE
,	O
which	O
include	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
influenza	O
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
mediate	O
viral	O
entry	O
by	O
first	O
binding	O
to	O
their	O
cellular	O
receptors	O
and	O
subsequently	O
inducing	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	O
membranes	O
.	O

The	O
flow	O
cytometry	O
assay	O
showed	O
that	O
the	O
purified	O
RBD	B-PRGE
-	I-PRGE
Fc	I-PRGE
protein	I-PRGE
could	O
bind	O
to	O
ACE2	B-PRGE
.	O

Retrospective	O
analysis	O
using	O
the	O
TR	B-PRGE
-	I-PRGE
DGU	I-PRGE
database	O
(	O
Trauma	O
Registry	O
of	O
the	O
Deutsche	O
Gesellschaft	O
fÃ¼r	O
Unfallchirurgie	O
2002	O
-	O
2006	O
)	O
on	O
primary	O
admissions	O
with	O
substantial	O
injury	O
(	O
Injury	O
Severity	O
Score	O
>	O
16	O
)	O
and	O
massive	O
transfusion	O
(>	O
10	O
pRBCs	O
).	O

TITLE	O
:	O
A	O
structural	O
view	O
of	O
the	O
inactivation	O
of	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
main	I-PRGE
proteinase	I-PRGE
by	O
benzotriazole	O
esters	O
.	O

ABSTRACT	O
:	O
The	O
type	B-PRGE
1	I-PRGE
interferons	I-PRGE
(	O
INF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
INF	B-PRGE
-	I-PRGE
beta	I-PRGE
)	O
are	O
potent	O
antiviral	O
agents	O
.	O

Albumin	B-PRGE
-	O
INF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
albumin	B-PRGE
-	I-PRGE
INF	I-PRGE
-	I-PRGE
beta	I-PRGE
are	O
novel	O
recombinant	O
proteins	O
consisting	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
genetically	O
fused	O
to	O
human	B-PRGE
albumin	I-PRGE
.	O

TITLE	O
:	O
Cathepsin	B-PRGE
L	I-PRGE
functionally	O
cleaves	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
class	O
I	O
fusion	O
protein	O
upstream	O
of	O
rather	O
than	O
adjacent	O
to	O
the	O
fusion	O
peptide	O
.	O

To	O
test	O
the	O
efficacy	O
of	O
activated	B-PRGE
protein	I-PRGE
C	I-PRGE
(	O
APC	B-PRGE
)	O
as	O
a	O
therapy	O
for	O
patients	O
with	O
ALI	O
.	O

Reports	O
using	O
historical	O
matched	O
controls	O
have	O
suggested	O
that	O
treatment	O
with	O
interferon	B-PRGE
alfacon	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
a	O
synthetic	O
interferon	O
)	O
combined	O
with	O
steroid	O
,	O
protease	O
inhibitors	O
together	O
with	O
ribavirin	O
,	O
or	O
convalescent	O
plasma	O
containing	O
neutralizing	O
antibody	O
,	O
could	O
be	O
useful	O
.	O

Based	O
on	O
the	O
X	O
-	O
ray	O
structure	O
of	O
3CL	O
(	O
Pro	B-PRGE
)	O
co	O
-	O
crystallized	O
with	O
a	O
trans	O
-	O
alpha	O
,	O
beta	O
-	O
unsaturated	O
ethyl	O
ester	O
(	O
Michael	O
acceptor	O
),	O
a	O
set	O
of	O
QM	O
/	O
QM	O
and	O
QM	O
/	O
MM	O
calculations	O
were	O
performed	O
,	O
yielding	O
three	O
models	O
with	O
increasingly	O
higher	O
the	O
number	O
of	O
atoms	O
.	O

Identification	O
of	O
IBV	O
was	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
of	O
RNA	O
extracted	O
from	O
oropharyngeal	O
swabs	O
taken	O
from	O
poultry	O
flocks	O
exhibiting	O
signs	O
of	O
clinical	O
disease	O
thought	O
to	O
be	O
attributable	O
to	O
IBV	O
.	O

Zoonotic	O
SARS	O
-	O
CoV	O
was	O
completely	O
dependent	O
on	O
ACE2	B-PRGE
for	O
entry	O
.	O

MBL	B-PRGE
is	O
a	O
serum	O
lectin	B-PRGE
that	O
mediates	O
phagocytosis	O
and	O
activates	O
the	O
lectin	B-PRGE
pathway	O
of	O
complement	O
involving	O
MASP	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

Based	O
on	O
this	O
assay	O
system	O
,	O
we	O
screened	O
7035	O
small	O
molecule	O
compounds	O
from	O
which	O
we	O
identified	O
7	O
compounds	O
with	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
activity	O
.	O

ABSTRACT	O
:	O
The	O
pathology	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
in	O
cats	O
and	O
ferrets	O
is	O
poorly	O
described	O
,	O
and	O
the	O
distribution	O
of	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
a	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
in	O
the	O
respiratory	O
tracts	O
of	O
these	O
species	O
is	O
unknown	O
.	O

We	O
observed	O
SARS	B-PRGE
-	O
CoV	O
antigen	O
expression	O
and	O
lesions	O
in	O
the	O
respiratory	O
tracts	O
of	O
4	O
cats	O
and	O
4	O
ferrets	O
at	O
4	O
days	O
postinoculation	O
and	O
ACE2	B-PRGE
expression	O
in	O
the	O
respiratory	O
tracts	O
of	O
3	O
cats	O
and	O
3	O
ferrets	O
without	O
infection	O
.	O

ACE2	B-PRGE
expression	O
occurred	O
mainly	O
in	O
type	O
I	O
and	O
II	O
pneumocytes	O
,	O
tracheo	O
-	O
bronchial	O
goblet	O
cells	O
,	O
serous	O
epithelial	O
cells	O
of	O
tracheo	O
-	O
bronchial	O
submucosal	O
glands	O
in	O
cats	O
,	O
and	O
type	O
II	O
pneumocytes	O
and	O
serous	O
epithelial	O
cells	O
of	O
tracheo	O
-	O
bronchial	O
submucosal	O
glands	O
in	O
ferrets	O
.	O

Results	O
from	O
a	O
capture	O
assay	O
show	O
that	O
DC	O
-	O
SIGN	O
-	O
expressing	O
cells	O
(	O
including	O
B	O
-	O
THP	O
-	O
1	O
/	O
DC	O
-	O
SIGN	O
and	O
T	O
-	O
THP	O
-	O
1	O
/	O
DC	O
-	O
SIGN	O
)	O
and	O
peripheral	O
blood	O
dendritic	O
cells	O
are	O
capable	O
of	O
transferring	O
H5N1	O
pseudotyped	O
and	O
RG	O
virus	O
particles	O
to	O
target	O
cells	O
;	O
this	O
action	O
can	O
be	O
blocked	O
by	O
anti	B-PRGE
-	I-PRGE
DC	I-PRGE
-	I-PRGE
SIGN	I-PRGE
monoclonal	I-PRGE
antibodies	I-PRGE
.	O

ABSTRACT	O
:	O
Experimental	O
and	O
clinical	O
studies	O
support	O
the	O
key	O
role	O
of	O
interleukin	B-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
),	O
a	O
potent	O
proinflammatory	O
cytokine	O
,	O
in	O
the	O
development	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

ABSTRACT	O
:	O
DUBs	O
(	O
deubiquitinating	O
enzymes	O
)	O
are	O
a	O
family	O
of	O
proteases	O
responsible	O
for	O
the	O
specific	O
removal	O
of	O
ubiquitin	B-PRGE
attached	O
to	O
target	O
proteins	O
and	O
thus	O
control	O
the	O
free	O
cellular	O
pools	O
of	O
this	O
molecule	O
.	O

Surprisingly	O
,	O
screening	O
of	O
the	O
P2	O
position	O
revealed	O
that	O
UCH	B-PRGE
-	I-PRGE
L3	I-PRGE
,	O
in	O
contrast	O
with	O
all	O
the	O
other	O
tested	O
DUBs	O
,	O
demonstrates	O
substantial	O
tolerance	O
of	O
alanine	O
and	O
valine	O
at	O
P2	O
,	O
and	O
a	O
parallel	O
analysis	O
using	O
the	O
appropriate	O
mutation	O
of	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
ubiquitin	I-PRGE
confirms	O
this	O
.	O

We	O
identified	O
several	O
amino	O
acid	O
substitutions	O
,	O
including	O
Y442F	O
and	O
V601G	O
in	O
the	O
S1	B-PRGE
domain	I-PRGE
and	O
D757N	O
and	O
A834V	O
in	O
the	O
S2	O
region	O
.	O

In	O
contrast	O
,	O
host	O
cell	O
entry	O
by	O
the	O
FIPV	O
strains	O
WSU	O
79	O
-	O
1146	O
(	O
FIPV	O
-	O
1146	O
)	O
and	O
FIPV	O
-	O
DF2	O
proceeds	O
independently	O
of	O
cathepsin	B-PRGE
L	I-PRGE
activity	O
and	O
low	O
pH	O
,	O
but	O
is	O
still	O
highly	O
dependent	O
on	O
cathepsin	B-PRGE
B	I-PRGE
activity	O
.	O

TITLE	O
:	O
A	O
second	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S2	I-PRGE
glycoprotein	I-PRGE
internal	O
membrane	O
-	O
active	O
peptide	O
.	O

Therefore	O
,	O
we	O
have	O
carried	O
out	O
a	O
study	O
of	O
the	O
binding	O
and	O
interaction	O
with	O
model	O
membranes	O
of	O
a	O
peptide	O
corresponding	O
to	O
segment	O
873	O
-	O
888	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
glycoprotein	I-PRGE
,	O
peptide	O
SARS	O
IFP	O
,	O
as	O
well	O
as	O
the	O
structural	O
changes	O
taking	O
place	O
in	O
both	O
the	O
phospholipid	O
and	O
the	O
peptide	O
induced	O
by	O
the	O
binding	O
of	O
the	O
peptide	O
to	O
the	O
membrane	O
.	O

These	O
data	O
support	O
its	O
role	O
in	O
SARS	O
-	O
mediated	O
membrane	O
fusion	O
and	O
suggest	O
that	O
the	O
regions	O
where	O
this	O
peptide	O
resides	O
might	O
assist	O
the	O
fusion	O
peptide	O
and	O
/	O
or	O
the	O
pretransmembrane	O
segment	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
in	O
the	O
fusion	O
process	O
.	O

The	O
same	O
replicons	O
containing	O
further	O
deletion	O
of	O
the	O
coding	O
regions	O
for	O
non	O
-	O
structural	O
proteins	O
(	O
nsp	O
)	O
1	O
,	O
2	O
or	O
16	O
confirmed	O
previous	O
observation	O
that	O
nsp16	O
,	O
but	O
not	O
nsp1	B-PRGE
or	O
nsp2	B-PRGE
,	O
was	O
essential	O
for	O
efficient	O
viral	O
replication	O
or	O
transcription	O
.	O

The	O
key	O
feature	O
of	O
this	O
simple	O
immunoswab	O
diagnostic	O
assay	O
is	O
its	O
ability	O
to	O
detect	O
the	O
presence	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antigen	I-PRGE
within	O
45	O
-	O
60	O
min	O
with	O
the	O
availability	O
of	O
the	O
body	O
fluid	O
samples	O
.	O

TITLE	O
:	O
Frameshifting	O
RNA	B-PRGE
pseudoknots	I-PRGE
:	O
structure	O
and	O
mechanism	O
.	O

These	O
two	O
elements	O
are	O
separated	O
by	O
six	O
to	O
eight	O
nucleotides	O
,	O
a	O
distance	O
that	O
places	O
the	O
5	O
'	O
edge	O
of	O
the	O
downstream	O
stimulatory	O
element	O
in	O
direct	O
contact	O
with	O
the	O
mRNA	O
entry	O
channel	O
of	O
the	O
30S	B-PRGE
ribosomal	I-PRGE
subunit	I-PRGE
.	O

Incorporation	O
of	O
S	B-PRGE
protein	I-PRGE
of	O
vAcBS	O
(	O
BS	O
)	O
into	O
VLPs	O
was	O
confirmed	O
by	O
western	O
blot	O
and	O
immunogold	O
labeling	O
.	O

Further	O
study	O
indicated	O
that	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
+	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
+	I-PRGE
populations	O
in	O
CD4	B-PRGE
+	I-PRGE
T	O
cells	O
increased	O
upon	O
co	O
-	O
cultivation	O
with	O
DCs	O
pre	O
-	O
exposed	O
with	O
BVLPs	O
or	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
VLPs	I-PRGE
.	O

Finding	O
in	O
this	O
study	O
may	O
provide	O
important	O
information	O
for	O
vaccine	O
development	O
as	O
well	O
as	O
for	O
understanding	O
the	O
pathogenesis	O
of	O
SARS	B-PRGE
-	I-PRGE
like	I-PRGE
CoV	I-PRGE
.	O

This	O
was	O
the	O
result	O
of	O
increased	O
Bax	B-PRGE
oligomerization	O
and	O
higher	O
levels	O
of	O
p53	B-PRGE
in	O
3a	O
protein	O
-	O
expressing	O
cells	O
,	O
which	O
depended	O
on	O
the	O
activation	O
of	O
p38	O
MAP	B-PRGE
kinase	I-PRGE
(	O
MAPK	B-PRGE
)	O
in	O
these	O
cells	O
.	O

Based	O
upon	O
the	O
rotavirus	B-PRGE
NSP4	I-PRGE
gene	I-PRGE
sequence	I-PRGE
,	O
the	O
chicken	O
and	O
turkey	O
origin	O
rotaviruses	O
assorted	O
in	O
a	O
species	O
-	O
specific	O
manner	O
.	O

TITLE	O
:	O
Essential	O
role	O
of	O
pre	B-PRGE
-	I-PRGE
B	I-PRGE
-	I-PRGE
cell	I-PRGE
colony	I-PRGE
enhancing	I-PRGE
factor	I-PRGE
in	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

Thus	O
,	O
MHV	O
induces	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
in	O
macrophages	O
and	O
microglia	O
in	O
the	O
brains	O
of	O
infected	O
animals	O
and	O
is	O
recognized	O
by	O
an	O
MDA5	B-PRGE
-	O
dependent	O
pathway	O
in	O
macrophages	O
.	O

In	O
addition	O
to	O
a	O
common	O
set	O
of	O
genes	O
for	O
replicase	B-PRGE
and	O
structural	O
proteins	O
,	O
each	O
coronavirus	O
may	O
carry	O
multiple	O
group	O
-	O
specific	O
genes	O
apparently	O
acquired	O
through	O
relatively	O
recent	O
heterologous	O
recombination	O
events	O
.	O

In	O
contrast	O
,	O
the	O
structure	O
of	O
the	O
Cys69Ala	O
mutant	O
of	O
HCoV	O
-	O
229E	O
Nsp9	O
shows	O
the	O
same	O
dimer	O
organization	O
as	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
Polymorphisms	O
in	O
the	O
C	B-PRGE
-	I-PRGE
type	I-PRGE
lectin	I-PRGE
genes	I-PRGE
cluster	O
in	O
chromosome	O
19	O
and	O
predisposition	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
indicated	O
that	O
the	O
genetic	O
predisposition	O
allele	O
was	O
not	O
found	O
in	O
this	O
lectin	B-PRGE
gene	I-PRGE
cluster	I-PRGE
and	O
population	O
stratification	O
might	O
cause	O
the	O
previous	O
positive	O
association	O
.	O

ABSTRACT	O
:	O
The	O
sialylation	O
pattern	O
of	O
serum	B-PRGE
alpha1	I-PRGE
-	I-PRGE
acid	I-PRGE
glycoprotein	I-PRGE
(	O
AGP	B-PRGE
)	O
in	O
non	O
-	O
symptomatic	O
cats	O
infected	O
by	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
and	O
its	O
possible	O
relationship	O
with	O
the	O
amount	O
of	O
FCoVs	O
shed	O
in	O
faeces	O
were	O
investigated	O
.	O

These	O
results	O
suggest	O
that	O
hypersialylation	O
of	O
AGP	B-PRGE
may	O
be	O
involved	O
in	O
host	O
-	O
virus	O
interactions	O
.	O

SARS	B-PRGE
6	I-PRGE
and	O
SARS	B-PRGE
8b	I-PRGE
proteins	I-PRGE
are	O
localised	O
to	O
the	O
endoplasmic	O
reticulum	O
and	O
nucleus	O
/	O
cytoplasm	O
,	O
respectively	O
,	O
and	O
both	O
proteins	O
stimulate	O
host	O
cell	O
DNA	O
synthesis	O
.	O

2	O
.	O
Using	O
high	O
throughput	O
screen	O
and	O
chemical	O
synthesis	O
,	O
several	O
lead	O
compounds	O
targeting	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
helicase	I-PRGE
have	O
been	O
identified	O
.	O

We	O
have	O
shown	O
that	O
these	O
compounds	O
can	O
inhibit	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
helicase	I-PRGE
activity	O
and	O
viral	O
growth	O
in	O
cell	O
culture	O
systems	O
.	O

We	O
have	O
explored	O
the	O
capacity	O
of	O
these	O
selected	O
membrane	O
-	O
interacting	O
regions	O
of	O
the	O
S2	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
fusion	I-PRGE
protein	I-PRGE
,	O
alone	O
or	O
in	O
equimolar	O
mixtures	O
,	O
to	O
insert	O
into	O
the	O
membrane	O
as	O
well	O
as	O
to	O
perturb	O
the	O
dipole	O
potential	O
of	O
the	O
bilayer	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
VLP	I-PRGE
formation	O
depends	O
on	O
either	O
M	O
and	O
E	O
proteins	O
or	O
M	O
and	O
N	O
proteins	O
.	O

This	O
suggests	O
that	O
the	O
mechanism	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
assembly	O
differs	O
from	O
that	O
of	O
other	O
studied	O
coronaviruses	O
,	O
which	O
only	O
require	O
M	O
and	O
E	O
proteins	O
for	O
VLP	O
formation	O
.	O

Rho	B-PRGE
GTPases	I-PRGE
were	O
inhibited	O
by	O
Clostridium	O
difficile	O
toxin	O
B	O
,	O
but	O
no	O
effect	O
was	O
observed	O
.	O

The	O
A2	O
virus	O
had	O
the	O
highest	O
identity	O
to	O
S14	B-PRGE
and	O
BJ	O
in	O
terms	O
of	O
full	O
genome	O
,	O
whereas	O
had	O
a	O
further	O
distance	O
to	O
Massachusetts	O
strains	O
.	O

K99	O
,	O
F41	O
,	O
STa	B-PRGE
,	O
Stx1	B-PRGE
and	O
Stx2	B-PRGE
were	O
found	O
as	O
the	O
most	O
common	O
virulence	O
gene	O
markers	O
of	O
E	O
.	O
coli	O
strains	O
isolated	O
from	O
calves	O
with	O
diarrhoea	O
.	O

The	O
addition	O
of	O
an	O
eight	O
amino	O
acid	O
HIV	O
-	O
1	O
gp41	B-PRGE
envelope	I-PRGE
incorporation	O
motif	O
further	O
increased	O
scFvFc	O
expression	O
on	O
human	O
cells	O
and	O
incorporation	O
into	O
lentiviral	O
particles	O
.	O

Acute	O
reduction	O
of	O
SOD3	B-PRGE
led	O
to	O
a	O
fivefold	O
increase	O
in	O
lung	O
superoxide	O
,	O
marked	O
inflammatory	O
cell	O
infiltration	O
,	O
a	O
threefold	O
increase	O
in	O
the	O
arterial	O
-	O
alveolar	O
gradient	O
,	O
respiratory	O
acidosis	O
,	O
histological	O
changes	O
similar	O
to	O
those	O
observed	O
in	O
adult	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
85	O
%	O
mortality	O
.	O

These	O
studies	O
show	O
that	O
SOD3	B-PRGE
is	O
essential	O
for	O
survival	O
in	O
the	O
presence	O
of	O
ambient	O
oxygen	O
and	O
that	O
acute	O
loss	O
of	O
this	O
enzyme	O
can	O
lead	O
to	O
severe	O
lung	O
damage	O
.	O

TITLE	O
:	O
Interactions	O
between	O
M	B-PRGE
protein	I-PRGE
and	O
other	O
structural	O
proteins	O
of	O
severe	O
,	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
.	O

Interactions	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
and	O
other	O
structural	O
proteins	O
but	O
not	O
interactions	O
between	O
S	O
and	O
E	O
,	O
S	O
and	O
NC	O
,	O
or	O
E	O
and	O
NC	O
were	O
further	O
demonstrated	O
by	O
co	O
-	O
immunoprecipitation	O
assay	O
.	O

These	O
results	O
indicate	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
,	O
similar	O
to	O
the	O
M	O
proteins	O
of	O
other	O
coronaviruses	O
,	O
plays	O
a	O
pivotal	O
role	O
in	O
virus	O
assembly	O
.	O

A	O
model	O
for	O
the	O
interactions	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
and	O
other	O
structural	O
proteins	O
is	O
proposed	O
.	O

The	O
convoluted	O
membranes	O
were	O
most	O
abundantly	O
immunolabeled	O
for	O
viral	B-PRGE
replicase	I-PRGE
subunits	I-PRGE
.	O

We	O
showed	O
that	O
entry	O
of	O
the	O
serotype	O
II	O
feline	O
coronavirus	O
strains	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
WSU	O
79	O
-	O
1146	O
and	O
DF2	O
into	O
nonpermissive	O
mouse	O
3T3	O
cells	O
can	O
be	O
rescued	O
by	O
the	O
expression	O
of	O
human	B-PRGE
DC	I-PRGE
-	I-PRGE
SIGN	I-PRGE
(	O
hDC	B-PRGE
-	I-PRGE
SIGN	I-PRGE
)	O
and	O
that	O
infection	O
of	O
a	O
permissive	O
feline	O
cell	O
line	O
(	O
Crandall	O
-	O
Reese	O
feline	O
kidney	O
)	O
was	O
markedly	O
enhanced	O
by	O
the	O
overexpression	O
of	O
hDC	B-PRGE
-	I-PRGE
SIGN	I-PRGE
.	O

TITLE	O
:	O
Rhesus	O
angiotensin	B-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
supports	O
entry	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
in	O
Chinese	O
macaques	O
.	O

Rh	B-PRGE
-	I-PRGE
ACE2	I-PRGE
genes	I-PRGE
were	O
amplified	O
from	O
all	O
animals	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
,	O
and	O
their	O
function	O
was	O
studied	O
in	O
vitro	O
using	O
a	O
pseudovirus	O
entry	O
assay	O
.	O

Additional	O
sporadic	O
NS	O
substitutions	O
in	O
clone	O
Rh11	O
-	O
7	O
reduced	O
the	O
level	O
of	O
rh	B-PRGE
-	I-PRGE
ACE2	I-PRGE
protein	I-PRGE
expression	O
and	O
did	O
not	O
support	O
viral	O
entry	O
effectively	O
.	O

Moreover	O
,	O
introduction	O
of	O
the	O
Y217N	O
mutation	O
into	O
hu	B-PRGE
-	I-PRGE
ACE2	I-PRGE
caused	O
the	O
down	O
-	O
regulation	O
of	O
expression	O
and	O
reduced	O
viral	O
entry	O
efficiency	O
.	O

TITLE	O
:	O
Murine	O
coronaviruses	O
encoding	O
nsp2	B-PRGE
at	O
different	O
genomic	O
loci	O
have	O
altered	O
replication	O
,	O
protein	O
expression	O
,	O
and	O
localization	O
.	O

ABSTRACT	O
:	O
Partial	O
or	O
complete	O
deletion	O
of	O
several	O
coronavirus	O
nonstructural	O
proteins	O
(	O
nsps	O
),	O
including	O
open	O
reading	O
frame	O
1a	O
(	O
ORF1a	O
)-	O
encoded	O
nsp2	B-PRGE
,	O
results	O
in	O
viable	O
mutant	O
proteins	O
with	O
specific	O
replication	O
defects	O
.	O

Alternate	O
encoding	O
or	O
duplication	O
of	O
the	O
nsp2	B-PRGE
gene	I-PRGE
sequence	I-PRGE
resulted	O
in	O
differences	O
in	O
nsp2	B-PRGE
expression	O
,	O
processing	O
,	O
and	O
localization	O
,	O
was	O
neutral	O
or	O
detrimental	O
to	O
replication	O
,	O
and	O
did	O
not	O
complement	O
an	O
ORF1a	O
Deltansp2	O
replication	O
defect	O
.	O

The	O
heavily	O
glycosylated	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
binds	O
to	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
which	O
serves	O
as	O
a	O
cellular	O
receptor	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
cellular	O
model	O
of	O
adhesion	O
to	O
investigate	O
whether	O
natural	O
antibodies	O
of	O
the	O
ABO	O
system	O
could	O
block	O
the	O
S	B-PRGE
protein	I-PRGE
and	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
interaction	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
3CL	B-PRGE
protease	I-PRGE
is	O
an	O
attractive	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
drugs	O
.	O

ABSTRACT	O
:	O
The	O
antiviral	O
role	O
of	O
CD4	B-PRGE
(+)	O
T	O
cells	O
in	O
virus	O
-	O
induced	O
pathologies	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
has	O
not	O
been	O
explored	O
extensively	O
.	O

A	O
fecal	O
sample	O
from	O
a	O
sable	O
antelope	O
was	O
collected	O
in	O
2003	O
from	O
an	O
Ohio	O
wild	O
-	O
animal	O
habitat	O
during	O
the	O
same	O
outbreak	O
when	O
a	O
bovine	B-PRGE
-	I-PRGE
like	I-PRGE
CoV	I-PRGE
from	O
a	O
giraffe	O
(	O
GiCoV	O
)	O
was	O
isolated	O
(	O
M	O
.	O
Hasoksuz	O
,	O
K	O
.	O
Alekseev	O
,	O
A	O
.	O
Vlasova	O
,	O
X	O
.	O
Zhang	O
,	O
D	O
.	O
Spiro	O
,	O
R	O
.	O
Halpin	O
,	O
S	O
.	O
Wang	O
,	O
E	O
.	O
Ghedin	O
,	O
and	O
L	O
.	O
J	O
.	O
Saif	O
,	O
J	O
.	O
Virol	O
.	O

We	O
found	O
for	O
the	O
first	O
time	O
that	O
the	O
mature	B-PRGE
SARS	I-PRGE
3CL	I-PRGE
protease	I-PRGE
is	O
subject	O
to	O
degradation	O
at	O
188Arg	O
/	O
189Gln	O
.	O

While	O
normal	O
DPD	B-PRGE
enzyme	I-PRGE
activity	O
is	O
rate	O
limiting	O
in	O
5	O
-	O
FU	O
catabolism	O
,	O
its	O
deficiency	O
could	O
increase	O
concentrations	O
of	O
bioavailable	O
5	O
-	O
FU	O
anabolic	O
products	O
leading	O
to	O
5	O
-	O
FU	O
related	O
toxicity	O
syndrome	O
.	O

Cleavage	O
of	O
S	O
and	O
release	O
of	O
HCoV	O
-	O
HKU1	O
S	O
pseudotyped	O
virus	O
were	O
inhibited	O
by	O
furin	B-PRGE
or	O
furin	B-PRGE
-	I-PRGE
like	I-PRGE
enzyme	I-PRGE
inhibitors	O
.	O

This	O
unique	O
protease	O
is	O
not	O
only	O
responsible	O
for	O
processing	O
the	O
viral	O
polyprotein	O
into	O
its	O
functional	O
units	O
but	O
is	O
also	O
capable	O
of	O
cleaving	O
ubiquitin	B-PRGE
and	O
ISG15	B-PRGE
conjugates	O
and	O
plays	O
a	O
significant	O
role	O
in	O
helping	O
SARS	O
-	O
CoV	O
evade	O
the	O
human	O
immune	O
system	O
.	O

TITLE	O
:	O
Mechanistic	O
analysis	O
of	O
macrophage	O
response	O
to	O
IRAK	B-PRGE
-	I-PRGE
1	I-PRGE
gene	I-PRGE
knockdown	O
by	O
a	O
smart	O
polymer	O
-	O
antisense	O
oligonucleotide	O
therapeutic	O
.	O

Management	O
of	O
excessive	O
inflammation	O
may	O
be	O
possible	O
through	O
control	O
of	O
key	O
inflammatory	O
pathways	O
such	O
as	O
those	O
mediated	O
by	O
the	O
important	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
associated	I-PRGE
kinase	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
IRAK	B-PRGE
-	I-PRGE
1	I-PRGE
).	O

In	O
both	O
assays	O
,	O
we	O
find	O
that	O
the	O
NL63	B-PRGE
S	I-PRGE
protein	I-PRGE
has	O
a	O
weaker	O
interaction	O
with	O
ACE	B-PRGE
-	I-PRGE
2	I-PRGE
than	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
,	O
particularly	O
in	O
solution	O
binding	O
,	O
but	O
the	O
residues	O
required	O
for	O
contact	O
are	O
similar	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
lifethreatening	O
emerging	O
respiratory	O
disease	O
caused	O
by	O
the	O
coronavirus	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
highly	O
antigenic	O
and	O
may	O
be	O
a	O
suitable	O
candidate	O
for	O
diagnostic	O
applications	O
.	O

These	O
results	O
suggest	O
that	O
the	O
middle	O
or	O
C	O
-	O
terminal	O
region	O
of	O
the	O
SARS	B-PRGE
N	I-PRGE
protein	I-PRGE
is	O
important	O
for	O
eliciting	O
antibodies	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
during	O
the	O
immune	O
response	O
,	O
and	O
ELISA	O
reactions	O
using	O
N1	O
or	O
N3	O
may	O
be	O
a	O
valuable	O
tool	O
for	O
SARS	O
diagnosis	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
229E	O
,	O
classified	O
as	O
a	O
group	O
I	O
coronavirus	O
,	O
utilizes	O
human	O
aminopeptidase	B-PRGE
N	I-PRGE
(	O
APN	B-PRGE
)	O
as	O
a	O
receptor	O
;	O
however	O
,	O
its	O
entry	O
mechanism	O
has	O
not	O
yet	O
been	O
fully	O
elucidated	O
.	O

In	O
addition	O
,	O
trypsin	B-PRGE
induced	O
cleavage	O
of	O
the	O
229E	B-PRGE
S	I-PRGE
protein	I-PRGE
.	O

By	O
using	O
infectious	O
viruses	O
and	O
pseudotyped	O
viruses	O
bearing	O
the	O
229E	B-PRGE
S	I-PRGE
protein	I-PRGE
,	O
we	O
found	O
that	O
its	O
infection	O
was	O
profoundly	O
blocked	O
by	O
lysosomotropic	O
agents	O
as	O
well	O
as	O
by	O
protease	O
inhibitors	O
that	O
also	O
prevented	O
infection	O
with	O
SARS	O
-	O
CoV	O
but	O
not	O
that	O
caused	O
by	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
strain	O
JHMV	O
,	O
which	O
enters	O
cells	O
directly	O
from	O
the	O
cell	O
surface	O
.	O

The	O
3CL	O
(	O
pro	O
),	O
Pol	B-PRGE
,	O
helicase	B-PRGE
,	O
and	O
nucleocapsid	O
of	O
the	O
three	O
CoVs	O
possessed	O
higher	O
amino	O
acid	O
identities	O
to	O
those	O
of	O
group	O
3a	O
CoVs	O
than	O
to	O
those	O
of	O
group	O
1	O
and	O
group	O
2	O
CoVs	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
the	O
CXC	B-PRGE
chemokine	I-PRGE
ligand	I-PRGE
9	I-PRGE
(	O
CXCL9	B-PRGE
)	O
in	O
host	O
defense	O
following	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
was	O
determined	O
.	O

In	O
addition	O
,	O
infection	O
of	O
RAG1	B-PRGE
-/-	O
or	O
CXCL9	O
-/-	O
mice	O
with	O
a	O
recombinant	O
MHV	O
expressing	O
CXCL9	B-PRGE
(	O
MHV	B-PRGE
-	I-PRGE
CXCL9	I-PRGE
)	O
resulted	O
in	O
protection	O
from	O
disease	O
that	O
correlated	O
with	O
reduced	O
viral	O
titers	O
within	O
the	O
brain	O
and	O
NK	O
cell	O
-	O
mediated	O
protection	O
in	O
the	O
liver	O
.	O

ABSTRACT	O
:	O
The	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
on	O
spike	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
the	O
main	O
region	O
interacting	O
with	O
the	O
viral	B-PRGE
receptor	I-PRGE
-	I-PRGE
ACE2	I-PRGE
and	O
is	O
a	O
useful	O
target	O
for	O
induction	O
of	O
neutralizing	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Identification	O
of	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
class	I-PRGE
I	I-PRGE
C	I-PRGE
molecule	O
as	O
an	O
attachment	O
factor	O
that	O
facilitates	O
coronavirus	O
HKU1	O
spike	O
-	O
mediated	O
infection	O
.	O

Our	O
data	O
suggest	O
that	O
HLA	B-PRGE
-	I-PRGE
C	I-PRGE
is	O
involved	O
in	O
the	O
attachment	O
of	O
HCoV	O
-	O
HKU1	O
to	O
A549	O
cells	O
and	O
is	O
a	O
potential	O
candidate	O
to	O
facilitate	O
cell	O
entry	O
.	O

However	O
,	O
the	O
variation	O
of	O
the	O
S	O
gene	O
between	O
viruses	O
may	O
affect	O
the	O
efficacy	O
of	O
a	O
vaccine	O
,	O
particularly	O
for	O
cross	O
-	O
protection	O
against	O
SARS	B-PRGE
-	I-PRGE
like	I-PRGE
CoV	I-PRGE
(	O
SL	O
-	O
CoV	O
).	O

Of	O
interest	O
,	O
the	O
frequency	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
-	O
positive	O
cells	O
elicited	O
by	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3a	I-PRGE
DNA	O
vaccine	O
was	O
significantly	O
higher	O
than	O
that	O
elicited	O
by	O
the	O
SL	O
-	O
CoV	O
3a	O
DNA	O
vaccine	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
devote	O
more	O
than	O
three	O
quarters	O
of	O
their	O
coding	O
capacity	O
to	O
encode	O
two	O
large	O
polyproteins	O
(	O
1a	O
and	O
1ab	O
polyproteins	O
),	O
which	O
are	O
proteolytically	O
processed	O
into	O
15	O
-	O
16	O
mature	O
,	O
nonstructural	O
replicase	B-PRGE
proteins	I-PRGE
(	O
nsp1	B-PRGE
to	O
16	O
).	O

The	O
results	O
showed	O
that	O
substitution	O
mutation	O
of	O
a	O
conserved	O
Gly	O
(	O
G98	O
)	O
residue	O
in	O
the	O
C	O
-	O
terminal	O
alpha	O
-	O
helix	O
domain	O
with	O
an	O
Asp	O
greatly	O
destabilized	O
the	O
IBV	B-PRGE
nsp9	I-PRGE
homodimer	I-PRGE
and	O
abolished	O
its	O
RNA	O
-	O
binding	O
activity	O
.	O

Meanwhile	O
,	O
mutations	O
of	O
some	O
positively	O
charged	O
residues	O
in	O
the	O
beta	O
-	O
barrel	O
regions	O
of	O
the	O
IBV	B-PRGE
nsp9	I-PRGE
protein	I-PRGE
significantly	O
reduced	O
its	O
RNA	O
-	O
binding	O
activity	O
,	O
but	O
with	O
no	O
obvious	O
effect	O
on	O
dimerization	O
of	O
the	O
protein	O
.	O

ABSTRACT	O
:	O
Turkey	O
coronavirus	O
(	O
TCoV	O
)	O
polyprotein	O
was	O
predicted	O
to	O
be	O
cleaved	O
into	O
15	O
non	O
-	O
structural	O
proteins	O
(	O
nsp2	B-PRGE
to	O
nsp16	O
),	O
but	O
none	O
of	O
these	O
nsps	O
have	O
been	O
characterized	O
.	O

ABSTRACT	O
:	O
Four	O
canine	B-PRGE
coronavirus	I-PRGE
type	I-PRGE
II	I-PRGE
(	O
CCoV	O
-	O
II	O
)	O
strains	O
were	O
identified	O
in	O
the	O
guts	O
and	O
internal	O
organs	O
of	O
pups	O
which	O
had	O
died	O
of	O
acute	O
gastroenteritis	O
.	O

The	O
truncated	O
S	B-PRGE
-	I-PRGE
N	I-PRGE
fusion	I-PRGE
protein	I-PRGE
is	O
a	O
suitable	O
immunodiagnostic	O
antigen	O
and	O
vaccine	O
candidate	O
.	O

We	O
concentrate	O
on	O
HIV	B-PRGE
-	I-PRGE
1	I-PRGE
protease	I-PRGE
inhibitors	I-PRGE
,	O
as	O
these	O
have	O
made	O
the	O
most	O
significant	O
advances	O
in	O
the	O
recent	O
past	O
.	O

Sixteen	O
HLA	B-PRGE
-	O
DR0401	O
-	O
and	O
14	O
HLA	O
-	O
DR0701	O
-	O
restricted	O
epitopes	O
within	O
spike	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
identified	O
.	O

The	O
effects	O
of	O
the	O
compounds	O
were	O
specific	O
to	O
NS1	B-PRGE
,	O
because	O
they	O
had	O
no	O
effect	O
on	O
the	O
ability	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papainlike	O
protease	B-PRGE
protein	I-PRGE
to	O
block	O
beta	B-PRGE
interferon	I-PRGE
promoter	I-PRGE
activation	O
.	O

Neutralization	O
assay	O
with	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
antibody	I-PRGE
revealed	O
that	O
VSV	O
-	O
SARS	B-PRGE
-	O
St19	B-PRGE
/	O
GFP	O
pseudotype	O
infection	O
is	O
mediated	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
.	O

In	O
addition	O
to	O
the	O
cellular	O
receptor	O
,	O
porcine	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
,	O
the	O
TGEV	B-PRGE
spike	I-PRGE
protein	I-PRGE
binds	O
to	O
sialic	O
acid	O
residues	O
.	O

Because	O
of	O
the	O
reactivity	O
with	O
specific	O
lectins	O
we	O
assume	O
that	O
the	O
recognized	O
glycoprotein	O
has	O
the	O
characteristics	O
of	O
a	O
mucin	B-PRGE
.	O

IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
mediated	O
control	O
of	O
JHMV	O
replication	O
is	O
dampened	O
in	O
glial	O
cultures	O
derived	O
from	O
the	O
neural	O
progenitor	O
cells	O
of	O
type	B-PRGE
I	I-PRGE
receptor	I-PRGE
knock	O
-	O
out	O
mice	O
.	O

Further	O
,	O
assuming	O
that	O
the	O
general	O
principles	O
underlying	O
MIRR	O
-	O
mediated	O
transmembrane	O
signaling	O
mechanisms	O
are	O
similar	O
,	O
the	O
SCHOOL	O
model	O
can	O
be	O
applied	O
to	O
any	O
particular	O
receptor	O
of	O
the	O
MIRR	B-PRGE
family	I-PRGE
.	O

TITLE	O
:	O
Infectious	O
Bronchitis	O
Virus	O
induces	O
acute	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
production	O
through	O
polyclonal	O
stimulation	O
of	O
chicken	O
leukocytes	O
.	O

These	O
results	O
indicate	O
that	O
IBV	O
acts	O
as	O
a	O
polyclonal	O
stimulus	O
,	O
inducing	O
a	O
rapid	O
production	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
even	O
without	O
previous	O
exposure	O
to	O
the	O
virus	O
.	O

Recently	O
,	O
our	O
laboratory	O
and	O
others	O
developed	O
a	O
recombinant	O
mouse	O
-	O
adapted	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
rMA15	O
)	O
that	O
was	O
lethal	O
in	O
BALB	O
/	O
c	O
mice	O
.	O

Here	O
,	O
we	O
report	O
that	O
mice	O
deficient	O
in	O
MyD88	B-PRGE
(	O
MyD88	B-PRGE
(-/-)),	O
an	O
adapter	O
protein	O
that	O
mediates	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
(	O
TLR	O
),	O
IL	O
-	O
1R	O
,	O
and	O
IL	O
-	O
18R	O
signaling	O
,	O
are	O
far	O
more	O
susceptible	O
to	O
rMA15	O
infection	O
.	O

TITLE	O
:	O
Complete	O
genomic	O
sequence	O
analysis	O
of	O
infectious	O
bronchitis	O
virus	O
Ark	B-PRGE
DPI	O
strain	O
and	O
its	O
evolution	O
by	O
recombination	O
.	O

Pretreatment	O
of	O
cells	O
with	O
beta	B-PRGE
interferon	I-PRGE
prior	O
to	O
SARS	O
-	O
CoV	O
infection	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
PERK	B-PRGE
activation	O
,	O
eIF2alpha	B-PRGE
phosphorylation	O
,	O
and	O
SARS	O
-	O
CoV	O
replication	O
.	O

The	O
expression	O
of	O
LSECtin	B-PRGE
in	O
myeloid	O
cells	O
was	O
further	O
corroborated	O
through	O
the	O
analysis	O
of	O
the	O
proximal	O
regulatory	O
region	O
of	O
the	O
human	B-PRGE
LSECtin	I-PRGE
gene	I-PRGE
,	O
whose	O
activity	O
was	O
maximal	O
in	O
LSECtin	O
+	O
myeloid	O
cells	O
,	O
and	O
which	O
contains	O
a	O
highly	O
conserved	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
-	I-PRGE
binding	I-PRGE
site	I-PRGE
.	O

PU	B-PRGE
.	I-PRGE
1	I-PRGE
transactivated	O
the	O
LSECtin	B-PRGE
regulatory	O
region	O
in	O
collaboration	O
with	O
hematopoietic	B-PRGE
-	I-PRGE
restricted	I-PRGE
transcription	I-PRGE
factors	I-PRGE
(	O
Myb	B-PRGE
,	O
RUNX3	B-PRGE
),	O
and	O
was	O
found	O
to	O
bind	O
constitutively	O
to	O
the	O
LSECtin	B-PRGE
proximal	I-PRGE
promoter	I-PRGE
.	O

LSECtin	B-PRGE
is	O
expressed	O
by	O
liver	O
myeloid	O
cells	O
,	O
and	O
its	O
expression	O
is	O
dependent	O
on	O
the	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
transcription	I-PRGE
factor	I-PRGE
.	O

IRF3	B-PRGE
translocation	O
was	O
independent	O
of	O
p38	B-PRGE
kinase	I-PRGE
activity	O
,	O
indicating	O
that	O
IRF3	B-PRGE
and	O
p38	B-PRGE
kinase	O
are	O
distinct	O
pathways	O
leading	O
to	O
cytokine	O
production	O
by	O
H5N1	O
virus	O
.	O

This	O
genetic	O
analysis	O
revealed	O
that	O
IFNAR	B-PRGE
expression	O
on	O
LysM	O
+	O
macrophages	O
and	O
CD11c	O
+	O
dendritic	O
cells	O
was	O
most	O
important	O
for	O
the	O
early	O
containment	O
of	O
MHV	O
within	O
secondary	O
lymphoid	O
organs	O
and	O
to	O
prevent	O
lethal	O
liver	O
disease	O
.	O

This	O
study	O
identifies	O
type	O
I	O
IFN	B-PRGE
-	O
mediated	O
cross	O
-	O
talk	O
between	O
plasmacytoid	O
dendritic	O
cells	O
on	O
one	O
side	O
and	O
macrophages	O
and	O
conventional	O
dendritic	O
cells	O
on	O
the	O
other	O
,	O
as	O
an	O
essential	O
cellular	O
pathway	O
for	O
the	O
control	O
of	O
fatal	O
cytopathic	O
virus	O
infection	O
.	O

ABSTRACT	O
:	O
Gamma	B-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
plays	O
a	O
major	O
role	O
in	O
the	O
protection	O
against	O
lethal	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
A59	O
.	O

Birds	O
were	O
either	O
unvaccinated	O
or	O
vaccinated	O
with	O
both	O
A3	O
and	O
Vic	B-PRGE
S	I-PRGE
and	O
then	O
mock	O
-	O
infected	O
,	O
challenged	O
with	O
the	O
same	O
attenuated	O
strains	O
,	O
either	O
A3	O
or	O
Vic	O
S	O
.	O
Some	O
respiratory	O
signs	O
were	O
observed	O
,	O
but	O
were	O
mild	O
and	O
short	O
-	O
lived	O
.	O

The	O
relatively	O
higher	O
inhibition	O
of	O
chemokine	O
mRNAs	O
compared	O
with	O
reduction	O
in	O
MPO	B-PRGE
activity	O
and	O
CD11b	B-PRGE
is	O
in	O
accordance	O
with	O
an	O
antioxidant	O
effect	O
of	O
NACA	O
on	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
accumulation	O
,	O
rather	O
than	O
by	O
an	O
effect	O
on	O
neutrophil	O
sequestration	O
.	O

However	O
,	O
compared	O
to	O
inf	O
-	O
MHV	O
-	O
A59	O
,	O
the	O
inf	B-PRGE
-	I-PRGE
ns2	I-PRGE
H46A	I-PRGE
and	O
inf	B-PRGE
-	I-PRGE
ns2	I-PRGE
-	I-PRGE
H126R	I-PRGE
mutants	I-PRGE
are	O
highly	O
attenuated	O
for	O
replication	O
in	O
mouse	O
liver	O
following	O
intrahepatic	O
inoculation	O
.	O

In	O
previous	O
studies	O
,	O
feasibility	O
and	O
safety	O
of	O
the	O
iLA	B-PRGE
system	O
was	O
demonstrated	O
,	O
but	O
no	O
survival	O
benefit	O
was	O
observed	O
.	O

iLA	B-PRGE
could	O
serve	O
as	O
an	O
extracorporeal	O
assist	O
to	O
support	O
mechanical	O
ventilation	O
by	O
enabling	O
low	O
tidal	O
volume	O
and	O
a	O
reduced	O
inspiratory	O
plateau	O
pressure	O
.	O

The	O
PCRs	O
,	O
or	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
PCRs	O
,	O
may	O
be	O
general	O
,	O
designed	O
to	O
detect	O
all	O
or	O
most	O
variants	O
of	O
a	O
pathogen	O
,	O
or	O
to	O
be	O
serotype	O
,	O
genotype	O
or	O
pathotype	O
specific	O
.	O

Activation	O
and	O
translocation	O
of	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
was	O
shown	O
to	O
occur	O
rapidly	O
following	O
exposure	O
of	O
PBMC	O
or	O
THP	O
-	O
1	O
cells	O
to	O
S	B-PRGE
protein	I-PRGE
using	O
a	O
highly	O
sensitive	O
assay	O
for	O
active	O
nuclear	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
p65	B-PRGE
transcription	I-PRGE
factor	I-PRGE
.	O

In	O
addition	O
,	O
APC	O
limited	O
the	O
increase	O
in	O
plasminogen	B-PRGE
activator	I-PRGE
inhibitor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
PAI	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
both	O
in	O
plasma	O
(	O
control	O
group	O
was	O
(	O
0	O
.	O
68	O
+/-	O
0	O
.	O
12	O
)	O
ng	O
/	O
ml	O
at	O
1	O
hour	O
,	O
(	O
0	O
.	O
84	O
+/-	O
0	O
.	O
06	O
)	O
ng	O
/	O
ml	O
at	O
2	O
hours	O
,	O
(	O
0	O
.	O
87	O
+/-	O
0	O
.	O
08	O
)	O
ng	O
/	O
ml	O
at	O
4	O
hours	O
and	O
(	O
0	O
.	O
91	O
+/-	O
0	O
.	O
05	O
)	O
ng	O
/	O
ml	O
at	O
6	O
hours	O
,	O
vs	O
APC	B-PRGE
group	O
(	O
0	O
.	O
42	O
+/-	O
0	O
.	O
16	O
)	O
ng	O
/	O
ml	O
at	O
1	O
hour	O
,	O
(	O
0	O
.	O
43	O
+/-	O
0	O
.	O
04	O
)	O
ng	O
/	O
ml	O
at	O
2	O
hours	O
,	O
(	O
0	O
.	O
45	O
+/-	O
0	O
.	O
09	O
)	O
ng	O
/	O
ml	O
at	O
4	O
hours	O
and	O
(	O
0	O
.	O
45	O
+/-	O
0	O
.	O
14	O
)	O
ng	O
/	O
ml	O
at	O
6	O
hours	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
at	O
6	O
hours	O
:	O
sham	O
,	O
(	O
1	O
.	O
05	O
+/-	O
0	O
.	O
05	O
)	O
ng	O
/	O
ml	O
;	O
control	O
,	O
(	O
1	O
.	O
13	O
+/-	O
0	O
.	O
06	O
)	O
ng	O
/	O
ml	O
;	O
APC	O
,	O
(	O
1	O
.	O
06	O
+/-	O
0	O
.	O
06	O
)	O
ng	O
/	O
ml	O
;	O
P	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
APC	B-PRGE
failed	O
to	O
prevent	O
the	O
decrease	O
in	O
PaO	O
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
.	O

APC	B-PRGE
-	O
treated	O
rabbits	O
showed	O
no	O
significant	O
difference	O
in	O
platelet	O
count	O
and	O
antithrombin	B-PRGE
but	O
exhibited	O
less	O
D	O
-	O
dimer	O
production	O
than	O
did	O
the	O
controls	O
.	O

The	O
sensitivity	O
of	O
IHC	O
in	O
detecting	O
IBV	O
antigens	O
in	O
the	O
CAM	O
of	O
inoculated	O
eggs	O
matched	O
the	O
virus	O
reisolation	O
and	O
detection	O
in	O
CEK	B-PRGE
.	O

ABSTRACT	O
:	O
The	O
N7	O
-	O
methylguanosine	O
(	O
m7G	B-PRGE
)	O
cap	O
is	O
the	O
defining	O
structural	O
feature	O
of	O
eukaryotic	O
mRNAs	O
.	O

Mutational	O
analysis	O
in	O
a	O
replicon	O
system	O
showed	O
that	O
the	O
N7	B-PRGE
-	I-PRGE
MTase	I-PRGE
activity	O
was	O
important	O
for	O
SARS	O
virus	O
replication	O
/	O
transcription	O
and	O
can	O
thus	O
be	O
used	O
as	O
an	O
attractive	O
drug	O
target	O
to	O
develop	O
antivirals	O
for	O
control	O
of	O
coronaviruses	O
including	O
the	O
deadly	O
SARS	O
virus	O
.	O

Furthermore	O
,	O
the	O
observation	O
that	O
the	O
N7	B-PRGE
-	I-PRGE
MTase	I-PRGE
of	O
RNA	O
life	O
could	O
function	O
in	O
lieu	O
of	O
that	O
in	O
DNA	O
life	O
provides	O
interesting	O
evolutionary	O
insight	O
and	O
practical	O
possibilities	O
in	O
antiviral	O
drug	O
screening	O
.	O

Seven	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
proteins	I-PRGE
(	O
S	O
,	O
SQ	O
,	O
S1	O
,	O
RBD	O
,	O
S2	O
,	O
S2Q	O
,	O
and	O
CX	O
)	O
were	O
generated	O
using	O
the	O
modified	O
vaccinia	O
virus	O
(	O
Tiantan	O
strain	O
)	O
as	O
a	O
vector	O
,	O
and	O
their	O
antigenicity	O
and	O
immunogenicity	O
were	O
evaluated	O
.	O

Our	O
results	O
demonstrate	O
that	O
SQ	B-PRGE
protein	I-PRGE
may	O
be	O
an	O
effective	O
vaccine	O
candidate	O
and	O
a	O
convenient	O
and	O
safe	O
diagnostic	O
antigen	O
for	O
SARS	O
-	O
CoV	O
.	O

Bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
samples	O
of	O
128	O
patients	O
with	O
atypical	O
pneumonia	O
(	O
HIV	O
-	O
infected	O
n	O
=	O
50	O
,	O
hematological	O
malignancy	O
n	O
=	O
51	O
,	O
immunosuppressive	O
treatment	O
n	O
=	O
27	O
)	O
were	O
prospectively	O
evaluated	O
for	O
P	O
.	O
jirovecii	O
and	O
retrospectively	O
for	O
new	O
respiratory	O
viruses	O
(	O
HMPV	O
,	O
HBoV	O
,	O
HCoV	O
-	O
NL63	O
/	O
SARS	B-PRGE
/	O
HKU1	O
).	O

Widespread	O
dissemination	O
was	O
observed	O
in	O
mice	O
lacking	O
a	O
functional	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
response	O
.	O

The	O
importance	O
of	O
the	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
system	O
in	O
limiting	O
viral	O
spread	O
was	O
also	O
demonstrated	O
by	O
the	O
administration	O
of	O
type	O
I	O
interferons	O
to	O
mice	O
.	O

Blood	O
gases	O
,	O
lung	O
histology	O
,	O
and	O
protein	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
concentrations	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
examined	O
.	O

We	O
reported	O
previously	O
the	O
presence	O
of	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	B-PRGE
hydrolase	I-PRGE
(	O
FAH	B-PRGE
)	O
in	O
sera	O
from	O
mice	O
infected	O
with	O
MHV	O
-	O
A59	O
.	O

Carbon	O
tetrachloride	O
(	O
CCl	O
(	O
4	O
))	O
was	O
injected	O
into	O
mice	O
30	O
days	O
after	O
MHV	O
infection	O
,	O
and	O
serum	O
was	O
assayed	O
for	O
autoAb	O
and	O
total	O
IgG	B-PRGE
20	O
days	O
later	O
.	O

Other	O
branches	O
of	O
the	O
UPR	O
pathways	O
controlled	O
by	O
IRE1	B-PRGE
and	O
ATF6	B-PRGE
proteins	I-PRGE
,	O
respectively	O
,	O
are	O
not	O
involved	O
.	O

The	O
protease	O
inhibitor	O
Ben	B-PRGE
-	I-PRGE
HCl	I-PRGE
effectively	O
suppresses	O
SARS	O
-	O
CoV	O
infection	O
by	O
blocking	O
virus	O
entry	O
.	O

The	O
polymorphisms	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	O
-	O
12	O
,	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
Mig	B-PRGE
and	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
are	O
not	O
associated	O
with	O
SARS	B-PRGE
susceptibility	I-PRGE
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
originated	O
from	O
bats	O
and	O
that	O
the	O
spill	O
over	O
into	O
civets	O
and	O
humans	O
were	O
more	O
recent	O
events	O
.	O

In	O
the	O
case	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
,	O
truncation	O
of	O
the	O
cytoplasmic	O
tail	O
resulted	O
in	O
increased	O
infectivity	O
.	O

Rm1	B-PRGE
nsp1	B-PRGE
expression	O
in	O
trans	O
strongly	O
inhibited	O
the	O
induction	O
of	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
I	I-PRGE
)	O
and	O
IFN	B-PRGE
-	O
stimulated	O
genes	O
in	O
cells	O
infected	O
with	O
an	O
IFN	B-PRGE
-	O
inducing	O
SARS	O
-	O
CoV	O
mutant	O
,	O
while	O
133	O
and	O
HKU9	B-PRGE
-	I-PRGE
1	I-PRGE
nsp1	I-PRGE
proteins	I-PRGE
had	O
relatively	O
moderate	O
IFN	B-PRGE
-	O
inhibitory	O
activities	O
.	O

In	O
addition	O
,	O
corticosteroid	O
and	O
calcitonin	B-PRGE
were	O
able	O
to	O
reduce	O
the	O
plasma	O
calcium	O
and	O
to	O
prevent	O
the	O
occurrence	O
of	O
ARDS	O
and	O
ALI	O
.	O

He	O
was	O
diagnosed	O
with	O
subclinical	O
measles	O
infection	O
since	O
no	O
anthema	O
was	O
observed	O
despite	O
the	O
fact	O
that	O
his	O
serum	O
and	O
cerebrospinal	O
fluid	O
samples	O
were	O
positive	O
for	O
measles	B-PRGE
IgM	I-PRGE
antibodies	I-PRGE
.	O

We	O
also	O
found	O
that	O
CD8	B-PRGE
(+)	O
T	O
cells	O
were	O
partially	O
effective	O
in	O
attenuating	O
the	O
pathogenesis	O
of	O
SARS	O
-	O
CoV	O
infection	O
in	O
lethality	O
-	O
resistant	O
AC22	O
mice	O
.	O

TITLE	O
:	O
[	O
Successful	O
treatment	O
of	O
life	O
-	O
threatening	O
Panton	B-PRGE
-	I-PRGE
Valentine	I-PRGE
leucocidin	I-PRGE
positive	O
Staphylococcus	O
aureus	O
pneumonia	O
with	O
antibiotics	B-PRGE
and	I-PRGE
immunoglobulins	I-PRGE
targeting	O
the	O
toxin	O
production	O
].	O

In	O
the	O
present	O
work	O
,	O
the	O
method	O
for	O
purification	O
of	O
duck	B-PRGE
immunoglobulin	I-PRGE
A	I-PRGE
was	O
developed	O
,	O
and	O
the	O
induction	O
of	O
intestinal	O
mucosal	O
immune	O
responses	O
against	O
DEV	O
was	O
studied	O
by	O
orally	O
infected	O
ducklings	O
with	O
virulent	O
DEV	O
.	O

Furthermore	O
,	O
a	O
marked	O
increased	O
level	O
of	O
DEV	B-PRGE
-	I-PRGE
specific	I-PRGE
IgA	I-PRGE
and	O
IgG	B-PRGE
antibodies	I-PRGE
in	O
bile	O
,	O
serum	O
and	O
the	O
intestinal	O
tract	O
,	O
as	O
well	O
as	O
the	O
density	O
of	O
IgA	B-PRGE
(+)	O
cells	O
in	O
intestine	O
were	O
detected	O
between	O
1	O
and	O
12days	O
p	O
.	O
i	O
.,	O
followed	O
by	O
a	O
drastic	O
reduction	O
of	O
the	O
antibody	O
levels	O
and	O
the	O
density	O
of	O
IgA	B-PRGE
(+)	O
cells	O
at	O
15days	O
p	O
.	O
i	O
.	O

ABSTRACT	O
:	O
To	O
construct	O
the	O
expression	O
plasmid	O
of	O
S2	B-PRGE
extracellular	I-PRGE
domain	I-PRGE
(	O
S2ED	O
)	O
of	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
Cov	O
)	O
spike	B-PRGE
protein	I-PRGE
(	O
S	B-PRGE
protein	I-PRGE
)	O
and	O
enhanced	B-PRGE
green	I-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
EGFP	O
)	O
to	O
obtain	O
the	O
fusion	O
protein	O
expressed	O
in	O
prokaryotic	O
cells	O
.	O

The	O
expression	O
plasmid	O
containing	O
S2ED	O
of	O
SARS	B-PRGE
-	I-PRGE
Cov	I-PRGE
S	I-PRGE
protein	I-PRGE
and	O
EGFP	O
sequence	O
is	O
constructed	O
successfully	O
.	O

The	O
structure	O
of	O
the	O
M	O
(	O
pro	O
)-	O
C	O
monomer	O
is	O
almost	O
identical	O
to	O
that	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
in	O
the	O
crystal	O
structure	O
of	O
M	B-PRGE
(	I-PRGE
pro	I-PRGE
).	I-PRGE

ABSTRACT	O
:	O
The	O
coronavirus	O
spike	O
protein	O
(	O
S	O
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
early	O
steps	O
of	O
viral	O
infection	O
,	O
with	O
the	O
S1	B-PRGE
domain	I-PRGE
responsible	O
for	O
receptor	O
binding	O
and	O
the	O
S2	O
domain	O
mediating	O
membrane	O
fusion	O
.	O

We	O
also	O
introduced	O
a	O
furin	B-PRGE
cleavage	O
site	O
at	O
both	O
the	O
S2	O
'	O
cleavage	O
site	O
within	O
S2	O
793	O
-	O
KPTKR	O
-	O
797	O
(	O
S2	O
'),	O
as	O
well	O
as	O
at	O
the	O
junction	O
of	O
S1	O
and	O
S2	O
.	O

TITLE	O
:	O
Expression	O
and	O
membrane	O
integration	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
and	O
its	O
interaction	O
with	O
M	B-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	B-PRGE
E	I-PRGE
gene	I-PRGE
fragment	I-PRGE
was	O
cloned	O
and	O
expressed	O
as	O
a	O
recombinant	O
protein	O
fused	O
with	O
a	O
myc	B-PRGE
tag	I-PRGE
at	O
the	O
N	O
-	O
terminus	O
in	O
vitro	O
and	O
in	O
Vero	O
E6	O
cells	O
.	O

Both	O
the	O
transmembrane	O
domains	O
of	O
E	B-PRGE
protein	I-PRGE
are	O
required	O
to	O
interact	O
with	O
M	B-PRGE
protein	I-PRGE
,	O
while	O
either	O
of	O
the	O
hydrophilic	O
regions	O
(	O
a	O
.	O
a	O
.	O

Reported	O
here	O
is	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
RBD	O
in	O
complex	O
with	O
the	O
Fab	B-PRGE
of	O
a	O
neutralizing	O
mouse	B-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
,	O
F26G19	O
,	O
elicited	O
by	O
immunization	O
with	O
chemically	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
The	O
RBD	O
-	O
F26G19	O
Fab	B-PRGE
complex	I-PRGE
represents	O
the	O
first	O
example	O
of	O
the	O
structural	O
characterization	O
of	O
an	O
antibody	O
elicited	O
by	O
an	O
immune	O
response	O
to	O
SARS	O
-	O
CoV	O
or	O
any	O
fragment	O
of	O
it	O
.	O

Thirty	O
C3H	O
/	O
Hej	O
mice	O
received	O
10	O
Pfu	O
MHV	O
-	O
3	O
intraperitoneally	O
,	O
the	O
CD4	B-PRGE
-	O
CD8	B-PRGE
-	O
T	O
cells	O
were	O
isolated	O
using	O
magnetic	O
bead	O
sorting	O
on	O
0	O
,	O
4	O
,	O
15	O
,	O
30	O
,	O
40	O
days	O
post	O
MHV	O
-	O
3	O
infection	O
.	O

RESULTS	O
:	O
MHV	O
-	O
3	O
infected	O
CD4	B-PRGE
-	O
CD8	B-PRGE
-	O
T	O
cells	O
showed	O
significant	O
cytotoxic	O
effect	O
on	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
,	O
but	O
not	O
on	O
infected	O
hepatocytes	O
or	O
MCMV	O
infected	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
.	O

Infection	O
of	O
mice	O
defective	O
in	O
both	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
23	I-PRGE
(	O
p40	B-PRGE
(-/-)),	O
in	O
IL	O
-	O
12	O
alone	O
(	O
p35	B-PRGE
(-/-)),	O
and	O
in	O
IL	B-PRGE
-	I-PRGE
23	I-PRGE
alone	O
(	O
p19	B-PRGE
(-/-))	O
revealed	O
that	O
the	O
symptoms	O
of	O
coronavirus	O
-	O
induced	O
encephalitis	O
are	O
regulated	O
by	O
IL	O
-	O
12	O
.	O

Like	O
HIV	O
-	O
1	O
NC	O
,	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
or	O
HCoV	O
-	O
229E	O
N	O
-	O
associated	O
with	O
hA3G	O
depends	O
on	O
the	O
presence	O
of	O
RNA	O
,	O
with	O
the	O
first	O
linker	O
region	O
essential	O
for	O
hA3G	O
packaging	O
into	O
both	O
HIV	O
-	O
1	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
VLPs	I-PRGE
.	O

Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
-	I-PRGE
3	I-PRGE
(	O
TLR	O
-	O
3	O
)	O
is	O
an	O
integral	O
part	O
of	O
the	O
host	O
'	O
s	O
innate	O
immune	O
system	O
and	O
serves	O
as	O
an	O
important	O
signaling	O
pathway	O
for	O
the	O
recognition	O
of	O
dsRNA	O
for	O
the	O
triggering	O
of	O
antiviral	O
and	O
inflammatory	O
responses	O
to	O
combat	O
viral	O
infections	O
.	O

The	O
concentration	O
of	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
alone	O
was	O
considerably	O
increased	O
in	O
the	O
patients	O
who	O
later	O
developed	O
respiratory	O
failure	O
.	O

At	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
concentrations	O
>	O
650	O
pg	O
/	O
ml	O
,	O
AP	O
patients	O
are	O
likely	O
to	O
develop	O
pulmonary	O
dysfunction	O
(	O
sensitivity	O
58	O
%,	O
specificity	O
100	O
%,	O
LR	O
-	O
positive	O
>	O
58	O
)	O
which	O
allows	O
us	O
to	O
use	O
it	O
as	O
a	O
screening	O
test	O
.	O

RESULTS	O
:	O
When	O
admitted	O
to	O
the	O
hospital	O
,	O
severe	O
AP	O
patients	O
had	O
increased	O
concentrations	O
of	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
,	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
,	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

TITLE	O
:	O
Thiopurine	O
analogue	O
inhibitors	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
,	O
a	O
deubiquitinating	O
and	O
deISGylating	O
enzyme	O
.	O

ABSTRACT	O
:	O
In	O
the	O
search	O
for	O
effective	O
therapeutics	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
6	O
-	O
mercaptopurine	O
(	O
6MP	O
)	O
and	O
6	O
-	O
thioguanine	O
(	O
6TG	O
)	O
were	O
found	O
to	O
be	O
specific	O
inhibitors	O
for	O
the	O
SARS	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
(	I-PRGE
CoV	I-PRGE
)	I-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLpro	O
),	O
a	O
cysteine	B-PRGE
protease	I-PRGE
with	O
deubiquitinating	O
and	O
deISGylating	O
activity	O
.	O

Development	O
and	O
optimization	O
of	O
6MP	B-PRGE
and	I-PRGE
6TG	I-PRGE
will	O
not	O
only	O
be	O
important	O
for	O
antiviral	O
studies	O
,	O
but	O
also	O
for	O
further	O
elucidating	O
the	O
biological	O
functions	O
of	O
cellular	O
deubiquitinating	O
enzymes	O
(	O
DUBs	O
)	O
and	O
deISGylating	O
enzymes	O
.	O

A	O
similar	O
treatment	O
of	O
the	O
HIV	B-PRGE
-	I-PRGE
1	I-PRGE
gp120	I-PRGE
yielded	O
a	O
number	O
of	O
fragments	O
that	O
are	O
associated	O
with	O
the	O
critical	O
CD4	B-PRGE
binding	I-PRGE
site	I-PRGE
,	O
or	O
the	O
partially	O
buried	O
CCR5	O
binding	O
site	O
of	O
the	O
protein	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
M	O
protein	O
inhibits	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
production	O
by	O
impeding	O
the	O
formation	O
of	O
TRAF3	B-PRGE
.	O
TANK	B-PRGE
.	O
TBK1	B-PRGE
/	O
IKKepsilon	B-PRGE
complex	O
.	O

M	B-PRGE
protein	I-PRGE
potently	O
antagonizes	O
the	O
activation	O
of	O
interferon	B-PRGE
-	O
stimulated	O
response	O
element	O
-	O
dependent	O
transcription	O
by	O
double	O
-	O
stranded	O
RNA	O
,	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
,	O
MDA5	B-PRGE
,	O
TBK1	B-PRGE
,	O
IKKepsilon	B-PRGE
,	O
and	O
virus	O
-	O
induced	O
signaling	O
adaptor	O
(	O
VISA	O
)	O
but	O
has	O
no	O
influence	O
on	O
the	O
transcriptional	O
activity	O
of	O
this	O
element	O
when	O
IRF3	B-PRGE
or	O
IRF7	B-PRGE
is	O
overexpressed	O
.	O

ABSTRACT	O
:	O
The	O
neurotropic	O
coronavirus	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
persists	O
in	O
oligodendroglia	O
despite	O
the	O
presence	O
of	O
virus	O
-	O
specific	O
CD8	B-PRGE
T	O
cells	O
.	O

Expression	O
of	O
programmed	O
death	O
1	O
(	O
PD	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
B7	B-PRGE
-	I-PRGE
H1	I-PRGE
were	O
studied	O
during	O
acute	O
and	O
persistent	O
infection	O
to	O
examine	O
whether	O
this	O
negative	O
regulatory	O
mechanism	O
contributes	O
to	O
CNS	O
viral	O
persistence	O
.	O

However	O
,	O
whether	O
9b	B-PRGE
protein	I-PRGE
is	O
a	O
structural	O
component	O
of	O
SARS	O
-	O
CoV	O
particles	O
remains	O
unknown	O
.	O

The	O
ORF	B-PRGE
3b	I-PRGE
protein	I-PRGE
is	O
154	O
amino	O
acids	O
and	O
is	O
predicted	O
to	O
express	O
from	O
the	O
second	O
ORF	O
in	O
subgenomic	O
RNA3	O
.	O

Western	O
blotting	O
tests	O
revealed	O
that	O
all	O
of	O
these	O
11	O
MAbs	O
were	O
specific	O
for	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
HEV	O
.	O

The	O
chimeric	O
DNA	O
-	O
RNA	O
hammerhead	O
ribozyme	O
targeting	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
significantly	O
inhibited	O
the	O
expression	O
of	O
SARS	O
-	O
CoV	O
RNA	O
in	O
3T3	O
cells	O
transfected	O
with	O
the	O
recombinant	O
plasmid	O
.	O

ScFvs	O
of	O
mouse	B-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
which	O
was	O
verified	O
to	O
neutralize	O
PEDV	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
expression	O
system	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
2003	O
,	O
the	O
three	O
-	O
dimensional	O
structures	O
of	O
several	O
of	O
the	O
replicase	B-PRGE
/	I-PRGE
transcriptase	I-PRGE
components	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
the	O
non	O
-	O
structural	O
proteins	O
(	O
Nsps	O
),	O
have	O
been	O
determined	O
.	O

Monoclonal	O
antibodies	O
,	O
protease	O
inhibitors	O
,	O
interferon	B-PRGE
-	O
based	O
drugs	O
and	O
nucleic	O
-	O
acid	O
based	O
antivirals	O
are	O
most	O
advanced	O
,	O
each	O
having	O
its	O
own	O
advantages	O
and	O
disadvantages	O
.	O

The	O
dramatic	O
increase	O
in	O
virus	O
-	O
specific	O
mucosal	O
IgA	B-PRGE
15	O
days	O
after	O
inoculation	O
was	O
accompanied	O
by	O
reductions	O
in	O
the	O
DEV	O
intestinal	O
load	O
,	O
suggesting	O
that	O
the	O
IgA	B-PRGE
response	O
has	O
a	O
role	O
in	O
controlling	O
viral	O
replication	O
.	O

The	O
kinetics	O
of	O
virus	O
-	O
specific	O
IgA	B-PRGE
production	O
closely	O
correlated	O
with	O
the	O
presence	O
of	O
IgA	B-PRGE
+	I-PRGE
plasma	O
cells	O
in	O
the	O
intestinal	O
lamina	O
propria	O
.	O

TITLE	O
:	O
SARS	O
-	O
coronavirus	O
modulation	O
of	O
myocardial	O
ACE2	B-PRGE
expression	O
and	O
inflammation	O
in	O
patients	O
with	O
SARS	O
.	O

The	O
presence	O
of	O
SARS	O
-	O
CoV	O
in	O
the	O
heart	O
was	O
also	O
associated	O
with	O
marked	O
reductions	O
in	O
ACE2	B-PRGE
protein	I-PRGE
expression	O
.	O

Lung	B-PRGE
metastases	I-PRGE
and	O
tuberculosis	O
were	O
excluded	O
and	O
fungal	O
infection	O
suspected	O
.	O

Additional	O
T	B-PRGE
-	I-PRGE
cell	I-PRGE
epitopes	I-PRGE
within	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
that	O
may	O
contribute	O
to	O
cell	O
-	O
mediated	O
immunity	O
in	O
vivo	O
were	O
also	O
identified	O
.	O

TITLE	O
:	O
Synthetic	O
peptides	O
coupled	O
to	O
the	O
surface	O
of	O
liposomes	O
effectively	O
induce	O
SARS	O
coronavirus	O
-	O
specific	O
cytotoxic	O
T	O
lymphocytes	O
and	O
viral	O
clearance	O
in	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
0201	I-PRGE
transgenic	O
mice	O
.	O

We	O
first	O
identified	O
four	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
0201	I-PRGE
-	O
restricted	O
CTL	O
epitopes	O
derived	O
from	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
using	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
0201	I-PRGE
transgenic	O
mice	O
and	O
recombinant	O
adenovirus	O
expressing	O
predicted	O
epitopes	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
pulmonary	O
injury	O
in	O
acute	O
pancreatitis	O
is	O
mediated	O
by	O
PMN	B-PRGE
-	I-PRGE
derived	I-PRGE
matrix	I-PRGE
metalloproteinase	I-PRGE
-	I-PRGE
9	I-PRGE
(	O
MMP	B-PRGE
-	I-PRGE
9	I-PRGE
).	O

ABSTRACT	O
:	O
A	O
chimeric	O
gene	O
encoding	O
enhanced	B-PRGE
green	I-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
EGFP	O
)	O
and	O
a	O
S	O
-	O
layer	O
protein	O
from	O
Lactobacillus	O
brevis	O
KCTC3102	O
,	O
and	O
/	O
or	O
two	O
copies	O
of	O
the	O
Fc	B-PRGE
-	I-PRGE
binding	I-PRGE
Z	I-PRGE
-	I-PRGE
domain	I-PRGE
,	O
a	O
synthetic	O
analog	O
of	O
the	O
B	O
-	O
domain	O
of	O
protein	O
A	O
,	O
was	O
constructed	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
BL21	O
(	O
DE3	O
).	O

(	O
III	B-PRGE
-	I-PRGE
A	I-PRGE
).	O

TITLE	O
:	O
Genetic	O
analysis	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
of	O
4	O
/	O
91	O
type	O
infectious	O
bronchitis	O
virus	O
isolated	O
in	O
Japan	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
S1	B-PRGE
gene	I-PRGE
of	O
JP	O
/	O
Wakayama	O
-	O
2	O
/	O
2004	O
revealed	O
high	O
sequence	O
similarity	O
with	O
that	O
of	O
the	O
4	O
/	O
91	O
vaccine	O
strain	O
and	O
appeared	O
to	O
be	O
a	O
vaccine	O
-	O
like	O
virus	O
derived	O
from	O
a	O
vaccine	O
.	O

RESULTS	O
:	O
Our	O
results	O
demonstrates	O
that	O
SARS	O
-	O
CoV	O
did	O
not	O
modulate	O
TLR	O
-	O
1	O
to	O
TLR	B-PRGE
-	I-PRGE
10	I-PRGE
gene	I-PRGE
expression	O
but	O
significantly	O
induced	O
the	O
expression	O
of	O
CCR	O
-	O
1	O
,	O
CCR	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
and	O
CCR	B-PRGE
-	I-PRGE
5	I-PRGE
.	O

Gene	O
fragments	O
encoding	O
N	O
protein	O
,	O
M	B-PRGE
protein	I-PRGE
and	O
S2	B-PRGE
protein	I-PRGE
of	O
SARS	O
-	O
CoV	O
were	O
amplified	O
by	O
PCR	O
using	O
cDNA	O
obtained	O
from	O
lung	O
samples	O
of	O
SARS	O
patients	O
as	O
template	O
,	O
and	O
subcloned	O
into	O
pcDNA3	O
.	O
1	O
vector	O
to	O
form	O
eukaryotic	O
expression	O
plasmids	O
.	O

Rats	O
with	O
LC	O
+	O
CASP	O
versus	O
LC	O
had	O
more	O
severe	O
inflammation	O
based	O
on	O
higher	O
levels	O
of	O
PMN	O
in	O
BAL	O
at	O
5	O
h	O
,	O
increased	O
whole	O
lung	O
myeloperoxidase	B-PRGE
(	O
MPO	B-PRGE
)	O
activity	O
at	O
5	O
and	O
24	O
h	O
,	O
and	O
increased	O
levels	O
of	O
inflammatory	O
mediators	O
in	O
BAL	B-PRGE
(	O
TNFalpha	B-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
and	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
at	O
5	O
and	O
24	O
h	O
;	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
MIP	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
and	O
CINC	O
-	O
1	O
at	O
5	O
h	O
).	O

The	O
virus	O
was	O
partially	O
attenuated	O
at	O
passage	O
40	O
(	O
P40	O
)	O
and	O
P70	B-PRGE
,	O
and	O
was	O
fully	O
attenuated	O
at	O
P110	O
.	O

A	O
109	O
-	O
bp	O
deletion	O
in	O
the	O
3	O
'-	O
UTR	O
was	O
observed	O
in	O
most	O
subpopulations	O
of	O
P70	B-PRGE
and	O
P110	B-PRGE
,	O
and	O
might	O
be	O
related	O
to	O
virus	O
replication	O
,	O
transcription	O
and	O
pathogenicity	O
.	O

The	O
membrane	O
topology	O
of	O
SARS	O
-	O
CoV	O
M	O
and	O
the	O
functional	O
significance	O
of	O
its	O
N	O
-	O
glycosylation	O
are	O
not	O
completely	O
understood	O
as	O
is	O
its	O
interaction	O
with	O
the	O
surface	O
glycoprotein	B-PRGE
S	I-PRGE
.	O
Using	O
biochemical	O
and	O
immunofluorescence	O
analyses	O
we	O
found	O
that	O
M	O
consists	O
of	O
a	O
short	O
glycosylated	O
N	O
-	O
terminal	O
ectodomain	O
,	O
three	O
transmembrane	O
segments	O
and	O
a	O
long	O
,	O
immunogenic	O
C	O
-	O
terminal	O
endodomain	O
.	O

Further	O
functional	O
analysis	O
of	O
truncated	B-PRGE
M	I-PRGE
proteins	I-PRGE
showed	O
that	O
the	O
N	O
-	O
terminal	O
134	O
amino	O
acids	O
comprising	O
the	O
three	O
transmembrane	O
domains	O
are	O
sufficient	O
to	O
mediate	O
accumulation	O
of	O
M	O
in	O
the	O
Golgi	O
complex	O
and	O
to	O
enforce	O
recruitment	O
of	O
the	O
viral	O
spike	O
protein	O
S	O
to	O
the	O
sites	O
of	O
virus	O
assembly	O
and	O
budding	O
in	O
the	O
ERGIC	O
.	O

Three	O
recombination	O
hot	O
regions	O
were	O
found	O
on	O
the	O
S	B-PRGE
gene	I-PRGE
,	O
namely	O
at	O
nt	O
337	O
-	O
437	O
,	O
1545	O
-	O
3405	O
,	O
and	O
4203	O
-	O
4356	O
,	O
which	O
shared	O
a	O
common	O
recombination	O
signal	O
with	O
Group	O
2	O
coronaviruses	O
.	O

Plasmids	O
carrying	O
the	O
S1	B-PRGE
gene	I-PRGE
of	O
IBV	O
(	O
pVAX	O
-	O
S1	O
)	O
and	O
the	O
chicken	B-PRGE
GM	I-PRGE
-	I-PRGE
CSF	I-PRGE
gene	I-PRGE
(	O
pVAX	B-PRGE
-	I-PRGE
chGM	I-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
were	O
constructed	O
.	O

The	O
effect	O
of	O
dobutamine	O
on	O
AFC	O
and	O
the	O
expression	O
of	O
aquaporin	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
aquaporin	B-PRGE
-	I-PRGE
5	I-PRGE
were	O
examined	O
.	O

Our	O
study	O
indicates	O
that	O
dobutamine	O
may	O
enhance	O
alveolar	O
fluid	O
reabsorption	O
by	O
increasing	O
the	O
expression	O
of	O
aquaporin	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
aquaporin	B-PRGE
-	I-PRGE
5	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
nsp14	B-PRGE
protein	I-PRGE
,	O
an	O
exoribonuclease	O
of	O
the	O
DEDD	B-PRGE
superfamily	I-PRGE
encoded	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
was	O
expressed	O
in	O
fusion	O
with	O
different	O
affinity	O
tags	O
.	O

TITLE	O
:	O
Proteolytic	O
activation	O
of	O
the	O
spike	O
protein	O
at	O
a	O
novel	O
RRRR	O
/	O
S	O
motif	O
is	O
implicated	O
in	O
furin	B-PRGE
-	O
dependent	O
entry	O
,	O
syncytium	O
formation	O
,	O
and	O
infectivity	O
of	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
in	O
cultured	O
cells	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
studies	O
revealed	O
that	O
the	O
S1	O
/	O
S2	O
cleavage	O
by	O
furin	B-PRGE
was	O
not	O
necessary	O
for	O
,	O
but	O
could	O
promote	O
,	O
syncytium	O
formation	O
by	O
and	O
infectivity	O
of	O
IBV	O
in	O
Vero	O
cells	O
.	O

The	O
GBP	B-PRGE
domain	I-PRGE
of	O
the	O
fusion	O
protein	O
serves	O
as	O
an	O
anchoring	O
component	O
onto	O
the	O
gold	O
surface	O
,	O
exploiting	O
the	O
gold	O
binding	O
affinity	O
of	O
the	O
domain	O
,	O
whereas	O
the	O
SCVme	B-PRGE
domain	I-PRGE
is	O
a	O
recognition	O
element	O
for	O
anti	O
-	O
SCVme	O
antibody	O
,	O
the	O
target	O
analyte	O
in	O
this	O
study	O
.	O

All	O
patients	O
had	O
fever	O
,	O
cough	O
,	O
dyspnea	O
or	O
respiratory	O
distress	O
,	O
increased	O
serum	O
lactate	B-PRGE
dehydrogenase	I-PRGE
levels	O
,	O
and	O
bilateral	O
patchy	O
pneumonia	O
.	O

In	O
A	O
/	O
J	O
and	O
C3H	O
/	O
HeJ	O
mice	O
,	O
which	O
are	O
highly	O
susceptible	O
to	O
MHV	O
-	O
1	O
-	O
induced	O
disease	O
,	O
we	O
demonstrate	O
that	O
both	O
CD4	B-PRGE
and	O
CD8	B-PRGE
T	I-PRGE
cells	O
contribute	O
to	O
morbidity	O
during	O
primary	O
infection	O
,	O
and	O
memory	O
responses	O
can	O
enhance	O
morbidity	O
and	O
mortality	O
during	O
subsequent	O
reexposure	O
to	O
MHV	O
-	O
1	O
.	O

Interestingly	O
,	O
the	O
silencing	O
of	O
glyceraldehyde	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	B-PRGE
),	O
initially	O
used	O
as	O
a	O
control	O
gene	O
,	O
caused	O
a	O
2	O
to	O
3	O
-	O
fold	O
increase	O
in	O
viral	O
RNA	O
synthesis	O
in	O
both	O
systems	O
.	O

The	O
concentrations	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
BALF	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
serum	O
were	O
higher	O
in	O
nonsurvivors	O
than	O
in	O
survivor	O
patients	O
with	O
CAP	O
.	O

TITLE	O
:	O
Structure	O
and	O
inhibition	O
of	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
envelope	I-PRGE
protein	I-PRGE
ion	O
channel	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
known	O
to	O
efficiently	O
suppress	O
the	O
induction	O
of	O
antiviral	B-PRGE
type	I-PRGE
I	I-PRGE
interferons	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
/	I-PRGE
beta	I-PRGE
)	O
in	O
non	O
-	O
lymphatic	O
cells	O
through	O
inhibition	O
of	O
the	O
transcription	O
factor	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
.	O

The	O
results	O
showed	O
that	O
rdACE2	O
is	O
a	O
more	O
efficient	O
receptor	O
for	O
human	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
but	O
not	O
for	O
SARS	O
-	O
CoV	O
-	O
like	O
viruses	O
of	O
masked	O
palm	O
civets	O
and	O
raccoon	O
dogs	O
,	O
than	O
huACE2	O
or	O
pcACE2	O
.	O

In	O
addition	O
,	O
differential	O
signals	O
are	O
required	O
for	O
trafficking	O
and	O
retention	O
of	O
virus	O
-	O
specific	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
during	O
chronic	O
demyelination	O
in	O
JHMV	O
-	O
infected	O
mice	O
.	O

Recombinant	O
L	O
.	O
lactis	O
,	O
expressing	O
the	O
SN	B-PRGE
protein	I-PRGE
,	O
was	O
constructed	O
with	O
the	O
pNZ8112	O
plasmid	O
.	O

ABSTRACT	O
:	O
Sequence	O
-	O
specific	O
NMR	O
assignments	O
of	O
an	O
internal	O
domain	O
of	O
the	O
protein	O
nsp3	B-PRGE
,	O
nsp3	B-PRGE
(	I-PRGE
513	I-PRGE
-	I-PRGE
651	I-PRGE
),	I-PRGE
which	O
is	O
a	O
part	O
of	O
the	O
SARS	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
replicase	B-PRGE
polyprotein	O
,	O
have	O
been	O
determined	O
,	O
using	O
triple	O
-	O
resonance	O
NMR	O
experiments	O
with	O
the	O
uniformly	O
[(	O
13	O
)	O
C	O
,(	O
15	O
)	O
N	O
]-	O
labeled	O
protein	O
.	O

The	O
mRT	B-PRGE
-	I-PRGE
PCR	I-PRGE
remains	O
a	O
simple	O
,	O
rapid	O
,	O
and	O
specific	O
assay	O
for	O
the	O
specific	O
detection	O
of	O
respiratory	O
viruses	O
,	O
and	O
can	O
be	O
easily	O
implemented	O
with	O
standards	O
in	O
clinical	O
laboratories	O
at	O
a	O
low	O
cost	O
.	O

For	O
nsp2	B-PRGE
,	O
we	O
identified	O
an	O
interaction	O
with	O
two	O
host	O
proteins	O
,	O
prohibitin	B-PRGE
1	I-PRGE
(	O
PHB1	B-PRGE
)	O
and	O
PHB2	B-PRGE
.	O

A	O
minority	O
(<	O
5	O
%)	O
of	O
COPD	O
patients	O
exhibit	O
severe	O
or	O
""""	O
disproportionate	O
""""	O
PH	O
(	O
PAP	B-PRGE
>	O
40	O
mmHg	O
),	O
the	O
mechanism	O
of	O
which	O
is	O
not	O
well	O
understood	O
.	O

Immunohistochemical	O
staining	O
for	O
types	B-PRGE
I	I-PRGE
and	I-PRGE
IV	I-PRGE
collagen	I-PRGE
,	O
alpha	B-PRGE
-	I-PRGE
smooth	I-PRGE
muscle	I-PRGE
actin	I-PRGE
,	O
and	O
Ki	B-PRGE
-	I-PRGE
67	I-PRGE
was	O
carried	O
out	O
,	O
and	O
the	O
sites	O
of	O
myofibroblast	O
proliferation	O
and	O
type	B-PRGE
I	I-PRGE
collagen	I-PRGE
production	O
were	O
examined	O
.	O

Gene	O
expression	O
profiling	O
of	O
these	O
mice	O
identified	O
type	O
I	O
IFN	B-PRGE
-	O
independent	O
responses	O
to	O
infection	O
,	O
with	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
as	O
the	O
central	O
player	O
.	O

The	O
subsequent	O
PRCV	O
infection	O
led	O
to	O
enhanced	O
PRRSV	O
replication	O
in	O
the	O
lungs	O
and	O
a	O
trend	O
towards	O
increased	O
serum	O
T	O
-	O
helper	O
type	O
1	O
(	O
Th1	O
)	O
(	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
)	O
but	O
decreased	O
Th2	B-PRGE
[	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)-	I-PRGE
4	I-PRGE
]	O
responses	O
,	O
further	O
exacerbating	O
PRRSV	O
pneumonia	O
.	O

Experimentally	O
,	O
a	O
linear	O
relationship	O
between	O
the	O
fluorescence	O
signal	O
and	O
the	O
concentration	O
of	O
recombinant	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
(	O
GST	B-PRGE
-	O
N	O
)	O
protein	O
in	O
buffer	O
solution	O
could	O
be	O
observed	O
from	O
0	O
.	O
1	O
pg	O
/	O
mL	O
to	O
1	O
ng	O
/	O
mL	O
.	O
In	O
addition	O
,	O
the	O
concentration	O
of	O
GST	B-PRGE
-	O
N	B-PRGE
protein	I-PRGE
in	O
diluted	O
serum	O
across	O
a	O
similar	O
range	O
could	O
also	O
be	O
measured	O
.	O

TITLE	O
:	O
Large	O
Arf1	B-PRGE
guanine	I-PRGE
nucleotide	I-PRGE
exchange	I-PRGE
factors	I-PRGE
:	O
evolution	O
,	O
domain	O
structure	O
,	O
and	O
roles	O
in	O
membrane	O
trafficking	O
and	O
human	O
disease	O
.	O

Members	O
of	O
the	O
GBF	B-PRGE
/	O
Gea	O
and	O
BIG	B-PRGE
/	O
Sec7	B-PRGE
subfamilies	O
are	O
large	O
proteins	O
on	O
the	O
order	O
of	O
200	O
kDa	O
,	O
and	O
they	O
possess	O
multiple	O
homology	O
domains	O
.	O

TITLE	O
:	O
Recombinant	B-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
expressed	O
in	O
mammalian	O
,	O
insect	O
and	O
E	O
.	O
coli	O
cells	O
elicits	O
potent	O
neutralizing	O
antibody	O
and	O
protective	O
immunity	O
.	O

Studies	O
in	O
the	O
putative	O
human	O
VASP	B-PRGE
promoter	I-PRGE
identified	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
as	O
a	O
key	O
regulator	O
of	O
VASP	B-PRGE
transcription	O
.	O

To	O
study	O
the	O
role	O
of	O
ORF	B-PRGE
7b	I-PRGE
in	O
the	O
context	O
of	O
virus	O
replication	O
,	O
we	O
cloned	O
a	O
full	O
genome	O
cDNA	O
copy	O
of	O
Frankfurt	O
-	O
1	O
in	O
a	O
bacterial	O
artificial	O
chromosome	O
downstream	O
of	O
a	O
T7	B-PRGE
RNA	I-PRGE
polymerase	I-PRGE
promoter	I-PRGE
.	O

Here	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
this	O
well	O
conserved	O
region	O
for	O
SARS	B-PRGE
-	O
CoV	O
S	O
-	O
mediated	O
fusion	O
activation	O
.	O

The	O
selective	O
forces	O
underlying	O
HE	O
diversity	O
and	O
the	O
molecular	O
basis	O
for	O
Sia	B-PRGE
specificity	O
are	O
poorly	O
understood	O
.	O

Structure	O
-	O
guided	O
biochemical	O
analysis	O
of	O
the	O
esterase	B-PRGE
domains	I-PRGE
revealed	O
that	O
a	O
functionally	O
,	O
but	O
not	O
structurally	O
conserved	O
arginine	O
-	O
Sia	O
carboxylate	O
interaction	O
is	O
critical	O
for	O
the	O
binding	O
and	O
positioning	O
of	O
glycosidically	O
bound	O
Sias	O
in	O
the	O
catalytic	O
pocket	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
clinical	O
value	O
of	O
CD4	B-PRGE
(+)	O
T	O
lymphocyte	O
detection	O
in	O
the	O
treatment	O
of	O
cytomegalovirus	O
(	O
CMV	O
)	O
pneumonia	O
following	O
kidney	O
transplantation	O
.	O

But	O
in	O
4	O
non	O
-	O
survival	O
patients	O
,	O
the	O
number	O
of	O
CD4	B-PRGE
(+)	O
T	O
cell	O
kept	O
continuously	O
in	O
lower	O
level	O
.	O

The	O
interaction	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
and	O
MAP19	B-PRGE
was	O
demonstrated	O
by	O
immuno	O
-	O
coprecipitation	O
,	O
and	O
the	O
amount	O
of	O
MAP19	B-PRGE
influenced	O
by	O
SARS	O
-	O
CoV	O
N	O
was	O
investgated	O
by	O
Western	O
blot	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
identify	O
the	O
mechanisms	O
used	O
by	O
MHV	O
type	O
3	O
to	O
modulate	O
the	O
production	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
by	O
NK	O
cells	O
during	O
the	O
acute	O
hepatitis	O
in	O
susceptible	O
C57BL	O
/	O
6	O
mice	O
.	O

Ex	O
vivo	O
and	O
in	O
vitro	O
experiments	O
revealed	O
that	O
NK	O
cells	O
,	O
expressing	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecules	O
(	O
CEACAM	O
)	O
1a	O
(	O
the	O
MHV	B-PRGE
receptor	I-PRGE
),	O
can	O
produce	O
a	O
higher	O
level	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
the	O
presence	O
of	O
both	O
L2	O
-	O
MHV3	O
and	O
interleukin	B-PRGE
-	I-PRGE
12	I-PRGE
(	O
IL	O
-	O
12	O
)/	O
IL	O
-	O
18	O
.	O

However	O
,	O
the	O
signal	O
triggered	O
through	O
the	O
engagement	O
of	O
CEACAM1a	O
decreases	O
the	O
production	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
when	O
these	O
molecules	O
are	O
cross	O
-	O
linked	O
using	O
specific	O
monoclonal	O
antibodies	O
.	O

These	O
results	O
suggest	O
that	O
control	O
of	O
acute	O
hepatitis	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
producing	O
NK	O
cells	O
may	O
depend	O
on	O
both	O
production	O
of	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
in	O
the	O
liver	O
environment	O
and	O
viral	O
infection	O
of	O
NK	O
cells	O
.	O

Here	O
,	O
we	O
attempted	O
to	O
identify	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
0201	I-PRGE
-	O
restricted	O
CTL	O
epitopes	O
derived	O
from	O
a	O
non	O
-	O
structural	O
polyprotein	B-PRGE
1a	I-PRGE
(	O
pp1a	B-PRGE
)	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
and	O
investigated	O
whether	O
liposomal	O
peptides	O
derived	O
from	O
pp1a	B-PRGE
were	O
effective	O
for	O
CTL	O
induction	O
.	O

Solution	O
nuclear	O
magnetic	O
resonance	O
experiments	O
are	O
consistent	O
with	O
a	O
5	O
'-	O
uYNMG	O
(	O
U	O
)	O
a	O
or	O
uCUYG	O
(	O
U	O
)	O
a	O
tetraloop	O
conformation	O
characterized	O
by	O
an	O
anti	B-PRGE
-	I-PRGE
C47	I-PRGE
-	I-PRGE
syn	I-PRGE
-	O
G50	O
base	O
-	O
pairing	O
interaction	O
,	O
with	O
U51	O
flipped	O
out	O
into	O
solution	O
and	O
G50	O
stacked	O
on	O
A52	O
.	O

The	O
results	O
obtained	O
by	O
the	O
two	O
methods	O
were	O
substantially	O
identical	O
and	O
showed	O
that	O
the	O
structure	O
of	O
the	O
Orf	B-PRGE
9b	I-PRGE
protein	I-PRGE
consisted	O
mostly	O
of	O
beta	O
-	O
sheet	O
,	O
and	O
comprised	O
only	O
few	O
alpha	O
-	O
helix	O
.	O

This	O
finding	O
was	O
further	O
confirmed	O
with	O
knockdown	O
experiments	O
using	O
small	O
interfering	O
RNAs	O
specific	O
for	O
Janus	B-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
kinase	I-PRGE
.	O

One	O
of	O
the	O
common	O
viral	O
targets	O
is	O
the	O
alpha	O
subunit	O
of	O
eukaryotic	B-PRGE
initiation	I-PRGE
factor	I-PRGE
2	I-PRGE
(	O
eIF	B-PRGE
-	I-PRGE
2alpha	I-PRGE
).	O

Taken	O
together	O
,	O
these	O
results	O
confirm	O
that	O
IBV	O
has	O
developed	O
a	O
combination	O
of	O
two	O
mechanisms	O
,	O
i	O
.	O
e	O
.,	O
blocking	O
PKR	B-PRGE
activation	O
and	O
inducing	O
GADD34	B-PRGE
expression	O
,	O
to	O
maintain	O
de	O
novo	O
protein	O
synthesis	O
in	O
IBV	O
-	O
infected	O
cells	O
and	O
,	O
meanwhile	O
,	O
to	O
enhance	O
viral	O
replication	O
.	O

In	O
conclusion	O
,	O
the	O
oral	O
immunizations	O
with	O
recombinant	O
L	O
.	O
casei	O
393	O
can	O
induce	O
significant	O
specific	O
mucosal	O
PEDV	O
N	O
-	O
specific	O
IgA	B-PRGE
response	O
as	O
well	O
as	O
serum	B-PRGE
IgG	I-PRGE
responses	O
,	O
and	O
can	O
evoke	O
both	O
mucosal	O
immune	O
and	O
system	O
immune	O
responses	O
.	O

TITLE	O
:	O
Bid	O
cleavage	O
,	O
cytochrome	B-PRGE
c	I-PRGE
release	I-PRGE
and	O
caspase	B-PRGE
activation	O
in	O
canine	O
coronavirus	O
-	O
induced	O
apoptosis	O
.	O

Both	O
virus	O
-	O
specific	O
CD4	B-PRGE
and	O
CD8	B-PRGE
T	I-PRGE
cells	O
are	O
functional	O
,	O
as	O
assessed	O
by	O
cytokine	O
expression	O
and	O
degranulation	O
after	O
peptide	O
exposure	O
.	O

In	O
addition	O
,	O
populations	O
of	O
virus	O
-	O
specific	O
CD4	B-PRGE
T	O
cells	O
undergo	O
dynamic	O
changes	O
in	O
the	O
infected	O
CNS	O
,	O
as	O
previously	O
shown	O
for	O
CD8	B-PRGE
T	I-PRGE
cells	O
,	O
because	O
ratios	O
of	O
cells	O
responding	O
to	O
two	O
CD4	B-PRGE
T	I-PRGE
cell	I-PRGE
epitopes	I-PRGE
change	O
by	O
a	O
factor	O
of	O
five	O
during	O
the	O
course	O
of	O
persistence	O
.	O

The	O
serum	B-PRGE
C	I-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
)	O
level	O
recovered	O
more	O
quickly	O
in	O
patients	O
in	O
the	O
PCD	O
group	O
compared	O
to	O
those	O
in	O
the	O
surgery	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
ATE	O
medium	O
,	O
which	O
contains	O
chicken	O
embryo	O
extract	O
and	O
fetal	O
bovine	O
serum	O
,	O
supports	O
the	O
growth	O
of	O
ciliated	O
cells	O
,	O
goblet	O
cells	O
and	O
basal	O
cells	O
from	O
chicken	O
tracheas	O
on	O
fibronectin	B-PRGE
-	O
or	O
matrigel	O
-	O
coated	O
dishes	O
.	O

Human	B-PRGE
A	I-PRGE
/	O
H5N1	O
infection	O
is	O
a	O
severe	O
and	O
rapidly	O
progressive	O
disease	O
mostly	O
manifested	O
as	O
ARDS	O
.	O

CONCLUSIONS	O
:	O
Human	B-PRGE
A	I-PRGE
/	O
H5N1	O
infection	O
is	O
a	O
severe	O
and	O
rapidly	O
progressive	O
disease	O
mostly	O
manifested	O
as	O
ARDS	O
.	O

Secondly	O
,	O
NO	O
or	O
its	O
derivatives	O
cause	O
a	O
reduction	O
in	O
viral	O
RNA	O
production	O
in	O
the	O
early	O
steps	O
of	O
viral	O
replication	O
,	O
and	O
this	O
could	O
possibly	O
be	O
due	O
to	O
an	O
effect	O
on	O
one	O
or	O
both	O
of	O
the	O
cysteine	B-PRGE
proteases	I-PRGE
encoded	O
in	O
Orf1a	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O

Data	O
indicated	O
that	O
neither	O
the	O
FAH	B-PRGE
minimal	I-PRGE
epitopes	I-PRGE
nor	O
the	O
key	O
residues	O
important	O
for	O
binding	O
to	O
Ab	O
from	O
MHV	O
-	O
infected	O
mice	O
have	O
their	O
counterparts	O
in	O
the	O
viral	O
proteins	O
.	O

After	O
infection	O
of	O
hPMEC	O
,	O
cell	O
activation	O
markers	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
and	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
were	O
upregulated	O
,	O
and	O
the	O
proinflammatory	O
cytokines	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
beta	B-PRGE
interferon	I-PRGE
were	O
secreted	O
.	O

ABSTRACT	O
:	O
The	O
envelope	B-PRGE
glycoproteins	O
S1	O
and	O
S2	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
mediate	O
viral	O
entry	O
by	O
conformational	O
change	O
from	O
a	O
prefusion	O
state	O
to	O
a	O
postfusion	O
state	O
that	O
enables	O
fusion	O
of	O
the	O
viral	O
and	O
target	O
membranes	O
.	O

In	O
all	O
groups	O
,	O
hemolysis	O
remained	O
negligible	O
,	O
indicated	O
by	O
low	O
plasma	O
hemoglobin	B-PRGE
concentration	O
.	O

Interleukin	B-PRGE
8	I-PRGE
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
concentration	O
as	O
well	O
as	O
leukocyte	O
count	O
remained	O
unchanged	O
.	O

Patients	O
who	O
died	O
had	O
greater	O
initial	O
severity	O
of	O
illness	O
,	O
worse	O
hypoxemia	O
,	O
higher	O
creatine	B-PRGE
kinase	I-PRGE
levels	O
,	O
higher	O
creatinine	O
levels	O
,	O
and	O
ongoing	O
organ	O
dysfunction	O
.	O

It	O
is	O
characterized	O
by	O
acute	O
-	O
onset	O
difficulty	O
in	O
walking	O
as	O
a	O
result	O
of	O
severe	O
bilateral	O
calf	O
pain	O
and	O
by	O
elevated	O
muscle	O
enzymes	O
including	O
creatinine	B-PRGE
kinase	I-PRGE
.	O

The	O
nsp4	B-PRGE
glycosylation	O
mutants	O
exhibited	O
impaired	O
virus	O
growth	O
and	O
RNA	O
synthesis	O
,	O
with	O
the	O
N237A	O
and	O
N176A	O
/	O
N237A	O
mutant	O
viruses	O
demonstrating	O
more	O
profound	O
defects	O
in	O
virus	O
growth	O
and	O
RNA	O
synthesis	O
.	O

Thereafter	O
,	O
six	O
animals	O
were	O
assigned	O
randomly	O
into	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
group	O
,	O
whereas	O
another	O
six	O
animals	O
served	O
as	O
control	O
.	O

Three	O
animals	O
received	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
without	O
lipopolysaccharide	O
pretreatment	O
.	O

Furthermore	O
,	O
angiotensin	B-PRGE
II	I-PRGE
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
levels	O
,	O
both	O
of	O
which	O
were	O
substantially	O
increased	O
,	O
returned	O
to	O
basal	O
values	O
.	O

Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
attenuates	O
arterial	O
hypoxemia	O
,	O
pulmonary	O
hypertension	O
,	O
and	O
redistribution	O
of	O
pulmonary	O
blood	O
flow	O
in	O
a	O
piglet	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
may	O
be	O
a	O
promising	O
substance	O
for	O
clinical	O
use	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
novel	O
linear	O
B	O
-	O
cell	O
epitope	O
in	O
the	O
M	B-PRGE
protein	I-PRGE
of	O
avian	O
infectious	O
bronchitis	O
coronaviruses	O
.	O

A	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
(	O
designated	O
as	O
15E2	O
)	O
against	O
the	O
IBV	B-PRGE
M	I-PRGE
protein	I-PRGE
was	O
prepared	O
and	O
a	O
series	O
of	O
14	O
partially	O
-	O
overlapping	O
fragments	O
of	O
the	O
IBV	B-PRGE
M	I-PRGE
gene	I-PRGE
were	O
expressed	O
with	O
a	O
GST	B-PRGE
tag	I-PRGE
.	O

The	O
identified	O
epitope	O
should	O
be	O
useful	O
in	O
clinical	O
applications	O
and	O
as	O
a	O
tool	O
for	O
the	O
further	O
study	O
of	O
the	O
structure	O
and	O
function	O
of	O
the	O
M	B-PRGE
protein	I-PRGE
of	O
IBV	O
.	O

ABSTRACT	O
:	O
The	O
human	O
coronaviruses	O
(	O
CoVs	O
)	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
and	O
NL63	O
employ	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
for	O
cell	O
entry	O
.	O

Bleeding	O
occurred	O
six	O
and	O
12	O
days	O
in	O
male	O
and	O
female	O
mice	O
,	O
respectively	O
,	O
after	O
the	O
initiation	O
of	O
dosing	O
suggesting	O
that	O
mtPA	B-PRGE
accumulated	O
in	O
the	O
lungs	O
.	O

Furthermore	O
,	O
nuclear	O
translocation	O
of	O
activated	O
STAT1	B-PRGE
and	O
a	O
range	O
of	O
interferon	B-PRGE
-	O
stimulated	O
genes	O
could	O
be	O
demonstrated	O
in	O
the	O
lungs	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
macaques	O
.	O

Recent	O
data	O
have	O
indicated	O
that	O
members	O
of	O
the	O
tetraspanin	B-PRGE
superfamily	I-PRGE
,	O
proteins	O
with	O
a	O
widespread	O
distribution	O
in	O
eukaryotic	O
organisms	O
and	O
33	O
members	O
in	O
humans	O
,	O
may	O
provide	O
such	O
an	O
approach	O
.	O

TITLE	O
:	O
Improved	O
health	O
and	O
survival	O
of	O
FIV	O
-	O
infected	O
cats	O
is	O
associated	O
with	O
the	O
presence	O
of	O
autoantibodies	O
to	O
the	O
primary	O
receptor	O
,	O
CD134	B-PRGE
.	O

Anti	B-PRGE
-	I-PRGE
CD134	I-PRGE
binding	O
caused	O
displacement	O
of	O
SU	O
from	O
the	O
surface	O
of	O
the	O
cell	O
and	O
inhibition	O
of	O
infection	O
.	O

TITLE	O
:	O
Humanized	O
monoclonal	O
antibody	O
against	O
the	O
chemokine	B-PRGE
CXCL	I-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	O
-	O
8	O
)	O
effectively	O
prevents	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
As	O
one	O
of	O
the	O
most	O
important	O
endogenous	O
chemotactic	O
factors	O
for	O
neutrophils	O
,	O
the	O
chemokine	O
CXCL8	B-PRGE
(	O
IL	O
-	O
8	O
)	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
characterized	O
by	O
massive	O
neutrophil	O
infiltration	O
in	O
the	O
lung	O
.	O

The	O
average	O
amount	O
of	O
TCoV	B-PRGE
RNA	I-PRGE
in	O
the	O
cloacal	O
fecal	O
samples	O
was	O
10	O
times	O
higher	O
than	O
that	O
in	O
the	O
fecal	O
droppings	O
on	O
the	O
floor	O
.	O

Mutation	O
of	O
R667	O
or	O
R797	O
did	O
not	O
affect	O
the	O
expression	O
of	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
but	O
resulted	O
in	O
a	O
differential	O
efficacy	O
of	O
pseudotyping	O
into	O
SARS	O
-	O
CoVpp	O
.	O

ABSTRACT	O
:	O
Plausible	O
representatives	O
of	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDCs	O
)	O
in	O
pigs	O
have	O
been	O
characterized	O
as	O
being	O
CD4	B-PRGE
(	O
hi	O
)	O
CD172	O
(	O
lo	O
).	O

The	O
resultant	O
subset	O
was	O
greater	O
than	O
98	O
%	O
homogeneous	O
in	O
regards	O
to	O
the	O
selected	O
phenotype	O
and	O
contained	O
the	O
preponderance	O
of	O
individuals	O
secreting	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
after	O
exposure	O
to	O
a	O
known	O
stimulant	O
,	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
).	O

TITLE	O
:	O
Protein	O
transfer	O
enhances	O
cellular	O
immune	O
responses	O
to	O
DNA	O
vaccination	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
ABSTRACT	O
:	O
The	O
current	O
DNA	O
vaccine	O
formulations	O
are	O
not	O
optimal	O
for	O
stimulation	O
of	O
CD8	B-PRGE
(+)	O
T	O
cells	O
,	O
which	O
are	O
required	O
for	O
clearing	O
virally	O
-	O
infected	O
cells	O
.	O

Results	O
of	O
our	O
study	O
suggest	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
muscle	O
cells	O
may	O
be	O
modified	O
in	O
situ	O
,	O
at	O
the	O
DNA	O
injection	O
site	O
,	O
into	O
APC	O
-	O
like	O
cells	O
to	O
allow	O
direct	O
priming	O
of	O
CD8	B-PRGE
(+)	O
T	O
cells	O
and	O
thereby	O
improve	O
the	O
efficacy	O
of	O
DNA	O
vaccines	O
.	O

TITLE	O
:	O
Coronavirus	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
facilitates	O
template	O
switching	O
and	O
is	O
required	O
for	O
efficient	O
transcription	O
.	O

Among	O
the	O
four	O
candidate	O
peptides	O
,	O
Sp8	B-PRGE
(	O
S958	O
-	O
966	O
,	O
VLNDILSRL	O
)	O
induced	O
specific	O
CTLs	O
both	O
ex	O
vivo	O
in	O
PBLs	O
of	O
healthy	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
+	I-PRGE
donors	O
and	O
in	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
.	I-PRGE
1	I-PRGE
/	O
Kb	O
transgenic	O
mice	O
immunized	O
with	O
a	O
plasmid	O
encoding	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
S	I-PRGE
protein	I-PRGE
.	O

Previously	O
,	O
we	O
showed	O
that	O
the	O
cellular	O
factor	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
(	O
TACE	B-PRGE
),	O
activated	O
by	O
the	O
spike	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
S	I-PRGE
protein	I-PRGE
),	O
was	O
positively	O
involved	O
in	O
viral	O
entry	O
,	O
implying	O
that	O
TACE	B-PRGE
is	O
a	O
possible	O
target	O
for	O
developing	O
antiviral	O
compounds	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
data	O
revealed	O
that	O
the	O
TACE	B-PRGE
inhibitor	O
TAPI	O
-	O
2	O
attenuated	O
entry	O
of	O
both	O
pseudotyped	O
virus	O
expressing	O
the	O
SARS	B-PRGE
-	I-PRGE
S	I-PRGE
protein	I-PRGE
in	O
a	O
lentiviral	O
vector	O
backbone	O
and	O
infectious	O
SARS	O
-	O
CoV	O
.	O
TAPI	O
-	O
2	O
blocked	O
both	O
the	O
SARS	B-PRGE
-	I-PRGE
S	I-PRGE
protein	I-PRGE
-	O
induced	O
shedding	O
of	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
a	O
receptor	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
in	O
lung	O
tissues	O
.	O

TITLE	O
:	O
Effect	O
of	O
recombinant	O
lactobacillus	O
expressing	O
canine	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
on	O
immune	O
function	O
in	O
dogs	O
.	O

After	O
the	O
administration	O
of	O
CCV	O
vaccine	O
,	O
CCV	O
-	O
specific	O
IgG	B-PRGE
in	O
serum	O
increased	O
more	O
in	O
the	O
group	O
supplemented	O
with	O
L	O
.	O
casei	O
expressing	O
cGM	B-PRGE
-	I-PRGE
CSF	I-PRGE
than	O
the	O
other	O
two	O
groups	O
.	O

This	O
result	O
was	O
confirmed	O
by	O
the	O
observation	O
that	O
preexisting	O
RTCs	O
did	O
not	O
exchange	O
fluorescence	O
after	O
fusion	O
of	O
cells	O
expressing	O
either	O
a	O
green	O
or	O
a	O
red	B-PRGE
fluorescent	I-PRGE
nsp2	I-PRGE
.	O

TITLE	O
:	O
The	O
murine	B-PRGE
coronavirus	I-PRGE
nucleocapsid	I-PRGE
gene	I-PRGE
is	O
a	O
determinant	O
of	O
virulence	O
.	O

Specific	O
parameters	O
assessed	O
in	O
the	O
innate	O
pulmonary	O
inflammatory	O
response	O
were	O
leukocytes	O
,	O
macrophages	O
,	O
and	O
polymorphonuclear	O
neutrophils	O
(	O
PMNs	O
)	O
in	O
BAL	O
;	O
whole	O
lung	B-PRGE
myeloperoxidase	I-PRGE
activity	O
;	O
and	O
a	O
series	O
of	O
cytokines	O
or	O
chemokines	O
present	O
in	O
BAL	O
at	O
5	O
or	O
24	O
hours	O
after	O
injury	O
:	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
interleukin	B-PRGE
(	O
IL	O
)-	O
1beta	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
macrophage	B-PRGE
inflammatory	I-PRGE
protein	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
-	O
1	O
,	O
and	O
monocyte	B-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
Chinese	O
rufous	O
horseshoe	O
bat	O
(	O
Rhinolophus	O
sinicus	O
)	O
has	O
been	O
suggested	O
to	O
carry	O
the	O
direct	O
ancestor	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SCoV	O
),	O
and	O
the	O
diversity	O
of	O
SARS	B-PRGE
-	I-PRGE
like	I-PRGE
CoVs	I-PRGE
(	O
SLCoV	O
)	O
within	O
this	O
Rhinolophus	O
species	O
is	O
therefore	O
worth	O
investigating	O
.	O

Since	O
the	O
3a	B-PRGE
protein	I-PRGE
localizes	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)-	O
Golgi	O
compartment	O
,	O
its	O
role	O
in	O
causing	O
ER	O
stress	O
was	O
investigated	O
in	O
transiently	O
transfected	O
cells	O
.	O

There	O
were	O
34	O
patients	O
subjected	O
to	O
DPA	B-PRGE
and	O
78	O
to	O
diversion	O
.	O

Alignment	O
analysis	O
of	O
the	O
S1	B-PRGE
amino	I-PRGE
acid	I-PRGE
sequences	I-PRGE
indicated	O
that	O
the	O
amino	O
acid	O
substitutions	O
,	O
insertions	O
,	O
and	O
deletions	O
are	O
polymorphic	O
and	O
diverse	O
,	O
showing	O
no	O
sign	O
of	O
predominant	O
genetic	O
changes	O
among	O
the	O
isolated	O
strains	O
.	O

More	O
data	O
are	O
needed	O
to	O
explore	O
the	O
potential	O
role	O
of	O
IV	B-PRGE
gamma	I-PRGE
globulin	I-PRGE
and	O
other	O
drugs	O
with	O
immunomodulating	O
properties	O
,	O
such	O
as	O
statins	O
,	O
gemfibrozil	O
,	O
and	O
N	O
-	O
acetyl	O
-	O
cysteine	O
.	O

TITLE	O
:	O
Vitamin	O
K3	O
attenuates	O
lipopolysaccharide	O
-	O
induced	O
acute	O
lung	O
injury	O
through	O
inhibition	O
of	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
kappaB	I-PRGE
activation	O
.	O

Importantly	O
,	O
the	O
initial	O
specimen	O
evaluated	O
by	O
real	O
-	O
time	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
was	O
negative	O
for	O
novel	O
2009	O
H1N1	O
influenza	O
virus	O
.	O

Therefore	O
,	O
one	O
strategy	O
to	O
overcome	O
the	O
weakness	O
of	O
the	O
immune	O
response	O
is	O
a	O
co	O
-	O
administration	O
of	O
mucosal	O
adjuvant	O
with	O
the	O
vaccine	B-PRGE
antigen	I-PRGE
.	O

ABSTRACT	O
:	O
Viral	O
spread	O
during	O
the	O
early	O
stages	O
after	O
infection	O
was	O
compared	O
between	O
a	O
highly	O
neurovirulent	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
JHMV	B-PRGE
cl	I-PRGE
-	I-PRGE
2	I-PRGE
strain	O
(	O
cl	O
-	O
2	O
),	O
and	O
its	O
low	O
-	O
virulent	O
mutant	O
,	O
soluble	O
-	O
receptor	O
-	O
resistant	O
(	O
srr	O
)	O
7	O
.	O

However	O
,	O
48	O
h	O
after	O
infection	O
with	O
cl	O
-	O
2	O
,	O
viral	O
antigen	O
-	O
positive	O
cells	O
in	O
the	O
grey	O
matter	O
with	O
the	O
shape	O
of	O
neurons	O
,	O
which	O
do	O
not	O
express	O
MHVR	B-PRGE
,	O
were	O
detected	O
,	O
while	O
srr7	O
infection	O
was	O
observed	O
primarily	O
in	O
the	O
white	O
matter	O
.	O

Moreover	O
,	O
recombination	O
was	O
detected	O
between	O
SARSr	B-PRGE
-	I-PRGE
Rh	I-PRGE
-	I-PRGE
BatCoV	I-PRGE
Rp3	I-PRGE
from	O
Guangxi	O
,	O
China	O
,	O
and	O
Rf1	O
from	O
Hubei	O
,	O
China	O
,	O
in	O
the	O
possible	O
generation	O
of	O
civet	O
SARSr	O
-	O
CoV	O
SZ3	O
,	O
with	O
a	O
breakpoint	O
at	O
the	O
nsp16	O
/	O
spike	O
region	O
.	O

As	O
with	O
the	O
other	O
members	O
in	O
the	O
group	O
1	O
,	O
theses	O
viruses	O
are	O
also	O
known	O
to	O
use	O
the	O
host	O
aminopeptidase	B-PRGE
N	I-PRGE
(	O
APN	B-PRGE
)	O
as	O
the	O
major	O
receptor	O
for	O
cell	O
entry	O
.	O

Weaning	O
from	O
HFOV	O
/	O
iLA	B-PRGE
was	O
successful	O
in	O
10	O
patients	O
.	O

Subcellular	O
localization	O
studies	O
using	O
recombinant	B-PRGE
ORF	I-PRGE
3	I-PRGE
protein	I-PRGE
transfected	O
in	O
Huh	O
-	O
7	O
cells	O
revealed	O
occurrence	O
in	O
ERGIC	O
,	O
Golgi	O
-	O
and	O
lysosomal	O
compartments	O
.	O

Analysis	O
of	O
purified	O
viral	O
particles	O
revealed	O
that	O
ORF	B-PRGE
3	I-PRGE
protein	I-PRGE
is	O
incorporated	O
into	O
virions	O
and	O
is	O
therefore	O
an	O
additional	O
structural	O
protein	O
.	O

The	O
envelope	B-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
gene	I-PRGE
showed	O
a	O
moderate	O
nucleotide	O
sequence	O
similarity	O
of	O
91	O
.	O
6	O
%.	O

Previously	O
,	O
we	O
have	O
identified	O
two	O
shRNA	O
-	O
expressing	O
plasmids	O
pEGFP	O
-	O
U6	O
/	O
P1	O
and	O
pEGFP	O
-	O
U6	O
/	O
P2	O
that	O
target	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRP	O
)	O
gene	O
of	O
TGEV	O
with	O
more	O
than	O
95	O
%	O
of	O
virus	O
inhibition	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
whether	O
selected	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
myosin	B-PRGE
light	I-PRGE
chain	I-PRGE
kinase	I-PRGE
gene	I-PRGE
are	O
associated	O
with	O
more	O
severe	O
lung	O
injury	O
in	O
children	O
and	O
adults	O
with	O
community	O
-	O
acquired	O
pneumonia	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
association	O
between	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
myosin	B-PRGE
light	I-PRGE
chain	I-PRGE
kinase	I-PRGE
gene	I-PRGE
and	O
increased	O
severity	O
of	O
acute	O
lung	O
injury	O
in	O
adults	O
.	O

Four	O
of	O
the	O
six	O
patients	O
survived	O
(	O
66	O
.	O
6	O
%),	O
one	O
of	O
the	O
surviving	O
patients	O
was	O
supported	O
with	O
iLA	B-PRGE
and	O
the	O
other	O
three	O
surviving	O
patients	O
were	O
supported	O
with	O
ECMO	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
attempted	O
to	O
establish	O
a	O
simple	O
detection	O
method	O
for	O
classification	O
of	O
IBV	O
S1	O
genotypes	O
by	O
direct	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Pathohistological	O
analysis	O
of	O
the	O
samples	O
retrieved	O
by	O
bronchoscopy	O
pointed	O
to	O
a	O
pneumonia	O
,	O
and	O
diagnosis	O
of	O
LD	O
was	O
confirmed	O
by	O
positive	O
urine	O
test	O
for	O
LP	B-PRGE
antigen	I-PRGE
.	O

In	O
conclusion	O
,	O
extracts	O
from	O
Rheum	O
palmatum	O
L	O
.	O
have	O
a	O
high	O
level	O
of	O
inhibitory	O
activity	O
against	O
3CL	B-PRGE
protease	I-PRGE
,	O
suggesting	O
that	O
extracts	O
from	O
Rheum	O
palmatum	O
L	O
.	O
may	O
represent	O
a	O
potential	O
therapeutic	O
for	O
SARS	O
.	O

A	O
variable	O
increase	O
(	O
of	O
up	O
to	O
50	O
%)	O
on	O
the	O
release	O
of	O
NO	O
(-)	O
and	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
(	O
ROS	O
)	O
was	O
obtained	O
when	O
LAB	O
strains	O
were	O
co	O
-	O
incubated	O
with	O
the	O
cell	O
lines	O
,	O
but	O
the	O
results	O
were	O
found	O
to	O
be	O
LAB	B-PRGE
strain	O
and	O
cell	O
line	O
specific	O
,	O
apart	O
from	O
a	O
small	O
number	O
of	O
strains	O
which	O
were	O
able	O
to	O
induce	O
strong	O
ROS	O
release	O
in	O
more	O
than	O
one	O
cell	O
line	O
.	O

This	O
size	O
difference	O
was	O
due	O
to	O
the	O
combined	O
presence	O
of	O
notable	O
15	O
bp	O
insertion	O
and	O
6	O
bp	O
deletion	O
within	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
S1	B-PRGE
domain	I-PRGE
of	O
the	O
Korean	O
isolates	O
.	O

Therefore	O
,	O
our	O
data	O
implicates	O
a	O
potential	O
usefulness	O
of	O
the	O
partial	B-PRGE
S	I-PRGE
protein	I-PRGE
gene	I-PRGE
including	O
the	O
N	O
-	O
terminal	O
region	O
in	O
unveiling	O
genetic	O
relatedness	O
of	O
PEDV	O
isolates	O
.	O

Furthermore	O
,	O
the	O
recent	O
explosion	O
of	O
research	O
into	O
the	O
ACE2	B-PRGE
homolog	I-PRGE
,	O
collectrin	B-PRGE
,	O
has	O
revealed	O
a	O
new	O
physiological	O
function	O
of	O
ACE2	B-PRGE
as	O
an	O
amino	O
acid	O
transporter	O
,	O
which	O
explains	O
the	O
pathogenic	O
role	O
of	O
gene	O
mutations	O
in	O
Hartnup	O
disorder	O
.	O

The	O
anti	O
-	O
inflammatory	O
action	O
of	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
reveals	O
a	O
potential	O
intervention	O
strategy	O
for	O
virus	O
-	O
induced	O
ALI	O
.	O

We	O
conclude	O
that	O
RS	O
cells	O
irrespective	O
of	O
LMP1	B-PRGE
expression	O
are	O
end	O
-	O
stage	O
tumor	O
cells	O
in	O
which	O
the	O
extent	O
of	O
their	O
inability	O
to	O
divide	O
further	O
is	O
proportional	O
to	O
the	O
increase	O
of	O
very	O
short	O
telomeres	O
,	O
telomere	O
loss	O
,	O
aggregate	O
formation	O
and	O
the	O
generation	O
of	O
'	O
ghost	O
'	O
nuclei	O
.	O

We	O
have	O
found	O
that	O
increasing	O
mitochondrial	B-PRGE
hexokinase	I-PRGE
II	I-PRGE
activity	O
can	O
prevent	O
cell	O
death	O
in	O
neuronal	O
cultures	O
treated	O
with	O
rotenone	O
.	O

In	O
this	O
study	O
we	O
present	O
data	O
demonstrating	O
that	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
7a	I-PRGE
protein	I-PRGE
interacts	O
with	O
human	B-PRGE
Ap4A	I-PRGE
-	I-PRGE
hydrolase	I-PRGE
(	O
asymmetrical	O
diadenosine	B-PRGE
tetraphosphate	I-PRGE
hydrolase	I-PRGE
,	O
EC	O
3	O
.	O
6	O
.	O
1	O
.	O
17	O
).	O

Infants	O
with	O
an	O
SNAP	B-PRGE
>	O
or	O
=	O
10	O
were	O
considered	O
to	O
have	O
severe	O
illness	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
studies	O
revealed	O
that	O
Leu250	O
and	O
Gln251	O
are	O
required	O
for	O
recognition	O
by	O
the	O
'	B-PRGE
MLK3	I-PRGE
protease	I-PRGE
',	I-PRGE
reminiscent	O
of	O
the	O
substrate	O
specificity	O
of	O
the	O
coronavirus	O
3C	O
and	O
3CL	O
proteases	O
.	O

Thus	O
this	O
novel	O
proteolytic	O
processing	O
of	O
MLK3	B-PRGE
may	O
negatively	O
control	O
MLK3	B-PRGE
signalling	O
to	O
JNK	B-PRGE
.	O

In	O
ALI	O
/	O
ARDS	O
patients	O
,	O
SP	B-PRGE
-	I-PRGE
D	I-PRGE
and	O
KL	O
-	O
6	O
levels	O
increased	O
over	O
time	O
,	O
which	O
was	O
attenuated	O
by	O
lung	O
-	O
protective	O
mechanical	O
ventilation	O
using	O
lower	O
tidal	O
volumes	O
(	O
P	O
=	O
0	O
.	O
02	O
for	O
both	O
biological	O
markers	O
).	O

Isolated	O
quinone	O
-	O
methide	O
triterpenes	O
(	O
1	O
-	O
4	O
)	O
and	O
5	O
were	O
evaluated	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibitory	O
activities	O
and	O
showed	O
potent	O
inhibitory	O
activities	O
with	O
IC	O
(	O
50	O
)	O
values	O
of	O
10	O
.	O
3	O
,	O
5	O
.	O
5	O
,	O
9	O
.	O
9	O
,	O
and	O
2	O
.	O
6	O
microM	O
,	O
respectively	O
,	O
whereas	O
the	O
corresponding	O
5	O
having	O
phenol	O
moiety	O
was	O
observed	O
in	O
low	O
activity	O
(	O
IC	O
(	O
50	O
)=	O
21	O
.	O
7	O
microM	O
).	O

Previously	O
we	O
generated	O
a	O
panel	O
of	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
to	O
whole	O
inactivated	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
which	O
neutralize	O
the	O
virus	O
in	O
vitro	O
.	O

In	O
cases	O
like	O
this	O
,	O
the	O
dominance	O
of	O
a	O
compact	O
RBD	O
antigenic	O
domain	O
and	O
the	O
central	O
role	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
in	O
pathogenesis	O
may	O
inherently	O
create	O
immunoselection	O
pressure	O
on	O
viruses	O
to	O
evolve	O
more	O
complex	O
evasion	O
strategies	O
or	O
die	O
out	O
of	O
a	O
host	O
species	O
.	O

However	O
,	O
early	O
prophylactic	O
use	O
of	O
iNO	B-PRGE
in	O
preterm	O
infants	O
with	O
respiratory	O
distress	O
seems	O
to	O
improve	O
survival	O
without	O
BPD	O
or	O
severe	O
cerebral	O
damage	O
.	O

We	O
demonstrated	O
that	O
in	O
contrast	O
to	O
PLP2	B-PRGE
DUB	I-PRGE
activity	O
,	O
PLP2	B-PRGE
-	O
mediated	O
interferon	B-PRGE
antagonism	O
did	O
not	O
require	O
enzymatic	O
activity	O
.	O

Another	O
isolate	O
demonstrated	O
the	O
incorporation	O
of	O
China	O
-	O
like	O
and	O
H120	O
-	O
like	O
genome	O
fragments	O
within	O
the	O
S2	B-PRGE
gene	I-PRGE
and	O
the	O
membrane	O
protein	O
(	O
M	O
)	O
gene	O
region	O
,	O
respectively	O
.	O

Most	O
recently	O
,	O
an	O
inhalable	O
insulin	B-PRGE
formulation	O
was	O
shown	O
to	O
effectively	O
reduce	O
glucose	O
concentrations	O
with	O
minimal	O
impact	O
on	O
long	O
-	O
term	O
pulmonary	O
function	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
qingyi	O
decoction	O
in	O
treating	O
severe	O
acute	O
pancreatitis	O
and	O
its	O
impacts	O
on	O
blood	O
level	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
inteleukin	O
-	O
8	O
].	O

There	O
were	O
significant	O
differences	O
between	O
the	O
2	O
groups	O
confirmed	O
by	O
t	O
-	O
Test	O
and	O
chi	O
(	O
2	O
)	O
test	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
while	O
no	O
significant	O
differences	O
were	O
observed	O
in	O
prothrombin	B-PRGE
time	O
,	O
thrombin	B-PRGE
time	O
,	O
prothrombin	B-PRGE
activity	O
,	O
and	O
international	O
normalized	O
ratio	O
results	O
between	O
the	O
2	O
groups	O
.	O

TITLE	O
:	O
Trypsin	B-PRGE
-	O
induced	O
hemagglutination	O
activity	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

This	O
study	O
was	O
designed	O
to	O
explore	O
the	O
efficacy	O
of	O
dual	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
interference	O
with	O
fgl2	B-PRGE
and	O
TNFR1	B-PRGE
in	O
the	O
treatment	O
of	O
murine	O
hepatitis	O
virus	O
strain	O
3	O
(	O
MHV	O
-	O
3	O
)-	O
induced	O
fulminant	O
hepatitis	O
in	O
mice	O
.	O

Cotransfection	O
of	O
individual	O
shRNA	O
plasmids	O
and	O
pcDNA3	O
.	O
0	O
-	O
mfgl2	O
and	O
pcDNA3	O
.	O
0	O
-	O
mTNFR1	O
expression	O
constructs	O
into	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
significantly	O
inhibited	O
mfgl2	O
and	O
mTNFR1	B-PRGE
gene	I-PRGE
expression	O
,	O
as	O
evidenced	O
by	O
fluorescence	O
microscopy	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
,	O
and	O
Western	O
blotting	O
.	O

While	O
there	O
are	O
many	O
studies	O
of	O
the	O
adaptive	O
immune	O
response	O
to	O
MHV	O
,	O
there	O
has	O
until	O
recently	O
been	O
scant	O
information	O
on	O
the	O
type	O
I	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
response	O
to	O
MHV	O
.	O

The	O
relationship	O
between	O
MHV	O
and	O
the	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
/	I-PRGE
beta	I-PRGE
response	O
is	O
paradoxical	O
.	O

Messenger	O
RNA	O
expression	O
levels	O
of	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
beta4	I-PRGE
(	O
TGF	B-PRGE
-	I-PRGE
beta4	I-PRGE
)	O
are	O
also	O
upregulated	O
in	O
cortisosterone	O
-	O
treated	O
birds	O
.	O

Viroporins	O
E	O
from	O
mouse	B-PRGE
hepatitis	I-PRGE
virus	I-PRGE
,	I-PRGE
6K	I-PRGE
from	I-PRGE
Sindbis	I-PRGE
virus	I-PRGE
and	I-PRGE
NS4A	I-PRGE
protein	I-PRGE
from	O
hepatitis	O
C	O
virus	O
were	O
also	O
able	O
to	O
permeabilize	O
neighbouring	O
cells	O
to	O
different	O
extents	O
.	O

Moreover	O
,	O
the	O
presence	O
of	O
connexin	B-PRGE
43	I-PRGE
was	O
confirmed	O
in	O
both	O
mock	O
and	O
2B	O
-	O
transfected	O
cells	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
a	O
recombinant	O
MVTT	O
expressing	O
the	O
spike	O
glycoprotein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
namely	O
MVTT	O
-	O
S	O
)	O
is	O
superior	O
to	O
the	O
non	O
-	O
replicating	O
modified	O
vaccinia	O
Ankara	O
(	O
MVA	O
-	O
S	O
)	O
for	O
inducing	O
high	O
level	O
of	O
neutralizing	O
antibodies	O
through	O
mucosal	O
vaccination	O
.	O

Samples	O
collected	O
from	O
the	O
asymptomatic	O
contactors	O
were	O
all	O
negative	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antibody	I-PRGE
.	O

ABSTRACT	O
:	O
To	O
verify	O
if	O
secretory	B-PRGE
phospholipase	I-PRGE
A2	I-PRGE
(	O
sPLA2	B-PRGE
)	O
is	O
increased	O
in	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
triggered	O
or	O
not	O
by	O
respiratory	O
syncytial	O
virus	O
infection	O
and	O
to	O
clarify	O
how	O
the	O
enzyme	O
may	O
influence	O
the	O
disease	O
severity	O
and	O
the	O
degree	O
of	O
ventilatory	O
support	O
.	O

Significant	O
positive	O
correlations	O
exist	O
between	O
sPLA2	B-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
and	O
oxygen	O
need	O
,	O
mean	O
airway	O
pressure	O
,	O
ventilatory	O
index	O
,	O
and	O
the	O
Murray	O
'	O
s	O
lung	O
injury	O
score	O
.	O

The	O
sPLA2	B-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
are	O
increased	O
in	O
ARDS	O
and	O
seem	O
correlated	O
with	O
clinical	O
severity	O
,	O
higher	O
oxygen	O
requirement	O
,	O
and	O
more	O
aggressive	O
ventilation	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
delays	O
expression	O
of	O
a	O
subset	O
of	O
interferon	B-PRGE
-	O
stimulated	O
genes	O
.	O

Replication	O
of	O
other	O
RNA	O
viruses	O
,	O
including	O
Theiler	O
'	O
s	O
murine	O
encephalitis	O
virus	O
(	O
TMEV	O
),	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
),	O
Sindbis	O
virus	O
,	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
and	O
Sendai	O
virus	O
(	O
SeV	O
),	O
was	O
significantly	O
inhibited	O
in	O
L2	O
cells	O
treated	O
with	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
/	I-PRGE
beta	I-PRGE
,	O
and	O
MHV	O
had	O
the	O
ability	O
to	O
rescue	O
only	O
SeV	O
replication	O
.	O

TITLE	O
:	O
A	O
219	O
-	O
mer	O
CHO	O
-	O
expressing	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
induces	O
potent	O
immune	O
responses	O
and	O
protective	O
immunity	O
.	O

These	O
results	O
suggest	O
that	O
the	O
recombinant	B-PRGE
RBD219	I-PRGE
-	I-PRGE
CHO	I-PRGE
protein	I-PRGE
has	O
great	O
potential	O
for	O
the	O
development	O
of	O
an	O
effective	O
and	O
safe	O
SARS	O
subunit	O
vaccine	O
.	O

TITLE	O
:	O
Identification	O
of	O
SARS	O
-	O
COV	O
spike	O
protein	O
-	O
derived	O
and	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
-	O
restricted	O
human	O
CTL	O
epitopes	O
by	O
using	O
a	O
new	O
muramyl	O
dipeptidederivative	O
adjuvant	O
.	O

These	O
findings	O
demonstrated	O
that	O
SARS	O
-	O
CoV	O
pathogenesis	O
is	O
regulated	O
by	O
a	O
STAT1	B-PRGE
dependent	O
but	O
type	O
I	O
,	O
II	O
and	O
III	O
interferon	B-PRGE
receptor	I-PRGE
independent	O
,	O
mechanism	O
.	O

TITLE	O
:	O
[	O
Characterization	O
of	O
human	O
coronavirus	O
229E	O
infection	O
among	O
patients	O
with	O
respiratory	O
symptom	O
in	O
Beijing	O
,	O
Oct	B-PRGE
-	I-PRGE
Dec	I-PRGE
,	O
2007	O
].	O

TITLE	O
:	O
Quantitative	O
proteomics	O
analysis	O
reveals	O
BAG3	B-PRGE
as	O
a	O
potential	O
target	O
to	O
suppress	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replication	O
.	O

By	O
recombinant	B-PRGE
expression	I-PRGE
and	I-PRGE
purification	I-PRGE
of	I-PRGE
secretory	I-PRGE
HE	I-PRGE
(	O
recHE	O
)	O
proteins	O
,	O
receptor	O
-	O
binding	O
and	O
quantitative	O
analyses	O
of	O
enzymatic	O
activities	O
displayed	O
by	O
ISAV	O
HE	O
molecules	O
are	O
presented	O
for	O
the	O
first	O
time	O
.	O

The	O
three	O
amino	O
acid	O
differences	O
between	O
the	O
high	O
and	O
low	O
virulent	O
variants	O
,	O
of	O
which	O
two	O
localized	O
to	O
the	O
putative	O
receptor	O
-	O
binding	O
domain	O
and	O
one	O
in	O
the	O
esterase	B-PRGE
domain	I-PRGE
,	O
had	O
no	O
impact	O
on	O
receptor	O
-	O
binding	O
or	O
-	O
release	O
activities	O
.	O

Immune	O
responses	O
,	O
including	O
the	O
production	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
serum	O
immunoglobulin	B-PRGE
G	I-PRGE
(	O
IgG	B-PRGE
)	O
and	O
secretory	B-PRGE
immunoglobulin	I-PRGE
A	I-PRGE
(	O
sIgA	B-PRGE
),	O
were	O
determined	O
in	O
mucosal	O
secretions	O
and	O
tissues	O
.	O

ABSTRACT	O
:	O
Infectious	O
bronchitis	O
viruses	O
(	O
IBVs	O
)	O
in	O
Taiwan	O
have	O
been	O
divided	O
into	O
two	O
genogroups	O
,	O
Taiwan	B-PRGE
group	I-PRGE
I	I-PRGE
(	O
TW	O
-	O
I	O
)	O
and	O
Taiwan	O
group	O
II	O
(	O
TW	O
-	O
II	O
).	O

All	O
PRCV	B-PRGE
-	I-PRGE
LTA	I-PRGE
-	O
inoculated	O
pigs	O
except	O
one	O
developed	O
severe	O
respiratory	O
disease	O
,	O
whereas	O
clinical	O
signs	O
in	O
the	O
control	O
groups	O
were	O
minimal	O
or	O
absent	O
.	O

TITLE	O
:	O
Activating	O
transcription	B-PRGE
factor	I-PRGE
3	I-PRGE
confers	O
protection	O
against	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

The	O
coronavirus	B-PRGE
main	I-PRGE
protease	I-PRGE
,	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
),	I-PRGE
is	O
a	O
key	O
target	O
for	O
broad	O
-	O
spectrum	O
antiviral	O
development	O
because	O
of	O
its	O
critical	O
role	O
in	O
viral	O
maturation	O
and	O
high	O
degree	O
of	O
structural	O
conservation	O
among	O
coronaviruses	O
.	O

Here	O
we	O
report	O
that	O
Asn28	O
,	O
a	O
residue	O
11	O
A	O
from	O
the	O
closest	O
residue	O
in	O
the	O
opposing	O
monomer	O
,	O
is	O
essential	O
for	O
the	O
enzymatic	O
activity	O
and	O
dimerization	O
of	O
SARS	B-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
).	I-PRGE

Shock	O
,	O
ARF	B-PRGE
,	O
seizure	O
and	O
ARDS	O
were	O
associated	O
with	O
higher	O
mortality	O
.	O

No	O
significant	O
differences	O
in	O
disease	O
severity	O
,	O
lung	O
lesions	O
,	O
virus	O
replication	O
,	O
lung	O
cell	O
infiltration	O
or	O
levels	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
12	I-PRGE
/	I-PRGE
IL	I-PRGE
-	I-PRGE
23	I-PRGE
were	O
observed	O
between	O
the	O
two	O
groups	O
.	O

The	O
compound	O
also	O
displayed	O
cathepsin	B-PRGE
L	I-PRGE
/	I-PRGE
B	I-PRGE
selectivity	O
of	O
>	O
700	O
-	O
fold	O
and	O
was	O
nontoxic	O
to	O
human	O
aortic	O
endothelial	O
cells	O
at	O
100	O
muM	O
.	O
The	O
oxocarbazate	O
and	O
a	O
related	O
thiocarbazate	O
(	O
PubChem	O
CID	O
16725315	O
)	O
were	O
tested	O
in	O
a	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
and	O
Ebola	O
virus	O
-	O
pseudotype	O
infection	O
assay	O
with	O
the	O
oxocarbazate	O
but	O
not	O
the	O
thiocarbazate	O
,	O
demonstrating	O
activity	O
in	O
blocking	O
both	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
IC	O
(	O
50	O
)	O
=	O
273	O
+/-	O

The	O
reduction	O
in	O
active	O
cathepsin	B-PRGE
L	I-PRGE
in	O
inhibitor	O
-	O
treated	O
cells	O
correlated	O
well	O
with	O
the	O
observed	O
potency	O
of	O
inhibitors	O
observed	O
in	O
the	O
virus	O
pseudotype	O
infection	O
assay	O
.	O

p42	B-PRGE
is	O
a	O
subunit	O
of	O
the	O
26S	B-PRGE
proteasome	I-PRGE
;	O
this	O
large	O
,	O
multi	B-PRGE
-	I-PRGE
protein	I-PRGE
complex	I-PRGE
is	O
a	O
component	O
of	O
the	O
ubiquitin	B-PRGE
-	O
proteasome	O
pathway	O
,	O
which	O
is	O
involved	O
in	O
a	O
variety	O
of	O
basic	O
cellular	O
processes	O
and	O
inflammatory	O
responses	O
.	O

CONCLUSIONS	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
NP	I-PRGE
interacts	O
with	O
the	O
proteasome	O
subunit	O
p42	O
within	O
host	O
cells	O
.	O

The	O
decreased	O
Bcl2	B-PRGE
protein	I-PRGE
level	O
was	O
concurrent	O
with	O
an	O
increased	O
Bax	B-PRGE
protein	I-PRGE
level	O
in	O
all	O
3	O
cell	O
lines	O
.	O

Results	O
from	O
oligonucleotide	O
-	O
based	O
microarray	O
,	O
real	O
-	O
time	O
PCR	O
,	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
indicated	O
an	O
upregulation	O
of	O
the	O
fibrosis	B-PRGE
-	I-PRGE
associated	I-PRGE
chemokine	I-PRGE
(	I-PRGE
C	I-PRGE
-	I-PRGE
C	I-PRGE
motif	I-PRGE
)	I-PRGE
ligand	I-PRGE
2	I-PRGE
(	O
CCL2	B-PRGE
)	O
by	O
the	O
viral	O
spike	O
protein	O
and	O
the	O
virus	O
-	O
like	O
particles	O
.	O

These	O
results	O
indicate	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
triggers	O
ACE2	B-PRGE
signaling	O
and	O
activates	O
fibrosis	O
-	O
associated	O
CCL2	B-PRGE
expression	O
through	O
the	O
Ras	B-PRGE
-	O
ERK	B-PRGE
-	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
pathway	O
.	O

The	O
non	O
-	O
structural	O
proteins	O
of	O
the	O
viral	B-PRGE
replication	I-PRGE
complex	I-PRGE
are	O
thought	O
to	O
be	O
associated	O
with	O
these	O
newly	O
synthesized	O
membranes	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
the	O
efficacy	O
of	O
live	O
attenuated	O
Salmonella	O
enterica	O
serovar	O
Typhimurium	O
designed	O
to	O
secrete	O
swine	B-PRGE
IFN	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
swIFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
protein	O
for	O
preventing	O
the	O
clinical	O
signs	O
caused	O
by	O
infection	O
with	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
one	O
of	O
the	O
diarrhea	O
-	O
causing	O
viruses	O
in	O
the	O
swine	O
industry	O
.	O

TITLE	O
:	O
Maturation	O
mechanism	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
.	O

The	O
exponential	O
model	O
developed	O
here	O
is	O
the	O
sole	O
dose	O
-	O
response	O
model	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
at	O
the	O
present	O
and	O
would	O
enable	O
us	O
to	O
understand	O
the	O
possibility	O
for	O
reemergence	O
of	O
SARS	O
.	O

TITLE	O
:	O
Serum	O
and	O
lung	B-PRGE
endothelin	I-PRGE
-	I-PRGE
1	I-PRGE
increased	O
in	O
a	O
canine	O
model	O
of	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

However	O
,	O
the	O
profile	O
of	O
ET	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
the	O
balance	O
of	O
ET	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
NO	O
are	O
still	O
unknown	O
in	O
a	O
VILI	O
model	O
.	O

The	O
levels	O
of	O
ET	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
NO	O
in	O
serum	O
and	O
tissue	O
homogenates	O
of	O
lung	O
were	O
observed	O
throughout	O
the	O
trial	O
.	O

The	O
production	O
of	O
ET	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
NO	O
was	O
increased	O
in	O
serum	O
and	O
lung	O
tissue	O
in	O
a	O
VILI	O
model	O
.	O

Compared	O
with	O
well	O
control	O
participants	O
,	O
detection	O
of	O
RSV	B-PRGE
was	O
associated	O
with	O
severe	O
disease	O
(	O
5	O
%	O
[	O
corrected	O
]	O
in	O
control	O
participants	O
;	O
adjusted	O
odds	O
ratio	O
,	O
6	O
.	O
11	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
65	O
-	O
22	O
.	O
6	O
])	O
while	O
collectively	O
,	O
other	O
respiratory	O
viruses	O
were	O
not	O
associated	O
with	O
severe	O
disease	O
(	O
23	O
%	O
in	O
control	O
participants	O
;	O
adjusted	O
odds	O
ratio	O
,	O
1	O
.	O
27	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
64	O
-	O
2	O
.	O
52	O
]).	O

Here	O
,	O
the	O
expression	O
and	O
crystallization	O
of	O
the	O
MHV	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
C	I-PRGE
-	I-PRGE
terminal	I-PRGE
domain	I-PRGE
are	O
reported	O
.	O

ABSTRACT	O
:	O
The	O
type	O
I	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
response	O
plays	O
an	O
essential	O
role	O
in	O
the	O
control	O
of	O
in	O
vivo	O
infection	O
by	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

Conversely	O
,	O
insertion	O
of	O
gene	B-PRGE
5a	I-PRGE
,	O
or	O
its	O
homologs	O
from	O
related	O
group	O
2	O
coronaviruses	O
,	O
at	O
an	O
upstream	O
genomic	O
position	O
in	O
an	O
MHV	O
-	O
A59	O
/	O
S	O
chimera	O
restored	O
IFN	B-PRGE
resistance	O
.	O

A	O
protein	O
-	O
ligand	O
X	O
-	O
ray	O
structure	O
of	O
15	O
g	O
-	O
bound	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
and	O
a	O
corresponding	O
model	O
of	O
15	O
h	O
docked	O
to	O
PLpro	O
provide	O
intriguing	O
molecular	O
insight	O
into	O
the	O
ligand	O
-	O
binding	O
site	O
interactions	O
.	O

These	O
data	O
highlight	O
the	O
importance	O
of	O
the	O
CXCL12	B-PRGE
:	O
CXCR4	B-PRGE
pathway	O
in	O
regulating	O
homing	O
of	O
engrafted	O
stem	O
cells	O
to	O
sites	O
of	O
tissue	O
damage	O
within	O
the	O
CNS	O
of	O
mice	O
persistently	O
infected	O
with	O
a	O
neurotropic	O
virus	O
undergoing	O
immune	O
-	O
mediated	O
demyelination	O
.	O

ABSTRACT	O
:	O
The	O
members	O
of	O
Betacoronavirus	O
phylocluster	O
A	O
possess	O
two	O
types	O
of	O
surface	O
projections	O
,	O
one	O
comprised	O
of	O
the	O
spike	O
protein	O
(	O
S	O
)	O
and	O
the	O
other	O
of	O
hemagglutinin	B-PRGE
-	I-PRGE
esterase	I-PRGE
(	O
HE	O
).	O

Apparently	O
,	O
expansion	O
of	O
group	O
A	O
betacoronaviruses	O
into	O
new	O
hosts	O
and	O
niches	O
was	O
accompanied	O
by	O
changes	O
in	O
HE	O
ligand	O
and	O
substrate	O
preference	O
and	O
in	O
the	O
roles	O
of	O
HE	B-PRGE
and	I-PRGE
S	I-PRGE
in	I-PRGE
Sia	I-PRGE
receptor	I-PRGE
usage	O
.	O

MHV	O
infection	O
causes	O
accumulation	O
of	O
EDEM1	O
and	O
OS	O
-	O
9	O
,	O
another	O
short	O
-	O
living	O
ER	B-PRGE
chaperone	I-PRGE
,	O
in	O
the	O
DMVs	O
.	O

DMVs	O
are	O
coated	O
with	O
the	O
nonlipidated	O
LC3	B-PRGE
/	O
Atg8	B-PRGE
autophagy	O
marker	O
.	O

Our	O
study	O
identifies	O
the	O
host	O
cellular	O
pathway	O
hijacked	O
for	O
supplying	O
CoV	O
replication	O
membranes	O
and	O
describes	O
an	O
autophagy	O
-	O
independent	O
role	O
for	O
nonlipidated	O
LC3	B-PRGE
-	I-PRGE
I	I-PRGE
.	O

Susceptible	O
C3H	O
/	O
HeJ	O
mice	O
mount	O
robust	O
and	O
broad	O
MHV	B-PRGE
-	I-PRGE
1	I-PRGE
-	I-PRGE
specific	I-PRGE
CD4	I-PRGE
T	I-PRGE
cell	O
responses	O
,	O
whereas	O
in	O
resistant	O
B6	O
mice	O
,	O
Ag	O
-	O
specific	O
CD8	B-PRGE
T	O
cell	O
responses	O
dominate	O
.	O

In	O
particular	O
,	O
while	O
the	O
CD8	B-PRGE
(+)	O
and	O
the	O
B	O
lymphocytes	O
returned	O
to	O
baseline	O
levels	O
by	O
day	O
7	O
p	O
.	O
i	O
.,	O
the	O
CD4	B-PRGE
(+)	O
T	O
cells	O
remained	O
significantly	O
low	O
until	O
day	O
30	O
p	O
.	O
i	O
.	O
and	O
recovered	O
completely	O
only	O
at	O
day	O
60	O
p	O
.	O
i	O
.	O

The	O
prolonged	O
depletion	O
of	O
peripheral	O
CD4	O
(+)	O
T	O
cells	O
did	O
not	O
alter	O
the	O
levels	O
of	O
serum	B-PRGE
IgG	I-PRGE
or	O
IgM	B-PRGE
.	O
The	O
impact	O
of	O
CB	O
/	O
05	O
infection	O
on	O
the	O
immune	O
performance	O
of	O
infected	O
pups	O
is	O
discussed	O
.	O

TITLE	O
:	O
Alternative	O
splicing	O
of	O
CD200	B-PRGE
is	O
regulated	O
by	O
an	O
exonic	B-PRGE
splicing	I-PRGE
enhancer	I-PRGE
and	O
SF2	B-PRGE
/	O
ASF	B-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
an	O
exonic	O
splicing	O
enhancer	O
(	O
ESE	O
)	O
located	O
in	O
exon	O
2	O
,	O
which	O
is	O
a	O
putative	O
binding	O
site	O
for	O
a	O
splicing	O
regulatory	O
protein	O
SF2	B-PRGE
/	O
ASF	B-PRGE
.	O

Self	O
-	O
administered	O
questionnaires	O
were	O
used	O
to	O
assess	O
nurses	O
'	O
acceptance	O
of	O
vaccination	O
against	O
seasonal	O
flu	B-PRGE
and	O
H1N1	O
.	O

ABSTRACT	O
:	O
The	O
discovery	O
of	O
SARS	O
-	O
like	O
coronavirus	O
in	O
bats	O
suggests	O
that	O
bats	O
could	O
be	O
the	O
natural	O
reservoir	O
of	O
SARS	O
-	O
CoV	O
.	O
However	O
,	O
previous	O
studies	O
indicated	O
the	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
protein	O
,	O
a	O
known	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
,	O
from	O
a	O
horseshoe	O
bat	O
was	O
unable	O
to	O
act	O
as	O
a	O
functional	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Here	O
,	O
we	O
extended	O
our	O
previous	O
study	O
to	O
ACE2	O
molecules	O
from	O
seven	O
additional	O
bat	O
species	O
and	O
tested	O
their	O
interactions	O
with	O
human	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
using	O
both	O
HIV	O
-	O
based	O
pseudotype	O
and	O
live	O
SARS	O
-	O
CoV	O
infection	O
assays	O
.	O

Furthermore	O
,	O
our	O
current	O
study	O
also	O
demonstrates	O
that	O
the	O
genetic	O
diversity	O
of	O
ACE2	B-PRGE
among	O
bats	O
is	O
greater	O
than	O
that	O
observed	O
among	O
known	O
SARS	O
-	O
CoV	O
susceptible	O
mammals	O
,	O
highlighting	O
the	O
possibility	O
that	O
there	O
are	O
many	O
more	O
uncharacterized	O
bat	O
species	O
that	O
can	O
act	O
as	O
a	O
reservoir	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
or	O
its	O
progenitor	O
viruses	O
.	O

Moreover	O
,	O
the	O
interaction	O
between	O
MBL	B-PRGE
and	O
SARS	B-PRGE
-	I-PRGE
S	I-PRGE
blocked	O
viral	O
binding	O
to	O
the	O
C	B-PRGE
-	I-PRGE
type	I-PRGE
lectin	I-PRGE
,	O
DC	O
-	O
SIGN	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
monitor	O
changes	O
in	O
behavioral	O
and	O
emotional	O
responses	O
to	O
human	B-PRGE
H5N1	I-PRGE
in	O
the	O
community	O
over	O
a	O
28	O
-	O
month	O
period	O
(	O
from	O
November	O
2005	O
to	O
February	O
2008	O
).	O

27	O
pg	O
/	O
mL	O
.	O
The	O
values	O
of	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
Protein	I-PRGE
(	O
CRP	B-PRGE
)	O
measured	O
after	O
48h	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
II	O
)	O
score	O
on	O
admission	O
and	O
Ranson	O
score	O
showed	O
the	O
similar	O
correlation	O
,	O
but	O
serum	O
amylase	B-PRGE
level	O
did	O
not	O
correlate	O
significantly	O
with	O
Ranson	O
score	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
concentration	O
and	O
APACHE	O
II	O
score	O
.	O

JHMV	O
infection	O
of	O
enriched	O
oligodendrocyte	O
progenitor	O
cell	O
(	O
OPC	O
)	O
cultures	O
revealed	O
that	O
apoptosis	O
was	O
associated	O
with	O
elevated	O
expression	O
of	O
cleaved	O
caspase	B-PRGE
3	I-PRGE
and	O
muted	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
HB	B-PRGE
-	I-PRGE
EGF	I-PRGE
to	O
protect	O
the	O
lungs	O
from	O
remote	O
organ	O
injury	O
after	O
intestinal	O
ischemia	O
/	O
reperfusion	O
(	O
I	O
/	O
R	O
).	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
the	O
multiple	O
biological	O
functions	O
of	O
ACE2	B-PRGE
.	O

Due	O
to	O
the	O
different	O
biochemical	O
properties	O
of	O
some	O
amino	O
acids	O
that	O
changed	O
in	O
the	O
S1	B-PRGE
glycoprotein	I-PRGE
,	O
we	O
anticipate	O
that	O
phenotypic	O
shift	O
occurred	O
during	O
the	O
invasion	O
process	O
.	O

However	O
,	O
nsp1	B-PRGE
may	O
not	O
be	O
the	O
key	O
determinant	O
of	O
viral	O
pathogenicity	O
,	O
or	O
the	O
factor	O
used	O
by	O
the	O
SARS	O
coronavirus	O
to	O
evade	O
host	O
innate	O
immunity	O
.	O

Challenge	O
studies	O
in	O
mice	O
demonstrated	O
that	O
expression	O
of	O
the	O
MHV	B-PRGE
-	I-PRGE
1	I-PRGE
S	I-PRGE
gene	I-PRGE
within	O
the	O
MHV	O
-	O
A59	O
background	O
(	O
rA59	O
/	O
S	O
(	O
MHV	O
-	O
1	O
))	O
increased	O
the	O
pneumovirulence	O
of	O
MHV	O
-	O
A59	O
,	O
and	O
mice	O
infected	O
with	O
this	O
recombinant	O
virus	O
developed	O
pulmonary	O
lesions	O
that	O
were	O
similar	O
to	O
those	O
observed	O
with	O
MHV	O
-	O
1	O
,	O
although	O
rA59	O
/	O
S	O
(	O
MHV	O
-	O
1	O
)	O
was	O
significantly	O
less	O
virulent	O
.	O

These	O
data	O
suggest	O
that	O
important	O
determinants	O
of	O
pneumopathogenicity	O
are	O
contained	O
within	O
the	O
3	O
'	O
one	O
-	O
third	O
of	O
the	O
MHV	O
-	O
1	O
genome	O
,	O
but	O
additional	O
important	O
virulence	O
factors	O
must	O
be	O
encoded	O
in	O
the	O
genome	O
upstream	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
.	O

Our	O
findings	O
demonstrate	O
that	O
the	O
direct	O
anti	O
-	O
influenza	O
activity	O
of	O
pomegranate	B-PRGE
PPs	I-PRGE
is	O
substantially	O
modulated	O
by	O
small	O
changes	O
in	O
envelope	O
glycoproteins	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
induced	O
indirect	O
lung	O
injury	O
by	O
intraperitoneal	O
injection	O
of	O
LPS	O
and	O
direct	O
lung	O
injury	O
by	O
intratracheal	O
injection	O
of	O
LPS	O
in	O
wild	O
-	O
type	O
and	O
Sftpd	O
(-/-)	O
mice	O
to	O
elucidate	O
the	O
role	O
of	O
SP	B-PRGE
-	I-PRGE
D	I-PRGE
during	O
ALI	O
/	O
ARDS	O
.	O

After	O
indirect	O
injury	O
,	O
the	O
concentration	O
of	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
was	O
approximately	O
5	O
-	O
fold	O
greater	O
in	O
Sftpd	O
(-/-)	O
mice	O
than	O
wild	O
-	O
type	O
mice	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
serum	O
levels	O
of	O
prolactin	B-PRGE
(	O
PRL	B-PRGE
),	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	B-PRGE
),	O
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
of	O
SARS	O
patients	O
are	O
significantly	O
higher	O
than	O
those	O
of	O
control	O
groups	O
,	O
while	O
estradiol	O
(	O
E2	O
),	O
pregnancy	O
hormone	O
(	O
P	O
),	O
and	O
thyroid	B-PRGE
stimulating	I-PRGE
hormone	I-PRGE
(	O
TSH	B-PRGE
)	O
are	O
considerably	O
lower	O
than	O
those	O
of	O
normal	O
controls	O
.	O

TEM	O
examinations	O
of	O
mixed	O
infections	O
with	O
Chlamydia	O
abortus	O
and	O
Chlamydia	O
pecorum	O
revealed	O
aberrant	O
chlamydial	O
inclusions	O
containing	O
reticulate	B-PRGE
-	I-PRGE
like	I-PRGE
,	I-PRGE
pleomorphic	I-PRGE
ABs	I-PRGE
,	O
which	O
were	O
up	O
to	O
2	O
microm	O
in	O
diameter	O
.	O

TITLE	O
:	O
A	O
new	O
cistron	O
in	O
the	O
murine	O
hepatitis	B-PRGE
virus	I-PRGE
replicase	I-PRGE
gene	I-PRGE
.	O

Here	O
we	O
report	O
the	O
first	O
structural	O
and	O
biochemical	O
characterization	O
of	O
a	O
purified	O
coronavirus	O
PL1	B-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
domain	I-PRGE
,	O
that	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
).	O

Appearing	O
in	O
1997	O
and	O
becoming	O
epidemic	O
in	O
2003	O
,	O
influenza	O
A	O
/	O
H5N1	O
provoked	O
many	O
deadly	O
enzootics	O
in	O
poultry	O
batteries	O
(	O
highly	O
pathogenic	O
avian	O
influenza	O
of	O
HPAI	B-PRGE
).	O

Phylogenetic	O
analysis	O
of	O
the	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
gene	I-PRGE
showed	O
that	O
groups	O
1	O
and	O
2	O
CoVs	O
were	O
similar	O
to	O
Bat	B-PRGE
-	I-PRGE
CoV	I-PRGE
/	O
China	O
/	O
A515	O
/	O
2005	O
(	O
95	O
%	O
nt	O
sequence	O
identity	O
)	O
and	O
Bat	B-PRGE
-	I-PRGE
CoV	I-PRGE
/	O
HKU9	O
-	O
1	O
/	O
China	O
/	O
2007	O
(	O
83	O
%	O
identity	O
),	O
respectively	O
.	O

TITLE	O
:	O
Transcriptomic	O
analysis	O
reveals	O
a	O
mechanism	O
for	O
a	O
prefibrotic	O
phenotype	O
in	O
STAT1	B-PRGE
knockout	O
mice	O
during	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
.	O

TITLE	O
:	O
ORF8a	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
forms	O
an	O
ion	O
channel	O
:	O
experiments	O
and	O
molecular	O
dynamics	O
simulations	O
.	O

IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
(+)	O
CD8	B-PRGE
(+)	O
T	O
cells	O
and	O
CD107a	B-PRGE
/	I-PRGE
b	I-PRGE
(+)	I-PRGE
CD8	I-PRGE
(+)	O
T	O
cells	O
distributed	O
throughout	O
the	O
lymphoid	O
and	O
non	O
-	O
lymphoid	O
tissues	O
,	O
but	O
the	O
frequency	O
of	O
peptide	O
-	O
specific	O
CD8	B-PRGE
(+)	O
T	O
cells	O
was	O
higher	O
in	O
lungs	O
than	O
in	O
spleens	O
and	O
lymph	O
nodes	O
.	O

TITLE	O
:	O
Panton	B-PRGE
-	I-PRGE
Valentine	I-PRGE
leukocidin	I-PRGE
expressing	O
Staphylococcus	O
aureus	O
pneumonia	O
managed	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
:	O
experience	O
and	O
outcome	O
.	O

ABSTRACT	O
:	O
Panton	B-PRGE
-	I-PRGE
Valentine	I-PRGE
leukocidin	I-PRGE
expressing	O
Staphylococcus	O
aureus	O
pneumonia	O
,	O
an	O
infection	O
that	O
affects	O
predominantly	O
young	O
people	O
,	O
has	O
a	O
mortality	O
rate	O
of	O
>	O
70	O
%	O
despite	O
aggressive	O
conventional	O
management	O
.	O

The	O
MAb	O
achieved	O
in	O
this	O
study	O
can	O
be	O
used	O
as	O
a	O
specific	O
diagnostic	O
reagent	O
for	O
detecting	O
TGEV	B-PRGE
S	I-PRGE
protein	I-PRGE
.	O

Lysine	O
(	O
K	O
)	O
and	O
arginine	O
(	O
R	O
)	O
substitutions	O
were	O
replaced	O
in	O
recovered	O
viruses	O
by	O
neutrally	O
charged	O
glutamine	B-PRGE
(	I-PRGE
Q	I-PRGE
)	I-PRGE
and	I-PRGE
leucine	I-PRGE
(	I-PRGE
L	I-PRGE
),	I-PRGE
respectively	O
,	O
after	O
only	O
one	O
passage	O
.	O

The	O
disease	O
was	O
diagnosed	O
by	O
clinical	O
symptoms	O
,	O
gross	O
and	O
histopathology	O
and	O
viral	O
detection	O
using	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
assay	O
.	O

TITLE	O
:	O
Atrial	O
natriuretic	O
peptide	O
attenuates	O
LPS	O
-	O
induced	O
lung	O
vascular	O
leak	O
:	O
role	O
of	O
PAK1	B-PRGE
.	O

In	O
conclusion	O
,	O
RT	B-PRGE
-	I-PRGE
LAMP	I-PRGE
with	O
HNB	B-PRGE
dye	I-PRGE
was	O
shown	O
to	O
be	O
a	O
sensitive	O
,	O
simple	O
assay	O
for	O
the	O
rapid	O
diagnosis	O
of	O
TCoV	O
infection	O
,	O
either	O
directly	O
from	O
feces	O
or	O
in	O
association	O
with	O
virus	O
isolation	O
methods	O
.	O

TITLE	O
:	O
The	O
coronavirus	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
is	O
dynamically	O
associated	O
with	O
the	O
replication	O
-	O
transcription	O
complexes	O
.	O

Recruitment	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
to	O
the	O
RTCs	O
requires	O
the	O
C	O
-	O
terminal	O
N2b	O
domain	O
,	O
which	O
interacts	O
with	O
other	O
N	O
proteins	O
in	O
an	O
RNA	O
-	O
independent	O
manner	O
.	O

Quantification	O
of	O
mRNA	O
for	O
the	O
ceacam1a	B-PRGE
-	I-PRGE
related	I-PRGE
genes	I-PRGE
ceacam2	I-PRGE
and	O
psg16	O
(	O
bCEA	O
),	O
which	O
encode	O
proposed	O
alternative	O
MHV	O
receptors	O
,	O
revealed	O
low	O
ceacam2	O
expression	O
in	O
microglia	O
and	O
oligodendrocytes	O
and	O
psg16	O
expression	O
exclusively	O
in	O
neurons	O
;	O
however	O
,	O
only	O
CEACAM2	O
mediated	O
infection	O
in	O
human	O
293T	O
cells	O
.	O

Reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
has	O
been	O
used	O
to	O
detect	O
FCoV	O
and	O
is	O
rapid	O
and	O
sensitive	O
,	O
but	O
results	O
must	O
be	O
interpreted	O
in	O
the	O
context	O
of	O
clinical	O
findings	O
.	O

Growth	B-PRGE
hormone	I-PRGE
releasing	I-PRGE
peptide	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
GHRP	B-PRGE
-	I-PRGE
2	I-PRGE
),	O
a	O
ghrelin	O
agonist	O
,	O
has	O
been	O
shown	O
to	O
exert	O
beneficial	O
effects	O
on	O
various	O
inflammatory	O
diseases	O
.	O

We	O
thus	O
found	O
that	O
pretreatment	O
with	O
GHRP	B-PRGE
-	I-PRGE
2	I-PRGE
markedly	O
suppressed	O
the	O
activation	O
of	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
in	O
lung	O
tissues	O
.	O

The	O
present	O
study	O
indicates	O
that	O
GHRP	B-PRGE
-	I-PRGE
2	I-PRGE
acts	O
as	O
a	O
potential	O
therapeutic	O
reagent	O
for	O
treating	O
ALI	O
.	O

Advances	O
in	O
the	O
standardisation	O
of	O
care	O
for	O
ARDS	O
patients	O
involving	O
innovative	O
therapeutic	O
procedures	O
such	O
as	O
extracorporeal	O
gas	B-PRGE
exchange	I-PRGE
systems	I-PRGE
will	O
lead	O
to	O
a	O
further	O
improvement	O
in	O
ARDS	O
management	O
and	O
outcome	O
.	O

The	O
IgG	B-PRGE
Ab	I-PRGE
was	O
almost	O
undetectable	O
after	O
5	O
years	O
post	O
infection	O
.	O

TITLE	O
:	O
Muscarinic	B-PRGE
receptor	I-PRGE
antagonist	O
therapy	O
improves	O
acute	O
pulmonary	O
dysfunction	O
after	O
smoke	O
inhalation	O
injury	O
in	O
sheep	O
.	O

EMBASE	O
-	O
PubMed	O
,	O
MEDLINE	O
(	O
OVID	O
),	O
SCI	B-PRGE
/	O
Web	O
of	O
Science	O
,	O
the	O
Cochrane	O
Library	O
,	O
Google	O
Scholar	O
,	O
and	O
personal	O
files	O
.	O

The	O
results	O
showed	O
that	O
the	O
chickens	O
vaccinated	O
in	O
ovo	O
with	O
rAd	B-PRGE
-	I-PRGE
S1	I-PRGE
,	O
rAd	B-PRGE
-	I-PRGE
GM	I-PRGE
-	I-PRGE
S1	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
fused	O
with	O
S1	O
using	O
glycine	O
linkers	O
)	O
and	O
rAd	B-PRGE
-	I-PRGE
GM	I-PRGE
-	I-PRGE
CSF	I-PRGE
plus	O
rAd	B-PRGE
-	I-PRGE
S1	I-PRGE
(	O
co	O
-	O
administered	O
)	O
developed	O
specific	O
anti	O
-	O
IBV	O
HI	O
antibodies	O
.	O

Comparing	O
these	O
results	O
with	O
some	O
obtained	O
previously	O
with	O
chlorhexidine	O
and	O
hexamidine	O
,	O
(	O
i	O
)	O
these	O
two	O
calixarenes	O
did	O
not	O
show	O
any	O
cytotoxicity	O
contrary	O
to	O
chlorhexidine	O
and	O
hexamidine	O
,	O
(	O
ii	O
)	O
C	O
[	O
4	O
]	O
S	O
showed	O
as	O
did	O
hexamidine	O
,	O
a	O
very	O
weak	O
activity	O
against	O
HCoV	O
229E	O
,	O
and	O
(	O
iii	O
)	O
the	O
C	B-PRGE
[	I-PRGE
4	I-PRGE
]	I-PRGE
S	I-PRGE
-	I-PRGE
BTZ	I-PRGE
showed	O
a	O
stronger	O
activity	O
than	O
chlorhexidine	O
,	O
i	O
.	O
e	O
.	O
2	O
.	O
7	O
and	O
1	O
.	O
4logââ	O
reduction	O
in	O
viral	O
titer	O
after	O
5min	O
of	O
contact	O
with	O
10	O
â»	O
Â³mol	O
L	O
â»	O
Â¹	O
solutions	O
of	O
C	O
[	O
4	O
]	O
S	O
-	O
BTZ	O
and	O
chlorhexidine	O
,	O
respectively	O
.	O

Here	O
we	O
report	O
that	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
small	I-PRGE
envelope	I-PRGE
protein	I-PRGE
(	O
E	O
)	O
binds	O
to	O
human	B-PRGE
PALS1	I-PRGE
.	O

Using	O
coimmunoprecipitation	O
and	O
pull	O
-	O
down	O
assays	O
,	O
we	O
show	O
that	O
E	O
interacts	O
with	O
PALS1	B-PRGE
in	O
mammalian	O
cells	O
and	O
further	O
demonstrate	O
that	O
the	O
last	O
four	O
carboxy	O
-	O
terminal	O
amino	O
acids	O
of	O
E	O
form	O
a	O
novel	O
PDZ	B-PRGE
-	I-PRGE
binding	I-PRGE
motif	I-PRGE
that	O
binds	O
to	O
PALS1	B-PRGE
PDZ	B-PRGE
domain	I-PRGE
.	O

TITLE	O
:	O
Identification	O
of	O
NCAM	O
that	O
interacts	O
with	O
the	O
PHE	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

Normal	O
leukocyte	O
counts	O
,	O
moderate	O
to	O
severe	O
thrombocytopenia	O
,	O
renal	O
failure	O
,	O
splenomegaly	O
and	O
hyperbilirubinaemia	O
with	O
mildly	O
elevated	O
serum	B-PRGE
transaminases	I-PRGE
were	O
associated	O
with	O
malaria	O
.	O

However	O
,	O
higher	O
levels	O
of	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
mRNA	I-PRGE
in	O
CNS	O
-	O
infiltrating	O
virus	O
-	O
specific	O
CD8	B-PRGE
T	I-PRGE
cells	O
as	O
well	O
as	O
CD4	B-PRGE
T	I-PRGE
cells	O
contributed	O
to	O
elevated	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
protein	I-PRGE
in	O
the	O
B7	B-PRGE
-	I-PRGE
H1	I-PRGE
(-/-)	O
CNS	O
.	O

Despite	O
enhanced	O
clinical	O
recovery	O
,	O
surviving	O
B7	B-PRGE
-	I-PRGE
H1	I-PRGE
(-/-)	O
mice	O
still	O
harbored	O
persisting	O
viral	O
mRNA	O
,	O
albeit	O
at	O
reduced	O
levels	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O

Subsequently	O
,	O
in	O
association	O
with	O
clinical	O
signs	O
we	O
observed	O
elevated	O
levels	O
of	O
proinflammatory	O
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
),	O
Th	O
-	O
1	O
(	O
IL	O
-	O
12	O
),	O
and	O
regulatory	O
(	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
TGF	O
-	O
Î²	O
)	O
cytokines	O
.	O

CD4	B-PRGE
(+)	O
CD25	O
(+)	O
Foxp3	O
(+)	O
regulatory	O
T	O
Cells	O
(	O
Foxp3	O
(+)	O
Tregs	O
),	O
iNOS	O
and	O
cytokines	O
may	O
affect	O
these	O
severe	O
conditions	O
such	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
multiple	O
organ	O
failure	O
after	O
hemorrhagic	O
shock	O
and	O
resuscitation	O
.	O

In	O
silico	O
simulations	O
indicated	O
that	O
the	O
binding	O
site	O
of	O
1	O
,	O
8	O
-	O
cineole	O
was	O
located	O
at	O
the	O
N	O
terminus	O
of	O
phosphorylated	B-PRGE
nucleocapsid	I-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
protein	I-PRGE
,	O
with	O
interaction	O
energy	O
equaling	O
-	O
40	O
.	O
33	O
kcal	O
mol	O
(-	O
1	O
).	O

Lymphopenia	O
and	O
increased	O
creatine	B-PRGE
kinase	I-PRGE
levels	O
were	O
frequently	O
observed	O
(	O
83	O
%	O
and	O
65	O
%	O
among	O
PCR	O
+	O
and	O
PCR	O
-	O
respectively	O
).	O

ABSTRACT	O
:	O
The	O
coronavirus	B-PRGE
small	I-PRGE
envelope	I-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
plays	O
a	O
crucial	O
,	O
but	O
poorly	O
defined	O
,	O
role	O
in	O
the	O
assembly	O
of	O
virions	O
.	O

Each	O
different	O
variant	B-PRGE
M	I-PRGE
gene	I-PRGE
encoded	O
an	O
expressed	O
protein	O
(	O
M	O
*)	O
containing	O
a	O
truncated	O
endodomain	O
.	O

ABSTRACT	O
:	O
The	O
distribution	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
receptor	O
,	O
an	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
does	O
not	O
strictly	O
correlate	O
with	O
SARS	O
-	O
CoV	O
cell	O
tropism	O
in	O
lungs	O
;	O
therefore	O
,	O
other	O
cellular	O
factors	O
have	O
been	O
predicted	O
to	O
be	O
required	O
for	O
activation	O
of	O
virus	O
infection	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
transmembrane	B-PRGE
protease	I-PRGE
serine	I-PRGE
2	I-PRGE
(	O
TMPRSS2	B-PRGE
),	O
whose	O
expression	O
does	O
correlate	O
with	O
SARS	O
-	O
CoV	O
infection	O
in	O
the	O
upper	O
lobe	O
of	O
the	O
lung	O
.	O

ABSTRACT	O
:	O
As	O
part	O
of	O
our	O
search	O
for	O
botanical	O
sources	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibitors	O
,	O
we	O
selected	O
Torreya	O
nucifera	O
,	O
which	O
is	O
traditionally	O
used	O
as	O
a	O
medicinal	O
plant	O
in	O
Asia	O
.	O

Of	O
these	O
compounds	O
,	O
the	O
biflavone	O
amentoflavone	O
(	O
9	O
)	O
(	O
IC	O
(	O
50	O
)=	O
8	O
.	O
3Î¼M	O
)	O
showed	O
most	O
potent	O
3CL	B-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibitory	O
effect	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
evaluation	O
of	O
pyrazolone	O
compounds	O
as	O
SARS	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
inhibitors	O
.	O

Therefore	O
,	O
the	O
S	B-PRGE
protein	I-PRGE
is	O
not	O
anchored	O
in	O
the	O
viral	O
membrane	O
DRMs	O
as	O
they	O
are	O
known	O
to	O
occur	O
in	O
the	O
plasma	O
membrane	O
.	O

Our	O
results	O
show	O
that	O
the	O
protective	O
efficacy	O
of	O
the	O
rFPV	O
-	O
S1	O
vaccine	O
could	O
be	O
enhanced	O
significantly	O
by	O
simultaneous	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
.	O

The	O
co	O
-	O
localization	O
of	O
SARS	B-PRGE
-	O
CoVN	O
and	O
CXCL16	B-PRGE
in	O
the	O
cytoplasm	O
of	O
HEK293FT	O
cells	O
was	O
also	O
shown	O
using	O
confocal	O
laser	O
scanning	O
microscopy	O
.	O

These	O
results	O
demonstrated	O
that	O
the	O
immunogenicity	O
of	O
the	O
SL	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
is	O
distinct	O
from	O
that	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
which	O
may	O
cause	O
the	O
immunological	O
differences	O
between	O
human	O
SARS	O
-	O
CoV	O
and	O
bat	O
SL	O
-	O
CoV	O
.	O
Furthermore	O
,	O
the	O
recombinant	O
virus	O
could	O
serve	O
as	O
a	O
potential	O
vaccine	O
candidate	O
against	O
bat	O
SL	O
-	O
CoV	O
infection	O
.	O

However	O
,	O
we	O
found	O
that	O
N	B-PRGE
protein	I-PRGE
could	O
not	O
inhibit	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
production	O
induced	O
by	O
overexpression	O
of	O
downstream	O
signaling	O
molecules	O
of	O
two	O
important	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
induction	O
pathways	O
,	O
toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
3	I-PRGE
(	O
TLR3	B-PRGE
)-	O
and	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
-	I-PRGE
like	I-PRGE
receptors	I-PRGE
(	O
RLR	B-PRGE
)-	O
dependent	O
pathways	O
.	O

ACoRN	O
Respiratory	O
Score	O
which	O
correlated	O
with	O
SNAP	B-PRGE
-	I-PRGE
II	I-PRGE
score	O
is	O
easy	O
to	O
use	O
and	O
may	O
be	O
helpful	O
in	O
facilitating	O
the	O
caregivers	O
in	O
local	O
hospital	O
to	O
identify	O
the	O
early	O
signs	O
and	O
make	O
the	O
transfer	O
decision	O
promptly	O
.	O

Here	O
,	O
we	O
showed	O
that	O
the	O
down	O
-	O
regulation	O
of	O
E	O
is	O
not	O
dependent	O
on	O
the	O
lysine	O
residues	O
on	O
8b	O
and	O
the	O
reduction	O
of	O
polyubiquitination	O
of	O
E	O
mutants	O
is	O
not	O
correlated	O
with	O
their	O
down	O
-	O
regulation	O
by	O
8b	O
,	O
suggesting	O
an	O
ubiquitin	B-PRGE
-	O
independent	O
proteasome	O
pathway	O
is	O
involved	O
.	O

By	O
using	O
Vero	O
E6	O
cells	O
stably	O
expressing	O
green	B-PRGE
fluorescence	I-PRGE
protein	I-PRGE
-	O
tagged	O
8b	O
,	O
ectopic	O
expression	O
of	O
8b	O
was	O
shown	O
to	O
significantly	O
reduce	O
the	O
production	O
of	O
progeny	O
virus	O
and	O
down	O
-	O
regulate	O
E	O
expression	O
.	O

However	O
,	O
there	O
are	O
no	O
data	O
addressing	O
the	O
independent	O
association	O
between	O
troponin	B-PRGE
levels	O
and	O
mortality	O
,	O
adjusted	O
for	O
the	O
severity	O
of	O
the	O
underlying	O
disease	O
,	O
in	O
patients	O
hospitalized	O
for	O
acute	O
respiratory	O
disorders	O
.	O

IHC	O
and	O
RT	O
-	O
PCR	O
were	O
performed	O
for	O
WNv	B-PRGE
antigen	I-PRGE
on	O
41	O
dead	O
birds	O
(	O
belonging	O
to	O
five	O
orders	O
)	O
collected	O
from	O
the	O
northwest	O
region	O
of	O
the	O
Riverside	O
County	O
of	O
California	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
not	O
only	O
mediates	O
receptor	O
-	O
binding	O
but	O
also	O
induces	O
neutralizing	O
antibodies	O
.	O

Our	O
data	O
suggested	O
that	O
HeLa	O
cell	O
extracts	O
and	O
cultured	O
host	O
cells	O
,	O
but	O
not	O
RRL	O
,	O
contain	O
a	O
host	O
factor	O
(	O
s	O
)	O
that	O
is	O
essential	O
for	O
TGEV	B-PRGE
nsp1	I-PRGE
-	O
induced	O
translational	O
suppression	O
.	O

TITLE	O
:	O
The	O
hydrophobic	O
domain	O
of	O
infectious	O
bronchitis	B-PRGE
virus	I-PRGE
E	I-PRGE
protein	I-PRGE
alters	O
the	O
host	O
secretory	O
pathway	O
and	O
is	O
important	O
for	O
release	O
of	O
infectious	O
virus	O
.	O

When	O
compared	O
to	O
culture	O
,	O
the	O
xTAG	B-PRGE
PRV	I-PRGE
showed	O
a	O
sensitivity	O
and	O
specificity	O
of	O
100	O
%	O
and	O
91	O
%,	O
compared	O
to	O
MultiCode	O
-	O
PLx	O
with	O
89	O
%	O
and	O
87	O
%,	O
and	O
ResPlex	O
II	O
with	O
89	O
%	O
and	O
94	O
%,	O
respectively	O
.	O

Intravenous	B-PRGE
immunoglobulin	B-PRGE
(	I-PRGE
IVIG	I-PRGE
)	I-PRGE
was	O
used	O
in	O
all	O
4	O
patients	O
.	O

RESULTS	O
:	O
In	O
the	O
nvA	O
(	O
H1N1	O
)-	O
ARDS	O
group	O
,	O
obesity	O
and	O
lymphocytopenia	O
were	O
more	O
common	O
and	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
interleukin	B-PRGE
(	O
IL	O
)-	O
12	O
,	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	O
)	O
Î±	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
and	O
IL	B-PRGE
-	I-PRGE
9	I-PRGE
were	O
significantly	O
increased	O
versus	O
control	O
.	O

ABSTRACT	O
:	O
Spike	O
(	O
S	O
)	O
proteins	O
,	O
the	O
defining	O
projections	O
of	O
the	O
enveloped	O
coronaviruses	O
(	O
CoVs	O
),	O
mediate	O
cell	O
entry	O
by	O
connecting	O
viruses	O
to	O
plasma	B-PRGE
membrane	I-PRGE
receptors	I-PRGE
and	O
by	O
catalyzing	O
subsequent	O
virus	O
-	O
cell	O
membrane	O
fusions	O
.	O

ACE2	B-PRGE
immunoprecipitation	O
captured	O
transmembrane	B-PRGE
protease	O
/	O
serine	O
subfamily	O
member	O
2	O
(	O
TMPRSS2	B-PRGE
),	O
a	O
known	O
human	O
airway	O
and	O
alveolar	O
protease	O
.	O

Further	O
data	O
suggest	O
that	O
neither	O
the	O
internal	O
(	O
I	O
)	O
protein	O
nor	O
nonstructural	O
proteins	O
ns4	B-PRGE
,	O
and	O
ns2	O
are	O
significant	O
contributors	O
to	O
neurovirulence	O
.	O

TITLE	O
:	O
2	O
'-	O
O	O
methylation	O
of	O
the	O
viral	O
mRNA	O
cap	O
evades	O
host	O
restriction	O
by	O
IFIT	B-PRGE
family	I-PRGE
members	I-PRGE
.	O

Here	O
we	O
show	O
that	O
a	O
West	O
Nile	O
virus	O
(	O
WNV	O
)	O
mutant	O
(	O
E218A	O
)	O
that	O
lacks	O
2	O
'-	O
O	O
MTase	B-PRGE
activity	O
was	O
attenuated	O
in	O
wild	O
-	O
type	O
primary	O
cells	O
and	O
mice	O
but	O
was	O
pathogenic	O
in	O
the	O
absence	O
of	O
type	O
I	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
signalling	O
.	O

In	O
this	O
study	O
,	O
the	O
increase	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
peptidase	I-PRGE
activity	O
in	O
presence	O
of	O
kosmotropic	O
salts	O
and	O
crowding	O
agents	O
is	O
described	O
.	O

The	O
reactivity	O
of	O
the	O
antibody	O
to	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S1	I-PRGE
protein	I-PRGE
was	O
confirmed	O
by	O
Western	O
blot	O
analysis	O
.	O

Three	O
kinds	O
of	O
protein	O
derived	O
from	O
the	O
C	O
-	O
terminal	O
S2	O
domain	O
of	O
S	B-PRGE
protein	I-PRGE
of	O
the	O
FIPV	O
KU	O
-	O
2	O
strain	O
were	O
developed	O
using	O
a	O
baculovirus	O
expression	O
system	O
.	O

TITLE	O
:	O
Single	O
-	O
dose	O
intranasal	O
administration	O
with	O
mDEF201	O
(	O
adenovirus	O
vectored	O
mouse	O
interferon	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
confers	O
protection	O
from	O
mortality	O
in	O
a	O
lethal	O
SARS	O
-	O
CoV	O
BALB	O
/	O
c	O
mouse	O
model	O
.	O

Patients	O
who	O
received	O
corticosteroids	O
had	O
significantly	O
higher	O
ICU	O
mortality	O
than	O
patients	O
who	O
did	O
not	O
(	O
46	O
.	O
0	O
%	O
versus	O
18	O
.	O
1	O
%,	O
p	O
<	O
0	O
.	O
01	O
;	O
OR	O
3	O
.	O
8	O
,	O
CI	B-PRGE
2	I-PRGE
.	I-PRGE
1	I-PRGE
-	I-PRGE
7	I-PRGE
.	I-PRGE
2	I-PRGE
).	O

TITLE	O
:	O
Expression	O
of	O
neutral	O
endopeptidase	B-PRGE
activity	O
during	O
clinical	O
and	O
experimental	O
acute	O
lung	O
injury	O
.	O

Proximal	O
skeletal	O
muscle	O
symptoms	O
and	O
signs	O
,	O
elevation	O
of	O
creatine	B-PRGE
kinase	I-PRGE
,	O
and	O
myogenic	O
changes	O
in	O
electromyography	O
were	O
found	O
in	O
all	O
of	O
the	O
cases	O
,	O
and	O
magnetic	O
resonance	O
imaging	O
clearly	O
revealed	O
thickening	O
of	O
the	O
fascia	O
.	O

In	O
addition	O
,	O
CD20	B-PRGE
+	I-PRGE
B	I-PRGE
-	O
cell	O
infiltration	O
into	O
the	O
fascia	O
was	O
also	O
detected	O
in	O
all	O
of	O
the	O
cases	O
,	O
indicating	O
further	O
transition	O
to	O
DM	O
.	O

The	O
etiological	O
diagnosis	O
of	O
S	O
-	O
OIV	O
infection	O
was	O
performed	O
by	O
use	O
of	O
a	O
real	O
time	O
RT	O
-	O
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
assay	O
allowing	O
the	O
detection	O
of	O
all	O
the	O
known	O
human	O
influenza	O
A	O
viruses	O
(	O
rRT	O
-	O
PCR	O
targeting	O
the	O
influenza	B-PRGE
gene	I-PRGE
M	I-PRGE
)	O
and	O
of	O
the	O
new	O
influenza	O
A	O
/	O
H1N1	O
pandemic	O
strain	O
.	O

By	O
testing	O
the	O
special	O
IgG	B-PRGE
,	I-PRGE
IgM	I-PRGE
,	I-PRGE
nucleocapsid	I-PRGE
antibody	I-PRGE
to	O
SARS	O
-	O
CoV	O
of	O
the	O
14	O
family	O
clustering	O
cases	O
,	O
we	O
found	O
that	O
they	O
all	O
decreased	O
in	O
the	O
7	O
(	O
th	O
)	O
year	O
,	O
and	O
most	O
of	O
them	O
disappeared	O
.	O

During	O
hospitalization	O
the	O
foal	O
developed	O
hyperglycemia	O
concomitantly	O
with	O
low	O
insulin	B-PRGE
concentration	O
and	O
an	O
adequate	O
response	O
to	O
exogenous	O
insulin	B-PRGE
therapy	O
supported	O
a	O
diagnosis	O
of	O
Type	O
1	O
diabetes	O
mellitus	O
.	O

Hence	O
,	O
tissue	O
cells	O
infected	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
are	O
unable	O
to	O
launch	O
an	O
IFN	B-PRGE
response	O
.	O

Plasmacytoid	O
dendritic	O
cells	O
,	O
however	O
,	O
produce	O
high	O
levels	O
of	O
IFN	B-PRGE
after	O
infection	O
.	O

TITLE	O
:	O
North	O
American	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
viruses	O
inhibit	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
production	O
by	O
plasmacytoid	O
dendritic	O
cells	O
.	O

The	O
ASC	B-PRGE
survival	I-PRGE
factors	I-PRGE
B	I-PRGE
cell	I-PRGE
-	I-PRGE
activating	I-PRGE
factor	I-PRGE
of	O
the	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	O
)	O
family	O
(	O
BAFF	B-PRGE
)	O
and	O
a	O
proliferating	O
-	O
inducing	O
ligand	O
(	O
APRIL	O
)	O
were	O
also	O
significantly	O
elevated	O
in	O
the	O
infected	O
CNS	O
,	O
albeit	O
delayed	O
relative	O
to	O
the	O
chemokines	O
.	O

In	O
IFN	B-PRGE
-	I-PRGE
Î³R	I-PRGE
(-/-)	O
mice	O
,	O
Th17	O
response	O
is	O
enhanced	O
and	O
the	O
elevated	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
production	O
contributes	O
to	O
severe	O
liver	O
damage	O
as	O
well	O
as	O
detrimental	O
inflammation	O
because	O
neutralization	O
of	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
effectively	O
suppresses	O
inflammation	O
and	O
protects	O
mice	O
from	O
liver	O
injury	O
.	O

The	O
replacement	O
of	O
the	O
MHV	O
2a	O
/	O
haemagglutinin	O
-	O
esterase	B-PRGE
gene	O
with	O
a	O
membrane	O
-	O
anchored	O
protein	O
hook	O
(	O
HK	O
)	O
and	O
replacement	O
of	O
gene	B-PRGE
4	I-PRGE
with	O
EGFP	O
did	O
not	O
change	O
the	O
adaptability	O
and	O
cytopathology	O
of	O
recombinant	O
viruses	O
in	O
these	O
cells	O
.	O

The	O
size	O
of	O
the	O
PEI	O
/	O
pci	B-PRGE
-	O
S	O
nanoparticles	O
appeared	O
to	O
be	O
around	O
194	O
.	O
7	O
Â±	O
99	O
.	O
3	O
nm	O
,	O
and	O
the	O
expression	O
of	O
the	O
S	B-PRGE
mRNA	I-PRGE
and	O
protein	O
was	O
confirmed	O
in	O
vitro	O
.	O

Co	O
-	O
stimulatory	O
molecules	O
(	O
CD80	B-PRGE
and	O
CD86	B-PRGE
)	O
and	O
class	B-PRGE
II	I-PRGE
major	I-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
molecules	I-PRGE
(	O
I	O
-	O
Ad	O
)	O
were	O
increased	O
on	O
CD11c	O
+	O
dendritic	O
cells	O
in	O
cervical	O
lymph	O
node	O
from	O
the	O
mice	O
after	O
PEI	O
/	O
pci	O
-	O
S	O
vaccination	O
.	O

TITLE	O
:	O
New	O
nsp8	B-PRGE
isoform	I-PRGE
suggests	O
mechanism	O
for	O
tuning	O
viral	O
RNA	O
synthesis	O
.	O

We	O
subsequently	O
crystallized	O
the	O
complex	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp8C	I-PRGE
and	O
nsp7	O
,	O
and	O
the	O
3	O
-	O
D	O
structure	O
of	O
this	O
domain	O
revealed	O
its	O
capability	O
to	O
interfuse	O
into	O
the	O
hexadecamer	O
super	O
-	O
complex	O
.	O

TITLE	O
:	O
Liberation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
main	I-PRGE
protease	I-PRGE
from	O
the	O
viral	O
polyprotein	O
:	O
N	O
-	O
terminal	O
autocleavage	O
does	O
not	O
depend	O
on	O
the	O
mature	O
dimerization	O
mode	O
.	O

Compared	O
with	O
age	O
-	O
and	O
sex	O
-	O
matched	O
control	O
subjects	O
,	O
blood	O
pressure	O
levels	O
were	O
lower	O
and	O
KL	O
-	O
6	O
,	O
high	O
mobility	O
group	O
box	O
1	O
(	O
HMGB1	B-PRGE
),	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
sRAGE	O
levels	O
were	O
higher	O
in	O
ARDS	O
patients	O
.	O

Highly	O
significant	O
decreases	O
in	O
haematocrit	O
and	O
albumin	B-PRGE
levels	O
and	O
an	O
increase	O
in	O
total	O
bilirubin	O
level	O
were	O
noted	O
in	O
both	O
effusive	O
and	O
non	O
-	O
effusive	O
FIP	O
,	O
at	O
first	O
presentation	O
and	O
before	O
death	O
.	O

This	O
study	O
determined	O
the	O
kinetics	O
for	O
binding	O
of	O
a	O
soluble	O
S1	B-PRGE
protein	I-PRGE
to	O
the	O
APN	B-PRGE
protein	I-PRGE
.	O

Moreover	O
,	O
the	O
S1	O
region	O
of	O
the	O
TGEV	B-PRGE
S	I-PRGE
protein	I-PRGE
was	O
dissected	O
,	O
with	O
the	O
aim	O
of	O
identifying	O
discrete	O
modules	O
displaying	O
unique	O
antigenic	O
sites	O
and	O
receptor	O
-	O
binding	O
functions	O
.	O

IL	O
-	O
8	O
,	O
eosinophil	B-PRGE
cationic	I-PRGE
protein	I-PRGE
(	O
ECP	B-PRGE
)	O
and	O
Î±	O
(	O
2	O
)-	O
macroglobulin	O
were	O
measured	O
as	O
indices	O
of	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
,	O
eosinophil	O
activity	O
,	O
and	O
plasma	O
exudation	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
interferon	B-PRGE
-	I-PRGE
Î²	I-PRGE
specifically	O
restricted	O
filovirus	O
and	O
IAV	O
entry	O
processes	O
.	O

We	O
further	O
demonstrate	O
that	O
replication	O
of	O
infectious	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
entry	O
mediated	O
by	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
are	O
restricted	O
by	O
IFITM	O
proteins	O
.	O

Here	O
we	O
tested	O
the	O
hypothesis	O
that	O
simultaneous	O
blockade	O
of	O
inducible	O
and	O
neuronal	B-PRGE
NO	I-PRGE
synthase	I-PRGE
effectively	O
prevents	O
the	O
pulmonary	O
lesions	O
in	O
an	O
ovine	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
induced	O
by	O
combined	O
burn	O
and	O
smoke	O
inhalation	O
injury	O
.	O

This	O
study	O
investigated	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
antagonist	O
mechanism	O
of	O
PLpro	O
in	O
human	O
promonocytes	O
.	O

A	O
proteomics	O
approach	O
demonstrated	O
downregulation	O
of	O
extracellular	B-PRGE
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
1	O
and	O
upregulation	O
of	O
ubiquitin	B-PRGE
-	I-PRGE
conjugating	I-PRGE
enzyme	I-PRGE
(	O
UBC	B-PRGE
)	O
E2	B-PRGE
-	I-PRGE
25k	I-PRGE
as	O
inhibitory	O
mechanism	O
of	O
PLpro	O
on	O
IFN	B-PRGE
-	I-PRGE
Î±	I-PRGE
-	O
induced	O
responses	O
.	O

ABSTRACT	O
:	O
To	O
express	O
the	O
nuclear	B-PRGE
capsid	I-PRGE
protein	I-PRGE
(	O
N	B-PRGE
protein	I-PRGE
)	O
and	O
the	O
spike	B-PRGE
protein	I-PRGE
(	O
S	B-PRGE
protein	I-PRGE
)	O
of	O
HCoV	O
-	O
HKU1	O
,	O
and	O
to	O
develop	O
the	O
corresponding	O
serum	O
assay	O
for	O
antibody	O
detection	O
.	O

The	O
most	O
obvious	O
example	O
is	O
anti	O
-	O
AIDS	O
research	O
,	O
where	O
HIV	B-PRGE
protease	I-PRGE
and	O
reverse	B-PRGE
transcriptase	I-PRGE
have	O
triggered	O
enormous	O
efforts	O
in	O
developing	O
and	O
improving	O
computational	O
methods	O
.	O

TITLE	O
:	O
The	O
leader	O
proteinase	O
of	O
foot	O
-	O
and	O
-	O
mouth	O
disease	O
virus	O
negatively	O
regulates	O
the	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
pathway	O
by	O
acting	O
as	O
a	O
viral	O
deubiquitinase	O
.	O

Mutations	O
in	O
Lb	O
(	O
pro	O
)	O
that	O
ablate	O
the	O
catalytic	O
activity	O
(	O
C51A	O
or	O
D163N	O
/	O
D164N	O
)	O
or	O
disrupt	O
the	O
SAP	O
(	O
for	O
SAF	B-PRGE
-	I-PRGE
A	I-PRGE
/	I-PRGE
B	I-PRGE
,	O
Acinus	O
,	O
and	O
PIAS	O
)	O
domain	O
(	O
I83A	O
/	O
L86A	O
)	O
abrogated	O
the	O
DUB	O
activity	O
of	O
Lb	B-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
as	O
well	O
as	O
its	O
ability	O
to	O
block	O
signaling	O
to	O
the	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
promoter	I-PRGE
.	O

There	O
were	O
also	O
statistically	O
significant	O
differences	O
between	O
survivors	O
and	O
nonsurvivors	O
in	O
success	O
of	O
noninvasive	O
ventilation	O
,	O
time	O
to	O
confirmation	O
of	O
the	O
H1N1	O
virus	O
after	O
ICU	O
admission	O
,	O
creatinine	O
,	O
lactate	B-PRGE
dehydrogenase	I-PRGE
,	O
pH	O
,	O
P	O
(	O
aCO	O
(	O
2	O
)),	O
and	O
P	O
(	O
aO	O
(	O
2	O
))/	O
F	O
(	O
IO	O
(	O
2	O
)).	O

Given	O
that	O
little	O
was	O
known	O
about	O
this	O
new	O
emergent	O
IBV	O
we	O
have	O
characterized	O
five	O
field	O
isolates	O
by	O
sequencing	O
the	O
entire	O
S1	B-PRGE
gene	I-PRGE
.	O

In	O
this	O
article	O
,	O
we	O
show	O
that	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
a	O
potent	O
anti	O
-	O
inflammatory	O
cytokine	O
,	O
is	O
produced	O
transiently	O
at	O
the	O
peak	O
of	O
infection	O
by	O
CD8	B-PRGE
T	I-PRGE
cells	O
in	O
the	O
brains	O
of	O
coronavirus	O
-	O
infected	O
mice	O
.	O

Furthermore	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
produced	O
by	O
CD8	B-PRGE
T	I-PRGE
cells	O
diminished	O
disease	O
severity	O
in	O
mice	O
with	O
coronavirus	O
-	O
induced	O
acute	O
encephalitis	O
,	O
suggesting	O
a	O
self	O
-	O
regulatory	O
mechanism	O
that	O
minimizes	O
immunopathological	O
changes	O
.	O

Expression	O
of	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
was	O
significantly	O
decreased	O
in	O
3CLpro	O
-	O
transfected	O
cells	O
by	O
both	O
RT	O
-	O
PCR	O
and	O
ELISA	O
,	O
but	O
without	O
changes	O
in	O
other	O
cytokines	O
,	O
i	O
.	O
e	O
.,	O
IL	O
-	O
1Î²	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
,	O
IL12p40	B-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
,	O
and	O
TGF	O
-	O
Î²	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
3CLpro	O
may	O
suppress	O
expression	O
of	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
in	O
transfected	O
A549	O
cells	O
through	O
down	O
-	O
regulation	O
of	O
NF	B-PRGE
-	I-PRGE
kB	I-PRGE
production	O
.	O

This	O
study	O
assessed	O
the	O
effect	O
of	O
human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
(	O
HCoV	O
-	O
NL63	O
)	O
on	O
the	O
adherence	O
of	O
bacterial	O
pathogens	O
associated	O
with	O
respiratory	O
tract	O
illnesses	O
.	O

Four	O
genotypes	O
of	O
IBV	O
and	O
three	O
new	O
isolates	O
were	O
identified	O
by	O
phylogenetic	O
analysis	O
and	O
BLAST	O
searches	O
of	O
the	O
entire	O
S1	B-PRGE
gene	I-PRGE
.	O

Both	O
passage	O
levels	O
were	O
tested	O
for	O
efficacy	O
in	O
SPF	B-PRGE
chickens	I-PRGE
and	O
passage	O
level	O
85	O
was	O
tested	O
for	O
efficacy	O
in	O
commercial	O
chickens	O
with	O
maternally	O
derived	O
antibodies	O
(	O
MDA	O
)	O
against	O
a	O
challenge	O
with	O
QX	O
-	O
like	O
strain	O
IB	O
D388	O
.	O

Especially	O
,	O
CD8	B-PRGE
(+)	I-PRGE
fIFN	I-PRGE
-	I-PRGE
Î³	I-PRGE
(+)	O
cells	O
,	O
but	O
not	O
CD4	B-PRGE
(+)	I-PRGE
fIFN	I-PRGE
-	I-PRGE
Î³	I-PRGE
(+)	O
cells	O
,	O
were	O
increased	O
.	O

Multivariate	O
predictors	O
for	O
use	O
of	O
rescue	O
therapy	O
included	O
age	O
(	O
odds	O
ratio	O
per	O
10	O
yrs	O
and	O
95	O
%	O
confidence	O
interval	O
:	O
0	O
.	O
88	O
;	O
0	O
.	O
78	O
-	O
0	O
.	O
99	O
;	O
p	O
=	O
.	O
049	O
),	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
odds	O
ratio	O
per	O
5	O
-	O
cm	O
H2O	O
increase	O
:	O
1	O
.	O
33	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
05	O
-	O
1	O
.	O
69	O
;	O
p	O
=	O
.	O
019	O
),	O
Pao2	B-PRGE
/	O
Fio2	O
;	O
odds	O
ratio	O
per	O
5	O
-	O
cm	O
H2O	O
increase	O
:	O
0	O
.	O
98	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
96	O
-	O
0	O
.	O
99	O
;	O
p	O
=	O
.	O
017	O
),	O
peak	O
airway	O
pressure	O
(	O
odds	O
ratio	O
per	O
5	O
-	O
cm	O
H2O	O
increase	O
:	O
1	O
.	O
11	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
001	O
-	O
1	O
.	O
237	O
;	O
p	O
=	O
.	O
047	O
),	O
and	O
study	O
order	O
(	O
odds	O
ratio	O
per	O
subsequent	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Clinical	O
Trials	O
Network	O
study	O
:	O
1	O
.	O
21	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
03	O
-	O
1	O
.	O
41	O
;	O
p	O
=	O
.	O
02	O
).	O

TITLE	O
:	O
Inhibition	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replication	O
in	O
a	O
lethal	O
SARS	O
-	O
CoV	O
BALB	O
/	O
c	O
mouse	O
model	O
by	O
stinging	O
nettle	O
lectin	B-PRGE
,	O
Urtica	O
dioica	O
agglutinin	O
.	O

ABSTRACT	O
:	O
Urtica	O
dioica	O
agglutinin	O
(	O
UDA	O
)	O
is	O
a	O
small	O
plant	O
monomeric	O
lectin	B-PRGE
,	O
8	O
.	O
7	O
kDa	O
in	O
size	O
,	O
with	O
an	O
N	O
-	O
acetylglucosamine	O
specificity	O
that	O
inhibits	O
viruses	O
from	O
Nidovirales	O
in	O
vitro	O
.	O

These	O
data	O
support	O
the	O
conclusion	O
that	O
UDA	O
might	O
bind	O
to	O
N	O
-	O
acetylglucosamine	O
-	O
like	O
residues	O
present	O
on	O
the	O
glycosylated	B-PRGE
envelope	I-PRGE
glycoproteins	I-PRGE
,	O
thereby	O
preventing	O
virus	O
attachment	O
to	O
cells	O
.	O

In	O
addition	O
,	O
the	O
coexpression	O
of	O
nsp4	B-PRGE
with	O
nsp3	B-PRGE
affected	O
the	O
subcellular	O
localization	O
of	O
the	O
two	O
proteins	O
.	O

TITLE	O
:	O
Development	O
and	O
immunogenicity	O
of	O
recombinant	O
GapA	B-PRGE
(+)	O
Mycoplasma	O
gallisepticum	O
vaccine	O
strain	O
ts	O
-	O
11	O
expressing	O
infectious	O
bronchitis	B-PRGE
virus	I-PRGE
-	I-PRGE
S1	I-PRGE
glycoprotein	I-PRGE
and	I-PRGE
chicken	I-PRGE
interleukin	I-PRGE
-	I-PRGE
6	I-PRGE
.	O

ABSTRACT	O
:	O
Sterile	O
protection	O
against	O
infection	O
with	O
Plasmodium	O
sporozoites	O
requires	O
high	O
numbers	O
of	O
memory	O
CD8	B-PRGE
T	I-PRGE
cells	O
.	O

At	O
48	O
h	O
post	O
-	O
infection	O
,	O
only	O
a	O
few	O
siRNA	O
-	O
treated	O
cells	O
were	O
positive	O
for	O
viral	B-PRGE
antigen	I-PRGE
staining	O
,	O
whereas	O
most	O
untreated	O
virus	O
-	O
infected	O
cells	O
were	O
positive	O
.	O

The	O
highly	O
conserved	O
pentaloop	O
of	O
SL2	B-PRGE
is	O
stacked	O
on	O
5	O
-	O
bp	O
stem	O
and	O
adopts	O
a	O
canonical	O
CUYG	O
tetraloop	O
fold	O
with	O
the	O
3	O
'	O
nucleotide	O
(	O
U51	O
)	O
flipped	O
out	O
of	O
the	O
stack	O
.	O

Multiple	O
observational	O
studies	O
have	O
suggested	B-PRGE
that	I-PRGE
HMGCoA	I-PRGE
reductase	I-PRGE
inhibitors	I-PRGE
(	O
statins	O
)	O
can	O
exert	O
a	O
class	O
effect	O
in	O
attenuating	O
inflammation	O
.	O

Previously	O
,	O
the	O
extra	O
domain	O
was	O
demonstrated	O
to	O
regulate	O
the	O
catalysis	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
by	O
controlling	O
its	O
dimerization	O
.	O

Nsp16	O
is	O
an	O
RNA	B-PRGE
-	I-PRGE
cap	I-PRGE
AdoMet	I-PRGE
-	I-PRGE
dependent	I-PRGE
(	I-PRGE
nucleoside	I-PRGE
-	I-PRGE
2	I-PRGE
'-	I-PRGE
O	I-PRGE
-)-	I-PRGE
methyltransferase	I-PRGE
that	O
is	O
only	O
active	O
in	O
the	O
presence	O
of	O
nsp10	O
.	O

Comparisons	O
of	O
global	O
miRNA	O
profiles	O
in	O
animal	O
models	O
of	O
ALI	O
and	O
VILI	O
identified	O
several	O
miRNAs	O
(	O
eg	O
,	O
miR	B-PRGE
-	I-PRGE
146a	I-PRGE
and	O
miR	O
-	O
155	O
)	O
previously	O
implicated	O
in	O
immune	O
response	O
and	O
inflammatory	O
pathways	O
.	O

The	O
SLI	B-PRGE
/	I-PRGE
II	I-PRGE
domain	I-PRGE
(	O
nucleotides	O
1	O
to	O
84	O
)	O
and	O
SLIII	B-PRGE
domain	I-PRGE
(	O
nucleotides	O
85	O
to	O
141	O
)	O
each	O
immediately	O
enabled	O
near	O
-	O
wild	O
-	O
type	O
(	O
wt	O
)	O
MHV	O
-	O
like	O
progeny	O
,	O
thus	O
behaving	O
similarly	O
to	O
comparable	O
5	O
'-	O
proximal	O
regions	O
of	O
the	O
SCoV	B-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
as	O
shown	O
by	O
others	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
two	O
bacterial	O
pathogens	O
(	O
Fusobacterium	O
necrophorum	O
and	O
Acinetobacter	O
baumannii	O
)	O
causing	O
sepsis	O
were	O
detected	O
by	O
DNA	O
-	O
probe	O
hybridization	O
and	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
was	O
detected	O
by	O
antigen	B-PRGE
-	I-PRGE
antibody	I-PRGE
interaction	O
using	O
the	O
functional	O
PCs	O
.	O

We	O
determined	O
that	O
antiviral	O
activity	O
was	O
dependent	O
on	O
both	O
the	O
Tat	B-PRGE
sequence	I-PRGE
and	O
the	O
native	O
EboV	O
CHR	O
sequence	O
.	O

When	O
intranasal	O
immunization	O
was	O
used	O
,	O
PIKA	O
was	O
obligatorily	O
for	O
inducing	O
neutralizing	O
activity	O
in	O
serum	O
as	O
well	O
as	O
in	O
mucosal	O
sites	O
and	O
was	O
correlated	O
with	O
both	O
mucosal	O
IgA	B-PRGE
and	O
mucosal	O
IgG	B-PRGE
response	O
.	O

Overall	O
,	O
PIKA	B-PRGE
could	O
be	O
a	O
good	O
mucosal	O
adjuvant	O
candidate	O
for	O
inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
for	O
use	O
in	O
possible	O
future	O
pandemic	O
.	O

The	O
second	O
test	O
,	O
a	O
genotyping	O
method	O
,	O
was	O
developed	O
for	O
identification	O
of	O
the	O
strain	O
of	O
IBV	O
present	O
in	O
field	O
samples	O
based	O
on	O
nucleotide	O
variations	O
within	O
the	O
gene	O
encoding	O
the	O
S1	O
subunit	O
of	O
the	O
surface	B-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
.	O

Puppies	O
were	O
also	O
infected	O
by	O
canine	O
parvovirus	B-PRGE
type	I-PRGE
2	I-PRGE
(	O
CPV	O
-	O
2	O
).	O

Faecal	O
samples	O
from	O
84	O
Australian	O
dairy	O
and	O
dairy	O
beef	O
properties	O
(	O
597	O
samples	O
)	O
were	O
screened	O
for	O
rotavirus	O
and	O
coronavirus	O
using	O
real	O
-	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
,	O
for	O
Salmonella	B-PRGE
spp	I-PRGE
.	O

Higher	O
divergence	O
with	O
NA	O
TCoV	O
was	O
observed	O
in	O
the	O
S1	B-PRGE
-	I-PRGE
encoding	I-PRGE
domain	I-PRGE
.	O

TITLE	O
:	O
Immunogenic	O
characterization	O
and	O
epitope	O
mapping	O
of	O
transmissible	O
gastroenteritis	O
virus	O
RNA	O
dependent	O
RNA	B-PRGE
polymerase	I-PRGE
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
sialosides	O
modified	O
at	O
the	O
4	O
-	O
and	O
9	O
-	O
hydroxy	O
group	O
were	O
synthesised	O
and	O
tested	O
for	O
inhibition	O
of	O
the	O
viral	O
haemagglutinin	O
-	O
esterase	B-PRGE
activity	O
from	O
various	O
Orthomyxoviruses	O
and	O
Coronaviruses	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
envelope	B-PRGE
(	O
E	O
)	O
protein	O
is	O
a	O
transmembrane	O
protein	O
.	O

Patients	O
with	O
H1N1	O
associated	O
with	O
ARDS	O
may	O
be	O
given	O
a	O
trial	O
of	O
IV	O
IgG	B-PRGE
.	O
More	O
case	O
reports	O
and	O
trials	O
are	O
required	O
to	O
ascertain	O
the	O
efficacy	O
of	O
IV	O
IgG	B-PRGE
and	O
the	O
best	O
dosage	O
and	O
timing	O
of	O
starting	O
IV	O
IgG	B-PRGE
in	O
relation	O
to	O
antiviral	O
therapy	O
.	O

Overall	O
,	O
the	O
majority	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	I-PRGE
producing	I-PRGE
CD8	I-PRGE
(+)	O
T	O
cells	O
were	O
specific	O
for	O
the	O
immunodominant	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
(	O
MHC	O
)	O
class	O
I	O
epitope	O
.	O

Furthermore	O
,	O
elevated	O
frequencies	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	I-PRGE
producing	I-PRGE
CD4	I-PRGE
(+)	O
T	O
cells	O
in	O
the	O
spinal	O
cord	O
supported	O
preferential	O
maintenance	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
production	O
at	O
the	O
site	O
of	O
viral	O
persistence	O
and	O
tissue	O
damage	O
.	O

The	O
polyclonal	O
antibody	O
against	O
PRRSV	B-PRGE
N	I-PRGE
protein	I-PRGE
used	O
as	O
a	O
diagnostic	O
agent	O
was	O
capable	O
of	O
differentiating	O
PRRSV	O
from	O
the	O
other	O
viruses	O
.	O

Also	O
,	O
PaOâ	B-PRGE
/	O
Fioâ	O
may	O
increase	O
when	O
Fio2	O
is	O
raised	O
from	O
moderate	O
to	O
high	O
levels	O
,	O
suggesting	O
that	O
patients	O
with	O
similar	O
PaOâ	B-PRGE
/	O
Fioâ	O
ratios	O
but	O
different	O
Fioâ	O
levels	O
have	O
different	O
risks	O
of	O
mortality	O
.	O

In	O
contrast	O
,	O
the	O
addition	O
of	O
baseline	O
Fio2	O
to	O
PaOâ	B-PRGE
/	O
Fioâ	O
could	O
be	O
used	O
to	O
identify	O
subsets	O
of	O
patients	O
with	O
low	O
or	O
high	O
mortality	O
.	O

TITLE	O
:	O
Activation	O
and	O
maturation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
main	I-PRGE
protease	I-PRGE
.	O

Interestingly	O
,	O
S	B-PRGE
protein	I-PRGE
of	O
the	O
attenuated	O
100th	O
-	O
passaged	O
83P	O
-	O
5	O
showed	O
a	O
remarkable	O
sequence	O
similarity	O
to	O
that	O
of	O
previously	O
reported	O
DR	O
-	O
13	O
strain	O
of	O
attenuated	O
PEDV	O
that	O
also	O
had	O
been	O
established	O
by	O
serial	O
passage	O
in	O
Vero	O
cells	O
.	O

TITLE	O
:	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
accessory	I-PRGE
protein	I-PRGE
3b	I-PRGE
induces	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
transcriptional	O
activity	O
through	O
activation	O
of	O
JNK	B-PRGE
and	O
ERK	B-PRGE
pathways	O
.	O

Our	O
findings	O
elucidate	O
augmentation	O
of	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
dependent	O
gene	O
expression	O
in	O
3b	O
-	O
transfected	O
Huh7	O
cells	O
.	O

ABSTRACT	O
:	O
ADAM17	B-PRGE
,	O
also	O
known	O
as	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
Î±	I-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
,	O
is	O
involved	O
in	O
the	O
ectodomain	O
shedding	O
of	O
many	O
integral	O
membrane	O
proteins	O
.	O

We	O
hypothesized	O
that	O
a	O
known	O
functional	O
polymorphism	O
in	O
the	O
promoter	O
of	O
the	O
NFKB1	B-PRGE
gene	I-PRGE
may	O
affect	O
susceptibility	O
to	O
and	O
outcome	O
from	O
ARDS	O
.	O

No	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
Ag	I-PRGE
-	O
specific	O
memory	O
B	O
cell	O
response	O
was	O
detected	O
in	O
either	O
23	O
former	O
SARS	O
patients	O
or	O
22	O
close	O
contacts	O
of	O
SARS	O
patients	O
.	O

Memory	O
T	O
cell	O
responses	O
to	O
a	O
pool	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
peptides	I-PRGE
were	O
identified	O
in	O
14	O
of	O
23	O
(	O
60	O
.	O
9	O
%)	O
recovered	O
SARS	O
patients	O
,	O
whereas	O
there	O
was	O
no	O
such	O
specific	O
response	O
in	O
either	O
close	O
contacts	O
or	O
healthy	O
controls	O
.	O

The	O
RBD	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
plays	O
important	O
roles	O
in	O
receptor	O
binding	O
and	O
induction	O
of	O
specific	O
neutralizing	O
antibodies	O
against	O
virus	O
infection	O
.	O

Finally	O
,	O
a	O
SARS	O
pseudovirus	O
neutralization	O
assay	O
was	O
introduced	O
in	O
the	O
protocol	O
and	O
used	O
to	O
detect	O
the	O
neutralizing	O
activity	O
of	O
sera	O
of	O
mice	O
vaccinated	O
with	O
rRBD	B-PRGE
protein	I-PRGE
.	O

Here	O
,	O
we	O
examined	O
the	O
therapeutic	O
effects	O
of	O
increased	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
at	O
early	O
times	O
after	O
infection	O
by	O
engineering	O
a	O
recombinant	O
J2	O
.	O
2	O
virus	O
to	O
produce	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
.	O

fDC	B-PRGE
-	I-PRGE
SIGN	I-PRGE
was	O
not	O
involved	O
in	O
FIPV	O
II	O
binding	O
but	O
infection	O
was	O
reduced	O
with	O
64	O
%	O
when	O
fDC	O
-	O
SIGN	O
was	O
blocked	O
.	O

TITLE	O
:	O
Uric	O
acid	O
and	O
HMGB1	B-PRGE
are	O
involved	O
in	O
the	O
induction	O
of	O
autoantibodies	O
elicited	O
in	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
A59	O
.	O

Univariate	O
and	O
multivariate	O
logistic	O
regression	O
analyses	O
showed	O
that	O
sES	B-PRGE
was	O
the	O
only	O
significant	O
factor	O
for	O
identifying	O
complicating	O
ALI	O
/	O
cALI	O
,	O
independently	O
of	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
)	O
and	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
LDH	B-PRGE
).	O

TITLE	O
:	O
Kidney	O
transplantation	O
from	O
hepatitis	O
B	O
virus	O
core	O
antibody	O
-	O
positive	O
donors	O
:	O
prophylaxis	O
with	O
hepatitis	B-PRGE
B	I-PRGE
immunoglobulin	I-PRGE
.	O

RESULTS	O
:	O
Two	O
hours	O
after	O
the	O
RM	O
,	O
the	O
PaO	B-PRGE
(	I-PRGE
2	I-PRGE
)/	I-PRGE
FiO	I-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
was	O
higher	O
than	O
at	O
baseline	O
(	O
187	O
Â±	O
102	O
versus	O
339	O
Â±	O
136	O
mmHg	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
9b	I-PRGE
protein	I-PRGE
diffuses	O
into	O
nucleus	O
,	O
undergoes	O
active	O
Crm1	B-PRGE
mediated	O
nucleocytoplasmic	O
export	O
and	O
triggers	O
apoptosis	O
when	O
retained	O
in	O
the	O
nucleus	O
.	O

These	O
data	O
suggest	O
that	O
EPA	B-PRGE
/	O
GLA	B-PRGE
may	O
play	O
a	O
beneficial	O
role	O
in	O
the	O
treatment	O
of	O
enterally	O
fed	O
patients	O
in	O
the	O
early	O
stages	O
of	O
sepsis	O
without	O
associated	O
organ	O
dysfunction	O
by	O
contributing	O
to	O
slowing	O
the	O
progression	O
of	O
sepsis	O
-	O
related	O
organ	O
dysfunction	O
,	O
especially	O
with	O
regard	O
to	O
cardiovascular	O
and	O
respiratory	O
dysfunction	O
.	O

TITLE	O
:	O
Receptor	O
-	O
bound	O
porcine	O
epidemic	O
diarrhea	O
virus	O
spike	O
protein	O
cleaved	O
by	O
trypsin	B-PRGE
induces	O
membrane	O
fusion	O
.	O

The	O
present	O
study	O
describes	O
the	O
mode	O
of	O
action	O
of	O
trypsin	B-PRGE
in	O
enhancing	O
PEDV	O
infection	O
in	O
Vero	O
cells	O
during	O
different	O
stage	O
of	O
the	O
virus	O
life	O
cycle	O
.	O

During	O
the	O
viral	O
entry	O
stage	O
,	O
trypsin	B-PRGE
increased	O
the	O
penetration	O
of	O
Vero	O
-	O
cell	O
-	O
attached	O
PEDV	O
by	O
approximately	O
twofold	O
.	O

Furthermore	O
,	O
we	O
also	O
show	O
that	O
the	O
PEDV	B-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
is	O
cleaved	O
by	O
trypsin	B-PRGE
in	O
virions	O
that	O
are	O
bound	O
to	O
the	O
receptor	O
,	O
but	O
not	O
in	O
free	O
virions	O
.	O

Continuous	O
and	O
categorical	O
data	O
from	O
index	O
cases	O
were	O
compared	O
with	O
that	O
from	O
71	O
control	O
cases	O
of	O
ACS	O
in	O
patients	O
with	O
hemoglobin	B-PRGE
SS	O
disease	O
.	O

We	O
examined	O
serial	O
pathological	O
changes	O
in	O
the	O
lungs	O
of	O
mice	O
infected	O
with	O
influenza	O
virus	O
to	O
determine	O
the	O
progress	O
from	O
viral	O
pneumonia	O
to	O
ARDS	O
/	O
DAD	B-PRGE
.	O

The	O
results	O
indicated	O
that	O
the	O
recombination	O
events	O
occurred	O
in	O
the	O
S1	B-PRGE
gene	I-PRGE
between	O
the	O
field	O
strains	O
.	O

The	O
second	O
-	O
site	O
mutations	O
are	O
predicted	O
to	O
change	O
either	O
the	O
spacing	O
between	O
SL1	B-PRGE
and	O
SL2	B-PRGE
or	O
that	O
between	O
SL2	B-PRGE
and	O
SL4	O
or	O
to	O
destabilize	O
the	O
proximal	O
portion	O
of	O
SL4a	O
in	O
our	O
model	O
.	O

As	O
a	O
result	O
of	O
the	O
research	O
,	O
it	O
has	O
been	O
established	O
that	O
acylation	O
by	O
succinic	O
anhydride	O
of	O
two	O
lysines	O
in	O
the	O
structure	O
of	O
interferon	B-PRGE
-	I-PRGE
Î³	I-PRGE
(	O
Gammaferon	O
)	O
leads	O
to	O
both	O
an	O
increase	O
in	O
its	O
affinity	O
to	O
cell	O
receptors	O
and	O
a	O
decrease	O
in	O
the	O
time	O
of	O
maximum	O
effect	O
from	O
48	O
hours	O
to	O
15	O
minutes	O
.	O

The	O
ensemble	O
of	O
succinylated	O
interferon	B-PRGE
-	I-PRGE
Î³	I-PRGE
with	O
two	O
modified	O
lysines	O
may	O
hold	O
promise	O
for	O
the	O
treatment	O
of	O
severe	O
viral	O
infections	O
with	O
fast	O
courses	O
,	O
such	O
as	O
influenza	O
and	O
the	O
diseases	O
caused	O
by	O
the	O
Ebola	O
,	O
Marburg	O
,	O
SARS	O
,	O
and	O
other	O
viruses	O
.	O

Finally	O
,	O
we	O
detected	O
greatly	O
increased	O
expression	O
of	O
GRP78	B-PRGE
(	O
78	O
kDa	O
glucose	O
-	O
regulated	O
protein	O
),	O
a	O
typical	O
marker	O
of	O
ERS	O
(	O
ER	O
stress	O
)	O
and	O
found	O
that	O
the	O
formation	O
of	O
autophagosomes	O
was	O
closely	O
related	O
to	O
the	O
expanded	O
ER	O
membrane	O
.	O

We	O
sequenced	O
the	O
TSFM	B-PRGE
gene	I-PRGE
,	O
encoding	O
the	O
mitochondrial	B-PRGE
translation	I-PRGE
factor	I-PRGE
EFTs	I-PRGE
and	O
identified	O
a	O
homozygous	O
mutation	O
changing	O
a	O
highly	O
conserved	O
arginine	O
into	O
a	O
tryptophan	O
(	O
R312W	O
).	O

ABSTRACT	O
:	O
The	O
induction	O
of	O
antigen	B-PRGE
specific	I-PRGE
memory	I-PRGE
CD8	I-PRGE
(+)	O
T	O
cells	O
in	O
vivo	O
is	O
very	O
important	O
to	O
new	O
vaccines	O
against	O
infectious	O
diseases	O
.	O

Our	O
results	O
showed	O
that	O
antigen	B-PRGE
specific	O
CD8	B-PRGE
(+)	O
T	O
cells	O
were	O
elicited	O
by	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
0201	I-PRGE
restricted	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
epitopes	I-PRGE
.	O

SARS	O
-	O
CoV	O
S	O
peptide	O
-	O
specific	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
(+)	O
CD8	B-PRGE
(+)	O
T	O
cells	O
were	O
distributed	O
throughout	O
the	O
lymphoid	O
and	O
non	O
-	O
lymphoid	O
tissues	O
.	O

Furthermore	O
,	O
these	O
T	B-PRGE
reg	I-PRGE
cells	O
express	O
both	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
after	O
peptide	O
stimulation	O
.	O

Identification	O
of	O
T	B-PRGE
reg	I-PRGE
cell	O
target	O
epitopes	O
by	O
cytokine	O
production	O
is	O
also	O
applicable	O
in	O
autoimmune	O
disease	O
because	O
myelin	B-PRGE
oligodendrocyte	I-PRGE
glycoprotein	I-PRGE
-	I-PRGE
specific	I-PRGE
Foxp3	I-PRGE
(+)	I-PRGE
T	I-PRGE
reg	I-PRGE
cells	O
express	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
at	O
the	O
peak	O
of	O
disease	O
in	O
mice	O
with	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

TITLE	O
:	O
Cell	B-PRGE
-	I-PRGE
type	I-PRGE
-	I-PRGE
specific	I-PRGE
type	I-PRGE
I	I-PRGE
interferon	I-PRGE
antagonism	O
influences	O
organ	O
tropism	O
of	O
murine	O
coronavirus	O
.	O

In	O
addition	O
,	O
mutation	O
of	O
MHV	O
nonstructural	B-PRGE
protein	I-PRGE
2	I-PRGE
(	O
ns2	B-PRGE
)	O
abrogates	O
the	O
ability	O
of	O
the	O
virus	O
to	O
replicate	O
in	O
the	O
liver	O
and	O
induce	O
hepatitis	O
but	O
does	O
not	O
affect	O
replication	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
).	O

Our	O
results	O
further	O
support	O
the	O
notion	O
that	O
viral	O
tissue	O
tropism	O
is	O
determined	O
in	O
part	O
by	O
postentry	O
events	O
,	O
including	O
the	O
early	B-PRGE
type	I-PRGE
I	I-PRGE
interferon	I-PRGE
response	O
.	O

ABSTRACT	O
:	O
Renin	B-PRGE
-	O
angiotensin	B-PRGE
II	I-PRGE
-	O
aldosterone	O
axis	O
has	O
long	O
been	O
known	O
as	O
a	O
regulator	O
of	O
blood	O
pressure	O
and	O
fluid	O
homeostasis	O
.	O

Yet	O
,	O
local	O
renin	B-PRGE
-	O
angiotensin	B-PRGE
II	I-PRGE
systems	O
have	O
been	O
discovered	O
and	O
novel	O
actions	O
of	O
angiotensin	B-PRGE
II	I-PRGE
(	O
AngII	B-PRGE
)	O
have	O
emerged	O
among	O
which	O
its	O
ability	O
to	O
act	O
as	O
a	O
immunomodulator	O
and	O
profibrotic	O
molecule	O
.	O

Moreover	O
,	O
drugs	O
that	O
inhibit	O
the	O
synthesis	O
of	O
AngII	B-PRGE
(	O
ACE	B-PRGE
inhibitors	O
)	O
or	O
that	O
antagonize	O
its	O
actions	O
on	O
its	O
receptors	O
(	O
Angiotensin	B-PRGE
II	I-PRGE
receptor	I-PRGE
blockers	O
-	O
ARBs	O
)	O
have	O
been	O
shown	O
to	O
provide	O
beneficial	O
effects	O
.	O

Another	O
recent	O
discovery	O
reviewed	O
is	O
the	O
presence	O
of	O
a	O
homologue	O
of	O
ACE	B-PRGE
,	O
ACE2	B-PRGE
,	O
which	O
cleaves	O
a	O
single	O
amino	O
acid	O
from	O
AngII	B-PRGE
and	O
forms	O
a	O
heptapeptide	O
with	O
vasodilatory	O
actions	O
,	O
Ang	B-PRGE
1	I-PRGE
-	I-PRGE
7	I-PRGE
.	O

The	O
SARS	O
VLP	O
vaccine	O
,	O
containing	O
0	O
.	O
8	O
Î¼g	O
of	O
SARS	B-PRGE
S	I-PRGE
protein	I-PRGE
,	O
completely	O
protected	O
mice	O
from	O
death	O
when	O
administered	O
intramuscular	O
(	O
IM	O
)	O
or	O
intranasal	O
(	O
IN	O
)	O
routes	O
in	O
the	O
absence	O
of	O
an	O
adjuvant	O
.	O

The	O
potential	O
for	O
re	O
-	O
emergence	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
or	O
a	O
similar	O
virus	O
with	O
unknown	O
but	O
potentially	O
serious	O
consequences	O
remains	O
high	O
.	O

Phylogenetic	O
analysis	O
of	O
a	O
conserved	O
CoV	O
genome	O
region	O
(	O
RdRp	B-PRGE
gene	I-PRGE
)	O
shows	O
a	O
wide	O
diversity	O
and	O
distribution	O
of	O
alpha	O
and	O
betacoronavirus	O
in	O
Spain	O
.	O

Antibody	O
-	O
mediated	O
infection	O
was	O
dependent	O
on	O
FcÎ³	B-PRGE
receptor	I-PRGE
II	I-PRGE
but	O
did	O
not	O
use	O
the	O
endosomal	O
/	O
lysosomal	O
pathway	O
utilized	O
by	O
angiotensin	B-PRGE
I	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
the	O
accepted	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
This	O
suggests	O
that	O
ADE	O
of	O
SARS	O
-	O
CoV	O
utilizes	O
a	O
novel	O
cell	O
entry	O
mechanism	O
into	O
immune	O
cells	O
.	O

Our	O
results	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
SARS	B-PRGE
-	O
CoV	O
can	O
enter	O
target	O
cells	O
and	O
illustrate	O
the	O
potential	O
pitfalls	O
associated	O
with	O
immunization	O
against	O
it	O
.	O

Marginal	O
nonsynonymous	O
variation	O
was	O
detected	O
in	O
spike	O
(	O
S	O
)	O
gene	O
of	O
the	O
predominant	O
population	O
of	O
IBV	O
replicating	O
in	O
the	O
testes	O
compared	O
to	O
the	O
S	B-PRGE
gene	I-PRGE
of	O
the	O
predominant	O
population	O
of	O
viruses	O
prior	O
to	O
inoculation	O
.	O

Here	O
,	O
we	O
further	O
characterized	O
the	O
S	B-PRGE
protein	I-PRGE
by	O
investigating	O
the	O
roles	O
of	O
the	O
cytoplasmic	O
tail	O
and	O
19	O
residues	O
located	O
in	O
the	O
RBD	O
in	O
protein	O
accumulation	O
,	O
receptor	O
binding	O
,	O
and	O
pseudotype	O
virus	O
entry	O
.	O

Base	B-PRGE
-	O
pairing	O
to	O
create	O
the	O
pseudoknot	O
-	O
forming	O
stem	O
(	O
P1	O
(	O
pk	O
))	O
is	O
mutually	O
exclusive	O
with	O
formation	O
of	O
stem	O
P0a	O
at	O
the	O
base	O
of	O
the	O
bulged	O
stem	O
-	O
loop	O
;	O
as	O
a	O
result	O
,	O
the	O
two	O
structures	O
cannot	O
be	O
present	O
simultaneously	O
.	O

These	O
multiple	O
-	O
spanning	O
transmembrane	O
proteins	O
located	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
where	O
they	O
generated	O
Atg5	B-PRGE
and	O
LC3II	O
-	O
positive	O
vesicles	O
,	O
and	O
vesicle	O
formation	O
was	O
dependent	O
on	O
Atg5	B-PRGE
and	O
class	B-PRGE
III	I-PRGE
PI3	I-PRGE
kinase	I-PRGE
.	O

TITLE	O
:	O
MMP9	B-PRGE
deficiency	O
does	O
not	O
decrease	O
blood	O
-	O
brain	O
barrier	O
disruption	O
,	O
but	O
increases	O
astrocyte	O
MMP3	O
expression	O
during	O
viral	O
encephalomyelitis	O
.	O

Unimpaired	O
T	O
cell	O
mediated	O
virus	O
control	O
supported	O
an	O
unexpectedly	O
redundant	O
role	O
of	O
MMP9	B-PRGE
in	O
promoting	O
leukocyte	O
access	O
to	O
the	O
brain	O
parenchyma	O
.	O

These	O
data	O
demonstrate	O
that	O
neutrophil	O
-	O
derived	O
MMP9	B-PRGE
is	O
not	O
the	O
sole	O
mediator	O
facilitating	O
parenchymal	O
leukocyte	O
entry	O
via	O
BBB	O
disruption	O
during	O
viral	O
encephalomyelitis	O
.	O

Moreover	O
,	O
significantly	O
enhanced	O
MMP3	B-PRGE
expression	O
by	O
astrocytes	O
in	O
infected	O
MMP9	O
(-/-)	O
mice	O
suggests	O
an	O
active	O
role	O
of	O
resident	O
cells	O
in	O
participating	O
and	O
potentially	O
collaborating	O
with	O
infiltrating	O
cells	O
in	O
regulating	O
BBB	O
permeability	O
.	O

The	O
results	O
will	O
help	O
to	O
identify	O
the	O
nucleolar	O
localization	O
signals	O
in	O
PEDV	B-PRGE
N	I-PRGE
protein	I-PRGE
and	O
to	O
elucidate	O
the	O
mechanism	O
of	O
N	B-PRGE
protein	I-PRGE
located	O
in	O
nucleus	O
.	O

To	O
develop	O
an	O
antigen	O
that	O
is	O
more	O
specific	O
,	O
more	O
sensitive	O
,	O
and	O
easier	O
to	O
prepare	O
for	O
serological	O
diagnosis	O
,	O
the	O
antigenic	O
sites	O
in	O
the	O
MHV	B-PRGE
-	I-PRGE
nucleocapsid	I-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
protein	I-PRGE
were	O
screened	O
in	O
this	O
study	O
.	O

The	O
expression	O
of	O
aquaporins	O
(	O
AQPs	O
)	O
1	O
,	O
AQP5	B-PRGE
,	O
and	O
estrogen	O
receptor	O
-	O
Î²	O
(	O
ERÎ²	O
)	O
was	O
measured	O
by	O
western	O
blotting	O
and	O
immunohistochemical	O
methods	O
.	O

Although	O
a	O
number	O
of	O
promising	O
potential	O
vaccines	O
and	O
therapeutic	O
agents	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
have	O
been	O
described	O
,	O
no	O
effective	O
antiviral	O
drug	O
against	O
SARS	O
-	O
CoV	O
is	O
currently	O
available	O
.	O

All	O
patients	O
presented	O
with	O
respiratory	O
symptoms	O
and	O
pulmonary	O
infiltrates	O
prior	O
to	O
AML	B-PRGE
FAB	I-PRGE
-	I-PRGE
M5	I-PRGE
diagnosis	O
.	O

In	O
recent	O
years	O
our	O
research	O
group	O
has	O
been	O
engaged	O
in	O
the	O
stucture	O
-	O
function	O
study	O
of	O
this	O
enzyme	O
and	O
in	O
the	O
development	O
of	O
some	O
three	O
-	O
dimensional	O
pharmacophore	O
models	O
which	O
have	O
led	O
to	O
the	O
identification	O
of	O
a	O
large	O
series	O
of	O
potent	O
HIV	O
-	O
1	O
integrase	B-PRGE
strand	O
-	O
transfer	O
inhibitors	O
(	O
INSTIs	O
)	O
bearing	O
an	O
indole	O
core	O
.	O

Blunt	O
chest	O
injury	O
resulted	O
in	O
the	O
activation	O
of	O
circulating	O
neutrophils	O
,	O
as	O
characterized	O
by	O
a	O
decreased	O
expression	O
of	O
l	B-PRGE
-	I-PRGE
selectin	I-PRGE
(	O
CD62L	B-PRGE
),	O
CXCR2	B-PRGE
(	O
CD182b	O
)	O
and	O
C5aR	B-PRGE
(	O
CD88	B-PRGE
)	O
compared	O
to	O
control	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Murine	O
-	O
adapted	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
MK	B-PRGE
-	I-PRGE
p10	I-PRGE
,	O
shows	O
high	O
neurovirulence	O
and	O
increased	O
fusion	O
activity	O
compared	O
with	O
a	O
non	O
-	O
adapted	O
MK	O
strain	O
.	O

We	O
expressed	O
and	O
compared	O
the	O
fusion	O
activity	O
of	O
MK	B-PRGE
-	I-PRGE
p10	I-PRGE
S	I-PRGE
,	O
S	O
with	O
the	O
H1381R	O
mutation	O
,	O
S	O
with	O
the	O
three	O
other	O
mutations	O
that	O
were	O
not	O
thought	O
to	O
be	O
involved	O
in	O
high	O
fusion	O
activity	O
,	O
and	O
the	O
original	O
S	O
protein	O
.	O

We	O
also	O
examined	O
the	O
distribution	O
of	O
these	O
S	O
proteins	O
;	O
the	O
MK	O
-	O
p10	B-PRGE
and	O
MK	O
-	O
H1381R	O
S	O
proteins	O
were	O
transported	O
onto	O
the	O
cell	O
surface	O
more	O
efficiently	O
than	O
others	O
.	O

ABSTRACT	O
:	O
Although	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
-	I-PRGE
OC43	I-PRGE
(	O
HCoV	O
-	O
OC43	O
)	O
is	O
the	O
coronavirus	O
most	O
commonly	O
associated	O
with	O
human	O
infections	O
,	O
little	O
is	O
known	O
about	O
its	O
molecular	O
epidemiology	O
and	O
evolution	O
.	O

TITLE	O
:	O
Peptide	O
aldehyde	O
inhibitors	O
challenge	O
the	O
substrate	O
specificity	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
main	I-PRGE
protease	I-PRGE
.	O

Two	O
primer	O
sets	O
were	O
used	O
for	O
the	O
detection	O
of	O
BtCoV	O
:	O
one	O
was	O
for	O
the	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
region	O
and	O
the	O
other	O
was	O
for	O
the	O
spike	O
(	O
S	O
)	O
protein	O
region	O
.	O

Eleven	O
and	O
73	O
%	O
of	O
intestinal	O
and	O
fecal	O
specimens	O
,	O
respectively	O
,	O
were	O
positive	O
for	O
RdRp	O
region	O
,	O
and	O
2	O
and	O
40	O
%	O
of	O
those	O
were	O
positive	O
for	O
S	B-PRGE
protein	I-PRGE
region	O
.	O

FHF	B-PRGE
also	O
occurs	O
in	O
acute	O
disorders	O
like	O
Reye	O
'	O
s	O
syndrome	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
heparinase	O
or	O
exogenous	O
heparin	O
prevented	O
binding	O
of	O
spike	O
protein	O
to	O
host	O
cells	O
and	O
inhibited	O
SARS	O
pseudovirus	O
infection	O
,	O
demonstrating	O
that	O
HSPGs	O
provide	O
the	O
binding	O
sites	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
invasion	O
at	O
the	O
early	O
attachment	O
phase	O
.	O

TITLE	O
:	O
The	O
2	O
-	O
thiouridylase	O
function	O
of	O
the	O
human	B-PRGE
MTU1	I-PRGE
(	O
TRMU	B-PRGE
)	O
enzyme	O
is	O
dispensable	O
for	O
mitochondrial	O
translation	O
.	O

ABSTRACT	O
:	O
MTU1	B-PRGE
(	O
TRMU	B-PRGE
)	O
is	O
a	O
mitochondrial	O
enzyme	O
responsible	O
for	O
the	O
2	O
-	O
thiolation	O
of	O
the	O
wobble	O
U	O
in	O
tRNA	O
(	O
Lys	O
),	O
tRNA	O
(	O
Glu	O
)	O
and	O
tRNA	O
(	O
Gln	O
),	O
a	O
post	O
-	O
transcriptional	O
modification	O
believed	O
to	O
be	O
important	O
for	O
accurate	O
and	O
efficient	O
synthesis	O
of	O
the	O
13	O
respiratory	O
chain	O
subunits	O
encoded	O
by	O
mtDNA	O
.	O

Further	O
,	O
the	O
SNP	O
rs2248690	O
affected	O
the	O
transcriptional	O
activity	O
of	O
the	O
AHSG	B-PRGE
promoter	I-PRGE
and	O
thus	O
regulated	O
the	O
AHSG	O
serum	O
level	O
.	O

Another	O
TGEV	O
strain	O
,	O
TGEV	O
Miller	O
,	O
and	O
IBV	O
Beaudette	O
showed	O
a	O
reduction	O
in	O
infectivity	O
after	O
neuraminidase	B-PRGE
treatment	O
of	O
the	O
cultured	O
cells	O
irrespective	O
of	O
the	O
virion	O
adsorption	O
time	O
.	O

Our	O
results	O
confirm	O
and	O
extend	O
our	O
previous	O
findings	O
and	O
conclusions	O
that	O
swapping	O
of	O
the	O
ectodomain	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
is	O
a	O
precise	O
and	O
effective	O
way	O
of	O
generating	O
genetically	O
defined	O
candidate	O
IBV	O
vaccines	O
.	O

Suppression	O
of	O
the	O
ATR	B-PRGE
kinase	I-PRGE
activity	O
by	O
chemical	O
inhibitors	O
and	O
siRNA	O
-	O
mediated	O
knockdown	O
of	O
ATR	O
reduced	O
the	O
IBV	O
-	O
induced	O
ATR	O
signaling	O
and	O
inhibited	O
the	O
replication	O
of	O
IBV	O
.	O

Furthermore	O
,	O
yeast	O
two	O
-	O
hybrid	O
screens	O
and	O
subsequent	O
biochemical	O
and	O
functional	O
studies	O
demonstrated	O
that	O
interaction	O
between	O
Coronavirus	O
nsp13	O
and	O
DNA	B-PRGE
polymerase	I-PRGE
Î´	I-PRGE
induced	O
DNA	O
replication	O
stress	O
in	O
IBV	O
-	O
infected	O
cells	O
.	O

TITLE	O
:	O
Annexin	B-PRGE
A2	I-PRGE
binds	O
RNA	O
and	O
reduces	O
the	O
frameshifting	O
efficiency	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

Here	O
,	O
we	O
identified	O
ANXA2	B-PRGE
as	O
a	O
RNA	B-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
RBP	B-PRGE
)	O
that	O
binds	O
IBV	O
(	O
Infectious	O
Bronchitis	O
Virus	O
)	O
pseudoknot	O
RNA	O
.	O

Of	O
the	O
several	O
SARS	B-PRGE
CoV	I-PRGE
structural	I-PRGE
proteins	I-PRGE
,	O
the	O
nucleocapsid	O
protein	O
has	O
been	O
shown	O
to	O
be	O
a	O
good	O
diagnostic	O
marker	O
.	O

Replication	O
of	O
picornaviruses	O
and	O
coronaviruses	O
requires	O
3Cpro	O
(	O
3C	O
protease	O
)	O
and	O
3CLpro	O
(	O
3C	O
-	O
like	O
protease	O
)	O
respectively	O
,	O
which	O
are	O
structurally	O
analogous	O
with	O
chymotrypsin	B-PRGE
-	O
fold	O
,	O
but	O
the	O
former	O
is	O
a	O
monomer	O
and	O
the	O
latter	O
is	O
dimeric	O
due	O
to	O
an	O
extra	O
third	O
domain	O
for	O
dimerization	O
.	O

A	O
specific	O
therapy	O
by	O
intravenous	O
polyvalent	B-PRGE
immunoglobulin	I-PRGE
was	O
prescribed	O
for	O
14	O
patients	O
.	O

Although	O
activation	O
of	O
NF	B-PRGE
-	I-PRGE
ÎºB	I-PRGE
and	I-PRGE
Erk	I-PRGE
MAPK	I-PRGE
has	O
been	O
implicated	O
for	O
HSV	O
replication	O
and	O
growth	O
,	O
HCWE	O
showed	O
no	O
effect	O
on	O
HSV	O
-	O
2	O
-	O
induced	O
Erk	B-PRGE
activation	O
.	O

Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
Î±	I-PRGE
was	O
significantly	O
elevated	O
in	O
all	O
types	O
of	O
organ	O
failures	O
,	O
except	O
for	O
intestinal	O
failure	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
commonly	O
produced	O
during	O
viral	O
infection	O
specifically	O
augments	O
a	O
proinflammatory	O
response	O
by	O
directly	O
synergizing	O
with	O
antiviral	O
signaling	O
.	O

Activation	O
of	O
viral	O
glycoprotein	B-PRGE
(	O
GP	O
)	O
by	O
protease	O
also	O
has	O
been	O
reported	O
for	O
influenza	O
virus	O
.	O

The	O
eyes	O
are	O
typically	O
involved	O
in	O
TEN	B-PRGE
.	O

Here	O
,	O
we	O
analyzed	O
the	O
role	O
of	O
the	O
type	B-PRGE
II	I-PRGE
transmembrane	I-PRGE
serine	I-PRGE
proteases	I-PRGE
(	O
TTSPs	O
)	O
human	B-PRGE
airway	I-PRGE
trypsin	O
-	O
like	O
protease	O
(	O
HAT	B-PRGE
)	O
and	O
transmembrane	O
protease	O
,	O
serine	B-PRGE
2	I-PRGE
(	O
TMPRSS2	B-PRGE
),	O
in	O
SARS	O
-	O
S	O
activation	O
.	O

A	O
fourth	O
genus	O
,	O
Deltacoronavirus	O
,	O
which	O
includes	O
bulbul	O
coronavirus	O
HKU11	O
,	O
thrush	B-PRGE
coronavirus	I-PRGE
HKU12	I-PRGE
and	I-PRGE
munia	I-PRGE
coronavirus	I-PRGE
HKU13	I-PRGE
,	O
is	O
emerging	O
.	O

We	O
used	O
the	O
SARS	O
-	O
CoV	O
apo	B-PRGE
X	I-PRGE
-	O
ray	O
structure	O
to	O
develop	O
a	O
model	O
of	O
the	O
NL63	B-PRGE
-	I-PRGE
PLP2	I-PRGE
catalytic	I-PRGE
site	I-PRGE
.	O

TITLE	O
:	O
Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
insertion	O
/	O
deletion	O
polymorphism	O
is	O
associated	O
with	O
severe	O
hypoxemia	O
in	O
pediatric	O
ARDS	O
.	O

These	O
data	O
do	O
not	O
support	O
the	O
association	O
between	O
ACE	B-PRGE
I	I-PRGE
/	I-PRGE
D	I-PRGE
genotype	I-PRGE
and	O
ARDS	O
,	O
although	O
severe	O
hypoxemia	O
was	O
less	O
frequent	O
in	O
D	O
allele	O
carriers	O
.	O

ACE	B-PRGE
I	I-PRGE
/	I-PRGE
D	I-PRGE
polymorphism	I-PRGE
modified	O
angiotensin	O
-	O
II	O
levels	O
in	O
pediatric	O
ARDS	O
,	O
but	O
its	O
pathogenic	O
role	O
is	O
not	O
well	O
understood	O
and	O
needs	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

Intravenous	O
administration	O
of	O
immunoglobulin	B-PRGE
resolved	O
her	O
potentially	O
life	O
-	O
threatening	O
autonomic	O
instability	O
.	O

TITLE	O
:	O
Crosstalk	O
between	O
innate	O
and	O
adaptive	O
immune	O
responses	O
to	O
infectious	O
bronchitis	O
virus	O
after	O
vaccination	O
and	O
challenge	O
of	O
chickens	O
varying	O
in	O
serum	O
mannose	B-PRGE
-	I-PRGE
binding	I-PRGE
lectin	I-PRGE
concentrations	O
.	O

MBL	B-PRGE
selectively	O
binds	O
distinct	O
chemical	O
patterns	O
,	O
including	O
carbohydrates	O
expressed	O
on	O
all	O
kinds	O
of	O
pathogens	O
.	O

Sequencing	O
of	O
the	O
hypervariable	O
region	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
of	O
the	O
kidney	O
IBV	O
isolate	O
,	O
designated	O
IBV	O
/	O
CA99variant	O
/	O
07	O
,	O
revealed	O
that	O
the	O
virus	O
was	O
98	O
%	O
homologous	O
to	O
the	O
Cal99	O
serotype	O
of	O
IBV	O
.	O

Compared	O
to	O
H120	O
vaccine	O
strain	O
,	O
point	O
mutation	O
,	O
short	O
insertion	O
,	O
and	O
deletion	O
occurred	O
at	O
many	O
positions	O
in	O
the	O
S1	B-PRGE
protein	I-PRGE
of	O
the	O
seven	O
strains	O
.	O

The	O
homology	O
of	O
the	O
nucleotide	O
and	O
amino	O
acid	O
sequences	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
among	O
the	O
seven	O
isolates	O
was	O
81	O
.	O
7	O
%-	O
99	O
.	O
7	O
%	O
and	O
79	O
.	O
0	O
%-	O
99	O
.	O
4	O
%,	O
respectively	O
.	O

Phylogenetic	O
analysis	O
on	O
a	O
527	O
base	O
pair	O
-	O
long	O
region	O
from	O
the	O
NS1	B-PRGE
gene	I-PRGE
revealed	O
two	O
main	O
clusters	O
,	O
a	O
chicken	O
parvovirus	O
(	O
ChPV	O
)	O
and	O
a	O
TuPV	O
group	O
,	O
but	O
also	O
the	O
presence	O
of	O
a	O
divergent	O
branch	O
of	O
tentatively	O
named	O
""""	O
TuPV	O
-	O
like	O
ChPV	O
""""	O
strains	O
.	O

We	O
found	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp16	I-PRGE
MTase	I-PRGE
methylated	O
m7GpppA	O
-	O
RNA	O
but	O
not	O
m7GpppG	O
-	O
RNA	O
,	O
which	O
is	O
in	O
contrast	O
with	O
nsp14	B-PRGE
MTase	I-PRGE
that	O
functions	O
in	O
a	O
sequence	O
-	O
independent	O
manner	O
.	O

Urine	O
sTREM	O
-	O
1	O
and	O
serum	O
PCT	O
levels	O
continuously	O
increased	O
among	O
non	O
-	O
survivors	O
,	O
while	O
WBC	O
and	O
serum	O
CRP	B-PRGE
levels	O
in	O
both	O
groups	O
declined	O
.	O

For	O
17	O
patients	O
with	O
AKI	O
,	O
urine	O
sTREM	O
-	O
1	O
,	O
SCr	B-PRGE
and	O
BUN	O
levels	O
at	O
48	O
h	O
before	O
AKI	O
diagnosis	O
were	O
higher	O
,	O
and	O
CCr	O
level	O
was	O
lower	O
than	O
those	O
for	O
non	O
-	O
AKI	B-PRGE
subjects	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
virus	O
(	O
SARS	O
-	O
CoV	O
)	O
that	O
lacks	O
the	O
envelope	B-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
gene	I-PRGE
(	O
rSARS	O
-	O
CoV	O
-	O
ÎE	O
)	O
is	O
attenuated	O
in	O
vivo	O
.	O

Administration	O
of	O
E	B-PRGE
protein	I-PRGE
in	O
trans	O
reduced	O
the	O
stress	O
response	O
in	O
cells	O
infected	O
with	O
rSARS	O
-	O
CoV	O
-	O
ÎE	O
or	O
with	O
respiratory	O
syncytial	O
virus	O
,	O
or	O
treated	O
with	O
drugs	O
,	O
such	O
as	O
tunicamycin	O
and	O
thapsigargin	O
that	O
elicit	O
cell	O
stress	O
by	O
different	O
mechanisms	O
.	O

The	O
current	O
study	O
investigated	O
the	O
ability	O
of	O
aerosolized	O
extracellular	O
superoxide	B-PRGE
dismutase	I-PRGE
(	O
EC	B-PRGE
-	I-PRGE
SOD	I-PRGE
)	O
to	O
protect	O
the	O
lungs	O
from	O
hyperoxic	O
injury	O
.	O

In	O
enzyme	O
assays	O
,	O
1m	O
,	O
2h	O
,	O
5m	O
and	O
5n	O
proved	O
to	O
be	O
potent	O
inhibitors	O
of	O
the	O
BVDV	B-PRGE
RNA	I-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
),	O
while	O
only	O
2h	O
also	O
inhibited	O
the	O
recombinant	O
HCV	O
enzyme	O
.	O

Despite	O
3CL	O
(	O
pro	O
)	O
from	O
different	O
groups	O
of	O
CoVs	O
share	O
many	O
similarities	O
in	O
substrate	O
specificities	O
,	O
differences	O
in	O
substrate	O
specificities	O
were	O
observed	O
at	O
P4	O
positions	O
,	O
with	O
IBV	O
3CL	O
(	O
pro	O
)	O
prefers	O
P4	B-PRGE
-	I-PRGE
Pro	I-PRGE
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
)	O
prefers	O
P4	O
-	O
Val	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
levels	O
of	O
secreted	O
IgA	B-PRGE
decreased	O
significantly	O
at	O
42	O
d	O
of	O
age	O
in	O
the	O
chickens	O
that	O
were	O
treated	O
with	O
LPS	O
or	O
CPM	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
n	O
our	O
previous	O
study	O
,	O
we	O
have	O
shown	O
that	O
canine	B-PRGE
coronavirus	I-PRGE
type	I-PRGE
II	I-PRGE
(	O
CCoV	O
-	O
II	O
)	O
activates	O
both	O
extrinsic	O
and	O
intrinsic	O
apoptotic	O
pathway	O
in	O
a	O
canine	O
fibrosarcoma	O
cell	O
line	O
(	O
A	O
-	O
72	O
cells	O
).	O

In	O
addition	O
,	O
CCoV	O
-	O
II	O
induces	O
a	O
remarkable	O
increase	O
in	O
the	O
expression	O
of	O
TNF	B-PRGE
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
),	O
while	O
we	O
observed	O
a	O
slight	O
up	O
-	O
regulation	O
of	O
FasL	B-PRGE
/	O
Fas	B-PRGE
at	O
36	O
p	O
.	O
i	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
coronavirus	O
RNA	O
-	O
dependent	O
RNA	B-PRGE
polymerase	I-PRGE
and	O
nonstructural	O
proteins	O
2	O
,	O
3	O
,	O
and	O
8	O
are	O
incorporated	O
into	O
viral	O
particles	O
.	O

The	O
innate	O
immune	O
response	O
of	O
AMs	O
to	O
HCoV	O
-	O
229E	O
infection	O
was	O
evaluated	O
for	O
cytokine	O
production	O
and	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
gene	O
expression	O
.	O

Nonstructural	O
proteins	O
include	O
the	O
small	O
accessory	O
proteins	O
that	O
are	O
not	O
at	O
all	O
conserved	O
between	O
MHV	O
and	O
SARS	O
-	O
CoV	O
and	O
the	O
16	O
conserved	O
proteins	O
encoded	O
in	O
the	O
replicase	B-PRGE
locus	I-PRGE
,	O
many	O
of	O
which	O
have	O
enzymatic	O
activities	O
in	O
RNA	O
metabolism	O
or	O
protein	O
processing	O
in	O
addition	O
to	O
functions	O
in	O
antagonizing	O
host	O
response	O
.	O

After	O
exercise	O
,	O
the	O
peak	O
level	O
of	O
TBARS	O
significantly	O
increased	O
in	O
groups	O
II	O
,	O
III	O
and	O
IV	O
,	O
and	O
the	O
variations	O
in	O
HSP27	B-PRGE
and	O
HSP70	B-PRGE
were	O
attenuated	O
or	O
suppressed	O
,	O
with	O
the	O
greatest	O
effects	O
in	O
groups	O
III	O
and	O
IV	O
.	O

CONCLUSIONS	O
:	O
The	O
presence	O
of	O
stress	O
factors	O
in	O
the	O
history	O
of	O
CFS	O
patients	O
is	O
associated	O
with	O
severe	O
oxidative	O
stress	O
and	O
the	O
suppression	O
of	O
protective	O
HSP27	B-PRGE
and	O
HSP70	B-PRGE
responses	O
to	O
exercise	O
.	O

TITLE	O
:	O
High	O
-	O
level	O
mucosal	O
and	O
systemic	O
immune	O
responses	O
induced	O
by	O
oral	O
administration	O
with	O
Lactobacillus	O
-	O
expressed	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
S1	O
region	O
combined	O
with	O
Lactobacillus	O
-	O
expressed	O
N	B-PRGE
protein	I-PRGE
.	O

Taken	O
together	O
,	O
Lc	O
-	O
expressed	O
N	B-PRGE
protein	I-PRGE
as	O
molecular	O
adjuvant	O
or	O
immunoenhancer	O
was	O
able	O
to	O
effectively	O
facilitate	O
the	O
induction	O
of	O
mucosal	O
and	O
systemic	O
immune	O
responses	O
by	O
Lc	O
-	O
expressing	O
S1	O
region	O
.	O

Cell	B-PRGE
adhesion	I-PRGE
molecules	I-PRGE
were	O
expressed	O
at	O
higher	O
levels	O
in	O
FXR	B-PRGE
-/-	O
mice	O
as	O
compared	O
with	O
control	O
mice	O
.	O

The	O
analysis	O
of	O
cytopathic	O
effects	O
(	O
CPE	O
)	O
demonstrated	O
that	O
shN2	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
shN2	B-PRGE
-	I-PRGE
2	I-PRGE
were	O
capable	O
of	O
protecting	O
cells	O
against	O
PHEV	O
infection	O
with	O
high	O
specificity	O
and	O
efficiency	O
.	O

A	O
yeast	O
-	O
based	O
assay	O
was	O
established	O
for	O
PLP	B-PRGE
activity	O
that	O
relies	O
on	O
the	O
ability	O
of	O
PLP	B-PRGE
to	O
induce	O
a	O
pronounced	O
slow	O
-	O
growth	O
phenotype	O
when	O
expressed	O
in	O
S	O
.	O
cerevisiae	O
.	O

Induction	O
of	O
the	O
slow	O
-	O
growth	O
phenotype	O
was	O
shown	O
to	O
take	O
place	O
over	O
a	O
60	O
-	O
hour	O
time	O
course	O
,	O
providing	O
the	O
basis	O
for	O
conducting	O
a	O
screen	O
for	O
small	O
molecules	O
that	O
restore	O
growth	O
by	O
inhibiting	O
the	O
function	O
of	O
PLP	B-PRGE
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
the	O
BToV	O
nucleocapsid	O
,	O
spike	O
,	O
and	O
hemagglutinin	B-PRGE
-	I-PRGE
esterase	I-PRGE
(	O
HE	O
)	O
genes	O
revealed	O
a	O
close	O
relatedness	O
among	O
the	O
detected	O
BToV	O
strains	O
from	O
each	O
outbreak	O
and	O
those	O
of	O
Japanese	O
BToV	O
strain	O
Aichi	O
/	O
2004	O
.	O

In	O
addition	O
,	O
our	O
findings	O
indicate	O
that	O
the	O
HE	B-PRGE
protein	I-PRGE
of	O
BToV	O
may	O
not	O
be	O
necessary	O
for	O
viral	O
replication	O
.	O

For	O
the	O
5	O
years	O
following	O
the	O
initial	O
treatment	O
for	O
SLE	O
,	O
the	O
patient	O
experienced	O
a	O
number	O
of	O
infections	O
and	O
had	O
a	O
low	O
serum	O
total	O
IgG	B-PRGE
level	O
;	O
she	O
was	O
eventually	O
diagnosed	O
with	O
CVID	O
.	O

MPO	B-PRGE
(-/-)	O
mice	O
also	O
suppressed	O
viral	O
load	O
in	O
the	O
lung	O
.	O

The	O
physical	O
interaction	O
between	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
and	I-PRGE
cellular	I-PRGE
pyruvate	I-PRGE
kinase	I-PRGE
(	O
liver	O
)	O
proteins	O
was	O
further	O
confirmed	O
by	O
GST	B-PRGE
pull	O
-	O
down	O
assay	O
,	O
co	O
-	O
immunoprecipitation	O
assay	O
and	O
confocal	O
microscopy	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
SARS	O
-	O
CoV	O
could	O
reduce	O
pyruvate	B-PRGE
kinase	I-PRGE
activity	O
via	O
its	O
nucleocapsid	O
protein	O
,	O
and	O
this	O
may	O
in	O
turn	O
cause	O
disease	O
.	O

They	O
were	O
panned	O
against	O
different	O
HIV	O
-	O
1	O
envelope	B-PRGE
glycoproteins	I-PRGE
(	O
Envs	O
),	O
SARS	B-PRGE
CoV	I-PRGE
protein	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
RBD	O
),	O
and	O
soluble	O
Hendra	O
virus	O
G	O
protein	O
(	O
sG	O
).	O

Despite	O
a	O
high	O
sequence	O
and	O
combinatorial	O
diversity	O
observed	O
in	O
the	O
cord	O
blood	O
-	O
derived	O
IgM	B-PRGE
antibody	O
repertoire	O
,	O
no	O
enrichment	O
for	O
binders	O
of	O
Envs	O
was	O
observed	O
in	O
contrast	O
to	O
considerable	O
specific	O
enrichments	O
produced	O
with	O
panning	O
against	O
RBD	O
and	O
sG	O
;	O
one	O
of	O
the	O
selected	O
monoclonal	O
antibodies	O
(	O
against	O
the	O
RBD	O
)	O
was	O
of	O
high	O
(	O
nM	O
)	O
affinity	O
with	O
only	O
few	O
somatic	O
mutations	O
.	O

These	O
results	O
further	O
support	O
and	O
expand	O
our	O
initial	O
hypothesis	O
for	O
fundamental	O
differences	O
in	O
immune	O
responses	O
leading	O
to	O
elicitation	O
of	O
bnAbs	O
against	O
HIV	O
-	O
1	O
compared	O
to	O
SARS	B-PRGE
CoV	I-PRGE
and	O
Hendra	O
virus	O
.	O

When	O
comparing	O
the	O
baseline	O
cytokine	O
production	O
prior	O
to	O
microbial	O
stimulation	O
,	O
we	O
observed	O
that	O
cord	O
plasmacytoid	O
DC	O
were	O
stronger	O
inducers	O
of	O
Th2	B-PRGE
cytokines	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
)	O
compared	O
with	O
cord	O
myeloid	O
DC	O
and	O
to	O
adult	O
DC	O
.	O

TITLE	O
:	O
Human	B-PRGE
serum	I-PRGE
albumin	I-PRGE
:	O
from	O
bench	O
to	O
bedside	O
.	O

TITLE	O
:	O
PEDV	B-PRGE
ORF3	I-PRGE
encodes	O
an	O
ion	B-PRGE
channel	I-PRGE
protein	I-PRGE
and	O
regulates	O
virus	O
production	O
.	O

ACE2	B-PRGE
,	O
a	O
recently	O
discovered	O
ACE	B-PRGE
homologue	O
,	O
acts	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
RAS	O
and	O
counterbalances	O
the	O
function	O
of	O
ACE	B-PRGE
.	O

Compared	O
with	O
ACE2	O
(-/	O
y	O
)	O
exposed	O
to	O
BLM	O
,	O
ACE2	O
(-/-)	O
exhibited	O
better	O
lung	O
function	O
and	O
architecture	O
and	O
decreased	O
collagen	B-PRGE
deposition	O
.	O

Female	O
BLM	O
WT	O
mice	O
had	O
mild	O
fibrosis	O
and	O
displayed	O
a	O
possible	O
compensatory	O
upregulation	O
of	O
the	O
AT2	B-PRGE
receptor	I-PRGE
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
a	O
new	O
function	O
for	O
PI4KB	B-PRGE
and	O
suggest	O
a	O
new	O
drug	O
target	O
for	O
preventing	O
SARS	O
-	O
CoV	O
infection	O
.	O

Among	O
them	O
,	O
accessory	O
protein	O
3b	O
(	O
also	O
known	O
as	O
ORF4	O
)	O
was	O
lately	O
identified	O
as	O
one	O
of	O
the	O
viral	B-PRGE
interferon	I-PRGE
antagonist	O
.	O

Chromatin	O
immunoprecipitaion	O
(	O
ChIP	O
)	O
and	O
reporter	O
gene	O
assays	O
in	O
3b	O
expressing	O
jurkat	O
cells	O
showed	O
recruitment	O
of	O
3b	O
on	O
the	O
RUNX1	B-PRGE
binding	I-PRGE
element	I-PRGE
that	O
led	O
to	O
an	O
increase	O
in	O
RUNX1b	O
transactivation	O
potential	O
on	O
the	O
IL2	B-PRGE
promoter	I-PRGE
.	O

On	O
human	O
cells	O
both	O
viruses	O
utilize	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
as	O
entry	O
receptor	O
.	O

(	O
438	O
)	O
YKYRYL	O
(	O
443	O
)	O
carries	O
the	O
dominant	B-PRGE
binding	I-PRGE
epitope	I-PRGE
and	O
binds	O
to	O
ACE2	B-PRGE
with	O
K	O
(	O
D	O
)=	O
46	O
Î¼M	O
.	O
The	O
binding	O
mode	O
was	O
further	O
characterized	O
by	O
saturation	O
transfer	O
difference	O
(	O
STD	O
)	O
NMR	O
spectroscopy	O
and	O
molecular	O
dynamic	O
simulations	O
.	O

Exposure	O
to	O
alcohol	O
reduced	O
alveolar	O
fluid	O
clearance	O
,	O
downregulated	O
Na	O
,	O
K	B-PRGE
-	I-PRGE
ATPase	I-PRGE
in	O
the	O
lung	O
tissue	O
and	O
worsened	O
hyperoxia	O
-	O
induced	O
lung	O
injury	O
.	O

The	O
endoribonuclease	O
activity	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
Nsp15	I-PRGE
(	O
sNsp15	O
)	O
was	O
stimulated	O
by	O
retinoblastoma	B-PRGE
protein	I-PRGE
(	O
pRb	B-PRGE
)	O
in	O
vitro	O
,	O
and	O
the	O
two	O
proteins	O
can	O
be	O
coimmunoprecipitated	O
from	O
cellular	O
extracts	O
.	O

This	O
study	O
reveals	O
that	O
pRb	B-PRGE
and	O
its	O
interaction	O
with	O
Nsp15	O
can	O
affect	O
coronavirus	O
infection	O
and	O
adds	O
coronaviruses	O
to	O
a	O
small	O
but	O
growing	O
family	O
of	O
RNA	O
viruses	O
that	O
encode	O
a	O
protein	O
to	O
interact	O
with	O
pRb	B-PRGE
.	O

Although	O
CoV	O
-	O
HKU1	O
was	O
not	O
identified	O
in	O
any	O
of	O
the	O
studied	O
animals	O
,	O
a	O
coronavirus	O
closely	O
related	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
bat	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
was	O
identified	O
in	O
23	O
(	O
19	O
%)	O
of	O
118	O
wild	O
Chinese	O
horseshoe	O
bats	O
by	O
reverse	O
transcriptase	B-PRGE
polymerase	I-PRGE
chain	I-PRGE
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Use	O
of	O
a	O
selective	O
inhibitor	O
of	O
CXCR2	B-PRGE
,	O
SB265610	O
,	O
demonstrated	O
that	O
CXCR2	B-PRGE
signaling	O
was	O
required	O
for	O
RCoV	O
-	O
AT1	B-PRGE
-	O
mediated	O
inhibition	O
of	O
PMN	O
apoptosis	O
.	O

The	O
FCoV	O
/	O
FIP	B-PRGE
-	O
free	O
status	O
of	O
the	O
Falkland	O
Islands	O
cats	O
should	O
be	O
maintained	O
by	O
FCoV	O
testing	O
incoming	O
cats	O
.	O

We	O
used	O
conditional	O
targeting	O
of	O
pDC	B-PRGE
-	I-PRGE
specific	I-PRGE
transcription	I-PRGE
factor	I-PRGE
E2	I-PRGE
-	I-PRGE
2	I-PRGE
to	O
generate	O
mice	O
that	O
constitutively	O
lack	O
pDCs	O
in	O
peripheral	O
lymphoid	O
organs	O
and	O
tissues	O
.	O

These	O
data	O
suggest	O
that	O
pDCs	O
facilitate	O
CD4	B-PRGE
(+)	O
helper	O
T	O
-	O
cell	O
responses	O
to	O
persistent	O
viruses	O
independently	O
of	O
direct	O
antigen	O
presentation	O
.	O

Patients	O
with	O
""""	O
de	O
novo	O
""""	O
ARF	B-PRGE
failed	O
NIV	O
more	O
frequently	O
than	O
patients	O
with	O
previous	O
cardiac	O
or	O
respiratory	O
disease	O
(	O
47	O
,	O
46	O
%	O
versus	O
21	O
,	O
26	O
%,	O
p	O
=	O
0	O
.	O
007	O
).	O

If	O
predictors	O
for	O
NIV	O
failure	O
are	O
present	O
,	O
avoiding	O
delayed	O
intubation	O
of	O
patients	O
with	O
""""	O
de	O
novo	O
""""	O
ARF	B-PRGE
would	O
potentially	O
minimise	O
mortality	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
prepared	O
full	O
-	O
length	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
NP	I-PRGE
expressed	O
in	O
Escherichia	O
coli	O
and	O
purified	O
.	O

Full	O
-	O
length	O
NP	O
was	O
used	O
for	O
the	O
preparation	O
of	O
mouse	B-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
and	I-PRGE
chicken	I-PRGE
polyclonal	I-PRGE
IgY	I-PRGE
antibodies	I-PRGE
for	O
the	O
development	O
of	O
heterosandwich	O
ELISA	O
for	O
early	O
diagnostics	O
of	O
SARS	O
-	O
suspected	O
individuals	O
.	O

In	O
addition	O
,	O
TGEV	O
infection	O
down	O
-	O
regulated	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
up	O
-	O
regulated	O
Bax	B-PRGE
expression	O
,	O
promoted	O
translocation	O
of	O
Bax	B-PRGE
to	O
mitochondria	O
,	O
activated	O
mitochondria	O
-	O
mediated	O
apoptotic	O
pathway	O
,	O
which	O
in	O
turn	O
caused	O
the	O
release	O
of	O
cytochrome	B-PRGE
c	I-PRGE
and	O
the	O
activation	O
of	O
caspase	B-PRGE
-	I-PRGE
9	I-PRGE
.	O

Analysis	O
of	O
multiple	O
CoV	B-PRGE
nsp5	I-PRGE
structures	O
,	O
and	O
alignment	O
of	O
nonredundant	O
nsp5	B-PRGE
primary	O
sequences	O
,	O
demonstrated	O
that	O
ts	O
and	O
suppressor	O
residues	O
are	O
not	O
conserved	O
across	O
CoVs	O
and	O
are	O
physically	O
distant	O
(>	O
10	O
Ã	O
)	O
from	O
each	O
other	O
,	O
from	O
catalytic	O
and	O
substrate	O
-	O
binding	O
residues	O
,	O
and	O
from	O
the	O
nsp5	B-PRGE
dimer	I-PRGE
interface	I-PRGE
.	O

These	O
findings	O
demonstrate	O
that	O
long	O
-	O
distance	O
communication	O
pathways	O
between	O
multiple	O
residues	O
and	O
domains	O
of	O
nsp5	B-PRGE
play	O
a	O
significant	O
role	O
in	O
nsp5	B-PRGE
activity	O
and	O
viral	O
replication	O
,	O
suggesting	O
possible	O
novel	O
targets	O
for	O
non	O
-	O
active	O
site	O
inhibitors	O
of	O
nsp5	B-PRGE
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
drug	O
FK506	O
(	O
Tacrolimus	O
)	O
inhibited	O
strongly	O
the	O
growth	O
of	O
human	B-PRGE
coronaviruses	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
229E	O
at	O
low	O
,	O
non	O
-	O
cytotoxic	O
concentrations	O
in	O
cell	O
culture	O
.	O

The	O
new	O
assay	O
combines	O
the	O
M	B-PRGE
gene	I-PRGE
subgenomic	O
messenger	O
RNA	O
(	O
sg	O
-	O
mRNA	O
)	O
detection	O
and	O
the	O
quantitation	O
of	O
the	O
genome	O
copies	O
of	O
FCoV	O
.	O
In	O
order	O
to	O
detect	O
the	O
broadest	O
spectrum	O
of	O
potential	O
FCoV	O
variants	O
and	O
to	O
achieve	O
the	O
most	O
accurate	O
results	O
in	O
the	O
detection	O
ability	O
the	O
new	O
assay	O
is	O
applying	O
the	O
primer	O
-	O
probe	O
energy	O
transfer	O
(	O
PriProET	O
)	O
principle	O
.	O

The	O
RNA	O
-	O
binding	O
domain	O
was	O
mapped	O
to	O
the	O
N	O
-	O
terminal	O
region	O
of	O
MADP1	B-PRGE
and	O
the	O
protein	O
binding	O
sequence	O
to	O
stem	O
-	O
loop	O
I	O
of	O
IBV	O
5	O
'-	O
UTR	O
.	O

Thus	O
,	O
short	O
-	O
term	O
paired	O
IgM	B-PRGE
serologic	O
tests	O
may	O
be	O
mandatory	O
for	O
an	O
early	O
and	O
definitive	O
diagnosis	O
.	O

We	O
report	O
the	O
first	O
case	O
of	O
BTHS	O
confirmed	O
by	O
TAZ	B-PRGE
gene	I-PRGE
analysis	O
in	O
a	O
female	O
patient	O
.	O

TITLE	O
:	O
Biflavonoids	O
of	O
Dacrydium	O
balansae	O
with	O
potent	O
inhibitory	O
activity	O
on	O
dengue	B-PRGE
2	I-PRGE
NS5	I-PRGE
polymerase	I-PRGE
.	O

Characterization	O
of	O
the	O
plaques	O
produced	O
by	O
recSARS	O
-	O
CoV	O
showed	O
that	O
they	O
were	O
similar	O
in	O
size	O
to	O
the	O
parental	O
SARS	O
-	O
CoV	O
isolate	O
HKU	O
-	O
39849	O
but	O
smaller	O
than	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
isolate	I-PRGE
Frankfurt	I-PRGE
-	I-PRGE
1	I-PRGE
.	O

Using	O
this	O
approach	O
,	O
we	O
demonstrate	O
that	O
,	O
in	O
contrast	O
to	O
HCoV	O
-	O
229E	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
not	O
able	O
to	O
mediate	O
efficient	O
heterologous	O
gene	O
expression	O
in	O
hDCs	O
.	O

Furthermore	O
,	O
levels	O
of	O
T1	O
-	O
Î±	O
(	O
a	O
membrane	O
protein	O
of	O
alveolar	O
type	O
I	O
epithelium	O
)	O
and	O
thrombomodulin	B-PRGE
(	O
an	O
endothelial	O
protein	O
)	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
were	O
evaluated	O
by	O
Western	O
blot	O
analysis	O
.	O

Feline	O
leukemia	B-PRGE
virus	I-PRGE
p27	I-PRGE
antigen	I-PRGE
was	O
detected	O
in	O
13	O
/	O
50	O
serum	O
/	O
lung	O
tissue	O
extract	O
samples	O
(	O
26	O
%),	O
canine	O
distemper	O
virus	O
antibodies	O
were	O
detected	O
in	O
2	O
/	O
26	O
serum	O
/	O
lung	O
tissue	O
extract	O
samples	O
(	O
7	O
.	O
7	O
%),	O
feline	O
coronavirus	O
RNA	O
was	O
present	O
in	O
6	O
/	O
29	O
stool	O
samples	O
(	O
20	O
.	O
7	O
%)	O
and	O
feline	O
parvovirus	O
DNA	O
in	O
2	O
/	O
29	O
stool	O
samples	O
(	O
6	O
.	O
9	O
%).	O

Various	O
samples	O
including	O
spleen	O
,	O
liver	O
and	O
lymphocytes	O
from	O
mice	O
of	O
two	O
model	O
groups	O
and	O
the	O
controls	O
were	O
examined	O
for	O
KCTD9	B-PRGE
expression	O
by	O
real	O
time	O
quantitative	O
PCR	O
and	O
Immunohistochemistry	O
.	O

A	O
novel	O
potassium	O
channel	O
gene	O
KCTD9	B-PRGE
was	O
highly	O
expressed	O
in	O
hepatic	O
NK	O
cells	O
and	O
T	O
cells	O
of	O
fulminant	O
hepatitis	O
mice	O
induced	O
by	O
MHV	O
-	O
3	O
.	O

RESULTS	O
:	O
Increased	O
expressions	O
of	O
KCTD9	B-PRGE
mRNA	I-PRGE
was	O
observed	O
in	O
livers	O
of	O
both	O
model	O
mice	O
of	O
fulminant	O
viral	O
hepatitis	O
and	O
chronic	O
hepatitis	O
.	O

There	O
was	O
also	O
poor	O
agreement	O
between	O
the	O
LAT	B-PRGE
and	O
qRT	O
-	O
PCR	O
assays	O
.	O

TITLE	O
:	O
Olig1	B-PRGE
function	O
is	O
required	O
for	O
remyelination	O
potential	O
of	O
transplanted	O
neural	O
progenitor	O
cells	O
in	O
a	O
model	O
of	O
viral	O
-	O
induced	O
demyelination	O
.	O

In	O
vivo	O
characterization	O
of	O
NPCs	O
revealed	O
that	O
Olig1	B-PRGE
+/+	I-PRGE
NPCs	I-PRGE
preferentially	O
differentiated	O
into	O
NG2	O
-	O
positive	O
OPCs	O
and	O
formed	O
processes	O
expressing	O
myelin	B-PRGE
basic	I-PRGE
protein	I-PRGE
that	O
encircled	O
axons	O
.	O

We	O
first	O
clarified	O
the	O
roles	O
of	O
Heme	B-PRGE
/	I-PRGE
HO	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
CXCL10	B-PRGE
/	O
CXCR3	B-PRGE
and	O
STAT3	B-PRGE
in	O
CM	O
pathogenesis	O
utilizing	O
a	O
well	O
established	O
experimental	O
cerebral	O
malaria	O
mouse	O
(	O
ECM	O
,	O
P	O
.	O
berghei	O
ANKA	O
)	O
model	O
.	O

(	O
2	O
)	O
Heme	O
up	O
-	O
regulates	O
HO	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
CXCL10	B-PRGE
production	O
through	O
STAT3	B-PRGE
pathway	O
,	O
and	O
regulates	O
CXCL10	O
at	O
the	O
transcriptional	O
level	O
in	O
vitro	O
.	O

To	O
investigate	O
single	O
-	O
chain	O
fragment	O
variable	O
(	O
scFv	O
)	O
repertoire	O
against	O
pAPN	O
,	O
the	O
genes	O
encoding	O
the	O
immunoglobulin	B-PRGE
light	I-PRGE
chain	I-PRGE
variable	I-PRGE
region	I-PRGE
(	O
VL	O
)	O
and	O
heavy	O
chain	O
variable	O
region	O
(	O
VH	O
)	O
were	O
amplified	O
by	O
reverse	O
transcript	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
using	O
a	O
series	O
of	O
degenerate	O
primers	O
from	O
the	O
spleen	O
of	O
BABL	O
/	O
c	O
mice	O
immunized	O
with	O
native	O
pAPN	O
.	O

Amylase	B-PRGE
was	O
markedly	O
elevated	O
and	O
he	O
was	O
admitted	O
for	O
supportive	O
management	O
of	O
pancreatitis	O
,	O
with	O
subsequent	O
transfer	O
to	O
intensive	O
care	O
due	O
to	O
severe	O
systemic	O
inflammatory	O
syndrome	O
.	O

In	O
the	O
absence	O
of	O
TMPRSS2	B-PRGE
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
achieves	O
cell	O
entry	O
via	O
an	O
endosomal	O
pathway	O
in	O
which	O
cathepsin	B-PRGE
L	I-PRGE
may	O
play	O
an	O
important	O
role	O
,	O
i	O
.	O
e	O
.,	O
the	O
activation	O
of	O
spike	O
protein	O
fusogenicity	O
.	O

The	O
PHE	O
-	O
CoV	O
DNA	O
vaccine	O
was	O
constructed	O
by	O
subcloning	O
the	O
S1	B-PRGE
gene	I-PRGE
of	O
PHE	O
-	O
CoV	O
into	O
the	O
pVAX1	O
vector	O
to	O
create	O
the	O
recombinant	O
plasmid	O
pV	O
-	O
S1	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
complete	O
M	B-PRGE
gene	I-PRGE
showed	O
that	O
all	O
south	O
China	O
PEDV	O
strains	O
have	O
a	O
close	O
relationship	O
with	O
most	O
of	O
the	O
strains	O
in	O
Korea	O
and	O
Thailand	O
,	O
but	O
differ	O
genetically	O
from	O
the	O
vaccine	O
strain	O
(	O
CV777	O
).	O

Vaccination	O
of	O
mice	O
with	O
recombinant	O
S450	O
-	O
650	O
(	O
rS450	O
-	O
650	O
)	O
can	O
induce	O
Abs	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
although	O
the	O
titer	O
is	O
relatively	O
low	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
fusion	O
protein	O
linking	O
a	O
fragment	O
(	O
residues	O
39	O
-	O
272	O
)	O
of	O
murine	O
calreticulin	B-PRGE
(	O
CRT	B-PRGE
)	O
to	O
S450	O
-	O
650	O
in	O
a	O
prokaryotic	O
expression	O
system	O
was	O
created	O
.	O

Four	O
candidate	O
vaccines	O
for	O
humans	O
with	O
or	O
without	O
alum	O
adjuvant	O
were	O
evaluated	O
in	O
a	O
mouse	O
model	O
of	O
SARS	O
,	O
a	O
VLP	O
vaccine	O
,	O
the	O
vaccine	O
given	O
to	O
ferrets	O
and	O
NHP	O
,	O
another	O
whole	O
virus	O
vaccine	O
and	O
an	O
rDNA	O
-	O
produced	O
S	B-PRGE
protein	I-PRGE
.	O

In	O
contrast	O
,	O
monocytes	O
are	O
much	O
more	O
resistant	O
to	O
infection	O
and	O
cytopathic	O
effects	O
despite	O
similar	O
expression	O
levels	O
of	O
CD13	B-PRGE
,	O
the	O
membrane	O
receptor	O
for	O
HCoV	O
-	O
229E	O
.	O

Cell	O
death	O
induced	O
by	O
HCoV	O
-	O
229E	O
is	O
independent	O
of	O
TRAIL	B-PRGE
,	O
FasL	B-PRGE
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
,	O
and	O
caspase	B-PRGE
activity	O
,	O
indicating	O
that	O
viral	O
replication	O
is	O
directly	O
responsible	O
for	O
the	O
observed	O
cytopathic	O
effects	O
.	O

TITLE	O
:	O
Influenza	O
and	O
SARS	O
-	O
coronavirus	O
activating	O
proteases	O
TMPRSS2	B-PRGE
and	O
HAT	B-PRGE
are	O
expressed	O
at	O
multiple	O
sites	O
in	O
human	O
respiratory	O
and	O
gastrointestinal	O
tracts	O
.	O

ABSTRACT	O
:	O
In	O
many	O
countries	O
,	O
the	O
predominant	O
field	O
isolates	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
have	O
been	O
classified	O
as	O
QX	B-PRGE
-	I-PRGE
like	I-PRGE
strains	O
since	O
1996	O
.	O

RESULTS	O
:	O
A	O
recombinant	O
Marek	O
'	O
s	O
disease	O
virus	O
(	O
MDV	O
),	O
rMDV	O
-	O
S1	O
,	O
that	O
expresses	O
the	O
S1	O
subunit	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
from	O
the	O
QX	O
-	O
like	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
was	O
constructed	O
by	O
inserting	O
the	O
IBV	B-PRGE
S1	I-PRGE
gene	I-PRGE
into	O
the	O
genome	O
of	O
the	O
CVI988	O
/	O
Rispens	O
strain	O
of	O
MDV	O
.	O

TITLE	O
:	O
A	O
single	O
polar	O
residue	O
and	O
distinct	O
membrane	O
topologies	O
impact	O
the	O
function	O
of	O
the	O
infectious	O
bronchitis	B-PRGE
coronavirus	I-PRGE
E	I-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
Acylguanidines	O
are	O
a	O
new	O
class	O
of	O
antiviral	O
compounds	O
with	O
the	O
unique	O
ability	O
to	O
target	O
both	O
RNA	B-PRGE
polymerase	I-PRGE
and	I-PRGE
transmembrane	I-PRGE
proteins	I-PRGE
of	O
viruses	O
from	O
different	O
families	O
.	O

In	O
this	O
context	O
,	O
the	O
use	O
of	O
NOX	B-PRGE
inhibitors	O
could	O
be	O
a	O
possible	O
therapeutic	O
perspective	O
in	O
the	O
management	O
of	O
this	O
syndrome	O
.	O

Early	O
following	O
JHMV	O
infection	O
,	O
ELR	O
-	O
positive	O
chemokines	O
contribute	O
to	O
host	O
defense	O
by	O
attracting	O
CXCR2	B-PRGE
-	O
expressing	O
cells	O
including	O
polymorphonuclear	O
cells	O
to	O
the	O
CNS	O
that	O
aid	O
in	O
host	O
defense	O
through	O
increasing	O
the	O
permeability	O
the	O
blood	O
-	O
brain	O
-	O
barrier	O
(	O
BBB	O
).	O

During	O
chronic	O
disease	O
,	O
CXCR2	B-PRGE
signaling	O
on	O
oligodendroglia	O
protects	O
these	O
cells	O
from	O
apoptosis	O
and	O
restricts	O
the	O
severity	O
of	O
demyelination	O
.	O

This	O
review	O
covers	O
aspects	O
related	O
to	O
host	O
defense	O
and	O
disease	O
in	O
response	O
to	O
JHMV	O
infection	O
and	O
highlights	O
the	O
different	O
roles	O
of	O
CXCR2	B-PRGE
signaling	O
in	O
these	O
processes	O
.	O

Factor	B-PRGE
VIII	I-PRGE
(	O
FVIII	O
)	O
levels	O
were	O
very	O
low	O
and	O
evidence	O
of	O
FVIII	B-PRGE
inhibitor	O
was	O
found	O
.	O

TITLE	O
:	O
Characterization	O
of	O
a	O
recombinant	O
canine	O
coronavirus	O
with	O
a	O
distinct	O
receptor	B-PRGE
-	I-PRGE
binding	I-PRGE
(	I-PRGE
S1	I-PRGE
)	I-PRGE
domain	I-PRGE
.	O

However	O
,	O
absence	O
of	O
CD200R	B-PRGE
in	O
influenza	O
A	O
virus	O
infection	O
results	O
in	O
enhanced	O
lung	O
neutrophil	O
influx	O
and	O
pathology	O
in	O
females	O
.	O

Thus	O
,	O
CD200	B-PRGE
-	O
CD200R	B-PRGE
and	O
sex	O
are	O
host	O
factors	O
that	O
together	O
determine	O
the	O
outcome	O
of	O
viral	O
infection	O
.	O

Notably	O
,	O
the	O
rOv	B-PRGE
-	I-PRGE
ASP	I-PRGE
-	I-PRGE
1	I-PRGE
adjuvant	O
did	O
not	O
induce	O
high	O
titer	O
antibodies	O
against	O
self	O
in	O
NHPs	O
.	O

It	O
was	O
found	O
that	O
the	O
effects	O
of	O
EGFP	O
-	O
nsp15s	O
on	O
MHV	O
replication	O
were	O
both	O
virus	O
species	O
-	O
and	O
nsp15	B-PRGE
domain	I-PRGE
-	O
dependent	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
a	O
designed	O
biochip	O
could	O
analyze	O
inhibitors	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
using	O
nanoparticle	O
-	O
based	O
RNA	O
oligonucleotide	O
.	O

This	O
effect	O
is	O
due	O
to	O
rapid	O
,	O
TRAIL	B-PRGE
(	O
TNF	B-PRGE
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
)-	O
dependent	O
apoptosis	O
of	O
MHV	O
-	O
3	O
-	O
infected	O
macrophages	O
in	O
BTLA	O
-/-	O
mice	O
.	O

Encephalitis	O
induced	O
by	O
a	O
gliatropic	O
murine	O
coronavirus	O
was	O
used	O
as	O
a	O
model	O
to	O
assess	O
the	O
direct	O
contributions	O
of	O
neutrophils	O
,	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
to	O
virus	O
-	O
induced	O
mortality	O
.	O

CNS	O
inflammatory	O
conditions	O
were	O
selectively	O
manipulated	O
by	O
adoptive	O
transfer	O
of	O
virus	O
-	O
primed	O
wild	O
-	O
type	O
(	O
WT	O
)	O
or	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
deficient	O
(	O
GKO	O
)	O
memory	O
CD4	B-PRGE
+	I-PRGE
T	O
cells	O
into	O
infected	O
SCID	O
mice	O
,	O
coupled	O
with	O
antibody	O
-	O
mediated	O
neutrophil	O
depletion	O
and	O
cytokine	O
blockade	O
.	O

In	O
all	O
cases	O
,	O
results	O
showed	O
that	O
pVAX1	O
-(	O
PEDV	O
-	O
S	O
)	O
and	O
the	O
combination	O
of	O
pVAX1	O
-(	O
PEDV	O
-	O
S1	O
)	O
with	O
pVAX1	O
-(	O
IL	O
-	O
18	O
)	O
induced	O
the	O
strongest	O
responses	O
;	O
however	O
,	O
pIL	B-PRGE
-	I-PRGE
18	I-PRGE
had	O
no	O
adjuvant	O
effects	O
when	O
given	O
in	O
combination	O
with	O
pVAX1	O
-(	O
PEDV	O
-	O
S1	O
).	O

As	O
nsp10	O
acts	O
as	O
an	O
essential	O
trigger	O
to	O
activate	O
the	O
2	O
'-	O
O	O
-	O
methyltransferase	O
activity	O
of	O
nsp16	O
,	O
short	O
peptides	O
derived	O
from	O
nsp10	O
may	O
have	O
inhibitory	O
effect	O
on	O
viral	B-PRGE
2	I-PRGE
'-	I-PRGE
O	I-PRGE
-	I-PRGE
methyltransferase	I-PRGE
activity	O
.	O

We	O
further	O
showed	O
that	O
two	O
short	O
peptides	O
derived	O
from	O
the	O
interaction	O
domain	O
of	O
nsp10	O
could	O
inhibit	O
the	O
2	O
'-	O
O	O
-	O
methyltransferase	O
activity	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp16	I-PRGE
/	O
10	O
complex	O
,	O
thus	O
providing	O
a	O
novel	O
strategy	O
and	O
proof	O
-	O
of	O
-	O
principle	O
study	O
for	O
developing	O
peptide	O
inhibitors	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O

ABSTRACT	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
(	O
HCoV	O
)	O
is	O
a	O
causative	O
agent	O
of	O
the	O
common	O
cold	O
.	O

We	O
determined	O
the	O
quantities	O
of	O
Ceacam1	B-PRGE
transcripts	I-PRGE
encoding	O
membrane	O
-	O
bound	O
and	O
secreted	O
isoforms	O
in	O
mouse	O
organs	O
and	O
a	O
set	O
of	O
cell	O
lines	O
.	O

As	O
expected	O
,	O
antigen	O
affinity	O
was	O
shown	O
to	O
correlate	O
directly	O
with	O
neutralization	O
potency	O
toward	O
the	O
icUrbani	O
strain	O
of	O
SARS	O
-	O
CoV	O
.	O
Additionally	O
,	O
the	O
highest	O
-	O
affinity	O
antibody	O
fragment	O
displayed	O
10	O
-	O
fold	O
-	O
increased	O
broad	O
neutralization	O
in	O
vitro	O
and	O
completely	O
protected	O
against	O
several	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
strains	O
containing	O
substitutions	O
associated	O
with	O
antibody	O
escape	O
.	O

An	O
ns2	O
mutant	O
virus	O
was	O
unable	O
to	O
replicate	O
in	O
the	O
liver	O
or	O
induce	O
hepatitis	O
in	O
wild	O
-	O
type	O
mice	O
,	O
but	O
was	O
highly	O
pathogenic	O
in	O
RNase	B-PRGE
L	I-PRGE
deficient	O
mice	O
.	O

Pdm	B-PRGE
H1N1	I-PRGE
2009	O
infection	O
has	O
been	O
reported	O
to	O
cause	O
fatal	O
encephalopathy	O
and	O
myocarditis	O
as	O
well	O
as	O
pneumonia	O
.	O

To	O
investigate	O
the	O
actual	O
characteristics	O
of	O
the	O
encephalopathy	O
associated	O
with	O
pdm	B-PRGE
H1N1	I-PRGE
2009	O
infection	O
in	O
Japan	O
,	O
questionnaires	O
were	O
distributed	O
and	O
information	O
collected	O
on	O
207	O
cases	O
of	O
encephalopathy	O
during	O
one	O
season	O
.	O

We	O
conclude	O
that	O
the	O
decline	O
of	O
ACE2	B-PRGE
expression	O
is	O
dependent	O
on	O
the	O
efficiency	O
of	O
HCoV	O
-	O
NL63	O
replication	O
,	O
and	O
that	O
HCoV	O
-	O
NL63	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
both	O
affect	O
cellular	O
ACE2	O
expression	O
during	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
increase	O
immune	O
responses	O
of	O
plant	O
-	O
based	O
vaccines	O
in	O
intestine	O
mucosal	O
immune	O
systems	O
,	O
a	O
synthetic	O
neutralizing	O
epitope	O
(	O
sCOE	O
)	O
gene	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
was	O
fused	O
with	O
M	O
cell	O
-	O
targeting	O
ligand	O
(	O
Co1	O
)	O
and	O
introduced	O
into	O
a	O
plant	O
expression	O
vector	O
under	O
the	O
control	O
of	O
rice	B-PRGE
amylase	I-PRGE
3D	I-PRGE
promoter	I-PRGE
.	O

The	O
systemic	O
and	O
mucosal	O
immune	O
responses	O
were	O
confirmed	O
by	O
measuring	O
COE	O
-	O
specific	O
IgG	B-PRGE
and	O
IgA	B-PRGE
antibody	O
-	O
secreting	O
cells	O
in	O
the	O
lymphocytes	O
extracted	O
from	O
the	O
spleen	O
and	O
COE	O
-	O
specific	O
IgA	B-PRGE
antibody	O
-	O
secreting	O
cells	O
in	O
the	O
Peyer	O
'	O
s	O
patches	O
from	O
immunized	O
mice	O
.	O

Compared	O
with	O
microglia	O
,	O
oligodendroglia	O
were	O
characterized	O
by	O
low	O
basal	O
expression	O
of	O
mRNA	O
encoding	O
viral	O
RNA	O
sensing	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
),	O
IFNÎ±	B-PRGE
/	I-PRGE
Î²	I-PRGE
receptor	I-PRGE
chains	I-PRGE
,	O
interferon	B-PRGE
sensitive	I-PRGE
genes	I-PRGE
(	O
ISG	O
),	O
as	O
well	O
as	O
kinases	O
and	O
transcription	O
factors	O
critical	O
in	O
IFNÎ±	O
/	O
Î²	O
signaling	O
.	O

After	O
purification	O
by	O
cation	O
-	O
exchange	O
chromatography	O
and	O
gel	O
electrophoresis	O
,	O
proteomic	O
features	O
of	O
m	O
/	O
z	O
7769	O
and	O
m	O
/	O
z	O
8865	O
were	O
found	O
to	O
be	O
platelet	B-PRGE
factor	I-PRGE
4	I-PRGE
(	O
PF4	B-PRGE
)	O
and	O
beta	B-PRGE
-	I-PRGE
thromboglobulin	I-PRGE
(	O
beta	B-PRGE
-	I-PRGE
TG	I-PRGE
)	O
by	O
tandem	O
mass	O
spectrometry	O
,	O
respectively	O
.	O

Other	O
CD4	B-PRGE
(+),	I-PRGE
CD4	B-PRGE
(-)	O
CD8	B-PRGE
(-),	O
and	O
CD8	B-PRGE
(+)	O
CD28	O
(-)	O
T	O
cells	O
can	O
be	O
induced	O
to	O
acquire	O
regulatory	O
function	O
by	O
antigenic	O
stimulation	O
,	O
depending	O
on	O
the	O
cytokine	O
milieu	O
.	O

Atypical	O
T	O
(	O
regs	O
)	O
express	O
FoxP3	B-PRGE
and	O
CD4	B-PRGE
but	O
have	O
no	O
surface	O
expression	O
of	O
CD25	B-PRGE
.	O

Type	O
1	O
regulatory	O
T	O
cells	O
(	O
Tr1	O
cells	O
)	O
produce	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
while	O
T	O
helper	O
3	O
cells	O
(	O
Th3	O
)	O
produce	O
TGF	O
-	O
Î²	O
.	O

We	O
assessed	O
the	O
effect	O
of	O
triggering	O
TLR2	B-PRGE
,	O
TLR3	B-PRGE
,	O
TLR4	B-PRGE
,	O
and	O
TLR7	O
with	O
selected	O
ligands	O
on	O
the	O
susceptibility	O
of	O
the	O
J774A	O
.	O
1	O
macrophage	O
cell	O
line	O
to	O
infection	O
with	O
murine	O
coronavirus	O
(	O
mouse	O
hepatitis	O
virus	O
,	O
[	O
MHV	O
]).	O

Stimulation	O
of	O
TLR2	B-PRGE
,	O
TLR4	B-PRGE
,	O
or	O
TLR7	O
did	O
not	O
affect	O
MHV	O
production	O
.	O

This	O
process	O
is	O
accomplished	O
by	O
the	O
virus	O
-	O
coded	O
reverse	B-PRGE
transcriptase	I-PRGE
(	O
RT	O
)	O
protein	O
,	O
which	O
is	O
a	O
primary	O
target	O
in	O
the	O
current	O
treatments	O
for	O
HIV	O
-	O
1	O
infection	O
.	O

Both	O
classes	O
inhibit	O
the	O
RT	B-PRGE
-	I-PRGE
associated	I-PRGE
polymerase	I-PRGE
activity	O
:	O
the	O
NRTIs	O
compete	O
with	O
the	O
natural	O
dNTP	O
substrate	O
and	O
act	O
as	O
chain	O
terminators	O
,	O
while	O
the	O
NNRTIs	O
bind	O
to	O
an	O
allosteric	O
pocket	O
and	O
inhibit	O
polymerization	O
noncompetitively	O
.	O

Studies	O
suggest	O
a	O
likely	O
inhibition	O
of	O
thiol	O
/	O
thiol	O
enzymes	O
by	O
the	O
lignan	O
-	O
lactones	O
,	O
depletion	O
of	O
glutathione	B-PRGE
and	I-PRGE
ATPases	I-PRGE
in	O
tissues	O
.	O

The	O
purified	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp12	I-PRGE
showed	O
both	O
primer	O
-	O
dependent	O
and	O
primer	O
-	O
independent	O
RNA	O
synthesis	O
activities	O
using	O
homopolymeric	O
RNA	O
templates	O
.	O

Reduction	O
of	O
infiltration	O
of	O
inflammatory	O
cells	O
,	O
deposition	O
of	O
fibroblastic	O
loci	O
and	O
collagen	B-PRGE
,	O
formation	O
of	O
reactive	O
oxygen	O
species	O
,	O
and	O
production	O
of	O
cytokines	O
,	O
as	O
well	O
as	O
recovery	O
from	O
imbalance	O
of	O
MMP	B-PRGE
-	I-PRGE
9	I-PRGE
/	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
were	O
observed	O
in	O
fibrotic	O
rats	O
after	O
treatment	O
with	O
Cordyceps	O
in	O
preventive	O
(	O
from	O
the	O
day	O
of	O
BLM	O
administration	O
)	O
and	O
therapeutic	O
(	O
from	O
14	O
days	O
after	O
BLM	O
)	O
regimens	O
.	O

The	O
average	O
duration	O
of	O
CBP	B-PRGE
treatment	O
was	O
52	O
hours	O
(	O
12	O
hours	O
to	O
232	O
hours	O
).	O

It	O
is	O
classified	O
as	O
a	O
class	O
I	O
fusion	O
protein	O
,	O
and	O
is	O
responsible	O
for	O
binding	O
to	O
the	O
receptor	O
on	O
the	O
host	O
cell	O
as	O
well	O
as	O
mediating	O
the	O
fusion	O
of	O
host	O
and	O
viral	O
membranes	O
-	O
A	O
process	O
driven	O
by	O
major	O
conformational	O
changes	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

This	O
review	O
discusses	O
coronavirus	O
entry	O
mechanisms	O
focusing	O
on	O
the	O
different	O
triggers	O
used	O
by	O
coronaviruses	O
to	O
initiate	O
the	O
conformational	O
change	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
:	O
receptor	O
binding	O
,	O
low	O
pH	O
exposure	O
and	O
proteolytic	O
activation	O
.	O

However	O
,	O
ZnCl	O
(	O
2	O
)	O
and	O
ZnSO	O
(	O
4	O
)	O
markedly	O
reduced	O
viral	O
titers	O
as	O
well	O
as	O
TGEV	B-PRGE
RNA	I-PRGE
and	O
viral	B-PRGE
protein	I-PRGE
synthesis	O
when	O
applied	O
during	O
virus	O
penetration	O
and	O
at	O
different	O
time	O
points	O
after	O
viral	O
cell	O
entry	O
.	O

Lipid	O
charge	O
also	O
regulated	O
the	O
selectivity	O
of	O
a	O
HCoV	B-PRGE
-	I-PRGE
229E	I-PRGE
E	I-PRGE
protein	I-PRGE
derived	I-PRGE
peptide	I-PRGE
.	O

Chickens	O
were	O
sacrificed	O
every	O
3	O
days	O
to	O
monitor	O
antigen	B-PRGE
specific	I-PRGE
serum	I-PRGE
IgG	I-PRGE
and	O
IBV	O
nucleoprotein	O
-	O
specific	O
immune	O
responses	O
using	O
a	O
chicken	B-PRGE
MHC	I-PRGE
I	I-PRGE
tetramer	I-PRGE
developed	O
in	O
our	O
laboratory	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
SCoV	O
viral	O
proteins	O
are	O
efficiently	O
produced	O
in	O
infected	O
cells	O
in	O
which	O
host	O
protein	O
synthesis	O
is	O
impaired	O
by	O
nsp1	B-PRGE
is	O
unknown	O
.	O

We	O
obtained	O
four	O
hybridoma	O
cell	O
lines	O
secreting	O
mAbs	O
against	O
recombinant	B-PRGE
N	I-PRGE
protein	I-PRGE
.	O

mAbs	O
against	O
N	B-PRGE
protein	I-PRGE
of	O
MHV	O
with	O
high	O
activity	O
and	O
specificity	O
were	O
prepared	O
successfully	O
,	O
which	O
provides	O
a	O
potential	O
basis	O
for	O
further	O
researches	O
on	O
N	B-PRGE
protein	I-PRGE
function	O
and	O
diagnostic	O
methods	O
.	O

High	O
plasma	B-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
,	O
thrombomodulin	B-PRGE
,	O
and	O
mini	O
-	O
BAL	O
protein	O
were	O
all	O
significantly	O
associated	O
with	O
fewer	O
ventilator	O
-	O
free	O
days	O
(	O
VFDs	O
)	O
(	O
P	O
=	O
0	O
.	O
01	O
,	O
0	O
.	O
01	O
,	O
and	O
0	O
.	O
05	O
,	O
respectively	O
);	O
no	O
markers	O
were	O
associated	O
with	O
mortality	O
,	O
but	O
we	O
hypothesized	O
that	O
this	O
was	O
due	O
to	O
the	O
small	O
size	O
of	O
our	O
cohort	O
and	O
the	O
low	O
death	O
rate	O
.	O

TITLE	O
:	O
Origin	O
,	O
diversity	O
,	O
and	O
maturation	O
of	O
human	B-PRGE
antiviral	I-PRGE
antibodies	I-PRGE
analyzed	O
by	O
high	O
-	O
throughput	O
sequencing	O
.	O

We	O
found	O
that	O
the	O
human	B-PRGE
IgM	I-PRGE
repertoires	O
from	O
the	O
454	O
sequencing	O
have	O
diverse	O
germline	O
usages	O
,	O
recombination	O
patterns	O
,	O
junction	O
diversity	O
,	O
and	O
a	O
lower	O
extent	O
of	O
somatic	O
mutation	O
.	O

We	O
have	O
identified	O
that	O
all	O
of	O
the	O
isolated	O
tanshinones	O
are	O
good	O
inhibitors	O
of	O
both	O
cysteine	B-PRGE
proteases	I-PRGE
.	O

The	O
correlation	O
between	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
level	O
and	O
liver	O
injury	O
was	O
studied	O
.	O

Our	O
results	O
showed	O
that	O
the	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
expression	O
was	O
significantly	O
elevated	O
in	O
the	O
liver	O
and	O
serum	O
of	O
BALB	O
/	O
cJ	O
mice	O
infected	O
with	O
MHV	O
-	O
3	O
.	O

Increased	O
effusion	O
cholesterol	O
concentration	O
and	O
specific	O
gravity	O
as	O
well	O
as	O
decreased	O
serum	B-PRGE
albumin	I-PRGE
:	I-PRGE
globulin	I-PRGE
ratio	O
and	O
hyperbilirubinemia	O
were	O
positively	O
correlated	O
with	O
positive	O
Rivalta	O
test	O
results	O
.	O

TITLE	O
:	O
Monitoring	O
of	O
S	B-PRGE
protein	I-PRGE
maturation	O
in	O
the	O
endoplasmic	O
reticulum	O
by	O
calnexin	O
is	O
important	O
for	O
the	O
infectivity	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Poly	O
(	O
I	O
Â·	O
C	O
)	O
pretreatment	O
upregulated	O
beta	O
interferon	B-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
),	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
,	O
IL	O
-	O
1Î²	O
,	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	B-PRGE
)	O
gene	O
expression	O
in	O
the	O
lungs	O
.	O

Intranasal	O
pretreatment	O
with	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
but	O
not	O
IL	O
-	O
1Î²	O
or	O
TNF	B-PRGE
also	O
protected	O
aged	O
mice	O
,	O
consistent	O
with	O
the	O
notion	O
that	O
poly	O
(	O
I	O
Â·	O
C	O
)	O
pretreatment	O
functioned	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
inducing	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
antigen	O
characteristics	O
of	O
different	O
fragments	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
expressed	O
in	O
E	O
.	O
Coli	O
and	O
their	O
application	O
in	O
the	O
serological	O
diagnosis	O
.	O

RESULTS	O
:	O
An	O
immunochromatographic	O
strip	O
was	O
developed	O
for	O
the	O
detection	O
of	O
PHE	O
-	O
CoV	O
.	O
The	O
colloidal	O
gold	O
-	O
labeled	O
MAb	O
4D4	O
was	O
used	O
as	O
the	O
detection	O
reagent	O
,	O
and	O
the	O
MAb	O
1E2	O
and	O
goat	B-PRGE
anti	I-PRGE
-	I-PRGE
mouse	I-PRGE
IgG	I-PRGE
coated	O
the	O
strip	O
'	O
s	O
test	O
and	O
control	O
lines	O
,	O
respectively	O
.	O

Myeloperoxidase	B-PRGE
(	O
MPO	B-PRGE
)	O
activity	O
in	O
lung	O
tissue	O
was	O
reduced	O
in	O
the	O
MCR	O
-	O
LPS	O
and	O
LPS	O
-	O
MCR	O
groups	O
at	O
16h	O
after	O
LPS	O
administration	O
.	O

Unfolding	O
of	O
this	O
foldon	O
promotes	O
self	O
-	O
association	O
of	O
M	O
(	O
pro	O
)-	O
C	O
monomers	O
and	O
functions	O
to	O
mediate	O
the	O
3D	O
domain	O
swapping	O
,	O
without	O
which	O
M	B-PRGE
(	I-PRGE
pro	I-PRGE
)-	I-PRGE
C	I-PRGE
can	O
no	O
longer	O
form	O
the	O
domain	O
-	O
swapped	O
dimer	O
.	O

In	O
the	O
reporter	O
assays	O
,	O
three	O
of	O
four	O
shRNA	O
expression	O
plasmids	O
were	O
able	O
to	O
inhibit	O
significantly	O
the	O
expression	O
of	O
ORF	O
7	O
gene	O
and	O
replication	O
of	O
TGEV	O
,	O
as	O
shown	O
by	O
real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
analysis	O
of	O
viral	B-PRGE
ORF	I-PRGE
7	I-PRGE
and	O
N	O
genes	O
and	O
detection	O
of	O
virus	O
titers	O
(	O
TCID50	O
/	O
ml	O
).	O

TITLE	O
:	O
[	O
Comprehensive	O
analysis	O
on	O
variation	O
of	O
cardiac	B-PRGE
enzyme	I-PRGE
and	O
troponin	B-PRGE
induced	O
by	O
acute	O
organophosphorous	O
poisoning	O
].	O

The	O
data	O
of	O
the	O
cardiac	O
enzyme	O
and	O
troponin	B-PRGE
were	O
collected	O
.	O

ABSTRACT	O
:	O
We	O
present	O
a	O
case	O
of	O
severe	O
interstitial	O
pneumonitis	O
,	O
mild	O
polyarthritis	O
and	O
polymyositis	O
,	O
and	O
Raynaud	O
'	O
s	O
syndrome	O
with	O
the	O
presence	O
of	O
anti	O
-	O
Jo	O
-	O
1	O
antibodies	O
,	O
which	O
had	O
been	O
diagnosed	O
as	O
anti	B-PRGE
-	I-PRGE
synthetase	I-PRGE
syndrome	O
.	O

ABSTRACT	O
:	O
The	O
whey	O
acidic	O
protein	O
family	O
member	O
,	O
WFDC1	B-PRGE
/	O
ps20	B-PRGE
is	O
a	O
permissivity	O
factor	O
in	O
HIV	O
infection	O
.	O

We	O
examined	O
the	O
rates	O
of	O
DAI	B-PRGE
by	O
antimicrobial	O
-	O
resistant	O
pathogens	O
,	O
and	O
30	O
-	O
day	O
and	O
in	O
-	O
hospital	O
mortality	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
).	O

Fluid	O
balance	O
lowered	O
in	O
both	O
groups	O
,	O
and	O
it	O
was	O
the	O
lowest	O
on	O
PBD	O
10	O
in	O
control	O
group	O
and	O
PBD	B-PRGE
6	I-PRGE
in	O
treatment	O
group	O
.	O

Furthermore	O
,	O
administration	O
of	O
PGRN	O
resulted	O
in	O
remarkable	O
reversal	O
of	O
LPS	O
-	O
induced	O
increases	O
in	O
lung	O
permeability	O
as	O
assessed	O
by	O
reductions	O
in	O
total	O
protein	O
,	O
albumin	B-PRGE
,	O
and	O
IgM	B-PRGE
in	O
BAL	O
fluid	O
.	O

A	O
VRDAL	O
multiplex	O
PCR	O
for	O
10	O
common	O
respiratory	O
viruses	O
was	O
performed	O
on	O
collected	O
specimens	O
compared	O
with	O
the	O
Seeplex	B-PRGE
Â®	I-PRGE
RV15	I-PRGE
ACE	I-PRGE
Detection	O
kit	O
for	O
15	O
respiratory	O
viruses	O
.	O

Here	O
,	O
we	O
show	O
by	O
molecular	O
clock	O
analysis	O
that	O
alphacoronavirus	O
(	O
Î±	O
-	O
CoV	O
)	O
sequences	O
derived	O
from	O
the	O
North	O
American	O
tricolored	O
bat	O
(	O
Perimyotis	O
subflavus	O
)	O
are	O
predicted	O
to	O
share	O
common	O
ancestry	O
with	O
human	B-PRGE
CoV	I-PRGE
(	O
HCoV	O
)-	O
NL63	O
,	O
with	O
the	O
most	O
recent	O
common	O
ancestor	O
between	O
these	O
viruses	O
occurring	O
approximately	O
563	O
to	O
822	O
years	O
ago	O
.	O

In	O
conclusion	O
,	O
the	O
method	O
described	O
in	O
this	O
study	O
allows	O
sensitive	O
detection	O
of	O
a	O
recombinant	B-PRGE
SARS	I-PRGE
spike	I-PRGE
protein	I-PRGE
by	O
sandwich	O
ELISA	O
with	O
bi	O
-	O
specific	O
monoclonal	O
antibody	O
and	O
could	O
be	O
used	O
for	O
the	O
diagnosis	O
of	O
patients	O
suspected	O
with	O
SARS	O
.	O

Thirteen	O
1	O
.	O
5	O
-	O
2	O
.	O
8	O
kb	O
fragments	O
contiguously	O
spanning	O
the	O
virus	O
genome	O
were	O
amplified	O
and	O
cloned	O
into	O
pMD19	O
-	O
T	O
.	O
Transcription	O
grade	O
complete	O
length	O
cDNA	O
was	O
acquired	O
by	O
a	O
modified	O
""""	O
No	O
See	O
'	O
m	O
""""	O
ligation	O
strategy	O
,	O
which	O
employed	O
restriction	O
enzyme	O
Bsa	B-PRGE
I	I-PRGE
and	O
BsmB	O
I	O
and	O
ligated	O
more	O
than	O
two	O
fragments	O
in	O
one	O
T4	B-PRGE
ligase	I-PRGE
reaction	O
.	O

Results	O
for	O
urine	O
sCD163	O
were	O
recorded	O
on	O
the	O
day	O
of	O
admission	O
to	O
the	O
ICU	O
,	O
and	O
AKI	B-PRGE
occurrence	O
was	O
noted	O
.	O

The	O
complication	O
rate	O
,	O
time	O
of	O
recovery	O
of	O
cholinesterase	B-PRGE
(	O
ChE	B-PRGE
)	O
activity	O
to	O
70	O
ï¼,	O
hospital	O
stay	O
time	O
and	O
cost	O
,	O
the	O
cure	O
rate	O
,	O
mortality	O
rate	O
in	O
three	O
groups	O
were	O
analyzed	O
.	O

In	O
atropine	O
group	O
,	O
3	O
patients	O
were	O
found	O
to	O
have	O
atropine	O
resistance	O
,	O
3	O
patients	O
showed	O
intermediate	O
syndrome	O
,	O
rebound	O
was	O
observed	O
in	O
2	O
cases	O
,	O
atropine	O
poisoning	O
in	O
2	O
patients	O
,	O
and	O
the	O
incidence	O
of	O
complications	O
was	O
16	O
.	O
67	O
ï¼.	O
Three	O
patients	O
died	O
of	O
respiratory	O
or	O
circulatory	O
failure	O
,	O
and	O
the	O
mortality	O
rate	O
was	O
5	O
.	O
00	O
ï¼.	O
Fifty	O
-	O
seven	O
patients	O
were	O
cured	O
,	O
the	O
cure	O
rate	O
was	O
95	O
.	O
00	O
ï¼.	O
The	O
time	O
of	O
ChE	B-PRGE
activity	O
recovery	O
to	O
70	O
ï¼	O
was	O
(	O
8	O
.	O
0	O
Â±	O
0	O
.	O
9	O
)	O
days	O
.	O

RESULTS	O
:	O
In	O
penehyclidine	O
hydrochloride	O
sequential	O
to	O
atropine	O
group	O
,	O
except	O
for	O
1	O
case	O
of	O
cancer	O
of	O
gastric	O
cardia	O
with	O
poisoning	O
after	O
operation	O
showing	O
intermediate	O
syndrome	O
of	O
poisoning	O
,	O
the	O
remaining	O
patients	O
did	O
not	O
have	O
any	O
complication	O
,	O
and	O
the	O
incidence	O
of	O
complications	O
was	O
1	O
.	O
67	O
ï¼.	O
No	O
death	O
occurred	O
in	O
all	O
the	O
patients	O
,	O
and	O
the	O
cure	O
rate	O
was	O
100	O
.	O
00	O
ï¼.	O
Time	O
of	O
recovery	O
from	O
ChE	B-PRGE
activity	O
to	O
70	O
ï¼	O
was	O
(	O
4	O
.	O
0	O
Â±	O
1	O
.	O
1	O
)	O
days	O
;	O
hospital	O
stay	O
was	O
(	O
7	O
.	O
0	O
+	O
2	O
.	O
2	O
)	O
days	O
;	O
hospital	O
expenses	O
were	O
(	O
6268	O
Â±	O
238	O
)	O
yuan	O
.	O

TITLE	O
:	O
Lack	O
of	O
innate	O
interferon	B-PRGE
responses	O
during	O
SARS	O
coronavirus	O
infection	O
in	O
a	O
vaccination	O
and	O
reinfection	O
ferret	O
model	O
.	O

We	O
used	O
an	O
nsp1	B-PRGE
mutant	I-PRGE
,	O
nsp1	B-PRGE
-	I-PRGE
CD	I-PRGE
,	O
lacking	O
the	O
RNA	O
cleavage	O
function	O
,	O
to	O
delineate	O
the	O
mechanism	O
of	O
nsp1	B-PRGE
-	O
mediated	O
translation	O
inhibition	O
and	O
identify	O
the	O
translation	O
step	O
(	O
s	O
)	O
targeted	O
by	O
nsp1	B-PRGE
.	O

nsp1	B-PRGE
had	O
a	O
differential	O
,	O
mRNA	O
template	O
-	O
dependent	O
,	O
inhibitory	O
effect	O
on	O
48S	O
and	O
80S	O
initiation	O
complex	O
formation	O
.	O

The	O
present	O
report	O
describes	O
the	O
use	O
of	O
a	O
new	O
set	O
of	O
degenerate	O
primers	O
that	O
amplify	O
a	O
636	O
-	O
bp	O
fragment	O
within	O
the	O
S1	B-PRGE
gene	I-PRGE
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
to	O
detect	O
the	O
occurrence	O
of	O
IBV	O
-	O
QX	O
infection	O
in	O
Switzerland	O
.	O

Plasma	O
levels	O
of	O
Î±B	B-PRGE
-	I-PRGE
crystallin	I-PRGE
were	O
studied	O
in	O
163	O
patients	O
:	O
52	O
healthy	O
non	O
-	O
COPD	O
smokers	O
;	O
20	O
COPD	O
smokers	O
in	O
Global	O
Initiative	O
for	O
Chronic	O
Obstructive	O
Lung	O
Disease	O
(	O
GOLD	O
)	O
stages	O
I	O
-	O
II	O
;	O
43	O
COPD	O
smokers	O
in	O
GOLD	O
stages	O
III	O
-	O
IV	O
.	O

The	O
plasma	O
levels	O
of	O
Î±B	B-PRGE
-	I-PRGE
crystallin	I-PRGE
antibodies	I-PRGE
were	O
determined	O
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
Calbiochem	O
),	O
and	O
were	O
confirmed	O
with	O
Western	O
blotting	O
.	O

Î±B	B-PRGE
-	I-PRGE
crystallin	I-PRGE
is	O
increased	O
in	O
patients	O
with	O
inflammatory	O
lung	O
diseases	O
.	O

CONCLUSIONS	O
:	O
Î±B	B-PRGE
-	I-PRGE
crystallin	I-PRGE
is	O
increased	O
in	O
patients	O
with	O
inflammatory	O
lung	O
diseases	O
.	O

In	O
contrast	O
,	O
phylogenetic	O
analysis	O
based	O
on	O
the	O
N	B-PRGE
gene	I-PRGE
showed	O
that	O
L748	O
was	O
more	O
closely	O
related	O
to	O
the	O
SE17	O
type	O
,	O
indicating	O
that	O
there	O
had	O
been	O
exchange	O
of	O
S1	O
genetic	O
materials	O
between	O
Mass	O
-	O
and	O
SE17	O
-	O
like	O
viruses	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
multifunctional	O
roles	O
of	O
mammalian	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
.	O
ABSTRACT	O
:	O
Mammalian	O
aminopeptidase	B-PRGE
N	I-PRGE
(	O
APN	B-PRGE
)	O
plays	O
multifunctional	O
roles	O
in	O
many	O
physiological	O
processes	O
,	O
including	O
peptide	O
metabolism	O
,	O
cell	O
motility	O
and	O
adhesion	O
,	O
and	O
coronavirus	O
entry	O
.	O

APN	B-PRGE
also	O
provides	O
an	O
exposed	O
outer	O
surface	O
for	O
coronavirus	O
binding	O
,	O
without	O
its	O
physiological	O
functions	O
being	O
affected	O
.	O

This	O
study	O
elucidates	O
multifunctional	O
roles	O
of	O
APN	B-PRGE
and	O
can	O
guide	O
therapeutic	O
efforts	O
to	O
treat	O
APN	O
-	O
related	O
diseases	O
.	O

Fischer	O
et	O
al	O
.	O
reported	O
their	O
first	O
experience	O
on	O
the	O
use	O
of	O
ILA	B-PRGE
as	O
a	O
bridge	O
to	O
LTx	O
.	O

Six	O
hours	O
after	O
initiation	O
of	O
ILA	B-PRGE
,	O
the	O
partial	O
pressure	O
of	O
CO	O
(	O
2	O
)	O
in	O
arterial	O
blood	O
significantly	O
decreased	O
(	O
P	O
<	O
.	O
05	O
)	O
and	O
arterial	O
blood	O
pH	O
significantly	O
improved	O
(	O
P	O
<	O
.	O
05	O
)	O
and	O
remained	O
stable	O
for	O
one	O
week	O
(	O
last	O
time	O
point	O
reported	O
).	O

Using	O
mutagenesis	O
,	O
we	O
have	O
located	O
the	O
sugar	O
-	O
binding	O
site	O
in	O
BCoV	O
NTD	O
,	O
which	O
overlaps	O
with	O
the	O
galactose	B-PRGE
-	I-PRGE
binding	I-PRGE
site	I-PRGE
in	O
human	B-PRGE
galectins	I-PRGE
.	O

In	O
October	O
2011	O
,	O
Xigris	O
(	O
drotrecogin	O
alfa	O
,	O
a	O
recombinant	B-PRGE
activated	I-PRGE
protein	I-PRGE
C	I-PRGE
)	O
was	O
withdrawn	O
from	O
the	O
market	O
following	O
the	O
failure	O
of	O
its	O
worldwide	O
trial	O
that	O
had	O
attempted	O
to	O
demonstrate	O
improved	O
outcome	O
.	O

The	O
sensitivity	O
of	O
RT	B-PRGE
-	I-PRGE
LAMP	I-PRGE
was	O
3	O
.	O
2	O
-	O
fold	O
higher	O
than	O
that	O
of	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
31	O
.	O
6	O
-	O
fold	O
lower	O
than	O
that	O
of	O
nested	O
RT	O
-	O
PCR	O
.	O

TITLE	O
:	O
Fine	O
level	O
epitope	O
mapping	O
and	O
conservation	O
analysis	O
of	O
two	O
novel	O
linear	O
B	O
-	O
cell	O
epitopes	O
of	O
the	O
avian	O
infectious	O
bronchitis	B-PRGE
coronavirus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
two	O
monoclonal	O
antibodies	O
(	O
mAbs	O
),	O
designated	O
as	O
6D10	O
and	O
4F10	O
,	O
which	O
were	O
directed	O
against	O
the	O
N	B-PRGE
protein	I-PRGE
of	O
IBV	O
using	O
the	O
whole	O
viral	O
particles	O
as	O
immunogens	O
.	O

Moreover	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
ssRNA	I-PRGE
was	O
able	O
to	O
cause	O
acute	O
lung	O
injury	O
in	O
mice	O
with	O
a	O
high	O
mortality	O
rate	O
in	O
vivo	O
experiment	O
.	O

ABSTRACT	O
:	O
The	O
degradative	O
activity	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
reverse	B-PRGE
transcriptase	I-PRGE
(	O
RT	O
),	O
termed	O
ribonuclease	B-PRGE
H	I-PRGE
(	O
RNase	B-PRGE
H	I-PRGE
),	O
which	O
hydrolyzes	O
the	O
RNA	O
component	O
of	O
the	O
heteroduplex	O
RNA	O
:	O
DNA	O
replication	O
intermediate	O
,	O
is	O
an	O
excellent	O
target	O
for	O
drug	O
discovery	O
.	O

RESULTS	O
:	O
The	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
was	O
1	O
.	O
31	O
plaque	O
-	O
forming	O
units	O
(	O
PFU	O
)/	O
mL	O
for	O
human	O
rhinoviruses	O
(	O
hRVs	O
),	O
4	O
.	O
93	O
PFU	O
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
/	O
NL63	O
,	O
2	O
.	O
67	O
PFU	O
/	O
mL	O
for	O
human	B-PRGE
coronavirus	I-PRGE
HCoV	I-PRGE
-	I-PRGE
OC43	I-PRGE
,	O
18	O
.	O
20	O
PFU	O
/	O
mL	O
for	O
parainfluenza	O
virus	O
1	O
(	O
PIV	O
)-	O
1	O
,	O
24	O
.	O
57	O
PFU	O
/	O
mL	O
for	O
PIV	O
-	O
2	O
,	O
1	O
.	O
73	O
PFU	O
/	O
mL	O
for	O
PIV	O
-	O
3	O
,	O
1	O
.	O
79	O
PFU	O
/	O
mL	O
for	O
influenza	O
virus	O
group	O
(	O
Flu	O
)	O
A	O
,	O
59	O
.	O
51	O
PFU	O
/	O
mL	O
for	O
FluB	O
,	O
5	O
.	O
46	O
PFU	O
/	O
mL	O
for	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
hRSV	O
)-	O
A	O
,	O
17	O
.	O
23	O
PFU	O
/	O
mL	O
for	O
hRSV	O
-	O
B	O
,	O
9	O
.	O
99	O
PFU	O
/	O
mL	O
for	O
human	O
adenovirus	O
(	O
ADVs	O
).	O

We	O
found	O
that	O
the	O
mice	O
lacking	O
CXCL10	B-PRGE
or	O
CXCR3	B-PRGE
demonstrated	O
improved	O
severity	O
and	O
survival	O
of	O
nonviral	O
and	O
viral	O
ARDS	O
,	O
whereas	O
mice	O
that	O
lack	O
IFNAR1	B-PRGE
did	O
not	O
control	O
the	O
severity	O
of	O
ARDS	O
in	O
vivo	O
.	O

Our	O
results	O
showed	O
that	O
mice	O
immunized	O
orogastrically	O
with	O
L	O
.	O
casei	O
expressing	O
COE	O
or	O
LTB	B-PRGE
-	I-PRGE
COE	I-PRGE
produced	O
secretory	B-PRGE
immunoglobulin	I-PRGE
A	I-PRGE
and	O
immunoglobulin	B-PRGE
G	I-PRGE
with	O
the	O
ability	O
to	O
neutralize	O
PEDV	O
in	O
sera	O
and	O
mucus	O
.	O

Î²	B-PRGE
-	I-PRGE
actin	I-PRGE
concentration	O
was	O
lower	O
in	O
the	O
self	O
-	O
swabs	O
collected	O
on	O
day	O
1	O
than	O
in	O
those	O
collected	O
on	O
a	O
subsequent	O
day	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

infusion	O
of	O
diuretics	O
,	O
calcium	O
gluconate	O
and	O
short	O
-	O
acting	O
insulin	B-PRGE
),	O
and	O
also	O
by	O
antibiotics	O
and	O
anticoagulants	O
.	O

Surprisingly	O
,	O
converting	O
either	O
of	O
the	O
two	O
residues	O
to	O
the	O
amino	O
acid	O
present	O
in	O
most	O
CH	O
IBVs	O
resulted	O
in	O
significantly	O
reduced	O
affinity	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
for	O
the	O
synthetic	O
RNA	O
repeats	O
of	O
the	O
viral	O
transcriptional	O
regulatory	O
sequence	O
.	O

Furthermore	O
,	O
potential	O
recombination	O
events	O
associated	O
with	O
GX	O
-	O
NN09032	O
were	O
found	O
in	O
four	O
IBV	O
strains	O
,	O
including	O
GX	B-PRGE
-	I-PRGE
YL5	I-PRGE
,	O
DY07	O
,	O
CK	O
/	O
CH	O
/	O
SD09	O
/	O
005	O
,	O
TC07	O
-	O
2	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
replicase	B-PRGE
gene	I-PRGE
of	O
coronaviruses	O
with	O
completely	O
sequenced	O
genomes	O
showed	O
that	O
HCoV	O
-	O
EMC	O
/	O
2012	O
is	O
most	O
closely	O
related	O
to	O
Tylonycteris	B-PRGE
bat	I-PRGE
coronavirus	I-PRGE
HKU4	I-PRGE
(	O
BtCoV	O
-	O
HKU4	O
)	O
and	O
Pipistrellus	B-PRGE
bat	I-PRGE
coronavirus	I-PRGE
HKU5	I-PRGE
(	O
BtCoV	O
-	O
HKU5	O
),	O
which	O
prototype	O
two	O
species	O
in	O
lineage	O
C	O
of	O
the	O
genus	O
Betacoronavirus	O
.	O

The	O
present	O
study	O
indicated	O
that	O
type	B-PRGE
I	I-PRGE
FCoV	I-PRGE
is	O
more	O
prevalent	O
among	O
cats	O
in	O
Malaysia	O
.	O

We	O
report	O
a	O
14	O
years	O
old	O
white	O
girl	O
,	O
with	O
a	O
history	O
of	O
type	O
1	O
von	B-PRGE
Willebrand	I-PRGE
disease	I-PRGE
(	O
vWd	B-PRGE
),	O
recipient	O
of	O
2	O
units	O
'	O
fresh	O
-	O
frozen	O
plasma	O
(	O
FFP	O
)	O
and	O
1	O
unit	O
whole	O
blood	O
transfusion	O
who	O
developed	O
an	O
acute	O
respiratory	O
distress	O
with	O
severe	O
hypoxemia	O
and	O
bilateral	O
pulmonary	O
infiltrate	O
on	O
chest	O
X	O
-	O
ray	O
within	O
3	O
hours	O
of	O
the	O
whole	O
blood	O
transfusion	O
,	O
completely	O
reversible	O
after	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
reported	O
that	O
a	O
prokaryotic	O
-	O
expressed	O
recombinant	O
nucleocapsid	B-PRGE
protein	I-PRGE
(	O
NP	O
)	O
is	O
a	O
suitable	O
reagent	O
for	O
the	O
epidemiological	O
screening	O
of	O
coronavirus	O
infection	O
.	O

The	O
C	O
-	O
terminal	O
tail	O
peptide	O
is	O
able	O
to	O
interfere	O
with	O
the	O
oligomerization	O
of	O
the	O
CTD	O
of	O
HCoV	B-PRGE
-	I-PRGE
229E	I-PRGE
N	I-PRGE
protein	I-PRGE
and	O
performs	O
the	O
inhibitory	O
effect	O
on	O
viral	O
titre	O
of	O
HCoV	O
-	O
229E	O
.	O

While	O
many	O
aspirates	O
were	O
dilute	O
and	O
showed	O
no	O
mRNA	O
signal	O
,	O
viral	O
infection	O
significantly	O
increased	O
the	O
number	O
of	O
samples	O
that	O
were	O
positive	O
for	O
IFN	B-PRGE
-	I-PRGE
Î»1	I-PRGE
,	O
IFN	B-PRGE
-	I-PRGE
Î»2	I-PRGE
/	I-PRGE
3	I-PRGE
,	O
TLR3	B-PRGE
,	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
,	O
and	O
IRF7	B-PRGE
mRNA	I-PRGE
.	O

These	O
data	O
indicate	O
that	O
HmAbs	O
which	O
bind	O
to	O
conserved	O
regions	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
are	O
more	O
suitable	O
for	O
conferring	O
protection	O
against	O
a	O
wide	O
range	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
variants	I-PRGE
and	O
have	O
implications	O
for	O
generating	O
therapeutic	O
antibodies	O
or	O
subunit	O
vaccines	O
against	O
other	O
enveloped	O
viruses	O
.	O

Here	O
we	O
review	O
current	O
knowledge	O
of	O
coronavirus	O
induced	O
membrane	O
rearrangements	O
and	O
the	O
involvement	O
of	O
autophagy	B-PRGE
or	O
autophagy	O
protein	O
microtubule	O
associated	O
protein	O
1B	O
light	B-PRGE
chain	I-PRGE
3	I-PRGE
(	O
LC3	B-PRGE
)	O
in	O
coronavirus	O
replication	O
.	O

These	O
findings	O
highlight	O
growing	O
evidence	O
of	O
the	O
diverse	O
and	O
important	O
role	O
of	O
CXCR2	B-PRGE
in	O
regulating	O
neuroinflammatory	O
diseases	O
.	O

However	O
,	O
five	O
samples	O
were	O
negative	O
by	O
RT	B-PRGE
-	I-PRGE
PCR	I-PRGE
,	O
so	O
the	O
presence	O
of	O
virus	O
alone	O
may	O
not	O
explain	O
all	O
cases	O
of	O
false	O
-	O
negative	O
FCoV	O
antibody	O
tests	O
,	O
although	O
it	O
is	O
a	O
possible	O
explanation	O
in	O
71	O
%	O
of	O
discordant	O
samples	O
.	O

In	O
in	O
vitro	O
systems	O
,	O
histones	O
damaged	O
endothelial	O
cells	O
,	O
stimulated	O
cytokine	O
release	O
,	O
and	O
induced	O
neutrophil	O
extracellular	O
trap	O
formation	O
and	O
myeloperoxidase	B-PRGE
release	O
.	O

In	O
mouse	O
models	O
,	O
cytokines	O
and	O
markers	O
for	O
endothelial	O
damage	O
and	O
coagulation	O
activation	O
significantly	O
increased	O
immediately	O
after	O
trauma	O
or	O
histone	B-PRGE
infusion	O
.	O

An	O
anti	B-PRGE
-	I-PRGE
histone	I-PRGE
antibody	I-PRGE
could	O
reduce	O
these	O
changes	O
and	O
protect	O
mice	O
from	O
histone	B-PRGE
-	O
induced	O
lethality	O
.	O

Here	O
we	O
investigated	O
whether	O
it	O
might	O
utilize	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
.	O

Single	O
-	O
fibre	O
electromyography	O
showed	O
a	O
pathological	O
jitter	O
and	O
acetylcholine	B-PRGE
anti	I-PRGE
-	I-PRGE
receptor	I-PRGE
antibodies	I-PRGE
were	O
positive	O
.	O

B7	B-PRGE
-	I-PRGE
H1	I-PRGE
-	O
mediated	O
restraint	O
of	O
CD4	B-PRGE
T	O
-	O
cell	O
activity	O
is	O
thus	O
crucial	O
to	O
dampen	O
both	O
CD8	B-PRGE
T	O
-	O
cell	O
function	O
and	O
microglia	O
/	O
macrophage	O
activation	O
,	O
thereby	O
providing	O
protection	O
from	O
T	O
-	O
cell	O
-	O
mediated	O
bystander	O
damage	O
.	O

Despite	O
nearly	O
six	O
decades	O
having	O
passed	O
since	O
its	O
first	O
emergence	O
,	O
different	O
studies	O
have	O
shown	O
that	O
type	B-PRGE
II	I-PRGE
FCoV	I-PRGE
represents	O
only	O
a	O
small	O
portion	O
of	O
the	O
total	O
FCoV	O
seropositivity	O
in	O
cats	O
;	O
hence	O
,	O
there	O
is	O
very	O
limited	O
knowledge	O
of	O
the	O
evolution	O
of	O
type	B-PRGE
II	I-PRGE
FCoV	I-PRGE
.	O
To	O
elucidate	O
the	O
correlation	O
between	O
viral	O
emergence	O
and	O
FIP	O
,	O
a	O
local	O
isolate	O
(	O
NTU156	O
)	O
that	O
was	O
derived	O
from	O
a	O
FIP	O
cat	O
was	O
analyzed	O
along	O
with	O
other	O
worldwide	O
strains	O
.	O

TITLE	O
:	O
Design	O
and	O
synthesis	O
of	O
new	O
tripeptide	B-PRGE
-	I-PRGE
type	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
protease	O
inhibitors	O
containing	O
an	O
electrophilic	O
arylketone	O
moiety	O
.	O

Efficacy	O
was	O
evaluated	O
as	O
changes	O
in	O
lung	O
compliance	O
(	O
Cdyn	O
)	O
and	O
gas	B-PRGE
exchange	I-PRGE
1	I-PRGE
,	O
12	O
,	O
and	O
24	O
hr	O
after	O
the	O
RM	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
obesity	O
,	O
intraperitoneal	O
fat	O
volume	O
,	O
and	O
a	O
longer	O
cumulative	O
duration	O
spent	O
in	O
the	O
prone	O
position	O
may	O
put	O
patients	O
with	O
ARDS	O
at	O
risk	O
of	O
developing	O
SC	B-PRGE
-	I-PRGE
CIP	I-PRGE
.	O

For	O
the	O
first	O
PCR	O
,	O
primers	O
that	O
were	O
specific	O
for	O
each	O
virus	O
were	O
newly	O
designed	O
from	O
the	O
nucleoprotein	O
gene	O
of	O
AIV	O
,	O
the	O
nucleocapsid	B-PRGE
protein	I-PRGE
gene	I-PRGE
of	O
IBV	O
and	O
the	O
fusion	O
protein	O
gene	O
of	O
NDV	O
to	O
amplify	O
products	O
of	O
665	O
,	O
386	O
and	O
236	O
nucleotides	O
,	O
respectively	O
.	O

To	O
examine	O
the	O
role	O
of	O
CCL2	B-PRGE
during	O
virus	O
infection	O
,	O
we	O
infected	O
mice	O
transgenically	O
expressing	O
CCL2	B-PRGE
in	O
the	O
central	O
nervous	O
system	O
(	O
CCL2	B-PRGE
Tg	O
)	O
with	O
an	O
attenuated	O
neurotropic	O
coronavirus	O
(	O
rJ2	O
.	O
2	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
).	O

ABSTRACT	O
:	O
Coronavirus	O
nsp1	B-PRGE
has	O
been	O
shown	O
to	O
induce	O
suppression	O
of	O
host	O
gene	O
expression	O
and	O
to	O
interfere	O
with	O
the	O
host	O
immune	O
response	O
.	O

The	O
only	O
available	O
structural	O
information	O
on	O
coronavirus	O
nsp1	B-PRGE
is	O
the	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
structure	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
nsp1	B-PRGE
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
from	O
the	O
betacoronavirus	O
genus	O
.	O

ABSTRACT	O
:	O
Conditional	O
ligands	O
have	O
enabled	O
the	O
high	O
-	O
throughput	O
production	O
of	O
human	B-PRGE
leukocyte	I-PRGE
antigen	I-PRGE
(	O
HLA	B-PRGE
)	O
libraries	O
that	O
present	O
defined	O
peptides	O
.	O

TITLE	O
:	O
Astrocyte	O
-	O
derived	O
CXCL10	B-PRGE
drives	O
accumulation	O
of	O
antibody	O
-	O
secreting	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
during	O
viral	O
encephalomyelitis	O
.	O

The	O
CoV	B-PRGE
nucleocapsid	I-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
protein	I-PRGE
contains	O
two	O
structurally	O
independent	O
RNA	O
binding	O
domains	O
,	O
designated	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
and	O
the	O
dimeric	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
),	O
joined	O
by	O
a	O
charged	O
linker	O
region	O
rich	O
in	O
serine	O
and	O
arginine	O
residues	O
(	O
SR	O
-	O
rich	O
linker	O
).	O

This	O
indicates	O
that	O
the	O
key	O
nsp3a	B-PRGE
binding	I-PRGE
determinants	I-PRGE
localize	O
to	O
the	O
SR	O
-	O
rich	O
linker	O
,	O
a	O
finding	O
consistent	O
with	O
those	O
of	O
reverse	O
genetics	O
studies	O
.	O

We	O
found	O
,	O
however	O
,	O
a	O
correlation	O
between	O
HBP	B-PRGE
levels	O
and	O
development	O
of	O
ARDS	O
(	O
P	O
=	O
0	O
.	O
026	O
,	O
n	O
=	O
47	O
),	O
but	O
not	O
to	O
severe	O
sepsis	O
.	O

We	O
found	O
,	O
however	O
,	O
a	O
correlation	O
between	O
HBP	B-PRGE
levels	O
and	O
development	O
of	O
ARDS	O
(	O
P	O
=	O
0	O
.	O
026	O
,	O
n	O
=	O
47	O
),	O
but	O
not	O
to	O
severe	O
sepsis	O
.	O

TITLE	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
EMC	I-PRGE
is	O
not	O
the	O
same	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

The	O
ethanol	O
extract	O
of	O
the	O
seeds	O
of	O
Psoralea	O
corylifolia	O
showed	O
high	O
activity	O
against	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
with	O
an	O
IC50	O
of	O
value	O
of	O
15	O
Âµg	O
/	O
ml	O
.	O

TITLE	O
:	O
Activation	O
of	O
the	O
heat	O
shock	O
response	O
attenuates	O
the	O
interleukin	B-PRGE
1Î²	I-PRGE
-	O
mediated	O
inhibition	O
of	O
the	O
amiloride	O
-	O
sensitive	O
alveolar	O
epithelial	O
ion	O
transport	O
.	O

Heat	O
shock	O
results	O
in	O
IRAK1	B-PRGE
detergent	O
insolubility	O
and	O
a	O
disruption	O
of	O
Hsp90	B-PRGE
binding	O
to	O
IRAK1	B-PRGE
.	O

We	O
hypothesized	O
that	O
NOS	B-PRGE
substrate	O
levels	O
are	O
low	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
that	O
low	O
levels	O
of	O
the	O
NOS	O
substrate	O
citrulline	O
would	O
be	O
associated	O
with	O
end	O
organ	O
damage	O
including	O
ARDS	O
in	O
severe	O
sepsis	O
.	O

This	O
review	O
summarizes	O
and	O
discusses	O
the	O
structure	O
and	O
multiple	O
functions	O
of	O
ACE2	B-PRGE
and	O
the	O
relevance	O
of	O
this	O
key	O
enzyme	O
in	O
disease	O
pathogenesis	O
.	O

The	O
PEDV	B-PRGE
E	I-PRGE
protein	I-PRGE
has	O
no	O
effect	O
on	O
the	O
intestinal	O
epithelial	O
cells	O
(	O
IEC	O
)	O
growth	O
,	O
cell	O
cycle	O
and	O
cyclin	B-PRGE
A	I-PRGE
expression	O
.	O

Further	O
studies	O
show	O
that	O
PEDV	B-PRGE
E	I-PRGE
protein	I-PRGE
induced	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
activated	O
NF	O
-	O
ÎºB	O
which	O
is	O
responsible	O
for	O
the	O
up	O
-	O
regulation	O
of	O
IL	O
-	O
8	O
and	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

RESULTS	O
:	O
The	O
results	O
show	O
that	O
plenty	O
of	O
PEDV	B-PRGE
E	I-PRGE
protein	I-PRGE
is	O
localized	O
in	O
the	O
ER	O
,	O
with	O
small	O
quantities	O
localized	O
in	O
the	O
nucleus	O
.	O

TITLE	O
:	O
Interferon	B-PRGE
alpha	I-PRGE
-	O
armed	O
nanoparticles	O
trigger	O
rapid	O
and	O
sustained	O
STAT1	B-PRGE
-	I-PRGE
dependent	O
anti	O
-	O
viral	O
cellular	O
responses	O
.	O

In	O
conclusion	O
,	O
an	O
appropriate	O
dose	O
of	O
SPP	B-PRGE
may	O
be	O
a	O
safe	O
and	O
efficacious	O
immune	O
stimulator	O
candidate	O
that	O
is	O
suitable	O
for	O
vaccines	O
to	O
produce	O
early	O
and	O
persistent	O
prophylaxis	O
.	O

Across	O
intracellular	O
and	O
extracellular	O
GSH	O
pools	O
in	O
alveolar	O
type	O
II	O
cells	O
and	O
alveolar	O
macrophages	O
,	O
chronic	O
alcohol	O
ingestion	O
consistently	O
induced	O
a	O
40	O
-	O
60	O
mV	O
oxidation	O
of	O
GSH	B-PRGE
/	O
GSSG	O
suggesting	O
that	O
the	O
redox	O
potentials	O
of	O
different	O
alveolar	O
GSH	O
pools	O
are	O
in	O
equilibrium	O
.	O

ADORA2A	B-PRGE
is	O
protective	O
against	O
lung	O
injury	O
after	O
LPS	O
and	O
oxygen	O
.	O

Recommendations	O
specific	O
to	O
pediatric	O
severe	O
sepsis	O
include	O
:	O
therapy	O
with	O
face	O
mask	O
oxygen	O
,	O
high	O
flow	O
nasal	O
cannula	O
oxygen	O
,	O
or	O
nasopharyngeal	O
continuous	O
PEEP	O
in	O
the	O
presence	O
of	O
respiratory	O
distress	O
and	O
hypoxemia	O
(	O
2C	O
),	O
use	O
of	O
physical	O
examination	O
therapeutic	O
endpoints	O
such	O
as	O
capillary	O
refill	O
(	O
2C	O
);	O
for	O
septic	O
shock	O
associated	O
with	O
hypovolemia	O
,	O
the	O
use	O
of	O
crystalloids	O
or	O
albumin	B-PRGE
to	O
deliver	O
a	O
bolus	O
of	O
20	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
or	O
albumin	B-PRGE
equivalent	O
)	O
over	O
5	O
-	O
10	O
min	O
(	O
2C	O
);	O
more	O
common	O
use	O
of	O
inotropes	O
and	O
vasodilators	O
for	O
low	O
cardiac	O
output	O
septic	O
shock	O
associated	O
with	O
elevated	O
systemic	O
vascular	O
resistance	O
(	O
2C	O
);	O
and	O
use	O
of	O
hydrocortisone	O
only	O
in	O
children	O
with	O
suspected	O
or	O
proven	O
""""	O
absolute	O
"""'"	O
adrenal	O
insufficiency	O
(	O
2C	O
).	O

We	O
genotyped	O
the	O
insertion	O
/	O
deletion	O
polymorphism	O
of	O
the	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
(	O
ACE	B-PRGE
)	O
gene	O
(	O
polymerase	O
chain	O
reaction	O
)	O
and	O
the	O
following	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
TaqMan	O
SNP	O
genotyping	O
assay	O
):	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
Î±	I-PRGE
-	O
376	O
G	O
/	O
A	O
,	O
-	O
308	O
G	O
/	O
A	O
,	O
and	O
-	O
238	O
G	O
/	O
A	O
;	O
interleukin	B-PRGE
8	I-PRGE
-	O
251	O
T	O
/	O
A	O
;	O
pre	O
-	O
B	O
cell	O
colony	O
-	O
enhancing	O
factor	O
-	O
1001	O
G	O
/	O
T	O
;	O
and	O
vascular	B-PRGE
endothelial	I-PRGE
growth	I-PRGE
factor	I-PRGE
+	I-PRGE
405	I-PRGE
C	I-PRGE
/	O
G	O
and	O
+	O
936	O
C	O
/	O
T	O
.	O
Polymorphisms	O
were	O
selected	O
based	O
on	O
reports	O
on	O
their	O
association	O
with	O
ARDS	O
.	O

By	O
bioinformatic	O
and	O
systems	O
biology	O
approaches	O
,	O
we	O
evaluated	O
the	O
impact	O
of	O
nuclear	O
import	O
antagonism	O
on	O
host	O
expression	O
networks	O
by	O
using	O
human	O
lung	O
epithelial	O
cells	O
infected	O
with	O
either	O
wild	O
-	O
type	O
virus	O
or	O
a	O
mutant	O
that	O
does	O
not	O
express	O
ORF6	B-PRGE
protein	I-PRGE
.	O

In	O
this	O
study	O
,	O
the	O
N	O
genes	O
of	O
15	O
PEDV	O
strains	O
were	O
amplified	O
by	O
RT	O
-	O
PCR	O
and	O
cloned	O
into	O
the	O
pMT	B-PRGE
-	I-PRGE
19T	I-PRGE
vector	O
,	O
sequenced	O
,	O
and	O
compared	O
to	O
each	O
other	O
as	O
well	O
as	O
to	O
PEDV	O
reference	O
strains	O
.	O

Higher	O
levels	O
of	O
sVEGFR1	O
and	O
Ang2	B-PRGE
were	O
observed	O
in	O
the	O
ALI	O
and	O
ARDS	O
patients	O
than	O
in	O
the	O
non	O
-	O
ALI	O
/	O
ARDS	O
patients	O
during	O
the	O
entire	O
study	O
period	O
.	O

Angiogenic	O
factors	O
and	O
their	O
soluble	O
receptors	O
,	O
particularly	O
sVEGFR2	O
and	O
Ang2	B-PRGE
,	O
are	O
thus	O
considered	O
to	O
be	O
valuable	O
predictive	O
biomarkers	O
in	O
the	O
development	O
of	O
ALI	O
/	O
ARDS	O
associated	O
with	O
critical	O
illness	O
and	O
mortality	O
in	O
ALI	O
/	O
ARDS	O
patients	O
.	O

Moreover	O
,	O
Ang2	B-PRGE
and	O
sVEGFR2	O
also	O
independently	O
predicted	O
the	O
mortality	O
in	O
ALI	O
/	O
ARDS	O
patients	O
.	O

Kallistatin	B-PRGE
,	O
an	O
endogenous	O
tissue	O
kallikrein	O
inhibitor	O
,	O
has	O
been	O
reported	O
to	O
be	O
protective	O
in	O
various	O
human	O
diseases	O
.	O

We	O
observed	O
lower	O
antibody	O
responses	O
to	O
the	O
vaccines	O
that	O
produced	O
lower	O
viral	O
loads	O
,	O
which	O
might	O
contribute	O
to	O
the	O
persistence	O
of	O
Ark	B-PRGE
serotype	O
IBV	O
vaccines	O
observed	O
in	O
commercial	O
flocks	O
.	O

To	O
dissect	O
this	O
dual	O
specificity	O
,	O
which	O
relies	O
on	O
a	O
single	O
catalytic	O
site	O
,	O
we	O
determined	O
the	O
crystal	O
structure	O
of	O
equine	O
arteritis	O
virus	O
PLP2	B-PRGE
in	O
complex	O
with	O
ubiquitin	O
(	O
1	O
.	O
45	O
Ã	O
).	O

HBP	B-PRGE
concentrations	O
are	O
markedly	O
elevated	O
in	O
all	O
critically	O
ill	O
patients	O
with	O
influenza	O
A	O
(	O
H1N1	O
)	O
infection	O
.	O

The	O
small	O
open	O
reading	O
frames	O
situated	O
between	O
the	O
spike	O
and	O
envelope	B-PRGE
genes	O
of	O
most	O
of	O
the	O
CRCoV	O
strains	O
(	O
except	O
the	O
CRCoV	O
4180	O
strain	O
)	O
were	O
found	O
to	O
encode	O
three	O
nonstructural	O
proteins	O
(	O
4	O
.	O
9	O
kDa	O
,	O
2	O
.	O
7	O
kDa	O
,	O
and	O
12	O
.	O
8	O
kDa	O
),	O
while	O
those	O
of	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
encode	O
another	O
three	O
nonstructural	O
proteins	O
(	O
4	O
.	O
9	O
kDa	O
,	O
4	O
.	O
8	O
kDa	O
,	O
and	O
12	O
.	O
7	O
kDa	O
)	O
and	O
those	O
of	O
a	O
recently	O
isolated	O
bovine	O
respiratory	O
coronavirus	O
(	O
BRCoV	O
)	O
were	O
found	O
to	O
encode	O
only	O
two	O
nonstructural	O
proteins	O
(	O
4	O
.	O
9	O
kDa	O
and	O
12	O
.	O
7	O
kDa	O
).	O

IAH	O
and	O
ACS	B-PRGE
are	O
relatively	O
frequent	O
findings	O
in	O
patiens	O
with	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
)	O
and	O
are	O
associated	O
with	O
deterioration	O
in	O
organ	O
functions	O
.	O

Interferon	B-PRGE
(	O
IFN	O
)-	O
Î±	O
is	O
well	O
known	O
as	O
an	O
antiviral	O
cytokine	O
and	O
low	O
-	O
dose	O
IFN	B-PRGE
-	I-PRGE
Î±	I-PRGE
has	O
been	O
reported	O
to	O
show	O
antiinflammatory	O
effects	O
.	O

This	O
case	O
expands	O
our	O
understanding	O
of	O
the	O
complications	O
of	O
PNL	O
and	O
underscores	O
the	O
importance	O
of	O
differentiating	O
CIP	B-PRGE
/	O
CIM	B-PRGE
from	O
GBS	O
in	O
case	O
of	O
such	O
patients	O
developing	O
weakness	O
after	O
the	O
treatment	O
.	O

ABSTRACT	O
:	O
Bovine	O
torovirus	O
(	O
BToV	O
)-	O
Aichi	O
,	O
recently	O
isolated	O
in	O
cultured	O
cells	O
,	O
showed	O
hemagglutination	O
(	O
HA	O
)	O
activity	O
,	O
although	O
the	O
virus	O
has	O
a	O
truncated	O
hemagglutinin	B-PRGE
-	I-PRGE
esterase	I-PRGE
(	O
HE	O
)	O
protein	O
,	O
judging	O
from	O
its	O
gene	O
structure	O
,	O
indicating	O
the	O
existence	O
of	O
another	O
viral	O
protein	O
with	O
HA	O
activity	O
.	O

Acute	O
rejection	O
,	O
lymphocytic	O
bronchiolitis	O
,	O
colonization	O
with	O
pseudomonas	O
,	O
infection	O
,	O
and	O
BAL	O
eosinophilia	O
and	O
neutrophilia	O
are	O
risk	O
factors	O
for	O
the	O
later	O
development	O
not	O
only	O
of	O
RAS	B-PRGE
but	O
also	O
of	O
BOS	O
.	O

Eight	O
markers	O
(	O
Bartonella	O
spp	O
,	O
CD11d	B-PRGE
,	O
high	O
molecular	O
weight	O
cytokeratins	O
,	O
feline	O
coronavirus	O
,	O
GATA	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
insulin	B-PRGE
,	O
p63	B-PRGE
,	O
progesterone	B-PRGE
receptor	I-PRGE
)	O
had	O
minimal	O
decrease	O
in	O
immunoreactivity	O
,	O
regardless	O
of	O
treatment	O
.	O

An	O
immunoassay	O
specific	O
for	O
p14	B-PRGE
endocan	I-PRGE
fragment	I-PRGE
was	O
then	O
developed	O
,	O
and	O
revealed	O
increased	O
plasma	O
levels	O
of	O
p14	B-PRGE
in	O
20	O
out	O
of	O
55	O
severe	O
septic	O
patients	O
,	O
ranging	O
from	O
0	O
.	O
52	O
to	O
10	O
.	O
40	O
ng	O
/	O
mL	O
versus	O
undetectable	O
p14	B-PRGE
in	O
plasma	O
from	O
32	O
control	O
subjects	O
(	O
p	O
=	O
0	O
.	O
0011	O
).	O

A	O
Gram	O
-	O
positive	O
,	O
chain	O
-	O
forming	O
coccus	O
was	O
isolated	O
from	O
the	O
primary	O
organs	O
and	O
tissues	O
of	O
diseased	O
rabbits	O
and	O
then	O
identified	O
as	O
S	O
.	O
agalactiae	O
by	O
morphology	O
,	O
biochemical	O
and	O
physiological	O
characteristics	O
,	O
16S	O
rDNA	O
and	O
gyrB	B-PRGE
gene	O
sequences	O
analysis	O
.	O

Directed	O
protease	O
expression	O
and	O
inhibition	O
analyses	O
revealed	O
that	O
TMPRSS2	B-PRGE
and	O
endosomal	O
cathepsins	O
activate	O
EMC	O
-	O
S	O
for	O
virus	O
-	O
cell	O
fusion	O
and	O
constitute	O
potential	O
targets	O
for	O
antiviral	O
intervention	O
.	O

For	O
primary	O
response	O
to	O
SRBC	O
administered	O
at	O
7	O
d	O
of	O
age	O
,	O
HYPER	O
chicks	O
recorded	O
higher	O
total	O
,	O
IgM	B-PRGE
(	O
d	O
14	O
),	O
and	O
IgG	B-PRGE
(	O
d	O
21	O
)	O
anti	O
-	O
SRBC	O
antibody	O
titers	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
severe	O
Cushing	O
'	O
s	O
syndrome	O
developing	O
into	O
life	O
-	O
threatening	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
cryptococcus	O
and	O
cytomegalovirus	O
co	O
-	O
infection	O
soon	O
after	O
hypercortisolism	O
treatment	O
using	O
metyrapone	O
,	O
an	O
11	B-PRGE
-	I-PRGE
beta	I-PRGE
-	I-PRGE
hydroxylase	I-PRGE
inhibitor	O
.	O

Here	O
we	O
identify	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
;	O
also	O
known	O
as	O
CD26	B-PRGE
)	O
as	O
a	O
functional	O
receptor	O
for	O
hCoV	B-PRGE
-	I-PRGE
EMC	I-PRGE
.	O

TITLE	O
:	O
Crystal	O
structure	O
-	O
based	O
exploration	O
of	O
the	O
important	O
role	O
of	O
Arg106	O
in	O
the	O
RNA	O
-	O
binding	O
domain	O
of	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
.	O

Twenty	O
-	O
nine	O
out	O
of	O
150	O
pooled	O
fecal	O
samples	O
tested	O
positive	O
by	O
reverse	O
transcription	O
-	O
PCR	O
contained	O
fragments	O
of	O
the	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
gene	I-PRGE
of	O
coronavirus	O
-	O
related	O
viruses	O
.	O

CVVH	O
was	O
employed	O
when	O
the	O
values	O
of	O
creatine	O
phosphokinase	O
(	O
CPK	B-PRGE
),	O
myoglobin	B-PRGE
(	O
Mb	O
),	O
and	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
LDH	B-PRGE
)	O
increased	O
significantly	O
.	O

The	O
incidences	O
of	O
pancreatic	O
sepsis	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
and	O
mortality	O
were	O
lower	O
in	O
the	O
somatostatin	B-PRGE
,	O
somatostatin	B-PRGE
+	I-PRGE
ulinastatin	I-PRGE
,	O
somatostatin	B-PRGE
+	I-PRGE
S	I-PRGE
miltiorrhiza	I-PRGE
and	O
somatostatin	B-PRGE
+	O
ulinastatin	B-PRGE
+	I-PRGE
S	I-PRGE
miltiorrhiza	O
subgroups	O
compared	O
with	O
the	O
basic	O
treatment	O
subgroup	O
.	O

RESULTS	O
:	O
Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
Î±	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
levels	O
on	O
the	O
fourth	O
and	O
seventh	O
days	O
,	O
and	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
on	O
the	O
seventh	O
day	O
after	O
treatment	O
showed	O
significant	O
decrease	O
in	O
the	O
somatostatin	B-PRGE
,	O
somatostatin	B-PRGE
+	I-PRGE
ulinastatin	I-PRGE
,	O
somatostatin	B-PRGE
+	I-PRGE
S	I-PRGE
miltiorrhiza	I-PRGE
and	O
somatostatin	B-PRGE
+	O
ulinastatin	B-PRGE
+	I-PRGE
S	I-PRGE
miltiorrhiza	O
subgroups	O
compared	O
with	O
the	O
basic	O
treatment	O
subgroup	O
.	O

Lymphocyte	O
proliferation	O
assay	O
,	O
virus	O
neutralization	O
assay	O
,	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
assay	O
and	O
CTL	O
activity	O
assay	O
were	O
performed	O
.	O

The	O
viral	O
spike	O
(	O
S	O
)	O
protein	O
is	O
incorporated	O
into	O
the	O
viral	B-PRGE
envelope	I-PRGE
and	O
mediates	O
infectious	O
entry	O
of	O
HCoV	O
-	O
229E	O
into	O
host	O
cells	O
,	O
a	O
process	O
that	O
depends	O
on	O
the	O
activation	O
of	O
the	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
by	O
host	O
cell	O
proteases	O
.	O

Finally	O
,	O
immunohistochemistry	O
revealed	O
that	O
TMPRSS2	B-PRGE
is	O
coexpressed	O
with	O
CD13	B-PRGE
,	O
the	O
HCoV	B-PRGE
-	I-PRGE
229E	I-PRGE
receptor	I-PRGE
,	O
in	O
human	O
airway	O
epithelial	O
(	O
HAE	O
)	O
cells	O
,	O
and	O
that	O
CD13	B-PRGE
(+)	O
TMPRSS2	O
(+)	O
cells	O
are	O
preferentially	O
targeted	O
by	O
HCoV	O
-	O
229E	O
,	O
suggesting	O
that	O
TMPRSS2	B-PRGE
can	O
activate	O
HCoV	O
-	O
229E	O
in	O
infected	O
humans	O
.	O

Two	O
of	O
the	O
12	O
critical	O
residues	O
identified	O
to	O
be	O
essential	O
for	O
the	O
N7	B-PRGE
-	I-PRGE
MTase	I-PRGE
were	O
located	O
at	O
the	O
N	O
terminus	O
of	O
the	O
core	O
ExoN	B-PRGE
domain	I-PRGE
,	O
reinforcing	O
a	O
role	O
of	O
the	O
ExoN	B-PRGE
domain	I-PRGE
in	O
the	O
N7	B-PRGE
-	I-PRGE
MTase	I-PRGE
activity	O
of	O
nsp14	O
.	O

In	O
this	O
series	O
,	O
seven	O
cases	O
of	O
AAC	B-PRGE
from	O
a	O
cohort	O
of	O
42	O
adult	O
patients	O
with	O
severe	O
imported	O
falciparum	O
malaria	O
[	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
criteria	O
]	O
are	O
presented	O
.	O

HCoV	B-PRGE
-	I-PRGE
EMC	I-PRGE
productively	O
replicated	O
in	O
human	O
bronchial	O
and	O
lung	O
ex	O
vivo	O
organ	O
cultures	O
.	O

While	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
productively	O
replicated	O
in	O
lung	O
tissue	O
,	O
replication	O
in	O
human	O
bronchial	O
tissue	O
was	O
limited	O
.	O

In	O
addition	O
,	O
other	O
PS	B-PRGE
-	I-PRGE
binding	I-PRGE
proteins	I-PRGE
,	O
such	O
as	O
Axl	B-PRGE
and	O
TIM4	B-PRGE
,	O
promoted	O
infection	O
similarly	O
to	O
TIM1	B-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
established	O
a	O
porcine	O
intestinal	O
epithelial	O
cell	O
(	O
IEC	O
)	O
line	O
which	O
can	O
stably	O
express	O
PEDV	B-PRGE
N	I-PRGE
protein	I-PRGE
.	O

An	O
oxygenator	O
used	O
in	O
conjunction	O
with	O
a	O
VAD	B-PRGE
may	O
be	O
a	O
life	O
-	O
saving	O
therapy	O
,	O
allowing	O
adequate	O
oxygenation	O
and	O
ventilation	O
in	O
severe	O
respiratory	O
and	O
cardiac	O
failure	O
.	O

TITLE	O
:	O
Complete	O
protection	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
-	O
mediated	O
lethal	O
respiratory	O
disease	O
in	O
aged	O
mice	O
by	O
immunization	O
with	O
a	O
mouse	O
-	O
adapted	O
virus	O
lacking	O
E	B-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
Acute	O
-	O
phase	O
concentrations	O
of	O
soluble	O
fibrinogen	B-PRGE
inhibit	O
neutrophil	O
adhesion	O
under	O
flow	O
conditions	O
in	O
vitro	O
through	O
interactions	O
with	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
MAC	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
CD11b	B-PRGE
/	O
CD18	B-PRGE
).	O

Ornithobacterium	O
rhinotracheale	O
(	O
ORT	O
)	O
was	O
isolated	O
from	O
respiratory	O
tract	O
tissues	O
,	O
and	O
16S	B-PRGE
rRNA	I-PRGE
gene	I-PRGE
sequencing	O
on	O
three	O
isolates	O
revealed	O
two	O
distinct	O
genotypes	O
,	O
one	O
previously	O
associated	O
with	O
some	O
electrophoretic	O
type	O
(	O
ET	O
)	O
1	O
strains	O
and	O
the	O
other	O
a	O
novel	O
genotype	O
that	O
clustered	O
among	O
sequences	O
previously	O
associated	O
with	O
ET	O
3	O
,	O
ET	O
4	O
,	O
ET	O
5	O
and	O
ET	O
6	O
isolates	O
.	O

Plasminogen	B-PRGE
activator	I-PRGE
inhibitor	I-PRGE
(	O
PAI	B-PRGE
)	O
by	O
means	O
of	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
PAI	O
-	O
1	O
4G	O
/	O
5G	O
polymorphism	O
was	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
and	O
solid	O
phase	O
oligonucleotide	O
assay	O
.	O

RESULTS	O
:	O
The	O
blood	O
agents	O
of	O
post	O
-	O
SARS	O
patients	O
changed	O
obviously	O
with	O
15	O
.	O
64	O
Â±	O
13	O
.	O
85	O
U	O
/	O
ml	O
while	O
the	O
control	O
group	O
7	O
.	O
96	O
Â±	O
4	O
.	O
27	O
U	O
/	O
ml	O
;	O
4G	O
/	O
4G	O
genotype	O
for	O
the	O
PAI	B-PRGE
-	I-PRGE
1	I-PRGE
polymorphism	O
detected	O
in	O
post	O
-	O
SARS	O
group	O
was	O
more	O
than	O
that	O
of	O
the	O
control	O
group	O
,	O
but	O
had	O
no	O
statistical	O
significance	O
.	O

To	O
assess	O
the	O
function	O
of	O
a	O
relatively	O
conserved	O
domain	O
(	O
LLRKxGxKG	O
)	O
of	O
MHV	B-PRGE
nsp1	I-PRGE
,	O
a	O
mutant	O
virus	O
,	O
MHV	B-PRGE
-	I-PRGE
nsp1	I-PRGE
-	I-PRGE
27D	I-PRGE
,	O
with	O
a	O
27	O
nts	O
(	O
LLRKxGxKG	O
)	O
deletion	O
in	O
nsp1	B-PRGE
,	O
was	O
constructed	O
using	O
a	O
reverse	O
genetic	O
system	O
with	O
a	O
vaccinia	O
virus	O
vector	O
.	O

Furthermore	O
,	O
urine	O
L	O
/	O
M	O
ratio	O
and	O
serum	B-PRGE
endotoxin	I-PRGE
were	O
significantly	O
lower	O
in	O
the	O
SH	O
group	O
and	O
further	O
decreased	O
in	O
the	O
SHG	O
group	O
.	O

TITLE	O
:	O
Expression	O
and	O
Purification	O
of	O
the	O
scFv	O
from	O
hybridoma	O
cells	O
secreting	O
a	O
monoclonal	O
antibody	O
against	O
S	B-PRGE
PROTEIN	I-PRGE
of	O
PEDV	O
.	O

TITLE	O
:	O
A	O
monoclonal	O
antibody	O
against	O
transmissible	O
gastroenteritis	O
virus	O
generated	O
via	O
immunization	O
of	O
a	O
DNA	O
plasmid	O
bearing	O
TGEV	B-PRGE
S1	I-PRGE
gene	I-PRGE
.	O

rTM	O
administration	O
prolonged	O
the	O
survival	O
time	O
and	O
ameliorated	O
the	O
development	O
of	O
ARDS	O
,	O
which	O
was	O
associated	O
with	O
increased	O
T	O
(	O
reg	O
)	O
cells	O
and	O
synthesis	O
of	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)-	I-PRGE
10	I-PRGE
and	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
(	I-PRGE
TGF	I-PRGE
)-	I-PRGE
Î²	I-PRGE
in	O
the	O
lungs	O
.	O

TITLE	O
:	O
MERS	O
-	O
coronavirus	O
replication	O
induces	O
severe	O
in	O
vitro	O
cytopathology	O
and	O
is	O
strongly	O
inhibited	O
by	O
cyclosporin	O
A	O
or	O
interferon	B-PRGE
-	I-PRGE
Î±	I-PRGE
treatment	O
.	O

MERS	O
-	O
CoV	O
infection	O
did	O
not	O
prevent	O
the	O
IFN	B-PRGE
-	O
induced	O
nuclear	O
translocation	O
of	O
phosphorylated	O
STAT1	B-PRGE
,	O
in	O
contrast	O
to	O
infection	O
with	O
SARS	O
-	O
CoV	O
where	O
this	O
block	O
inhibits	O
the	O
expression	O
of	O
antiviral	O
genes	O
.	O

ABSTRACT	O
:	O
Anti	B-PRGE
-	I-PRGE
NMDA	I-PRGE
receptor	I-PRGE
encephalitis	O
is	O
a	O
newly	O
characterized	O
severe	O
neuroautoimmune	O
syndrome	O
with	O
a	O
progressive	O
,	O
clinical	O
course	O
.	O

Overall	O
,	O
142	O
cellular	O
proteins	O
were	O
selected	O
as	O
potentially	O
binding	O
to	O
the	O
N	B-PRGE
protein	I-PRGE
,	O
many	O
as	O
part	O
of	O
larger	O
possible	O
complexes	O
.	O

These	O
included	O
ribosomal	O
proteins	O
,	O
nucleolar	O
proteins	O
,	O
translation	O
initiation	O
factors	O
,	O
helicases	B-PRGE
,	O
and	O
hnRNPs	O
.	O

Thus	O
,	O
nsp1	B-PRGE
is	O
a	O
promising	O
target	O
for	O
drugs	O
,	O
as	O
inhibition	O
of	O
nsp1	B-PRGE
would	O
make	O
SARS	O
-	O
CoV	O
more	O
susceptible	O
to	O
the	O
host	O
antiviral	O
defenses	O
.	O

High	O
-	O
level	O
expression	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
was	O
achieved	O
in	O
Escherichia	O
coli	O
.	O

The	O
immunoreactivity	O
between	O
PEDV	O
particles	O
or	O
the	O
bacterially	O
expressed	O
N	B-PRGE
protein	I-PRGE
and	O
rabbit	O
anti	O
-	O
PEDV	O
serum	O
was	O
confirmed	O
by	O
immunofluorescence	O
assays	O
and	O
Western	O
blot	O
.	O

ICU	O
-	O
admitted	O
patients	O
with	O
SCAP	B-PRGE
were	O
studied	O
prospectively	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
p53	B-PRGE
and	O
p38	B-PRGE
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinases	I-PRGE
(	O
MAPK	B-PRGE
)	O
signalling	O
pathways	O
in	O
the	O
interaction	O
of	O
TGEV	O
with	O
host	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
TGEV	O
infection	O
promoted	O
the	O
activation	O
of	O
p38	B-PRGE
MAPK	I-PRGE
and	O
p53	B-PRGE
signalling	I-PRGE
,	O
and	O
p53	B-PRGE
signalling	O
might	O
play	O
a	O
dominant	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
apoptosis	O
.	O

The	O
HLH	O
continued	O
to	O
progress	O
after	O
discontinuation	O
of	O
blinatumomab	O
;	O
however	O
,	O
he	O
had	O
rapid	O
improvement	O
after	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
receptor	O
-	O
directed	O
therapy	O
with	O
tocilizumab	O
.	O

We	O
report	O
the	O
discovery	O
and	O
characterization	O
of	O
small	B-PRGE
-	I-PRGE
molecule	I-PRGE
inhibitors	O
of	O
SARS	O
-	O
CoV	O
replication	O
that	O
block	O
viral	O
entry	O
by	O
three	O
different	O
mechanisms	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
activation	O
of	O
the	O
protein	B-PRGE
kinase	I-PRGE
R	O
-	O
like	O
ER	O
kinase	O
(	O
PERK	B-PRGE
)	O
pathway	O
of	O
UPR	O
in	O
cells	O
infected	O
with	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
its	O
relationship	O
with	O
IBV	O
-	O
induced	O
apoptosis	O
.	O

Mutations	O
in	O
MMADHC	B-PRGE
lead	O
to	O
three	O
distinct	O
phenotypes	O
:	O
cblD	B-PRGE
-	O
MMA	B-PRGE
,	O
cblD	B-PRGE
-	I-PRGE
HC	I-PRGE
,	O
and	O
cblD	B-PRGE
-	O
MMA	B-PRGE
/	O
HC	O
.	O

One	O
of	O
these	O
patients	O
presented	O
with	O
a	O
metabolic	O
decompensation	O
at	O
11	O
months	O
;	O
the	O
second	O
one	O
,	O
born	O
prematurely	O
,	O
was	O
diagnosed	O
with	O
cblD	B-PRGE
after	O
being	O
treated	O
for	O
intracranial	O
hemorrhage	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
necrotizing	O
enterocolitis	O
,	O
and	O
convulsions	O
at	O
birth	O
;	O
the	O
third	O
one	O
was	O
diagnosed	O
at	O
5	O
years	O
of	O
age	O
.	O

Here	O
we	O
present	O
a	O
case	O
of	O
a	O
cblD	B-PRGE
-	O
MMA	O
patient	O
who	O
had	O
an	O
acute	O
neonatal	O
onset	O
with	O
severe	O
hyperammonemia	O
requiring	O
hemodiafiltration	O
.	O

TITLE	O
:	O
Analysis	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
ion	O
channel	O
activity	O
by	O
tuning	O
the	O
protein	O
and	O
lipid	O
charge	O
.	O

No	O
severe	O
adverse	O
event	O
was	O
observed	O
related	O
to	O
CART	B-PRGE
,	O
and	O
25	O
.	O
2	O
-	O
98	O
.	O
0	O
(	O
median	O
30	O
.	O
2	O
)	O
grams	O
of	O
albumin	B-PRGE
was	O
collected	O
and	O
reinfused	O
.	O

The	O
median	O
times	O
from	O
the	O
onset	O
of	O
illness	O
and	O
from	O
the	O
initiation	O
of	O
antiviral	O
therapy	O
to	O
a	O
negative	O
viral	O
test	O
result	O
on	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-PRGE
-	I-PRGE
polymerase	I-PRGE
-	O
chain	O
-	O
reaction	O
assay	O
were	O
11	O
days	O
(	O
interquartile	O
range	O
,	O
9	O
to	O
16	O
)	O
and	O
6	O
days	O
(	O
interquartile	O
range	O
,	O
4	O
to	O
7	O
),	O
respectively	O
.	O

Activation	O
of	O
RNase	B-PRGE
L	I-PRGE
correlated	O
with	O
the	O
induction	O
of	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
and	O
the	O
consequent	O
high	O
levels	O
of	O
OAS	B-PRGE
mRNA	I-PRGE
induced	O
in	O
these	O
cell	O
types	O
.	O

The	O
inhibition	O
of	O
calcineurin	O
blocks	O
the	O
translocation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
from	O
the	O
cytosol	O
into	O
the	O
nucleus	O
,	O
thus	O
preventing	O
the	O
transcription	O
of	O
genes	O
encoding	O
cytokines	O
such	O
as	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
.	O

To	O
identify	O
important	O
M	O
amino	O
acid	O
residues	O
for	O
VLP	B-PRGE
assembly	O
,	O
we	O
coexpressed	O
N	O
with	O
multiple	O
M	O
mutants	O
containing	O
substitution	O
mutations	O
at	O
the	O
amino	O
-	O
terminal	O
ectodomain	O
,	O
carboxyl	O
-	O
terminal	O
endodomain	O
,	O
or	O
transmembrane	O
segments	O
.	O

VLP	B-PRGE
production	O
was	O
not	O
significantly	O
affected	O
by	O
a	O
tryptophan	O
replacement	O
of	O
Y94	O
or	O
F95	O
or	O
a	O
phenylalanine	O
replacement	O
of	O
W19	O
,	O
W57	O
or	O
W91	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
guanine	B-PRGE
-	I-PRGE
N7	I-PRGE
methyltransferase	I-PRGE
activity	O
of	O
coronavirus	O
nsp14	O
on	O
nucleotide	O
GTP	O
.	O

These	O
findings	O
reveal	O
a	O
new	O
function	O
for	O
ApoE	B-PRGE
by	O
regulating	O
ApoD	B-PRGE
gene	I-PRGE
expression	O
.	O

TITLE	O
:	O
Experimental	O
study	O
on	O
histopathological	O
changes	O
and	O
tissue	O
tropism	O
of	O
Iranian	O
infectious	O
bronchitis	O
serotype	O
793	O
/	O
B	O
-	O
like	O
virus	O
in	O
SPF	B-PRGE
chickens	I-PRGE
.	O

Sequencing	O
of	O
their	O
RNA	B-PRGE
polymerase	I-PRGE
(	O
RdRp	O
),	O
spike	O
(	O
S	O
),	O
and	O
nucleocapsid	O
(	O
N	O
)	O
genes	O
revealed	O
that	O
MERS	O
-	O
CoV	O
is	O
more	O
closely	O
related	O
to	O
Pi	O
-	O
BatCoV	O
HKU5	O
in	O
RdRp	O
(	O
92	O
.	O
1	O
%	O
to	O
92	O
.	O
3	O
%	O
amino	O
acid	O
[	O
aa	O
]	O
identity	O
)	O
but	O
is	O
more	O
closely	O
related	O
to	O
Ty	O
-	O
BatCoV	O
HKU4	O
in	O
S	O
(	O
66	O
.	O
8	O
%	O
to	O
67	O
.	O
4	O
%	O
aa	O
identity	O
)	O
and	O
N	O
(	O
71	O
.	O
9	O
%	O
to	O
72	O
.	O
3	O
%	O
aa	O
identity	O
).	O

In	O
addition	O
,	O
the	O
entire	O
S	O
genes	O
of	O
eleven	O
central	O
China	O
PEDV	O
isolates	O
were	O
found	O
to	O
be	O
nine	O
nucleotides	O
longer	O
in	O
length	O
than	O
CV777	O
and	O
large	O
number	O
of	O
amino	O
acid	O
variations	O
was	O
accumulated	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
S	B-PRGE
gene	I-PRGE
.	O

Moreover	O
,	O
the	O
tripeptide	O
pan	O
-	O
ICE	B-PRGE
(	O
caspase	B-PRGE
)	O
inhibitor	O
Z	B-PRGE
-	I-PRGE
VAD	I-PRGE
-	I-PRGE
FMK	I-PRGE
blocked	O
PHEV	O
-	O
induced	O
apoptosis	O
but	O
did	O
not	O
have	O
an	O
effect	O
on	O
virus	O
production	O
by	O
96h	O
post	O
-	O
infection	O
.	O

TITLE	O
:	O
Synergistic	O
inhibitor	O
binding	O
to	O
the	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
of	O
human	O
SARS	O
coronavirus	O
:	O
mechanistic	O
and	O
inhibitor	O
design	O
implications	O
.	O

ABSTRACT	O
:	O
Human	B-PRGE
serum	I-PRGE
albumin	I-PRGE
(	O
HSA	B-PRGE
)	O
is	O
the	O
most	O
abundant	O
circulating	O
protein	O
and	O
accounts	O
for	O
about	O
70	O
%	O
of	O
the	O
plasma	O
colloid	O
osmotic	O
pressure	O
.	O

While	O
all	O
RT	O
inhibitors	O
approved	O
for	O
therapy	O
target	O
the	O
DNA	B-PRGE
polymerase	I-PRGE
activity	O
,	O
there	O
is	O
the	O
pressing	O
need	O
for	O
new	O
RT	O
inhibitors	O
possibly	O
targeting	O
the	O
RNase	B-PRGE
H	I-PRGE
function	O
.	O

The	O
genome	O
and	O
the	O
immunoglobulin	B-PRGE
genes	I-PRGE
in	O
rhesus	O
macaques	O
and	O
humans	O
are	O
highly	O
homologous	O
;	O
therefore	O
,	O
we	O
investigated	O
whether	O
neutralizing	O
mAbs	O
that	O
are	O
highly	O
homologous	O
to	O
those	O
of	O
humans	O
(	O
human	O
-	O
like	O
)	O
could	O
be	O
generated	O
.	O

In	O
this	O
study	O
,	O
three	O
U	O
.	O
S	O
.	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
molecular	O
multiplex	O
platforms	O
(	O
Prodesse	O
ProFLU	O
+/	O
FAST	B-PRGE
+,	I-PRGE
FilmArray	B-PRGE
RP	I-PRGE
,	I-PRGE
and	I-PRGE
Verigene	I-PRGE
RV	I-PRGE
+)	I-PRGE
were	O
evaluated	O
for	O
influenza	O
virus	O
detection	O
in	O
171	O
clinical	O
samples	O
collected	O
during	O
the	O
Belgian	O
2011	O
-	O
2012	O
influenza	O
season	O
.	O

In	O
this	O
study	O
,	O
the	O
M	B-PRGE
protein	I-PRGE
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
was	O
used	O
to	O
biopan	O
a	O
12	O
-	O
mer	O
phage	O
display	O
random	O
peptide	O
library	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
glycoprotein	O
(	O
S	O
)	O
of	O
recently	O
identified	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
targets	O
the	O
cellular	O
receptor	O
,	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
).	O

The	O
atomic	O
details	O
at	O
the	O
interface	O
between	O
MERS	O
-	O
CoV	O
RBD	O
and	O
DPP4	B-PRGE
provide	O
structural	O
understanding	O
of	O
the	O
virus	O
and	O
receptor	O
interaction	O
,	O
which	O
can	O
guide	O
development	O
of	O
therapeutics	O
and	O
vaccines	O
against	O
MERS	O
-	O
CoV	O
infection	O
.	O

Mean	O
peripheral	O
neutrophil	O
counts	O
and	O
mean	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
levels	O
were	O
elevated	O
significantly	O
in	O
patients	O
with	O
systemic	O
involvement	O
.	O

Factors	O
associated	O
with	O
ACP	B-PRGE
,	O
PFO	O
,	O
and	O
28	O
-	O
day	O
mortality	O
were	O
identified	O
using	O
multivariate	O
regression	O
analysis	O
.	O

The	O
patient	O
was	O
immediately	O
treated	O
with	O
a	O
steroid	B-PRGE
and	I-PRGE
neutrophil	I-PRGE
elastase	I-PRGE
inhibitor	O
under	O
respiratory	O
supportive	O
therapy	O
.	O

Through	O
summarizing	O
the	O
available	O
information	O
and	O
progress	O
in	O
coronavirus	O
research	O
,	O
this	O
review	O
provides	O
a	O
systematic	O
assessment	O
of	O
the	O
potential	O
wide	O
-	O
spectrum	O
features	O
on	O
the	O
most	O
popular	O
drug	O
targets	O
including	O
viral	B-PRGE
proteases	I-PRGE
,	I-PRGE
spike	I-PRGE
protein	I-PRGE
,	O
RNA	B-PRGE
polymerases	I-PRGE
and	O
editing	O
enzymes	O
as	O
well	O
as	O
host	O
-	O
virus	O
interaction	O
pathways	O
associated	O
with	O
coronaviruses	O
.	O

The	O
CD69	B-PRGE
expression	O
in	O
NK	O
cells	O
in	O
the	O
liver	O
,	O
spleen	O
,	O
bone	O
marrow	O
and	O
peripheral	O
blood	O
was	O
detected	O
by	O
using	O
flow	O
cytometry	O
.	O

The	O
correlation	O
between	O
the	O
CD69	B-PRGE
level	O
in	O
hepatic	O
NK	O
cells	O
and	O
liver	O
injury	O
was	O
studied	O
.	O

In	O
contrast	O
,	O
the	O
NKG2A	B-PRGE
expression	O
was	O
increased	O
in	O
hepatic	O
CD69	O
-	O
NK	O
cells	O
but	O
not	O
in	O
CD69	O
+	O
NK	O
cells	O
.	O

These	O
results	O
suggested	O
that	O
hepatic	O
CD69	B-PRGE
+	I-PRGE
NK	I-PRGE
cells	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	O
of	O
FHF	O
by	O
enhancing	O
degranulation	O
and	O
cytotoxic	O
ability	O
of	O
NK	O
cells	O
and	O
increasing	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

TITLE	O
:	O
The	O
replication	O
of	O
a	O
mouse	O
adapted	O
SARS	O
-	O
CoV	O
in	O
a	O
mouse	O
cell	O
line	O
stably	O
expressing	O
the	O
murine	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
mACE2	I-PRGE
efficiently	O
induces	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
.	O

These	O
cell	O
lines	O
are	O
valuable	O
tools	O
to	O
perform	O
in	O
vitro	O
studies	O
in	O
a	O
mouse	O
cell	O
system	O
that	O
reflects	O
the	O
species	O
used	O
for	O
in	O
vivo	O
studies	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
MA15	I-PRGE
pathogenesis	O
.	O

Eleven	O
ICU	O
patients	O
died	O
(	O
42	O
%),	O
three	O
of	O
them	O
carrying	O
the	O
D222G	O
variant	O
,	O
which	O
was	O
associated	O
with	O
RBS	B-PRGE
mutation	I-PRGE
S183P	I-PRGE
in	O
two	O
.	O

This	O
method	O
should	O
be	O
generally	O
useful	O
for	O
engineering	O
TCR	B-PRGE
Tg	I-PRGE
mice	O
without	O
introduction	O
of	O
bias	O
caused	O
by	O
in	O
vitro	O
manipulation	O
and	O
propagation	O
.	O

The	O
new	O
PEDV	O
reverse	O
genetics	O
system	O
will	O
enable	O
functional	O
studies	O
of	O
the	O
structural	O
proteins	O
and	O
the	O
accessory	B-PRGE
ORF3	I-PRGE
protein	I-PRGE
and	O
will	O
allow	O
the	O
rational	O
design	O
and	O
development	O
of	O
next	O
generation	O
PEDV	O
vaccines	O
.	O

Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
was	O
identified	O
as	O
an	O
enzyme	O
that	O
negatively	O
regulates	O
the	O
RAS	B-PRGE
by	O
converting	O
Ang	B-PRGE
II	I-PRGE
,	O
the	O
main	O
bioactive	O
molecule	O
of	O
the	O
RAS	O
,	O
to	O
Ang	B-PRGE
1	I-PRGE
-	I-PRGE
7	I-PRGE
.	O

In	O
this	O
study	O
,	O
long	O
-	O
term	O
feline	O
intestinal	O
epithelial	O
cell	O
cultures	O
were	O
established	O
from	O
primary	O
ileocytes	O
and	O
colonocytes	O
by	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
T	O
-	O
antigen	O
-	O
and	O
human	B-PRGE
Telomerase	I-PRGE
Reverse	I-PRGE
Transcriptase	I-PRGE
(	O
hTERT	B-PRGE
)-	O
induced	O
immortalization	O
.	O

Immunization	O
with	O
C	O
vaccine	O
allowed	O
to	O
harvest	O
eggs	O
with	O
satisfactory	O
levels	O
of	O
E	B-PRGE
.	I-PRGE
coli	I-PRGE
,	I-PRGE
rotavirus	I-PRGE
and	I-PRGE
coronavirus	I-PRGE
IgY	I-PRGE
antibodies	I-PRGE
which	O
may	O
be	O
used	O
to	O
evaluate	O
their	O
protective	O
effect	O
by	O
oral	O
administration	O
in	O
calves	O
.	O

Furthermore	O
,	O
one	O
small	O
molecule	O
HIV	O
entry	O
inhibitor	O
targeting	O
gp41	O
(	O
ADS	B-PRGE
-	I-PRGE
J1	I-PRGE
)	O
and	O
the	O
3	O
-	O
hydroxyphthalic	O
anhydride	O
-	O
modified	O
human	B-PRGE
serum	I-PRGE
albumin	I-PRGE
(	O
HP	B-PRGE
-	I-PRGE
HSA	I-PRGE
)	O
could	O
significantly	O
inhibit	O
MERS	O
-	O
CoV	O
pseudovirus	O
infection	O
.	O

TITLE	O
:	O
Treatment	O
with	O
interferon	B-PRGE
-	I-PRGE
Î±2b	I-PRGE
and	O
ribavirin	O
improves	O
outcome	O
in	O
MERS	O
-	O
CoV	O
-	O
infected	O
rhesus	O
macaques	O
.	O

Our	O
results	O
identify	O
high	O
-	O
molecular	O
weight	O
Î³	O
-	O
PGA	O
as	O
a	O
TLR4	B-PRGE
ligand	I-PRGE
and	O
demonstrate	O
that	O
Î³	O
-	O
PGA	O
requires	O
both	O
CD14	B-PRGE
and	O
MD2	B-PRGE
for	O
the	O
activation	O
of	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
responses	O
.	O

The	O
infectious	O
virus	O
was	O
rescued	O
and	O
propagated	O
in	O
cells	O
expressing	O
the	O
E	B-PRGE
protein	I-PRGE
in	O
trans	O
,	O
indicating	O
that	O
this	O
virus	O
was	O
replication	O
competent	O
and	O
propagation	O
defective	O
.	O

Here	O
we	O
analyzed	O
accessory	O
proteins	O
3	O
,	O
4a	O
,	O
4b	O
,	O
and	O
5	O
for	O
their	O
abilities	O
to	O
inhibit	O
the	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
response	O
.	O

Accessory	O
protein	O
4a	O
was	O
found	O
to	O
block	O
interferon	B-PRGE
induction	O
at	O
the	O
level	O
of	O
melanoma	O
differentiation	O
-	O
associated	O
protein	O
5	O
(	O
MDA5	B-PRGE
)	O
activation	O
presumably	O
by	O
direct	O
interaction	O
with	O
double	O
-	O
stranded	O
RNA	O
.	O

In	O
contrast	O
,	O
a	O
single	O
camostat	O
treatment	O
suppressed	O
MERS	O
-	O
CoV	O
entry	O
into	O
human	O
bronchial	O
submucosal	O
gland	O
-	O
derived	O
Calu	O
-	O
3	O
cells	O
by	O
10	O
-	O
fold	O
and	O
virus	O
growth	O
by	O
270	O
-	O
fold	O
,	O
although	O
treatment	O
with	O
both	O
camostat	O
and	O
(	O
23	O
,	O
25	O
)-	O
trans	O
-	O
epoxysuccinyl	O
-	O
L	O
-	O
leucylamindo	O
-	O
3	O
-	O
methylbutane	O
ethyl	O
ester	O
,	O
a	O
cathepsin	B-PRGE
inhibitor	O
,	O
or	O
treatment	O
with	O
leupeptin	O
,	O
an	O
inhibitor	O
of	O
cysteine	O
,	O
serine	O
,	O
and	O
threonine	O
peptidases	O
,	O
was	O
no	O
more	O
efficacious	O
than	O
treatment	O
with	O
camostat	O
alone	O
.	O

To	O
test	O
for	O
conservation	O
of	O
nsp5	B-PRGE
structure	O
-	O
function	O
determinants	O
,	O
we	O
engineered	O
chimeric	O
betacoronavirus	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
genomes	O
encoding	O
nsp5	B-PRGE
proteases	I-PRGE
of	O
human	O
and	O
bat	O
alphacoronaviruses	O
and	O
betacoronaviruses	O
.	O

These	O
data	O
indicate	O
tight	O
genetic	O
linkage	O
and	O
coevolution	O
between	O
nsp5	B-PRGE
protease	I-PRGE
and	O
the	O
genomic	O
background	O
and	O
identify	O
differences	O
in	O
intramolecular	O
networks	O
regulating	O
nsp5	B-PRGE
function	O
.	O

However	O
,	O
the	O
experimental	O
documentation	O
of	O
efficacy	O
of	O
vaporization	O
of	O
PFC	B-PRGE
in	O
the	O
treatment	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
still	O
lacking	O
.	O

Leukocyte	O
aquaporin	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
was	O
induced	O
at	O
the	O
onset	O
of	O
sepsis	O
(	O
median	O
1	O
.	O
71	O
-	O
fold	O
increase	O
;	O
interquartile	O
range	O
:	O
0	O
.	O
99	O
to	O
2	O
.	O
42	O
,	O
P	O
=	O
0	O
.	O
012	O
from	O
baseline	O
)	O
and	O
was	O
further	O
increased	O
upon	O
septic	O
shock	O
(	O
median	O
3	O
.	O
00	O
-	O
fold	O
increase	O
;	O
interquartile	O
range	O
:	O
1	O
.	O
20	O
to	O
5	O
.	O
40	O
,	O
P	O
=	O
0	O
.	O
023	O
from	O
sepsis	O
,	O
Wilcoxon	O
signed	O
-	O
rank	O
test	O
);	O
no	O
difference	O
was	O
observed	O
between	O
baseline	O
and	O
discharge	O
in	O
patients	O
who	O
did	O
not	O
develop	O
sepsis	O
.	O

Large	O
proportions	O
of	O
children	O
and	O
adults	O
in	O
Beijing	O
have	O
evidence	O
of	O
anti	B-PRGE
-	I-PRGE
S	I-PRGE
IgG	I-PRGE
against	O
four	O
the	O
HCoVs	O
,	O
and	O
first	O
infections	O
by	O
all	O
four	O
non	O
-	O
SARS	O
HCoVs	O
takes	O
place	O
during	O
childhood	O
.	O

While	O
the	O
M41	B-PRGE
spike	I-PRGE
ectodomain	I-PRGE
showed	O
increased	O
attachment	O
to	O
both	O
CAM	O
and	O
chicken	O
trachea	O
,	O
no	O
binding	O
to	O
mammalian	O
cells	O
was	O
observed	O
.	O

Recombinant	O
rMERS	O
-	O
CoV	O
,	O
rMERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
â¢	I-PRGE
ORF5	I-PRGE
,	O
and	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
RFP	I-PRGE
replicated	O
to	O
high	O
titers	O
,	O
whereas	O
MERS	O
-	O
ÎORF3	O
-	O
5	O
showed	O
1	O
-	O
1	O
.	O
5	O
logs	O
reduced	O
titer	O
compared	O
with	O
rMERS	O
-	O
CoV	O
.	O
Northern	O
blot	O
analyses	O
confirmed	O
the	O
associated	O
molecular	O
changes	O
in	O
the	O
recombinant	O
viruses	O
,	O
and	O
sequence	O
analysis	O
demonstrated	O
that	O
RFP	B-PRGE
was	O
expressed	O
from	O
the	O
appropriate	O
consensus	O
sequence	O
AACGAA	O
.	O

Although	O
the	O
mutation	O
of	O
FCoV	B-PRGE
accessory	I-PRGE
gene	I-PRGE
3c	I-PRGE
has	O
been	O
suggested	O
to	O
be	O
related	O
to	O
the	O
occurrence	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
),	O
how	O
the	O
3C	B-PRGE
protein	I-PRGE
is	O
involved	O
in	O
this	O
phenomenon	O
remains	O
unknown	O
.	O

The	O
CD1d	B-PRGE
KO	I-PRGE
(	O
NKT	B-PRGE
deficient	O
)	O
mice	O
showed	O
hepatoprotection	O
against	O
poly	O
(	O
I	O
:	O
C	O
)-	O
induced	O
hepatitis	O
in	O
association	O
with	O
increased	O
number	O
of	O
IL	B-PRGE
-	I-PRGE
33	I-PRGE
expressing	O
hepatocytes	O
in	O
CD1d	B-PRGE
KO	I-PRGE
mice	O
than	O
WT	O
controls	O
.	O

Notably	O
,	O
MERS	O
-	O
CoV	O
induced	O
significantly	O
higher	O
expression	O
levels	O
of	O
interleukin	B-PRGE
12	I-PRGE
,	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
,	O
and	O
chemokines	O
(	O
IP	O
-	O
10	O
/	O
CXCL	O
-	O
10	O
,	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
CCL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
MIP	B-PRGE
-	I-PRGE
1Î±	I-PRGE
/	O
CCL	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
RANTES	B-PRGE
/	O
CCL	B-PRGE
-	I-PRGE
5	I-PRGE
,	O
and	O
interleukin	B-PRGE
8	I-PRGE
)	O
than	O
SARS	O
-	O
CoV	O
.	O
The	O
expression	O
of	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
class	I-PRGE
I	I-PRGE
and	I-PRGE
costimulatory	I-PRGE
molecules	I-PRGE
were	O
significantly	O
higher	O
in	O
MERS	O
-	O
CoV	O
-	O
infected	O
MDMs	O
than	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
a	O
series	O
of	O
biochemical	O
and	O
biophysical	O
analyses	O
characterizing	O
the	O
HR1	O
/	O
HR2	B-PRGE
complexes	O
of	O
this	O
novel	O
virus	O
.	O

Antemortem	O
DIF	O
testing	O
was	O
positive	O
in	O
all	O
10	O
cases	O
confirmed	O
as	O
FIP	B-PRGE
at	O
postmortem	O
examination	O
.	O

ABSTRACT	O
:	O
Herein	O
we	O
report	O
the	O
discovery	O
and	O
SAR	O
of	O
a	O
novel	O
series	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
inhibitors	O
identified	O
through	O
the	O
NIH	O
Molecular	O
Libraries	O
Probe	O
Production	O
Centers	O
Network	O
(	O
MLPCN	O
).	O

The	O
X	O
-	O
ray	O
structure	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
bound	O
with	O
a	O
ML300	O
analog	O
highlights	O
a	O
unique	O
induced	O
-	O
fit	O
reorganization	O
of	O
the	O
S2	O
-	O
S4	O
binding	O
pockets	O
leading	O
to	O
the	O
first	O
sub	O
-	O
micromolar	O
noncovalent	O
3CLpro	O
inhibitors	O
retaining	O
a	O
single	O
amide	O
bond	O
.	O

Infiltrating	O
cells	O
include	O
foamy	O
macrophages	O
and	O
surface	O
markers	O
were	O
characterized	O
as	O
CD11b	B-PRGE
(	O
lo	O
/-),	O
F4	O
/	O
80	O
(	O
hi	O
).	O

The	O
codon	O
adaptation	O
index	O
(	O
CAI	O
)	O
showed	O
a	O
lower	O
adaptation	O
of	O
S	O
to	O
G	O
.	O
gallus	O
compared	O
to	O
NSP2	B-PRGE
,	O
PL	O
(	O
pro	O
)	O
and	O
N	O
.	O
The	O
effective	O
number	O
of	O
codons	O
(	O
Nc	O
)	O
and	O
GC3	B-PRGE
%	O
revealed	O
that	O
natural	O
selection	O
and	O
genetic	O
drift	O
are	O
the	O
evolutionary	O
forces	O
driving	O
the	O
codon	O
usage	O
evolution	O
of	O
both	O
A	O
.	O
coronavirus	O
and	O
G	O
.	O
gallus	O
regardless	O
of	O
the	O
gene	O
being	O
considered	O
.	O

Thus	O
,	O
the	O
administration	O
of	O
a	O
feline	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	I-PRGE
neutralizing	I-PRGE
antibody	I-PRGE
to	O
cats	O
with	O
FIP	O
may	O
reduce	O
the	O
disease	O
progression	O
.	O

The	O
50	O
%	O
inhibitory	O
concentrations	O
(	O
IC50	O
)	O
of	O
the	O
MAbs	O
for	O
the	O
cytotoxicity	O
of	O
recombinant	B-PRGE
TNF	I-PRGE
-	I-PRGE
alpha	I-PRGE
were	O
5	O
-	O
684	O
ng	O
/	O
ml	O
.	O

Then	O
,	O
female	O
BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
the	O
purified	O
recombinant	B-PRGE
S1	I-PRGE
protein	I-PRGE
(	O
rS1	B-PRGE
),	O
and	O
a	O
monoclonal	O
antibody	O
(	O
MAb	O
designated	O
as	O
5E12	O
)	O
against	O
the	O
rS1	B-PRGE
protein	I-PRGE
was	O
achieved	O
by	O
hybridoma	O
technique	O
.	O

As	O
RNA	O
viruses	O
may	O
coevolve	O
with	O
their	O
hosts	O
,	O
we	O
sought	O
to	O
investigate	O
the	O
closest	O
sister	O
taxon	O
to	O
bats	O
,	O
the	O
Eulipotyphla	O
,	O
and	O
screened	O
European	O
hedgehogs	O
(	O
Erinaceus	O
europaeus	O
)	O
from	O
Germany	O
for	O
CoV	O
by	O
nested	O
reverse	B-PRGE
transcriptase	I-PRGE
PCR	O
.	O

TITLE	O
:	O
Activity	O
of	O
and	O
effect	O
of	O
subcutaneous	O
treatment	O
with	O
the	O
broad	O
-	O
spectrum	O
antiviral	O
lectin	B-PRGE
griffithsin	I-PRGE
in	O
two	O
laboratory	O
rodent	O
models	O
.	O

CD4	B-PRGE
âº	I-PRGE
and	O
CD8	B-PRGE
âº	I-PRGE
T	O
cells	O
are	O
essential	O
to	O
control	O
infectious	O
virus	O
but	O
at	O
the	O
cost	O
of	O
tissue	O
damage	O
.	O

CD4	B-PRGE
âº	I-PRGE
T	O
cells	O
transiently	O
accumulate	O
within	O
the	O
perivascular	O
space	O
,	O
whereas	O
CD8	B-PRGE
âº	I-PRGE
T	I-PRGE
cells	O
migrate	O
directly	O
into	O
the	O
CNS	O
parenchyma	O
.	O

Moreover	O
,	O
decreased	O
CD4	B-PRGE
âº	I-PRGE
T	I-PRGE
cell	O
recruitment	O
into	O
the	O
CNS	O
parenchyma	O
of	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
deficient	O
mice	O
was	O
not	O
associated	O
with	O
impaired	O
T	O
cell	O
recruiting	O
chemokines	O
or	O
MMP	O
expression	O
,	O
and	O
no	O
compensation	O
by	O
other	O
TIMP	B-PRGE
molecules	I-PRGE
was	O
identified	O
.	O

Most	O
importantly	O
,	O
we	O
report	O
the	O
first	O
recorded	O
isolation	O
of	O
a	O
live	O
SL	O
-	O
CoV	O
(	O
bat	O
SL	O
-	O
CoV	O
-	O
WIV1	O
)	O
from	O
bat	O
faecal	O
samples	O
in	O
Vero	O
E6	O
cells	O
,	O
which	O
has	O
typical	O
coronavirus	O
morphology	O
,	O
99	O
.	O
9	O
%	O
sequence	O
identity	O
to	O
Rs3367	O
and	O
uses	O
ACE2	B-PRGE
from	O
humans	O
,	O
civets	O
and	O
Chinese	O
horseshoe	O
bats	O
for	O
cell	O
entry	O
.	O

A	O
phylogenetic	O
analysis	O
of	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
sequence	I-PRGE
fragments	I-PRGE
aided	O
in	O
identifying	O
two	O
alphacoronaviruses	O
from	O
Kuhl	O
'	O
s	O
pipistrelle	O
(	O
Pipistrellus	O
kuhlii	O
),	O
three	O
clade	O
2b	O
betacoronaviruses	O
from	O
lesser	O
horseshoe	O
bats	O
(	O
Rhinolophus	O
hipposideros	O
),	O
and	O
10	O
clade	O
2c	O
betacoronaviruses	O
from	O
Kuhl	O
'	O
s	O
pipistrelle	O
,	O
common	O
noctule	O
(	O
Nyctalus	O
noctula	O
),	O
and	O
Savi	O
'	O
s	O
pipistrelle	O
(	O
Hypsugo	O
savii	O
).	O

Phylogenetic	O
analyses	O
using	O
different	O
genes	O
of	O
PEDV	O
suggested	O
that	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
spike	I-PRGE
gene	I-PRGE
or	O
the	O
S1	O
portion	O
is	O
appropriate	O
for	O
sequencing	O
to	O
study	O
the	O
genetic	O
relatedness	O
of	O
these	O
viruses	O
.	O

Although	O
IFN	B-PRGE
-	I-PRGE
Î±	I-PRGE
/	I-PRGE
Î²	I-PRGE
induction	O
by	O
coronaviruses	O
is	O
modest	O
,	O
it	O
effectively	O
limits	O
viral	O
spread	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
protects	O
against	O
mortality	O
.	O

Ifit2	O
(-/-)	O
mice	O
also	O
expressed	O
significantly	O
reduced	O
IFN	B-PRGE
-	I-PRGE
Î±	I-PRGE
/	I-PRGE
Î²	I-PRGE
and	O
downstream	O
ISG	O
mRNAs	O
Ifit1	B-PRGE
,	O
Isg15	B-PRGE
,	O
and	O
Pkr	B-PRGE
,	O
while	O
expression	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
was	O
only	O
modestly	O
affected	O
in	O
the	O
CNS	O
.	O

Similarly	O
,	O
Pao2	B-PRGE
/	O
Fio2	O
ratio	O
decreased	O
less	O
in	O
NAVA	O
than	O
in	O
PSV	O
(	O
P	O
<	O
.	O
001	O
).	O

Sequence	O
analysis	O
of	O
the	O
M	B-PRGE
protein	I-PRGE
grouped	O
eight	O
strains	O
with	O
CCoV	O
-	O
I	O
and	O
another	O
19	O
with	O
CCoV	O
-	O
II	O
prototypes	O
.	O

ABSTRACT	O
:	O
In	O
2012	O
,	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
)	O
associated	O
with	O
severe	O
respiratory	O
disease	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
-	O
CoV	O
;	O
previously	O
known	O
as	O
human	B-PRGE
coronavirus	I-PRGE
-	I-PRGE
Erasmus	I-PRGE
Medical	I-PRGE
Center	I-PRGE
or	O
hCoV	B-PRGE
-	I-PRGE
EMC	I-PRGE
),	O
emerged	O
in	O
the	O
Arabian	O
Peninsula	O
.	O

However	O
,	O
no	O
mechanistic	O
insights	O
into	O
this	O
process	O
were	O
obtained	O
and	O
the	O
relevance	O
of	O
ACE2	O
cleavage	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
S	I-PRGE
)	O
activation	O
has	O
not	O
been	O
determined	O
.	O

This	O
study	O
was	O
conducted	O
to	O
elucidate	O
two	O
questions	O
:	O
first	O
,	O
whether	O
the	O
activation	O
of	O
PARP	B-PRGE
and	O
NF	O
-	O
ÎºB	O
mediates	O
the	O
renal	O
inflammation	O
secondary	O
to	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
acute	O
lung	O
inflammation	O
;	O
second	O
,	O
whether	O
a	O
PARP	B-PRGE
inhibitor	O
,	O
3	O
-	O
aminobenzamide	O
(	O
3	O
-	O
AB	O
),	O
attenuates	O
lung	O
and	O
kidney	O
inflammation	O
by	O
inhibiting	O
NF	B-PRGE
-	I-PRGE
ÎºB	I-PRGE
-	I-PRGE
dependent	I-PRGE
proinflammatory	I-PRGE
cytokines	I-PRGE
.	O

We	O
identified	O
human	O
proteins	O
that	O
interact	O
with	O
the	O
glycoproteins	O
(	O
GPs	O
)	O
of	O
a	O
prototypic	O
arenavirus	O
and	O
hantavirus	O
and	O
show	O
that	O
the	O
lectin	O
endoplasmic	B-PRGE
reticulum	I-PRGE
(	O
ER	O
)-	O
Golgi	O
intermediate	O
compartment	O
53	O
kDa	O
protein	O
(	O
ERGIC	O
-	O
53	O
),	O
a	O
cargo	O
receptor	O
required	O
for	O
glycoprotein	O
trafficking	O
within	O
the	O
early	O
exocytic	O
pathway	O
,	O
associates	O
with	O
arenavirus	O
,	O
hantavirus	O
,	O
coronavirus	O
,	O
orthomyxovirus	O
,	O
and	O
filovirus	O
GPs	O
.	O

Here	O
we	O
show	O
the	O
resistance	O
of	O
ferrets	O
to	O
MERS	O
-	O
CoV	O
infection	O
and	O
inability	O
of	O
ferret	O
DDP4	O
to	O
bind	O
MERS	O
-	O
CoV	O
.	O
Site	O
-	O
directed	O
mutagenesis	O
of	O
amino	O
acids	O
variable	O
in	O
ferret	O
DPP4	B-PRGE
thus	O
revealed	O
the	O
functional	O
human	B-PRGE
DPP4	I-PRGE
virus	I-PRGE
binding	I-PRGE
site	I-PRGE
.	O

TITLE	O
:	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
ORF1b	I-PRGE
-	O
encoded	O
nonstructural	O
proteins	O
12	O
-	O
16	O
:	O
replicative	O
enzymes	O
as	O
antiviral	O
targets	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
coronavirus	O
,	O
MERS	O
-	O
CoV	O
(	O
NCoV	O
,	O
HCoV	B-PRGE
-	I-PRGE
EMC	I-PRGE
/	I-PRGE
2012	I-PRGE
),	O
originating	O
from	O
the	O
Middle	O
-	O
East	O
,	O
has	O
been	O
discovered	O
.	O

TITLE	O
:	O
Akt2	B-PRGE
deficiency	O
protects	O
from	O
acute	O
lung	O
injury	O
via	O
alternative	O
macrophage	O
activation	O
and	O
miR	B-PRGE
-	I-PRGE
146a	I-PRGE
induction	O
in	O
mice	O
.	O

In	O
conclusion	O
,	O
Akt2	B-PRGE
suppression	O
and	O
miR	B-PRGE
-	I-PRGE
146a	I-PRGE
induction	O
promote	O
the	O
M2	O
macrophage	O
phenotype	O
,	O
resulting	O
in	O
amelioration	O
of	O
acid	O
-	O
induced	O
lung	O
injury	O
.	O

Moreover	O
,	O
the	O
infiltration	O
of	O
neutrophils	O
rather	O
than	O
Foxp3	O
(+)	O
regulatory	O
T	O
cells	O
,	O
which	O
produce	O
proinflammatory	O
factors	O
and	O
FGL2	B-PRGE
directly	O
,	O
into	O
the	O
infected	O
liver	O
and	O
spleen	O
tissues	O
was	O
also	O
decreased	O
in	O
TNFR1	B-PRGE
(-/-)	O
mice	O
.	O

This	O
finding	O
might	O
help	O
in	O
providing	O
further	O
information	O
that	O
replacement	O
of	O
the	O
ectodomain	O
fragment	O
of	O
the	O
IBV	B-PRGE
Beaudette	I-PRGE
S1	I-PRGE
gene	I-PRGE
with	O
that	O
from	O
a	O
present	O
field	O
strain	O
is	O
promising	O
for	O
IBV	O
vaccine	O
development	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
the	O
complete	B-PRGE
ORF3	I-PRGE
gene	I-PRGE
showed	O
that	O
the	O
PEDVs	O
in	O
central	O
China	O
and	O
the	O
reference	O
strains	O
could	O
be	O
divided	O
into	O
three	O
groups	O
:	O
G1	O
,	O
G2	O
,	O
and	O
G3	O
.	O

The	O
L10H	O
chickens	O
as	O
well	O
as	O
the	O
L10L	O
chickens	O
also	O
showed	O
an	O
increased	O
number	O
of	O
CD4	B-PRGE
-	O
CD8Î±	O
-	O
Î³Î´	O
T	O
-	O
cells	O
when	O
an	O
MBL	O
ligand	O
was	O
added	O
to	O
the	O
vaccine	O
,	O
most	O
pronouncedly	O
after	O
the	O
first	O
vaccination	O
.	O

As	O
MBL	O
ligands	O
co	O
-	O
administered	O
with	O
IBV	O
vaccine	O
induced	O
differences	O
between	O
the	O
two	O
chicken	O
lines	O
,	O
these	O
results	O
indirectly	O
suggest	O
that	O
MBL	B-PRGE
is	O
involved	O
in	O
the	O
immune	O
response	O
to	O
IBV	O
vaccination	O
.	O

Hence	O
,	O
in	O
order	O
to	O
investigate	O
the	O
test	O
agreement	O
between	O
serum	O
and	O
milk	O
,	O
both	O
serum	O
and	O
milk	O
samples	O
from	O
105	O
cows	O
in	O
27	O
dairy	O
herds	O
were	O
analyzed	O
in	O
parallel	O
for	O
presence	O
of	O
immunoglobulin	B-PRGE
G	I-PRGE
antibodies	I-PRGE
to	O
BCV	O
and	O
BRSV	O
.	O

TITLE	O
:	O
Interferon	B-PRGE
-	I-PRGE
Î²	I-PRGE
and	O
mycophenolic	O
acid	O
are	O
potent	O
inhibitors	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
in	O
cell	O
-	O
based	O
assays	O
.	O

In	O
contrast	O
,	O
MPA	B-PRGE
showed	O
strong	O
inhibition	O
,	O
with	O
an	O
ICââ	O
of	O
2	O
.	O
87	O
ÂµM	O
.	O
This	O
drug	O
has	O
not	O
been	O
previously	O
tested	O
against	O
MERS	O
-	O
CoV	O
and	O
may	O
provide	O
an	O
alternative	O
to	O
ribavirin	O
for	O
treatment	O
of	O
MERS	O
-	O
CoV	O
.	O
In	O
conclusion	O
,	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
,	O
MPA	B-PRGE
or	O
a	O
combination	O
of	O
the	O
two	O
may	O
be	O
beneficial	O
in	O
the	O
treatment	O
of	O
MERS	O
-	O
CoV	O
or	O
as	O
a	O
post	O
-	O
exposure	O
intervention	O
in	O
high	O
-	O
risk	O
patients	O
with	O
known	O
exposures	O
to	O
MERS	O
-	O
CoV	O
.	O

TITLE	O
:	O
A	O
truncated	O
receptor	O
-	O
binding	O
domain	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
potently	O
inhibits	O
MERS	O
-	O
CoV	O
infection	O
and	O
induces	O
strong	O
neutralizing	O
antibody	O
responses	O
:	O
implication	O
for	O
developing	O
therapeutics	O
and	O
vaccines	O
.	O

The	O
recombinant	O
S377	O
-	O
588	O
-	O
Fc	O
is	O
able	O
to	O
induce	O
in	O
the	O
vaccinated	O
mice	O
strong	O
MERS	O
-	O
CoV	O
S	O
-	O
specific	O
antibodies	O
,	O
which	O
blocks	O
the	O
binding	O
of	O
RBD	O
to	O
DPP4	B-PRGE
receptor	I-PRGE
and	O
effectively	O
neutralizes	O
MERS	O
-	O
CoV	O
infection	O
.	O

Genetic	O
variation	O
affecting	O
interferon	B-PRGE
lambda	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
Î»	I-PRGE
)	O
expression	O
is	O
now	O
known	O
to	O
influence	O
the	O
outcome	O
of	O
both	O
hepatitis	O
C	O
virus	O
and	O
herpes	O
simplex	O
virus	O
type	O
1	O
infection	O
in	O
humans	O
.	O

Furthermore	O
,	O
defective	O
IFN	B-PRGE
-	I-PRGE
Î»	I-PRGE
production	O
by	O
humans	O
with	O
asthma	O
impairs	O
the	O
control	O
of	O
rhinovirus	O
infection	O
.	O

Given	O
that	O
BCoV	O
is	O
better	O
studied	O
than	O
equine	O
coronaviruses	O
and	O
given	O
the	O
possibility	O
of	O
interspecies	O
transmission	O
of	O
these	O
viruses	O
,	O
this	O
research	O
was	O
designed	O
to	O
compare	O
the	O
partial	O
sequences	O
of	O
the	O
spike	O
glycoprotein	O
(	O
S	O
),	O
hemagglutinin	B-PRGE
-	I-PRGE
esterase	I-PRGE
protein	I-PRGE
(	O
HE	O
),	O
and	O
nucleoprotein	O
(	O
N	O
)	O
genes	O
from	O
coronaviruses	O
from	O
adult	O
cattle	O
with	O
winter	O
dysentery	O
,	O
calves	O
with	O
neonatal	O
diarrhea	O
,	O
and	O
horses	O
.	O

To	O
optimize	O
expression	O
conditions	O
for	O
scale	O
-	O
up	O
production	O
of	O
the	O
RBD	O
vaccine	O
candidate	O
,	O
we	O
hypothesized	O
that	O
this	O
could	O
be	O
potentially	O
achieved	O
by	O
removing	O
glycosylation	O
sites	O
in	O
the	O
RBD	B-PRGE
protein	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
constructed	O
two	O
RBD	B-PRGE
protein	I-PRGE
variants	O
:	O
1	O
)	O
RBD193	O
-	O
WT	O
(	O
193	O
-	O
aa	O
,	O
residues	O
318	O
-	O
510	O
)	O
and	O
its	O
deglycosylated	O
forms	O
(	O
RBD193	O
-	O
N1	O
,	O
RBD193	O
-	O
N2	O
,	O
RBD193	O
-	O
N3	O
);	O
2	O
)	O
RBD219	O
-	O
WT	O
(	O
219	O
-	O
aa	O
,	O
residues	O
318	O
-	O
536	O
)	O
and	O
its	O
deglycosylated	O
forms	O
(	O
RBD219	O
-	O
N1	O
,	O
RBD219	O
-	O
N2	O
,	O
and	O
RBD219	O
-	O
N3	O
).	O

TITLE	O
:	O
Proteolytic	O
processing	O
,	O
deubiquitinase	O
and	O
interferon	B-PRGE
antagonist	O
activities	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
.	O

It	O
acts	O
on	O
both	O
K48	O
-	O
and	O
K63	O
-	O
linked	O
ubiquitination	O
and	O
ISG15	B-PRGE
-	O
linked	O
ISGylation	O
.	O

HE	O
proteins	O
mediate	O
reversible	O
binding	O
to	O
sialic	B-PRGE
acid	I-PRGE
receptor	I-PRGE
determinants	I-PRGE
,	O
very	O
abundant	O
glycan	O
residues	O
in	O
the	O
enteric	O
and	O
respiratory	O
tracts	O
.	O

Compared	O
with	O
patients	O
with	O
the	O
rs12252	O
-	O
T	O
/	O
T	O
or	O
rs12252	O
-	O
T	O
/	O
C	O
genotype	O
of	O
IFITM3	B-PRGE
,	O
patients	O
with	O
the	O
C	O
/	O
C	O
genotype	O
had	O
a	O
shorter	O
time	O
from	O
disease	O
onset	O
to	O
the	O
time	O
point	O
when	O
they	O
sought	O
medical	O
aid	O
(	O
hospital	O
admission	O
or	O
antiviral	O
therapy	O
)	O
and	O
a	O
shorter	O
interval	O
to	O
development	O
of	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
stage	O
(	O
reflected	O
by	O
shorter	O
intervals	O
between	O
clinical	O
onset	O
and	O
methylprednisolone	O
treatments	O
and	O
higher	O
rates	O
of	O
mechanical	O
ventilator	O
use	O
),	O
as	O
well	O
as	O
experiencing	O
elevated	O
/	O
prolonged	O
lung	O
virus	O
titers	O
and	O
cytokine	O
production	O
and	O
higher	O
mortality	O
.	O

The	O
HNE	B-PRGE
inhibitory	O
activity	O
of	O
ursolic	O
acid	O
was	O
further	O
verified	O
using	O
a	O
mouse	O
model	O
of	O
acute	O
smoke	O
-	O
induced	O
lung	O
inflammation	O
.	O

The	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
including	O
TNFÎ±	O
,	O
IL	O
-	O
1Î²	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
were	O
dose	O
-	O
dependently	O
suppressed	O
by	O
FJU	O
-	O
C4	O
both	O
in	O
mRNA	O
and	O
protein	O
levels	O
.	O

TITLE	O
:	O
Cytokine	O
levels	O
(	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
and	O
TGFÎ²	O
)	O
as	O
potential	O
biomarkers	O
of	O
systemic	O
inflammatory	O
response	O
in	O
trauma	O
patients	O
.	O

The	O
median	O
time	O
from	O
admission	O
to	O
therapy	O
with	O
ribavirin	O
and	O
interferon	B-PRGE
was	O
19	O
(	O
range	O
10	O
-	O
22	O
)	O
days	O
.	O

RESULTS	O
:	O
Salivary	B-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
33	I-PRGE
concentrations	O
were	O
similar	O
in	O
the	O
two	O
OSAS	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
),	O
which	O
were	O
statistically	O
higher	O
than	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
addition	O
,	O
the	O
UPR	B-PRGE
-	I-PRGE
activating	I-PRGE
domain	I-PRGE
in	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
remains	O
to	O
be	O
identified	O
.	O

TITLE	O
:	O
The	O
effects	O
of	O
Nigella	O
sativa	O
(	O
Ns	O
),	O
Anthemis	O
hyalina	O
(	O
Ah	O
)	O
and	O
Citrus	O
sinensis	O
(	O
Cs	O
)	O
extracts	O
on	O
the	O
replication	O
of	O
coronavirus	O
and	O
the	O
expression	O
of	O
TRP	B-PRGE
genes	I-PRGE
family	I-PRGE
.	O

ABSTRACT	O
:	O
Bone	B-PRGE
marrow	I-PRGE
stromal	I-PRGE
antigen	I-PRGE
2	I-PRGE
(	O
BST2	B-PRGE
),	O
an	O
interferon	B-PRGE
-	O
inducible	O
antiviral	O
factor	O
,	O
has	O
been	O
shown	O
to	O
block	O
the	O
release	O
of	O
various	O
enveloped	O
viruses	O
from	O
cells	O
.	O

The	O
sequence	O
variations	O
between	O
the	O
two	O
strains	O
were	O
in	O
an	O
antigenic	O
important	O
part	O
of	O
the	O
G	B-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
Loss	O
of	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
adiponectin	B-PRGE
induces	O
severe	O
inflammatory	O
lung	O
injury	O
following	O
LPS	O
challenge	O
through	O
excessive	O
oxidative	O
/	O
nitrative	O
stress	O
.	O

The	O
apoptotic	O
cells	O
,	O
indicated	O
by	O
caspase	B-PRGE
3	I-PRGE
-	O
activation	O
,	O
were	O
a	O
mixed	O
population	O
of	O
infected	O
and	O
a	O
higher	O
number	O
of	O
uninfected	O
cells	O
.	O

We	O
believe	O
Epac	B-PRGE
-	I-PRGE
1	I-PRGE
inhibitors	O
deserve	O
further	O
study	O
as	O
potential	O
therapeutic	O
agents	O
for	O
MERS	O
-	O
CoV	O
infection	O
.	O

We	O
immunized	O
cats	O
with	O
peptides	O
containing	O
T	O
-	O
helper	O
(	O
Th	O
)	O
1	O
epitopes	O
derived	O
from	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
the	O
type	B-PRGE
I	I-PRGE
FIPV	I-PRGE
KU	I-PRGE
-	I-PRGE
2	I-PRGE
strain	O
(	O
NP7	O
and	O
NP8	O
)	O
with	O
feline	O
CpG	O
-	O
oligodeoxynucleotides	O
(	O
fCpG	O
-	O
ODNs	O
)	O
as	O
a	O
vaccine	O
adjuvant	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
the	O
development	O
of	O
a	O
reverse	O
transcription	O
isothermal	O
Recombinase	B-PRGE
Polymerase	I-PRGE
Amplification	O
(	O
RT	B-PRGE
-	I-PRGE
RPA	I-PRGE
)	O
assay	O
for	O
the	O
identification	O
of	O
MERS	O
-	O
CoV	O
.	O
A	O
partial	O
nucleocapsid	O
gene	O
RNA	O
molecular	O
standard	O
of	O
MERS	O
-	O
coronavirus	O
was	O
used	O
to	O
determine	O
the	O
assay	O
sensitivity	O
.	O

The	O
developed	O
isothermal	O
real	O
-	O
time	O
RT	B-PRGE
-	I-PRGE
RPA	I-PRGE
is	O
ideal	O
for	O
rapid	O
mobile	O
molecular	O
MERS	O
-	O
CoV	O
monitoring	O
in	O
acute	O
patients	O
and	O
may	O
also	O
facilitate	O
the	O
search	O
for	O
the	O
animal	O
reservoir	O
of	O
MERS	O
-	O
CoV	O
.	O

However	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
caused	O
by	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
-	O
producing	O
lung	O
cancer	O
is	O
extremely	O
rare	O
.	O

Recent	O
identification	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
NSP16	I-PRGE
as	O
a	O
viral	O
2	O
'-	O
O	O
-	O
methyltransferase	O
(	O
2	O
'-	O
O	O
-	O
MTase	O
)	O
led	O
to	O
the	O
possibility	O
of	O
utilizing	O
this	O
pathway	O
to	O
both	O
attenuate	O
SARS	O
-	O
CoV	O
infection	O
and	O
develop	O
novel	O
therapeutic	O
treatment	O
options	O
.	O

While	O
viruses	O
lacking	O
2	B-PRGE
'-	I-PRGE
O	I-PRGE
-	I-PRGE
MTase	I-PRGE
activity	O
had	O
enhanced	O
sensitivity	O
to	O
type	O
I	O
interferon	B-PRGE
(	O
IFN	B-PRGE
),	O
they	O
were	O
not	O
completely	O
restored	O
in	O
their	O
absence	O
in	O
vivo	O
.	O

Pulmonary	O
hypertension	O
has	O
rarely	O
been	O
reported	O
in	O
mitochondrial	O
disorders	O
and	O
,	O
so	O
far	O
,	O
it	O
has	O
been	O
described	O
in	O
association	O
with	O
TMEM70	B-PRGE
deficiency	O
only	O
in	O
one	O
patient	O
.	O

Flaviviruses	O
defective	O
in	O
2	B-PRGE
'-	I-PRGE
O	I-PRGE
methyltransferase	I-PRGE
are	O
replicative	O
,	O
but	O
their	O
viral	O
RNAs	O
lack	O
2	O
'-	O
O	O
methylation	O
and	O
are	O
recognized	O
and	O
eliminated	O
by	O
the	O
host	O
immune	O
response	O
.	O

We	O
screened	O
a	O
library	O
of	O
5	O
,	O
000	O
small	O
molecules	O
and	O
discovered	O
a	O
small	O
molecule	O
that	O
can	O
inhibit	O
the	O
cathepsin	B-PRGE
L	I-PRGE
cleavage	I-PRGE
of	I-PRGE
all	I-PRGE
viral	I-PRGE
peptides	I-PRGE
with	O
minimal	O
inhibition	O
of	O
cleavage	O
of	O
a	O
host	O
protein	O
-	O
derived	O
peptide	O
(	O
pro	O
-	O
neuropeptide	O
Y	O
).	O

We	O
developed	O
a	O
novel	O
high	O
-	O
throughput	O
screening	O
assay	O
to	O
identify	O
small	O
molecules	O
that	O
can	O
prevent	O
cathepsin	B-PRGE
L	I-PRGE
cleavage	I-PRGE
of	I-PRGE
viral	I-PRGE
glycoproteins	I-PRGE
derived	I-PRGE
from	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
Ebola	O
,	O
Hendra	O
,	O
and	O
Nipah	O
viruses	O
that	O
are	O
required	O
for	O
their	O
entry	O
into	O
the	O
host	O
cell	O
.	O

N	B-PRGE
protein	I-PRGE
has	O
also	O
been	O
proposed	O
to	O
participate	O
in	O
the	O
replication	O
and	O
selective	O
packaging	O
of	O
genomic	O
RNA	O
and	O
the	O
transcription	O
and	O
translation	O
of	O
subgenomic	O
mRNA	O
.	O

We	O
show	O
that	O
expression	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
PLpros	O
blocks	O
upregulation	O
of	O
cytokines	O
CCL5	B-PRGE
,	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
and	O
CXCL10	B-PRGE
in	O
stimulated	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
IFN	B-PRGE
-	O
antagonizing	O
activity	O
is	O
specific	O
to	O
SARS	B-PRGE
coronavirus	I-PRGE
M	I-PRGE
protein	I-PRGE
and	O
is	O
mediated	O
through	O
its	O
first	O
transmembrane	O
domain	O
(	O
TM1	O
)	O
located	O
at	O
the	O
N	O
terminus	O
.	O

Whereas	O
N	O
-	O
linked	O
glycosylation	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
M	I-PRGE
protein	I-PRGE
has	O
no	O
influence	O
on	O
IFN	B-PRGE
antagonism	O
,	O
TM1	O
is	O
indispensable	O
for	O
the	O
suppression	O
of	O
IFN	B-PRGE
production	O
.	O

Our	O
work	O
defines	O
the	O
molecular	O
architecture	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
M	I-PRGE
protein	I-PRGE
required	O
for	O
suppression	O
of	O
innate	O
antiviral	O
response	O
.	O

Importantly	O
,	O
mutations	O
that	O
alter	O
DUB	B-PRGE
activity	O
but	O
not	O
viral	B-PRGE
protease	I-PRGE
activity	O
have	O
been	O
identified	O
and	O
arteriviruses	O
expressing	O
DUB	B-PRGE
mutants	I-PRGE
stimulated	O
higher	O
levels	O
of	O
acute	O
inflammatory	O
cytokines	O
after	O
infection	O
.	O

Intracellular	O
trafficking	O
over	O
microtubules	O
was	O
mediated	O
by	O
MLCK	B-PRGE
,	O
myosin	B-PRGE
1	I-PRGE
and	O
a	O
small	B-PRGE
actin	I-PRGE
tail	O
.	O

TITLE	O
:	O
Influence	O
of	O
hydrophobic	O
and	O
electrostatic	O
residues	O
on	O
SARS	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
S2	I-PRGE
protein	I-PRGE
stability	O
:	O
insights	O
into	O
mechanisms	O
of	O
general	O
viral	O
fusion	O
and	O
inhibitor	O
design	O
.	O

MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
4a	I-PRGE
protein	I-PRGE
contains	O
a	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	O
domain	O
capable	O
of	O
interacting	O
with	O
poly	O
(	O
I	O
Â·	O
C	O
).	O

Of	O
the	O
peptides	O
derived	O
from	O
the	O
S	O
,	O
M	O
,	O
and	O
N	O
proteins	O
of	O
FIPV	O
,	O
those	O
that	O
induced	O
significantly	O
stronger	O
Th1	O
activity	O
than	O
that	O
of	O
the	O
FIPV	B-PRGE
antigen	I-PRGE
were	O
rescreened	O
,	O
and	O
4	O
peptides	O
were	O
identified	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
developed	O
a	O
yeast	O
-	O
based	O
system	O
for	O
identifying	O
and	O
screening	O
inhibitors	O
against	O
coronavirus	O
N7	B-PRGE
-	I-PRGE
MTase	I-PRGE
using	O
both	O
96	O
-	O
well	O
and	O
384	O
-	O
well	O
microtiter	O
plates	O
.	O

The	O
MTase	B-PRGE
inhibitors	O
previously	O
identified	O
by	O
in	O
vitro	O
biochemical	O
assays	O
were	O
tested	O
,	O
and	O
some	O
,	O
such	O
as	O
sinefungin	O
,	O
effectively	O
suppressed	O
N7	B-PRGE
-	I-PRGE
MTase	I-PRGE
in	O
the	O
yeast	O
system	O
.	O

The	O
yeast	O
system	O
was	O
applied	O
to	O
the	O
screening	O
of	O
3000	O
natural	O
product	O
extracts	O
,	O
and	O
three	O
were	O
observed	O
to	O
more	O
potently	O
inhibit	O
the	O
activity	O
of	O
coronavirus	O
than	O
human	B-PRGE
N7	I-PRGE
-	I-PRGE
MTase	I-PRGE
.	O

ABSTRACT	O
:	O
Intravenous	B-PRGE
immunoglobulin	B-PRGE
(	I-PRGE
IVIg	I-PRGE
)	I-PRGE
is	O
the	O
treatment	O
of	O
choice	O
for	O
Guillain	O
-	O
BarrÃ©	O
syndrome	O
(	O
GBS	O
),	O
an	O
immune	O
-	O
mediated	O
peripheral	O
neuropathy	O
causing	O
rapidly	O
progressive	O
limb	O
weakness	O
and	O
respiratory	O
failure	O
.	O

These	O
IgG	B-PRGE
subclasses	O
were	O
purified	O
from	O
the	O
serum	O
of	O
174	O
GBS	O
patients	O
before	O
and	O
in	O
150	O
patients	O
2	O
weeks	O
after	O
standard	O
IVIg	O
treatment	O
regimen	O
.	O

IVIg	O
preparations	O
contained	O
relatively	O
high	O
levels	O
of	O
galactosylated	O
and	O
sialylated	O
IgG	B-PRGE
Fc	I-PRGE
glycoforms	O
compared	O
with	O
serum	B-PRGE
IgG	I-PRGE
in	O
patients	O
.	O

ABSTRACT	O
:	O
Our	O
previous	O
studies	O
showed	O
that	O
TGEV	O
infection	O
could	O
induce	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
via	O
activation	O
of	O
p53	B-PRGE
signaling	O
in	O
cultured	O
host	O
cells	O
.	O

Further	O
studies	O
showed	O
that	O
p53	B-PRGE
inhibitor	O
attenuated	O
TGEV	O
N	O
protein	O
induced	O
cell	O
cycle	O
arrest	O
at	O
S	O
and	O
G2	O
/	O
M	O
phases	O
and	O
apoptosis	O
through	O
reversing	O
the	O
expression	O
changes	O
of	O
cdc2	B-PRGE
,	O
cdk2	B-PRGE
and	O
cyclin	B-PRGE
B1	I-PRGE
and	O
the	O
translocation	O
changes	O
of	O
Bax	B-PRGE
and	O
cytochrome	B-PRGE
c	I-PRGE
induced	O
by	O
TGEV	B-PRGE
N	I-PRGE
protein	I-PRGE
.	O

The	O
patient	O
with	O
a	O
poor	O
outcome	O
(	O
patient	O
1	O
),	O
compared	O
to	O
patient	O
2	O
,	O
did	O
not	O
promote	O
type	O
-	O
1	O
Interferon	B-PRGE
(	O
IFN	B-PRGE
),	O
and	O
particularly	O
IFNÎ±	O
,	O
in	O
response	O
to	O
double	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
from	O
MERS	O
-	O
CoV	O
.	O
The	O
absence	O
of	O
IFNÎ±	O
,	O
known	O
to	O
promote	O
antigen	O
presentation	O
in	O
response	O
to	O
viruses	O
,	O
impairs	O
the	O
development	O
of	O
a	O
robust	O
antiviral	O
adaptive	O
Th	O
-	O
1	O
immune	O
response	O
.	O

A	O
heat	B-PRGE
-	I-PRGE
shock	I-PRGE
protein	I-PRGE
(	O
GrpE	B-PRGE
),	O
a	O
nicotinamide	O
adenine	O
dinucleotide	O
-	O
dependent	O
glyceraldehyde	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPN	B-PRGE
),	O
and	O
4	O
proteins	O
from	O
paralogous	O
gene	O
families	O
(	O
PGFs	O
)	O
were	O
identified	O
as	O
antigens	O
by	O
Western	O
blot	O
.	O

A	O
MIA	B-PRGE
using	I-PRGE
GrpE	I-PRGE
,	O
GAPN	B-PRGE
,	O
and	O
the	O
strongly	O
reactive	O
PGF	B-PRGE
protein	I-PRGE
was	O
developed	O
.	O

TITLE	O
:	O
The	O
discovery	O
of	O
asunaprevir	O
(	O
BMS	O
-	O
650032	O
),	O
an	O
orally	O
efficacious	O
NS3	B-PRGE
protease	I-PRGE
inhibitor	O
for	O
the	O
treatment	O
of	O
hepatitis	O
C	O
virus	O
infection	O
.	O

Knockdown	O
of	O
the	O
cellular	B-PRGE
Cyclophilin	I-PRGE
A	I-PRGE
(	O
CypA	B-PRGE
/	O
PPIA	B-PRGE
)	O
gene	O
in	O
Caco	O
-	O
2	O
cells	O
prevents	O
replication	O
of	O
HCoV	O
-	O
NL63	O
,	O
suggesting	O
that	O
CypA	B-PRGE
is	O
required	O
for	O
virus	O
replication	O
.	O

and	O
51	O
calves	O
(	O
3	O
.	O
3	O
%)	O
with	O
Eimeria	B-PRGE
spp	I-PRGE
.	O

FECV	O
and	O
FIP	B-PRGE
also	O
exhibit	O
functional	O
differences	O
,	O
since	O
FECVs	O
replicate	O
mainly	O
in	O
intestinal	O
epithelium	O
and	O
are	O
shed	O
in	O
feces	O
,	O
and	O
FIPVs	O
replicate	O
efficiently	O
in	O
monocytes	O
and	O
induce	O
systemic	O
disease	O
.	O

The	O
survival	O
ratio	O
showed	O
statistically	O
significant	O
differences	O
in	O
mild	O
and	O
moderate	O
ARDS	O
-	O
patients	O
treated	O
with	O
the	O
neutrophil	B-PRGE
elastase	I-PRGE
inhibitor	O
.	O

The	O
survival	O
ratio	O
showed	O
statistically	O
significant	O
differences	O
in	O
mild	O
and	O
moderate	O
ARDS	O
-	O
patients	O
treated	O
with	O
the	O
neutrophil	B-PRGE
elastase	I-PRGE
inhibitor	O
.	O

In	O
this	O
study	O
,	O
a	O
one	O
-	O
step	O
,	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	O
(	O
RT	O
-	O
LAMP	O
)	O
assay	O
was	O
developed	O
that	O
targets	O
a	O
region	O
in	O
the	O
FHMNV	B-PRGE
spike	I-PRGE
protein	I-PRGE
gene	I-PRGE
.	O

It	O
is	O
anticipated	O
that	O
the	O
developed	O
RT	B-PRGE
-	I-PRGE
LAMP	I-PRGE
and	O
quantitative	O
RT	B-PRGE
-	I-PRGE
LAMP	I-PRGE
methods	O
will	O
be	O
instrumental	O
for	O
diagnosis	O
and	O
surveillance	O
of	O
FHMNV	O
.	O

Here	O
,	O
we	O
show	O
that	O
mice	O
were	O
sensitized	O
to	O
MERS	O
-	O
CoV	O
infection	O
by	O
prior	O
transduction	O
with	O
adenoviral	O
vectors	O
expressing	O
the	O
human	B-PRGE
host	I-PRGE
-	I-PRGE
cell	I-PRGE
receptor	I-PRGE
dipeptidyl	I-PRGE
peptidase	I-PRGE
4	I-PRGE
.	O

Clinical	O
disease	O
and	O
histopathological	O
changes	O
were	O
more	O
severe	O
in	O
the	O
absence	O
of	O
type	B-PRGE
-	I-PRGE
I	I-PRGE
IFN	I-PRGE
signaling	O
whereas	O
the	O
T	O
-	O
cell	O
response	O
was	O
required	O
for	O
virus	O
clearance	O
.	O

Among	O
the	O
viral	O
membrane	O
proteins	O
,	O
the	O
spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
mediates	O
receptor	O
recognition	O
/	O
attachment	O
to	O
the	O
host	O
cell	O
and	O
fusion	O
of	O
viral	O
and	O
cellular	O
membranes	O
.	O

In	O
accordance	O
,	O
biopsy	O
of	O
FH	O
patients	O
shows	O
a	O
dramatic	O
increase	O
of	O
Fgl2	B-PRGE
expression	O
,	O
which	O
correlates	O
with	O
C5aR	B-PRGE
up	O
-	O
regulation	O
in	O
the	O
liver	O
.	O

Acute	O
hippocampal	O
slices	O
of	O
adult	O
mice	O
were	O
incubated	O
with	O
the	O
vitamin	O
E	O
derivative	O
Trolox	O
for	O
3	O
-	O
5	O
h	O
.	O
In	O
Mecp2	B-PRGE
(-)	O
(/	O
y	O
)	O
slices	O
this	O
treatment	O
dampened	O
neuronal	O
hyperexcitability	O
,	O
improved	O
synaptic	O
short	O
-	O
term	O
plasticity	O
,	O
and	O
fully	O
restored	O
synaptic	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
).	O

Gene	O
expression	O
of	O
IL	O
-	O
1Î²	O
and	O
IL	O
-	O
6receptors	O
in	O
the	O
tubular	O
gland	O
cells	O
of	O
the	O
isthmus	O
and	O
uterus	O
was	O
analyzed	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	I-PRGE
chain	O
reaction	O
.	O

The	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
receptor	I-PRGE
,	O
but	O
not	O
IL	B-PRGE
-	I-PRGE
1Î²	I-PRGE
receptor	I-PRGE
,	O
was	O
identified	O
in	O
the	O
tubular	O
gland	O
cells	O
in	O
the	O
isthmus	O
and	O
uterus	O
.	O

These	O
results	O
suggest	O
that	O
IBV	O
infection	O
causes	O
disorder	O
of	O
eggshell	O
formation	O
by	O
disturbing	O
gene	O
expression	O
of	O
collagen	B-PRGE
type	I-PRGE
I	I-PRGE
in	O
the	O
isthmus	O
and	O
CaBP	B-PRGE
-	I-PRGE
D28K	I-PRGE
in	O
the	O
uterus	O
,	O
probably	O
via	O
the	O
effects	O
of	O
substances	O
from	O
cytotoxic	O
cells	O
and	O
proinflammatory	O
cytokines	O
.	O

Investigations	O
revealed	O
neutrophilic	O
leucocytosis	O
(	O
30	O
,	O
000	O
/	O
cubic	O
millimeter	O
;	O
86	O
%)	O
with	O
high	O
serum	B-PRGE
lipase	I-PRGE
(	O
770	O
Unit	O
/	O
Liter	O
)	O
and	O
alanine	B-PRGE
transaminase	I-PRGE
(	O
379	O
Unit	O
/	O
Liter	O
)	O
and	O
low	O
serum	O
potassium	O
(	O
3	O
.	O
0	O
millimol	O
/	O
Liter	O
).	O

This	O
review	O
discusses	O
the	O
effects	O
of	O
ITSN	B-PRGE
-	I-PRGE
1s	I-PRGE
deficiency	O
on	O
pulmonary	O
endothelium	O
and	O
its	O
significance	O
in	O
the	O
pathology	O
of	O
ALI	O
/	O
ARDS	O
.	O

Additionally	O
,	O
live	O
-	O
imaging	O
studies	O
of	O
coronavirus	B-PRGE
replicase	I-PRGE
proteins	I-PRGE
have	O
used	O
fluorescent	O
reporter	O
molecules	O
fused	O
to	O
replicase	B-PRGE
proteins	I-PRGE
,	O
but	O
expressed	O
from	O
nonnative	O
locations	O
,	O
mostly	O
late	O
-	O
transcribed	O
subgenomic	O
mRNAs	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
native	O
protein	O
.	O

TITLE	O
:	O
PKR	B-PRGE
mediated	O
regulation	O
of	O
inflammation	O
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
during	O
viral	O
encephalomyelitis	O
.	O

Gliatropic	O
coronavirus	O
infection	O
induced	O
PKR	B-PRGE
activation	O
in	O
infected	O
as	O
well	O
uninfected	O
cells	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
).	O

Furthermore	O
,	O
PKR	B-PRGE
deficiency	O
selectively	O
reduced	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
production	O
in	O
CD4	B-PRGE
,	O
but	O
not	O
CD8	B-PRGE
T	I-PRGE
cells	O
,	O
without	O
affecting	O
CNS	O
pathology	O
.	O

TITLE	O
:	O
Protein	B-PRGE
interferon	I-PRGE
-	I-PRGE
stimulated	I-PRGE
gene	I-PRGE
15	O
conjugation	O
delays	O
but	O
does	O
not	O
overcome	O
coronavirus	O
proliferation	O
in	O
a	O
model	O
of	O
fulminant	O
hepatitis	O
.	O

MMP	B-PRGE
-	I-PRGE
8	I-PRGE
and	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
levels	O
were	O
analyzed	O
from	O
blood	O
samples	O
taken	O
on	O
enrollment	O
in	O
the	O
study	O
and	O
48	O
hours	O
later	O
.	O

Admission	B-PRGE
TIMP	I-PRGE
-	I-PRGE
1	I-PRGE
levels	O
were	O
higher	O
in	O
nonsurvivors	O
,	O
median	O
367	O
ng	O
/	O
mL	O
(	O
interquartile	O
range	O
199	O
-	O
562	O
),	O
than	O
survivors	O
,	O
median	O
240	O
ng	O
/	O
mL	O
(	O
interquartile	O
range	O
142	O
-	O
412	O
),	O
WMWodds	O
1	O
.	O
68	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
43	O
-	O
2	O
.	O
08	O
).	O

TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
associated	O
with	O
severity	O
of	O
hypoxemia	O
.	O

The	O
OCT	B-PRGE
at	O
T24	O
is	O
related	O
to	O
outcome	O
but	O
is	O
influenced	O
by	O
the	O
severity	O
of	O
respiratory	O
failure	O
.	O

However	O
,	O
in	O
the	O
Znhigh	O
group	O
,	O
we	O
found	O
a	O
prevention	O
of	O
villus	O
atrophy	O
and	O
decreased	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
mediated	O
apoptosis	O
of	O
jejunal	O
epithelium	O
.	O

A	O
negative	O
correlation	O
between	O
antiviral	O
cytokines	O
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
,	O
IL	O
-	O
37	O
,	O
FOXP3	B-PRGE
,	O
and	O
RORC2	O
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
viruses	O
,	O
and	O
interestingly	O
,	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
strongly	O
correlated	O
with	O
antiviral	O
cytokines	O
.	O

We	O
also	O
found	O
that	O
the	O
amount	O
of	O
Ark	B-PRGE
vaccine	O
virus	O
was	O
low	O
or	O
undetectable	O
in	O
choanal	O
swabs	O
out	O
to	O
35	O
days	O
postvaccination	O
when	O
vaccine	O
was	O
administered	O
by	O
eyedrop	O
or	O
drinking	O
water	O
.	O

JMML	B-PRGE
are	O
all	O
stem	O
cell	O
diseases	O
the	O
common	O
denominator	O
of	O
which	O
is	O
RAS	B-PRGE
pathway	O
dysregulation	O
,	O
due	O
to	O
mutations	O
in	O
RAS	B-PRGE
(	O
NRAS	B-PRGE
,	O
KRAS	B-PRGE
)	O
or	O
RAS	B-PRGE
regulatory	I-PRGE
components	I-PRGE
(	O
PTPN11	B-PRGE
,	O
NF1	B-PRGE
or	O
CBL	B-PRGE
).	O

The	O
resulting	O
selective	O
index	O
values	O
(	O
SI	O
=	O
CC50	O
/	O
EC50	O
)	O
of	O
the	O
most	O
effective	O
extracts	O
CBE	O
,	O
GSH	B-PRGE
,	O
DBM	B-PRGE
,	O
CTH	B-PRGE
and	O
TCH	B-PRGE
were	O
>	O
59	O
.	O
4	O
,	O
>	O
57	O
.	O
5	O
,	O
>	O
62	O
.	O
1	O
,	O
>	O
59	O
.	O
4	O
,	O
and	O
>	O
92	O
.	O
9	O
,	O
respectively	O
.	O

Additional	O
information	O
about	O
norepinephrine	O
dosage	O
,	O
fraction	O
of	O
inspired	O
oxygen	O
,	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
and	O
fibrinogen	B-PRGE
concentrations	O
the	O
first	O
day	O
following	O
ECMO	O
initiation	O
further	O
improved	O
discrimination	O
(	O
AUC	O
:	O
0	O
.	O
79	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
and	O
predictive	O
ability	O
(	O
likelihood	O
ratio	O
test	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Antigenic	O
analysis	O
showed	O
that	O
the	O
S1	B-PRGE
domain	I-PRGE
of	O
LYRa11	O
could	O
be	O
efficiently	O
recognized	O
by	O
SARS	O
-	O
convalescent	O
human	O
serum	O
,	O
indicating	O
that	O
LYRa11	O
is	O
a	O
novel	O
virus	O
antigenically	O
close	O
to	O
SARS	B-PRGE
CoV	I-PRGE
.	O
Recombination	O
analyses	O
indicate	O
that	O
LYRa11	O
is	O
likely	O
a	O
recombinant	O
descended	O
from	O
parental	O
lineages	O
that	O
had	O
evolved	O
into	O
a	O
number	O
of	O
bat	O
SARS	O
-	O
like	O
CoVs	O
.	O

Notably	O
,	O
full	O
genomic	O
sequencing	O
and	O
antigenic	O
study	O
demonstrated	O
that	O
LYRa11	O
is	O
phylogenetically	O
and	O
antigenically	O
closely	O
related	O
to	O
SARS	B-PRGE
CoV	I-PRGE
.	O
Recombination	O
analyses	O
indicate	O
that	O
LYRa11	O
is	O
a	O
recombinant	O
from	O
certain	O
bat	O
SARS	O
-	O
like	O
CoVs	O
circulating	O
in	O
Yunnan	O
Province	O
.	O

Initial	O
appropriate	O
antibiotics	O
use	O
and	O
day	O
1	O
level	O
of	O
HMGB1	B-PRGE
were	O
independent	O
factors	O
for	O
predicting	O
ICU	O
mortality	O
.	O

An	O
internal	O
amplification	O
control	O
was	O
included	O
into	O
the	O
RT	O
-	O
PCR	O
assays	O
targeting	O
the	O
genomic	O
region	O
upstream	B-PRGE
of	I-PRGE
the	I-PRGE
Envelope	I-PRGE
gene	I-PRGE
(	O
upE	O
)	O
and	O
within	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1A	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
terms	O
of	O
mean	O
age	O
,	O
immune	O
status	O
,	O
leukocyte	O
count	O
,	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
)	O
values	O
,	O
hospitalization	O
duration	O
and	O
CURB	O
-	O
65	O
score	O
between	O
bacterial	O
and	O
mixed	O
viral	O
-	O
bacterial	O
detections	O
.	O

Focusing	O
on	O
modes	O
of	O
security	O
and	O
quarantine	O
practices	O
,	O
I	O
examine	O
how	O
globalization	O
and	O
the	O
social	O
crises	O
surrounding	O
SARS	B-PRGE
and	O
H1N1	B-PRGE
flu	I-PRGE
operated	O
to	O
regulate	O
differently	O
certain	O
bodies	O
and	O
areas	O
.	O

SimPlot	O
analysis	O
of	O
the	O
7	O
.	O
2	O
-	O
kb	O
3	O
'	O
end	O
of	O
the	O
N1	O
/	O
08	O
genome	O
with	O
the	O
same	O
region	O
for	O
other	O
Australian	O
reference	O
strains	O
identified	O
the	O
sites	O
of	O
recombination	O
as	O
immediately	O
upstream	O
and	O
downstream	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
.	O

TITLE	O
:	O
Mechanical	O
ventilation	O
drives	O
pneumococcal	O
pneumonia	O
into	O
lung	O
injury	O
and	O
sepsis	O
in	O
mice	O
:	O
protection	O
by	O
adrenomedullin	B-PRGE
.	O

Lung	O
and	O
blood	O
bacterial	O
burden	O
was	O
not	O
affected	O
by	O
MV	O
pneumonia	O
and	O
MV	O
increased	O
lung	O
AM	O
expression	O
,	O
whereas	O
receptor	B-PRGE
activity	I-PRGE
modifying	I-PRGE
protein	B-PRGE
(	I-PRGE
RAMP	I-PRGE
)	I-PRGE
1	I-PRGE
-	I-PRGE
3	I-PRGE
expression	O
was	O
increased	O
in	O
pneumonia	O
and	O
reduced	O
by	O
MV	O
.	O

A	O
phenomenon	O
in	O
common	O
with	O
other	O
strains	O
was	O
that	O
nucleotide	O
(	O
nt	O
)	O
655	O
of	O
the	O
spike	O
(	O
S	O
)	O
gene	O
was	O
G	O
,	O
and	O
a	O
common	O
change	O
in	O
nt	O
1753	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
was	O
a	O
T	O
-	O
to	O
-	O
G	O
mutation	O
that	O
caused	O
a	O
serine	O
-	O
to	O
-	O
alanine	O
mutation	O
at	O
amino	O
acid	O
585	O
,	O
which	O
is	O
in	O
the	O
region	O
of	O
the	O
main	O
major	O
antigenic	O
sites	O
A	O
and	O
B	O
of	O
the	O
TGEV	B-PRGE
S	I-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
Recent	O
evidence	O
suggests	O
that	O
a	O
mutation	O
in	O
the	O
spike	O
protein	O
gene	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
which	O
results	O
in	O
an	O
amino	O
acid	O
change	O
from	O
methionine	O
to	O
leucine	O
at	O
position	O
1058	O
,	O
may	O
be	O
associated	O
with	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	B-PRGE
).	O

This	O
study	O
aimed	O
to	O
retrospectively	O
investigate	O
the	O
clinical	O
status	O
and	O
outcomes	O
in	O
IPF	O
patients	O
receiving	O
NIV	O
for	O
ARF	B-PRGE
and	O
to	O
identify	O
those	O
clinical	O
and	O
laboratory	O
characteristics	O
,	O
which	O
could	O
be	O
considered	O
risk	O
factors	O
for	O
its	O
failure	O
.	O

At	O
admission	O
,	O
the	O
patients	O
in	O
the	O
failure	O
group	O
had	O
significantly	O
higher	O
respiratory	O
rate	O
values	O
(	O
36	O
.	O
9	O
Â±	O
7	O
.	O
8	O
vs	O
30	O
.	O
5	O
Â±	O
3	O
.	O
3	O
breaths	O
/	O
min	O
;	O
P	O
=.	O
036	O
),	O
plasma	O
N	O
-	O
terminal	O
fragment	O
of	O
the	O
prohormone	O
of	O
B	B-PRGE
-	I-PRGE
type	I-PRGE
natriuretic	I-PRGE
peptide	I-PRGE
(	O
NT	O
-	O
proBNP	O
)	O
levels	O
(	O
4528	O
.	O
8	O
Â±	O
4012	O
.	O
8	O
vs	O
634	O
.	O
6	O
Â±	O
808	O
.	O
0	O
pg	O
/	O
mL	O
;	O
P	O
=.	O
023	O
)	O
and	O
serum	B-PRGE
C	I-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
values	O
(	O
72	O
.	O
0	O
Â±	O
50	O
.	O
0	O
vs	O
20	O
.	O
7	O
Â±	O
24	O
.	O
0	O
Î¼g	O
/	O
mL	O
;	O
P	O
=.	O
0289	O
)	O
with	O
respect	O
to	O
those	O
in	O
the	O
success	O
group	O
.	O

Here	O
we	O
show	O
that	O
rhesus	O
macaques	O
infected	O
with	O
Sin	B-PRGE
Nombre	I-PRGE
virus	I-PRGE
(	O
SNV	O
),	O
the	O
primary	O
etiological	O
agent	O
of	O
HPS	O
in	O
North	O
America	O
,	O
propagated	O
in	O
deer	O
mice	O
develop	O
HPS	O
,	O
which	O
is	O
characterized	O
by	O
thrombocytopenia	O
,	O
leukocytosis	O
,	O
and	O
rapid	O
onset	O
of	O
respiratory	O
distress	O
caused	O
by	O
severe	O
interstitial	O
pneumonia	O
.	O

MERS	O
-	O
4	O
also	O
showed	O
inhibitory	O
activity	O
against	O
syncytia	O
formation	O
mediated	O
by	O
interaction	O
between	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
and	O
DPP4	B-PRGE
.	O

Consensus	O
dromedary	O
MERS	O
-	O
CoV	O
genome	O
sequences	O
were	O
the	O
same	O
with	O
either	O
template	O
source	O
and	O
identical	O
to	O
published	O
human	B-PRGE
MERS	I-PRGE
-	I-PRGE
CoV	I-PRGE
sequences	I-PRGE
.	O

The	O
highest	O
-	O
affinity	O
MAb	O
,	O
m336	O
,	O
neutralized	O
both	O
pseudotyped	O
and	O
live	O
MERS	O
-	O
CoV	O
with	O
exceptional	O
potency	O
,	O
50	O
%	O
neutralization	O
at	O
0	O
.	O
005	O
and	O
0	O
.	O
07	O
Î¼g	O
/	O
ml	O
,	O
respectively	O
,	O
likely	O
by	O
competing	O
with	O
DPP4	B-PRGE
for	O
binding	O
to	O
the	O
S	B-PRGE
glycoprotein	I-PRGE
.	O

Influenza	O
A	O
virus	O
,	O
RSV	B-PRGE
A	I-PRGE
,	O
HRV	O
,	O
coronavirus	O
OC43	O
,	O
and	O
adenovirus	O
were	O
detected	O
more	O
frequently	O
in	O
sputum	O
samples	O
than	O
in	O
nasopharyngeal	O
swabs	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Thus	O
,	O
we	O
examined	O
whether	O
PFV	B-PRGE
RNase	I-PRGE
H	I-PRGE
can	O
serve	O
as	O
an	O
HIV	O
-	O
1	O
RNase	B-PRGE
H	I-PRGE
model	O
for	O
inhibitor	O
interaction	O
studies	O
.	O

Five	O
HIV	O
-	O
1	O
RHIs	O
inhibited	O
PFV	O
RNase	B-PRGE
H	I-PRGE
activity	O
at	O
low	O
-	O
micromolar	O
concentrations	O
similar	O
to	O
those	O
of	O
HIV	O
-	O
1	O
RNase	B-PRGE
H	I-PRGE
,	O
suggesting	O
pocket	O
similarity	O
of	O
the	O
RNase	B-PRGE
H	I-PRGE
domains	I-PRGE
.	O

TITLE	O
:	O
Akt2	B-PRGE
deficiency	O
as	O
a	O
therapeutic	O
strategy	O
protects	O
against	O
acute	O
lung	O
injury	O
.	O

Vergadi	O
et	O
al	O
.	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
depletion	O
of	O
Akt2	B-PRGE
kinase	I-PRGE
and	O
microRNA	O
-	O
146a	O
induction	O
in	O
mice	O
resulted	O
in	O
polarization	O
of	O
alveolar	O
macrophages	O
towards	O
an	O
M2	O
activation	O
phenotype	O
and	O
resulted	O
in	O
less	O
severe	O
injury	O
following	O
acid	O
-	O
induced	O
lung	O
injury	O
.	O

TITLE	O
:	O
Ribavirin	O
and	O
interferon	B-PRGE
-	I-PRGE
Î±2b	I-PRGE
as	O
primary	O
and	O
preventive	O
treatment	O
for	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
:	O
a	O
preliminary	O
report	O
of	O
two	O
cases	O
.	O

Because	O
of	O
similarities	O
between	O
the	O
two	O
coronaviruses	O
,	O
treatment	O
with	O
ribavarin	O
and	O
interferon	B-PRGE
-	I-PRGE
Î±2b	I-PRGE
has	O
been	O
suggested	O
as	O
a	O
potential	O
therapy	O
for	O
MERS	O
-	O
CoV	O
.	O
Studies	O
in	O
animal	O
models	O
of	O
MERS	O
-	O
CoV	O
have	O
shown	O
the	O
combination	O
of	O
ribavirin	O
and	O
interferon	B-PRGE
-	I-PRGE
Î±2b	I-PRGE
to	O
be	O
effective	O
both	O
as	O
primary	O
treatment	O
and	O
prophylaxis	O
.	O

Prompt	O
diagnosis	O
,	O
multidisciplinary	O
management	O
,	O
including	O
aggressive	O
resuscitation	O
,	O
cardiorespiratory	O
support	O
,	O
intravenous	O
immunoglobulin	B-PRGE
therapy	O
,	O
and	O
daily	O
wound	O
care	O
resulted	O
in	O
a	O
positive	O
outcome	O
despite	O
a	O
predicted	O
mortality	O
greater	O
than	O
60	O
%.	O

Notably	O
,	O
influenza	B-PRGE
A	I-PRGE
virus	I-PRGE
NS1	I-PRGE
appears	O
to	O
play	O
a	O
central	O
role	O
in	O
this	O
histone	B-PRGE
-	O
mediated	O
downregulation	O
in	O
highly	O
pathogenic	O
influenza	O
strains	O
.	O

In	O
particular	O
,	O
CD11b	B-PRGE
(+)	O
cells	O
in	O
the	O
lungs	O
of	O
UV	O
-	O
V	O
-	O
immunized	O
mice	O
showed	O
the	O
upregulation	O
of	O
genes	O
associated	O
with	O
the	O
induction	O
of	O
eosinophils	O
after	O
challenge	O
.	O

Multiplex	O
reverse	O
transcriptase	B-PRGE
polymerase	I-PRGE
chain	I-PRGE
reaction	O
(	O
MRT	O
-	O
PCR	O
)	O
assays	O
for	O
detection	O
of	O
multiple	O
viruses	O
are	O
being	O
used	O
increasingly	O
in	O
clinical	O
settings	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
encodes	O
a	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLpro	O
)	O
with	O
both	O
deubiquitinating	O
(	O
DUB	O
)	O
and	O
deISGylating	O
activities	O
that	O
are	O
proposed	O
to	O
counteract	O
the	O
post	O
-	O
translational	O
modification	O
of	O
signaling	O
molecules	O
that	O
activate	O
the	O
innate	O
immune	O
response	O
.	O

We	O
propose	O
that	O
PLpro	O
'	O
s	O
higher	O
affinity	O
for	O
K48	B-PRGE
-	I-PRGE
linked	I-PRGE
ubiquitin	I-PRGE
chains	I-PRGE
and	O
ISG15	B-PRGE
stems	O
from	O
a	O
bivalent	O
mechanism	O
of	O
binding	O
,	O
where	O
two	O
ubiquitin	B-PRGE
-	O
like	O
domains	O
prefer	O
to	O
bind	O
in	O
the	O
palm	O
domain	O
of	O
PLpro	O
with	O
the	O
most	O
distal	O
ubiquitin	B-PRGE
domain	I-PRGE
interacting	O
with	O
a	O
""""	O
ridge	O
""""	O
region	O
of	O
the	O
thumb	O
domain	O
.	O

We	O
then	O
used	O
reverse	O
-	O
transcription	O
PCR	O
to	O
look	O
for	O
the	O
coronavirus	O
RNA	O
-	O
dependent	O
RNA	B-PRGE
polymerase	I-PRGE
gene	I-PRGE
in	O
fecal	O
samples	O
collected	O
from	O
27	O
little	O
Japanese	O
horseshoe	O
bats	O
and	O
found	O
eight	O
were	O
provisionally	O
positive	O
.	O

(	O
ii	O
)	O
In	O
the	O
second	O
examination	O
,	O
analyses	O
of	O
multiple	O
frame	O
shifts	O
,	O
truncations	O
,	O
and	O
point	O
mutations	O
within	O
the	O
partial	O
nsp1	B-PRGE
-	I-PRGE
coding	I-PRGE
region	I-PRGE
showed	O
that	O
synthesis	O
of	O
a	O
PEFP	B-PRGE
core	I-PRGE
amino	I-PRGE
acid	I-PRGE
sequence	I-PRGE
within	O
a	O
group	O
A	O
lineage	O
betacoronavirus	O
-	O
conserved	O
NH2	O
-	O
proximal	O
WAPEFPWM	B-PRGE
domain	I-PRGE
is	O
required	O
in	O
cis	O
for	O
DI	O
RNA	O
replication	O
.	O

A	O
detailed	O
analysis	O
revealed	O
that	O
the	O
PEDV	B-PRGE
N	I-PRGE
protein	I-PRGE
targets	O
TBK1	B-PRGE
by	O
direct	O
interaction	O
and	O
that	O
this	O
binding	O
sequesters	O
the	O
association	O
between	O
TBK1	B-PRGE
and	O
IRF3	B-PRGE
,	O
which	O
in	O
turn	O
inhibits	O
both	O
IRF3	B-PRGE
activation	O
and	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
production	O
.	O

K22	O
-	O
resistant	O
viruses	O
contained	O
substitutions	O
in	O
non	O
-	O
structural	O
protein	B-PRGE
6	I-PRGE
(	O
nsp6	O
),	O
a	O
membrane	O
-	O
spanning	O
integral	O
component	O
of	O
the	O
viral	O
replication	O
complex	O
implicated	O
in	O
DMV	O
formation	O
,	O
corroborating	O
that	O
K22	O
targets	O
membrane	O
bound	O
viral	O
RNA	O
synthesis	O
.	O

Treatment	O
of	O
cells	O
with	O
neuraminidase	B-PRGE
(	O
NA	O
)	O
enhanced	O
infection	O
efficiency	O
,	O
showing	O
that	O
terminal	O
sialic	O
acid	O
residues	O
on	O
the	O
cell	O
surface	O
were	O
not	O
receptor	O
determinants	O
and	O
even	O
hampered	O
efficient	O
virus	O
-	O
receptor	O
engagement	O
.	O

In	O
addition	O
to	O
studying	O
this	O
unusual	O
presentation	O
the	O
authors	O
have	O
also	O
provided	O
a	O
brief	O
review	O
of	O
TENS	O
and	O
SJS	B-PRGE
along	O
with	O
several	O
common	O
complications	O
of	O
this	O
disease	O
process	O
.	O

The	O
resolution	O
of	O
alveolar	O
edema	O
across	O
the	O
normally	O
tight	O
epithelial	O
barrier	O
can	O
be	O
up	O
-	O
regulated	O
by	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)-	O
dependent	O
mechanisms	O
through	O
adrenergic	O
or	O
dopamine	B-PRGE
receptor	I-PRGE
stimulation	O
,	O
and	O
by	O
several	O
cAMP	O
-	O
independent	O
mechanisms	O
,	O
including	O
glucocorticoids	O
,	O
thyroid	O
hormone	O
,	O
dopamine	O
,	O
and	O
growth	O
factors	O
.	O

TITLE	O
:	O
Papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLpro	O
)	O
inhibitory	O
effects	O
of	O
cinnamic	O
amides	O
from	O
Tribulus	O
terrestris	O
fruits	O
.	O

These	O
compounds	O
(	O
1	O
-	O
7	O
)	O
were	O
evaluated	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
PLpro	O
inhibitory	O
activity	O
to	O
identify	O
their	O
potencies	O
and	O
kinetic	O
behavior	O
.	O

From	O
1960	O
,	O
six	O
strains	O
of	O
human	O
coronaviruses	O
have	O
emerged	O
that	O
includes	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
the	O
recent	O
infection	O
by	O
deadly	O
MERS	O
-	O
CoV	O
which	O
is	O
now	O
going	O
to	O
cause	O
another	O
outbreak	O
.	O

Our	O
aim	O
was	O
to	O
evaluate	O
the	O
levels	O
of	O
activin	B-PRGE
A	I-PRGE
,	O
activin	B-PRGE
B	I-PRGE
,	O
FS	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
their	O
association	O
with	O
the	O
severity	O
of	O
respiratory	O
failure	O
in	O
critically	O
ill	O
H1N1	O
patients	O
.	O

Clinical	O
information	O
was	O
recorded	O
during	O
ICU	O
treatment	O
,	O
and	O
serum	B-PRGE
activin	I-PRGE
A	I-PRGE
,	O
activin	B-PRGE
B	I-PRGE
,	O
FS	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
were	O
measured	O
at	O
admission	O
to	O
ICU	O
and	O
on	O
days	O
2	O
and	O
7	O
.	O

Among	O
these	O
SNP	O
,	O
the	O
fFING	O
+	O
428	O
T	O
allele	O
was	O
shown	O
to	O
be	O
a	O
FIP	O
-	O
resistant	O
allele	O
(	O
p	O
=	O
0	O
.	O
03	O
),	O
and	O
the	O
heterozygous	O
genotypes	O
01C	O
/	O
T	O
and	O
+	O
408C	O
/	O
T	O
were	O
found	O
to	O
be	O
FIP	B-PRGE
-	I-PRGE
susceptible	I-PRGE
factors	O
(	O
p	O
=	O
0	O
.	O
004	O
).	O

Furthermore	O
,	O
the	O
reduction	O
in	O
cell	O
numbers	O
in	O
the	O
spleens	O
of	O
wild	O
-	O
type	O
mice	O
after	O
infection	O
was	O
not	O
observed	O
in	O
the	O
infected	O
Fut9	B-PRGE
(-/-)	O
mice	O
.	O

Although	O
there	O
were	O
no	O
clear	O
differences	O
in	O
the	O
levels	O
of	O
cytokines	O
examined	O
in	O
the	O
brains	O
between	O
Fut9	B-PRGE
(-/-)	O
and	O
wild	O
-	O
type	O
mice	O
except	O
for	O
interferon	B-PRGE
-	I-PRGE
Î²	I-PRGE
expression	O
,	O
some	O
of	O
those	O
in	O
the	O
spleens	O
,	O
including	O
interferon	B-PRGE
-	I-PRGE
Î³	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
monocyte	B-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
1	I-PRGE
,	O
showed	O
higher	O
levels	O
in	O
Fut9	B-PRGE
(-/-)	O
than	O
in	O
wild	O
-	O
type	O
mice	O
.	O

TITLE	O
:	O
IL	B-PRGE
-	I-PRGE
27	I-PRGE
limits	O
central	O
nervous	O
system	O
viral	O
clearance	O
by	O
promoting	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
enhances	O
demyelination	O
.	O

Contributions	O
of	O
IL	B-PRGE
-	I-PRGE
27	I-PRGE
to	O
viral	O
pathogenesis	O
were	O
evaluated	O
by	O
infection	O
of	O
IL	O
-	O
27RÎ±	O
-	O
chain	O
-	O
deficient	O
(	O
IL	O
-	O
27RÎ±	O
(-/-))	O
mice	O
.	O

Cultured	O
NPCs	O
derived	O
from	O
C57BL	O
/	O
6	O
(	O
H	O
-	O
2	O
(	O
b	O
)	O
)	O
mice	O
express	O
the	O
NKG2D	B-PRGE
ligand	O
retinoic	B-PRGE
acid	I-PRGE
early	I-PRGE
precursor	I-PRGE
transcript	I-PRGE
(	O
RAE	O
)-	O
1	O
but	O
expression	O
was	O
dramatically	O
reduced	O
upon	O
differentiation	O
into	O
either	O
glia	O
or	O
neurons	O
.	O

TITLE	O
:	O
Glyceraldehyde	B-PRGE
-	I-PRGE
3	I-PRGE
-	I-PRGE
phosphate	I-PRGE
dehydrogenase	I-PRGE
(	O
GAPDH	B-PRGE
)	O
prevents	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
,	O
sepsis	O
-	O
related	O
severe	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

We	O
propose	O
,	O
based	O
on	O
the	O
analysis	O
of	O
a	O
large	O
number	O
of	O
nsp3	B-PRGE
and	O
nsp4	B-PRGE
mutants	I-PRGE
,	O
that	O
interaction	O
between	O
the	O
large	O
luminal	O
loops	O
of	O
these	O
proteins	O
drives	O
the	O
formation	O
of	O
membrane	O
rearrangements	O
,	O
onto	O
which	O
the	O
coronavirus	O
replication	O
-	O
transcription	O
complexes	O
assemble	O
in	O
infected	O
cells	O
.	O

In	O
this	O
study	O
,	O
a	O
multiplex	O
TaqMan	O
probe	O
-	O
based	O
real	O
-	O
time	O
PCR	O
was	O
developed	O
for	O
detecting	O
PEDV	O
and	O
differentiating	O
the	O
variant	O
from	O
classical	O
PEDV	O
,	O
by	O
using	O
two	O
sets	O
of	O
primers	O
and	O
probes	O
based	O
on	O
the	O
S	B-PRGE
gene	I-PRGE
of	O
PEDV	O
.	O

Our	O
results	O
showed	O
that	O
the	O
SOCS3	B-PRGE
expression	O
was	O
significantly	O
elevated	O
in	O
both	O
the	O
liver	O
tissue	O
and	O
PBMCs	O
from	O
patients	O
with	O
HBV	O
-	O
ACLF	O
compared	O
to	O
mild	O
chronic	O
hepatitis	O
B	O
(	O
CHB	O
).	O

RESULTS	O
:	O
IN	O
BOTH	B-PRGE
PATIENTS	I-PRGE
,	I-PRGE
CHARACTERISTIC	I-PRGE
LUNG	I-PRGE
ULTRASOUND	I-PRGE
FINDINGS	I-PRGE
HAVE	I-PRGE
BEEN	I-PRGE
OBSERVED	I-PRGE
AS	I-PRGE
PREVIOUSLY	I-PRGE
DESCRIBED	I-PRGE
IN	I-PRGE
VIRAL	I-PRGE
PULMONARY	I-PRGE
INFECTIONS	I-PRGE
:	O
subpleural	O
consolidations	O
associated	O
or	O
not	O
with	O
local	O
pleural	O
effusion	O
.	O

Oseltamivir	O
,	O
anti	O
-	O
infective	O
drugs	O
,	O
methylprednisolone	O
,	O
albumin	B-PRGE
,	O
and	O
intravenous	O
immunoglobulin	B-PRGE
were	O
administered	O
.	O

Knockdown	O
of	O
EF1A	B-PRGE
impairs	O
N	O
protein	O
proliferation	O
and	O
TGEV	O
replication	O
in	O
host	O
cell	O
.	O

Beta	B-PRGE
-	I-PRGE
2	I-PRGE
agonist	O
therapy	O
does	O
not	O
accelerate	O
edema	O
clearance	O
and	O
is	O
potentially	O
dangerous	O
.	O

ABSTRACT	O
:	O
Data	O
on	O
the	O
efficacy	O
of	O
Peg	B-PRGE
-	O
interferon	B-PRGE
/	O
ribavirin	O
therapy	O
for	O
chronic	O
hepatitis	O
C	O
are	O
mostly	O
derived	O
from	O
treatment	O
of	O
selected	O
patients	O
enrolled	O
in	O
clinical	O
trials	O
.	O

The	O
proviral	O
effect	O
requires	O
cytoplasmic	O
localization	O
of	O
the	O
AKAP7	B-PRGE
PDE	I-PRGE
domain	I-PRGE
.	O

A	O
statistical	O
analysis	O
of	O
MAP1LC3B	B-PRGE
puncta	I-PRGE
showed	O
that	O
NSP6	O
induced	O
greater	O
numbers	O
of	O
autophagosomes	O
per	O
cell	O
compared	O
with	O
starvation	O
,	O
but	O
the	O
autophagosomes	O
induced	O
by	O
NSP6	O
had	O
smaller	O
diameters	O
compared	O
with	O
starvation	O
controls	O
.	O

Analysis	O
of	O
WIPI2	B-PRGE
puncta	I-PRGE
induced	O
by	O
NSP6	O
suggests	O
that	O
NSP6	O
limits	O
autophagosome	O
diameter	O
at	O
the	O
point	O
of	O
omegasome	O
formation	O
.	O

The	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PL	O
(	O
pro	O
))	O
is	O
a	O
potential	O
target	O
for	O
the	O
development	O
of	O
antiviral	O
drugs	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
muramyl	O
dipeptide	O
(	O
MDP	O
)	O
and	O
tuftsin	B-PRGE
in	O
oral	O
immune	O
adjustment	O
remains	O
unclear	O
,	O
particularly	O
in	O
a	O
Lactobacillus	O
casei	O
(	O
L	O
.	O
casei	O
)	O
vaccine	O
.	O

These	O
molecules	O
inhibit	O
not	O
only	O
HIV	B-PRGE
integrase	I-PRGE
catalytic	O
activity	O
,	O
but	O
they	O
also	O
interfere	O
with	O
the	O
function	O
of	O
the	O
RNase	B-PRGE
H	I-PRGE
component	O
of	O
the	O
HIV	B-PRGE
reverse	I-PRGE
transcriptase	I-PRGE
.	O

We	O
found	O
that	O
up	O
-	O
regulation	O
of	O
miR	B-PRGE
-	I-PRGE
125b	I-PRGE
expression	O
maintained	O
the	O
body	O
weight	O
and	O
survival	O
of	O
ALI	O
mice	O
,	O
and	O
significantly	O
reduced	O
LPS	O
-	O
induced	O
pulmonary	O
inflammation	O
as	O
reflected	O
by	O
reductions	O
in	O
total	O
cell	O
and	O
neutrophil	O
counts	O
,	O
proinflammatory	O
cytokines	O
,	O
as	O
well	O
as	O
chemokines	O
in	O
BAL	O
fluid	O
.	O

Further	O
,	O
enforced	O
expression	O
of	O
miR	B-PRGE
-	I-PRGE
125b	I-PRGE
resulted	O
in	O
remarkable	O
reversal	O
of	O
LPS	O
-	O
induced	O
increases	O
in	O
lung	O
permeability	O
as	O
assessed	O
by	O
reductions	O
in	O
total	O
protein	O
,	O
albumin	B-PRGE
and	O
IgM	B-PRGE
in	O
BAL	O
fluid	O
,	O
and	O
ameliorated	O
the	O
histopathology	O
changes	O
of	O
lung	O
in	O
LPS	O
-	O
induced	O
ALI	O
mice	O
.	O

Of	O
interest	O
,	O
serum	O
miR	B-PRGE
-	I-PRGE
125b	I-PRGE
expression	O
was	O
also	O
decreased	O
and	O
inversely	O
correlated	O
with	O
the	O
disease	O
severity	O
in	O
patients	O
with	O
ARDS	O
.	O

Late	O
-	O
term	O
pregnant	O
sows	O
were	O
inoculated	O
intramuscularly	O
with	O
the	O
purified	O
S1	B-PRGE
protein	I-PRGE
,	O
and	O
the	O
outcome	O
was	O
investigated	O
in	O
passively	O
immunized	O
suckling	O
piglets	O
after	O
a	O
virulent	O
PEDV	O
challenge	O
.	O

In	O
our	O
experiments	O
,	O
CpG	B-PRGE
ODN	I-PRGE
2007	O
or	O
PBS	O
solution	O
was	O
injected	O
on	O
18th	O
embryonic	O
day	O
(	O
ED	O
)	O
via	O
the	O
chorioallontoic	O
route	O
.	O

TITLE	O
:	O
Sensitivity	O
of	O
SARS	B-PRGE
/	O
MERS	O
CoV	O
to	O
interferons	O
and	O
other	O
drugs	O
based	O
on	O
achievable	O
serum	O
concentrations	O
in	O
humans	O
.	O

Here	O
we	O
describe	O
novel	O
,	O
highly	O
adaptable	O
viral	O
entry	O
assays	O
making	O
use	O
of	O
minimal	O
complementation	O
of	O
the	O
E	B-PRGE
.	I-PRGE
coli	I-PRGE
Î²	I-PRGE
-	I-PRGE
galactosidase	I-PRGE
in	O
mammalian	O
cells	O
.	O

TITLE	O
:	O
Travel	O
implications	O
of	O
emerging	O
coronaviruses	O
:	O
SARS	B-PRGE
and	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
emergence	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
of	O
the	O
Middle	O
East	O
Syndrome	O
Cornavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
caused	O
widespread	O
fear	O
and	O
concern	O
for	O
their	O
potential	O
threat	O
to	O
global	O
health	O
security	O
.	O

IgA	B-PRGE
antibody	I-PRGE
levels	O
were	O
higher	O
than	O
IgG	B-PRGE
antibody	I-PRGE
levels	O
throughout	O
the	O
primary	O
response	O
in	O
tears	O
and	O
were	O
similar	O
in	O
magnitude	O
in	O
plasma	O
.	O

In	O
summary	O
,	O
ocular	O
vaccination	O
induced	O
higher	O
IgA	B-PRGE
antibodies	I-PRGE
in	O
the	O
primary	O
IBV	O
response	O
,	O
while	O
the	O
memory	O
response	O
is	O
dominated	O
by	O
IgG	B-PRGE
antibodies	I-PRGE
.	O

Thus	O
,	O
lower	O
mucosal	O
IgA	B-PRGE
antibody	I-PRGE
levels	O
are	O
observed	O
upon	O
secondary	O
exposure	O
to	O
IBV	O
,	O
which	O
may	O
contribute	O
to	O
vulnerability	O
of	O
host	O
epithelial	O
cells	O
to	O
infection	O
by	O
IBV	O
and	O
persistence	O
of	O
the	O
Ark	B-PRGE
serotype	I-PRGE
.	O

TITLE	O
:	O
Virus	O
-	O
specific	O
memory	O
CD8	B-PRGE
T	I-PRGE
cells	O
provide	O
substantial	O
protection	O
from	O
lethal	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
.	O

Intravenous	O
immunization	O
with	O
peptide	O
-	O
loaded	O
dendritic	O
cells	O
(	O
DCs	O
)	O
followed	O
by	O
intranasal	O
boosting	O
with	O
recombinant	O
vaccinia	O
virus	O
(	O
rVV	O
)	O
encoding	O
S436	O
or	O
S525	O
resulted	O
in	O
accumulation	O
of	O
virus	O
-	O
specific	O
memory	O
CD8	B-PRGE
T	I-PRGE
cells	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BAL	O
),	O
lungs	O
,	O
and	O
spleen	O
.	O

Thus	O
,	O
future	O
vaccines	O
against	O
emerging	O
coronaviruses	O
should	O
emphasize	O
the	O
generation	O
of	O
a	O
memory	O
CD8	B-PRGE
T	I-PRGE
cell	O
response	O
for	O
optimal	O
protection	O
.	O

The	O
HA	O
and	O
M1	O
proteins	O
from	O
the	O
H3N2	O
influenza	O
virus	O
and	O
the	O
PRRSV	B-PRGE
GP5	I-PRGE
protein	I-PRGE
fused	O
to	O
the	O
cytoplasmic	O
and	O
transmembrane	O
domains	O
of	O
the	O
NA	B-PRGE
protein	I-PRGE
were	O
both	O
incorporated	O
into	O
the	O
chimeric	O
VLPs	O
.	O

Here	O
we	O
describe	O
our	O
observations	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
using	O
ADE	O
to	O
enhance	O
the	O
infectivity	O
of	O
a	O
HL	O
-	O
CZ	O
human	O
promonocyte	O
cell	O
line	O
.	O

According	O
to	O
flow	O
cytometry	O
data	O
,	O
the	O
HL	O
-	O
CZ	O
cells	O
also	O
expressed	O
angiotensin	B-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
,	O
a	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
)	O
and	O
higher	O
levels	O
of	O
the	O
FcÎ³RII	B-PRGE
receptor	I-PRGE
.	O

Results	O
from	O
infectivity	O
assays	O
indicate	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
ADE	I-PRGE
is	O
primarily	O
mediated	O
by	O
diluted	O
antibodies	O
against	O
envelope	B-PRGE
spike	I-PRGE
proteins	I-PRGE
rather	O
than	O
nucleocapsid	O
proteins	O
.	O

The	O
most	O
severely	O
ill	O
patient	O
presented	O
an	O
expression	O
of	O
the	O
virus	O
in	O
blood	O
and	O
urine	O
,	O
consistent	O
with	O
a	O
type	B-PRGE
-	I-PRGE
1	I-PRGE
interferon	I-PRGE
mediated	O
immunological	O
response	O
impaired	O
in	O
patient	O
1	O
,	O
but	O
developed	O
by	O
patient	O
2	O
.	O

The	O
148	B-PRGE
-	I-PRGE
amino	I-PRGE
acid	I-PRGE
nsp10	I-PRGE
subunit	I-PRGE
contains	O
two	O
zinc	O
fingers	O
and	O
is	O
known	O
to	O
interact	O
with	O
both	O
nsp14	O
and	O
nsp16	O
,	O
stimulating	O
their	O
respective	O
3	O
'-	O
5	O
'	O
exoribonuclease	O
and	O
2	O
'-	O
O	O
-	O
methyltransferase	O
activities	O
.	O

We	O
further	O
showed	O
that	O
the	O
nsp10	O
surface	O
interacting	O
with	O
nsp14	O
overlaps	O
with	O
the	O
surface	O
involved	O
in	O
the	O
nsp10	O
-	O
mediated	O
activation	O
of	O
nsp16	B-PRGE
2	I-PRGE
'-	I-PRGE
O	I-PRGE
-	I-PRGE
methyltransferase	I-PRGE
activity	O
,	O
suggesting	O
that	O
nsp10	O
is	O
a	O
major	O
regulator	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
replicase	I-PRGE
function	O
.	O

In	O
this	O
study	O
,	O
the	O
main	O
protease	O
of	O
human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
was	O
crystallized	O
in	O
complex	O
with	O
a	O
Michael	O
acceptor	O
.	O

The	O
internalized	O
PEDV	O
was	O
co	O
-	O
localized	O
with	O
the	O
clathrin	B-PRGE
-	O
mediated	O
endocytic	O
marker	O
,	O
but	O
not	O
with	O
the	O
caveolae	O
-	O
mediated	O
endocytic	O
marker	O
.	O

In	O
addition	O
,	O
cells	O
treated	O
with	O
lysosomotropic	O
agents	O
and	O
serine	B-PRGE
protease	I-PRGE
inhibitors	O
were	O
resistant	O
to	O
PEDV	O
.	O

For	O
on	O
-	O
farm	O
detection	O
of	O
PEDV	B-PRGE
RNA	I-PRGE
in	O
feed	O
,	O
paint	O
rollers	O
were	O
used	O
to	O
collect	O
material	O
from	O
at	O
-	O
risk	O
feed	O
bins	O
from	O
3	O
clinically	O
affected	O
breeding	O
herds	O
.	O

The	O
ester	O
derivative	O
RDS1759	O
selectively	O
inhibited	O
RNase	B-PRGE
H	I-PRGE
activity	O
and	O
viral	O
replication	O
in	O
the	O
low	O
micromolar	O
range	O
,	O
making	O
contacts	O
with	O
residues	O
Q475	O
,	O
N474	O
,	O
and	O
Y501	O
.	O

In	O
fact	O
,	O
E	B-PRGE
protein	I-PRGE
is	O
responsible	O
in	O
a	O
significant	O
proportion	O
of	O
the	O
inflammasome	O
activation	O
and	O
the	O
associated	O
inflammation	O
elicited	O
by	O
SARS	O
-	O
CoV	O
in	O
the	O
lung	O
parenchyma	O
.	O

ABSTRACT	O
:	O
Viral	B-PRGE
protease	I-PRGE
inhibitors	O
are	O
remarkably	O
effective	O
at	O
blocking	O
the	O
replication	O
of	O
viruses	O
such	O
as	O
human	O
immunodeficiency	O
virus	O
and	O
hepatitis	O
C	O
virus	O
,	O
but	O
they	O
inevitably	O
lead	O
to	O
the	O
selection	O
of	O
inhibitor	O
-	O
resistant	O
mutants	O
,	O
which	O
may	O
contribute	O
to	O
ongoing	O
disease	O
.	O

TITLE	O
:	O
A	O
chimeric	O
virus	O
-	O
mouse	O
model	O
system	O
for	O
evaluating	O
the	O
function	O
and	O
inhibition	O
of	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
proteases	I-PRGE
of	O
emerging	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Several	O
studies	O
have	O
demonstrated	O
the	O
presence	O
of	O
pathogen	B-PRGE
-	I-PRGE
specific	I-PRGE
Foxp3	I-PRGE
+	I-PRGE
CD4	I-PRGE
regulatory	O
T	O
cells	O
(	O
Treg	O
)	O
in	O
infected	O
animals	O
,	O
but	O
little	O
is	O
known	O
about	O
where	O
and	O
how	O
these	O
cells	O
affect	O
the	O
effector	O
T	O
cell	O
responses	O
and	O
whether	O
they	O
are	O
more	O
suppressive	O
than	O
bulk	O
Treg	O
populations	O
.	O

Later	O
,	O
at	O
7	O
dpi	O
,	O
the	O
most	O
prominent	O
increases	O
of	O
CD8Î±Î±	B-PRGE
mRNA	I-PRGE
and	O
Granzyme	B-PRGE
homolog	I-PRGE
A	I-PRGE
mRNA	I-PRGE
were	O
followed	O
by	O
a	O
significant	O
decrease	O
of	O
scores	O
of	O
tracheal	O
lesions	O
and	O
viral	O
load	O
.	O

Nitazoxanide	O
inhibits	O
a	O
broad	O
range	O
of	O
influenza	O
A	O
and	O
B	O
viruses	O
including	O
influenza	O
A	O
(	O
pH1N1	O
)	O
and	O
the	O
avian	B-PRGE
A	I-PRGE
(	O
H7N9	O
)	O
as	O
well	O
as	O
viruses	O
that	O
are	O
resistant	O
to	O
neuraminidase	B-PRGE
inhibitors	O
.	O

Mortality	O
is	O
high	O
in	O
ILD	B-PRGE
-	I-PRGE
associated	I-PRGE
ARF	I-PRGE
.	O

These	O
studies	O
clearly	O
indicate	O
a	O
significant	O
change	O
in	O
the	O
conformation	O
of	O
the	O
Cyto3a	B-PRGE
protein	I-PRGE
after	O
binding	O
with	O
calcium	O
.	O

All	O
PEDV	O
-	O
CONTROL	O
pigs	O
began	O
shedding	O
PEDV	O
in	O
feces	O
by	O
dpi	B-PRGE
3	I-PRGE
and	O
seroconverted	O
between	O
dpi	O
7	O
and	O
14	O
,	O
whereas	O
pigs	O
in	O
NEG	O
-	O
CONTROL	O
and	O
SDPP	O
-	O
CONTROL	O
groups	O
remained	O
PEDV	O
RNA	O
negative	O
and	O
did	O
not	O
seroconvert	O
to	O
PEDV	O
for	O
the	O
study	O
duration	O
.	O

ABSTRACT	O
:	O
A	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
lacking	O
the	O
envelope	B-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
is	O
attenuated	O
in	O
vivo	O
.	O

Cellular	B-PRGE
protein	I-PRGE
syntenin	I-PRGE
was	O
identified	O
to	O
bind	O
the	O
E	B-PRGE
protein	I-PRGE
PBM	O
during	O
SARS	O
-	O
CoV	O
infection	O
by	O
using	O
three	O
complementary	O
strategies	O
,	O
yeast	O
two	O
-	O
hybrid	O
,	O
reciprocal	O
coimmunoprecipitation	O
and	O
confocal	O
microscopy	O
assays	O
.	O

Infection	O
of	O
the	O
type	B-PRGE
I	I-PRGE
FCoV	I-PRGE
was	O
dominant	O
,	O
with	O
a	O
seropositive	O
rate	O
of	O
70	O
.	O
4	O
%,	O
whereas	O
3	O
.	O
5	O
%	O
of	O
cats	O
were	O
infected	O
with	O
the	O
type	B-PRGE
II	I-PRGE
FCoV	I-PRGE
.	O
In	O
most	O
cases	O
,	O
results	O
derived	O
from	O
serotyping	O
and	O
genotyping	O
were	O
highly	O
agreeable	O
.	O

Moreover	O
,	O
most	O
of	O
the	O
cats	O
(	O
84	O
.	O
6	O
%,	O
22	O
/	O
26	O
)	O
infected	O
with	O
a	O
genotypic	O
untypable	O
virus	O
bearing	O
a	O
type	B-PRGE
I	I-PRGE
FCoV	I-PRGE
antibody	I-PRGE
.	O

Also	O
,	O
acting	O
on	O
mitochondria	O
,	O
ORF	B-PRGE
-	I-PRGE
9b	I-PRGE
targets	O
the	O
mitochondrial	O
-	O
associated	O
adaptor	O
molecule	O
MAVS	O
signalosome	O
by	O
usurping	O
PCBP2	B-PRGE
and	O
the	O
HECT	B-PRGE
domain	I-PRGE
E3	B-PRGE
ligase	I-PRGE
AIP4	O
to	O
trigger	O
the	O
degradation	O
of	O
MAVS	B-PRGE
,	O
TRAF3	B-PRGE
,	O
and	O
TRAF	B-PRGE
6	I-PRGE
.	O

Levels	O
of	O
brain	O
damage	O
markers	O
S100	O
calcium	O
binding	O
protein	O
B	O
and	O
neuron	O
-	O
specific	O
enolase	B-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
macrophage	B-PRGE
inflammatory	I-PRGE
protein	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
as	O
well	O
as	O
matrix	B-PRGE
metalloproteinase	I-PRGE
-	I-PRGE
9	I-PRGE
increased	O
significantly	O
after	O
treating	O
brain	O
cells	O
with	O
â¥	O
2	O
%	O
conditioned	O
medium	O
.	O

Steady	O
-	O
state	O
kinetic	O
analyses	O
of	O
purified	O
MERS	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
PLpros	O
uncovered	O
significant	O
differences	O
in	O
their	O
rates	O
of	O
hydrolysis	O
of	O
5	O
-	O
aminomethyl	O
coumarin	O
(	O
AMC	O
)	O
from	O
C	O
-	O
terminally	O
labeled	O
peptide	O
,	O
ubiquitin	B-PRGE
,	O
and	O
ISG15	B-PRGE
substrates	O
,	O
as	O
well	O
as	O
in	O
their	O
rates	O
of	O
isopeptide	O
bond	O
cleavage	O
of	O
K48	B-PRGE
-	I-PRGE
and	I-PRGE
K63	I-PRGE
-	I-PRGE
linked	I-PRGE
polyubiquitin	I-PRGE
chains	I-PRGE
.	O

Application	O
of	O
BDNF	O
can	O
reverse	O
hyperexcitability	O
in	O
acute	O
brainstem	O
slices	O
from	O
Mecp2	B-PRGE
-	O
null	O
mice	O
,	O
suggesting	O
that	O
therapies	O
targeting	O
BDNF	O
or	O
its	O
receptor	O
,	O
TrkB	B-PRGE
,	O
could	O
be	O
effective	O
at	O
acute	O
reversal	O
of	O
respiratory	O
abnormalities	O
in	O
RTT	O
.	O

The	O
M	B-PRGE
protein	I-PRGE
gene	I-PRGE
was	O
found	O
to	O
be	O
conserved	O
between	O
FECV	O
and	O
FIPV	O
samples	O
.	O

Tested	O
combinations	O
targeted	O
the	O
FCoV	O
leader	O
and	O
3	O
'	O
untranslated	O
region	O
,	O
FCoV	O
leader	O
region	O
and	O
nucleocapsid	B-PRGE
gene	I-PRGE
,	O
and	O
FCoV	O
leader	O
region	O
,	O
3	O
'	O
untranslated	O
region	O
,	O
and	O
nucleocapsid	B-PRGE
gene	I-PRGE
.	O

Inhaled	O
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
a	O
common	O
rescue	O
therapy	O
for	O
severe	O
ARDS	O
which	O
can	O
be	O
easily	O
tracked	O
in	O
the	O
EMR	O
,	O
and	O
some	O
patients	O
started	O
on	O
iNO	B-PRGE
may	O
have	O
indications	O
for	O
initiating	O
ECMO	O
.	O

The	O
purified	O
recombinant	B-PRGE
N	I-PRGE
protein	I-PRGE
based	O
single	O
serum	O
dilution	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
developed	O
for	O
IBV	O
to	O
measure	O
specific	O
antibody	O
in	O
the	O
sera	O
of	O
chickens	O
.	O

TITLE	O
:	O
Distinct	O
CD4	B-PRGE
T	I-PRGE
-	O
cell	O
effects	O
on	O
primary	O
versus	O
recall	O
CD8	B-PRGE
T	O
-	O
cell	O
responses	O
during	O
viral	O
encephalomyelitis	O
.	O

However	O
,	O
memory	O
CD8	B-PRGE
T	O
cells	O
primed	O
without	O
CD4	B-PRGE
T	I-PRGE
cells	O
and	O
transferred	O
into	O
infected	O
CD4	B-PRGE
-	O
sufficient	O
recipients	O
expanded	O
less	O
efficiently	O
and	O
were	O
not	O
sustained	O
in	O
the	O
CNS	O
,	O
contrasting	O
with	O
their	O
helped	O
counterparts	O
.	O

Changes	O
were	O
observed	O
in	O
nsp4	B-PRGE
,	O
nsp9	O
,	O
nsp11	O
/	O
12	O
,	O
nsp14	O
,	O
nsp15	O
,	O
nsp16	O
,	O
and	O
ORF3a	O
,	O
but	O
these	O
did	O
not	O
result	O
in	O
amino	O
acid	O
substitutions	O
or	O
did	O
not	O
show	O
functional	O
variations	O
.	O

Without	O
a	O
loss	O
of	O
processivity	O
,	O
the	O
nsp7	O
/	O
nsp8	O
/	O
nsp12	O
complex	O
can	O
associate	O
with	O
nsp14	O
,	O
a	O
bifunctional	O
enzyme	O
bearing	O
3	O
'-	O
5	O
'	O
exoribonuclease	O
and	O
RNA	B-PRGE
cap	I-PRGE
N7	I-PRGE
-	I-PRGE
guanine	I-PRGE
methyltransferase	I-PRGE
activities	O
involved	O
in	O
replication	O
fidelity	O
and	O
5	O
'-	O
RNA	O
capping	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
non	O
-	O
nucleoside	B-PRGE
reverse	I-PRGE
transcriptase	I-PRGE
inhibitors	O
derived	O
from	O
indole	O
-	O
based	O
Î±	O
-	O
amino	O
acids	O
were	O
designed	O
and	O
synthesized	O
.	O

In	O
this	O
case	O
,	O
early	O
administration	O
of	O
acyclovir	O
and	O
a	O
high	O
-	O
dose	O
of	O
immunoglobulin	B-PRGE
,	O
combined	O
with	O
mechanical	O
respiratory	O
support	O
,	O
proved	O
adequate	O
for	O
treatment	O
of	O
this	O
severe	O
illness	O
.	O

A	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
envelope	I-PRGE
-	I-PRGE
embedded	I-PRGE
spike	I-PRGE
protein	I-PRGE
specifically	O
engages	O
human	B-PRGE
CD26	I-PRGE
(	O
hCD26	O
)	O
to	O
initiate	O
viral	O
entry	O
.	O

Western	O
blot	O
showed	O
expression	O
of	O
the	O
recombinant	B-PRGE
fusion	I-PRGE
protein	I-PRGE
mostly	O
in	O
soluble	O
monomeric	O
form	O
.	O

Quantification	O
of	O
the	O
recombinant	B-PRGE
fusion	I-PRGE
protein	I-PRGE
CTB	I-PRGE
-	I-PRGE
RBD	I-PRGE
was	O
conducted	O
by	O
ELISA	O
analysis	O
from	O
the	O
transplastomic	O
leaves	O
at	O
different	O
developmental	O
stages	O
,	O
attachment	O
positions	O
and	O
time	O
points	O
in	O
a	O
day	O
and	O
the	O
different	O
expression	O
levels	O
of	O
the	O
CTB	O
-	O
RBD	O
were	O
observed	O
with	O
the	O
highest	O
expression	O
of	O
10	O
.	O
2	O
%	O
total	O
soluble	O
protein	O
obtained	O
from	O
mature	O
transplastomic	O
leaves	O
.	O

Interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	O
-	O
8	O
),	O
as	O
a	O
proinflammatory	O
mediator	O
causing	O
recruitment	O
of	O
inflammatory	O
cells	O
,	O
induces	O
an	O
increase	O
in	O
oxidant	O
stress	O
mediators	O
and	O
makes	O
it	O
as	O
a	O
key	O
parameter	O
for	O
localized	O
inflammation	O
.	O

Interestingly	O
,	O
both	O
plasma	O
vWF	B-PRGE
and	O
serum	B-PRGE
IL	I-PRGE
-	I-PRGE
8	I-PRGE
levels	O
steadily	O
increased	O
in	O
the	O
non	O
-	O
survivor	O
group	O
.	O

The	O
elevated	O
levels	O
of	O
plasma	B-PRGE
vWF	I-PRGE
and	O
serum	B-PRGE
IL	I-PRGE
-	I-PRGE
8	I-PRGE
in	O
severe	O
pulmonary	O
contusion	O
patients	O
reflect	O
the	O
severity	O
of	O
pulmonary	O
injury	O
and	O
patients	O
outcomes	O
,	O
suggesting	O
that	O
the	O
plasma	O
vWF	B-PRGE
and	O
serum	B-PRGE
IL	I-PRGE
-	I-PRGE
8	I-PRGE
are	O
sensitive	O
markers	O
for	O
clinical	O
evaluation	O
of	O
the	O
severity	O
of	O
pulmonary	O
injury	O
and	O
predication	O
of	O
patient	O
prognosis	O
.	O

Representative	O
strains	O
of	O
these	O
three	O
genetic	O
groups	O
were	O
passaged	O
serially	O
and	O
grew	O
to	O
titers	O
of	O
â¼	O
5	O
-	O
6log10	O
plaque	O
forming	O
units	O
/	O
mL	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
the	O
isolation	O
in	O
cell	O
culture	O
of	O
an	O
S	O
INDEL	O
PEDV	O
strain	O
and	O
a	O
PEDV	O
strain	O
with	O
a	O
large	O
(	O
197aa	O
)	O
deletion	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

Consequently	O
,	O
we	O
have	O
hypothesized	O
that	O
germline	O
antibodies	O
may	O
not	O
bind	O
to	O
the	O
HIV	O
-	O
1	O
envelope	B-PRGE
glycoprotein	I-PRGE
(	O
Env	B-PRGE
)	O
because	O
they	O
are	O
so	O
different	O
compared	O
to	O
the	O
highly	O
somatically	O
mutated	O
HIV	O
-	O
1	O
-	O
specific	O
bnAbs	O
.	O

A	O
defined	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
can	O
potentially	O
serve	O
as	O
a	O
subunit	O
vaccine	O
candidate	O
against	O
MERS	O
-	O
CoV	O
infections	O
.	O

RAGE	B-PRGE
and	O
cytokeratin	B-PRGE
18	I-PRGE
isoforms	I-PRGE
have	O
the	O
potential	O
to	O
act	O
as	O
diagnostic	O
or	O
prognostic	O
biomarkers	O
of	O
lung	O
and	O
hepatic	O
dysfunction	O
.	O

RESULTS	O
:	O
Both	O
RAGE	O
isoforms	O
were	O
transiently	O
increased	O
in	O
plasma	O
within	O
24	O
hours	O
after	O
trauma	O
,	O
while	O
cytokeratin	B-PRGE
18	I-PRGE
levels	O
were	O
unchanged	O
.	O

Positive	O
results	O
were	O
recorded	O
for	O
72	O
.	O
4	O
%	O
of	O
the	O
samples	O
;	O
influenza	O
virus	O
type	O
A	O
was	O
detected	O
in	O
43	O
and	O
type	O
B	O
in	O
38	O
cases	O
,	O
whereas	O
in	O
71	O
cases	O
other	O
respiratory	O
viruses	O
were	O
detected	O
,	O
which	O
included	O
Human	B-PRGE
parainfluenza	I-PRGE
virus	I-PRGE
type	I-PRGE
1	I-PRGE
-	I-PRGE
4	I-PRGE
;	O
Human	B-PRGE
respiratory	I-PRGE
syncytial	I-PRGE
virus	I-PRGE
type	I-PRGE
A	I-PRGE
and	I-PRGE
B	I-PRGE
;	O
Human	B-PRGE
coronavirus	I-PRGE
229E	I-PRGE
/	O
NL63	O
,	O
OC43	O
;	O
Human	B-PRGE
rhinovirus	I-PRGE
type	I-PRGE
A	I-PRGE
,	O
B	O
,	O
and	O
C	O
;	O
Human	O
enterovirus	O
;	O
and	O
Human	O
adenovirus	O
.	O

Furthermore	O
,	O
TRIM56	B-PRGE
was	O
revealed	O
to	O
impair	O
YFV	O
and	O
DENV2	O
propagation	O
by	O
suppressing	O
intracellular	O
viral	O
RNA	O
accumulation	O
but	O
to	O
compromise	O
HCoV	O
-	O
OC43	O
infection	O
at	O
a	O
later	O
step	O
in	O
the	O
viral	O
life	O
cycle	O
,	O
suggesting	O
that	O
distinct	O
TRIM56	B-PRGE
domains	I-PRGE
accommodate	O
differing	O
antiviral	O
mechanisms	O
.	O

Serum	O
SP	O
-	O
A	O
levels	O
may	O
allow	O
the	O
detection	O
of	O
SAP	B-PRGE
-	O
induced	O
ARDS	O
and	O
may	O
help	O
to	O
support	O
the	O
clinical	O
diagnosis	O
of	O
ARDS	O
.	O

The	O
optimal	O
serum	O
SP	O
-	O
A	O
cut	O
-	O
off	O
value	O
to	O
discriminate	O
SAP	B-PRGE
-	O
induced	O
ARDS	O
and	O
other	O
groups	O
(	O
SO	O
group	O
and	O
non	O
-	O
ARDS	O
group	O
)	O
is	O
around	O
150	O
ug	O
/	O
ml	O
.	O

RESULTS	O
:	O
Serum	O
SP	B-PRGE
-	I-PRGE
A	I-PRGE
levels	O
in	O
Baseline	O
,	O
SO	O
group	O
,	O
SAP	B-PRGE
group	O
,	O
ARDS	O
group	O
,	O
and	O
non	O
-	O
ARDS	O
group	O
were	O
43	O
.	O
15	O
Â±	O
14	O
.	O
29	O
,	O
51	O
.	O
91	O
Â±	O
16	O
.	O
99	O
,	O
193	O
.	O
4	O
Â±	O
35	O
.	O
37	O
,	O
198	O
.	O
0	O
+	O
29	O
.	O
73	O
,	O
and	O
185	O
.	O
7	O
Â±	O
43	O
.	O
21	O
ug	O
/	O
ml	O
,	O
respectively	O
.	O

The	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
predictive	O
value	O
,	O
negative	O
predictive	O
value	O
,	O
and	O
accuracy	O
of	O
SP	O
-	O
A	O
in	O
the	O
diagnosis	O
of	O
SAP	B-PRGE
-	O
induced	O
ARDS	O
were	O
100	O
.	O
0	O
%,	O
81	O
.	O
8	O
%,	O
71	O
.	O
4	O
%,	O
100	O
.	O
0	O
%,	O
and	O
87	O
.	O
5	O
%,	O
respectively	O
.	O

In	O
order	O
to	O
do	O
so	O
,	O
the	O
sequences	O
of	O
S	B-PRGE
glycoprotein	I-PRGE
that	O
belong	O
to	O
different	O
geographical	O
regions	O
were	O
aligned	O
to	O
observe	O
the	O
conservancy	O
of	O
MERS	O
-	O
CoV	O
RBD	O
.	O

A	O
9	O
-	O
mer	O
epitope	O
CYSSLILDY	O
displayed	O
interactions	O
with	O
the	O
maximum	O
number	O
of	O
MHC	B-PRGE
class	I-PRGE
-	I-PRGE
I	I-PRGE
molecules	I-PRGE
and	O
projected	O
the	O
highest	O
peak	O
in	O
the	O
B	O
-	O
cell	O
antigenicity	O
plot	O
which	O
concludes	O
that	O
it	O
could	O
be	O
a	O
better	O
choice	O
for	O
designing	O
an	O
epitope	O
based	O
peptide	O
vaccine	O
against	O
MERSCoV	O
considering	O
that	O
it	O
must	O
undergo	O
further	O
in	O
vitro	O
and	O
in	O
vivo	O
experiments	O
.	O

Insulin	B-PRGE
is	O
known	O
to	O
participate	O
in	O
the	O
ion	O
transport	O
;	O
however	O
,	O
its	O
role	O
in	O
pulmonary	O
edema	O
clearance	O
and	O
the	O
regulatory	O
mechanism	O
involved	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O

We	O
previously	O
reported	O
the	O
pro	O
-	O
apoptotic	O
property	O
of	O
the	O
SARS	O
-	O
CoV	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
)	O
M	O
(	O
membrane	O
)-	O
protein	B-PRGE
and	O
a	O
down	O
-	O
regulation	O
of	O
the	O
phosphorylation	O
level	O
of	O
the	O
cell	O
-	O
survival	O
protein	O
PKB	B-PRGE
(	O
protein	B-PRGE
kinase	I-PRGE
B	I-PRGE
)/	O
Akt	B-PRGE
in	O
cells	O
expressing	O
M	B-PRGE
-	I-PRGE
protein	I-PRGE
.	O

This	O
illustrates	O
that	O
M	B-PRGE
-	I-PRGE
protein	I-PRGE
perturbs	O
the	O
PDK1	B-PRGE
and	O
PKB	B-PRGE
/	O
Akt	B-PRGE
cell	O
survival	O
signalling	O
pathway	O
.	O

The	O
leading	O
five	O
viruses	O
that	O
resulted	O
in	O
ILI	O
Shijiazhuang	O
in	O
2011	O
were	O
HEV	O
,	O
ADV	O
,	O
RSV	B-PRGE
-	I-PRGE
A	I-PRGE
,	O
HRV	O
,	O
and	O
FluA	O
,	O
and	O
these	O
viruses	O
have	O
different	O
epidemiological	O
features	O
.	O

Specific	O
knock	O
down	O
of	O
Spred	O
-	O
2	O
augmented	O
LPS	O
-	O
induced	O
cytokine	O
and	O
chemokine	O
responses	O
in	O
RAW264	O
.	O
7	O
cells	O
and	O
MLE	O
-	O
12	O
cells	O
,	O
whereas	O
Spred	B-PRGE
-	I-PRGE
2	I-PRGE
overexpression	O
decreased	O
this	O
response	O
in	O
RAW264	O
.	O
7	O
cells	O
.	O

Microscopic	O
lesions	O
included	O
severe	O
diffuse	O
atrophic	O
enteritis	O
with	O
significantly	O
reduced	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
villous	O
length	O
observed	O
on	O
dpi	B-PRGE
3	I-PRGE
,	O
4	O
,	O
and	O
7	O
.	O

Immunoglobulin	B-PRGE
G	I-PRGE
(	O
IgG	B-PRGE
)	O
titres	O
peaked	O
3	O
weeks	O
after	O
the	O
onset	O
of	O
illness	O
,	O
whilst	O
IgM	B-PRGE
levels	O
remained	O
constantly	O
elevated	O
during	O
the	O
follow	O
-	O
up	O
period	O
(	O
second	O
to	O
fifth	O
week	O
of	O
illness	O
).	O

The	O
ability	O
of	O
MERS	O
-	O
CoV	O
to	O
use	B-PRGE
furin	I-PRGE
in	O
this	O
manner	O
,	O
along	O
with	O
other	O
proteases	O
,	O
may	O
explain	O
the	O
polytropic	O
nature	O
of	O
the	O
virus	O
.	O

These	O
findings	O
are	O
in	O
line	O
with	O
differences	O
in	O
the	O
induction	O
of	O
cytopathological	O
changes	O
,	O
induction	O
of	O
host	O
gene	O
responses	O
and	O
sensitivity	O
to	O
the	O
antiviral	O
effect	O
of	O
interferons	O
in	O
vitro	O
when	O
comparing	O
both	O
MERS	O
-	O
CoV	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
challenge	O
will	O
be	O
to	O
translate	O
these	O
findings	O
into	O
an	O
integrated	O
picture	O
of	O
MERS	O
pathogenesis	O
in	O
humans	O
and	O
to	O
develop	O
intervention	O
strategies	O
that	O
will	O
eventually	O
allow	O
the	O
effective	O
control	O
of	O
this	O
newly	O
emerging	O
infectious	O
disease	O
.	O

TITLE	O
:	O
Nucleocapsid	O
phosphorylation	O
and	O
RNA	B-PRGE
helicase	I-PRGE
DDX1	I-PRGE
recruitment	O
enables	O
coronavirus	O
transition	O
from	O
discontinuous	O
to	O
continuous	O
transcription	O
.	O

We	O
find	O
that	O
phosphorylation	O
of	O
the	O
viral	O
nucleocapsid	O
(	O
N	O
)	O
by	O
host	O
glycogen	B-PRGE
synthase	I-PRGE
kinase	I-PRGE
-	I-PRGE
3	I-PRGE
(	O
GSK	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
is	O
required	O
for	O
template	O
switching	O
.	O

The	O
most	O
important	O
laboratory	O
findings	O
were	O
thrombocytopenia	O
,	O
elevated	O
hematocrit	O
and	O
hemoglobin	B-PRGE
concentrations	O
,	O
elevated	O
liver	O
enzymes	O
,	O
elevated	O
lactate	B-PRGE
dehydrogenase	I-PRGE
and	O
a	O
positive	O
sorology	O
for	O
Hantavirus	O
(	O
ELISA	O
IgM	B-PRGE
positive	O
).	O

When	O
the	O
results	O
of	O
the	O
ACTH	B-PRGE
test	O
are	O
available	O
,	O
treatment	O
should	O
be	O
continued	O
for	O
7	O
days	O
in	O
the	O
non	O
responders	O
to	O
ACTH	B-PRGE
and	O
withdraw	O
in	O
the	O
responders	O
.	O

There	O
was	O
statistical	O
association	O
between	O
diarrheic	O
animals	O
carrying	O
E	B-PRGE
.	I-PRGE
coli	I-PRGE
Stx1	I-PRGE
/	O
eae	O
(+)	O
in	O
their	O
feces	O
at	O
2	O
and	O
4	O
weeks	O
of	O
age	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
and	O
E	O
.	O
coli	O
Stx2	O
(+)	O
at	O
5	O
weeks	O
of	O
age	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

These	O
results	O
suggested	O
that	O
coronavirus	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
induces	O
incomplete	O
autophagy	O
by	O
interacting	O
with	O
Beclin1	B-PRGE
,	O
which	O
in	O
turn	O
modulates	O
coronavirus	O
replication	O
and	O
antiviral	O
innate	O
immunity	O
.	O

In	O
addition	O
,	O
H9N2	O
viral	O
infection	O
resulted	O
in	O
severe	O
progressive	O
hypoxemia	O
,	O
lymphopenia	O
,	O
and	O
a	O
significant	O
increase	O
in	O
interleukin	B-PRGE
1	I-PRGE
,	O
interleukin	B-PRGE
6	I-PRGE
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
,	O
and	O
interferon	B-PRGE
in	O
BALF	O
and	O
serum	O
.	O

To	O
understand	O
the	O
molecular	O
basis	O
for	O
ubiquitin	B-PRGE
(	O
Ub	O
)	O
recognition	O
and	O
deconjugation	O
by	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	B-PRGE
),	O
we	O
determined	O
its	O
crystal	O
structure	O
in	O
complex	O
with	O
Ub	O
.	O

In	O
vitro	O
studies	O
examining	O
human	O
lung	O
EC	O
viability	O
and	O
HMGB1	B-PRGE
release	O
following	O
exposure	O
to	O
allogenic	O
RBCs	O
were	O
conducted	O
under	O
static	O
conditions	O
and	O
using	O
a	O
microengineered	O
model	O
of	O
RBC	O
perfusion	O
.	O

Only	O
4	O
significantly	O
dysregulated	O
genes	O
are	O
common	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
,	O
including	O
NFKBIA	B-PRGE
that	O
is	O
a	O
key	O
regulator	O
of	O
immune	O
responsiveness	O
implicated	O
in	O
susceptibility	O
to	O
infectious	O
and	O
inflammatory	O
diseases	O
.	O

Because	O
most	O
of	O
the	O
viral	B-PRGE
envelope	I-PRGE
glycoproteins	I-PRGE
contain	O
N	O
-	O
linked	O
glycans	O
,	O
inhibition	O
of	O
ER	O
glucosidases	O
with	O
derivatives	O
of	O
1	O
-	O
deoxynojirimycin	O
,	O
i	O
.	O
e	O
.,	O
iminosugars	O
,	O
efficiently	O
disrupts	O
the	O
morphogenesis	O
of	O
a	O
broad	O
spectrum	O
of	O
enveloped	O
viruses	O
.	O

However	O
,	O
like	O
viral	B-PRGE
envelope	I-PRGE
proteins	I-PRGE
,	O
the	O
cellular	O
receptors	O
of	O
many	O
viruses	O
are	O
also	O
glycoproteins	O
.	O

ABSTRACT	O
:	O
Recommendations	O
concerning	O
the	O
management	O
of	O
hemoglobin	B-PRGE
levels	O
and	O
hematocrit	O
in	O
patients	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
still	O
advise	O
maintenance	O
of	O
a	O
normal	O
hematocrit	O
.	O

The	O
authors	O
found	O
that	O
:	O
(	O
1	O
)	O
UP	O
-	O
MVcontr	O
reduced	O
diffuse	O
alveolar	O
damage	O
score	O
in	O
dorsal	O
lung	O
zones	O
(	O
median	O
[	O
interquartile	O
])	O
(	O
12	O
.	O
0	O
[	O
7	O
.	O
0	O
to	O
16	O
.	O
8	O
]	O
vs	O
.	O
22	O
.	O
5	O
[	O
13	O
.	O
8	O
to	O
40	O
.	O
8	O
]),	O
but	O
worsened	O
oxygenation	O
and	O
intrapulmonary	O
shunt	O
,	O
compared	O
to	O
P	O
-	O
MVcontr	O
;	O
(	O
2	O
)	O
UP	O
-	O
MVspont	O
and	O
UP	O
-	O
MVPS	O
improved	O
oxygenation	O
and	O
intrapulmonary	O
shunt	O
,	O
and	O
redistributed	O
ventilation	O
towards	O
dorsal	O
areas	O
,	O
as	O
compared	O
to	O
UP	O
-	O
MVcontr	O
;	O
(	O
3	O
)	O
compared	O
to	O
P	O
-	O
MVcontr	O
,	O
UP	O
-	O
MVcontr	O
and	O
UP	O
-	O
MVspont	O
,	O
UP	O
-	O
MVPS	O
yielded	O
higher	O
levels	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
Î±	I-PRGE
(	O
6	O
.	O
9	O
[	O
6	O
.	O
5	O
to	O
10	O
.	O
1	O
]	O
vs	O
.	O
2	O
.	O
8	O
[	O
2	O
.	O
2	O
to	O
3	O
.	O
0	O
],	O
3	O
.	O
6	O
[	O
3	O
.	O
0	O
to	O
4	O
.	O
7	O
]	O
and	O
4	O
.	O
0	O
[	O
2	O
.	O
8	O
to	O
4	O
.	O
4	O
]	O
pg	O
/	O
mg	O
,	O
respectively	O
)	O
and	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
216	O
.	O
8	O
[	O
113	O
.	O
5	O
to	O
343	O
.	O
5	O
]	O
vs	O
.	O
59	O
.	O
8	O
[	O
45	O
.	O
3	O
to	O
66	O
.	O
7	O
],	O
37	O
.	O
6	O
[	O
18	O
.	O
8	O
to	O
52	O
.	O
0	O
],	O
and	O
59	O
.	O
5	O
[	O
36	O
.	O
1	O
to	O
79	O
.	O
7	O
]	O
pg	O
/	O
mg	O
,	O
respectively	O
)	O
in	O
dorsal	O
lung	O
zones	O
.	O

Its	O
efficacy	O
is	O
believed	O
to	O
be	O
due	O
to	O
Î¼	B-PRGE
-	I-PRGE
opioid	I-PRGE
receptor	I-PRGE
agonist	O
activity	O
and	O
inhibition	O
of	O
norepinephrine	O
reuptake	O
resulting	O
in	O
increased	O
norepinephrine	O
concentrations	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
SP3	B-PRGE
peptide	I-PRGE
,	O
corresponding	O
to	O
amino	O
-	O
acid	O
residues	O
736	O
-	O
761	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
,	O
elicited	O
robust	O
neutralizing	O
activities	O
by	O
blocking	O
viral	O
entry	O
at	O
the	O
postbinding	O
and	O
membrane	O
fusion	O
steps	O
.	O

Among	O
recombinant	O
spike	O
S1	O
,	O
S2	O
,	O
S3	O
,	O
and	O
nucleocapsid	B-PRGE
N	I-PRGE
protein	I-PRGE
of	O
PEDV	O
,	O
S3	B-PRGE
protein	I-PRGE
presented	O
the	O
highest	O
antibody	O
level	O
in	O
the	O
K	O
/	O
K	O
group	O
.	O

ABSTRACT	O
:	O
To	O
approach	O
the	O
correlation	O
between	O
angiopoietin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
Ang	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
levels	O
and	O
degree	O
of	O
lung	O
injury	O
and	O
prognosis	O
and	O
its	O
clinical	O
significance	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Factors	O
,	O
APACHEII	O
score	O
,	O
LIS	O
score	O
,	O
PaO2	O
/	O
FiO2	O
,	O
Ang	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
founded	O
statistical	O
significance	O
in	O
univariate	O
analysis	O
were	O
analyzed	O
using	O
multivariable	O
logistic	O
regression	O
.	O

The	O
plasma	O
level	O
of	O
Ang	B-PRGE
-	I-PRGE
2	I-PRGE
was	O
significantly	O
increased	O
in	O
patients	O
with	O
ARDS	O
.	O

ATF3	B-PRGE
overexpression	O
abrogated	O
LPS	O
induced	O
membrane	O
permeability	O
.	O

We	O
evaluated	O
the	O
induction	O
of	O
RBD	O
-	O
specific	O
humoral	O
immunity	O
(	O
total	O
IgG	B-PRGE
and	O
neutralizing	O
antibodies	O
)	O
and	O
cellular	O
immunity	O
(	O
ELISpot	O
assay	O
for	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
spot	O
-	O
forming	O
cells	O
and	O
splenocyte	O
cytokine	O
production	O
).	O

Sequence	O
comparisons	O
analysis	O
of	O
the	O
housekeeping	O
genes	O
ftsZ	B-PRGE
,	O
ribC	O
,	O
and	O
groEL	B-PRGE
showed	O
the	O
highest	O
homology	O
to	O
B	O
.	O
chomelii	O
,	O
B	O
.	O
capreoli	O
,	O
and	O
B	O
.	O
birtlesii	O
,	O
respectively	O
.	O

A	O
comprehensive	O
multilocus	O
sequence	O
typing	O
(	O
MLST	O
)	O
analysis	O
based	O
on	O
nine	O
genetic	O
loci	O
(	O
gltA	B-PRGE
,	O
rpoB	B-PRGE
,	O
ftsZ	B-PRGE
,	O
internal	O
transcribed	O
spacer	O
(	O
ITS	O
),	O
16S	B-PRGE
rRNA	I-PRGE
,	O
ribC	O
,	O
groEL	B-PRGE
,	O
nuoG	O
,	O
and	O
SsrA	O
)	O
identified	O
seven	O
sequence	O
types	O
of	O
the	O
new	O
dromedary	O
isolates	O
.	O

Together	O
,	O
these	O
results	O
imply	O
that	O
bats	O
indeed	O
could	O
be	O
among	O
the	O
MERS	O
-	O
CoV	O
host	O
spectrum	O
,	O
and	O
that	O
cellular	O
restriction	O
of	O
MERS	O
-	O
CoV	O
is	O
determined	O
by	O
CD26	B-PRGE
/	O
DPP4	B-PRGE
expression	O
rather	O
than	O
by	O
downstream	O
restriction	O
factors	O
.	O

Our	O
findings	O
indicate	O
that	O
the	O
orf9b	B-PRGE
gene	I-PRGE
features	O
a	O
discordant	O
codon	O
-	O
usage	O
pattern	O
.	O

The	O
antibody	O
profiling	O
data	O
presented	O
the	O
correlation	O
of	O
neutralizing	O
activity	O
with	O
the	O
level	O
of	O
spike	B-PRGE
protein	I-PRGE
antibody	I-PRGE
.	O

The	O
region	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
may	O
have	O
a	O
stronger	O
neutralizing	O
KPEDV	O
-	O
9	O
epitope	O
and	O
could	O
be	O
useful	O
for	O
the	O
evaluation	O
of	O
future	O
PEDV	O
vaccine	O
efficacy	O
.	O

TITLE	O
:	O
Detection	O
of	O
the	O
human	B-PRGE
coronavirus	I-PRGE
229E	I-PRGE
,	O
HKU1	O
,	O
NL63	O
,	O
and	O
OC43	O
between	O
2010	O
and	O
2013	O
in	O
Yamagata	O
,	O
Japan	O
.	O

TITLE	O
:	O
The	O
nsp3	B-PRGE
macrodomain	I-PRGE
promotes	O
virulence	O
in	O
mice	O
with	O
coronavirus	O
-	O
induced	O
encephalitis	O
.	O

While	O
coronavirus	O
cell	O
and	O
tissue	O
tropism	O
,	O
host	O
range	O
,	O
and	O
pathogenesis	O
are	O
initially	O
controlled	O
by	O
interactions	O
between	O
the	O
spike	B-PRGE
envelope	I-PRGE
glycoprotein	I-PRGE
and	O
host	B-PRGE
cell	I-PRGE
receptor	I-PRGE
,	O
it	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
proteolytic	O
activation	O
of	O
spike	O
by	O
host	O
cell	O
proteases	O
also	O
plays	O
a	O
critical	O
role	O
.	O

These	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
endosomal	O
cathepsins	O
,	O
cell	O
surface	O
transmembrane	B-PRGE
protease	O
/	O
serine	O
(	O
TMPRSS	O
)	O
proteases	O
,	O
furin	B-PRGE
,	O
and	O
trypsin	B-PRGE
.	O

TITLE	O
:	O
The	O
avian	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
our	O
current	O
understanding	O
of	O
SARS	O
-	O
CoV	O
enzymes	O
involved	O
in	O
RNA	O
biochemistry	O
,	O
such	O
as	O
the	O
in	O
vitro	O
characterization	O
of	O
a	O
highly	O
active	O
and	O
processive	O
RNA	B-PRGE
polymerase	I-PRGE
complex	I-PRGE
which	O
can	O
associate	O
with	O
methyltransferase	O
and	O
3	O
'-	O
5	O
'	O
exoribonuclease	O
activities	O
involved	O
in	O
RNA	O
capping	O
,	O
and	O
RNA	O
proofreading	O
,	O
respectively	O
.	O

The	O
most	O
significant	O
change	O
was	O
a	O
W99R	O
substitution	O
in	O
GP2	B-PRGE
,	O
which	O
was	O
present	O
in	O
the	O
inoculum	O
at	O
a	O
frequency	O
of	O
35	O
%,	O
but	O
eventually	O
disappeared	O
from	O
all	O
pigs	O
regardless	O
of	O
immune	O
status	O
.	O

Here	O
,	O
we	O
summarize	O
recent	O
advances	O
in	O
identifying	O
human	O
neutralizing	O
monoclonal	B-PRGE
antibodies	I-PRGE
(	O
mAbs	O
)	O
against	O
MERS	O
-	O
CoV	O
,	O
describe	O
their	O
mechanisms	O
of	O
action	O
,	O
and	O
analyze	O
their	O
potential	O
for	O
treatment	O
of	O
MERS	O
-	O
CoV	O
infections	O
.	O

Treatment	O
also	O
included	O
transfusion	O
of	O
two	O
red	O
-	O
cell	O
pack	O
on	O
day	O
1	O
and	O
2	O
after	O
admission	O
in	O
order	O
to	O
maintain	O
hemoglobin	B-PRGE
level	O
above	O
8g	O
/	O
dL	O
,	O
and	O
a	O
daily	O
folic	O
acid	O
supplementation	O
.	O

Although	O
the	O
present	O
data	O
suggest	O
the	O
consideration	O
of	O
enteral	O
nutrition	O
enriched	O
with	O
fish	O
oil	O
,	O
borage	O
oil	O
and	O
antioxidants	O
in	O
mild	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
only	O
one	O
of	O
the	O
three	O
meta	O
-	O
analyses	O
found	O
a	O
trend	O
(	O
p	O
=	O
0	O
.	O
08	O
)	O
of	O
lower	O
mortality	O
in	O
ICU	O
patients	O
receiving	O
intravenous	O
omega	B-PRGE
-	I-PRGE
3	I-PRGE
fatty	O
acids	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
whether	O
mutations	O
across	O
nsp4	B-PRGE
,	O
both	O
alone	O
and	O
in	O
combination	O
with	O
mutations	O
that	O
abolish	O
nsp4	B-PRGE
glycosylation	O
,	O
affected	O
DMV	O
formation	O
,	O
replication	O
,	O
and	O
fitness	O
.	O

Residues	O
in	O
nsp4	B-PRGE
distinct	O
from	O
glycosylation	O
sites	O
,	O
particularly	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
luminal	O
loop	O
1	O
,	O
independently	O
disrupted	O
both	O
the	O
number	O
and	O
morphology	O
of	O
DMVs	O
and	O
exacerbated	O
DMV	O
changes	O
associated	O
with	O
loss	O
of	O
glycosylation	O
.	O

TITLE	O
:	O
Pan	B-PRGE
-	I-PRGE
human	I-PRGE
coronavirus	I-PRGE
and	I-PRGE
human	I-PRGE
bocavirus	I-PRGE
SYBR	I-PRGE
Green	O
and	O
TaqMan	O
PCR	O
assays	O
;	O
use	O
in	O
studying	O
influenza	O
A	O
viruses	O
co	O
-	O
infection	O
and	O
risk	O
of	O
hospitalization	O
.	O

Case	O
2	O
was	O
admitted	O
due	O
to	O
SAP	B-PRGE
induced	O
by	O
overeating	O
one	O
day	O
before	O
admission	O
.	O

Patients	O
were	O
classified	O
into	O
mild	O
,	O
moderate	O
and	O
severe	O
ARDS	O
categories	O
and	O
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
DAD	B-PRGE
on	O
the	O
OLB	O
.	O

ABSTRACT	O
:	O
P34	B-PRGE
is	O
an	O
antimicrobial	O
peptide	O
produced	O
by	O
a	O
Bacillus	O
sp	O
.	O
strain	O
isolated	O
from	O
the	O
intestinal	O
contents	O
of	O
a	O
fish	O
in	O
the	O
Brazilian	O
Amazon	O
basin	O
with	O
reported	O
antibacterial	O
activity	O
.	O

Here	O
we	O
show	O
that	O
PLpro	O
also	O
inhibits	O
IRF3	B-PRGE
activation	O
at	O
a	O
step	O
after	O
phosphorylation	O
and	O
that	O
this	O
inhibition	O
is	O
dependent	O
on	O
the	O
de	O
-	O
ubiquitination	O
(	O
DUB	O
)	O
activity	O
of	O
PLpro	O
.	O

Immunofluorescence	O
assays	O
confirmed	O
a	O
co	O
-	O
localization	O
between	O
the	O
TGEV	B-PRGE
S	I-PRGE
protein	I-PRGE
and	I-PRGE
filamin	I-PRGE
A	I-PRGE
.	O
Further	O
experiments	O
have	O
to	O
be	O
performed	O
to	O
prove	O
a	O
significant	O
impact	O
of	O
filamin	B-PRGE
A	I-PRGE
on	O
TGEV	O
infection	O
.	O

While	O
none	O
of	O
the	O
type	B-PRGE
I	I-PRGE
FCoVs	I-PRGE
and	O
chimeric	O
FCoVs	O
induced	O
FIP	B-PRGE
,	O
the	O
recombinant	B-PRGE
type	I-PRGE
II	I-PRGE
FCoV	I-PRGE
strain	O
79	O
-	O
1146	O
was	O
as	O
pathogenic	O
as	O
the	O
parental	O
isolate	O
.	O

TITLE	O
:	O
Expression	O
,	O
crystallization	O
and	O
preliminary	O
crystallographic	O
study	O
of	O
the	O
functional	O
mutant	B-PRGE
(	I-PRGE
N60K	I-PRGE
)	I-PRGE
of	I-PRGE
nonstructural	I-PRGE
protein	I-PRGE
9	I-PRGE
from	O
Human	B-PRGE
coronavirus	I-PRGE
HKU1	I-PRGE
.	O

Coronavirus	O
genomes	O
encode	O
16	O
nonstructural	O
proteins	O
(	O
nsp1	B-PRGE
-	I-PRGE
16	I-PRGE
),	O
which	O
assemble	O
into	O
a	O
large	O
replication	O
-	O
transcription	O
complex	O
mediating	O
virus	O
propagation	O
.	O

Therefore	O
,	O
NIV	O
is	O
not	O
routinely	O
recommended	O
in	O
all	O
patients	O
with	O
severe	O
hypoxemic	O
ARF	B-PRGE
.	O

The	O
median	O
activated	O
partial	O
thromboplastin	B-PRGE
time	O
was	O
46	O
.	O
5	O
seconds	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
that	O
PLP2	B-PRGE
,	O
a	O
catalytic	O
domain	O
of	O
the	O
nonstructural	O
protein	O
3	O
of	O
human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
(	O
HCoV	O
-	O
NL63	O
),	O
deubiquitinates	O
and	O
stabilizes	O
the	O
cellular	O
oncoprotein	O
MDM2	B-PRGE
and	O
induces	O
the	O
proteasomal	O
degradation	O
of	O
p53	B-PRGE
.	O

Meanwhile	O
,	O
we	O
identify	O
IRF7	B-PRGE
(	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
7	I-PRGE
)	O
as	O
a	O
bona	O
fide	O
target	O
gene	O
of	O
p53	B-PRGE
to	O
mediate	O
the	O
p53	B-PRGE
-	O
directed	O
production	O
of	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
and	O
the	O
innate	O
immune	O
response	O
.	O

This	O
research	O
measured	O
the	O
UV	O
spectral	O
sensitivity	O
,	O
called	O
action	O
spectra	O
,	O
of	O
Cryptosporidium	O
parvum	O
,	O
and	O
MS2	B-PRGE
,	O
T1UV	O
,	O
Q	B-PRGE
Beta	I-PRGE
,	O
T7	O
,	O
and	O
T7m	O
Coliphages	O
,	O
as	O
well	O
as	O
Bacillus	O
pumilus	O
spores	O
.	O

In	O
contrast	O
,	O
among	O
the	O
five	O
Birman	B-PRGE
FIP	I-PRGE
cat	I-PRGE
-	I-PRGE
associated	I-PRGE
SNPs	I-PRGE
,	O
no	O
genotype	O
or	O
allele	O
showed	O
significant	O
differences	O
between	O
our	O
FIP	O
and	O
non	O
-	O
FIP	O
groups	O
.	O

Sixty	O
-	O
one	O
percent	O
(	O
n	O
=	O
68	O
)	O
claimed	O
prior	O
,	O
significant	O
reactions	O
to	O
ASA	B-PRGE
,	O
and	O
all	O
patients	O
had	O
features	O
of	O
AERD	O
.	O

The	O
nine	O
residues	O
at	O
the	O
interface	O
between	O
the	O
virus	O
spikes	O
and	O
the	O
lancets	O
4	O
and	O
5	O
of	O
host	O
DPP4	B-PRGE
can	O
be	O
used	O
as	O
a	O
predictive	O
tool	O
for	O
the	O
host	O
tropism	O
and	O
virus	O
affinity	O
to	O
host	B-PRGE
cell	I-PRGE
receptors	I-PRGE
.	O

This	O
study	O
shows	O
that	O
formulation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
or	O
inactivated	O
whole	O
-	O
virus	O
vaccines	O
with	O
novel	O
delta	O
inulin	O
-	O
based	O
polysaccharide	O
adjuvants	O
enhances	O
neutralizing	O
-	O
antibody	O
titers	O
and	O
protection	O
against	O
clinical	O
disease	O
but	O
at	O
the	O
same	O
time	O
also	O
protects	O
against	O
development	O
of	O
lung	O
eosinophilic	O
immunopathology	O
.	O

ABSTRACT	O
:	O
Hereditary	O
angioedema	O
(	O
HAE	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disease	O
most	O
commonly	O
associated	O
with	O
defects	O
in	O
C1	B-PRGE
esterase	I-PRGE
inhibitor	I-PRGE
(	O
C1	O
-	O
INH	O
).	O

Therefore	O
,	O
pdC1	B-PRGE
-	I-PRGE
INH	I-PRGE
concentrate	O
may	O
be	O
an	O
effective	O
treatment	O
option	O
to	O
consider	O
for	O
critically	O
-	O
ill	O
patients	O
with	O
HAE	O
.	O

N	B-PRGE
protein	I-PRGE
possibly	O
interacts	O
with	O
host	O
factors	O
to	O
modulate	O
cellular	O
functions	O
.	O

Analysis	O
of	O
interacting	O
proteins	O
by	O
mass	O
spectrometry	O
allowed	O
identification	O
of	O
15	O
cellular	O
protein	O
bands	O
representative	O
of	O
12	O
cellular	O
proteins	O
including	O
vimentin	B-PRGE
that	O
bound	O
to	O
N	B-PRGE
protein	I-PRGE
.	O

Furthermore	O
,	O
the	O
function	O
of	O
vimentin	B-PRGE
cytoskeleton	O
in	O
ST	O
cells	O
during	O
TGEV	O
infection	O
was	O
examined	O
.	O

Using	O
topological	O
techniques	O
,	O
including	O
persistence	O
homology	O
and	O
filtered	O
clustering	O
,	O
we	O
performed	O
a	O
comparative	O
transcriptional	O
analysis	O
of	O
human	O
Calu	O
-	O
3	O
cell	O
host	O
responses	O
to	O
the	O
different	O
MERS	O
-	O
CoV	O
strains	O
,	O
with	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
Eng	I-PRGE
1	I-PRGE
inducing	O
early	O
kinetic	O
changes	O
,	O
between	O
3	O
and	O
12	O
hours	O
post	O
infection	O
,	O
compared	O
to	O
MERS	O
-	O
CoV	O
SA	O
1	O
.	O

Patients	O
with	O
increased	O
cTnI	B-PRGE
levels	O
showed	O
higher	O
in	O
-	O
ICU	O
mortality	O
(	O
38	O
.	O
6	O
%	O
vs	O
21	O
.	O
9	O
%,	O
P	O
=	O
.	O
028	O
).	O

The	O
association	O
between	O
elevated	O
cTnI	B-PRGE
levels	O
and	O
mortality	O
remained	O
significant	O
after	O
adjustment	O
using	O
a	O
multivariate	O
model	O
(	O
adjusted	O
hazard	O
ratio	O
=	O
1	O
.	O
398	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
005	O
-	O
1	O
.	O
945	O
;	O
P	O
=	O
.	O
047	O
).	O

TITLE	O
:	O
Blood	O
MxA	B-PRGE
protein	I-PRGE
as	O
a	O
marker	O
for	O
respiratory	O
virus	O
infections	O
in	O
young	O
children	O
.	O

We	O
conclude	O
that	O
INO	O
in	O
short	O
-	O
term	O
experiments	O
,	O
in	O
addition	O
to	O
causing	O
selective	O
pulmonary	O
vasodilation	O
in	O
ventilated	O
lung	O
regions	O
,	O
increases	O
the	O
ET	B-PRGE
-	I-PRGE
A	I-PRGE
/	O
ET	B-PRGE
-	I-PRGE
B	I-PRGE
mRNA	I-PRGE
expression	O
ratio	O
in	O
lung	O
tissue	O
.	O

The	O
porcine	O
APN	O
transgene	O
was	O
constructed	O
by	O
fusing	O
with	O
mouse	B-PRGE
proximal	I-PRGE
APN	I-PRGE
promoter	I-PRGE
at	O
5	O
'	O
terminus	O
and	O
bovine	B-PRGE
growth	I-PRGE
hormone	I-PRGE
polyadenylation	O
site	O
at	O
its	O
3	O
'	O
terminus	O
.	O

Since	O
the	O
only	O
endosomal	O
requirement	O
for	O
SARS	O
entry	O
is	O
cathepsin	B-PRGE
L	I-PRGE
activity	O
,	O
we	O
tested	O
and	O
provide	O
evidence	O
that	O
NPC1	B-PRGE
(+)	O
LE	O
/	O
Lys	O
have	O
higher	O
cathepsin	B-PRGE
L	I-PRGE
activity	O
than	O
LE	O
,	O
with	O
no	O
detectable	O
activity	O
in	O
earlier	O
endosomes	O
.	O

Its	O
unique	O
putative	O
cleavage	O
sites	O
between	O
nonstructural	O
proteins	O
1	O
and	O
2	O
and	O
in	O
the	O
spike	O
(	O
S	O
)	O
protein	O
and	O
low	O
sequence	O
identities	O
to	O
other	O
lineage	O
A	O
betacoronaviruses	O
(	O
Î²CoVs	O
)	O
in	O
conserved	O
replicase	B-PRGE
domains	O
support	O
ChRCoV	O
HKU24	O
as	O
a	O
separate	O
species	O
.	O

Other	O
rats	O
,	O
including	O
Norway	O
rats	O
from	O
Hong	O
Kong	O
,	O
possessed	O
antibodies	O
only	O
against	O
N	B-PRGE
protein	I-PRGE
and	O
not	O
against	O
the	O
spike	O
polypeptide	O
,	O
suggesting	O
infection	O
by	O
Î²CoVs	O
different	O
from	O
ChRCoV	O
HKU24	O
.	O

Further	O
studies	O
confirmed	O
that	O
LiCl	O
inhibited	O
PRRSV	O
replication	O
at	O
an	O
early	O
stage	O
and	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
,	O
an	O
antiviral	O
cytokine	O
,	O
was	O
significantly	O
increased	O
after	O
LiCl	O
treatment	O
.	O

Western	O
blot	O
analysis	O
also	O
demonstrated	O
their	O
inhibitory	O
effects	O
on	O
PEDV	B-PRGE
GP6	I-PRGE
nucleocapsid	I-PRGE
and	O
GP2	B-PRGE
spike	I-PRGE
protein	I-PRGE
synthesis	O
during	O
viral	O
replication	O
.	O

Values	O
for	O
aspartate	B-PRGE
aminotransferase	I-PRGE
(	O
AST	B-PRGE
),	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
LDH	B-PRGE
),	O
bilirubin	O
,	O
platelets	O
(	O
Plt	O
),	O
urea	O
,	O
and	O
creatinine	O
at	O
0	O
,	O
8	O
,	O
16	O
,	O
24	O
,	O
48	O
,	O
and	O
72	O
hours	O
postpartum	O
in	O
both	O
groups	O
were	O
analyzed	O
and	O
compared	O
.	O

ABSTRACT	O
:	O
Mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
develop	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	B-PRGE
hydrolase	I-PRGE
(	O
FAH	B-PRGE
)	O
with	O
a	O
concomitant	O
enhancement	O
of	O
transaminases	O
and	O
release	O
of	O
alarmins	O
such	O
as	O
uric	O
acid	O
and	O
high	B-PRGE
-	I-PRGE
mobility	I-PRGE
group	I-PRGE
box	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
HMGB1	B-PRGE
).	O

Moreover	O
,	O
infected	O
mice	O
treated	O
with	O
MT	O
did	O
express	O
anti	B-PRGE
-	I-PRGE
FAH	I-PRGE
autoAb	I-PRGE
and	O
high	O
levels	O
of	O
serum	B-PRGE
HMGB1	I-PRGE
.	O

The	O
remaining	O
four	O
SNPs	O
had	O
'	O
suggestive	O
'	O
genome	O
-	O
wide	O
significance	O
levels	O
(	O
1	O
.	O
1E	O
-	O
05	O
)	O
and	O
they	O
were	O
within	O
or	O
near	O
the	O
Plexin	B-PRGE
B1	I-PRGE
,	O
LRRN1	B-PRGE
and	O
PDGFC	B-PRGE
genes	I-PRGE
.	O

Bioinformatics	O
,	O
GO	O
annotation	O
and	O
pathway	O
analysis	O
indicated	O
that	O
five	O
of	O
these	O
genes	O
(	O
Plexin	B-PRGE
B1	I-PRGE
,	O
TRIM27	B-PRGE
,	O
PDGFC	B-PRGE
,	O
SETBP1	B-PRGE
and	O
USP7	B-PRGE
)	O
may	O
be	O
important	O
for	O
the	O
generation	O
of	O
protective	O
antibodies	O
against	O
NDV	O
and	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

Although	O
a	O
mouse	O
lung	O
infection	O
model	O
has	O
been	O
described	O
using	O
adenovirus	O
vectors	O
expressing	O
human	O
CD26	B-PRGE
/	I-PRGE
dipeptidyl	I-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
),	O
it	O
is	O
believed	O
that	O
a	O
transgenic	O
mouse	O
model	O
is	O
needed	O
for	O
MERS	O
-	O
CoV	O
research	O
.	O

The	O
standard	O
small	O
animals	O
,	O
mice	O
,	O
hamsters	O
,	O
and	O
ferrets	O
,	O
all	O
lack	O
the	O
functional	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
and	O
are	O
not	O
susceptible	O
to	O
infection	O
.	O

ABSTRACT	O
:	O
Papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLpro	O
)	O
of	O
coronaviruses	O
(	O
CoVs	O
)	O
carries	O
out	O
proteolytic	O
maturation	O
of	O
non	O
-	O
structural	O
proteins	O
that	O
play	O
a	O
role	O
in	O
replication	O
of	O
the	O
virus	O
and	O
performs	O
deubiquitination	O
of	O
host	O
cell	O
factors	O
to	O
scuttle	O
antiviral	O
responses	O
.	O

Here	O
,	O
we	O
show	O
that	O
IBV	O
PLpro	O
can	O
degrade	O
Lys	O
(	O
48	O
)-	O
and	O
Lys	O
(	O
63	O
)-	O
linked	O
polyubiquitin	B-PRGE
chains	I-PRGE
to	O
monoubiquitin	O
but	O
not	O
linear	O
polyubiquitin	O
.	O

In	O
particular	O
,	O
P3	O
and	O
P4	O
subsites	O
as	O
well	O
as	O
residues	O
interacting	O
with	O
the	O
Î²	O
-	O
barrel	O
of	O
ubiquitin	B-PRGE
are	O
different	O
,	O
suggesting	O
different	O
catalytic	O
efficiencies	O
and	O
substrate	O
specificities	O
.	O

All	O
decahydroisoquinolin	O
inhibitors	O
synthesized	O
showed	O
moderate	O
but	O
clear	O
inhibitory	O
activities	O
for	O
SARS	B-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
),	I-PRGE
which	O
confirmed	O
the	O
fused	O
ring	O
structure	O
of	O
the	O
decahydroisoquinolin	O
functions	O
as	O
a	O
novel	O
scaffold	O
for	O
SARS	B-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibitor	O
.	O

We	O
previously	O
demonstrated	O
that	O
residues	O
377	O
-	O
588	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
RBD	O
)	O
is	O
a	O
very	O
promising	O
MERS	O
subunit	O
vaccine	O
candidate	O
,	O
capable	O
of	O
inducing	O
potent	O
neutralization	O
antibody	O
responses	O
.	O

Using	O
gene	O
silencing	O
,	O
the	O
ATP1A1	B-PRGE
protein	O
was	O
shown	O
to	O
be	O
critical	O
for	O
infection	O
of	O
cells	O
with	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
),	O
and	O
VSV	O
but	O
not	O
with	O
IAV	O
.	O

We	O
report	O
here	O
that	O
the	O
cysteine	B-PRGE
protease	I-PRGE
inhibitor	O
K11777	O
,	O
((	O
2S	O
)-	O
N	O
-[(	O
1E	O
,	O
3S	O
)-	O
1	O
-(	O
benzenesulfonyl	O
)-	O
5	O
-	O
phenylpent	O
-	O
1	O
-	O
en	O
-	O
3	O
-	O
yl	O
]-	O
2	O
-{[(	O
E	O
)-	O
4	O
-	O
methylpiperazine	O
-	O
1	O
-	O
carbonyl	O
]	O
amino	O
}-	O
3	O
-	O
phenylpropanamide	O
)	O
and	O
closely	O
-	O
related	O
vinylsulfones	O
act	O
as	O
broad	O
-	O
spectrum	O
antivirals	O
by	O
targeting	O
cathepsin	B-PRGE
-	O
mediated	O
cell	O
entry	O
.	O

In	O
order	O
to	O
assess	O
whether	O
cysteine	O
or	O
serine	B-PRGE
proteases	I-PRGE
promote	O
viral	O
spread	O
in	O
the	O
host	O
,	O
we	O
compared	O
the	O
antiviral	O
activity	O
of	O
an	O
optimized	O
K11777	O
-	O
derivative	O
with	O
that	O
of	O
camostat	O
,	O
an	O
inhibitor	O
of	O
TMPRSS2	B-PRGE
and	O
related	B-PRGE
serine	I-PRGE
proteases	I-PRGE
.	O

Our	O
results	O
indicate	O
that	O
camostat	O
,	O
or	O
similar	B-PRGE
serine	I-PRGE
protease	I-PRGE
inhibitors	I-PRGE
,	O
might	O
be	O
an	O
effective	O
option	O
for	O
treatment	O
of	O
SARS	O
and	O
potentially	O
MERS	O
,	O
while	O
vinyl	O
sulfone	O
-	O
based	O
inhibitors	O
are	O
excellent	O
lead	O
candidates	O
for	O
Ebola	O
virus	O
therapeutics	O
.	O

We	O
tested	O
170	O
(	O
57	O
.	O
6	O
%)	O
of	O
the	O
295	O
HRV	O
-	O
positive	O
samples	O
:	O
117	O
HRV	O
strains	O
were	O
typed	O
by	O
using	O
the	O
VP4	B-PRGE
/	O
VP2	B-PRGE
method	O
and	O
53	O
by	O
using	O
5	O
'	O
UTR	O
method	O
.	O

Kallistatin	B-PRGE
is	O
a	O
protective	O
hormokine	O
released	O
during	O
monocyte	O
activation	O
and	O
low	O
levels	O
in	O
the	O
setting	O
of	O
septic	O
shock	O
can	O
predict	O
adverse	O
outcomes	O
.	O

Infection	O
involved	O
porcine	O
aminpeptidase	O
N	O
(	O
pAPN	O
),	O
a	O
reported	O
cellular	O
receptor	O
for	O
PEDV	O
,	O
transient	O
expression	O
of	O
pAPN	B-PRGE
and	I-PRGE
siRNA	I-PRGE
targeted	O
pAPN	O
increased	O
and	O
decreased	O
the	O
infectivity	O
of	O
PEDV	O
in	O
IECs	O
,	O
respectively	O
.	O

While	O
FCoV	O
and	O
FCV	O
belong	O
to	O
two	O
distinct	O
virus	O
families	O
,	O
the	O
Coronaviridae	O
and	O
the	O
Caliciviridae	O
,	O
respectively	O
,	O
they	O
share	O
a	O
dependence	O
on	O
viral	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CLpro	O
)	O
for	O
their	O
replication	O
.	O

ABSTRACT	O
:	O
Ubiquitin	B-PRGE
-	O
like	O
domains	O
(	O
Ubls	O
)	O
now	O
are	O
recognized	O
as	O
common	O
elements	O
adjacent	O
to	O
viral	O
and	O
cellular	O
proteases	O
;	O
however	O
,	O
their	O
function	O
is	O
unclear	O
.	O

Structural	O
studies	O
of	O
the	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLP	B-PRGE
)	O
domains	O
of	O
coronaviruses	O
(	O
CoVs	O
)	O
revealed	O
an	O
adjacent	O
Ubl	B-PRGE
domain	I-PRGE
in	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
CoV	O
,	O
and	O
the	O
murine	O
CoV	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

To	O
evaluate	O
the	O
effect	O
of	O
the	O
mutation	O
on	O
protease	O
activity	O
,	O
we	O
purified	O
WT	O
and	O
Ubl	B-PRGE
mutant	I-PRGE
PLP2	I-PRGE
and	O
found	O
that	O
the	O
proteases	O
exhibit	O
similar	O
specific	O
activities	O
at	O
25	O
Â°	O
C	O
.	O

ABSTRACT	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
(	O
HCoV	O
)	O
NL63	O
was	O
first	O
described	O
in	O
2004	O
and	O
is	O
associated	O
with	O
respiratory	O
tract	O
disease	O
of	O
varying	O
severity	O
.	O

We	O
related	O
structures	O
of	O
influenza	B-PRGE
A	I-PRGE
N10	I-PRGE
and	I-PRGE
N11	I-PRGE
proteins	I-PRGE
that	O
have	O
no	O
established	O
function	O
to	O
structures	O
of	O
proteins	O
with	O
known	O
function	O
by	O
identifying	O
spatially	O
conserved	O
atoms	O
.	O

These	O
viruses	O
require	O
proteolytic	O
activation	O
of	O
surface	B-PRGE
envelope	I-PRGE
glycoproteins	I-PRGE
needed	O
for	O
entry	O
,	O
and	O
cellular	O
cathepsins	O
have	O
been	O
shown	O
to	O
be	O
involved	O
in	O
proteolysis	O
of	O
glycoproteins	O
from	O
these	O
distinct	O
virus	O
families	O
.	O

Sequence	O
analysis	O
comparing	O
Pteropus	B-PRGE
alecto	I-PRGE
furin	I-PRGE
and	O
cathepsin	B-PRGE
L	I-PRGE
to	O
proteases	O
from	O
other	O
mammalian	O
species	O
showed	O
a	O
high	O
degree	O
of	O
conservation	O
;	O
however	O
significant	O
amino	O
acid	O
variation	O
occurs	O
at	O
the	O
C	O
-	O
terminus	O
of	O
Pteropus	B-PRGE
alecto	I-PRGE
furin	I-PRGE
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
the	O
unusual	O
role	O
of	O
cathepsin	B-PRGE
proteases	I-PRGE
in	O
the	O
life	O
cycle	O
of	O
bat	O
-	O
borne	O
viruses	O
is	O
not	O
due	O
to	O
the	O
lack	O
of	O
active	O
furin	B-PRGE
-	I-PRGE
like	I-PRGE
proteases	I-PRGE
in	O
these	O
natural	O
reservoir	O
species	O
;	O
however	O
,	O
differences	O
may	O
exist	O
between	O
furin	B-PRGE
proteases	O
present	O
in	O
fruit	O
bats	O
compared	O
to	O
furins	O
in	O
other	O
mammalian	O
species	O
,	O
and	O
these	O
differences	O
may	O
impact	O
protease	O
usage	O
for	O
viral	O
glycoprotein	O
processing	O
.	O

Infectious	O
recombinant	O
IBVs	O
are	O
generated	O
in	O
situ	O
following	O
the	O
transfection	O
of	O
vaccinia	O
virus	O
DNA	O
,	O
containing	O
the	O
modified	O
IBV	O
cDNA	O
,	O
into	O
cells	O
infected	O
with	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
T7	O
DNA	O
-	O
dependent	O
RNA	B-PRGE
polymerase	I-PRGE
.	O

Compared	O
with	O
VicS	O
-	O
v	O
,	O
the	O
more	O
attenuated	O
VicS	B-PRGE
-	I-PRGE
del	I-PRGE
strain	O
had	O
two	O
non	O
-	O
synonymous	O
changes	O
in	O
the	O
non	O
-	O
structural	O
protein	B-PRGE
6	I-PRGE
(	O
nsp6	O
),	O
a	O
transmembrane	O
(	O
TM	O
)	O
domain	O
that	O
may	O
participate	O
in	O
autocatalytic	O
release	O
of	O
the	O
3	B-PRGE
-	I-PRGE
chymotrypsin	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
,	O
a	O
polymorphic	O
difference	O
at	O
the	O
end	O
of	O
the	O
S2	B-PRGE
gene	I-PRGE
,	O
which	O
coincided	O
with	O
the	O
body	O
transcription	O
-	O
regulating	O
sequence	O
(	O
B	O
-	O
TRS	O
)	O
of	O
mRNA	O
3	O
and	O
a	O
truncated	O
open	O
reading	O
frame	O
for	O
a	O
peptide	O
encoded	O
by	O
gene	B-PRGE
4	I-PRGE
(	O
4b	O
).	O

TITLE	O
:	O
Development	O
and	O
characterization	O
of	O
neutralizing	O
monoclonal	O
antibodies	O
against	O
the	O
S1	B-PRGE
subunit	I-PRGE
protein	O
of	O
QX	O
-	O
like	O
avian	O
infectious	O
bronchitis	O
virus	O
strain	O
Sczy3	O
.	O

TITLE	O
:	O
Monoclonal	O
antibody	O
to	O
N	B-PRGE
protein	I-PRGE
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
N	B-PRGE
gene	I-PRGE
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
using	O
specific	O
primers	O
,	O
and	O
inserted	O
into	O
the	O
expression	O
vector	O
pCold	O
-	O
I	O
to	O
construct	O
a	O
recombinant	O
plasmid	O
pCold	O
-	O
I	O
-	O
N	O
.	O
The	O
recombinant	O
plasmid	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
BL21	O
(	O
DE3	O
)	O
under	O
IPTG	O
induction	O
.	O

E	B-PRGE
protein	I-PRGE
localized	O
in	O
the	O
ERGIC	O
and	O
Golgi	O
with	O
the	O
amino	O
and	O
carboxy	O
termini	O
in	O
the	O
lumen	O
and	O
cytoplasm	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
HIV	O
-	O
1	O
reverse	B-PRGE
transcriptase	I-PRGE
(	O
RT	O
)	O
is	O
still	O
an	O
extremely	O
attractive	O
pharmaceutical	O
target	O
for	O
the	O
identification	O
of	O
new	O
inhibitors	O
possibly	O
active	O
on	O
drug	O
resistant	O
strains	O
.	O

TITLE	O
:	O
CD107a	B-PRGE
as	O
a	O
marker	O
of	O
activation	O
in	O
chicken	O
cytotoxic	O
T	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
study	O
aimed	O
to	O
evaluate	O
cell	O
surface	O
mobilisation	O
of	O
CD107a	B-PRGE
as	O
a	O
general	O
activation	O
marker	O
on	O
chicken	O
cytotoxic	O
T	O
cells	O
(	O
CTL	O
).	O

ABSTRACT	O
:	O
Nucleocapsid	B-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
protein	I-PRGE
gene	I-PRGE
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
was	O
expressed	O
in	O
a	O
prokaryotic	O
system	O
and	O
used	O
to	O
develop	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
detection	O
of	O
antibody	O
to	O
TCoV	O
.	O
Anti	O
-	O
TCoV	O
hyperimmune	O
turkey	O
serum	O
and	O
normal	O
turkey	O
serum	O
were	O
used	O
as	O
positive	O
or	O
negative	O
controls	O
for	O
optimization	O
of	O
the	O
ELISA	O
.	O

Four	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
lead	O
inhibitors	O
were	O
tested	O
against	O
MERS	O
-	O
CoV	O
PLpro	O
,	O
none	O
of	O
which	O
were	O
effective	O
against	O
MERS	O
-	O
CoV	O
PLpro	O
.	O

The	O
therapeutic	O
index	O
of	O
recombinant	B-PRGE
human	I-PRGE
interferon	I-PRGE
alpha	I-PRGE
2b	I-PRGE
anti	O
-	O
influenza	O
B	O
virus	O
was	O
2	O
.	O
74	O
,	O
with	O
modest	O
effect	O
.	O

Intragastric	O
administration	O
of	O
either	O
Ad5	B-PRGE
-	I-PRGE
S	I-PRGE
or	O
Ad41	O
-	O
S	O
induced	O
antigen	B-PRGE
-	I-PRGE
specific	I-PRGE
IgG	I-PRGE
and	I-PRGE
neutralizing	I-PRGE
antibody	I-PRGE
in	O
serum	O
;	O
however	O
,	O
antigen	O
-	O
specific	O
T	O
-	O
cell	O
responses	O
were	O
not	O
detected	O
.	O

Both	O
rAd	O
-	O
based	O
vaccines	O
administered	O
intramuscularly	O
induced	O
systemic	O
humoral	O
immune	O
responses	O
(	O
neutralizing	O
IgG	B-PRGE
antibodies	I-PRGE
).	O

TITLE	O
:	O
SARS	B-PRGE
hCoV	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
is	O
a	O
unique	O
Lys48	O
linkage	O
-	O
specific	O
di	O
-	O
distributive	O
deubiquitinating	O
enzyme	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
compare	O
substrate	O
specificities	O
of	O
the	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLpro	O
)	O
from	O
the	O
recently	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
hCoV	O
to	O
the	O
related	O
protease	O
from	O
SARS	O
,	O
SARS	O
PLpro	O
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
eucalyptol	O
acts	O
through	O
a	O
mechanism	O
involving	O
decreased	O
MMP	B-PRGE
-	I-PRGE
9	I-PRGE
expression	O
and	O
an	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
-	O
dependent	O
NF	O
-	O
ÎºB	O
pathway	O
to	O
exert	O
anti	O
-	O
inflammatory	O
actions	O
in	O
acute	O
lung	O
inflammation	O
.	O

Among	O
the	O
disease	O
-	O
related	O
functions	O
,	O
certain	O
anti	O
-	O
viral	O
pathways	O
and	O
proteins	O
,	O
such	O
as	O
the	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
,	O
Rap1	B-PRGE
,	O
autophagy	O
,	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
,	O
PI3K	B-PRGE
-	O
Akt	B-PRGE
and	O
Jak	B-PRGE
-	O
STAT	B-PRGE
signaling	O
pathways	O
,	O
and	O
integrin	B-PRGE
Î²2	I-PRGE
/	O
Î²3	O
and	O
cystatin	B-PRGE
-	I-PRGE
C	I-PRGE
proteins	I-PRGE
,	O
represented	O
potential	O
factors	O
in	O
PEDV	O
infection	O
.	O

TITLE	O
:	O
Self	O
-	O
assembly	O
of	O
a	O
nine	O
-	O
residue	O
amyloid	O
-	O
forming	O
peptide	O
fragment	O
of	O
SARS	B-PRGE
corona	I-PRGE
virus	I-PRGE
E	I-PRGE
-	I-PRGE
protein	I-PRGE
:	O
mechanism	O
of	O
self	O
aggregation	O
and	O
amyloid	O
-	O
inhibition	O
of	O
hIAPP	O
.	O

Western	O
blot	O
analysis	O
using	O
recombinant	B-PRGE
DcEV	I-PRGE
VP1	I-PRGE
polypeptide	I-PRGE
showed	O
a	O
high	O
seroprevalence	O
of	O
52	O
%	O
among	O
serum	O
samples	O
from	O
172	O
dromedaries	O
for	O
IgG	B-PRGE
,	O
concurring	O
with	O
its	O
much	O
higher	O
infection	O
rates	O
in	O
dromedary	O
calves	O
than	O
in	O
adults	O
.	O

Subsequent	O
hunting	O
for	O
novel	O
coronaviruses	O
(	O
CoVs	O
)	O
led	O
to	O
the	O
discovery	O
of	O
two	O
additional	O
human	O
and	O
over	O
40	O
animal	O
CoVs	O
,	O
including	O
the	O
prototype	O
lineage	O
C	O
betacoronaviruses	O
,	O
Tylonycteris	B-PRGE
bat	I-PRGE
CoV	I-PRGE
HKU4	I-PRGE
and	O
Pipistrellus	B-PRGE
bat	I-PRGE
CoV	I-PRGE
HKU5	I-PRGE
;	O
these	O
are	O
phylogenetically	O
closely	O
related	O
to	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
CoV	O
,	O
which	O
has	O
affected	O
more	O
than	O
1	O
,	O
000	O
patients	O
with	O
over	O
35	O
%	O
fatality	O
since	O
its	O
emergence	O
in	O
2012	O
.	O

Clinical	O
severity	O
may	O
be	O
related	O
to	O
MERS	O
-	O
CoV	O
'	O
s	O
ability	O
to	O
infect	O
a	O
broad	O
range	O
of	O
cells	O
with	O
DPP4	B-PRGE
expression	O
,	O
evade	O
the	O
host	O
innate	O
immune	O
response	O
,	O
and	O
induce	O
cytokine	O
dysregulation	O
.	O

Among	O
these	O
,	O
nsp3	B-PRGE
is	O
the	O
largest	O
and	O
the	O
first	O
to	O
be	O
inserted	O
into	O
the	O
endoplasmic	O
reticulum	O
.	O

This	O
provided	O
a	O
platform	O
for	O
further	O
dissection	O
of	O
amino	O
-	O
terminal	O
domains	O
of	O
nsp3	B-PRGE
.	O

From	O
this	O
,	O
we	O
found	O
that	O
catalytic	O
mutation	O
of	O
PLP1	B-PRGE
or	O
complete	O
deletion	O
of	O
PLP1	B-PRGE
and	O
the	O
adjacent	O
ADRP	O
domain	O
was	O
tolerated	O
by	O
the	O
virus	O
.	O

The	O
largest	O
component	O
of	O
the	O
coronavirus	B-PRGE
replicase	I-PRGE
-	I-PRGE
transcriptase	I-PRGE
complex	O
,	O
nsp3	B-PRGE
,	O
contains	O
multiple	O
modules	O
,	O
many	O
of	O
which	O
do	O
not	O
have	O
clearly	O
defined	O
functions	O
in	O
genome	O
replication	O
or	O
transcription	O
.	O

This	O
demonstrated	O
that	O
neither	O
PLP1	B-PRGE
nor	O
ADRP	B-PRGE
plays	O
an	O
essential	O
role	O
in	O
coronavirus	O
RNA	O
synthesis	O
.	O

To	O
investigate	O
the	O
RVs	O
etiology	O
among	O
adolescents	O
and	O
adults	O
with	O
CAP	O
,	O
according	O
to	O
age	O
and	O
pneumonia	O
severity	O
index	O
(	O
PSI	B-PRGE
),	O
a	O
multi	O
-	O
center	O
,	O
prospective	O
study	O
was	O
conducted	O
from	O
November	O
2010	O
to	O
April	O
2012	O
.	O

When	O
assessed	O
under	O
SVS	O
,	O
61	O
.	O
3	O
%	O
of	O
patients	O
with	O
severe	O
ARDS	O
were	O
reclassified	O
as	O
moderate	O
,	O
mild	O
and	O
non	O
-	O
ARDS	O
,	O
while	O
lung	O
severity	O
and	O
hospital	O
mortality	O
changed	O
markedly	O
with	O
every	O
PaOâ	B-PRGE
/	O
FiOâ	O
category	O
(	O
p	O
<	O
0	O
.	O
000001	O
).	O

Our	O
model	O
of	O
risk	O
stratification	O
outperformed	O
the	O
stratification	O
using	O
baseline	O
PaOâ	B-PRGE
/	O
FiOâ	O
and	O
non	O
-	O
standardised	O
PaOâ	B-PRGE
/	O
FiOâ	O
at	O
24	O
h	O
,	O
when	O
analysed	O
by	O
the	O
predictive	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
:	O
area	O
under	O
the	O
ROC	O
curve	O
for	O
stratification	O
at	O
baseline	O
was	O
0	O
.	O
583	O
(	O
95	O
%	O
CI	O
0	O
.	O
525	O
to	O
0	O
.	O
636	O
),	O
0	O
.	O
605	O
(	O
95	O
%	O
CI	O
0	O
.	O
552	O
to	O
0	O
.	O
658	O
)	O
at	O
24	O
h	O
without	O
SVS	O
and	O
0	O
.	O
693	O
(	O
95	O
%	O
CI	O
0	O
.	O
645	O
to	O
0	O
.	O
742	O
)	O
at	O
24	O
h	O
under	O
SVS	O
(	O
p	O
<	O
0	O
.	O
000001	O
).	O

ABSTRACT	O
:	O
To	O
assess	O
associations	O
between	O
the	O
functional	O
polymorphisms	O
G	O
-	O
2518A	O
at	O
the	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	O
2	O
gene	O
(	O
CCL2	B-PRGE
)	O
and	O
mannose	B-PRGE
binding	I-PRGE
lectin	I-PRGE
(	O
MBL	B-PRGE
)	O
codon	O
54	O
variant	O
(	O
A	O
/	O
B	O
)	O
and	O
susceptibility	O
to	O
SARS	O
.	O

We	O
genotyped	O
the	O
CCL2	B-PRGE
G	I-PRGE
-	I-PRGE
2518A	I-PRGE
and	O
MBL	O
codon	O
54	O
variant	O
(	O
A	O
/	O
B	O
)	O
in	O
4	O
case	O
-	O
control	O
populations	O
of	O
Chinese	O
descent	O
,	O
totally	O
consisting	O
of	O
932	O
patients	O
with	O
SARS	O
and	O
982	O
control	O
subjects	O
.	O

RESULTS	O
:	O
Both	O
the	O
high	O
-	O
CCL2	B-PRGE
-	O
producing	O
GG	O
genotype	O
and	O
the	O
low	O
-	O
MBL	O
-	O
producing	O
B	B-PRGE
allele	I-PRGE
were	O
consistently	O
associated	O
with	O
increased	O
risks	O
of	O
SARS	O
-	O
CoV	O
infection	O
in	O
all	O
4	O
case	O
-	O
control	O
populations	O
(	O
joint	O
P	O
=	O
1	O
.	O
6	O
Ã	O
10	O
(-	O
4	O
)	O
and	O
4	O
.	O
9	O
Ã	O
10	O
(-	O
8	O
),	O
for	O
CCL2	B-PRGE
and	O
MBL	B-PRGE
respectively	O
),	O
with	O
no	O
interaction	O
between	O
polymorphisms	O
could	O
be	O
detected	O
.	O

The	O
MERS	O
CoV	O
infection	O
was	O
confirmed	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
detection	O
of	O
the	O
consensus	O
viral	O
RNA	O
targets	O
upstream	B-PRGE
of	I-PRGE
the	I-PRGE
E	I-PRGE
gene	I-PRGE
(	O
UPE	O
)	O
and	O
open	O
reading	O
frame	O
(	O
ORF1b	O
)	O
on	O
a	O
sputum	O
sample	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
multi	B-PRGE
-	I-PRGE
epitope	I-PRGE
antigen	I-PRGE
of	O
S	B-PRGE
protein	I-PRGE
-	O
based	O
ELISA	O
for	O
antibodies	O
detection	O
against	O
infectious	O
bronchitis	O
virus	O
.	O

The	O
optimal	O
concentration	O
of	O
the	O
coating	B-PRGE
antigen	I-PRGE
SE	I-PRGE
was	O
3	O
.	O
689	O
Î¼g	O
/	O
mL	O
and	O
the	O
dilution	O
of	O
the	O
primary	O
antibodies	O
was	O
identified	O
as	O
1	O
:	O
1000	O
using	O
a	O
checkerboard	O
titration	O
.	O

However	O
,	O
FOB	B-PRGE
-	I-PRGE
BAL	I-PRGE
carries	O
a	O
risk	O
of	O
significant	O
hypoxaemia	O
and	O
subsequent	O
tracheal	O
intubation	O
during	O
and	O
after	O
the	O
procedure	O
.	O

Data	O
regarding	O
the	O
recovered	O
volume	O
of	O
BAL	O
fluid	O
,	O
incidence	O
of	O
tracheal	O
intubation	O
within	O
eight	O
hours	O
after	O
the	O
completion	O
of	O
FOB	B-PRGE
-	I-PRGE
BAL	I-PRGE
,	O
respiratory	O
and	O
haemodynamic	O
parameters	O
and	O
treatment	O
modifications	O
were	O
collected	O
for	O
the	O
evaluation	O
.	O

A	O
phylogenetic	O
analysis	O
based	O
on	O
the	O
S1	B-PRGE
gene	I-PRGE
clustered	O
ck	O
/	O
CH	O
/	O
LHLJ	O
/	O
140906	O
with	O
the	O
793	O
/	O
B	O
group	O
;	O
however	O
,	O
a	O
pairwise	O
comparison	O
showed	O
that	O
the	O
5	O
'	O
terminal	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
(	O
containing	O
hypervariable	O
regions	O
I	O
and	O
II	O
)	O
had	O
high	O
sequence	O
identity	O
with	O
the	O
H120	O
strain	O
,	O
while	O
the	O
3	O
'	O
terminal	O
sequence	O
was	O
very	O
similar	O
to	O
that	O
of	O
IBV	O
4	O
/	O
91	O
strain	O
.	O

The	O
structural	O
destruction	O
and	O
disorganization	O
of	O
TJ	O
and	O
AJ	O
were	O
extensive	O
in	O
PEDV	O
-	O
infected	O
pigs	O
at	O
PIDs	O
1	O
-	O
3	O
,	O
but	O
then	O
appeared	O
to	O
reversibly	O
recover	O
at	O
PID	O
5	O
,	O
as	O
evident	O
by	O
increased	O
numbers	O
of	O
ZO	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
positive	O
epithelial	O
cells	O
and	O
markedly	O
improved	O
appearance	O
of	O
E	B-PRGE
-	I-PRGE
Cadherin	I-PRGE
-	O
positive	O
villous	O
epithelium	O
.	O

The	O
RT	O
-	O
LAMP	O
assays	O
are	O
designed	O
to	O
amplify	O
MERS	O
-	O
CoV	O
genomic	O
loci	O
located	O
within	O
the	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1a	O
and	O
ORF1b	O
genes	O
and	O
upstream	O
of	O
the	O
E	B-PRGE
gene	I-PRGE
.	O

IgM	B-PRGE
antibody	O
was	O
positive	O
in	O
all	O
the	O
17	O
cases	O
,	O
which	O
included	O
9	O
male	O
cases	O
,	O
8	O
female	O
cases	O
,	O
and	O
their	O
age	O
was	O
from	O
2	O
months	O
to	O
10	O
years	O
.	O

The	O
plasma	O
level	O
of	O
sRAGE	O
and	O
AQP5	B-PRGE
might	O
be	O
associated	O
with	O
the	O
severity	O
of	O
RDS	O
in	O
preterm	O
infants	O
.	O

RESULTS	O
:	O
The	O
plasma	O
levels	O
of	O
sRAGE	O
and	O
AQP5	B-PRGE
of	O
the	O
control	O
group	O
were	O
significantly	O
lower	O
than	O
that	O
of	O
experimental	O
group	O
at	O
three	O
time	O
points	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
clinical	O
feature	O
like	O
dyspnoea	O
,	O
cough	O
,	O
low	O
blood	O
pressure	O
(	O
MAP	O
<	O
65	O
mmHg	O
),	O
IVC	O
collapsibility	O
(	O
by	O
ultrasound	O
)	O
and	O
laboratory	O
parameters	O
like	O
decreased	O
Hemoglobin	B-PRGE
,	O
Hematocrit	O
,	O
Serum	B-PRGE
albumin	I-PRGE
,	O
and	O
increased	O
serum	O
creatinine	O
,	O
serum	O
total	O
bilirubin	O
,	O
SGOT	O
,	O
SGPT	O
,	O
LDH	B-PRGE
,	O
CPK	B-PRGE
,	O
and	O
serum	O
lactate	O
were	O
statistically	O
significant	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
in	O
scrub	O
typhus	O
patients	O
group	O
with	O
ARDS	O
.	O

Among	O
355	O
arbitrarily	O
selected	O
serum	O
samples	O
collected	O
in	O
2014	O
and	O
originating	O
from	O
51	O
farms	O
across	O
18	O
U	O
.	O
S	O
.	O
states	O
,	O
anti	B-PRGE
-	I-PRGE
PDCoV	I-PRGE
IgG	I-PRGE
antibodies	I-PRGE
were	O
detected	O
in	O
8	O
.	O
7	O
%	O
of	O
the	O
samples	O
and	O
in	O
25	O
.	O
5	O
%	O
of	O
the	O
farms	O
whereas	O
anti	B-PRGE
-	I-PRGE
PEDV	I-PRGE
IgG	I-PRGE
was	O
detected	O
in	O
22	O
.	O
8	O
%	O
of	O
the	O
samples	O
and	O
in	O
54	O
.	O
9	O
%	O
of	O
the	O
farms	O
.	O

The	O
posttraumatic	O
lung	O
injury	O
group	O
demonstrated	O
significantly	O
higher	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
levels	O
when	O
compared	O
with	O
HS	O
group	O
(	O
744	O
.	O
8	O
Â±	O
104	O
versus	O
297	O
.	O
7	O
Â±	O
134	O
pg	O
/	O
mL	O
;	O
P	O
=	O
0	O
.	O
004	O
).	O

RESULTS	O
:	O
The	O
posttraumatic	O
lung	O
injury	O
group	O
demonstrated	O
significantly	O
higher	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
levels	O
when	O
compared	O
with	O
HS	O
group	O
(	O
744	O
.	O
8	O
Â±	O
104	O
versus	O
297	O
.	O
7	O
Â±	O
134	O
pg	O
/	O
mL	O
;	O
P	O
=	O
0	O
.	O
004	O
).	O

ACP	B-PRGE
was	O
defined	O
by	O
the	O
association	O
of	O
right	O
ventricular	O
(	O
RV	O
)	O
dilatation	O
and	O
systolic	O
paradoxical	O
ventricular	O
septal	O
motion	O
.	O

ABSTRACT	O
:	O
Recent	O
studies	O
have	O
revealed	O
that	O
lung	O
inflammation	O
mediated	O
by	O
CD4	B-PRGE
+	I-PRGE
T	O
cells	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

We	O
analyzed	O
fecal	O
and	O
throat	O
swabs	O
to	O
detect	O
the	O
presence	O
of	O
virus	O
through	O
amplification	O
of	O
the	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
gene	O
,	O
which	O
is	O
highly	O
conserved	O
in	O
all	O
known	O
coronaviruses	O
.	O

Furthermore	O
,	O
the	O
active	O
compound	O
c26	O
dose	O
-	O
dependently	O
inhibited	O
ERK	B-PRGE
phosphorylation	O
.	O

Forty	O
-	O
three	O
percent	O
of	O
patients	O
had	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
on	O
HSBP	B-PRGE
day	I-PRGE
1	I-PRGE
;	O
this	O
decreased	O
to	O
26	O
%	O
on	O
day	O
three	O
and	O
to	O
30	O
%	O
on	O
day	O
seven	O
.	O

The	O
results	O
showed	O
that	O
DON	O
reduced	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
the	O
titre	O
against	O
IBV	O
,	O
decreased	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
the	O
level	O
of	O
alanine	B-PRGE
transaminase	I-PRGE
(	O
ALT	B-PRGE
)	O
(	O
4	O
.	O
2	O
Â±	O
0	O
.	O
5	O
U	O
/	O
l	O
)	O
compared	O
with	O
control	O
birds	O
(	O
6	O
.	O
4	O
Â±	O
0	O
.	O
5	O
U	O
/	O
l	O
),	O
increased	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
the	O
serum	O
cholesterol	O
concentration	O
(	O
144	O
Â±	O
6	O
mg	O
/	O
dl	O
)	O
compared	O
with	O
their	O
control	O
counterparts	O
(	O
123	O
Â±	O
5	O
mg	O
/	O
dl	O
)	O
and	O
increased	O
(	O
p	O
=	O
0	O
.	O
074	O
)	O
the	O
amount	O
of	O
circulating	O
triglycerides	O
(	O
62	O
.	O
25	O
Â±	O
7	O
.	O
50	O
mg	O
/	O
dl	O
)	O
compared	O
with	O
controls	O
(	O
39	O
.	O
55	O
Â±	O
4	O
.	O
74	O
).	O

This	O
is	O
the	O
first	O
reported	O
case	O
of	O
acquired	O
factor	B-PRGE
V	I-PRGE
deficiency	O
in	O
a	O
patient	O
receiving	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
Legionella	O
pneumonia	O
.	O

This	O
study	O
revealed	O
a	O
new	O
mechanism	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
P6	I-PRGE
in	O
limiting	O
the	O
IFN	B-PRGE
signaling	O
to	O
promote	O
SARS	O
-	O
CoV	O
survival	O
in	O
host	O
cells	O
.	O

In	O
addition	O
,	O
IgG	B-PRGE
antibodies	I-PRGE
from	O
the	O
1	O
-	O
day	O
-	O
old	O
group	O
had	O
lower	O
avidity	O
indices	O
than	O
day	O
28	O
vaccinated	O
birds	O
.	O

A	O
small	O
fragment	O
(	O
258	O
-	O
amino	O
-	O
acid	O
fragment	O
,	O
residues	O
291	O
-	O
548	O
)	O
on	O
the	O
PHEV	B-PRGE
S	I-PRGE
protein	I-PRGE
was	O
posited	O
to	O
be	O
the	O
minimum	O
number	O
of	O
amino	O
acids	O
necessary	O
to	O
interact	O
with	O
NCAM	O
.	O

We	O
established	O
a	O
miniaturized	O
luciferase	O
gene	O
reporter	O
assay	O
in	O
A549	O
cells	O
that	O
measures	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
induction	O
by	O
viral	O
dsRNA	O
and	O
is	O
dose	O
-	O
dependently	O
inhibited	O
by	O
VP35	O
expression	O
.	O

NCD	O
was	O
only	O
positively	O
associated	O
with	O
the	O
alpha	B-PRGE
-	I-PRGE
2	I-PRGE
globulin	I-PRGE
concentration	O
.	O

Calves	O
with	O
Ig	O
'	O
s	O
below	O
7	O
.	O
5g	O
/	O
L	O
and	O
with	O
increased	O
levels	O
of	O
alpha	B-PRGE
-	I-PRGE
2	I-PRGE
globulins	I-PRGE
showed	O
a	O
decrease	O
in	O
ADG	O
.	O

TITLE	O
:	O
A	O
Single	O
Point	O
Mutation	O
Creating	O
a	O
Furin	B-PRGE
Cleavage	O
Site	O
in	O
the	O
Spike	O
Protein	O
Renders	O
Porcine	O
Epidemic	O
Diarrhea	O
Coronavirus	O
Trypsin	O
Independent	O
for	O
Cell	O
Entry	O
and	O
Fusion	O
.	O

NDV	O
-	O
infected	O
cells	O
also	O
upregulated	O
several	O
genes	O
not	O
previously	O
characterized	O
to	O
be	O
antiviral	O
,	O
such	O
as	O
RND1	B-PRGE
,	O
SERTAD1	B-PRGE
,	O
CHAC1	B-PRGE
,	O
and	O
MORC3	B-PRGE
.	O

ABSTRACT	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
(	O
HCoV	O
-	O
OC43	O
)	O
is	O
one	O
of	O
five	O
currently	O
circulating	O
human	O
coronaviruses	O
responsible	O
for	O
respiratory	O
infections	O
.	O

In	O
contrast	O
,	O
mice	O
deficient	O
in	O
the	O
TLR3	B-PRGE
/	O
TLR4	B-PRGE
adaptor	O
TRIF	B-PRGE
are	O
highly	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
infection	O
,	O
showing	O
increased	O
weight	O
loss	O
,	O
mortality	O
,	O
reduced	O
lung	O
function	O
,	O
increased	O
lung	O
pathology	O
,	O
and	O
higher	O
viral	O
titers	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
TLR	O
signaling	O
through	O
the	O
TRIF	B-PRGE
adaptor	I-PRGE
protein	I-PRGE
protects	O
mice	O
from	O
lethal	O
SARS	O
-	O
CoV	O
disease	O
.	O

TITLE	O
:	O
Impact	O
of	O
statin	B-PRGE
therapy	O
on	O
mortality	O
in	O
patients	O
with	O
sepsis	O
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
depends	O
on	O
ARDS	O
severity	O
:	O
a	O
prospective	O
observational	O
cohort	O
study	O
.	O

We	O
hypothesized	O
that	O
HGF	B-PRGE
/	O
c	B-PRGE
-	I-PRGE
Met	I-PRGE
and	O
TGF	O
-	O
Î±	O
/	O
EGFR	B-PRGE
would	O
regulate	O
innate	O
immune	O
responses	O
to	O
influenza	O
A	O
virus	O
infection	O
in	O
human	O
AECs	O
.	O

Interestingly	O
,	O
nine	O
putative	O
non	O
-	O
canonical	O
cleavage	O
sites	O
were	O
predicted	O
and	O
three	O
of	O
them	O
could	O
be	O
cleaved	O
by	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp5	I-PRGE
.	O

The	O
genome	O
of	O
HCoV	O
-	O
EMC	O
is	O
most	O
closely	O
related	O
to	O
Tylonycteris	B-PRGE
bat	I-PRGE
coronavirus	I-PRGE
HKU4	I-PRGE
(	O
Ty	O
-	O
BatCoV	O
HKU4	O
)	O
and	O
Pipistrellus	B-PRGE
bat	I-PRGE
coronavirus	I-PRGE
HKU5	I-PRGE
(	O
Pi	O
-	O
BatCoV	O
HKU5	O
)	O
we	O
discovered	O
in	O
2006	O
.	O

This	O
review	O
covers	O
the	O
available	O
literature	O
on	O
the	O
emerging	O
importance	O
of	O
T	O
cell	O
responses	O
in	O
SARS	O
-	O
CoV	O
infection	O
,	O
particularly	O
on	O
the	O
mapping	O
of	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
epitopes	O
,	O
longevity	O
,	O
polyfunctionality	O
and	O
human	B-PRGE
leukocyte	I-PRGE
antigen	I-PRGE
(	O
HLA	B-PRGE
)	O
association	O
as	O
well	O
as	O
their	O
potential	O
implications	O
on	O
treatment	O
and	O
vaccine	O
development	O
.	O

TITLE	O
:	O
A	O
Kinome	O
-	O
Wide	O
Small	O
Interfering	O
RNA	O
Screen	O
Identifies	O
Proviral	O
and	O
Antiviral	O
Host	O
Factors	O
in	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
Replication	O
,	O
Including	O
Double	O
-	O
Stranded	O
RNA	O
-	O
Activated	O
Protein	B-PRGE
Kinase	I-PRGE
and	O
Early	B-PRGE
Secretory	I-PRGE
Pathway	I-PRGE
Proteins	I-PRGE
.	O

Protein	B-PRGE
kinases	I-PRGE
are	O
key	O
regulators	O
of	O
many	O
cellular	O
functions	O
,	O
and	O
the	O
systematic	O
knockdown	O
of	O
their	O
expression	O
should	O
provide	O
a	O
broad	O
perspective	O
on	O
factors	O
and	O
pathways	O
promoting	O
or	O
antagonizing	O
coronavirus	O
replication	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
stimulation	O
of	O
nsp16	B-PRGE
2	I-PRGE
'-	I-PRGE
O	I-PRGE
-	I-PRGE
MTase	I-PRGE
activity	O
by	O
nsp10	O
is	O
a	O
universal	O
and	O
conserved	O
mechanism	O
in	O
coronaviruses	O
,	O
including	O
FCoV	O
,	O
and	O
that	O
nsp10	O
is	O
functionally	O
interchangeable	O
in	O
the	O
stimulation	O
of	O
nsp16	O
of	O
different	O
coronaviruses	O
.	O

Our	O
current	O
results	O
demonstrate	O
that	O
stimulation	O
of	O
nsp16	B-PRGE
2	I-PRGE
'-	I-PRGE
O	I-PRGE
-	I-PRGE
MTase	I-PRGE
activity	O
by	O
nsp10	O
is	O
a	O
common	O
mechanism	O
for	O
coronaviruses	O
,	O
and	O
nsp10	O
is	O
functionally	O
interchangeable	O
in	O
the	O
stimulation	O
of	O
nsp16	O
among	O
different	O
coronaviruses	O
,	O
which	O
underlies	O
the	O
rationale	O
for	O
developing	O
inhibitory	O
peptides	O
.	O

We	O
demonstrate	O
that	O
a	O
peptide	O
derived	O
from	O
the	O
nsp16	B-PRGE
-	I-PRGE
interacting	I-PRGE
domain	I-PRGE
of	O
MHV	O
nsp10	O
could	O
inhibit	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
of	O
different	O
coronaviruses	O
in	O
vitro	O
and	O
viral	O
replication	O
of	O
MHV	O
and	O
SARS	O
-	O
CoV	O
replicon	O
in	O
cell	O
culture	O
,	O
and	O
it	O
could	O
strongly	O
inhibit	O
virus	O
replication	O
and	O
pathogenesis	O
in	O
MHV	O
-	O
infected	O
mice	O
.	O

We	O
recently	O
described	O
an	O
important	O
role	O
for	O
extracellular	B-PRGE
histones	I-PRGE
during	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
mice	O
(	O
Bosmann	O
et	O
al	O
.,	O

Activation	O
of	O
MERS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
through	O
ligand	O
-	O
induced	O
dimerization	O
appears	O
to	O
be	O
unique	O
within	O
the	O
genogroup	O
2c	O
and	O
may	O
potentially	O
increase	O
the	O
complexity	O
in	O
the	O
development	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibitors	O
as	O
antiviral	O
agents	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
C5a	B-PRGE
in	O
acute	O
lung	O
injury	O
induced	O
by	O
highly	O
pathogenic	O
viral	O
infections	O
.	O

Glycan	O
array	O
analyses	O
revealed	O
that	O
,	O
in	O
contrast	O
to	O
the	O
S1	B-PRGE
protein	I-PRGE
of	O
IBV	O
,	O
S1	O
proteins	O
of	O
enteric	O
gammacoronaviruses	O
recognize	O
a	O
unique	O
set	O
of	O
nonsialylated	O
type	O
2	O
poly	O
-	O
N	O
-	O
acetyl	O
-	O
lactosamines	O
.	O

Possible	O
and	O
proven	O
lower	O
respiratory	O
tract	O
disease	O
was	O
less	O
common	O
compared	O
to	O
other	O
respiratory	O
viruses	O
except	O
RhV	O
/	O
EnV	B-PRGE
.	O

ABSTRACT	O
:	O
The	O
elevated	O
level	O
of	O
endothelin	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
ET	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
has	O
been	O
detected	O
in	O
the	O
bronchoalveolar	O
lavage	O
of	O
patients	O
with	O
severe	O
asthma	O
,	O
acute	O
lung	O
injury	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
sepsis	O
.	O

ABSTRACT	O
:	O
Sickle	O
cell	O
disease	O
,	O
the	O
most	O
common	O
inherited	O
hemoglobinopathy	O
in	O
the	O
United	O
States	O
,	O
is	O
a	O
group	O
of	O
autosomal	O
recessive	O
red	O
cell	O
disorders	O
resulting	O
from	O
hemoglobin	B-PRGE
S	I-PRGE
.	O
Hemoglobin	B-PRGE
S	O
forms	O
rigid	O
polymers	O
when	O
deoxygenated	O
that	O
give	O
red	O
blood	O
cells	O
their	O
sickle	O
crescent	O
shape	O
.	O

To	O
identify	O
the	O
receptor	O
-	O
binding	O
domain	O
in	O
the	O
spike	O
of	O
human	B-PRGE
Î²	I-PRGE
-	I-PRGE
CoV	I-PRGE
HKU1	I-PRGE
in	O
group	O
A	O
,	O
we	O
generated	O
and	O
mapped	O
a	O
panel	O
of	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
to	O
the	O
ectodomain	O
of	O
HKU1	B-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

Mouse	O
hepatitis	O
virus	O
,	O
a	O
Î²	O
-	O
CoV	O
in	O
group	O
A	O
,	O
uses	O
the	O
galectin	B-PRGE
-	I-PRGE
like	I-PRGE
NTD	I-PRGE
in	O
its	O
spike	O
protein	O
to	O
bind	O
its	O
receptor	O
protein	O
,	O
while	O
HCoV	O
-	O
OC43	O
,	O
another	O
Î²	O
-	O
CoV	O
in	O
group	O
A	O
,	O
uses	O
the	O
NTD	O
to	O
bind	O
to	O
its	O
sialic	O
-	O
acid	O
containing	O
receptor	O
.	O

In	O
marked	O
contrast	O
,	O
the	O
NTD	O
of	O
the	O
spike	O
glycoprotein	O
of	O
human	B-PRGE
respiratory	I-PRGE
Î²	I-PRGE
-	I-PRGE
CoV	I-PRGE
HKU1	I-PRGE
,	O
which	O
is	O
also	O
in	O
group	O
A	O
,	O
does	O
not	O
bind	O
sugar	O
.	O

Thus	O
,	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
HKU1	B-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
is	O
located	O
in	O
the	O
C	O
domain	O
.	O

TITLE	O
:	O
The	O
Nucleocapsid	B-PRGE
Protein	I-PRGE
of	O
Coronaviruses	O
Acts	O
as	O
a	O
Viral	O
Suppressor	O
of	O
RNA	O
Silencing	O
in	O
Mammalian	O
Cells	O
.	O

TITLE	O
:	O
Platelet	B-PRGE
-	I-PRGE
Derived	I-PRGE
Growth	I-PRGE
Factor	I-PRGE
and	O
Transforming	B-PRGE
Growth	I-PRGE
Factor	I-PRGE
Î²1	I-PRGE
Regulate	O
ARDS	O
-	O
Associated	O
Lung	O
Fibrosis	O
Through	O
Distinct	O
Signaling	O
Pathways	O
.	O

PDGF	B-PRGE
activated	O
p38	B-PRGE
MAPK	O
and	O
p42	B-PRGE
/	O
p44	B-PRGE
MAPK	O
,	O
but	O
not	O
SMAD3	B-PRGE
in	O
HLF	O
cells	O
.	O

In	O
this	O
study	O
,	O
six	O
anti	B-PRGE
-	I-PRGE
IBV	I-PRGE
chicken	I-PRGE
scFvs	I-PRGE
,	O
ZL	O
.	O
10	O
,	O
ZL	O
.	O
64	O
,	O
ZL	O
.	O
78	O
,	O
ZL	O
.	O
80	O
,	O
ZL	O
.	O
138	O
,	O
and	O
ZL	O
.	O
256	O
,	O
were	O
obtained	O
by	O
screening	O
random	O
clones	O
from	O
an	O
immune	O
antibody	O
library	O
.	O

Neutralization	O
tests	O
showed	O
that	O
ZL	O
.	O
10	O
,	O
which	O
bound	O
the	O
S1	B-PRGE
protein	I-PRGE
in	O
western	O
blots	O
,	O
inhibited	O
the	O
formation	O
of	O
syncytia	O
in	O
Vero	O
cells	O
48	O
h	O
post	O
IBV	O
infection	O
and	O
decreased	O
the	O
transcriptional	O
level	O
of	O
nucleoprotein	O
mRNA	O
to	O
17	O
.	O
2	O
%,	O
while	O
the	O
other	O
five	O
scFvs	O
,	O
including	O
ZL	O
.	O
78	O
and	O
ZL	O
.	O
256	O
,	O
that	O
bound	O
the	O
N	B-PRGE
protein	I-PRGE
did	O
not	O
.	O

Among	O
the	O
five	O
known	O
HCoV	O
-	O
OC43	O
genotypes	O
(	O
A	O
to	O
E	O
),	O
higher	O
substitution	O
rates	O
and	O
dN	O
/	O
dS	O
values	O
as	O
well	O
as	O
more	O
positive	O
selection	O
sites	O
were	O
detected	O
in	O
the	O
S	B-PRGE
gene	I-PRGE
of	O
genotype	O
D	O
,	O
corresponding	O
to	O
the	O
most	O
dominant	O
HCoV	O
epidemic	O
in	O
recent	O
years	O
.	O

Among	O
them	O
,	O
seven	O
positive	O
selection	O
sites	O
were	O
chronologically	O
traced	O
in	O
the	O
temporal	O
evolution	O
routes	O
of	O
genotype	O
D	O
,	O
and	O
six	O
were	O
located	O
around	O
the	O
critical	O
sugar	O
binding	O
region	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
S	B-PRGE
protein	I-PRGE
,	O
an	O
important	O
sugar	O
binding	O
domain	O
of	O
CoV	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
genetic	O
drift	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
may	O
play	O
an	O
important	O
role	O
in	O
genotype	O
persistence	O
in	O
human	O
populations	O
,	O
providing	O
insights	O
into	O
the	O
mechanisms	O
of	O
HCoV	O
-	O
OC43	O
adaptive	O
evolution	O
.	O

These	O
proteomic	O
data	O
will	O
provide	O
insights	O
into	O
the	O
specific	O
cellular	O
response	O
to	O
the	O
N	B-PRGE
protein	I-PRGE
during	O
PDCoV	O
infection	O
.	O

Results	O
showed	O
that	O
the	O
recombinant	B-PRGE
S1	I-PRGE
protein	I-PRGE
was	O
highly	O
glycosylated	O
,	O
and	O
the	O
neutralizing	O
antigenicity	O
of	O
recombinant	B-PRGE
S1	I-PRGE
protein	I-PRGE
was	O
lower	O
than	O
that	O
of	O
inactivated	O
virus	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
relationships	O
between	O
xanthine	B-PRGE
oxidase	I-PRGE
(	O
XOD	O
)	O
and	O
nephropathogenic	O
infectious	O
bronchitis	O
virus	O
(	O
NIBV	O
)	O
infection	O
,	O
240	O
growing	O
layers	O
(	O
35	O
days	O
old	O
)	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
(	O
infected	O
and	O
control	O
)	O
of	O
120	O
chickens	O
each	O
.	O

TITLE	O
:	O
Pre	O
-	O
and	O
postexposure	O
efficacy	O
of	O
fully	O
human	O
antibodies	O
against	O
Spike	B-PRGE
protein	I-PRGE
in	O
a	O
novel	O
humanized	O
mouse	O
model	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

Accelerated	O
virus	O
control	O
in	O
mice	O
lacking	O
the	O
anti	B-PRGE
-	I-PRGE
inflammatory	I-PRGE
cytokine	I-PRGE
IL	I-PRGE
-	I-PRGE
10	I-PRGE
was	O
associated	O
with	O
limited	O
initial	O
demyelination	O
,	O
but	O
low	O
viral	O
mRNA	O
persistence	O
similar	O
to	O
WT	O
mice	O
and	O
declining	O
antiviral	O
cellular	O
immunity	O
.	O

ABSTRACT	O
:	O
Myd88	B-PRGE
signaling	O
is	O
critical	O
to	O
the	O
control	O
of	O
numerous	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
infections	O
by	O
promoting	O
both	O
innate	O
and	O
adaptive	O
immune	O
responses	O
.	O

However	O
,	O
a	O
contribution	O
of	O
Myd88	B-PRGE
-	O
dependent	O
signals	O
to	O
CNS	O
pathogenesis	O
has	O
not	O
been	O
assessed	O
.	O

In	O
SIRS	O
,	O
the	O
substantial	O
activation	O
of	O
endothelial	O
inducible	B-PRGE
nitric	I-PRGE
oxide	I-PRGE
synthase	I-PRGE
(	O
iNOS	B-PRGE
)	O
and	O
smooth	O
muscle	O
guanylate	B-PRGE
cyclase	I-PRGE
(	O
GC	O
)	O
is	O
observed	O
,	O
which	O
can	O
produce	O
severe	O
hypotension	O
that	O
is	O
unresponsive	O
to	O
conventional	O
vasopressors	O
.	O

It	O
was	O
shown	O
by	O
multivariate	O
logistic	O
regression	O
analysis	O
that	O
LIPS	O
[	O
odds	O
ratio	O
(	O
OR	O
)=	O
5	O
.	O
124	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)=	O
3	O
.	O
642	O
-	O
10	O
.	O
153	O
,	O
P	O
=	O
0	O
.	O
002	O
],	O
Lac	B-PRGE
(	O
OR	O
=	O
18	O
.	O
180	O
,	O
95	O
%	O
CI	O
=	O
7	O
.	O
677	O
-	O
32	O
.	O
989	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
were	O
independent	O
risk	O
factors	O
for	O
ARDS	O
.	O

It	O
was	O
shown	O
by	O
area	O
under	O
ROC	O
(	O
AUC	O
)	O
that	O
the	O
predictive	O
value	O
of	O
LIPS	O
and	O
Lac	B-PRGE
in	O
ARDS	O
occurrence	O
was	O
significant	O
.	O

TITLE	O
:	O
Inability	O
of	O
rat	O
DPP4	B-PRGE
to	O
allow	O
MERS	O
-	O
CoV	O
infection	O
revealed	O
by	O
using	O
a	O
VSV	B-PRGE
pseudotype	I-PRGE
bearing	I-PRGE
truncated	I-PRGE
MERS	I-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

While	O
the	O
SUD	O
-	O
N	O
and	O
the	O
X	O
domains	O
were	O
found	O
to	O
be	O
dispensable	O
,	O
the	O
SUD	B-PRGE
-	I-PRGE
M	I-PRGE
domain	I-PRGE
was	O
crucial	O
for	O
viral	O
genome	O
replication	O
/	O
transcription	O
.	O

Moreover	O
,	O
our	O
data	O
demonstrated	O
that	O
CQ	O
increased	O
lysosome	O
-	O
associated	O
membrane	O
protein	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
lysosome	B-PRGE
-	I-PRGE
associated	I-PRGE
membrane	I-PRGE
protein	I-PRGE
-	I-PRGE
2	I-PRGE
and	O
light	O
chain	O
-	O
3	O
expressions	O
,	O
suggesting	O
that	O
the	O
mechanism	O
by	O
which	O
CQ	O
rescues	O
PQ	O
-	O
induced	O
cytotoxicity	O
may	O
be	O
through	O
protection	O
of	O
the	O
lysosomal	O
membrane	O
or	O
up	O
-	O
regulation	O
of	O
autophagy	O
.	O

In	O
Central	O
African	O
chimpanzee	O
,	O
OAS1	B-PRGE
has	O
evolved	O
under	O
long	O
-	O
term	O
balancing	O
selection	O
,	O
resulting	O
in	O
the	O
persistence	O
of	O
polymorphisms	O
since	O
the	O
origin	O
of	O
hominoids	O
,	O
whereas	O
human	O
populations	O
have	O
acquired	O
and	O
retained	O
OAS1	B-PRGE
alleles	I-PRGE
from	O
Neanderthal	O
and	O
Denisovan	O
origin	O
.	O

However	O
,	O
vaccine	O
formulations	O
should	O
be	O
evaluated	O
for	O
their	O
potential	O
to	O
induce	O
IgA	B-PRGE
.	O

In	O
conclusion	O
,	O
differentially	O
expressed	O
miR	O
-	O
4331	O
that	O
is	O
caused	O
by	O
TGEV	O
infection	O
can	O
suppress	O
transcription	O
of	O
TGEV	B-PRGE
gene	I-PRGE
7	I-PRGE
via	O
targeting	O
cellular	O
CDCA7	B-PRGE
.	O

TITLE	O
:	O
Structural	O
basis	O
and	O
functional	O
analysis	O
of	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
nsp14	I-PRGE
-	I-PRGE
nsp10	I-PRGE
complex	I-PRGE
.	O

Previous	O
work	O
identified	O
a	O
peptide	O
derived	O
from	O
the	O
heptad	O
repeat	O
(	O
HR	O
)	O
2	O
domain	O
in	O
S2	O
subunit	O
,	O
HR2P	O
,	O
which	O
potently	O
blocked	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
-	O
mediated	O
membrane	O
fusion	O
.	O

The	O
aeration	O
score	O
of	O
the	O
lung	O
at	O
T1	O
,	O
T2	O
,	O
T3	O
,	O
T4	O
was	O
significantly	O
reduced	O
than	O
T0	O
all	O
,	O
the	O
ventilation	O
situation	O
of	O
mainly	O
areas	O
was	O
improved	O
after	O
2	O
h	O
PPV	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
4	O
h	O
later	O
it	O
was	O
not	O
distinguished	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
the	O
value	O
of	O
PaO	B-PRGE
(	I-PRGE
2	I-PRGE
),	I-PRGE
PaO	I-PRGE
(	I-PRGE
2	I-PRGE
)/	I-PRGE
FiO	I-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
was	O
greater	O
at	O
T1	O
,	O
T2	O
,	O
T3	O
,	O
T4	O
than	O
T0	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
the	O
value	O
of	O
the	O
oxygen	O
fraction	O
was	O
significant	O
increased	O
at	O
T2	O
than	O
T1	O
(	O
t	O
=	O
2	O
.	O
840	O
,	O
P	O
<	O
0	O
.	O
05	O
);	O
the	O
number	O
of	O
patients	O
with	O
oxygen	O
fractions	O
>	O
300	O
mmHg	O
after	O
5	O
days	O
PPV	O
was	O
65	O
(	O
83	O
.	O
3	O
%);	O
there	O
were	O
30	O
(	O
38	O
.	O
5	O
%)	O
patients	O
free	O
of	O
mechanical	O
ventilation	O
after	O
7	O
days	O
;	O
the	O
28	O
-	O
day	O
mortality	O
was	O
7	O
(	O
8	O
.	O
97	O
%).	O

CONCLUSIONS	O
:	O
Ulinastatin	B-PRGE
plus	O
octreotide	O
can	O
significantly	O
improve	O
the	O
serum	O
and	O
clinical	O
parameters	O
and	O
reduce	O
the	O
incidence	O
of	O
complications	O
in	O
SAP	O
patients	O
.	O

We	O
established	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
describing	O
the	O
important	O
ligand	O
-	O
based	O
features	O
required	O
for	O
potent	O
HKU4	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibition	O
and	O
identified	O
a	O
seemingly	O
favored	O
peptidic	O
backbone	O
for	O
HKU4	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibition	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
structural	O
reasons	O
for	O
such	O
potent	O
HKU4	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibition	O
by	O
the	O
peptidomimetics	O
having	O
the	O
22A	O
backbone	O
,	O
we	O
determined	O
the	O
X	O
-	O
ray	O
structures	O
of	O
HKU4	O
-	O
CoV	O
3CL	O
(	O
pro	B-PRGE
)	O
in	O
complex	O
with	O
three	O
peptidomimetic	O
inhibitors	O
.	O

TITLE	O
:	O
Treatment	O
With	O
Lopinavir	O
/	O
Ritonavir	O
or	O
Interferon	B-PRGE
-	I-PRGE
Î²1b	I-PRGE
Improves	O
Outcome	O
of	O
MERS	O
-	O
CoV	O
Infection	O
in	O
a	O
Nonhuman	O
Primate	O
Model	O
of	O
Common	O
Marmoset	O
.	O

In	O
contrast	O
,	O
all	O
MMF	O
-	O
treated	O
animals	O
developed	O
severe	O
and	O
/	O
or	O
fatal	O
disease	O
with	O
higher	O
mean	O
viral	O
loads	O
(â	O
0	O
.	O
15	O
-	O
0	O
.	O
54	O
log10	O
copies	O
/	O
GAPDH	B-PRGE
)	O
than	O
the	O
untreated	O
animals	O
.	O

BBB	O
breakdown	O
in	O
MHV3	O
infection	O
was	O
not	O
related	O
to	O
production	O
of	O
barrier	O
-	O
dysregulating	O
inflammatory	O
cytokines	O
or	O
chemokines	O
by	O
infected	O
BMECs	O
but	O
rather	O
to	O
a	O
downregulation	O
of	O
barrier	O
protective	O
beta	O
interferon	B-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
)	O
production	O
.	O

A	O
significant	O
increase	O
in	O
lachrymal	O
IgA	B-PRGE
levels	O
was	O
observed	O
at	O
4	O
doa	O
and	O
then	O
peaked	O
at	O
14	O
doa	O
in	O
the	O
vaccinated	O
groups	O
.	O

The	O
IgA	B-PRGE
levels	O
in	O
group	O
II	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
group	O
I	O
from	O
14	O
doa	O
.	O

ABSTRACT	O
:	O
Necrotizing	O
tracheobronchitis	O
due	O
to	O
Aspergillus	B-PRGE
spp	I-PRGE
is	O
a	O
rare	O
form	O
of	O
invasive	O
aspergillosis	O
.	O

Design	O
and	O
synthesis	O
of	O
quinoxalin	O
-	O
2	O
(	O
1H	O
)-	O
one	O
derivatives	O
as	O
new	O
non	O
-	O
nucleoside	B-PRGE
small	I-PRGE
-	I-PRGE
molecule	I-PRGE
HCV	I-PRGE
inhibitors	O
.	O

The	O
major	O
specific	O
technique	O
used	O
was	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
using	O
the	O
WHO	O
recommended	O
targets	O
upE	O
,	O
ORF1a	B-PRGE
and	I-PRGE
ORF1b	I-PRGE
.	O

TITLE	O
:	O
Quantitative	O
Proteomics	O
Identifies	O
Serum	B-PRGE
Response	I-PRGE
Factor	I-PRGE
Binding	O
Protein	B-PRGE
1	I-PRGE
as	O
a	O
Host	O
Factor	O
for	O
Hepatitis	O
C	O
Virus	O
Entry	O
.	O

ABSTRACT	O
:	O
Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
enters	O
human	O
hepatocytes	O
through	O
a	O
multistep	O
mechanism	O
involving	O
,	O
among	O
other	O
host	O
proteins	O
,	O
the	O
virus	B-PRGE
receptor	I-PRGE
CD81	I-PRGE
.	O

How	O
CD81	B-PRGE
governs	O
HCV	O
entry	O
is	O
poorly	O
characterized	O
,	O
and	O
CD81	B-PRGE
protein	I-PRGE
interactions	O
after	O
virus	O
binding	O
remain	O
elusive	O
.	O

However	O
,	O
the	O
balance	O
between	O
Wnt3a	B-PRGE
and	O
Wnt5a	B-PRGE
signaling	O
pathway	O
in	O
the	O
lung	O
of	O
rats	O
with	O
endotoxic	O
shock	O
has	O
not	O
been	O
determined	O
.	O

Thus	O
,	O
we	O
investigated	O
the	O
major	O
components	O
of	O
Wnt3a	B-PRGE
and	O
Wnt5a	B-PRGE
signaling	O
pathway	O
in	O
the	O
lung	O
of	O
endotoxemic	O
rats	O
.	O

At	O
6	O
h	O
after	O
saline	O
or	O
LPS	O
,	O
animals	O
were	O
sacrificed	O
,	O
and	O
lungs	O
were	O
obtained	O
for	O
analyzing	O
superoxide	O
production	O
,	O
water	O
accumulation	O
,	O
histologic	O
assessment	O
,	O
and	O
protein	O
expressions	O
of	O
Wnt3a	B-PRGE
and	O
Wnt5a	B-PRGE
signaling	O
pathway	O
.	O

Genetic	O
studies	O
on	O
MERS	O
-	O
CoV	O
have	O
shown	O
that	O
ORF1ab	O
encodes	O
replicase	B-PRGE
polyproteins	I-PRGE
and	O
play	O
a	O
foremost	O
role	O
in	O
viral	O
infection	O
.	O

The	O
possibility	O
of	O
vaccine	O
interference	O
after	O
simultaneous	O
combined	O
vaccination	O
with	O
Arkansas	O
(	O
Ark	B-PRGE
)	O
and	O
Massachusetts	O
(	O
Mass	O
)-	O
type	O
vaccines	O
was	O
evaluated	O
in	O
an	O
effort	O
to	O
explain	O
the	O
high	O
prevalence	O
of	O
Ark	O
-	O
type	O
infectious	O
bronchitis	O
virus	O
in	O
vaccinated	O
chickens	O
.	O

Viral	O
RNA	O
was	O
extracted	O
using	O
phenol	O
chloroform	O
and	O
subjected	O
to	O
nested	O
RT	O
-	O
PCR	O
targeting	O
a	O
393	O
bp	O
region	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
before	O
being	O
followed	O
by	O
sequencing	O
.	O

The	O
etiology	O
of	O
AEP	B-PRGE
is	O
unknown	O
,	O
though	O
many	O
drugs	O
have	O
been	O
implicated	O
,	O
including	O
minocycline	O
.	O

ABSTRACT	O
:	O
Immunoadhesins	O
are	O
recombinant	O
proteins	O
that	O
combine	O
the	O
ligand	O
-	O
binding	O
region	O
of	O
a	O
receptor	O
or	O
adhesion	O
molecule	O
with	O
immunoglobulin	B-PRGE
constant	O
domains	O
.	O

Pairwise	O
comparisons	O
were	O
performed	O
using	O
the	O
Clustal	O
W	O
program	O
,	O
revealing	O
90	O
.	O
0	O
%	O
to	O
98	O
.	O
4	O
%	O
sequence	O
identity	O
in	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
S	I-PRGE
protein	I-PRGE
,	O
77	O
.	O
6	O
%	O
to	O
96	O
.	O
6	O
%	O
in	O
the	O
amino	O
terminus	O
of	O
the	O
S1	O
subunit	O
(	O
containing	O
one	O
hypervariable	O
region	O
in	O
S1a	B-PRGE
),	O
and	O
92	O
.	O
1	O
%	O
to	O
99	O
.	O
3	O
%	O
in	O
the	O
S2	O
subunit	O
at	O
the	O
deduced	O
amino	O
acid	O
sequence	O
level	O
.	O

Gamma	B-PRGE
globulin	I-PRGE
was	O
given	O
for	O
7	O
days	O
(	O
20	O
g	O
,	O
qd	O
).	O

The	O
expression	O
of	O
ORF8	O
subgenomic	O
mRNA	O
suggested	O
that	O
the	O
ORF8	B-PRGE
protein	I-PRGE
may	O
be	O
functional	O
in	O
SARSr	O
-	O
Rf	O
-	O
BatCoVs	O
.	O

The	O
risk	O
of	O
MERS	O
death	O
in	O
Korea	O
was	O
consistent	O
with	O
published	O
CFR	B-PRGE
.	O

Here	O
we	O
determined	O
the	O
crystal	O
structure	O
of	O
MERS	O
-	O
CoV	O
RBD	O
bound	O
to	O
the	O
Fab	B-PRGE
fragment	I-PRGE
of	O
MERS	O
-	O
27	O
antibody	O
at	O
3	O
.	O
20	O
Ã	O
resolution	O
.	O

As	O
the	O
key	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
transcription	I-PRGE
factors	I-PRGE
,	O
we	O
found	O
that	O
dsRNA	O
-	O
induced	O
activation	O
of	O
IFN	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
3	I-PRGE
(	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
was	O
inhibited	O
after	O
PEDV	O
infection	O
,	O
but	O
not	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
kappaB	I-PRGE
(	O
NF	O
-	O
ÎºB	O
).	O

Taken	O
together	O
,	O
our	O
data	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
PEDV	O
infection	O
of	O
its	O
target	O
cell	O
line	O
,	O
IECs	O
,	O
inhibited	O
dsRNA	O
-	O
mediated	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
production	O
by	O
blocking	O
the	O
activation	O
of	O
IPS	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
-	O
mediated	O
pathway	O
.	O

In	O
the	O
upstream	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
TANK	B-PRGE
-	I-PRGE
binding	I-PRGE
kinase	I-PRGE
1	I-PRGE
(	O
TBK1	B-PRGE
)-	O
or	O
inhibitor	O
of	O
ÎºB	B-PRGE
kinase	I-PRGE
-	I-PRGE
Îµ	I-PRGE
(	O
IKKÎµ	O
)-	O
mediated	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
production	O
was	O
not	O
blocked	O
by	O
PEDV	O
,	O
while	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
-	O
and	O
its	O
adapter	O
molecule	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
promoter	I-PRGE
stimulator	I-PRGE
1	I-PRGE
(	O
IPS	B-PRGE
-	I-PRGE
1	I-PRGE
)-	O
mediated	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
production	O
were	O
completely	O
inhibited	O
after	O
PEDV	O
infection	O
.	O

Specifically	O
,	O
13	O
amino	O
acid	O
(	O
aa	O
)	O
positions	O
seemed	O
to	O
be	O
targets	O
of	O
selection	O
when	O
comparing	O
the	O
vaccine	O
genome	O
prior	O
to	O
and	O
after	O
seven	O
passages	O
in	O
CEK	B-PRGE
(	O
CEKp7	O
).	O

Based	O
on	O
these	O
data	O
,	O
it	O
appears	O
that	O
mechanical	O
damage	O
to	O
the	O
Ark	B-PRGE
-	O
DPI	O
vaccine	O
is	O
not	O
occurring	O
when	O
delivered	O
by	O
a	O
hatchery	O
spray	O
cabinet	O
,	O
suggesting	O
that	O
some	O
other	O
factor	O
is	O
contributing	O
to	O
the	O
failure	O
of	O
that	O
vaccine	O
when	O
given	O
by	O
that	O
method	O
.	O

To	O
identify	O
antigen	O
epitopes	O
with	O
specificity	O
for	O
PEDV	O
,	O
a	O
monoclonal	O
antibody	O
(	O
MAb	O
-	O
5E12	O
)	O
against	O
the	O
immunodominant	O
region	O
of	O
the	O
PEDV	B-PRGE
Spike	I-PRGE
protein	I-PRGE
(	O
S1	O
)	O
was	O
used	O
as	O
the	O
target	O
for	O
biopanning	O
a	O
12	O
-	O
mer	O
phage	O
display	O
,	O
random	O
peptide	O
library	O
.	O

In	O
combination	O
with	O
software	O
analysis	O
for	O
the	O
prediction	O
of	O
B	O
cell	O
epitopes	O
,	O
aa	O
201	O
-	O
212	O
exhibited	O
characteristics	O
of	O
a	O
linear	O
epitope	O
on	O
the	O
PEDV	B-PRGE
S1	I-PRGE
protein	I-PRGE
.	O

iNO	B-PRGE
and	O
iEPO	O
have	O
shown	O
similar	O
efficacy	O
profiles	O
;	O
however	O
,	O
they	O
differ	O
with	O
respect	O
to	O
cost	O
and	O
ease	O
of	O
therapeutic	O
administration	O
.	O

Non	B-PRGE
-	I-PRGE
structural	I-PRGE
protein	I-PRGE
3	I-PRGE
(	O
nsp3	B-PRGE
)	O
is	O
the	O
largest	O
nsp	O
in	O
the	O
coronavirus	O
genome	O
,	O
and	O
it	O
contains	O
multiple	O
functional	O
domains	O
that	O
are	O
required	O
for	O
coronavirus	O
replication	O
.	O

These	O
studies	O
extend	O
substantially	O
our	O
structural	O
knowledge	O
of	O
MHV	B-PRGE
nsp3	I-PRGE
,	O
providing	O
a	O
platform	O
for	O
further	O
investigation	O
of	O
the	O
role	O
of	O
nsp3	B-PRGE
domains	I-PRGE
in	O
MHV	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
This	O
research	O
aimed	O
to	O
develop	O
an	O
oral	O
vaccine	O
for	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
based	O
on	O
the	O
TGEV	B-PRGE
N	I-PRGE
gene	I-PRGE
expressed	O
in	O
an	O
attenuated	O
Salmonella	O
typhimurium	O
vector	O
and	O
aimed	O
to	O
evaluate	O
the	O
vaccine	O
'	O
s	O
immune	O
response	O
in	O
piglets	O
.	O

Humoral	O
(	O
neutralization	O
titer	O
and	O
specific	O
IgG	B-PRGE
),	O
cellular	O
(	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
Î³	B-PRGE
-	I-PRGE
interferon	I-PRGE
,	O
and	O
peripheral	O
lymphocyte	O
proliferation	O
),	O
and	O
mucosal	O
(	O
sIgA	B-PRGE
)	O
immune	O
responses	O
were	O
detected	O
and	O
evaluated	O
.	O

Furthermore	O
,	O
significant	O
downregulation	O
was	O
observed	O
as	O
early	O
as	O
10	O
min	O
after	O
trauma	O
for	O
cytokines	B-PRGE
and	I-PRGE
complement	I-PRGE
factors	I-PRGE
(	O
LCR	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
C4	O
)	O
as	O
well	O
as	O
for	O
intracellular	O
signaling	O
molecules	O
(	O
inhibitory	O
protein	O
phosphatase	O
)	O
and	O
ion	O
-	O
channels	O
(	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+)	O
channel	O
).	O

Both	O
groups	O
had	O
the	O
same	O
frequency	O
of	O
upper	O
respiratory	O
and	O
gastrointestinal	O
symptoms	O
and	O
had	O
the	O
same	O
incidence	O
of	O
admission	O
to	O
the	O
PICU	O
,	O
intravenous	O
immunoglobulin	B-PRGE
-	O
resistant	O
disease	O
,	O
and	O
coronary	O
artery	O
lesions	O
.	O

Both	O
of	O
the	O
methods	O
yielded	O
positive	O
results	O
for	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
.	O

Results	O
define	O
cellular	O
cyclophilin	B-PRGE
A	I-PRGE
as	O
a	O
host	O
target	O
for	O
inhibition	O
of	O
coronaviruses	O
ranging	O
from	O
relatively	O
mild	O
common	O
cold	O
to	O
highly	O
pathogenic	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
viruses	O
with	O
the	O
perspective	O
of	O
disclosing	O
non	O
-	O
immunosuppressive	O
cyclosporin	O
A	O
analogs	O
to	O
broadly	O
inactivate	O
the	O
coronavirus	O
family	O
.	O

Confocal	O
imaging	O
revealed	O
a	O
close	O
colocalization	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
ORF6	I-PRGE
protein	I-PRGE
with	O
NPIPB3	O
in	O
human	O
promonocytes	O
.	O

ABSTRACT	O
:	O
Nonstructural	B-PRGE
protein	I-PRGE
15	I-PRGE
(	O
nsp15	O
),	O
also	O
called	O
endoribonuclease	O
,	O
is	O
a	O
gene	O
product	O
of	O
open	O
reading	O
frame	O
1b	O
(	O
ORF	O
1b	O
)	O
in	O
coronaviruses	O
.	O

These	O
findings	O
strikingly	O
link	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
IC	I-PRGE
induced	O
ionic	O
disturbances	O
at	O
the	O
cell	O
level	O
to	O
immunopathological	O
consequences	O
and	O
disease	O
worsening	O
in	O
the	O
infected	O
organism	O
.	O

We	O
also	O
established	O
that	O
interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
induced	O
Siglec	B-PRGE
-	I-PRGE
E	I-PRGE
expression	O
and	O
Î±2	O
,	O
8	O
NANA	O
-	O
NP	O
further	O
augmented	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
.	O

Systematic	O
dissection	O
of	O
single	O
-	O
cycle	O
replication	O
revealed	O
that	O
ns12	B-PRGE
.	I-PRGE
9	I-PRGE
protein	I-PRGE
had	O
no	O
measurable	O
effect	O
on	O
virus	O
entry	O
,	O
subgenomic	O
mRNA	O
(	O
sgmRNA	O
)	O
synthesis	O
,	O
and	O
protein	O
expression	O
.	O

TITLE	O
:	O
The	O
detection	O
and	O
genetic	O
characterization	O
based	O
on	O
the	O
S1	B-PRGE
gene	I-PRGE
region	O
of	O
BCoVs	O
from	O
respiratory	O
and	O
enteric	O
infections	O
in	O
Turkey	O
.	O

The	O
partial	O
S1	B-PRGE
gene	I-PRGE
regions	O
of	O
BCoVs	O
(	O
An	O
-	O
4	O
and	O
An	O
-	O
11	O
)	O
detected	O
in	O
feces	O
samples	O
from	O
two	O
herd	O
-	O
mate	O
dairy	O
calves	O
were	O
compared	O
.	O

The	O
BNP	B-PRGE
level	O
may	O
be	O
of	O
value	O
in	O
evaluating	O
severity	O
and	O
prognosis	O
in	O
patients	O
with	O
ALI	O
/	O
ARDS	O
.	O

Comprehensive	O
studies	O
have	O
revealed	O
that	O
the	O
PEDV	O
virulent	O
strain	O
suppressed	O
protein	O
synthesis	O
of	O
Vero	O
cells	O
through	O
down	O
-	O
regulating	O
mTOR	B-PRGE
as	O
well	O
as	O
its	O
downstream	O
targets	O
4EBP1	B-PRGE
and	O
p70S6K	B-PRGE
activities	O
,	O
which	O
were	O
validated	O
by	O
immunoblotting	O
.	O

CONCLUSIONS	O
:	O
SAR	B-PRGE
for	O
laboratory	O
-	O
confirmed	O
influenza	O
in	O
South	O
Africa	O
was	O
higher	O
than	O
previously	O
reported	O
SARs	O
.	O

Further	O
work	O
has	O
shown	O
that	O
BST	B-PRGE
-	I-PRGE
2	I-PRGE
restricts	O
the	O
release	O
of	O
many	O
other	O
viruses	O
,	O
including	O
the	O
human	O
coronavirus	O
229E	O
(	O
hCoV	O
-	O
229E	O
),	O
and	O
the	O
genomes	O
of	O
many	O
of	O
these	O
viruses	O
encode	O
BST	B-PRGE
-	I-PRGE
2	I-PRGE
antagonists	O
to	O
overcome	O
BST	O
-	O
2	O
restriction	O
.	O

The	O
mean	O
duration	O
of	O
PMX	B-PRGE
-	I-PRGE
DHP	I-PRGE
therapy	O
was	O
15	O
.	O
8	O
Â±	O
7	O
.	O
9	O
h	O
,	O
and	O
none	O
of	O
the	O
patients	O
developed	O
adverse	O
events	O
,	O
which	O
enabled	O
the	O
therapy	O
to	O
be	O
performed	O
safely	O
.	O

Up	O
-	O
regulations	O
of	O
both	O
pro	O
-	O
apoptotic	O
(	O
i	O
.	O
e	O
.	O
PDCD5	O
)	O
and	O
anti	O
-	O
apoptotic	O
(	O
i	O
.	O
e	O
.	O
TRAF2	B-PRGE
)	O
were	O
detected	O
from	O
first	O
hpi	O
and	O
continuing	O
to	O
deregulate	O
during	O
apoptosis	O
process	O
in	O
the	O
infected	O
cells	O
.	O

Based	O
on	O
the	O
structure	O
,	O
we	O
further	O
humanized	O
4C2	O
by	O
preserving	O
only	O
the	O
paratope	O
residues	O
and	O
substituting	O
the	O
remaining	O
amino	O
acids	O
with	O
the	O
counterparts	O
from	O
human	B-PRGE
immunoglobulins	I-PRGE
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
directed	O
inhibition	O
of	O
a	O
single	O
inducible	O
phospholipase	O
,	O
PLA2G2D	B-PRGE
,	O
in	O
the	O
lungs	O
of	O
older	O
patients	O
with	O
severe	O
respiratory	O
infections	O
is	O
potentially	O
an	O
attractive	O
therapeutic	O
intervention	O
to	O
restore	O
immune	O
function	O
.	O

This	O
study	O
demonstrates	O
that	O
the	O
gammacoronavirus	O
IBV	O
,	O
similar	O
to	O
its	O
mammalian	O
counterparts	O
,	O
has	O
evolved	O
multiple	O
strategies	O
to	O
efficiently	O
counteract	O
the	O
IFN	B-PRGE
response	O
of	O
its	O
avian	O
host	O
,	O
and	O
it	O
identifies	O
accessory	B-PRGE
protein	I-PRGE
3a	I-PRGE
as	O
multifaceted	O
antagonist	O
of	O
the	O
avian	B-PRGE
IFN	I-PRGE
system	O
.	O

Mice	O
deficient	O
in	O
MDA5	B-PRGE
expression	O
(	O
MDA5	B-PRGE
(-/-)	O
mice	O
)	O
experienced	O
more	O
severe	O
disease	O
following	O
MHV	O
infection	O
,	O
with	O
reduced	O
survival	O
,	O
increased	O
spread	O
of	O
virus	O
to	O
additional	O
sites	O
of	O
infection	O
,	O
and	O
more	O
extensive	O
liver	O
damage	O
than	O
did	O
wild	O
-	O
type	O
mice	O
.	O

Although	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
transcription	O
decreased	O
in	O
MDA5	O
(-/-)	O
mice	O
,	O
the	O
interferon	B-PRGE
-	O
stimulated	O
gene	O
response	O
remained	O
intact	O
.	O

Viral	O
replication	O
in	O
the	O
liver	O
was	O
similar	O
in	O
mice	O
with	O
and	O
without	O
MDA5	B-PRGE
,	O
but	O
liver	O
damage	O
was	O
increased	O
in	O
MDA5	B-PRGE
(-/-)	O
mice	O
,	O
suggesting	O
that	O
the	O
immune	O
response	O
is	O
causing	O
the	O
damage	O
.	O

STAT1	B-PRGE
,	O
NS2	B-PRGE
,	O
CD5	B-PRGE
,	O
NCKX6	B-PRGE
and	O
PDGFB	B-PRGE
were	O
significant	O
DEPs	O
in	O
these	O
GO	O
terms	O
.	O

In	O
conclusion	O
,	O
the	O
observations	O
of	O
impaired	O
lytic	O
activity	O
and	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
production	O
by	O
NK	O
cells	O
in	O
suckling	O
pigs	O
coincided	O
with	O
the	O
increased	O
severity	O
of	O
PEDV	O
infection	O
in	O
the	O
suckling	O
pigs	O
compared	O
with	O
the	O
weaned	O
pigs	O
.	O

ABSTRACT	O
:	O
The	O
oral	O
drug	O
FTY720	O
affects	O
sphingosine	O
-	O
1	O
-	O
phosphate	O
(	O
S1P	B-PRGE
)	O
signaling	O
on	O
targeted	O
cells	O
that	O
bear	O
the	O
S1P	B-PRGE
receptors	I-PRGE
S1P1	I-PRGE
,	O
S1P3	B-PRGE
,	O
S1P4	B-PRGE
,	O
and	O
S1P5	B-PRGE
.	O

Cultured	O
NPCs	O
expressed	O
transcripts	O
for	O
S1P	B-PRGE
receptors	I-PRGE
S1P1	I-PRGE
,	O
S1P2	B-PRGE
,	O
S1P3	B-PRGE
,	O
S1P4	B-PRGE
,	O
and	O
S1P5	B-PRGE
.	O

FTY720	O
treatment	O
of	O
cultured	O
NPCs	O
resulted	O
in	O
increased	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
phosphorylation	O
and	O
migration	O
after	O
exposure	O
to	O
the	O
chemokine	O
CXCL12	O
.	O

TITLE	O
:	O
SiaÎ±2	B-PRGE
-	I-PRGE
3GalÎ²1	I-PRGE
-	I-PRGE
Receptor	I-PRGE
Genetic	O
Variants	O
Are	O
Associated	O
with	O
Influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
Severity	O
.	O

This	O
study	O
demonstrated	O
for	O
the	O
first	O
time	O
the	O
association	O
of	O
ST3GAL1	B-PRGE
gene	I-PRGE
haplotypes	O
on	O
the	O
risk	O
of	O
more	O
severe	O
disease	O
and	O
death	O
in	O
patients	O
infected	O
with	O
Influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
virus	O
.	O

Here	O
,	O
we	O
further	O
characterized	O
a	O
lethal	O
transgenic	O
mouse	O
model	O
of	O
MERS	O
-	O
CoV	O
infection	O
and	O
disease	O
that	O
globally	O
expresses	O
human	B-PRGE
CD26	I-PRGE
(	O
hCD26	O
)/	O
DPP4	B-PRGE
.	O

Cold	O
medicines	O
including	O
nonsteroidal	O
antiinflammatory	O
drugs	O
,	O
which	O
are	O
the	O
main	O
causative	O
drugs	O
for	O
SJS	B-PRGE
/	O
TEN	B-PRGE
with	O
SOCs	B-PRGE
,	O
downregulate	O
the	O
production	O
of	O
prostanoids	O
,	O
including	O
PGE2	O
.	O

The	O
plot	O
of	O
Nc	O
values	O
against	O
GC3	O
as	O
well	O
as	O
the	O
correlation	O
between	O
base	O
composition	O
and	O
codon	O
usage	O
bias	O
suggest	O
that	O
mutational	O
pressure	O
rather	O
than	O
natural	O
selection	O
is	O
the	O
main	O
factor	O
that	O
determines	O
the	O
codon	O
usage	O
bias	O
in	O
the	O
S	B-PRGE
gene	I-PRGE
.	O

Serum	O
levels	O
of	O
alanine	B-PRGE
aminotransferase	I-PRGE
,	O
aspartate	B-PRGE
aminotransferase	I-PRGE
and	O
total	O
bilirubin	O
increased	O
,	O
accompanied	O
by	O
massive	O
hepatocyte	O
necrosis	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Causes	O
Multiple	O
Organ	O
Damage	O
and	O
Lethal	O
Disease	O
in	O
Mice	O
Transgenic	O
for	O
Human	B-PRGE
Dipeptidyl	I-PRGE
Peptidase	I-PRGE
4	I-PRGE
.	O

The	O
infection	O
of	O
target	O
cells	O
by	O
the	O
SARS	B-PRGE
CoV	I-PRGE
is	O
mediated	O
through	O
the	O
interaction	O
of	O
the	O
viral	O
Spike	O
(	O
S	O
)	O
protein	O
(	O
1255	O
amino	O
acids	O
)	O
and	O
its	O
cellular	O
receptor	O
,	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
).	O

40	O
amino	O
acids	O
)	O
that	O
can	O
bind	O
both	O
the	O
ACE2	B-PRGE
receptor	I-PRGE
and	O
the	O
neutralizing	O
mAb	O
80R	O
.	O

We	O
show	O
that	O
there	O
is	O
markedly	O
reduced	O
expression	O
of	O
E1B	B-PRGE
20K	I-PRGE
in	O
Ad14p1	O
-	O
infected	O
human	O
cells	O
and	O
that	O
this	O
causes	O
an	O
increased	O
proinflammatory	O
cytokine	O
response	O
of	O
human	O
alveolar	O
macrophages	O
and	O
more	O
severe	O
inflammatory	O
lung	O
disease	O
in	O
infected	O
hamsters	O
.	O

TITLE	O
:	O
Combination	O
therapy	O
with	O
lopinavir	O
/	O
ritonavir	O
,	O
ribavirin	O
and	O
interferon	B-PRGE
-	I-PRGE
Î±	I-PRGE
for	O
Middle	O
East	O
respiratory	O
syndrome	O
.	O

The	O
combination	O
of	O
ribavirin	O
and	O
interferon	B-PRGE
-	I-PRGE
Î±	I-PRGE
has	O
been	O
the	O
most	O
widely	O
used	O
therapy	O
for	O
this	O
infection	O
.	O

The	O
only	O
previous	O
study	O
focusing	O
on	O
the	O
in	O
vitro	O
activity	O
of	O
nsp9	O
of	O
an	O
arterivirus	O
(	O
equine	O
arteritis	O
virus	O
;	O
EAV	O
)	O
reported	O
weak	O
de	O
novo	B-PRGE
polymerase	I-PRGE
activity	O
on	O
homopolymeric	O
RNA	O
templates	O
.	O

RT	O
-	O
Bst	B-PRGE
PCR	O
was	O
shown	O
to	O
have	O
particular	O
utility	O
in	O
the	O
detection	O
of	O
RSV	B-PRGE
RNA	I-PRGE
as	O
this	O
was	O
present	O
in	O
20	O
%	O
of	O
the	O
samples	O
studied	O
compared	O
to	O
8	O
%	O
when	O
using	O
RT	O
-	O
PCR	O
.	O

The	O
sugar	O
recognition	O
properties	O
of	O
C3	B-PRGE
-	I-PRGE
symmetrical	I-PRGE
TAZ	I-PRGE
derivative	I-PRGE
4e	I-PRGE
are	O
also	O
described	O
.	O

One	O
single	O
-	O
nucleotide	O
polymorphism	O
from	O
IL4	B-PRGE
gene	I-PRGE
was	O
significant	O
for	O
pooled	O
respiratory	O
infections	O
(	O
rs2070874	O
;	O
1	O
.	O
66	O
[	O
1	O
.	O
29	O
-	O
2	O
.	O
14	O
]).	O

Interaction	O
of	O
integrin	B-PRGE
receptors	I-PRGE
with	O
targeted	O
liposomes	O
was	O
assumed	O
to	O
contribute	O
to	O
intense	O
NIRF	B-PRGE
signal	O
.	O

CAT	B-PRGE
score	O
may	O
be	O
a	O
predictor	O
of	O
longer	O
LOS	O
in	O
AECOPD	O
.	O

The	O
duplex	O
UNDP	O
-	O
PCR	O
showed	O
similar	O
sensitivity	O
as	O
that	O
of	O
single	O
UNDP	O
-	O
PCR	O
and	O
was	O
able	O
to	O
detect	O
20	O
copies	O
each	O
of	O
PCV2	O
and	O
TGEV	O
in	O
the	O
serum	O
,	O
showing	O
approximately	O
250	O
-	O
fold	O
more	O
sensitivity	O
than	O
conventional	O
duplex	O
PCR	B-PRGE
/	O
RT	O
-	O
PCR	O
assays	O
.	O

Similar	O
to	O
other	O
knottins	O
,	O
cystine	O
knot	O
Î±	O
-	O
amylase	B-PRGE
inhibitors	O
are	O
highly	O
resistant	O
to	O
degradation	O
by	O
heat	B-PRGE
and	I-PRGE
protease	I-PRGE
treatments	O
.	O

Immunoglobulin	B-PRGE
M	O
detection	O
provided	O
no	O
advantage	O
in	O
sensitivity	O
over	O
immunoglobulin	B-PRGE
G	I-PRGE
(	O
IgG	B-PRGE
)	O
detection	O
.	O

All	O
surviving	O
patients	O
,	O
but	O
only	O
slightly	O
more	O
than	O
half	O
of	O
all	O
fatal	O
cases	O
,	O
produced	O
IgG	B-PRGE
and	O
neutralizing	O
antibodies	O
.	O

ABSTRACT	O
:	O
Design	O
of	O
inhibitors	O
against	O
severe	B-PRGE
acute	I-PRGE
respiratory	I-PRGE
syndrome	I-PRGE
(	O
SARS	B-PRGE
)	O
chymotrypsin	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CL	O
(	O
pro	O
)	O
)	O
is	O
a	O
potentially	O
important	O
approach	O
to	O
fight	O
against	O
SARS	O
.	O

This	O
is	O
the	O
first	O
report	O
describing	O
direct	O
visualization	O
of	O
interactions	O
among	O
accessory	O
proteins	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
These	O
findings	O
attest	O
to	O
the	O
general	O
applicability	O
of	O
the	O
BiFC	O
system	O
for	O
the	O
verification	O
of	O
protein	O
-	O
protein	O
interactions	O
.	O

This	O
astrocytic	O
reactivity	O
was	O
associated	O
with	O
areas	O
of	O
granulomatous	O
or	O
pyogranulomatous	O
vasculitis	O
/	O
perivasculitis	O
in	O
most	O
cases	O
,	O
and	O
it	O
was	O
characterized	O
by	O
multifocal	O
to	O
coalescing	O
astrocytosis	O
and	O
astrogliosis	O
with	O
an	O
increase	O
in	O
the	O
expression	O
of	O
intermediate	O
filaments	O
,	O
such	O
as	O
GFAP	B-PRGE
.	O

The	O
present	O
study	O
indicates	O
a	O
strong	O
astrocytic	O
response	O
,	O
including	O
the	O
presence	O
of	O
many	O
less	O
differentiated	O
vimentin	B-PRGE
-	O
positive	O
astrocytes	O
and	O
gitter	O
cells	O
positive	O
for	O
RCA	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
severe	O
lesions	O
in	O
the	O
CNS	O
of	O
cats	O
with	O
FIP	O
.	O

A	O
prospective	O
randomized	O
trial	O
using	O
features	O
of	O
macrophage	O
activation	O
syndrome	O
for	O
mortality	O
risk	O
stratification	O
should	O
be	O
undertaken	O
to	O
confirm	O
the	O
role	O
of	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
blockage	O
.	O

TITLE	O
:	O
X	O
-	O
ray	O
structure	O
and	O
inhibition	O
of	O
the	O
feline	O
infectious	O
peritonitis	B-PRGE
virus	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
:	O
Structural	O
implications	O
for	O
drug	O
design	O
.	O

We	O
investigated	O
the	O
spatial	O
and	O
cellular	O
localization	O
of	O
DPP4	B-PRGE
to	O
evaluate	O
an	O
association	O
MERS	O
clinical	O
disease	O
.	O

We	O
speculate	O
that	O
the	O
preferential	O
spatial	O
localization	O
of	O
DPP4	B-PRGE
in	O
alveolar	O
regions	O
may	O
explain	O
why	O
MERS	O
is	O
characterized	O
by	O
lower	O
respiratory	O
tract	O
disease	O
.	O

The	O
whole	O
genome	O
sequencing	O
of	O
SDZB0808	O
of	O
different	O
generations	O
(	O
P1	O
-	O
P110	O
)	O
indicated	O
that	O
the	O
replicase	B-PRGE
1a	I-PRGE
sequences	I-PRGE
of	O
P60	B-PRGE
-	O
P110	B-PRGE
all	O
lost	O
a	O
length	O
of	O
30bp	O
in	O
the	O
same	O
region	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
after	O
2	O
days	O
of	O
initial	O
PBMC	O
/	O
EPO	B-PRGE
application	O
,	O
lung	O
function	O
improved	O
and	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
support	O
was	O
reduced	O
.	O

The	O
PaO2	O
/	O
FiO2	O
ratio	O
increased	O
significantly	O
in	O
RM1	B-PRGE
and	O
RM3	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
viral	O
clearance	O
,	O
type	B-PRGE
-	I-PRGE
I	I-PRGE
interferon	I-PRGE
production	O
,	O
and	O
the	O
development	O
of	O
anti	O
-	O
viral	O
B	O
and	O
T	O
cell	O
immunity	O
were	O
not	O
compromised	O
by	O
CARD9	B-PRGE
deficiency	O
.	O

Syk	B-PRGE
or	O
CARD9	B-PRGE
-	O
deficient	O
DCs	O
but	O
not	O
macrophages	O
showed	O
impaired	O
cytokine	O
but	O
not	O
type	B-PRGE
-	I-PRGE
I	I-PRGE
interferon	I-PRGE
production	O
in	O
response	O
to	O
IFV	O
in	O
vitro	O
,	O
indicating	O
a	O
possible	O
role	O
for	O
the	O
Syk	B-PRGE
-	O
CARD9	B-PRGE
pathway	O
in	O
DCs	O
in	O
excessive	O
inflammation	O
of	O
IFV	O
-	O
infected	O
lungs	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
the	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
antagonism	O
mechanism	O
of	O
MERS	O
-	O
CoV	O
ORF4b	O
.	O

We	O
propose	O
a	O
simple	O
clinical	O
risk	O
score	O
for	O
early	O
identification	O
of	O
ACP	B-PRGE
that	O
could	O
trigger	O
specific	O
therapeutic	O
strategies	O
to	O
reduce	O
RV	O
afterload	O
.	O

Our	O
study	O
provides	O
new	O
insight	O
into	O
the	O
pharmaceutical	O
strategy	O
against	O
CoV	B-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
through	O
using	O
zinc	O
as	O
an	O
adjuvant	O
therapy	O
to	O
enhance	O
the	O
efficacy	O
of	O
an	O
irreversible	O
peptidomimetic	O
inhibitor	O
.	O

The	O
ability	O
to	O
circumvent	O
the	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
antiviral	O
response	O
,	O
as	O
suggested	O
for	O
PEDV	O
,	O
promotes	O
viral	O
survival	O
and	O
regulates	O
pathogenesis	O
of	O
PEDV	O
infections	O
,	O
but	O
the	O
underlying	O
mechanisms	O
remain	O
obscure	O
.	O

Mutations	O
specifically	O
disrupting	O
the	O
cysteine	B-PRGE
protease	I-PRGE
activity	O
of	O
PEDV	B-PRGE
nsp5	I-PRGE
abrogated	O
NEMO	B-PRGE
cleavage	O
and	O
the	O
inhibition	O
of	O
IFN	B-PRGE
induction	O
.	O

Plasma	B-PRGE
Ang	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
von	B-PRGE
Willebrand	I-PRGE
Factor	I-PRGE
antigen	I-PRGE
(	O
vWF	B-PRGE
),	O
and	O
vascular	B-PRGE
endothelial	I-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
VEGF	B-PRGE
)	O
were	O
measured	O
on	O
ARDS	O
days	O
1	O
and	O
3	O
and	O
correlated	O
with	O
patient	O
outcomes	O
.	O

Here	O
we	O
demonstrated	O
that	O
genetic	O
silencing	O
or	O
knockout	O
of	O
Pin1	B-PRGE
resulted	O
in	O
decreased	O
FCoV	O
replication	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Glucose	B-PRGE
-	I-PRGE
6	I-PRGE
-	I-PRGE
phosphate	I-PRGE
dehydrogenase	I-PRGE
(	O
G6PD	B-PRGE
)-	O
deficient	O
cells	O
are	O
highly	O
susceptible	O
to	O
viral	O
infection	O
.	O

This	O
study	O
examined	O
the	O
mechanism	O
underlying	O
this	O
phenomenon	O
by	O
measuring	O
the	O
expression	O
of	O
antiviral	O
genes	O
-	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
)	O
and	O
GTPase	O
myxovirus	O
resistance	O
1	O
(	O
MX1	B-PRGE
)-	O
in	O
G6PD	O
-	O
knockdown	O
cells	O
upon	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
enterovirus	O
71	O
(	O
EV71	O
)	O
infection	O
.	O

Molecular	O
analysis	O
revealed	O
that	O
the	O
promoter	O
activities	O
of	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
and	O
MX1	B-PRGE
were	O
downregulated	O
in	O
G6PD	O
-	O
knockdown	O
cells	O
,	O
and	O
that	O
the	O
IÎºB	O
degradation	O
and	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
ÎºB	O
were	O
decreased	O
.	O

Quantitative	O
real	O
-	O
time	O
PCR	O
data	O
revealed	O
the	O
inhibitory	O
effect	O
of	O
2	O
on	O
genes	O
encoding	O
essential	O
structural	O
proteins	O
(	O
GP6	B-PRGE
nucleocapsid	I-PRGE
,	O
GP2	B-PRGE
spike	O
,	O
and	O
GP5	B-PRGE
membrane	O
)	O
for	O
PEDV	O
replication	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

TITLE	O
:	O
Multi	O
-	O
Organ	O
Damage	O
in	O
Human	B-PRGE
Dipeptidyl	I-PRGE
Peptidase	I-PRGE
4	I-PRGE
Transgenic	O
Mice	O
Infected	O
with	O
Middle	O
East	O
Respiratory	O
Syndrome	O
-	O
Coronavirus	O
.	O

The	O
role	O
of	O
ribavirin	O
and	O
interferon	B-PRGE
warrants	O
urgent	O
further	O
evaluation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
use	O
of	O
a	O
combined	O
reverse	B-PRGE
transcriptase	I-PRGE
nested	O
polymerase	O
chain	O
reaction	O
(	O
RT	B-PRGE
-	I-PRGE
nPCR	I-PRGE
)	O
and	O
sequencing	O
approach	O
in	O
the	O
diagnosis	O
of	O
FIP	O
,	O
detecting	O
mutations	O
at	O
two	O
different	O
nucleotide	O
positions	O
within	O
the	O
spike	O
(	O
S	O
)	O
gene	O
.	O

Serum	O
/	O
plasma	O
and	O
/	O
or	O
effusion	O
samples	O
of	O
these	O
cats	O
were	O
examined	O
for	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
RNA	O
by	O
RT	O
-	O
nPCR	O
and	O
,	O
if	O
positive	O
,	O
PCR	O
products	O
were	O
sequenced	O
for	O
nucleotide	O
transitions	O
within	O
the	O
S	B-PRGE
gene	I-PRGE
.	O

Conclusions	O
and	O
relevance	O
A	O
positive	O
result	O
is	O
highly	O
indicative	O
of	O
the	O
presence	O
of	O
FIP	B-PRGE
,	O
but	O
as	O
none	O
of	O
the	O
control	O
cats	O
tested	O
positive	O
by	O
RT	B-PRGE
-	I-PRGE
nPCR	I-PRGE
,	O
it	O
was	O
not	O
possible	O
to	O
confirm	O
that	O
the	O
FCoV	O
mutant	O
described	O
can	O
only	O
be	O
found	O
in	O
cats	O
with	O
FIP	O
.	O

MS2	B-PRGE
virus	I-PRGE
-	I-PRGE
like	I-PRGE
particles	I-PRGE
(	O
VLPs	O
)	O
encapsulating	O
specific	O
RNA	O
sequences	O
of	O
MERS	O
-	O
CoV	O
were	O
prepared	O
as	O
positive	O
specimens	O
.	O

While	O
the	O
disease	O
was	O
seldom	O
reported	O
in	O
Europe	O
within	O
the	O
last	O
few	O
decades	O
,	O
a	O
few	O
recent	O
reports	O
re	O
-	O
emergence	O
of	O
PED	B-PRGE
in	O
German	O
pig	O
farms	O
.	O

H9N2	O
infection	O
rapidly	O
triggered	O
the	O
activation	O
of	O
innate	O
immunity	O
through	O
phosphorylation	O
of	O
signaling	O
molecules	O
including	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinases	I-PRGE
(	O
MAPKs	O
)	O
and	O
signal	B-PRGE
transducer	I-PRGE
and	I-PRGE
activator	I-PRGE
of	I-PRGE
transcription	I-PRGE
(	O
STAT	O
)	O
proteins	O
.	O

PDE	B-PRGE
activity	O
is	O
required	O
for	O
robust	O
replication	O
in	O
myeloid	O
cells	O
,	O
as	O
a	O
mutant	O
of	O
MHV	O
(	O
ns2	O
(	O
H126R	O
))	O
encoding	O
an	O
inactive	O
PDE	O
fails	O
to	O
antagonize	O
RNase	B-PRGE
L	I-PRGE
activation	O
and	O
replicates	O
poorly	O
in	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
(	O
BMM	O
),	O
while	O
ns2	O
(	O
H126R	O
)	O
replicates	O
to	O
high	O
titer	O
in	O
several	O
types	O
of	O
nonmyeloid	O
cells	O
,	O
as	O
well	O
as	O
in	O
IFN	B-PRGE
receptor	I-PRGE
-	O
deficient	O
(	O
Ifnar1	O
(-/-))	O
BMM	O
.	O

However	O
,	O
ns2	B-PRGE
(	O
H126R	O
)	O
failed	O
to	O
induce	O
RNase	B-PRGE
L	I-PRGE
activation	O
in	O
BMM	O
treated	O
with	O
IFNAR1	B-PRGE
-	I-PRGE
blocking	I-PRGE
antibody	I-PRGE
,	O
as	O
well	O
as	O
in	O
Ifnar1	O
(-/-)	O
BMM	O
,	O
both	O
expressing	O
low	O
basal	O
levels	O
of	O
Oas	O
genes	O
.	O

ABSTRACT	O
:	O
Prior	O
studies	O
have	O
demonstrated	O
that	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
A59	O
strain	O
ns2	O
protein	O
is	O
a	O
member	O
of	O
the	O
2H	B-PRGE
phosphoesterase	I-PRGE
family	I-PRGE
and	O
exhibits	O
2	O
',	O
5	O
'-	O
phosphodiesterase	O
(	O
PDE	O
)	O
activity	O
.	O

Sustained	O
CXCL1	B-PRGE
expression	O
within	O
the	O
CNS	O
resulted	O
in	O
increased	O
mortality	O
that	O
correlated	O
with	O
elevated	O
neutrophil	O
infiltration	O
,	O
diminished	O
numbers	O
of	O
mature	O
oligodendrocytes	O
,	O
and	O
an	O
increase	O
in	O
the	O
severity	O
of	O
demyelination	O
.	O

Neutrophil	O
ablation	O
in	O
CXCL1	B-PRGE
-	O
transgenic	O
mice	O
reduced	O
the	O
severity	O
of	O
demyelination	O
in	O
mice	O
,	O
arguing	O
for	O
a	O
role	O
for	O
these	O
cells	O
in	O
white	O
matter	O
damage	O
.	O

Of	O
16	O
PEDV	O
nonstructural	O
proteins	O
(	O
nsps	O
),	O
nsp1	B-PRGE
,	O
nsp3	B-PRGE
,	O
nsp7	O
,	O
nsp14	O
,	O
nsp15	O
and	O
nsp16	O
were	O
found	O
to	O
inhibit	O
the	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
and	O
IRF3	B-PRGE
promoter	I-PRGE
activities	O
.	O

PEDV	B-PRGE
nsp1	I-PRGE
did	O
not	O
interfere	O
the	O
IRF3	B-PRGE
phosphorylation	O
and	O
nuclear	O
translocation	O
but	O
interrupted	O
the	O
enhanceosome	O
assembly	O
of	O
IRF3	B-PRGE
and	O
CREB	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
CBP	B-PRGE
)	O
by	O
degrading	O
CBP	B-PRGE
.	O

Selected	O
sites	O
were	O
unevenly	O
distributed	O
,	O
with	O
nsp3	B-PRGE
representing	O
the	O
preferential	O
target	O
.	O

The	O
in	O
vitro	O
surface	O
activity	O
and	O
inhibition	O
resistance	O
of	O
synthetic	O
S	O
-	O
MB	O
DATK	O
surfactant	O
was	O
assessed	O
in	O
the	O
presence	O
and	O
absence	O
of	O
albumin	B-PRGE
,	O
lysophosphatidylcholine	O
(	O
lyso	O
-	O
PC	O
),	O
and	O
free	O
fatty	O
acids	O
(	O
palmitoleic	O
and	O
oleic	O
acid	O
).	O

An	O
intense	O
immunoreaction	O
for	O
FIV	B-PRGE
antigen	I-PRGE
in	O
the	O
cytoplasm	O
and	O
nucleus	O
of	O
lymphocytes	O
and	O
the	O
cytoplasm	O
of	O
some	O
macrophages	O
was	O
observed	O
via	O
immunohistochemistry	O
(	O
IHC	O
).	O

We	O
report	O
on	O
the	O
mechanisms	O
of	O
allosteric	O
inhibition	O
of	O
a	O
newly	O
synthesized	O
isatin	O
-	O
based	O
compound	O
designated	O
as	O
RMNC6	O
that	O
showed	O
IC50	O
values	O
of	O
1	O
.	O
4	O
and	O
9	O
.	O
8	O
Î¼M	O
on	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNase	B-PRGE
H	I-PRGE
and	O
polymerase	O
activities	O
,	O
respectively	O
.	O

The	O
other	O
four	O
coinfections	O
were	O
caused	O
by	O
:	O
adenovirus	O
and	O
hCoVOC43	O
,	O
adenovirus	O
,	O
and	O
rhinovirus	O
,	O
RSV	O
A	O
and	O
PIV	O
-	O
1	O
,	O
influenza	O
B	O
,	O
and	O
RSV	B-PRGE
B	I-PRGE
.	O
We	O
did	O
not	O
observe	O
any	O
significant	O
differences	O
in	O
the	O
clinical	O
course	O
of	O
infections	O
caused	O
either	O
by	O
a	O
single	O
or	O
multiple	O
viral	O
factors	O
.	O

Soon	O
after	O
the	O
deadly	O
disease	O
outbreak	O
,	O
the	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
was	O
identified	O
as	O
a	O
functional	O
cellular	O
receptor	O
in	O
vitro	O
and	O
in	O
vivo	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
value	O
of	O
serum	B-PRGE
cholinesterase	I-PRGE
(	O
S	B-PRGE
-	I-PRGE
ChE	I-PRGE
)	O
levels	O
in	O
judgment	O
of	O
severity	O
and	O
prognosis	O
in	O
patients	O
with	O
severe	O
pneumonia	O
.	O

Lab	B-PRGE
data	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
score	O
,	O
the	O
improved	O
pneumonia	O
score	O
of	O
British	O
Thoracic	O
Society	O
(	O
confusion	O
,	O
uremia	O
,	O
respiratory	O
,	O
blood	O
pressure	O
,	O
age	O
65	O
years	O
,	O
CURB	O
-	O
65	O
),	O
and	O
S	O
-	O
ChE	O
levels	O
of	O
all	O
patients	O
were	O
collected	O
after	O
they	O
were	O
hospitalized	O
into	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
within	O
24	O
hours	O
.	O

We	O
also	O
limited	O
tidal	O
volume	O
to	O
keep	O
Ptp	B-PRGE
at	O
less	O
than	O
25	O
cm	O
of	O
water	O
at	O
end	O
inspiration	O
.	O

Compared	O
with	O
baseline	O
,	O
after	O
guiding	O
MV	O
with	O
Ptp	O
,	O
the	O
Level	O
of	O
PEEP	O
(	O
14	O
.	O
6	O
Â±	O
4	O
.	O
2	O
)	O
cmH2O	O
vs	O
(	O
8	O
.	O
3	O
Â±	O
2	O
.	O
0	O
)	O
cmH2O	O
,	O
and	O
Ptp	O
-	O
e	O
(	O
1	O
.	O
5	O
Â±	O
0	O
.	O
5	O
)	O
cmH2O	O
vs	O
(-	O
2	O
.	O
3	O
Â±	O
1	O
.	O
4	O
)	O
cmH2O	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
Ptp	B-PRGE
-	I-PRGE
i	I-PRGE
did	O
not	O
increase	O
significantly	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

The	O
isolated	O
viruses	O
were	O
characterized	O
by	O
RT	O
-	O
PCR	O
amplification	O
and	O
sequencing	O
of	O
the	O
partial	O
polymerase	B-PRGE
(	O
pol	B-PRGE
)	O
gene	O
.	O

In	O
addition	O
,	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
the	O
activity	O
of	O
myeloperoxidase	B-PRGE
in	O
pulmonary	O
tissues	O
were	O
notably	O
repressed	O
.	O

Importantly	O
,	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
kappaB	I-PRGE
(	O
NF	O
-	O
ÎºB	O
)	O
activation	O
was	O
attenuated	O
.	O

Alveolar	O
epithelial	O
injury	O
after	O
LPS	O
was	O
more	O
severe	O
in	O
smokers	O
than	O
non	O
-	O
smokers	O
,	O
with	O
increased	O
plasma	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
decreased	O
BAL	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
surfactant	O
protein	O
D	O
.	O
Finally	O
,	O
smokers	O
had	O
decreased	O
BAL	B-PRGE
vascular	B-PRGE
endothelial	I-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
VEGF	B-PRGE
)	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
with	O
increased	O
soluble	O
VEGF	B-PRGE
receptor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
p	O
=	O
0	O
.	O
0001	O
).	O

This	O
anti	B-PRGE
-	I-PRGE
fTNF	I-PRGE
-	I-PRGE
alpha	I-PRGE
mAb	I-PRGE
2	I-PRGE
-	I-PRGE
4	I-PRGE
was	O
confirmed	O
to	O
inhibit	O
the	O
following	O
fTNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
conditions	O
in	O
vitro	O
.	O

Moreover	O
,	O
troponin	B-PRGE
release	O
can	O
be	O
related	O
to	O
right	O
ventricular	O
dysfunction	O
,	O
thus	O
highlighting	O
the	O
clinical	O
role	O
of	O
echocardiography	O
in	O
ARDS	O
patients	O
.	O

The	O
antiviral	O
activities	O
of	O
various	O
concentrations	O
of	O
the	O
EA	O
fraction	O
of	O
H	O
.	O
cordata	O
and	O
flavonoids	O
were	O
assessed	O
using	O
virus	O
neutralization	O
tests	O
against	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
DENV	B-PRGE
type	I-PRGE
2	I-PRGE
(	O
DENV	O
-	O
2	O
).	O

TITLE	O
:	O
Characterization	O
of	O
monoclonal	O
antibodies	O
against	O
feline	B-PRGE
coronavirus	I-PRGE
accessory	I-PRGE
protein	I-PRGE
7b	I-PRGE
.	O

A	O
recombinant	O
form	O
of	O
the	O
7b	B-PRGE
protein	I-PRGE
was	O
expressed	O
as	O
a	O
fusion	O
protein	O
in	O
Escherichia	O
coli	O
,	O
purified	O
by	O
immobilized	O
metal	O
affinity	O
chromatography	O
and	O
used	O
as	O
immunogen	O
.	O

We	O
here	O
report	O
a	O
case	O
of	O
HCoV	O
infection	O
in	O
a	O
leukemia	O
patient	O
with	O
fatal	O
ARDS	O
despite	O
successful	O
virus	O
elimination	O
by	O
pegylated	O
interferon	B-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
PEG	B-PRGE
-	I-PRGE
IFN	I-PRGE
-	I-PRGE
Î±	I-PRGE
).	O

Therapies	O
that	O
expedite	O
IFN	B-PRGE
I	I-PRGE
induction	O
as	O
well	O
as	O
interventions	O
that	O
antagonize	O
immunoevasive	O
virus	O
proteins	O
are	O
thus	O
promising	O
candidates	O
for	O
immune	O
modulation	O
.	O

Double	O
staining	O
immunoassays	O
that	O
used	O
anti	O
-	O
MERS	O
-	O
CoV	O
antibodies	O
paired	O
with	O
immunohistochemistry	O
for	O
cytokeratin	O
and	O
surfactant	O
identified	O
pneumocytes	O
and	O
epithelial	O
syncytial	O
cells	O
as	O
important	O
targets	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antigen	I-PRGE
;	O
double	O
immunostaining	O
with	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
showed	O
colocalization	O
in	O
scattered	O
pneumocytes	O
and	O
syncytial	O
cells	O
.	O

Blocking	O
the	O
secretion	O
of	O
M	B-PRGE
protein	I-PRGE
by	O
brefeldin	O
A	O
(	O
BFA	O
)	O
failed	O
to	O
reverse	O
the	O
M	O
-	O
mediated	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
induction	O
.	O

Using	O
mice	O
infected	O
with	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)-	O
CoV	O
,	O
we	O
show	O
that	O
robust	O
virus	O
replication	O
accompanied	O
by	O
delayed	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
I	I-PRGE
)	O
signaling	O
orchestrates	O
inflammatory	O
responses	O
and	O
lung	O
immunopathology	O
with	O
diminished	O
survival	O
.	O

Several	O
animal	O
models	O
of	O
MERS	O
-	O
CoV	O
have	O
been	O
developed	O
,	O
including	O
New	O
Zealand	O
white	O
rabbits	O
,	O
transduced	O
or	O
transgenic	O
mice	O
that	O
express	O
human	B-PRGE
dipeptidyl	I-PRGE
peptidase	I-PRGE
4	I-PRGE
,	O
rhesus	O
macaques	O
,	O
and	O
common	O
marmosets	O
.	O

At	O
the	O
end	O
of	O
lectin	B-PRGE
exposure	O
,	O
the	O
genome	O
of	O
the	O
isolated	O
strains	O
was	O
sequenced	O
and	O
several	O
potential	O
resistance	O
mutations	O
in	O
the	O
E1E2	B-PRGE
envelope	I-PRGE
glycoproteins	I-PRGE
were	O
identified	O
.	O

TITLE	O
:	O
Design	O
and	O
synthesis	O
of	O
a	O
series	O
of	O
serine	O
derivatives	O
as	O
small	O
molecule	O
inhibitors	O
of	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
3CL	I-PRGE
protease	I-PRGE
.	O

TITLE	O
:	O
S1	B-PRGE
gene	I-PRGE
-	O
based	O
phylogeny	O
of	O
infectious	O
bronchitis	O
virus	O
:	O
An	O
attempt	O
to	O
harmonize	O
virus	O
classification	O
.	O

ABSTRACT	O
:	O
Ligands	O
of	O
the	O
endothelial	O
-	O
enriched	O
tunica	B-PRGE
interna	I-PRGE
endothelial	I-PRGE
cell	I-PRGE
kinase	I-PRGE
2	I-PRGE
(	O
Tie2	B-PRGE
)	O
are	O
markedly	O
imbalanced	O
in	O
severe	O
infections	O
associated	O
with	O
vascular	O
leakage	O
,	O
yet	O
regulation	O
of	O
the	O
receptor	O
itself	O
has	O
been	O
understudied	O
in	O
this	O
context	O
.	O

In	O
contrast	O
,	O
the	O
most	O
common	O
haplotype	O
was	O
associated	O
with	O
both	O
the	O
lowest	O
TIE2	B-PRGE
expression	O
and	O
31	O
%	O
higher	O
ARDS	O
risk	O
.	O

One	O
Chinese	O
-	O
like	O
recombinant	O
virus	O
(	O
DY12	B-PRGE
-	I-PRGE
2	I-PRGE
-	I-PRGE
like	I-PRGE
)	O
that	O
had	O
not	O
been	O
reported	O
in	O
the	O
Middle	O
East	O
was	O
detected	O
.	O

In	O
order	O
to	O
further	O
define	O
M	O
-	O
M	O
and	O
M	O
-	O
N	O
interactions	O
,	O
we	O
constructed	O
mutants	O
of	O
the	O
model	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
in	O
which	O
all	O
or	O
part	O
of	O
the	O
M	B-PRGE
protein	I-PRGE
was	O
replaced	O
by	O
its	O
phylogenetically	O
divergent	O
counterpart	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
bats	O
as	O
a	O
potential	O
reservoir	O
for	O
MERS	O
-	O
CoV	O
.	O
In	O
vitro	O
,	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
interacted	O
with	O
Jamaican	O
fruit	O
bat	O
(	O
Artibeus	O
jamaicensis	O
)	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
)	O
receptor	O
and	O
MERS	O
-	O
CoV	O
replicated	O
efficiently	O
in	O
Jamaican	O
fruit	O
bat	O
cells	O
,	O
suggesting	O
there	O
is	O
no	O
restriction	O
at	O
the	O
receptor	O
or	O
cellular	O
level	O
for	O
MERS	O
-	O
CoV	O
.	O
To	O
shed	O
light	O
on	O
the	O
intrinsic	O
host	O
-	O
virus	O
relationship	O
,	O
we	O
inoculated	O
10	O
Jamaican	O
fruit	O
bats	O
with	O
MERS	O
-	O
CoV	O
.	O
Although	O
all	O
bats	O
showed	O
evidence	O
of	O
infection	O
,	O
none	O
of	O
the	O
bats	O
showed	O
clinical	O
signs	O
of	O
disease	O
.	O

ABSTRACT	O
:	O
Although	O
Lewis	B-PRGE
X	I-PRGE
(	O
Le	O
(	O
x	O
)),	O
a	O
carbohydrate	O
structure	O
,	O
is	O
involved	O
in	O
innate	O
immunity	O
through	O
cell	O
-	O
to	O
-	O
cell	O
and	O
pathogen	O
recognition	O
,	O
its	O
expression	O
has	O
not	O
been	O
observed	O
in	O
mouse	O
monocytes	O
/	O
macrophages	O
(	O
Mo	O
/	O
Mas	B-PRGE
).	O

The	O
Mo	O
/	O
Mas	B-PRGE
that	O
infiltrate	O
the	O
meninges	O
after	O
infection	O
with	O
the	O
neuropathogenic	O
murine	O
coronavirus	O
strain	O
srr7	O
are	O
an	O
initial	O
target	O
of	O
infection	O
.	O

This	O
review	O
focuses	O
on	O
the	O
role	O
of	O
ROS	B-PRGE
signaling	O
in	O
controlling	O
endothelial	O
permeability	O
with	O
particular	O
focus	O
on	O
ALI	O
.	O

In	O
light	O
of	O
the	O
broad	O
antiviral	O
activity	O
of	O
Î²	O
-	O
defensins	O
,	O
we	O
tested	O
the	O
antiviral	O
activity	O
of	O
11	O
peptides	O
derived	O
from	O
mouse	B-PRGE
Î²	I-PRGE
-	I-PRGE
defensin	I-PRGE
-	I-PRGE
4	I-PRGE
and	O
found	O
that	O
a	O
short	O
peptide	O
,	O
P9	O
,	O
exhibited	O
potent	O
and	O
broad	O
-	O
spectrum	O
antiviral	O
effects	O
against	O
multiple	O
respiratory	O
viruses	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
including	O
influenza	O
A	O
virus	O
H1N1	O
,	O
H3N2	O
,	O
H5N1	O
,	O
H7N7	O
,	O
H7N9	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
.	O
The	O
antiviral	O
activity	O
of	O
P9	O
was	O
attributed	O
to	O
its	O
high	O
-	O
affinity	O
binding	O
to	O
viral	O
glycoproteins	O
,	O
as	O
well	O
as	O
the	O
abundance	O
of	O
basic	O
amino	O
acids	O
in	O
its	O
composition	O
.	O

ABSTRACT	O
:	O
Porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
RNA	O
endoribonuclease	O
nsp11	O
belongs	O
to	O
the	O
XendoU	B-PRGE
superfamily	I-PRGE
and	O
plays	O
a	O
crucial	O
role	O
in	O
arterivirus	O
replication	O
.	O

Here	O
,	O
we	O
report	O
the	O
first	O
crystal	O
structure	O
of	O
the	O
arterivirus	B-PRGE
nsp11	I-PRGE
protein	I-PRGE
from	O
PRRSV	O
,	O
which	O
exhibits	O
a	O
unique	O
structure	O
and	O
assembles	O
into	O
an	O
asymmetric	O
dimer	O
whose	O
structure	O
is	O
completely	O
different	O
from	O
the	O
hexameric	O
structure	O
of	O
coronavirus	O
nsp15	O
.	O

The	O
first	O
EQA	O
phase	O
results	O
for	O
46	O
participants	O
showed	O
a	O
linear	O
relationship	O
between	O
the	O
threshold	O
cycle	O
(	O
C	O
(	O
T	O
))	O
values	O
of	O
RNA	O
materials	O
and	O
the	O
logarithmic	O
concentrations	O
for	O
both	O
upE	O
and	O
ORF1a	B-PRGE
gene	I-PRGE
targets	I-PRGE
(	O
RÂ²	O
=	O
0	O
.	O
73	O
and	O
0	O
.	O
75	O
,	O
respectively	O
).	O

TITLE	O
:	O
Molecular	O
epidemiology	O
and	O
evolutionary	O
histories	O
of	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
and	I-PRGE
HKU1	I-PRGE
among	O
patients	O
with	O
upper	O
respiratory	O
tract	O
infections	O
in	O
Kuala	O
Lumpur	O
,	O
Malaysia	O
.	O

Therefore	O
,	O
the	O
3D	O
structure	O
models	O
of	O
these	O
proteins	O
were	O
built	O
with	O
using	O
the	O
crystal	O
structure	O
of	O
the	O
CoV	B-PRGE
family	I-PRGE
members	I-PRGE
as	O
a	O
template	O
.	O

Finally	O
,	O
protein	O
-	O
protein	O
docking	O
was	O
performed	O
to	O
prove	O
accuracy	O
of	O
model	O
structures	O
of	O
the	O
MHV	O
N	O
and	O
to	O
clarify	O
the	O
interaction	O
with	O
nsp3	B-PRGE
.	O

One	O
set	O
of	O
MERS	O
-	O
CoV	O
related	O
microarray	O
data	O
and	O
27	O
target	O
genes	O
of	O
ribavirin	O
and	O
interferon	B-PRGE
-	I-PRGE
Î±	I-PRGE
were	O
acquired	O
from	O
the	O
online	O
databases	O
.	O

The	O
CoV	O
proteases	O
,	O
which	O
play	O
pivotal	O
roles	O
in	O
viral	O
gene	O
expression	O
and	O
replication	O
through	O
a	O
highly	O
complex	O
cascade	O
involving	O
the	O
proteolytic	O
processing	O
of	O
replicase	B-PRGE
polyproteins	I-PRGE
,	O
are	O
attractive	O
targets	O
for	O
drug	O
design	O
.	O

Here	O
we	O
present	O
the	O
4	O
.	O
0	O
Ã	O
resolution	O
structure	O
of	O
the	O
trimeric	O
HKU1	B-PRGE
S	I-PRGE
protein	I-PRGE
determined	O
using	O
single	O
-	O
particle	O
cryo	O
-	O
electron	O
microscopy	O
.	O

CoV	O
genomes	O
encode	O
an	O
integral	O
viral	O
component	O
,	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
which	O
is	O
essential	O
for	O
viral	O
replication	O
through	O
proteolytic	O
processing	O
of	O
RNA	B-PRGE
replicase	I-PRGE
machinery	O
.	O

Through	O
comparative	O
study	O
with	O
M	B-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
s	I-PRGE
from	O
other	O
human	O
CoVs	O
(	O
including	O
the	O
deadly	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
)	O
and	O
their	O
related	O
zoonotic	O
CoVs	O
,	O
our	O
structure	O
of	O
HCoV	B-PRGE
-	I-PRGE
NL63	I-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
provides	O
critical	O
insight	O
into	O
rational	O
development	O
of	O
wide	O
spectrum	O
antiviral	O
therapeutics	O
to	O
treat	O
infections	O
caused	O
by	O
human	O
CoVs	O
.	O

In	O
this	O
study	O
,	O
the	O
screening	O
for	O
the	O
presence	O
of	O
SARS	O
-	O
specific	O
T	O
cells	O
in	O
a	O
cohort	O
of	O
three	O
SARS	O
-	O
recovered	O
individuals	O
at	O
9	O
and	O
11	O
years	O
post	O
-	O
infection	O
was	O
carried	O
out	O
,	O
and	O
all	O
memory	O
T	O
cell	O
responses	O
detected	O
target	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
structural	I-PRGE
proteins	I-PRGE
.	O

Two	O
CD8	B-PRGE
(+)	O
T	O
cell	O
responses	O
targeting	O
the	O
SARS	O
-	O
CoV	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
were	O
characterized	O
by	O
determining	O
their	O
HLA	B-PRGE
restriction	O
and	O
minimal	O
T	O
cell	O
epitope	O
regions	O
.	O

An	O
absence	O
of	O
cross	O
-	O
reactivity	O
of	O
these	O
CD8	B-PRGE
(+)	O
T	O
cell	O
responses	O
against	O
the	O
newly	O
-	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
also	O
demonstrated	O
.	O

In	O
addition	O
to	O
many	O
viral	O
nonstructural	O
proteins	O
,	O
the	O
presence	O
of	O
cell	O
nuclear	O
proteins	O
and	O
the	O
viral	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
increases	O
virus	O
amplification	O
efficacy	O
.	O

It	O
is	O
of	O
importance	O
to	O
elucidate	O
the	O
shared	O
antigenic	O
-	O
sites	O
and	O
extent	O
of	O
conservation	O
between	O
them	O
to	O
understand	O
the	O
evolutionary	O
dynamics	O
of	O
MERS	O
-	O
CoV	O
.	O
Multiple	O
sequence	O
alignment	O
of	O
the	O
spike	O
(	O
S	O
),	O
membrane	O
(	O
M	O
),	O
enveloped	O
(	O
E	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
was	O
employed	O
to	O
identify	O
the	O
sequence	O
conservation	O
among	O
MERS	O
and	O
Bat	B-PRGE
(	O
HKU4	O
,	O
HKU5	O
)	O
coronaviruses	O
.	O

The	O
continuing	O
threat	O
posed	O
by	O
pandemic	O
influenza	O
as	O
well	O
as	O
the	O
emergence	O
of	O
novel	O
respiratory	O
viruses	O
also	O
capable	O
of	O
producing	O
severe	O
acute	O
lung	O
injury	O
such	O
as	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
MERS	O
-	O
CoV	O
,	O
and	O
enterovirus	O
D68	O
,	O
highlights	O
the	O
need	O
for	O
an	O
understanding	O
of	O
the	O
immune	O
mechanisms	O
that	O
contribute	O
to	O
virus	O
elimination	O
and	O
immune	O
-	O
mediated	O
injury	O
.	O

Significantly	O
increased	O
pneumonia	O
severity	O
index	O
(	O
PSI	O
),	O
respiratory	O
rate	O
,	O
and	O
lower	O
PaO2	O
/	O
FiO2	O
,	O
hypersensitive	O
CRP	B-PRGE
were	O
reported	O
in	O
non	O
-	O
survivors	O
compared	O
to	O
survivors	O
(	O
P	O
=	O
0	O
.	O
013	O
,	O
0	O
.	O
022	O
,	O
0	O
.	O
019	O
and	O
0	O
.	O
026	O
,	O
respectively	O
).	O

The	O
phylogenetic	O
trees	O
based	O
on	O
the	O
complete	O
spike	O
-	O
and	O
nucleocapsid	O
protein	O
-	O
coding	O
genes	O
showed	O
that	O
SL2	B-PRGE
and	O
SL5	O
closely	O
related	O
to	O
the	O
US	O
PDCoV	O
strains	O
rather	O
than	O
those	O
in	O
China	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
well	O
characterized	O
that	O
piglets	O
can	O
absorb	O
colostrum	O
IgG	B-PRGE
across	O
the	O
intestine	O
to	O
neonatal	O
bloodstream	O
and	O
a	O
certain	O
level	O
of	O
IgG	B-PRGE
has	O
been	O
found	O
in	O
the	O
mucosal	O
secretions	O
of	O
the	O
porcine	O
intestinal	O
tract	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
association	O
of	O
plasma	B-PRGE
adiponectin	I-PRGE
level	O
at	O
ICU	O
admission	O
with	O
ARDS	O
and	O
30	O
-	O
day	O
mortality	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
septic	O
shock	O
.	O

We	O
recommend	O
against	O
the	O
routine	O
use	O
of	O
other	O
drugs	O
,	O
including	O
corticosteroids	O
,	O
beta2	B-PRGE
agonists	O
,	O
statins	O
,	O
and	O
inhaled	O
nitric	O
oxide	O
(	O
iNO	O
)	O
or	O
prostanoids	O
in	O
adults	O
with	O
ARDS	O
(	O
strong	O
recommendations	O
:	O
low	O
-	O
to	O
high	O
-	O
quality	O
evidence	O
).	O

Novel	O
kinase	O
inhibitors	O
SB203580	O
(	O
MAPK	B-PRGE
-	I-PRGE
2	I-PRGE
antagonist	O
)	O
and	O
LY294002	O
(	O
phosphoinositide	O
-	O
3	O
kinases	O
antagonist	O
)	O
exhibit	O
promising	O
anti	O
-	O
MERS	O
-	O
CoV	O
activity	O
.	O

The	O
present	O
study	O
reports	O
the	O
case	O
of	O
a	O
62	O
-	O
year	O
-	O
old	O
man	O
with	O
immunoglobulin	B-PRGE
(	O
Ig	O
)	O
G	O
-	O
type	O
MM	O
who	O
was	O
treated	O
with	O
bortezomib	O
,	O
thalidomide	O
and	O
dexamethasone	O
.	O

It	O
was	O
indicated	O
that	O
patients	O
who	O
were	O
male	O
,	O
of	O
IgG	B-PRGE
type	O
,	O
with	O
a	O
relapse	O
status	O
and	O
a	O
previous	O
history	O
of	O
auto	O
-	O
PBSCT	O
had	O
a	O
higher	O
possibility	O
of	O
developing	O
bortezomib	O
-	O
induced	O
severe	O
pulmonary	O
complications	O
.	O

This	O
reduction	O
of	O
Na	O
,	O
K	B-PRGE
-	I-PRGE
ATPase	I-PRGE
expression	O
decreases	O
alveolar	O
fluid	O
clearance	O
,	O
which	O
in	O
turn	O
leads	O
to	O
pulmonary	O
edema	O
.	O

We	O
expect	O
to	O
see	O
further	O
pathophysiological	O
data	O
and	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
SAD	O
now	O
that	O
reliable	O
and	O
consistent	O
definitions	O
of	O
SAD	B-PRGE
have	O
been	O
established	O
.	O

Hyperbilirubinemia	O
(	O
Serum	O
bilirubin	O
>	O
3mg	O
/	O
dL	O
)	O
with	O
>	O
3	O
-	O
fold	O
rise	O
in	O
serum	B-PRGE
aminotransferases	I-PRGE
in	O
absence	O
of	O
a	O
different	O
explanation	O
for	O
such	O
derangement	O
was	O
considered	O
as	O
malarial	O
hepatopathy	O
.	O

Activated	O
RNase	B-PRGE
L	I-PRGE
cleaves	O
viral	O
and	O
host	O
single	O
-	O
stranded	O
RNA	O
(	O
ssRNA	O
),	O
which	O
leads	O
to	O
translational	O
arrest	O
and	O
subsequent	O
cell	O
death	O
,	O
preventing	O
viral	O
replication	O
and	O
spread	O
.	O

However	O
,	O
the	O
expression	O
level	O
of	O
cytoplasmic	B-PRGE
MERS	I-PRGE
-	I-PRGE
CoV	I-PRGE
NS4b	I-PRGE
protein	I-PRGE
is	O
sufficient	O
to	O
prevent	O
activation	O
of	O
RNase	B-PRGE
L	I-PRGE
.	O
Finally	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
RNase	B-PRGE
L	I-PRGE
antagonist	O
expressed	O
by	O
a	O
human	O
or	O
bat	O
coronavirus	O
and	O
provides	O
a	O
specific	O
mechanism	O
by	O
which	O
this	O
occurs	O
.	O

Like	O
murine	B-PRGE
coronavirus	I-PRGE
NS2	I-PRGE
,	O
a	O
previously	O
characterized	O
PDE	B-PRGE
,	I-PRGE
MERS	I-PRGE
NS4b	I-PRGE
,	O
can	O
antagonize	O
activation	O
of	O
the	O
OAS	B-PRGE
-	I-PRGE
RNase	I-PRGE
L	I-PRGE
pathway	O
,	O
an	O
interferon	B-PRGE
-	O
induced	O
potent	O
antiviral	O
activity	O
.	O

Meanwhile	O
,	O
TGEV	O
also	O
induces	O
DJ	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
some	O
antioxidant	O
genes	O
upregulation	O
to	O
suppress	O
oxidative	O
stress	O
induced	O
by	O
viral	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
emerging	O
coronavirus	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
binds	O
to	O
its	O
receptor	O
,	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
),	O
via	O
14	O
interacting	O
amino	O
acids	O
.	O

ABSTRACT	O
:	O
The	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
(	O
VEEV	O
)	O
nonstructural	B-PRGE
protein	I-PRGE
2	I-PRGE
(	O
nsP2	B-PRGE
)	O
cysteine	B-PRGE
protease	I-PRGE
(	O
EC	B-PRGE
3	I-PRGE
.	I-PRGE
4	I-PRGE
.	O
22	O
.-)	O
is	O
essential	O
for	O
viral	O
replication	O
and	O
is	O
involved	O
in	O
the	O
cytopathic	O
effects	O
(	O
CPE	O
)	O
of	O
the	O
virus	O
.	O

Affinity	O
tagged	O
PEDV	B-PRGE
S1	I-PRGE
protein	I-PRGE
was	O
expressed	O
in	O
a	O
secretory	O
form	O
in	O
yeast	O
,	O
insect	O
and	O
mammalian	O
cells	O
to	O
identify	O
the	O
most	O
suitable	O
production	O
system	O
.	O

These	O
results	O
suggest	O
that	O
the	O
alveolar	O
release	O
of	O
sRAGE	O
may	O
play	O
a	O
protective	O
role	O
against	O
HMGB1	B-PRGE
as	O
well	O
as	O
exogenous	O
pathogen	O
-	O
associated	O
molecular	O
patterns	O
.	O

The	O
GCS	O
arrival	O
and	O
ICU	O
stay	O
a	O
predicate	O
factor	O
for	O
HAD	B-PRGE
-	I-PRGE
A	I-PRGE
(	O
p	O
<	O
0	O
.	O
05	O
,	O
OR	O
:	O
1	O
.	O
73	O
,	O
1	O
.	O
38	O
respectively	O
).	O

Our	O
findings	O
support	O
the	O
virus	O
-	O
host	O
co	O
-	O
evolution	O
hypothesis	O
,	O
with	O
the	O
detection	O
of	O
Miniopterus	B-PRGE
bat	I-PRGE
coronavirus	I-PRGE
HKU8	I-PRGE
(	O
previously	O
reported	O
in	O
Miniopterus	O
species	O
in	O
China	O
,	O
Hong	O
Kong	O
and	O
Bulgaria	O
)	O
in	O
Australian	O
Miniopterus	O
species	O
.	O

Systemic	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
levels	O
and	O
leukocyte	O
counts	O
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
:	O
65	O
.	O
0	O
Â±	O
8	O
.	O
0	O
vs	O
.	O
151	O
.	O
8	O
Â±	O
22	O
.	O
3	O
;	O
leukocytes	O
:	O
10	O
.	O
2	O
Â±	O
0	O
.	O
9	O
vs	O
.	O
13	O
.	O
2	O
Â±	O
0	O
.	O
8	O
,	O
both	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
significantly	O
lower	O
in	O
BAC	O
-	O
positive	O
patients	O
.	O

However	O
,	O
lowered	O
systemic	B-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
levels	O
and	O
leukocyte	O
counts	O
in	O
the	O
BAC	O
group	O
were	O
also	O
detected	O
after	O
matching	O
,	O
indicating	O
that	O
this	O
effect	O
is	O
ISS	O
-	O
independent	O
.	O

The	O
risk	O
factors	O
described	O
can	O
help	O
clinicians	O
to	O
suspect	O
P	O
aeruginosa	O
and	O
MDR	B-PRGE
P	I-PRGE
aeruginosa	I-PRGE
.	O

As	O
expected	O
,	O
PED	B-PRGE
and	O
PRP	B-PRGE
treatments	O
resulted	O
in	O
duodenum	O
,	O
jejunum	O
,	O
and	O
ileum	O
villus	O
atrophy	O
compared	O
with	O
the	O
CON	O
treatment	O
(	O
<	O
0	O
.	O
01	O
).	O

The	O
jejunum	B-PRGE
AA	I-PRGE
transporter	I-PRGE
,	O
SLC6A14	B-PRGE
,	O
and	O
mucin	B-PRGE
2	I-PRGE
mRNA	I-PRGE
abundance	O
tended	O
to	O
be	O
increased	O
in	O
PED	O
-	O
only	O
pigs	O
(	O
<	O
0	O
.	O
10	O
).	O

We	O
retrospectively	O
reviewed	O
all	O
lung	B-PRGE
transplants	I-PRGE
at	O
our	O
center	O
from	O
January	O
1	O
,	O
2000	O
through	O
August	O
31	O
,	O
2012	O
(	O
n	O
=	O
562	O
),	O
comparing	O
the	O
SSc	O
group	O
(	O
n	O
=	O
35	O
)	O
to	O
the	O
following	O
lung	O
transplant	O
diagnostic	O
subsets	O
:	O
all	O
non	O
-	O
SSc	O
(	O
n	O
=	O
527	O
),	O
non	O
-	O
SSc	O
diffuse	O
fibrotic	O
lung	O
disease	O
(	O
n	O
=	O
264	O
),	O
and	O
a	O
non	O
-	O
SSc	O
matched	O
group	O
(	O
n	O
=	O
109	O
).	O

We	O
demonstrated	O
that	O
elevated	O
numbers	O
of	O
gut	O
-	O
homing	O
CD8	B-PRGE
(+)	O
T	O
cells	O
(	O
which	O
express	O
Î±4Î²7	O
and	O
CCR9	B-PRGE
molecules	O
)	O
were	O
presented	O
in	O
porcine	O
inguinal	O
lymph	O
nodes	O
and	O
were	O
recruited	O
to	O
the	O
small	O
intestine	O
by	O
RA	O
.	O

Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
a	O
relatively	O
new	O
member	O
of	O
the	O
RAS	O
,	O
has	O
drawn	O
extensive	O
attention	O
since	O
2003	O
,	O
because	O
of	O
the	O
findings	O
that	O
ACE2	B-PRGE
is	O
the	O
receptor	O
for	O
SARS	O
Corona	O
virus	O
and	O
that	O
maintenance	O
of	O
normal	O
ACE2	B-PRGE
levels	O
in	O
the	O
lung	O
is	O
beneficial	O
for	O
the	O
host	O
to	O
combat	O
inflammatory	O
lung	O
disease	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
matrix	B-PRGE
metalloproteinase	I-PRGE
-	I-PRGE
3	I-PRGE
deficiency	O
on	O
pulmonary	O
surfactant	O
in	O
a	O
mouse	O
model	O
of	O
acute	O
lung	O
injury	O
.	O

Wild	O
type	O
(	O
WT	O
)	O
and	O
Mmp3	B-PRGE
(-/-)	O
mice	O
were	O
subjected	O
to	O
acid	O
-	O
aspiration	O
followed	O
by	O
mechanical	O
ventilation	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
the	O
partial	B-PRGE
S	I-PRGE
gene	I-PRGE
showed	O
that	O
the	O
CH	O
/	O
QX	O
-	O
2	O
isolate	O
was	O
genetically	O
closer	O
to	O
strains	O
more	O
commonly	O
found	O
in	O
China	O
,	O
but	O
differed	O
genetically	O
from	O
two	O
domestic	O
strains	O
(	O
CH	O
/	O
S	O
,	O
1986	O
and	O
LZC	O
,	O
2007	O
),	O
Korean	O
strains	O
(	O
DR13	O
,	O
2007	O
),	O
and	O
the	O
vaccine	O
strain	O
(	O
CV777	O
vs	O
)	O
currently	O
being	O
used	O
in	O
China	O
.	O

TITLE	O
:	O
Diminished	O
COX	O
-	O
2	O
/	O
PGE2	O
-	O
Mediated	O
Antiviral	O
Response	O
Due	O
to	O
Impaired	O
NOX	B-PRGE
/	O
MAPK	B-PRGE
Signaling	O
in	O
G6PD	B-PRGE
-	O
Knockdown	O
Lung	O
Epithelial	O
Cells	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
role	O
of	O
G6PD	B-PRGE
on	O
the	O
inflammatory	O
response	O
was	O
determined	O
in	O
both	O
scramble	O
control	O
and	O
G6PD	O
-	O
knockdown	O
(	O
G6PD	O
-	O
kd	O
)	O
A549	O
cells	O
upon	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
Î±	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
)	O
stimulation	O
.	O

A	O
decreased	O
expression	O
pattern	O
of	O
induced	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
reduced	O
production	O
of	O
downstream	O
PGE2	O
occurred	O
upon	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
stimulation	O
in	O
G6PD	B-PRGE
-	O
kd	O
A549	O
cells	O
compared	O
with	O
scramble	O
control	O
A549	O
cells	O
.	O

In	O
addition	O
,	O
NOX	O
activity	O
with	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
treatment	O
in	O
G6PD	O
-	O
kd	O
A549	O
cells	O
was	O
not	O
up	O
-	O
regulated	O
and	O
was	O
coupled	O
with	O
a	O
decrease	O
in	O
NOX	O
subunit	O
expression	O
at	O
the	O
transcriptional	O
level	O
,	O
implying	O
that	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
-	O
mediated	O
NOX	O
signaling	O
requires	O
the	O
participation	O
of	O
G6PD	B-PRGE
.	O

The	O
amino	O
acid	O
(	O
AA	O
)	O
sequence	O
of	O
S	B-PRGE
gene	I-PRGE
of	O
YC2014	O
shared	O
only	O
92	O
.	O
8	O
%	O
~	O
93	O
.	O
4	O
%	O
identities	O
with	O
classical	O
CV777	O
,	O
DR13	O
and	O
JS2008	O
strains	O
,	O
with	O
5	O
AA	O
insertion	O
in	O
two	O
sites	O
and	O
1	O
AA	O
deletion	O
in	O
one	O
site	O
.	O

Furthermore	O
,	O
whole	O
gene	O
5	O
and	O
parts	O
of	O
nsp	B-PRGE
3	I-PRGE
,	O
nsp	B-PRGE
4	I-PRGE
,	O
nsp	B-PRGE
16	I-PRGE
,	O
and	O
N	O
genes	O
are	O
involved	O
in	O
the	O
recombination	O
events	O
,	O
and	O
the	O
uptake	O
of	O
these	O
regions	O
from	O
YN	O
and	O
Mass	O
strains	O
by	O
SAIBK2	O
may	O
increase	O
its	O
replication	O
efficiency	O
and	O
be	O
responsible	O
for	O
its	O
increased	O
virulence	O
in	O
specific	O
-	O
pathogen	O
-	O
free	O
chickens	O
.	O

After	O
ECMO	O
running	O
3	O
days	O
,	O
most	O
factors	O
of	O
the	O
ECMO	O
survival	O
group	O
were	O
better	O
than	O
those	O
of	O
the	O
control	O
group	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
except	O
MAP	B-PRGE
,	O
but	O
most	O
factors	O
between	O
the	O
ECMO	O
non	O
-	O
survival	O
group	O
and	O
the	O
control	O
group	O
were	O
not	O
significantly	O
different	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
),	O
while	O
the	O
serum	O
lactate	O
level	O
was	O
higher	O
(	O
t	O
=-	O
3	O
.	O
156	O
,	O
P	O
=	O
0	O
.	O
003	O
)	O
and	O
the	O
MAP	O
lower	O
(	O
t	O
=	O
3	O
.	O
578	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

At	O
48	O
hpi	O
,	O
the	O
passage	O
was	O
found	O
to	O
be	O
constructed	O
by	O
ER	B-PRGE
-	I-PRGE
TR7	I-PRGE
antigen	I-PRGE
(	O
ERag	O
)-	O
positive	O
fibers	O
(	O
ERfibs	O
)	O
associated	O
with	O
laminin	B-PRGE
and	O
collagen	B-PRGE
III	I-PRGE
between	O
the	O
fourth	O
ventricle	O
and	O
meninges	O
at	O
the	O
cerebellopontine	O
angle	O
.	O

In	O
the	O
meninges	O
,	O
ERfibs	O
together	O
with	O
collagen	B-PRGE
fibers	O
,	O
lining	O
in	O
a	O
striped	O
pattern	O
,	O
made	O
up	O
a	O
pile	O
of	O
thin	O
sheets	O
.	O

The	O
recombinant	B-PRGE
VP8	I-PRGE
-	I-PRGE
S2	I-PRGE
protein	I-PRGE
was	O
purified	O
by	O
Ni	O
-	O
NTA	O
chromatography	O
column	O
.	O

The	O
central	O
venous	O
pressure	O
(	O
CVP	O
),	O
central	O
venous	O
oxygen	O
saturation	O
(	O
ScvOâ	O
),	O
blood	O
lactate	O
(	O
Lac	B-PRGE
),	O
and	O
the	O
monitor	O
of	O
other	O
parameters	O
of	O
patients	O
in	O
late	O
group	O
were	O
consummated	O
late	O
.	O

In	O
this	O
study	O
,	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	O
assays	O
for	O
the	O
detection	O
and	O
differentiation	O
of	O
different	O
US	O
PEDV	O
variants	O
were	O
developed	O
based	O
on	O
the	O
differences	O
in	O
the	O
S1	B-PRGE
domain	I-PRGE
of	O
the	O
spike	O
(	O
S	O
)	O
gene	O
.	O

TITLE	O
:	O
Trigger	O
factor	O
assisted	O
soluble	O
expression	O
of	O
recombinant	B-PRGE
spike	I-PRGE
protein	I-PRGE
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
Escherichia	O
coli	O
.	O

RESULTS	O
:	O
We	O
firstly	O
tested	O
various	O
chaperone	O
co	O
-	O
expression	O
systems	O
and	O
found	O
that	O
co	O
-	O
expression	O
of	O
trigger	O
factor	O
(	O
TF	O
)	O
with	O
recombinant	O
proteins	O
at	O
15	O
Â°	O
C	O
was	O
most	O
useful	O
in	O
soluble	O
production	O
of	O
rGST	O
-	O
COE	O
and	O
rGST	O
-	O
S1D	O
compared	O
to	O
GroEL	B-PRGE
-	I-PRGE
ES	I-PRGE
and	O
DnaK	B-PRGE
-	O
DnaJ	B-PRGE
-	O
GrpE	B-PRGE
/	O
GroEL	B-PRGE
-	O
ES	O
systems	O
.	O

The	O
blood	O
levels	O
of	O
cytokines	O
such	O
as	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
,	O
TGF	O
-	O
Î²	O
,	O
and	O
EGF	B-PRGE
were	O
either	O
positively	O
or	O
negatively	O
correlated	O
with	O
disease	O
mortality	O
.	O

Indirect	O
immunofluorescence	O
assay	O
and	O
western	O
blot	O
analysis	O
showed	O
that	O
the	O
MAb	O
was	O
specifically	O
reacted	O
with	O
the	O
overexpressed	O
porcine	B-PRGE
BST	I-PRGE
-	I-PRGE
2	I-PRGE
protein	I-PRGE
in	O
Vero	O
cells	O
.	O

RVA	O
isolation	O
was	O
achieved	O
for	O
nine	O
clinical	O
samples	O
following	O
one	O
or	O
two	O
passages	O
(	O
60	O
%)	O
and	O
was	O
properly	O
depended	O
on	O
HA	O
activity	O
and	O
trypsin	B-PRGE
treatment	O
of	O
inoculates	O
.	O

The	O
pathogenesis	O
of	O
BRD	B-PRGE
is	O
complex	O
and	O
includes	O
contributions	O
from	O
microbial	O
pathogens	O
as	O
well	O
as	O
host	O
,	O
environmental	O
and	O
animal	O
management	O
factors	O
.	O

We	O
initially	O
developed	O
a	O
three	O
-	O
dimensional	O
common	O
-	O
feature	O
pharmacophore	O
model	O
according	O
to	O
which	O
two	O
hydrogen	O
bond	O
acceptors	O
and	O
one	O
hydrophobic	O
aromatic	O
feature	O
are	O
shared	O
by	O
all	O
molecular	O
series	O
in	O
binding	O
the	O
viral	B-PRGE
polymerase	I-PRGE
.	O

The	O
cases	O
were	O
classified	O
as	O
autochthonous	B-PRGE
if	I-PRGE
PTPs	I-PRGE
were	O
in	O
the	O
DF	O
area	O
.	O

Western	O
blot	O
analysis	O
with	O
anti	O
-	O
Lys48	O
and	O
anti	B-PRGE
-	I-PRGE
Lys63	I-PRGE
ubiquitin	I-PRGE
antibodies	I-PRGE
indicated	O
the	O
SARS	O
-	O
CoV	O
PLPro	O
removed	O
Lys63	B-PRGE
-	I-PRGE
linked	I-PRGE
ubiquitin	I-PRGE
chains	I-PRGE
of	O
TRAF3	B-PRGE
and	O
TRAF6	B-PRGE
,	O
but	O
not	O
Lys48	B-PRGE
-	I-PRGE
linked	I-PRGE
ubiquitin	I-PRGE
chains	I-PRGE
in	O
un	O
-	O
treated	O
and	O
treated	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
constructed	O
a	O
full	O
-	O
length	O
cDNA	O
clone	O
of	O
SL	O
-	O
CoV	O
WIV1	O
(	O
rWIV1	O
),	O
an	O
ORFX	B-PRGE
deletion	I-PRGE
mutant	I-PRGE
(	O
rWIV1	O
-	O
ÎX	O
),	O
and	O
a	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
GFP	O
)-	O
expressing	O
mutant	O
(	O
rWIV1	O
-	O
GFP	O
-	O
ÎX	O
).	O

TITLE	O
:	O
SARS	B-PRGE
coronavirus	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
induces	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
dependent	O
up	O
-	O
regulation	O
of	O
TGF	O
-	O
Î²1	O
via	O
ROS	B-PRGE
/	O
p38	B-PRGE
MAPK	O
/	O
STAT3	B-PRGE
pathway	O
.	O

The	O
results	O
revealed	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
significantly	O
triggered	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
dependent	O
activation	O
of	O
TGF	O
-	O
Î²1	O
promoter	O
via	O
ROS	B-PRGE
/	O
p38	B-PRGE
MAPK	O
/	O
STAT3	B-PRGE
pathway	O
,	O
correlating	O
with	O
up	O
-	O
regulation	O
of	O
pro	O
-	O
fibrotic	O
responses	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Analysis	O
of	O
the	O
PEDV	B-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
structure	O
and	O
comparison	O
to	O
other	O
coronaviral	O
3CL	O
(	O
pro	O
)'	O
s	O
from	O
the	O
same	O
alpha	O
-	O
coronavirus	O
phylogeny	O
shows	O
that	O
the	O
overall	O
structures	O
and	O
active	O
site	O
architectures	O
across	O
3CL	O
(	O
pro	O
)'	O
s	O
are	O
conserved	O
,	O
with	O
the	O
exception	O
of	O
a	O
loop	O
that	O
comprises	O
the	O
protease	O
S2	O
pocket	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
changes	O
in	O
the	O
serum	B-PRGE
concentrations	O
of	O
haptoglobin	B-PRGE
(	O
Hp	O
),	O
serum	B-PRGE
amyloid	I-PRGE
A	I-PRGE
(	O
SAA	B-PRGE
)	O
and	O
IgG	B-PRGE
,	O
IgA	B-PRGE
in	O
calves	O
with	O
diarrhea	O
caused	O
by	O
rotavirus	O
,	O
coronavirus	O
,	O
Escherichia	O
coli	O
F5	O
and	O
Eimeria	O
species	O
.	O

The	O
results	O
showed	O
that	O
pretreatment	O
with	O
QF	O
significantly	O
inhibits	O
the	O
release	O
of	O
cytokines	O
(	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	I-PRGE
and	I-PRGE
chemokines	I-PRGE
(	I-PRGE
IL	I-PRGE
-	I-PRGE
8	I-PRGE
and	O
RANTES	B-PRGE
),	O
reduces	O
leukocytes	O
recruitment	O
into	O
inflamed	O
tissues	O
and	O
ameliorates	O
pulmonary	O
edema	O
and	O
necrosis	O
.	O

In	O
addition	O
,	O
ATG	O
was	O
identified	O
as	O
the	O
primary	O
anti	O
-	O
inflammatory	O
agent	O
with	O
action	O
on	O
the	O
PI3K	B-PRGE
/	O
AKT	B-PRGE
and	O
Ras	B-PRGE
/	O
MAPK	B-PRGE
pathways	O
.	O

The	O
results	O
indicated	O
that	O
PTX	O
â	O
induced	O
increases	O
in	O
cAMP	O
may	O
have	O
partly	O
restored	O
the	O
Treg	O
/	O
Th17	O
balance	O
by	O
modulating	O
the	O
transcription	O
of	O
Foxp3	B-PRGE
and	O
RORÎ³t	O
through	O
the	O
STAT3	B-PRGE
pathway	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
an	O
affinity	O
purification	O
/	O
mass	O
spectrometry	O
approach	O
to	O
demonstrate	O
that	O
a	O
bat	B-PRGE
MHC	I-PRGE
class	I-PRGE
I	I-PRGE
molecule	I-PRGE
,	O
Ptal	O
-	O
N	O
*	O
01	O
:	O
01	O
,	O
binds	O
antigenic	O
peptides	O
and	O
associates	O
with	O
peptide	O
-	O
loading	O
complex	O
components	O
.	O

Previously	O
,	O
a	O
partially	O
disordered	O
crystal	O
structure	O
of	O
a	O
type	O
II	O
HE	O
revealed	O
how	O
the	O
shift	O
in	O
lectin	B-PRGE
ligand	I-PRGE
specificity	O
was	O
achieved	O
.	O

Necroptosis	O
is	O
a	O
newly	O
identified	O
programmed	O
necrosis	O
that	O
is	O
mediated	O
by	O
receptor	B-PRGE
interacting	I-PRGE
protein	I-PRGE
3	I-PRGE
(	O
RIP3	B-PRGE
).	O

The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLpro	O
)	O
is	O
a	O
DUB	O
that	O
cleaves	O
ISG15	B-PRGE
,	O
a	O
two	O
-	O
domain	O
Ub	B-PRGE
-	I-PRGE
like	I-PRGE
protein	I-PRGE
,	O
and	O
Lys48	O
-	O
linked	O
polyUb	O
chains	O
,	O
releasing	O
diUb	O
(	O
Lys48	O
)	O
products	O
.	O

Both	O
the	O
crude	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
19	O
.	O
9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
6	O
.	O
6	O
-	O
60	O
;	O
P	O
<	O
0	O
.	O
0001	O
),	O
multivariable	O
adjustment	O
(	O
OR	O
,	O
27	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
8	O
.	O
2	O
-	O
91	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
propensity	O
-	O
matched	O
(	O
OR	O
,	O
11	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
110	O
.	O
8	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
analyses	O
found	O
a	O
significant	O
association	O
between	O
ACS	B-PRGE
-	O
ARDS	O
and	O
ACP	B-PRGE
.	O

Therefore	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
activation	O
of	O
p38	B-PRGE
MAPK	O
and	O
JNK	B-PRGE
cascades	O
is	O
required	O
for	O
PEDV	O
replication	O
.	O

Furthermore	O
,	O
direct	O
pharmacological	O
inhibition	O
of	O
p38	B-PRGE
MAPK	I-PRGE
or	O
JNK1	B-PRGE
/	I-PRGE
2	I-PRGE
activation	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
viral	O
RNA	O
synthesis	O
,	O
viral	B-PRGE
protein	I-PRGE
expression	O
,	O
and	O
progeny	O
release	O
.	O

Our	O
isolates	O
and	O
findings	O
will	O
be	O
useful	O
for	O
future	O
investigations	O
aimed	O
at	O
understanding	O
,	O
controlling	O
,	O
and	O
preventing	O
PED	B-PRGE
.	O

This	O
review	O
describes	O
the	O
synthesis	O
,	O
bioactivities	O
and	O
SARs	O
of	O
indole	O
-	O
based	O
agents	O
targeting	O
tubulin	B-PRGE
polymerization	O
during	O
the	O
past	O
decade	O
.	O

Ubiquitin	B-PRGE
binding	O
by	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	B-PRGE
)	O
involves	O
remarkable	O
differences	O
compared	O
to	O
the	O
corresponding	O
complex	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PL	I-PRGE
(	O
pro	B-PRGE
).	O

In	O
contrast	O
,	O
substitution	O
of	O
alanine	O
at	O
MHV	O
nsp14	O
D330	O
did	O
not	O
affect	O
viral	O
replication	O
,	O
sensitivity	O
to	O
mutagen	O
,	O
or	O
inhibition	O
by	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
compared	O
to	O
WT	O
MHV	O
.	O

Finally	O
,	O
mouse	O
antisera	O
against	O
S25	O
-	O
229	O
showed	O
immune	O
reactivity	O
with	O
native	O
PEDV	B-PRGE
S	I-PRGE
protein	I-PRGE
in	O
an	O
immunofluorescence	O
assay	O
.	O

Intrahepatic	O
recruited	O
neutrophils	O
,	O
natural	O
killer	O
cells	O
,	O
natural	O
killer	O
T	O
cells	O
or	O
macrophages	O
rapidly	O
decreased	O
in	O
MHV3	O
-	O
infected	O
WT	O
mice	O
whereas	O
they	O
were	O
sustained	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
WT	O
mice	O
and	O
MHV3	O
-	O
infected	O
TLR2	B-PRGE
KO	I-PRGE
.	O

Fecal	O
calprotectin	O
and	O
IgA	B-PRGE
concentrations	O
in	O
puppies	O
are	O
not	O
influenced	O
by	O
fecal	O
moisture	O
in	O
puppies	O
but	O
by	O
enteropathogen	O
shedding	O
.	O

For	O
each	O
marker	O
(	O
IgA	B-PRGE
and	O
calprotectin	O
),	O
a	O
strong	O
positive	O
correlation	O
was	O
observed	O
between	O
concentration	O
in	O
fresh	O
feces	O
and	O
concentration	O
in	O
fecal	O
dry	O
matter	O
.	O

TITLE	O
:	O
Airway	B-PRGE
Memory	I-PRGE
CD4	I-PRGE
(+)	O
T	O
Cells	O
Mediate	O
Protective	O
Immunity	O
against	O
Emerging	O
Respiratory	O
Coronaviruses	O
.	O

Airway	O
memory	O
CD4	B-PRGE
(+)	O
T	O
cells	O
differed	O
phenotypically	O
and	O
functionally	O
from	O
lung	O
-	O
derived	O
cells	O
and	O
were	O
crucial	O
for	O
protection	O
against	O
both	O
CoVs	O
in	O
mice	O
.	O

Analysis	O
of	O
the	O
PEDV	B-PRGE
oral	I-PRGE
fluid	I-PRGE
IgA	I-PRGE
WV	I-PRGE
ELISA	I-PRGE
found	O
that	O
a	O
cutoff	O
of	O
S	O
/	O
P	O
â¥	O
0	O
.	O
80	O
provided	O
a	O
diagnostic	O
sensitivity	O
of	O
1	O
.	O
00	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
92	O
,	O
1	O
.	O
00	O
)	O
and	O
a	O
diagnostic	O
specificity	O
of	O
1	O
.	O
00	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
99	O
,	O
1	O
.	O
00	O
).	O

Similarities	O
in	O
amino	O
-	O
acid	O
sequences	O
among	O
the	O
15	O
isolates	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
were	O
54	O
.	O
3	O
%-	O
99	O
.	O
6	O
%,	O
and	O
43	O
.	O
3	O
%-	O
99	O
.	O
3	O
%	O
among	O
15	O
isolates	O
and	O
reference	O
strains	O
.	O

Moreover	O
,	O
overexpression	O
of	O
ACE2	B-PRGE
significantly	O
reduced	O
the	O
Ang	B-PRGE
II	I-PRGE
/	O
Ang	O
-(	O
1	O
-	O
7	O
)	O
ratio	O
in	O
BALF	O
and	O
up	O
-	O
regulated	O
Mas	B-PRGE
mRNA	I-PRGE
expression	O
in	O
lung	O
,	O
which	O
was	O
reversed	O
by	O
A779	O
.	O

In	O
contrast	O
,	O
Ark	B-PRGE
passaging	O
resulted	O
in	O
the	O
detection	O
of	O
13	O
different	O
subpopulations	O
,	O
and	O
the	O
field	O
sequence	O
became	O
extinct	O
after	O
the	O
first	O
passage	O
.	O

Dampened	O
neuroinflammation	O
and	O
remyelination	O
was	O
correlated	O
with	O
a	O
transient	B-PRGE
increase	I-PRGE
in	I-PRGE
CD4	I-PRGE
+	I-PRGE
FOXP3	I-PRGE
+	I-PRGE
regulatory	I-PRGE
T	I-PRGE
cells	I-PRGE
(	O
Tregs	O
)	O
concentrated	O
within	O
the	O
peripheral	O
lymphatics	O
.	O

hMS	O
-	O
1	O
significantly	O
blocked	O
MERS	O
-	O
CoV	O
RBD	O
binding	O
to	O
its	O
viral	O
receptor	O
,	O
human	B-PRGE
dipeptidyl	I-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
hDPP4	O
),	O
potently	O
neutralized	O
infection	O
by	O
a	O
prototype	O
MERS	O
-	O
CoV	O
,	O
and	O
effectively	O
cross	O
-	O
neutralized	O
evolved	O
MERS	O
-	O
CoV	O
isolates	O
through	O
recognizing	O
highly	O
conserved	O
RBD	O
epitopes	O
.	O

Cellular	O
entry	O
of	O
this	O
enveloped	O
virus	O
is	O
mediated	O
by	O
the	O
large	O
spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
,	O
trimers	O
of	O
which	O
mediate	O
virus	O
attachment	O
to	O
the	O
target	O
cell	O
and	O
subsequent	O
membrane	O
fusion	O
.	O

TITLE	O
:	O
SARS	O
Coronavirus	O
Fusion	O
Peptide	O
-	O
Derived	O
Sequence	O
Suppresses	O
Collagen	B-PRGE
-	O
Induced	O
Arthritis	O
in	O
DBA	O
/	O
1J	O
Mice	O
.	O

TITLE	O
:	O
The	O
Role	O
of	O
ACTH	B-PRGE
and	O
Corticosteroids	O
for	O
Sepsis	O
and	O
Septic	O
Shock	O
:	O
An	O
Update	O
.	O

TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
concentrations	O
in	O
the	O
alveolar	O
lavage	O
,	O
probability	O
of	O
survival	O
and	O
days	O
without	O
organ	O
failure	O
were	O
similar	O
in	O
both	O
groups	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
STAT1	B-PRGE
expression	O
was	O
markedly	O
reduced	O
in	O
PEDV	O
-	O
infected	O
cells	O
and	O
that	O
this	O
reduction	O
was	O
not	O
due	O
to	O
inhibition	O
of	O
STAT1	B-PRGE
transcription	O
.	O

STAT1	B-PRGE
downregulation	O
was	O
blocked	O
by	O
a	O
proteasome	O
inhibitor	O
but	O
not	O
by	O
an	O
autophagy	O
inhibitor	O
,	O
strongly	O
implicating	O
the	O
ubiquitin	B-PRGE
-	O
proteasome	O
targeting	O
degradation	O
system	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
PEDV	O
is	O
resistant	O
to	O
the	O
antiviral	O
effect	O
of	O
IFN	B-PRGE
.	O

Therefore	O
,	O
hypercytokinemia	O
with	O
DS	O
might	O
have	O
induced	O
BehÃ§et	O
'	O
s	O
disease	O
-	O
like	O
symptoms	O
,	O
including	O
stomatitis	O
and	O
ileocecal	O
perforation	O
,	O
complications	O
that	O
are	O
particularly	O
observed	O
in	O
patients	O
with	O
HLA	B-PRGE
-	I-PRGE
B51	I-PRGE
.	O

CONCLUSIONS	O
:	O
Plasma	O
levels	O
of	O
Presepsin	O
were	O
useful	O
for	O
the	O
diagnosis	O
of	O
SS	O
,	O
SSh	O
and	O
sCAP	B-PRGE
and	O
may	O
predict	O
ICU	O
mortality	O
in	O
these	O
patients	O
.	O

Due	O
to	O
its	O
wide	O
expression	O
profile	O
,	O
TRPV4	B-PRGE
is	O
implicated	O
in	O
multiple	O
pathophysiological	O
states	O
.	O

TITLE	O
:	O
Destabilized	O
SMC5	B-PRGE
/	I-PRGE
6	I-PRGE
complex	I-PRGE
leads	O
to	O
chromosome	O
breakage	O
syndrome	O
with	O
severe	O
lung	O
disease	O
.	O

Whole	O
exome	O
sequencing	O
revealed	O
biallelic	O
missense	O
mutations	O
in	O
the	O
NSMCE3	B-PRGE
(	O
also	O
known	O
as	O
NDNL2	B-PRGE
)	O
gene	O
,	O
which	O
encodes	O
a	O
subunit	O
of	O
the	O
SMC5	B-PRGE
/	I-PRGE
6	I-PRGE
complex	I-PRGE
that	O
is	O
essential	O
for	O
DNA	O
damage	O
response	O
and	O
chromosome	O
segregation	O
.	O

Neutropenia	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
AKI	B-PRGE
(	O
RR	O
1	O
.	O
28	O
;	O
95	O
%	O
CI	O
1	O
.	O
04	O
,	O
1	O
.	O
57	O
;	O
p	O
=	O
0	O
.	O
03	O
),	O
but	O
not	O
ARDS	O
(	O
RR	O
0	O
.	O
90	O
;	O
95	O
%	O
CI	O
0	O
.	O
70	O
,	O
1	O
.	O
17	O
;	O
p	O
=	O
0	O
.	O
42	O
)	O
or	O
30	O
-	O
day	O
mortality	O
(	O
RR	O
1	O
.	O
05	O
;	O
95	O
%	O
CI	O
0	O
.	O
85	O
,	O
1	O
.	O
31	O
;	O
p	O
=	O
0	O
.	O
65	O
).	O

ABSTRACT	O
:	O
Three	O
experiments	O
were	O
conducted	O
to	O
evaluate	O
the	O
effect	O
of	O
yeast	O
-	O
derived	O
carbohydrates	O
(	O
YDC	O
),	O
and	O
a	O
blend	O
of	O
probiotics	O
and	O
YDC	O
(	O
synbiotic	O
,	O
SNB	O
)	O
on	O
serum	B-PRGE
IgG	I-PRGE
concentration	O
,	O
maternal	O
-	O
derived	O
antibody	O
(	O
MDA	O
)	O
decay	O
,	O
and	O
specific	O
antibody	O
-	O
mediated	O
immune	O
response	O
in	O
chick	O
pullets	O
following	O
immunization	O
with	O
T	O
-	O
cell	O
dependent	O
antigens	O
.	O

Finally	O
,	O
in	O
experiment	O
3	O
,	O
on	O
d	O
21	O
and	O
28	O
posthatch	O
,	O
10	O
birds	O
per	O
treatment	O
were	O
immunized	O
intramuscularly	O
with	O
both	O
sheep	O
red	O
blood	O
cells	O
(	O
SRBC	O
)	O
and	O
bovine	B-PRGE
serum	I-PRGE
albumin	I-PRGE
(	O
BSA	B-PRGE
),	O
and	O
11	O
after	O
immunization	O
serum	O
samples	O
were	O
analyzed	O
by	O
hemagglutination	O
assay	O
for	O
antibody	O
response	O
to	O
SRBC	B-PRGE
,	O
and	O
by	O
ELISA	O
for	O
serum	B-PRGE
IgM	I-PRGE
and	O
IgG	B-PRGE
response	O
to	O
BSA	B-PRGE
.	O

12	O
hrs	O
after	O
DH	O
in	O
mice	O
the	O
local	O
and	O
systemic	O
cytokines	O
and	O
chemokines	O
were	O
quantified	O
by	O
multiplex	O
bead	O
array	O
or	O
ELISA	O
,	O
activated	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
by	O
western	O
blot	O
.	O

A	O
circulating	O
form	O
of	O
CD74	B-PRGE
(	O
soluble	O
CD74	B-PRGE
,	O
sCD74	O
)	O
was	O
recently	O
discovered	O
in	O
autoimmune	O
liver	O
disease	O
.	O

TITLE	O
:	O
Porcine	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
is	O
not	O
a	O
cellular	O
receptor	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
,	O
but	O
promotes	O
its	O
infectivity	O
via	O
aminopeptidase	B-PRGE
activity	O
.	O

Most	O
PLIs	O
occurred	O
during	O
the	O
systemic	O
onset	O
of	O
AOSD	O
.	O
PLI	B-PRGE
may	O
occur	O
in	O
5	O
%	O
of	O
AOSDs	O
,	O
of	O
which	O
ARDS	O
is	O
the	O
most	O
severe	O
.	O

In	O
this	O
study	O
we	O
demonstrated	O
that	O
the	O
last	O
39	O
amino	O
acid	O
stretches	O
of	O
Alphacoronavirus	O
spike	O
cytoplasmic	O
domains	O
of	O
the	O
human	O
coronavirus	O
229E	O
,	O
NL63	O
,	O
and	O
the	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
TGEV	O
interact	O
with	O
tubulin	B-PRGE
alpha	I-PRGE
and	I-PRGE
beta	I-PRGE
chains	I-PRGE
.	O

Negative	O
bacteria	O
by	O
PCR	O
and	O
culture	O
suggest	O
unnecessary	O
antibiotic	O
use	O
in	O
ILI	O
/	O
ARI	B-PRGE
.	O

The	O
out	O
of	O
frame	O
deletion	O
predicted	O
loss	O
of	O
most	O
of	O
the	O
S2	O
subunit	O
of	O
the	O
spike	O
protein	O
leaving	O
the	O
S1	B-PRGE
subunit	I-PRGE
with	O
an	O
intact	O
receptor	O
binding	O
domain	O
.	O

Such	O
hepatic	O
inflammatory	O
disorders	O
correlated	O
with	O
disturbed	O
production	O
of	O
interleukin	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
and	O
vascular	O
factors	O
by	O
LSECs	O
.	O

However	O
,	O
additional	O
cellular	O
binding	O
targets	O
of	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
that	O
may	O
augment	O
MERS	O
-	O
CoV	O
infection	O
have	O
not	O
been	O
further	O
explored	O
.	O

More	O
importantly	O
,	O
the	O
entry	O
of	O
MERS	O
-	O
CoV	O
was	O
increased	O
when	O
CEACAM5	O
was	O
overexpressed	O
in	O
permissive	O
cells	O
,	O
which	O
suggested	O
that	O
CEACAM5	B-PRGE
could	O
facilitate	O
MERS	O
-	O
CoV	O
entry	O
in	O
conjunction	O
with	O
DPP4	B-PRGE
despite	O
not	O
being	O
able	O
to	O
support	O
MERS	O
-	O
CoV	O
entry	O
independently	O
.	O

Moreover	O
,	O
CCL2	B-PRGE
and	O
CCL7	B-PRGE
synergised	O
with	O
CXCL8	B-PRGE
to	O
promote	O
neutrophil	O
migration	O
.	O

After	O
immunization	O
,	O
animals	O
vaccinated	O
with	O
fusion	O
proteins	O
rS1	B-PRGE
-	I-PRGE
HA2	I-PRGE
and	O
rS1	B-PRGE
-	I-PRGE
H3	I-PRGE
(	O
TM	O
)	O
demonstrated	O
stronger	O
robust	O
humoral	O
and	O
cellular	O
immune	O
responses	O
than	O
that	O
of	O
rS1	B-PRGE
and	O
inactivated	O
M41	O
vaccine	O
.	O

TITLE	O
:	O
Association	O
of	O
human	B-PRGE
leukocyte	I-PRGE
antigen	I-PRGE
class	I-PRGE
II	I-PRGE
alleles	I-PRGE
with	O
severe	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
coronavirus	O
infection	O
.	O

Similarly	O
to	O
SUD	O
,	O
the	O
PL	B-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
s	I-PRGE
from	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
MERS	O
-	O
CoV	O
,	O
and	O
HCoV	O
-	O
NL63	O
physically	O
interact	O
with	O
and	O
stabilize	O
RCHY1	B-PRGE
,	O
and	O
thus	O
trigger	O
degradation	O
of	O
endogenous	B-PRGE
p53	I-PRGE
.	O

The	O
significance	O
of	O
these	O
findings	O
is	O
that	O
down	O
-	O
regulation	O
of	O
p53	B-PRGE
as	O
a	O
major	O
player	O
in	O
antiviral	O
innate	O
immunity	O
provides	O
a	O
long	O
-	O
sought	O
explanation	O
for	O
delayed	O
activities	O
of	O
respective	O
genes	O
.	O

In	O
particular	O
,	O
the	O
extra	O
stem	O
of	O
SARS	B-PRGE
-	I-PRGE
PK	I-PRGE
was	O
replaced	O
by	O
an	O
RNA	O
aptamer	O
of	O
theophylline	O
and	O
designed	O
to	O
couple	O
theophylline	O
binding	O
with	O
the	O
stimulation	O
of	O
-	O
1	O
PRF	O
.	O

Chest	O
ultrasonography	O
provides	O
further	O
insights	O
into	O
pleural	O
and	O
lung	O
abnormalities	O
associated	O
with	O
ARF	B-PRGE
,	O
irrespective	O
of	O
its	O
origin	O
.	O

The	O
viruses	O
used	O
the	O
human	B-PRGE
entry	I-PRGE
receptor	I-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
and	O
replicated	O
in	O
human	O
hepatoma	O
cells	O
,	O
suggesting	O
a	O
principal	O
ability	O
to	O
cause	O
human	O
infections	O
.	O

Wortmannin	O
,	O
a	O
PI3	B-PRGE
-	I-PRGE
kinase	I-PRGE
inhibitor	O
,	O
inhibited	O
ROS	O
-	O
induced	O
cell	O
adhesion	O
and	O
FAK	B-PRGE
phosphorylation	O
.	O

Orthovanadate	O
,	O
a	O
protein	B-PRGE
tyrosine	I-PRGE
phosphatase	I-PRGE
inhibitor	O
,	O
and	O
Resveratrol	O
(	O
Resv	O
),	O
an	O
antioxidant	O
agent	O
,	O
protected	O
FAK	B-PRGE
and	O
ERK1	B-PRGE
/	I-PRGE
2	I-PRGE
from	O
dephosphorylation	O
and	O
HUVEC	O
from	O
ROS	O
-	O
induced	O
loss	O
of	O
adhesion	O
.	O

Hence	O
,	O
the	O
role	O
of	O
iNO	B-PRGE
by	O
various	O
mechanisms	O
and	O
in	O
various	O
age	O
groups	O
warrants	O
further	O
investigation	O
.	O

Our	O
goal	O
was	O
to	O
determine	O
if	O
syndecan	B-PRGE
-	I-PRGE
1	I-PRGE
level	O
is	O
associated	O
with	O
the	O
risk	O
of	O
intubation	O
and	O
modifying	O
effect	O
of	O
intravenous	O
fluids	O
(	O
IVFs	O
)	O
in	O
these	O
patients	O
.	O

Syndecan	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
measured	O
at	O
enrollment	O
in	O
patients	O
underdoing	O
protocolized	O
resuscitation	O
for	O
severe	O
sepsis	O
or	O
septic	O
shock	O
.	O

Fluid	O
volume	O
was	O
not	O
associated	O
with	O
intubation	O
in	O
patients	O
with	O
a	O
low	O
syndecan	B-PRGE
-	I-PRGE
1	I-PRGE
level	O
but	O
was	O
associated	O
with	O
intubation	O
in	O
those	O
with	O
high	O
syndecan	O
-	O
1	O
levels	O
.	O

RESULTS	O
:	O
Syndecan	B-PRGE
-	I-PRGE
1	I-PRGE
was	O
measured	O
in	O
175	O
patients	O
.	O

Based	O
on	O
the	O
reverse	O
genetics	O
of	O
our	O
previous	O
research	O
work	O
,	O
we	O
constructed	O
the	O
recombinant	O
R	O
-	O
H120	O
-	O
Beaudette	O
-	O
p65	B-PRGE
(	O
S	O
)	O
strain	O
by	O
replacing	O
the	O
complete	O
spike	O
gene	O
of	O
H120	O
with	O
the	O
corresponding	O
spike	O
gene	O
from	O
the	O
Beaudette	O
p65	B-PRGE
strain	O
.	O

TITLE	O
:	O
Suppression	O
of	O
Virulent	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Proliferation	O
by	O
the	O
PI3K	B-PRGE
/	O
Akt	B-PRGE
/	O
GSK	B-PRGE
-	O
3Î±	O
/	O
Î²	O
Pathway	O
.	O

Inhibiting	O
PI3K	B-PRGE
,	O
an	O
upstream	O
activator	O
of	O
Akt	B-PRGE
,	O
enhanced	O
PEDV	O
replication	O
.	O

Inhibiting	O
GSK	B-PRGE
-	I-PRGE
3Î±	I-PRGE
/	I-PRGE
Î²	I-PRGE
,	O
one	O
of	O
the	O
downstream	O
effectors	O
of	O
PI3K	B-PRGE
/	O
Akt	B-PRGE
pathway	O
and	O
regulated	O
by	O
Akt	B-PRGE
during	O
PEDV	O
infected	O
Vero	O
cells	O
,	O
also	O
enhanced	O
PEDV	O
replication	O
.	O

TITLE	O
:	O
Discovery	O
of	O
a	O
Potent	O
Acyclic	O
,	O
Tripeptidic	O
,	O
Acyl	O
Sulfonamide	O
Inhibitor	O
of	O
Hepatitis	B-PRGE
C	I-PRGE
Virus	I-PRGE
NS3	I-PRGE
Protease	I-PRGE
as	O
a	O
Back	O
-	O
up	O
to	O
Asunaprevir	O
with	O
the	O
Potential	O
for	O
Once	O
-	O
Daily	O
Dosing	O
.	O

A	O
recombination	O
analysis	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
showed	O
that	O
the	O
new	O
isolate	O
evolved	O
from	O
the	O
IBV	O
BJ	O
strain	O
and	O
the	O
KM91	O
vaccine	O
strain	O
.	O

Conversely	O
,	O
knockdown	O
of	O
Smad7	B-PRGE
effectively	O
inhibited	O
MERS	O
-	O
CoV	O
replication	O
and	O
protected	O
cells	O
from	O
virus	O
-	O
induced	O
cytopathic	O
effects	O
.	O

We	O
further	O
demonstrated	O
that	O
hyperexpression	O
of	O
Smad7	B-PRGE
or	O
FGF2	B-PRGE
induced	O
a	O
strong	O
apoptotic	O
response	O
in	O
kidney	O
cells	O
.	O

RESULTS	O
:	O
We	O
observed	O
that	O
:	O
(	O
1	O
)	O
there	O
were	O
striking	O
differences	O
between	O
cases	O
and	O
controls	O
with	O
regard	O
to	O
three	O
biological	O
variables	O
:	O
post	O
-	O
exercise	O
M	O
-	O
wave	O
,	O
TBARS	O
variations	O
and	O
CD26	B-PRGE
-	I-PRGE
expression	O
at	O
rest	O
;	O
(	O
2	O
)	O
each	O
of	O
these	O
three	O
variables	O
correlated	O
with	O
the	O
other	O
two	O
;	O
(	O
3	O
)	O
abnormalities	O
in	O
the	O
biomarkers	O
associated	O
with	O
health	O
-	O
related	O
quality	O
of	O
life	O
:	O
the	O
LHS	O
score	O
was	O
negatively	O
correlated	O
with	O
the	O
exercise	O
-	O
induced	O
TBARS	O
increase	O
and	O
positively	O
correlated	O
with	O
CD26	B-PRGE
-	O
expression	O
while	O
the	O
pain	O
component	O
of	O
SF	O
-	O
36	O
was	O
negatively	O
correlated	O
with	O
CD26	B-PRGE
-	O
expression	O
;	O
(	O
4	O
)	O
the	O
TBARS	O
increase	O
and	O
the	O
M	O
-	O
wave	O
decrease	O
were	O
the	O
highest	O
,	O
and	O
the	O
CD26	B-PRGE
-	I-PRGE
expression	O
level	O
the	O
lowest	O
in	O
patients	O
who	O
had	O
been	O
submitted	O
to	O
infectious	O
stressors	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
severe	O
chronic	O
inflammatory	O
demyelinating	O
polyradiculoneuropathy	O
with	O
monoclonal	O
gammopathy	O
of	O
undetermined	O
significance	O
with	O
alternating	O
immunoglobulin	B-PRGE
class	O
to	O
IgM	B-PRGE
from	O
IgA	B-PRGE
.	O
ABSTRACT	O
:	O
A	O
71	O
-	O
year	O
-	O
old	O
woman	O
with	O
chronic	O
inflammatory	O
demyelinating	O
polyradiculoneuropathy	O
(	O
CIDP	O
)	O
with	O
IgA	B-PRGE
-	I-PRGE
Î»	I-PRGE
monoclonal	O
gammopathy	O
of	O
undetermined	O
significance	O
(	O
MGUS	O
)	O
showed	O
the	O
acute	O
development	O
of	O
tetraplegia	O
,	O
respiratory	O
failure	O
,	O
and	O
a	O
marked	O
fluctuation	O
of	O
the	O
blood	O
pressure	O
.	O

At	O
this	O
time	O
,	O
serum	O
components	O
of	O
IgA	B-PRGE
-	I-PRGE
Î»	I-PRGE
and	O
IgM	B-PRGE
-	I-PRGE
Î»	I-PRGE
were	O
biclonally	O
positive	O
.	O

The	O
cases	O
were	O
divided	O
into	O
three	O
groups	O
:	O
the	O
control	O
group	O
(	O
amylase	B-PRGE
or	O
lipase	B-PRGE
were	O
normal	O
),	O
mildly	O
elevated	O
group	O
(	O
1	O
time	O
<	O
increase	O
of	O
serum	O
amylase	B-PRGE
or	O
<	O
3	O
times	O
increase	O
of	O
lipase	B-PRGE
),	O
highly	O
elevated	O
group	O
(	O
serum	B-PRGE
amylase	I-PRGE
or	O
lipase	B-PRGE
increased	O
>	O
3	O
times	O
).	O

To	O
determine	O
the	O
impact	O
of	O
miR	O
-	O
155	O
on	O
trafficking	O
,	O
T	O
cells	O
from	O
infected	O
WT	O
or	O
miR	O
-	O
155	O
(-/-)	O
mice	O
were	O
adoptively	O
transferred	O
into	O
RAG1	B-PRGE
(-/-)	O
mice	O
,	O
and	O
T	O
cell	O
accumulation	O
into	O
the	O
CNS	O
was	O
assessed	O
using	O
flow	O
cytometry	O
.	O

Sequence	O
analysis	O
of	O
Nucleocapsid	B-PRGE
gene	I-PRGE
of	O
TioV	O
demonstrated	O
sequence	O
identity	O
of	O
99	O
.	O
87	O
%	O
and	O
99	O
.	O
99	O
%	O
nucleotide	O
and	O
amino	O
acid	O
respectively	O
with	O
of	O
TioV	O
strain	O
isolated	O
in	O
Malaysia	O
,	O
2001	O
.	O

The	O
diagnosis	O
was	O
confirmed	O
by	O
NS1	B-PRGE
antigen	O
-	O
based	O
ELISA	O
test	O
or	O
dengue	O
serology	O
for	O
IgM	B-PRGE
and	O
IgG	B-PRGE
antibodies	I-PRGE
,	O
and	O
the	O
data	O
were	O
analyzed	O
using	O
SPSS	O
16	O
.	O
0	O
statistical	O
software	O
.	O

The	O
study	O
was	O
a	O
secondary	O
analysis	O
of	O
the	O
safety	O
of	O
a	O
randomized	O
trial	O
of	O
erythropoietin	B-PRGE
and	O
transfusion	O
threshold	O
in	O
patients	O
with	O
severe	O
TBI	O
.	O

Plasma	B-PRGE
proinflammatory	I-PRGE
markers	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	O
-	O
8	O
and	O
anti	B-PRGE
-	I-PRGE
inflammatory	I-PRGE
marker	I-PRGE
IL	I-PRGE
-	I-PRGE
10	I-PRGE
were	O
associated	O
with	O
the	O
development	O
of	O
ARDS	O
(	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
1	O
.	O
55	O
,	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1	O
.	O
14	O
,	O
2	O
.	O
11	O
,	O
P	O
=	O
0	O
.	O
005	O
for	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
;	O
adjusted	O
HR	O
=	O
1	O
.	O
32	O
,	O
CI	O
=	O
1	O
.	O
10	O
,	O
1	O
.	O
59	O
,	O
P	O
=	O
0	O
.	O
003	O
for	O
IL	O
-	O
8	O
).	O

The	O
knowledge	O
obtained	O
from	O
this	O
study	O
might	O
be	O
used	O
to	O
identify	O
an	O
inhibitor	O
of	O
MERS	O
-	O
CoV	O
replication	O
,	O
and	O
the	O
helicase	B-PRGE
might	O
be	O
used	O
as	O
a	O
therapeutic	O
target	O
.	O

ABSTRACT	O
:	O
Initial	O
success	O
with	O
chimeric	B-PRGE
antigen	I-PRGE
receptor	I-PRGE
-	O
modified	O
T	O
cell	O
therapy	O
for	O
relapsed	O
/	O
refractory	O
acute	O
lymphoblastic	O
leukemia	O
is	O
leading	O
to	O
expanded	O
use	O
through	O
multicenter	O
trials	O
.	O

TITLE	O
:	O
Generation	O
and	O
Characterization	O
of	O
Eptesicus	O
fuscus	O
(	O
Big	O
brown	O
bat	O
)	O
kidney	O
cell	O
lines	O
immortalized	O
using	O
the	O
Myotis	B-PRGE
polyomavirus	I-PRGE
large	I-PRGE
T	I-PRGE
-	I-PRGE
antigen	I-PRGE
.	O

Therefore	O
,	O
many	O
different	O
antigenic	O
forms	O
,	O
serotypes	O
or	O
variant	O
strains	O
of	O
avian	B-PRGE
coronaviruses	I-PRGE
(	O
AvCoV	O
)	O
exist	O
worldwide	O
.	O

A	O
total	O
of	O
250	O
swabs	O
were	O
randomly	O
selected	O
and	O
analyzed	O
by	O
multiplex	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
including	O
research	O
of	O
18	O
viruses	O
and	O
4	O
bacteria	O
.	O

Accessory	O
proteins	O
are	O
genus	O
-	O
specific	O
for	O
coronavirus	O
,	O
and	O
two	O
putative	O
accessory	O
proteins	O
,	O
NS6	B-PRGE
and	O
NS7	B-PRGE
,	O
are	O
predicted	O
to	O
be	O
encoded	O
by	O
PDCoV	O
;	O
however	O
,	O
this	O
remains	O
to	O
be	O
confirmed	O
experimentally	O
.	O

TITLE	O
:	O
SURVEILLANCE	B-PRGE
FOR	I-PRGE
VIRAL	I-PRGE
AND	I-PRGE
PARASITIC	I-PRGE
PATHOGENS	I-PRGE
IN	I-PRGE
A	I-PRGE
VULNERABLE	I-PRGE
AFRICAN	I-PRGE
LION	I-PRGE
(	O
PANTHERA	O
LEO	O
)	O
POPULATION	O
IN	O
THE	O
NORTHERN	O
TULI	O
GAME	O
RESERVE	O
,	O
BOTSWANA	O
.	O

Herein	O
,	O
we	O
identified	O
a	O
novel	O
coronavirus	O
,	O
provisionally	O
designated	O
Rousettus	B-PRGE
bat	I-PRGE
coronavirus	I-PRGE
GCCDC1	I-PRGE
(	O
Ro	O
-	O
BatCoV	O
GCCDC1	O
),	O
in	O
the	O
rectal	O
swab	O
samples	O
of	O
Rousettus	O
leschenaulti	O
bats	O
by	O
using	O
pan	O
-	O
coronavirus	O
RT	O
-	O
PCR	O
and	O
next	O
-	O
generation	O
sequencing	O
.	O

In	O
addition	O
,	O
the	O
antibodies	O
represent	O
useful	O
tools	O
for	O
investigating	O
the	O
antigenic	O
properties	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
.	O

Elevated	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(>	O
1	O
,	O
000	O
U	O
/	O
l	O
)	O
was	O
detected	O
in	O
4	O
(	O
66	O
.	O
7	O
%)	O
patients	O
and	O
elevated	O
alanine	B-PRGE
aminotransferase	I-PRGE
was	O
exhibited	O
by	O
5	O
(	O
83	O
/	O
3	O
%)	O
patients	O
.	O

Case	O
fatality	O
rate	O
for	O
Malaysian	O
children	O
below	O
5	O
years	O
of	O
age	O
with	O
RSV	B-PRGE
ALRI	I-PRGE
in	O
our	O
centre	O
is	O
higher	O
than	O
what	O
is	O
seen	O
in	O
developed	O
countries	O
,	O
suggesting	O
that	O
there	O
is	O
room	O
for	O
improvement	O
.	O

We	O
found	O
that	O
a	O
subset	O
of	O
avian	O
influenza	O
viruses	O
,	O
including	O
potentially	O
pandemic	O
H5N1	O
,	O
H7N9	O
,	O
and	O
H9N2	O
viruses	O
,	O
could	O
infect	O
human	O
pulmonary	O
endothelial	O
cells	O
(	O
HULEC	O
)	O
with	O
high	O
efficiency	O
compared	O
to	O
human	B-PRGE
H1N1	I-PRGE
or	O
H3N2	O
viruses	O
.	O

Collectively	O
,	O
our	O
study	O
demonstrates	O
that	O
the	O
human	O
pulmonary	O
endothelium	O
possesses	O
intrinsic	O
immunity	O
to	O
human	O
influenza	O
viruses	O
,	O
in	O
part	O
due	O
to	O
the	O
constitutive	O
expression	O
of	O
IFITM3	B-PRGE
proteins	I-PRGE
.	O

We	O
show	O
that	O
human	O
influenza	O
virus	O
infection	O
is	O
blocked	O
during	O
the	O
early	O
stages	O
of	O
virus	O
entry	O
,	O
which	O
is	O
likely	O
due	O
to	O
the	O
relatively	O
high	O
expression	O
of	O
the	O
host	O
antiviral	O
factors	O
IFITMs	O
(	O
interferon	B-PRGE
-	O
induced	O
transmembrane	O
proteins	O
)	O
located	O
in	O
membrane	O
-	O
bound	O
compartments	O
inside	O
cells	O
.	O

In	O
the	O
second	O
week	O
of	O
illness	O
,	O
the	O
severe	O
group	O
had	O
higher	O
serum	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
54	O
vs	O
.	O
4	O
pg	O
/	O
mL	O
,	O
P	O
=	O
0	O
.	O
006	O
)	O
and	O
CXCL	O
-	O
10	O
(	O
2	O
,	O
642	O
vs	O
.	O
382	O
pg	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

IFN	B-PRGE
-	I-PRGE
Î±	I-PRGE
response	O
was	O
not	O
observed	O
in	O
mild	O
cases	O
.	O

Elevated	O
C	B-PRGE
-	I-PRGE
creative	I-PRGE
protein	I-PRGE
,	O
aspartate	B-PRGE
aminotransferase	I-PRGE
,	O
creatine	B-PRGE
kinase	I-PRGE
,	O
and	O
lymphocytopenia	O
predicted	O
a	O
higher	O
risk	O
of	O
developing	O
ARDS	O
.	O

This	O
dichotomy	O
is	O
exemplified	O
by	O
cathepsin	B-PRGE
L	I-PRGE
(	O
CTSL	O
),	O
which	O
helps	O
Hendra	O
virus	O
and	O
SARS	O
coronavirus	O
to	O
invade	O
cells	O
,	O
but	O
is	O
essential	O
for	O
survival	O
in	O
mice	O
with	O
mycoplasma	O
pneumonia	O
.	O

Extracellular	B-PRGE
trypsin	I-PRGE
activates	O
PEDV	O
entry	O
when	O
lysosomal	B-PRGE
cysteine	I-PRGE
proteases	I-PRGE
are	O
inhibited	O
.	O

We	O
found	O
that	O
,	O
compared	O
with	O
a	O
laboratory	O
strain	O
isolated	O
in	O
1966	O
and	O
passaged	O
for	O
a	O
half	O
century	O
,	O
clinical	O
isolates	O
of	O
HCoV	O
-	O
229E	O
were	O
less	O
likely	O
to	O
utilize	O
cathepsin	B-PRGE
L	I-PRGE
;	O
rather	O
,	O
they	O
showed	O
a	O
preference	O
for	O
TMPRSS2	O
.	O

TITLE	O
:	O
A	O
recombinant	B-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
of	O
MERS	O
-	O
CoV	O
in	O
trimeric	O
form	O
protects	O
human	B-PRGE
dipeptidyl	I-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
hDPP4	O
)	O
transgenic	O
mice	O
from	O
MERS	O
-	O
CoV	O
infection	O
.	O

Among	O
the	O
isolated	O
constituents	O
,	O
Sennoside	O
A	O
and	O
B	O
were	O
effective	O
on	O
both	O
RDDP	O
and	O
RNase	B-PRGE
H	I-PRGE
RT	I-PRGE
-	O
associated	O
functions	O
in	O
biochemical	O
assays	O
.	O

Pharmacological	O
activation	O
of	O
Nur77	O
by	O
cytosporone	O
B	O
(	O
CsnB	B-PRGE
)	O
inhibited	O
ET	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
in	O
ARDS	O
rats	O
,	O
decreased	O
LPS	O
-	O
induced	O
phosphorylation	O
of	O
NF	O
-	O
ÎºB	O
and	O
p38	B-PRGE
MAPK	O
,	O
and	O
relieved	O
lung	O
,	O
liver	O
,	O
and	O
kidney	O
injury	O
.	O

Besides	O
the	O
well	O
-	O
known	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
Î±	I-PRGE
/	I-PRGE
Î²	I-PRGE
)	O
response	O
,	O
the	O
protein	B-PRGE
kinase	I-PRGE
R	I-PRGE
(	O
PKR	B-PRGE
)-	O
mediated	O
stress	O
response	O
is	O
being	O
recognized	O
as	O
an	O
important	O
innate	O
response	O
pathway	O
.	O

By	O
inserting	O
p4a	O
in	O
a	O
picornavirus	O
lacking	O
its	O
natural	O
PKR	B-PRGE
antagonist	O
,	O
we	O
showed	O
that	O
p4a	O
exerts	O
PKR	B-PRGE
antagonistic	O
activity	O
also	O
under	O
infection	O
conditions	O
.	O

Three	O
compounds	O
,	O
trichlormethiazide	O
,	O
D	O
-(+)	O
biotin	O
,	O
and	O
glutathione	O
successfully	O
bound	O
to	O
the	O
N	B-PRGE
protein	I-PRGE
,	O
in	O
vitro	O
,	O
with	O
the	O
IC	O

Sequence	O
analysis	O
of	O
the	O
hypervariable	O
regions	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
revealed	O
a	O
close	O
relation	O
to	O
the	O
QX	B-PRGE
-	I-PRGE
like	I-PRGE
genotype	I-PRGE
which	O
has	O
not	O
been	O
detected	O
in	O
Sudan	O
before	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
revealed	O
that	O
the	O
IBV	O
/	O
Ck	O
/	O
Sudan	O
/	O
AR251	O
-	O
15	O
/	O
2014	O
isolate	O
clustered	O
together	O
with	O
viruses	O
of	O
the	O
GI	O
-	O
19	O
lineage	O
.	O

In	O
summary	O
,	O
our	O
structures	O
provide	O
new	O
insight	O
into	O
this	O
key	O
multifunctional	O
NendoU	B-PRGE
family	I-PRGE
of	O
proteins	O
and	O
lay	O
a	O
foundation	O
for	O
better	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
and	O
antiviral	O
drug	O
development	O
.	O

TITLE	O
:	O
Recombinant	B-PRGE
Receptor	I-PRGE
-	I-PRGE
Binding	I-PRGE
Domains	I-PRGE
of	O
Multiple	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronaviruses	O
(	O
MERS	O
-	O
CoVs	O
)	O
Induce	O
Cross	O
-	O
Neutralizing	O
Antibodies	O
against	O
Divergent	O
Human	O
and	O
Camel	O
MERS	O
-	O
CoVs	O
and	O
Antibody	O
Escape	O
Mutants	O
.	O

Depletion	O
of	O
CD4	B-PRGE

At	O
the	O
beginning	O
of	O
the	O
mock	O
loop	O
experiments	O
,	O
the	O
septic	O
blood	O
showed	O
significantly	O
increased	O
thrombin	B-PRGE
-	O
antithrombin	B-PRGE
complexes	O
(	O
76	O
.	O
9	O
vs	O
27	O
.	O
7	O
Âµg	O
/	O
l	O
),	O
D	O
-	O
dimers	O
(	O
1	O
.	O
2	O
vs	O
0	O
.	O
3	O
mg	O
/	O
l	O
)	O
and	O
fibrinogen	B-PRGE
concentration	O
(	O
1	O
.	O
8	O
vs	O
1	O
.	O
5	O
g	O
/	O
l	O
),	O
as	O
well	O
as	O
elevated	O
extrinsic	O
coagulation	O
activity	O
(	O
shorter	O
EXTEM	O
-	O
CT	O
:	O
44	O
.	O
2	O
vs	O
57	O
s	O
)	O
and	O
higher	O
lactate	O
(	O
3	O
.	O
4	O
vs	O
1	O
.	O
5	O
mmol	O
/	O
l	O
)	O
and	O
cytokine	O
levels	O
(	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
:	O
827	O
vs	O
31	O
pg	O
/	O
ml	O
)	O
when	O
compared	O
with	O
the	O
blood	O
from	O
healthy	O
animals	O
.	O

Here	O
,	O
we	O
report	O
a	O
unique	O
phenomenon	O
of	O
PEDV	O
nucleocapsid	O
(	O
N	O
)	O
cleavage	O
by	O
the	O
PEDV	B-PRGE
-	I-PRGE
encoded	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3Cpro	O
)	O
during	O
infection	O
.	O

Here	O
we	O
show	O
that	O
inactivated	O
rabies	O
virus	O
particles	O
containing	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S1	I-PRGE
protein	I-PRGE
induce	O
potent	O
immune	O
responses	O
against	O
MERS	O
-	O
CoV	O
and	O
RABV	O
.	O

GLTSCR2	O
-	O
mediated	O
attenuation	O
of	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
led	O
to	O
alleviation	O
of	O
host	O
cell	O
innate	O
immune	O
response	O
to	O
viral	O
infection	O
.	O

Inhibitor	O
screening	O
assays	O
with	O
this	O
model	O
showed	O
a	O
reduction	O
in	O
neutrophil	O
migration	O
into	O
the	O
LPS	O
-	O
injected	O
swim	O
bladder	O
in	O
response	O
to	O
Shp2	B-PRGE
inhibition	O
.	O

RESULTS	O
:	O
Levels	O
of	O
sPD	B-PRGE
-	I-PRGE
1	I-PRGE
are	O
increased	O
in	O
both	O
the	O
serum	O
(	O
11	O
,	O
429	O
.	O
3	O
pg	O
/	O
mL	O
(	O
SD	O
2133	O
.	O
3	O
)	O
vs	O
.	O
8061	O
.	O
4	O
(	O
SD	O
4187	O
.	O
8	O
),	O
p	O
=	O
0	O
.	O
036	O
)	O
and	O
bronchial	O
alveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
(	O
6	O
,	O
311	O
.	O
1	O
pg	O
/	O
mL	O
(	O
SD	O
3758	O
.	O
0	O
)	O
vs	O
.	O
90	O
.	O
7	O
pg	O
/	O
mL	O
(	O
SD	O
202	O
.	O
8	O
),	O
p	O
=	O
0	O
.	O
002	O
)	O
of	O
humans	O
with	O
ARDS	O
.	O

TITLE	O
:	O
[	O
Dermatomyositis	O
associated	O
with	O
anti	B-PRGE
-	I-PRGE
MDA5	I-PRGE
antibodies	I-PRGE
and	O
pneumocystis	O
pneumonia	O
:	O
Two	O
lethal	O
cases	O
].	O

Case	O
n	O
In	O
dermatomyositis	O
,	O
anti	B-PRGE
-	I-PRGE
MDA5	I-PRGE
antibody	I-PRGE
screening	O
is	O
essential	O
for	O
the	O
prognosis	O
since	O
the	O
disease	O
carries	O
a	O
risk	O
of	O
complication	O
with	O
severe	O
lung	O
disease	O
.	O

ABSTRACT	O
:	O
Currently	O
,	O
there	O
is	O
no	O
registered	O
treatment	O
for	O
infections	O
with	O
emerging	O
zoonotic	O
coronaviruses	O
like	O
SARS	B-PRGE
-	O
and	O
MERS	O
-	O
coronavirus	O
.	O

Interestingly	O
,	O
the	O
plaque	O
-	O
purified	O
virus	O
had	O
a	O
large	O
deletion	O
in	O
ORF3abc	O
and	O
E	O
genes	O
(	O
1	O
,	O
165	O
nt	O
),	O
and	O
a	O
short	O
deletion	O
in	O
ORF7b	O
gene	O
(	O
60	O
nt	O
),	O
suggesting	O
that	O
these	O
regions	O
are	O
not	O
necessary	O
for	O
in	O
vitro	O
replication	O
of	O
CCoV	O
.	O
Next	O
,	O
the	O
antigenicity	O
between	O
the	O
isolated	O
CCoV	B-PRGE
-	I-PRGE
IIb	I-PRGE
and	O
the	O
other	O
CCoV	B-PRGE
-	I-PRGE
IIa	I-PRGE
was	O
compared	O
by	O
VN	O
test	O
,	O
revealing	O
that	O
antigenicty	O
of	O
the	O
isolated	O
CCoV	O
is	O
equal	O
or	O
higher	O
than	O
that	O
of	O
the	O
other	O
CCoV	O
.	O
In	O
summary	O
,	O
two	O
subgenotypes	O
of	O
CCoV	O
-	O
II	O
are	O
spreading	O
among	O
Vietnamese	O
dogs	O
.	O

To	O
exploit	O
the	O
possibility	O
of	O
using	O
RNA	O
interference	O
(	O
RNAi	O
)	O
as	O
a	O
strategy	O
against	O
TGEV	O
infection	O
,	O
three	O
plasmids	O
(	O
pRNAT	O
-	O
1	O
,	O
pRNAT	O
-	O
2	O
,	O
and	O
pRNAT	O
-	O
3	O
)	O
expressing	O
short	O
hairpin	O
RNAs	O
were	O
designed	O
to	O
target	O
three	O
different	O
coding	O
regions	O
of	O
the	O
M	B-PRGE
gene	I-PRGE
of	O
TGEV	O
.	O

In	O
the	O
adjusted	O
analysis	O
,	O
a	O
statistically	O
significant	O
relationship	O
between	O
PEEP	O
and	O
ICP	B-PRGE
and	O
PEEP	O
and	O
CPP	O
was	O
found	O
only	O
among	O
observations	O
occurring	O
during	O
periods	O
of	O
severe	O
lung	O
injury	O
.	O

TITLE	O
:	O
Transmissible	O
Gastroenteritis	O
Virus	O
Infection	O
Enhances	O
SGLT1	B-PRGE
and	O
GLUT2	B-PRGE
Expression	O
to	O
Increase	O
Glucose	O
Uptake	O
.	O

However	O
,	O
patients	O
from	O
the	O
ECLS	O
group	O
had	O
preoperatively	O
higher	O
lactate	O
(	O
P	O
=	O
0	O
.	O
037	O
),	O
aspartate	B-PRGE
aminotransferase	I-PRGE
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
alanine	B-PRGE
aminotransferase	I-PRGE
(	O
P	O
<	O
0	O
.	O
001	O
)	O
levels	O
,	O
all	O
of	O
them	O
significantly	O
decreased	O
after	O
surgery	O
(	O
P	O
=	O
0	O
.	O
004	O
,	O
P	O
=	O
0	O
.	O
017	O
,	O
and	O
P	O
=	O
0	O
.	O
001	O
,	O
respectively	O
)	O
and	O
did	O
not	O
show	O
any	O
statistical	O
differences	O
to	O
the	O
corresponding	O
values	O
from	O
the	O
control	O
group	O
(	O
P	O
=	O
0	O
.	O
597	O
,	O
P	O
=	O
0	O
.	O
491	O
,	O
and	O
P	O
=	O
0	O
.	O
339	O
,	O
respectively	O
).	O

ABSTRACT	O
:	O
CHARGE	O
(	O
coloboma	O
,	O
heart	O
defect	O
,	O
atresia	O
choanae	O
,	O
retarded	O
growth	O
and	O
development	O
,	O
genital	O
hypoplasia	O
,	O
and	O
ear	O
anomalies	O
/	O
deafness	O
)	O
syndrome	O
is	O
a	O
rare	O
genetic	O
disorder	O
caused	O
by	O
CHD7	B-PRGE
mutation	I-PRGE
and	O
is	O
related	O
to	O
immunodeficiency	O
.	O

TITLE	O
:	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
protein	I-PRGE
levels	O
in	O
both	O
induced	O
sputum	O
and	O
plasma	O
are	O
increased	O
in	O
stable	O
but	O
not	O
acute	O
asthma	O
individuals	O
with	O
obesity	O
.	O

TITLE	O
:	O
Passive	O
immunotherapy	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
infection	O
with	O
equine	B-PRGE
immunoglobulin	I-PRGE
or	O
immunoglobulin	B-PRGE
fragments	I-PRGE
in	O
a	O
mouse	O
model	O
.	O

Models	O
of	O
MERS	O
-	O
CoV	O
-	O
induced	O
severe	O
respiratory	O
disease	O
have	O
been	O
difficult	O
to	O
achieve	O
,	O
and	O
small	O
-	O
animal	O
models	O
traditionally	O
used	O
to	O
investigate	O
viral	O
pathogenesis	O
(	O
mouse	O
,	O
hamster	O
,	O
guinea	O
-	O
pig	O
and	O
ferret	O
)	O
are	O
naturally	O
resistant	O
to	O
MERS	O
-	O
CoV	O
.	O
Therefore	O
,	O
we	O
used	O
CRISPR	O
-	O
Cas9	O
gene	O
editing	O
to	O
modify	O
the	O
mouse	O
genome	O
to	O
encode	O
two	O
amino	O
acids	O
(	O
positions	O
288	O
and	O
330	O
)	O
that	O
match	O
the	O
human	O
sequence	O
in	O
the	O
dipeptidyl	O
peptidase	B-PRGE
4	I-PRGE
receptor	I-PRGE
,	O
making	O
mice	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
infection	O
and	O
replication	O
.	O

In	O
the	O
stratified	O
analysis	O
,	O
we	O
found	O
that	O
older	O
aged	O
patients	O
(â¥	O
65	O
years	O
)	O
were	O
more	O
susceptible	O
to	O
iNO	B-PRGE
-	O
associated	O
kidney	O
injury	O
than	O
younger	O
patients	O
(	O
p	O
=	O
0	O
.	O
05	O
).	O

Prompt	O
recognition	O
and	O
initiation	O
of	O
immunotherapy	O
including	O
intravenous	O
immunoglobulin	B-PRGE
or	O
plasmapheresis	O
,	O
together	O
with	O
supportive	O
care	O
including	O
treatment	O
of	O
underlying	O
infections	O
and	O
physical	O
therapy	O
,	O
can	O
improve	O
outcomes	O
in	O
both	O
myasthenic	O
crisis	O
and	O
GBS	O
.	O

TITLE	O
:	O
Differential	O
Cell	O
Count	O
and	O
CRP	B-PRGE
Level	O
in	O
Blood	O
as	O
Predictors	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
in	O
Acute	O
Febrile	O
Patients	O
during	O
Nosocomial	O
Outbreak	O
.	O

Chicks	O
were	O
divided	O
into	O
seven	O
groups	O
,	O
with	O
two	O
groups	O
receiving	O
single	O
Massachusetts	O
(	O
Mass	O
)	O
vaccinations	O
while	O
the	O
other	O
four	O
were	O
inoculated	O
with	O
combinations	O
of	O
different	O
IBV	O
serotypes	O
;	O
Mass	O
,	O
793B	O
,	O
D274	O
and	O
Arkansas	O
(	O
Ark	B-PRGE
).	O

Differences	O
in	O
detection	O
among	O
assays	O
seem	O
to	O
be	O
more	O
related	O
to	O
intrinsic	O
factors	O
of	O
an	O
assay	O
than	O
to	O
the	O
PEDV	B-PRGE
antigen	I-PRGE
used	O
.	O

The	O
Î²CoVs	O
group	O
is	O
known	O
to	O
include	O
some	O
coronaviruses	O
highly	O
pathogenic	O
to	O
human	O
,	O
such	O
as	O
SARS	B-PRGE
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
All	O
coronavirus	O
sequences	O
generated	O
from	O
frugivorous	O
bats	O
(	O
family	O
Pteropodidae	O
)	O
(	O
n	O
=	O
55	O
)	O
clustered	O
with	O
other	O
bat	O
Î²CoVs	O
of	O
lineage	O
D	O
,	O
whereas	O
one	O
coronavirus	O
from	O
Pipistrellus	O
coromandra	O
fell	O
in	O
the	O
lineage	O
C	O
of	O
Î²CoVs	O
which	O
also	O
includes	O
the	O
MERS	O
-	O
CoV	O
.	O
Î±CoVs	O
were	O
all	O
detected	O
in	O
various	O
genera	O
of	O
insectivorous	O
bats	O
and	O
clustered	O
with	O
diverse	O
bat	O
Î±CoV	O
sequences	O
previously	O
published	O
.	O

However	O
detection	O
of	O
flu	B-PRGE
emphasises	O
preventive	O
strategies	O
like	O
vaccination	O
.	O

A	O
surface	O
spike	O
(	O
S	O
)	O
protein	O
guides	O
MERS	O
-	O
CoV	O
entry	O
into	O
host	O
cells	O
by	O
binding	O
to	O
cellular	O
receptor	O
dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	B-PRGE
),	O
followed	O
by	O
fusion	O
between	O
virus	O
and	O
host	O
cell	O
membranes	O
.	O

In	O
this	O
study	O
we	O
sequenced	O
the	O
complete	O
genomes	O
of	O
three	O
emergent	O
Australian	O
strains	O
of	O
IBV	O
(	O
IBV	O
/	O
Ck	O
/	O
Aus	O
/	O
N1	O
/	O
88	O
,	O
IBV	O
/	O
Ck	O
/	O
Aus	O
/	O
N1	O
/	O
03	O
and	O
IBV	O
/	O
Ck	O
/	O
Aus	O
/	O
N1	O
/	O
08	O
)	O
and	O
a	O
previously	O
incompletely	O
characterised	O
vaccine	O
strain	O
,	O
IBV	O
/	O
Ck	O
/	O
Aus	B-PRGE
/	O
Armidale	O
,	O
and	O
compared	O
them	O
to	O
the	O
genome	O
of	O
the	O
vaccine	O
strain	O
VicS	O
.	O
We	O
detected	O
multiple	O
recombination	O
events	O
throughout	O
the	O
genome	O
between	O
wild	O
type	O
viruses	O
and	O
the	O
vaccine	O
strains	O
in	O
all	O
three	O
emergent	O
isolates	O
.	O

The	O
S	B-PRGE
glycoprotein	I-PRGE
genes	O
of	O
N1	O
/	O
88	O
and	O
N1	O
/	O
03	O
were	O
known	O
to	O
be	O
genetically	O
distinct	O
from	O
previously	O
characterised	O
circulating	O
strains	O
and	O
from	O
each	O
other	O
,	O
and	O
the	O
original	O
donors	O
of	O
these	O
genes	O
remains	O
unknown	O
.	O

As	O
the	O
subgroup	O
2	O
strains	O
have	O
not	O
been	O
isolated	O
for	O
at	O
least	O
20	O
years	O
,	O
it	O
appears	O
likely	O
that	O
an	O
unknown	O
avian	O
coronavirus	O
that	O
was	O
the	O
donor	O
of	O
the	O
S1	B-PRGE
glycoprotein	I-PRGE
sequence	O
of	O
N1	O
/	O
88	O
in	O
the	O
1980s	O
is	O
still	O
recombining	O
with	O
IBV	O
strains	O
in	O
the	O
field	O
.	O

Spreaders	O
exhibited	O
lower	O
cycle	O
thresholds	O
for	O
the	O
upE	B-PRGE
and	I-PRGE
ORF1a	I-PRGE
genes	I-PRGE
(	O
22	O
.	O
7	O
vs	O
.	O
27	O
.	O
2	O
and	O
23	O
.	O
7	O
vs	O
.	O
27	O
.	O
9	O
,	O
respectively	O
).	O

Median	O
plasma	O
concentrations	O
of	O
TF	O
and	O
PAI	B-PRGE
-	I-PRGE
1	I-PRGE
were	O
significantly	O
higher	O
at	O
This	O
pilot	O
study	O
showed	O
that	O
increased	O
plasma	O
concentrations	O
of	O
TF	O
and	O
PAI	B-PRGE
-	I-PRGE
1	I-PRGE
might	O
support	O
ARDS	O
diagnoses	O
in	O
mechanically	O
ventilated	O
patients	O
after	O
7	O
days	O
in	O
ICU	O
.	O

The	O
1C3	O
mAb	O
can	O
be	O
used	O
for	O
the	O
detection	O
of	O
the	O
TGEV	B-PRGE
M	I-PRGE
protein	I-PRGE
in	O
different	O
assays	O
.	O

An	O
immunodominant	O
epitope	O
in	O
the	O
TGEV	B-PRGE
membrane	I-PRGE
protein	I-PRGE
endodomain	I-PRGE
was	O
identified	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
shown	O
previously	O
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
that	O
two	O
point	O
mutations	O
,	O
N15A	O
and	O
V25F	O
,	O
in	O
the	O
transmembrane	O
domain	O
(	O
TMD	O
)	O
of	O
the	O
envelope	B-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
abolished	O
channel	O
activity	O
and	O
led	O
to	O

TITLE	O
:	O
Association	O
of	O
Heme	B-PRGE
Oxygenase	I-PRGE
1	I-PRGE
with	O
Lung	O
Protection	O
in	O
Malaria	O
-	O
Associated	O
ALI	O
/	O
ARDS	O
.	O

ABSTRACT	O
:	O
Granulocyte	B-PRGE
-	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
is	O
widely	O
used	O
to	O
mobilize	O
peripheral	O
blood	O
stem	O
cells	O
(	O
PBSCs	O
)	O
in	O
healthy	O
donors	O
.	O

TITLE	O
:	O
Regulation	O
of	O
S1P	B-PRGE
receptors	I-PRGE
and	O
sphingosine	O
kinases	O
expression	O
in	O
acute	O
pulmonary	O
endothelial	O
cell	O
injury	O
.	O

Another	O
potential	O
use	O
of	O
aptamers	O
is	O
for	O
therapeutics	O
of	O
viral	O
infections	O
,	O
interfering	O
in	O
the	O
interaction	O
between	O
the	O
virus	O
and	O
the	O
host	O
using	O
aptamers	O
targeting	O
host	B-PRGE
-	I-PRGE
cell	I-PRGE
matrix	I-PRGE
receptors	I-PRGE
,	O
or	O
attacking	O
the	O
virus	O
intracellularly	O
,	O
targeting	O
proteins	O
implicated	O
in	O
the	O
viral	O
replication	O
cycle	O
.	O

The	O
substitutions	O
resulted	O
in	O
a	O
loss	O
of	O
furin	B-PRGE
-	O
mediated	O
cleavage	O
,	O
as	O
shown	O
by	O
fluorogenic	O
peptide	O
cleavage	O
and	O
western	O
blot	O
assays	O
.	O

TITLE	O
:	O
Cryo	O
-	O
electron	O
microscopy	O
structures	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
reveal	O
a	O
prerequisite	O
conformational	O
state	O
for	O
receptor	O
binding	O
.	O

The	O
sequence	O
was	O
analysed	O
for	O
the	O
presence	O
of	O
coding	O
and	O
non	O
-	O
coding	O
features	O
,	O
its	O
similarity	O
with	O
reported	O
isolates	O
and	O
epitope	O
analysis	O
of	O
capsid	B-PRGE
structural	I-PRGE
protein	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
confirm	O
that	O
a	O
nucleolar	O
phosphoprotein	O
nucleophosmin	B-PRGE
(	O
NPM1	B-PRGE
)	O
interacts	O
and	O
co	O
-	O
localizes	O
with	O
the	O
N	B-PRGE
protein	I-PRGE
in	O
the	O
nucleolus	O
.	O

In	O
addition	O
,	O
binding	O
of	O
N	B-PRGE
protein	I-PRGE
to	O
NPM1	B-PRGE
protects	O
it	O
from	O
proteolytic	O
degradation	O
by	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
leading	O
to	O
increased	O
cell	O
survival	O
.	O

While	O
the	O
structures	O
were	O
nearly	O
identical	O
,	O
the	O
PLpro	B-PRGE
-â	I-PRGE
Ubl2	I-PRGE
enzyme	I-PRGE
revealed	O
the	O
intact	O
structure	O
of	O
the	O
substrate	O
-	O
binding	O
loop	O
.	O

Moreover	O
,	O
PLpro	O
-â	O
Ubl2	B-PRGE
catalysis	O
against	O
different	O
substrates	O
and	O
a	O
purported	O
inhibitor	O
revealed	O
no	O
differences	O
in	O
catalytic	O
efficiency	O
,	O
substrate	O
specificity	O
,	O
and	O
inhibition	O
.	O

Among	O
17	O
PEDV	O
samples	O
isolated	O
from	O
individual	O
pigs	O
,	O
all	O
of	O
them	O
contained	O
at	O
least	O
two	O
distinct	O
genotypes	O
with	O
large	O
genomic	O
deletions	O
,	O
and	O
94	O
.	O
1	O
%	O
of	O
them	O
were	O
found	O
to	O
consist	O
of	O
strains	O
with	O
an	O
intact	O
S	B-PRGE
gene	I-PRGE
.	O

Langmuir	O
binding	O
analysis	O
determined	O
how	O
the	O
immobilized	O
Ab	O
affinity	O
for	O
the	O
NP	O
-	O
Ab	O
/	O
NS1	B-PRGE
was	O
impacted	O
by	O
corona	O
formation	O
conditions	O
,	O
quantified	O
as	O
an	O
effective	O
dissociation	O
constant	O
,	O
K	O

TITLE	O
:	O
Monitoring	O
of	O
vascular	B-PRGE
endothelial	I-PRGE
growth	I-PRGE
factor	I-PRGE
and	O
its	O
soluble	O
receptor	O
levels	O
in	O
early	O
trauma	O
.	O

The	O
serum	B-PRGE
VEGF	I-PRGE
levels	O
between	O
the	O
ARDS	O
group	O
and	O
the	O
non	O
-	O
ARDS	O
group	O
showed	O
no	O
significant	O
difference	O
(	O
p	O
>	O
0	O
.	O
05	O
).	O

A	O
total	O
of	O
183	O
and	O
236	O
hospitalized	O
children	O
with	O
acute	O
encephalitis	O
-	O
like	O
syndrome	O
and	O
respiratory	O
tract	O
infection	O
,	O
respectively	O
,	O
were	O
screened	O
for	O
anti	B-PRGE
-	I-PRGE
CoV	I-PRGE
IgM	I-PRGE
antibodies	I-PRGE
.	O

The	O
total	O
protein	O
,	O
albumin	B-PRGE
,	O
and	O
globulin	O
levels	O
in	O
the	O
infected	O
group	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
the	O
control	O
group	O
.	O

Finally	O
,	O
the	O
activation	O
of	O
IFN	B-PRGE
responses	O
induced	O
by	O
TGEV	O
infection	O
cannot	O
inhibit	O
viral	O
replication	O
.	O

A	O
set	O
of	O
six	O
LAMP	O
primers	O
[	O
F3	O
,	O
B3	O
,	O
FIP	O
,	O
BIP	O
,	O
LF	O
(	O
Loop	O
-	O
F	O
),	O
and	O
LB	O
(	O
Loop	O
-	O
B	O
)]	O
were	O
designed	O
using	O
the	O
sequence	O
of	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
with	O
optimized	O
RT	B-PRGE
-	I-PRGE
LAMP	I-PRGE
enzyme	I-PRGE
conditions	O
:	O
100	O
U	O
M	O
-	O
MLV	O
RTase	O
and	O
4	O
U	O

nsp15	O
contains	O
an	O
endoribonuclease	O
domain	O
that	O
is	O
conserved	O
in	O
the	O
CoV	B-PRGE
family	I-PRGE
.	O

Utilizing	O
this	O
knowledge	O
,	O
we	O
constructed	O
an	O
internal	O
hemagglutinin	O
(	O
HA	O
)	O
tag	B-PRGE
that	O
replaced	O
the	O
P	O
/	O
S	O
.	O
We	O
found	O
that	O
nsp15	O
-	O
HA	O
was	O
localized	O
to	O
discrete	O
perinuclear	O
puncta	O
and	O
strongly	O
colocalized	O
with	O
nsp8	O
and	O
nsp12	O
,	O
both	O
well	O
-	O
defined	O
members	O
of	O
the	O
RTC	O
,	O
but	O
not	O
the	O
membrane	O
(	O
M	O
)	O
protein	O
,	O
involved	O
in	O
virus	O
assembly	O
.	O

Furthermore	O
,	O
the	O
use	O
of	O
in	O
situ	O
epitope	O
tags	O
could	O
be	O
used	O
to	O
determine	O
novel	O
nsp	B-PRGE
-	O
nsp	B-PRGE
interactions	O
in	O
coronaviruses	O
.	O

Suppression	O
of	O
virus	O
by	O
metalloprotease	B-PRGE
inhibition	O
varied	O
among	O
tested	O
cell	O
lines	O
and	O
MHV	O
S	O
proteins	O
,	O
suggesting	O
a	O
role	O
for	O
metalloprotease	B-PRGE
use	O
in	O
strain	O
-	O
dependent	O
tropism	O
.	O

We	O
conclude	O
that	O
zinc	B-PRGE
metalloproteases	I-PRGE
must	O
be	O
considered	O
potential	O
contributors	O
to	O
coronavirus	O
fusion	O
.	O

In	O
this	O
study	O
,	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
was	O
found	O
to	O
bind	O
to	O
the	O
SPRY	O
domain	O
of	O
the	O
tripartite	B-PRGE
motif	I-PRGE
protein	I-PRGE
25	I-PRGE
(	O
TRIM25	B-PRGE
)	O
E3	B-PRGE
ubiquitin	I-PRGE
ligase	I-PRGE
,	O
thereby	O
interfering	O
with	O
the	O
association	O
between	O
TRIM25	B-PRGE
and	O
retinoic	O
acid	O
-	O
inducible	O
gene	B-PRGE
I	I-PRGE
(	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
)	O
and	O
inhibiting	O
TRIM25	B-PRGE
-	O
mediated	O
RIG	O
-	O
I	O
ubiquitination	O
and	O
activation	O
.	O

Type	O
I	O
IFN	B-PRGE
production	O
induced	O
by	O
poly	O
I	O
Â·	O
C	O
or	O
Sendai	O
virus	O
(	O
SeV	O
)	O
was	O
suppressed	O
by	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
.	O

Compounds	O
2	O
and	O
17	O
significantly	O
reduced	O
PEDV	B-PRGE
nucleocapsid	I-PRGE
and	I-PRGE
spike	I-PRGE
protein	I-PRGE
synthesis	O
compared	O
with	O
azauridin	O
as	O
a	O
positive	O
control	O
.	O

Here	O
we	O
show	O
that	O
the	O
coronavirus	O
endonuclease	B-PRGE
(	O
EndoU	B-PRGE
)	O
activity	O
is	O
key	O
to	O
prevent	O
early	O
induction	O
of	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
host	O
cell	O
responses	O
.	O

Plasma	B-PRGE
miR	I-PRGE
-	I-PRGE
155	I-PRGE
and	O
miR	B-PRGE
-	I-PRGE
146a	I-PRGE
were	O
determined	O
by	O
qRT	O
-	O
PCR	O
.	O

Coronaviruses	O
(	O
26	O
-	O
34	O
kilobases	O
)	O
have	O
the	O
largest	O
known	O
RNA	O
genomes	O
and	O
their	O
replication	O
presumably	O
requires	O
a	O
processive	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
and	O
enzymatic	O
functions	O
that	O
suppress	O
the	O
consequences	O
of	O
the	O
typically	O
high	O
error	O
rate	O
of	O
viral	O
RdRps	O
.	O

Pen	O
feed	O
intake	O
and	O
BW	O
were	O
recorded	O
on	O
dpi	B-PRGE
2	I-PRGE
,	O
5	O
,	O
7	O
,	O
and	O
weekly	O
thereafter	O
until	O
dpi	O
42	O
.	O

RESULTS	O
:	O
We	O
'	O
ve	O
investigated	O
the	O
development	O
of	O
URT	O
and	O
systemic	O
,	O
cell	O
-	O
mediated	O
and	O
humoral	O
immunity	O
in	O
commercial	O
broiler	O
chickens	O
vaccinated	O
with	O
Ma5	B-PRGE
and	O
/	O
or	O
4	O
/	O
91	O
strains	O
at	O
hatch	O
day	O
.	O

We	O
ascertained	O
the	O
epidemiologic	O
link	O
between	O
patients	O
and	O
calculated	O
the	O
secondary	O
attack	O
rate	O
per	O
10	O
,	O
000	O
patients	O
visiting	O
the	O
ER	O
(	O
SAR	B-PRGE
/	O
10	O
,	O
000	O
)	O
in	O
3	O
phases	O
of	O
the	O
outbreak	O
.	O

We	O
detected	O
a	O
suppressive	O
effect	O
on	O
the	O
early	O
activation	O
of	O
TLR7	B-PRGE
pathway	O
,	O
followed	O
by	O
lower	O
expression	O
levels	O
of	O
inflammatory	O
related	O
genes	O
induced	O
by	O
challenge	O
with	O
the	O
IBV	O
B	O
isolate	O
when	O
compared	O
to	O
the	O
challenge	O
with	O
to	O
the	O
IBV	O
A	O
isolate	O
.	O

Poor	O
prognosis	O
of	O
severe	O
adenovirus	O
pneumonia	O
in	O
children	O
is	O
associated	O
with	O
anemia	O
,	O
low	O
serum	O
albumin	B-PRGE
,	O
inflammatory	O
response	O
,	O
concurrent	O
multiple	O
complications	O
and	O
underlying	O
lung	O
diseases	O
.	O

The	O
ARF	B-PRGE
and	O
hematologic	O
parameters	O
improved	O
with	O
conservative	O
treatment	O
.	O

Epigenetic	O
modifications	O
,	O
such	O
as	O
histone	B-PRGE
modifications	O
,	O
DNA	O
methylation	O
,	O
chromatin	O
remodeling	O
,	O
and	O
non	O
-	O
coding	O
RNAs	O
,	O
function	O
as	O
important	O
regulators	O
that	O
remodel	O
host	O
chromatin	O
,	O
altering	O
host	O
expression	O
patterns	O
and	O
networks	O
in	O
a	O
highly	O
flexible	O
manner	O
.	O

Analogous	O
to	O
picornavirus	B-PRGE
3C	I-PRGE
protease	I-PRGE
(	O
3C	O

Therefore	O
,	O
this	O
newly	O
developed	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
method	O
is	O
expected	O
to	O
detect	O
not	O
only	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
in	O
humans	O
but	O
also	O
several	O
bat	O
CoVs	O
that	O
are	O
closely	O
related	O
to	O
these	O
viruses	O
in	O
bats	O
.	O

TITLE	O
:	O
Development	O
and	O
application	O
of	O
nsp5	B-PRGE
-	I-PRGE
ELISA	I-PRGE
for	O
the	O
detection	O
of	O
antibody	O
to	O
infectious	O
bronchitis	O
virus	O
.	O

Herein	O
,	O
an	O
alternative	O
indirect	O
ELISA	O
for	O
detection	O
of	O
IBV	O
antibody	O
was	O
developed	O
with	O
IBV	O
nonstructural	B-PRGE
protein	I-PRGE
5	I-PRGE
(	O
nsp5	B-PRGE
)	O
produced	O
by	O
Escherichia	O
coli	O
.	O

The	O
diagnostic	O
sensitivity	O
(	O
DSN	O
),	O
specificity	O
(	O
DSP	O
)	O
and	O
accuracy	O
of	O
the	O
nsp5	B-PRGE
-	I-PRGE
ELISA	I-PRGE
were	O
93	O
.	O
11	O
%,	O
95	O
.	O
38	O
%	O
and	O
93	O
.	O
33	O
%,	O
respectively	O
,	O
compared	O
with	O
IFA	O
in	O
660	O
field	O
serum	O
samples	O
,	O
and	O
were	O
98	O
.	O
11	O
%,	O
95	O
.	O
00	O
%	O
and	O
97	O
.	O
62	O
%,	O
respectively	O
,	O
compared	O
with	O
the	O
commercial	O
IBV	O
ELISA	O
kit	O
(	O
IDEXX	O
)	O
in	O
126	O
field	O
sera	O
samples	O
.	O

The	O
results	O
presented	O
in	O
this	O
study	O
indicate	O
that	O
nsp5	B-PRGE
-	I-PRGE
ELISA	I-PRGE
has	O
the	O
potential	O
to	O
serve	O
as	O
a	O
rapid	O
,	O
reliable	O
and	O
cost	O
-	O
effective	O
method	O
for	O
IBV	O
antibody	O
detection	O
.	O

It	O
detected	O
one	O
coronavirus	O
229E	O
and	O
eight	O
influenza	O
A	O
/	O
H3N2	O
viruses	O
that	O
were	O
missed	O
by	O
the	O
xTAG	B-PRGE
RVP	I-PRGE
FAST	I-PRGE
v2	I-PRGE
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
NxTAG	O
RPP	O
missed	O
one	O
enterovirus	O
/	O
rhinovirus	O
and	O
one	O
metapneumovirus	O
that	O
were	O
detected	O
by	O
FAST	B-PRGE
v2	I-PRGE
.	O

A	O
multiple	O
logistic	O
regression	O
model	O
incorporating	O
oxygenation	O
index	O
,	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
R2	I-PRGE
was	O
superior	O
to	O
a	O
model	O
of	O
oxygenation	O
index	O
alone	O
in	O
predicting	O
the	O
composite	O
outcome	O
of	O
mortality	O
or	O
severe	O
morbidity	O
(	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
,	O
0	O
.	O
77	O
[	O
0	O
.	O
70	O
-	O
0	O
.	O
83	O
]	O
vs	O
0	O
.	O
70	O
[	O
0	O
.	O
62	O
-	O
0	O
.	O
77	O
];	O
p	O
=	O
0	O
.	O
042	O
).	O

The	O
nonstructural	O
protein	O
nsp5	B-PRGE
is	O
a	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
of	O
coronavirus	O
,	O
and	O
our	O
previous	O
study	O
showed	O
that	O
PDCoV	B-PRGE
nsp5	I-PRGE
inhibits	O
type	O
I	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
production	O
.	O

In	O
this	O
study	O
,	O
molecular	O
dynamics	O
approaches	O
were	O
used	O
to	O
investigate	O
MERS	B-PRGE
CoV	I-PRGE
Non	I-PRGE
-	I-PRGE
Structural	I-PRGE
Protein	I-PRGE
3	I-PRGE
(	O
NSP3	B-PRGE
)	O
specific	O
proteins	O
that	O
resist	O
host	O
innate	O
immunity	O
.	O

Four	O
major	O
residues	O
involved	O
in	O
deubiquitination	O
,	O
L106	O
,	O
P163	O
,	O
R168	O
and	O
F265	O
,	O
were	O
conserved	O
in	O
all	O
MERS	O
CoVs	O
and	O
differed	O
from	O
other	O
Beta	B-PRGE
CoVs	I-PRGE
.	O

The	O
number	O
of	O
residues	O
and	O
total	O
interactions	O
with	O
ubiquitin	B-PRGE
were	O
lower	O
for	O
the	O
MERS	O
CoV	O
Plpro	O
than	O
for	O
the	O
SARS	O
CoV	O
.	O
These	O
factors	O
contribute	O
to	O
the	O
lower	O
deubiquitinating	O
actions	O
of	O
MERS	B-PRGE
CoV	I-PRGE
NSP3	I-PRGE
and	O
its	O
subsequently	O
lower	O
interaction	O
with	O
the	O
host	O
immune	O
system	O
.	O

In	O
addition	O
to	O
the	O
involvement	O
of	O
GAS	B-PRGE
,	O
the	O
following	O
findings	O
suggest	O
a	O
pathogenic	O
role	O
for	O
FN	O
in	O
PTA	O
:	O
1	O
.	O

Antibody	O
responses	O
in	O
serum	O
,	O
colostrum	O
,	O
and	O
milk	O
samples	O
were	O
measured	O
by	O
IgG	B-PRGE
/	O
IgA	B-PRGE
ELISA	O
and	O
virus	O
neutralization	O
assay	O
(	O
VN	O
).	O

Immunofluorescence	O
confocal	O
microscopy	O
showed	O
that	O
PEDV	O
was	O
trapped	O
at	O
cellular	O
junctional	O
regions	O
upon	O
macropinocytosis	O
inhibitor	O
treatment	O
,	O
indicating	O
that	O
occludin	B-PRGE
may	O
serve	O
as	O
a	O
scaffold	O
in	O
the	O
vicinity	O
of	O
virus	O
entry	O
.	O

Comparative	O
analysis	O
of	O
the	O
amino	O
acids	O
encoded	O
by	O
the	O
S	O
genes	O
revealed	O
the	O
N	O
-	O
terminal	O
of	O
the	O
deduced	O
JSCZ1601	B-PRGE
S	I-PRGE
protein	I-PRGE
had	O
a	O
novel	O
two	O
-	O
amino	O
-	O
acid	O
deletion	O
(	O
N58	O
and	O
S59	O
)	O
compared	O
with	O
all	O
identified	O
genogroups	O
.	O

Loss	O
of	O
HE	B-PRGE
lectin	I-PRGE
function	O
was	O
also	O
observed	O
for	O
another	O
respiratory	O
human	O
coronavirus	O
,	O
HKU1	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
the	O
virulent	O
viruses	O
[	O
P3	O
and	O
P95C13	O
(	O
CCL81	O
)]	O
had	O
one	O
,	O
one	O
,	O
sixteen	O
(	O
including	O
an	O
early	O
termination	O
of	O
nine	O
amino	O
acids	O
)	O
and	O
two	O
amino	O
acid	O
differences	O
in	O
non	O
-	O
structure	B-PRGE
protein	I-PRGE
1	I-PRGE
(	O
nsp1	B-PRGE
),	O
nsp4	B-PRGE
,	O
spike	O
and	O
membrane	O
proteins	O
,	O
respectively	O
,	O
from	O
the	O
fully	O
attenuated	O
P160	O
.	O

Pneumonia	O
occurred	O
in	O
63	O
.	O
64	O
%,	O
42	O
.	O
31	O
%,	O
and	O
32	O
.	O
42	O
%	O
of	O
adenovirus	O
,	O
influenza	O
,	O
and	O
RSV	B-PRGE
RVI	I-PRGE
episodes	O
,	O
respectively	O
,	O
but	O
was	O
also	O
non	O
-	O
negligible	O
in	O
the	O
more	O
benign	O
viruses	O
,	O
such	O
as	O
coronavirus	O
(	O
31	O
.	O
58	O
%)	O
and	O
rhinovirus	O
(	O
23	O
.	O
68	O
%).	O

We	O
identified	O
the	O
small	O
molecule	O
N30	O
,	O
as	O
an	O
inhibitor	O
of	O
IMPDH	B-PRGE
,	O
might	O
be	O
a	O
potential	O
candidate	O
to	O
inhibit	O
the	O
replication	O
of	O
various	O
viruses	O
.	O

In	O
addition	O
,	O
mutations	O
of	O
the	O
catalytic	O
residues	O
of	O
PLP	B-PRGE
-	I-PRGE
TM	I-PRGE
,	O
Cys1274Ser	O
and	O
His1437Lys	O
,	O
reduced	O
DUB	O
activity	O
against	O
Ub	O
-,	O
K48	O
-	O
and	O
K63	O
-	O
conjugated	O
proteins	O
,	O
indicating	O
that	O
the	O
DUB	O
activity	O
of	O
the	O
PLP	B-PRGE
-	I-PRGE
TM	I-PRGE
wild	I-PRGE
-	I-PRGE
type	I-PRGE
protein	I-PRGE
is	O
not	O
completely	O
dependent	O
on	O
its	O
catalytic	O
activity	O
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
Candidate	O
MERS	O
-	O
CoV	O
DNA	O
Vaccines	O
Based	O
on	O
the	O
Spike	B-PRGE
Protein	I-PRGE
.	O

Here	O
,	O
we	O
investigated	O
the	O
immunogenicity	O
of	O
naked	O
DNA	O
vaccines	O
expressing	O
different	O
fragments	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
in	O
mice	O
.	O

IP	O
-	O
10	O
concentrations	O
were	O
higher	O
with	O
an	O
ARI	B-PRGE
in	O
which	O
a	O
viral	O
pathogen	O
was	O
detected	O
compared	O
to	O
no	O
viral	O
pathogen	O
detected	O
(	O
median	O
366pg	O
/	O
ml	O
[	O
IQR	O
:	O
227	O
-	O
486	O
]	O
vs	O
163pg	O
/	O
ml	O
[	O
IQR	O
:	O
127	O
-	O
295	O
],	O
p	O
<	O
0	O
.	O
0001	O
).	O

Phylogenetic	O
and	O
recombination	O
analyses	O
of	O
F46	O
provided	O
evidence	O
of	O
natural	O
recombination	O
between	O
bat	B-PRGE
SARS	I-PRGE
-	I-PRGE
like	I-PRGE
CoVs	I-PRGE
(	O
Rs3367	O
and	O
LYRa11	O
)	O
or	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
BJ01	O
),	O
suggesting	O
that	O
F46	O
could	O
be	O
a	O
new	O
recombinant	O
virus	O
from	O
SARS	O
-	O
like	O
CoVs	O
or	O
SARS	O
-	O
CoVs	O
.	O

Furthermore	O
,	O
both	O
HCoV	B-PRGE
-	I-PRGE
229E	I-PRGE
replication	I-PRGE
and	I-PRGE
IL	I-PRGE
-	I-PRGE
1	I-PRGE
were	O
shown	O
to	O
upregulate	O
a	O
small	O
set	O
of	O
genes	O
encoding	O
immunomodulatory	O
factors	O
that	O
bind	O
p65	B-PRGE
at	O
promoters	O
and	O
require	O
IKKÎ²	O
activity	O
and	O
p65	B-PRGE
for	O
expression	O
.	O

GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
-	O
treated	O
patients	O
reported	O
more	O
severe	O
posttraumatic	O
stress	O
and	O
depression	O
symptoms	O
than	O
patients	O
in	O
the	O
placebo	O
group	O
.	O

ABSTRACT	O
:	O
ADAR1	B-PRGE
isoforms	O
are	O
adenosine	O
deaminases	O
that	O
edit	O
and	O
destabilize	O
double	O
-	O
stranded	O
RNA	O
reducing	O
its	O
immunostimulatory	O
activities	O
.	O

Interaction	O
of	O
the	O
viral	O
spike	O
(	O
S	O
)	O
surface	O
glycoprotein	O
-	O
through	O
its	O
S1	O
subunit	O
-	O
with	O
the	O
host	B-PRGE
cell	I-PRGE
receptor	I-PRGE
is	O
the	O
first	O
step	O
in	O
infection	O
and	O
the	O
main	O
determinant	O
for	O
virus	O
tropism	O
.	O

TITLE	O
:	O
An	O
East	B-PRGE
Asian	I-PRGE
Common	I-PRGE
Variant	I-PRGE
Vinculin	I-PRGE
P	I-PRGE
.	I-PRGE
Asp841His	I-PRGE
Was	I-PRGE
Associated	O
With	O
Sudden	O
Unexplained	O
Nocturnal	O
Death	O
Syndrome	O
in	O
the	O
Chinese	O
Han	O
Population	O
.	O

Here	O
we	O
describe	O
the	O
generation	O
and	O
characterization	O
of	O
10	O
neutralizing	O
and	O
nonneutralizing	O
mouse	O
monoclonal	O
antibodies	O
raised	O
against	O
the	O
S1	B-PRGE
receptor	I-PRGE
binding	I-PRGE
subunit	I-PRGE
of	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

However	O
,	O
IFNs	B-PRGE
and	I-PRGE
ISGs	I-PRGE
do	O
not	O
only	O
play	O
a	O
key	O
role	O
in	O
the	O
limitation	O
of	O
pathogen	O
spread	O
but	O
have	O
also	O
been	O
recently	O
found	O
to	O
provoke	O
an	O
unbalanced	O
,	O
overshooting	O
inflammatory	O
response	O
causing	O
tissue	O
injury	O
and	O
hampering	O
repair	O
processes	O
.	O

CRFK	O
cells	O
infected	O
with	O
FIPV	O
79	O
-	O
1146	O
showed	O
an	O
increase	O
in	O
the	O
expression	O
of	O
interferon	B-PRGE
-	I-PRGE
related	I-PRGE
genes	I-PRGE
and	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
MX1	B-PRGE
,	O
viperin	B-PRGE
,	O
CXCL10	B-PRGE
,	O
CCL8	B-PRGE
,	O
RANTES	B-PRGE
,	O
KC	O
,	O
MCP1	B-PRGE
,	O
and	O
IL8	B-PRGE
.	O

As	O
expected	O
,	O
the	O
secretion	O
of	O
IL1Î²	O
,	O
IL6	B-PRGE
and	O
TNFÎ±	O
was	O
readily	O
detected	O
in	O
the	O
supernatant	O
of	O
peritoneal	O
effusions	O
of	O
the	O
FCoV	O
-	O
positive	O
cats	O
.	O

As	O
expected	O
,	O
the	O
secretion	O
of	O
IL1Î²	O
,	O
IL6	B-PRGE
and	O
TNFÎ±	O
was	O
readily	O
detected	O
in	O
the	O
supernatant	O
of	O
peritoneal	O
effusions	O
of	O
the	O
FCoV	O
-	O
positive	O
cats	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
receptor	I-PRGE
(	O
EGFR	B-PRGE
)	O
signaling	O
in	O
SARS	O
coronavirus	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O

In	O
this	O
article	O
,	O
we	O
summarize	O
pulmonary	O
fibrotic	O
changes	O
observed	O
after	O
a	O
SARS	O
-	O
CoV	O
infection	O
,	O
discuss	O
the	O
extent	O
to	O
which	O
other	O
respiratory	O
viruses	O
induce	O
fibrosis	O
,	O
describe	O
available	O
animal	O
models	O
to	O
study	O
the	O
development	O
of	O
SARS	O
-	O
CoV	O
induced	O
fibrosis	O
and	O
review	O
evidence	O
that	O
pulmonary	O
fibrosis	O
is	O
caused	O
by	O
a	O
hyperactive	O
host	O
response	O
to	O
lung	O
injury	O
mediated	O
by	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
receptor	I-PRGE
(	O
EGFR	B-PRGE
)	O
signaling	O
.	O

TITLE	O
:	O
Cryo	O
-	O
EM	O
structures	O
of	O
MERS	O
-	O
CoV	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoproteins	I-PRGE
reveal	O
the	O
dynamic	O
receptor	O
binding	O
domains	O
.	O

One	O
protease	O
,	O
transmembrane	B-PRGE
protease	I-PRGE
serine	I-PRGE
2	I-PRGE
(	O
TMPRSS2	B-PRGE
)	O
was	O
recently	O
proven	O
to	O
be	O
crucial	O
for	O
hemagglutinin	O
cleavage	O
of	O
some	O
human	O
influenza	O
viruses	O
.	O

TITLE	O
:	O
C	B-PRGE
-	I-PRGE
C	I-PRGE
Motif	I-PRGE
Chemokine	I-PRGE
Ligand	I-PRGE
2	I-PRGE
(	O
CCL2	B-PRGE
)	O
Mediates	O
Acute	O
Lung	O
Injury	O
Induced	O
by	O
Lethal	O
Influenza	O
H7N9	O
Virus	O
.	O

TITLE	O
:	O
Interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
displays	O
lung	O
anti	O
-	O
inflammatory	O
properties	O
and	O
exerts	O
protective	O
hemodynamic	O
effects	O
in	O
a	O
double	O
-	O
hit	O
murine	O
acute	O
lung	O
injury	O
.	O

However	O
,	O
two	O
deletions	O
in	O
two	O
respective	O
loops	O
located	O
in	O
HKU5	B-PRGE
-	I-PRGE
CTD	I-PRGE
result	O
in	O
conformational	O
variations	O
in	O
CD26	O
-	O
binding	O
interface	O
and	O
are	O
responsible	O
for	O
the	O
non	O
-	O
binding	O
of	O
HKU5	O
-	O
CTD	O
to	O
CD26	B-PRGE
.	O

Ub	O
is	O
known	O
to	O
be	O
highly	O
conserved	O
among	O
eukaryotes	O
,	O
but	O
surprisingly	O
,	O
ISG15	B-PRGE
is	O
highly	O
divergent	O
among	O
animals	O
.	O

Therefore	O
,	O
the	O
activity	O
of	O
PLPs	O
from	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
MERS	O
-	O
CoV	O
,	O
and	O
mouse	O
hepatitis	O
virus	O
was	O
evaluated	O
against	O
seven	O
ISG15s	O
originating	O
from	O
an	O
assortment	O
of	O
animal	O
species	O
susceptible	O
,	O
and	O
not	O
,	O
to	O
certain	O
coronavirus	O
infections	O
.	O

In	O
the	O
frugivorous	O
bats	O
,	O
DPP4	B-PRGE
was	O
present	O
in	O
epithelial	O
cells	O
of	O
both	O
the	O
respiratory	O
and	O
the	O
intestinal	O
tract	O
,	O
similar	O
to	O
what	O
has	O
been	O
reported	O
for	O
camels	O
and	O
humans	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
infection	O
induces	O
NF	O
-	O
ÎºB	O
activation	O
through	O
RLR	B-PRGE
-	O
mediated	O
signaling	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
the	O
RLR	B-PRGE
signaling	O
pathway	O
is	O
involved	O
in	O
TGEV	O
-	O
induced	O
inflammatory	O
responses	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
value	O
of	O
procalcitonin	O
(	O
PCT	B-PRGE
)	O
on	O
predicting	O
the	O
severity	O
and	O
prognosis	O
in	O
patients	O
with	O
early	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Kaplan	O
-	O
Meier	O
survival	O
curve	O
analysis	O
indicated	O
that	O
the	O
patients	O
whose	O
PCT	O
more	O
than	O
4	O
.	O
35	O
Î¼g	O
/	O
L	O
,	O
had	O
lower	O
28	O
-	O
day	O
cummulative	O
survival	O
rate	O
as	O
compared	O
with	O
those	O
with	O
PCT	B-PRGE
â¤	I-PRGE
4	I-PRGE
.	I-PRGE
35	I-PRGE
Î¼g	I-PRGE
/	O
L	O
(	O
log	O
-	O
rank	O
test	O
:	O
Ï	O

Three	O
sheep	O
that	O
received	O
E	B-PRGE
.	I-PRGE
coli	I-PRGE
endotoxin	I-PRGE
were	O
treated	O
with	O
veno	O
-	O
venous	O
ECMO	O
support	O
in	O
group	O
2	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
receptor	I-PRGE
attenuates	O
LPS	O
-	O
induced	O
inflammation	O
and	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

However	O
,	O
it	O
is	O
still	O
unclear	O
whether	O
EGFR	B-PRGE
inhibition	O
can	O
prevent	O
ALI	O
.	O

This	O
study	O
aimed	O
to	O
validate	O
the	O
EGFR	B-PRGE
'	O
s	O
role	O
in	O
ALI	O
and	O
investigated	O
the	O
effects	O
of	O
EGFR	B-PRGE
inhibition	O
on	O
lipopolysaccharides	O
(	O
LPS	O
)-	O
induced	O
ALI	O
in	O
rats	O
.	O

Mechanistically	O
,	O
LPS	B-PRGE
induced	O
EGFR	B-PRGE
activation	O
via	O
TLR4	B-PRGE
and	O
c	B-PRGE
-	I-PRGE
Src	I-PRGE
signaling	O
.	O

It	O
was	O
observed	O
that	O
AG1478	O
and	O
451	O
blocked	O
the	O
activation	O
of	O
EGFR	B-PRGE
signaling	O
in	O
lung	O
tissue	O
and	O
reduced	O
the	O
LPS	O
-	O
induced	O
infiltration	O
of	O
inflammatory	O
cells	O
,	O
inflammatory	O
gene	O
expression	O
,	O
and	O
lung	O
injuries	O
.	O

When	O
siRNA	O
was	O
used	O
to	O
interfere	O
with	O
p47phox	B-PRGE
expression	O
following	O
stimulation	O
with	O
LPS	O
,	O
a	O
lower	O
level	O
of	O
ROS	B-PRGE
-	O
mediated	O
inflammatory	O
cytokines	O
were	O
released	O
.	O

Brain	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
showed	O
a	O
heart	O
-	O
shaped	O
region	O
of	O
diffusion	O
abnormality	O
,	O
characteristic	O
of	O
BMP	B-PRGE
infarction	O
.	O

CRP	B-PRGE
(	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
),	O
procalcitonin	O
(	O
PCT	B-PRGE
),	O
and	O
Blood	O
G	O
(	O
BG	O
)	O
test	O
are	O
the	O
sensitivity	O
markers	O
for	O
inflammatory	O
,	O
sepsis	O
,	O
and	O
fungemia	O
,	O
respectively	O
.	O

TITLE	O
:	O
IL	B-PRGE
-	I-PRGE
33	I-PRGE
protects	O
murine	O
viral	O
fulminant	O
hepatitis	O
by	O
targeting	O
coagulation	B-PRGE
hallmark	I-PRGE
protein	I-PRGE
FGL2	B-PRGE
/	O
fibroleukin	B-PRGE
expression	O
.	O

Using	O
the	O
optimized	O
TLR7	B-PRGE
/	O
8	O
stimulation	O
protocol	O
,	O
we	O
compared	O
virus	O
-	O
specific	O
IgG	B-PRGE
Bmem	O
versus	O
pre	O
-	O
existing	O
ASC	O
within	O
the	O
brain	O
and	O
spinal	O
cord	O
.	O

RESULTS	O
:	O
Immunohistochemical	O
studies	O
have	O
suggested	O
that	O
over	O
-	O
expression	O
of	O
GPC3	B-PRGE
is	O
associated	O
with	O
a	O
poorer	O
prognosis	O
for	O
hepatocellular	O
carcinoma	O
patients	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
lung	O
epithelium	O
,	O
specifically	O
alveolar	O
type	O
II	O
cells	O
,	O
is	O
the	O
predominant	O
site	O
of	O
LIF	B-PRGE
transcript	I-PRGE
induction	O
in	O
pneumonic	O
mouse	O
lungs	O
.	O

TITLE	O
:	O
Diagnostic	O
and	O
prognostic	O
values	O
of	O
Club	B-PRGE
cell	I-PRGE
protein	I-PRGE
16	I-PRGE
(	O
CC16	B-PRGE
)	O
in	O
critical	O
care	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
diagnostic	O
and	O
prognostic	O
values	O
of	O
Club	B-PRGE
cell	I-PRGE
protein	I-PRGE
16	I-PRGE
(	O
CC16	B-PRGE
)	O
in	O
critical	O
care	O
patients	O
with	O
ARDS	O
.	O

TITLE	O
:	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PL	O
ABSTRACT	O
:	O
Within	O
a	O
decade	O
,	O
MERS	O
-	O
CoV	O
emerged	O
with	O
nearly	O
four	O
times	O
higher	O
case	O
fatality	O
rate	O
than	O
an	O
earlier	O
outbreak	O
of	O
SARS	O
-	O
CoV	O
and	O
spread	O
out	O
in	O
27	O
countries	O
in	O
short	O
span	O
of	O
time	O
.	O

ABSTRACT	O
:	O
Intracellular	O
trafficking	O
and	O
localization	O
studies	O
of	O
spike	O
protein	O
from	O
SARS	B-PRGE
and	O
OC43	O
showed	O
that	O
SARS	B-PRGE
spike	I-PRGE
protein	I-PRGE
is	O
localized	O
in	O
the	O
ER	O
or	O
ERGIC	O
compartment	O
and	O
OC43	B-PRGE
spike	I-PRGE
protein	I-PRGE
is	O
predominantly	O
localized	O
in	O
the	O
lysosome	O
.	O

To	O
predict	O
the	O
potential	O
B	O
cell	O
epitopes	O
of	O
E	B-PRGE
protein	I-PRGE
,	O
three	O
most	O
effective	O
online	O
epitope	O
prediction	O
programs	O
,	O
the	O
ABCpred	O
,	O
Bepipred	O
,	O
and	O
Protean	O
programs	O
from	O
the	O
LaserGene	O
software	O
were	O
used	O
.	O

Although	O
many	O
causes	O
are	O
known	O
,	O
ALF	B-PRGE
remains	O
unexplained	O
in	O
about	O
half	O
of	O
the	O
cases	O
.	O

Patient	O
2	O
,	O
currently	O
9	O
years	O
old	O
,	O
had	O
multiple	O
episodes	O
of	O
ELT	O
(>	O
30	O
),	O
twice	O
with	O
ALF	B-PRGE
,	O
often	O
accompanied	O
by	O
extensive	O
urticaria	O
and	O
facial	O
angioedema	O
.	O

All	O
vaccines	O
contained	O
the	O
full	O
-	O
length	O
spike	O
gene	O
of	O
MERS	O
-	O
CoV	O
;	O
ChAdOx1	O
MERS	O
vaccines	O
were	O
produced	O
with	O
or	O
without	O
the	O
leader	O
sequence	O
of	O
the	O
human	O
tissue	B-PRGE
plasminogen	I-PRGE
activator	I-PRGE
gene	I-PRGE
(	O
tPA	B-PRGE
)	O
where	O
MVA	O
MERS	O
vaccines	O
were	O
produced	O
with	O
tPA	B-PRGE
,	O
but	O
either	O
the	O
mH5	O
or	O
F11	B-PRGE
promoter	I-PRGE
driving	O
expression	O
of	O
the	O
spike	O
gene	O
.	O

The	O
N	O
-	O
PACT	O
interaction	O
sequestered	O
the	O
association	O
of	O
PACT	B-PRGE
and	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
/	O
MDA5	B-PRGE
,	O
which	O
in	O
turn	O
inhibited	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
production	O
.	O

TITLE	O
:	O
Co	O
-	O
infection	O
of	O
H9N2	O
subtype	O
avian	O
influenza	O
virus	O
and	O
infectious	O
bronchitis	O
virus	O
decreases	O
SP	B-PRGE
-	I-PRGE
A	I-PRGE
expression	O
level	O
in	O
chickens	O
.	O

However	O
,	O
cSP	B-PRGE
-	I-PRGE
A	I-PRGE
expression	O
in	O
the	O
respiratory	O
tract	O
of	O
chickens	O
after	O
viral	O
co	O
-	O
infection	O
remains	O
unclear	O
.	O

Further	O
study	O
revealed	O
that	O
HSP27	B-PRGE
could	O
significantly	O
activate	O
the	O
NF	O
-	O
ÎºB	O
phosphorylation	O
,	O
and	O
thus	O
increase	O
the	O
mRNA	O
level	O
of	O
IFNB1	B-PRGE
and	O
downstream	O
interferon	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
)	O
in	O
MARC	O
-	O
145	O
cells	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
link	O
HSP27	B-PRGE
to	O
PEDV	O
replication	O
via	O
the	O
innate	O
immunity	O
response	O
,	O
which	O
contributed	O
to	O
further	O
clarify	O
the	O
mechanism	O
of	O
PEDV	O
infection	O
and	O
the	O
development	O
of	O
novel	O
antiviral	O
therapies	O
.	O

LUNG	B-PRGE
SAFE	I-PRGE
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
number	O
NCT02010073	O
.	O

TITLE	O
:	O
Discovery	O
of	O
unsymmetrical	O
aromatic	O
disulfides	O
as	O
novel	O
inhibitors	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
main	I-PRGE
protease	I-PRGE
:	O
Chemical	O
synthesis	O
,	O
biological	O
evaluation	O
,	O
molecular	O
docking	O
and	O
3D	O
-	O
QSAR	O
study	O
.	O

Therefore	O
,	O
tea	B-PRGE
saponins	I-PRGE
may	O
be	O
a	O
potential	O
agent	O
to	O
improve	O
imunosuppression	O
induced	O
by	O
oxidative	O
stress	O
in	O
chickens	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
mediates	O
viral	O
entry	O
into	O
target	O
cells	O
.	O

The	O
type	B-PRGE
II	I-PRGE
transmembrane	I-PRGE
serine	I-PRGE
protease	I-PRGE
TMPRSS2	I-PRGE
cleaves	O
and	O
activates	O
SARS	B-PRGE
S	I-PRGE
in	O
cell	O
culture	O
and	O
potentially	O
also	O
in	O
the	O
infected	O
host	O
.	O

We	O
found	O
that	O
SARS	O
S	O
residue	O
R667	O
,	O
a	O
previously	O
identified	O
trypsin	B-PRGE
cleavage	O
site	O
,	O
is	O
also	O
required	O
for	O
S	B-PRGE
protein	I-PRGE
cleavage	O
by	O
TMPRSS2	O
.	O

Of	O
the	O
254	O
respiratory	O
specimens	O
,	O
there	O
was	O
total	O
agreement	O
in	O
the	O
results	O
between	O
the	O
xTAG	B-PRGE
RVP	I-PRGE
Fast	I-PRGE
v2	I-PRGE
assay	O
and	O
the	O
other	O
real	O
-	O
time	O
PCR	O
assay	O
in	O
94	O
.	O
1	O
-	O
100	O
%	O
of	O
the	O
specimens	O
.	O

Alone	O
,	O
resveratrol	O
does	O
not	O
inhibit	O
HIV	O
-	O
1	O
infection	O
of	O
activated	O
T	O
cells	O
,	O
but	O
it	O
does	O
synergize	O
with	O
nucleoside	B-PRGE
reverse	I-PRGE
transcriptase	I-PRGE
inhibitors	O
in	O
these	O
cells	O
to	O
inhibit	O
reverse	O
transcription	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
reported	O
ability	O
of	O
resveratrol	O
to	O
inhibit	O
ribonucleotide	B-PRGE
reductase	I-PRGE
and	O
to	O
lower	O
dNTP	O
levels	O
in	O
cells	O
.	O

The	O
GDS04	O
strain	O
of	O
this	O
coronavirus	O
shares	O
high	O
aa	O
identities	O
(>	O
90	O
%)	O
with	O
the	O
reported	O
bat	B-PRGE
-	I-PRGE
HKU2	I-PRGE
strains	O
in	O
Coronaviridae	O
-	O
wide	O
conserved	O
domains	O
,	O
suggesting	O
that	O
the	O
GDS04	O
strain	O
belongs	O
to	O
the	O
same	O
species	O
as	O
HKU2	O
.	O

Nucleotide	O
sequences	O
of	O
CPPV	O
-	O
1	O
were	O
closely	O
related	O
to	O
sequences	O
detected	O
in	O
other	O
wild	O
carnivores	O
,	O
comparing	O
294	O
nucleotides	O
of	O
the	O
VP1	B-PRGE
gene	I-PRGE
.	O

Then	O
,	O
we	O
found	O
that	O
nonstructural	O
protein	O
1	O
and	O
viral	O
RNA	O
of	O
H5N1	O
contributed	O
to	O
the	O
induction	O
of	O
miR	B-PRGE
-	I-PRGE
200c	I-PRGE
-	I-PRGE
3p	I-PRGE
during	O
viral	O
infection	O
.	O

Of	O
the	O
total	O
of	O
22	O
viral	O
proteins	O
,	O
nine	O
proteins	O
were	O
identified	O
as	O
NF	O
-	O
ÎºB	O
antagonists	O
,	O
and	O
nsp1	B-PRGE
was	O
the	O
most	O
potent	O
suppressor	O
of	O
proinflammatory	O
cytokines	O
.	O

Nsp1	B-PRGE
interfered	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IÎºBÎ±	O
,	O
and	O
thus	O
blocked	O
the	O
p65	B-PRGE
activation	O
.	O

Human	O
and	O
camel	O
sera	O
were	O
tested	O
for	O
anti	B-PRGE
-	I-PRGE
MERS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
using	O
a	O
commercial	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
test	O
.	O

TITLE	O
:	O
Two	O
-	O
amino	O
acids	O
change	O
in	O
the	O
nsp4	B-PRGE
of	O
SARS	O
coronavirus	O
abolishes	O
viral	O
replication	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
SP4	B-PRGE
is	O
a	O
promising	O
serological	O
testing	O
protein	O
for	O
use	O
in	O
the	O
field	O
.	O

2	O
-	O
Conversely	O
,	O
nsp1	B-PRGE
has	O
a	O
six	O
-	O
stranded	O
,	O
mixed	O
parallel	O
/	O
antiparallel	O
Î²	O
-	O
barrel	O
with	O
intricate	O
long	O
-	O
range	O
interactions	O
,	O
indicating	O
it	O
will	O
need	O
the	O
full	O
-	O
length	O
protein	O
to	O
fold	O
properly	O
.	O

We	O
set	O
up	O
three	O
systems	O
:	O
(	O
i	O
)	O
Man4	B-PRGE
bound	O
to	O
both	O
domains	O
(	O
SD1	O
+	O
SD2	O
)	O
using	O
the	O
full	O
-	O
length	O
protein	O
;	O
(	O
ii	O
)	O
Man4	B-PRGE
bound	O
to	O
an	O
incomplete	O
protein	O
,	O
containing	O
only	O
SD1	O
and	O
(	O
iii	O
)	O
Man4	B-PRGE
bound	O
to	O
an	O
incomplete	O
protein	O
containing	O
only	O
SD2	O
.	O

The	O
data	O
show	O
that	O
(	O
i	O
)	O
7b	O
localizes	O
to	O
and	O
is	O
retained	O
in	O
the	O
medial	O
-	O
and	O
/	O
or	O
trans	O
-	O
Golgi	O
compartment	O
,	O
(	O
ii	O
)	O
the	O
C	O
-	O
terminal	O
KTEL	O
sequence	O
acts	O
as	O
a	O
Golgi	O
[	O
rather	O
than	O
an	O
endoplasmic	O
reticulum	O
(	O
ER	O
)]	O
retention	O
signal	O
,	O
(	O
iii	O
)	O
minor	O
changes	O
in	O
the	O
KTEL	O
motif	O
(	O
such	O
as	O
KTE	B-PRGE
,	O
KTEV	O
,	O
or	O
the	O
addition	O
of	O
a	O
C	O
-	O
terminal	O
tag	O
)	O
abolish	O
Golgi	O
retention	O
,	O
resulting	O
in	O
relocalization	O
and	O
secretion	O
of	O
7b	O
,	O
and	O
(	O
iv	O
)	O
a	O
KTEL	O
-	O
to	O
-	O
KDEL	O
replacement	O
causes	O
retention	O
of	O
7b	O
in	O
the	O
ER	O
of	O
rFIPV	O
-	O
infected	O
feline	O
cells	O
.	O

Using	O
knockout	O
cell	O
lines	O
,	O
we	O
found	O
that	O
the	O
tetraspanin	B-PRGE
CD9	I-PRGE
,	O
but	O
not	O
the	O
tetraspanin	B-PRGE
CD81	I-PRGE
,	O
formed	O
cell	O
-	O
surface	O
complexes	O
of	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
),	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
,	O
and	O
the	O
type	B-PRGE
II	I-PRGE
transmembrane	I-PRGE
serine	I-PRGE
protease	I-PRGE
(	O
TTSP	B-PRGE
)	O
member	O
TMPRSS2	O
,	O
a	O
CoV	B-PRGE
-	I-PRGE
activating	I-PRGE
protease	I-PRGE
.	O

In	O
conclusion	O
,	O
both	O
M41	B-PRGE
and	O
Con	B-PRGE
A5968	I-PRGE
IBV	O
strains	O
infect	O
macrophages	O
in	O
vivo	O
and	O
in	O
vitro	O
resulting	O
productive	O
replications	O
.	O

rotavirus	O
and	O
coronavirus	O
,	O
Salmonella	B-PRGE
spp	I-PRGE
.,	I-PRGE
Escherichia	I-PRGE
coli	I-PRGE
,	O
Clostridium	O
perfringens	O
and	O
Eimeria	O
spp	O
.	O

Resolvin	O
D1	O
Improves	O
the	O
Resolution	O
of	O
Inflammation	O
via	O
Activating	O
NF	O
-	O
ÎºB	O
p50	B-PRGE
/	O
p50	B-PRGE
-	O
Mediated	B-PRGE
Cyclooxygenase	I-PRGE
-	I-PRGE
2	I-PRGE
Expression	O
in	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

This	O
case	O
demonstrates	O
a	O
per	O
-	O
acute	O
onset	O
of	O
APT	B-PRGE
caused	O
by	O
a	O
low	O
loading	O
dose	O
in	O
association	O
with	O
thoracic	O
surgery	O
.	O

The	O
ratio	O
of	O
non	O
-	O
synonymous	O
substitutions	O
per	O
non	O
-	O
synonymous	O
site	O
(	O
dN	O
)	O
to	O
synonymous	O
substitutions	O
per	O
synonymous	O
site	O
(	O
dS	O
),	O
i	O
.	O
e	O
.	O
dN	O
/	O
dS	O
,	O
revealed	O
a	O
predominance	O
of	O
codons	O
with	O
non	O
-	O
synonymous	O
substitutions	O
in	O
the	O
first	O
third	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
and	O
a	O
dN	O
/	O
dS	O
ratio	O
of	O
0	O
.	O
67	O
.	O

Compared	O
with	O
World	O
Health	O
Organization	O
-	O
recommended	O
singleplex	O
real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	B-PRGE
(	O
RT	O
-	O
qPCR	O
)	O
assays	O
,	O
both	O
RT	O
-	O
iiPCR	O
assays	O
had	O
comparable	O
analytical	O
sensitivity	O
for	O
the	O
detection	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
in	O
tissue	O
culture	O
fluid	O
and	O
in	O
sputum	O
samples	O
spiked	O
with	O
infectious	O
virus	O
.	O

The	O
analytical	O
sensitivity	O
of	O
RT	B-PRGE
-	I-PRGE
RPA	I-PRGE
was	O
31	O
.	O
8	O
copies	O
in	O
vitro	O
transcribed	O
CDV	O
RNA	O
,	O
which	O
is	O
10	O
times	O
lower	O
than	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

At	O
14	O
,	O
28	O
,	O
and	O
42	O
days	O
after	O
the	O
first	O
vaccination	O
,	O
serum	B-PRGE
anti	I-PRGE
-	I-PRGE
IBV	I-PRGE
antibody	I-PRGE
titers	O
;	O
peripheral	O
lymphocyte	O
proliferation	O
;	O
and	O
the	O
mRNA	O
expression	O
of	O
IL	O
-	O
1Î²	O
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	O
-	O
8	O
,	O
and	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
in	O
the	O
spleen	O
were	O
assessed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
the	O
cell	O
counting	O
kit	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
CCK	B-PRGE
-	I-PRGE
8	I-PRGE
),	O
and	O
real	O
time	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
),	O
respectively	O
.	O

These	O
data	O
suggest	O
that	O
APS	B-PRGE
could	O
be	O
used	O
as	O
an	O
adjuvant	O
for	O
IBV	O
vaccination	O
to	O
provide	O
better	O
protection	O
against	O
IBV	O
infection	O
.	O

To	O
determine	O
whether	O
neurons	O
or	O
other	O
CNS	O
cells	O
survive	O
acute	O
infection	O
with	O
this	O
virulent	O
virus	O
,	O
we	O
developed	O
a	O
recombinant	O
JHMV	O
that	O
expresses	O
Cre	B-PRGE
recombinase	I-PRGE
(	O
rJ	O
-	O
Cre	O
)	O
and	O
infected	O
mice	O
that	O
universally	O
expressed	O
a	O
silent	O
(	O
floxed	O
)	O
version	O
of	O
tdTomato	O
.	O

The	O
nsp1	B-PRGE
of	I-PRGE
CoV	I-PRGE
is	O
thought	O
to	O
be	O
a	O
major	O
virulence	O
factor	O
because	O
it	O
suppresses	O
protein	O
synthesis	O
through	O
the	O
degradation	O
of	O
host	B-PRGE
mRNA	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
amino	O
acid	O
residue	O
in	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp1	I-PRGE
that	O
differ	O
from	O
those	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp1	I-PRGE
,	O
and	O
that	O
appear	O
to	O
be	O
crucial	O
for	O
circumventing	O
the	O
translational	O
shutoff	O
.	O

Based	O
on	O
analysis	O
of	O
the	O
complete	O
deduced	O
VP2	B-PRGE
amino	O
acid	O
sequences	O
,	O
20	O
of	O
the	O
KNA	O
CPV	O
strains	O
were	O
assigned	O
to	O
new	O
CPV	O
-	O
2a	O
(	O
also	O
designated	O
as	O
CPV	O
-	O
2a	O
-	O
297A	O
).	O

Based	O
on	O
analysis	O
of	O
partial	O
M	B-PRGE
-	I-PRGE
protein	I-PRGE
gene	I-PRGE
,	O
the	O
KNA	O
CCoV	O
strains	O
were	O
assigned	O
to	O
CCoV	O
-	O
I	O
genotype	O
,	O
and	O
were	O
closely	O
related	O
to	O
CCoV	O
-	O
I	O
strains	O
from	O
Brazil	O
.	O

Preliminary	O
laboratory	O
analysis	O
ruled	O
out	O
important	O
enteropathogens	O
(	O
Cryptosporidium	O
spp	O
;	O
Eimeria	B-PRGE
spp	I-PRGE
.,	I-PRGE
E	I-PRGE
.	I-PRGE
coli	I-PRGE
F5	I-PRGE
,	O
and	O
bovine	O
coronavirus	O
).	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
high	O
rate	O
of	O
aichivirus	O
B	O
detection	O
in	O
a	O
diarrhea	O
outbreak	O
in	O
dairy	O
calves	O
,	O
and	O
the	O
first	O
phylogenetic	O
study	O
of	O
the	O
VP1	B-PRGE
gene	I-PRGE
of	O
aichivirus	O
B	O
wild	O
-	O
type	O
strains	O
performed	O
in	O
South	O
America	O
.	O

M1	O
induced	O
more	O
Th17	O
while	O
M2	O
induced	O
more	O
CD4	B-PRGE
In	O
conclusion	O
,	O
MP	O
ameliorated	O
ALI	O
by	O
promoting	O
M2	O
polarization	O
.	O

In	O
conclusion	O
,	O
FER	B-PRGE
rs4957796	I-PRGE
might	O
act	O
as	O
a	O
prognostic	O
variable	O
for	O
survival	O
in	O
patients	O
with	O
severe	O
ARDS	O
due	O
to	O
pneumonia	O
.	O

Otherwise	O
,	O
a	O
novel	O
variation	O
(	O
16	O
-	O
20	O
aa	O
deletion	O
and	O
an	O
L25P	O
mutation	O
)	O
in	O
the	O
transmembrane	O
domain	O
of	O
the	O
E	O
protein	O
affected	O
multiple	O
infection	O
processes	O
,	O
including	O
up	O
-	O
regulation	O
of	O
the	O
production	O
of	O
the	O
ER	O
stress	O
indicator	O
GRP78	B-PRGE
,	O
improving	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	B-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	O
-	O
8	O
,	O
and	O
promoting	O
apoptosis	O
.	O

Then	O
cytokines	O
including	O
lung	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
1Î²	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
plasma	B-PRGE
HMGB1	I-PRGE
,	O
apoptosis	O
of	O
splenic	O
immune	O
cells	O
and	O
Foxp3	B-PRGE
level	O
on	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
were	O
studied	O
to	O
demonstrate	O
the	O
mechanisms	O
of	O
EP	O
administration	O
on	O
two	O
-	O
hit	O
mice	O
.	O

All	O
underwent	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
and	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
IgG	I-PRGE
testing	O
.	O

We	O
also	O
observed	O
a	O
markedly	O
increased	O
transcription	O
of	O
interferon	B-PRGE
inducible	O
protein	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
).	O

ABSTRACT	O
:	O
The	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
S1	O
subunit	O
of	O
the	O
spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
mediates	O
viral	O
attachment	O
to	O
host	O
cells	O
and	O
the	O
S2	O
subunit	O
is	O
responsible	O
for	O
membrane	O
fusion	O
.	O

Consistent	O
with	O
viral	O
loads	O
,	O
significantly	O
reduced	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
tracheal	O
mucosal	O
thickness	O
and	O
tracheal	O
lesion	O
scores	O
revealed	O
that	O
recombinant	B-PRGE
S	I-PRGE
-	I-PRGE
ectodomain	I-PRGE
protein	I-PRGE
provided	O
improved	O
protection	O
of	O
tracheal	O
integrity	O
compared	O
to	O
S1	B-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
Objectives	O
The	O
safety	O
and	O
efficacy	O
of	O
the	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
inhibitor	O
GC376	O
was	O
tested	O
on	O
a	O
cohort	O
of	O
client	O
-	O
owned	O
cats	O
with	O
various	O
forms	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

However	O
,	O
in	O
patients	O
with	O
syndromic	O
CIDs	O
,	O
autosomal	O
recessive	O
mutations	O
in	O
ataxia	O
-	O
telangiectasia	O
mutated	O
(	O
ATM	O
),	O
autosomal	O
dominant	O
mutations	O
in	O
signal	B-PRGE
transducer	I-PRGE
and	I-PRGE
activator	I-PRGE
of	I-PRGE
transcription	I-PRGE
3	I-PRGE
(	O
STAT3	B-PRGE
),	O
and	O
microdeletions	O
in	O
22q11	O
.	O
21	O
were	O
the	O
most	O
commonly	O
affected	O
genomic	O
loci	O
.	O

We	O
also	O
discuss	O
various	O
cellular	O
processes	O
,	O
such	O
as	O
apoptosis	O
,	O
innate	O
immunity	O
,	O
ER	O
stress	O
response	O
,	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
MAPK	B-PRGE
)	O
pathway	O
and	O
nuclear	B-PRGE
factor	I-PRGE
kappa	I-PRGE
B	I-PRGE
(	O
NF	O
-	O
ÎºB	O
)	O
pathway	O
that	O
may	O
be	O
modulated	O
by	O
HCoVs	O
.	O

TITLE	O
:	O
An	O
exceptional	O
cause	O
of	O
hemoptysis	O
in	O
the	O
elderly	O
patient	O
:	O
IgA	B-PRGE
vasculitis	O
.	O

Here	O
,	O
we	O
review	O
the	O
progresses	O
of	O
different	O
reverse	O
genetics	O
platforms	O
developed	O
for	O
PEDV	O
and	O
their	O
applications	O
,	O
covering	O
the	O
roles	O
of	O
trypsin	B-PRGE
in	O
PEDV	O
propagation	O
,	O
functions	O
of	O
S	O
and	O
ORF3	O
protein	O
and	O
the	O
development	O
of	O
next	O
generation	O
PED	O
vaccines	O
,	O
and	O
the	O
perspectives	O
of	O
reverse	O
genetics	O
for	O
PEDV	O
.	O

TITLE	O
:	O
Understanding	O
Immune	O
Resistance	O
to	O
Infectious	O
Bronchitis	O
Using	O
Major	B-PRGE
Histocompatibility	I-PRGE
Complex	I-PRGE
Chicken	I-PRGE
Lines	O
.	O

ABSTRACT	O
:	O
Genetic	O
resistance	O
or	O
susceptibility	O
to	O
infectious	O
diseases	O
has	O
been	O
largely	O
associated	O
with	O
the	O
avian	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
(	O
MHC	O
)	O
genes	O
.	O

A	O
possible	O
basis	O
for	O
the	O
reported	O
ability	O
of	O
IBV	O
4	O
/	O
91	O
(	O
serotype	O
793	O
/	O
B	O
)	O
vaccine	O
to	O
protect	O
against	O
divergent	O
IBV	O
strains	O
(	O
e	O
.	O
g	O
.,	O
QX	O
,	O
Q1	O
,	O
and	O
D1466	O
)	O
in	O
a	O
prime	O
-	O
boost	O
approach	O
with	O
an	O
IBV	O
Mass	O
vaccine	O
is	O
that	O
an	O
immune	O
response	O
against	O
the	O
S2	B-PRGE
protein	I-PRGE
of	O
IBV	O
4	O
/	O
91	O
is	O
cross	O
-	O
protective	O
.	O

Therefore	O
,	O
we	O
evaluated	O
the	O
protective	O
capabilities	O
of	O
the	O
S2	B-PRGE
protein	I-PRGE
of	O
IBV	O
4	O
/	O
91	O
expressed	O
from	O
rLS	O
.	O

Strains	O
belonging	O
to	O
the	O
Q1	O
,	O
Ark	B-PRGE
,	O
D274	O
,	O
D1466	O
,	O
Italy	O
-	O
02	O
and	O
B1648	O
genotypes	O
were	O
detected	O
as	O
well	O
,	O
although	O
less	O
frequently	O
.	O

The	O
separate	O
sampling	O
of	O
tracheas	O
and	O
kidneys	O
for	O
IBV	O
detection	O
using	O
reverse	B-PRGE
transcriptase	I-PRGE
PCR	O
was	O
very	O
useful	O
,	O
as	O
different	O
genotypes	O
or	O
significant	O
differences	O
in	O
sequences	O
of	O
the	O
same	O
genotype	O
were	O
detected	O
between	O
both	O
organs	O
.	O

This	O
study	O
demonstrates	O
that	O
LQJD	O
has	O
a	O
protective	O
effect	O
on	O
LPS	O
-	O
induced	O
inflammatory	O
rats	O
through	O
the	O
signaling	O
pathway	O
of	O
TLR4	B-PRGE
and	O
NF	O
-	O
ÎºBp65	O
.	O

These	O
findings	O
demonstrate	O
that	O
S	B-PRGE
gene	I-PRGE
mutation	O
analysis	O
in	O
FCoVs	O
does	O
not	O
substantially	O
improve	O
the	O
ability	O
to	O
diagnose	O
FIP	O
as	O
compared	O
to	O
detection	O
of	O
FCoV	O
alone	O
.	O

Plasma	B-PRGE
syndecan	I-PRGE
-	I-PRGE
1	I-PRGE
was	O
measured	O
at	O
study	O
enrollment	O
.	O

RESULTS	O
:	O
The	O
data	O
indicated	O
that	O
seventy	O
-	O
five	O
dromedary	O
camels	O
were	O
positive	O
for	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
;	O
the	O
virus	O
was	O
not	O
detected	O
in	O
sheep	O
,	O
goats	O
,	O
and	O
cattle	O
.	O

DPP4	B-PRGE
expression	O
was	O
measured	O
in	O
lung	O
tissue	O
of	O
lung	O
resection	O
specimens	O
of	O
never	O
-	O
smokers	O
,	O
smokers	O
without	O
airflow	O
limitation	O
,	O
COPD	O
GOLD	O
stage	O
II	O
patients	O
and	O
in	O
lung	O
explants	O
of	O
end	O
-	O
stage	O
COPD	O
patients	O
.	O

These	O
data	O
also	O
highlight	O
a	O
possible	O
role	O
of	O
DPP4	B-PRGE
in	O
COPD	O
pathogenesis	O
.	O

Depletion	O
of	O
pathogenic	O
CD8	B-PRGE

Notably	O
,	O
codon	O
1020	O
was	O
positively	O
selected	O
among	O
B	O
and	O
B5	O
strains	O
,	O
and	O
can	O
distinguish	O
between	O
clade	O
A	O
(	O
Q1020	O
)	O
and	O
B	O
(	O
R1020	O
/	O
H1020	O
)	O
strains	O
,	O
suggesting	O
that	O
this	O
residue	O
may	O
play	O
a	O
role	O
in	O
the	O
evolution	O
of	O
S	B-PRGE
protein	I-PRGE
during	O
divergence	O
of	O
different	O
lineages	O
.	O

Nsp8	O
has	O
been	O
reported	O
to	O
interact	O
with	O
nsp7	O
and	O
functions	O
as	O
a	O
primase	B-PRGE
synthesizing	O
RNA	O
primers	O
for	O
nsp12	O
.	O

However	O
,	O
most	O
evidence	O
suggests	O
that	O
the	O
domain	O
immediately	O
downstream	O
of	O
the	O
S2	O
'	O
cleavage	O
site	O
is	O
the	O
FP	O
(	O
amino	O
acids	O
798	O
-	O
818	O
SFIEDLLFNKVTLADAGFMKQY	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
FP1	O
).	O

PdCoV	B-PRGE
S1	I-PRGE
-	I-PRGE
CTD	I-PRGE
binds	O
to	O
an	O
unidentified	O
receptor	O
on	O
host	O
cell	O
surfaces	O
.	O

Based	O
on	O
the	O
structures	O
and	O
functions	O
of	O
these	O
structural	O
elements	O
,	O
we	O
discussed	O
the	O
evolution	O
of	O
PdCoV	B-PRGE
spike	I-PRGE
protein	I-PRGE
in	O
relation	O
to	O
the	O
spike	O
proteins	O
from	O
other	O
coronavirus	O
genera	O
.	O

Among	O
all	O
groups	O
,	O
VAC	O
-	O
IM	O
-	O
2b	O
pigs	O
had	O
significantly	O
higher	O
anti	B-PRGE
-	I-PRGE
PEDV	I-PRGE
IgG	I-PRGE
levels	O
on	O
dpv	O
21	O
and	O
28	O
while	O
EXP	B-PRGE
-	I-PRGE
ORAL	I-PRGE
-	I-PRGE
1b	I-PRGE
pigs	O
had	O
significantly	O
higher	O
anti	B-PRGE
-	I-PRGE
PEDV	I-PRGE
IgA	I-PRGE
levels	O
on	O
dpv	O
14	O
,	O
21	O
,	O
28	O
and	O
35	O
.	O

Patient	O
demographics	O
,	O
length	O
of	O
ventilations	O
days	O
,	O
number	O
of	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admission	O
days	O
,	O
chest	O
radiographic	O
score	O
,	O
chest	O
radiographic	O
deterioration	O
pattern	O
(	O
Types	O
1	O
-	O
4	O
)	O
and	O
peak	O
lactate	B-PRGE
dehydrogenase	I-PRGE
level	O
were	O
compared	O
between	O
the	O
two	O
groups	O
using	O
the	O
student	O
Follow	O
-	O
up	O
chest	O
radiographs	O
were	O
normal	O
in	O
23	O
out	O
of	O
36	O
(	O
64	O
%)	O
patients	O
.	O

The	O
present	O
study	O
illustrated	O
the	O
regulatory	O
importance	O
of	O
these	O
immune	O
pathways	O
in	O
response	O
to	O
alterations	O
in	O
the	O
expression	O
of	O
gene	B-PRGE
families	I-PRGE
,	O
particularly	O
in	O
perpetual	O
lung	O
injury	O
leading	O
to	O
NRDS	O
.	O

The	O
H120	O
and	O
Ma5	B-PRGE
are	O
the	O
only	O
viral	O
strains	O
approved	O
by	O
the	O
Brazilian	O
government	O
as	O
the	O
constituent	O
of	O
vaccines	O
.	O

Our	O
results	O
revealed	O
up	O
to	O
13	O
amino	O
acid	O
substitutions	O
among	O
vaccines	O
and	O
some	O
of	O
them	O
were	O
localized	O
in	O
regions	O
of	O
the	O
S1	B-PRGE
glycoprotein	I-PRGE
that	O
play	O
a	O
role	O
in	O
virus	O
-	O
host	O
interaction	O
.	O

ABSTRACT	O
:	O
Melanoma	O
differentiation	O
associated	O
gene	O
5	O
(	O
MDA5	O
)	O
and	O
retinoic	O
acid	O
-	O
inducible	O
gene	B-PRGE
-	I-PRGE
I	I-PRGE
(	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
)	O
selectively	O
sense	O
cytoplasmic	O
viral	O
RNA	O
to	O
induce	O
an	O
antiviral	O
immune	O
response	O
.	O

We	O
also	O
found	O
that	O
IBV	O
can	O
cleave	O
MAVS	O
,	O
an	O
adaptor	O
protein	O
downstream	O
of	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
and	O
MDA5	B-PRGE
that	O
acts	O
as	O
a	O
platform	O
for	O
antiviral	O
innate	O
immunity	O
at	O
an	O
early	O
stage	O
of	O
infection	O
.	O

We	O
also	O
found	O
that	O
IBV	O
can	O
cleave	O
MAVS	O
,	O
an	O
adaptor	O
protein	O
downstream	O
of	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
and	O
MDA5	B-PRGE
that	O
acts	O
as	O
a	O
platform	O
for	O
antiviral	O
innate	O
immunity	O
at	O
an	O
early	O
stage	O
of	O
infection	O
.	O

Subjects	O
underwent	O
impedance	O
-	O
based	O
platelet	O
aggregometry	O
in	O
response	O
to	O
platelet	O
agonists	O
arachidonic	O
acid	O
,	O
adenosine	O
diphosphate	O
,	O
collagen	B-PRGE
,	O
and	O
thrombin	B-PRGE
receptor	I-PRGE
activating	O
peptide	O
-	O
6	O
.	O

TITLE	O
:	O
Entry	O
of	O
Human	B-PRGE
Coronavirus	I-PRGE
NL63	I-PRGE
into	O
the	O
Cell	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
miR	O
-	O
223	O
limits	O
the	O
number	O
of	O
Ly6G	O
+	O
neutrophils	O
and	O
inhibits	O
the	O
activity	O
of	O
the	O
NLRP3	B-PRGE
inflammasome	I-PRGE
to	O
alleviate	O
ALI	O
induced	O
by	O
mitochondrial	O
damage	O
-	O
associated	O
molecular	O
patterns	O
(	O
DAMPs	O
)	O
(	O
MTDs	O
).	O

A	O
MERS	O
screening	O
clinic	O
(	O
MSC	O
)	O
for	O
HCP	B-PRGE
was	O
setup	O
in	O
the	O
National	O
Medical	O
Center	O
during	O
the	O
MERS	O
outbreak	O
in	O
2015	O
.	O

TITLE	O
:	O
Macrophage	B-PRGE
scavenger	I-PRGE
receptor	I-PRGE
1	I-PRGE
contributes	O
to	O
pathogenesis	O
of	O
fulminant	O
hepatitis	O
via	O
neutrophil	O
-	O
mediated	O
complement	O
activation	O
.	O

RESULTS	O
:	O
Our	O
results	O
showed	O
that	O
Msr1	B-PRGE

We	O
also	O
review	O
the	O
application	O
of	O
recently	O
developed	O
human	B-PRGE
mAbs	I-PRGE
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
MERS	O
-	O
CoV	O
,	O
and	O
Ebola	O
virus	O
and	O
discuss	O
prospects	O
for	O
the	O
development	O
of	O
mAbs	O
as	O
therapeutic	O
agents	O
against	O
emerging	O
viral	O
diseases	O
.	O

Moreover	O
,	O
when	O
inactivating	O
nsp3	B-PRGE
-	I-PRGE
4	I-PRGE
polyprotein	O
cleavage	O
by	O
mutagenesis	O
,	O
we	O
established	O
that	O
cleavage	O
of	O
the	O
nsp3	B-PRGE
/	O
nsp4	B-PRGE
junction	O
is	O
essential	O
for	O
MERS	O
-	O
CoV	O
DMV	O
formation	O
.	O

These	O
RBD	O
classes	O
differ	O
in	O
their	O
affinity	O
for	O
APN	B-PRGE
and	O
their	O
ability	O
to	O
bind	O
an	O
HCoV	O
-	O
229E	O
neutralizing	O
antibody	O
.	O

Protein	B-PRGE
-	I-PRGE
Protein	I-PRGE
Interaction	O
(	O
PPI	O
)	O
analysis	O
showed	O
that	O
DE	O
genes	O
in	O
SCDY2	O
group	O
formed	O
a	O
network	O
,	O
and	O
the	O
core	O
of	O
the	O
network	O
was	O
composed	O
by	O
cell	O
apoptosis	O
and	O
immune	O
response	O
proteins	O
.	O

In	O
addition	O
,	O
the	O
system	O
was	O
7	O
and	O
22	O
times	O
more	O
efficient	O
for	O
viability	O
preservation	O
of	O
MS2	B-PRGE
bacteriophage	O
than	O
the	O
commonly	O
used	O
All	O
Glass	O
Impinger	O
30	O
(	O
AGI	O
-	O
30	O
)	O
and	O
BioSampler	O
Â®,	O
respectively	O
.	O

Lactobacillus	O
casei	O
delivering	O
the	O
COE	B-PRGE
antigen	I-PRGE
of	O
PEDV	O
conjugated	O
with	O
a	O
M	O
cell	O
-	O
targeting	O
peptide	O
Co1	O
as	O
an	O
immune	O
adjuvant	O
is	O
a	O
promising	O
oral	O
vaccine	O
candidate	O
for	O
PEDV	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
BAL	B-PRGE
E	I-PRGE
coli	I-PRGE
colony	I-PRGE
-	I-PRGE
forming	I-PRGE
units	I-PRGE
,	O
macrophage	O
,	O
or	O
neutrophil	O
numbers	O
at	O
any	O
time	O
point	O
.	O

ABSTRACT	O
:	O
Mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
develop	O
hepatitis	O
and	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	B-PRGE
hydrolase	I-PRGE
(	O
FAH	B-PRGE
),	O
a	O
fact	O
closely	O
related	O
to	O
the	O
release	O
of	O
alarmins	O
such	O
as	O
uric	O
acid	O
and	O
/	O
or	O
high	B-PRGE
-	I-PRGE
mobility	I-PRGE
group	I-PRGE
box	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
HMGB1	B-PRGE
).	O

Cell	O
entry	O
studies	O
demonstrated	O
that	O
three	O
newly	O
identified	O
SARSr	O
-	O
CoVs	O
with	O
different	O
S	O
protein	O
sequences	O
are	O
all	O
able	O
to	O
use	O
human	B-PRGE
ACE2	I-PRGE
as	O
the	O
receptor	O
,	O
further	O
exhibiting	O
the	O
close	O
relationship	O
between	O
strains	O
in	O
this	O
cave	O
and	O
SARS	O
-	O
CoV	O
.	O
This	O
work	O
provides	O
new	O
insights	O
into	O
the	O
origin	O
and	O
evolution	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
highlights	O
the	O
necessity	O
of	O
preparedness	O
for	O
future	O
emergence	O
of	O
SARS	O
-	O
like	O
diseases	O
.	O

We	O
previously	O
reported	O
that	O
clinical	O
isolates	O
of	O
HCoV	O
-	O
229E	O
preferred	O
cell	O
-	O
surface	O
TMPRSS2	B-PRGE
to	O
endosomal	B-PRGE
cathepsin	I-PRGE
for	O
cell	O
entry	O
,	O
and	O
that	O
they	O
acquired	O
the	O
ability	O
to	O
use	O
cathepsin	B-PRGE
L	I-PRGE
by	O
repeated	O
passage	O
in	O
cultured	O
cells	O
and	O
were	O
then	O
able	O
to	O
enter	O
cells	O
via	O
the	O
endosomal	O
pathway	O
.	O

We	O
report	O
on	O
two	O
siblings	O
with	O
AGS6	O
due	O
to	O
compound	O
heterozygosity	O
for	O
a	O
known	O
and	O
a	O
novel	O
mutation	O
in	O
the	O
ADAR	B-PRGE
gene	I-PRGE
and	O
a	O
strikingly	O
variable	O
phenotype	O
.	O

Using	O
estimated	O
sensitivity	O
and	O
specificity	O
values	O
from	O
cutoffs	O
determined	O
with	O
the	O
ROC	O
analysis	O
(	O
cutoff	O
level	O
:	O
ST2	O
,	O
21	O
ng	O
/	O
mL	O
;	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
61	O
pg	O
/	O
mL	O
;	O
TNFR1	B-PRGE
,	O
3421	O
pg	O
/	O
mL	O
),	O
we	O
calculated	O
positive	O
predictive	O
values	O
(	O
PPV	O
)	O
for	O
a	O
range	O
of	O
estimated	O
population	O
prevalence	O
values	O
of	O
IPS	O
.	O

TITLE	O
:	O
Age	B-PRGE
is	O
a	O
predictor	O
of	O
a	O
small	O
decrease	O
in	O
lung	O
function	O
in	O
children	O
with	O
sickle	O
cell	O
anemia	O
.	O

In	O
addition	O
,	O
intestinal	O
IR	O
induced	O
a	O
significant	O
increase	O
in	O
the	O
ex	O
-	O
vivo	O
lung	O
levels	O
of	O
IL	O
-	O
1Î²	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
and	O
VEGF	B-PRGE
.	O

In	O
addition	O
,	O
17Î²	O
-	O
estradiol	O
significantly	O
prevented	O
the	O
ex	O
-	O
vivo	O
release	O
of	O
IL	O
-	O
1Î²	O
and	O
VEGF	B-PRGE
from	O
lung	O
tissue	O
.	O

RNA	O
viruses	O
,	O
including	O
PEDV	O
,	O
can	O
interact	O
with	O
a	O
large	O
number	O
of	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
in	O
the	O
intestinal	O
mucosa	O
,	O
including	O
toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
and	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
-	I-PRGE
like	I-PRGE
receptors	I-PRGE
(	O
RLRs	O
).	O

We	O
investigated	O
the	O
differential	O
gene	O
modulation	O
of	O
TLRs	O
,	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
,	O
and	O
downstream	O
mediators	O
on	O
the	O
intestinal	O
mucosa	O
of	O
neonatal	O
pigs	O
infected	O
with	O
PEDV	O
S	O
-	O
INDEL	O
and	O
non	O
-	O
S	O
-	O
INDEL	O
strains	O
.	O

The	O
replication	O
of	O
these	O
viruses	O
was	O
compared	O
in	O
the	O
same	O
parental	O
Huh7	O
cells	O
and	O
in	O
CypA	B-PRGE
-	O
knockout	O
Huh7	O
cells	O
generated	O
using	O
CRISPR	O
/	O
Cas9	O
-	O
technology	O
.	O

The	O
comparison	O
of	O
the	O
secondary	O
and	O
3DMMS	O
of	O
the	O
RBD	O
of	O
IT	O
-	O
batCoVs	O
with	O
MERS	O
,	O
HKU4	O
and	O
HKU5	B-PRGE
bat	I-PRGE
sequences	I-PRGE
showed	O
two	O
aa	O
deletions	O
located	O
in	O
a	O
region	O
corresponding	O
to	O
the	O
external	O
subdomain	O
of	O
MERS	O
-	O
RBD	O
in	O
IT	O
-	O
batCoV	O
and	O
HKU5	O
RBDs	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
the	O
plant	O
compound	O
silvestrol	O
,	O
a	O
specific	O
inhibitor	O
of	O
the	O
DEAD	B-PRGE
-	I-PRGE
box	I-PRGE
RNA	I-PRGE
helicase	I-PRGE
eIF4A	I-PRGE
,	O
on	O
viral	O
translation	O
using	O
a	O
dual	O
luciferase	O
assay	O
and	O
virus	O
-	O
infected	O
primary	O
cells	O
.	O

MDMA	O
-	O
induced	O
hyponatremia	O
is	O
hypothesized	O
to	O
result	O
from	O
enhanced	O
serotonergic	O
activity	O
and	O
arginine	B-PRGE
vasopressin	I-PRGE
(	O
AVP	B-PRGE
)	O
release	O
in	O
the	O
brain	O
leading	O
to	O
hyperthermia	O
-	O
induced	O
polydipsia	O
and	O
syndrome	B-PRGE
of	I-PRGE
inappropriate	I-PRGE
antidiuretic	I-PRGE
hormone	I-PRGE
(	O
SIADH	O
)	O
secretion	O
.	O

Coronavirus	O
structural	O
envelope	B-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
possesses	O
specific	O
motifs	O
involved	O
in	O
protein	O
-	O
protein	O
interaction	O
or	O
in	O
homo	O
-	O
oligomeric	O
ion	O
channel	O
formation	O
,	O
which	O
are	O
known	O
to	O
play	O
various	O
roles	O
including	O
in	O
virion	O
morphology	O
/	O
assembly	O
and	O
in	O
cell	O
response	O
to	O
infection	O
and	O
/	O
or	O
virulence	O
.	O

Furthermore	O
,	O
HCoV	O
-	O
OC43	O
infection	O
of	O
human	O
epithelial	O
and	O
neuronal	O
cell	O
lines	O
,	O
of	O
mixed	O
murine	O
primary	O
cultures	O
from	O
the	O
central	O
nervous	O
system	O
and	O
of	O
mouse	O
central	O
nervous	O
system	O
showed	O
that	O
the	O
E	B-PRGE
protein	I-PRGE
is	O
critical	O
for	O
efficient	O
and	O
optimal	O
virus	O
replication	O
and	O
propagation	O
,	O
and	O
thereby	O
for	O
neurovirulence	O
.	O

Moreover	O
,	O
the	O
conserved	O
region	O
encoded	O
by	O
the	O
S	B-PRGE
gene	I-PRGE
can	O
be	O
considered	O
a	O
target	O
for	O
establishing	O
a	O
new	O
diagnostic	O
method	O
and	O
is	O
a	O
new	O
candidate	O
for	O
vaccine	O
design	O
.	O

In	O
this	O
study	O
,	O
use	O
of	O
anchorin	B-PRGE
pgsA	I-PRGE
'	I-PRGE
allowed	O
the	O
fusion	O
protein	O
of	O
S	O
-	O
DCpep	O
to	O
express	O
on	O
the	O
surface	O
of	O
recombinant	O
Lactobacillus	O
plantarum	O
(	O
NC8	B-PRGE
-	I-PRGE
pSIP409	I-PRGE
-	I-PRGE
pgsA	I-PRGE
'-	I-PRGE
S	I-PRGE
-	I-PRGE
DCpep	I-PRGE
)	O
NC8	O
strain	O
.	O

Activities	O
such	O
as	O
performing	O
more	O
thorough	O
cleanings	O
to	O
remove	O
residual	O
virus	O
or	O
implementing	O
stricter	O
on	O
-	O
farm	O
biosecurity	O
to	O
cease	O
between	O
-	O
house	O
virus	O
transfer	O
demonstrated	O
little	O
effectiveness	O
for	O
the	O
control	O
of	O
PED	B-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
screened	O
a	O
library	O
of	O
1000	O
compounds	O
and	O
identified	O
two	O
specific	O
inhibitors	O
,	O
designated	O
compounds	O
2	O
and	O
3	O
,	O
which	O
target	O
the	O
PRRSV	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
serine	I-PRGE
protease	I-PRGE
(	O
3CLSP	O
).	O

ABSTRACT	O
:	O
Memory	O
CD8	B-PRGE
T	O
cells	O
can	O
provide	O
protection	O
from	O
re	O
-	O
infection	O
by	O
respiratory	O
viruses	O
such	O
as	O
influenza	O
and	O
SARS	O
.	O

However	O
,	O
the	O
relative	O
contribution	O
of	O
memory	O
CD8	B-PRGE
T	O
cells	O
in	O
providing	O
protection	O
against	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
infection	O
is	O
currently	O
unclear	O
.	O

Memory	O
CD8	B-PRGE
T	O
cells	O
rapidly	O
produced	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
following	O
RSV	O
infection	O
resulting	O
in	O
elevated	O
protein	O
levels	O
in	O
the	O
lung	O
and	O
periphery	O
.	O

These	O
results	O
demonstrate	O
that	O
in	O
contrast	O
to	O
other	O
respiratory	O
viruses	O
,	O
RSV	O
-	O
specific	O
memory	O
CD8	B-PRGE
T	O
cells	O
can	O
induce	O
lethal	O
immunopathology	O
despite	O
mediating	O
enhanced	O
viral	O
clearance	O
.	O

Coronaviruses	O
are	O
one	O
of	O
the	O
most	O
common	O
viruses	O
discovered	O
in	O
bats	O
,	O
which	O
were	O
considered	O
as	O
the	O
natural	O
source	O
of	O
recent	O
human	O
-	O
susceptible	O
coronaviruses	O
,	O
i	O
.	O
e	O
.	O
SARS	O
-	O
COV	O
and	O
MERS	O
-	O
CoV	O
.	O
Our	O
previous	O
study	O
reported	O
the	O
discovery	O
of	O
a	O
bat	O
-	O
derived	O
putative	O
cross	O
-	O
family	O
recombinant	O
coronavirus	O
with	O
a	O
reovirus	O
gene	O
p10	B-PRGE
,	O
named	O
as	O
Ro	O
-	O
BatCoV	O
GCCDC1	O
.	O

Moreover	O
,	O
in	O
P	O
.	O
berghei	O
NK65	O
infected	O
mice	O
,	O
increased	O
lipid	O
peroxidation	O
,	O
accumulation	O
of	O
triglycerides	O
,	O
impairment	O
of	O
anti	O
-	O
oxidant	O
enzymes	O
and	O
higher	O
collagen	B-PRGE
deposition	O
were	O
detected	O
.	O

The	O
protein	O
expression	O
of	O
collagen	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
concentration	O
of	O
cytokine	O
CXCL12	O
in	O
ALI	O
/	O
ARDS	O
group	O
were	O
higher	O
than	O
that	O
in	O
control	O
group	O
.	O

In	O
both	O
PCV	O
and	O
PSV	O
,	O
peak	O
transpulmonary	O
pressure	O
was	O
lower	O
,	O
whereas	O
E	B-PRGE
-	I-PRGE
cadherin	I-PRGE
tissue	O
expression	O
,	O
which	O
is	O
related	O
to	O
epithelial	O
integrity	O
,	O
was	O
higher	O
at	O
PEEP	O
=	O
5	O
cmH2O	O
than	O
at	O
PEEP	O
=	O
2	O
cmH2O	O
.	O

Peak	O
transpulmonary	O
pressure	O
correlated	O
positively	O
with	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
[	O
Spearman	O
'	O
s	O
rho	O
(	O
Ï	O
)	O
=	O
0	O
.	O
62	O
,	O
P	O
=	O
0	O
.	O
0007	O
]	O
and	O
CINC	B-PRGE
-	I-PRGE
1	I-PRGE
expressions	O
(	O
Ï	O
=	O
0	O
.	O
50	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
negatively	O
with	O
E	B-PRGE
-	I-PRGE
cadherin	I-PRGE
expression	O
(	O
Ï	O
=	O
-	O
0	O
.	O
67	O
,	O
P	O
=	O
0	O
.	O
0002	O
).	O

Ulinastatin	B-PRGE
(	O
UTI	B-PRGE
),	O
a	O
serine	B-PRGE
protease	I-PRGE
inhibitor	I-PRGE
,	O
possesses	O
anti	O
-	O
inflammatory	O
properties	O
and	O
has	O
been	O
suggested	O
to	O
modulate	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
sepsis	O
;	O
thus	O
,	O
it	O
is	O
now	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
pancreatitis	O
,	O
sepsis	O
,	O
and	O
septic	O
shock	O
.	O

Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
4	I-PRGE
(	O
TLR4	B-PRGE
),	O
an	O
essential	O
LPS	O
signaling	O
receptor	O
,	O
plays	O
a	O
critical	O
role	O
in	O
the	O
activation	O
of	O
innate	O
immunity	O
.	O

In	O
this	O
review	O
,	O
we	O
address	O
important	O
aspects	O
in	O
FCoV	O
genetics	O
,	O
replication	O
and	O
pathogenesis	O
,	O
focusing	O
on	O
the	O
role	O
of	O
S	O
.	O
To	O
better	O
understand	O
this	O
,	O
FCoV	B-PRGE
S	I-PRGE
protein	I-PRGE
models	O
were	O
constructed	O
,	O
based	O
on	O
the	O
human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
(	O
HCoV	O
-	O
NL63	O
)	O
S	O
structure	O
.	O

Above	O
all	O
,	O
we	O
found	O
that	O
IFN	B-PRGE
-	I-PRGE
Î»	I-PRGE
also	O
have	O
an	O
effect	O
on	O
IBV	O
infection	O
in	O
trachea	O
besides	O
many	O
other	O
respiratory	O
virus	O
.	O

We	O
amplified	O
partial	O
RNA	O
-	O
dependent	O
RNA	B-PRGE
polymerase	I-PRGE
genes	I-PRGE
of	O
Alpha	O
and	O
Betacoronavirus	O
together	O
with	O
the	O
partial	B-PRGE
polymerase	I-PRGE
gene	I-PRGE
of	O
Paramyxovirus	O
.	O

TITLE	O
:	O
Surfactant	B-PRGE
protein	I-PRGE
C	I-PRGE
dampens	O
inflammation	O
by	O
decreasing	O
JAK	B-PRGE
/	O
STAT	B-PRGE
activation	O
during	O
lung	O
repair	O
.	O

SPC	B-PRGE
-	O
TK	O
/	O
SPC	B-PRGE
-	O
KO	O
mice	O
had	O
highly	O
elevated	O
inflammatory	O
cytokines	O
and	O
granulocyte	O
infiltration	O
in	O
the	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
.	O

The	O
HKU25	B-PRGE
-	I-PRGE
receptor	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
RBD	O
)	O
can	O
bind	O
to	O
hDPP4	B-PRGE
protein	I-PRGE
and	O
hDPP4	O
-	O
expressing	O
cells	O
,	O
but	O
it	O
does	O
so	O
with	O
lower	O
efficiency	O
than	O
that	O
of	O
MERS	O
-	O
RBD	O
.	O

AKI	B-PRGE
was	O
defined	O
by	O
acute	O
renal	O
failure	O
receiving	O
CRRT	O
and	O
the	O
outcomes	O
of	O
patients	O
on	O
VV	O
ECMO	O
were	O
compared	O
between	O
the	O
AKI	O
and	O
non	O
-	O
AKI	B-PRGE
groups	O
.	O

However	O
,	O
similar	O
levels	O
of	O
the	O
inflammasome	O
component	O
of	O
nucleotide	O
oligomerization	O
domain	O
-	O
like	O
receptor	O
protein	O
3	O
(	O
NLRP3	B-PRGE
)	O
were	O
observed	O
in	O
two	O
genotypes	O
of	O
BMMs	O
.	O

Co	O
-	O
immunoprecipitation	O
data	O
indicated	O
galectin	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
NLRP3	B-PRGE
interaction	O
in	O
BMMs	O
infected	O
with	O
H5N1	O
.	O

An	O
association	O
was	O
also	O
observed	O
between	O
galectin	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
NLRP3	B-PRGE
/	O
apoptosis	O
-	O
associated	O
speck	O
-	O
like	O
proteins	O
containing	O
caspase	B-PRGE
-	I-PRGE
associated	I-PRGE
recruitment	I-PRGE
domain	I-PRGE
complex	I-PRGE
.	O

However	O
,	O
there	O
is	O
limited	O
information	O
on	O
the	O
specific	O
contribution	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
accessory	I-PRGE
protein	I-PRGE
4b	I-PRGE
to	O
the	O
repression	O
of	O
the	O
innate	O
antiviral	O
response	O
in	O
the	O
context	O
of	O
infection	O
.	O

With	O
aCGH	O
and	O
/	O
or	O
MLPA	O
,	O
pathogenic	O
CNV	O
variants	O
were	O
confirmed	O
:	O
COL4A5	B-PRGE
or	O
HNF1B	B-PRGE
in	O
two	O
cases	O
each	O
,	O
and	O
EYA1	B-PRGE
,	O
CLCNKB	O
,	O
or	O
PAX2	B-PRGE
in	O
one	O
each	O
.	O

We	O
measured	O
anti	B-PRGE
-	I-PRGE
HEV	I-PRGE
IgG	I-PRGE
prevalence	O
in	O
10	O
407	O
adults	O
participating	O
in	O
two	O
linked	O
,	O
population	O
-	O
representative	O
serosurveys	O
(	O
total	O
n	O
=	O
12	O
971	O
)	O
conducted	O
in	O
1998	O
and	O
2010	O
.	O

The	O
molecular	O
mechanisms	O
of	O
ALI	O
and	O
ARDS	O
are	O
still	O
not	O
well	O
explored	O
,	O
but	O
available	O
reports	O
indicate	O
the	O
involvement	O
of	O
several	O
pro	O
-	O
inflammatory	O
mediators	O
including	O
cytokines	O
(	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
,	O
IL	O
-	O
1Î²	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
and	O
chemokines	O
[	O
like	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	O
-	O
8	O
)	O
and	O
macrophage	B-PRGE
inhibitory	I-PRGE
factor	I-PRGE
(	O
MIF	B-PRGE
)],	O
as	O
well	O
as	O
macrophage	O
polarization	O
regulating	O
the	O
migration	O
and	O
pulmonary	O
infiltration	O
of	O
neutrophils	O
into	O
the	O
pulmonary	O
interstitial	O
tissue	O
,	O
causing	O
injury	O
to	O
the	O
pulmonary	O
parenchyma	O
.	O

Results	O
indicated	O
that	O
the	O
mTOR	B-PRGE
signaling	O
pathway	O
played	O
a	O
vital	O
role	O
in	O
the	O
PEDV	O
antiviral	O
regulation	O
in	O
the	O
Vero	O
E6	O
cells	O
.	O

A	O
prominent	O
pro	O
-	O
inflammatory	O
Th1	O
and	O
Th17	O
response	O
was	O
clearly	O
seen	O
in	O
patients	O
with	O
MERS	O
-	O
CoV	O
infection	O
,	O
with	O
markedly	O
increased	O
concentrations	O
of	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
compared	O
to	O
controls	O
.	O

In	O
this	O
study	O
,	O
an	O
oral	O
recombinant	O
Lactobacillus	O
casei	O
vaccine	O
against	O
PEDV	O
infection	O
targeting	O
the	O
intestinal	O
microfold	O
(	O
M	O
)	O
cells	O
and	O
dendritic	O
cells	O
(	O
DCs	O
)	O
for	O
delivering	O
the	O
core	O
neutralizing	O
epitope	O
(	O
COE	O
)	O
of	O
PEDV	B-PRGE
spike	I-PRGE
protein	I-PRGE
was	O
developed	O
with	O
M	B-PRGE
cell	I-PRGE
-	I-PRGE
targeting	I-PRGE
peptide	I-PRGE
(	O
Col	B-PRGE
)	O
and	O
dendritic	O
cell	O
-	O
targeting	O
peptide	O
(	O
DCpep	O
).	O

Moreover	O
,	O
in	O
response	O
to	O
restimulation	O
with	O
the	O
PEDV	B-PRGE
COE	I-PRGE
antigen	I-PRGE
in	O
vitro	O
,	O
a	O
significant	O
difference	O
in	O
splenocyte	O
proliferation	O
response	O
and	O
Th2	B-PRGE
-	I-PRGE
associated	I-PRGE
cytokine	I-PRGE
IL	I-PRGE
-	I-PRGE
4	I-PRGE
level	O
was	O
observed	O
in	O
the	O
group	O
of	O
mice	O
orally	O
immunized	O
with	O
pPG	B-PRGE
-	I-PRGE
COE	I-PRGE
-	I-PRGE
Col	I-PRGE
-	I-PRGE
DCpep	I-PRGE
/	O
L393	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
compared	O
to	O
the	O
groups	O
of	O
mice	O
that	O
received	O
pPG	B-PRGE
-	I-PRGE
COE	I-PRGE
-	I-PRGE
Col	I-PRGE
/	O
L393	O
and	O
pPG	B-PRGE
-	I-PRGE
COE	I-PRGE
-	I-PRGE
DCpep	I-PRGE
/	I-PRGE
L393	I-PRGE
,	O
respectively	O
.	O

COE	O
fused	O
to	O
the	O
flanking	O
C	O
'/	O
N	O
'	O
terminal	O
of	O
rSF	O
yielded	O
rSF	O
-	O
COE	O
-	O
C	O
and	O
rSF	O
-	O
COE	O
-	O
N	O
.	O
As	O
a	O
result	O
,	O
rSF	O
-	O
COE	O
-	O
3D	O
could	O
significantly	O
improve	O
COE	O
specific	O
antibody	O
production	O
including	O
serum	O
IgG	B-PRGE
,	O
serum	B-PRGE
IgA	I-PRGE
,	O
mucosal	B-PRGE
IgA	I-PRGE
and	O
PEDV	O
neutralizing	O
antibody	O
.	O

TITLE	O
:	O
Insights	O
into	O
the	O
homo	O
-	O
oligomerization	O
properties	O
of	O
N	O
-	O
terminal	O
coiled	O
-	O
coil	O
domain	O
of	O
Ebola	B-PRGE
virus	I-PRGE
VP35	I-PRGE
protein	I-PRGE
.	O

Serum	B-PRGE
angiopoietin	I-PRGE
levels	O
were	O
quantified	O
in	O
pneumonia	O
patients	O
of	O
two	O
independent	O
cohorts	O
(	O
n	O
=	O
148	O
,	O
n	O
=	O
395	O
).	O

This	O
protein	O
is	O
composed	O
of	O
an	O
N	B-PRGE
-	I-PRGE
terminal	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
S1	O
)	O
and	O
a	O
C	O
-	O
terminal	O
trans	O
-	O
membrane	O
fusion	O
domain	O
(	O
S2	O
).	O

We	O
found	O
no	O
clinical	O
differences	O
between	O
patients	O
with	O
short	O
and	O
medium	O
duration	O
AKI	O
,	O
even	O
when	O
accounting	O
for	O
AKI	B-PRGE
severity	O
and	O
recurrent	O
AKI	O
.	O

Herein	O
,	O
we	O
report	O
a	O
structural	O
model	O
of	O
a	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
construct	I-PRGE
in	O
LMPG	O
micelles	O
with	O
,	O
for	O
the	O
first	O
time	O
,	O
unequivocal	O
intermolecular	O
NOEs	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
ADAM17	B-PRGE
suppressed	O
PEDV	O
infection	O
in	O
HEK293	O
and	O
IPEC	O
-	O
J2	O
cells	O
,	O
whereas	O
ablation	O
of	O
ADAM17	B-PRGE
expression	O
using	O
ADAM17	B-PRGE
specific	I-PRGE
siRNA	I-PRGE
resulted	O
in	O
a	O
corresponding	O
increase	O
of	O
PEDV	O
infection	O
and	O
an	O
upregulation	O
of	O
cell	O
surface	O
APN	B-PRGE
expression	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
modulation	O
of	O
APN	O
expression	O
by	O
metalloprotease	B-PRGE
ADAM17	B-PRGE
regulates	O
PEDV	O
infection	O
.	O

Haptoglobin	B-PRGE
levels	O
of	O
between	O
1	O
.	O
32	O
and	O
1	O
.	O
60	O
mg	O
/	O
ml	O
at	O
d	O
-	O
14	O
were	O
significantly	O
associated	O
with	O
decreases	O
in	O
BHV	O
-	O
1	O
S	O
/	O
N	O
during	O
the	O
peri	O
-	O
weaning	O
period	O
.	O

TITLE	O
:	O
Engineering	O
a	O
stable	O
CHO	O
cell	O
line	O
for	O
the	O
expression	O
of	O
a	O
MERS	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
vaccine	I-PRGE
antigen	I-PRGE
.	O

We	O
conclude	O
that	O
administration	O
of	O
IgM	B-PRGE
-	I-PRGE
enriched	I-PRGE
immunoglobulins	I-PRGE
as	O
an	O
additional	O
therapy	O
did	O
not	O
have	O
a	O
beneficial	O
effect	O
in	O
patients	O
with	O
severe	O
ARDS	O
requiring	O
ECMO	O
support	O
.	O

We	O
cloned	O
the	O
partial	O
Vero	B-PRGE
-	I-PRGE
APN	I-PRGE
gene	I-PRGE
(	O
3340	O
-	O
bp	O
)	O
containing	O
exons	O
1	O
to	O
9	O
from	O
cellular	O
DNA	O
and	O
subsequently	O
generated	O
two	O
APN	O
-	O
knockout	O
Vero	O
cell	O
lines	O
by	O
CRISPR	O
/	O
Cas9	O
approach	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
glycoprotein	O
(	O
S	O
)	O
of	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
strain	O
A59	O
uses	O
murine	O
carcinoembryonic	B-PRGE
antigen	I-PRGE
-	I-PRGE
related	I-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
1a	I-PRGE
as	O
its	O
receptor	O
for	O
cell	O
entry	O
,	O
but	O
S	B-PRGE
protein	I-PRGE
can	O
also	O
be	O
triggered	O
in	O
the	O
absence	O
of	O
receptor	O
by	O
pH	O
8	O
.	O
0	O
alone	O
at	O
37	O
Â°	O
C	O
.	O

ABSTRACT	O
:	O
The	O
detection	O
of	O
avian	B-PRGE
coronaviruses	I-PRGE
(	O
AvCoV	O
)	O
in	O
wild	O
birds	O
and	O
the	O
emergence	O
of	O
new	O
AvCoV	O
have	O
increased	O
in	O
the	O
past	O
few	O
years	O
.	O

However	O
,	O
patients	O
with	O
a	O
P	O
/	O
F	O
ratio	O
of	O
greater	O
than	O
120	O
or	O
receiving	O
high	O
tidal	O
volume	O
ventilation	O
had	O
either	O
no	O
change	O
or	O
an	O
increase	O
in	O
SP	B-PRGE
-	I-PRGE
D	I-PRGE
,	O
WVF	O
,	O
or	O
IL	O
-	O
8	O
concentrations	O
.	O

Replication	O
of	O
PEDV	O
was	O
inhibited	O
by	O
silencing	O
the	O
expression	O
of	O
hnRNP	B-PRGE
A1	I-PRGE
in	O
CCL	O
-	O
81	O
cells	O
,	O
suggesting	O
the	O
positive	O
effect	O
of	O
hnRNP	O
A1	O
on	O
PEDV	O
infection	O
.	O

She	O
was	O
given	O
comprehensive	O
treatment	O
,	O
including	O
oseltamivir	O
,	O
methylprednisolone	O
,	O
immunoglobulin	B-PRGE
,	O
gastric	O
protection	O
,	O
and	O
noninvasive	O
mechanical	O
ventilation	O
.	O

CS	O
-	O
exposed	O
antibiotic	O
-	O
treated	O
mice	O
also	O
had	O
higher	O
serum	O
surfactant	B-PRGE
protein	I-PRGE
D	I-PRGE
and	O
angiopoietin	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
consistent	O
with	O
more	O
severe	O
lung	O
epithelial	O
and	O
endothelial	O
injury	O
.	O

DIC	B-PRGE
and	O
AKI	B-PRGE
are	O
frequent	O
complications	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

ABSTRACT	O
:	O
Clinical	O
samples	O
were	O
evaluated	O
with	O
the	O
Mobile	O
Analysis	O
Platform	O
(	O
MAP	O
)	O
to	O
determine	O
platform	O
performance	O
for	O
detecting	O
respiratory	O
viruses	O
in	O
samples	O
previously	O
characterized	O
using	O
clinical	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
assays	O
.	O

Using	O
the	O
in	O
vitro	O
transcribed	O
TGEV	O
RNA	O
as	O
template	O
,	O
the	O
limit	O
of	O
detection	O
of	O
the	O
developed	O
RT	B-PRGE
-	I-PRGE
RPA	I-PRGE
was	O
100	O
copies	O
per	O
reaction	O
.	O

The	O
model	O
included	O
male	O
sex	O
,	O
contact	O
with	O
a	O
sick	O
patient	O
or	O
camel	O
,	O
diabetes	O
,	O
severe	O
illness	O
,	O
low	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
count	O
,	O
low	O
alanine	B-PRGE
aminotransferase	I-PRGE
(	O
ALT	B-PRGE
),	O
and	O
high	O
aspartate	B-PRGE
aminotransferase	I-PRGE
(	O
AST	B-PRGE
).	O

SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
are	O
classified	O
as	O
BSL	O
-	O
3	O
viruses	O
,	O
which	O
makes	O
experimentation	O
into	O
the	O
cellular	O
mechanisms	O
involved	O
in	O
infection	O
more	O
challenging	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
our	O
patient	O
is	O
the	O
first	O
to	O
have	O
Cbl	B-PRGE
C	I-PRGE
defect	O
-	O
HUS	O
accompanied	O
by	O
complement	O
dysregulation	O
,	O
who	O
responded	O
well	O
to	O
eculizumab	O
therapy	O
.	O

Furthermore	O
,	O
these	O
studies	O
also	O
highlight	O
the	O
role	O
of	O
APCs	B-PRGE
in	O
stimulating	O
a	O
robust	O
protective	O
immune	O
response	O
to	O
MERS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Complete	O
Genome	O
Sequence	O
of	O
Human	B-PRGE
Coronavirus	I-PRGE
NL63	I-PRGE
CN0601	O
/	O
14	O
,	O
First	O
Isolated	O
in	O
South	O
Korea	O
.	O

All	O
IBV	B-PRGE
S1	I-PRGE
gene	I-PRGE
sequences	I-PRGE
,	O
with	O
local	O
and	O
year	O
of	O
collection	O
information	O
available	O
on	O
GenBank	O
,	O
were	O
retrieved	O
.	O

Contrary	O
to	O
the	O
wild	O
-	O
type	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strain	O
,	O
infection	O
induced	O
by	O
H120	O
vaccine	O
virus	O
exerts	O
only	O
a	O
moderate	O
influence	O
on	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
of	O
the	O
CM	O
capillary	O
web	O
and	O
on	O
follicular	O
development	O
compared	O
to	O
the	O
untreated	O
controls	O
.	O

Most	O
animal	O
models	O
of	O
ALI	O
are	O
limited	O
by	O
the	O
fact	O
that	O
they	O
focus	O
on	O
a	O
singular	O
cause	O
of	O
acute	B-PRGE
lung	I-PRGE
injury	I-PRGE
(	O
ALI	O
)	O
and	O
therefore	O
fail	O
to	O
mimic	O
the	O
complex	O
,	O
multifactorial	O
pathobiology	O
of	O
ARDS	O
.	O

All	O
six	O
isolated	O
compounds	O
have	O
been	O
evaluated	O
firstly	O
for	O
the	O
inhibition	O
of	O
both	O
Human	O
Immunodeficiency	O
Virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Reverse	B-PRGE
Transcriptase	I-PRGE
(	O
RT	O
)-	O
associated	O
DNA	O
Polymerase	O
(	O
RDDP	O
)	O
and	O
Ribonuclease	B-PRGE
H	I-PRGE
(	O
RNase	B-PRGE
H	I-PRGE
)	O
activities	O
,	O
for	O
the	O
inhibition	O
of	O
HIV	O
-	O
1	O
integrase	B-PRGE
(	O
IN	O
)	O
in	O
biochemical	O
assays	O
,	O
and	O
also	O
for	O
their	O
effect	O
on	O
viral	O
replication	O
.	O

PVP	O
-	O
I	O
7	O
%	O
gargle	O
/	O
mouthwash	O
was	O
diluted	O
1	O
:	O
30	O
with	O
water	O
to	O
a	O
concentration	O
of	O
0	O
.	O
23	O
%	O
(	O
the	O
recommended	O
concentration	O
for	O
""""	O
real	O
-	O
life	O
""""	O
use	O
in	O
Japan	O
)	O
and	O
tested	O
at	O
room	O
temperature	O
under	O
clean	O
conditions	O
[	O
0	O
.	O
3	O
g	O
/	O
l	O
bovine	B-PRGE
serum	I-PRGE
albumin	I-PRGE
(	O
BSA	B-PRGE
),	O
viruses	O
only	O
]	O
and	O
dirty	O
conditions	O
(	O
3	O
.	O
0	O
g	O
/	O
l	O
BSA	O
+	O
3	O
.	O
0	O
ml	O
/	O
l	O
erythrocytes	O
)	O
as	O
an	O
interfering	O
substance	O
for	O
defined	O
contact	O
times	O
(	O
minimum	O
15	O
s	O
).	O

However	O
,	O
treatment	O
with	O
APN	B-PRGE
-	I-PRGE
specific	I-PRGE
antibody	I-PRGE
and	O
inhibitors	O
did	O
not	O
completely	O
block	O
PDCoV	O
infection	O
in	O
IPI	O
-	O
2I	O
porcine	O
intestinal	O
epithelial	O
cells	O
.	O

Accordingly	O
,	O
early	O
acute	O
respiratory	O
distress	O
syndrome	O
-	O
bronchoalveolar	O
lavage	O
fluid	O
drives	O
an	O
acute	O
respiratory	O
distress	O
syndrome	O
-	O
specific	O
anti	O
-	O
inflammatory	O
macrophage	O
polarization	O
in	O
vitro	O
,	O
close	O
to	O
that	O
induced	O
by	O
recombinant	B-PRGE
interleukin	I-PRGE
-	I-PRGE
10	I-PRGE
.	O

TITLE	O
:	O
A	O
novel	O
mechanism	O
of	O
RNase	B-PRGE
L	I-PRGE
inhibition	O
:	O
Theiler	O
'	O
s	O
virus	O
L	O
*	O
protein	O
prevents	O
2	O
-	O
5A	O
from	O
binding	O
to	O
RNase	B-PRGE
L	I-PRGE
.	O
ABSTRACT	O
:	O
The	O
OAS	O
/	O
RNase	B-PRGE
L	O
pathway	O
is	O
one	O
of	O
the	O
best	O
-	O
characterized	O
effector	O
pathways	O
of	O
the	O
IFN	B-PRGE
antiviral	O
response	O
.	O

Previously	O
we	O
found	O
that	O
L	O
*	O
was	O
the	O
first	O
viral	O
protein	O
binding	O
directly	O
RNase	B-PRGE
L	I-PRGE
.	O
Our	O
current	O
data	O
show	O
that	O
L	O
*	O
binds	O
the	O
ankyrin	B-PRGE
repeats	O
R1	O
and	O
R2	O
of	O
RNase	B-PRGE
L	I-PRGE
and	O
inhibits	O
2	O
'-	O
5	O
'	O
oligoadenylates	O
(	O
2	O
-	O
5A	O
)	O
binding	O
to	O
RNase	B-PRGE
L	I-PRGE
.	O
Thereby	O
,	O
L	O
*	O
prevents	O
dimerization	O
and	O
oligomerization	O
of	O
RNase	B-PRGE
L	I-PRGE
in	O
response	O
to	O
2	O
-	O
5A	O
.	O

Moreover	O
,	O
APOBEC3	B-PRGE
proteins	I-PRGE
bound	O
to	O
the	O
coronaviral	O
nucleoprotein	O
,	O
and	O
this	O
interaction	O
also	O
affected	O
viral	O
replication	O
.	O

In	O
conclusion	O
,	O
there	O
is	O
no	O
difference	O
between	O
IFN	B-PRGE
treatment	O
and	O
supportive	O
treatment	O
for	O
MERS	O
patients	O
in	O
terms	O
of	O
mortality	O
.	O

On	O
the	O
day	O
of	O
weaning	O
,	O
increased	O
levels	O
of	O
linoleic	O
acid	O
and	O
IGF	B-PRGE
-	I-PRGE
I	I-PRGE
was	O
associated	O
with	O
higher	O
body	O
weight	O
.	O

TITLE	O
:	O
The	O
CD8	B-PRGE
T	I-PRGE
Cell	O
Response	O
to	O
Respiratory	O
Virus	O
Infections	O
.	O

Interestingly	O
,	O
blocking	O
C5a	O
production	O
by	O
targeting	O
its	O
receptor	O
,	O
C5aR	B-PRGE
,	O
alleviated	O
lung	O
and	O
spleen	O
tissue	O
damage	O
and	O
reduced	O
inflammatory	O
responses	O
.	O

When	O
tested	O
in	O
the	O
2	O
-	O
day	O
-	O
old	O
piglet	O
model	O
,	O
wild	O
-	O
type	O
(	O
WT	O
)	O
BJ2011C	O
caused	O
severe	O
diarrhea	O
and	O
death	O
of	O
the	O
piglets	O
within	O
72	O
h	O
.	O
In	O
contrast	O
,	O
its	O
chimeric	O
derivative	O
carrying	O
the	O
S	B-PRGE
gene	I-PRGE
from	O
CHM2013	O
(	O
BJ2011C	O
-	O
S	O

Full	B-PRGE
S1	I-PRGE
gene	I-PRGE
amplification	O
was	O
achieved	O
using	O
primer	O
A	O
and	O
primer	O
22	O
.	O
51	O
.	O

PEDV	O
NA	O
,	O
IgG	B-PRGE
and	O
IgA	B-PRGE
were	O
detected	O
in	O
the	O
serum	O
of	O
piglets	O
born	O
to	O
immunized	O
gilts	O
,	O
demonstrating	O
the	O
transfer	O
of	O
antibodies	O
through	O
colostrum	O
and	O
milk	O
.	O

Both	O
THERAFLEX	O
UV	O
-	O
Platelets	O
(	O
UVC	O
)	O
and	O
THERAFLEX	B-PRGE
MB	I-PRGE
-	I-PRGE
Plasma	I-PRGE
(	O
MB	O
/	O
light	O
)	O
effectively	O
reduce	O
EBOV	O
and	O
MERS	O
-	O
CoV	O
infectivity	O
in	O
platelets	O
and	O
plasma	O
,	O
respectively	O
.	O

We	O
identified	O
57	O
patients	O
with	O
HMP	O
and	O
161	O
patients	O
with	O
RSV	O
:	O
the	O
proportions	O
of	O
patients	O
with	O
either	O
virus	O
who	O
developed	O
PARDS	O
(	O
HMP	B-PRGE
:	O
23	O
%,	O
RSV	O
:	O
20	O
%)	O
and	O
severe	O
PARDS	O
(	O
HMP	O
:	O
9	O
%,	O
RSV	O
:	O
7	O
%)	O
were	O
similar	O
,	O
as	O
were	O
the	O
proportions	O
of	O
patients	O
with	O
acute	O
(	O
or	O
acute	O
-	O
on	O
-	O
chronic	O
)	O
respiratory	O
failure	O
who	O
developed	O
PARDS	O
(	O
HMP	B-PRGE
:	O
41	O
%,	O
RSV	O
:	O
31	O
%).	O

TITLE	O
:	O
Human	B-PRGE
Coronavirus	I-PRGE
NL63	I-PRGE
Molecular	O
Epidemiology	O
and	O
Evolutionary	O
Patterns	O
in	O
Rural	O
Coastal	O
Kenya	O
.	O

Further	O
analyses	O
revealed	O
that	O
NS6	B-PRGE
is	O
not	O
an	O
RNA	O
-	O
binding	O
protein	O
;	O
however	O
,	O
it	O
interacts	O
with	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
/	O
MDA5	B-PRGE
.	O

We	O
used	O
in	O
-	O
vitro	O
and	O
human	O
ex	O
-	O
vivo	O
explant	O
cultures	O
to	O
investigate	O
the	O
effect	O
of	O
two	O
immunomodulatory	O
agents	O
,	O
interferon	B-PRGE
alpha	I-PRGE
and	O
cyclosporine	O
,	O
singly	O
and	O
in	O
combination	O
,	O
on	O
MERS	O
-	O
CoV	O
replication	O
.	O

ABSTRACT	O
:	O
CD26	B-PRGE
is	O
a	O
110	B-PRGE
kDa	I-PRGE
surface	I-PRGE
glycoprotein	I-PRGE
with	O
intrinsic	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
IV	O
activity	O
that	O
is	O
expressed	O
on	O
numerous	O
cell	O
types	O
and	O
has	O
a	O
multitude	O
of	O
biological	O
functions	O
.	O

The	O
secondary	O
objectives	O
included	O
measuring	O
the	O
effect	O
of	O
anti	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
10	I-PRGE
antibodies	I-PRGE
on	O
calf	O
health	O
,	O
performance	O
,	O
and	O
shedding	O
of	O
less	O
common	O
diarrheal	O
pathogens	O
.	O

Fecal	O
pH	O
was	O
measured	O
at	O
enrollment	O
and	O
on	O
d	O
5	O
and	O
14	O
,	O
and	O
fecal	O
pathogen	O
(	O
C	O
.	O
parvum	O
,	O
coronavirus	O
,	O
rotavirus	O
,	O
and	O
Salmonella	B-PRGE
spp	I-PRGE
.	O

In	O
summary	O
,	O
feeding	O
anti	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
10	I-PRGE
antibodies	I-PRGE
was	O
associated	O
with	O
increased	O
fecal	O
pH	O
,	O
reduced	O
risk	O
of	O
respiratory	O
disease	O
later	O
in	O
the	O
preweaning	O
period	O
,	O
and	O
decreased	O
antibiotic	O
usage	O
despite	O
higher	O
rotavirus	O
infection	O
.	O

Pirfenidone	O
substantially	O
reduced	O
NLRP3	B-PRGE
and	O
ASC	B-PRGE
expression	O
and	O
inhibited	O
caspase	B-PRGE
-	I-PRGE
1	I-PRGE
activation	O
and	O
IL	O
-	O
1Î²	O
maturation	O
in	O
lung	O
tissues	O
.	O

The	O
binding	O
system	O
of	O
biotin	O
-	O
streptavidin	O
,	O
RCA	B-PRGE
,	O
and	O
Ru	O
(	O
bpy	O
)	O

This	O
is	O
the	O
first	O
report	O
on	O
coinfection	O
of	O
S1	B-PRGE
NTD	I-PRGE
-	I-PRGE
del	I-PRGE
PEDV	I-PRGE
variants	I-PRGE
and	O
the	O
original	O
US	O
PEDV	O
strain	O
in	O
US	O
pigs	O
,	O
indicating	O
that	O
PEDV	O
continues	O
to	O
evolve	O
in	O
pigs	O
and	O
might	O
be	O
responsible	O
for	O
disease	O
pattern	O
changes	O
.	O

Further	O
research	O
results	O
showed	O
that	O
inhibition	O
of	O
p53	B-PRGE
signaling	O
pathway	O
can	O
reverse	O
the	O
cell	O
cycle	O
arrest	O
in	O
G0	O
/	O
G1	O
phase	O
induced	O
by	O
PEDV	O
infection	O
and	O
cancel	O
out	O
the	O
up	O
-	O
regulation	O
of	O
p21	B-PRGE
and	O
corresponding	O
Cyclin	B-PRGE
/	O
cdk	B-PRGE
mentioned	O
above	O
.	O

Meanwhile	O
,	O
the	O
coiled	O
-	O
coil	O
-	O
forming	O
Leu	O
/	O
Ile	O
heptad	O
repeat	O
sequences	O
within	O
the	O
S	B-PRGE
protein	I-PRGE
were	O
under	O
-	O
represented	O
during	O
peptide	O
array	O
scanning	O
,	O
in	O
agreement	O
with	O
that	O
long	O
peptide	O
lengths	O
were	O
required	O
to	O
attain	O
high	O
helix	O
-	O
mediated	O
interaction	O
avidity	O
.	O

Infection	O
by	O
its	O
causative	O
agent	O
PED	O
virus	O
(	O
PEDV	O
),	O
an	O
Alpha	O
-	O
coronavirus	O
,	O
was	O
previously	O
proven	O
to	O
be	O
mediated	O
by	O
its	O
spike	O
(	O
S	O
)	O
glycoprotein	O
and	O
a	O
cellular	O
receptor	O
porcine	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
(	O
pAPN	O
).	O

Various	O
databases	O
were	O
searched	O
to	O
identify	O
both	O
randomized	O
clinical	O
trials	O
and	O
cohort	O
studies	O
,	O
where	O
statin	O
users	O
were	O
compared	O
to	O
non	O
-	O
statin	B-PRGE
users	O
.	O

The	O
inhibitory	O
effect	O
on	O
virus	O
spread	O
is	O
due	O
to	O
an	O
inhibition	O
of	O
the	O
DEAD	B-PRGE
-	I-PRGE
box	I-PRGE
RNA	I-PRGE
helicase	I-PRGE
eIF4A	I-PRGE
,	O
which	O
is	O
required	O
to	O
unwind	O
structured	O
5	O
'-	O
untranslated	O
regions	O
(	O
UTRs	O
).	O

This	O
goes	O
along	O
with	O
a	O
strongly	O
reduced	O
HEV	B-PRGE
capsid	I-PRGE
protein	I-PRGE
translation	O
,	O
retention	O
of	O
viral	O
RNA	O
inside	O
the	O
cytoplasm	O
,	O
and	O
without	O
major	O
cytotoxic	O
effects	O
.	O

We	O
report	O
that	O
Unc51	B-PRGE
-	I-PRGE
like	I-PRGE
kinase	I-PRGE
1	I-PRGE
(	O
Ulk1	B-PRGE
/	O
Unc51	B-PRGE
.	I-PRGE
1	I-PRGE
)	O
is	O
a	O
pivotal	O
regulator	O
of	O
PHEV	O
-	O
induced	O
neurological	O
disorders	O
and	O
functions	O
to	O
selectively	O
control	O
the	O
initiation	O
of	O
nerve	B-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
NGF	B-PRGE
)/	O
TrkA	B-PRGE
endosome	O
trafficking	O
.	O

We	O
first	O
identified	O
the	O
function	O
of	O
Ulk1	B-PRGE
by	O
histopathologic	O
evaluation	O
in	O
a	O
PHEV	O
-	O
infected	O
mouse	O
model	O
in	O
which	O
neuronal	O
loss	O
was	O
accompanied	O
by	O
the	O
suppression	O
of	O
Ulk1	B-PRGE
expression	O
.	O

Patients	O
with	O
AKI	O
had	O
significantly	O
higher	O
serum	O
creatinine	O
(	O
P	O
<	O
.	O
001	O
)	O
and	O
lower	O
estimated	O
creatinine	O
clearance	O
(	O
P	O
<	O
.	O
001	O
)	O
compared	O
with	O
those	O
without	O
AKI	B-PRGE
.	O

In	O
patients	O
with	O
ARF	B-PRGE
and	O
AKI	B-PRGE
,	O
AKI	B-PRGE
is	O
associated	O
with	O
ARDS	O
and	O
longer	O
PICU	O
and	O
hospital	O
length	O
of	O
stay	O
.	O

The	O
receptor	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
).	O

Remarkably	O
,	O
ACGs	O
inhibited	O
the	O
LPS	B-PRGE
-	I-PRGE
dependent	I-PRGE
TLR4	I-PRGE
and	O
TRPC6	B-PRGE
upregulation	O
observed	O
during	O
ALI	O
.	O

The	O
improved	O
protective	O
efficiency	O
of	O
rSF	O
-	O
COE	O
-	O
3D	O
compared	O
with	O
COE	O
was	O
mostly	O
benefited	O
from	O
the	O
enhanced	O
production	O
of	O
serum	B-PRGE
IgA	I-PRGE
,	O
mucosal	B-PRGE
IgA	I-PRGE
in	O
feces	O
and	O
serum	O
neutralizing	O
antibody	O
titers	O
.	O

TITLE	O
:	O
The	O
ADRP	B-PRGE
domain	I-PRGE
from	O
a	O
virulent	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
is	O
not	O
sufficient	O
to	O
confer	O
a	O
pathogenic	O
phenotype	O
to	O
the	O
attenuated	O
Beaudette	O
strain	O
.	O

The	O
results	O
showed	O
that	O
TGEV	B-PRGE
N	I-PRGE
protein	I-PRGE
localised	O
in	O
the	O
cytoplasm	O
,	O
inhibited	O
IEC	O
growth	O
,	O
prolonged	O
the	O
S	O
-	O
phase	O
cell	O
cycle	O
by	O
down	O
-	O
regulating	O
cell	O
cycle	O
protein	O
cyclin	B-PRGE
A	I-PRGE
,	O
and	O
was	O
mainly	O
degraded	O
through	O
the	O
proteasome	O
pathway	O
.	O

Moreover	O
,	O
TGEV	B-PRGE
N	I-PRGE
protein	I-PRGE
induced	O
ER	O
stress	O
and	O
activated	O
NF	O
-	O
ÎºB	O
,	O
which	O
was	O
responsible	O
for	O
the	O
up	O
-	O
regulation	O
of	O
IL	O
-	O
8	O
and	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
.	O

Although	O
FHS	B-PRGE
-	I-PRGE
1	I-PRGE
cells	O
lost	O
the	O
expression	O
of	O
MHC	B-PRGE
class	I-PRGE
II	I-PRGE
and	O
CD163	B-PRGE
,	O
our	O
findings	O
indicate	O
that	O
FHS	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
feline	O
HS	O
cell	O
line	O
that	O
retains	O
functional	O
properties	O
of	O
dendritic	O
cells	O
/	O
macrophages	O
in	O
terms	O
of	O
phagocytic	O
and	O
antigen	O
uptake	O
/	O
processing	O
activities	O
.	O

The	O
results	O
show	O
that	O
the	O
genome	O
of	O
QY16	O
consists	O
of	O
27	O
,	O
670	O
nucleotides	O
,	O
excluding	O
poly	O
(	O
A	O
)	O
tail	O
,	O
and	O
that	O
its	O
genome	O
organization	O
is	O
5	B-PRGE
'	I-PRGE
UTR	I-PRGE
-	I-PRGE
1a	I-PRGE
-	I-PRGE
1b	I-PRGE
-	I-PRGE
S	I-PRGE
-	I-PRGE
3a	I-PRGE
-	I-PRGE
3b	I-PRGE
-	I-PRGE
E	I-PRGE
-	I-PRGE
M	I-PRGE
-	I-PRGE
4b	I-PRGE
-	I-PRGE
4c	I-PRGE
-	I-PRGE
5a	I-PRGE
-	I-PRGE
5b	I-PRGE
-	I-PRGE
N	I-PRGE
-	I-PRGE
6b	I-PRGE
-	I-PRGE
3	I-PRGE
'	I-PRGE
UTR	I-PRGE
-	I-PRGE
poly	I-PRGE
(	I-PRGE
A	I-PRGE
)	I-PRGE
tail	O
.	O

TITLE	O
:	O
Functional	O
plasticity	O
of	O
antibacterial	B-PRGE
EndoU	I-PRGE
toxins	I-PRGE
.	O

Here	O
,	O
we	O
present	O
the	O
first	O
structure	O
of	O
a	O
prokaryotic	O
EndoU	B-PRGE
toxin	I-PRGE
in	O
complex	O
with	O
its	O
cognate	O
immunity	O
protein	O
.	O

ABSTRACT	O
:	O
GBF1	B-PRGE
has	O
emerged	O
as	O
a	O
host	O
factor	O
required	O
for	O
the	O
replication	O
of	O
positive	O
-	O
sense	O
single	O
-	O
stranded	O
RNA	O
viruses	O
of	O
different	O
families	O
,	O
but	O
its	O
mechanism	O
of	O
action	O
is	O
still	O
unknown	O
.	O

In	O
addition	O
,	O
another	O
Arf	O
pair	O
,	O
Arf1	B-PRGE
and	O
Arf4	B-PRGE
,	O
appears	O
to	O
be	O
essential	O
for	O
YFV	O
and	O
SINV	O
infection	O
,	O
but	O
not	O
for	O
infection	O
by	O
other	O
viruses	O
.	O

Finally	O
,	O
CVB4	O
infection	O
was	O
not	O
inhibited	O
by	O
any	O
combination	O
of	O
Arf	B-PRGE
depletion	O
.	O

TITLE	O
:	O
Telocytes	O
promote	O
VEGF	B-PRGE
expression	O
and	O
alleviate	O
ventilator	O
-	O
induced	O
lung	O
injury	O
in	O
mice	O
.	O

Collectively	O
,	O
our	O
results	O
revealed	O
novel	O
functions	O
of	O
TCs	O
in	O
VILA	B-PRGE
repair	O
and	O
shed	O
light	O
on	O
the	O
complications	O
that	O
are	O
caused	O
by	O
MV	O
.	O

Overexpression	O
of	O
wild	O
-	O
type	O
or	O
dominant	O
-	O
negative	O
ULK1	B-PRGE
constructs	I-PRGE
does	O
not	O
affect	O
virus	O
replication	O
,	O
indicating	O
that	O
ULK1	B-PRGE
degradation	O
may	O
be	O
a	O
side	O
effect	O
of	O
the	O
ULK1	B-PRGE
-	O
independent	O
signaling	O
mechanism	O
used	O
by	O
PV	O
,	O
inducing	O
complex	O
instability	O
.	O

This	O
demonstration	O
of	O
ULK1	B-PRGE
-	O
independent	O
autophagic	O
signaling	O
is	O
novel	O
and	O
leads	O
to	O
a	O
model	O
by	O
which	O
the	O
virus	O
is	O
signaling	O
to	O
generate	O
autophagosomes	O
downstream	O
of	O
ULK1	B-PRGE
,	O
while	O
at	O
the	O
same	O
time	O
,	O
cleaving	O
cargo	O
receptors	O
,	O
which	O
may	O
affect	O
cargo	O
loading	O
and	O
autophagic	O
degradative	O
flux	O
.	O

ACTB	B-PRGE
-	I-PRGE
actin	I-PRGE
beta	I-PRGE
;	O
ATG13	B-PRGE
-	I-PRGE
autophagy	I-PRGE
related	I-PRGE
13	I-PRGE
;	O
ATG14	B-PRGE
-	I-PRGE
autophagy	I-PRGE
related	I-PRGE
14	I-PRGE
;	O
ATG101	B-PRGE
-	I-PRGE
autophagy	I-PRGE
related	I-PRGE
101	I-PRGE
;	O
BECN1	B-PRGE
-	O
beclin	B-PRGE
1	I-PRGE
;	O
CVB3	O
-	O
coxsackievirus	O
B3	O
;	O
DMV	O
-	O
double	O
-	O
membraned	O
vesicles	O
;	O
EM	O
-	O
electron	O
microscopy	O
;	O
EMCV	O
-	O
encephalomyocarditis	O
virus	O
;	O
EV	O
-	O
71	O
-	O
enterovirus	O
71	O
;	O
FMDV	O
-	O
foot	O
and	O
mouth	O
disease	O
virus	O
;	O
GFP	B-PRGE
-	I-PRGE
green	I-PRGE
fluorescent	I-PRGE
protein	I-PRGE
;	O
MAP1LC3B	B-PRGE
/	O
LC3B	B-PRGE
-	I-PRGE
microtubule	I-PRGE
associated	I-PRGE
protein	I-PRGE
1	I-PRGE
light	I-PRGE
chain	I-PRGE
3	I-PRGE
beta	I-PRGE
;	O
MOI	O
-	O
multiplicity	O
of	O
infection	O
;	O
MTOR	O
-	O
mechanistic	O
target	O
of	O
rapamycin	B-PRGE
kinase	I-PRGE
;	O
PIK3C3	B-PRGE
-	I-PRGE
phosphatidylinositol	I-PRGE
3	I-PRGE
-	I-PRGE
kinase	I-PRGE
catalytic	I-PRGE
subunit	I-PRGE
type	I-PRGE
3	I-PRGE
;	O
PRKAA2	B-PRGE
-	I-PRGE
protein	I-PRGE
kinase	I-PRGE
AMP	I-PRGE
-	I-PRGE
activated	I-PRGE
catalytic	I-PRGE
subunit	I-PRGE
alpha	I-PRGE
2	I-PRGE
;	O
PSMG1	B-PRGE
-	I-PRGE
proteasome	I-PRGE
assembly	I-PRGE
chaperone	I-PRGE
1	I-PRGE
;	O
PSMG2	B-PRGE
-	I-PRGE
proteasome	I-PRGE
assembly	I-PRGE
chaperone	I-PRGE
2PV	I-PRGE
-	I-PRGE
poliovirus	I-PRGE
;	O
RB1CC1	B-PRGE
-	O
RB1	B-PRGE
inducible	O
coiled	B-PRGE
-	I-PRGE
coil	I-PRGE
1	I-PRGE
;	O
SQSTM1	B-PRGE
-	I-PRGE
sequestosome	I-PRGE
1	I-PRGE
;	O
ULK1	B-PRGE
-	I-PRGE
unc	I-PRGE
-	I-PRGE
51	I-PRGE
like	I-PRGE
autophagy	I-PRGE
activating	B-PRGE
kinase	I-PRGE
1	I-PRGE
;	O
ULK2	B-PRGE
-	I-PRGE
unc	I-PRGE
-	I-PRGE
51	I-PRGE
like	I-PRGE
autophagy	I-PRGE
activating	B-PRGE
kinase	I-PRGE
2	I-PRGE
;	O
WIPI1	B-PRGE
-	I-PRGE
WD	I-PRGE
repeat	I-PRGE
domain	I-PRGE
,	I-PRGE
phosphoinositide	I-PRGE
interacting	I-PRGE
1	I-PRGE
.	O

The	O
amount	O
of	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
,	O
in	O
supernatants	O
of	O
co	O
-	O
infected	O
cell	O
cultures	O
,	O
was	O
determined	O
using	O
an	O
ELISA	O
assay	O
.	O

Patients	O
with	O
tonsillar	O
hypertrophy	O
were	O
younger	O
,	O
smoked	O
less	O
often	O
,	O
had	O
less	O
pollen	O
allergy	O
and	O
had	O
more	O
adenovirus	O
,	O
bocavirus	O
-	O
1	O
,	O
coronavirus	O
and	O
rhinovirus	O
in	O
nasopharynx	O
(	O
all	O
Intratonsillar	O
T	O
cell	O
and	O
interferon	B-PRGE
gene	I-PRGE
expressions	O
appeared	O
to	O
be	O
relatively	O
stable	O
for	O
both	O
tonsillar	O
hypertrophy	O
and	O
recurrent	O
tonsillitis	O
.	O

Our	O
predicted	O
compounds	O
may	O
be	O
capable	O
of	O
inhibiting	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
but	O
need	O
some	O
further	O
validation	O
in	O
wet	O
lab	O
.	O

TITLE	O
:	O
Differential	O
clinical	O
features	O
of	O
patients	O
with	O
clinically	O
amyopathic	O
dermatomyositis	O
who	O
have	O
circulating	O
anti	B-PRGE
-	I-PRGE
MDA5	I-PRGE
autoantibodies	I-PRGE
with	O
or	O
without	O
myositis	O
-	O
associated	O
autoantibodies	O
.	O

Besides	O
anti	B-PRGE
-	I-PRGE
MDA5	I-PRGE
autoantibodies	I-PRGE
,	O
patients	O
with	O
CADM	O
may	O
have	O
myositis	O
-	O
associated	O
autoantibodies	O
(	O
MAAs	O
),	O
which	O
characterize	O
other	O
connective	O
tissue	O
diseases	O
such	O
as	O
rheumatoid	O
arthritis	O
and	O
SjÃ¶gren	O
'	O
s	O
syndrome	O
.	O

Their	O
clinical	O
phenotypes	O
including	O
laboratory	O
test	O
results	O
,	O
high	O
-	O
resolution	O
lung	O
computed	O
tomography	O
data	O
,	O
response	O
to	O
therapy	O
,	O
and	O
prognosis	O
were	O
compared	O
between	O
those	O
who	O
were	O
positive	O
and	O
negative	O
for	O
MAAs	O
,	O
such	O
as	O
antinuclear	O
antibody	O
(	O
ANA	O
),	O
anti	O
-	O
cyclic	O
citrullinated	O
peptide	O
(	O
CCP	O
),	O
anti	B-PRGE
-	I-PRGE
SSA	I-PRGE
,	O
and	O
anti	B-PRGE
-	I-PRGE
SSB	I-PRGE
antibodies	I-PRGE
.	O

The	O
trimeric	O
structure	O
,	O
bio	O
-	O
reactivity	O
to	O
PEDV	O
-	O
specific	O
antibodies	O
,	O
and	O
the	O
N	O
-	O
glycosylation	O
level	O
of	O
the	O
recombinant	B-PRGE
S	I-PRGE
protein	I-PRGE
were	O
characterized	O
.	O

The	O
results	O
show	O
that	O
the	O
virus	O
hijacks	O
caveolin	B-PRGE
-	O
dependent	O
endocytosis	O
to	O
enter	O
cells	O
via	O
endocytic	O
internalization	O
.	O

On	O
day	O
70	O
,	O
serum	O
IgA	B-PRGE
was	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
FVW	O
fed	O
groups	O
than	O
in	O
the	O
control	O
group	O
;	O
IgG	B-PRGE
was	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
FVW	O
groups	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
.	O

TITLE	O
:	O
Nucleocapsid	B-PRGE
protein	I-PRGE
from	O
porcine	O
epidemic	O
diarrhea	O
virus	O
isolates	O
can	O
antagonize	O
interferon	B-PRGE
-	I-PRGE
Î»	I-PRGE
production	O
by	O
blocking	O
the	O
nuclear	O
factor	O
-	O
ÎºB	O
nuclear	O
translocation	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
PEDV	B-PRGE
nucleocapsid	I-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
protein	I-PRGE
on	O
type	B-PRGE
III	I-PRGE
IFN	I-PRGE
-	I-PRGE
Î»	I-PRGE
.	O

With	O
this	O
in	O
mind	O
,	O
we	O
explored	O
whether	O
manipulation	O
of	O
CoV	O
NSP16	O
,	O
a	O
conserved	O
2	O
'	O
O	O
methyltransferase	B-PRGE
(	O
MTase	B-PRGE
),	O
could	O
provide	O
a	O
broad	O
attenuation	O
platform	O
against	O
future	O
emergent	O
strains	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
isolated	O
a	O
new	O
Korean	O
PEDV	O
epidemic	O
strain	O
,	O
PED	B-PRGE
-	I-PRGE
CUP	I-PRGE
-	I-PRGE
B2014	I-PRGE
,	O
in	O
Vero	O
cells	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
spike	O
gene	O
demonstrated	O
that	O
the	O
PED	B-PRGE
-	I-PRGE
CUP	I-PRGE
-	I-PRGE
B2014	I-PRGE
belongs	O
in	O
genogroup	O
G2b	O
and	O
is	O
close	O
to	O
PEDVs	O
currently	O
circulating	O
in	O
many	O
countries	O
including	O
the	O
United	O
States	O
,	O
and	O
is	O
distinct	O
from	O
many	O
current	O
vaccine	O
strains	O
.	O

DNA	O
sequencing	O
of	O
amplicons	O
of	O
the	O
16S	B-PRGE
ribosomal	I-PRGE
RNA	I-PRGE
gene	I-PRGE
revealed	O
a	O
varying	O
gastrointestinal	O
bacterial	O
composition	O
between	O
BF	O
and	O
SPF	O
mice	O
.	O

Fat	B-PRGE
embolism	O
syndrome	O
is	O
a	O
rare	O
but	O
serious	O
complication	O
of	O
long	O
bone	O
fractures	O
.	O

ABSTRACT	O
:	O
The	O
major	O
mechanism	O
of	O
antibody	O
-	O
mediated	O
neutralization	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
involves	O
competition	O
with	O
the	O
cellular	O
receptor	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
)	O
for	O
binding	O
to	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
.	O

Analyses	O
based	O
on	O
full	O
genomes	O
of	O
BCoV	O
and	O
HCoV	O
-	O
OC43	O
and	O
on	O
both	O
human	O
and	O
bovine	O
mRNAs	O
sequences	O
of	O
cholecystokinin	B-PRGE
(	O
CCK	B-PRGE
)	O
and	O
surfactant	B-PRGE
protein	I-PRGE
1	I-PRGE
A	I-PRGE
(	O
SFTP1	B-PRGE
-	I-PRGE
A	I-PRGE
),	O
representing	O
the	O
enteric	O
and	O
respiratory	O
tract	O
codon	O
usage	O
,	O
respectively	O
,	O
have	O
shown	O
natural	O
selection	O
leading	O
to	O
optimization	O
or	O
deoptimization	O
of	O
viral	O
codon	O
usage	O
to	O
the	O
human	O
enteric	O
and	O
respiratory	O
tracts	O
depending	O
on	O
the	O
virus	O
genes	O
under	O
consideration	O
.	O

As	O
time	O
went	O
on	O
,	O
PaO	O
The	O
Qingfeihuayutongfu	O
prescription	O
may	O
improve	O
oxygenation	O
of	O
ARDS	O
patients	O
,	O
reduce	O
the	O
levels	O
of	O
serum	B-PRGE
PC	I-PRGE
III	I-PRGE
and	O
PLD	B-PRGE
,	O
and	O
inhibit	O
pulmonary	O
fibrosis	O
,	O
thus	O
improve	O
prognosis	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
furin	B-PRGE
does	O
not	O
play	O
a	O
role	O
in	O
entry	O
of	O
MERS	O
-	O
CoV	O
into	O
cells	O
and	O
that	O
the	O
inhibitory	O
effect	O
of	O
dec	B-PRGE
-	I-PRGE
RVKR	I-PRGE
-	I-PRGE
CMK	I-PRGE
is	O
specific	O
for	O
TMPRSS2	B-PRGE
and	O
cathepsin	B-PRGE
L	I-PRGE
rather	O
than	O
furin	B-PRGE
.	O

Tissue	O
inhibitor	O
of	O
matrix	B-PRGE
metalloproteinase	I-PRGE
-	I-PRGE
3	I-PRGE
(	O
TIMP	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
is	O
a	O
regulator	O
of	O
matrix	B-PRGE
metalloproteinase	I-PRGE
activity	O
,	O
inflammation	O
,	O
and	O
vascular	O
permeability	O
,	O
and	O
hence	O
has	O
plausibility	O
as	O
a	O
biomarker	O
for	O
the	O
systemic	O
response	O
to	O
TBI	O
.	O

Notably	O
,	O
we	O
discovered	O
calpain	B-PRGE
-	I-PRGE
5	I-PRGE
(	O
CAPN5	B-PRGE
)	O
and	O
the	O
ubiquitin	B-PRGE
ligase	I-PRGE
Casitas	O
B	O
-	O
lineage	O
lymphoma	O
proto	O
-	O
oncogene	B-PRGE
B	I-PRGE
(	O
CBLB	B-PRGE
)	O
to	O
form	O
a	O
complex	O
with	O
CD81	B-PRGE
and	O
support	O
HCV	O
entry	O
.	O

Our	O
findings	O
reveal	O
a	O
comprehensive	O
CD81	B-PRGE
network	I-PRGE
in	O
human	O
liver	O
cells	O
and	O
show	O
that	O
HCV	O
and	O
Plasmodium	O
highjack	O
selective	O
CD81	B-PRGE
interactions	O
,	O
including	O
CAPN5	B-PRGE
and	O
CBLB	B-PRGE
for	O
HCV	O
,	O
to	O
invade	O
cells	O
.	O

ABSTRACT	O
:	O
Aim	B-PRGE
of	O
our	O
study	O
was	O
assessment	O
of	O
developmental	O
outcome	O
of	O
neonates	O
with	O
respiratory	O
distress	O
syndrome	O
,	O
evaluation	O
of	O
the	O
impact	O
of	O
RDS	O
on	O
child	O
'	O
s	O
health	O
,	O
growth	O
and	O
neurodevelopment	O
at	O
2	O
years	O
of	O
age	O
.	O

The	O
results	O
show	O
that	O
S	B-PRGE
antigen	I-PRGE
could	O
be	O
detected	O
on	O
the	O
surface	O
of	O
L	O
.	O
plantarum	O
by	O
different	O
detection	O
methods	O
.	O

Efficacy	O
against	O
homologous	O
challenge	O
was	O
investigated	O
also	O
in	O
day	O
-	O
old	O
SPF	B-PRGE
chickens	I-PRGE
.	O

We	O
conclude	O
that	O
HBD	B-PRGE
2	I-PRGE
activates	O
the	O
primary	O
antiviral	O
innate	O
immune	O
response	O
and	O
may	O
also	O
mediate	O
the	O
induction	O
of	O
an	O
effective	O
adaptive	O
immune	O
response	O
against	O
a	O
conjugated	O
Ag	O
.	O

Feed	O
was	O
then	O
analyzed	O
for	O
PEDV	O
RNA	O
by	O
real	O
-	O
time	O
reverse	B-PRGE
transcriptase	I-PRGE
semiquantitative	O
polymerase	O
chain	O
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
as	O
measured	O
by	O
cycle	O
threshold	O
(	O
Ct	O
)	O
and	O
for	O
infectivity	O
by	O
bioassay	O
.	O

TITLE	O
:	O
Cryo	O
-	O
EM	O
structure	O
of	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
in	O
complex	O
with	O
its	O
host	B-PRGE
cell	I-PRGE
receptor	I-PRGE
ACE2	I-PRGE
.	O

To	O
better	O
understand	O
the	O
species	O
adaptability	O
of	O
MERS	O
-	O
CoV	O
,	O
we	O
identified	O
a	O
suboptimal	O
species	O
-	O
derived	O
variant	O
of	O
DPP4	B-PRGE
to	O
study	O
viral	O
adaption	O
.	O

Passaging	O
virus	O
on	O
cells	O
expressing	O
this	O
DPP4	B-PRGE
variant	O
led	O
to	O
accumulation	O
of	O
mutations	O
in	O
the	O
viral	O
spike	O
which	O
increased	O
replication	O
.	O

Parallel	O
passages	O
revealed	O
distinct	O
paths	O
of	O
viral	O
adaptation	O
to	O
the	O
same	O
DPP4	B-PRGE
variant	O
.	O

Structural	O
analysis	O
and	O
functional	O
assays	O
showed	O
that	O
these	O
mutations	O
enhanced	O
viral	O
entry	O
with	O
suboptimal	O
DPP4	B-PRGE
by	O
altering	O
the	O
surface	O
charge	O
of	O
spike	O
.	O

TITLE	O
:	O
The	O
Endonucleolytic	O
RNA	O
Cleavage	O
Function	O
of	O
nsp1	B-PRGE
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Promotes	O
the	O
Production	O
of	O
Infectious	O
Virus	O
Particles	O
in	O
Specific	O
Human	O
Cell	O
Lines	O
.	O

In	O
293	O
-	O
derived	O
cells	O
,	O
the	O
three	O
viruses	O
accumulated	O
similar	O
levels	O
of	O
nsp1	B-PRGE
and	O
major	O
viral	O
structural	O
proteins	O
and	O
did	O
not	O
induce	O

ABSTRACT	O
:	O
Antisynthetase	O
syndrome	O
is	O
a	O
clinical	O
entity	O
characterized	O
by	O
specific	O
anti	B-PRGE
-	I-PRGE
aminoacyl	I-PRGE
-	I-PRGE
tRNA	I-PRGE
-	I-PRGE
synthetase	I-PRGE
antibodies	I-PRGE
usually	O
associated	O
with	O
inflammatory	O
myopathy	O
and	O
interstitial	O
lung	O
disease	O
.	O

TITLE	O
:	O
Protein	B-PRGE
kinase	I-PRGE
R	I-PRGE
-	O
like	O
endoplasmatic	B-PRGE
reticulum	I-PRGE
kinase	I-PRGE
is	O
a	O
mediator	O
of	O
stretch	O
in	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

The	O
effect	O
of	O
stretch	O
-	O
induced	O
epithelial	O
ER	O
Ca	O
Our	O
studies	O
revealed	O
increased	O
PERK	B-PRGE
-	O
specific	O
ER	O
stress	O
signaling	O
in	O
response	O
to	O
overstretch	O
.	O

TITLE	O
:	O
A	O
Human	B-PRGE
DPP4	I-PRGE
-	I-PRGE
Knockin	I-PRGE
Mouse	O
'	O
s	O
Susceptibility	O
to	O
Infection	O
by	O
Authentic	O
and	O
Pseudotyped	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Infection	O
by	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
respiratory	O
illness	O
and	O
has	O
a	O
high	O
mortality	O
rate	O
(~	O
35	O
%).	O

TITLE	O
:	O
Single	B-PRGE
-	I-PRGE
domain	I-PRGE
antibodies	I-PRGE
as	O
promising	O
experimental	O
tools	O
in	O
imaging	O
and	O
isolation	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

ABSTRACT	O
:	O
Single	B-PRGE
-	I-PRGE
domain	I-PRGE
antibody	I-PRGE
(	O
sdAb	O
)	O
or	O
nanobody	O
possesses	O
specific	O
features	O
non	O
-	O
accessible	O
for	O
conventional	O
antibodies	O
that	O
make	O
them	O
suitable	O
for	O
research	O
and	O
biotechnological	O
applications	O
.	O

TITLE	O
:	O
ISOLATION	B-PRGE
AND	I-PRGE
MOLECULAR	I-PRGE
IDENTIFICATION	I-PRGE
OF	I-PRGE
IBV	I-PRGE
ISOLATES	I-PRGE
IN	I-PRGE
DIFFERENT	I-PRGE
GOVERNORATES	I-PRGE
IN	I-PRGE
EGYPT	I-PRGE
.	O

Four	O
IBV	O
isolates	O
are	O
detected	O
in	O
vaccinated	O
chickens	O
by	O
RT	O
-	O
PCR	O
and	O
are	O
identified	O
by	O
sequence	O
and	O
phylogenetic	O
analysis	O
of	O
portion	O
of	O
Si	B-PRGE
gene	I-PRGE
.	O

The	O
genetic	O
analysis	O
revealed	O
the	O
patient	O
to	O
be	O
compound	O
heterozygous	O
for	O
a	O
new	O
mutation	O
of	O
the	O
SCL5A7	B-PRGE
gene	I-PRGE
.	O

Both	O
the	O
Malaysian	B-PRGE
QX	I-PRGE
-	I-PRGE
like	I-PRGE
and	I-PRGE
variant	I-PRGE
IBV	I-PRGE
strains	O
are	O
able	O
to	O
infect	O
the	O
respiratory	O
tract	O
and	O
kidney	O
of	O
chickens	O
irrespective	O
of	O
age	O
.	O

In	O
addition	O
,	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
LDH	B-PRGE
)	O
>	O
246	O
IU	O
/	O
L	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
7	O
.	O
06	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
):	O
2	O
.	O
15	O
-	O
23	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
001	O
],	O
and	O
serum	O
calcium	O
<	O
2	O
.	O
18	O
mmol	O
/	O
L	O
(	O
OR	O
=	O
6	O
.	O
67	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
42	O
-	O
31	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
016	O
)	O
were	O
associated	O
with	O
death	O
.	O

We	O
show	O
that	O
SARS	B-PRGE
3a	I-PRGE
interacts	O
with	O
Receptor	B-PRGE
Interacting	I-PRGE
Protein	I-PRGE
3	I-PRGE
(	O
Rip3	B-PRGE
),	O
which	O
augments	O
the	O
oligomerization	O
of	O
SARS	B-PRGE
3a	I-PRGE
helping	O
drive	O
necrotic	O
cell	O
death	O
.	O

In	O
summary	O
,	O
Rip3	B-PRGE
-	O
mediated	O
oligomerization	O
of	O
SARS	B-PRGE
3a	I-PRGE
causes	O
necrotic	O
cell	O
death	O
,	O
lysosomal	O
damage	O
,	O
and	O
caspase	B-PRGE
-	I-PRGE
1	I-PRGE
activation	O
-	O
all	O
likely	O
contributing	O
to	O
the	O
clinical	O
manifestations	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
fluorescence	O
properties	O
of	O
immuno	O
-	O
conjugated	O
QD	B-PRGE
-	I-PRGE
MP	I-PRGE
NPs	I-PRGE
nanohybrids	O
through	O
separation	O
by	O
an	O
external	O
magnetic	O
field	O
enabled	O
biosensing	O
of	O
coronavirus	O
with	O
a	O
limit	O
of	O
detection	O
of	O
79	O
.	O
15	O
EID	O
/	O
50	O
Î¼L	O
.	O

LPS	O
induced	O
the	O
release	O
of	O
TNFÎ±	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
IL	O
-	O
8	O
by	O
HLMVECs	O
that	O
were	O
inhibited	O
by	O
sitagliptin	O
.	O

We	O
report	O
two	O
potential	O
nidovirus	O
genomes	O
,	O
a	O
highly	O
divergent	O
35	O
.	O
9	O
kb	O
likely	O
complete	O
genome	O
from	O
the	O
California	O
sea	O
hare	O
Aplysia	B-PRGE
californica	O
,	O
which	O
we	O
assign	O
to	O
a	O
nidovirus	O
named	O
Aplysia	B-PRGE
abyssovirus	I-PRGE
1	I-PRGE
(	O
AAbV	O
),	O
and	O
a	O
coronavirus	O
-	O
like	O
22	O
.	O
3	O
kb	O
partial	O
genome	O
from	O
the	O
ornamented	O
pygmy	O
frog	O
Microhyla	O
fissipes	O
,	O
which	O
we	O
assign	O
to	O
a	O
nidovirus	O
named	O
Microhyla	O
alphaletovirus	O
1	O
(	O
MLeV	O
).	O

The	O
application	O
of	O
the	O
IBV	B-PRGE
nsp5	I-PRGE
protein	I-PRGE
microarray	O
showed	O
that	O
the	O
positive	O
rate	O
of	O
the	O
CIT	O
was	O
96	O
.	O
77	O
%,	O
that	O
of	O
the	O
nsp5	B-PRGE
ELISA	I-PRGE
was	O
91	O
.	O
40	O
%,	O
and	O
that	O
of	O
the	O
RDT	O
was	O
90	O
.	O
32	O
%.	O

TITLE	O
:	O
Severe	O
Respiratory	O
Illness	O
Outbreak	O
Associated	O
with	O
Human	B-PRGE
Coronavirus	I-PRGE
NL63	I-PRGE
in	O
a	O
Long	O
-	O
Term	O
Care	O
Facility	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
an	O
outbreak	O
of	O
severe	O
respiratory	O
illness	O
associated	O
with	O
human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
in	O
a	O
long	O
-	O
term	O
care	O
facility	O
in	O
Louisiana	O
in	O
November	O
2017	O
.	O

Small	O
intestinal	O
and	O
lung	O
washings	O
were	O
collected	O
on	O
30th	O
and	O
47th	O
day	O
after	O
the	O
second	O
immunization	O
to	O
measure	O
PEDV	O
-	O
specific	O
IgA	B-PRGE
levels	O
,	O
and	O
SP	O
immunohistochemical	O
method	O
staining	O
was	O
employed	O
to	O
analyze	O
the	O
deviations	O
of	O
IgA	B-PRGE
+	I-PRGE
positive	O
cells	O
in	O
the	O
small	O
intestinal	O
of	O
the	O
immunized	O
mice	O
.	O

The	O
resulting	O
virus	O
replicated	O
like	O
SARS	O
-	O
CoV	O
in	O
Vero	O
cells	O
but	O
was	O
suppressed	O
in	O
IFN	B-PRGE
competent	I-PRGE
MA	I-PRGE
-	I-PRGE
104	I-PRGE
(	O
3	O
.	O
7	O
-	O
fold	O
),	O
Calu	O
-	O
3	O
(	O
2	O
.	O
6	O
-	O
fold	O
)	O
and	O
human	O
airway	O
epithelial	O
cells	O
(	O
10	O
.	O
3	O
-	O
fold	O
).	O

Moreover	O
,	O
the	O
protein	O
levels	O
in	O
nucleus	O
and	O
the	O
mRNA	O
levels	O
of	O
AIF	B-PRGE
were	O
inhibited	O
in	O
the	O
presence	O
of	O
the	O
p53	B-PRGE
inhibitor	I-PRGE
,	O
piï¬thrin	O
-	O
Î±	O
(	O
PFT	O
-	O
Î±	O
)	O
or	O
in	O
TGEV	O
-	O
infected	O
p53	B-PRGE
-/-	O
cells	O
.	O

Multivariate	O
Cox	O
regression	O
analysis	O
identified	O
PSI	B-PRGE
(	O
hazard	O
ratio	O
1	O
.	O
020	O
,	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
009	O
-	O
1	O
.	O
032	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
renal	O
replacement	O
therapy	O
(	O
hazard	O
ratio	O
6	O
.	O
248	O
,	O
95	O
%	O
confidence	O
interval	O
2	O
.	O
245	O
-	O
17	O
.	O
389	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
increase	O
in	O
dynamic	O
driving	O
pressure	O
(	O
hazard	O
ratio	O
1	O
.	O
372	O
,	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
095	O
-	O
1	O
.	O
718	O
;	O
p	O
=	O
0	O
.	O
006	O
)	O
which	O
were	O
independent	O
predictors	O
associated	O
with	O
60	O
-	O
day	O
mortality	O
.	O

Despite	O
the	O
importance	O
of	O
lysosomal	B-PRGE
proteases	I-PRGE
in	O
both	O
coronavirus	O
entry	O
and	O
cell	O
metabolism	O
,	O
the	O
correlation	O
between	O
lysosomal	B-PRGE
proteases	I-PRGE
and	O
cell	O
tropism	O
of	O
coronaviruses	O
has	O
not	O
been	O
established	O
.	O

TITLE	O
:	O
TRAIL	B-PRGE
(	O
CD253	B-PRGE
)	O
Sensitizes	O
Human	O
Airway	O
Epithelial	O
Cells	O
to	O
Toxin	O
-	O
Induced	O
Cell	O
Death	O
.	O

TITLE	O
:	O
Differential	O
induction	O
of	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
by	O
type	O
I	O
and	O
type	O
II	O
feline	O
coronaviruses	O
in	O
vitro	O
.	O

Both	O
type	O
I	O
and	O
II	O
FCoV	O
can	O
replicate	O
in	O
Felis	O
catus	O
whole	O
fetus	O
(	O
fcwf	O
)-	O
4	O
cells	O
,	O
but	O
the	O
replicability	O
of	O
type	O
I	O
FCoV	O
in	O
feline	O
cell	O
lines	O
is	O
lower	O
than	O
that	O
of	O
type	B-PRGE
II	I-PRGE
FCoV	I-PRGE
,	O
the	O
reason	O
for	O
which	O
is	O
unclear	O
.	O

CH	O
/	O
hubei	O
/	O
2016	O
had	O
one	O
recombination	O
event	O
in	O
S2	O
gene	O
which	O
may	O
have	O
resulted	O
from	O
AH2012	O
-	O
12	O
(	O
from	O
G2b	O
group	O
)	O
and	O
CH	O
-	O
ZMDZY	O
-	O
11	O
(	O
from	O
G2a	B-PRGE
group	I-PRGE
).	O

Furthermore	O
,	O
10	O
purifying	O
selection	O
sites	O
in	O
S	B-PRGE
gene	I-PRGE
indicated	O
an	O
adaptive	O
evolution	O
of	O
PEDV	O
in	O
central	O
China	O
swine	O
herds	O
.	O

Specific	O
primers	O
were	O
designed	O
to	O
target	O
the	O
highly	O
-	O
conserved	O
region	O
of	O
L	B-PRGE
gene	I-PRGE
of	O
SFTSV	O
.	O

The	O
S1	B-PRGE
subunit	I-PRGE
from	O
Spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
plays	O
the	O
major	O
role	O
in	O
protective	O
immunity	O
and	O
is	O
involved	O
in	O
the	O
host	O
-	O
virus	O
interactions	O
,	O
as	O
well	O
as	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
serotyping	O
.	O

One	O
hundred	O
and	O
eighty	O
-	O
one	O
patients	O
were	O
diagnosed	O
with	O
AKI	B-PRGE
caused	O
by	O
venomous	O
creatures	O
.	O

As	O
compared	O
to	O
the	O
survival	O
group	O
,	O
the	O
white	O
blood	O
cell	O
count	O
,	O
serum	O
bilirubin	O
,	O
aspartate	B-PRGE
aminotransferase	I-PRGE
,	O
alanine	B-PRGE
aminotransferase	I-PRGE
,	O
creatine	B-PRGE
kinase	I-PRGE
,	O
and	O
lactate	B-PRGE
dehydrogenase	I-PRGE
were	O
significantly	O
higher	O
,	O
and	O
serum	B-PRGE
albumin	I-PRGE
levels	O
were	O
significantly	O
lower	O
in	O
patients	O
who	O
died	O
.	O

Snakebite	O
and	O
multiple	O
Hymenoptera	O
stings	O
(	O
bees	O
and	O
wasps	O
)	O
were	O
the	O
leading	O
causes	O
of	O
AKI	B-PRGE
due	O
to	O
venomous	O
animals	O
.	O

An	O
in	O
-	O
house	O
ELISA	O
was	O
developed	O
to	O
detect	O
IgG	B-PRGE
against	O
MERS	O
-	O
CoV	O
.	O
A	O
total	O
of	O
794	O
camels	O
were	O
found	O
seropositive	O
for	O
MERS	O
-	O
CoV	O
.	O
Prevalence	O
increased	O
with	O
the	O
age	O
and	O
the	O
highest	O
seroprevalence	O
was	O
recorded	O
in	O
camels	O
aged	O
>	O
10	O
years	O
(	O
81	O
.	O
37	O
%)	O
followed	O
by	O
those	O
aged	O
3	O
.	O
1	O
-	O
10	O
years	O
(	O
78	O
.	O
65	O
%)	O
and	O
â¤	O
3	O
years	O
(	O
58	O
.	O
19	O
%).	O

Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
analysis	O
showed	O
differentially	O
expressed	O
mRNAs	O
were	O
linked	O
to	O
inflammation	O
-	O
related	O
pathways	O
,	O
including	O
NF	O
-	O
ÎºB	O
,	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
,	O
NOD	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
,	O
Jak	B-PRGE
-	O
STAT	B-PRGE
,	O
TNF	B-PRGE
,	O
and	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
pathways	O
.	O

We	O
also	O
observed	O
that	O
overexpression	O
of	O
miR	B-PRGE
-	I-PRGE
22	I-PRGE
led	O
to	O
a	O
reduction	O
of	O
p	O
-	O
IÎºB	O
-	O
Î±	O
and	O
accumulation	O
of	O
p65	B-PRGE
in	O
nucleus	O
in	O
TGEV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggested	O
that	O
NF	O
-	O
ÎºB	O
activation	O
was	O
a	O
major	O
contributor	O
to	O
TGEV	O
infection	O
-	O
induced	O
inflammation	O
,	O
and	O
that	O
Nsp2	B-PRGE
was	O
the	O
key	O
viral	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
inflammation	O
,	O
with	O
amino	O
acids	O
1	O
-	O
120	O
playing	O
a	O
critical	O
role	O
in	O
activating	O
NF	O
-	O
ÎºB	O
.	O
Abbreviations	O
:	O
TCID50	O
:	O
50	O
%	O
tissue	O
culture	O
infectious	O
dose	O
;	O
DMEM	O
:	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
Medium	O
;	O
eNOS	O
:	O
Endothelial	B-PRGE
nitric	I-PRGE
oxide	I-PRGE
synthase	I-PRGE
;	O
FBS	O
:	O
fetal	O
bovine	O
serum	O
;	O
IFA	O
:	O
Indirect	O
immunofluorescence	O
;	O
IÎºB	O
:	O
inhibitor	O
of	O
nuclear	B-PRGE
factor	I-PRGE
kappa	I-PRGE
-	I-PRGE
B	I-PRGE
;	O
IL	B-PRGE
:	I-PRGE
interleukin	I-PRGE
;	O
IPEC	O
-	O
J2	O
:	O
intestinal	O
epithelial	O
cell	O
lines	O
J2	O
;	O
IKK	O
:	O
IÎºB	B-PRGE
kinase	I-PRGE
;	O
Luc	O
:	O
luciferase	B-PRGE
reporter	I-PRGE
gene	I-PRGE
;	O
mAbs	O
:	O
monoclonal	O
antibodies	O
;	O
MOI	O
:	O
multiple	O
of	O
infection	O
;	O
Nsp	O
:	O
nonstructural	O
protein	O
;	O
NF	O
-	O
ÎºB	O
:	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
kappa	I-PRGE
;	O
ORFs	O
:	O
open	O
reading	O
frames	O
;	O
PBS	O
:	O
phosphate	O
-	O
buffered	O
saline	O
;	O
p65	B-PRGE
p	I-PRGE
-	O
p65	B-PRGE
:	O
phosphorylated	O
;	O
RT	O
-	O
PCR	O
:	O
reverse	O
transcription	O
PC	O
;	O
SeV	O
:	O
Sendai	O
virus	O
;	O
ST	O
:	O
swine	O
testicular	O
;	O
TGEV	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
;	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
:	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
Î±	I-PRGE
;	O
UV	O
-	O
TGEV	O
:	O
Ultraviolet	O
light	O
-	O
inactivated	O
TGEV	O
;	O
ZnF	O
:	O
zinc	O
finger	O
.	O

Pharmacologic	O
correction	O
of	O
CFTR	B-PRGE
function	O
ameliorated	O
IAV	O
-	O
induced	O
physiologic	O
changes	O
.	O

Moreover	O
,	O
PHD2	B-PRGE
knockdown	O
can	O
increase	O
hypoxia	O
-	O
inducible	O
factor	O
/	O
vascular	B-PRGE
endothelial	I-PRGE
protein	I-PRGE
tyrosine	I-PRGE
phosphatase	I-PRGE
signaling	O
and	O
reactive	O
oxygen	O
species	O
-	O
dependent	O
p38	B-PRGE
activation	O
,	O
leading	O
to	O
the	O
induction	O
of	O
vascular	B-PRGE
endothelial	I-PRGE
cadherin	I-PRGE
.	O

The	O
S	O
genes	O
contained	O
typical	O
insertions	O
and	O
deletions	O
that	O
were	O
also	O
found	O
in	O
other	O
recently	O
isolated	O
highly	O
virulent	O
PEDV	O
strains	O
from	O
China	O
and	O
other	O
countries	O
and	O
had	O
two	O
neighboring	O
unique	O
insertion	O
mutations	O
,	O
which	O
resulted	O
in	O
four	O
amino	O
acid	O
changes	O
in	O
the	O
S1	O
region	O
of	O
passages	O
P10	B-PRGE
and	O
P60	B-PRGE
.	O

Transferrin	B-PRGE
receptor	I-PRGE
1	I-PRGE
(	O
TfR1	B-PRGE
),	O
which	O
is	O
highly	O
expressed	O
in	O
piglets	O
with	O
anemia	O
,	O
may	O
play	O
a	O
role	O
in	O
TGEV	O
infection	O
.	O

Initial	O
laboratory	O
investigations	O
were	O
significant	O
for	O
a	O
lipase	B-PRGE
level	O
of	O
4143	O
U	O
/	O
L	O
and	O
a	O
triglyceride	O
level	O
of	O
600	O
mg	O
/	O
dL	O
.	O
Computed	O
tomography	O
(	O
CT	O
)	O
of	O
the	O
abdomen	O
showed	O
diffuse	O
enlargement	O
of	O
the	O
pancreas	O
consistent	O
with	O
pancreatitis	O
.	O

Herein	O
,	O
we	O
employed	O
a	O
bioinorganic	O
perspective	O
to	O
develop	O
an	O
SAR	O
for	O
inhibition	O
of	O
the	O
metalloenzyme	B-PRGE
influenza	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
PA	I-PRGE

In	O
this	O
study	O
,	O
we	O
selected	O
two	O
epitope	O
peptide	O
sequences	O
within	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
.	O

Thus	O
,	O
we	O
successfully	O
produced	O
a	O
monoclonal	O
antibody	O
directed	O
against	O
the	O
RBD	B-PRGE
domain	I-PRGE
of	O
the	O
S	B-PRGE
protein	I-PRGE
which	O
could	O
be	O
used	O
in	O
the	O
development	O
of	O
diagnostics	O
and	O
therapeutic	O
applications	O
in	O
the	O
future	O
.	O

Analysis	O
of	O
potential	O
recombination	O
sites	O
showed	O
that	O
CHN	O
-	O
HG	O
-	O
2017	O
is	O
a	O
possible	O
recombinant	O
originating	O
from	O
the	O
strains	O
CH	O
/	O
SXD1	B-PRGE
/	O
2015	O
and	O
Vietnam	O
/	O
HaNoi6	O
/	O
2015	O
.	O

While	O
a	O
3	O
-	O
nt	O
rewired	O
TRN	O
reverts	O
via	O
second	O
-	O
site	O
mutation	O
upon	O
serial	O
passage	O
,	O
a	O
7	O
-	O
nt	O
rewired	O
TRN	O
is	O
more	O
stable	O
,	O
suggesting	O
that	O
a	O
more	O
extensively	O
rewired	O
TRN	B-PRGE
might	O
be	O
essential	O
for	O
avoiding	O
growth	O
selection	O
.	O

The	O
patients	O
were	O
classified	O
as	O
having	O
lung	O
fibroproliferation	O
when	O
the	O
alveolar	O
N	O
-	O
terminal	O
peptide	O
for	O
type	B-PRGE
III	I-PRGE
procollagen	I-PRGE
(	O
NT	B-PRGE
-	I-PRGE
PCP	I-PRGE
-	I-PRGE
III	I-PRGE
)	O
measured	O
on	O
day	O
3	O
was	O
>	O
9	O
Î¼g	O
/	O
L	O
as	O
recently	O
reported	O
.	O

This	O
meant	O
that	O
CPAP	O
was	O
often	O
not	O
available	O
for	O
babies	O
who	O
were	O
identified	O
to	O
need	O
CPAP	B-PRGE
,	O
or	O
that	O
CPAP	B-PRGE
use	I-PRGE
was	O
not	O
perceived	O
to	O
be	O
of	O
the	O
highest	O
quality	O
.	O

S1	B-PRGE
Spike	I-PRGE
protein	I-PRGE
is	O
one	O
of	O
the	O
most	O
critical	O
functional	O
proteins	O
that	O
contribute	O
to	O
cell	O
apoptosis	O
.	O

The	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
binds	O
to	O
the	O
cellular	O
protein	O
DPP4	B-PRGE
via	O
its	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
and	O
mediates	O
viral	O
entry	O
into	O
target	O
cells	O
.	O

Viruses	O
were	O
detected	O
in	O
1254	O
(	O
64	O
.	O
6	O
%)	O
children	O
at	O
enrollment	O
;	O
HRV	O
,	O
RSV	B-PRGE
,	O
HAdV	O
and	O
hMPV	O
were	O
detected	O
in	O
499	O
(	O
25	O
.	O
7	O
%),	O
439	O
(	O
22	O
.	O
6	O
%),	O
156	O
(	O
8	O
.	O
0	O
%)	O
and	O
47	O
(	O
2	O
.	O
4	O
%)	O
children	O
,	O
respectively	O
.	O

Respiratory	O
specimens	O
(	O
nasopharyngeal	O
and	O
throat	O
swabs	O
)	O
were	O
collected	O
from	O
300	O
consenting	O
pilgrims	O
with	O
ARI	B-PRGE
in	O
the	O
past	O
one	O
week	O
and	O
tested	O
for	O
influenza	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
other	O
respiratory	O
viruses	O
using	O
in	O
-	O
house	O
standardized	O
quantitative	O
real	O
-	O
time	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O

Phylogenetic	O
analyses	O
based	O
on	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
sequences	O
assigned	O
the	O
detected	O
CoV	O
to	O
clade	O
2b	O
within	O
betacoronaviruses	O
,	O
clustering	O
with	O
SARS	O
-	O
like	O
bat	O
CoVs	O
previously	O
reported	O
.	O

TITLE	O
:	O
Hydrophobic	O
Derivatives	O
of	O
Glycopeptide	O
Antibiotics	O
as	O
Inhibitors	O
of	O
Protein	B-PRGE
Kinases	I-PRGE
.	O

In	O
addition	O
,	O
TGEV	O
-	O
induced	O
the	O
changes	O
in	O
mRNA	O
levels	O
of	O
TRIF	B-PRGE
,	O
TRAM	B-PRGE
,	O
MDA5	B-PRGE
,	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
,	O
IPS	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
IRF9	B-PRGE
,	O
IRF3	B-PRGE
,	O
ISG15	B-PRGE
and	O
ISG20	B-PRGE
were	O
notably	O
hindered	O
in	O
p53	B-PRGE
-/-	I-PRGE
PK	I-PRGE
-	O
15	O
cells	O
before	O
36	O
h	O
post	O
infection	O
(	O
p	O
.	O
i	O
.).	O

And	O
viral	O
titers	O
were	O
observably	O
enhanced	O
in	O
p53	B-PRGE
-/-	I-PRGE
PK	I-PRGE
-	O
15	O
cells	O
.	O

Furthermore	O
,	O
exogenous	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
and	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
(	O
poly	O
(	O
I	O
:	O
C	O
))	O
treatment	O
markedly	O
inhibited	O
the	O
mRNA	O
levels	O
of	O
TGEV	O
gRNA	O
,	O
N	O
and	O
ORF7	O
in	O
WT	O
PK	O
-	O
15	O
cells	O
and	O
p53	B-PRGE
-/-	I-PRGE
PK	I-PRGE
-	O
15	O
cells	O
compared	O
to	O
control	O
.	O

The	O
boy	O
had	O
compound	O
heterozygous	O
mutations	O
in	O
the	O
ETFDH	B-PRGE
gene	I-PRGE
,	O
i	O
.	O
e	O
.,	O
a	O
known	O
mutation	O
,	O
c	O
.	O
341G	O
>	O
A	O
(	O
p	O
.	O

Finally	O
,	O
he	O
was	O
diagnosed	O
with	O
multiple	O
acyl	B-PRGE
-	I-PRGE
CoA	I-PRGE
dehydrogenase	I-PRGE
deficiency	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
the	O
hotel	O
industry	O
in	O
the	O
response	O
to	O
emerging	O
epidemics	O
:	O
a	O
case	O
study	O
of	O
SARS	O
in	O
2003	O
and	O
H1N1	B-PRGE
swine	I-PRGE
flu	I-PRGE
in	O
2009	O
in	O
Hong	O
Kong	O
.	O

Obese	O
adults	O
with	O
H1N1	O
had	O
a	O
sixfold	O
increase	O
in	O
odds	O
of	O
hospitalization	O
over	O
H3N2	O
and	O
B	O
(	O
obese	O
OR	B-PRGE
:	I-PRGE
8	I-PRGE
.	I-PRGE
96	I-PRGE
vs	I-PRGE
1	I-PRGE
.	I-PRGE
35	I-PRGE
,	I-PRGE
morbidly	I-PRGE
obese	I-PRGE
OR	I-PRGE
:	O
35	O
.	O
13	O
vs	O
5	O
.	O
58	O
,	O
respectively	O
)	O
compared	O
to	O
normal	O
-	O
weight	O
adults	O
.	O

Notably	O
,	O
several	O
nasal	O
epithelial	O
cells	O
in	O
pigs	O
were	O
found	O
to	O
express	O
viral	O
antigen	O
but	O
not	O
DPP4	B-PRGE
,	O
suggesting	O
the	O
possible	O
existence	O
of	O
other	O
molecule	O
/	O
s	O
facilitating	O
virus	O
entry	O
or	O
down	O
regulation	O
of	O
DPP4	B-PRGE
upon	O
infection	O
.	O

Several	O
relevant	O
factors	O
were	O
considered	O
,	O
including	O
patient	O
age	O
,	O
burn	O
size	O
,	O
intrathoracic	O
blood	O
volume	O
index	O
(	O
ITBVI	O
),	O
pulmonary	O
vascular	O
permeability	O
index	O
(	O
PVPI	O
),	O
cardiac	O
index	O
(	O
CI	O
),	O
systemic	O
vascular	O
resistance	O
index	O
(	O
SVRI	O
),	O
serum	O
albumin	B-PRGE
,	O
time	O
of	O
first	O
excision	O
and	O
grafting	O
,	O
and	O
number	O
of	O
operations	O
and	O
daily	O
fluid	O
administration	O
.	O

Suppressing	O
TRIM8	B-PRGE
markedly	O
ameliorated	O
LPS	O
-	O
elicited	O
inflammatory	O
response	O
,	O
as	O
evidenced	O
by	O
the	O
down	O
-	O
regulated	O
mRNA	O
levels	O
of	O
interleukin	B-PRGE
-	I-PRGE
1Î²	I-PRGE
(	O
IL	O
-	O
1Î²	O
),	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
Î±	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
)	O
in	O
cells	O
mainly	O
through	O
inactivating	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
kappa	I-PRGE
B	I-PRGE
(	O
NF	O
-	O
ÎºB	O
)	O
signaling	O
pathway	O
;	O
however	O
,	O
over	O
-	O
expressing	O
TRIM8	B-PRGE
markedly	O
promoted	O
inflammation	O
in	O
LPS	O
-	O
challenged	O
cells	O
.	O

Importantly	O
,	O
TRIM8	B-PRGE
could	O
negatively	O
meditate	O
AMP	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
-	I-PRGE
Î±	I-PRGE
(	O
AMPKÎ±	O
)	O
activation	O
to	O
modulate	O
LPS	O
-	O
triggered	O
inflammatory	O
response	O
and	O
ROS	O
generation	O
in	O
vitro	O
.	O

Additionally	O
,	O
our	O
in	O
vivo	O
findings	O
suggested	O
that	O
TRIM8	B-PRGE
knockdown	O
effectively	O
attenuated	O
LPS	O
-	O
induced	O
lung	O
injury	O
nu	O
decrease	O
of	O
lung	O
wet	O
/	O
dry	O
(	O
W	O
/	O
T	O
)	O
ratio	O
,	O
protein	O
concentrations	O
,	O
neutrophil	O
infiltration	O
,	O
myeloperoxidase	B-PRGE
(	O
MPO	B-PRGE
)	O
activity	O
,	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
and	O
superoxide	B-PRGE
dismutase	I-PRGE
(	O
SOD	B-PRGE
)	O
depletion	O
.	O

Meanwhile	O
,	O
the	O
loss	O
of	O
TRIM8	B-PRGE
markedly	O
lessened	O
IL	O
-	O
1Î²	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
expression	O
in	O
lung	O
tissues	O
of	O
LPS	O
-	O
challenged	O
mice	O
,	O
and	O
reduced	O
NF	O
-	O
ÎºB	O
phosphorylation	O
.	O

Both	O
viruses	O
likely	O
originated	O
in	O
bats	O
,	O
and	O
genetically	O
diverse	O
coronaviruses	O
that	O
are	O
related	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
were	O
discovered	O
in	O
bats	O
worldwide	O
.	O

Bat	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
)	O
sequences	O
were	O
closely	O
related	O
to	O
those	O
of	O
human	O
and	O
non	O
-	O
human	O
primates	O
but	O
distinct	O
from	O
dromedary	B-PRGE
DPP4	I-PRGE
sequence	I-PRGE
.	O

Critical	O
residues	O
for	O
binding	O
to	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
were	O
mostly	O
conserved	O
in	O
bat	O
DPP4	B-PRGE
.	O

TITLE	O
:	O
Regulation	O
of	O
in	O
vivo	O
behavior	O
of	O
TAT	B-PRGE
-	O
modified	O
liposome	O
by	O
associated	O
protein	O
corona	O
and	O
avidity	O
to	O
tumor	O
cells	O
.	O

PLDs	B-PRGE
were	O
installed	O
with	O
25	O
-	O
400	O
TAT	O
peptides	O
per	O
liposome	O
without	O
an	O
effect	O
on	O
PLD	O
stability	O
.	O

The	O
design	O
of	O
both	O
the	O
multi	O
-	O
epitope	O
vaccines	O
(	O
MEVs	O
)	O
are	O
composed	O
of	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
and	O
helper	O
T	O
lymphocyte	O
(	O
HTL	O
)	O
epitopes	O
,	O
screened	O
form	O
thirteen	O
different	O
proteins	O
of	O
MERS	O
-	O
CoV	O
.	O
Both	O
the	O
MEVs	O
also	O
carry	O
potential	O
B	O
-	O
cell	O
linear	O
epitope	O
regions	O
,	O
B	O
-	O
cell	O
discontinuous	O
epitopes	O
as	O
well	O
as	O
interferon	B-PRGE
-	I-PRGE
Î³	I-PRGE
-	O
inducing	O
epitopes	O
.	O

The	O
expected	O
cDNA	O
fragment	O
of	O
approximately	O
1240	O
bp	O
was	O
successfully	O
amplified	O
by	O
PCR	O
using	O
primers	O
designed	O
to	O
select	O
for	O
the	O
coding	O
region	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
.	O

RESULTS	O
:	O
The	O
expected	O
cDNA	O
fragment	O
of	O
approximately	O
1240	O
bp	O
was	O
successfully	O
amplified	O
by	O
PCR	O
using	O
primers	O
designed	O
to	O
select	O
for	O
the	O
coding	O
region	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
.	O

Sera	O
that	O
tested	O
negative	O
in	O
the	O
ELISA	O
-	O
rN	O
and	O
positive	O
in	O
the	O
commercial	O
test	O
also	O
reacted	O
with	O
the	O
rN	B-PRGE
protein	I-PRGE
in	O
Western	O
blot	O
.	O

Currently	O
,	O
the	O
regulation	O
pattern	O
of	O
the	O
actin	B-PRGE
cytoskeleton	O
and	O
its	O
molecular	O
mechanism	O
remain	O
unclear	O
when	O
PHEV	O
enters	O
the	O
host	O
cells	O
.	O

A	O
78	O
-	O
year	O
-	O
old	O
Japanese	O
woman	O
presented	O
with	O
severe	O
renal	O
dysfunction	O
,	O
which	O
was	O
diagnosed	O
as	O
MPO	B-PRGE
-	O
ANCA	B-PRGE
-	O
associated	O
systemic	O
vasculitis	O
.	O

Considering	O
the	O
present	O
case	O
and	O
the	O
previously	O
reported	O
coexisting	O
cases	O
of	O
takotsubo	O
syndrome	O
and	O
AAV	O
,	O
we	O
propose	O
that	O
female	O
sex	O
,	O
initiation	O
of	O
glucocorticoid	O
therapy	O
,	O
and	O
high	O
titer	O
of	O
MPO	B-PRGE
-	O
ANCA	B-PRGE
are	O
potential	O
risk	O
factors	O
of	O
developing	O
takotsubo	O
syndrome	O
.	O

Antibodies	O
directed	O
against	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
are	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
controlling	O
MERS	O
-	O
CoV	O
infection	O
and	O
in	O
mediating	O
vaccine	O
-	O
induced	O
protective	O
immunity	O
.	O

This	O
variant	O
was	O
located	O
in	O
the	O
C3b	B-PRGE
-	I-PRGE
binding	I-PRGE
site	I-PRGE
and	O
functional	O
tests	O
revealed	O
that	O
it	O
perturbed	O
the	O
regulatory	O
activity	O
of	O
factor	B-PRGE
H	I-PRGE
.	O
This	O
case	O
suggests	O
that	O
pertussis	O
is	O
a	O
strong	O
trigger	O
of	O
HUS	O
and	O
that	O
complement	O
investigations	O
are	O
necessary	O
to	O
guide	O
treatment	O
and	O
understand	O
the	O
pathophysiology	O
.	O

A	O
collection	O
of	O
worldwide	O
available	O
hypervariable	O
region	O
1	O
and	O
2	O
(	O
HVR12	O
)	O
and	O
3	O
(	O
HVR3	O
)	O
sequences	O
of	O
the	O
S1	B-PRGE
protein	I-PRGE
was	O
analysed	O
together	O
with	O
258	O
HVR3	O
sequences	O
obtained	O
from	O
samples	O
collected	O
in	O
Italy	O
(	O
the	O
country	O
where	O
this	O
genotype	O
was	O
initially	O
identified	O
)	O
since	O
1963	O
.	O

TITLE	O
:	O
EIF4A2	B-PRGE
interacts	O
with	O
the	O
membrane	O
protein	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
and	O
plays	O
a	O
role	O
in	O
virus	O
replication	O
.	O

Furthermore	O
,	O
the	O
function	O
of	O
EIF4A2	B-PRGE
in	O
intestinal	O
cells	O
during	O
TGEV	O
infection	O
was	O
examined	O
.	O

However	O
,	O
on	O
farms	O
they	O
often	O
co	O
-	O
infect	O
pigs	O
with	O
the	O
PEDV	O
containing	O
an	O
intact	O
S	B-PRGE
protein	I-PRGE
(	O
S	O
-	O
intact	O
PEDV	O
).	O

Blood	O
samples	O
were	O
collected	O
at	O
7	O
,	O
14	O
,	O
21	O
days	O
post	O
infection	O
(	O
dpi	O
)	O
and	O
subjected	O
for	O
the	O
analyses	O
of	O
serum	B-PRGE
antibody	I-PRGE
production	O
,	O
T	O
cell	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
frequencies	O
,	O
NK	O
cytotoxicity	O
and	O
serum	O
cytokine	O
levels	O
.	O

Oral	O
inoculation	O
led	O
to	O
higher	O
levels	O
of	O
PEDV	B-PRGE
-	I-PRGE
specific	I-PRGE
IgA	I-PRGE
antibodies	I-PRGE
in	O
both	O
serum	O
and	O
gut	O
mucosal	O
sites	O
than	O
did	O
other	O
routes	O
of	O
inoculation	O
.	O

Intranasal	O
inoculation	O
elicited	O
significantly	O
higher	O
titers	O
of	O
virus	O
-	O
specific	O
IgG	B-PRGE
antibodies	I-PRGE
in	O
serum	O
.	O

Serum	B-PRGE
IL	I-PRGE
-	I-PRGE
10	I-PRGE
levels	O
were	O
induced	O
drastically	O
in	O
orally	O
infected	O
pigs	O
at	O
7	O
dpi	O
and	O
then	O
gradually	O
declined	O
.	O

No	O
specific	O
drug	O
treatment	O
exists	O
for	O
MERS	O
;	O
however	O
,	O
the	O
neutralizing	O
antibodies	O
,	O
ribavirin	O
and	O
interferon	B-PRGE
have	O
been	O
shown	O
to	O
be	O
potentially	O
useful	O
anti	O
-	O
MERS	O
-	O
CoV	O
drugs	O
.	O

Hence	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
is	O
assumed	O
to	O
provide	O
a	O
target	O
for	O
a	O
broad	O
range	O
of	O
antiviral	O
agents	O
.	O

It	O
is	O
known	O
that	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
via	O
its	O
soluble	O
receptor	O
(	O
sIL	B-PRGE
-	I-PRGE
6R	I-PRGE
),	O
initiates	O
a	O
pro	O
-	O
inflammatory	O
response	O
while	O
an	O
anti	O
-	O
inflammatory	O
response	O
is	O
triggered	O
by	O
the	O
membrane	O
-	O
bound	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
receptor	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6R	I-PRGE
).	O

We	O
engineered	O
a	O
biotin	B-PRGE
ligase	I-PRGE
into	O
a	O
coronaviral	O
replication	O
/	O
transcription	O
complex	O
(	O
RTC	O
)	O
and	O
identified	O
>	O
500	O
host	O
proteins	O
constituting	O
the	O
RTC	O
microenvironment	O
.	O

However	O
,	O
when	O
the	O
C5a	B-PRGE
-	I-PRGE
C5aR1	I-PRGE
axis	O
was	O
blocked	O
by	O
an	O
anti	O
-	O
C5aR1	O
antibody	O
(	O
Ab	O
),	O
expression	O
of	O
caspase	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
IL	O
-	O
1Î²	O
fell	O
.	O

Pathogens	O
were	O
detected	O
in	O
82	O
samples	O
,	O
which	O
included	O
Respiratory	O
syncytial	O
viruses	O
(	O
RSV	O
)	O
A	O
/	O
B	O
(	O
35	O
.	O
4	O
%),	O
Human	O
rhinovirus	O
(	O
25	O
.	O
6	O
%),	O
Adenovirus	O
(	O
22	O
%),	O
Human	O
Parainfluenza	O
viruses	O
(	O
11	O
%),	O
Human	O
bocavirus	O
(	O
9	O
.	O
8	O
),	O
Human	B-PRGE
metapneumovirus	I-PRGE
A	I-PRGE
/	I-PRGE
B	I-PRGE
(	O
8	O
.	O
5	O
%),	O
Influenza	O
A	O
(	O
H1N1	O
)	O
pdm	O
09	O
(	O
6	O
.	O
1	O
%),	O
Parechovirus	O
(	O
3	O
.	O
7	O
%),	O
Human	O
coronaviruses	O
(	O
3	O
.	O
66	O
%),	O
Haemophilus	O
influenzae	O
type	O
b	O
(	O
6	O
.	O
1	O
%),	O
Chlamydia	O
pneumoniae	O
(	O
2	O
.	O
4	O
%)	O
and	O
Mycoplasma	O
pneumoniae	O
(	O
2	O
.	O
4	O
%).	O

The	O
immune	O
-	O
enhancing	O
effect	O
of	O
IFN	B-PRGE
-	I-PRGE
Î±	I-PRGE
adjuvant	O
was	O
excellent	O
compared	O
with	O
pig	B-PRGE
spleen	I-PRGE
transfer	I-PRGE
factor	I-PRGE
and	O
IL	O
-	O
12	O
adjuvant	O
.	O

TITLE	O
:	O
Structure	O
of	O
interferon	B-PRGE
-	I-PRGE
stimulated	I-PRGE
gene	I-PRGE
product	I-PRGE
15	I-PRGE
(	O
ISG15	B-PRGE
)	O
from	O
the	O
bat	O
species	O
Myotis	O
davidii	O
and	O
the	O
impact	O
of	O
interdomain	O
ISG15	O
interactions	O
on	O
viral	O
protein	O
engagement	O
.	O

Comparison	O
of	O
this	O
ISG15	O
structure	O
with	O
those	O
from	O
human	O
and	O
mouse	O
not	O
only	O
underscores	O
the	O
structural	O
impact	O
of	O
ISG15	B-PRGE
species	O
-	O
species	O
differences	O
,	O
but	O
also	O
highlights	O
a	O
conserved	O
hydrophobic	O
motif	O
formed	O
between	O
the	O
two	O
domains	O
of	O
ISG15	B-PRGE
.	O

Moreover	O
,	O
these	O
peptides	O
,	O
particularly	O
HKU4	O
-	O
HR2P2	O
and	O
HKU4	O
-	O
HR2P3	O
,	O
exhibited	O
potent	O
inhibitory	O
activity	O
against	O
MERS	O
-	O
CoV	O
S	O
-	O
mediated	O
cell	O
â»	O
cell	O
fusion	O
and	O
viral	O
infection	O
,	O
suggesting	O
that	O
these	O
HKU4	B-PRGE
HR2	I-PRGE
-	I-PRGE
derived	I-PRGE
peptides	I-PRGE
could	O
be	O
candidates	O
for	O
futher	O
development	O
as	O
antiviral	O
agents	O
against	O
MERS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Single	O
Chain	O
Fragment	O
Variable	O
(	O
scFv	O
)	O
Antibodies	O
Targeting	O
the	O
Spike	B-PRGE
Protein	I-PRGE
of	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Provide	O
Protection	O
against	O
Viral	O
Infection	O
in	O
Piglets	O
.	O

TITLE	O
:	O
Two	O
critical	O
N	O
-	O
terminal	O
epitopes	O
of	O
the	O
nucleocapsid	B-PRGE
protein	I-PRGE
contribute	O
to	O
the	O
cross	O
-	O
reactivity	O
between	O
porcine	O
epidemic	O
diarrhea	O
virus	O
and	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
.	O

Furthermore	O
,	O
the	O
PEDV	B-PRGE
N	I-PRGE
protein	I-PRGE
harbouring	O
truncations	O
of	O
amino	O
acids	O
(	O
aa	O
)	O
1	O
to	O
170	O
or	O
aa	O
125	O
to	O
301	O
was	O
demonstrated	O
to	O
cross	O
-	O
react	O
with	O
the	O
anti	O
-	O
TGEV	O
N	O
polyclonal	B-PRGE
antibody	I-PRGE
(	O
PAb	B-PRGE
),	O
whereas	O
the	O
truncation	O
-	O
expressing	O
aa	O
302	O
to	O
401	O
resulted	O
in	O
a	O
specific	O
reaction	O
with	O
the	O
anti	B-PRGE
-	I-PRGE
PEDV	I-PRGE
N	I-PRGE
PAb	I-PRGE
but	O
not	O
with	O
the	O
anti	B-PRGE
-	I-PRGE
TGEV	I-PRGE
N	I-PRGE
PAb	I-PRGE
.	O

In	O
a	O
cohort	O
study	O
with	O
critically	O
ill	O
patients	O
,	O
AGPT1	B-PRGE
and	O
AGPT2	B-PRGE
were	O
assayed	O
in	O
plasma	O
collected	O
within	O
the	O
first	O
24	O
h	O
after	O
admission	O
to	O
intensive	O
care	O
unit	O
(	O
ICU	O
).	O

We	O
recorded	O
58	O
AE	O
reports	O
with	O
fatal	O
outcomes	O
,	O
including	O
9	O
Stevens	O
-	O
Johnson	O
syndrome	O
/	O
toxic	O
epidermal	O
necrolysis	O
cases	O
(	O
SJS	B-PRGE
/	O
TEN	B-PRGE
),	O
10	O
anaphylactic	O
reactions	O
,	O
21	O
cases	O
of	O
hepatic	O
failure	O
and	O
a	O
further	O
18	O
cases	O
which	O
occurred	O
for	O
other	O
reasons	O
.	O

TITLE	O
:	O
Vascular	B-PRGE
endothelial	I-PRGE
cadherin	I-PRGE
shedding	O
is	O
more	O
severe	O
in	O
sepsis	O
patients	O
with	O
severe	O
acute	O
kidney	O
injury	O
.	O

Plasma	B-PRGE
sVE	I-PRGE
-	I-PRGE
cadherin	I-PRGE
levels	O
by	O
quartile	O
were	O
significantly	O
higher	O
in	O
severe	O
sepsis	O
patients	O
with	O
acute	O
kidney	O
injury	O
stage	O
3	O
(	O
p	O
=	O
0	O
.	O
044	O
)	O
as	O
defined	O
by	O
Kidney	O
Disease	O
Improving	O
Global	O
Outcomes	O
(	O
KDIGO	O
)	O
criteria	O
.	O

Plasma	B-PRGE
sVE	I-PRGE
-	I-PRGE
cadherin	I-PRGE
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
non	O
-	O
pulmonary	O
sepsis	O
compared	O
to	O
pulmonary	O
sepsis	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Shedding	O
of	O
sVE	B-PRGE
-	I-PRGE
cadherin	I-PRGE
is	O
associated	O
with	O
severe	O
acute	O
kidney	O
injury	O
and	O
with	O
more	O
severe	O
organ	O
dysfunction	O
in	O
patients	O
with	O
sepsis	O
,	O
suggesting	O
that	O
breakdown	O
of	O
endothelial	O
adherens	O
junctions	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
organ	O
dysfunction	O
in	O
sepsis	O
.	O

Plasma	B-PRGE
sVE	I-PRGE
-	I-PRGE
cadherin	I-PRGE
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
non	O
-	O
pulmonary	O
sepsis	O
compared	O
to	O
pulmonary	O
sepsis	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

VAPiD	O
is	O
programmed	O
in	O
Python	O
and	O
is	O
compatible	O
with	O
Windows	O
,	O
Linux	O
,	O
and	O
Mac	B-PRGE
OS	I-PRGE
systems	I-PRGE
.	O

We	O
identified	O
407	O
relevant	O
,	O
peer	O
-	O
reviewed	O
publications	O
and	O
selected	O
208	O
of	O
these	O
based	O
on	O
their	O
contributions	O
to	O
four	O
key	O
areas	O
:	O
virology	O
;	O
clinical	O
characteristics	O
,	O
outcomes	O
,	O
therapeutic	O
and	O
preventive	O
options	O
;	O
epidemiology	O
and	O
transmission	O
;	O
and	O
animal	O
interface	O
and	O
the	O
search	O
for	O
natural	O
hosts	O
of	O
MERS	O
-	O
CoV	O
.	O
Dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
/	O
CD26	B-PRGE
)	O
was	O
identified	O
as	O
the	O
human	O
receptor	O
for	O
MERS	O
-	O
CoV	O
,	O
and	O
a	O
variety	O
of	O
molecular	O
and	O
serological	O
assays	O
developed	O
.	O

Bronchoalveolar	O
concentrations	O
of	O
patients	O
were	O
higher	O
than	O
those	O
of	O
controls	O
(	O
154	O
[	O
74	O
to	O
1	O
,	O
000	O
]	O
vs	O
.	O
4	O
[	O
4	O
to	O
4	O
]	O
arbitrary	O
units	O
,	O
difference	O
:	O
-	O
150	O
;	O
95	O
%	O
CI	O
,	O
-	O
996	O
to	O
-	O
64	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
associated	O
with	O
bronchoalveolar	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
Spearman	O
'	O
s	O
Ï	O
=	O
0	O
.	O
42	O
;	O
P	O
=	O
0	O
.	O
012	O
)	O
and	O
neutrophil	O
concentrations	O
(	O
Ï	O
=	O
0	O
.	O
57	O
;	O
P	O
<	O
0	O
.	O
0001	O
).	O

An	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
based	O
on	O
rS1	B-PRGE
(	O
rS1	B-PRGE
-	I-PRGE
ELISA	I-PRGE
)	O
was	O
then	O
developed	O
and	O
optimized	O
by	O
checkerboard	O
assays	O
with	O
serial	O
dilutions	O
of	O
antigen	O
and	O
serum	O
.	O

These	O
results	O
indicated	O
that	O
the	O
rS1	B-PRGE
-	I-PRGE
ELISA	I-PRGE
established	O
in	O
this	O
study	O
provides	O
a	O
promising	O
and	O
reliable	O
tool	O
for	O
serologic	O
detection	O
of	O
anti	B-PRGE
-	I-PRGE
PEDV	I-PRGE
IgG	I-PRGE
antibodies	I-PRGE
in	O
infected	O
or	O
vaccinated	O
pigs	O
.	O

We	O
constructed	O
an	O
infectious	O
clone	O
of	O
PEDV	O
-	O
Colorado	O
strain	O
(	O
icPEDV	O
-	O
wt	O
)	O
and	O
an	O
EndoU	B-PRGE
-	I-PRGE
mutant	I-PRGE
PEDV	I-PRGE
(	O
icPEDV	O
-	O
EnUmt	O
)	O
by	O
changing	O
the	O
codon	O
for	O
a	O
catalytic	O
histidine	O
residue	O
of	O
EndoU	O
to	O
alanine	O
(	O
His226Ala	O
).	O

A	O
high	O
level	O
of	O
S	B-PRGE
protein	I-PRGE
expression	O
was	O
detected	O
in	O
vitro	O
by	O
Western	O
blot	O
and	O
immunofluorescence	O
analyses	O
.	O

ABSTRACT	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
HKU1	I-PRGE
(	O
HCoV	O
-	O
HKU1	O
)	O
was	O
first	O
detected	O
in	O
a	O
patient	O
with	O
viral	O
pneumonia	O
from	O
Hong	O
Kong	O
in	O
2004	O
.	O

In	O
contrast	O
,	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
which	O
is	O
responsible	O
for	O
membrane	O
fusion	O
had	O
an	O
amino	O
acid	O
homology	O
of	O
96	O
.	O
9	O
%.	O

We	O
previously	O
showed	O
that	O
influenza	O
virus	O
M2	O
or	O
encephalomyocarditis	O
virus	O
(	O
EMCV	O
)	O
2B	O
proteins	O
stimulate	O
IL	O
-	O
1Î²	O
secretion	O
following	O
activation	O
of	O
the	O
NLRP3	B-PRGE
inflammasome	I-PRGE
.	O

Here	O
,	O
we	O
provide	O
direct	O
evidence	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3a	I-PRGE
protein	I-PRGE
activates	O
the	O
NLRP3	B-PRGE
inflammasome	I-PRGE
in	O
lipopolysaccharide	O
-	O
primed	O
macrophages	O
.	O

ABSTRACT	O
:	O
p53	B-PRGE
is	O
a	O
tumor	O
suppressor	O
gene	O
that	O
can	O
be	O
activated	O
in	O
many	O
contexts	O
,	O
such	O
as	O
DNA	O
damage	O
or	O
stressful	O
conditions	O
.	O

These	O
findings	O
demonstrate	O
that	O
p53	B-PRGE
suppresses	O
PEDV	O
infection	O
,	O
offering	O
a	O
novel	O
therapeutic	O
strategy	O
for	O
combatting	O
this	O
deadly	O
disease	O
in	O
piglets	O
.	O

From	O
the	O
bioassay	O
results	O
,	O
the	O
best	O
AHAS	B-PRGE
inhibitor	I-PRGE
6	I-PRGE
-	I-PRGE
22	I-PRGE
displayed	O
weaker	O
herbicidal	O
activity	O
but	O
stronger	O
anti	O
-	O
Candida	O
activity	O
than	O
PTB	B-PRGE
did	O
.	O

ABSTRACT	O
:	O
Chimeric	B-PRGE
antigen	I-PRGE
receptor	I-PRGE
(	O
CAR	B-PRGE
)	O
T	O
cell	O
immunotherapy	O
has	O
demonstrated	O
remarkable	O
anti	O
-	O
tumor	O
activity	O
in	O
B	O
-	O
cell	O
malignancies	O
and	O
is	O
under	O
investigation	O
in	O
other	O
hematologic	O
malignancies	O
and	O
solid	O
tumors	O
.	O

Moreover	O
,	O
overexpression	O
and	O
siRNA	O
silencing	O
assays	O
showed	O
that	O
overexpression	O
of	O
IL	O
-	O
1Î±	O
,	O
IL	O
-	O
1Î²	O
,	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
,	O
CCL2	B-PRGE
,	O
CCL5	B-PRGE
and	O
CXCL8	B-PRGE
could	O
significantly	O
inhibit	O
PEDV	O
replication	O
,	O
while	O
silencing	O
of	O
IL	O
-	O
1Î±	O
,	O
IL	O
-	O
1Î²	O
,	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
,	O
CCL2	B-PRGE
,	O
CCL5	B-PRGE
and	O
CXCL8	B-PRGE
could	O
significantly	O
promote	O
PEDV	O
replication	O
.	O

In	O
summary	O
,	O
the	O
real	O
-	O
time	O
RT	B-PRGE
-	I-PRGE
RPA	I-PRGE
assay	O
offers	O
a	O
promising	O
alternative	O
to	O
RT	O
-	O
qPCR	O
for	O
point	O
-	O
of	O
-	O
care	O
detection	O
of	O
PDCoV	O
.	O

We	O
identified	O
dampened	O
transcriptional	O
priming	O
,	O
a	O
novel	O
splice	O
variant	O
and	O
an	O
altered	O
leucine	O
-	O
rich	O
repeat	O
domain	O
of	O
bat	B-PRGE
NLRP3	I-PRGE
as	O
the	O
cause	O
.	O

Treatment	O
with	O
neuraminidase	B-PRGE
inhibitors	O
and	O
other	O
antivirals	O
is	O
reviewed	O
.	O

TITLE	O
:	O
[	O
The	O
role	O
of	O
nicotinamide	B-PRGE
-	I-PRGE
adenine	I-PRGE
dinucleotide	I-PRGE
phosphate	I-PRGE
oxidase	I-PRGE
NOX	I-PRGE
family	I-PRGE
in	O
acute	O
lung	O
injury	O
].	O

This	O
review	O
mainly	O
describes	O
the	O
cell	O
distribution	O
,	O
activation	O
factors	O
,	O
and	O
its	O
relationship	O
with	O
the	O
occurrence	O
and	O
development	O
of	O
ALI	O
of	O
the	O
NOX	B-PRGE
family	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
carried	O
out	O
detailed	O
phylogenetic	O
analysis	O
and	O
sequence	O
comparisons	O
based	O
on	O
74	O
complete	O
nucleotide	O
sequences	O
of	O
the	O
IBV	B-PRGE
S1	I-PRGE
gene	I-PRGE
,	O
including	O
strain	O
I0636	O
/	O
16	O
and	O
73	O
representative	O
sequences	O
from	O
each	O
genotype	O
and	O
lineage	O
.	O

In	O
SARS	O
-	O
CoV	O
/	O
macaque	O
models	O
,	O
we	O
determined	O
that	O
anti	B-PRGE
-	I-PRGE
spike	I-PRGE
IgG	I-PRGE
(	O
S	B-PRGE
-	I-PRGE
IgG	I-PRGE
),	O
in	O
productively	O
infected	O
lungs	O
,	O
causes	O
severe	O
ALI	O
by	O
skewing	O
inflammation	O
-	O
resolving	O
response	O
.	O

The	O
presence	O
of	O
S	B-PRGE
-	I-PRGE
IgG	I-PRGE
prior	O
to	O
viral	O
clearance	O
,	O
however	O
,	O
abrogated	O
wound	O
-	O
healing	O
responses	O
and	O
promoted	O
MCP1	B-PRGE
and	O
IL	O
-	O
8	O
production	O
and	O
proinflammatory	O
monocyte	O
/	O
macrophage	O
recruitment	O
and	O
accumulation	O
.	O

ABSTRACT	O
:	O
Type	B-PRGE
-	I-PRGE
I	I-PRGE
IFNs	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
I	I-PRGE
)	O
provide	O
a	O
key	O
mediator	O
of	O
innate	O
antiviral	O
response	O
during	O
virus	O
proliferation	O
.	O

Whereas	O
the	O
PEDV	O
nsp13	O
barely	O
regulates	O
type	O
I	O
IFN	O
,	O
inflammatory	O
cytokines	O
(	O
IL	O
-	O
6	O
,	O
TNF	B-PRGE
-	I-PRGE
a	I-PRGE
)	O
and	O
MHCII	O
,	O
nsp16	O
and	O
nsp14	O
(	O
to	O
a	O
lesser	O
extent	O
)	O
down	O
-	O
regulate	O
these	O
antiviral	O
effectors	O
.	O

In	O
addition	O
,	O
nsp10	O
enhanced	O
the	O
inhibitory	O
effect	O
of	O
nsp16	O
on	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
.	O

TITLE	O
:	O
Profiling	O
DUBs	O
and	O
Ubl	B-PRGE
-	O
specific	O
proteases	O
with	O
activity	O
-	O
based	O
probes	O
.	O

Studying	O
the	O
activity	O
of	O
DUBs	O
and	O
Ubl	B-PRGE
-	I-PRGE
specific	I-PRGE
proteases	I-PRGE
,	O
both	O
human	O
as	O
well	O
as	O
pathogen	O
-	O
derived	O
,	O
gives	O
fundamental	O
insights	O
into	O
their	O
physiological	O
roles	O
.	O

In	O
this	O
chapter	O
,	O
we	O
explain	O
the	O
potential	O
of	O
ABPs	O
to	O
assess	O
substrate	O
preferences	O
,	O
structural	O
features	O
,	O
and	O
activity	O
of	O
Ub	O
and	O
Ubl	B-PRGE
deconjugating	O
enzymes	O
.	O

The	O
incidence	O
of	O
thrombosis	O
was	O
correlated	O
with	O
risk	O
factors	O
such	O
as	O
coagulation	O
variables	O
(	O
mean	O
activated	O
partial	O
thromboplastin	B-PRGE
time	O
â¤	O
50	O
s	O
,	O
international	O
normalized	O
ratio	O
antithrombin	B-PRGE
III	I-PRGE
,	O
fibrinogen	B-PRGE
,	O
plasma	O
-	O
free	O
hemoglobin	B-PRGE
,	O
platelets	O
,	O
and	O
decline	O
in	O
D	O
-	O
dimer	O
â¤	O
50	O
%	O
the	O
day	O
after	O
decannulation	O
),	O
cannula	O
size	O
,	O
time	O
on	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
renal	O
failure	O
,	O
and	O
underlying	O
malignant	O
disease	O
.	O

Sequencing	O
and	O
phylogenetic	O
analysis	O
showed	O
that	O
strain	O
CH	O
/	O
HBXT	O
/	O
2018	O
contained	O
novel	O
insertion	O
and	O
deletion	O
mutations	O
in	O
the	O
S	B-PRGE
gene	I-PRGE
region	O
relative	O
to	O
the	O
classical	O
strain	O
and	O
belonged	O
to	O
the	O
genotype	O
GIIa	O
,	O
similar	O
to	O
other	O
recently	O
isolated	O
PEDV	O
strains	O
from	O
China	O
and	O
the	O
United	O
States	O
.	O

We	O
detected	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
in	O
swabs	O
from	O
three	O
sheep	O
(	O
1	O
.	O
2	O
%)	O
of	O
254	O
and	O
five	O
goats	O
(	O
4	O
.	O
1	O
%)	O
of	O
121	O
from	O
Egypt	O
and	O
Senegal	O
,	O
as	O
well	O
as	O
one	O
cow	O
(	O
1	O
.	O
9	O
%)	O
of	O
53	O
and	O
three	O
donkeys	O
(	O
7	O
.	O
1	O
%)	O
of	O
42	O
from	O
Egypt	O
.	O

To	O
Protect	O
the	O
Spike	B-PRGE
Protein	I-PRGE
and	O
Promote	O
the	O
Release	O
of	O
Infectious	O
Virus	O
.	O

The	O
following	O
parameters	O
were	O
associated	O
with	O
increased	O
mortality	O
,	O
age	O
,	O
WBC	O
,	O
neutrophil	O
count	O
,	O
serum	B-PRGE
albumin	I-PRGE
level	O
,	O
use	O
of	O
a	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
)	O
and	O
corticosteroid	O
use	O
.	O

To	O
further	O
locate	O
the	O
core	O
aa	O
of	O
the	O
3F10	O
epitope	O
,	O
12	O
random	O
peptide	O
libraries	O
were	O
used	O
,	O
and	O
the	O
result	O
showed	O
that	O
the	O
key	O
aa	O
located	O
at	O
aa	O
685	O
-	O
688	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
(	O
LLAF	O
)	O
were	O
recognized	O
by	O
3F10	O
.	O

A	O
limitation	O
of	O
the	O
methodology	O
is	O
that	O
it	O
can	O
only	O
recapitulate	O
virus	O
entry	O
steps	O
mediated	O
by	O
the	O
envelope	B-PRGE
protein	O
being	O
investigated	O
.	O

TITLE	O
:	O
A	O
Single	O
V672F	O
Substitution	O
in	O
the	O
Spike	B-PRGE
Protein	I-PRGE
of	O
Field	O
-	O
Isolated	O
PEDV	O
Promotes	O
Cell	O
â»	O
Cell	O
Fusion	O
and	O
Replication	O
in	O
VeroE6	O
Cells	O
.	O

Comparing	O
with	O
the	O
CV777	O
vaccine	O
strain	O
,	O
amino	O
acid	O
sequence	O
analysis	O
of	O
CH	O
/	O
JLDH	O
/	O
2016	O
strain	O
showed	O
that	O
15	O
nucleotides	O
were	O
inserted	O
and	O
9	O
were	O
absent	O
in	O
S	B-PRGE
gene	I-PRGE
,	O
whose	O
amino	O
acid	O
sequence	O
it	O
educed	O
insertions	O
of	O
5	O
amino	O
acids	O
(	O

Samples	O
from	O
CP	O
but	O
not	O
from	O
BD	O
were	O
also	O
reactive	O
by	O
whole	B-PRGE
-	I-PRGE
virus	I-PRGE
anti	I-PRGE
-	I-PRGE
MERS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
(	O

Early	O
intervention	O
with	O
intravenous	O
immunoglobulin	B-PRGE
may	O
benefit	O
these	O
patients	O
.	O

To	O
search	O
for	O
effective	O
inhibitory	O
agents	O
,	O
we	O
performed	O
high	O
-	O
throughput	O
screening	O
(	O
HTS	O
)	O
of	O
a	O
2	O
,	O
000	O
-	O
compound	O
library	O
of	O
approved	O
drugs	O
and	O
pharmacologically	O
active	O
compounds	O
using	O
the	O
established	O
genetically	O
engineered	B-PRGE
human	I-PRGE
CoV	I-PRGE
OC43	I-PRGE
(	O
HCoV	O
-	O
OC43	O
)	O
strain	O
expressing	O

Three	O
days	O
after	O
initiation	O
of	O
ECMO	O
,	O
the	O
patient	O
developed	O
jaundice	O
,	O
with	O
increase	O
of	O
bilirubin	O
,	O
Gamma	B-PRGE
-	I-PRGE
glutamyltransferase	I-PRGE
and	O
Alkaline	B-PRGE
phosphatase	I-PRGE
,	O
without	O
elevation	O
of	O
alanine	B-PRGE
aminotransferase	I-PRGE
and	O
INR	B-PRGE
.	O

The	O
N	B-PRGE
-	I-PRGE
Terminal	I-PRGE
Domain	I-PRGE
of	O
Spike	B-PRGE
Protein	I-PRGE
Is	O
Not	O
the	O
Enteric	O
Tropism	O
Determinant	O
for	O
Transmissible	O
Gastroenteritis	O
Virus	O
in	O
Piglets	O
.	O

TITLE	O
:	O
Arterivirus	O
nsp4	B-PRGE
Antagonizes	O
Interferon	B-PRGE
Beta	I-PRGE
Production	O
by	O
Proteolytically	O
Cleaving	O
NEMO	O
at	O
Multiple	O
Sites	O
.	O

TITLE	O
:	O
Cholesterol	B-PRGE
25	I-PRGE
-	I-PRGE
hydroxylase	I-PRGE
negatively	O
regulates	O
porcine	O
intestinal	O
coronavirus	O
replication	O
by	O
the	O
production	O
of	O
25	O
-	O
hydroxycholesterol	O
.	O

ABSTRACT	O
:	O
Despite	O
high	O
similarity	O
of	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
),	O
bovine	O
coronavirus	O
,	O
(	O
BCoV	O
)	O
and	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
(	O
HCoV	O
-	O
OC43	O
),	O
these	O
viruses	O
differ	O
in	O
species	O
specificity	O
.	O

CRCoV	O
and	O
BCoV	O
appear	O
to	O
employ	O
human	B-PRGE
leukocyte	I-PRGE
antigen	I-PRGE
class	I-PRGE
I	I-PRGE
(	O
HLA	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
as	O
the	O
entry	O
receptor	O
.	O

The	O
selectivity	O
index	O
of	O
SLP5	B-PRGE
is	O
52	O
,	O
while	O
the	O
SI	O
for	O
surfactin	O
is	O
4	O
,	O
in	O
other	O
words	O
,	O
the	O
safe	O
and	O
effective	O
concentration	O
range	O
of	O
SLP5	O
is	O
12	O
times	O
greater	O
than	O
that	O
of	O
surfactin	O
.	O

TITLE	O
:	O
Effect	O
of	O
Fc	O
Fusion	O
on	O
Folding	O
and	O
Immunogenicity	O
of	O
Middle	B-PRGE
East	I-PRGE
Respiratory	I-PRGE
Syndrome	I-PRGE
Coronavirus	I-PRGE
Spike	I-PRGE
Protein	I-PRGE
.	O

Contrary	O
to	O
expectations	O
,	O
non	O
-	O
Fc	O
spike	O
proteins	O
(	O
eS770	O
-	O
ÎFc	O
,	O
eS770	O
-	O
His	O
;	O
90	O
kDa	O
)	O
showed	O
higher	O
immunogenicity	O
than	O
the	O
Fc	B-PRGE
fusion	I-PRGE
protein	I-PRGE
(	O
eS770	O
-	O
Fc	O
).	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
IgG	B-PRGE
Fc	I-PRGE
fusion	O
reduces	O
the	O
immunogenicity	O
of	O
eS770	O
by	O
interfering	O
with	O
the	O
proper	O
folding	O
structure	O
.	O

TITLE	O
:	O
A	O
pan	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
fusion	I-PRGE
inhibitor	O
targeting	O
the	O
HR1	B-PRGE
domain	I-PRGE
of	O
human	O
coronavirus	O
spike	O
.	O

The	O
genes	O
of	O
FABP	B-PRGE
family	I-PRGE
members	I-PRGE
in	O
the	O
PPAR	B-PRGE
signaling	O
pathway	O
were	O
the	O
most	O
highly	O
altered	O
and	O
played	O
important	O
roles	O
in	O
metabolism	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
rabbits	O
to	O
further	O
characterize	O
the	O
transmission	O
potential	O
of	O
MERS	O
-	O
CoV	O
.	O
In	O
line	O
with	O
the	O
presence	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
in	O
the	O
rabbit	O
nasal	O
epithelium	O
,	O
high	O
levels	O
of	O
viral	O
RNA	O
were	O
shed	O
from	O
the	O
nose	O
following	O
virus	O
inoculation	O
.	O

TITLE	O
:	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
(	O
PEDV	O
)	O
ORF3	O
Interactome	O
Reveals	O
Inhibition	O
of	O
Virus	O
Replication	O
by	O
Cellular	B-PRGE
VPS36	I-PRGE
Protein	I-PRGE
.	O

Interestingly	O
,	O
the	O
ORF3	O
protein	O
expression	O
was	O
diminished	O
in	O
VPS36	B-PRGE
-	O
overexpressing	O
cells	O
,	O
an	O
effect	O
that	O
could	O
not	O
be	O
restored	O
by	O
treatment	O
of	O
lysosomal	O
inhibitors	O
.	O

ABSTRACT	O
:	O
The	O
tumor	B-PRGE
suppressor	I-PRGE
protein	I-PRGE
P53	I-PRGE
is	O
strongly	O
involved	O
in	O
orchestrating	O
cellular	O
defenses	O
in	O
the	O
diverse	O
variety	O
of	O
human	O
tissues	O
.	O

Only	O
immunization	O
with	O
membrane	O
forms	O
of	O
the	O
glycoprotein	O
(	O
rAd5	B-PRGE
-	I-PRGE
S	I-PRGE
,	O
rAd5	B-PRGE
-	I-PRGE
S	I-PRGE
-	I-PRGE
G	I-PRGE
,	O
and	O
rAd5	O
-	O
RBD	O
-	O
G	O
)	O
elicited	O
neutralizing	O
antibodies	O
among	O
all	O
vaccinated	O
animals	O
.	O

The	O
most	O
significant	O
cellular	O
immune	O
response	O
was	O
induced	O
after	O
vaccination	O
of	O
the	O
animals	O
with	O
the	O
full	O
-	O
length	O
S	O
(	O
rAd5	B-PRGE
-	I-PRGE
S	I-PRGE
).	O

These	O
investigations	O
suggest	O
that	O
the	O
full	O
-	O
length	O
S	O
and	O
the	O
membrane	O
form	O
of	O
the	O
RBD	O
(	O
RBD	O
-	O
G	O
)	O
are	O
the	O
most	O
promising	O
vaccine	O
candidates	O
among	O
all	O
the	O
studied	O
forms	O
of	O
S	B-PRGE
glycoprotein	I-PRGE
.	O

Our	O
previous	O
study	O
demonstrated	O
that	O
the	O
vasoactive	B-PRGE
intestinal	I-PRGE
peptide	B-PRGE
(	I-PRGE
VIP	I-PRGE
)	I-PRGE
is	O
mediated	O
by	O
lentivirus	O
attenuates	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
ARDS	O
in	O
a	O
murine	O
model	O
,	O
and	O
VIP	B-PRGE
inhibits	O
the	O
release	O
of	O
interleukin	B-PRGE
-	I-PRGE
17A	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
17A	I-PRGE
)	O
from	O
activation	O
macrophages	O
.	O

In	O
vitro	O
,	O
LPS	O
activated	O
NIH3T3	O
cells	O
,	O
which	O
was	O
suppressed	O
by	O
VIP	B-PRGE
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

TRAF3	B-PRGE
-	O
dependent	O
K63	O
-	O
linked	O
ubiquitination	O
of	O
ASC	O
was	O
more	O
pronounced	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
or	O
when	O
ORF3a	O
was	O
expressed	O
.	O

Full	O
-	O
length	O
spike	O
,	O
hemagglutinin	O
/	O
esterase	B-PRGE
(	O
HE	O
),	O
nucleocapsid	O
and	O
transmembrane	O
genes	O
were	O
simultaneously	O
cloned	O
from	O
13	O
clinical	O
samples	O
(	O
eight	O
farms	O
in	O
four	O
provinces	O
),	O
and	O
most	O
of	O
the	O
BCoV	O
strains	O
showed	O
a	O
unique	O
evolutionary	O
pattern	O
based	O
on	O
the	O
phylogenetic	O
analysis	O
of	O
these	O
genes	O
.	O

Moreover	O
,	O
the	O
ER	O
stress	O
sensor	O
inositol	B-PRGE
requiring	I-PRGE
enzyme	I-PRGE
1	I-PRGE
(	O
IRE1	B-PRGE
),	O
but	O
not	O
its	O
substrate	O
X	O
-	O
box	O
protein	B-PRGE
1	I-PRGE
(	O
XBP1	B-PRGE
),	O
was	O
also	O
essential	O
for	O
the	O
induction	O
of	O
autophagy	O
during	O
IBV	O
infection	O
.	O

To	O
test	O
applicability	O
of	O
in	O
vitro	O
results	O
to	O
real	O
life	O
,	O
virus	O
load	O
was	O
measured	O
in	O
two	O
households	O
in	O
a	O
double	O
crossover	O
study	O
of	O
four	O
Fuller	O
'	O
s	O
earth	O
-	O
based	O
cat	O
litters	O
by	O
testing	O
rectal	O
swabs	O
using	O
FCoV	B-PRGE
reverse	I-PRGE
transcriptase	I-PRGE
quantitative	O
PCR	O
.	O

These	O
results	O
suggest	O
that	O
macrodomains	O
counter	O
cellular	O
ADP	O
-	O
ribosylation	O
,	O
but	O
whether	O
PARPs	O
or	O
,	O
alternatively	O
,	O
other	O
ADP	B-PRGE
-	I-PRGE
ribosyltransferases	I-PRGE
cause	O
this	O
modification	O
is	O
not	O
clear	O
.	O

Here	O
we	O
show	O
that	O
pan	B-PRGE
-	O
PARP	B-PRGE
inhibition	O
enhanced	O
replication	O
and	O
inhibited	O
interferon	B-PRGE
production	O
in	O
primary	O
macrophages	O
infected	O
with	O
macrodomain	O
-	O
mutant	O
but	O
not	O
wild	O
-	O
type	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
heptad	O
repeat	O
1	O
(	O
HR1	O
)	O
peptide	O
inhibitors	O
have	O
been	O
developed	O
to	O
inhibit	O
HR1	O
/	O
HR2	B-PRGE
-	O
mediated	O
membrane	O
fusion	O
between	O
MERS	O
-	O
CoV	O
and	O
host	O
cells	O
,	O
which	O
is	O
the	O
major	O
pathway	O
of	O
MERS	O
-	O
CoV	O
-	O
induced	O
host	O
infections	O
.	O

TITLE	O
:	O
von	B-PRGE
Willebrand	I-PRGE
factor	I-PRGE
in	O
experimental	O
malaria	O
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

To	O
investigate	O
the	O
role	O
of	O
VWF	B-PRGE
in	O
the	O
pathogenesis	O
of	O
experimental	O
MA	O
-	O
ARDS	O
.	O

The	O
neutral	O
red	O
phagocytosis	O
ability	O
of	O
alveolar	O
macrophages	O
in	O
ARDS	O
patients	O
caused	O
by	O
abdominal	O
infection	O
was	O
negatively	O
correlated	O
with	O
age	O
,	O
APACHE	O
II	O
score	O
and	O
the	O
length	O
of	O
ICU	O
stay	O
(	O
r	O
value	O
was	O
-	O
0	O
.	O
328	O
,	O
-	O
0	O
.	O
572	O
,	O
-	O
0	O
.	O
809	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
);	O
alkaline	B-PRGE
phosphatase	I-PRGE
activity	O
was	O
negatively	O
correlated	O
with	O
age	O
,	O
APACHE	O
II	O
score	O
,	O
the	O
length	O
of	O
ICU	O
stay	O
and	O
hospitalization	O
expenses	O
(	O
r	O
value	O
was	O
-	O
0	O
.	O
334	O
,	O
-	O
0	O
.	O
583	O
,	O
-	O
0	O
.	O
470	O
,	O
-	O
0	O
.	O
517	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Human	B-PRGE
Î²	I-PRGE
-	I-PRGE
defensin	I-PRGE
2	I-PRGE
is	O
involved	O
in	O
CCR2	B-PRGE
-	O
mediated	O
Nod2	B-PRGE
signal	O
transduction	O
,	O
leading	O
to	O
activation	O
of	O
the	O
innate	O
immune	O
response	O
in	O
macrophages	O
.	O

We	O
previously	O
reported	O
that	O
human	B-PRGE
Î²	I-PRGE
-	I-PRGE
defensin	I-PRGE
2	I-PRGE
(	O
HBD	B-PRGE
2	I-PRGE
)	O
activates	O
primary	O
innate	O
immunity	O
against	O
viral	O
infection	O
and	O
suggested	O
that	O
it	O
plays	O
a	O
role	O
in	O
the	O
induction	O
of	O
the	O
adaptive	O
immune	O
response	O
.	O

Finally	O
,	O
HBD	B-PRGE
2	I-PRGE
-	O
conjugated	O
S	O
RBD	O
interacted	O
with	O
C	O
-	O
C	O
chemokine	B-PRGE
receptor	I-PRGE
2	I-PRGE
(	O
CCR2	B-PRGE
),	O
and	O
Nod2	B-PRGE
was	O
involved	O
in	O
HBD	B-PRGE
2	I-PRGE
-	O
mediated	O
CCR2	B-PRGE
signaling	O
,	O
which	O
was	O
associated	O
with	O
the	O
activation	O
and	O
M1	O
polarization	O
of	O
THP	O
-	O
1	O
cells	O
.	O

Two	O
single	O
-	O
guide	O
RNAs	O
targeting	O
the	O
CMAH	B-PRGE
gene	I-PRGE
and	O
Cas9	B-PRGE
mRNA	I-PRGE
were	O
microinjected	O
into	O
the	O
cytoplasm	O
of	O
newly	O
fertilized	O
eggs	O
.	O

TITLE	O
:	O
Porcine	B-PRGE
Deltacoronavirus	I-PRGE
Nucleocapsid	I-PRGE
Protein	I-PRGE
Suppressed	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
Production	O
by	O
Interfering	O
Porcine	O
RIG	O
-	O
I	O
dsRNA	O
-	O
Binding	O
and	O
K63	O
-	O
Linked	O
Polyubiquitination	O
.	O

PDCoV	B-PRGE
N	I-PRGE
protein	I-PRGE
also	O
suppressed	O
the	O
activation	O
of	O
porcine	B-PRGE
IFN	I-PRGE
-	I-PRGE
Î²	I-PRGE
promoter	I-PRGE
when	O
it	O
was	O
stimulated	O
by	O
porcine	O
RLR	O
signaling	O
molecules	O
.	O

Taken	O
together	O
,	O
our	O
results	O
revealed	O
a	O
novel	O
mechanism	O
by	O
which	O
PDCoV	B-PRGE
N	I-PRGE
protein	I-PRGE
interferes	O
with	O
the	O
early	O
activation	O
of	O
pRIG	O
-	O
I	O
in	O
the	O
host	O
antiviral	O
response	O
.	O

Laboratory	O
investigation	O
showed	O
high	O
erythrocyte	O
sedimentation	O
rate	O
and	O
C	B-PRGE
reactive	I-PRGE
protein	I-PRGE
,	O
leucocytosis	O
,	O
anaemia	O
,	O
mild	O
thrombocytopaenia	O
,	O
renal	O
impairment	O
,	O
hyperbilirubinaemia	O
and	O
abnormal	O
liver	O
function	O
tests	O
;	O
arterial	O
blood	O
gas	O
analysis	O
showed	O
respiratory	O
alkalosis	O
with	O
severe	O
hypoxia	O
.	O

The	O
most	O
notable	O
studies	O
include	O
the	O
recent	O
discoveries	O
of	O
monoclonal	O
antibodies	O
and	O
development	O
of	O
candidate	O
vaccines	O
against	O
the	O
S	B-PRGE
glycoprotein	I-PRGE
.	O

In	O
the	O
current	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
NBP	B-PRGE
on	O
ALI	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
treated	O
mice	O
.	O

ABSTRACT	O
:	O
Fat	B-PRGE
embolism	O
syndrome	O
is	O
a	O
rare	O
but	O
fatal	O
complication	O
seen	O
commonly	O
in	O
patients	O
with	O
polytrauma	O
.	O

However	O
,	O
unlike	O
Vpu	O
(	O
which	O
downmodulates	O
BST2	O
by	O
means	O
of	O
proteasomal	O
and	O
lysosomal	O
degradation	O
pathways	O
),	O
BST2	B-PRGE
downregulation	O
is	O
apparently	O
mediated	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
through	O
the	O
lysosomal	O
degradation	O
pathway	O
only	O
.	O

We	O
found	O
that	O
SARS	O
-	O
CoV	O
S	O
colocalized	O
with	O
both	O
BST2	B-PRGE
and	O
reduced	O
cell	O
surface	O
BST2	B-PRGE
,	O
suggesting	O
an	O
association	O
between	O
SARS	B-PRGE
-	O
CoV	O
S	O
and	O
BST2	B-PRGE
that	O
targets	O
the	O
lysosomal	O
degradation	O
pathway	O
.	O

Aim	B-PRGE
of	O
this	O
multicenter	O
retrospective	O
observational	O
study	O
was	O
to	O
evaluate	O
whether	O
poractant	O
alfa	O
use	O
in	O
pediatric	O
ARDS	O
might	O
improve	O
gas	O
exchange	O
in	O
children	O
less	O
than	O
2	O
years	O
old	O
,	O
according	O
to	O
a	O
shared	O
protocol	O
.	O

We	O
developed	O
multiple	O
assays	O
to	O
further	O
define	O
the	O
breadth	O
of	O
RDV	O
antiviral	O
activity	O
against	O
the	O
CoV	B-PRGE
family	I-PRGE
.	O

TITLE	O
:	O
Effect	O
of	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)-	O
mediated	O
overexpression	O
of	O
PEPCK	B-PRGE
-	I-PRGE
M	I-PRGE
(	O
Pck2	B-PRGE
)	O
on	O
Clenbuterol	O
-	O
induced	O
muscle	O
growth	O
.	O

Here	O
,	O
we	O
used	O
whole	O
-	O
transcriptome	O
sequencing	O
(	O
RNASeq	O
)	O
and	O
ribosome	O
profiling	O
(	O
RiboSeq	O
)	O
to	O
delineate	O
gene	O
expression	O
in	O
the	O
IBV	B-PRGE
M41	I-PRGE
-	I-PRGE
CK	I-PRGE
and	O
Beau	O
-	O
R	O
strains	O
at	O
subcodon	O
resolution	O
.	O

We	O
used	O
a	O
combat	O
relevant	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
SII	O
to	O
study	O
temporal	O
changes	O
in	O
ventilation	O
-	O
perfusion	O
(	O
V	O
/	O
Q	O
)	O
matching	O
,	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
data	O
,	O
and	O
histopathology	O
and	O
hypothesized	O
that	O
SII	B-PRGE
leads	O
to	O
increase	O
in	O
shunt	O
(	O
Qshunt	O
),	O
V	O
/	O
Q	O
mismatch	O
,	O
lung	O
consolidation	O
,	O
and	O
diffuse	O
alveolar	O
damage	O
.	O

A	O
fully	O
human	O
polyclonal	O
IgG	B-PRGE
antibody	I-PRGE
(	O
SAB	O
-	O
301	O
)	O
was	O
safe	O
and	O
well	O
tolerated	O
in	O
healthy	O
individuals	O
and	O
this	O
agent	O
may	O
deserve	O
further	O
testing	O
for	O
efficacy	O
.	O

TITLE	O
:	O
NETs	B-PRGE
promote	O
ALI	O
/	O
ARDS	O
inflammation	O
by	O
regulating	O
alveolar	O
macrophage	O
polarization	O
.	O

The	O
primary	O
therapies	O
were	O
antibiotics	O
(	O
99	O
.	O
0	O
%),	O
immunoglobulin	B-PRGE
(	O
88	O
.	O
3	O
%),	O
mechanical	O
ventilation	O
(	O
78	O
.	O
4	O
%),	O
vasoactive	O
infusions	O
(	O
59	O
.	O
6	O
%),	O
and	O
corticosteroids	O
(	O
46	O
.	O
1	O
%).	O

In	O
PEDV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	O
,	O
the	O
mRNA	O
expression	O
of	O
the	O
six	O
tight	O
junction	O
proteins	O
showed	O
a	O
downward	O
trend	O
;	O
in	O
particular	O
,	O
the	O
expression	O
of	O
the	O
Occludin	B-PRGE
and	O
Claudin	B-PRGE
-	I-PRGE
4	I-PRGE
genes	I-PRGE
was	O
significantly	O
lower	O
(	O
p	O
â¨	O
0	O
.	O
01	O
).	O

On	O
multivariate	O
analysis	O
,	O
ASA	O
classification	O
â¥	O
3	O
,	O
lower	O
BMI	O
,	O
ILA	B-PRGE
,	O
and	O
extent	O
of	O
resection	O
were	O
independently	O
associated	O
with	O
PPC	O
risk	O
.	O

Vascular	O
permeability	O
was	O
also	O
assessed	O
through	O
Evans	O
blue	O
dye	O
tissue	O
extravasation	O
and	O
fluorescein	O
isothiocyanate	O
-	O
labeled	O
albumin	B-PRGE
(	O
FITC	B-PRGE
-	I-PRGE
albumin	I-PRGE
)	O
leakage	O
.	O

Fraxin	O
was	O
also	O
related	O
to	O
the	O
inhibition	O
of	O
the	O
increase	O
in	O
matrix	B-PRGE
metalloproteinase	I-PRGE
-	I-PRGE
9	I-PRGE
,	O
which	O
is	O
a	O
glycocalyx	O
-	O
degrading	O
enzyme	O
,	O
and	O
the	O
relief	O
of	O
damages	O
to	O
the	O
endothelial	O
glycocalyx	O
.	O

Recombinant	O
EMC	O
isolates	O
of	O
MERS	O
-	O
CoV	O
,	O
in	O
which	O
the	O
S	B-PRGE
protein	I-PRGE
is	O
replaced	O
with	O
those	O
of	O
Amibara	O
isolates	O
,	O
were	O
then	O
generated	O
to	O
test	O
the	O
roles	O
of	O
these	O
proteins	O
in	O
viral	O
properties	O
.	O

In	O
neutralizing	O
assays	O
,	O
Amibara	O
S	O
recombinants	O
were	O
neutralized	O
by	O
lower	O
concentrations	O
of	O
sera	O
from	O
both	O
Ethiopian	O
dromedaries	O
and	O
EMC	O
isolate	O
(	O
wild	O
-	O
type	O
)-	O
immunized	O
mouse	O
sera	O
,	O
relative	O
to	O
the	O
EMC	B-PRGE
S	I-PRGE
recombinants	I-PRGE
,	O
indicating	O
that	O
viruses	O
coated	O
in	O
the	O
Amibara	B-PRGE
S	I-PRGE
protein	I-PRGE
were	O
easier	O
to	O
neutralize	O
than	O
the	O
EMC	B-PRGE
S	I-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
High	O
Hemoglobin	B-PRGE
Level	O
As	O
a	O
Limiting	O
Factor	O
for	O
Extracorporeal	O
Membrane	O
Oxygenation	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
high	O
fat	O
diet	O
induced	O
obesity	O
increases	O
the	O
severity	O
of	O
hyperoxic	O
acute	O
lung	O
injury	O
in	O
mice	O
in	O
part	O
by	O
altering	O
fatty	B-PRGE
acid	I-PRGE
synthase	I-PRGE
(	O
FASN	B-PRGE
)	O
levels	O
in	O
the	O
lung	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
show	O
that	O
a	O
high	O
fat	O
diet	O
leads	O
to	O
altered	O
FASN	B-PRGE
expression	O
in	O
the	O
lung	O
and	O
that	O
both	O
a	O
high	O
fat	O
diet	O
and	O
reduced	O
FASN	B-PRGE
expression	O
in	O
alveolar	O
epithelial	O
cells	O
promote	O
lung	O
injury	O
.	O

TITLE	O
:	O
Staphylococcal	B-PRGE
phosphatidylinositol	I-PRGE
-	I-PRGE
specific	I-PRGE
phospholipase	I-PRGE
C	I-PRGE
potentiates	O
lung	O
injury	O
via	O
complement	O
sensitisation	O
.	O

ARDS	O
is	O
associated	O
with	O
staphylococcal	O
phosphatidylinositol	O
-	O
specific	O
phospholipase	B-PRGE
C	I-PRGE
(	O
PI	B-PRGE
-	I-PRGE
PLC	I-PRGE
);	O
however	O
,	O
the	O
role	O
of	O
PI	B-PRGE
-	I-PRGE
PLC	I-PRGE
in	O
the	O
pathogenesis	O
and	O
progression	O
of	O
ARDS	O
remains	O
unknown	O
.	O

In	O
this	O
retrospective	O
cohort	O
study	O
,	O
serum	O
SP	B-PRGE
-	I-PRGE
D	I-PRGE
levels	O
were	O
analyzed	O
in	O
37	O
CDH	O
infants	O
and	O
5	O
control	O
infants	O
using	O
a	O
commercially	O
available	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
kit	O
.	O

TITLE	O
:	O
Structural	O
definition	O
of	O
a	O
neutralization	O
epitope	O
on	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
.	O

The	O
mean	O
ACE	B-PRGE
level	O
in	O
the	O
study	O
population	O
was	O
66	O
.	O
54	O
+-	O
11	O
.	O
18	O
.	O

A	O
strong	O
positive	O
correlation	O
was	O
found	O
among	O
serum	O
ACE	B-PRGE
levels	O
and	O
Thoracic	O
Trauma	O
Severity	O
Score	O
(	O
TTSS	O
).	O

To	O
define	O
the	O
evolution	O
of	O
recent	O
IBVs	O
in	O
Iran	O
,	O
a	O
genetic	O
analysis	O
based	O
on	O
hypervariable	O
nucleotide	O
sequences	O
of	O
S1	B-PRGE
gene	I-PRGE
was	O
carried	O
out	O
.	O

The	O
results	O
proposed	O
that	O
infection	O
with	O
heterologous	O
virus	O
may	O
result	O
in	O
temporary	O
competition	O
for	O
cell	O
receptors	O
or	O
competent	O
cells	O
for	O
replication	O
,	O
most	O
likely	O
interferon	B-PRGE
-	O
mediated	O
.	O

Recent	O
studies	O
indicated	O
that	O
Cxc	B-PRGE
chemokine	I-PRGE
ligand	I-PRGE
5	I-PRGE
(	O
CXCL5	B-PRGE
),	O
an	O
inflammatory	O
chemokine	O
,	O
was	O
associated	O
with	O
tumorigenesis	O
.	O

Antiviral	O
therapy	O
within	O
48	O
h	O
after	O
onset	O
,	O
avoidance	O
of	O
corticosteroids	O
and	O
rescue	O
therapies	O
for	O
ARF	B-PRGE
or	O
myocarditis	O
,	O
such	O
as	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
improve	O
survival	O
.	O

ABSTRACT	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
(	O
HCoV	O
-	O
NL63	O
)	O
is	O
a	O
common	O
respiratory	O
virus	O
that	O
causes	O
moderately	O
severe	O
infections	O
.	O

The	O
decreased	O
levels	O
of	O
the	O
fibrinogen	B-PRGE
and	O
antithrombin	B-PRGE
activity	O
were	O
significantly	O
associated	O
with	O
an	O
increase	O
in	O
mortality	O
(	O
P	O
=	O
0	O
.	O
011	O
and	O
0	O
.	O
002	O
,	O
respectively	O
).	O

P53	B-PRGE
has	O
been	O
associated	O
with	O
anti	O
-	O
inflammatory	O
activities	O
.	O

Since	O
it	O
has	O
been	O
shown	O
that	O
a	O
mild	O
induction	O
of	O
the	O
unfolded	O
protein	O
response	O
opposes	O
inflammation	O
,	O
we	O
suggest	O
that	O
P53	B-PRGE
is	O
involved	O
in	O
those	O
protective	O
activities	O
in	O
the	O
lung	O
.	O

To	O
increase	O
the	O
translatability	O
of	O
this	O
model	O
,	O
we	O
validated	O
and	O
established	O
the	O
use	O
of	O
an	O
automated	O
veterinary	O
hematology	O
analyzer	O
(	O
VetScan	B-PRGE
HM5	I-PRGE
)	O
at	O
biosafety	O
level	O
3	O
for	O
analysis	O
of	O
peripheral	O
blood	O
.	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
revealed	O
that	O
all	O
17	O
fecal	O
samples	O
from	O
post	O
-	O
weaned	O
calves	O
with	O
diarrhea	O
and	O
one	O
out	O
of	O
15	O
from	O
diarrhea	O
-	O
recovered	O
calves	O
were	O
positive	O
for	O
BCoV	O
and	O
negative	O
for	O
Cryptosporidium	B-PRGE
spp	I-PRGE
.,	I-PRGE
Escherichia	I-PRGE
coli	I-PRGE
K99	I-PRGE
,	I-PRGE
Salmonella	I-PRGE
spp	I-PRGE
.,	O
bovine	O
rotavirus	O
,	O
and	O
bovine	O
viral	O
diarrhea	O
virus	O
.	O

PDCoV	O
nsp15	O
disrupts	O
the	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
NF	B-PRGE
-	I-PRGE
ÎºB	I-PRGE
p65	I-PRGE
subunit	I-PRGE
,	O
but	O
not	O
antagonizes	O
the	O
activation	O
of	O
transcription	B-PRGE
factor	I-PRGE
IRF3	I-PRGE
.	O

We	O
found	O
that	O
single	O
strand	O
RNA	O
(	O
termed	O
RNA	O
adjuvant	O
)	O
derived	O
from	O
cricket	O
paralysis	O
virus	O
intergenic	O
region	O
internal	O
ribosome	O
entry	O
site	O
induced	O
the	O
expression	O
of	O
various	O
adjuvant	O
-	O
function	O
-	O
related	O
genes	O
,	O
such	O
as	O
type	O
1	O
and	O
2	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
and	O
toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
(	O
TLR	O
),	O
T	O
cell	O
activation	O
,	O
and	O
leukocyte	O
chemotaxis	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
;	O
furthermore	O
,	O
its	O
innate	O
and	O
IFN	B-PRGE
transcriptome	O
profile	O
patterns	O
were	O
similar	O
to	O
those	O
of	O
a	O
live	O
-	O
attenuated	O
yellow	O
fever	O
vaccine	O
.	O

The	O
reported	O
isolate	O
was	O
identified	O
by	O
a	O
real	O
-	O
time	O
reverse	B-PRGE
transcriptase	I-PRGE
PCR	O
assay	O
targeting	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
and	O
,	O
further	O
characterized	O
by	O
full	O
-	O
length	O
spike	O
(	O
S1	O
)	O
gene	O
sequencing	O
.	O

Finally	O
,	O
stabilization	O
of	O
the	O
NTD	O
by	O
G29P	O
had	O
almost	O
no	O
effect	O
on	O
pH	O
-	O
independent	O
RIS	O
induced	O
by	O
the	O
Y320A	O
mutation	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
of	O
the	O
S1	B-PRGE
subunit	I-PRGE
,	O
indicating	O
that	O
there	O
might	O
be	O
an	O
absence	O
of	O
cross	O
talk	O
between	O
the	O
NTD	O
and	O
CTD	O
during	O
conformational	O
changes	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

We	O
analysed	O
the	O
changes	O
in	O
S	B-PRGE
gene	I-PRGE
and	O
its	O
protein	O
of	O
PEDV	O
HLJBY	O
with	O
65	O
historic	O
PEDV	O
strains	O
.	O

The	O
deubiquitination	O
of	O
Nsp3	B-PRGE
domains	I-PRGE
and	O
its	O
effect	O
on	O
IÎºBÎ±	O
and	O
p65	B-PRGE
were	O
analyzed	O
by	O
western	O
blotting	O
.	O

CONCLUSIONS	O
:	O
TGEV	O
infection	O
can	O
inhibit	O
the	O
activation	O
of	O
the	O
NF	O
-	O
ÎºB	O
signaling	O
pathway	O
,	O
which	O
is	O
mainly	O
mediated	O
by	O
Nsp3	B-PRGE
through	O
the	O
canonical	O
pathway	O
.	O

In	O
addition	O
,	O
our	O
results	O
showed	O
that	O
PEDV	B-PRGE
ORF3	I-PRGE
could	O
induce	O
the	O
autophagy	O
through	O
inducing	O
conversion	O
of	O
LC3	B-PRGE
-	I-PRGE
I	I-PRGE
to	O
LC3	B-PRGE
-	I-PRGE
II	I-PRGE
,	O
but	O
couldn	O
'	O
t	O
influence	O
the	O
apoptosis	O
.	O

Moreover	O
,	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
suppressed	O
TGEV	O
infection	O
in	O
ST	O
cells	O
more	O
efficiently	O
than	O
did	O
IFN	B-PRGE
-	I-PRGE
Î±	I-PRGE
,	O
and	O
the	O
combination	O
of	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
Î±	I-PRGE
displayed	O
a	O
synergistic	O
effect	O
against	O
TGEV	O
.	O

In	O
vivo	O
,	O
miR	O
-	O
150	O
decreased	O
total	O
cell	O
and	O
neutrophil	O
counts	O
,	O
and	O
production	O
of	O
inflammatory	O
cytokines	B-PRGE
interleukin	I-PRGE
-	I-PRGE
1Î²	I-PRGE
(	O
IL	O
-	O
1Î²	O
),	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
Î±	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
)	O
as	O
well	O
as	O
levels	O
of	O
total	O
protein	O
,	O
albumin	B-PRGE
and	O
IgM	B-PRGE
in	O
the	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
in	O
LPS	O
-	O
induced	O
ALI	O
mice	O
.	O

In	O
addition	O
,	O
miR	O
-	O
150	O
or	O
si	O
-	O
AKT3	B-PRGE
effectively	O
inhibited	O
the	O
phosphorylation	O
levels	O
of	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
kinase	I-PRGE
(	O
JNK	B-PRGE
)	O
and	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
ÎºB	I-PRGE
(	O
NF	O
-	O
ÎºB	O
)	O
(	O
p65	B-PRGE
and	O
IÎºBÎ±	O
).	O

Here	O
,	O
we	O
investigated	O
the	O
intracellular	O
trafficking	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
M	B-PRGE
protein	I-PRGE
.	O

Subcellular	O
localization	O
analyses	O
revealed	O
that	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
is	O
retained	O
intracellularly	O
in	O
the	O

In	O
total	O
137	O
cat	O
serum	O
samples	O
and	O
25	O
FCoV	O
type	O
1	O
or	O
type	O
2	O
-	O
specific	O
antisera	O
were	O
screened	O
for	O
the	O
presence	O
of	O
antibodies	O
against	O
the	O
S1	B-PRGE
receptor	I-PRGE
binding	O
subunit	O
of	O
the	O
CoV	B-PRGE
spike	I-PRGE
protein	I-PRGE
,	O
which	O
is	O
immunogenic	O
and	O
possesses	O
low	O
amino	O
acid	O
sequence	O
identity	O
among	O
coronavirus	O
species	O
.	O

We	O
observed	O
antigenic	O
cross	O
-	O
reactivity	O
between	O
S1s	B-PRGE
of	I-PRGE
type	I-PRGE
1	I-PRGE
and	I-PRGE
type	I-PRGE
2	I-PRGE
FCoVs	I-PRGE
,	O
and	O
between	O
FCoV	B-PRGE
type	I-PRGE
1	I-PRGE
and	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

Gender	O
distribution	O
,	O
rate	O
of	O
smokers	O
,	O
exposure	O
to	O
biofuels	O
,	O
blood	O
leukocyte	O
count	O
,	O
neutrophil	O
percentage	O
,	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
)	O
level	O
,	O
FEV1	O
/	O
FVC	O
ratio	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
two	O
groups	O
(	O
p	O
>	O
0	O
.	O
05	O
).	O

After	O
conducting	O
univariate	O
analysis	O
of	O
risk	O
factors	O
,	O
statistically	O
significant	O
risk	O
factors	O
affecting	O
the	O
development	O
of	O
ROP	O
in	O
our	O
study	O
were	O
:	O
low	O
gestational	O
age	O
,	O
low	O
birth	O
weight	O
,	O
type	O
of	O
multiple	O
gestation	O
,	O
the	O
presence	O
of	O
affected	O
sibling	O
,	O
low	O
level	O
of	O
Hemoglobin	B-PRGE
at	O
birth	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
low	O
Hemoglobin	B-PRGE
level	O
,	O
blood	O
transfusion	O
and	O
days	O
on	O
oxygen	O
supplements	O
with	O
either	O
mechanical	O
,	O
non	O
-	O
mechanical	O
methods	O
or	O
both	O
combined	O
.	O

We	O
present	O
an	O
unusual	O
case	O
of	O
left	O
upper	O
limb	O
acute	O
arterial	O
thrombosis	O
with	O
purpura	O
fulminans	O
like	O
skin	O
lesions	O
precipitated	O
by	O
swine	B-PRGE
flu	I-PRGE
(	O
H1N1	O
)	O
infection	O
with	O
adult	O
respiratory	O
distress	O
syndrome	O
subsequently	O
developing	O
acute	O
renal	O
failure	O
,	O
retinal	O
infarcts	O
,	O
multiple	O
acute	O
cerebral	O
infarcts	O
,	O
cardiac	O
valvular	O
vegetations	O
and	O
hemolytic	O
anemia	O
with	O
recurrent	O
bleeding	O
episodes	O
.	O

TITLE	O
:	O
Characteristics	O
of	O
flavonoids	O
as	O
potent	O
MERS	O
-	O
CoV	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
inhibitors	O
.	O

Phylogenetic	O
analyses	O
of	O
GuCoV	B-PRGE
B29	I-PRGE
suggested	O
that	O
this	O
virus	O
could	O
represent	O
a	O
novel	O
species	O
within	O
the	O
genus	O

The	O
modeling	O
studies	O
calculated	O
the	O
theoretical	O
binding	O
affinity	O
of	O
the	O
synthesized	O
compounds	O
on	O
both	O
HIV	O
-	O
1	O
IN	O
and	O
RT	O
-	O
associated	O
Ribonuclease	B-PRGE
H	I-PRGE
(	O
RNase	B-PRGE
H	I-PRGE
)	O
active	O
sites	O
,	O
which	O
was	O
confirmed	O
by	O
biological	O
assays	O
.	O

Our	O
results	O
provide	O
a	O
basis	O
for	O
the	O
identification	O
of	O
dual	O
HIV	O
-	O
1	O
IN	O
and	O
RT	B-PRGE
RNase	I-PRGE
H	I-PRGE
inhibitors	O
compounds	O
.	O

Severity	O
of	O
AKI	B-PRGE
and	O
use	O
of	O
RRT	O
were	O
associated	O
with	O
poor	O
prognosis	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
was	O
the	O
main	O
reason	O
of	O
ARF	B-PRGE
(	O
n	O
=	O
37	O
,	O
26	O
.	O
8	O
%).	O

Further	O
,	O
a	O
subset	O
of	O
exosomal	O
miRNAs	O
,	O
including	O
the	O
miR	B-PRGE
-	I-PRGE
146a	I-PRGE
,	O
miR	B-PRGE
-	I-PRGE
27a	I-PRGE
,	O
miR	O
-	O
126	O
,	O
and	O
miR	O
-	O
155	O
in	O
ARDS	O
group	O
exhibited	O
significantly	O
elevated	O
levels	O
than	O
those	O
in	O
non	O
-	O
ARDS	O
group	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
potential	O
of	O
TGEV	O
S1	O
as	O
a	O
DNA	O
vaccine	O
and	O
porcine	B-PRGE
interleukin	I-PRGE
(	O
pIL	B-PRGE
)-	O
12	O
as	O
an	O
adjuvant	O
in	O
a	O
mouse	O
model	O
.	O

Mutations	O
preventing	O
membrane	O
binding	O
in	O
vitro	O
also	O
abolished	O
S	O
-	O
mediated	O
syncytium	O
formation	O
consistent	O
with	O
the	O
identified	O
peptide	O
acting	O
as	O
the	O
fusion	O
peptide	O
for	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
MERS	O
-	O
CoV	O
.	O

Notably	O
,	O
the	O
features	O
of	O
bat	B-PRGE
MHC	I-PRGE
I	I-PRGE
may	O
be	O
shared	O
by	O
MHC	B-PRGE
I	I-PRGE
from	O
various	O
marsupials	O
.	O

According	O
to	O
western	O
blots	O
,	O
serum	O
antibody	O
interactions	O
with	O
the	O
S1	B-PRGE
protein	I-PRGE
were	O
relatively	O
more	O
sensitive	O
and	O
specific	O
than	O
ORF3C	O
,	O
E	O
and	O
Ac	O
.	O

We	O
observed	O
that	O
knockdown	O
of	O
G3BP1	B-PRGE
by	O
silencing	O
RNA	O
significantly	O
increased	O
PEDV	O
replication	O
.	O

An	O
increase	O
in	O
the	O
levels	O
of	O
mRNAs	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
interleukin	B-PRGE
-	I-PRGE
1Î²	I-PRGE
(	O
IL	O
-	O
1Î²	O
)	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
Î±	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
Î±	I-PRGE
)	O
was	O
also	O
observed	O
in	O
PEDV	O
-	O
infected	O
G3BP1	O
depleted	O
cells	O
compared	O
to	O
PEDV	O
-	O
infected	O
control	O
cells	O
.	O

S2	B-PRGE
protein	I-PRGE
is	O
an	O
invariant	O
that	O
harbors	O
broad	O
neutralizing	O
epitopes	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
key	O
amino	O
acids	O
that	O
contribute	O
to	O
the	O
broad	B-PRGE
-	I-PRGE
spectrum	I-PRGE
S2	I-PRGE
epitopes	I-PRGE
.	O

Site	O
mutagenesis	O
and	O
peptide	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISAs	O
)	O
showed	O
that	O
16R	O
in	O
S2	B-PRGE
protein	I-PRGE
was	O
a	O
key	O
amino	O
acid	O
mediating	O
the	O
antigenicity	O
of	O
S2	B-PRGE
protein	I-PRGE
.	O

Phylogenetic	O
analysis	O
of	O
the	O
penton	O
base	O
sequences	O
of	O
HAdV	O
-	O
C	O
revealed	O
six	O
genetic	O
groups	O
(	O
labelled	O
as	O
Px1	B-PRGE
-	I-PRGE
6	I-PRGE
),	O
which	O
showed	O
that	O
the	O
penton	O
base	O
had	O
more	O
variation	O
than	O
previously	O
thought	O
.	O

Furthermore	O
,	O
the	O
TGEV	O
L	O
.	O
acidophilus	O
oral	O
vaccine	O
induced	O
higher	O
levels	O
of	O
IFN	B-PRGE
-	I-PRGE
Î³	I-PRGE
,	O
which	O
suggested	O
that	O
the	O
vaccine	O
was	O
able	O
to	O
induce	O
immune	O
response	O
.	O

RESULTS	O
:	O
While	O
no	O
differences	O
were	O
found	O
in	O
terms	O
of	O
nonadherence	O
and	O
use	O
problems	O
between	O
the	O
current	O
and	O
the	O
redesigned	O
gown	O
,	O
differences	O
in	O
usability	O
and	O
task	O
load	O
ratings	O
suggested	O
that	O
the	O
redesigned	O
gown	O
is	O
perceived	O
more	O
favorably	O
by	O
HCP	B-PRGE
.	O

Among	O
pastoral	O
herds	O
,	O
the	O
age	O
-	O
dependent	O
quadratic	O
FOI	O
was	O
the	O
best	O
fit	O
model	O
,	O
while	O
the	O
age	O
-	O
independent	O
FOI	B-PRGE
was	O
the	O
best	O
fit	O
for	O
the	O
ranching	O
herd	O
data	O
.	O

Understanding	O
how	O
diabetes	O
affects	O
MERS	O
is	O
important	O
because	O
of	O
the	O
global	O
burden	O
of	O
diabetes	O
and	O
pandemic	O
potential	O
of	O
MERS	O
-	O
CoV	O
.	O
We	O
used	O
a	O
model	O
in	O
which	O
mice	O
were	O
made	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
by	O
expressing	O
human	B-PRGE
DPP4	I-PRGE
,	O
and	O
type	O
2	O
diabetes	O
was	O
induced	O
by	O
administering	O
a	O
high	O
-	O
fat	O
diet	O
.	O

HIV	O
and	O
HBV	O
reverse	O
transcriptases	O
contain	O
DNA	B-PRGE
polymerase	I-PRGE
and	O
RNase	B-PRGE
H	I-PRGE
domains	I-PRGE
that	O
act	O
in	O
a	O
coordinated	O
manner	O
to	O
produce	O
double	O
-	O
stranded	O
viral	O
DNA	O
.	O

Although	O
RNase	B-PRGE
H	I-PRGE
inhibitors	O
have	O
not	O
been	O
developed	O
into	O
licensed	O
drugs	O
,	O
recent	O
progress	O
has	O
led	O
to	O
the	O
identification	O
of	O
a	O
number	O
of	O
small	O
molecules	O
with	O
inhibitory	O
activity	O
at	O
low	O
micromolar	O
or	O
even	O
nanomolar	O
concentrations	O
.	O

Among	O
them	O
,	O
Î±	O
-	O
hydroxytropolones	O
,	O
N	O
-	O
hydroxyisoquinolinediones	O
and	O
N	O
-	O
hydroxypyridinediones	O
represent	O
chemotypes	O
active	O
against	O
both	O
HIV	O
and	O
HBV	O
RNases	O
H	O
.	O
In	O
this	O
review	O
we	O
summarize	O
recent	O
developments	O
in	O
the	O
field	O
including	O
the	O
identification	O
of	O
novel	O
RNase	B-PRGE
H	I-PRGE
inhibitors	O
,	O
compounds	O
with	O
dual	O
inhibitory	O
activity	O
,	O
broad	O
specificity	O
and	O
efforts	O
to	O
decrease	O
their	O
toxicity	O
.	O

Cell	O
-	O
surface	O
binding	O
studies	O
and	O
in	O
vitro	O
competition	O
experiments	O
demonstrate	O
that	O
G2	O
strongly	O
disrupts	O
the	O
attachment	O
of	O
MERS	O
-	O
CoV	O
S	O
to	O
its	O
receptor	O
,	O
dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	B-PRGE
),	O
with	O
the	O
inhibition	O
requiring	O
the	O
native	O
trimeric	O
S	O
conformation	O
.	O

ABSTRACT	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
(	O
HCoV	O
-	O
NL63	O
),	O
one	O
of	O
the	O
main	O
circulating	O
HCoVs	O
worldwide	O
,	O
causes	O
respiratory	O
tract	O
illnesses	O
like	O
runny	O
nose	O
,	O
cough	O
,	O
bronchiolitis	O
and	O
pneumonia	O
.	O

Based	O
on	O
the	O
S1	B-PRGE
gene	I-PRGE
phylogenetic	O
tree	O
,	O
LX4	O
-	O
type	O
(	O
GI	O
-	O
19	O
)	O
was	O
the	O
most	O
dominant	O
genotype	O
,	O
which	O
was	O
different	O
from	O
that	O
during	O
1985	O
-	O
2008	O
.	O

TITLE	O
:	O
Activation	O
of	O
C	B-PRGE
-	I-PRGE
Type	I-PRGE
Lectin	I-PRGE
Receptor	I-PRGE
and	O
(	O
RIG	O
)-	O
I	O
-	O
Like	O
Receptors	O
Contributes	O
to	O
Proinflammatory	O
Response	O
in	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
-	O
Infected	O
Macrophages	O
.	O

Significant	O
FECV	O
-	O
specific	O
mucosal	O
T	B-PRGE
cell	I-PRGE
IFNÎ³	I-PRGE
responses	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
three	O
groups	O
.	O

TITLE	O
:	O
Quantitative	O
Proteomics	O
of	O
Uukuniemi	O
Virus	O
-	O
host	O
Cell	O
Interactions	O
Reveals	O
GBF1	B-PRGE
as	O
Proviral	O
Host	O
Factor	O
for	O
Phleboviruses	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
used	O
bovine	O
pulmonary	O
arterial	O
cells	O
in	O
order	O
to	O
investigate	O
the	O
effects	O
of	O
GHRH	B-PRGE
and	O
its	O
antagonistic	O
and	O
agonistic	O
analogs	O
in	O
key	O
intracellular	O
pathways	O
that	O
regulate	O
endothelial	O
permeability	O
.	O

Our	O
observations	O
support	O
the	O
evidence	O
for	O
the	O
anti	O
-	O
inflammatory	O
role	O
of	O
GHRH	B-PRGE
antagonists	O
in	O
the	O
vasculature	O
.	O

Sequence	O
alignments	O
showed	O
that	O
these	O
four	O
novel	O
strains	O
exhibited	O
16	O
nucleotide	O
mutations	O
and	O
resultant	O
10	O
amino	O
acid	O
substitutions	O
in	O
open	O
reading	O
frame	O
1a	O
/	O
1b	O
,	O
spike	O
,	O
NS3a	B-PRGE
,	I-PRGE
envelope	I-PRGE
,	I-PRGE
membrane	I-PRGE
and	I-PRGE
nucleocapsid	I-PRGE
proteins	I-PRGE
.	O

We	O
have	O
previously	O
reported	O
the	O
synthesis	O
of	O
potent	B-PRGE
coronavirus	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CLpro	O
)	O
inhibitors	O
and	O
the	O
efficacy	O
of	O
a	O
protease	O
inhibitor	O
,	O
GC376	O
,	O
in	O
client	O
-	O
owned	O
cats	O
with	O
FIP	O
.	O

So	O
,	O
we	O
speculate	O
that	O
circEZH2	O
may	O
regulate	O
TGEV	O
-	O
induced	O
mPTP	B-PRGE
opening	O
via	O
NF	B-PRGE
-	I-PRGE
kB	I-PRGE
pathway	O
.	O

Silencing	O
HK2	O
enhanced	O
TGEV	O
-	O
induced	O
mPTP	B-PRGE
opening	O
,	O
while	O
no	O
effect	O
on	O
NF	O
-	O
ÎºB	O
pathway	O
.	O

Silencing	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
promoted	O
TGEV	O
-	O
induced	O
mPTP	O
opening	O
and	O
inhibited	O
NF	O
-	O
ÎºB	O
pathway	O
.	O

On	O
the	O
3rd	O
day	O
,	O
GAS	B-PRGE
was	O
isolated	O
from	O
blood	O
culture	O
.	O

ABSTRACT	O
:	O
Interferon	B-PRGE
-	I-PRGE
inducible	I-PRGE
p200	I-PRGE
family	I-PRGE
protein	I-PRGE
IFI204	B-PRGE
was	O
reported	O
to	O
be	O
involved	O
in	O
DNA	O
sensing	O
,	O
and	O
subsequently	O
induces	O
the	O
production	O
of	O
type	B-PRGE
I	I-PRGE
interferons	I-PRGE
and	O
proinflammatory	O
mediators	O
.	O

Furthermore	O
,	O
viral	O
protease	O
-	O
mediated	O
immune	O
evasion	O
and	O
viral	O
manipulation	O
of	O
the	O
ubiquitin	B-PRGE
system	O
will	O
be	O
addressed	O
.	O

To	O
produce	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
like	I-PRGE
particles	I-PRGE
(	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
LPs	I-PRGE
),	O
the	O
coexpression	O
of	O
spike	O
proteins	O
was	O
performed	O
in	O
Bm5	O
cells	O
and	O
envelope	B-PRGE
(	O
E	O
)	O
and	O
membrane	O
(	O
M	O
)	O
proteins	O
secreted	O
E	O
and	O
M	O
proteins	O
extracellularly	O
,	O
suggesting	O
that	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
LPs	I-PRGE
may	O
be	O
formed	O
.	O

We	O
also	O
found	O
that	O
the	O
induction	O
of	O
GILT	O
expression	O
reduced	O
the	O
level	O
and	O
activity	O
of	O
cathepsin	B-PRGE
L	I-PRGE
,	O
which	O
is	O
required	O
for	O
the	O
entry	O
of	O
these	O
RNA	O
viruses	O
in	O
lysosomes	O
.	O

TITLE	O
:	O
Influences	O
of	O
cyclosporin	O
A	O
and	O
non	O
-	O
immunosuppressive	O
derivatives	O
on	O
cellular	B-PRGE
cyclophilins	I-PRGE
and	O
viral	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
during	O
human	O
coronavirus	O
229E	O
replication	O
.	O

The	O
BRoV	B-PRGE
antigen	I-PRGE
distribution	O
was	O
prominent	O
within	O
the	O
lining	O
epithelium	O
of	O
the	O
villi	O
,	O
peyer	O
'	O
s	O
patches	O
in	O
the	O
ileum	O
and	O
strong	O
immunoreactions	O
in	O
the	O
lymphocytes	O
and	O
some	O
macrophages	O
of	O
the	O
mesenteric	O
lymph	O
nodes	O
.	O

Opioid	B-PRGE
receptor	I-PRGE
antagonists	O
are	O
used	O
to	O
reverse	O
the	O
effects	O
of	O
opioids	O
and	O
are	O
invaluable	O
in	O
the	O
management	O
of	O
opioid	O
overdose	O
(	O
naloxone	O
,	O
naltrexone	O
,	O
nalmifene	O
).	O

Ampicillin	O
is	O
also	O
used	O
as	O
a	O
combination	O
antibiotic	O
with	O
sulbactam	O
(	O
sul	B-PRGE
bak	I-PRGE
'	I-PRGE
tam	I-PRGE
)	O
sodium	O
which	O
provides	O
coverage	O
against	O
penicillinase	O
-	O
resistant	O
bacteria	O
.	O

Here	O
,	O
we	O
found	O
that	O
PSN	B-PRGE
exhibits	O
anti	O
-	O
inflammatory	O
effects	O
and	O
alleviates	O
heat	O
-	O
killed	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
HKMRSA	O
)-	O
induced	O
pneumonia	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
overexpression	O
and	O
knockdown	O
methods	O
to	O
determine	O
if	O
MDA5	B-PRGE
affected	O
DEV	O
infection	O
in	O
ducks	O
.	O

The	O
HEV	O
added	O
the	O
percentage	O
of	O
CD4	B-PRGE
The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
HEV	O
infection	O
impairs	O
the	O
immune	O
function	O
in	O
turkeys	O
.	O

In	O
the	O
uninfected	O
turkeys	O
,	O
the	O
higher	O
by	O
40	O
%	O
(	O
than	O
recommended	O
by	O
NRC	B-PRGE
)	O
level	O
of	O
Met	O
in	O
the	O
feeds	O
had	O
a	O
positive	O
effect	O
on	O
humoral	O
immunity	O
parameters	O
.	O

Meanwhile	O
,	O
we	O
found	O
that	O
the	O
differentially	O
expressed	O
lncRNA	O
TCONS_00058367	O
might	O
lead	O
to	O
a	O
reduction	O
of	O
phosphorylation	O
of	O
transcription	O
factor	O
p65	B-PRGE
(	O
p	B-PRGE
-	I-PRGE
p65	I-PRGE
)	O
in	O
TGEV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	O
by	O
negatively	O
regulating	O
its	O
antisense	O
gene	O
promyelocytic	O
leukemia	O
(	O
PML	O
).	O

Whereas	O
similar	O
virus	O
titers	O
were	O
observed	O
in	O
the	O
control	O
animals	O
and	O
the	O
animals	O
immunized	O
with	O
S	B-PRGE
protein	I-PRGE
with	O
or	O
without	O
AuNPs	O
,	O
Type	B-PRGE
1	I-PRGE
interferon	I-PRGE
and	O
pro	O
-	O
inflammatory	O
responses	O
were	O
moderate	O
in	O
the	O
mice	O
treated	O
with	O
S	B-PRGE
protein	I-PRGE
with	O
and	O
without	O
AuNPs	O
.	O

TITLE	O
:	O
Murine	O
Coronavirus	O
Infection	O
Activates	O
the	O
Aryl	B-PRGE
Hydrocarbon	I-PRGE
Receptor	I-PRGE
in	O
an	O
Indoleamine	O
2	O
,	O
3	O
-	O
Dioxygenase	O
-	O
Independent	O
Manner	O
,	O
Contributing	O
to	O
Cytokine	O
Modulation	O
and	O
Proviral	O
TCDD	O
-	O
Inducible	O
-	O
PARP	B-PRGE
Expression	O
.	O

According	O
to	O
the	O
management	O
suggestions	O
of	O
the	O
American	O
Centers	O
of	O
Disease	O
Control	O
,	O
uses	O
of	O
corticosteroids	O
and	O
plasmapheresis	O
are	O
either	O
preferred	O
or	O
avoided	O
and	O
intravenous	O
immunoglobulin	B-PRGE
also	O
has	O
no	O
clear	O
indication	O
in	O
the	O
treatment	O
for	O
acute	O
flaccid	O
myelitis	O
.	O

We	O
considered	O
an	O
alternative	O
diagnosis	O
of	O
Goodpasture	O
syndrome	O
or	O
anti	B-PRGE
-	I-PRGE
neutrophil	I-PRGE
cytoplasmic	I-PRGE
antibody	I-PRGE
(	O
ANCA	B-PRGE
)	O
related	O
vasculitis	O
.	O

Therefore	O
,	O
we	O
also	O
initiated	O
intravenous	B-PRGE
immunoglobulin	I-PRGE
(	O
IVIG	O
)	O
therapy	O
for	O
the	O
treatment	O
of	O
potential	O
vasculitis	O
.	O

With	O
the	O
aim	O
to	O
block	O
virus	O
transmission	O
,	O
we	O
examined	O
the	O
efficacy	O
of	O
a	O
recombinant	B-PRGE
spike	I-PRGE
S1	I-PRGE
-	I-PRGE
protein	I-PRGE
vaccine	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
protease	I-PRGE
by	O
flavonoids	O
.	O

Mutations	O
in	O
the	O
LPIN2	B-PRGE
gene	I-PRGE
located	O
on	O
the	O
short	O
arm	O
of	O
chromosome	O
18	O
have	O
been	O
identified	O
as	O
being	O
responsible	O
for	O
Majeed	O
syndrome	O
.	O

Only	O
a	O
few	O
cases	O
with	O
LPIN2	B-PRGE
mutation	I-PRGE
have	O
been	O
reported	O
,	O
mainly	O
in	O
the	O
Middle	O
East	O
with	O
homozygous	O
variants	O
.	O

TITLE	O
:	O
Genome	O
Sequences	O
of	O
Human	B-PRGE
Coronavirus	I-PRGE
OC43	I-PRGE
and	O
NL63	O
,	O
Associated	O
with	O
Respiratory	O
Infections	O
in	O
Kilifi	O
,	O
Kenya	O
.	O

Recently	O
,	O
sacubitril	O
/	O
valsartan	O
-	O
an	O
angiotensin	B-PRGE
receptor	I-PRGE
blocker	O
-	O
neprilysin	B-PRGE
inhibitor	O
-	O
has	O
been	O
added	O
in	O
clinical	O
practice	O
as	O
a	O
standard	O
therapy	O
for	O
heart	O
failure	O
.	O

TITLE	O
:	O
Decoupling	O
deISGylating	O
and	O
deubiquitinating	O
activities	O
of	O
the	O
MERS	B-PRGE
virus	I-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
.	O

In	O
SPF	B-PRGE
chickens	I-PRGE
,	O
rIBYZ	O
-	O
ScAUG3a	O
had	O
a	O
lower	O
mortality	O
than	O
rIBYZ	O
.	O

Mortalin	B-PRGE
protein	I-PRGE
is	O
involved	O
in	O
a	O
variety	O
of	O
cellular	O
functions	O
and	O
plays	O
a	O
role	O
in	O
viral	O
infection	O
.	O

Finally	O
,	O
we	O
confirmed	O
that	O
this	O
host	O
-	O
mounted	O
antiviral	O
mechanism	O
was	O
broadly	O
applicable	O
to	O
other	O
viruses	O
,	O
such	O
as	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
),	O
rotavirus	O
(	O
RV	O
),	O
and	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
which	O
use	O
the	O
same	O
clathrin	B-PRGE
-	O
mediated	O
endocytic	O
to	O
entry	O
.	O

These	O
results	O
reveal	O
a	O
new	O
function	O
of	O
mortalin	B-PRGE
in	O
inhibiting	O
endocytosis	O
,	O
and	O
provide	O
a	O
novel	O
strategy	O
for	O
treating	O
PEDV	O
infections	O
.	O

A	O
reliable	O
serological	O
assay	O
for	O
evaluating	O
the	O
PEDV	O
-	O
specific	O
humoral	O
and	O
mucosal	O
immune	O
response	O
is	O
important	O
for	O
disease	O
survey	O
,	O
monitoring	O
the	O
efficacy	O
of	O
immunization	O
,	O
and	O
designing	O
strategies	O
for	O
the	O
prevention	O
and	O
control	O
of	O
PED	B-PRGE
.	O

Analyses	O
of	O
amino	O
acids	O
substitutions	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
sequences	O
identified	O
substitutions	O
specific	O
for	O
genotype	O
F	O
strains	O
circulating	O
among	O
European	O
people	O
.	O

Compared	O
with	O
controls	O
,	O
the	O
experimental	O
group	O
had	O
a	O
significantly	O
higher	O
proportion	O
of	O
antibiotics	O
discontinuation	O
or	O
de	O
-	O
escalation	O
in	O
the	O
ED	O
(	O
26	O
.	O
0	O
%	O
vs	O
16	O
.	O
1	O
%,	O
P	O
=	O
.	O
007	O
),	O
neuraminidase	B-PRGE
inhibitor	O
uses	O
(	O
8	O
.	O
9	O
%	O
vs	O
0	O
.	O
6	O
%,	O
P	O
<	O
.	O
001	O
),	O
and	O
shorter	O
duration	O
of	O
intravenous	O
antibiotics	O
(	O
10	O
.	O
0	O
vs	O
14	O
.	O
5	O
days	O
,	O
P	O
<	O
.	O
001	O
).	O

Infections	O
are	O
initiated	O
via	O
binding	O
of	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
to	O
sialosides	O
and	O
dipeptidyl	O
-	O
peptidase	O
4	O
(	O
the	O
attachment	O
and	O
entry	O
receptors	O
,	O
respectively	O
).	O

TITLE	O
:	O
Trypsin	B-PRGE
Treatment	O
Unlocks	O
Barrier	O
for	O
Zoonotic	O
Bat	O
Coronavirus	O
Infection	O
.	O

Using	O
receptor	B-PRGE
-	I-PRGE
blocking	I-PRGE
antibodies	I-PRGE
,	O
we	O
show	O
that	O
infection	O
with	O
the	O
PDF2180	O
spike	O
does	O
not	O
require	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
DPP4	I-PRGE
and	O
antibodies	O
developed	O
against	O
the	O
MERS	B-PRGE
spike	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
and	O
S2	O
portion	O
are	O
ineffective	O
in	O
neutralizing	O
the	O
PDF2180	O
chimera	O
.	O

The	O
chimeric	O
bivalent	O
5	O
+	O
3	O
vaccine	O
strain	O
comprises	O
a	O
recombinant	O
PR8	O
-	O
based	O
vaccine	O
,	O
expressing	O
the	O
PB1	B-PRGE
,	O
HA	O
,	O
and	O
chimeric	O
NA	O
of	O
pandemic	O
2009	O
H1N1	O
.	O

Known	O
coronaviruses	O
detected	O
included	O
the	O
betacorona	O
viruses	O
:	O
Kenya	O
bat	O
coronaviruses	O
,	O
Eidolon	O
bat	O
coronavirus	O
,	O
and	O
Bat	B-PRGE
coronavirus	I-PRGE
HKU9	I-PRGE
,	O
as	O
well	O
as	O
an	O
alphacoronavirus	O
,	O
Chaerephon	O
Bat	O
coronavirus	O
.	O

TITLE	O
:	O
Discovery	O
of	O
dihydroxyindole	O
-	O
2	O
-	O
carboxylic	O
acid	O
derivatives	O
as	O
dual	O
allosteric	O
HIV	B-PRGE
-	I-PRGE
1	I-PRGE
Integrase	I-PRGE
and	O
Reverse	B-PRGE
Transcriptase	I-PRGE
associated	O
Ribonuclease	B-PRGE
H	I-PRGE
inhibitors	O
.	O

Moreover	O
,	O
compound	O
5	O
also	O
inhibited	O
HIV	O
-	O
1	O
RNase	B-PRGE
H	I-PRGE
function	O
,	O
classifying	O
this	O
molecule	O
as	O
a	O
dual	O
HIV	O
-	O
1	O
IN	O
and	O
RNase	B-PRGE
H	I-PRGE
inhibitor	O
able	O
to	O
impair	O
the	O
HIV	O
-	O
1	O
virus	O
replication	O
in	O
cell	O
culture	O
.	O

Meanwhile	O
,	O
MAb	O
binds	O
to	O
cell	O
surface	O
IgG	B-PRGE
Fc	I-PRGE
receptor	I-PRGE
,	O
guiding	O
viral	O
entry	O
through	O
canonical	O
viral	B-PRGE
-	I-PRGE
receptor	I-PRGE
-	O
dependent	O
pathways	O
.	O

TITLE	O
:	O
Genetic	O
diversity	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
gene	I-PRGE
in	O
Saudi	O
Arabia	O
.	O

The	O
Spike	B-PRGE
protein	I-PRGE
gene	I-PRGE
plays	O
a	O
significant	O
role	O
in	O
virus	O
attachment	O
to	O
host	O
cells	O
.	O

In	O
this	O
study	O
samples	O
were	O
collected	O
from	O
both	O
human	O
and	O
camels	O
and	O
the	O
Spike	B-PRGE
protein	I-PRGE
gene	I-PRGE
was	O
amplified	O
and	O
sequenced	O
.	O

The	O
IL	O
-	O
12	O
:	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
ratio	O
,	O
a	O
marker	O
of	O
the	O
immune	O
system	O
'	O
s	O
inflammatory	O
balance	O
,	O
was	O
skewed	O
towards	O
the	O
pro	O
-	O
inflammatory	O
IL	O
-	O
12	O
in	O
the	O
liver	O
of	O
cats	O
with	O
FIP	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
belongs	O
to	O
the	O
beta	B-PRGE
coronavirus	I-PRGE
subfamily	I-PRGE
and	O
causes	O
severe	O
morbidity	O
and	O
mortality	O
in	O
humans	O
especially	O
when	O
infected	O
patients	O
have	O
underlying	O
diseases	O
such	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
).	O

All	O
synthesized	O
compounds	O
exhibited	O
potent	O
inhibitory	O
activity	O
towards	O
SAH	B-PRGE
hydrolase	I-PRGE
,	O
among	O
which	O
6	O
'-	O
Î²	O
-	O
fluoroadenosine	O
analogue	O
3a	O
was	O
the	O
most	O
potent	O
(	O
IC	O

Moreover	O
,	O
an	O
engineered	O
virus	O
containing	O
U655	O
>	O
G	O
and	O
a	O
6	O
nt	O
insertion	O
at	O
position	O
1124	O
(	O
Y374	O
-	O
T375insND	O
in	O
S	B-PRGE
protein	I-PRGE
)	O
was	O
genetically	O
stable	O
after	O
passage	O
in	O
cell	O
cultures	O
,	O
and	O
increased	O
virus	O
titers	O
in	O
gut	O
by	O
1000	O
-	O
fold	O
.	O

The	O
interaction	O
between	O
MALAT1	B-PRGE
and	O
miR	B-PRGE
-	I-PRGE
425	I-PRGE
was	O
predicted	O
using	O
a	O
bioinformatics	O
tool	O
and	O
verified	O
by	O
dual	O
luciferase	O
assay	O
.	O

As	O
few	O
as	O
five	O
copies	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
can	O
be	O
detected	O
within	O
20	O
min	O
using	O
the	O
WHO	O
standard	O
assays	O
with	O
similar	O
sensitivity	O
and	O
specificity	O
to	O
those	O
of	O
a	O
conventional	O
real	O
-	O
time	O
PCR	O
instrument	O
such	O
as	O
the	O
LightCyler	O
,	O
enabling	O
timely	O
intervention	O
to	O
control	O
MERS	O
-	O
CoV	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	B-PRGE
spike	I-PRGE
envelope	I-PRGE
glycoprotein	I-PRGE
is	O
an	O
essential	O
viral	O
component	O
that	O
mediates	O
virus	O
entry	O
events	O
.	O

TITLE	O
:	O
Crystallization	O
and	O
Structural	O
Determination	O
of	O
the	O
Receptor	B-PRGE
-	I-PRGE
Binding	I-PRGE
Domain	I-PRGE
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
Spike	I-PRGE
Glycoprotein	I-PRGE
.	O

ABSTRACT	O
:	O
Three	O
-	O
dimensional	O
structures	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
bound	O
to	O
cellular	B-PRGE
receptor	I-PRGE
and	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
have	O
been	O
determined	O
by	O
X	O
-	O
ray	O
crystallography	O
,	O
providing	O
structural	O
information	O
about	O
receptor	O
recognition	O
and	O
neutralizing	O
mechanisms	O
of	O
mAbs	O
at	O
the	O
atomic	O
level	O
.	O

Here	O
,	O
we	O
describe	O
protocols	O
of	O
deducing	O
the	O
crystal	O
structure	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
helicase	B-PRGE
in	O
detail	O
,	O
which	O
include	O
protein	O
expression	O
,	O
purification	O
,	O
crystallization	O
,	O
enzymatic	O
characterization	O
,	O
and	O
structure	O
determination	O
.	O

In	O
the	O
present	O
method	O
,	O
a	O
step	O
-	O
by	O
-	O
step	O
guide	O
to	O
perform	O
a	O
MERS	O
-	O
CoV	O
nucleocapsid	B-PRGE
protein	I-PRGE
(	O
NP	O
)	O
capture	O
ELISA	O
using	O
two	O
NP	B-PRGE
-	I-PRGE
specific	I-PRGE
monoclonal	I-PRGE
antibodies	I-PRGE
is	O
provided	O
for	O
readers	O
to	O
develop	O
their	O
in	O
-	O
house	O
workflow	O
or	O
diagnostic	O
kit	O
for	O
clinical	O
use	O
and	O
for	O
mass	O
-	O
screening	O
project	O
of	O
animals	O
(	O
e	O
.	O
g	O
.,	O
dromedaries	O
and	O
bats	O
)	O
to	O
better	O
understand	O
the	O
spread	O
and	O
evolution	O
of	O
the	O
virus	O
.	O

Identification	O
of	O
human	B-PRGE
dipeptidyl	I-PRGE
peptidase	I-PRGE
IV	I-PRGE
(	O
hDPP4	O
)	O
as	O
the	O
receptor	O
for	O
MERS	O
-	O
CoV	O
infection	O
opened	O
the	O
door	O
for	O
genetic	O
engineering	O
of	O
mice	O
.	O

It	O
has	O
two	O
serotypes	O
(	O
type	B-PRGE
I	I-PRGE
FCoV	I-PRGE
and	I-PRGE
type	I-PRGE
II	I-PRGE
FCoV	I-PRGE
).	O

ABSTRACT	O
:	O
TER94	B-PRGE
is	O
a	O
multifunctional	O
AAA	B-PRGE
+	I-PRGE
ATPase	I-PRGE
crucial	O
for	O
diverse	O
cellular	O
processes	O
,	O
especially	O
protein	O
quality	O
control	O
and	O
chromatin	O
dynamics	O
in	O
eukaryotic	O
organisms	O
.	O

TITLE	O
:	O
Treatment	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
with	O
a	O
combination	O
of	O
lopinavir	O
/	O
ritonavir	O
and	O
interferon	B-PRGE
-	I-PRGE
Î²1b	I-PRGE
(	O
MIRACLE	O
trial	O
):	O
statistical	O
analysis	O
plan	O
for	O
a	O
recursive	O
two	O
-	O
stage	O
group	O
sequential	O
randomized	O
controlled	O
trial	O
.	O

We	O
examined	O
the	O
pathogenic	O
effects	O
of	O
the	O
viruses	O
in	O
chicken	O
embryos	O
and	O
the	O
size	O
and	O
morphology	O
of	O
the	O
virus	O
particles	O
,	O
performed	O
phylogenetic	O
analysis	O
based	O
on	O
the	O
S1	B-PRGE
gene	I-PRGE
and	O
complete	O
genomic	O
sequences	O
,	O
and	O
examined	O
the	O
antibody	O
responses	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

Subsequently	O
,	O
we	O
found	O
that	O
one	O
of	O
the	O
non	O
-	O
structural	O
proteins	O
encoded	O
by	O
the	O
FIPV	O
genome	O
,	O
nsp5	O
,	O
interrupted	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
signaling	O
in	O
a	O
protease	O
-	O
dependent	O
manner	O
by	O
cleaving	O
the	O
nuclear	B-PRGE
factor	I-PRGE
ÎºB	I-PRGE
(	O
NF	O
-	O
ÎºB	O
)	O
essential	O
modulator	O
(	O
NEMO	O
)	O
at	O
three	O
sites	O
-	O
glutamine132	O
(	O
Q132	O
),	O
Q205	O
,	O
and	O
Q231	O
.	O

Some	O
enzymatic	O
activities	O
are	O
generally	O
associated	O
with	O
RNA	O
viruses	O
such	O
as	O
RNA	O
-	O
or	O
DNA	O
-	O
dependent	O
RNA	B-PRGE
polymerases	I-PRGE
,	O
RNA	B-PRGE
helicases	I-PRGE
or	O
proteases	O
.	O

TITLE	O
:	O
Comparative	O
therapeutic	O
efficacy	O
of	O
remdesivir	O
and	O
combination	O
lopinavir	O
,	O
ritonavir	O
,	O
and	O
interferon	B-PRGE
beta	I-PRGE
against	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
the	O
causative	O
agent	O
of	O
a	O
severe	O
respiratory	O
disease	O
associated	O
with	O
more	O
than	O
2468	O
human	O
infections	O
and	O
over	O
851	O
deaths	O
in	O
27	O
countries	O
since	O
2012	O
.	O

There	O
are	O
no	O
approved	O
treatments	O
for	O
MERS	O
-	O
CoV	O
infection	O
although	O
a	O
combination	O
of	O
lopinavir	O
,	O
ritonavir	O
and	O
interferon	B-PRGE
beta	I-PRGE
(	O
LPV	O
/	O
RTV	B-PRGE
-	O
IFNb	B-PRGE
)	O
is	O
currently	O
being	O
evaluated	O
in	O
humans	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O

Here	O
,	O
we	O
show	O
that	O
remdesivir	O
(	O
RDV	O
)	O
and	O
IFNb	B-PRGE
have	O
superior	O
antiviral	O
activity	O
to	O
LPV	O
and	O
RTV	O
in	O
vitro	O
.	O

This	O
study	O
investigated	O
the	O
prevalence	O
of	O
bovine	O
coronavirus	O
(	O
BCoV	O
),	O
bovine	O
norovirus	O
(	O
BNoV	O
),	O
bovine	B-PRGE
group	I-PRGE
A	I-PRGE
rotavirus	I-PRGE
(	I-PRGE
BoRVA	I-PRGE
),	I-PRGE
and	O
bovine	O
torovirus	O
(	O
BToV	O
)	O
in	O
calves	O
aged	O
â¤	O
60	O
days	O
,	O
regardless	O
of	O
diarrhea	O
,	O
across	O
nine	O
different	O
regions	O
in	O
the	O
Republic	O
of	O
Korea	O
(	O
ROK	O
)	O
and	O
reported	O
associations	O
between	O
these	O
viruses	O
and	O
diarrhea	O
.	O

Interestingly	O
,	O
the	O
HEV	B-PRGE
5	I-PRGE
'-	I-PRGE
UTR	I-PRGE
conferred	O
sensitivity	O
towards	O
Silvestrol	O
but	O
not	O
to	O
CR	O
-	O
31	O
-	O
B	O
(-).	O

Moreover	O
,	O
thermodynamic	O
destabilization	O
of	O
the	O
HEV	B-PRGE
5	I-PRGE
'-	I-PRGE
UTR	I-PRGE
led	O
to	O
reduced	O
translational	O
inhibition	O
by	O
Silvestrol	O
,	O
suggesting	O
differences	O
between	O
rocaglates	O
in	O
their	O
mode	O
of	O
action	O
,	O
most	O
probably	O
by	O
engaging	O
Silvestrol	O
'	O
s	O
additional	O
dioxane	O
moiety	O
.	O

TITLE	O
:	O
Isolation	O
and	O
Identification	O
of	O
Porcine	O
Deltacoronavirus	O
and	O
Alteration	O
of	O
Immunoglobulin	B-PRGE
Transport	I-PRGE
Receptors	I-PRGE
in	O
the	O
Intestinal	O
Mucosa	O
of	O
PDCoV	O
-	O
Infected	O
Piglets	O
.	O

The	O
neonatal	O
Fc	B-PRGE
receptor	I-PRGE
(	O
FcRn	B-PRGE
)	O
and	O
polymeric	O
immunoglobulin	B-PRGE
receptor	O
(	O
pIgR	B-PRGE
)	O
are	O
crucial	B-PRGE
immunoglobulin	I-PRGE
(	O
Ig	O
)	O
receptors	O
for	O
the	O
transcytosis	O
ofimmunoglobulin	O
G	O
(	O
IgG	B-PRGE
),	O
IgA	B-PRGE
,	O
or	O
IgM	B-PRGE
.	O
Importantly	O
,	O
CHN	O
-	O
JS	O
-	O
2017	O
infected	O
five	O
-	O
day	O
-	O
old	O
piglets	O
could	O
significantly	O
down	O
-	O
regulate	O
the	O
expression	O
of	O
FcRn	B-PRGE
,	O
pIgR	B-PRGE
,	O
and	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
kappa	I-PRGE
B	I-PRGE
(	O
NF	O
-	O
ÎºB	O
)	O
in	O
the	O
intestinal	O
mucosa	O
.	O

Viral	B-PRGE
antigen	I-PRGE
and	O
high	O
levels	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
were	O
detected	O
in	O
the	O
aerosol	O
and	O
instillation	O
groups	O
.	O

3D	O
structural	O
analysis	O
revealed	O
that	O
amino	O
acids	O
of	O
EP	O
-	O
4E88	O
were	O
in	O
close	O
proximity	O
and	O
may	O
be	O
exposed	O
on	O
the	O
surface	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
.	O

Here	O
,	O
we	O
asked	O
whether	O
naturally	O
-	O
occurring	O
polymorphisms	O
in	O
DPP4	B-PRGE
,	O
that	O
alter	O
amino	O
acid	O
residues	O
required	O
for	O
MERS	O
-	O
CoV	O
S	O
binding	O
,	O
influence	O
cellular	O
entry	O
of	O
MERS	O
-	O
CoV	O
.	O
By	O
screening	O
of	O
public	O
databases	O
,	O
we	O
identified	O
fourteen	O
such	O
polymorphisms	O
.	O

The	O
number	O
and	O
presence	O
of	O
circulating	O
EPC	B-PRGE
and	O
MSC	B-PRGE
was	O
detected	O
by	O
flow	O
cytometry	O
.	O

Furthermore	O
,	O
its	O
new	O
orf8	B-PRGE
likely	O
encodes	O
a	O
secreted	O
protein	O
with	O
an	O
alpha	O
-	O
helix	O
,	O
following	O
with	O
a	O
beta	O
-	O
sheet	O
(	O
s	O
)	O
containing	O
six	O
strands	O
.	O

This	O
paper	O
seeks	O
to	O
highlight	O
the	O
implications	O
and	O
importance	O
of	O
a	O
One	O
Health	O
-	O
based	O
approach	O
into	O
the	O
infectious	O
diseases	O
control	O
program	O
implementation	O
in	O
DRC	B-PRGE
.	O

Last	O
,	O
while	O
phylogenetic	O
analysis	O
indicates	O
a	O
bat	O
origin	O
of	O
2019	O
-	O
nCoV	O
,	O
2019	O
-	O
nCoV	O
also	O
potentially	O
recognizes	O
ACE2	B-PRGE
from	O
a	O
diversity	O
of	O
animal	O
species	O
(	O
except	O
mice	O
and	O
rats	O
),	O
implicating	O
these	O
animal	O
species	O
as	O
possible	O
intermediate	O
hosts	O
or	O
animal	O
models	O
for	O
2019	O
-	O
nCoV	O
infections	O
.	O

The	O
virus	O
is	O
phylogenetically	O
closest	O
to	O
a	O
bat	B-PRGE
SARS	I-PRGE
-	I-PRGE
like	I-PRGE
CoV	I-PRGE
(	O
SL	O
-	O
ZC45	O
,	O
GenBank	O
MG772933	O
)	O
with	O
87	O
.	O
6	O
%	O
to	O
87	O
.	O
7	O
%	O
nucleotide	O
identity	O
,	O
but	O
is	O
in	O
a	O
separate	O
clade	O
.	O

However	O
,	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
tentative	O
receptor	O
-	O
binding	O
domain	O
resembles	O
that	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
indicating	O
that	O
these	O
viruses	O
might	O
use	O
the	O
same	O
receptor	O
.	O

Phylogenetic	O
analysis	O
revealed	O
that	O
2019	O
-	O
nCoV	O
fell	O
within	O
the	O
subgenus	O
Sarbecovirus	O
of	O
the	O
genus	O
Betacoronavirus	O
,	O
with	O
a	O
relatively	O
long	O
branch	O
length	O
to	O
its	O
closest	O
relatives	O
bat	O
-	O
SL	O
-	O
CoVZC45	O
and	O
bat	O
-	O
SL	O
-	O
CoVZXC21	O
,	O
and	O
was	O
genetically	O
distinct	O
from	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Notably	O
,	O
homology	O
modelling	O
revealed	O
that	O
2019	O
-	O
nCoV	O
had	O
a	O
similar	O
receptor	O
-	O
binding	O
domain	O
structure	O
to	O
that	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
despite	O
amino	O
acid	O
variation	O
at	O
some	O
key	O
residues	O
.	O

The	O
identified	O
camel	B-PRGE
IFN	I-PRGE
-	I-PRGE
Î±	I-PRGE
protein	I-PRGE
and	O
the	O
subtypes	O
will	O
facilitate	O
a	O
better	O
understanding	O
of	O
the	O
host	O
immune	O
response	O
to	O
viral	O
infections	O
in	O
camel	O
and	O
the	O
development	O
of	O
potential	O
antiviral	O
biologicals	O
for	O
zoonotic	O
diseases	O
for	O
which	O
camel	O
act	O
as	O
a	O
reservoir	O
.	O

We	O
observed	O
that	O
TGEVs	O
could	O
be	O
internalized	O
through	O
clathrin	B-PRGE
-	O
and	O
caveolae	O
-	O
mediated	O
endocytosis	O
,	O
and	O
the	O
internalization	O
of	O
TGEVs	O
was	O
almost	O
completed	O
within	O
~	O
2	O
minutes	O
after	O
TGEVs	O
attached	O
to	O
the	O
cell	O
membrane	O
.	O

Furthermore	O
,	O
the	O
interactions	O
of	O
TGEVs	O
with	O
actin	B-PRGE
and	O
dynamin	B-PRGE
2	I-PRGE
in	O
real	O
time	O
during	O
the	O
TGEV	O
internalization	O
were	O
visualized	O
.	O

Also	O
,	O
interactions	O
between	O
identified	O
CTL	O
epitopes	O
and	O
their	O
corresponding	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
(	O
MHC	B-PRGE
)	O
class	O
I	O
supertype	O
representatives	O
prevalent	O
in	O
China	O
were	O
studied	O
by	O
molecular	O
dynamics	O
simulations	O
.	O

Other	O
key	O
drug	O
targets	O
,	O
including	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
and	I-PRGE
coronavirus	I-PRGE
main	I-PRGE
proteinase	I-PRGE
(	O
3CLpro	O
),	O
share	O
a	O
strikingly	O
high	O
(>	O
95	O
%)	O
homology	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Herein	O
,	O
we	O
suggest	O
four	O
potential	O
drug	O
candidates	O
(	O
an	O
ACE2	O
-	O
based	O
peptide	O
,	O
remdesivir	O
,	O
3CLpro	O
-	O
1	O
and	O
a	O
novel	O
vinylsulfone	B-PRGE
protease	I-PRGE
inhibitor	O
)	O
that	O
could	O
be	O
used	O
to	O
treat	O
patients	O
suffering	O
with	O
the	O
2019	O
-	O
nCoV	O
.	O
We	O
also	O
summarize	O
previous	O
efforts	O
into	O
drugging	O
these	O
targets	O
and	O
hope	O
to	O
help	O
in	O
the	O
development	O
of	O
broad	O
-	O
spectrum	O
anti	O
-	O
coronaviral	O
agents	O
for	O
future	O
epidemics	O
.	O

ABSTRACT	O
:	O
Currently	O
,	O
the	O
emergence	O
of	O
a	O
novel	O
human	O
coronavirus	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
has	O
become	O
a	O
global	O
health	O
concern	O
causing	O
severe	O
respiratory	O
tract	O
infections	O
in	O
humans	O
.	O

In	O
murine	O
lung	O
vascular	O
endothelial	O
cells	O
(	O
MLECs	O
)	O
we	O
further	O
confirmed	O
that	O
RUS	O
(	O
1	O
Î¼mol	O
/	O
L	O
)	O
markedly	O
ameliorated	O
MLECs	O
apoptosis	O
by	O
suppressing	O
TLR4	B-PRGE
signaling	O
.	O

By	O
using	O
TLR4	O
knockout	O
mice	O
we	O
found	O
that	O
TLR4	B-PRGE
was	O
essential	O
for	O
the	O
RUS	O
-	O
mediated	O
eï¬	O
;	O
ect	O
on	O
LPS	O
-	O
stimulated	O
pulmonary	O
endothelial	O
apoptosis	O
.	O

Griffithsin	O
(	O
GRFT	O
)	O
is	O
high	B-PRGE
-	I-PRGE
mannose	I-PRGE
oligosaccharide	I-PRGE
binding	I-PRGE
lectin	I-PRGE
that	O
has	O
shown	O
in	O
vivo	O
broad	O
-	O
spectrum	O
activity	O
against	O
viruses	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
human	O
immunodeficiency	O
virus	O
1	O
,	O
hepatitis	O
C	O
virus	O
,	O
and	O
Japanese	O
encephalitis	O
virus	O
.	O

The	O
3mG	O
had	O
comparatively	O
greater	O
potency	O
than	O
GRFT	O
against	O
NiV	O
due	O
to	O
its	O
enhanced	O
ability	O
to	O
block	O
NiV	B-PRGE
glycoprotein	I-PRGE
-	O
induced	O
syncytia	O
formation	O
.	O

EIC	B-PRGE
-	O
defective	O
mutants	O
also	O
formed	O
smaller	O
plaques	O
,	O
released	O
significantly	O
less	O
infectious	O
virions	O
into	O
the	O
culture	O
supernatant	O
,	O
and	O
had	O
lower	O
levels	O
of	O
viral	O
fitness	O
in	O
cell	O
culture	O
.	O

We	O
utilized	O
TGEV	O
as	O
a	O
model	O
pathogen	O
to	O
explore	O
the	O
role	O
of	O
FcRn	B-PRGE
in	O
resisting	O
viral	O
invasion	O
in	O
overall	O
intestinal	O
mucosal	O
immunity	O
.	O

TGEV	O
induced	O
FcRn	B-PRGE
expression	O
by	O
activating	O
NF	O
-	O
ÎºB	O
signaling	O
in	O
porcine	O
small	O
intestinal	O
epithelial	O
(	O
IPEC	O
-	O
J2	O
)	O
cells	O
,	O
however	O
,	O
the	O
underlying	O
mechanisms	O
are	O
unclear	O
.	O

Additionally	O
,	O
N	B-PRGE
protein	I-PRGE
-	O
mediated	O
FcRn	O
up	O
-	O
regulation	O
promotes	O
IgG	B-PRGE
transcytosis	O
.	O

Several	O
adjunctive	O
pharmacologic	O
interventions	O
have	O
been	O
studied	O
for	O
their	O
immunomodulatory	O
effects	O
,	O
including	O
macrolides	O
,	O
corticosteroids	O
,	O
cyclooxygenase	B-PRGE
-	I-PRGE
2	I-PRGE
inhibitors	O
,	O
sirolimus	O
,	O
statins	O
,	O
anti	O
-	O
influenza	O
immune	O
plasma	O
,	O
and	O
vitamin	O
C	O
,	O
but	O
none	O
is	O
recommended	O
at	O
present	O
in	O
severe	O
RVIs	O
.	O

The	O
most	O
common	O
laboratory	O
abnormalities	O
were	O
hypoalbuminemia	O
,	O
lymphopenia	O
,	O
decreased	O
percentage	O
of	O
lymphocytes	O
(	O
LYM	O
)	O
and	O
neutrophils	O
(	O
NEU	O
),	O
elevated	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
)	O
and	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
LDH	B-PRGE
),	O
and	O
decreased	O
CD8	B-PRGE
count	O
.	O

All	O
patients	O
received	O
positive	O
pressure	O
mechanical	O
ventilation	O
within	O
24	O
h	O
after	O
trauma	O
because	O
of	O
ARF	B-PRGE
.	O

TITLE	O
:	O
Development	O
of	O
an	O
indirect	O
ELISA	O
for	O
detecting	O
porcine	B-PRGE
deltacoronavirus	I-PRGE
IgA	I-PRGE
antibodies	I-PRGE
.	O

Here	O
,	O
an	O
indirect	O
anti	B-PRGE
-	I-PRGE
PDCoV	I-PRGE
IgA	I-PRGE
antibody	I-PRGE
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
PDCoV	B-PRGE
S1	I-PRGE
IgA	I-PRGE
ELISA	I-PRGE
)	O
using	O
the	O
purified	O
S1	O
portion	O
of	O
S	B-PRGE
protein	I-PRGE
as	O
the	O
coating	B-PRGE
antigen	I-PRGE
was	O
developed	O
to	O
detect	O
PDCoV	B-PRGE
IgA	I-PRGE
antibodies	I-PRGE
in	O
serum	O
and	O
sow	O
'	O
s	O
milk	O
.	O

Compared	O
to	O
rH120	O
vaccination	O
group	O
,	O
when	O
the	O
efficacy	O
of	O
this	O
strain	O
was	O
evaluated	O
against	O
the	O
QX	B-PRGE
-	I-PRGE
like	I-PRGE
IBV	I-PRGE
strain	O
,	O
better	O
protection	O
,	O
with	O
100	O
%	O
survival	O
rate	O
and	O
no	O
disease	O
symptom	O
or	O
gross	O
lesion	O
was	O
observed	O
in	O
the	O
chickens	O
vaccinated	O
with	O
rH120	O
-	O
S1	O
/	O
YZ	O
.	O

TITLE	O
:	O
[	O
Inhibitors	O
of	O
RAS	B-PRGE
Might	I-PRGE
Be	I-PRGE
a	O
Good	O
Choice	O
for	O
the	O
Therapy	O
of	O
COVID	O
-	O
19	O
Pneumonia	O
].	O

Patients	O
were	O
randomized	O
to	O
receive	O
an	O
intravenous	O
injection	O
of	O
10	O
Î¼g	O
of	O
IFN	B-PRGE
-	I-PRGE
Î²	I-PRGE
-	I-PRGE
1a	I-PRGE
(	O
144	O
patients	O
)	O
or	O
placebo	O
(	O
152	O
patients	O
)	O
once	O
daily	O
for	O
6	O
days	O
.	O

Thus	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
possible	O
involvement	O
of	O
RIPK3	B-PRGE
in	O
ARDS	O
-	O
associated	O
necroptosis	O
.	O

Here	O
we	O
analyzed	O
the	O
clinical	O
features	O
,	O
susceptible	O
population	O
,	O
potential	O
causes	O
and	O
therapeutic	O
strategies	O
of	O
NCP	B-PRGE
related	O
liver	O
injury	O
.	O

Structural	O
analysis	O
suggests	O
that	O
ACE2	B-PRGE
from	O
these	O
animals	O
can	O
potentially	O
bind	O
RBD	O
of	O
2019	O
-	O
nCoV	O
,	O
making	O
them	O
all	O
possible	O
natural	O
hosts	O
for	O
the	O
virus	O
.	O

During	O
the	O
formation	O
of	O
the	O
coronaviral	O
replication	O
/	O
transcription	O
complex	O
,	O
essential	O
steps	O
include	O
processing	O
of	O
the	O
conserved	O
polyprotein	O
nsp7	O
-	O
10	O
region	O
by	O
the	O
main	B-PRGE
protease	I-PRGE
Mpro	O
and	O
subsequent	O
complex	O
formation	O
of	O
the	O
released	O
nsp	O
'	O
s	O
.	O

Here	O
,	O
we	O
systematically	O
investigated	O
the	O
role	O
of	O
trypsin	B-PRGE
in	O
PDCoV	O
replication	O
including	O
cell	O
entry	O
,	O
cell	O
-	O
to	O
-	O
cell	O
membrane	O
fusion	O
and	O
virus	O
release	O
.	O

Using	O
pseudovirus	O
entry	O
assays	O
,	O
we	O
demonstrated	O
that	O
PDCoV	O
entry	O
is	O
not	O
trypsin	B-PRGE
dependent	O
.	O

Most	O
importantly	O
,	O
our	O
study	O
illustrates	O
two	O
distinct	O
spreading	O
patterns	O
from	O
infected	O
cells	O
to	O
uninfected	O
cells	O
during	O
PDCoV	O
transmission	O
,	O
and	O
the	O
role	O
of	O
trypsin	B-PRGE
in	O
PDCoV	O
replication	O
in	O
cells	O
with	O
different	O
virus	O
spreading	O
types	O
.	O

Correlation	O
analysis	O
showed	O
that	O
the	O
PII	O
value	O
was	O
significantly	O
correlated	O
with	O
the	O
values	O
of	O
lymphocyte	O
count	O
,	O
monocyte	O
count	O
,	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
,	O
procalcitonin	O
,	O
days	O
from	O
illness	O
onset	O
and	O
body	O
temperature	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
COVID	O
-	O
19	O
is	O
a	O
viral	O
respiratory	O
illness	O
caused	O
by	O
a	O
new	O
coronavirus	O
called	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

A	O
novel	O
coronavirus	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
was	O
identified	O
to	O
be	O
accountable	O
for	O
this	O
disease	O
.	O

Pretreatment	O
of	O
HNE	O
cells	O
with	O
glycopyrronium	O
or	O
formoterol	O
reduced	O
the	O
susceptibility	O
to	O
infection	O
,	O
and	O
pretreatment	O
with	O
the	O
three	O
drugs	O
inhibited	O
activation	O
of	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
kappa	I-PRGE
B	I-PRGE
p50	B-PRGE
and	O
p65	B-PRGE
proteins	I-PRGE
.	O

RDV	O
is	O
a	O
nucleotide	O
analog	O
inhibitor	O
of	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerases	I-PRGE
(	O
RdRps	O
).	O

RNA	O
-	O
seq	O
profiling	O
data	O
of	O
13	O
organ	O
types	O
with	O
para	O
-	O
carcinoma	O
normal	O
tissues	O
from	O
TCGA	O
and	O
14	O
organ	O
types	O
with	O
normal	O
tissues	O
from	O
FANTOM5	O
CAGE	O
were	O
analyzed	O
in	O
order	O
to	O
explore	O
and	O
validate	O
the	O
expression	O
of	O
ACE2	B-PRGE
on	O
the	O
mucosa	O
of	O
oral	O
cavity	O
.	O

TITLE	O
:	O
Early	O
phylogenetic	O
estimate	O
of	O
the	O
effective	O
reproduction	O
number	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

Western	O
blot	O
assay	O
and	O
immunofluorescence	O
staining	O
showed	O
that	O
the	O
expressions	O
of	O
synaptic	B-PRGE
-	I-PRGE
related	I-PRGE
proteins	I-PRGE
(	O
PSD	B-PRGE
-	I-PRGE
95	I-PRGE
and	O
SYP	B-PRGE
)	O
were	O
increased	O
,	O
and	O
these	O
findings	O
were	O
in	O
accordance	O
with	O
the	O
results	O
mentioned	O
above	O
.	O

TITLE	O
:	O
Systematic	O
Comparison	O
of	O
Two	O
Animal	O
-	O
to	O
-	O
Human	O
Transmitted	O
Human	O
Coronaviruses	O
:	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
ABSTRACT	O
:	O
After	O
the	O
outbreak	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
the	O
world	O
in	O
2003	O
,	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
have	O
been	O
reported	O
as	O
pathogens	O
that	O
cause	O
severe	O
symptoms	O
in	O
respiratory	O
tract	O
infections	O
.	O

SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
is	O
spreading	O
among	O
the	O
public	O
and	O
causing	O
substantial	O
burden	O
due	O
to	O
its	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
systematic	O
comparison	O
and	O
analysis	O
to	O
predict	O
the	O
interaction	O
between	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
coronavirus	O
spike	O
protein	O
and	O
the	O
host	O
receptor	O
,	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
).	O

The	O
interaction	O
between	O
the	O
key	O
amino	O
acids	O
of	O
S	B-PRGE
protein	I-PRGE
RBD	O
and	O
ACE2	B-PRGE
indicated	O
that	O
,	O
other	O
than	O
pangolins	O
and	O
snakes	O
,	O
as	O
previously	O
suggested	O
,	O
turtles	O
(	O
Chrysemys	O
picta	O
bellii	O
,	O
Chelonia	O
mydas	O
,	O
and	O
Pelodiscus	O
sinensis	O
)	O
may	O
act	O
as	O
the	O
potential	O
intermediate	O
hosts	O
transmitting	O
SARS	O
-	O
CoV	O
-	O
2	O
to	O
humans	O
.	O

Based	O
on	O
Bayesian	O
time	O
-	O
scaled	O
phylogenetic	O
analysis	O
using	O
the	O
tip	O
-	O
dating	O
method	O
,	O
we	O
estimated	O
the	O
time	O
to	O
the	O
most	O
recent	O
common	O
ancestor	O
and	O
evolutionary	O
rate	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
which	O
ranged	O
from	O
22	O
to	O
24	O
November	O
2019	O
and	O
1	O
.	O
19	O
to	O
1	O
.	O
31	O
Ã	O
10	O

The	O
IgM	B-PRGE
-	O
IgG	B-PRGE
combined	O
assay	O
has	O
better	O
utility	O
and	O
sensitivity	O
compared	O
with	O
a	O
single	O
IgM	B-PRGE
or	O
IgG	B-PRGE
test	O
.	O

For	O
the	O
T	O
cell	O
epitopes	O
,	O
we	O
performed	O
a	O
population	O
coverage	O
analysis	O
of	O
the	O
associated	B-PRGE
MHC	I-PRGE
alleles	I-PRGE
and	O
proposed	O
a	O
set	O
of	O
epitopes	O
that	O
is	O
estimated	O
to	O
provide	O
broad	O
coverage	O
globally	O
,	O
as	O
well	O
as	O
in	O
China	O
.	O

Our	O
findings	O
provide	O
a	O
screened	O
set	O
of	O
epitopes	O
that	O
can	O
help	O
guide	O
experimental	O
efforts	O
towards	O
the	O
development	O
of	O
vaccines	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

The	O
tool	O
has	O
been	O
tested	O
and	O
validated	O
with	O
hundreds	O
of	O
whole	O
genomes	O
from	O
ten	O
coronavirus	O
species	O
,	O
and	O
correctly	O
classified	O
all	O
of	O
the	O
SARS	O
-	O
related	O
coronavirus	O
(	O
SARSr	O
-	O
CoV	O
)	O
and	O
all	O
of	O
the	O
available	O
public	O
data	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

Fever	O
,	O
cough	O
and	O
expectoration	O
were	O
the	O
most	O
common	O
symptoms	O
,	O
14	O
patients	O
had	O
decreased	O
oxygen	O
saturation	O
,	O
33	O
had	O
leukopenia	O
,	O
53	O
had	O
lymphopenia	O
,	O
and	O
82	O
had	O
elevated	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
.	O

Considered	O
a	O
relative	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
),	O
COVID	O
-	O
19	O
is	O
caused	O
by	O
a	O
betacoronavirus	O
named	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
that	O
affects	O
the	O
lower	O
respiratory	O
tract	O
and	O
manifests	O
as	O
pneumonia	O
in	O
humans	O
.	O

Fibrinogen	B-PRGE
levels	O
,	O
fibrin	O
polymerization	O
,	O
platelet	O
activation	O
,	O
and	O
microparticle	O
release	O
were	O
increased	O
in	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
compared	O
to	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	O
patients	O
.	O

TITLE	O
:	O
Epidemiologic	O
Features	O
and	O
Clinical	O
Course	O
of	O
Patients	O
Infected	O
With	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
in	O
Singapore	O
.	O

In	O
the	O
absence	O
of	O
a	O
proven	O
clinical	O
FcR	O
blocker	O
,	O
the	O
use	O
of	O
intravenous	O
immunoglobulin	B-PRGE
to	O
block	O
FcR	O
activation	O
may	O
be	O
a	O
viable	O
option	O
for	O
the	O
urgent	O
treatment	O
of	O
pulmonary	O
inflammation	O
to	O
prevent	O
severe	O
lung	O
injury	O
.	O

Only	O
patients	O
who	O
met	O
all	O
of	O
the	O
following	O
criteria	O
were	O
included	O
in	O
this	O
analysis	O
:	O
sustained	O
blunt	O
injuries	O
,	O
presented	O
with	O
severe	O
traumatic	O
brain	O
injury	O
,	O
sustained	O
an	O
associated	O
SDH	B-PRGE
,	O
presented	O
with	O
an	O
initial	O
Glasgow	O
Coma	O
Scale	O
(	O
GCS	O
)	O
score	O
â¤	O
8	O
and	O
an	O
Abbreviated	O
Injury	O
Scale	O
score	O
of	O
head	O
â¥	O
3	O
,	O
and	O
underwent	O
a	O
CO	O
or	O
DC	O
within	O
4	O
hours	O
of	O
hospital	O
arrival	O
.	O

TITLE	O
:	O
Differential	O
diagnosis	O
of	O
illness	O
in	O
patients	O
under	O
investigation	O
for	O
the	O
novel	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
),	O
Italy	O
,	O
February	O
2020	O
.	O

Developing	O
vaccines	O
against	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
virus	O
may	O
take	O
many	O
months	O
.	O

A	O
tentative	O
suggestion	O
based	O
on	O
existing	O
therapeutics	O
,	O
which	O
would	O
likely	O
be	O
resistant	O
to	O
new	O
coronavirus	O
mutations	O
,	O
is	O
to	O
use	O
available	O
angiotensin	B-PRGE
receptor	I-PRGE
1	I-PRGE
(	O
AT1R	B-PRGE
)	O
blockers	O
,	O
such	O
as	O
losartan	O
,	O
as	O
therapeutics	O
for	O
reducing	O
the	O
aggressiveness	O
and	O
mortality	O
from	O
SARS	O
-	O
CoV	O
-	O
2	O
virus	O
infections	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
infection	O
control	O
preparedness	O
for	O
Coronavirus	O
Disease	O
(	O
COVID	O
-	O
19	O
)	O
due	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
[	O
previously	O
known	O
as	O
2019	O
-	O
novel	O
coronavirus	O
]	O
in	O
the	O
first	O
42	O
days	O
after	O
announcement	O
of	O
a	O
cluster	O
of	O
pneumonia	O
in	O
China	O
,	O
on	O
31	O
December	O
2019	O
(	O
day	O
1	O
)	O
in	O
Hong	O
Kong	O
.	O

None	O
of	O
them	O
was	O
infected	O
and	O
nosocomial	O
transmission	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
was	O
not	O
observed	O
.	O

SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
revealed	O
in	O
1	O
(	O
7	O
.	O
7	O
%)	O
of	O
13	O
environmental	O
samples	O
,	O
but	O
not	O
in	O
8	O
air	O
samples	O
collected	O
at	O
a	O
distance	O
of	O
10	O
cm	O
from	O
patient	O
'	O
s	O
chin	O
with	O
or	O
without	O
wearing	O
a	O
surgical	O
mask	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
clinical	O
and	O
economic	O
impact	O
between	O
iNO	B-PRGE
and	O
fixed	O
-	O
dosed	O
iEPO	O
for	O
ARDS	O
in	O
adult	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
patients	O
.	O

The	O
primary	O
end	O
point	O
was	O
to	O
compare	O
the	O
mean	O
change	O
in	O
partial	O
arterial	O
oxygen	O
pressure	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
Pao	O
A	O
total	O
of	O
239	O
patients	O
were	O
included	O
with	O
139	O
(	O
58	O
.	O
2	O
%)	O
and	O
100	O
(	O
41	O
.	O
8	O
%)	O
in	O
the	O
iEPO	O
and	O
iNO	B-PRGE
groups	O
,	O
respectively	O
.	O

Comparison	O
of	O
the	O
genome	O
sequences	O
of	O
COVID	O
-	O
19	O
,	O
SARS	O
-	O
CoV	O
,	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
showed	O
that	O
COVID	O
-	O
19	O
has	O
a	O
better	O
sequence	O
identity	O
with	O
SARS	O
-	O
CoV	O
compared	O
to	O
MERS	O
CoV	O
.	O
However	O
,	O
the	O
amino	O
acid	O
sequence	O
of	O
COVID	O
-	O
19	O
differs	O
from	O
other	O
coronaviruses	O
specifically	O
in	O
the	O
regions	O
of	O
1ab	O
polyprotein	O
and	O
surface	O
glycoprotein	O
or	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
recent	O
emergence	O
of	O
the	O
novel	O
,	O
pathogenic	O
SARS	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
2	I-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
)	O
in	O
China	O
and	O
its	O
rapid	O
national	O
and	O
international	O
spread	O
pose	O
a	O
global	O
health	O
emergency	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
uses	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
ACE2	I-PRGE
for	O
entry	O
and	O
the	O
serine	B-PRGE
protease	I-PRGE
TMPRSS2	I-PRGE
for	O
S	B-PRGE
protein	I-PRGE
priming	O
.	O

The	O
continuous	O
evolution	O
of	O
coronaviruses	O
was	O
further	O
highlighted	O
with	O
the	O
emergence	O
of	O
the	O
Middle	B-PRGE
East	I-PRGE
Respiratory	I-PRGE
Syndrome	I-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
MERS	O
-	O
CoV	O
)	O
outbreak	O
in	O
2012	O
.	O

Semi	O
-	O
quantitative	O
anti	B-PRGE
-	I-PRGE
MERS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
ELISAs	I-PRGE
which	O
utilize	O
the	O
purified	O
spike	O
protein	B-PRGE
domain	I-PRGE
S1	I-PRGE
antigen	I-PRGE
of	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
S1	O
)	O
were	O
used	O
to	O
detect	O
specific	O
IgG	B-PRGE
antibodies	O
against	O
the	O
virus	O
.	O

And	O
there	O
are	O
also	O
negatives	O
trials	O
as	O
following	O
:	O
individual	O
mechanical	O
ventilation	O
,	O
maximal	O
recruitment	O
open	O
lung	O
ventilation	O
or	O
early	O
neuromuscular	O
blockade	O
for	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
,	O
N95	O
respirators	O
preventing	O
influenza	O
,	O
flexible	O
family	O
visit	O
program	O
against	O
delirium	O
or	O
early	O
sedation	O
with	O
dexmedetomidine	O
to	O
mechanically	O
ventilated	O
patients	O
,	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
diary	O
or	O
nurse	O
-	O
led	O
preventive	O
psychological	O
intervention	O
against	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
in	O
patients	O
with	O
mechanical	O
ventilation	O
,	O
recombinant	B-PRGE
human	I-PRGE
soluble	I-PRGE
thrombomodulin	I-PRGE
(	O
rhsTM	O
)	O
in	O
patients	O
with	O
sepsis	O
-	O
associated	O
coagulopathy	O
,	O
and	O
so	O
on	O
.	O

TITLE	O
:	O
In	O
Vitro	O
Antiviral	O
Activity	O
and	O
Projection	O
of	O
Optimized	O
Dosing	O
Design	O
of	O
Hydroxychloroquine	O
for	O
the	O
Treatment	O
of	O
Severe	O
Acute	B-PRGE
Respiratory	I-PRGE
Syndrome	I-PRGE
Coronavirus	I-PRGE
2	I-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
).	O

Three	O
patients	O
had	O
increased	O
aminotransferase	B-PRGE
concentrations	O
.	O

Here	O
,	O
we	O
discovered	O
that	O
the	O
expression	O
of	O
miR	B-PRGE
-	I-PRGE
10a	I-PRGE
-	I-PRGE
5p	I-PRGE
was	O
constitutively	O
up	O
-	O
regulated	O
by	O
PHEV	O
in	O
both	O
the	O
N2a	O
cells	O

We	O
found	O
that	O
the	O
SARS	O
-	O
CoV	O
-	O
2	O
S	O
glycoprotein	O
harbors	O
a	O
furin	B-PRGE
cleavage	O
site	O
at	O
the	O
boundary	O
between	O
the	O
S	O

TITLE	O
:	O
Positive	O
rate	O
of	O
RT	O
-	O
PCR	O
detection	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
in	O
4880	O
cases	O
from	O
one	O
hospital	O
in	O
Wuhan	O
,	O
China	O
,	O
from	O
Jan	B-PRGE
to	O
Feb	O
2020	O
.	O

4880	O
cases	O
that	O
had	O
respiratory	O
infection	O
symptoms	O
or	O
close	O
contact	O
with	O
COVID	O
-	O
19	O
patients	O
in	O
hospital	O
in	O
Wuhan	O
,	O
China	O
,	O
were	O
tested	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
by	O
use	O
of	O
quantitative	O
RT	B-PRGE
-	I-PRGE
PCR	I-PRGE
(	O
qRT	O
-	O
PCR	O
)	O
on	O
samples	O
from	O
the	O
respiratory	O
tract	O
.	O

Most	O
high	O
-	O
frequency	O
codons	O
were	O
ending	O
with	O
A	O
or	O
T	O
,	O
while	O
the	O
low	O
frequency	O
and	O
rare	O
codons	O
were	O
ending	O
with	O
G	O
or	O
C	O
.	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
structural	I-PRGE
proteins	I-PRGE
showed	O
5	O
to	O
20	O
lower	O
ENc	O
values	O
,	O
compared	O
with	O
SARS	O
,	O
bat	O
SARS	O
,	O
and	O
MERS	O
CoVs	O
.	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
a	O
new	O
virus	O
(	O
initially	O
called	O
'	O
Novel	O
Coronavirus	O
2019	O
-	O
nCoV	O
'	O
and	O
later	O
renamed	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
)	O
causing	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
coronavirus	O
disease	O
COVID	O
-	O
19	O
)	O
emerged	O
in	O
Wuhan	O
,	O
Hubei	O
Province	O
,	O
China	O
,	O
and	O
rapidly	O
spread	O
to	O
other	O
parts	O
of	O
China	O
and	O
other	O
countries	O
around	O
the	O
world	O
,	O
despite	O
China	O
'	O
s	O
massive	O
efforts	O
to	O
contain	O
the	O
disease	O
within	O
Hubei	O
.	O

Compared	O
to	O
NON	O
-	O
NCOVID	O
-	O
19	O
,	O
NCOVID	O
-	O
19	O
present	O
remarkably	O
more	O
abnormal	O
laboratory	O
tests	O
including	O
AST	B-PRGE
,	O
ALT	B-PRGE
,	O
Î³	O
-	O
GT	O
,	O
LDH	B-PRGE
and	O
Î±	O
-	O
HBDH	O
.	O

This	O
urgent	O
situation	O
is	O
pressing	O
the	O
world	O
to	O
respond	O
with	O
the	O
development	O
of	O
novel	O
vaccine	O
or	O
a	O
small	O
molecule	O
therapeutics	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

In	O
the	O
current	O
study	O
we	O
applied	O
DD	O
to	O
all	O
1	O
.	O
3	O
billion	O
compounds	O
from	O
ZINC15	O
library	O
to	O
identify	O
top	B-PRGE
1	I-PRGE
,	O
000	O
potential	O
ligands	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
Mpro	I-PRGE
protein	I-PRGE
.	O

Drugs	O
are	O
possibly	O
effective	O
for	O
2019	O
-	O
nCoV	O
include	O
:	O
remdesivir	O
,	O
lopinavir	O
/	O
ritonavir	O
,	O
lopinavir	O
/	O
ritonavir	O
combined	O
with	O
interferon	B-PRGE
-	I-PRGE
Î²	I-PRGE
,	O
convalescent	O
plasma	O
,	O
and	O
monoclonal	O
antibodies	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
TMPRSS2	O
-	O
expressing	O
VeroE6	O
cell	O
line	O
is	O
highly	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
,	O
making	O
it	O
useful	O
for	O
isolating	O
and	O
propagating	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

ABSTRACT	O
:	O
A	O
new	O
coronavirus	O
,	O
referred	O
to	O
as	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
is	O
responsible	O
for	O
the	O
recent	O
outbreak	O
of	O
severe	O
respiratory	O
disease	O
.	O

We	O
thought	O
that	O
it	O
is	O
timely	O
to	O
explain	O
the	O
connection	O
between	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
ACE2	B-PRGE
and	O
the	O
rationale	O
for	O
soluble	O
ACE2	B-PRGE
as	O
a	O
potential	O
therapy	O
.	O

We	O
found	O
that	O
theaflavin	O
has	O
a	O
lower	O
idock	O
score	O
in	O
the	O
catalytic	O
pocket	O
of	O
RdRp	O
in	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
(-	O
9	O
.	O
11	O
kcal	O
/	O
mol	O
),	O
SARS	O
-	O
CoV	O
(-	O
8	O
.	O
03	O
kcal	O
/	O
mol	O
),	O
and	O
MERS	O
-	O
CoV	O
(-	O
8	O
.	O
26	O
kcal	O
/	O
mol	O
)	O
from	O
idock	O
.	O

This	O
finding	O
raises	O
the	O
curiosity	O
of	O
investigating	O
the	O
expression	O
of	O
ACE2	B-PRGE
in	O
neurological	O
tissue	O
and	O
determining	O
the	O
possible	O
contribution	O
of	O
neurological	O
tissue	O
damage	O
to	O
the	O
morbidity	O
and	O
mortality	O
caused	O
by	O
COIVD	O
-	O
19	O
.	O

The	O
novel	O
coronavirus	O
uses	O
the	O
same	O
receptor	O
,	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
as	O
that	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
and	O
mainly	O
spreads	O
through	O
the	O
respiratory	O
tract	O
.	O

In	O
this	O
study	O
,	O
the	O
COVID	O
-	O
19	O
spike	O
binding	O
site	O
to	O
the	O
cell	O
-	O
surface	O
receptor	O
(	O
Glucose	O
Regulated	O
Protein	B-PRGE
78	I-PRGE
(	O
GRP78	B-PRGE
))	O
is	O
predicted	O
using	O
combined	O
molecular	O
modeling	O
docking	O
and	O
structural	O
bioinformatics	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
known	O
that	O
,	O
the	O
novel	O
Coronavirus	O
,	O
2019	O
-	O
nCoV	O
,	O
which	O
is	O
considered	O
similar	O
to	O
SARS	O
-	O
CoV	O
and	O
originated	O
from	O
Wuhan	O
(	O
China	O
),	O
invades	O
human	O
cells	O
via	O
the	O
receptor	O
angiotensin	B-PRGE
converting	I-PRGE
enzyme	I-PRGE
II	I-PRGE
(	O
ACE2	B-PRGE
).	O

In	O
this	O
review	O
,	O
the	O
characteristics	O
and	O
mechanism	O
of	O
liver	O
injury	O
caused	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
MERS	O
-	O
CoV	O
,	O
as	O
well	O
as	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
were	O
summarized	O
,	O
which	O
may	O
provide	O
help	O
for	O
further	O
studies	O
on	O
the	O
liver	O
injury	O
of	O
COVID	O
-	O
19	O
.	O

Combining	O
a	O
mathematical	O
model	O
of	O
severe	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
transmission	O
with	O
four	O
datasets	O
from	O
within	O
and	O
outside	O
Wuhan	O
,	O
we	O
estimated	O
how	O
transmission	O
in	O
Wuhan	O
varied	O
between	O
December	O
,	O
2019	O
,	O
and	O
February	O
,	O
2020	O
.	O

When	O
COVI	O
-	O
19	O
infect	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
it	O
can	O
cause	O
mild	O
or	O
highly	O
acute	O
respiratory	O
syndrome	O
with	O
consequent	O
release	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
including	O
interleukin	B-PRGE
(	O
IL	O
)-	O
1Î²	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

In	O
this	O
retrospective	O
,	O
single	O
-	O
center	O
study	O
,	O
we	O
included	O
confirmed	O
cases	O
of	O
COVID	O
-	O
19	O
from	O
Jan	B-PRGE
20	I-PRGE
to	O
Feb	O
6	O
,	O
2020	O
in	O
Shanghai	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
could	O
not	O
be	O
detected	O
for	O
12	O
(	O
75	O
%)	O
of	O
16	O
patients	O
'	O
nasopharyngeal	O
specimens	O
in	O
the	O
combination	O
group	O
after	O
seven	O
days	O
,	O
compared	O
with	O
6	O
(	O
35	O
%)	O
of	O
17	O
in	O
the	O
monotherapy	O
group	O
(	O
p	O
<	O
0	O
Â·	O
05	O
).	O

Up	O
to	O
now	O
,	O
clinical	O
features	O
and	O
treatment	O
of	O
patients	O
infected	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
have	O
been	O
reported	O
in	O
detail	O
.	O

Compared	O
with	O
healthy	O
controls	O
,	O
prothrombin	B-PRGE
time	O
activity	O
(	O
PT	O
-	O
act	O
)	O
was	O
lower	O
in	O
SARS	O
-	O
CoV	O
-	O
2	O
patients	O
.	O

Levels	O
of	O
potassium	O
,	O
albumin	B-PRGE
,	O
lymphocyte	O
were	O
low	O
,	O
but	O
increased	O
persistently	O
after	O
treatment	O
.	O

TITLE	O
:	O
Emerging	O
WuHan	O
(	O
COVID	O
-	O
19	O
)	O
coronavirus	O
:	O
glycan	O
shield	O
and	O
structure	O
prediction	O
of	O
spike	O
glycoprotein	O
and	O
its	O
interaction	O
with	O
human	B-PRGE
CD26	I-PRGE
.	O

Here	O
we	O
report	O
our	O
modelled	O
homo	O
-	O
trimer	O
structure	O
of	O
COVID	B-PRGE
-	I-PRGE
19	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
in	O
both	O
closed	O
(	O
ligand	O
-	O
free	O
)	O
and	O
open	O
(	O
ligand	O
-	O
bound	O
)	O
conformation	O
,	O
which	O
is	O
involved	O
in	O
host	O
cell	O
adhesion	O
.	O

He	O
was	O
admitted	O
8	O
days	O
later	O
and	O
tested	O
positive	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

Person	O
-	O
to	O
-	O
person	O
transmission	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
occurred	O
between	O
two	O
people	O
with	O
prolonged	O
,	O
unprotected	O
exposure	O
while	O
Patient	O
1	O
was	O
symptomatic	O
.	O

All	O
the	O
tests	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV2	I-PRGE
were	O
negative	O
.	O

For	O
1	O
/	O
3	O
COVID	O
-	O
19	O
can	O
present	O
as	O
pneumonia	O
with	O
less	O
onset	O
of	O
symptoms	O
,	O
and	O
the	O
infectivity	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV2	I-PRGE
may	O
gradually	O
decrease	O
in	O
the	O
tertiary	O
patients	O
.	O

TITLE	O
:	O
An	O
Analysis	O
of	O
38	O
Pregnant	O
Women	O
with	O
COVID	O
-	O
19	O
,	O
Their	O
Newborn	O
Infants	O
,	O
and	O
Maternal	O
-	O
Fetal	O
Transmission	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
:	O
Maternal	O
Coronavirus	O
Infections	O
and	O
Pregnancy	O
Outcomes	O
.	O

In	O
addition	O
,	O
it	O
analyzes	O
literature	O
describing	O
38	O
pregnant	O
women	O
with	O
COVID	O
-	O
19	O
and	O
their	O
newborns	O
in	O
China	O
to	O
assess	O
the	O
effects	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
on	O
the	O
mothers	O
and	O
infants	O
including	O
clinical	O
,	O
laboratory	O
and	O
virologic	O
data	O
,	O
and	O
the	O
transmissibility	O
of	O
the	O
virus	O
from	O
mother	O
to	O
fetus	O
.	O

Importantly	O
,	O
and	O
similar	O
to	O
pregnancies	O
with	O
SARS	O
and	O
MERS	O
,	O
there	O
were	O
no	O
confirmed	O
cases	O
of	O
intrauterine	O
transmission	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
from	O
mothers	O
with	O
COVID	O
-	O
19	O
to	O
their	O
fetuses	O
.	O

TITLE	O
:	O
Hypothesis	O
:	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
inhibitors	O
and	O
angiotensin	B-PRGE
receptor	I-PRGE
blockers	O
may	O
increase	O
the	O
risk	O
of	O
severe	O
COVID	O
-	O
19	O
.	O

TITLE	O
:	O
COVID	O
-	O
19	O
:	O
social	O
distancing	O
,	O
ACE	B-PRGE
2	I-PRGE
receptors	I-PRGE
,	O
protease	O
inhibitors	O
and	O
beyond	O
?	O

TITLE	O
:	O
A	O
doubt	O
of	O
multiple	O
introduction	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
in	O
Italy	O
:	O
a	O
preliminary	O
overview	O
.	O

ABSTRACT	O
:	O
Viral	O
infectivity	O
depends	O
on	O
interactions	O
between	O
components	O
of	O
the	O
host	O
cell	O
plasma	O
membrane	O
and	O
the	O
virus	O
envelope	B-PRGE
.	O

TITLE	O
:	O
Co	O
-	O
infection	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
and	O
Human	B-PRGE
Metapneumovirus	I-PRGE
.	O

The	O
patient	O
underwent	O
nasopharyngeal	O
swab	O
for	O
a	O
respiratory	O
pathogen	O
panel	O
as	O
well	O
as	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
RT	O
-	O
PCR	O
.	O

Other	O
findings	O
included	O
decreased	O
CD16	O
+	O
CD56	O
(	O
4	O
/	O
8	O
)	O
and	O
Th	O
/	O
Ts	O
*(	O
1	O
/	O
8	O
),	O
increased	O
CD3	O
(	O
2	O
/	O
8	O
),	O
CD4	O
(	O
4	O
/	O
8	O
)	O
and	O
CD8	B-PRGE
(	I-PRGE
1	I-PRGE
/	I-PRGE
8	I-PRGE
),	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
(	O
2	O
/	O
8	O
),	O
IL	O
-	O
10	O
(	O
5	O
/	O
8	O
)	O
and	O
IFN	O
-	O
Î³	O
(	O
2	O
/	O
8	O
).	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
2019	O
-	O
novel	O
coronavirus	O
disease	O
(	O
COVID	O
-	O
19	O
)	O
that	O
is	O
caused	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
has	O
spread	O
rapidly	O
in	O
China	O
,	O
and	O
has	O
developed	O
to	O
be	O
a	O
Public	O
Health	O
Emergency	O
of	O
International	O
Concern	O
.	O

All	O
of	O
them	O
accepted	O
mechanical	O
ventilation	O
,	O
intravenous	B-PRGE
immunoglobulin	I-PRGE
(	O
IVIG	O
),	O
blood	O
transfusion	O
,	O
glucocorticoid	O
,	O
and	O
multi	O
-	O
anti	O
-	O
infectious	O
therapy	O
.	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
coronavirus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
caused	O
by	O
the	O
2019	O
novel	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
)	O
began	O
in	O
the	O
city	O
of	O
Wuhan	O
in	O
China	O
and	O
has	O
widely	O
spread	O
worldwide	O
.	O

Currently	O
,	O
it	O
is	O
vital	O
to	O
explore	O
potential	O
intermediate	O
hosts	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
to	O
control	O
COVID	O
-	O
19	O
spread	O
.	O

Pangolin	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
91	O
.	O
02	O
%	O
and	O
90	O
.	O
55	O
%	O
identical	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
and	O
BatCoV	O
RaTG13	O
,	O
respectively	O
,	O
at	O
the	O
whole	O
-	O
genome	O
level	O
.	O

The	O
S1	B-PRGE
protein	I-PRGE
of	O
Pangolin	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
much	O
more	O
closely	O
related	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
than	O
to	O
RaTG13	O
.	O

The	O
tissue	O
receptor	O
for	O
COVID	O
-	O
19	O
is	O
ACE2	B-PRGE
,	O
and	O
higher	O
levels	O
of	O
ACE2	B-PRGE
can	O
protect	O
against	O
ARDS	O
.	O

Angiotensin	B-PRGE
I	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
is	O
the	O
host	O
receptor	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
to	O
infect	O
human	O
cells	O
.	O

Among	O
them	O
,	O
ANPEP	B-PRGE
and	O
DPP4	B-PRGE
are	O
the	O
known	O
receptors	O
for	O
human	O
CoVs	O
,	O
suggesting	O
ENPEP	O
as	O
another	O
potential	O
receptor	O
for	O
human	O
CoVs	O
.	O

The	O
CoV	B-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
plays	O
the	O
most	O
important	O
roles	O
in	O
viral	O
attachment	O
,	O
fusion	O
and	O
entry	O
,	O
and	O
serves	O
as	O
a	O
target	O
for	O
development	O
of	O
antibodies	O
,	O
entry	O
inhibitors	O
and	O
vaccines	O
.	O

SARS	O
-	O
CoV	O
RBD	O
-	O
specific	O
antibodies	O
could	O
cross	O
-	O
react	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
RBD	I-PRGE
protein	I-PRGE
,	O
and	O
SARS	O
-	O
CoV	O
RBD	O
-	O
induced	O
antisera	O
could	O
cross	O
-	O
neutralize	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
suggesting	O
the	O
potential	O
to	O
develop	O
SARS	O
-	O
CoV	O
RBD	O
-	O
based	O
vaccines	O
for	O
prevention	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
and	O
SARS	O
-	O
CoV	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
ongoing	O
outbreak	O
of	O
severe	O
pneumonia	O
associated	O
with	O
a	O
novel	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
),	O
currently	O
of	O
unknown	O
origin	O
,	O
creates	O
a	O
world	O
emergency	O
that	O
has	O
put	O
global	O
public	O
health	O
institutions	O
on	O
high	O
alert	O
.	O

These	O
manifestations	O
include	O
asymptomatic	O
infection	O
,	O
a	O
hyper	O
-	O
affinity	O
to	O
ACE2	B-PRGE
receptors	I-PRGE
resulting	O
in	O
high	O
transmissibility	O
,	O
false	O
negatives	O
,	O
and	O
an	O
incubation	O
period	O
of	O
up	O
to	O
22	O
days	O
.	O

TITLE	O
:	O
Lianhuaqingwen	O
exerts	O
anti	O
-	O
viral	O
and	O
anti	O
-	O
inflammatory	O
activity	O
against	O
novel	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
).	O

Over	O
our	O
study	O
period	O
,	O
no	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
was	O
detected	O
.	O

Higher	O
rate	O
of	O
fever	O
,	O
cough	O
,	O
expectoration	O
,	O
and	O
headache	O
,	O
lower	O
lymphocytes	O
,	O
albumin	B-PRGE
,	O
serum	O
sodium	O
levels	O
and	O
higher	O
total	O
bilirubin	O
,	O
creatine	B-PRGE
kinase	I-PRGE
,	O
lactate	B-PRGE
dehydrogenase	I-PRGE
and	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
levels	O
and	O
lower	O
oxygenation	O
index	O
were	O
observed	O
in	O
pneumonia	O
patients	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Updated	O
approaches	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

In	O
spite	O
of	O
the	O
variation	O
in	O
S	B-PRGE
protein	I-PRGE
amino	O
acid	O
composition	O
,	O
we	O
found	O
no	O
significant	O
difference	O
in	O
their	O
structures	O
.	O

TITLE	O
:	O
Practical	O
indications	O
for	O
the	O
prevention	O
and	O
management	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
in	O
ambulatory	O
dialysis	O
patients	O
:	O
lessons	O
from	O
the	O
first	O
phase	O
of	O
the	O
epidemics	O
in	O
Lombardy	O
.	O

As	O
a	O
mono	B-PRGE
-	I-PRGE
carboxypeptidase	I-PRGE
,	O
ACE2	B-PRGE
contributes	O
to	O
the	O
degradation	O
of	O
several	O
substrates	O
including	O
angiotensins	B-PRGE
I	I-PRGE
and	I-PRGE
II	I-PRGE
.	O

SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
with	O
potential	O
origin	O
of	O
bat	O
is	O
still	O
circulating	O
in	O
China	O
.	O

To	O
capture	O
the	O
key	O
information	O
of	O
the	O
spike	O
protein	O
,	O
three	O
feature	O
encoding	O
algorithms	O
(	O
amino	O
acid	O
composition	O
,	O
AAC	O
;	O
parallel	O
correlation	O
-	O
based	O
pseudo	O
-	O
amino	O
-	O
acid	O
composition	O
,	O
PC	O
-	O
PseAAC	O
and	O
G	B-PRGE
-	I-PRGE
gap	I-PRGE
dipeptide	O
composition	O
,	O
GGAP	O
)	O
were	O
used	O
to	O
train	O
41	O
random	O
forest	O
models	O
.	O

As	O
of	O
March	O
15	O
,	O
2020	O
,	O
there	O
are	O
over	O
3	O
,	O
700	O
confirmed	O
cases	O
and	O
68	O
deaths	O
ascribed	O
to	O
Covid	O
-	O
19	O
(	O
the	O
disease	O
caused	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
)	O
in	O
the	O
United	O
States	O
[	O
https	O
://	O
www	O
.	O
livescience	O
.	O
com	O
/	O
coronavirus	O
-	O
updates	O
-	O
unitedstates	O
.	O
html	O
].	O

TITLE	O
:	O
Role	O
of	O
changes	O
in	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
spike	I-PRGE
protein	I-PRGE
in	O
the	O
interaction	O
with	O
the	O
human	B-PRGE
ACE2	I-PRGE
receptor	I-PRGE
:	O
An	O
ABSTRACT	O
:	O
Many	O
human	O
viral	O
diseases	O
are	O
a	O
consequence	O
of	O
a	O
zoonotic	O
event	O
.	O

The	O
study	O
population	O
included	O
788	O
subjects	O
,	O
of	O
whom	O
54	O
(	O
6	O
.	O
9	O
%)	O
were	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
positive	O
and	O
734	O
(	O
93	O
.	O
1	O
%)	O
were	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
negative	O
.	O

